PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Enokizono, Y; Konishi, Y; Nagata, K; Ouhashi, K; Uesugi, S; Ishikawa, F; Katahira, M				Enokizono, Y; Konishi, Y; Nagata, K; Ouhashi, K; Uesugi, S; Ishikawa, F; Katahira, M			Structure of hnRNP D complexed with single-stranded telomere DNA and unfolding of the quadruplex by heterogeneous nuclear ribonucleoprotein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; TRIPLET REPEAT DNA; G-RICH STRAND; CRYSTAL-STRUCTURE; INTRAMOLECULAR QUADRUPLEX; 3-DIMENSIONAL STRUCTURES; PARALLEL QUADRUPLEXES; BACKBONE DYNAMICS; IN-VITRO; G-TETRAD	Heterogeneous nuclear ribonucleoprotein D, also known as AUF1, has two DNA/RNA-binding domains, each of which can specifically bind to single-stranded d(TTAGGG)(n), the human telomeric repeat. Here, the structure of the C-terminal-binding domain (BD2) complexed with single-stranded d(TTAGGG) determined by NMR is presented. The structure has revealed that each residue of the d(TAG) segment is recognized by BD2 in a base-specific manner. The interactions deduced from the structure have been confirmed by gel retardation experiments with mutant BD2 and DNA. It is known that single-stranded DNA with the telomeric repeat tends to form a quadruplex and that the quadruplex has an inhibitory effect on telomere elongation by telomerase. This time it is revealed that BD2 unfolds the quadruplex of such DNA upon binding. Moreover, the effect of BD2 on the elongation by telomerase was examined in vitro. These results suggest the possible involvement of heterogeneous nuclear ribonucleoprotein D in maintenance of the telomere 3'-overhang either through protection of a single-stranded DNA or destabilization of the potentially deleterious quadruplex structure for the elongation by telomerase.	Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068502, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Yokohama National University; Kyoto University; Yokohama City University	Katahira, M (corresponding author), Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Dept Environm & Nat Sci, Hodogaya Ku, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	katahira@tsurumi.yokohama-cu.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1993, SYSTEM XRAY CRYSTALL; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Catasti P, 1996, J MOL BIOL, V264, P534, DOI 10.1006/jmbi.1996.0659; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fletcher TM, 1998, BIOCHEMISTRY-US, V37, P5536, DOI 10.1021/bi972681p; Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gomez D, 2002, CANCER RES, V62, P3365; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Izbicka E, 1999, CANCER RES, V59, P639; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; Katahira M, 1999, BIOCHEM BIOPH RES CO, V264, P327, DOI 10.1006/bbrc.1999.1521; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Matsugami A, 2003, J BIOL CHEM, V278, P28147, DOI 10.1074/jbc.M303694200; Matsugami A, 2003, STRUCTURE, V11, P533, DOI 10.1016/S0969-2126(03)00069-8; Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Miyanoiri Y, 2003, J BIOL CHEM, V278, P41309, DOI 10.1074/jbc.M306210200; Myers JC, 2003, J BIOL CHEM, V278, P42300, DOI 10.1074/jbc.M306147200; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Phan AT, 2003, J AM CHEM SOC, V125, P15021, DOI 10.1021/ja037616j; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZIMMER DP, 1995, P NATL ACAD SCI USA, V92, P3091, DOI 10.1073/pnas.92.8.3091	43	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18862	18870		10.1074/jbc.M411822200	http://dx.doi.org/10.1074/jbc.M411822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15734733	hybrid			2022-12-27	WOS:000228932300038
J	Wang, DA; Sebti, SM				Wang, DA; Sebti, SM			Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; EXPRESSION; GTPASES; RAS; TRANSFORMATION; TRANSCRIPTION; PRENYLATION; PROGRESSION; METASTASIS; RECEPTORS	RhoA and RhoB share 86% amino acid sequence identity, yet RhoA promotes whereas RhoB suppresses malignant transformation. Amino acids 29, 100, 116, 123, 129, 140-143, 141, 146, 152, 154, 155, 173, 181, 183-187, 189, 190, 191, 192, and 193 in RhoB were mutated to the corresponding RhoA residues to determine those critical for RhoB tumor-suppressive activity. Of all the mutants made, only the cysteine 192 (one of two palmitoylation sites) and cysteine 193 (the prenylation site) point mutations abolish RhoB functions. In contrast, mutation of the other palmitoylation site, cysteine 189, did not affect RhoB functions. Moving cysteine 192 to position 190 did not affect RhoB function either. Mutation of cysteine 192 to glycine, alanine, or serine blocks the ability of RhoB to suppress transforming growth factor beta type II receptor, p2lwaf, and AP-1 promoter transcriptional activities. Furthermore, mutations of cysteines 192 and 193, but not 189, mislocalize RhoB and prevent RhoB from inhibiting anchorage-dependent and anchorage-independent tumor growth and colony formation as well as prevent it from inducing apoptosis. The cysteine 192 RhoB mutant is farnesylated and geranylgeranylated as efficiently as wild type RhoB. A RhoA-(1-180)/RhoB-(181-196) chimera inhibited tumor cell proliferation and induced apoptosis as efficiently as RhoB. These results demonstrate that the presence of neither cysteine 193 nor cysteine 192 alone is sufficient and that both palmitoylated cysteine 192 and prenylated cysteine 193, but not palmitoylated cysteine 189, are required for RhoB tumor-suppressive and proapoptotic activities.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Dept Interdisciplinary Oncol, 12902 Magnolia Dr,SRB3-DRDIS, Tampa, FL 33612 USA.	Sebti@moffitt.usf.edu						ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Adnane J, 2002, J BIOL CHEM, V277, P8500, DOI 10.1074/jbc.M104367200; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; BIERMANN BJ, 1994, J BIOL CHEM, V269, P25251; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Welsh CF, 2004, BREAST CANCER RES TR, V84, P33, DOI 10.1023/B:BREA.0000018425.31633.07	26	40	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19243	19249		10.1074/jbc.M411472200	http://dx.doi.org/10.1074/jbc.M411472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15713677	hybrid			2022-12-27	WOS:000228932300081
J	Angeletti, B; Waldron, KJ; Freeman, KB; Bawagan, H; Hussain, I; Miller, CCJ; Lau, KF; Tennant, ME; Dennison, C; Robinson, NJ; Dingwall, C				Angeletti, B; Waldron, KJ; Freeman, KB; Bawagan, H; Hussain, I; Miller, CCJ; Lau, KF; Tennant, ME; Dennison, C; Robinson, NJ; Dingwall, C			BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SECRETASE CYTOSOLIC DOMAIN; C-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; CLEAVING ENZYME; A-BETA; AXONAL-TRANSPORT; TRANSGENIC MICE; HYDROGEN-PEROXIDE	The amyloidogenic pathway leading to the production and deposition of A beta peptides, major constituents of Alzheimer disease senile plaques, is linked to neuronal metal homeostasis. The amyloid precursor protein binds copper and zinc in its extracellular domain, and the A beta peptides also bind copper, zinc, and iron. The first step in the generation of A beta is cleavage of amyloid precursor protein by the aspartic protease BACE1. Here we show that BACE1 interacts with CCS ( the copper chaperone for superoxide dismutase-1 (SOD1)) through domain I and the proteins co-immunoprecipitate from rat brain extracts. We have also been able to visualize the cotransport of membranous BACE1 and soluble CCS through axons. BACE1 expression reduces the activity of SOD1 in cells consistent with direct competition for available CCS as overexpression of CCS restores SOD1 activity. Finally, we demonstrate that the twenty-four residue C-terminal domain of BACE1 binds a single Cu(I) atom with high affinity through cysteine residues.	GlaxoSmithKline, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow CM19 5AW, Essex, England; Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; GlaxoSmithKline, Comparat Genom, Collegeville, PA 19426 USA; Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Inst Psychiat, Dept Neurol, London SE5 8AF, England	GlaxoSmithKline; Newcastle University - UK; GlaxoSmithKline; University of London; King's College London; University of London; King's College London	Dingwall, C (corresponding author), GlaxoSmithKline, Neurol & Gastrointestinal Ctr Excellence Drug Dis, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Colin_Dingwall@gsk.com	Robinson, Nigel J/J-6363-2012; Miller, Christopher/H-5733-2012; Waldron, Kevin/J-2368-2016; Waldron, Kevin John/HHM-8983-2022	Robinson, Nigel J/0000-0001-5586-1092; Waldron, Kevin/0000-0002-5577-7357; Waldron, Kevin John/0000-0002-5577-7357; Miller, Christopher/0000-0002-5130-1845; Dennison, Christopher/0000-0001-8665-052X; Lau, Kwok-Fai/0000-0002-0193-1152	MRC [G0000749] Funding Source: UKRI; Medical Research Council [G0000749] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bodendorf U, 2001, J BIOL CHEM, V276, P12019, DOI 10.1074/jbc.M008861200; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Bush AI, 2003, ALZ DIS ASSOC DIS, V17, P147, DOI 10.1097/00002093-200307000-00005; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasler DW, 1998, BIOCHEMISTRY-US, V37, P14966, DOI 10.1021/bi9813734; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Huang XD, 2004, ANN NY ACAD SCI, V1012, P153, DOI 10.1196/annals.1306.012; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Khvotchev M, 2004, J BIOL CHEM, V279, P47101, DOI 10.1074/jbc.M408474200; Kihlken MA, 2002, BIOCHEM J, V368, P729, DOI 10.1042/BJ20021036; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Sheng JG, 2003, EXP NEUROL, V184, P1053, DOI 10.1016/j.expneurol.2003.08.018; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	60	100	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17930	17937		10.1074/jbc.M412034200	http://dx.doi.org/10.1074/jbc.M412034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722349	hybrid			2022-12-27	WOS:000228807200046
J	Fujimori, K; Kadoyama, K; Urade, Y				Fujimori, K; Kadoyama, K; Urade, Y			Protein kinase C activates human lipocalin-type prostaglandin D synthase gene expression through de-repression of Notch-HES signaling and enhancement of AP-2 beta function in brain-derived TE671 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TRACE; CEREBROSPINAL-FLUID; TRANSCRIPTIONAL ACTIVATION; CYCLOOXYGENASE-2 GENE; ROLES; D-2; DIFFERENTIATION; LOCALIZATION; TARGET; SLEEP	Here we investigated the regulatory mechanism of lipocalin-type prostaglandin D synthase (L-PGDS) gene expression in human TE671 ( medulloblastoma of cerebellum) cells. Reporter analysis of the promoter region from - 730 to + 75 of the human L-PGDS gene demonstrated that deletion or mutation of the N-box at - 337 increased the promoter activity 220 - 300%. The N-box was bound by Hes-1, a mammalian homologue of Drosophila Hairy and enhancer of split, as examined by electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Functional expression of the Notch intracellular domain significantly increased Hes-1 expression and decreased L-PGDS expression level in TE671 cells. Moreover, knock-down of Hes-1 mRNA by RNA interference significantly enhanced the L-PGDS mRNA level, indicating that the L-PGDS gene expression is repressed by the Notch-Hes signaling. When the AP-2 element at - 98 of the promoter region was deleted or mutated, the promoter activity was drastically decreased to similar to 10% of normal. The AP-2 element was bound by AP-2 beta dominantly expressed in TE671 cells, according to the results of electrophoretic mobility shift assay and chromatin immunoprecipitation assay. L-PGDS expression was induced by 12-O-tetradecanoylphorbol-13-acetate in TE671 cells, and this induction was inhibited by a protein kinase C inhibitor. Stimulation of TE671 cells with 12-O-tetradecanoylphorbol-13- acetate or transfection with protein kinase C alpha expression vector induced phosphorylation of Hes-1, inhibition of DNA binding of Hes-1 to the N-box, and activation of the AP-2 beta function to up-regulate L-PGDS gene expression. These results reveal a novel transcriptional regulatory mechanism responsible for the high level expression of the human L-PGDS gene in TE671 cells.	Osaka Biosci Inst, Dept Mol Behav Biol, Osaka 5650874, Japan		Urade, Y (corresponding author), Osaka Biosci Inst, Dept Mol Behav Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.	uradey@obi.or.jp	Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beuckmann CT, 2000, J COMP NEUROL, V428, P62, DOI 10.1002/1096-9861(20001204)428:1<62::AID-CNE6>3.0.CO;2-E; Beuckmann CT, 1999, BIOCHEMISTRY-US, V38, P8006, DOI 10.1021/bi990261p; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CLAUSEN J, 1961, P SOC EXP BIOL MED, V107, P170; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Eguchi N, 2002, INT CONGR SER, V1233, P429, DOI 10.1016/S0531-5131(02)00529-0; Eguchi Y, 1997, P NATL ACAD SCI USA, V94, P14689, DOI 10.1073/pnas.94.26.14689; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Fujimori K, 2003, J BIOL CHEM, V278, P6018, DOI 10.1074/jbc.M208288200; Fujimori K, 2002, J BIOCHEM, V131, P383, DOI 10.1093/oxfordjournals.jbchem.a003113; Fujimori K, 2000, J BIOL CHEM, V275, P40511, DOI 10.1074/jbc.M007688200; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; Garcia-Fernandez LF, 2000, J NEUROCHEM, V75, P460, DOI 10.1046/j.1471-4159.2000.0750460.x; Gerena RL, 2000, BIOL REPROD, V62, P547, DOI 10.1095/biolreprod62.3.547; Gouni-Berthold Ioanna, 2004, Current Vascular Pharmacology, V2, P363, DOI 10.2174/1570161043385466; Hayaishi O, 2002, NEUROSCIENTIST, V8, P12, DOI 10.1177/107385840200800105; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Hirawa N, 2002, HYPERTENSION, V39, P449, DOI 10.1161/hy0202.102835; IGARASHI M, 1992, P NATL ACAD SCI USA, V89, P5376, DOI 10.1073/pnas.89.12.5376; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Irikura D, 2003, J BIOCHEM, V133, P29, DOI 10.1093/jb/mvg006; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Manya H, 2000, J BIOCHEM-TOKYO, V127, P1001, DOI 10.1093/oxfordjournals.jbchem.a022691; Mase M, 1999, NEUROSCI LETT, V270, P188, DOI 10.1016/S0304-3940(99)00494-2; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Mong JA, 2003, P NATL ACAD SCI USA, V100, P15206, DOI 10.1073/pnas.2436540100; Oda H, 2002, CLIN CHEM, V48, P1445; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Otsuki M, 2003, MOL ENDOCRINOL, V17, P1844, DOI 10.1210/me.2003-0016; Pinzar E, 2000, P NATL ACAD SCI USA, V97, P4903, DOI 10.1073/pnas.090093997; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ragolia L, 2003, J BIOL CHEM, V278, P22175, DOI 10.1074/jbc.M302769200; Ross DA, 2004, MOL CELL BIOL, V24, P3505, DOI 10.1128/MCB.24.8.3505-3513.2004; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shiota T, 1996, STROKE, V27, P1889, DOI 10.1161/01.STR.27.10.1889; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; Taniike M, 2002, J NEUROSCI, V22, P4885, DOI 10.1523/JNEUROSCI.22-12-04885.2002; Tokugawa Y, 1998, BIOL REPROD, V58, P600, DOI 10.1095/biolreprod58.2.600; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; Ungvari Z, 2003, CIRCULATION, V108, P1253, DOI 10.1161/01.CIR.0000079165.84309.4D; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; Urade Y, 2002, PROSTAG OTH LIPID M, V68-9, P375, DOI 10.1016/S0090-6980(02)00042-4; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; URADE Y, 1985, J BIOL CHEM, V260, P2410; Urade Y, 1999, BBA-MOL CELL BIOL L, V1436, P606, DOI 10.1016/S0005-2760(98)00163-5; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; White DM, 1997, J BIOL CHEM, V272, P14387, DOI 10.1074/jbc.272.22.14387; WHITE DM, 1992, J BIOL CHEM, V267, P23202; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wu YL, 2001, BIOL REPROD, V65, P1565, DOI 10.1095/biolreprod65.5.1565; Yamashima T, 1997, J NEUROSCI, V17, P2376; Yan B, 2002, J BIOL CHEM, V277, P29760, DOI 10.1074/jbc.M204721200; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200	64	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18452	18461		10.1074/jbc.M411755200	http://dx.doi.org/10.1074/jbc.M411755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743775	hybrid			2022-12-27	WOS:000228807200108
J	Lefebvre-Legendre, L; Salin, B; Schaeffer, J; Brethes, D; Dautant, A; Ackerman, SH; di Rago, JP				Lefebvre-Legendre, L; Salin, B; Schaeffer, J; Brethes, D; Dautant, A; Ackerman, SH; di Rago, JP			Failure to assemble the alpha(3)beta(3) subcomplex of the ATP synthase leads to accumulation of the alpha and beta subunits within inclusion bodies and the loss of mitochondrial cristae in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST MITOCHONDRIA; DELTA-SUBUNIT; GENES; COMPLEXES; F1-ATPASE; MEMBRANE; IDENTIFICATION; PROTEIN; FAMILY	The F-1 component of mitochondrial ATP synthase is an oligomeric assembly of five different subunits, alpha, beta, gamma, delta, and epsilon. In terms of mass, the bulk of the structure (similar to 90%) is provided by the alpha and beta subunits, which form an (alpha beta)(3) hexamer with adenine nucleotide binding sites at the alpha/beta interfaces. We report here ultrastructural and immunocytochemical analyses of yeast mutants that are unable to form the alpha(3)beta(3) oligomer, either because the alpha or the beta subunit is missing or because the cells are deficient for proteins that mediate F-1 assembly (e.g. Atp11p, Atp12p, or Fmc1p). The F-1 alpha and beta subunits of such mutant strains are detected within large electron-dense particles in the mitochondrial matrix. The composition of the aggregated species is principally full-length F-1 alpha and/or beta subunit protein that has been processed to remove the amino-terminal targeting peptide. To our knowledge this is the first demonstration of mitochondrial inclusion bodies that are formed largely of one particular protein species. We also show that yeast mutants lacking the alpha(3)beta(3) oligomer are devoid of mitochondrial cristae and are severely deficient for respiratory complexes III and IV. These observations are in accord with other studies in the literature that have pointed to a central role for the ATP synthase in biogenesis of the mitochondrial inner membrane.	Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Wayne State University	di Rago, JP (corresponding author), Univ Victor Segalen, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr			NIGMS NIH HHS [GM48157] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; Church C, 1998, J EXP BIOL, V201, P1729; CLAISSE ML, 1974, EUR J BIOCHEM, V49, P49, DOI 10.1111/j.1432-1033.1974.tb03810.x; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CRIVELLONE MD, 1994, J BIOL CHEM, V269, P21284; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PAUL MF, 1994, J BIOL CHEM, V269, P26158; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SLONIMSKI PP, 1949, ANN I PASTEUR PARIS, V77, P47; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963; YOTSUYANAGI Y, 1962, J ULTRA MOL STRUCT R, V7, P141, DOI 10.1016/S0022-5320(62)80032-X; YOTSUYANAGI Y, 1988, J ULTRA MOL STRUCT R, V98, P254, DOI 10.1016/S0889-1605(88)80918-2	54	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18386	18392		10.1074/jbc.M410789200	http://dx.doi.org/10.1074/jbc.M410789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15716275	hybrid			2022-12-27	WOS:000228807200100
J	Miura, S; Karnik, SS; Saku, K				Miura, S; Karnik, SS; Saku, K			Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; V2 VASOPRESSIN RECEPTORS; ENDOTHELIAL-CELLS; ACTIVATION; OLIGOMERIZATION; DIMERIZATION; INACTIVATION; APOPTOSIS; AT(1)	Members of the G-protein-coupled receptor superfamily (GPCRs) undergo homo- and/or hetero-oligomerization to induce cell signaling. Although some of these show constitutive activation, it is not clear how such GPCRs undergo homo- oligomerization with transmembrane helix movement. We previously reported that angiotensin II (Ang II) type 2 (AT(2)) receptor, a GPCR, showed constitutive activation and induced apoptosis independent of its ligand, Ang II. In the present study, we analyzed the translocation and oligomerization of the AT(2) receptor with transmembrane movement when the receptor induces cell signaling. Constitutively active homo- oligomerization, which was due to disulfide bonding between Cys(35) in one AT(2) receptor and Cys(290) in another AT(2) receptor, was localized in the cell membrane without Ang II stimulation and induced apoptosis without changes in receptor conformation. These results provide the direct evidence that the constitutively active homo- oligomeric GPCRs by intermolecular interaction in two extracellular loops is translocated to the cell membrane and induces cell signaling independent of receptor conformation and ligand stimulation.	Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, Fukuoka 8100180, Japan; Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Fukuoka University; Cleveland Clinic Foundation	Miura, S (corresponding author), Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8100180, Japan.	miuras@cis.fukuoka-u.ac.jp	Karnik, Sadashiva/Y-2477-2019; Saku, Keijiro/HGB-6168-2022	Karnik, Sadashiva/0000-0003-0746-2753; 	NHLBI NIH HHS [HL57470, R01 HL064845, R01 HL057470, R01 HL083243, HL64845] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064845, R01HL057470] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; Feng YH, 2000, FEBS LETT, V484, P133, DOI 10.1016/S0014-5793(00)02141-4; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Miura S, 2003, HYPERTENS RES, V26, P937, DOI 10.1291/hypres.26.937; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Nouet S, 2004, J BIOL CHEM, V279, P28989, DOI 10.1074/jbc.M403880200; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	28	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18237	18244		10.1074/jbc.M500639200	http://dx.doi.org/10.1074/jbc.M500639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746093	hybrid			2022-12-27	WOS:000228807200082
J	Borra, MT; Smith, BC; Denu, JM				Borra, MT; Smith, BC; Denu, JM			Mechanism of human SIRT1 activation by resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; SILENCING PROTEIN SIR2; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; HISTONE/PROTEIN DEACETYLASES; ANTIOXIDANT ACTIVITY; LIFE-SPAN; NAD(+)-DEPENDENT DEACETYLASES; SUBSTRATE-SPECIFICITY; HISTONE DEACETYLASE	The NAD(+)-dependent protein deacetylase family, Sir2 (or sirtuins), is important for many cellular processes including gene silencing, regulation of p53, fatty acid metabolism, cell cycle regulation, and life span extension. Resveratrol, a polyphenol found in wines and thought to harbor major health benefits, was reported to be an activator of Sir2 enzymes in vivo and in vitro. In addition, resveratrol was shown to increase life span in three model organisms through a Sir2-dependent pathway. Here, we investigated the molecular basis for Sir2 activation by resveratrol. Among the three enzymes tested ( yeast Sir2, human SIRT1, and human SIRT2), only SIRT1 exhibited significant enzyme activation (similar to 8-fold) using the commercially available Fluor de Lys kit (BioMol). To examine the requirements for resveratrol activation of SIRT1, we synthesized three p53 acetylpeptide substrates either lacking a fluorophore or containing a 7-amino-4-methylcoumarin (p53-AMC) or rhodamine 110 (p53-R110). Although SIRT1 activation was independent of the acetylpeptide sequence, resveratrol activation was completely dependent on the presence of a covalently attached fluorophore. Substrate competition studies indicated that the fluorophore decreased the binding affinity of the peptide, and, in the presence of resveratrol, fluorophore-containing substrates bound more tightly to SIRT1. Using available crystal structures, a model of SIRT1 bound to p53-AMC peptide was constructed. Without resveratrol, the coumarin of p53-AMC peptide is solvent-exposed and makes no significant contacts with SIRT1. We propose that binding of resveratrol to SIRT1 promotes a conformational change that better accommodates the attached coumarin group.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Denu, JM (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jmdenu@wisc.edu	Smith, Brian C/D-9949-2013	Smith, Brian C/0000-0001-6330-2768	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM066366, T32GM008349, R01GM065386] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM066366, NIH 5 T32 GM08349, R01 GM65386] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2005, J BIOL CHEM, V280, P9780, DOI 10.1074/jbc.M414080200; Borra MT, 2004, METHOD ENZYMOL, V376, P171; Borra MT, 2004, BIOCHEMISTRY-US, V43, P9877, DOI 10.1021/bi049592e; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; COPELAND RA, 2000, ENZYMES PRACTICAL IN, P276; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Fang JG, 2002, CHEM-EUR J, V8, P4191, DOI 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S; Fremont L, 1999, LIFE SCI, V64, P2511, DOI 10.1016/S0024-3205(99)00209-X; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gescher AJ, 2003, CANCER EPIDEM BIOMAR, V12, P953; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Granados-Soto V, 2003, DRUG NEWS PERSPECT, V16, P299, DOI 10.1358/dnp.2003.16.5.829318; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hirao M, 2003, J BIOL CHEM, V278, P52773, DOI 10.1074/jbc.M308966200; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marcotte PA, 2004, ANAL BIOCHEM, V332, P90, DOI 10.1016/j.ab.2004.05.039; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murcia MA, 2001, J FOOD PROTECT, V64, P379, DOI 10.4315/0362-028X-64.3.379; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Olas B, 2001, CELL BIOL TOXICOL, V17, P117, DOI 10.1023/A:1010962222305; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pinto MC, 1999, J AGR FOOD CHEM, V47, P4842, DOI 10.1021/jf990448n; Posakony J, 2004, J MED CHEM, V47, P2635, DOI 10.1021/jm030473r; Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5; RINE J, 1987, GENETICS, V116, P9; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schmidt MT, 2004, J BIOL CHEM, V279, P40122, DOI 10.1074/jbc.M407484200; Schultz J, 2004, J NATL CANCER I, V96, P1497, DOI 10.1093/jnci/96.20.1497; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wegener D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	67	822	876	1	145	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17187	17195		10.1074/jbc.M501250200	http://dx.doi.org/10.1074/jbc.M501250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749705	hybrid			2022-12-27	WOS:000228615500080
J	Bugaj, V; Alexeenko, V; Zubov, A; Glushankova, L; Nikolaev, A; Wang, ZN; Kaznacheyeva, E; Bezprozvanny, I; Mozhayeva, GN				Bugaj, V; Alexeenko, V; Zubov, A; Glushankova, L; Nikolaev, A; Wang, ZN; Kaznacheyeva, E; Bezprozvanny, I; Mozhayeva, GN			Functional properties of endogenous receptor- and store-operated calcium influx channels in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA A431 CELLS; PLASMA-MEMBRANE; CATION CHANNELS; CA2+ CHANNELS; TRP; DEPLETION; ACTIVATION; CURRENTS; ENTRY; PROTEIN	Activation of phospholipase C (PLC)-mediated signaling pathways in non-excitable cells causes the release of calcium (Ca2+) from inositol 1,4,5-trisphosphate (InsP(3))sensitive intracellular Ca-2+ stores and activation of Ca2+ influx via plasma membrane Ca2+ channels. The properties and molecular identity of plasma membrane Ca2+ influx channels in non-excitable cells is a focus of intense investigation. In the previous studies we used patch clamp electrophysiology to describe the properties of Ca2+ influx channels in human carcinoma A431 cell lines. Now we extend our studies to human embryonic kidney HEK293 cells. By using a combination of Ca2+ imaging and whole cell and single channel patch clamp recordings we discovered that: 1) HEK293 cells contain four types of plasma membrane Ca2+ influx channels: I-CRAC, I-min, I-max, and I-NS; 2) I-CRAC channels are highly Ca2+- selective (P-Ca/Cs > 1000) and I-CRAC single channel conductance is too small for single channel analysis; 3) Imin channels in HEK293 cells display functional properties identical to Imin channels in A431 cells, with single channel conductance of 1.2 pS for divalent cations, 10 pS for monovalent cations, and divalent cation selectivity P-Ba/K = 20; 4) I-min channels in HEK293 cells are activated by InsP3 and inhibited by phosphatidylinositol 4,5-bisphosphate, but store-independent; 5) when compared with Imin, Imax channels have higher conductance for divalent ( 17 pS) and monovalent ( 33 pS) cations, but less selective for divalent cations (P-Ba/K = 4), 6) I-max channels in HEK293 cells can be activated by InsP(3) or by Ca2+ store depletion; 7) INS channels are non-selective (P-Ba/K = 0.4) and display a single channel conductance of 5 pS; and 8) INS channels are not gated by InsP(3) but activated by depletion of intracellular Ca2+ stores. Our findings provide novel information about endogenous Ca2+ channels supporting receptor-operated and store-operated Ca2+ influx pathways in HEK293 cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Bezprozvanny, I (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, K4-112,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Ilya.Bezprozvanny@UTSouthwestern.edu; gnmozh@mail.cytspb.rssi.ru	Glushankova, Lyubov/AAE-9361-2021; Kaznacheyeva, Elena V/I-7260-2017	Glushankova, Lyubov/0000-0002-9995-1214; Kaznacheyeva, Elena V/0000-0003-1273-1188	NINDS NIH HHS [NS38082] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 2001, IONIC CHANNELS EXCIT, P448; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Kaznacheyeva E, 2001, P NATL ACAD SCI USA, V98, P148, DOI 10.1073/pnas.98.1.148; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; PREMACK BA, 1994, J IMMUNOL, V152, P5226; Putney JW, 2001, J CELL SCI, V114, P2223; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Shalabi A, 2004, J BIOL CHEM, V279, P1040, DOI 10.1074/jbc.M308234200; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Suzuki M, 2000, BIOCHEM BIOPH RES CO, V274, P344, DOI 10.1006/bbrc.2000.3135; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Yamada H, 2000, NEUROSCI LETT, V285, P111, DOI 10.1016/S0304-3940(00)01033-8; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	45	49	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16790	16797		10.1074/jbc.M500192200	http://dx.doi.org/10.1074/jbc.M500192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741171	hybrid			2022-12-27	WOS:000228615500031
J	Katabami, M; Donninger, H; Hommura, F; Leaner, VD; Kinoshita, I; Chick, JFB; Birrer, MJ				Katabami, M; Donninger, H; Hommura, F; Leaner, VD; Kinoshita, I; Chick, JFB; Birrer, MJ			Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED TRANSCRIPTION; CELLULAR-TRANSFORMATION; EMBRYO FIBROBLASTS; DEPENDENT KINASE-2; PROTEIN-KINASE; RAT-1A CELLS; S-PHASE; EXPRESSION; PROGRESSION; INDUCTION	Overexpression of c-Jun enables Rat1a cells to grow in an anchorage-independent manner. We used an inducible c-Jun system under the regulation of doxycycline in Rat1a cells to identify potential c-Jun target genes necessary for c-Jun-induced anchorage-independent growth. Induction of c-Jun results in sustained expression of cyclin A in the nonadherent state with only minimal expression in the absence of c-Jun. The promoter activity of cyclin A2 was 4-fold higher in Rat1a cells in which c-Jun expression was induced compared with the control cells. Chromatin immunoprecipitation demonstrated that c-Jun bound directly to the cyclin A2 promoter. Mutation analysis of the cyclin A2 promoter mapped the c-Jun regulatory site to an ATF site at position - 80. c-Jun was able to bind to this site both in vitro and in vivo, and mutation of this site completely abolished promoter activity. Cyclin A1 was also elevated in c-Jun-overexpressing Rat1a cells; however, c-Jun did not regulate this gene directly, since it did not bind directly to the cyclin A1 promoter. Suppression of cyclin A expression via the introduction of a cyclin A antisense sequences significantly reduced the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. Taken together, these results suggest that cyclin A is a target of c-Jun and is necessary but not sufficient for c-Jun-induced anchorage-independent growth. In addition, we demonstrated that the cytoplasmic oncogenes Ras and Src transcriptionally activated the cyclin A2 promoter via the ATF site at position - 80. Using a dominant negative c-Jun mutant, TAM67, we showed that this transcriptional activation of cyclin A2 requires c-Jun. Thus, our results suggest that c-Jun is a mediator of the aberrant cyclin A2 expression associated with Ras/Src-induced transformation.	NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Dept Cell & Canc Biol, NIH, 9610 Med Ctr Dr,Rm 300, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov	Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BROWN PH, 1993, ONCOGENE, V8, P877; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIEDERICHS S, 2004, J BIOL CHEM; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; El-Ghobashy AA, 2004, GYNECOL ONCOL, V92, P628, DOI 10.1016/j.ygyno.2003.11.010; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Haddad R, 2000, BIOCHEM BIOPH RES CO, V274, P188, DOI 10.1006/bbrc.2000.3124; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hommura F, 2004, MOL CANCER RES, V2, P305; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Lele KA, 2004, BIOL REPROD, V71, P1340, DOI 10.1095/biolreprod.104.030387; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; LIN PH, 1995, ONCOGENE, V10, P401; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; RAPP UR, 1994, ONCOGENE, V9, P3493; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOPRANO KJ, 1992, ANN NY ACAD SCI, V660, P231, DOI 10.1111/j.1749-6632.1992.tb21075.x; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Sweeney C, 1996, DEVELOPMENT, V122, P53; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067	72	31	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16728	16738		10.1074/jbc.M413892200	http://dx.doi.org/10.1074/jbc.M413892200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737994	hybrid			2022-12-27	WOS:000228615500024
J	Mehta, D; Konstantoulaki, M; Ahmmed, GU; Malik, AB				Mehta, D; Konstantoulaki, M; Ahmmed, GU; Malik, AB			Sphingosine 1-phosphate-induced mobilization of intracellular Ca2+ mediates Rac activation and adherens junction assembly in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BARRIER FUNCTION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; SHAPE CHANGE; PHOSPHORYLATION; PROTEIN; ENTRY; PERMEABILITY; RECEPTOR	Sphingosine 1-phosphate (S1P) ligation of endothelial differentiation gene-1 receptor coupled to the heterotrimeric G protein, G(i), promotes endothelial barrier strengthening via Rac-dependent assembly of adherens junctions (AJs). However, the mechanism of Rac activation induced by S1P stimulation remains unclear. In live endothelial cells expressing GFP-Rac, we observed that S1P induced the translocation of Rac to intercellular junctions, resulting in junctional sealing. We investigated the role of intracellular Ca2+ in signaling Rac activation and the enhancement of endothelial barrier function. We observed that S1P activated the release of Ca2+ from endoplasmic reticulum stores, and subsequent Ca2+ entry via lanthanum-sensitive store-operated Ca2+ channels (SOC) after store depletion. Inhibition of Gi, phospholipase C, or inositol trisphosphate receptor prevented the S1P-activated increase in intracellular Ca2+ as well as Rac activation, AJ assembly, and enhancement of endothelial barrier. Chelation of intracellular Ca2+ with BAPTA blocked S1P-induced Rac activation, indicating the requirement for Ca2+ in the response. Inhibition of SOC by lanthanum or transient receptor potential channel 1 (TRPC1), a SOC constituent, by TRPC1 antibody, failed to prevent S1P-induced Rac translocation to junctions and AJ assembly. Thus, our results demonstrate that S1P promotes endothelial junctional integrity by activating the release of endoplasmic reticulum-Ca2+, which induces Rac activation and promotes AJ annealing.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007829, R01HL045638, R01HL071794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71794, HL45638, R01 HL071794, T32 HL07829] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Kouklis P, 2004, CIRC RES, V94, P159, DOI 10.1161/01.RES.0000110418.38500.31; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; LUM H, 1994, AM J PHYSIOL, V267, P223; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Muraki K, 2001, J PHYSIOL-LONDON, V537, P431, DOI 10.1111/j.1469-7793.2001.00431.x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Paria BC, 2003, J BIOL CHEM, V278, P37195, DOI 10.1074/jbc.M304287200; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Young KW, 2002, CELL CALCIUM, V32, P335, DOI 10.1016/S0143416002001835	40	119	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17320	17328		10.1074/jbc.M411674200	http://dx.doi.org/10.1074/jbc.M411674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728185	hybrid			2022-12-27	WOS:000228615500096
J	Tian, B; Nowak, DE; Jamaluddin, M; Wang, SF; Brasier, AR				Tian, B; Nowak, DE; Jamaluddin, M; Wang, SF; Brasier, AR			Identification of direct genomic targets downstream of the nuclear factor-kappa B transcription factor mediating tumor necrosis factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-8 GENE-EXPRESSION; UBIQUITIN-PROTEASOME PATHWAY; PULMONARY EPITHELIAL-CELLS; DNA-BINDING SITES; FACTOR-ALPHA; TNF-ALPHA; DEPENDENT INDUCTION; INDUCED APOPTOSIS; RESPONSE ELEMENT; ACTIVATION	Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that controls expression of inflammatory genetic networks. Although the nuclear factor-kappa B (NF-kappa B) pathway is crucial for mediating cellular TNF responses, the complete spectrum of NF-kappa B-dependent genes is unknown. In this study, we used a tetracycline-regulated cell line expressing an NF-kappa B inhibitor to systematically identify NF-kappa B-dependent genes. A microarray data set generated from a time course of TNF stimulation in the presence or absence of NF-kappa B signaling was analyzed. We identified 50 unique genes that were regulated by TNF (Pr( F) < 0.001) and demonstrated a change in signal intensity of +/- 3-fold relative to control. Of these, 28 were NF-kappa B-dependent, encoding proteins involved in diverse cellular activities. Quantitative real-time PCR assays of eight characterized NF-kappa B-dependent genes and five genes not previously known to be NF-kappa B-dependent (Gro-beta and-gamma, I kappa B epsilon, interleukin (IL)-7R, and Naf-1) were used to determine whether they were directly or indirectly NF-kappa B regulated. Expression of constitutively active enhanced green fluorescent center dot NF-kappa B/Rel A fusion protein transactivated all but IL-6 and IL-7R in the absence of TNF stimulation. Moreover, TNF strongly induced all 12 genes in the absence of new protein synthesis. High probability NF-kappa B sites in novel genes were predicted by binding site analysis and confirmed by electrophoretic mobility shift assay. Chromatin immunoprecipitation assays show the endogenous I kappa B alpha/epsilon, Gro-beta/gamma, and Naf-1 promoters directly bound NF-kappa B/Rel A in TNF-stimulated cells. Together, these studies systematically identify the direct NF-kappa B-dependent gene network downstream of TNF signaling, extending our knowledge of biological processes regulated by this pathway.	Univ Texas, Med Branch, Div Endocrinol, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Med, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu		Brasier, Allan/0000-0002-5012-4090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40218] Funding Source: Medline; NIEHS NIH HHS [P30 ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BEUTLER B, 1995, J INVEST MED, V43, P227; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brasier AR, 2004, J VIROL, V78, P11461, DOI 10.1128/JVI.78.21.11461-11476.2004; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BRASIER AR, 1996, J HYPERTENS, V27, P465; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAN Y, 1997, J BIOL CHEM, V272, P9823; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Harant H, 2001, FEBS LETT, V509, P439, DOI 10.1016/S0014-5793(01)03138-6; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hromas R, 1997, BLOOD, V89, P3315; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jamaluddin M, 1998, J VIROL, V72, P4849, DOI 10.1128/JVI.72.6.4849-4857.1998; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lipniacki T, 2004, J THEOR BIOL, V228, P195, DOI 10.1016/j.jtbi.2004.01.001; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Phillips K, 2004, P NATL ACAD SCI USA, V101, P2011, DOI 10.1073/pnas.0400148101; Pickert L, 1998, BIOINFORMATICS, V14, P244, DOI 10.1093/bioinformatics/14.3.244; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ray S, 2004, J BIOL CHEM, V279, P35604, DOI 10.1074/jbc.M401851200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Thomas LH, 1998, J IMMUNOL, V161, P1007; Tian B, 2002, J VIROL, V76, P6800, DOI 10.1128/JVI.76.13.6800-6814.2002; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262; [No title captured]	75	191	200	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17435	17448		10.1074/jbc.M500437200	http://dx.doi.org/10.1074/jbc.M500437200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722553	hybrid			2022-12-27	WOS:000228615500110
J	Creagh, AL; Tiong, JWC; Tian, MM; Haynes, CA; Jefferies, WA				Creagh, AL; Tiong, JWC; Tian, MM; Haynes, CA; Jefferies, WA			Calorimetric studies of melanotransferrin (p97) and its interaction with iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; TERMINAL HALF-MOLECULE; HUMAN TRANSFERRIN; HYPOTRANSFERRINEMIC MICE; SCANNING CALORIMETRY; SERUM TRANSFERRIN; HUMAN MELANOMAS; FERRIC IONS; BOUND IRON; BINDING	The mammalian molecule melanotransferrin ( mTf), also called p97, is a member of the transferrin family of molecules. It exists in both secreted and glycosylphosphatidylinositol-anchored forms and is thought to play a role in angiogenesis and in transporting iron across the blood brain barrier. The binding affinity of iron to this molecule has not been formally established. Here, the binding of ferric ion ( chelated with a 2- fold molar ratio of nitrilotriacetate) to mTf has been studied using isothermal titration calorimetry and differential scanning calorimetry. One iron- binding site was determined for mTf with similar binding characteristics to other transferrins. In the absence of bicarbonate, binding occurs quickly with an apparent association constant of 2.6 x 10(7) M (-1) at 25 degrees C. The presence of bicarbonate introduces kinetic effects that prevent direct determination of the apparent binding constant by isothermal titration calorimetry. Differential scanning calorimetry thermograms of mTf unfolding in the presence and absence of iron were therefore used to determine the apparent binding constant in the bicarbonate- containing system; at pH 7.5 and 25 degrees C, iron binding occurs in a 1: 1 ratio with a K-app of 4.4 x 10(17) M-1. This affinity is intermediate between the high and low affinity lobes of transferrin and suggests that mTf is likely to play a significant role in iron transport where the high affinity lobe of transferrin is occupied or where transferrin is in proportionally low concentrations.	Univ British Columbia, Dept Microbiol & Immunol, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Biol & Chem Engn, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 East Mall, Vancouver, BC V6T 1Z3, Canada.	wilf@brc.ubc.ca						AISEN P, 1978, J BIOL CHEM, V253, P1930; ALEMANY R, 1993, J CELL SCI, V104, P1155; Andrews NC, 2000, ANNU REV GENOM HUM G, V1, P75, DOI 10.1146/annurev.genom.1.1.75; BAKER EN, 1992, FEBS LETT, V298, P215, DOI 10.1016/0014-5793(92)80060-T; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; BUYS SS, 1991, BLOOD, V78, P3288; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Creagh AL, 1998, BIOCHEMISTRY-US, V37, P3529, DOI 10.1021/bi971983o; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; GROSSMANN JG, 1993, J MOL BIOL, V231, P554, DOI 10.1006/jmbi.1993.1308; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1998, J CELL PHYSIOL, V177, P585, DOI 10.1002/(SICI)1097-4652(199812)177:4<585::AID-JCP9>3.3.CO;2-P; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; Kuser P, 2002, ACTA CRYSTALLOGR D, V58, P777, DOI 10.1107/S0907444902003724; LIN LN, 1993, BIOCHEMISTRY-US, V32, P9398, DOI 10.1021/bi00087a019; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; Martell A. E., 1974, CRITICAL STABILITY C; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Mcnamara L, 1999, J GASTROEN HEPATOL, V14, P126, DOI 10.1046/j.1440-1746.1999.01830.x; Moroo I, 2003, MICROCIRCULATION, V10, P457, DOI 10.1038/sj.mn.7800213; MOTEKAITIS RJ, 1994, J COORD CHEM, V31, P67, DOI 10.1080/00958979408022546; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; Takeda A, 1998, J NEUROSCI RES, V51, P454, DOI 10.1002/(SICI)1097-4547(19980215)51:4<454::AID-JNR5>3.0.CO;2-B; TIONG JWC, 2001, THESIS U BRIT COLUMB; Wessling-Resnick M, 2000, ANNU REV NUTR, V20, P129, DOI 10.1146/annurev.nutr.20.1.129; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183	37	19	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15735	15741		10.1074/jbc.M414650200	http://dx.doi.org/10.1074/jbc.M414650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705575	hybrid			2022-12-27	WOS:000228444800035
J	Jalota, A; Singh, K; Pavithra, L; Kaul-Ghanekar, R; Jameel, S; Chattopadhyay, S				Jalota, A; Singh, K; Pavithra, L; Kaul-Ghanekar, R; Jameel, S; Chattopadhyay, S			Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif (Publication with Expression of Concern. See vol. 294, pg. 17708, 2019) (Withdrawn Publication. See vol. 295, pg. 3390, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; POSTTRANSLATIONAL MODIFICATION; NEGATIVE REGULATORS; GENE-EXPRESSION; CDK INHIBITORS; NUCLEAR-MATRIX; REPLICATION; CANCER; REGION	Various stresses and DNA-damaging agents trigger transcriptional activity of p53 by post-translational modifications, making it a global regulatory switch that controls cell proliferation and apoptosis. Earlier we have shown that the novel MAR-associated protein SMAR1 interacts with p53. Here we delineate the minimal domain of SMAR1 ( the arginine-serine-rich domain) that is phosphorylated by protein kinase C family proteins and is responsible for p53 interaction, activation, and stabilization within the nucleus. SMAR1-mediated stabilization of p53 is brought about by inhibiting Mdm2-mediated degradation of p53. We also demonstrate that this arginine-serine (RS)-rich domain triggers the various cell cycle modulating proteins that decide cell fate. Furthermore, phenotypic knock-down experiments using small interfering RNA showed that SMAR1 is required for activation and nuclear retention of p53. The level of phosphorylated p53 was significantly increased in the thymus of SMAR1 transgenic mice, showing in vivo significance of SMAR1 expression. This is the first report that demonstrates the mechanism of action of the MAR-binding protein SMAR1 in modulating the activity of p53, often referred to as the "guardian of the genome."	Natl Ctr Cell Sci, Pune 11007, Maharashtra, India; Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Chattopadhyay, S (corresponding author), Natl Ctr Cell Sci, Pune Univ Campus, Pune 11007, Maharashtra, India.	samit@nccs.res.in						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Appella E, 2000, PATHOL BIOL, V48, P227; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Birot AM, 2000, GENE, V253, P189, DOI 10.1016/S0378-1119(00)00244-4; Chattopadhyay S, 2000, GENOMICS, V68, P93, DOI 10.1006/geno.2000.6279; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chattopadhyay S, 1998, J IMMUNOL, V160, P1256; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EL DW, 1993, CELL, V75, P817; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1993, CURR OPIN CELL BIOL, V6, P874; Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang M, 2001, ONCOGENE, V20, P5449, DOI 10.1038/sj.onc.1204705; KAUFMANN WK, 1995, CANCER RES, V55, P7; Kaul R, 2003, INT J CANCER, V103, P606, DOI 10.1002/ijc.10881; Kaul-Ghanekar R, 2004, NUCLEIC ACIDS RES, V32, P4862, DOI 10.1093/nar/gkh807; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu WM, 1999, CANCER RES, V59, P5695; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Mori Y, 1999, BRIT J CANCER, V80, P556, DOI 10.1038/sj.bjc.6690391; Muller BF, 1996, ONCOGENE, V12, P1941; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Powell JA, 2002, GENOMICS, V80, P303, DOI 10.1006/geno.2002.6828; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; RADFORD DM, 1995, CANCER RES, V55, P5180; Rampalli S, 2003, NUCLEIC ACIDS RES, V31, P3248, DOI 10.1093/nar/gkg410; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SIMONS AD, 1984, ARCH GEN PSYCHIAT, V41, P45; STEWART N, 1995, ONCOGENE, V10, P109; TUSDA H, 1994, CANCER RES, V54, P513; Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x; Wang X, 1999, INT J ONCOL, V14, P557; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yun CY, 2003, J BIOL CHEM, V278, P18050, DOI 10.1074/jbc.M211714200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	56	31	34	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16019	16029		10.1074/jbc.M413200200	http://dx.doi.org/10.1074/jbc.M413200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701641	hybrid			2022-12-27	WOS:000228444800069
J	Karaveg, K; Siriwardena, A; Tempel, W; Liu, ZJ; Glushka, J; Wang, BC; Moremen, KW				Karaveg, K; Siriwardena, A; Tempel, W; Liu, ZJ; Glushka, J; Wang, BC; Moremen, KW			Mechanism of class 1 (Glycosylhydrolase family 47) alpha-mannosidases involved in N-glycan processing and endoplasmic reticulum quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I ALPHA-1,2-MANNOSIDASE; CRYSTAL-STRUCTURE; MISFOLDED GLYCOPROTEINS; STRUCTURAL BASIS; PROTEIN; SUBSTRATE; CRYSTALLIZATION; GLYCOSIDASES; SPECIFICITY; CATALYSIS	Quality control in the endoplasmic reticulum ( ER) determines the fate of newly synthesized glycoproteins toward either correct folding or disposal by ER-associated degradation. Initiation of the disposal process involves selective trimming of N-glycans attached to misfolded glycoproteins by ER alpha-mannosidase I and subsequent recognition by the ER degradation-enhancing alpha-mannosidase-like protein family of lectins, both members of glycosylhydrolase family 47. The unusual inverting hydrolytic mechanism catalyzed by members of this family is investigated here by a combination of kinetic and binding analyses of wild type and mutant forms of human ER alpha-mannosidase I as well as by structural analysis of a co-complex with an uncleaved thiodisaccharide substrate analog. These data reveal the roles of potential catalytic acid and base residues and the identification of a novel S-3(1) sugar conformation for the bound substrate analog. The co-crystal structure described here, in combination with the C-1(4) conformation of a previously identified co-complex with the glycone mimic, 1-deoxymannojirimycin, indicates that glycoside bond cleavage proceeds through a least motion conformational twist of a properly predisposed substrate in the -1 subsite. A novel H-3(4) conformation is proposed as the exploded transition state.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Mississippi	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	moremen@uga.edu	Liu, Zhi-Jie/A-3946-2012; Moremen, Kelley/AAD-4661-2019	Liu, Zhi-Jie/0000-0001-7279-2893; 	NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; Cleland W W, 1979, Methods Enzymol, V63, P103; DArcy A, 1996, J CRYST GROWTH, V168, P175, DOI 10.1016/0022-0248(96)00351-X; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Deras IL, 1998, CARBOHYD RES, V306, P469; Deras IL, 2000, ANAL BIOCHEM, V278, P213, DOI 10.1006/abio.1999.4458; Evers DL, 1998, ANAL BIOCHEM, V265, P313, DOI 10.1006/abio.1998.2895; Golan G, 2004, J BIOL CHEM, V279, P3014, DOI 10.1074/jbc.M310098200; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guimaraes BG, 2002, J MOL BIOL, V320, P587, DOI 10.1016/S0022-2836(02)00497-7; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Johnston BD, 1998, CARBOHYD RES, V310, P17, DOI 10.1016/S0008-6215(98)00162-1; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; MAST SW, 2005, IN PRESS GLYCOBIOLOG; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miyake H, 2003, BIOCHEMISTRY-US, V42, P5574, DOI 10.1021/bi020712x; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; Mulakala C, 2002, PROTEINS, V49, P125, DOI 10.1002/prot.10206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; Rings S-M, 1980, EUR J BIOCHEM, V100, P295, DOI DOI 10.1111/J1432-1033.1980.TB04941.X; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Schlippe YVG, 2005, ARCH BIOCHEM BIOPHYS, V433, P266, DOI 10.1016/j.abb.2004.09.018; Stoddard J. F., 1971, STEREOCHEMISTRY CARB; Sutton C W, 1997, Methods Mol Biol, V64, P73; TAYLOR R, 1984, ACCOUNTS CHEM RES, V17, P320, DOI 10.1021/ar00105a004; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Winn MD, 2003, J SYNCHROTRON RADIAT, V10, P23, DOI 10.1107/S0909049502017235; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zechel DL, 2001, CURR OPIN CHEM BIOL, V5, P643, DOI 10.1016/S1367-5931(01)00260-5	56	93	95	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16197	16207		10.1074/jbc.M500119200	http://dx.doi.org/10.1074/jbc.M500119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713668	hybrid			2022-12-27	WOS:000228444800089
J	Schnizler, K; Saeger, B; Pfeffer, C; Gerbaulet, A; Ebbinghaus-Kintscher, U; Methfessel, C; Franken, EM; Raming, K; Wetzel, CH; Saras, A; Pusch, H; Hatt, H; Gisselmann, G				Schnizler, K; Saeger, B; Pfeffer, C; Gerbaulet, A; Ebbinghaus-Kintscher, U; Methfessel, C; Franken, EM; Raming, K; Wetzel, CH; Saras, A; Pusch, H; Hatt, H; Gisselmann, G			A novel chloride channel in Drosophila melanogaster is inhibited by protons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; RAT HIPPOCAMPAL SLICES; GATED ION CHANNELS; SENSORY NEURONS; GABA(A) RECEPTORS; XENOPUS-OOCYTES; EXTRACELLULAR PH; PHARMACOLOGICAL CHARACTERIZATION; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION	A systematic analysis of the Drosophila genome data reveals the existence of pHCl, a novel member of ligand-gated ion channel subunits. pHCl shows nearly identical similarity to glutamate-, glycine-, and histamine-gated ion channels, does however not belong to any of these ion channel types. We identified three different sites, where splicing generates multiple transcripts of the pHCl mRNA. The pHCl is expressed in Drosophila embryo, larvae, pupae, and the adult fly. In embryos, in situ hybridization detected pHCl in the neural cord and the hindgut. Functional expression of the three different splice variants of pHCl in oocytes of Xenopus laevis and Sf9 cells induces a chloride current with a linear current-voltage relationship that is inhibited by extracellular protons and activated by avermectins in a pH-dependent manner. Further, currents through pHCl channels were induced by a raise in temperature. Our data give genetic and electrophysiological evidence that pHCl is a member of a new branch of ligand-gated ion channels in invertebrates with, however, a hitherto unique combination of pharmacological and biophysical properties.	Bayer AG, Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany; Bayer AG, Bayer CropSci, D-40789 Mannheim, Germany; Ruhr Univ Bochum, Lehrstuhl Zellphysiol ND4, Fak Biol, D-44780 Bochum, Germany	Bayer AG; Bayer AG; Bayer CropScience; Ruhr University Bochum	Gisselmann, G (corresponding author), Bayer AG, Bayer Technol Serv GmbH, D-51368 Leverkusen, Germany.	guenter.gisselmann@rub.de	Wetzel, Christian/F-1366-2018; Wetzel, Christian/C-2501-2009; Wetzel, Christian H/N-9880-2017	Wetzel, Christian/0000-0002-5762-0003; Wetzel, Christian H/0000-0002-5762-0003				Ai T, 2004, MOL PHARMACOL, V65, P1415, DOI 10.1124/mol.65.6.1415; AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; BAKER MD, 1994, P ROY SOC B-BIOL SCI, V255, P259, DOI 10.1098/rspb.1994.0037; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; Bielefeldt K, 2000, NEUROSCIENCE, V101, P727, DOI 10.1016/S0306-4522(00)00375-4; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; CASTLE NA, 1992, CARDIOVASC RES, V26, P1137, DOI 10.1093/cvr/26.11.1137; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Cully DF, 1996, J BIOL CHEM, V271, P20187, DOI 10.1074/jbc.271.33.20187; DILGER JP, 1991, BIOCHIM BIOPHYS ACTA, V1063, P253, DOI 10.1016/0005-2736(91)90379-M; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FFRENCHMULLEN JMH, 1988, BRIT J PHARMACOL, V95, P753, DOI 10.1111/j.1476-5381.1988.tb11701.x; Fischer BS, 2001, J PHARMACOL EXP THER, V299, P238; Flemming R, 2003, BRIT J PHARMACOL, V139, P955, DOI 10.1038/sj.bjp.0705327; Gisselmann G, 2004, BRIT J PHARMACOL, V142, P409, DOI 10.1038/sj.bjp.0705818; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Gisselmann G, 2002, EUR J NEUROSCI, V16, P69, DOI 10.1046/j.1460-9568.2002.02070.x; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harrison JF, 2001, ANNU REV ENTOMOL, V46, P221, DOI 10.1146/annurev.ento.46.1.221; Hille B., 1992, ION CHANNELS EXCITAB, P51; KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3; KAILA K, 1992, NEUROREPORT, V3, P105, DOI 10.1097/00001756-199201000-00028; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEHL SJ, 1994, BRIT J PHARMACOL, V112, P616, DOI 10.1111/j.1476-5381.1994.tb13119.x; Kehoe J, 1998, J NEUROSCI, V18, P8198; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Krause RM, 1998, MOL PHARMACOL, V53, P283, DOI 10.1124/mol.53.2.283; Krishek BJ, 1996, J PHYSIOL-LONDON, V492, P431, DOI 10.1113/jphysiol.1996.sp021319; Krishek BJ, 2001, J PHYSIOL-LONDON, V530, P219, DOI 10.1111/j.1469-7793.2001.0219l.x; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; Kuenzi FM, 1996, BRIT J PHARMACOL, V119, P81, DOI 10.1111/j.1476-5381.1996.tb15680.x; Lankiewicz S, 1998, MOL PHARMACOL, V53, P202, DOI 10.1124/mol.53.2.202; Maksay G, 2003, NEUROPHARMACOLOGY, V44, P994, DOI 10.1016/S0028-3908(03)00116-3; Mozrzymas JW, 2003, J NEUROSCI, V23, P7981; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; PASTERNACK M, 1992, NEUROSCIENCE, V47, P921, DOI 10.1016/0306-4522(92)90040-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSEN M, 1987, PFLUG ARCH EUR J PHY, V409, P403, DOI 10.1007/BF00583794; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Rivera C, 2000, NEUROPHARMACOLOGY, V39, P977, DOI 10.1016/S0028-3908(99)00208-7; ROBELLO M, 1994, NEUROSCIENCE, V61, P833, DOI 10.1016/0306-4522(94)90406-5; Saeger B, 2001, FASEB J, V15, P1332, DOI 10.1096/fj.00-0664fje; Schnizler K, 2003, RECEPTOR CHANNEL, V9, P41, DOI 10.1080/10606820308253; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; Vyklicky L, 1999, J PHYSIOL-LONDON, V517, P181, DOI 10.1111/j.1469-7793.1999.0181z.x; Wegelius K, 1996, NEUROREPORT, V7, P2005, DOI 10.1097/00001756-199608120-00030; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Wilkins ME, 2002, J NEUROSCI, V22, P5328; Witte I, 2002, J NEUROCHEM, V83, P504, DOI 10.1046/j.1471-4159.2002.01076.x; Xue H, 1998, J MOL EVOL, V47, P323, DOI 10.1007/PL00006390; Zhai J, 1998, PFLUG ARCH EUR J PHY, V435, P539, DOI 10.1007/s004240050550; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zheng YC, 2002, J BIOL CHEM, V277, P2000, DOI 10.1074/jbc.M107635200	71	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16254	16262		10.1074/jbc.M411759200	http://dx.doi.org/10.1074/jbc.M411759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713676	hybrid			2022-12-27	WOS:000228444800095
J	Cam, JA; Zerbinatti, CV; Li, YH; Bu, GJ				Cam, JA; Zerbinatti, CV; Li, YH; Bu, GJ			Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; LIPID RAFTS; PEPTIDE; LRP; GENERATION; SIGNALS; FORMS; MODEL	The low density lipoprotein receptor-related protein (LRP) is a similar to 600-kDa multifunctional endocytic receptor that is highly expressed in the brain. LRP and its ligands apolipoprotein E, alpha 2-macroglobulin, and beta-amyloid precursor protein (APP), are genetically linked to Alzheimer disease and are found in characteristic plaque deposits in brains of patients with Alzheimer disease. To identify which extracellular domains of LRP interact with APP, we used minireceptors of each of the individual LRP ligand binding domains and assessed their ability to bind and degrade a soluble APP fragment. LRP minireceptors containing ligand binding domains II and IV, but not I or III, interacted with APP. To test whether APP trafficking is directly related to the rapid endocytosis of LRP, we generated stable Chinese hamster ovary cell lines expressing either a wild-type LRP minireceptor or its endocytosis mutants. Chinese hamster ovary cells stably expressing wild-type LRP minireceptor had less cell surface APP than pcDNA3 vector-transfected cells, whereas those stably expressing endocytosis-defective LRP minireceptors accumulated APP at the cell surface. We also found that the steady-state levels of the amyloid beta-peptides (A beta) is dictated by the relative expression levels of APP and LRP, probably reflecting the dual roles of LRP in both A beta production and clearance. Together, these data establish a relationship between LRP rapid endocytosis and APP trafficking and proteolytic processing to generate A beta.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [P50-AG05681] Funding Source: Medline; NINDS NIH HHS [NS41872] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cescato R, 2000, J NEUROCHEM, V74, P1131; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	34	77	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15464	15470		10.1074/jbc.M500613200	http://dx.doi.org/10.1074/jbc.M500613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705569	hybrid			2022-12-27	WOS:000228236800134
J	Fernandes, N; Sun, YL; Chen, SJ; Paul, P; Shaw, RJ; Cantley, LC; Price, BD				Fernandes, N; Sun, YL; Chen, SJ; Paul, P; Shaw, RJ; Cantley, LC; Price, BD			DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE SYNDROME GENE; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; IONIZING-RADIATION; FUNCTIONAL-LINK; KINASE; P53; ACTIVATION	The ATM protein kinase regulates the response of the cell to DNA damage by associating with and then phosphorylating proteins involved in cell cycle checkpoints and DNA repair. Here, we report on deletion studies designed to identify protein domains required for ATM to phosphorylate target proteins and to control cell survival following exposure to ionizing radiation. Deletion studies demonstrated that amino acids 1 - 150 of ATM were required for the ATM protein to regulate cellular radiosensitivity. Additional deletions and point mutations indicated that this domain extended from amino acids 81 - 106 of ATM, with amino acid substitutions located between amino acids 91 and 97 inactivating the functional activity of ATM. When ATM with mutations in this region ( termed ATM90) was expressed in AT cells, it was unable to restore normal radiosensitivity to the cells. However, ATM90 retained normal kinase activity and was autophosphorylated on serine 1981 following exposure to DNA damage. Furthermore, wild-type ATM displayed DNA-damage induced association with p53, brca1, and LKB1 in vivo, whereas ATM90 failed to form productive complexes with these target proteins either in vivo or in vitro. Furthermore, ATM90 did not phosphorylate p53 in vivo and did not form nuclear foci in response to ionizing radiation. We propose that amino acids 91 - 97 of ATM contain a protein interaction domain required for the DNA damage-induced association between ATM and its target proteins, including the brca1, p53, and LKB1 proteins. Furthermore, this domain of ATM is required for ATM to form nuclear foci following exposure to ionizing radiation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, JF513,44 Binney St, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA93602, CA64585] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064585, R01CA093602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bradbury JM, 2003, CURR BIOL, V13, pR468, DOI 10.1016/S0960-9822(03)00403-2; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Mochan TA, 2003, CANCER RES, V63, P8586; Price BD, 1996, CANCER RES, V56, P246; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	37	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15158	15164		10.1074/jbc.M412065200	http://dx.doi.org/10.1074/jbc.M412065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15713674	hybrid			2022-12-27	WOS:000228236800099
J	Iwakura, H; Hosoda, K; Son, C; Fujikura, J; Tomita, T; Noguchi, M; Ariyasu, H; Takaya, K; Masuzaki, H; Ogawa, Y; Hayashi, T; Inoue, G; Akamizu, T; Hosoda, H; Kojima, M; Itoh, H; Toytokuni, S; Kangawa, K; Nakao, K				Iwakura, H; Hosoda, K; Son, C; Fujikura, J; Tomita, T; Noguchi, M; Ariyasu, H; Takaya, K; Masuzaki, H; Ogawa, Y; Hayashi, T; Inoue, G; Akamizu, T; Hosoda, H; Kojima, M; Itoh, H; Toytokuni, S; Kangawa, K; Nakao, K			Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DES-ACYL GHRELIN; GROWTH-HORMONE SECRETAGOGUE; PANCREATIC-ISLET CELLS; GASTRIC-ACID-SECRETION; FOOD-INTAKE; BETA-CELLS; NONACYLATED GHRELIN; GH SECRETION; PEPTIDE; ENDOCRINE	We developed and analyzed two types of transgenic mice: rat insulin II promoter-ghrelin transgenic (RIP-G Tg) and rat glucagon promoter-ghrelin transgenic mice (RGP-G Tg). The pancreatic tissue ghrelin concentration measured by C-terminal radioimmuno-assay (RIA) and plasma desacyl ghrelin concentration ofRIP-G Tg were about 1000 and 3.4 times higher than those of nontransgenic littermates, respectively. The pancreatic tissue n-octanoylated ghrelin concentration measured by N-terminal RIA and plasma n-octanoylated ghrelin concentration of RIP-G Tg were not distinguishable from those of nontransgenic littermates. RIP-G Tg showed suppression of glucose-stimulated insulin secretion. Arginine-stimulated insulin secretion, pancreatic insulin mRNA and peptide levels, beta cell mass, islet architecture, and GLUT2 and PDX-1 immunoreactivity in RIP-G Tg pancreas were not significantly different from those of nontransgenic littermates. Islet batch incubation study did not show suppression of insulin secretion of RIP-G Tg in vitro. The insulin tolerance test showed lower tendency of blood glucose levels in RIP-G Tg. Taking lower tendency of triglyceride level of RIP-G Tg into consideration, these results may indicate that the suppression of insulin secretion is likely due to the effect of desacyl ghrelin on insulin sensitivity. RGP-G Tg, in which the pancreatic tissue ghrelin concentration measured by C-RIA was about 50 times higher than that of nontransgenic littermates, showed no significant changes in insulin secretion, glucose metabolism, islet mass, and islet architecture. The present study raises the possibility that desacyl ghrelin may have influence on glucose metabolism.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ Hosp, Translat Res Ctr, Kyoto 6068507, Japan; Kurume Univ, Inst Life Sci, Dept Mol Genet, Fukuoka 8390861, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan	Kyoto University; Kyoto University; Kyoto University; Kurume University; National Cerebral & Cardiovascular Center - Japan	Hosoda, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	kh@kuhp.kyoto-u.ac.jp	Toyokuni, Shinya/C-1358-2010; Fujikura, Junji/AAR-2684-2020; Toyokuni, Shinya/ABE-7714-2021	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Akamizu, Takashi/0000-0003-4960-8271; Iwakura, Hiroshi/0000-0001-8033-0736; Ogawa, Yoshihiro/0000-0002-0834-2836; hayashi, Tatsuya/0000-0001-7600-4735				Adeghate E, 2002, J NEUROENDOCRINOL, V14, P555, DOI 10.1046/j.1365-2826.2002.00811.x; Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Arvat E, 2000, J ENDOCRINOL INVEST, V23, P493, DOI 10.1007/BF03343763; Asakawa A, 2005, GUT, V54, P18, DOI 10.1136/gut.2004.038737; Asakawa A, 2001, NEUROENDOCRINOLOGY, V74, P143, DOI 10.1159/000054680; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Broglio F, 2003, J CLIN ENDOCR METAB, V88, P4268, DOI 10.1210/jc.2002-021940; Broglio F, 2003, J ENDOCRINOL INVEST, V26, P192, DOI 10.1007/BF03345156; Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003-031964; Broglio F, 2001, J CLIN ENDOCR METAB, V86, P5083, DOI 10.1210/jc.86.10.5083; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; Date Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/en.141.11.4255; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; Date Y, 2001, BIOCHEM BIOPH RES CO, V280, P904, DOI 10.1006/bbrc.2000.4212; Dheen ST, 1997, J ENDOCRINOL, V155, P551, DOI 10.1677/joe.0.1550551; Egido EM, 2002, EUR J ENDOCRINOL, V146, P241, DOI 10.1530/eje.0.1460241; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; Gauna C, 2004, J CLIN ENDOCR METAB, V89, P5035, DOI 10.1210/jc.2004-0363; Gauna C, 2005, J CLIN ENDOCR METAB, V90, P1055, DOI 10.1210/jc.2004-1069; GILON P, 1992, J BIOL CHEM, V267, P20713; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; GUZ Y, 1995, DEVELOPMENT, V121, P11; Herrera PL, 2002, ENDOCRINE, V19, P267, DOI 10.1385/ENDO:19:3:267; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Iwakura H, 2002, J CLIN ENDOCR METAB, V87, P4885, DOI 10.1210/jc.2002-020882; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korbonits M, 2001, ENDOCRINE, V14, P101, DOI 10.1385/ENDO:14:1:101; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; Masuda Y, 2000, BIOCHEM BIOPH RES CO, V276, P905, DOI 10.1006/bbrc.2000.3568; Mori K, 2000, FEBS LETT, V486, P213, DOI 10.1016/S0014-5793(00)02308-5; Murakami N, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740283; Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Petrik J, 1999, ENDOCRINOLOGY, V140, P2353, DOI 10.1210/en.140.5.2353; Porter SE, 1998, ENDOCRINOLOGY, V139, P3743, DOI 10.1210/en.139.9.3743; Prado CL, 2004, P NATL ACAD SCI USA, V101, P2924, DOI 10.1073/pnas.0308604100; Reimer MK, 2003, ENDOCRINOLOGY, V144, P916, DOI 10.1210/en.2002-220819; Salehi A, 2004, REGUL PEPTIDES, V118, P143, DOI 10.1016/j.regpep.2003.12.001; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; Seoane LM, 2000, EUR J ENDOCRINOL, V143, pR7, DOI 10.1530/eje.0.143R007; Shintani M, 2001, DIABETES, V50, P227, DOI 10.2337/diabetes.50.2.227; Smith PA, 1997, J PHYSIOL-LONDON, V499, P625, DOI 10.1113/jphysiol.1997.sp021955; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908; Tena-Sempere M, 2002, ENDOCRINOLOGY, V143, P717, DOI 10.1210/en.143.2.717; Thompson NM, 2004, ENDOCRINOLOGY, V145, P234, DOI 10.1210/en.2003-0899; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Volante M, 2002, J CLIN ENDOCR METAB, V87, P1300, DOI 10.1210/jc.87.3.1300; WEINHAUS AJ, 1995, DIABETES, V44, P118, DOI 10.2337/diabetes.44.1.118; Wierup N, 2004, J HISTOCHEM CYTOCHEM, V52, P301, DOI 10.1177/002215540405200301; Wierup N, 2002, REGUL PEPTIDES, V107, P63, DOI 10.1016/S0167-0115(02)00067-8; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325	55	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15247	15256		10.1074/jbc.M411358200	http://dx.doi.org/10.1074/jbc.M411358200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701644	hybrid			2022-12-27	WOS:000228236800110
J	Lu, GM; Chhum, S; Krishnaswamy, S				Lu, GM; Chhum, S; Krishnaswamy, S			The affinity of protein C for the thrombin center dot thrombomodulin complex is determined in a primary way by active site-dependent interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR SUBSTRATE RECOGNITION; EXTRINSIC XASE COMPLEX; FACTOR-X; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; SERINE PROTEASES; STRUCTURAL BASIS; ACTIVATION; BINDING; SPECIFICITY	The interaction of thrombin (IIa) with thrombomodulin (TM) is essential for the efficient activation of protein C (PC). Interactions between PC and extended surfaces, likely contributed by TM within the IIa.TM complex, have been proposed to play a key role in PC activation. Initial velocities of PC activation at different concentrations of PC and TM could be accounted for by a model that did not require consideration of direct binding interactions between PC and TM. Reversible inhibitors directed toward the active site of IIa within the IIa.TM complex behaved as classic competitive inhibitors of both peptidyl substrate cleavage as well as PC activation. The ability of these small molecule inhibitors to block PC binding to the enzyme points to a principal role for active site-dependent substrate recognition in determining the affinity of IIa.TM for its protein substrate. Selective abrogation of active site docking by mutation of the P1 Arg in PC to Gln yielded an uncleavable derivative (PCR15Q). PCR15Q was a poor inhibitor (K-i >= 30 mu M) of PC activation as well as peptidyl substrate cleavage by IIa.TM. Thus, inhibition by PCR15Q most likely results from its ability to weakly interfere with active site function rather than by blocking extended interactions with the enzyme complex. The data suggest a primary role for active site-dependent substrate recognition in driving the affinity of the IIa.TM complex for its protein substrate. Interactions between PC and extended surfaces contributed by IIa and/or TM within the IIa.TM complex likely contribute in a secondary or minor way to protein substrate affinity.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, R01HL047465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-74124, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1993, ANNU REV CELL BIOL, V9, P1; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FERSHT A, 1977, ENZYME STRUCTURE MEC, P84; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KLEIN JD, 1986, BIOCHEMISTRY-US, V25, P4175, DOI 10.1021/bi00363a001; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023	56	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15471	15478		10.1074/jbc.M500881200	http://dx.doi.org/10.1074/jbc.M500881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705565	hybrid			2022-12-27	WOS:000228236800135
J	Sadagurski, M; Weingarten, G; Rhodes, CJ; White, MF; Wertheimer, E				Sadagurski, M; Weingarten, G; Rhodes, CJ; White, MF; Wertheimer, E			Insulin receptor substrate 2 plays diverse cell-specific roles in the regulation of glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; SKIN COMPLICATIONS; SKELETAL-MUSCLE; RESISTANCE; BETA; DIFFERENTIATION; TRANSDUCTION; ACTIVATION	The insulin receptor substrate 2 (IRS-2) protein is one of the major insulin-signaling substrates. In the present study, we investigated the role of IRS-2 in skin epidermal keratinocytes and dermal fibroblasts. Although skin is not a classical insulin target tissue, we have previously demonstrated that insulin, via the insulin receptor, is essential for normal skin cell physiology. To identify the role of IRS-2 in skin cells, we studied cells isolated from IRS-2 knock-out ( KO) mice. Whereas proliferation and differentiation were not affected in the IRS-2 KO cells, a striking effect was observed on glucose transport. In IRS-2 KO keratinocytes, the lack of IRS-2 resulted in a dramatic increase in basal and insulin-stimulated glucose transport. The increase in glucose transport was associated with an increase in total phosphatidylinositol ( PI) 3-kinase and Akt activation. In contrast, fibroblasts lacking IRS-2 exhibited a significant decrease in basal and insulin- induced glucose transport. We identified the point of divergence, leading to these differences between keratinocytes and fibroblasts, at the IRS-PI3- kinase association step. In epidermal keratinocytes, PI 3-kinase is associated with and activated by only the IRS-1 protein. On the other hand, in dermal fibroblasts, PI 3-kinase is exclusively associated with and activated by the IRS-2 protein. These observations suggest that IRS-2 functions as a negative or positive regulator of glucose transport in a cell-specific manner. Our results also show that IRS-2 function depends on its cell-specific association with PI 3-kinase.	Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; Pacific NW Res Inst, Seattle, WA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Div Endocrinol, Boston, MA 02115 USA	Tel Aviv University; Sackler Faculty of Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Wertheimer, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel.	effy@patholog.tau.ac.il						Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Cushman SW, 1998, ADV EXP MED BIOL, V441, P63; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Friedman JE, 1999, DIABETES, V48, P1807, DOI 10.2337/diabetes.48.9.1807; Furtado LM, 2002, BIOCHEM CELL BIOL, V80, P569, DOI 10.1139/O02-156; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laviola L, 2001, DIABETES, V50, P2709, DOI 10.2337/diabetes.50.12.2709; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Li L, 2004, J BIOL CHEM, V279, P34107, DOI 10.1074/jbc.M312672200; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Shao JH, 2002, DIABETES, V51, P19, DOI 10.2337/diabetes.51.1.19; Spravchikov N, 2001, DIABETES, V50, P1627, DOI 10.2337/diabetes.50.7.1627; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WERTHEIMER E, 1994, J BIOL CHEM, V269, P7587; Wertheimer E, 2000, J INVEST DERMATOL, V115, P24, DOI 10.1046/j.1523-1747.2000.00008.x; Wertheimer E, 2004, ISR MED ASSOC J, V6, P287; WERTHEIMER E, 1990, J CELL PHYSIOL, V143, P330, DOI 10.1002/jcp.1041430217; Wertheimer E, 2001, ENDOCRINOLOGY, V142, P1234, DOI 10.1210/en.142.3.1234; Wertheimer E., 2004, DIABETES MELLITUS, P1411; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	36	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14536	14544		10.1074/jbc.M410227200	http://dx.doi.org/10.1074/jbc.M410227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705592	hybrid			2022-12-27	WOS:000228236800025
J	Hay, E; Faucheu, C; Suc-Royer, I; Touitou, R; Stiot, V; Vayssiere, B; Baron, R; Roman-Roman, S; Rawadi, G				Hay, E; Faucheu, C; Suc-Royer, I; Touitou, R; Stiot, V; Vayssiere, B; Baron, R; Roman-Roman, S; Rawadi, G			Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SIGNALING PATHWAY; BETA-CATENIN; XENOPUS DEVELOPMENT; RECEPTOR; AXIN; PROTEIN; DICKKOPF-1; MECHANISM; GBP	Low density lipoprotein receptor-related protein 5 (LRP5) has been identified as a Wnt co-receptor involved in the activation of the beta-catenin signaling pathway. To improve our understanding of the molecular mechanisms by which LRP5 triggers the canonical Wnt signaling cascade, we have screened for potential partners of LRP5 using the yeast two-hybrid system and identified Frat1 as a protein interacting with the cytoplasmic domain of LRP5. We demonstrate here that LRP5/Frat1 interaction is involved in beta-catenin nuclear translocation and TCF-1 transcriptional activation. The addition of Wnt3a or overexpression of constitutively active truncated LRP5 (LRP5C) induces Frat1 recruitment to the cell membrane. Overexpression of a dominant negative form of disheveled (Dvl) shows that this protein positively affects LRP5/Frat1 interaction. Furthermore, the fact that dominant negative Dvl does not interfere with LRP5C/Frat1 interaction can explain how LRP5C is capable of acting independently of this major Wnt signaling player. Axin, which has been shown to interact with LRP5 and to be recruited to the membrane through this interaction, was found to co-immunoprecipitate with Frat1 and LRP5. We propose that recruitment of Axin and Frat1 to the membrane by LRP5 leads to both Axin degradation and Frat1-mediated inhibition of glycogen synthase kinase-3. As a consequence, beta-catenin is no longer bound to Axin or phosphorylated by glycogen synthase kinase-3, resulting in TCF-1 activation.	Proskelia Pharmaceut, F-93230 Romainville, France		Rawadi, G (corresponding author), Proskelia Pharmaceut, 102 Route Noisy, F-93230 Romainville, France.	georges.rawadi@prostrakan.com	Roman-Roman, Sergio/K-9993-2014	Roman-Roman, Sergio/0000-0001-6459-2613; Rawadi, Georges/0000-0003-4735-2188; Hay, Eric/0000-0002-0131-9983				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Garcia T, 2002, BONE, V31, P205, DOI 10.1016/S8756-3282(02)00781-0; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Jossin Y, 2003, CEREB CORTEX, V13, P627, DOI 10.1093/cercor/13.6.627; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibamoto S, 1998, GENES CELLS, V3, P659; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	36	58	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13616	13623		10.1074/jbc.M411999200	http://dx.doi.org/10.1074/jbc.M411999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699046	hybrid			2022-12-27	WOS:000228095500055
J	Schulz, JM; Ross, KL; Malmstrom, K; Krieger, M; Fridovich-Keil, JL				Schulz, JM; Ross, KL; Malmstrom, K; Krieger, M; Fridovich-Keil, JL			Mediators of galactose sensitivity in UDP-galactose 4 '-epimerase-impaired mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; LOW-DENSITY-LIPOPROTEIN; DIPHOSPHATE GALACTOSE-4-EPIMERASE DEFICIENCY; HUMAN UDP-GALACTOSE-4-EPIMERASE; SACCHAROMYCES-CEREVISIAE; N-ACETYLGLUCOSAMINE; LELOIR PATHWAY; EXPRESSION; 4-EPIMERASE; PATIENT	UDP-galactose 4'-epimerase (GALE) catalyzes the final step in the Leloir pathway of galactose metabolism, interconverting UDP-galactose and UDP-glucose. Unlike its Escherichia coli counterpart, mammalian GALE also interconverts UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine. Considering the key roles played by all four of these UDP-sugars in glycosylation, human GALE therefore not only contributes to the Leloir pathway, but also functions as a gatekeeper overseeing the ratios of important substrate pools required for the synthesis of glycosylated macromolecules. Defects in human GALE result in the disorder epimerase-deficiency galactosemia. To explore the relationship among GALE activity, substrate specificity, metabolic balance, and galactose sensitivity in mammalian cells, we employed a previously described GALE-null line of Chinese hamster ovary cells, ldlD. Using a transfection protocol, we generated ldlD derivative cell lines that expressed different levels of wild-type human GALE or E. coli GALE and compared the phenotypes and metabolic profiles of these lines cultured in the presence versus absence of galactose. We found that GALE-null cells accumulated abnormally high levels of Gal-1-P and UDP-Gal and abnormally low levels of UDP-Glc and UDP-GlcNAc in the presence of galactose and that human GALE expression corrected each of these defects. Comparing the human GALE- and E. coli GALE- expressing cells, we found that although GALE activity toward both substrates was required to restore metabolic balance, UDPGalNAc activity was not required for cell proliferation in the presence of otherwise cytostatic concentrations of galactose. Finally, we found that uridine supplementation, which essentially corrected UDP-Glc and, to a lesser extent UDP-GlcNAc depletion, enabled ldlD cells to proliferate in the presence of galactose despite the continued accumulation of Gal-1-P and UDP-Gal. These data offer important insights into the mechanism of galactose sensitivity in epimerase-impaired cells and suggest a potential novel therapy for patients with epimerase-deficiency galactosemia.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Emory University; Emory University; Massachusetts Institute of Technology (MIT)	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 325-2 Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	jfridov@emory.edu						Alano A, 1998, J INHERIT METAB DIS, V21, P341, DOI 10.1023/A:1005342306080; Berry GT, 2000, PEDIATR RES, V48, P323, DOI 10.1203/00006450-200009000-00010; Berry GT, 2001, MOL GENET METAB, V72, P316, DOI 10.1006/mgme.2001.3151; DOUGLAS HC, 1964, GENETICS, V49, P837; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Henderson JM, 2001, CLIN GENET, V60, P350, DOI 10.1034/j.1399-0004.2001.600505.x; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; HOLTON JB, 1981, ARCH DIS CHILD, V56, P885, DOI 10.1136/adc.56.11.885; ISSELBACHER KJ, 1957, SCIENCE, V126, P652, DOI 10.1126/science.126.3275.652-a; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; KEPPLER DOR, 1974, J BIOL CHEM, V249, P211; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, NEW ENGL J MED, V314, P1257; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; Krieger M, 1986, Methods Enzymol, V129, P227; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; Lai K, 2003, GLYCOBIOLOGY, V13, P285, DOI 10.1093/glycob/cwg033; Leslie ND, 2001, MOL GENET METAB, V72, P31, DOI 10.1006/mgme.2000.3116; Mehta DV, 1999, BBA-MOL BASIS DIS, V1454, P217, DOI 10.1016/S0925-4439(99)00037-X; PILLER F, 1983, J BIOL CHEM, V258, P774; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Riehman K, 2001, J BIOL CHEM, V276, P10634, DOI 10.1074/jbc.M009583200; Ross KL, 2004, MOL GENET METAB, V83, P103, DOI 10.1016/j.ymgme.2004.07.005; SARDHARWALLA IB, 1988, J INHERIT METAB DIS, V11, P249, DOI 10.1007/BF01804249; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; SEGAL S, 1995, EUR J PEDIATR, V154, pS65, DOI 10.1007/BF02143806; SEGAL S, 1995, METABOLIC MOL BASIS, V7, P967; Shin YS, 2000, J INHERIT METAB DIS, V23, P383, DOI 10.1023/A:1005699719068; Smits HP, 1998, ANAL BIOCHEM, V261, P36, DOI 10.1006/abio.1998.2714; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Walter JH, 1999, ARCH DIS CHILD, V80, P374, DOI 10.1136/adc.80.4.374; Wasilenko J, 2005, MOL GENET METAB, V84, P32, DOI 10.1016/j.ymgme.2004.09.003; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	39	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13493	13502		10.1074/jbc.M414045200	http://dx.doi.org/10.1074/jbc.M414045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701638	hybrid			2022-12-27	WOS:000228095500040
J	Tsuji, T; Kunieda, T				Tsuji, T; Kunieda, T			A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; CN-CN MICE; ENDOCHONDRAL OSSIFICATION; GROWTH-PLATE; ACROMESOMELIC DYSPLASIA; GUANYLATE-CYCLASE; SKELETAL GROWTH; MESSENGER-RNA; CARTILAGE; CHONDROCYTES	The achondroplastic mouse is a spontaneous mutant characterized by disproportionate dwarfism with short limbs and tail due to disturbed chondrogenesis during endochondral ossification. These abnormal phenotypes are controlled by an autosomal recessive gene (cn). In this study, linkage analysis using 115 affected mice of F-2 progeny mapped the cn locus on an similar to 0.8-cM region of chromosome 4, and natriuretic peptide receptor 2 (Npr2) gene was identified as the most potent candidate for the cn mutant in this region. This gene encodes a receptor for C-type natriuretic peptide (CNP) that positively regulates longitudinal bone growth by producing cGMP in response to CNP binding to the extracellular domain. Sequence analyses of the Npr2 gene in cn/cn mice revealed a T to G transversion leading to the amino acid substitution of highly conserved Leu with Arg in the guanylyl cyclase domain. In cultured chondrocytes of cn/cn mice, stimulus with CNP did not significantly increase intracellular cGMP concentration, whereas it increased in +/+ mice. Transfection of the mutant Npr2 gene into COS-7 cells also showed similar results, indicating that the missense mutation of the Npr2 gene in cn/cn mice resulted in disruption of the guanylyl cyclase activity of the receptor. We therefore concluded that the dwarf phenotype of cn/cn mouse is caused by a loss-of-function mutation of the Npr2 gene, and cn/cn mouse will be a useful model to further study the molecular mechanism regulating endochondral ossification by CNP/natriuretic peptide receptor B signal.	Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan	Okayama University	Tsuji, T (corresponding author), Okayama Univ, Grad Sch Nat Sci & Technol, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	takehito@cc.okayama-u.ac.jp						Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013; Cameron VA, 2003, ENDOCRINOLOGY, V144, P2191, DOI 10.1210/en.2003-0127; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Cohen MM, 2002, AM J MED GENET, V112, P304, DOI 10.1002/ajmg.10780; DELMARCO A, 1981, REPROD NUTR DEV, V21, P1025, DOI 10.1051/rnd:19810715; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; JOHNSON DR, 1978, J ANAT, V125, P267; LANE PW, 1968, J HERED, V59, P300, DOI 10.1093/oxfordjournals.jhered.a107725; LANGER LO, 1980, RADIOLOGY, V137, P349, DOI 10.1148/radiology.137.2.7433666; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Levin ER, 1998, NEW ENGL J MED, V339, P321; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MAROTEAUX P, 1971, PRESSE MED, V79, P1839; Mericq V, 2000, PEDIATR RES, V47, P189, DOI 10.1203/00006450-200002000-00007; Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002-220307; Naski MC, 1998, DEVELOPMENT, V125, P4977; Newman B, 2003, CLIN GENET, V63, P241, DOI 10.1034/j.1399-0004.2003.00046.x; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; SANNASGALA SSMMK, 1990, J ANAT, V172, P245; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SILBERBERG R, 1975, GROWTH, V39, P17; Stepan H, 2000, REGUL PEPTIDES, V95, P81, DOI 10.1016/S0167-0115(00)00141-5; Suda M, 2002, J BONE MINER METAB, V20, P136, DOI 10.1007/s007740200019; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THURSTON MN, 1985, J ANAT, V140, P425; Tokudome T, 2004, ENDOCRINOLOGY, V145, P2131, DOI 10.1210/en.2003-1260; WIKSTROM B, 1986, COLLAGEN REL RES, V6, P279; Yamashita Y, 2000, J BIOCHEM-TOKYO, V127, P177, DOI 10.1093/oxfordjournals.jbchem.a022591; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695	34	102	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14288	14292		10.1074/jbc.C500024200	http://dx.doi.org/10.1074/jbc.C500024200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15722353	hybrid			2022-12-27	WOS:000228095500132
J	Prakash, P; Pathak, N; Hasnain, SE				Prakash, P; Pathak, N; Hasnain, SE			pheA (Rv3838c) of Mycobacterium tuberculosis encodes an allosterically regulated monofunctional prephenate dehydratase that requires both catalytic and regulatory domains for optimum activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORISMATE MUTASE; ESCHERICHIA-COLI; DEHYDROGENASE; BIOSYNTHESIS; GROWTH; ACID; IDER	Prephenate dehydratase (PDT) is a key regulatory enzyme in L-phenylalanine biosynthesis. In Mycobacterium tuberculosis, expression of pheA, the gene encoding PDT, has been earlier reported to be iron-dependent ( 1, 2). We report that M. tuberculosis pheA is also regulated at the protein level by aromatic amino acids. All of the three aromatic amino acids (phenylalanine, tyrosine, and tryptophan) are potent allosteric activators of M. tuberculosis PDT. We also provide in vitro evidence that M. tuberculosis PDT does not possess any chorismate mutase activity, which suggests that, unlike many other enteric bacteria (where PDT exists as a fusion protein with chorismate mutase), M. tuberculosis PDT is a monofunctional and a non-fusion protein. Finally, the biochemical and biophysical properties of the catalytic and regulatory domains (ACT domain) of M. tuberculosis PDT were studied to observe that, in the absence of the ACT domain, the enzyme not only loses its regulatory activity but also its catalytic activity. These novel results provide evidence for a monofunctional prephenate dehydratase enzyme from a pathogenic bacterium that exhibits extensive allosteric activation by aromatic amino acids and is absolutely dependent upon the presence of catalytic as well as the regulatory domains for optimum enzyme activity.	Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Hasnain, SE (corresponding author), Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India.	hasnain@cdfd.org.in	HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; Bange FC, 1996, INFECT IMMUN, V64, P1794, DOI 10.1128/IAI.64.5.1794-1799.1996; Chen SQ, 2003, EUR J BIOCHEM, V270, P757, DOI 10.1046/j.1432-1033.2003.03438.x; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; DAVIDSON BE, 1987, METHOD ENZYMOL, V142, P440; FISCHER R, 1987, METHOD ENZYMOL, V142, P507; FRIEDRICH B, 1976, J BACTERIOL, V126, P712, DOI 10.1128/JB.126.2.712-722.1976; GETHING MJH, 1977, EUR J BIOCHEM, V78, P111, DOI 10.1111/j.1432-1033.1977.tb11719.x; Gold B, 2001, MOL MICROBIOL, V42, P851, DOI 10.1046/j.1365-2958.2001.02684.x; GORCHAN BG, 2002, INFECT IMMUN, V7, P3080; Parish T, 2002, MICROBIOL-SGM, V148, P3069, DOI 10.1099/00221287-148-10-3069; PITTARD AJ, 1987, CELLULAR MOL BIOL, P368; Pohnert G, 1999, BIOCHEMISTRY-US, V38, P12212, DOI 10.1021/bi991134w; Prakash P, 2005, J BIOL CHEM, V280, P19641, DOI 10.1074/jbc.M413026200; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Zhang S, 1998, J BIOL CHEM, V273, P6248, DOI 10.1074/jbc.273.11.6248	19	17	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20666	20671		10.1074/jbc.M502107200	http://dx.doi.org/10.1074/jbc.M502107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15753077	hybrid			2022-12-27	WOS:000229242000064
J	Hitomi, K; Oyama, T; Han, SG; Arvai, AS; Getzoff, ED				Hitomi, K; Oyama, T; Han, SG; Arvai, AS; Getzoff, ED			Tetrameric architecture of the circadian clock protein KaiB - A novel interface for intermolecular interactions and its impact on the circadian rhythm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-ELONGATUS; CRYSTAL-STRUCTURE; HISTIDINE KINASE; CYANOBACTERIA; SASA; SYSTEM; OSCILLATION; MECHANISM; EVOLUTION; BACTERIA	Cyanobacteria are among the simplest organisms that show daily rhythmicity. Their circadian rhythms consist of the localization, interaction, and accumulation of various proteins, including KaiA, KaiB, KaiC, and SasA. We have determined the 1.9-angstrom resolution crystallographic structure of the cyanobacterial KaiB clock protein from Synechocystis sp. PCC6803. This homotetrameric structure reveals a novel KaiB interface for protein-protein interaction; the protruding hydrophobic helix-turn-helix motif of one subunit fits into a groove between two beta-strands of the adjacent subunit. A cyanobacterial mutant, in which the Asp-Lys salt bridge mediating this tetramer-forming interaction is disrupted by mutation of Asp to Gly, exhibits severely impaired rhythmicity (a short free-running period; similar to 19 h). The KaiB tetramer forms an open square, with positively charged residues around the perimeter. KaiB is localized on the phospholipid-rich membrane and translocates to the cytosol to interact with the other Kai components, KaiA and KaiC. KaiB antagonizes the action of KaiA on KaiC, and shares a sequence-homologous domain with the SasA kinase. Based on our structure, we discuss functional roles for KaiB in the circadian clock.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Japan Sci & Technol Agcy, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Scripps Research Institute; Scripps Research Institute; Japan Science & Technology Agency (JST)	Oyama, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furu Cho, Nagoya, Aichi 4648602, Japan.	oyama@bio.nagoya-u.ac.jp; edg@scripps.edu			NIGMS NIH HHS [R01 GM37684] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037684] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ditty JL, 2003, ANNU REV GENET, V37, P513, DOI 10.1146/annurev.genet.37.110801.142716; Dvornyk V, 2004, MOL BIOL EVOL, V21, P1468, DOI 10.1093/molbev/msh106; Dvornyk V, 2003, P NATL ACAD SCI USA, V100, P2495, DOI 10.1073/pnas.0130099100; Garces RG, 2004, EMBO J, V23, P1688, DOI 10.1038/sj.emboj.7600190; Golden SS, 2003, NAT REV MICROBIOL, V1, P191, DOI 10.1038/nrmicro774; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; Golden SS, 2003, CURR OPIN MICROBIOL, V6, P535, DOI 10.1016/j.mib.2003.10.012; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Iwase R, 2004, ACTA CRYSTALLOGR D, V60, P727, DOI 10.1107/S0907444904002112; Johnson CH, 2004, NATURE, V430, P23, DOI 10.1038/430023a; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; Klewer DA, 2002, J BIOMOL NMR, V24, P77, DOI 10.1023/A:1020649703380; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Vakonakis I, 2004, J MOL BIOL, V342, P9, DOI 10.1016/j.jmb.2004.07.010; Vakonakis L, 2004, P NATL ACAD SCI USA, V101, P1479, DOI 10.1073/pnas.0305516101; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Ye S, 2004, J BIOL CHEM, V279, P20511, DOI 10.1074/jbc.M400077200	29	72	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19127	19135		10.1074/jbc.M411284200	http://dx.doi.org/10.1074/jbc.M411284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15716274	hybrid			2022-12-27	WOS:000228932300069
J	Sato, K; Crowley, PB; Dennison, C				Sato, K; Crowley, PB; Dennison, C			Transient homodimer interactions studied using the electron self-exchange reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; CYTOCHROME-F; PROTEIN COMPLEXES; PHOTOSYSTEM-I; DRYOPTERIS-CRASSIRHIZOMA; REDUCED PLASTOCYANIN; ANABAENA-VARIABILIS; COPPER PROTEINS; BINDING-SITE; ACIDIC PATCH	Transient homodimer protein interactions have been investigated by analyzing the influence of ionic strength (NaCl) on the electron self-exchange (the bimolecular reaction whereby the two oxidation states of a redox protein interconvert) rate constant (k(ese)) of four plastocyanins. The k(ese) values for the plastocyanins from spinach, Dryopteris crassirhizoma (a fern), and the green alga Ulva pertusa, which possess acidic patches of varying size and locations, increase 190-, 29-, and 21-fold, respectively, at elevated ionic strength (I = 2.03 M). In contrast, the k(ese) for the almost neutral cyanobacterial plastocyanin from Anabaena variabilis exhibits very little dependence on ionic strength. The temperature dependence of the k(ese) for spinach plastocyanin (I = 0.28 M) provides evidence for poor packing at the homodimer interface. Representative structures of the transient homodimers involved in electron self-exchange, which are consistent with fits of the ionic strength dependence of k(ese) to van Leeuwen theory, have been obtained from protein modeling and docking simulations. The Coulombic energy of the docked homodimers follows the order spinach > D. crassirhizoma > U. pertusa > A. variabilis, which matches that of the overall influence of ionic strength on k(ese). Analysis of the homodimer structures indicates that poor packing and high planarity are features of the interface that favor transient interactions. The physiologically relevant Mg2+ ion has a much more pronounced influence on the k(ese) of spinach plastocyanin, which along with the known properties of the thylakoid lumen suggests a biological role for electron self-exchange.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Universidade Nova de Lisboa; Newcastle University - UK	Crowley, PB (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Da Republ,Apartado 127, P-2781901 Oeiras, Portugal.	crowley@itqb.unl.pt; christopher.dennison@ncl.ac.uk	Crowley, Peter B./A-7822-2013	Dennison, Christopher/0000-0001-8665-052X; Crowley, Peter/0000-0002-5365-0096				ANDREW SM, 1993, J AM CHEM SOC, V115, P5516, DOI 10.1021/ja00066a020; ARMSTRONG FA, 1985, FEBS LETT, V190, P242, DOI 10.1016/0014-5793(85)81292-8; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; Bond CS, 2001, J MOL BIOL, V306, P47, DOI 10.1006/jmbi.2000.4201; Bork P, 2004, CURR OPIN STRUC BIOL, V14, P292, DOI 10.1016/j.sbi.2004.05.003; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carrell CJ, 2004, BIOCHEMISTRY-US, V43, P9372, DOI 10.1021/bi049634z; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Crowley PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/ar0200955; Crowley PB, 2004, BIOCHEM J, V378, P45, DOI 10.1042/BJ20031423; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Crowley PB, 2004, PROTEINS, V55, P603, DOI 10.1002/prot.20043; De Rienzo F, 2000, PROTEIN SCI, V9, P1439, DOI 10.1110/ps.9.8.1439; DENNISON C, 1993, J CHEM SOC DALTON, P1959, DOI 10.1039/dt9930001959; Dennison C, 2002, BIOCHEMISTRY-US, V41, P552, DOI 10.1021/bi011514t; DIXON DW, 1990, J AM CHEM SOC, V112, P1082, DOI 10.1021/ja00159a030; Gavin AC, 2003, CURR OPIN CHEM BIOL, V7, P21, DOI 10.1016/S1367-5931(02)00007-8; Henrick K, 1998, TRENDS BIOCHEM SCI, V23, P358, DOI 10.1016/S0968-0004(98)01253-5; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Impagliazzo A, 2004, J AM CHEM SOC, V126, P5658, DOI 10.1021/ja049619h; Inoue T, 1999, BIOCHEMISTRY-US, V38, P13853, DOI 10.1021/bi990502t; Kanbi LD, 2002, J MOL BIOL, V320, P263, DOI 10.1016/S0022-2836(02)00443-6; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leigh R. A., 1986, Advances in Plant Nutrition, V2, P249; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; Nersissian AM, 2002, ADV PROTEIN CHEM, V60, P271; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Sato K, 2004, J AM CHEM SOC, V126, P3028, DOI 10.1021/ja038188k; Sato K, 2003, J AM CHEM SOC, V125, P2101, DOI 10.1021/ja021005u; Schlarb-Ridley BG, 2002, BIOCHEMISTRY-US, V41, P3279, DOI 10.1021/bi0116588; Schottler MA, 2004, PLANT PHYSIOL, V136, P4265, DOI 10.1104/pp.104.052324; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; Shibata N, 1999, J BIOL CHEM, V274, P4225, DOI 10.1074/jbc.274.7.4225; SOLA M, 1989, J AM CHEM SOC, V111, P6627, DOI 10.1021/ja00199a023; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Sugawara H, 1999, J BIOCHEM-TOKYO, V125, P899, DOI 10.1093/oxfordjournals.jbchem.a022366; Thompson JD, 2000, NUCLEIC ACIDS RES, V28, P2919, DOI 10.1093/nar/28.15.2919; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; van Amsterdam IMC, 2002, NAT STRUCT BIOL, V9, P48, DOI 10.1038/nsb736; VANDEKAMP M, 1990, J AM CHEM SOC, V112, P907, DOI 10.1021/ja00158a082; VANLEEUWEN JW, 1983, BIOCHIM BIOPHYS ACTA, V743, P408, DOI 10.1016/0167-4838(83)90400-4; Xue YF, 1998, PROTEIN SCI, V7, P2099, DOI 10.1002/pro.5560071006	58	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19281	19288		10.1074/jbc.M500842200	http://dx.doi.org/10.1074/jbc.M500842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743773	hybrid			2022-12-27	WOS:000228932300085
J	Nogami, K; Zhou, Q; Myles, T; Leung, LLK; Wakabayashi, H; Fay, PJ				Nogami, K; Zhou, Q; Myles, T; Leung, LLK; Wakabayashi, H; Fay, PJ			Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VIII; VON-WILLEBRAND-FACTOR; HUMAN-FACTOR-V; FACTOR XA; LIGHT-CHAIN; ALPHA-THROMBIN; BINDING-SITE; ACTIVE SITE; NA+ BINDING; PROTEIN-C	Thrombin catalyzes the proteolytic activation of factor VIII, cleaving two sites in the heavy chain and one site in the light chain of the procofactor. Evaluation of thrombin binding the reaction products from heavy chain cleavage by steady state fluorescence energy transfer using a fluorophore-labeled, active site-modified thrombin as well as by solid phase binding assays using a thrombin Ser(205) --> Ala mutant indicated a high affinity site in the A1 subunit ( K-d 5 nM) that was dependent upon the Na+-bound form of thrombin, whereas a moderate affinity site in the A2 subunit (K-d similar to 100 nM) was observed for both Na+-bound and - free forms. The solid phase assay also indicated that hirudin blocked thrombin interaction with the A1 subunit and had little, if any, effect on its interaction with the A2 subunit. Conversely, heparin blocked thrombin interaction with the A2 subunit and showed a marginal effect on A1 binding. Evaluation of the A2 sequence revealed two regions rich in acidic residues that are localized close to the N and C termini of this domain. Peptides encompassing these clustered acidic regions, residues 373 - 395 and 719 - 740, blocked thrombin cleavage of the isolated heavy chain at Arg(372) and Arg(740) and inhibited A2 binding to thrombin Ser(205) --> Ala, suggesting that both A2 domain regions potentially support interaction with thrombin. A B-domainless, factor VIII double mutant Asp(392) --> Ala/ Asp(394) --> Ala was constructed, expressed, and purified and possessed specific activity equivalent to a severe hemophilia phenotype. This mutant was resistant to cleavage at Arg(740), whereas cleavage at Arg(372) was not affected. These data suggest the acidic region comprising residues 389 - 394 in factor VIII A2 domain interacts with thrombin via its heparin-binding exosite and facilitates cleavage at Arg(740) during procofactor activation.	Univ Rochester, Sch Med & Dent, Dept Biochem, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biophys, Rochester, NY 14642 USA; Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA	University of Rochester; University of Rochester; Stanford University	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NHLBI NIH HHS [HL 76213, HL 38199, HL 57530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, R01HL076213, R01HL057530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHTON RW, 1995, BIOCHEMISTRY-US, V34, P6454, DOI 10.1021/bi00019a027; AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BARROW RT, 1994, J BIOL CHEM, V269, P593; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BINNIE CG, 1993, BLOOD, V81, P3186; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CONERY BG, 1983, BIOCHEMISTRY-US, V22, P369, DOI 10.1021/bi00271a021; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Donath MJSH, 1996, EUR J BIOCHEM, V240, P365, DOI 10.1111/j.1432-1033.1996.0365h.x; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; Hosokawa K, 2001, BIOCHEM J, V354, P309, DOI 10.1042/0264-6021:3540309; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kjalke M, 1995, EUR J BIOCHEM, V234, P773, DOI 10.1111/j.1432-1033.1995.773_a.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MCMULLEN BA, 1995, PROTEIN SCI, V4, P740; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NASKI MC, 1990, J BIOL CHEM, V265, P13484; Nogami K, 2004, J BIOL CHEM, V279, P33104, DOI 10.1074/jbc.M405537200; Nogami K, 2000, J BIOL CHEM, V275, P25774, DOI 10.1074/jbc.M002007200; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 2004, J BIOL CHEM, V279, P15763, DOI 10.1074/jbc.M400568200; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Singh LS, 2003, J BIOL CHEM, V278, P28335, DOI 10.1074/jbc.M300233200; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Voorberg J, 1996, J BIOL CHEM, V271, P20985, DOI 10.1074/jbc.271.35.20985; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	64	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18476	18487		10.1074/jbc.M412778200	http://dx.doi.org/10.1074/jbc.M412778200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746105	hybrid			2022-12-27	WOS:000228807200111
J	Coustou, V; Besteiro, S; Riviere, L; Biran, M; Biteau, N; Franconi, JM; Boshart, M; Baltz, T; Bringaud, F				Coustou, V; Besteiro, S; Riviere, L; Biran, M; Biteau, N; Franconi, JM; Boshart, M; Baltz, T; Bringaud, F			A mitochondrial NADH-dependent fumarate reductase involved in the production of succinate excreted by procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SUBSTRATE LEVEL PHOSPHORYLATION; MOLECULAR CHARACTERIZATION; ENERGY-METABOLISM; CARBOHYDRATE-METABOLISM; INTERFERENCE RNAI; COA-TRANSFERASE; GLYCEROL KINASE; DEHYDROGENASE; CRUZI	Trypanosoma brucei is a parasitic protist responsible for sleeping sickness in humans. The procyclic stage of T. brucei expresses a soluble NADH-dependent fumarate reductase (FRDg) in the peroxisome-like organelles called glycosomes. This enzyme is responsible for the production of about 70% of the excreted succinate, the major end product of glucose metabolism in this form of the parasite. Here we functionally characterize a new gene encoding FRD (FRDm1) expressed in the procyclic stage. FRDm1 is a mitochondrial protein, as evidenced by immunolocalization, fractionation of digitonin-permeabilized cells, and expression of EGFP-tagged FRDm1 in the parasite. RNA interference was used to deplete FRDm1, FRDg, or both together. The analysis of the resulting mutant cell lines showed that FRDm1 is responsible for 30% of the cellular NADH-FRD activity, which solves a long standing debate regarding the existence of a mitochondrial FRD in trypanosomatids. FRDg and FRDm1 together account for the total NADH-FRD activity in procyclics, because no activity was measured in the double mutant lacking expression of both proteins. Analysis of the end products of C-13-enriched glucose excreted by these mutant cell lines showed that FRDm1 contributes to the production of between 14 and 44% of the succinate excreted by the wild type cells. In addition, depletion of one or both FRD enzymes results in up to 2-fold reduction of the rate of glucose consumption. We propose that FRDm1 is involved in the maintenance of the redox balance in the mitochondrion, as proposed for the ancestral soluble FRD presumably present in primitive anaerobic cells.	Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; University of Munich	Bringaud, F (corresponding author), Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Besteiro, Sébastien/F-3622-2014; Boshart, Michael/A-2700-2011	Besteiro, Sébastien/0000-0003-1853-1494; Boshart, Michael/0000-0002-5070-2663; Biteau, Nicolas/0000-0003-1301-0665				Arikawa Y, 1998, FEMS MICROBIOL LETT, V165, P111, DOI 10.1111/j.1574-6968.1998.tb13134.x; Bastin P, 2000, J CELL SCI, V113, P3321; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; BESTEIRO S, 2005, IN PRESS TRENDS PARA; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Chen M, 2001, APMIS, V109, P801, DOI 10.1034/j.1600-0463.2001.091201.x; Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001; Christmas PB, 2000, FEMS MICROBIOL LETT, V183, P225, DOI 10.1111/j.1574-6968.2000.tb08962.x; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DaRocha WD, 2004, MOL BIOCHEM PARASIT, V133, P175, DOI 10.1016/j.molbiopara.2003.10.005; Denicola A, 2002, COMP BIOCHEM PHYS B, V133, P23, DOI 10.1016/S1096-4959(02)00094-5; DENICOLASEOANE A, 1992, MOL BIOCHEM PARASIT, V54, P43, DOI 10.1016/0166-6851(92)90093-Y; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fang J, 2002, BIOCHEMISTRY-US, V41, P3065, DOI 10.1021/bi015989w; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; HAMMOND DJ, 1980, MOL BIOCHEM PARASIT, V2, P77, DOI 10.1016/0166-6851(80)90033-X; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Harlow E., 1988, ANTIBODIES LAB MANUA; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Marche S, 2000, MOL BIOCHEM PARASIT, V106, P83, DOI 10.1016/S0166-6851(99)00204-2; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; MURATSUBAKI H, 1994, PREP BIOCHEM, V24, P289, DOI 10.1080/10826069408010100; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Obungu VH, 1999, INDIAN J BIOCHEM BIO, V36, P305; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; PEALING SL, 1992, BIOCHEMISTRY-US, V31, P12132, DOI 10.1021/bi00163a023; Riviere L, 2004, J BIOL CHEM, V279, P45337, DOI 10.1074/jbc.M407513200; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON L, 1972, INT REV CYTOL, V32, P139, DOI 10.1016/S0074-7696(08)60340-X; Takashima E, 2002, MOL BIOCHEM PARASIT, V122, P189, DOI 10.1016/S0166-6851(02)00100-7; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Tielens AGM, 1999, PARASITOL TODAY, V15, P347, DOI 10.1016/S0169-4758(99)01480-5; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	59	70	80	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16559	16570		10.1074/jbc.M500343200	http://dx.doi.org/10.1074/jbc.M500343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718239	hybrid			2022-12-27	WOS:000228615500005
J	Hee Ryu, OK; Choi, SJ; Firatli, E; Choi, SW; Hart, PS; Shen, RF; Wang, GH; Wu, WW; Hart, TC				Hee Ryu, OK; Choi, SJ; Firatli, E; Choi, SW; Hart, PS; Shen, RF; Wang, GH; Wu, WW; Hart, TC			Proteolysis of macrophage inflammatory protein-1 alpha isoforms LD78 beta and LD78 alpha by neutrophil-derived serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CC CHEMOKINES; ALPHA; MIP-1-ALPHA; MIP-1-BETA; EXPRESSION; IDENTIFICATION; INACTIVATION; CYTOKINE; RESIDUES	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a chemokine that leads to leukocyte recruitment and activation at sites of infection. Controlling chemokine activity at sites of infection is important, since excess accumulation of leukocytes may contribute to localized tissue damage. Neutrophil-derived serine proteases modulate the bioactivity of chemokine and cytokine networks through proteolytic cleavage. Because MIP-1 alpha is temporally expressed with neutrophils at sites of infection, we examined proteolysis of MIP-1 alpha in vitro by the neutrophil-derived serine proteases: cathepsin G, elastase, and proteinase 3. Recombinant human MIP-1 alpha isoforms LD78 beta and LD78 alpha were expressed and purified, and the protease cleavage sites were analyzed by mass spectrometry and peptide sequencing. Chemotactic activities of parent and cleavage molecules were also compared. Both LD78 beta and LD78 alpha were cleaved by neutrophil lysates at Thr(16)- Ser(17), Phe(24)- Ile(25), Tyr(28)- Phe(29), and Thr(31)-Ser(32). This degradation was inhibited by serine protease inhibitors phenylmethylsulfonyl fluoride and 4-(2-aminoethyl)-benzenesulfonyl fluoride. Incubation of the substrates with individual proteases revealed that cathepsin G preferentially cleaved at Phe24- Ile25 and Tyr28- Phe29, whereas elastase and proteinase 3 cleaved at Thr(16)- Ser(17) and Thr(31)- Ser(32). Proteolysis of LD78 beta resulted in loss of chemotactic activity. The role of these proteases in LD78 beta and LD78 alpha degradation was confirmed by incubation with neutrophil lysates from Papillon-Lefevre syndrome patients, demonstrating that the cell lysates containing inactivated serine proteases could not degrade LD78 beta and LD78 alpha. These findings suggest that severe periodontal tissue destruction in Papillon-Lefevre syndrome may be related to excess accumulation of LD78 beta and LD78 alpha and dysregulation of the microbial-induced inflammatory response in the periodontium.	NIDCR, Human Craniofacial Genet Sect, NIH, Bethesda, MD 20892 USA; Istanbul Univ, Sch Dent, Dept Periodontol, TR-34390 Istanbul, Turkey; NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA; NHLBI, Proteom Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Istanbul University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hart, TC (corresponding author), 10 Ctr Dr,Bldg 10,Rm 5-2531, Bethesda, MD 20892 USA.	thart@mail.nih.gov	FIRATLI, Erhan/AAS-6413-2020; FIRATLI, Erhan/E-4241-2013; Fıratlı, Sönmez/AAC-4795-2020	FIRATLI, Erhan/0000-0002-4154-6929; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000711, Z01DE000711] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; BLACK RA, 1988, J BIOL CHEM, V263, P9437; Choi SJ, 2000, BLOOD, V96, P671; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; de Haar Susanne F, 2004, Hum Mutat, V23, P524, DOI 10.1002/humu.9243; GANZ T, 1998, J CLIN INVEST, V85, P552; Gemmell E, 2001, CLIN EXP IMMUNOL, V125, P134, DOI 10.1046/j.1365-2249.2001.01511.x; Haringman JJ, 2004, ANN RHEUM DIS, V63, P1186, DOI 10.1136/ard.2004.020529; Hart PS, 2000, J MED GENET, V37, P927, DOI 10.1136/jmg.37.12.927; Hirashima M, 1992, DNA Seq, V3, P203, DOI 10.3109/10425179209034019; HIROAKI K, 2002, CYTOKINE, V20, P70; HYUN J, 2002, J ENDODONT, V28, P754; John AE, 2003, SARCOIDOSIS VASC DIF, V20, P180; KASAMA T, 1993, J EXP MED, V178, P63, DOI 10.1084/jem.178.1.63; Kim S, 2001, BIOCHEMISTRY-US, V40, P10782, DOI 10.1021/bi011065x; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; Leavell KJ, 1997, J LEUKOCYTE BIOL, V61, P361, DOI 10.1002/jlb.61.3.361; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x; Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; *MIAM VALL LAB PRO, 1994, EXP LUNG RES, V20, P473; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Patel DD, 2001, CLIN IMMUNOL, V98, P39, DOI 10.1006/clim.2000.4957; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCUDERI P, 1991, CELL IMMUNOL, V135, P299, DOI 10.1016/0008-8749(91)90275-G; STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852; VANKESSEL KPM, 1991, J IMMUNOL, V147, P3862; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Wolf M, 2003, AM J PATHOL, V162, P1183, DOI 10.1016/S0002-9440(10)63914-4; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516; YANLING J, 1999, J PERIODONTOL, V70, P1472	37	40	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17415	17421		10.1074/jbc.M500340200	http://dx.doi.org/10.1074/jbc.M500340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728180	hybrid			2022-12-27	WOS:000228615500107
J	Voisin, S; Houliston, RS; Kelly, J; Brisson, JR; Watson, D; Bardy, SL; Jarrell, KF; Logan, SM				Voisin, S; Houliston, RS; Kelly, J; Brisson, JR; Watson, D; Bardy, SL; Jarrell, KF; Logan, SM			Identification and characterization of the unique N-linked glycan common to the flagellins and S-layer glycoprotein of Methanococcus voltae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-JEJUNI; PLASMA-MEMBRANE; CAPSULAR POLYSACCHARIDE; PROTEIN GLYCOSYLATION; ARCHAEAL FLAGELLUM; ESCHERICHIA-COLI; TRANSLOCATION; BIOSYNTHESIS; BACTERIA; ACID	The flagellum of Methanococcus voltae is composed of four structural flagellin proteins FlaA, FlaB1, FlaB2, and FlaB3. These proteins possess a total of 15 potential N-linked sequons (NX(S/T)) and show a mass shift on an SDS-polyacrylamide gel indicating significant posttranslational modification. We describe here the structural characterization of the flagellin glycan from M. voltae using mass spectrometry to examine the proteolytic digests of the flagellin proteins in combination with NMR analysis of the purified glycan using a sensitive, cryogenically cooled probe. Nano-liquid chromatography-tandem mass spectrometry analysis of the proteolytic digests of the flagellin proteins revealed that they are post-translationally modified with a novel N-linked trisaccharide of mass 779 Da that is composed of three sugar residues with masses of 318, 258, and 203 Da, respectively. In every instance the glycan is attached to the peptide through the asparagine residue of a typical N-linked sequon. The glycan modification has been observed on 14 of the 15 sequon sites present on the four flagellin structural proteins. The novel glycan structure elucidated by NMR analysis was shown to be a trisaccharide composed of beta-ManpNAcA6Thr-(1 - 4)-beta-Glc-pNAc3NAcA( 1 - 3)-beta-GlcpNAc linked to Asn. In addition, the same trisaccharide was identified on a tryptic peptide of the S-layer protein from this organism implicating a common N-linked glycosylation pathway.	CNR, Inst Biol Sci, Ottawa, ON K1A OR6, Canada; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	National Research Council Canada; Queens University - Canada	Logan, SM (corresponding author), CNR, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A OR6, Canada.	susan.logan@nrc-cnrc.gc.ca		Voisin, Sebastien/0000-0001-5897-333X				Bardy S, 2004, J MOL MICROB BIOTECH, V7, P41, DOI 10.1159/000077868; Bardy SL, 2003, MOL MICROBIOL, V50, P1339, DOI 10.1046/j.1365-2958.2003.03758.x; Bardy SL, 2002, J BACTERIOL, V184, P5223, DOI 10.1128/JB.184.19.5223-5233.2002; BASU S, 1987, EUR J BIOCHEM, V162, P75, DOI 10.1111/j.1432-1033.1987.tb10544.x; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; BEYNON LM, 1990, CARBOHYD RES, V205, P347, DOI 10.1016/0008-6215(90)80152-S; BRANEFORSHELANDER P, 1981, CARBOHYD RES, V97, P285, DOI 10.1016/S0008-6215(00)80674-6; Brisson JR, 2002, CAN J CHEM, V80, P949, DOI 10.1139/V02-114; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Correia JD, 2000, J BACTERIOL, V182, P855, DOI 10.1128/JB.182.3.855-858.2000; DILL K, 1979, FEBS LETT, V107, P26, DOI 10.1016/0014-5793(79)80454-8; Eichler J, 2003, MICROBIOL-SGM, V149, P3347, DOI 10.1099/mic.0.26591-0; Eichler J, 2001, EUR J BIOCHEM, V268, P4366, DOI 10.1046/j.1432-1327.2001.02361.x; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; FAGUY DM, 1994, CAN J MICROBIOL, V40, P67, DOI 10.1139/m94-011; Faguy DM, 1996, J BACTERIOL, V178, P902, DOI 10.1128/jb.178.3.902-905.1996; Hashimoto M, 2003, EUR J BIOCHEM, V270, P2671, DOI 10.1046/j.1432-1033.2003.03644.x; KALMOKOFF ML, 1988, J BACTERIOL, V170, P1752, DOI 10.1128/jb.170.4.1752-1758.1988; KOVAL SF, 1987, J BACTERIOL, V169, P1298, DOI 10.1128/jb.169.3.1298-1306.1987; LECHNER J, 1985, J BIOL CHEM, V260, P860; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; MESSNER P, 2002, PROGR CHEM ORGANIC N, P51; Perepelov AV, 2000, J CHEM SOC PERK T 1, P363, DOI 10.1039/a908141k; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Rademaker G J, 1996, Methods Mol Biol, V61, P231; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; Schaffer C, 2004, GLYCOBIOLOGY, V14, p31R, DOI 10.1093/glycob/cwh064; Schirm M, 2004, J BACTERIOL, V186, P6721, DOI 10.1128/JB.186.20.6721-6727.2004; Schirm M, 2004, J BACTERIOL, V186, P2523, DOI 10.1128/JB.186.9.2523-2531.2004; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; SHASHKOV AS, 1995, CARBOHYD RES, V269, P157, DOI 10.1016/0008-6215(94)00351-F; Spiro R G, 1973, Adv Protein Chem, V27, P349, DOI 10.1016/S0065-3233(08)60451-9; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; SUMPER M, 1987, BIOCHIM BIOPHYS ACTA, V906, P69, DOI 10.1016/0304-4157(87)90005-0; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Thomas NA, 2001, FEMS MICROBIOL REV, V25, P147, DOI 10.1016/S0168-6445(00)00061-9; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Upreti RK, 2003, PROTEOMICS, V3, P363, DOI 10.1002/pmic.200390052; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Ventosa A, 1996, INT J SYST BACTERIOL, V46, P347, DOI 10.1099/00207713-46-1-347; Vinogradov E, 2005, CARBOHYD RES, V340, P85, DOI 10.1016/j.carres.2004.10.015; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1980, FEBS LETT, V120, P110, DOI 10.1016/0014-5793(80)81058-1; YANG LL, 1979, BIOCHIM BIOPHYS ACTA, V556, P265, DOI 10.1016/0005-2736(79)90047-6; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	46	117	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16586	16593		10.1074/jbc.M500329200	http://dx.doi.org/10.1074/jbc.M500329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723834	hybrid			2022-12-27	WOS:000228615500008
J	Brady, KL; Setzer, DR				Brady, KL; Setzer, DR			Is there a dynamic DNA-protein interface in the transcription factor IIIA-5 S rRNA gene complex?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL ZINC FINGERS; INTERNAL CONTROL REGION; 5S RNA; CRYSTAL-STRUCTURE; RECOGNITION; BINDING; TFIIIA; OOCYTES	Others ( Foster, M. P., Wuttke, D. S., Radhakrishnan, I., Case, D. A., Gottesfeld, J. M., and Wright, P. E. ( 1997) Nat. Struct. Biol. 4, 605 - 608; Wuttke, D. S., Foster, M. P., Case, D. A., Gottesfeld, J. M., and Wright, P. E. ( 1997) J. Mol. Biol. 273, 183 - 206) have proposed that several amino acid side chains exhibit considerable conformational mobility at the DNA-protein interface in the transcription factor IIIA center dot 5 S rRNA gene complex and that the rapid movements of these side chains permit them to make fluctuating contacts with adjacent bp in the DNA target site. This "dynamic interface" model makes biochemical predictions concerning the consequences of truncating specific amino acid side chains and the effects of these truncations on sequence selectivity in DNA binding. The model also makes predictions concerning the effects of DNA sequence context on the apparent energetic contributions to binding made by individual bp. We have tested these predictions, and our results are inconsistent with any significant energetic role being played by the contact of multiple bp by conformationally mobile amino acid side chains. They do, however, show that some individual amino acids affect the recognition of multiple bp through mechanisms other than direct interaction.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of Missouri System; University of Missouri Columbia; Case Western Reserve University	Setzer, DR (corresponding author), Univ Missouri, Div Biol Sci, 410 Tucker Hall, Columbia, MO 65211 USA.	setzerd@missouri.edu			NIGMS NIH HHS [GM48035] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; Kehres DG, 1997, J BIOL CHEM, V272, P20152, DOI 10.1074/jbc.272.32.20152; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RAWLINGS SL, 1996, J BIOL CHEM, V271, P868; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; Setzer DR, 1996, RNA, V2, P1254; SETZER DR, 1990, NUCLEIC ACIDS RES, V18, P4175, DOI 10.1093/nar/18.14.4175; Tsui V, 2000, J MOL BIOL, V302, P1101, DOI 10.1006/jmbi.2000.4108; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	25	2	2	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16115	16124		10.1074/jbc.M414660200	http://dx.doi.org/10.1074/jbc.M414660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713659	hybrid			2022-12-27	WOS:000228444800079
J	Joerger, AC; Ang, HC; Veprintsev, DB; Blair, CM; Fersht, AR				Joerger, AC; Ang, HC; Veprintsev, DB; Blair, CM; Fersht, AR			Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; CORE DOMAIN; 53BP1; MOLSCRIPT; PEPTIDE; SITE	We have solved the crystal structures of three oncogenic mutants of the core domain of the human tumor suppressor p53. The mutations were introduced into a stabilized variant. The cancer hot spot mutation R273H simply removes an arginine involved in DNA binding without causing structural distortions in neighboring residues. In contrast, the "structural" oncogenic mutations H168R and R249S induce substantial structural perturbation around the mutation site in the L2 and L3 loops, respectively. H168R is a specific intragenic suppressor mutation for R249S. When both cancer mutations are combined in the same molecule, Arg(168) mimics the role of Arg(249) in wild type, and the wild type conformation is largely restored in both loops. Our structural and biophysical data provide compelling evidence for the mechanism of rescue of mutant p53 by intragenic suppressor mutations and reveal features by which proteins can adapt to deleterious mutations.	MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge	Fersht, AR (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008; Veprintsev, Dmitry B/H-2228-2012	Veprintsev, Dmitry B/0000-0002-3583-5409; Joerger, Andreas/0000-0002-1232-0138				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baroni TE, 2004, P NATL ACAD SCI USA, V101, P4930, DOI 10.1073/pnas.0401162101; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 2000, ADV CANCER RES, V77, P81; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Turk D., 1992, THESIS TU MUNCHEN GE; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	34	130	133	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16030	16037		10.1074/jbc.M500179200	http://dx.doi.org/10.1074/jbc.M500179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703170	hybrid			2022-12-27	WOS:000228444800070
J	Komar, AA; Gross, SR; Barth-Baus, D; Strachan, R; Hensold, JO; Kinzy, TG; Merrick, WC				Komar, AA; Gross, SR; Barth-Baus, D; Strachan, R; Hensold, JO; Kinzy, TG; Merrick, WC			Novel characteristics of the biological properties of the yeast Saccharomyces cerevisiae eukaryotic initiation factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; MESSENGER-RNA; PURIFICATION; COMPLEX; OVEREXPRESSION; IDENTIFICATION; EXPRESSION; PREFOLDIN; SEQUENCES	Eukaryotic initiation factor 2A (eIF2A) has been shown to direct binding of the initiator methionyl-tRNA (Met-tRNA(i)) to 40 S ribosomal subunits in a codon-dependent manner, in contrast to eIF2, which requires GTP but not the AUG codon to bind initiator tRNA to 40 S subunits. We show here that yeast eIF2A genetically interacts with initiation factor eIF4E, suggesting that both proteins function in the same pathway. The double eIF2A/eIF4E-ts mutant strain displays a severe slow growth phenotype, which correlated with the accumulation of 85% of the double mutant cells arrested at the G(2)/M border. These cells also exhibited a disorganized actin cytoskeleton and elevated actin levels, suggesting that eIF2A might be involved in controlling the expression of genes involved in morphogenic processes. Further insights into eIF2A function were gained from the studies of eIF2A distribution in ribosomal fractions obtained from either an eIF5B Delta (fun12 Delta) strain or a eIF3b-ts (prt1-1) strain. It was found that the binding of eIF2A to 40 and 80 S ribosomes was not impaired in either strain. We also found that eIF2A functions as a suppressor of Ure2p internal ribosome entry site-mediated translation in yeast cells. The regulation of expression from the URE2 internal ribosome entry site appears to be through the levels of eIF2A protein, which has been found to be inherently unstable with a half-life of similar to 17 min. It was hypothesized that this instability allows for translational control through the level of eIF2A protein in yeast cells.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	wcm2@cwru.edu		Komar, Anton/0000-0003-4188-0633; gross, stephane/0000-0002-0867-8866; Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068079, R01GM026796, R01GM062789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43414] Funding Source: Medline; NIGMS NIH HHS [GM62789, GM26796, GM68079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; Altmann M, 1997, METHODS, V11, P343, DOI 10.1006/meth.1996.0432; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Benne R, 1979, Methods Enzymol, V60, P15; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; *CLONT, 2001, YEAST PROT HDB; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Danaie P, 1999, BIOCHEM J, V340, P135, DOI 10.1042/0264-6021:3400135; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DRUBIN DG, 2000, CELL POLARITY; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GUPTA NK, 1973, J BIOL CHEM, V248, P4500; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HINCK AP, 1993, PROTEIN ENG, V6, P221, DOI 10.1093/protein/6.2.221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Komar AA, 2003, EMBO J, V22, P1199, DOI 10.1093/emboj/cdg103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DH, 1973, P NATL ACAD SCI USA, V70, P41, DOI 10.1073/pnas.70.1.41; LIU HP, 1992, GENETICS, V132, P665; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Majumdar A, 1979, Methods Enzymol, V60, P35; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1975, J BIOL CHEM, V250, P1197; MUELLER PP, 1987, P NATL ACAD SCI USA, V84, P2863, DOI 10.1073/pnas.84.9.2863; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Norden C, 2004, MOL MICROBIOL, V53, P469, DOI 10.1111/j.1365-2958.2004.04148.x; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rose MD., 1990, METHODS YEAST GENETI; Saito TL, 2004, NUCLEIC ACIDS RES, V32, pD319, DOI 10.1093/nar/gkh113; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schneider BL, 1998, NATURE, V395, P86, DOI 10.1038/25774; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Staehelin T, 1979, Methods Enzymol, V60, P136; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zoll WL, 2002, J BIOL CHEM, V277, P37079, DOI 10.1074/jbc.M207109200	59	39	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15601	15611		10.1074/jbc.M413728200	http://dx.doi.org/10.1074/jbc.M413728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718232	hybrid, Green Accepted			2022-12-27	WOS:000228444800019
J	Martic, G; Karetsou, Z; Kefala, K; Politou, AS; Clapier, CR; Straub, T; Papamarcaki, T				Martic, G; Karetsou, Z; Kefala, K; Politou, AS; Clapier, CR; Straub, T; Papamarcaki, T			Parathymosin affects the binding of linker histone H1 to nucleosomes and remodels chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN2+-BINDING PROTEIN PARATHYMOSIN; PROTHYMOSIN-ALPHA; IN-VIVO; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; GENE-EXPRESSION; CORE PARTICLE; DNA; TRANSCRIPTION; SEQUENCE	Linker histone H1 is the major factor that stabilizes higher order chromatin structure and modulates the action of chromatin-remodeling enzymes. We have previously shown that parathymosin, an acidic, nuclear protein binds to histone H1 in vitro and in vivo. Confocal laser scanning microscopy reveals a nuclear punctuate staining of the endogenous protein in interphase cells, which is excluded from dense heterochromatic regions. Using an in vitro chromatin reconstitution system under physiological conditions, we show here that parathymosin (ParaT) inhibits the binding of H1 to chromatin in a dose-dependent manner. Consistent with these findings, H1-containing chromatin assembled in the presence of ParaT has reduced nucleosome spacing. These observations suggest that interaction of the two proteins might result in a conformational change of H1. Fluorescence spectroscopy and circular dichroism-based measurements on mixtures of H1 and ParaT confirm this hypothesis. Human sperm nuclei challenged with ParaT become highly decondensed, whereas overexpression of green fluorescent protein- or FLAG-tagged protein in HeLa cells induces global chromatin decondensation and increases the accessibility of chromatin to micrococcal nuclease digestion. Our data suggest a role of parathymosin in the remodeling of higher order chromatin structure through modulation of H1 interaction with nucleosomes and point to its involvement in chromatin-dependent functions.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; EMBL, Grenoble Outstn, F-38042 Grenoble, France; Adolf Butenandt Inst, D-80336 Munich, Germany; Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina 45110, Greece	University of Ioannina; European Molecular Biology Laboratory (EMBL); University of Munich; Foundation for Research & Technology - Hellas (FORTH)	Papamarcaki, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	thpapama@cc.uoi.gr	Straub, Tobias/B-2023-2009	Straub, Tobias/0000-0002-0547-0453				Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2003, NUCLEIC ACIDS RES, V31, P4264, DOI 10.1093/nar/gkg481; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; BRAND IA, 1991, J BIOL CHEM, V266, P20984; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Catez F, 2004, MOL CELL BIOL, V24, P4321, DOI 10.1128/MCB.24.10.4321-4328.2004; CLINTON M, 1989, ARCH BIOCHEM BIOPHYS, V269, P256, DOI 10.1016/0003-9861(89)90107-0; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Flavin M, 2004, MOL CELL BIOL, V24, P7891, DOI 10.1128/MCB.24.18.7891-7901.2004; FRANGOULAZARIDIS M, 1988, ARCH BIOCHEM BIOPHYS, V263, P305, DOI 10.1016/0003-9861(88)90640-6; GIANCOTTI V, 1980, BIOCHIM BIOPHYS ACTA, V624, P60, DOI 10.1016/0005-2795(80)90225-1; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Greenfield Norma J, 2004, Methods Mol Biol, V261, P55; Gunjan A, 2001, J BIOL CHEM, V276, P3635, DOI 10.1074/jbc.M007590200; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P1050, DOI 10.1073/pnas.82.4.1050; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Knapp S, 2004, BIOCHEMISTRY-US, V43, P11992, DOI 10.1021/bi049364k; Kondili K, 1996, EUR J BIOCHEM, V242, P67, DOI 10.1111/j.1432-1033.1996.0067r.x; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Okamoto K, 2000, EUR J BIOCHEM, V267, P155, DOI 10.1046/j.1432-1327.2000.00987.x; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Sambrook J., 2002, MOL CLONING LAB MANU; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Trompeter HI, 1996, J BIOL CHEM, V271, P1187, DOI 10.1074/jbc.271.2.1187; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Vareli K, 2000, EXP CELL RES, V257, P152, DOI 10.1006/excr.2000.4857; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev	65	23	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16143	16150		10.1074/jbc.M410175200	http://dx.doi.org/10.1074/jbc.M410175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716277	hybrid			2022-12-27	WOS:000228444800082
J	Elkabetz, Y; Argon, Y; Bar-Nun, S				Elkabetz, Y; Argon, Y; Bar-Nun, S			Cysteines in CH1 underlie retention of unassembled ig heavy chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT-CHAINS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; VARIABLE DOMAIN; QUALITY-CONTROL; DISULFIDE BOND; THIOREDOXIN FAMILY; IN-VIVO; BIP; SECRETION	Conformation, structure, and oligomeric state of immunoglobulins not only control quality and functional properties of antibodies but are also critical for immunoglobulins secretion. Unassembled immunoglobulin heavy chains are retained intracellularly by delayed folding of the C(H)1 domain and irreversible interaction of BiP with this domain. Here we show that the three C(H)1 cysteines play a central role in immunoglobulin folding, assembly, and secretion. Remarkably, ablating all three C(H)1 cysteines negates retention and enables BiP cycling and non-canonical folding and assembly. This phenomenon is explained by interdependent formation of intradomain and interchain disulfides, although both bonds are dispensable for secretion. Substituting Cys-195 prevents formation not only of the intradomain disulfide, but also of the interchain disulfide bond with light chain, BiP displacement, and secretion. Mutating the light chain-interacting Cys-128 hinders disulfide bonding of intradomain cysteines, allowing their opportunistic bonding with light chain, without hampering secretion. We propose that the role of C(H)1 cysteines in immunoglobulin assembly and secretion is not simply to engage in disulfide bridges, but to direct proper folding and interact with the retention machinery.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA	Tel Aviv University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Bar-Nun, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	shoshbn@tauex.tau.ac.il			FOGARTY INTERNATIONAL CENTER [F06TW002378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030178] Funding Source: NIH RePORTER; FIC NIH HHS [TW-002378] Funding Source: Medline; NIAID NIH HHS [AI-30178] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brewer JW, 1996, J CELL SCI, V109, P2383; Brumlik MJ, 1997, J BACTERIOL, V179, P3116, DOI 10.1128/jb.179.10.3116-3121.1997; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; Davis DP, 1999, J IMMUNOL, V163, P3842; Davis DP, 2000, IMMUNITY, V13, P433, DOI 10.1016/S1074-7613(00)00043-1; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M208730200; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; Gething M J, 1990, Semin Cell Biol, V1, P65; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KATAOKA T, 1979, P NATL ACAD SCI USA, V76, P4240, DOI 10.1073/pnas.76.9.4240; KEREM A, 1993, J BIOL CHEM, V268, P180; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Leitzgen K, 1997, J BIOL CHEM, V272, P3117, DOI 10.1074/jbc.272.5.3117; Liebeton K, 2001, J BACTERIOL, V183, P597, DOI 10.1128/JB.183.2.597-603.2001; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; ROSE DR, 1993, PROTEIN SCI, V2, P1106, DOI 10.1002/pro.5560020705; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; SECHER DS, 1977, IMMUNOL REV, V36, P51, DOI 10.1111/j.1600-065X.1977.tb00382.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Uson I, 1997, FOLD DES, V2, P357, DOI 10.1016/S1359-0278(97)00049-7; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7	50	17	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14402	14412		10.1074/jbc.M500161200	http://dx.doi.org/10.1074/jbc.M500161200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705573	hybrid			2022-12-27	WOS:000228236800008
J	Michael, IP; Sotiropoulou, G; Pampalakis, G; Magklara, A; Ghosh, M; Wasney, G; Diamandis, EP				Michael, IP; Sotiropoulou, G; Pampalakis, G; Magklara, A; Ghosh, M; Wasney, G; Diamandis, EP			Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; MOLECULAR-WEIGHT KININOGEN; HUMAN TISSUE KALLIKREINS; SOMATOMEDIN-B DOMAIN; PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN-PLASMA KALLIKREIN; HEPARIN-BINDING DOMAIN; FIBRIN BETA-CHAIN; GENE FAMILY; OVARIAN-CANCER	Human kallikrein 5 (KLK5) is a member of the human kallikrein gene family of serine proteases. Preliminary results indicate that the protein, hK5, may be a potential serological marker for breast and ovarian cancer. Other studies implicate hK5 with skin desquamation and skin diseases. To gain further insights on hK5 physiological functions, we studied its substrate specificity, the regulation of its activity by various inhibitors, and identified candidate physiological substrates. After producing and purifying recombinant hK5 in yeast, we determined the k(cat)/K-m ratio of the fluorogenic substrates Gly-Pro-Arg-AMC and Gly-Pro-Lys-AMC, and showed that it has trypsin-like activity with strong preference for Arg over Lys in the P1 position. The serpins alpha(2)-antiplasmin and antithrombin were able to inhibit hK5 with an inhibition constant (k(+2)/K-i) of 1.0 x 10(-2) and 4.2 x 10(-4) M-1 min(-1), respectively. No inhibition was observed with the serpins alpha(1)-antitrypsin and alpha(1)-antichymotrypsin, although alpha(2)-macroglobulin partially inhibited hK5 at high concentrations. We also demonstrated that hK5 can efficiently digest the extracellular matrix components, collagens type I, II, III, and IV, fibronectin, and laminin. Furthermore, our results suggest that hK5 can potentially release (a) angiostatin 4.5 from plasminogen, (b) "cystatin-like domain 3" from low molecular weight kininogen, and ( c) fibrinopeptide B and peptide beta 15-42 from the B beta chain of fibrinogen. hK5 could also play a role in the regulation of the binding of plasminogen activator inhibitor 1 to vitronectin. Our findings suggest that hK5 may be implicated in tumor progression, particularly in invasion and angiogenesis, and may represent a novel therapeutic target.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Patras, Dept Pharm, Sch Hlth Sci, Patras 26500, Greece	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Patras	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016; Magklara, Angeliki/AAK-8347-2020	Michael, Iacovos P/0000-0001-7674-1233; Magklara, Angeliki/0000-0003-3408-6722; Diamandis, Eleftherios/0000-0002-1589-820X				Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; Borgono CA, 2004, MOL CANCER RES, V2, P257; Borgono CA, 2003, CANCER RES, V63, P9032; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Denmeade SR, 2001, PROSTATE, V48, P122, DOI 10.1002/pros.1088; Deperthes D, 1996, J ANDROL, V17, P659; Diamandis EP, 2000, CLIN CHEM, V46, P1855; Diamandis EP, 2003, TUMOR BIOL, V24, P299, DOI 10.1159/000076462; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CLIN CHEM, V48, P1198; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Fortier AH, 2003, PROSTATE, V56, P212, DOI 10.1002/pros.10256; Foussias G, 2000, GENOMICS, V67, P171, DOI 10.1006/geno.2000.6208; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; Gettins PGW, 2000, GENOME RES, V10, P1833, DOI 10.1101/gr.168900; Ghosh MC, 2004, TUMOR BIOL, V25, P193, DOI 10.1159/000081102; HAMAGUCHI M, 1993, BLOOD, V81, P2348; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; Hsieh MC, 2002, BIOCHEMISTRY-US, V41, P2990, DOI 10.1021/bi0117450; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; Kapadia C, 2004, BIOCHEM BIOPH RES CO, V323, P1084, DOI 10.1016/j.bbrc.2004.08.206; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim H, 2001, BRIT J CANCER, V84, P643, DOI 10.1054/bjoc.2000.1649; KITZ R, 1962, J BIOL CHEM, V237, P3245; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Lannutti BJ, 1997, CANCER RES, V57, P5277; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Luo LY, 2001, CLIN CHEM, V47, P237; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; MORII M, 1983, J BIOL CHEM, V258, P2749; MORTENSEN SB, 1981, FEBS LETT, V135, P295, DOI 10.1016/0014-5793(81)80804-6; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; Odrljin TM, 1996, ARTERIOSCL THROM VAS, V16, P1544, DOI 10.1161/01.ATV.16.12.1544; Odrljin TM, 1996, BLOOD, V88, P2050, DOI 10.1182/blood.V88.6.2050.bloodjournal8862050; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; SCHAPIRA M, 1981, BIOCHEMISTRY-US, V20, P2738, DOI 10.1021/bi00513a006; SCHAPIRA M, 1982, BIOCHEMISTRY-US, V21, P567, DOI 10.1021/bi00532a024; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Sotiropoulou G, 2003, ONCOL RES, V13, P381; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; STENMAN UH, 1991, CANCER RES, V51, P222; VOGEL R, 1988, J BIOL CHEM, V263, P12661; Wang H, 2004, CANCER RES, V64, P162, DOI 10.1158/0008-5472.CAN-03-1862; WIMAN B, 1979, J BIOL CHEM, V254, P9291; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793; Yousef GM, 2004, TUMOR BIOL, V25, P122, DOI 10.1159/000079144; Yousef GM, 2002, BIOL CHEM, V383, P1045, DOI 10.1515/BC.2002.113; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 2003, CANCER RES, V63, P3958; Yousef GM, 2002, UROLOGY, V60, P714, DOI 10.1016/S0090-4295(02)01811-3; Yousef GM, 2002, PROSTATE, V51, P126, DOI 10.1002/pros.10067; Yousef GM, 2002, CLIN CHEM, V48, P1241; Yousef GM, 2001, GENOMICS, V74, P385, DOI 10.1006/geno.2001.6556; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	75	131	132	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14628	14635		10.1074/jbc.M408132200	http://dx.doi.org/10.1074/jbc.M408132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15713679	hybrid			2022-12-27	WOS:000228236800037
J	Schmitt, S; Ahting, U; Eichacker, L; Granvogl, B; Go, NE; Nargang, FE; Neupert, W; Nussberger, S				Schmitt, S; Ahting, U; Eichacker, L; Granvogl, B; Go, NE; Nargang, FE; Neupert, W; Nussberger, S			Role of TOM5 in maintaining the structural stability of the TOM complex of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; PROTEIN-IMPORT; NEUROSPORA-CRASSA; BIOCHEMICAL-CHARACTERIZATION; PREPROTEIN TRANSLOCASE; CORE COMPLEX; PORE; BIOGENESIS; CHANNEL; RECEPTORS	Transport of nuclear encoded proteins into mitochondria is mediated by multisubunit translocation machineries in the outer and inner membranes of mitochondria. The TOM complex contains receptor and pore components that facilitate the recognition of preproteins and their transfer through the outer membrane. In addition, the complex contains a set of small proteins. Tom7 and Tom6 have been found in Neurospora and yeast, Tom5 has been found so far only in the latter organism. In the present study, we identified Neurospora Tom5 and analyzed its function in comparison to yeast Tom5, which has been proposed to play a role as a receptor-like component. Neurospora Tom5 crosses the outer membrane with its carboxyl terminus facing the intermembrane space like the other small Tom components. The temperature-sensitive growth phenotype of the yeast TOM5 deletion was rescued by overexpression of Neurospora Tom5. On the other hand, Neurospora cells deficient in tom5 did not exhibit any defect in growth. The structural stability of TOM complexes from cells devoid of Tom5 was significantly altered in yeast but not in Neurospora. The efficiency of protein import in Neurospora mitochondria was not affected by deletion of tom5, whereas in yeast it was reduced as compared with wild type. We conclude that the main role of Tom5, rather than being a receptor, is maintaining the structural integrity of the TOM complex.	Univ Stuttgart, Biophys Abt, Inst Biol, D-70550 Stuttgart, Germany; Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Humangenet, D-85764 Neuherberg, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Stuttgart; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Alberta	Nussberger, S (corresponding author), Univ Stuttgart, Biophys Abt, Inst Biol, Pfaffenwaldring 57, D-70550 Stuttgart, Germany.	nussberger@bio.uni-stuttgart.de	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720; Nussberger, Stephan/0000-0003-3619-4452				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Braun HP, 1999, PLANTA, V209, P267, DOI 10.1007/s004250050632; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Habib SJ, 2003, FEBS LETT, V555, P511, DOI 10.1016/S0014-5793(03)01325-5; Hammen PK, 2000, FEBS LETT, V468, P101, DOI 10.1016/S0014-5793(00)01160-1; HARKNESS TAA, 1994, GENETICS, V136, P107; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Horie C, 2003, J BIOL CHEM, V278, P41462, DOI 10.1074/jbc.M307047200; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Muller A, 2002, EMBO J, V21, P1916, DOI 10.1093/emboj/21.8.1916; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Prokisch H, 2002, FUNGAL GENET BIOL, V36, P85, DOI 10.1016/S1087-1845(02)00018-X; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	38	48	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14499	14506		10.1074/jbc.M413667200	http://dx.doi.org/10.1074/jbc.M413667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701639	hybrid			2022-12-27	WOS:000228236800020
J	Sineshchevkov, OA; Trivedi, VD; Sasaki, J; Spudich, JL				Sineshchevkov, OA; Trivedi, VD; Sasaki, J; Spudich, JL			Photochromicity of Anabaena sensory rhodopsin, an atypical microbial receptor with a cis-retinal light-adapted form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON RELEASE; BACTERIORHODOPSIN; ISOMERIZATION; PHOTOTROPHY; ARGININE-82; ADAPTATION; PROTEINS; PK(A)	We characterize changes in isomeric states of the retinylidene chromophore during light-dark adaptation and photochemical reactions of Anabaena (Nostoc) sp. PCC7120 sensory rhodopsin (ASR). The results show that ASR represents a new type of microbial rhodopsin with a number of unusual characteristics. The three most striking are: (i) a primarily all-trans configuration of retinal in the dark-adapted state and (ii) a primarily 13-cis light-adapted state with a blue-shifted and lower extinction absorption spectrum, opposite of the case of bacteriorhodopsin; and (iii) efficient reversible light-induced interconversion between the 13-cis and all-trans unphotolyzed states of the pigment. The relative amount of ASR with cis and trans chromophore forms depends on the wavelength of illumination, providing a mechanism for single-pigment color sensing analogous to that of phytochrome pigments. In addition ASR exhibits unusually slow formation of L-like and M-like intermediates, with a dominant accumulation of M during the photocycle. Co-expression of ASR with its putative cytoplasmic transducer protein shifts the absorption maximum and strongly decreases the rate of dark adaptation of ASR, confirming interaction between the two proteins. Thus ASR, the first non-haloarchaeal sensory rhodopsin character-ized, demonstrates the diversity of photochemistry of microbial rhodopsins. Its photochromic properties and the position of its two ground state absorption maxima suggest it as a candidate for controlling differential photosynthetic light-harvesting pigment synthesis (chromatic adaptation) or other color-sensitive physiological responses in Anabaena cells.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Moscow MV Lomonosov State Univ, Dept Biol, Moscow 119899, Russia	University of Texas System; Lomonosov Moscow State University	Spudich, JL (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, MSB 6-130,6431 Fannin St, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 2000, BBA-BIOENERGETICS, V1460, P75, DOI 10.1016/S0005-2728(00)00131-6; BALASHOV SP, 1995, BIOCHEMISTRY-US, V34, P8820, DOI 10.1021/bi00027a034; BALASHOV SP, 1988, PHYSICOCHEMICAL BIOL, V8, P1; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Brown LS, 2004, PHOTOCH PHOTOBIO SCI, V3, P555, DOI 10.1039/b315527g; CASADIO R, 1980, BIOCHIM BIOPHYS ACTA, V590, P13, DOI 10.1016/0005-2728(80)90142-5; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; Gyula N, 2003, CURR OPIN PLANT BIOL, V6, P446, DOI 10.1016/S1369-5266(03)00082-7; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; JUNG KH, 2004, CRC HDB ORGANIC PHOT, P1; Kateriya S, 2004, NEWS PHYSIOL SCI, V19, P133, DOI 10.1152/nips.01517.2004; KORENSTEIN R, 1977, FEBS LETT, V82, P7, DOI 10.1016/0014-5793(77)80874-0; KOUYAMA T, 1985, BIOPHYS J, V48, P201, DOI 10.1016/S0006-3495(85)83773-5; OHNO K, 1977, BIOCHIM BIOPHYS ACTA, V462, P575, DOI 10.1016/0005-2728(77)90102-5; PETTEI MJ, 1977, BIOCHEMISTRY-US, V16, P1955, DOI 10.1021/bi00628a031; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; SPUDICH E N, 1986, Proteins Structure Function and Genetics, V1, P239, DOI 10.1002/prot.340010306; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Vogeley L, 2004, SCIENCE, V306, P1390, DOI 10.1126/science.1103943; WAGNER G, 2001, COMPREHENSIVE SERIES, V1, P421; Wang H.S.., 2002, ARABIDOPSIS BOOK, P1; Wang WW, 2003, J BIOL CHEM, V278, P33985, DOI 10.1074/jbc.M305716200	25	69	71	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14663	14668		10.1074/jbc.m501416200	http://dx.doi.org/10.1074/jbc.m501416200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710603	hybrid			2022-12-27	WOS:000228236800041
J	Wei, CJ; Francis, R; Xu, X; Lo, CW				Wei, CJ; Francis, R; Xu, X; Lo, CW			Connexin43 associated with an N-cadherin-containing multiprotein complex is required for gap junction formation in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; PLASMA-MEMBRANE; INTERCELLULAR COMMUNICATION; PROTEIN CONNEXIN-43; RAT CARDIOMYOCYTES; MEDIATED ADHESION; CATENIN COMPLEXES; CHANNEL PROTEIN; PHOSPHORYLATION; EXPRESSION	Previous studies have indicated an intimate linkage between gap junction and adherens junction formation. It was suggested this could reflect the close membrane-membrane apposition required for junction formation. In NIH3T3 cells, we observed the colocalization of connexin43 (Cx43 alpha 1) gap junction protein with N-cadherin, p120, and other N-cadherin-associated proteins at regions of cell-cell contact. We also found that Cx43 alpha 1, N-cadherin, and N-cadherin-associated proteins were coimmunoprecipitated by antibodies to either Cx43 alpha 1, N-cadherin, or various N-cadherin-associated proteins. These findings suggest that Cx43 alpha 1 and N-cadherin are coassembled in a multiprotein complex containing various N-cadherin-associated proteins. Studies using siRNA knockdown indicated that cell surface expression of Cx43 alpha 1 required N-cadherin, and conversely, N-cadherin cell surface expression required Cx43 alpha 1. Pulse-chase labeling and cell surface biotinylation experiments indicated that in the absence of N-cadherin, Cx43 alpha 1 cell surface trafficking is blocked. Surprisingly, siRNA knockdown of p120, an N-cadherin-associated protein known to modulate cell surface turnover of N-cadherin, reduced N-cadherin cell surface expression without altering Cx43 alpha 1 expression. These observations suggest that in contrast to the coregulated cell surface trafficking of Cx43 alpha 1 and N-cadherin, N-cadherin turnover at the cell surface may be regulated independently of Cx43 alpha 1. Functional studies showed gap junctional communication is reduced and cell motility inhibited with N-cadherin or Cx43 alpha 1 knockdown, consistent with the observed loss of both gap junction and cadherin contacts with either knockdown. Overall, these studies indicate that the intracellular coassembly of connexin and cadherin is required for gap junction and adherens junction formation, a process that likely underlies the intimate association between gap junction and adherens junction formation.	NHLBI, Dev Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lo, CW (corresponding author), 50 South Dr,MSC 8019,Rm 4537, Bethesda, MD 20892 USA.	loc@nhlbi.nih.gov	Francis, Richard/P-2524-2015	Francis, Richard/0000-0002-4401-1946	NHLBI NIH HHS [Z01-HL005701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005701, ZIAHL005701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Barker RJ, 2001, CELL COMMUN ADHES, V8, P205, DOI 10.3109/15419060109080724; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Bauer R, 2004, MOL BIOL CELL, V15, P2992, DOI 10.1091/mbc.E04-01-0056; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Frenzel EM, 1996, DEV BIOL, V179, P1, DOI 10.1006/dbio.1996.0237; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; Gutstein DE, 2003, J CELL SCI, V116, P875, DOI 10.1242/jcs.00258; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hertig CM, 1996, J CELL SCI, V109, P1; Herve JC, 2004, EUR BIOPHYS J BIOPHY, V33, P201, DOI 10.1007/s00249-003-0381-0; Huang GY, 1998, J CELL BIOL, V143, P1725, DOI 10.1083/jcb.143.6.1725; Jordan K, 2001, J CELL SCI, V114, P763; KEANE RW, 1988, J CELL BIOL, V106, P1307, DOI 10.1083/jcb.106.4.1307; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 1998, CARDIOVASC RES, V38, P711, DOI 10.1016/S0008-6363(98)00060-1; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; Li WEI, 2002, DEVELOPMENT, V129, P2031; Luo Y, 2003, J CELL SCI, V116, P1471, DOI 10.1242/jcs.00339; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MONIERGAVELLE F, 1995, J CELL SCI, V108, P3839; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; PAUL DL, 1995, DEVELOPMENT, V121, P371; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Stites J, 1998, CELL MOTIL CYTOSKEL, V39, P31, DOI 10.1002/(SICI)1097-0169(1998)39:1<31::AID-CM4>3.0.CO;2-J; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Wang YJ, 1997, J CELL SCI, V110, P301; Wu JC, 2003, J CELL BIOCHEM, V88, P823, DOI 10.1002/jcb.10390; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0	48	167	175	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19925	19936		10.1074/jbc.M412921200	http://dx.doi.org/10.1074/jbc.M412921200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15741167	Green Submitted, hybrid			2022-12-27	WOS:000229113700062
J	Barnich, N; Hisamatsu, T; Aguirre, JE; Xavier, R; Reinecker, HC; Podolsky, DK				Barnich, N; Hisamatsu, T; Aguirre, JE; Xavier, R; Reinecker, HC; Podolsky, DK			GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACID-ACTIVATED REGULATOR; CROHNS-DISEASE; INNATE IMMUNITY; NADPH OXIDASE; FAMILY-MEMBER; GENE-PRODUCT; IFN-BETA; NOD2; DEATH	Nucleotide oligomerization domain 2 (NOD2) functions as a mammalian cytosolic pathogen recognition molecule, and variants have been associated with risk for Crohn disease. We recently demonstrated that NOD2 functions as an anti-bacterial factor limiting survival of intracellular invasive bacteria. To gain further insight into the mechanism of NOD2 activation and signal transduction, we performed yeast two-hybrid screening. We demonstrate that GRIM-19, a protein with homology to the NADPH dehydrogenase complex, interacts with endogenous NOD2 in HT29 cells. GRIM-19 is required for NF-kappa B activation following NOD2-mediated recognition of bacterial muramyl dipeptide. GRIM-19 also controls pathogen invasion of intestinal epithelial cells. GRIM-19 expression is decreased in inflamed mucosa of patients with inflammatory bowel diseases. GRIM-19 may be a key component in NOD2-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes.	Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Inflammatory Bowel Dis, 55 Fruit St, Boston, MA 02114 USA.	dpodolsky@partners.org		Barnich, Nicolas/0000-0001-9465-7844	NIDDK NIH HHS [DK07191, R01 DK060049, DK43351, DK60049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, P30DK043351, R01DK060049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Elson CO, 2000, GASTROENTEROLOGY, V119, P254, DOI 10.1053/gast.2000.9159; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jarvelainen HA, 2003, TRENDS CELL BIOL, V13, P204, DOI 10.1016/S0962-8924(03)00032-1; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Shanahan F, 2002, LANCET, V359, P62, DOI 10.1016/S0140-6736(02)07284-7; Teshima S, 1999, FEBS LETT, V452, P243, DOI 10.1016/S0014-5793(99)00636-5; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443	34	107	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19021	19026		10.1074/jbc.M413776200	http://dx.doi.org/10.1074/jbc.M413776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753091	hybrid			2022-12-27	WOS:000228932300057
J	Cowan, JW; Wang, XD; Guan, R; He, K; Jiang, J; Baumann, G; Black, RA; Wolfe, MS; Frank, SJ				Cowan, JW; Wang, XD; Guan, R; He, K; Jiang, J; Baumann, G; Black, RA; Wolfe, MS; Frank, SJ			Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; UBIQUITIN-PROTEASOME PATHWAY; P75 NEUROTROPHIN RECEPTOR; AMYLOID PRECURSOR PROTEIN; JAK2 TYROSINE KINASE; BINDING-PROTEIN; GH RECEPTOR; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; DISULFIDE LINKAGE	Growth hormone receptor (GHR) is a cytokine receptor superfamily member that binds growth hormone (GH) via its extracellular domain and signals via interaction of its cytoplasmic domain with JAK2 and other signaling molecules. GHR is a target for inducible metalloprotease-mediated cleavage in its perimembranous extracellular domain, a process that liberates the extracellular domain as the soluble GH-binding protein and leaves behind a cell-associated GHR remnant protein containing the transmembrane and cytoplasmic domains. GHR metalloproteolysis can be catalyzed by tumor necrosis factor-alpha-converting enzyme (ADAM-17) and is associated with down-modulation of GH signaling. We now study the fate of the GHR remnant protein. By anti-GHR cytoplasmic domain immunoblotting, we observed that the remnant induced in response to phorbol ester or platelet-derived growth factor has a reliable pattern of appearance and disappearance in both mouse preadipocytes endogenously expressing GHR and transfected fibroblasts expressing rabbit GHR. Lactacystin, a specific proteasome inhibitor, did not appreciably change the time course of remnant appearance or clearance but allowed detection of the GHR stub, a receptor fragment slightly smaller than the remnant but containing the C terminus of the remnant (receptor cytoplasmic domain). In contrast, MG132, another (less specific) proteasome inhibitor, strongly inhibited remnant clearance and prevented stub appearance. Inhibitors of gamma-secretase, an aspartyl protease, also prevented the appearance of the stub, even in the presence of lactacystin, and concomitantly inhibited remnant clearance in the same fashion as MG132. In addition, mouse embryonic fibroblasts derived from presenilin 1 and 2 (PS1/2) knockouts recapitulated the gamma-secretase inhibitor studies, as compared with their littermate controls (PS1/2 wild type). Confocal microscopy indicated that the GHR cytoplasmic domain became localized to the nucleus in a fashion dependent on PS1/2 activity. These data indicate that the GHR is subject to sequential proteolysis by metalloprotease and gamma-secretase activities and may suggest GH-independent roles for the GHR.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metan & Mol Med, Chicago, IL 60611 USA; Vet Adm Chicago Hlth Syst, Lakeside Div, Chicago, IL 60611 USA; Amgen Inc, Seattle, WA 98101 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Northwestern University; Amgen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu	He, Kai/AHB-3118-2022	He, Kai/0000-0002-4378-9297	NIDDK NIH HHS [DK58259, DK46395] Funding Source: Medline; NIGMS NIH HHS [T-32 GM08111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R56DK046395, R56DK058259, R01DK058259, R01DK046395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Amit T, 2001, J ENDOCRINOL, V169, P397, DOI 10.1677/joe.0.1690397; Amit T, 1996, ENDOCRINOLOGY, V137, P3986, DOI 10.1210/en.137.9.3986; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Baumann G, 2001, J PEDIATR ENDOCR MET, V14, P355; Bick T, 1996, ENDOCRINOLOGY, V137, P3977, DOI 10.1210/en.137.9.3977; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; dos Santos CMA, 2001, J BIOL CHEM, V276, P10839, DOI 10.1074/jbc.M003635200; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Goh ELK, 2002, ENDOCRINOLOGY, V143, P3590, DOI 10.1210/en.2002-220374; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Gowrishankar K, 2004, J CELL SCI, V117, P4099, DOI 10.1242/jcs.01263; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARLOW E, 1988, ANTIBODIES LAB MANUA, P632; HARRISON SM, 1995, ENDOCRINOLOGY, V136, P651, DOI 10.1210/en.136.2.651; He K, 2003, MOL ENDOCRINOL, V17, P2211, DOI 10.1210/me.2003-0256; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Jiang J, 2004, MOL ENDOCRINOL, V18, P2981, DOI 10.1210/me.2004-0102; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; LARON Z, 1995, J CLIN ENDOCR METAB, V80, P1426; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lu CX, 2001, J BIOL CHEM, V276, P22892, DOI 10.1074/jbc.M011647200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MASSA G, 1993, ACTA ENDOCRINOL-COP, V129, P559, DOI 10.1530/acta.0.1290559; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MCGUFFIN WL, 1976, ENDOCRINOLOGY, V98, P1400; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moulin S, 2003, CELL SIGNAL, V15, P47, DOI 10.1016/S0898-6568(02)00054-2; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; MULLIS PE, 1995, MOL CELL ENDOCRINOL, V111, P181, DOI 10.1016/0303-7207(95)03567-Q; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Parks JS, 1997, J PEDIATR-US, V131, pS45, DOI 10.1016/S0022-3476(97)70011-8; RANK SJ, 2002, CYTOKINE REFERENCE O; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; SU CC, 1996, ANNU REV PHYSIOL, V58, P187; Takagi K, 2001, MOL CELL ENDOCRINOL, V182, P157, DOI 10.1016/S0303-7207(01)00583-4; Takagi K, 2001, BIOL PHARM BULL, V24, P744, DOI 10.1248/bpb.24.744; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2003, MOL CELL ENDOCRINOL, V201, P57, DOI 10.1016/S0303-7207(02)00434-3; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Wallace TA, 2004, AM J PHYSIOL-CELL PH, V287, pC981, DOI 10.1152/ajpcell.00085.2004; Wang XD, 2003, MOL ENDOCRINOL, V17, P1931, DOI 10.1210/me.2003-0120; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang Y, 2001, J BIOL CHEM, V276, P24565, DOI 10.1074/jbc.M101281200; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215	91	57	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19331	19342		10.1074/jbc.M500621200	http://dx.doi.org/10.1074/jbc.M500621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743767	hybrid			2022-12-27	WOS:000228932300090
J	Komander, D; Kular, G; Deak, M; Alessi, DR; van Aalten, DMF				Komander, D; Kular, G; Deak, M; Alessi, DR; van Aalten, DMF			Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; S6 KINASE; IDENTIFICATION; MECHANISM; DOMAIN; POCKET; CRYSTALLOGRAPHY; ANGSTROM	3-Phosphoinositide-dependent protein kinase-1 (PDK1) phosphorylates the T-loop of several AGC (cAMP-dependent, cGMP-dependent, protein kinase C) family protein kinases, resulting in their activation. Previous structural studies have revealed that the alpha C-helix, located in the small lobe of the kinase domain of PDK1, is a key regulatory element, as it links a substrate interacting site termed the hydrophobic motif (HM) pocket with the phosphorylated Ser-241 in the T-loop. In this study we have demonstrated by mutational analysis that interactions between the phosphorylated Ser-241 and the alpha C-helix are not required for PDK1 activity or substrate binding through the HM-pocket but are necessary for PDK1 to be activated or stabilized by a peptide that binds to this site. The structure of an inactive T-loop mutant of PDK1, in which Ser-241 is changed to Ala, was also determined. This structure, together with surface plasmon resonance binding studies, demonstrates that the PDK1(S241A)-inactive mutant possesses an intact HM-pocket as well as an ordered alpha C-helix. These findings reveal that the integrity of the alpha C-helix and HM-pocket in PDK1 is not regulated by T-loop phosphorylation.	Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee, Scotland; Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee, Scotland	University of Dundee; University of Dundee	Komander, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	david.komander@icr.ac.uk; dava@davapc1.bioch.dundee.ac.uk		Alessi, Dario/0000-0002-2140-9185; van Aalten, Daan/0000-0002-1499-6908	MRC [MC_U127015387] Funding Source: UKRI; Medical Research Council [MC_U127015387] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fuse E, 1999, CANCER RES, V59, P1054; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17; Leon BC, 2001, BIOCHEMISTRY-US, V40, P10078, DOI 10.1021/bi010838e; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; Yang J, 2004, J MOL BIOL, V336, P473, DOI 10.1016/j.jmb.2003.11.044; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6	47	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18797	18802		10.1074/jbc.M500977200	http://dx.doi.org/10.1074/jbc.M500977200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15741170	hybrid			2022-12-27	WOS:000228932300031
J	Lee, YJ; Lee, DH; Cho, CK; Bae, S; Jhon, GJ; Lee, SJ; Soh, JW; Lee, YS				Lee, YJ; Lee, DH; Cho, CK; Bae, S; Jhon, GJ; Lee, SJ; Soh, JW; Lee, YS			HSP25 inhibits protein kinase C delta-mediated cell death through direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; INDUCED APOPTOSIS; CYTOCHROME-C; PKC-DELTA; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; PHORBOL ESTER; L929 CELLS; KAPPA-B; RADIATION	Heat shock protein 25 (HSP25) interferes negatively with apoptosis through several pathways that involve its direct interaction with cytochrome c or Akt. Here we show that HSP25 inhibits protein kinase C (PKC) delta-mediated cell death through direct interaction. HSP25 binds to kinase-active PKC delta to inhibit its kinase activity and translocation to the membrane, which results in reduced cell death. Deletion constructs of HSP25 and PKC delta identified amino acids 90 - 103 of HSP25 and the C-terminal V5 region of PKC delta as binding sites. In addition, the interaction between HSP25 and PKC delta induced HSP25 phosphorylation at Ser-15 and Ser-86, and these phosphorylations permitted HSP25 release from PKC delta. Based on these observations, we propose that after PKC delta activation, HSP25 binds to the exposed V5 region of PKC delta. This novel function of HSP25 accounts for its cytoprotective properties via the inhibition of PKC delta and the enhancement of HSP25 phosphorylation.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Expt Radiat Therapeut, Seoul 139706, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Dept Chem, Lab Signal Transduct, Seoul 402751, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Ewha Womans University; Inha University	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850				BAEK SH, 2002, J CELL PHYSL, V183, P100; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Cho HN, 2002, CELL DEATH DIFFER, V9, P448, DOI 10.1038/sj.cdd.4400979; Cho HN, 2001, INT J RADIAT BIOL, V77, P225, DOI 10.1080/09553000010001024; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; DUTIL EM, 1998, CURR BIOL, V6, P806; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; Guay J, 1997, J CELL SCI, V110, P357; Guo ZY, 2000, BIOCHEM BIOPH RES CO, V270, P183, DOI 10.1006/bbrc.2000.2401; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Landry J, 1999, BIOCHEM SOC SYMP, P79; Lee YJ, 2004, FREE RADICAL BIO MED, V36, P429, DOI 10.1016/j.freeradbiomed.2003.11.009; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; LEE YJ, 2005, IN PRESS ONCOGENE; Leverrier S, 2002, BIOCHEM J, V368, P905, DOI 10.1042/BJ20021253; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mehlen P, 1999, CELL DEATH DIFFER, V6, P227, DOI 10.1038/sj.cdd.4400483; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Park SH, 2000, RADIAT RES, V154, P421, DOI 10.1667/0033-7587(2000)154[0421:HIRIAW]2.0.CO;2; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wang QMJ, 2004, MOL CANCER RES, V2, P129; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x; Yi MJ, 2002, RADIAT RES, V158, P641, DOI 10.1667/0033-7587(2002)158[0641:HSPHRM]2.0.CO;2; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	57	46	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18108	18119		10.1074/jbc.M501131200	http://dx.doi.org/10.1074/jbc.M501131200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15731106	hybrid			2022-12-27	WOS:000228807200068
J	Song, ES; Daily, A; Fried, MG; Juliano, MA; Juliano, L; Hersh, LB				Song, ES; Daily, A; Fried, MG; Juliano, MA; Juliano, L; Hersh, LB			Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; ENDOTHELIN-CONVERTING ENZYME; DIRECTED MUTAGENESIS; EXTRACELLULAR LEVELS; MISSENSE MUTATIONS; PLASMA A-BETA-42; MOUSE MODEL; IN-VIVO; DEGRADATION	The active site glutamate (Glu(111)) and the active site histidine (His(112)) of insulin-degrading enzyme (IDE) were mutated. These mutant enzymes exhibit, in addition to a large decrease in catalytic activity, a change in the substrate-velocity response from a sigmoidal one seen with the native enzyme (Hill coefficient >2), to a hyperbolic response. With 2-aminobenzoyl-GGFLRKHGQN-(2,4-dinitrophenyl)ethylenediamine as substrate, ATP and triphosphate increase the reaction rate of the wild type enzyme some 50-80-fold. This effect is dampened with glutamate mutants to no effect or less than a 3-fold increase in activity and changed to inhibition with the histidine mutants. Sedimentation equilibrium shows the IDE mutants exhibit a similar oligomeric distribution as the wild type enzyme, being predominantly monomeric, with triphosphate having little if any effect on the oligomeric state. Triphosphate did induce aggregation of many of the IDE mutants. Thus, the oligomeric state of IDE does not correlate with kinetic properties. The His(112) mutants were shown to bind zinc, but with a lower affinity than the wild type enzyme. The glutamate mutants displayed an altered cleavage profile for the peptide beta-endorphin. Wild type IDE cleaved beta-endorphin at Leu(17)-Phe(18) and Phe(18)-Lys(19), whereas the glutamate mutants cleaved at these sites, but in addition at Lys(19)-Asn(20) and at Met(5)-Thr(6). Thus, active site mutations of IDE are suggested to not only reduce catalytic activity but also cause local conformational changes that affect the allosteric properties of the enzyme.	Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lexington, KY 40536 USA; Escola Paulista Med, Dept Biophys, BR-04023900 Sao Paulo, Brazil	University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, 800 Rose St, Lexington, KY 40536 USA.	lhersh@uky.edu	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIA NIH HHS [AG19323] Funding Source: Medline; NIDA NIH HHS [DA02243] Funding Source: Medline; NIDDK NIH HHS [DK54289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Authier F, 1996, CLIN INVEST MED, V19, P149; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Ertekin-Taner N, 2004, HUM MUTAT, V23, P334, DOI 10.1002/humu.20016; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Hersh LB, 2003, CURR PHARM DESIGN, V9, P449, DOI 10.2174/1381612033391676; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KUBO M, 1992, APPL ENVIRON MICROB, V58, P3779, DOI 10.1128/AEM.58.11.3779-3783.1992; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LI D, 1992, J BIOL CHEM, V267, P2414; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Marr RA, 2004, J MOL NEUROSCI, V22, P5, DOI 10.1385/JMN:22:1-2:5; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Mukherjee A, 2002, J ALZHEIMERS DIS, V4, P341, DOI 10.3233/JAD-2002-4501; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; STGEORGEHYSLOP PH, 1993, MOL GENETICS ALZHEIM; Thompson MW, 2003, ARCH BIOCHEM BIOPHYS, V413, P236, DOI 10.1016/S0003-9861(03)00123-1; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zlokovic BV, 2004, J NEUROCHEM, V89, P807, DOI 10.1111/j.1471-4159.2004.02385.x	51	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17701	17706		10.1074/jbc.M501896200	http://dx.doi.org/10.1074/jbc.M501896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749695	hybrid			2022-12-27	WOS:000228807200019
J	Wu, ZZ; Chen, SR; Pan, HL				Wu, ZZ; Chen, SR; Pan, HL			Transient receptor potential vanilloid type 1 activation down-regulates voltage-gated calcium channels through calcium-dependent calcineurin in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; RAT DORSAL-ROOT; CA2+ CHANNEL; CAPSAICIN RECEPTOR; MICE LACKING; N-TYPE; PYRETHROID INSECTICIDES; SYNAPTIC-TRANSMISSION; SYMPATHETIC NEURONS; CURRENTS	Calcium influx through voltage- activated Ca2+ channels (VACCs) plays a critical role in neurotransmission. Capsaicin application inhibits VACCs and desensitizes nociceptors. In this study, we determined the signaling mechanisms of the inhibitory effect of capsaicin on VACCs in primary sensory neurons. Whole-cell voltage clamp recordings were performed in acutely isolated rat dorsal root ganglion neurons. Capsaicin caused a profound decrease in the Ca2+ current ( I-Ca) density in capsaicin-sensitive, but not - insensitive, dorsal root ganglion neurons. At 1 mu M, capsaicin suppressed about 60% of N-, P/Q-,L-, and R-type I-Ca density. Pretreatment with iodoresiniferatoxin, a specific transient receptor potential vanilloid type 1 (TRPV1) antagonist, or intracellular application of 1,2-bis(2-aminophenoxy) ethane-N, N, N',N'-tetraacetic acid blocked the inhibitory effect of capsaicin on I-ca. However, neither W-7, a calmodulin blocker, nor KN-93, a CaMKII inhibitor, attenuated the inhibitory effect of capsaicin on I-Ca. Furthermore, intracellular dialysis of deltamethrin or cyclosporin A, the specific calcineurin ( protein phosphatase 2B) inhibitors, but not okadaic acid ( a selective protein phosphatase 1/protein phosphatase 2A inhibitor), abolished the effect of capsaicin on ICa. Interestingly, 1,2-bis( 2-aminophenoxy) ethaneN, N, N', N'-tetraacetic acid, deltamethrin, cyclosporin A, and okadaic acid each alone significantly increased the I-Ca density and caused a depolarizing shift in the voltage dependence of activation. Immunofluorescence labeling revealed that capsaicin induced a rapid internalization of Ca(V)2.2 channels on the membrane. Thus, this study provides novel information that VACCs are tonically modulated by the intracellular Ca2+ level and endogenous phosphatases in sensory neurons. Stimulation of TRPV1 by capsaicin down-regulates VACCs by dephosphorylation through Ca2+-dependent activation of calcineurin.	Penn State Univ, Coll Med, Dept Anesthesiol, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pan, HL (corresponding author), Penn State Univ, Coll Med, Dept Anesthesiol, Dept Neural & Behav Sci, H187,500 Univ Dr, Hershey, PA 17033 USA.	hpan@psu.edu	Tuluc, Petronel/C-2527-2011	Pan, Hui-Lin/0000-0001-8444-3770	NIGMS NIH HHS [GM64830] Funding Source: Medline; NINDS NIH HHS [NS45602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beydoun A, 1996, PAIN, V65, P189, DOI 10.1016/0304-3959(95)00161-1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Burley JR, 2000, EUR J NEUROSCI, V12, P2881, DOI 10.1046/j.1460-9568.2000.00178.x; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; Chancellor MB, 1999, J UROLOGY, V162, P3, DOI 10.1097/00005392-199907000-00002; DOCHERTY RJ, 1991, NEUROSCIENCE, V40, P513, DOI 10.1016/0306-4522(91)90137-D; Dzhura I, 2002, J PHYSIOL-LONDON, V545, P399, DOI 10.1113/jphysiol.2002.021881; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Enz A, 1997, BIOCHEM PHARMACOL, V54, P321, DOI 10.1016/S0006-2952(97)00175-5; Fakata KL, 1998, BIOCHEM PHARMACOL, V55, P2017, DOI 10.1016/S0006-2952(98)00076-8; Frolenkov GI, 2000, J NEUROSCI, V20, P5940, DOI 10.1523/JNEUROSCI.20-16-05940.2000; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; HALL KE, 1995, J NEUROSCI, V15, P6069; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hoy M, 2001, J BIOL CHEM, V276, P924, DOI 10.1074/jbc.M007562200; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; IKEDA SR, 1996, NATURE, V380, P258; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Karai LJ, 2004, J BIOL CHEM, V279, P16377, DOI 10.1074/jbc.M310891200; Kim C, 2001, MOL CELL NEUROSCI, V18, P235, DOI 10.1006/mcne.2001.1013; King APJ, 1999, J PHARMACOL EXP THER, V289, P312; Kruglikov I, 2004, PFLUG ARCH EUR J PHY, V448, P395, DOI 10.1007/s00424-004-1263-8; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lukyanetz EA, 1997, NEUROSCIENCE, V78, P625, DOI 10.1016/S0306-4522(97)00020-1; Malmberg AB, 2004, PAIN, V111, P360, DOI 10.1016/j.pain.2004.07.017; McDonough SI, 1996, J NEUROSCI, V16, P2612; Michael GJ, 1999, J NEUROSCI, V19, P1844; MOISES HC, 1994, J NEUROSCI, V14, P5903; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Pan HL, 2003, J NEUROSCI, V23, P2911; PETERSEN M, 1991, BRAIN RES, V561, P20, DOI 10.1016/0006-8993(91)90744-G; RANDALL A, 1995, J NEUROSCI, V15, P2995; Ronde P, 2000, J PHYSIOL-LONDON, V529, P307, DOI 10.1111/j.1469-7793.2000.00307.x; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; SCHROEDER JE, 1993, J NEUROSCI, V13, P867; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Unno T, 1999, BRIT J PHARMACOL, V127, P1703, DOI 10.1038/sj.bjp.0702711; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; Wu ZZ, 2004, NEUROSCI LETT, V368, P96, DOI 10.1016/j.neulet.2004.06.067; Yang K, 1999, BRAIN RES, V830, P268, DOI 10.1016/S0006-8993(99)01408-0; Zhu Y, 1997, J NEUROPHYSIOL, V78, P1161, DOI 10.1152/jn.1997.78.2.1161	50	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18142	18151		10.1074/jbc.M501229200	http://dx.doi.org/10.1074/jbc.M501229200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746091	hybrid			2022-12-27	WOS:000228807200072
J	da Silva, GFZ; Tay, WM; Ming, LJ				da Silva, GFZ; Tay, WM; Ming, LJ			Catechol oxidase-like oxidation chemistry of the 1-20 and 1-16 fragments of Alzheimer's disease-related beta-amyloid peptide - Their structure-activity correlation and the fate of hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; SUPEROXIDE-DISMUTASE; COPPER(II) COMPLEX; PRECURSOR PROTEIN; STRAND SCISSION; ALPHA-SYNUCLEIN; BINDING; SITE; ANTIOXIDANT; REACTIVITY	The Cu2+ complexes of the 1 - 16 and the 1 - 20 fragments of the Alzheimer's disease-related beta-amyloid peptide (CuA beta) show significant oxidative activities toward a catechol-like substrate trihydroxylbenzene and plasmid DNA cleavage. The latter reflects possible oxidative stress to biological macromolecules, yielding supporting data to the pathological role of these soluble A beta fragments. The former exhibits enzyme-like kinetics and is dependent on [H2O2], exhibiting k(cat) of 0.066 s(-1) (6000-fold higher than the reaction without CuA beta) and k(cat)/K-m of 37.2 M-1 s(-1) under saturating [H2O2] of similar to 0.24%. This kinetic profile is consistent with metal-centered redox chemistry for the action of CuA beta. A mechanism is proposed by the use of the catalytic cycle of dinuclear catechol oxidase as a working model. Trihydroxylbenzene is also oxidized by CuA beta aerobically without H2O2, affording rate constants of 6.50 x 10(-3) s(-1) and 3.25 M-1 s(-1). This activity is also consistent with catechol oxidase action in the absence of H2O2, wherein the substrate binds and reduces the Cu2+ center first, followed by O-2 binding to afford the mu-eta(2): eta(2)-peroxo intermediate, which oxidizes a second substrate to complete the catalytic cycle. A tetragonally distorted octahedral metal coordination sphere with three coordinated His side chains and some specific H-bonding interactions is concluded from the electronic spectrum of CuA beta, hyperfine-shifted H-1 NMR spectrum of CoA beta, and molecular mechanics calculations. The results presented here are expected to add further insight into the chemistry of metallo-A beta, which may assist better understanding of the neuropathology of Alzheimer's disease.	Univ S Florida, Dept Chem, Tampa, FL 33620 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33620 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ming, LJ (corresponding author), Univ S Florida, Dept Chem, 4202 E Fowler Ave,SCA400, Tampa, FL 33620 USA.	ming@shell.cas.usf.edu						ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BERTINI I, 1994, BIOINORGANIC, pCH4; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; BURGER AR, 1980, BIOCHEMISTRY-US, V19, P4140; BURROWS CJ, 1999, INORG CHEM, V38, P3500; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Chen P, 2004, J AM CHEM SOC, V126, P4991, DOI 10.1021/ja031564g; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; COTTON FA, 1988, ADV INORG CHEM, P865; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; EHRENFELD GM, 1985, BIOCHEMISTRY-US, V24, P81, DOI 10.1021/bi00322a013; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Evin G, 2003, J NEUROSCI RES, V74, P386, DOI 10.1002/jnr.10745; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; FLORINI JR, 1957, BIOCHIM BIOPHYS ACTA, V25, P575, DOI 10.1016/0006-3002(57)90529-2; Garzon-Rodriguez W, 1999, BIOORG MED CHEM LETT, V9, P2243, DOI 10.1016/S0960-894X(99)00357-1; Hegg EL, 1999, INORG CHEM, V38, P2961, DOI 10.1021/ic981087g; Huang XD, 2004, J BIOL INORG CHEM, V9, P954, DOI 10.1007/s00775-004-0602-8; Humphreys KJ, 2002, J BIOL INORG CHEM, V7, P835, DOI 10.1007/s00775-002-0369-8; Jang JH, 2002, ANN NY ACAD SCI, V973, P228, DOI 10.1111/j.1749-6632.2002.tb04639.x; KITAJIMA N, 1990, J AM CHEM SOC, V112, P8833, DOI 10.1021/ja00180a026; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; Kontush A, 2001, FREE RADICAL BIO MED, V31, P1120, DOI 10.1016/S0891-5849(01)00688-8; Kowalik-Jankowska T, 2003, J INORG BIOCHEM, V95, P270, DOI 10.1016/S0162-0134(03)00128-4; LESKOVAC V, 2002, COMPREHENSIVE ENZYME; LEVER ABP, 1986, INORGANIC ELECT SPEC, P554; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X; Lonnrot K, 1996, FREE RADICAL BIO MED, V21, P211, DOI 10.1016/0891-5849(95)02207-4; Mahadevan V, 2000, J AM CHEM SOC, V122, P10249, DOI 10.1021/ja002527h; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MING LJ, 2000, PHYSICAL METHODS BIO, pCH8; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Miura T, 2001, J MOL STRUCT, V598, P79, DOI 10.1016/S0022-2860(01)00807-9; NUNOMURA A, 1999, J ANTI-AGING MED, V2, P227; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Park HI, 1998, J INORG BIOCHEM, V72, P57, DOI 10.1016/S0162-0134(98)10063-6; Que L, 2002, ANGEW CHEM INT EDIT, V41, P1114; RAO PS, 1988, BIOCHEM BIOPH RES CO, V150, P39, DOI 10.1016/0006-291X(88)90483-4; ROCHE E, 1993, MED HYPOTHESES, V40, P342, DOI 10.1016/0306-9877(93)90215-C; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; Seo SY, 2003, J AGR FOOD CHEM, V51, P2837, DOI 10.1021/jf020826f; SHINOBU LA, 1997, METALS OXIDATIVE DAM; SIGMAN DS, 1993, CHEM REV, V93, P2295, DOI 10.1021/cr00022a011; Srivatsan SG, 2001, APPL CATAL A-GEN, V209, P327, DOI 10.1016/S0926-860X(00)00765-1; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Tolman WB, 1997, ACCOUNTS CHEM RES, V30, P227, DOI 10.1021/ar960052m; Waiter MF, 1997, BIOCHEM BIOPH RES CO, V233, P760, DOI 10.1006/bbrc.1997.6547; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YAMAMOTO K, 1991, J BIOL CHEM, V266, P1509; Yamazaki S, 2003, J AM CHEM SOC, V125, P13034, DOI 10.1021/ja036425d; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	61	39	39	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16601	16609		10.1074/jbc.M411533200	http://dx.doi.org/10.1074/jbc.M411533200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15699049	hybrid			2022-12-27	WOS:000228615500010
J	Freedman, BD; Lee, EJ; Park, Y; Jameson, JL				Freedman, BD; Lee, EJ; Park, Y; Jameson, JL			A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; MICE; GENE; OBESITY; FAT; DISRUPTION; EXPRESSION; MUTATIONS; MUTANT	Peroxisome proliferator-activated receptor-gamma (PPAR gamma), a member of the nuclear hormone receptor family, is a master regulator of adipogenesis. Humans with dominant negative PPAR gamma mutations have features of the metabolic syndrome ( severe insulin resistance, dyslipidemia, and hypertension). We created a knock-in mouse model containing a potent dominant negative PPAR gamma L466A mutation, shown previously to inhibit wild-type PPAR gamma action in vitro. Homozygous PPAR gamma L466A knock-in mice die in utero. Heterozygous PPAR gamma L466A knock-in (PPARKI) mice exhibit hypoplastic adipocytes, hypoadiponectinemia, increased serum-free fatty acids, and hepatic steatosis. When subjected to high fat diet feeding, PPARKI mice gain significantly less weight than controls. Hyperinsulinemic-euglycemic clamp studies in PPARKI mice revealed insulin resistance and reduced glucose uptake into skeletal muscle. Female PPARKI mice exhibit hypertension independent of diet. The PPARKI mouse provides a novel model for studying the relationship between impaired PPAR gamma function and the metabolic syndrome.	Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Jameson, JL (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Galter Pavil,Suite 3-150,251 E Huron St, Chicago, IL 60611 USA.	ljameson@northwestern.edu		Jameson, James/0000-0001-9538-4059	NIDDK NIH HHS [U24 DK59637] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FRAYN KN, 1980, J LIPID RES, V21, P139; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Leiter EH, 2002, DIABETOLOGIA, V45, P296, DOI 10.1007/s00125-001-0743-z; LEITER EH, 1989, FASEB J, V3, P2231, DOI 10.1096/fasebj.3.11.2673897; Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336; Martin G, 1998, ATHEROSCLEROSIS, V137, pS75, DOI 10.1016/S0021-9150(97)00315-8; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Park Y, 2003, DIABETOLOGIA, V46, P365, DOI 10.1007/s00125-003-1037-4; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Savage DB, 2003, DIABETES, V52, P910, DOI 10.2337/diabetes.52.4.910; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tsai YS, 2004, J CLIN INVEST, V114, P240, DOI 10.1172/JCI200420964; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424	34	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17118	17125		10.1074/jbc.M407539200	http://dx.doi.org/10.1074/jbc.M407539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15716267	hybrid			2022-12-27	WOS:000228615500071
J	Yu, YD; Li, S; Xu, X; Li, Y; Guan, KL; Arnold, E; Ding, JP				Yu, YD; Li, S; Xu, X; Li, Y; Guan, KL; Arnold, E; Ding, JP			Structural basis for the unique biological function of small GTPase RHEB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR PROTEINS; RAS-RELATED PROTEIN; TSC2 GAP ACTIVITY; CELL-GROWTH; GENE-PRODUCTS; DIRECT TARGET; ACTIVATION; DROSOPHILA; MUTANTS	The small GTPase Rheb displays unique biological and biochemical properties different from other small GTPases and functions as an important mediator between the tumor suppressor proteins TSC1 and TSC2 and the mammalian target of rapamycin to stimulate cell growth. We report here the three-dimensional structures of human Rheb in complexes with GDP, GTP, and GppNHp (5'-(beta, gamma-imide) triphosphate), which reveal novel structural features of Rheb and provide a molecular basis for its distinct properties. During GTP/GDP cycling, switch I of Rheb undergoes conformational change while switch II maintains a stable, unusually extended conformation, which is substantially different from the alpha-helical conformation seen in other small GTPases. The unique switch II conformation results in a displacement of Gln(64) ( equivalent to the catalytic Gln(61) of Ras), making it incapable of participating in GTP hydrolysis and thus accounting for the low intrinsic GTPase activity of Rheb. This rearrangement also creates space to accommodate the side chain of Arg(15), avoiding its steric hindrance with the catalytic residue and explaining its noninvolvement in GTP hydrolysis. Unlike Ras, the phosphate moiety of GTP in Rheb is shielded by the conserved Tyr(35) of switch I, leading to the closure of the GTP-binding site, which appears to prohibit the insertion of a potential arginine finger from its GTPase-activating protein. Taking the genetic, biochemical, biological, and structural data together, we propose that Rheb forms a new group of the Ras/Rap subfamily and uses a novel GTP hydrolysis mechanism that utilizes Asn(1643) of the tuberous sclerosis complex 2 GTPase-activating protein domain instead of Gln(64) of Rheb as the catalytic residue.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Univ Michigan, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Michigan System; University of Michigan; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Ding, JP (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jpding@sibs.ac.cn	Xu, Xiang/G-5528-2012	ding, jian ping/0000-0001-7029-7346				Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Maheshwar MM, 1996, HUM MOL GENET, V5, P131, DOI 10.1093/hmg/5.1.131; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sparagana Steven P., 2000, Current Opinion in Neurology, V13, P115, DOI 10.1097/00019052-200004000-00001; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WITTINGHOFER A, 1999, GTPASE; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yu YD, 2004, ACTA CRYSTALLOGR D, V60, P1883, DOI 10.1107/S0907444904018232; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	41	57	62	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17093	17100		10.1074/jbc.M501253200	http://dx.doi.org/10.1074/jbc.M501253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728574	hybrid			2022-12-27	WOS:000228615500068
J	Batsche, E; Moschopoulos, P; Desroches, J; Bilodeau, S; Drouin, J				Batsche, E; Moschopoulos, P; Desroches, J; Bilodeau, S; Drouin, J			Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-BOX FACTOR; NUCLEAR RECEPTORS; CELL-CYCLE; NGFI-B; EXPRESSION; DIFFERENTIATION; MECHANISM; NUR77; TPIT; PTX1	Gene inactivation studies have suggested that the product of the retinoblastoma gene, Rb, is particularly limiting in pituitary pro-opiomelanocortin (POMC)-expressing cell lineages. Indeed, in Rb knock- out mice, these cells develop tumors with high frequency. To understand the implication of limiting Rb expression in these cells, we investigated the action of Rb and its related pocket proteins, p107 and p130, on POMC gene transcription. This led to the identification of the neurogenic basic helix-loop-helix transcription factor, NeuroD1, as a target of Rb action. Rb and to a lesser extent p107, but not p130, enhance NeuroD1-dependent transcription, and this activity appears to depend on direct protein interactions between the Rb pocket and the helix-loop-helix domain of NeuroD1. In vivo, NeuroD is found in a complex that includes Rb and also the orphan nuclear receptor NGFI-B, which mediates corticotropin-releasing hormone activation of POMC transcription. The formation of a similar complex in vitro requires the presence of Rb as a bridge between NeuroD and NGFI-B. In POMC-expressing AtT-20 cells, Rb and p107 are present on the POMC promoter and inhibition of their expression through small interfering RNA decreases POMC mRNA levels. The action of Rb and its related proteins on POMC transcription may contribute to the establishment and/or maintenance of the differentiation phenotype.	Inst Rech Clin Montreal, Genet Mol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Drouin, J (corresponding author), Inst Rech Clin Montreal, Genet Mol Lab, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	jacques.drouin@ircm.qc.ca		Drouin, Jacques/0000-0001-8226-5691; Bilodeau, Steve/0000-0002-9799-3832; Batsche, Eric/0000-0002-5145-5270				Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BATSCHE E, 2005, J BIOL CHEM, DOI DOI 10.1074/JBCM41328200; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Drouin J, 1998, J STEROID BIOCHEM, V65, P59, DOI 10.1016/S0960-0760(97)00180-5; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; HAMEL PA, 1992, ONCOGENE, V7, P693; Hinton DR, 1998, CANCER LETT, V126, P209, DOI 10.1016/S0304-3835(98)00013-5; HU NP, 1994, ONCOGENE, V9, P1021; Iavarone A, 2004, CANCER LETT, V204, P189, DOI 10.1016/S0304-3835(03)00455-5; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lamolet B, 2004, MOL ENDOCRINOL, V18, P995, DOI 10.1210/me.2003-0127; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LUNDBLAD JR, 1988, ENDOCR REV, V9, P135, DOI 10.1210/edrv-9-1-135; Maira M, 2003, J BIOL CHEM, V278, P46523, DOI 10.1074/jbc.M305626200; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Pulichino AM, 2003, GENE DEV, V17, P738, DOI 10.1101/gad.1065703; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Suh H, 2002, DEVELOPMENT, V129, P329; Suhardja A, 2001, J NEURO-ONCOL, V52, P195, DOI 10.1023/A:1010655419332; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; THERRIEN M, 1993, MELANOTROPIC PEPTIDE, P663; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; van Gurp MF, 1999, CANCER RES, V59, P5980; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	50	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16088	16095		10.1074/jbc.M413427200	http://dx.doi.org/10.1074/jbc.M413427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701640	hybrid			2022-12-27	WOS:000228444800076
J	Chung, MK; Guler, AD; Caterina, MJ				Chung, MK; Guler, AD; Caterina, MJ			Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR VR1; OPERATED CA2+ ENTRY; 2-AMINOETHOXYDIPHENYL BORATE; VANILLOID RECEPTOR; CATION CHANNEL; CALCIUM-ENTRY; DIRECT PHOSPHORYLATION; PORE PROPERTIES; BINDING-SITE; PAIN PATHWAY	2-Aminoethyl diphenylborinate was recently identified as a chemical activator of TRPV1, TRPV2, and TRPV3, three heat-gated members of the transient receptor potential vanilloid (TRPV) ion channel subfamily. Here we demonstrated that two structurally related compounds, diphenylboronic anhydride ( DPBA) and diphenyltetrahydrofuran (DPTHF), can also modulate the activity of these channels. DPBA acted as a TRPV3 agonist, whereas DPTHF exhibited prominent antagonistic activity. However, all three diphenyl-containing compounds promoted some degree of channel activation or potentiation, followed by channel block. Strong TRPV3 activation by DPBA often leads to the appearance of a secondary, enhanced, current phase. A similar biphasic response was observed during TRPV3 heat stimulation; an initial, gradually sensitizing phase (I-1) was followed by an abrupt transition to a secondary phase (I-2). I-2 was characterized by larger current amplitude, loss of outward rectification, and alterations in the following properties: permeability among cations; ruthenium red and DPTHF sensitivity; temperature dependence; and voltage-dependent gating. The I-1 to I-2 transition depended strongly on TRPV3 current density. Removal of extracellular divalent cations resulted in heat-evoked currents resembling I-2, whereas mutation of a putative Ca2+-binding residue in the pore loop domain, aspartate 641, facilitated detection of the I-1 to I-2 transition, suggesting that the conversion to I-2 resulted from the agonist- and time-dependent loss of divalent cationic inhibition. Primary keratinocytes overexpressing exogenous TRPV3 also exhibited biphasic agonist- evoked currents. Thus, strong activation by either chemical or thermal stimuli led to biphasic TRPV3 signaling behavior that may be associated with changes in the channel pore.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Caterina, MJ (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, Rm 408,Biophys Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	caterina@jhmi.edu	Chung, Man-Kyo/S-7433-2019	Chung, Man-Kyo/0000-0001-7637-1148; Guler, Ali Deniz/0000-0001-8218-850X				Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Braun FJ, 2003, MOL PHARMACOL, V63, P1304, DOI 10.1124/mol.63.6.1304; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V525, P747, DOI 10.1111/j.1469-7793.2000.t01-1-00747.x; Hellwig N, 2004, J BIOL CHEM, V279, P34553, DOI 10.1074/jbc.M402966200; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Lemonnier L, 2004, FEBS LETT, V556, P121, DOI 10.1016/S0014-5793(03)01387-5; Lyfenko A, 2002, PAIN, V95, P207, DOI 10.1016/S0304-3959(01)00401-8; Ma HT, 2003, BIOCHEM J, V376, P667, DOI 10.1042/BJ20031345; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Meyers JR, 2003, J NEUROSCI, V23, P4054; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Tu CL, 2004, CELL CALCIUM, V35, P265, DOI 10.1016/j.ceca.2003.10.019; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	45	111	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15928	15941		10.1074/jbc.M500596200	http://dx.doi.org/10.1074/jbc.M500596200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722340	hybrid			2022-12-27	WOS:000228444800059
J	Gongadze, GM; Korepanov, AP; Stolboushkina, EA; Zelinskaya, NV; Korobeinikova, AV; Ruzanov, MV; Eliseev, BD; Nikonov, OS; Nikonov, SV; Garber, MB; Lim, VI				Gongadze, GM; Korepanov, AP; Stolboushkina, EA; Zelinskaya, NV; Korobeinikova, AV; Ruzanov, MV; Eliseev, BD; Nikonov, OS; Nikonov, SV; Garber, MB; Lim, VI			The crucial role of conserved intermolecular H-bonds inaccessible to the solvent in formation and stabilization of the TL5 center dot 5 SrRNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN TL5; GENERAL STRESS-PROTEINS; THERMUS-THERMOPHILUS; RNA; EXPRESSION; INSIGHTS; PROVIDES; SUBUNIT; REGION	Analysis of the structures of two complexes of 5 S rRNA with homologous ribosomal proteins, Escherichia coli L25 and Thermus thermophilus TL5, revealed that amino acid residues interacting with RNA can be divided into two different groups. The first group consists of non-conserved residues, which form intermolecular hydrogen bonds accessible to solvent. The second group, comprised of strongly conserved residues, form intermolecular hydrogen bonds that are shielded from solvent. Site-directed mutagenesis was used to introduce mutations into the RNA-binding site of protein TL5. We found that replacement of residues of the first group does not influence the stability of the TL5 center dot 5 S rRNA complex, whereas replacement of residues of the second group leads to destabilization or disruption of the complex. Stereochemical analysis shows that the replacements of residues of the second group always create complexes with uncompensated losses of intermolecular hydrogen bonds. We suggest that these shielded intermolecular hydrogen bonds are responsible for the recognition between the protein and RNA.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Gongadze, GM (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	gongadze@vega.protres.ru	Korobeinikova, Anna/L-8964-2015; Korepanov, Alexey/I-9052-2012; Garber, Maria/I-4262-2013; Gongadze, George/E-6674-2012; Nikonov, Oleg/M-4253-2015; STOLBOUSHKINA, ELENA/J-7732-2015	Garber, Maria/0000-0002-3986-4848; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benson DA, 2004, NUCLEIC ACIDS RES, V32, pD23, DOI 10.1093/nar/gkh045; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; DOUTHWAITE S, 1979, NUCLEIC ACIDS RES, V6, P2453, DOI 10.1093/nar/6.7.2453; Fedorov R, 2001, ACTA CRYSTALLOGR D, V57, P968, DOI 10.1107/S0907444901006291; Frishman D, 2003, NUCLEIC ACIDS RES, V31, P207, DOI 10.1093/nar/gkg005; GONGADZE GM, 1993, FEBS LETT, V330, P46, DOI 10.1016/0014-5793(93)80916-I; Gongadze GM, 1999, FEBS LETT, V451, P51, DOI 10.1016/S0014-5793(99)00538-4; Gryaznova OI, 1996, BIOCHIMIE, V78, P915, DOI 10.1016/S0300-9084(97)86713-2; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein DJ, 2004, J MOL BIOL, V340, P141, DOI 10.1016/j.jmb.2004.03.076; Korepanov AP, 2004, BIOCHEMISTRY-MOSCOW+, V69, P607, DOI 10.1023/B:BIRY.0000033733.60180.e3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim VI, 2001, RNA, V7, P942, DOI 10.1017/S135583820100214X; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; Meshcheryakov VA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P537; Nevskaia N A, 2004, Mol Biol (Mosk), V38, P926; NEVSKAYA N, 2003, PROTEIN STRUCTURES K, P87; Nierhaus K H, 1979, Methods Enzymol, V59, P443; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serganov AA, 1996, RNA, V2, P1124; Stoldt M, 1998, EMBO J, V17, P6377, DOI 10.1093/emboj/17.21.6377; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szymanski M, 2002, NUCLEIC ACIDS RES, V30, P176, DOI 10.1093/nar/30.1.176; Treger M, 2001, J MOL RECOGNIT, V14, P199, DOI 10.1002/jmr.534; VOLKER U, 1994, MICROBIOL-UK, V140, P741, DOI 10.1099/00221287-140-4-741	29	14	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16151	16156		10.1074/jbc.M413596200	http://dx.doi.org/10.1074/jbc.M413596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718233	hybrid			2022-12-27	WOS:000228444800083
J	Jacob, C; Cottrell, GS; Gehringer, D; Schmidlin, F; Grady, EF; Bunnett, NW				Jacob, C; Cottrell, GS; Gehringer, D; Schmidlin, F; Grady, EF; Bunnett, NW			c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; GROWTH-FACTOR RECEPTOR; ARRESTIN-DEPENDENT ENDOCYTOSIS; BETA-ARRESTIN; EGF RECEPTOR; COUPLED RECEPTORS; CELL-PROLIFERATION; PLASMA-MEMBRANE; TRAFFICKING; PHOSPHORYLATION	Mechanisms that arrest G-protein- coupled receptor ( GPCR) signaling prevent uncontrolled stimulation that could cause disease. Although uncoupling from heterotrimeric G-proteins, which transiently arrests signaling, is well described, little is known about the mechanisms that permanently arrest signaling. Here we reported on the mechanisms that terminate signaling by protease-activated receptor 2 (PAR(2)), which mediated the proinflammatory and nociceptive actions of proteases. Given its irreversible mechanism of proteolytic activation, PAR(2) is a model to study the permanent arrest of GPCR signaling. By immunoprecipitation and immunoblotting, we observed that activated PAR(2) was mono-ubiquitinated. Immunofluorescence indicated that activated PAR(2) translocated from the plasma membrane to early endosomes and lysosomes where it was degraded, as determined by immunoblotting. Mutant PAR(2) lacking intracellular lysine residues (PAR(2)Delta 14K/R) was expressed at the plasma membrane and signaled normally but was not ubiquitinated. Activated PAR(2)Delta 14K/R internalized but was retained in early endosomes and avoided lysosomal degradation. Activation of wild type PAR(2) stimulated tyrosine phosphorylation of the ubiquitin-protein isopeptide ligase c-Cbl and promoted its interaction with PAR(2) at the plasma membrane and in endosomes in an Src-dependent manner. Dominant negative c-Cbl lacking the ring finger domain inhibited PAR(2) ubiquitination and induced retention in early endosomes, thereby impeding lysosomal degradation. Although wild type PAR(2) was degraded, and recovery of agonist responses required synthesis of new receptors, lysine mutation and dominant negative c-Cbl impeded receptor ubiquitination and degradation and allowed PAR(2) to recycle and continue to signal. Thus, c-Cbl mediated ubiquitination and lysosomal degradation of PAR(2) to irrevocably terminate signaling by this and perhaps other GPCRs.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus ave,Rm C317, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu	Jacob, Claire/C-1485-2012	Jacob, Claire/0000-0001-9567-3950; Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R01DK052388, R56DK043207, R37DK039957, R01DK039957, R01DK043207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207, DK52388, DK39957, DK57840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; de Melker AA, 2001, J CELL SCI, V114, P2167; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dupre DJ, 2003, J BIOL CHEM, V278, P48228, DOI 10.1074/jbc.M304082200; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Luttrell LM, 2002, J CELL SCI, V115, P455; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Scaife RM, 2000, J CELL SCI, V113, P215; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308	42	113	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16076	16087		10.1074/jbc.M500109200	http://dx.doi.org/10.1074/jbc.M500109200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708858	hybrid			2022-12-27	WOS:000228444800075
J	Yi, XP; McChargue, M; Laborde, S; Frankel, LK; Bricker, TM				Yi, XP; McChargue, M; Laborde, S; Frankel, LK; Bricker, TM			The manganese-stabilizing protein is required for photosystem II assembly/stability and photoautotrophy in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN EVOLUTION; COMPLEX; MUTANTS; TRANSFORMATION; COMPONENTS; PARTICLES; PCC6803; GENES; LUMEN; OEE1	Interfering RNA was used to suppress the expression of two genes that encode the manganese-stabilizing protein of photosystem II in Arabidopsis thaliana, MSP-1 ( encoded by psbO-1, At5g66570), and MSP-2 ( encoded by psbO-2, At3g50820). A phenotypic series of transgenic plants was recovered that expressed high, intermediate, and low amounts of these two manganese-stabilizing proteins. Chlorophyll fluorescence induction and decay analyses were performed. Decreasing amounts of expressed protein led to the progressive loss of variable fluorescence and a marked decrease in the fluorescence quantum yield (F-v/F-m) in both the absence and the presence of dichloromethylurea. This result indicated that the amount of functional photosystem II reaction centers was compromised in the plants that exhibited intermediate and low amounts of the manganese-stabilizing proteins. An analysis of the decay of the variable fluorescence in the presence of dichlorophenyldimethylurea indicated that charge recombination between Q(A)(-) and the S-2 state of the oxygen-evolving complex was seriously retarded in the plants that expressed low amounts of the manganese-stabilizing proteins. This may have indicated a stabilization of the S2 state in the absence of the extrinsic component. Immunological analysis of the photosystem II protein complement indicated that significant losses of the CP47, CP43, and D1 proteins occurred upon the loss of the manganese-stabilizing proteins. This indicated that these extrinsic proteins were required for photosystem II core assembly/stability. Additionally, although the quantity of the 24-kDa extrinsic protein was only modestly affected by the loss of the manganese-stabilizing proteins, the 17-kDa extrinsic protein dramatically decreased. The control proteins ribulose bisphosphate carboxylase and cytochrome f were not affected by the loss of the manganese-stabilizing proteins; the photosystem I PsaB protein, however, was significantly reduced in the low expressing transgenic plants. Finally, it was determined that the transgenic plants that expressed low amounts of the manganese-stabilizing proteins could not grow photoautotrophically.	Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Bricker, TM (corresponding author), Louisiana State Univ, Dept Biol Sci, Biochem & Mol Biol Sect, Baton Rouge, LA 70803 USA.	btbric@lsu.edu						ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 2005, PHOTOSYSTEM, V2; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6137, DOI 10.1021/bi00186a013; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; ENGELS DH, 1994, PHOTOSYNTH RES, V42, P227, DOI 10.1007/BF00018265; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Frankel LK, 1999, BIOCHEMISTRY-US, V38, P14271, DOI 10.1021/bi991366v; HAILTON AJ, 1999, SCIENCE, V286, P950; HASHIMOTO A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P397, DOI 10.1016/0005-2728(93)90245-B; Hashimoto A, 1996, FEBS LETT, V391, P29; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Murakami R, 2002, FEBS LETT, V523, P138, DOI 10.1016/S0014-5793(02)02963-0; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; ZHAO D, 2003, PLANT PHYSIOL, V133, P1	29	124	132	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16170	16174		10.1074/jbc.M501550200	http://dx.doi.org/10.1074/jbc.M501550200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722336	Green Published, hybrid			2022-12-27	WOS:000228444800086
J	Drury, J; Narayanaswami, V				Drury, J; Narayanaswami, V			Examination of lipid-bound conformation of apolipoprotein E4 by pyrene excimer fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; REVERSE CHOLESTEROL TRANSPORT; HUMAN-PLASMA-LIPOPROTEINS; HIGH-DENSITY-LIPOPROTEIN; C-TERMINAL DOMAIN; APOLIPOPHORIN-III; ALZHEIMERS-DISEASE; PROTEIN STABILITY; ESCHERICHIA-COLI; LACTOSE PERMEASE	Apolipoprotein E (apoE) is a 34-kDa resident of lipoproteins that plays a key role in cholesterol homeostasis in plasma and in brain. It is composed of an N-terminal (NT) domain (residues 1-191) and a C-terminal (CT) domain (residues 201-299). Of the three major isoforms (apoE2, -E3, and -E4), apoE4 is considered a risk factor for both cardiovascular and Alzheimer disease. Compared with apoE3, domain interaction between NT and CT domains is believed to direct the lipoprotein distribution preference of apoE4 for very low density lipoprotein-sized particles. We examined the relative disposition of apoE4 NT and CT domains in lipid-free and lipid-bound forms by monitoring pyrene excimer fluorescence emission as a direct indicator of spatial proximity. Site-specific labeling of apoE4 by N-(1-pyrene)maleimide was accomplished after substitution of Cys residues for Arg-61 in NT domain and Glu-255 in CT domain. Pyrene labeling did not alter the lipoprotein distribution pattern of apoE4 in plasma. Pyrene excimer fluorescence was noted in lipid-free pyrene-R61C/E255C/apoE4 in mixtures containing excess wildtype apoE4, which was attributed to intramolecular spatial proximity between these specified sites. Upon disruption of tertiary interaction, a large decrease in excimer fluorescence emission was noted in pyrene-R61C/E255C/apoE4. In dimyristoylphosphatidylcholine/pyrene-R61C/E255C/apoE4 discoidal complexes, pyrene excimer fluorescence emission was retained. Taken together with fluorescence quenching and cross-linking analysis, a looped-back model of apoE4 is proposed in lipid-bound state, including spherical lipoprotein particles, wherein residues Arg-61 and Glu-255 are proximal to one another.	Childrens Hosp Oakland, Res Inst, Lipid Biol Hlth & Dis Res Grp, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Narayanaswami, V (corresponding author), 5700 Martin Luther King Way, Oakland, CA 94609 USA.	vnarayan@chori.org		Narayanaswami, Vasanthy/0000-0001-7088-4057				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AKKE M, 1990, PROTEINS, V8, P23, DOI 10.1002/prot.340080106; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Hammarstrom P, 1997, FEBS LETT, V420, P63, DOI 10.1016/S0014-5793(97)01488-9; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; NAKAJIMA A, 1971, B CHEM SOC JPN, V44, P3272, DOI 10.1246/bcsj.44.3272; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2004, J BIOL CHEM, V279, P14273, DOI 10.1074/jbc.M313318200; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Sahoo D, 2000, BIOCHEMISTRY-US, V39, P6594, DOI 10.1021/bi992609m; Sahoo D, 1998, J BIOL CHEM, V273, P1403, DOI 10.1074/jbc.273.3.1403; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SEGREST JP, 1992, J LIPID RES, V33, P141; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Yamana K, 1999, NUCLEIC ACIDS RES, V27, P2387, DOI 10.1093/nar/27.11.2387; YOKOYAMA S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P99, DOI 10.1016/0005-2760(90)90266-Z; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	60	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14605	14610		10.1074/jbc.M414019200	http://dx.doi.org/10.1074/jbc.M414019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708851	hybrid			2022-12-27	WOS:000228236800034
J	Yamanaka, N; Hua, YJ; Mizoguchi, A; Watanabe, K; Niwa, R; Tanaka, Y; Kataoka, H				Yamanaka, N; Hua, YJ; Mizoguchi, A; Watanabe, K; Niwa, R; Tanaka, Y; Kataoka, H			Identification of a novel prothoracicostatic hormone and its receptor in the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ECDYSONE BIOSYNTHESIS; NEUROSECRETORY-CELLS; JUVENILE-HORMONE; BLOWFLY LARVAE; MANDUCA-SEXTA; NEUROPEPTIDE; BRAIN; PEPTIDE; DROSOPHILA	The insect brain regulates the activity of the prothoracic glands to secrete ecdysteroids, which affect growth, molting, and metamorphosis. Here we report the identification of a novel prothoracicostatic factor and its receptor in the silkworm Bombyx mori. The prothoracicostatic factor purified from pupal brains of B. mori is a decapeptide with the conserved structure of an insect myosuppressin and thus named Bommo-myosuppressin. Bommo-myosuppressin dose dependently suppressed the cAMP level and inhibited ecdysteroido-genesis in the larval prothoracic glands at much lower concentrations than the prothoracicostatic peptide, the other prothoracicostatic factor reported previously. In vitro analyses using a prothoracic gland incubation method revealed that Bommo-myosuppressin and prothoracicostatic peptide regulate the prothoracic gland activity via different receptors. In situ hybridization and immunohistochemistry revealed the existence of Bommo-myosuppressin in the brain neurosecretory cells projecting to neurohemal organs in which it is stored. We also identified and functionally characterized a specific receptor for Bommo-myosuppressin and showed its high expression in the prothoracic glands. All these results suggest that Bommo-myosuppressin functions as a prothoracicostatic hormone and plays an important role in controlling insect development.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan; Zhejiang Univ, Inst Nuclearagr Sci, Zhejiang 310029, Peoples R China; Nagoya Univ, Div Biol Sci, Grad Sch Sci, Nagoya, Aichi 4648602, Japan; Natl Inst Agrobiol Sci, Lab Insect Growth Regulat, Tsukuba 3058634, Japan	University of Tokyo; Zhejiang University; Nagoya University; National Institute of Agrobiological Sciences - Japan	Kataoka, H (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan.	kataoka@k.u-tokyo.ac.jp	Yamanaka, Naoki/F-1358-2010	Yamanaka, Naoki/0000-0002-6244-2686				BUDD E, 1993, ARCH INSECT BIOCHEM, V23, P181, DOI 10.1002/arch.940230405; CARLISLE DB, 1968, NATURE, V220, P706, DOI 10.1038/220706a0; Coast GM, 1998, PEPTIDES, V19, P469, DOI 10.1016/S0196-9781(97)00461-0; Egerod K, 2003, P NATL ACAD SCI USA, V100, P9808, DOI 10.1073/pnas.1632197100; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; Gu SH, 1996, J INSECT PHYSIOL, V42, P625, DOI 10.1016/0022-1910(96)00025-X; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V85, P329, DOI 10.1016/0742-8413(86)90202-1; Hua YJ, 1999, J BIOL CHEM, V274, P31169, DOI 10.1074/jbc.274.44.31169; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; Ichikawa T, 1995, ZOOL SCI, V12, P703, DOI 10.2108/zsj.12.703; ISHIBASHI J, 1994, BIOCHEMISTRY-US, V33, P5912, DOI 10.1021/bi00185a031; ISHIZAKI H, 1994, INT J DEV BIOL, V38, P301; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; KINGAN TG, 1990, PEPTIDES, V11, P849, DOI 10.1016/0196-9781(90)90203-H; KIRIISHI S, 1992, ZOOL SCI, V9, P149; Kopec S, 1922, BIOL BULL-US, V42, P323, DOI 10.2307/1536759; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Labrouche S, 1998, J NEUROENDOCRINOL, V10, P559, DOI 10.1046/j.1365-2826.1998.00241.x; Lange AB, 1998, PEPTIDES, V19, P459, DOI 10.1016/S0196-9781(97)00465-8; Liu X, 2004, ARCH INSECT BIOCHEM, V56, P155, DOI 10.1002/arch.20005; Lu D, 2002, J COMP NEUROL, V446, P377, DOI 10.1002/cne.10205; MACKEY SL, 1987, P NATL ACAD SCI USA, V84, P8730, DOI 10.1073/pnas.84.23.8730; MALA J, 1977, J INSECT PHYSIOL, V23, P309, DOI 10.1016/0022-1910(77)90267-0; Matsuoka T, 2000, DEV GENES EVOL, V210, P120, DOI 10.1007/s004270050018; Mita K, 2003, P NATL ACAD SCI USA, V100, P14121, DOI 10.1073/pnas.2234984100; MIZOGUCHI A, 1990, DEV GROWTH DIFFER, V32, P591; Mizoguchi A, 2001, J INSECT PHYSIOL, V47, P767, DOI 10.1016/S0022-1910(01)00052-X; NAGATA K, 1992, PEPTIDES, V13, P653, DOI 10.1016/0196-9781(92)90169-4; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; Nichols R, 2003, ANNU REV ENTOMOL, V48, P485, DOI 10.1146/annurev.ento.48.091801.112525; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; Orchard I, 2002, PEPTIDES, V23, P693, DOI 10.1016/S0196-9781(01)00663-5; ROBB S, 1989, BIOCHEM BIOPH RES CO, V160, P850, DOI 10.1016/0006-291X(89)92512-6; Roller L, 2003, CELL TISSUE RES, V312, P393, DOI 10.1007/s00441-003-0722-4; Sakurai S, 1998, J INSECT PHYSIOL, V44, P867, DOI 10.1016/S0022-1910(98)00075-4; WANG Z, 1995, NEUROPEPTIDES, V28, P147, DOI 10.1016/0143-4179(95)90109-4; WILLIAMS CM, 1947, BIOL BULL, V93, P89, DOI 10.2307/1538279; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	41	71	74	4	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14684	14690		10.1074/jbc.M500308200	http://dx.doi.org/10.1074/jbc.M500308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701625	hybrid			2022-12-27	WOS:000228236800044
J	Browne, RJ; Barr, EW; Stitt, BL				Browne, RJ; Barr, EW; Stitt, BL			Catalytic cooperativity among subunits of Escherichia coli transcription termination factor Rho - Kinetics and substrate structural requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ATP-BINDING DOMAINS; PROTEIN-RHO; CONFORMATIONAL-CHANGES; TRYPTOPHAN SYNTHASE; NUCLEOTIDE-BINDING; HYDROLYTIC SITES; AMP DEAMINASE; MECHANISM; RNA	Escherichia coli transcription termination factor Rho shows a 30-fold faster rate of ATP hydrolysis when all three catalytic sites are filled with ATP than when only a single site is filled (Stitt, B. L. and Xu, Y. ( 1998) J. Biol. Chem. 273, 26477-26486). To study the structural requirements of the substrate for this catalytic cooperativity, rapid mix/chemical quench experiments using various ATP analogs were performed. The results indicate that it is the configuration of the beta- and gamma-phosphoryl groups of ATP that is of primary importance for the rate enhancement. Our results also show that there are kinetically slow branches of the enzyme mechanism that are not seen when the chemistry step of the catalytic cycle is fast. These branches become prominent, however, when two of the three Rho active sites are empty or bear non-hydrolyzable compounds. A first-order step that is slow compared with V-max catalysis enables a single ATP molecule bound in any one of the three Rho active sites to be hydrolyzed and defines the kinetically slow branches. This first-order step could be a protein conformation change or a rearrangement of bound RNA. The results reinforce the importance of catalytic cooperativity in normal Rho function and suggest that several protein conformations exist along the catalytic pathway.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	stitt@temple.edu			NIGMS NIH HHS [GM60247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DAWSON RMC, 1986, DATA BIOCH RES, P485; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; Garcia JJ, 1997, EUR J BIOCHEM, V249, P622, DOI 10.1111/j.1432-1033.1997.00622.x; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GLYNN JM, 1964, BIOCHEM J, V90, P147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Jeong YJ, 2004, J BIOL CHEM, V279, P18370, DOI 10.1074/jbc.M309162200; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEET KE, 1995, METHOD ENZYMOL, V249, P519; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Raboni S, 2003, BBA-PROTEINS PROTEOM, V1647, P157, DOI 10.1016/S1570-9639(03)00084-0; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; WEBB MR, 1982, METHOD ENZYMOL, V87, P301; WEBER J, 1993, J BIOL CHEM, V268, P20126; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	33	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13292	13299		10.1074/jbc.M500221200	http://dx.doi.org/10.1074/jbc.M500221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703178	hybrid			2022-12-27	WOS:000228095500014
J	Shpanchenko, OV; Zvereva, MI; Ivanov, PV; Bugaeva, EY; Rozov, AS; Bogdanov, AA; Kalkum, M; Isaksson, LA; Nierhaus, KH; Dontsova, OA				Shpanchenko, OV; Zvereva, MI; Ivanov, PV; Bugaeva, EY; Rozov, AS; Bogdanov, AA; Kalkum, M; Isaksson, LA; Nierhaus, KH; Dontsova, OA			Stepping transfer messenger RNA through the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSLATION TERMINATION; STALLED RIBOSOME; TAGGING SYSTEM; 10SA RNA; TMRNA; PROTEINS; BINDING; SMPB; IDENTIFICATION	tmRNA ( transfer messenger RNA) is a unique molecule used by all bacteria to rescue stalled ribosomes and to mark unfinished peptides with a specific degradation signal. tmRNA is recruited by arrested ribosomes in which it facilitates the translational switch from cellular mRNA to the mRNA part of tmRNA. Small protein B (SmpB) is a key partner for the trans-translation activity of tmRNA both in vivo and in vitro. It was shown that SmpB acts at the initiation step of the trans-translation process by facilitating tmRNA aminoacylation and binding to the ribosome. Little is known about the subsequent steps of trans-translation. Here we demonstrated the first example of an investigation of tmRNA.ribosome complexes at different stages of trans-translation. Our results show that the structural element at the position of tmRNA pseudoknot 3 remains intact during the translation of the mRNA module of tmRNA and that it is localized on the surface of the ribosome. At least one SmpB molecule remains bound to a ribosome.tmRNA complex isolated from the cell when translation is blocked at different positions within the mRNA part of tmRNA.	Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia; AG Ribosomen, Max Planck Inst Mol Genet, D-14195 Berlin, Germany; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Stockholm Univ, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	Lomonosov Moscow State University; Max Planck Society; City of Hope; Beckman Research Institute of City of Hope; Stockholm University	Dontsova, OA (corresponding author), Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia.	dontsova@genebee.msu.su	Shpanchenko, Olga/C-7813-2015; Dontsova, Olga/T-6072-2019; Rozov, Andrei/C-1997-2015; Zvereva, Maria Imilievna/J-9724-2013; Ivanov, Pavel/AAZ-9197-2021; Bogdanov, Alexey A/L-1407-2013; Ivanov, Pavel/F-3339-2016	Zvereva, Maria Imilievna/0000-0002-7432-1574; Ivanov, Pavel/0000-0002-7986-7760; Ivanov, Pavel/0000-0002-7986-7760; Rozov, Alexey/0000-0003-2545-1978; Kalkum, Markus/0000-0002-9506-671X				Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bjornsson A, 1996, NUCLEIC ACIDS RES, V24, P1753, DOI 10.1093/nar/24.9.1753; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Ivanov PV, 2002, FEBS LETT, V514, P55, DOI 10.1016/S0014-5793(02)02310-4; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Leonov AA, 2003, J BIOL CHEM, V278, P25664, DOI 10.1074/jbc.M302873200; Mukherjee S, 2003, BIOTECHNOL APPL BIOC, V37, P183, DOI 10.1042/BA20020044; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; NOWOTNY P, 1988, METHOD ENZYMOL, V164, P131; ODOM OW, 1984, ARCH BIOCHEM BIOPHYS, V230, P178, DOI 10.1016/0003-9861(84)90099-7; PLATT T, 1972, EXPT MOL GENETICS, P352; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; RUDINGERTHIRION J, 1999, RNA, V5, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Srisawat C, 2001, RNA, V7, P632, DOI 10.1017/S135583820100245X; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063	37	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18368	18374		10.1074/jbc.M409094200	http://dx.doi.org/10.1074/jbc.M409094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15713678	hybrid			2022-12-27	WOS:000228807200098
J	Wagner, C; Russwurm, M; Jager, R; Friebe, A; Koesling, D				Wagner, C; Russwurm, M; Jager, R; Friebe, A; Koesling, D			Dimerization of nitric oxide-sensitive guanylyl cyclase requires the alpha(1) N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOVASCULAR-SYSTEM; HEME-BINDING; SUBUNITS; IDENTIFICATION; ACTIVATION; ISOFORM; ENZYME	The enzyme nitric oxide-sensitive guanylyl cyclase is an obligate heterodimer consisting of an alpha and a beta subunit. Whereas the C-terminal parts of the subunits have been shown to be sufficient for catalysis, regulation was assigned to the N termini. The central domains have been postulated to be responsible for the formation of alpha beta heterodimers. Here, we have analyzed dimerization by precipitation of various N- and C-terminally truncated alpha(1) mutants with beta(1) wild type or deletion mutants thereof after coexpression in the baculovirus/Sf9 system. In contrast to the current hypothesis, our analysis revealed that an N- terminal region of the alpha(1) subunit (amino acids 61-128) is mandatory for quantitative dimerization. The central domain (amino acids 367-462) contributes but is not sufficient to mediate robust alpha beta interaction. Wild type-like binding of the identified minimum dimerization region of alpha(1) (amino acids 61-462) requires the N- terminal and central region of alpha(1) (amino acids 1-385). Furthermore, we observed an unequal stability of the alpha(1) and beta(1) subunit. Whereas beta(1) forms heme containing homodimers and is stable, alpha(1) appears to be prone to misfolding and degradation when heterodimerization is impaired by deletion of important sequences.	Ruhr Univ Bochum, Inst Pharmakol & Toxikol, Fak Med, D-44780 Bochum, Germany	Ruhr University Bochum	Koesling, D (corresponding author), Ruhr Univ Bochum, Inst Pharmakol & Toxikol, Fak Med, MA N1, D-44780 Bochum, Germany.	doris.koesling@ruhr-uni-bochum.de						Biel M, 1999, ADV SEC MESS PHOSPH, V33, P231; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Gambaryan S, 2004, BLOOD, V103, P2593, DOI 10.1182/blood-2003-09-3349; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Koglin M, 2003, J BIOL CHEM, V278, P12590, DOI 10.1074/jbc.M212740200; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; Meurer S, 2004, J BIOL CHEM, V279, P49346, DOI 10.1074/jbc.M410565200; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B; Schultz G., 1984, METHOD ENZYMAT AN, P379; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhou ZM, 2004, J BIOL CHEM, V279, P24935, DOI 10.1074/jbc.M402105200	25	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17687	17693		10.1074/jbc.M412099200	http://dx.doi.org/10.1074/jbc.M412099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749699	hybrid			2022-12-27	WOS:000228807200017
J	Nakav, S; Jablonka-Shariff, A; Kaner, S; Chadna-Mohanty, P; Grotjan, HE; Ben-Menahem, D				Nakav, S; Jablonka-Shariff, A; Kaner, S; Chadna-Mohanty, P; Grotjan, HE; Ben-Menahem, D			The LH beta gene of several mammals embeds a carboxyl-terminal peptide-like sequence revealing a critical role for mucin oligosaccharides in the evolution of lutropin to chorionic gonadotropin in the animal phyla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE-BETA; O-GLYCOSYLATION SITES; SUBUNIT PRECURSOR MOLECULES; AMINO-ACID-SEQUENCES; LINKED GLYCOSYLATION; SECRETORY GRANULES; SUBMAXILLARY MUCIN; TRANSGENIC MICE; HUMAN PLACENTA; MESSENGER-RNA	The expression of a previously untranslated carboxyl-terminal sequence is associated with the ancestral lutropin (LH) beta to the beta-subunit gene evolution of choriogonadotropins (CG). The peptide extension ( denoted as CTP) is rich in mucin-type O-glycans and confers new hormonal properties on CG relative to the LH. Although the LH beta gene is conserved among mammals and only a few frameshift mutations account for the extension, it is merely seen in primates and equids. Bioinformatics identified a CTP-like sequence that is encrypted in the LH beta gene of several mammalian species but not in birds, amphibians, or fish. We then examined whether or not decoding of the cryptic CTP in the bovine LH beta gene (boCTP) would be sufficient to generate the LH beta species of a ruminant with properties typical to the CG beta subunit. The mutated bovine LH beta-boCTP subunit was expressed and N-glycosylated in transfected Chinese hamster ovary cells. However, unlike human ( h) CG beta CTP, the cryptic boCTP was devoid of mucin O-glycans. This deficiency was further confirmed when the boCTP domain was substituted for the natural CTP in the human CG beta subunit. Moreover, when expressed in polarized Madin-Darby canine kidney cells, this hCG beta-boCTP chimera was secreted basolaterally rather than from the apical compartment, which is the route of the wild type hCG beta subunit, a sorting function attributed to the O-glycans attached to the CTP. This result shows that the cryptic peptide does not orientate CG to the apical face of the placenta, to the maternal circulation as seen in primates. The absence of this function, which distinguishes CG from LH, provides an explanation as to why the LH beta to CG beta evolution did not occur in ruminants. We propose that in primates and equids, further natural mutations in the progenitor LH beta gene resulted in the efficient O-glycosylation of the CTP, thus favoring the retention of an elongated reading frame.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Nebraska, Dept Anim Sci, Lincoln, NE 68583 USA	Ben Gurion University; Washington University (WUSTL); University of Nebraska System; University of Nebraska Lincoln	Ben-Menahem, D (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel.	dbm@bgumail.bgu.ac.il		Ben-Menahem, David/0000-0002-8985-0591				ANDO H, 1994, GEN COMP ENDOCR, V93, P357, DOI 10.1006/gcen.1994.1040; Bousfield GR, 2001, BIOL REPROD, V64, P136, DOI 10.1095/biolreprod64.1.136; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; Catt KJ, 1986, REPRODUCTIVE ENDOCRI, P75; CHILDS GV, 1980, AM J ANAT, V158, P397, DOI 10.1002/aja.1001580403; CHOPINEAU M, 1995, GENE, V160, P253, DOI 10.1016/0378-1119(95)00150-5; Chopineau M, 1999, J REPROD FERTIL, V115, P159; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; CRAWFORD RJ, 1986, GENE, V46, P161, DOI 10.1016/0378-1119(86)90400-2; CURRIE RJW, 1995, J ENDOCRINOL, V147, P259, DOI 10.1677/joe.0.1470259; EZASHI T, 1990, J MOL ENDOCRINOL, V5, P137, DOI 10.1677/jme.0.0050137; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; Fritz TA, 2004, P NATL ACAD SCI USA, V101, P15307, DOI 10.1073/pnas.0405657101; Gerken TA, 2002, J BIOL CHEM, V277, P49850, DOI 10.1074/jbc.M205851200; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Harrison GA, 1998, MAMM GENOME, V9, P638; HASSIN S, 1995, J MOL ENDOCRINOL, V15, P23, DOI 10.1677/jme.0.0150023; HILL HD, 1977, J BIOL CHEM, V252, P3799; ILES RK, 1992, J ENDOCRINOL, V135, P563, DOI 10.1677/joe.0.1350563; Jablonka-Shariff A, 2004, BIOL REPROD, V70, P649, DOI 10.1095/biolreprod.103.022699; Jablonka-Shariff A, 2002, J BIOL CHEM, V277, P879, DOI 10.1074/jbc.C100402200; JAMESON L, 1984, J BIOL CHEM, V259, P5474; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; KAETZEL DM, 1989, MOL ENDOCRINOL, V3, P1765, DOI 10.1210/mend-3-11-1765; Komoike Y, 2003, GEN COMP ENDOCR, V132, P333, DOI 10.1016/S0016-6480(03)00095-9; Kumar TR, 1995, GENE, V166, P335, DOI 10.1016/0378-1119(96)81753-7; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; Mamluk R, 1998, BIOL REPROD, V58, P849, DOI 10.1095/biolreprod58.3.849; Maston GA, 2002, MOL BIOL EVOL, V19, P320, DOI 10.1093/oxfordjournals.molbev.a004085; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; Muyan M, 1998, MOL ENDOCRINOL, V12, P766, DOI 10.1210/me.12.5.766; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; RAO CV, 1981, J BIOL CHEM, V256, P2628; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; ROBERTS RM, 1989, BIOL REPROD, V40, P449, DOI 10.1095/biolreprod40.3.449; SEKINE S, 1989, P NATL ACAD SCI USA, V86, P8645, DOI 10.1073/pnas.86.22.8645; SENGER PL, 2003, PATHWAYS PREGNANCY P, P248; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; Sherman GB, 2001, J MOL ENDOCRINOL, V26, P267, DOI 10.1677/jme.0.0260267; Sherman GB, 1997, GENE, V195, P131, DOI 10.1016/S0378-1119(97)00080-2; SIMULA AP, 1995, BIOL REPROD, V53, P380, DOI 10.1095/biolreprod53.2.380; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THIEDE HA, 1963, OBSTET GYNECOL, V22, P433; Thomas SG, 1997, ENDOCRINOLOGY, V138, P1347, DOI 10.1210/en.138.3.1347; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WOLF DL, 1987, NUCLEIC ACIDS RES, V15, P10602, DOI 10.1093/nar/15.24.10602; WYNN RM, 1972, AM J OBSTET GYNECOL, V114, P339, DOI 10.1016/0002-9378(72)90612-6; Yoshiura Y, 1997, GEN COMP ENDOCR, V105, P379, DOI 10.1006/gcen.1996.6839; YOU S, 1995, J MOL ENDOCRINOL, V14, P117, DOI 10.1677/jme.0.0140117	57	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16676	16684		10.1074/jbc.M500730200	http://dx.doi.org/10.1074/jbc.M500730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723833	hybrid			2022-12-27	WOS:000228615500019
J	Snyder, EM; Colledge, M; Crozier, RA; Chen, WS; Scott, JD; Bear, MF				Snyder, EM; Colledge, M; Crozier, RA; Chen, WS; Scott, JD; Bear, MF			Role for A kinase-anchoring proteins (AKAPS) in glutamate receptor trafficking and long term synaptic depression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT SYNAPSES; PHOSPHORYLATION SITES; AMPA RECEPTORS; GLUR1 SUBUNIT; ACTIVATION; LTP; HIPPOCAMPUS; INVOLVEMENT; EXPRESSION; PLASTICITY	Expression of N-methyl D-aspartate ( NMDA) receptor-dependent homosynaptic long term depression at synapses in the hippocampus and neocortex requires the persistent dephosphorylation of postsynaptic protein kinase A substrates. An attractive mechanism for expression of long term depression is the loss of surface AMPA (alpha-amino-3-hydroxy-5-methylisoxazale-4-propionate) receptors at synapses. Here we show that a threshold level of NMDA receptor activation must be exceeded to trigger a stable loss of AMPA receptors from the surface of cultured hippocampal neurons. NMDA also causes displacement of protein kinase A from the synapse, and inhibiting protein kinase A (PKA) activity mimics the NMDA-induced loss of surface AMPA receptors. PKA is targeted to the synapse by an interaction with the A kinase-anchoring protein, AKAP79/150. Disruption of the PKA-AKAP interaction is sufficient to cause a long-lasting reduction in synaptic AMPA receptors in cultured neurons. In addition, we demonstrate in hippocampal slices that displacement of PKA from AKADs occludes synaptically induced long term depression. These data indicate that synaptic anchoring of PKA through association with AKAPs plays an important role in the regulation of AMPA receptor surface expression and synaptic plasticity.	MIT, Howard Hughes Med Inst, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97239 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Oregon Health & Science University	Bear, MF (corresponding author), MIT, Howard Hughes Med Inst, Picower Ctr Learning & Memory, E19-551,77 Massachusetts Ave, Cambridge, MA 02139 USA.	mbear@mit.edu		Crozier, Robert/0000-0003-0134-3972; Bear, Mark/0000-0002-9903-2541	NIGMS NIH HHS [GM48231, R37 GM048231, R01 GM048231] Funding Source: Medline; NINDS NIH HHS [P01 NS039321, NS39321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Becker JW, 1999, J MED CHEM, V42, P2798, DOI 10.1021/jm9806042; Bernstein MA, 1998, EUR J PHARMACOL, V341, P173, DOI 10.1016/S0014-2999(97)01502-1; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; CARR DW, 1992, J BIOL CHEM, V267, P16816; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Chung HJ, 2000, J NEUROSCI, V20, P7258; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Genin A, 2003, EUR J NEUROSCI, V17, P331, DOI 10.1046/j.1460-9568.2003.02462.x; Gomez LL, 2002, J NEUROSCI, V22, P7027; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Heynen AJ, 2003, NAT NEUROSCI, V6, P854, DOI 10.1038/nn1100; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kolleker A, 2003, NEURON, V40, P1199, DOI 10.1016/S0896-6273(03)00722-0; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lee HW, 1999, J NEUROCHEM, V73, P1769, DOI 10.1046/j.1471-4159.1999.731769.x; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liu JM, 2004, J NEUROSCI, V24, P2465, DOI 10.1523/JNEUROSCI.4331-03.2004; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Moita MAP, 2002, NAT NEUROSCI, V5, P837, DOI 10.1038/nn901; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002	44	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16962	16968		10.1074/jbc.M409693200	http://dx.doi.org/10.1074/jbc.M409693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718245	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000228615500052
J	Denton, CP; Lindahl, GE; Khan, K; Xu, SW; Ong, VH; Gaspar, NJ; Lazaridis, K; Edwards, DR; Leask, A; Eastwood, M; Leoni, P; Renzoni, EA; Gharios, GB; Abraham, DJ; Black, CM				Denton, CP; Lindahl, GE; Khan, K; Xu, SW; Ong, VH; Gaspar, NJ; Lazaridis, K; Edwards, DR; Leask, A; Eastwood, M; Leoni, P; Renzoni, EA; Gharios, GB; Abraham, DJ; Black, CM			Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-beta receptor (T beta RII Delta k)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SCLERODERMA FIBROBLASTS; SYSTEMIC-SCLEROSIS; GENE-EXPRESSION; SIGNALING PATHWAYS; DERMAL FIBROBLASTS; SKIN; FIBROSIS; MATRIX; INHIBITOR	We have generated transgenic mice expressing a kinase-deficient type II transforming growth factor-beta (TGF beta) receptor selectively on fibroblasts (T beta RII Delta k-fib). These mice develop dermal and pulmonary fibrosis. In the present study we explore activation of TGF beta signaling pathways in this strain and examine the profibrotic properties of explanted transgenic fibroblasts including myofibroblast differentiation and abnormal metalloproteinase production. Gene expression profiles of littermate wild type or transgenic fibroblasts were compared using high-density gene arrays and validated by Taqman reverse transcriptase-PCR, Northern and Western blotting. Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon T beta RI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGF beta together with increased levels of wild type T beta RII. Moreover, we confirm that transgene expression is itself regulated by TGF beta and that expression at low levels facilitates signaling, whereas high level expression is inhibitory. For a subset of TGF beta responsive genes basal up-regulation is normalized or suppressed by exogenous recombinant TGF beta 1 at time points coincident with increased transgene expression. These findings explain the profound refractoriness of T beta RII Delta k-fib fibroblasts to exogenous TGF beta 1, despite their activated phenotype. Thus, transgenic fibroblasts recapitulate many hallmark biochemical properties of fibrotic cells, including high level CTGF (CCN2) expression and type I collagen overproduction, altered MMP production, and myofibroblast differentiation. These cells also show an enhanced ability to contract collagen gel matrices. Our study demonstrates that altered high affinity TGF beta receptor function may lead to ligand-dependent activation of downstream signaling, and provides further evidence of a pivotal role for sustained TGF beta overactivity in fibrosis.	UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London NW3 2PF, England; Scios Inc, Fremont, CA 94555 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ London Imperial Coll Sci Technol & Med, Interstitial Lung Dis Unit, London SW7 2BU, England; Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2BU, England; Univ Westminster, London W1W 6UW, England	University of London; University College London; UCL Medical School; Scios; University of East Anglia; Imperial College London; Imperial College London; University of Westminster	Denton, CP (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, Rowland Hill St,Hampstead Campus, London NW3 2PF, England.	c.denton@medsch.ucl.ac.uk	Ong, Voon/AAB-9836-2020; Lazaridis, Konstantinos/AAB-2761-2022; Edwards, Dylan R/B-4734-2009; Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020	Edwards, Dylan R/0000-0002-3292-2064; Lazaridis, Konstantinos/0000-0003-4386-2578; Renzoni, Elisabetta/0000-0002-1118-797X				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels JT, 2003, AM J PATHOL, V163, P2043, DOI 10.1016/S0002-9440(10)63562-6; Denton CP, 2004, AUTOIMMUN REV, V3, P285, DOI 10.1016/j.autrev.2003.10.003; Denton CP, 2001, ARTHRITIS RHEUM-US, V44, P712; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; DENTON CP, 2004, ARTHRITIS RHEUM S34, V50; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Feghali CA, 1999, ARTHRITIS RHEUM-US, V42, P1451, DOI 10.1002/1529-0131(199907)42:7<1451::AID-ANR19>3.0.CO;2-6; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Haverty PM, 2004, BIOINFORMATICS, V20, P3431, DOI 10.1093/bioinformatics/bth421; Holmes A, 2003, J BIOL CHEM, V278, P41728, DOI 10.1074/jbc.M305019200; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jelaska A, 2000, ARTHRITIS RHEUM-US, V43, P2230, DOI 10.1002/1529-0131(200010)43:10<2230::AID-ANR10>3.0.CO;2-8; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; KIRK TZ, 1995, J BIOL CHEM, V270, P3423, DOI 10.1074/jbc.270.7.3423; Kissin Eugene, 2002, Curr Rheumatol Rep, V4, P129, DOI 10.1007/s11926-002-0008-y; Kubo M, 2002, J RHEUMATOL, V29, P2558; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2002, ARTHRITIS RHEUM-US, V46, P1857, DOI 10.1002/art.10333; Mirastschijski U, 2004, EXP CELL RES, V299, P465, DOI 10.1016/j.yexcr.2004.06.007; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Pannu J, 2004, ARTHRITIS RHEUM-US, V50, P1566, DOI 10.1002/art.20225; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Strehlow D, 1999, J CLIN INVEST, V103, P1179, DOI 10.1172/JCI1918; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Whitfield ML, 2003, P NATL ACAD SCI USA, V100, P12319, DOI 10.1073/pnas.1635114100; Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902; Xu SW, 1997, ARTHRITIS RHEUM-US, V40, P1237; Yamane K, 2002, ARTHRITIS RHEUM-US, V46, P2421, DOI 10.1002/art.10477; Zhou XD, 2001, J IMMUNOL, V167, P7126, DOI 10.4049/jimmunol.167.12.7126	47	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16053	16065		10.1074/jbc.M413134200	http://dx.doi.org/10.1074/jbc.M413134200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708853	Green Accepted, hybrid			2022-12-27	WOS:000228444800073
J	Zaric, B; Chami, M; Remigy, H; Engel, A; Ballmer-Hofer, K; Winkler, FK; Kambach, C				Zaric, B; Chami, M; Remigy, H; Engel, A; Ballmer-Hofer, K; Winkler, FK; Kambach, C			Reconstitution of two recombinant LSm protein complexes reveals aspects of their architecture, assembly, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; SNRNP CORE; U7 SNRNPS; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURES; RNA DEGRADATION; YEAST; HFQ; ASSOCIATION; STABILITY	Sm and Sm-like (LSm) proteins form complexes engaging in various RNA-processing events. Composition and architecture of the complexes determine their intracellular distribution, RNA targets, and function. We have reconstituted the human LSm1-7 and LSm2-8 complexes from their constituent components in vitro. Based on the assembly pathway of the canonical Sm core domain, we used heterodimeric and heterotrimeric sub-complexes to assemble LSm1-7 and LSm2-8. Isolated sub-complexes form ring-like higher order structures. LSm1-7 is assembled and stable in the absence of RNA. LSm1-7 forms ring-like structures very similar to LSm2-8 at the EM level. Our in vitro reconstitution results illustrate likely features of the LSm complex assembly pathway. We prove the complexes to be functional both in an RNA bandshift and an in vivo cellular transport assay.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Basel	Kambach, C (corresponding author), Paul Scherrer Inst, OFLC 110, CH-5232 Villigen, Switzerland.	christian.kambach@psi.ch	Zaric, Bozidarka/Y-9475-2019	Zaric, Bozidarka/0000-0003-4244-3283; Ballmer-Hofer, Kurt/0000-0002-3800-9129				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Albrecht M, 2004, FEBS LETT, V569, P18, DOI 10.1016/j.febslet.2004.03.126; Anantharaman V, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-45; Antson AA, 1996, CURR OPIN STRUC BIOL, V6, P142, DOI 10.1016/S0959-440X(96)80067-4; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; BOELENS WC, 1995, RNA, V1, P273; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Donahue WF, 2002, MOL CELL, V9, P7, DOI 10.1016/S1097-2765(02)00429-X; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Eystathioy T, 2002, ARTHRITIS RHEUM, V46, P726, DOI 10.1002/art.10220; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; Kufel J, 2003, NUCLEIC ACIDS RES, V31, P6788, DOI 10.1093/nar/gkg904; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; Lange TS, 2000, MOL BIOL CELL, V11, P2419, DOI 10.1091/mbc.11.7.2419; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; Pannone BK, 2000, CURR BIOL, V10, pR478, DOI 10.1016/S0960-9822(00)00552-2; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Stanek D, 2003, J CELL BIOL, V160, P505, DOI 10.1083/jcb.200210087; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; SUMPTER V, 1992, MOL BIOL REP, V16, P229, DOI 10.1007/BF00419662; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Thore S, 2003, J BIOL CHEM, V278, P1239, DOI 10.1074/jbc.M207685200; Tomasevic N, 2002, MOL CELL BIOL, V22, P4101, DOI 10.1128/MCB.22.12.4101-4112.2002; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; Walke S, 2001, J MOL BIOL, V308, P49, DOI 10.1006/jmbi.2001.4549; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	54	56	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16066	16075		10.1074/jbc.M414481200	http://dx.doi.org/10.1074/jbc.M414481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711010	hybrid, Green Published			2022-12-27	WOS:000228444800074
J	Zhang, YH; Su, ZL; Zhang, F; Chen, Y; Shin, YK				Zhang, YH; Su, ZL; Zhang, F; Chen, Y; Shin, YK			A partially zipped SNARE complex stabilized by the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-SNARE; CRYSTAL-STRUCTURE; SYNAPTIC EXOCYTOSIS; 4-HELIX BUNDLE; FUSION; PROTEINS; VESICLE; REGION; INHIBITION; RESONANCE	The SNARE complex acts centrally for intracellular membrane fusion, an essential process for vesicular transport in cells. Association between vesicle-associated (v-) SNARE and target membrane (t-) SNARE results in the coiled coil core that bridges two membranes. Here, the structure of the SNARE complex assembled by recombinant t- SNARE Sso1p/Sec9 and v- SNARE Snc2p, which are involved in post-Golgi trafficking in yeast, was investigated using EPR. In detergent solutions, SNAREs formed a fully assembled core. However, when t- SNAREs were reconstituted into the proteoliposome and mixed with the soluble SNARE motif of Snc2p, a partially zipped core in which the N-terminal region is structured, whereas the C-terminal region is frayed, was detected. The partially zipped and fully assembled complexes coexisted with little free energy difference between them. Thus, the core complex formation of yeast SNAREs might not serve as the energy source for the fusion, which is different from what has been known for neuronal SNAREs. On the other hand, the results from the proteoliposome fusion assay, employing cysteine- and nitroxide-scanning mutants of Sso1p, suggested that the formation of the complete core is required for membrane fusion. This implies that core SNARE assembly plays an essential role in setting up the proper geometry of the lipid-protein complex for the successful fusion.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu	Su, Zengliu/E-3156-2010; Zhang, Fan/A-3477-2011					Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Chen Y, 2004, EMBO J, V23, P681, DOI 10.1038/sj.emboj.7600083; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Kweon DH, 2003, J BIOL CHEM, V278, P12367, DOI 10.1074/jbc.M211123200; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P9264, DOI 10.1021/bi025934+; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Mahal LK, 2002, J CELL BIOL, V158, P273, DOI 10.1083/jcb.200203135; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matos MF, 2003, NEUROPHARMACOLOGY, V45, P777, DOI 10.1016/S0028-3908(03)00318-6; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; SCHNEIDER DJ, 1989, LASERS MOL METHOD, P385; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang F, 2004, J BIOL CHEM, V279, P38668, DOI 10.1074/jbc.M404904200; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	44	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15595	15600		10.1074/jbc.M500736200	http://dx.doi.org/10.1074/jbc.M500736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713667	hybrid			2022-12-27	WOS:000228444800018
J	Huang, LP; Kirschke, CP; Zhang, YF; Yu, YY				Huang, LP; Kirschke, CP; Zhang, YF; Yu, YY			The ZIP7 gene (Slc39a7) encodes a zinc transporter involved in zinc homeostasis of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; PROTEIN; EXPRESSION; CLONING; MOUSE; CELLS; DEFICIENCY	It has been suggested that ZIP7 (Ke4, Slc39a7) belongs to the ZIP family of zinc transporters. Transient expression of the V5-tagged human ZIP7 fusion protein in CHO cells led to elevation of the cytoplasmic zinc level. However, the precise function of ZIP7 in cellular zinc homeostasis is not clear. Here we report that the ZIP7 gene is ubiquitously expressed in human and mouse tissues. The endogenous ZIP7 was associated with the Golgi apparatus and was capable of transporting zinc from the Golgi apparatus into the cytoplasm of the cell. Moreover, by using the yeast mutant strain Delta zrt3 that was defective in release of stored zinc from vacuoles, we found that ZIP7 was able to decrease the level of accumulated zinc and in the meantime to increase the nuclear/cytoplasmic labile zinc level in the ZIP7-expressing zrt3 mutant. We showed that the protein expression of ZIP7 was repressed under zinc-rich condition, whereas there were no effects of zinc on ZIP7 gene expression and intracellular localization. Neither did zinc deficiency affect the intracellular distribution of ZIP7 in mammalian cells. Our study demonstrates that ZIP7 is a functional zinc transporter that acts by transporting zinc from the Golgi apparatus to the cytoplasm of the cell.	Univ Calif Davis, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, ARS, USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Davis	Huang, LP (corresponding author), Univ Calif Davis, Rowe Program Genet, 1 Shields Ave, Davis, CA 95616 USA.	lhuang@whnrc.usda.gov						Ando A, 1996, GENOMICS, V35, P600, DOI 10.1006/geno.1996.0405; Andree KB, 2004, J NUTR, V134, P1716, DOI 10.1093/jn/134.7.1716; Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Franklin RB, 2003, J INORG BIOCHEM, V96, P435, DOI 10.1016/S0162-0134(03)00249-6; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kelleher SL, 2003, J NUTR, V133, P3378, DOI 10.1093/jn/133.11.3378; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; LAI F, 1994, GENOMICS, V23, P338, DOI 10.1006/geno.1994.1509; Lasswell J, 2000, PLANT CELL, V12, P2395, DOI 10.1105/tpc.12.12.2395; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Palmiter RD, 2004, P NATL ACAD SCI USA, V101, P4918, DOI 10.1073/pnas.0401022101; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Prasad AS, 2001, NUTRITION, V17, P67, DOI 10.1016/S0899-9007(00)00469-X; Prasad AS, 1998, J AM COLL NUTR, V17, P542, DOI 10.1080/07315724.1998.10718800; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sehgal VN, 2000, CLIN DERMATOL, V18, P745, DOI 10.1016/S0738-081X(00)00150-4; Taylor KM, 2004, BIOCHEM J, V377, P131, DOI 10.1042/BJ20031183; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	40	154	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15456	15463		10.1074/jbc.M412188200	http://dx.doi.org/10.1074/jbc.M412188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705588	hybrid			2022-12-27	WOS:000228236800133
J	Eschenburg, S; Priestman, MA; Abdul-Latif, FA; Delachaume, C; Fassy, F; Schonbrunn, E				Eschenburg, S; Priestman, MA; Abdul-Latif, FA; Delachaume, C; Fassy, F; Schonbrunn, E			A novel inhibitor that suspends the induced fit mechanism of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PEPTIDOGLYCAN; FOSFOMYCIN RESISTANCE; SHIKIMATE PATHWAY; CRYSTAL-STRUCTURE; DIFFRACTION DATA; TARGET; ENZYME; SYNTHASE; BIOSYNTHESIS; GLYPHOSATE	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase, EC 2.5.1.7) catalyzes the first committed step in the synthesis of the bacterial cell wall. It is the target of the naturally occurring, broad-spectrum antibiotic fosfomycin. Fosfomycin, an epoxide, is a relatively poor drug because an ever-increasing number of bacteria have developed resistance to fosfomycin. Thus, there is a critical need for the development of novel drugs that target MurA by a different molecular mode of action. We have identified a new scaffold of potent MurA inhibitors, derivatives of 5-sulfonoxy-anthranilic acid, using high-throughput screening. T6361 and T6362 are competitive inhibitors of MurA with respect to the first substrate, UDP-N-acetylglucosamine (UNAG), with a K-i of 16 mu M. The crystal structure of the MurA.T6361 complex at 2.6 angstrom resolution, together with fluorescence data, revealed that the inhibitor targets a loop, Pro(112) to Pro(121), that is crucial for the structural changes of the enzyme during catalysis. Thus, this new class of MurA inhibitors is not active site-directed but instead obstructs the transition from the open (unliganded) to the closed (UNAG-liganded) enzyme form. The results provide evidence for the existence of a MurA.UNAG collision complex that may be specifically targeted by small molecules different from ground-state analogs of the enzymatic reaction.	Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany; Aventis Pharma, F-94403 Vitry Sur Seine, France; Novexel, F-93320 Romainville, France; Aventis Pharma, Combinatorial Technol Ctr, Tucson, AZ 85737 USA	University of Kansas; Max Planck Society; Sanofi-Aventis; Sanofi France; Sanofi-Aventis	Schonbrunn, E (corresponding author), Univ Kansas, Dept Med Chem, 4040A Malott Hall, Lawrence, KS 66045 USA.	eschoenb@ku.edu		Schonbrunn, Ernst/0000-0002-3589-3510; Fassy, Florence/0000-0001-8337-9674				An M, 2001, J ORG CHEM, V66, P1326, DOI 10.1021/jo001121k; ARCA P, 1988, ANTIMICROB AGENTS CH, V32, P1552, DOI 10.1128/AAC.32.10.1552; Baum EZ, 2001, ANTIMICROB AGENTS CH, V45, P3182, DOI 10.1128/AAC.45.11.3182-3188.2001; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BROWN ED, 1995, J BACTERIOL, V177, P4194, DOI 10.1128/jb.177.14.4194-4197.1995; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byczynski B, 2003, J AM CHEM SOC, V125, P12541, DOI 10.1021/ja0349655; Dai HJ, 2002, J CHROMATOGR B, V766, P123, DOI 10.1016/S0378-4347(01)00461-3; De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177; DeVito JA, 2002, NAT BIOTECHNOL, V20, P478, DOI 10.1038/nbt0502-478; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Du WS, 2000, J BACTERIOL, V182, P4146, DOI 10.1128/JB.182.15.4146-4152.2000; El Zoeiby A, 2003, MOL MICROBIOL, V47, P1, DOI 10.1046/j.1365-2958.2003.03289.x; Eschenburg S, 2003, J BIOL CHEM, V278, P49215, DOI 10.1074/jbc.M309741200; Eschenburg S, 2000, PROTEINS, V40, P290, DOI 10.1002/(SICI)1097-0134(20000801)40:2<290::AID-PROT90>3.0.CO;2-0; Eschenburg S, 2005, J BIOL CHEM, V280, P3757, DOI 10.1074/jbc.M411325200; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Green David W, 2002, Expert Opin Ther Targets, V6, P1, DOI 10.1517/14728222.6.1.1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; Kim DH, 1996, BIOCHEMISTRY-US, V35, P4923, DOI 10.1021/bi952937w; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; McCoy AJ, 2003, J BACTERIOL, V185, P1218, DOI 10.1128/JB.185.4.1218-1228.2003; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Rife CL, 2002, J AM CHEM SOC, V124, P11001, DOI 10.1021/ja026879v; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Schonbrunn E, 1998, EUR J BIOCHEM, V253, P406, DOI 10.1046/j.1432-1327.1998.2530406.x; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; Schonbrunn E, 1996, STRUCTURE, V4, P1065, DOI 10.1016/S0969-2126(96)00113-X; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; Schonbrunn E, 2000, BIOCHEMISTRY-US, V39, P2164, DOI 10.1021/bi991091j; Skarzynski T, 1996, STRUCTURE, V4, P1465, DOI 10.1016/S0969-2126(96)00153-0; STALLINGS WC, 1991, P NATL ACAD SCI USA, V88, P5046, DOI 10.1073/pnas.88.11.5046; Thomas AM, 2004, EUR J BIOCHEM, V271, P2682, DOI 10.1111/j.1432-1033.2004.04196.x; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; VENKATESWARAN PS, 1972, J BACTERIOL, V110, P935, DOI 10.1128/JB.110.3.935-944.1972	40	59	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14070	14075		10.1074/jbc.M414412200	http://dx.doi.org/10.1074/jbc.M414412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701635	hybrid			2022-12-27	WOS:000228095500109
J	Ishii, R; Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M; Yokoyama, S				Ishii, R; Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M; Yokoyama, S			Crystal structure of the tRNA 3 ' processing endoribonuclease tRNase Z from Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; CANCER SUSCEPTIBILITY GENE; PROTEIN FOLD; IN-VIVO; SEQUENCE; PRECURSORS; MATURATION; RESOLUTION; MOLECULES; MECHANISM	The maturation of the tRNA 3 ' end is catalyzed by a tRNA 3 ' processing endoribonuclease named tRNase Z ( RNase Z or 3 '- tRNase) in eukaryotes, Archaea, and some bacteria. The tRNase Z generally cuts the 3 ' extra sequence from the precursor tRNA after the discriminator nucleotide. In contrast, Thermotoga maritima tRNase Z cleaves the precursor tRNA precisely after the CCA sequence. In this study, we determined the crystal structure of T. maritima tRNase Z at 2.6-angstrom resolution. The tRNase Z has a four- layer alpha beta/beta alpha sandwich fold, which is classified as a metallo- beta- lactamase fold, and forms a dimer. The active site is located at one edge of the beta- sandwich and is composed of conserved motifs. Based on the structure, we constructed a docking model with the tRNAs that suggests how tRNase Z may recognize the substrate tRNAs.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; SPring 8, RIKEN Harima Inst, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; Niigata University; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Ishii, Ryohei/0000-0003-2486-1393				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Aravind L, 1999, In Silico Biol, V1, P69; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; Deutscher Murray P., 1995, P51; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papadimitriou A, 1996, EUR J BIOCHEM, V242, P747, DOI 10.1111/j.1432-1033.1996.0747r.x; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Takaku H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh092; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	42	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14138	14144		10.1074/jbc.M500355200	http://dx.doi.org/10.1074/jbc.M500355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701599	hybrid			2022-12-27	WOS:000228095500117
J	Komar, AA; Hatzoglou, M				Komar, AA; Hatzoglou, M			Internal ribosome entry sites in cellular mRNAs: Mystery of their existence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ENCEPHALOMYOCARDITIS VIRUS-RNA; TRANSLATION INITIATION-FACTORS; CAP-INDEPENDENT TRANSLATION; IRES-MEDIATED TRANSLATION; MYC PROTEIN-SYNTHESIS; TRANS-ACTING FACTORS; C-MYC; HEPATITIS-C; IN-VITRO; BINDING	Although studies on viral gene expression were essential for the discovery of internal ribosome entry sites (IRESs), it is becoming increasingly clear that IRES activities are present in a significant number of cellular mRNAs. Remarkably, many of these IRES elements initiate translation of mRNAs encoding proteins that protect cells from stress (when the translation of the vast majority of cellular mRNAs is significantly impaired). The purpose of this review is to summarize the progress on the discovery and function of cellular IRESs. Recent findings on the structures of these IRESs and specifically regulation of their activity during nutritional stress, differentiation, and mitosis will be discussed.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	mxh8@cwru.edu		Komar, Anton/0000-0003-4188-0633	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060596, R01DK053307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60596, DK53307] Funding Source: Medline; NIGMS NIH HHS [GM68079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agol VI, 2001, MOL BIOL+, V35, P591, DOI 10.1023/A:1010531228348; Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Bonnal S, 2005, J BIOL CHEM, V280, P4144, DOI 10.1074/jbc.M411492200; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 2001, PROG MOLEC, V27, P57; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; DEVALLOS RC, 2005, J VIROL, V79, P677; Fernandez J, 2005, MOL CELL, V17, P405, DOI 10.1016/j.molcel.2004.12.024; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holcik M, 2003, ANN NY ACAD SCI, V1010, P249, DOI 10.1196/annals.1299.043; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Jopling CL, 2004, RNA, V10, P287, DOI 10.1261/rna.5138804; Komar AA, 2003, EMBO J, V22, P1199, DOI 10.1093/emboj/cdg103; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Kuyumcu-Martinez NM, 2004, MOL CELL BIOL, V24, P1779, DOI 10.1128/MCB.24.4.1779-1790.2004; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LUZ N, 1991, J VIROL, V65, P6486, DOI 10.1128/JVI.65.12.6486-6494.1991; Lyons AJ, 2003, J BIOL CHEM, V278, P26844, DOI 10.1074/jbc.M304052200; Maag D, 2005, MOL CELL, V17, P265, DOI 10.1016/j.molcel.2004.11.051; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Maier D, 2002, P NATL ACAD SCI USA, V99, P15480, DOI 10.1073/pnas.242596699; Martin MM, 2003, MOL CELL ENDOCRINOL, V212, P51, DOI 10.1016/j.mce.2003.09.017; Martineau Y, 2004, MOL CELL BIOL, V24, P7622, DOI 10.1128/MCB.24.17.7622-7635.2004; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 2004, EMBO REP, V5, P906, DOI 10.1038/sj.embor.7400240; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Spahn CMT, 2004, CELL, V118, P465, DOI 10.1016/j.cell.2004.08.001; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Teshima-Kondo S, 2004, FASEB J, V18, P1583, DOI 10.1096/fj.03-1118fje; Thoma C, 2004, MOL CELL, V15, P925, DOI 10.1016/j.molcel.2004.08.021; Tinton SA, 2005, BIOCHEM J, V385, P155, DOI 10.1042/BJ20040963; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; van der Velden AW, 2002, INT J BIOCHEM CELL B, V34, P286, DOI 10.1016/S1357-2725(01)00116-9; Volpi S, 2004, ANN NY ACAD SCI, V1018, P293, DOI 10.1196/annals.1296.035; Vyas J, 2003, RNA, V9, P858, DOI 10.1261/rna.5330503; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; Zhang XS, 2002, DNA REPAIR, V1, P379, DOI 10.1016/S1568-7864(02)00015-0	81	195	206	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23425	23428		10.1074/jbc.R400041200	http://dx.doi.org/10.1074/jbc.R400041200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15749702	hybrid			2022-12-27	WOS:000229880000002
J	Miller-Podraza, H; Lanne, B; Angstrom, J; Teneberg, S; Milh, MA; Jovall, PA; Karlsson, H; Karlsson, KA				Miller-Podraza, H; Lanne, B; Angstrom, J; Teneberg, S; Milh, MA; Jovall, PA; Karlsson, H; Karlsson, KA			Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains - Structure and cross-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC EPITHELIUM; BLOOD-GROUP ANTIGENS; HUMAN-GRANULOCYTES; CAMPYLOBACTER-PYLORI; MASS-SPECTROMETRY; HEPARAN-SULFATE; RECOGNITION; GLYCOSPHINGOLIPIDS; RECEPTOR; CELLS	Helicobacter pylori is a bacterium that colonizes the stomach of a majority of the global human population causing common gastric diseases like ulcers and cancer. It has an unusually complex pattern of binding to various host glycoconjugates including interaction with sialylated, sulfated, and fucosylated sequences. The present study describes an additional binding epitope comprising the neolacto internal sequence of GlcNAc beta 3Gal beta 4GlcNAc beta. The binding was detected on TLC plates as an interaction with a seven-sugar ganglioside of rabbit thymus. The glycolipid was purified and characterized as Neu5Gc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer with less than 10% of the fraction carrying a repeated lacto (type-1) core chain, Gal beta 3GlcNAc beta 3Gal beta 3GlcNAc beta. After stepwise chemical and enzymatic degradation and structural analysis of products the strongest binder was found to be the pentaglycosylceramide GlcNAc beta 3Gal beta 4GlcNAc beta 3Gal beta 4Glc beta 1Cer, whereas the hexa- and tetraglycosylceramides were less active, and the trihexosylceramide was inactive. Further studies revealed that the terminal GlcNAc beta of the pentaglycosylceramide may be exchanged for either GalNAc beta 3, GalNAc alpha 3, or Gal alpha 3 without loss of the activity. Calculated minimum energy conformers of these four isoreceptors show a substantial topographical similarity suggesting that this binding is a result of a molecular mimicry. Although the glycoconjugate composition of human gastric epithelial cells is not known in detail it is proposed that repeating N-acetyllactosamine units of glycoconjugates may serve as bacterial attachment sites in the stomach.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden	University of Gothenburg	Miller-Podraza, H (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.	Halina.Miller-Podraza@medkem.gu.se						Abul-Milh M, 2001, GLYCOCONJUGATE J, V18, P253, DOI 10.1023/A:1012460824913; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; Bertin Y, 1996, INFECT IMMUN, V64, P332, DOI 10.1128/IAI.64.1.332-342.1996; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHMIELA M, 1995, APMIS, V103, P469, DOI 10.1111/j.1699-0463.1995.tb01133.x; CLAUSEN H, 1986, J BIOL CHEM, V261, P1380; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EGGE H, 1978, CHEM PHYS LIPIDS, V21, P349, DOI 10.1016/0009-3084(78)90046-4; EVANS DG, 1988, INFECT IMMUN, V56, P2896, DOI 10.1128/IAI.56.11.2896-2906.1988; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; HANSSON GC, 1990, METHOD ENZYMOL, V193, P733, DOI 10.1016/0076-6879(90)93447-S; HIRMO S, 1995, FEMS IMMUNOL MED MIC, V10, P301, DOI 10.1016/0928-8244(94)00081-4; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; IARC, 1994, IARC MONOGRAPHS EVAL, VVolume 61, P1; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; ITO M, 1989, METHOD ENZYMOL, V179, P488; KANNAGI R, 1982, CANCER RES, V42, P5249; Karlsson A, 2001, GLYCOCONJUGATE J, V18, P231, DOI 10.1023/A:1013183124004; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; Karlsson KA, 2000, GLYCOBIOLOGY, V10, P761, DOI 10.1093/glycob/10.8.761; KOBAYASHI Y, 1993, INFECT IMMUN, V61, P4058, DOI 10.1128/IAI.61.10.4058-4063.1993; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LELWALAGURUGE J, 1992, APMIS, V100, P908, DOI 10.1111/j.1699-0463.1992.tb04018.x; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Miller-Podraza H, 1999, INFECT IMMUN, V67, P6309; MillerPodraza H, 1997, GLYCOCONJUGATE J, V14, P467, DOI 10.1023/A:1018599401772; MillerPodraza H, 1997, INFECT IMMUN, V65, P2480, DOI 10.1128/IAI.65.6.2480-2482.1997; Mouricout M, 1997, ADV EXP MED BIOL, V412, P109; Muthing J, 1996, GLYCOBIOLOGY, V6, P147, DOI 10.1093/glycob/6.2.147; Mysore JV, 1999, GASTROENTEROLOGY, V117, P1316, DOI 10.1016/S0016-5085(99)70282-9; NEEDS PW, 1993, CARBOHYD RES, V245, P1, DOI 10.1016/0008-6215(93)80055-J; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Simon PM, 1997, INFECT IMMUN, V65, P750, DOI 10.1128/IAI.65.2.750-757.1997; SLOMIANY BL, 1989, BIOCHEM INT, V19, P929; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Teneberg S, 2000, GLYCOBIOLOGY, V10, P1171, DOI 10.1093/glycob/10.11.1171; TENEBERG S, 1994, J BIOL CHEM, V269, P8554; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Teneberg S, 2002, J BIOL CHEM, V277, P19709, DOI 10.1074/jbc.M201113200; Unemo M, 2005, J BIOL CHEM, V280, P15390, DOI 10.1074/jbc.M412725200; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015	55	31	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19695	19703		10.1074/jbc.M412688200	http://dx.doi.org/10.1074/jbc.M412688200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15743770	hybrid			2022-12-27	WOS:000229113700035
J	Cole, SL; Grudzien, A; Manhart, IO; Kelly, BL; Oakley, H; Vassar, R				Cole, SL; Grudzien, A; Manhart, IO; Kelly, BL; Oakley, H; Vassar, R			Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; INTRANEURONAL A-BETA-42 ACCUMULATION; TOTAL CHOLESTEROL LEVEL; ALZHEIMERS-DISEASE; A-BETA; APOLIPOPROTEIN-E; DOWN-SYNDROME; MEVALONATE PATHWAY; BINDING PROTEIN; LIPID RAFTS	The use of statins, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors that block the synthesis of mevalonate ( and downstream products such as cholesterol and nonsterol isoprenoids), as a therapy for Alzheimer disease is currently the subject of intense debate. It has been reported that statins reduce the risk of developing the disorder, and a link between cholesterol and Alzheimer disease pathophysiology has been proposed. Moreover, experimental studies focusing on the cholesterol-dependent effects of statins have demonstrated a close association between cellular cholesterol levels and amyloid production. However, evidence suggests that statins are pleiotropic, and the potential cholesterol-independent effects of statins on amyloid precursor protein (APP) metabolism and amyloid beta-peptide (A beta) genesis are unknown. In this study, we developed a novel in vitro system that enabled the discrete analysis of cholesterol-dependent and -independent (i.e. isoprenoid-dependent) statin effects on APP cleavage and A beta formation. Given the recent interest in the role that intracellular A beta may play in Alzheimer disease, we analyzed statin effects on both secreted and cell-associated A beta. As reported previously, low cellular cholesterol levels favored the alpha-secretase pathway and decreased A beta secretion presumably within the endocytic pathway. In contrast, low isoprenoid levels resulted in the accumulation of APP, amyloidogenic fragments, and A beta likely within biosynthetic compartments. Importantly, low cholesterol and low isoprenoid levels appeared to have completely independent effects on APP metabolism and A beta formation. Although the implications of these effects for Alzheimer disease pathophysiology have yet to be investigated, to our knowledge, these results provide the first evidence that isoprenylation is involved in determining levels of intracellular A beta.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Cole, SL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	s-cole4@northwestern.edu; r-vassar@northwestern.edu						Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BROWN MS, 1980, J LIPID RES, V21, P505; Burns M, 2003, J NEUROSCI, V23, P5645; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Buxbaum JD, 2001, J ALZHEIMERS DIS, V3, P221; Cataldo AM, 2004, NEUROBIOL AGING, V25, P1263, DOI 10.1016/j.neurobiolaging.2004.02.027; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goslin K., 1991, RAT HIPPOCAMPAL NEUR; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEIDER JG, 1978, J LIPID RES, V19, P514; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Kato T, 2004, BBA-MOL BASIS DIS, V1689, P267, DOI 10.1016/j.bbadis.2004.04.006; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; KNEBL J, 1994, MECH AGEING DEV, V73, P69, DOI 10.1016/0047-6374(94)90039-6; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Mason JC, 2003, CLIN SCI, V105, P251, DOI 10.1042/CS20030148; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; McIlroy SP, 2002, STROKE, V33, P2351, DOI 10.1161/01.STR.0000032550.90046.38; Meske V, 2003, EUR J NEUROSCI, V17, P93, DOI 10.1046/j.1460-9568.2003.02433.x; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Schmitz C, 2004, AM J PATHOL, V164, P1495, DOI 10.1016/S0002-9440(10)63235-X; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vicent D, 2000, MOL CELL BIOL, V20, P2158, DOI 10.1128/MCB.20.6.2158-2166.2000; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	71	120	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18755	18770		10.1074/jbc.M413895200	http://dx.doi.org/10.1074/jbc.M413895200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15718241	hybrid			2022-12-27	WOS:000228932300027
J	Givens, ML; Rave-Harel, N; Goonewardena, VD; Kurotani, R; Berdy, SE; Swan, CH; Rubenstein, JLR; Robert, B; Mellon, PL				Givens, ML; Rave-Harel, N; Goonewardena, VD; Kurotani, R; Berdy, SE; Swan, CH; Rubenstein, JLR; Robert, B; Mellon, PL			Developmental regulation of gonadotropin-releasing hormone gene expression by the MSX and DLX homeodomain protein families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR AP-2; HOMEOBOX GENES; CRANIOFACIAL DEVELOPMENT; RESTRICTED EXPRESSION; EMBRYONIC FOREBRAIN; OLFACTORY PLACODE; CELL-POPULATIONS; DEVELOPING MOUSE; BINDING-SITES	Gonadotropin-releasing hormone (GnRH) is the central regulator of the hypothalamic-pituitary-gonadal axis, controlling sexual maturation and fertility in diverse species from fish to humans. GnRH gene expression is limited to a discrete population of neurons that migrate through the nasal region into the hypothalamus during embryonic development. The GnRH regulatory region contains four conserved homeodomain binding sites (ATTA) that are essential for basal promoter activity and cell-specific expression of the GnRH gene. MSX and DLX are members of the Antennapedia class of non-Hox homeodomain transcription factors that regulate gene expression and influence development of the craniofacial structures and anterior forebrain. Here, we report that expression patterns of the Msx and Dlx families of homeodomain transcription factors largely coincide with the migratory route of GnRH neurons and co-express with GnRH in neurons during embryonic development. In addition, MSX and DLX family members bind directly to the ATTA consensus sequences and regulate transcriptional activity of the GnRH promoter. Finally, mice lacking MSX1 or DLX1 and 2 show altered numbers of GnRH-expressing cells in regions where these factors likely function. These findings strongly support a role for MSX and DLX in contributing to spatiotemporal regulation of GnRH transcription during development.	Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA; Inst Pasteur, CNRS, URA 2578, Unite Genet Mol & Morphogenese, F-75724 Paris, France	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pmellon@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072754, P50HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, R01DK044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007315] Funding Source: NIH RePORTER; NICHD NIH HHS [P50 HD012303, R01 HD072754] Funding Source: Medline; NIDA NIH HHS [T32 DA07315] Funding Source: Medline; NIDDK NIH HHS [R01 DK44838, R01 DK044838-17A1, R01 DK044838, R01 DK044838-16, P30 DK063491, P30 DK063491-019001] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bach A, 2003, DEVELOPMENT, V130, P4025, DOI 10.1242/dev.00609; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; BULFONE A, 1993, J NEUROSCI, V13, P3155; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Cornell RA, 2000, CURR OPIN NEUROBIOL, V10, P63, DOI 10.1016/S0959-4388(99)00049-5; Dubois EA, 2002, BRAIN RES BULL, V57, P413, DOI 10.1016/S0361-9230(01)00676-1; Eisenstat DD, 1999, J COMP NEUROL, V414, P217, DOI 10.1002/(SICI)1096-9861(19991115)414:2<217::AID-CNE6>3.0.CO;2-I; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; Grove EA, 1998, DEVELOPMENT, V125, P2315; Houzelstein D, 1997, MECH DEVELOP, V65, P123, DOI 10.1016/S0925-4773(97)00065-8; Hu GZ, 2001, DEVELOPMENT, V128, P2373; ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0; Iler N, 1996, BIOCHEM BIOPH RES CO, V227, P257, DOI 10.1006/bbrc.1996.1498; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kramer PR, 2000, ENDOCRINOLOGY, V141, P1823, DOI 10.1210/en.141.5.1823; Kramer PR, 2000, MECH DEVELOP, V94, P79, DOI 10.1016/S0925-4773(00)00316-6; Kraus P, 1999, J CELL BIOCHEM, P133; Lawson MA, 1998, MOL CELL ENDOCRINOL, V140, P157, DOI 10.1016/S0303-7207(98)00044-6; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; LIVNE I, 1993, DEV BIOL, V159, P643, DOI 10.1006/dbio.1993.1271; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Nelson SB, 2000, MOL ENDOCRINOL, V14, P1509, DOI 10.1210/me.14.9.1509; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; Pimpinelli F, 2003, EUR J NEUROSCI, V18, P1410, DOI 10.1046/j.1460-9568.2003.02866.x; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; Prioni S, 2002, NEUROCHEM RES, V27, P831, DOI 10.1023/A:1020217309987; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Rave-Harel N, 2004, J BIOL CHEM, V279, P30287, DOI 10.1074/jbc.M402960200; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; Romanelli RG, 2004, J BIOL CHEM, V279, P117, DOI 10.1074/jbc.M307955200; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHWANZELFUKUDA M, 1992, ENDOCR REV, V13, P623, DOI 10.1210/er.13.4.623; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Simonian SX, 2001, NEUROENDOCRINOLOGY, V73, P149, DOI 10.1159/000054631; Skynner MJ, 1999, J NEUROSCI, V19, P5955, DOI 10.1523/JNEUROSCI.19-14-05955.1999; Whitlock KE, 2003, DEV BIOL, V257, P140, DOI 10.1016/S0012-1606(03)00039-3; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WRAY S, 1994, DEV BIOL, V166, P349, DOI 10.1006/dbio.1994.1320; Wu TJ, 1995, J NEUROENDOCRINOL, V7, P899, DOI 10.1111/j.1365-2826.1995.tb00733.x; Yu GY, 2001, DEV BRAIN RES, V130, P217, DOI 10.1016/S0165-3806(01)00239-5; Yun K, 2002, DEVELOPMENT, V129, P5029; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000; Zerucha T, 2000, BIOCHEM CELL BIOL, V78, P593, DOI 10.1139/bcb-78-5-593; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	56	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19156	19165		10.1074/jbc.M502004200	http://dx.doi.org/10.1074/jbc.M502004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743757	Green Accepted, hybrid			2022-12-27	WOS:000228932300072
J	Gu, YJ; Gordon, DM; Amutha, B; Pain, D				Gu, YJ; Gordon, DM; Amutha, B; Pain, D			A GTP : AMP phosphotransferase, Adk2p, in Saccharomyces cerevisiae - Role of the C terminus in protein folding/stabilization, thermal tolerance, and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENYLATE KINASE; PRECURSOR PROTEIN; IN-VIVO; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; ATP SYNTHASE; YEAST; IMPORT; TRANSLOCATION; GENE	Adenylate kinases participate in maintaining the homeostasis of cellular nucleotides. Depending on the yeast strains, the GTP:AMP phosphotransferase is encoded by the nuclear gene ADK2 with or without a single base pair deletion/insertion near the 3' end of the open reading frame, and the corresponding protein exists as either Adk2p (short) or Adk2p (long) in the mitochondrial matrix. These two forms are identical except that the three C-terminal residues of Adk2p ( short) are changed in Adk2p ( long), and the latter contains an additional nine amino acids at the C terminus of the protein. The short form of Adk2p has so far been considered to be inactive (Schricker, R., Magdolen, V., Strobel, G., Bogengruber, E., Breitenbach, M., and Bandlow, W. (1995) J. Biol. Chem. 270, 31103-31110). Using purified proteins, we show that at the physiological temperature for yeast growth (30 degrees C), both short and long forms of Adk2p are enzymatically active. However, in contrast to the short form, Adk2p ( long) is quite resistant to thermal inactivation, urea denaturation, and degradation by trypsin. Unfolding of the long form by high concentrations of urea greatly stimulated its import into isolated mitochondria. Using an integration-based gene-swapping approach, we found that regardless of the yeast strains used, the steady state levels of endogenous Adk2p ( long) in mitochondria were 5-10-fold lower compared with those of Adk2p ( short). Together, these results suggest that the modified C-terminal domain in Adk2p ( long) is not essential for enzyme activity, but it contributes to and strengthens protein folding and/or stability and is particularly important for maintaining enzyme activity under stress conditions.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Pain, D (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,MSB I-669, Newark, NJ 07103 USA.	painde@umdnj.edu						Amutha B, 2003, BIOCHEM J, V370, P805, DOI 10.1042/BJ20021415; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Angermayr M, 2001, FEBS LETT, V508, P427, DOI 10.1016/S0014-5793(01)03122-2; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Bae E, 2004, J BIOL CHEM, V279, P28202, DOI 10.1074/jbc.M401865200; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; Boyer P.D, 1973, ENZYMES, P279; Criswell AR, 2003, J MOL BIOL, V330, P1087, DOI 10.1016/S0022-2836(03)00655-7; CRONAN JE, 1972, MOL GEN GENET, V116, P199, DOI 10.1007/BF00269765; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9; Gavel OY, 2004, BIOPHYS CHEM, V110, P83, DOI 10.1016/j.bpc.2004.01.006; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; Gordon DM, 2001, BIOCHEM J, V356, P207, DOI 10.1042/0264-6021:3560207; Gordon DM, 2001, HUM MOL GENET, V10, P259, DOI 10.1093/hmg/10.3.259; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Haney PJ, 1999, J BIOL CHEM, V274, P28453, DOI 10.1074/jbc.274.40.28453; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Janssen E, 2003, J BIOL CHEM, V278, P12937, DOI 10.1074/jbc.M211465200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; KHOO JC, 1972, BIOCHIM BIOPHYS ACTA, V268, P98, DOI 10.1016/0005-2744(72)90202-1; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KONRAD M, 1993, J BIOL CHEM, V268, P11326; Kumar S, 2001, BIOPHYS J, V80, P2439, DOI 10.1016/S0006-3495(01)76213-3; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MAGDOLEN V, 1987, CURR GENET, V12, P405, DOI 10.1007/BF00434817; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; Munier-Lehmann H, 1999, PROTEINS, V36, P238, DOI 10.1002/(SICI)1097-0134(19990801)36:2<238::AID-PROT9>3.0.CO;2-K; Munier-Lehmann H, 2003, BIOCHEM J, V373, P515, DOI 10.1042/BJ20030284; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nobumoto M, 1998, J BIOCHEM, V123, P128; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Okajima T, 2002, BIOSCI BIOTECH BIOCH, V66, P2112, DOI 10.1271/bbb.66.2112; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; Schricker R, 1995, J BIOL CHEM, V270, P31103, DOI 10.1074/jbc.270.52.31103; SCHRICKER R, 1992, GENE, V122, P111, DOI 10.1016/0378-1119(92)90038-Q; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; Sepuri NBV, 1998, J BIOL CHEM, V273, P20941, DOI 10.1074/jbc.273.33.20941; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; TOMASSELLI AG, 1980, EUR J BIOCHEM, V103, P481, DOI 10.1111/j.1432-1033.1980.tb05972.x; TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P257, DOI 10.1111/j.1432-1033.1979.tb12818.x; Ulschmid JK, 2004, MOL BIOCHEM PARASIT, V136, P211, DOI 10.1016/j.molbiopara.2004.04.001; Vieille C, 2003, BIOCHEM J, V372, P577, DOI 10.1042/BJ20021377; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; WATANABE K, 1982, EUR J BIOCHEM, V123, P587; Wolf-Watz M, 2004, NAT STRUCT MOL BIOL, V11, P945, DOI 10.1038/nsmb821; Yamada M, 1998, J MOL BIOL, V280, P551, DOI 10.1006/jmbi.1998.1876	53	5	7	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18604	18609		10.1074/jbc.M500847200	http://dx.doi.org/10.1074/jbc.M500847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753074	hybrid			2022-12-27	WOS:000228932300009
J	Blundell, CD; Almond, A; Mahoney, DJ; DeAngelis, PL; Campbell, ID; Day, AJ				Blundell, CD; Almond, A; Mahoney, DJ; DeAngelis, PL; Campbell, ID; Day, AJ			Towards a structure for a TSG-6 center dot hyaluronan complex by modeling and NMR spectroscopy - Insights into other members of the link module superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMONIAE HYALURONATE LYASE; FACTOR-STIMULATED GENE-6; NECROSIS-FACTOR-ALPHA; MOLECULAR-DYNAMICS SIMULATIONS; BINDING PROTEIN TSG-6; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; INDUCED ARTHRITIS; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION	The Link module from human TSG-6, a hyaladherin with roles in ovulation and inflammation, has a hyaluronan (HA)-binding groove containing two adjacent tyrosine residues that are likely to form CH-pi stacking interactions with sequential rings in the sugar. We have used this observation to construct a model of a protein center dot HA complex, which was then tested against existing experimental information and by acquisition of new NMR data sets of [C-13, N-15] HA (8-mer) complexed with unlabeled protein. A major finding of this analysis was that acetamido side chains of two GlcNAc rings fit into hydrophobic pockets on either side of the adjacent tyrosines, providing a selectivity mechanism of HA over other polysaccharides. Furthermore, two basic residues have a separation that matches that of glucuronic acids in the sugar, consistent with the formation of salt bridges; NMR experiments at a range of pH values identified protein groups that titrate due to their proximity to a free carboxylate in HA. Sequence alignment and construction of homology models for all human Link modules in their HA-bound states revealed that many of these features are conserved across the superfamily, thus allowing the prediction of functionally important residues. In the case of cartilage link protein, its two Link modules were docked together ( using bound HA as a guide), identifying hydrophobic residues likely to form an intra-Link module interface as well as amino acids that could be involved in supporting intermolecular interactions between link proteins and chondroitin sulfate proteoglycans. Here, we propose a mechanism for ternary complex formation that generates higher order helical structures, as may exist in cartilage aggregates.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Oxford; University of Oklahoma System; University of Oklahoma Health Sciences Center	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, South Pks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Blundell, Charles/0000-0002-1439-9126; Almond, Andrew/0000-0001-7471-6333	MRC [MC_U138274352] Funding Source: UKRI; Medical Research Council [MC_U138274352] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Almond A, 1998, GLYCOBIOLOGY, V8, P973, DOI 10.1093/glycob/8.10.973; Almond A, 1997, GLYCOBIOLOGY, V7, P597, DOI 10.1093/glycob/7.5.597; Almond A, 2004, BIOCHEMISTRY-US, V43, P5853, DOI 10.1021/bi0354886; Almond A, 2000, J PHYS CHEM B, V104, P5634, DOI 10.1021/jp000402t; ATKINS EDT, 1972, BIOCHEM J, V128, P1255, DOI 10.1042/bj1281255; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Blundell C. D., 2002, HYALURONAN, P161; Blundell CD, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P189; Blundell CD, 2004, GLYCOBIOLOGY, V14, P999, DOI 10.1093/glycob/cwh117; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; BROCCHIERI L, 1994, P NATL ACAD SCI USA, V91, P9297, DOI 10.1073/pnas.91.20.9297; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; CHRISTNER JE, 1979, J BIOL CHEM, V254, P2303; COWMAN MK, 1984, ARCH BIOCHEM BIOPHYS, V230, P203, DOI 10.1016/0003-9861(84)90101-2; Cowman MK, 1996, MACROMOLECULES, V29, P2894, DOI 10.1021/ma951701x; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; DAY AJ, 2004, HYAL 2003 P OCT 11 1; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; HOLMBECK SMA, 1994, BIOCHEMISTRY-US, V33, P14246, DOI 10.1021/bi00251a037; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Johnson MA, 2004, CARBOHYD RES, V339, P907, DOI 10.1016/j.carres.2003.12.028; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kogelberg H, 2003, CURR OPIN STRUC BIOL, V13, P646, DOI 10.1016/j.sbi.2003.08.001; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; Rauch U, 2004, MATRIX BIOL, V22, P629, DOI 10.1016/j.matbio.2003.11.007; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Seyfried NT, 2005, J BIOL CHEM, V280, P5435, DOI 10.1074/jbc.M411297200; Seyfried NT, 2005, GLYCOBIOLOGY, V15, P303, DOI 10.1093/glycob/cwi008; SICINSKA W, 1993, CARBOHYD RES, V242, P29, DOI 10.1016/0008-6215(93)80020-F; Spicer AP, 2003, J BIOL CHEM, V278, P21083, DOI 10.1074/jbc.M213100200; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Thompson SE, 2002, J AM CHEM SOC, V124, P442, DOI 10.1021/ja011973h; TOFFANIN R, 1993, CARBOHYD RES, V245, P113, DOI 10.1016/0008-6215(93)80064-L; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289	70	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18189	18201		10.1074/jbc.M414343200	http://dx.doi.org/10.1074/jbc.M414343200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718240	hybrid			2022-12-27	WOS:000228807200077
J	Braithwaite, EK; Prasad, R; Shock, DD; Hou, EW; Beard, WA; Wilson, SH				Braithwaite, EK; Prasad, R; Shock, DD; Hou, EW; Beard, WA; Wilson, SH			DNA polymerase lambda mediates a back-up base excision repair activity in extracts of mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MAMMALIAN-CELLS; LYASE ACTIVITY; SITE REPAIR; BETA; IDENTIFICATION; ENZYME; PATHWAY; CYTOTOXICITY; GLYCOSYLASE	Mammalian DNA polymerase (pol) lambda is a member of the X-family of DNA polymerases and has striking enzymatic and structural similarities to mammalian DNA pol beta. Because pol beta provides two important enzymatic activities for base excision repair (BER), we examined whether pol lambda might also contribute to BER. We used extracts from mouse embryonic fibroblasts representing wild-type and null genotypes for pol beta and pol lambda. In combination with neutralizing antibodies against pol beta and pol lambda, our results show a BER deficiency in the pol lambda -/- cell extract compared with extract from isogenic wild-type cells. In addition, the pol lambda antibody strongly reduced in vitro BER in the pol beta -/- cell extract. These data indicate that pol lambda is able to contribute to BER in mouse fibroblast cell extract.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, ZIAES050159] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Harlow E., 1988, ANTIBODIES LAB MANUA; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; LEE MYWT, 1986, NUCLEIC ACIDS RES, V14, P1719, DOI 10.1093/nar/14.4.1719; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MILLER MR, 1982, J BIOL CHEM, V257, P204; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; Ramadan K, 2002, J BIOL CHEM, V277, P18454, DOI 10.1074/jbc.M200421200; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599	40	127	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18469	18475		10.1074/jbc.M411864200	http://dx.doi.org/10.1074/jbc.M411864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749700	hybrid			2022-12-27	WOS:000228807200110
J	Conti, BJ; Davis, BK; Zhang, JH; O'Connor, W; Williams, KL; Ting, JPY				Conti, BJ; Davis, BK; Zhang, JH; O'Connor, W; Williams, KL; Ting, JPY			CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CLASS-II TRANSACTIVATOR; CONTAINING APAF1-LIKE PROTEIN; INFLAMMATORY-BOWEL-DISEASE; BARE LYMPHOCYTE SYNDROME; RICH REPEAT DOMAINS; CROHNS-DISEASE; NUCLEAR EXPORT; CUTTING EDGE; BACTERIAL PEPTIDOGLYCAN	The newly discovered mammalian CATERPILLER (NOD, NALP, PAN) family of proteins share similarities with the NBD-LRR superfamily of plant disease resistance (R) proteins and are predicted to mediate important immune regulatory function. This report describes the first cloning and characterization of a novel CATERPILLER gene, CLR16.2 that is located on human chromosome 16. The protein encoded by this gene has a typical NBD-LRR configuration. Analysis of CLR16.2 suggests the highest expression among T lymphocytes. Cellular localization studies of CLR16.2 revealed that it is a cytoplasmic protein. Querying microarray studies in the public data base showed that CLR16.2 was significantly (>90%) down-regulated 6 h after anti-CD3 and anti-CD28 stimulation of primary T lymphocytes. Its reduction upon T cell stimulation is consistent with a potential negative regulatory role. Indeed CLR16.2 decreased NF-kappa B, NFAT, and AP-1 induction of reporter gene constructs in response to T cell activation by anti-CD3 and anti-CD28 antibodies or PMA and ionomycin. Following T cell stimulation, the presence of CLR16.2 reduced the levels of the endogenous transcripts for the IL-2 and CD25 proteins that are central in maintaining T cell activation and preventing T cell anergy. This reduction was accompanied by a delay of I kappa B alpha degradation. We propose that CLR16.2 serves to attenuate T cell activation via TCR and co-stimulatory molecules, and its reduction during T cell stimulation allows the ensuing cellular activation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	panyun@med.unc.edu			NIAID NIH HHS [AI54309, AI29564] Funding Source: Medline; NIDDK NIH HHS [DK38108] Funding Source: Medline; NINDS NIH HHS [NS34910] Funding Source: Medline; PHS HHS [41751, 45580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029564, R56AI029564, R01AI029564, R01AI054309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038108] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; DOWDS TA, 2004, J BIOL CHEM; Galfalvy HC, 2003, BMC BIOINFORMATICS, V4, P1, DOI 10.1186/1471-2105-4-37; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hampe J, 2002, P NATL ACAD SCI USA, V99, P321, DOI 10.1073/pnas.261567999; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hillig RC, 1999, MOL CELL, V3, P781, DOI 10.1016/S1097-2765(01)80010-1; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hollander GA, 1999, SEMIN IMMUNOL, V11, P357; Huang SG, 2004, GENOMICS, V84, P767, DOI 10.1016/j.ygeno.2004.06.013; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kobayashi KS, 2003, NAT IMMUNOL, V4, P652, DOI 10.1038/ni0703-652; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LI J, 2005, IN PRESS PHYSL GENOM; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Lord GM, 1999, IMMUNOL TODAY, V20, P33, DOI 10.1016/S0167-5699(98)01379-6; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P901, DOI 10.1067/mai.2002.124965; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; Williams KL, 2003, J IMMUNOL, V170, P5354, DOI 10.4049/jimmunol.170.11.5354; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wong AW, 2003, NAT IMMUNOL, V4, P891, DOI 10.1038/ni960; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9	68	100	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18375	18385		10.1074/jbc.M413169200	http://dx.doi.org/10.1074/jbc.M413169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15705585	hybrid, Green Published			2022-12-27	WOS:000228807200099
J	Shin, DH; Oganesyan, N; Jancarik, J; Yokota, H; Kim, R; Kim, SH				Shin, DH; Oganesyan, N; Jancarik, J; Yokota, H; Kim, R; Kim, SH			Crystal structure of a nicotinate phosphoribosyltransferase from Thermoplasma acidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOLINIC ACID PHOSPHORIBOSYLTRANSFERASE; LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; PROTEIN; BIOSYNTHESIS; SPECIFICITY; DATABASE; PATHWAY; DOMAIN	We have determined the crystal structure of nicotinate phosphoribosyltransferase from Themoplasma acidophilum (TaNAPRTase). The TaNAPRTase has three domains, an N-terminal domain, a central functional domain, and a unique C-terminal domain. The crystal structure revealed that the functional domain has a type II phosphoribosyltransferase fold that may be a common architecture for both nicotinic acid and quinolinic acid (QA) phosphoribosyltransferases (PRTase) despite low sequence similarity between them. Unlike QAPRTase, TaNAPRTase has a unique extra C-terminal domain containing a zinc knuckle-like motif containing 4 cysteines. The TaNAPRTase forms a trimer of dimers in the crystal. The active site pocket is formed at dimer interfaces. The complex structures with phosphoribosylpyrophosphate (PRPP) and nicotinate mononucleotide (NAMN) showed, surprisingly, that functional residues lining on the active site of TaNAPRTase are quite different from those of QAPRTase, although their substrates are quite similar to each other. The phosphate moiety of PRPP and NAMN is anchored to the phosphate-binding loops formed by backbone amides, as found in many alpha/beta barrel enzymes. The pyrophosphate moiety of PRPP is located at the entrance of the active site pocket, whereas the nicotinate moiety of NAMN is located deep inside. Interestingly, the nicotinate moiety of NAMN is intercalated between highly conserved aromatic residues Tyr(21) and Phe(138). Careful structural analyses combined with other NAPRTase sequence subfamilies reveal that TaNAPRTase represents a unique sequence subfamily of NAPRTase. The structures of TaNAPRTase also provide valuable insight for other sequence subfamilies such as pre-B cell colony-enhancing factor, known to have nicotinamide phosphoribosyltransferase activity.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA.	SHKim@cchem.berkeley.edu			NIGMS NIH HHS [GM 62412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V20, P2069; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Gross JW, 1998, BIOCHEMISTRY-US, V37, P4189, DOI 10.1021/bi972014w; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kim KK, 1997, STRUCTURE, V5, P1571, DOI 10.1016/S0969-2126(97)00306-7; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kucharczyk R, 1998, FEBS LETT, V424, P127, DOI 10.1016/S0014-5793(98)00153-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rajavel M, 1998, BIOCHEMISTRY-US, V37, P4181, DOI 10.1021/bi9720134; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Sharma V, 1998, STRUCTURE, V6, P1587, DOI 10.1016/S0969-2126(98)00156-7; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRITZ GJ, 1987, ESCHERICHIA COLI SAL, P557; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006	34	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18326	18335		10.1074/jbc.M501622200	http://dx.doi.org/10.1074/jbc.M501622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753098	hybrid			2022-12-27	WOS:000228807200092
J	Roldan, A; Warren, OU; Russell, RS; Liang, C; Wainberg, MA				Roldan, A; Warren, OU; Russell, RS; Liang, C; Wainberg, MA			A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro tRNA(3)(Lys) annealing and exhibits multimerization-induced inhibition of reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER ACTIVATION SIGNAL; TYPE-1 GAG; TRANSFER-RNA; CAPSID PROTEIN; BINDING-SITE; GENOMIC RNA; RECOGNITION ELEMENT; SECONDARY STRUCTURE; VIRAL-RNA	HIV-1 uses tRNA(3)(Lys) to prime reverse transcription of its viral RNA. In this process, the 3'-end of tRNA(3)(Lys) must be annealed to the primer binding site of HIV-1 genomic RNA, and the two molecules together form a complex structure. During annealing, the nucleocapsid (NC) protein enhances the unwinding of tertiary structures within both RNA molecules. Moreover, the packaging of tRNA(3)(Lys) occurs prior to viral budding at a time when NC is still part of the Pr55(Gag) polyprotein. In contrast, Pr55(Gag) is able to produce virus-like particles on its own. We have recently shown that an N-terminal extended form of NC (mGag), containing all of the minimal elements required for virus-like particle formation, possesses greater affinity for HIV-1 genomic RNA than does NC alone. We have now studied the tRNA(3)(Lys)- annealing properties of mGag in comparison to those of NC and report that the former is more efficient in this regard than the latter. We have also tested each of a mutant version of mGag, an extended form of mGag, and an almost full-length form of Gag, and showed that all of these possessed greater tRNA-annealing capacity than did the viral NC protein. Yet, surprisingly, multimerization of Gag-related proteins did not abrogate this annealing process but rather resulted in dramatically reduced levels of reverse transcriptase processivity. These results suggest that the initial stages of reverse transcription may be regulated by the multimerization of Pr55(Gag) polyprotein at times prior to the cleavage of NC.	Jewish Gen Hosp, Lady Davis Inst, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Div Expt Med, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Wainberg, MA (corresponding author), Jewish Gen Hosp, Lady Davis Inst, McGill AIDS Ctr, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mark.wainberg@mcgill.ca	Russell, Rod/AAU-3109-2021	Roldan, Ariel/0000-0002-8159-5450				Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Andersen ES, 2003, J VIROL, V77, P3020, DOI 10.1128/JVI.77.5.3020-3030.2003; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; BERKOWITZ RD, 1993, J VIROL, V67, P7190, DOI 10.1128/JVI.67.12.7190-7200.1993; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; Callahan EM, 2003, J VIROL, V77, P9388, DOI 10.1128/JVI.77.17.9388-9398.2003; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; Cen S, 2000, J VIROL, V74, P10796, DOI 10.1128/JVI.74.22.10796-10800.2000; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CHAZAL N, 1994, J VIROL, V68, P111, DOI 10.1128/JVI.68.1.111-122.1994; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; CRAWFORD S, 1985, J VIROL, V53, P899, DOI 10.1128/JVI.53.3.899-907.1985; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; Feng YX, 1999, J VIROL, V73, P4251, DOI 10.1128/JVI.73.5.4251-4256.1999; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Kaye JF, 1998, J VIROL, V72, P5877, DOI 10.1128/JVI.72.7.5877-5885.1998; Kleiman L, 2002, IUBMB LIFE, V53, P107, DOI 10.1080/15216540211469; KLEIMAN L, 1991, BIOCHEM BIOPH RES CO, V174, P1272, DOI 10.1016/0006-291X(91)91559-U; Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002; LITVAK S, 1994, TRENDS BIOCHEM SCI, V19, P114, DOI 10.1016/0968-0004(94)90203-8; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; Maki AH, 2001, BIOCHEMISTRY-US, V40, P1403, DOI 10.1021/bi002010i; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l; Roldan A, 2004, J BIOL CHEM, V279, P39886, DOI 10.1074/jbc.M405632200; Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zabransky A, 2002, VIROLOGY, V294, P141, DOI 10.1006/viro.2001.1315	53	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17488	17496		10.1074/jbc.M501310200	http://dx.doi.org/10.1074/jbc.M501310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731102	hybrid			2022-12-27	WOS:000228615500116
J	Schroeder, LA; deHaseth, PL				Schroeder, LA; deHaseth, PL			Mechanistic differences in promoter DNA melting by Thermus aquaticus and Escherichia coli RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; AROMATIC-AMINO-ACIDS; OPEN COMPLEX-FORMATION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; SIGMA-FACTOR; TRANSCRIPTION INITIATION; CONFORMATIONAL-CHANGES; STRUCTURAL BASIS; HOLOENZYME	Formation of strand-separated, functional complexes at promoters was compared for RNA polymerases from the mesophile Escherichia coli and the thermophile Thermus aquaticus. The RNA polymerases contained sigma factors that were wild type or bearing homologous alanine substitutions for two aromatic amino acids involved in DNA melting. Substitutions in the sigma(A) subunit of T. aquaticus RNA polymerase impair promoter DNA melting equally at temperatures from 25 to 75 degrees C. However, homologous substitutions in sigma(70) render E. coli RNA polymerase progressively more melting-defective as the temperature is reduced below 37 degrees C. The effects of the mutations on the mechanism of promoter DNA melting were investigated by studying the interaction of wild type and mutant RNA polymerases with "partial promoters" mimicking promoter DNA where the nucleation of DNA melting had taken place. Because T. aquaticus and E. coli RNA polymerases bound these templates similarly, it was concluded that the different effects of the mutations on the two polymerases are exerted at a step preceding nucleation of DNA melting. A model is presented for how this mechanistic difference between the two RNA polymerase could explain our observations.	Case Western Reserve Univ, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Schroeder, LA (corresponding author), Case Western Reserve Univ, Ctr RNA Mol Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	las30@case.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; DeHaseth PL, 2003, METHOD ENZYMOL, V370, P553; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Fedoriw AM, 1998, BIOCHEMISTRY-US, V37, P11971, DOI 10.1021/bi980980o; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Fenton MS, 2003, J BIOL CHEM, V278, P39669, DOI 10.1074/jbc.M307412200; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; Kulbachinskiy A, 2004, J BACTERIOL, V186, P7818, DOI 10.1128/JB.186.22.7818-7820.2004; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; Kuznedelov K, 2003, METHOD ENZYMOL, V370, P94; Lozinski T, 2003, ANAL BIOCHEM, V320, P239, DOI 10.1016/S0003-2697(03)00381-6; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MANGEL WF, 1974, J BIOL CHEM, V249, P3007; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MASEDA H, 1995, FEMS MICROBIOL LETT, V128, P127, DOI 10.1111/j.1574-6968.1995.tb07511.x; MEIER T, 1995, NUCLEIC ACIDS RES, V23, P988, DOI 10.1093/nar/23.6.988; Minakhin L, 2001, J BACTERIOL, V183, P71, DOI 10.1128/JB.183.1.71-76.2001; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Panaghie G, 2000, J MOL BIOL, V299, P1217, DOI 10.1006/jmbi.2000.3808; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Sun L, 2004, J MOL BIOL, V343, P1171, DOI 10.1016/j.jmb.2004.09.025; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Tsujikawa L, 2002, P NATL ACAD SCI USA, V99, P3493, DOI 10.1073/pnas.062487299; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Xue Y, 2000, BIOCHEMISTRY-US, V39, P14356, DOI 10.1021/bi0012538; Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	40	20	22	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17422	17429		10.1074/jbc.M501281200	http://dx.doi.org/10.1074/jbc.M501281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731103	hybrid			2022-12-27	WOS:000228615500108
J	Murcha, MW; Elhafez, D; Millar, AH; Whelan, J				Murcha, MW; Elhafez, D; Millar, AH; Whelan, J			The C-terminal region of TIM17 links the outer and inner mitochondrial membranes in Arabidopsis and is essential for protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; PLANT-MITOCHONDRIA; INTERMEMBRANE SPACE; ALTERNATIVE OXIDASE; CARRIER PROTEINS; TOM COMPLEX; MACHINERY; EVOLUTION; BIOGENESIS; RECEPTOR	The translocase of the inner membrane 17 (AtTIM17-2) protein from Arabidopsis has been shown to link the outer and inner mitochondrial membranes. This was demonstrated by several approaches: (i) In vitro organelle import assays indicated the imported AtTIM17-2 protein remained protease accessible in the outer membrane when inserted into the inner membrane. (ii) N-terminal and C-terminal tagging indicated that it was the C-terminal region that was located in the outer membrane. (iii) Antibodies raised to the C-terminal 100 amino acids recognize a 31-kDa protein from purified mitochondria, but cross-reactivity was abolished when mitochondria were protease-treated to remove outer membrane-exposed proteins. Antibodies to AtTIM17-2 inhibited import of proteins via the general import pathway into outer membrane-ruptured mitochondria, but did not inhibit protein import via the carrier import pathway. Together these results indicate that the C-terminal region of AtTIM17-2 is exposed on the outer surface of the outer membrane, and the C-terminal region is essential for protein import into mitochondria.	Univ Western Australia, Plant Mol Biol Grp, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia	University of Western Australia	Whelan, J (corresponding author), Univ Western Australia, Plant Mol Biol Grp, Sch Biomed & Chem Sci, 35 Stirling Highway, Crawley, WA 6009, Australia.	seamus@cyllene.uwa.edu.au	Whelan, James/F-6402-2011; Millar, A. Harvey/A-5452-2008; Murcha, Monika W/H-5495-2014; Murcha, Monika W/C-3834-2011	Whelan, James/0000-0001-5754-025X; Millar, A. Harvey/0000-0001-9679-1473; Murcha, Monika W/0000-0002-3689-6158; 				Adams KL, 2003, MOL PHYLOGENET EVOL, V29, P380, DOI 10.1016/S1055-7903(03)00194-5; Ahting U, 2005, J BIOL CHEM, V280, P48, DOI 10.1074/jbc.M410905200; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Chew O, 2004, FEBS LETT, V557, P109, DOI 10.1016/S0014-5793(03)01457-1; Considine MJ, 2001, PLANT PHYSIOL, V126, P1619, DOI 10.1104/pp.126.4.1619; Dessi P, 1996, ARCH BIOCHEM BIOPHYS, V335, P358, DOI 10.1006/abbi.1996.0517; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Harlow D., 1988, ANTIBODIES LAB MANUA; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Hood DA, 2004, P NUTR SOC, V63, P293, DOI 10.1079/PNS2004342; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hwa JJ, 2004, FEBS LETT, V572, P141, DOI 10.1016/j.febslet.2004.07.025; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lister R, 2004, PLANT PHYSIOL, V134, P777, DOI 10.1104/pp.103.033910; Lister R, 2003, NUCLEIC ACIDS RES, V31, P325, DOI 10.1093/nar/gkg055; Lister R, 2002, PLANT J, V30, P555, DOI 10.1046/j.1365-313X.2002.01316.x; LISTER R, 2005, IN PRESS MOL MEMBR B; Lucattini R, 2004, MOL BIOL EVOL, V21, P652, DOI 10.1093/molbev/msh058; Macasev D, 2000, PLANT PHYSIOL, V123, P811, DOI 10.1104/pp.123.3.811; Macasev D, 2004, MOL BIOL EVOL, V21, P1557, DOI 10.1093/molbev/msh166; McFadden GI, 2001, PLANT PHYSIOL, V125, P50, DOI 10.1104/pp.125.1.50; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Murcha MW, 2004, J MOL BIOL, V344, P443, DOI 10.1016/j.jmb.2004.09.045; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Werhahn W, 2003, PLANT PHYSIOL BIOCH, V41, P407, DOI 10.1016/S0981-9428(03)00047-0; WHELAN J, 1995, PLANT MOL BIOL, V27, P769, DOI 10.1007/BF00020229; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833	47	35	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16476	16483		10.1074/jbc.M413299200	http://dx.doi.org/10.1074/jbc.M413299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722347	hybrid			2022-12-27	WOS:000228444800122
J	Duzhyy, D; Harvey, M; Sokolowski, B				Duzhyy, D; Harvey, M; Sokolowski, B			A secretory-type protein, containing a pentraxin domain, interacts with an A-type K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; NEURONAL PENTRAXIN; BETA-SUBUNIT; HAIR-CELLS; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNELS; VOLTAGE CLAMP; MEMBRANE; COCHLEA; MODULATION	A-type K+ channels belonging to the Shal subfamily are found in various receptor and neuronal cells. Although their kinetics and cell surface expression are regulated by auxiliary subunits, little is known about the proteins that may interact with Kv4 during development. A yeast two-hybrid screening of a cDNA library made from the sensory epithelium of embryonic chick cochlea revealed a novel association of Kv4.2 with a protein containing a pentraxin domain (PPTX). Sequence analysis shows that PPTX is a member of the long pentraxin family, is 53% identical to mouse PTX3, and has a signal peptide at the N terminus. Studies with chick cochlear tissues reveal that Kv4.2 coprecipitates PPTX and that both proteins are colocalized to the sensory and ganglion cells. A yeast two-hybrid assay demonstrated that the last 22 amino acids of the PPTX C terminus interact with the N terminus of Kv4.2. Chinese hamster ovary cells transfected with recombinant PPTX reveal secretory products in both non-truncated and truncated forms. Among the secreted variants are several blocked by Brefeldin A, suggesting export via a classical pathway. PPTX is soluble in the presence of sodium carbonate, suggesting localization to the cytosolic side of the plasmalemma. Immunohistochemical studies show that Kv4.2 and PPTX colocalize in the region of the plasmalemma of Chinese hamster ovary cells; however, both are locked in the endoplasmic reticulum of COS-7 cells, suggesting that PPTX does not act as a shuttle protein. Reverse transcription-PCR demonstrates that PPTX mRNA is found in tissues that include brain, eye, heart, and blood vessels.	Univ S Florida, Dept Otolaryngol Head & Neck Surg, Otol Lab MDC83, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sokolowski, B (corresponding author), Univ S Florida, Dept Otolaryngol Head & Neck Surg, Otol Lab MDC83, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	bsokolow@hsc.usf.edu		Duzhyy, Dmytro/0000-0001-8082-8913	NIDCD NIH HHS [DC43095] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BATTAZII B, 1997, J BIOL CHEM, V272, P32817; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Chen B, 2005, J COMP NEUROL, V481, P391, DOI 10.1002/cne.20391; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; FISCHER FP, 1992, HEARING RES, V61, P167, DOI 10.1016/0378-5955(92)90048-R; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1992, J NEUROSCI, V12, P800; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Kaltner H, 2001, ADV EXP MED BIOL, V491, P79; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Mehul B, 1997, J CELL SCI, V110, P1169; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; NEHER E, 1971, J GEN PHYSIOL, V58, P36, DOI 10.1085/jgp.58.1.36; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; OLIVEIRA EB, 1979, J BIOL CHEM, V254, P489; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROGAWSKI MA, 1985, ANN NY ACAD SCI, V448, P403, DOI 10.1111/j.1749-6632.1985.tb29934.x; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Shrive AK, 1999, J MOL BIOL, V290, P997, DOI 10.1006/jmbi.1999.2956; Sokolowski B, 2005, J NEUROSCI RES, V79, P459, DOI 10.1002/jnr.20376; Sokolowski BHA, 2004, J NEUROSCI, V24, P6265, DOI 10.1523/JNEUROSCI.1291-04.2004; Tsui CC, 1996, J NEUROSCI, V16, P2463; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	40	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15165	15172		10.1074/jbc.M500111200	http://dx.doi.org/10.1074/jbc.M500111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708850	hybrid			2022-12-27	WOS:000228236800100
J	Golks, A; Brenner, D; Fritsch, C; Krammer, PH; Lavrik, IN				Golks, A; Brenner, D; Fritsch, C; Krammer, PH; Lavrik, IN			c-FLIPR, a new regulator of death receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FLICE-INHIBITORY PROTEINS; CELL-DEATH; CD95-MEDIATED APOPTOSIS; CD95 APO-1/FAS; UP-REGULATION; ACTIVATION; CASPASE-8; FAS; INDUCTION	c-FLIPs (c-FLICE inhibitory proteins) play an essential role in regulation of death receptor-induced apoptosis. Multiple splice variants of c-FLIP have been described on the mRNA level; so far only two of them, c-FLIPL and c-FLIPS, had been found to be expressed at the protein level. In this report, we reveal the endogenous expression of a third isoform of c-FLIP. We demonstrate its presence in a number of T and B cell lines as well as in primary human T cells. We identified this isoform as c-FLIPR, a death effector domain-only splice variant previously identified on the mRNA level. Importantly, c-FLIPR is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex upon CD95 stimulation. Several properties of c-FLIPR are similar to c-FLIPS: both isoforms have a short half-life, a similar pattern of expression during activation of primary human T cells, and are strongly induced in T cells upon CD3/CD28 costimulation. Taken together, our data demonstrate endogenous expression of c-FLIPR and similar roles of c-FLIPR and c-FLIPS isoforms in death receptor-mediated apoptosis.	German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Lavrik, Inna N/C-1700-2009	Lavrik, Inna N/0000-0002-9324-309X; Brenner, Dirk/0000-0001-8979-1045				Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Fulda S, 2000, CANCER RES, V60, P3947; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	33	213	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14507	14513		10.1074/jbc.M414425200	http://dx.doi.org/10.1074/jbc.M414425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701649	hybrid			2022-12-27	WOS:000228236800021
J	Reinicke, AT; Hutchinson, JL; Magee, AI; Mastroeni, P; Trowsdale, J; Kelly, AP				Reinicke, AT; Hutchinson, JL; Magee, AI; Mastroeni, P; Trowsdale, J; Kelly, AP			A Salmonella typhimurium effector protein SifA is modified by host cell prenylation and S-acylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; INTRACELLULAR TRAFFICKING; CONTAINING VACUOLES; III SECRETION; MACROPHAGES; COMPARTMENTS; BIOGENESIS; MATURATION; PHAGOSOMES; INTEGRITY	SifA is a Salmonella effector protein that is required for maintenance of the vacuolar membrane that surrounds replicating bacteria. It associates with the Salmonella-containing vacuole but how it interacts with the membrane is unknown. Here we show by immunofluorescence, S100 fractionation and Triton X-114 partitioning that the membrane association and targeting properties of SifA are influenced by a motif encoded within the C-terminal six amino acids. This sequence shares homology with both CAAX and Rab geranylgeranyl transferase prenylation motifs. We characterized the post-translational processing of SifA and showed that the cysteine residue within the CAAX motif is modified by isoprenoid addition through the action of protein geranylgeranyl transferase I. SifA was additionally modified by S-acylation of an adjacent cysteine residue. Similar modifications to host cell proteins regulate numerous functions including protein targeting, membrane association, protein-protein interaction, and signal transduction. This is the only known example of a bacterial effector protein that is modified both by mammalian cell S-acylation and prenylation machinery.	Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Univ Cambridge, Bacterial Infect Grp, Dept Vet Clin Med, Ctr Vet Sci, Cambridge CB2 1QP, England; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	University of Cambridge; University of Cambridge; Imperial College London	Kelly, AP (corresponding author), Univ Cambridge, Dept Pathol, Div Immunol, Tennis Court Rd, Cambridge CB2 1QP, England.	apk23@mole.bio.cam.ac.uk	Magee, Anthony/V-8345-2019	Mastroeni, Pietro/0000-0003-3838-4962	MRC [G9800943] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boucrot E, 2003, J BIOL CHEM, V278, P14196, DOI 10.1074/jbc.M207901200; Brumell JH, 1999, CURR BIOL, V9, pR277, DOI 10.1016/S0960-9822(99)80178-X; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Coligan JE, 1995, CURRENT PROTOCOLS PR; Copier J, 1996, J IMMUNOL, V157, P1017; FINLAY BB, 1991, J CELL SCI, V99, P283; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Gorvel JP, 2001, MICROBES INFECT, V3, P1299, DOI 10.1016/S1286-4579(01)01490-3; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P237; Harrison RE, 2004, MOL BIOL CELL, V15, P3146, DOI 10.1091/mbc.E04-02-0092; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Knodler LA, 2003, TRAFFIC, V4, P587, DOI 10.1034/j.1600-0854.2003.00118.x; Magee Anthony I, 2003, Biochem J, V376, pe3, DOI 10.1042/BJ20031531; MARSMAN M, 2004, MOL BIOL CELL; Martinez-Lorenzo MJ, 2001, CELL MICROBIOL, V3, P407, DOI 10.1046/j.1462-5822.2001.00123.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Miao EA, 2000, P NATL ACAD SCI USA, V97, P7539, DOI 10.1073/pnas.97.13.7539; Mitchell EK, 2004, EUR J IMMUNOL, V34, P2559, DOI 10.1002/eji.200425314; Philippe N, 2004, PLASMID, V51, P246, DOI 10.1016/j.plasmid.2004.02.003; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Salcedo SP, 2001, CELL MICROBIOL, V3, P587, DOI 10.1046/j.1462-5822.2001.00137.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Tafazoli F, 2003, INFECT IMMUN, V71, P872, DOI 10.1128/IAI.71.2.872-881.2003; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	40	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14620	14627		10.1074/jbc.M500076200	http://dx.doi.org/10.1074/jbc.M500076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710609	hybrid			2022-12-27	WOS:000228236800036
J	Tye, CE; Hunter, GK; Goldberg, HA				Tye, CE; Hunter, GK; Goldberg, HA			Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SITE-DIRECTED MUTAGENESIS; HYDROXYAPATITE; OSTEOPONTIN; RECOMBINANT; BSP; EXPRESSION; INTERFACES; RESIDUES; AFFINITY	Bone sialoprotein (BSP) is an anionic phosphorylated glycoprotein that is expressed almost exclusively in mineralized tissues and has been shown to be a potent nucleator of hydroxyapatite formation. The binding of BSP to collagen is thought to be important for the initiation of bone mineralization and in the adhesion of bone cells to the mineralized matrix. Using a solid phase assay, we have investigated the interaction between BSP and collagen. Initial studies showed that raising the ionic strength, decreasing the pH below 7, or introducing divalent cations diminishes but does not abolish the binding of BSP to collagen, indicating that the interaction is only partly electrostatic in nature. Both bone-extracted and recombinant (r) BSP exhibited similar binding affinities, indicating that post-translational modifications are not critical for binding. To identify the collagen-binding domain, recombinant peptides of BSP were studied. Peptide rBSP-(1-100) binds to type I collagen with an affinity similar to that of full-length rBSP, whereas peptides containing the sequences 99 201 or 200-301 do not bind. Further studies showed that rBSP-(1-75) competitively inhibits the binding of rBSP (1-100), whereas rBSP-(21-100) inhibits binding to a lesser extent, and rBSP-(43-100) does not inhibit binding. These results suggest that the collagen-binding site of rat BSP is within the sequence 21-42, with residues N-terminal of this region likely also involved. This site was confirmed by the demonstration of collagen-binding activity of a synthetic peptide corresponding to residues 19-46. The collagen-binding domain, which is highly conserved among species, is enriched in hydrophobic residues and lacks acidic residues. We conclude that residues 19-46 of BSP represent a novel collagen-binding site.	Univ Western Ontario, Sch Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Goldberg, HA (corresponding author), Univ Western Ontario, Sch Dent, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, Dent Sci Bldg, London, ON N6A 5C1, Canada.	hagoldbe@uwo.ca	Goldberg, Harvey/B-5742-2015	Tye, Coralee/0000-0002-3349-1833				BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHEN Y, 1992, J BIOL CHEM, V267, P24871; Dahl T, 2003, CONNECT TISSUE RES, V44, P206, DOI 10.1080/03008200390181672; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; FRATZL P, 1991, CALCIFIED TISSUE INT, V48, P407, DOI 10.1007/BF02556454; Fratzl P, 1996, Connect Tissue Res, V34, P247, DOI 10.3109/03008209609005268; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; GERSTENFELD LC, 1994, CALCIFIED TISSUE INT, V55, P230, DOI 10.1007/BF00425880; Goldberg Harvey A., 1994, Journal of Tissue Culture Methods, V16, P211, DOI 10.1007/BF01540653; Harris NL, 2000, BONE, V27, P795, DOI 10.1016/S8756-3282(00)00392-6; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; Hunter GK, 2001, J BIOMED MATER RES, V55, P496, DOI 10.1002/1097-4636(20010615)55:4<496::AID-JBM1042>3.0.CO;2-2; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; POGULIS RJ, 1996, METH MOL B, V57, P167; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; STETLERSTEVENSON WG, 1986, CALCIFIED TISSUE INT, V38, P135, DOI 10.1007/BF02556873; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; Tsai CJ, 1997, PROTEIN SCI, V6, P53; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; VEIS A, 2000, CHEM BIOL MINERALIZE; WEINER S, 1991, FEBS LETT, V285, P49, DOI 10.1016/0014-5793(91)80722-F; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; ZHANG R, 1990, J BIOL CHEM, V265, P15375; Zhou HX, 2001, BIOPOLYMERS, V59, P427, DOI 10.1002/1097-0282(200111)59:6<427::AID-BIP1047>3.0.CO;2-7; Zhu XL, 2001, BIOCHEM CELL BIOL, V79, P737, DOI 10.1139/bcb-79-6-737	44	95	98	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13487	13492		10.1074/jbc.M408923200	http://dx.doi.org/10.1074/jbc.M408923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703183	hybrid			2022-12-27	WOS:000228095500039
J	Alt, JR; Bouska, A; Fernandez, MR; Cerny, RL; Xiao, H; Eischen, CM				Alt, JR; Bouska, A; Fernandez, MR; Cerny, RL; Xiao, H; Eischen, CM			Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; MYC-INDUCED LYMPHOMAGENESIS; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; PROTEIN COMPLEX; HISTONE H2AX; P53 PROTEIN; S-PHASE	Mdm2 directly regulates the p53 tumor suppressor. However, Mdm2 also has p53-independent activities, and the pathways that mediate these functions are unresolved. Here we report the identification of a specific association of Mdm2 with Mre11, Nbs1, and Rad50, a DNA double strand break repair complex. Mdm2 bound to the Mre11-Nbs1-Rad50 complex in primary cells and in cells containing inactivated p53 or p14/p19(ARF), a regulator of Mdm2. Further analysis revealed that Mdm2 directly bound to Nbs1 but not to Mre11 or Rad50. Amino acids 198-314 of Mdm(2) were required for Mdm2/Nbs1 association, and neither the N terminus forkhead-associated and breast cancer C-terminal domains nor the C terminus Mre11 binding domain of Nbs1 mediated the interaction of Nbs1 with Mdm2. Mdm2 co-localized with Nbs1 to sites of DNA damage following gamma-irradiation. Notably, Mdm2 overexpression inhibited DNA double strand break repair, and this was independent of p53 and ARF, the alternative reading frame of the Ink4alocus. The delay in DNA repair imposed by Mdm2 required the Nbs1 binding domain of Mdm2, but the ubiquitin ligase domain in Mdm2 was dispensable. Therefore, Nbs1 is a novel p53-independent Mdm2 binding protein and links Mdm2 to the Mre11-Nbs1-Rad50-regulated DNA repair response.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	ceischen@unmc.edu		Bouska, Alyssa/0000-0003-1324-6678; Fernandez, Mario/0000-0002-2017-9576	NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009139, T32CA009476] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009476, CA09476, P30 CA36727, CA09139] Funding Source: Medline; NCRR NIH HHS [P20 RR15635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALANI E, 1989, GENETICS, V122, P47; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Asahara H, 2003, NUCLEIC ACIDS RES, V31, P2451, DOI 10.1093/nar/gkg342; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dang JJ, 2002, CANCER RES, V62, P1222; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KOBAYASHI H, 1995, MMS COMMUN, P103; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tomlinson GE, 1998, CANCER RES, V58, P3237; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18771	18781		10.1074/jbc.M413387200	http://dx.doi.org/10.1074/jbc.M413387200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15734743	hybrid			2022-12-27	WOS:000228932300028
J	Fernandez-Tornero, C; Lozano, RM; Rivas, G; Jimenez, MA; Standker, L; Diaz-Gonzalez, D; Forssmann, WG; Cuevas, P; Romero, A; Gimenez-Gallego, G				Fernandez-Tornero, C; Lozano, RM; Rivas, G; Jimenez, MA; Standker, L; Diaz-Gonzalez, D; Forssmann, WG; Cuevas, P; Romero, A; Gimenez-Gallego, G			Synthesis of the blood circulating c-terminal fragment of insulin-like growth factor (IGF)-binding protein-4 in its native conformation - Crystallization, heparin and IGF binding, and osteogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; IN-VIVO; LIMITED PROTEOLYSIS; PURIFICATION; EXPRESSION; AFFINITY; IGFBP-4; DOMAIN; SITES	Insulin-like growth factor-binding proteins play a critical role in a wide variety of important physiological processes. It has been demonstrated that both an N-terminal and a C-terminal fragment of insulin-like growth factor-binding protein-4 exist and accumulate in the circulatory system, these fragments accounting for virtually the whole amino acid sequence of the protein. The circulating C-terminal fragment establishes three disulfide bridges, and the binding pattern of these has recently been defined. Here we show that the monodimensional H-1 NMR spectrum of the C-terminal fragment is typical of a protein with a relatively close packed tertiary structure. This fragment can be produced in its native conformation in Escherichia coli, without the requirement of further refolding procedures, when synthesis is coupled to its secretion from the cell. The recombinant protein crystallizes with the unit cell parameters of a hexagonal system. Furthermore, it binds strongly to heparin, acquiring a well defined oligomeric structure that interacts with insulin-like growth factors, and promotes bone formation in cultures of murine calvariae.	CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Madrid 28040, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; IPF Pharmaceut GmbH, D-30625 Hannover, Germany; Hosp Ramon & Cajal, Dept Invest, E-28034 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Hospital Universitario Ramon y Cajal	Gimenez-Gallego, G (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Ramiro Maeztu 9, Madrid 28040, Spain.	gimenez_gallego@cib.csic.es	Rivas, German/AFL-7528-2022; Romero, Antonio/K-5754-2014; Rivas, German/AAG-7458-2022; Fernandez-Tornero, Carlos/AAV-8028-2021; Fernandez-Tornero, Carlos/I-6888-2015; Jimenez, M. Angeles/C-7193-2008	Rivas, German/0000-0003-3450-7478; Romero, Antonio/0000-0002-6990-6973; Rivas, German/0000-0003-3450-7478; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Jimenez, M. Angeles/0000-0001-6835-5850				ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Binoux Michel, 1999, V17, P281; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; Chelius D, 2001, J ENDOCRINOL, V168, P283, DOI 10.1677/joe.0.1680283; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; Clemmons David R., 1999, V17, P273; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; DENEFLE P, 1989, GENE, V85, P499, DOI 10.1016/0378-1119(89)90444-7; DIDONATO A, 1993, ANAL BIOCHEM, V212, P291, DOI 10.1006/abio.1993.1328; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; Headey SJ, 2003, J BIOMOL NMR, V25, P251, DOI 10.1023/A:1022880328909; Headey SJ, 2004, MOL ENDOCRINOL, V18, P2740, DOI 10.1210/me.2004-0248; Hunt A, 2001, SCIENCE, V293, P1784, DOI 10.1126/science.1065206; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; LASSARRE C, 1994, ENDOCRINOLOGY, V134, P1254, DOI 10.1210/en.134.3.1254; Laue T., 1993, ANAL ULTRACENTRIFUGA, P90; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; Maile Laura A., 1999, V17, P633; MASUI Y, 1983, EXPT MANIPULATION GE, P15; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/en.142.6.2641; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Oh Youngman, 1999, V17, P257; Ooi Guck T., 1999, V17, P111; ORTEGA S, 1992, BIO-TECHNOL, V10, P795, DOI 10.1038/nbt0792-795; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rivas G, 1996, J MOL RECOGNIT, V9, P31, DOI 10.1002/(SICI)1099-1352(199601)9:1<31::AID-JMR237>3.3.CO;2-F; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; TANGEMANN K, 1997, INTEGRIN LIGAND INTE, P85; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Wu H., 1931, CHINESE J PHYSIOL, V5, P321; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	55	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18899	18907		10.1074/jbc.M500587200	http://dx.doi.org/10.1074/jbc.M500587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15735305	hybrid, Green Published			2022-12-27	WOS:000228932300042
J	Flaig, R; Greschik, H; Peluso-Iltis, C; Moras, D				Flaig, R; Greschik, H; Peluso-Iltis, C; Moras, D			Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; RETINOID-X-RECEPTOR; PROTEIN-KINASE-A; COACTIVATOR RECRUITMENT; TRANSCRIPTION FACTOR; HORMONE RECEPTORS; CRYSTAL-STRUCTURE; NUR77; HETERODIMERIZATION; ACTIVATION	NGFI-B is a ligand-independent orphan nuclear receptor of the NR4A subfamily that displays important functional differences with its homolog Nurr1. In particular, the NGFI-B ligand-binding domain (LBD) exhibits only modest activity in cell lines in which the Nurr1 LBD strongly activates transcription. To gain insight into the structural basis for the distinct activation potentials, we determined the crystal structure of the NGFI-B LBD at 2.4-angstrom resolution. Superimposition with the Nurr1 LBD revealed a significant shift of the position of helix 12, potentially caused by conservative amino acids exchanges in helix 3 or helix 12. Replacement of the helix 11-12 region of Nurr1 with that of NGFI-B dramatically reduces the transcriptional activity of the Nurr1 LBD. Similarly, mutation of Met(414) in helix 3 to leucine or of Leu(591) in helix 12 to isoleucine (the corresponding residues found in NGFI-B) significantly affects Nurr1 transactivation. In comparison, swapping the helix 11-12 region of Nurr1 into NGFI-B results in a modest increase of activity. These observations reveal a high sensitivity of LBD activity to changes that influence helix 12 positioning. Furthermore, mutation of hydrophobic surface residues in the helix 11-12 region (outside the canonical co-activator surface constituted by helices 3, 4, and 12) severely affects Nurr1 transactivation. Together, our data suggest that a novel co-regulator surface that includes helix 11 and a specifically positioned helix 12 determine the cell type-dependent activities of the NGFI-B and the Nurr1 LBD.	ULP, CNRS, INSERM, IGBMC,Dept Biol & Genom Struct, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, CNRS, INSERM, IGBMC,Dept Biol & Genom Struct, 1 Rue Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr						Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; Auwerx J, 1999, CELL, V97, P161; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Beitz E, 2000, BIOINFORMATICS, V16, P135, DOI 10.1093/bioinformatics/16.2.135; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castillo SO, 1998, GENE EXPRESSION, V7, P1; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DeLano W.L, PYMOL MOL GRAPHICS S; Ethier I, 2004, NEUROPSYCHOPHARMACOL, V29, P335, DOI 10.1038/sj.npp.1300318; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; He YW, 2002, J LEUKOCYTE BIOL, V72, P440; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; Maruyama K, 1998, INT J ONCOL, V12, P1237; Murphy EP, 1996, GENE EXPRESSION, V5, P169; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Paulsen RE, 1995, J MOL NEUROSCI, V6, P249, DOI 10.1007/BF02736784; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	50	97	100	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19250	19258		10.1074/jbc.M413175200	http://dx.doi.org/10.1074/jbc.M413175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15716272	Green Published, hybrid			2022-12-27	WOS:000228932300082
J	Alpy, F; Latchumanan, VK; Kedinger, V; Janoshazi, A; Thiele, C; Wendling, C; Rio, MC; Tomasetto, C				Alpy, F; Latchumanan, VK; Kedinger, V; Janoshazi, A; Thiele, C; Wendling, C; Rio, MC; Tomasetto, C			Functional characterization of the MENTAL domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; STEROL-SENSING DOMAIN; BREAST-CANCER; STAR; CHOLESTEROL; MLN64; MEMBRANE; BINDING; MITOCHONDRIA; MECHANISM	Human metastatic lymph node (MLN) 64 is composed of two conserved regions. The amino terminus contains a conserved membrane-spanning MENTAL (MLN64 NH2-terminal) domain shared with an unique protein called MENTHO ( MLN64 NH2-terminal domain homologue) and targets the protein to late endosome. The carboxyl-terminal domain is composed of a cholesterol binding steroidogenic acute regulatory-related lipid transfer domain exposed to the cytoplasm. MENTHO overexpression leads to the accumulation of enlarged endosomes. In this study, we show that MLN64 overexpression also induces the formation of enlarged endosomes, an effect that is probably mediated by the MENTAL domain. Using an in vivo photocholesterol binding assay, we find that the MENTAL domain of MLN64 is a cholesterol binding domain. Moreover, glutathione S-transferase pull-down or co-immunoprecipitation experiments demonstrate that this domain mediates homo- and hetero-interaction of MLN64 and MENTHO. In living cells, the expression of paired yellow fluorescent and cyan fluorescent fusion proteins show MENTHO homo- interaction and its interaction with MLN64. These data indicate that within late-endosomal membranes, MLN64 and MENTHO define discrete cholesterol-containing subdomains. The MENTAL domain might serve to maintain cholesterol at the membrane of late endosomes prior to its shuttle to cytoplasmic acceptor(s).	Univ Strasbourg 1, IGBMC, Dept Mol Pathol, CNRS,UPR 6520,INSERM,U596, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society	Tomasetto, C (corresponding author), Univ Strasbourg 1, IGBMC, Dept Mol Pathol, CNRS,UPR 6520,INSERM,U596, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	cat@igbmc.u-strasbg.fr	Alpy, Fabien/ABD-5893-2020; Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014; Lakshmanan, Vinoth Kumar/AEL-8027-2022	Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848; Lakshmanan, Vinoth Kumar/0000-0002-7420-8459				Alpy F, 2002, J BIOL CHEM, V277, P50780, DOI 10.1074/jbc.M208290200; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bieche I, 1996, CANCER RES, V56, P3886; Bose HS, 2000, ENDOCR RES, V26, P629, DOI 10.3109/07435800009048583; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Chikh K, 2004, MOL GENET METAB, V83, P220, DOI 10.1016/j.ymgme.2004.06.013; Dressman MA, 2003, CANCER RES, V63, P2194; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Gruenberg J, 2003, CURR OPIN CELL BIOL, V15, P382, DOI 10.1016/S0955-0674(03)00078-4; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; King SR, 2004, ENDOCRINOLOGY, V145, P4775, DOI 10.1210/en.2003-1740; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Millat G, 2001, AM J HUM GENET, V68, P1373, DOI 10.1086/320606; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2004, ENDOCRINOLOGY, V145, P1700, DOI 10.1210/en.2003-1034; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	40	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17945	17952		10.1074/jbc.M500723200	http://dx.doi.org/10.1074/jbc.M500723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718238	hybrid			2022-12-27	WOS:000228807200048
J	Beharry, Z; Palzkill, T				Beharry, Z; Palzkill, T			Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; IN-VITRO ACTIVITY; CATALYTIC MECHANISM; ESCHERICHIA-COLI; PROTEIN FOSA; ANTIBIOTIC-RESISTANCE; URINARY-TRACT; EVOLUTION; BACTERIA; BINDING	The metalloglutathione transferase FosA catalyzes the conjugation of glutathione to carbon-1 of the antibiotic fosfomycin, rendering it ineffective as an antibacterial drug. Codon randomization and selection for the ability of resulting clones to confer fosfomycin resistance to Escherichia coli were used to identify residues critical for FosA function. Of the 24 codons chosen for randomization, 16 were found to be essential because only the wild type amino acid was selected. These included ligands to the Mn2+ and the K+, residues that furnish hydrogen bonds to fosfomycin, and residues located in a putative glutathione/fosfomycin-binding site. The remaining eight positions randomized were tolerant to substitutions. Site-directed mutagenesis of some of the essential and tolerant amino acids to alanine was performed, and the activity of the purified proteins was determined. Mutation of the residues that are within hydrogen bonding distance to the oxirane or phosphonate oxygens of fosfomycin resulted in variants with very low or no activity. Mutation of Ser(94), which bridges one of the phosphonate oxygens with a potassium ion, resulted in insoluble protein. The Y39A mutation in the putative glutathione-binding site resulted in a 4-fold increase in the apparent K-m for glutathione. Only two of the amino acids in the substrate-binding site are conserved in the related fosfomycin resistance proteins FosB and FosX, whereas no amino acids in the putative glutathione-binding site are conserved.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu		Beharry, Zanna/0000-0002-3900-8523	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allerberger F, 1999, J ANTIMICROB CHEMOTH, V43, P211, DOI 10.1093/jac/43.2.211; Arca P, 1997, J ANTIMICROB CHEMOTH, V40, P393, DOI 10.1093/jac/40.3.393; ARCA P, 1988, ANTIMICROB AGENTS CH, V32, P1552, DOI 10.1128/AAC.32.10.1552; ARCA P, 1990, ANTIMICROB AGENTS CH, V34, P844, DOI 10.1128/AAC.34.5.844; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Armstrong RN, 2000, BIOCHEMISTRY-US, V39, P13625, DOI 10.1021/bi001814v; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; Bernat BA, 1999, BIOCHEMISTRY-US, V38, P7462, DOI 10.1021/bi990391y; Bernat BA, 1998, J ORG CHEM, V63, P3778, DOI 10.1021/jo980014b; Bernat BA, 1997, BIOCHEMISTRY-US, V36, P3050, DOI 10.1021/bi963172a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Cao M, 2001, J BACTERIOL, V183, P2380, DOI 10.1128/JB.183.7.2380-2383.2001; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; ETIENNE J, 1989, FEMS MICROBIOL LETT, V61, P133, DOI 10.1016/0378-1097(89)90184-5; Fillgrove KL, 2003, J AM CHEM SOC, V125, P15730, DOI 10.1021/ja039307z; GARCIA P, 1995, ANTIMICROB AGENTS CH, V39, P1569, DOI 10.1128/AAC.39.7.1569; Grif K, 2001, J ANTIMICROB CHEMOTH, V48, P209, DOI 10.1093/jac/48.2.209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horii T, 1999, ANTIMICROB AGENTS CH, V43, P789, DOI 10.1128/AAC.43.4.789; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Laughlin LT, 1998, CHEM-BIOL INTERACT, V112, P41, DOI 10.1016/S0009-2797(97)00150-6; LEON J, 1982, ANTIMICROB AGENTS CH, V21, P608, DOI 10.1128/AAC.21.4.608; LIU SX, 1992, J BIOL CHEM, V267, P4296; Monden Koichi, 2002, Journal of Infection and Chemotherapy, V8, P218, DOI 10.1007/s10156-002-0186-6; Nicolle LE, 2002, AM J MED, V113, p35S; Okazaki Mitsuhiro, 2002, Journal of Infection and Chemotherapy, V8, P37; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Rife CL, 2002, J AM CHEM SOC, V124, P11001, DOI 10.1021/ja026879v; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shimizu M, 2000, ANTIMICROB AGENTS CH, V44, P2007, DOI 10.1128/AAC.44.7.2007-2008.2000; Smoukov SK, 2002, J AM CHEM SOC, V124, P2318, DOI 10.1021/ja012480f; SUAREZ JE, 1991, ANTIMICROB AGENTS CH, V35, P791, DOI 10.1128/AAC.35.5.791; Ungheri D, 2002, J CHEMOTHERAPY, V14, P237, DOI 10.1179/joc.2002.14.3.237	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17786	17791		10.1074/jbc.M501052200	http://dx.doi.org/10.1074/jbc.M501052200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741169	hybrid			2022-12-27	WOS:000228807200029
J	Darsow, T; Booker, TK; Pina-Crespo, JC; Heinemann, SF				Darsow, T; Booker, TK; Pina-Crespo, JC; Heinemann, SF			Exocytic trafficking is required for nicotine-induced up-regulation of alpha(4)beta(2) nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; CHOLINERGIC RECEPTOR; QUALITY-CONTROL; BINDING-SITES; RAT-BRAIN; SUBUNIT; EXPRESSION; INFUSION; PROTEIN; MOUSE	The primary target for nicotine in the brain is the neuronal nicotinic acetylcholine receptor ( nAChR). It has been well documented that nAChRs respond to chronic nicotine exposure by up-regulation of receptor numbers, which may underlie some aspects of nicotine addiction. In order to investigate the mechanism of nicotine-induced nAChR up-regulation, we have developed a cell culture system to assess membrane trafficking and nicotine-induced up-regulation of surface-expressed alpha(4)beta(2) nAChRs. Previous reports have implicated stabilization of the nAChRs at the plasma membrane as the potential mechanism of up-regulation. We have found that whereas nicotine exposure results in up-regulation of surface receptors in our system, it does not alter surface receptor internalization from the plasma membrane, postendocytic trafficking, or lysosomal degradation. Instead, we find that transport of nAChRs through the secretory pathway to the plasma membrane is required for nicotine-induced up-regulation of surface receptors. Therefore, nicotine appears to regulate surface receptor levels at a step prior to initial insertion in the plasma membrane rather than by altering their endocytic trafficking or degradation rates as had been previously suggested.	Salk Inst Biol Studies, Mol Neurobiol Labs, La Jolla, CA 92037 USA	Salk Institute	Darsow, T (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	darsow@salk.edu	Piña-Crespo, Juan C./A-5579-2009	Piña-Crespo, Juan C./0000-0003-2803-7377; Darsow, Tamara/0000-0002-6650-6368	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013018] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA13018] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BENCHERIF M, 1995, J PHARMACOL EXP THER, V275, P987; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; Buisson B, 1996, J NEUROSCI, V16, P7880; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Lindstrom J.M., 1995, HDB RECEPTORS CHANNE, P153; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; Marks MJ, 1998, J PHARMACOL EXP THER, V285, P377; MARKS MJ, 1985, J PHARMACOL EXP THER, V235, P619; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Nashmi R, 2003, J NEUROSCI, V23, P11554; PENG X, 1994, MOL PHARMACOL, V46, P523; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; Ross SA, 2000, J NEUROSCI, V20, P6431, DOI 10.1523/JNEUROSCI.20-17-06431.2000; SANDERSON EM, 1993, BRAIN RES, V617, P349, DOI 10.1016/0006-8993(93)91104-Z; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/science.6828889; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; WHITING PJ, 1987, J NEUROSCI, V7, P4005; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	43	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18311	18320		10.1074/jbc.M501157200	http://dx.doi.org/10.1074/jbc.M501157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741168	hybrid			2022-12-27	WOS:000228807200090
J	Aoyagi, K; Sugaya, T; Umeda, M; Yamamoto, S; Terakawa, S; Takahashi, M				Aoyagi, K; Sugaya, T; Umeda, M; Yamamoto, S; Terakawa, S; Takahashi, M			The activation of exocytotic sites by the formation of phosphatidylinositol 4,5-bisphosphate microdomains at syntaxin clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADRENAL CHROMAFFIN CELLS; PLASMA-MEMBRANE; NEUROTRANSMITTER RELEASE; PC12 CELLS; CA2+-ACTIVATED SECRETION; PHOSPHOLIPASE-C; FUSION; PI(4,5)P-2; MICROSCOPY	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) is a minor component of the lipid bilayer but plays an important role in various cellular functions, including exocytosis and endocytosis. Recently, PI(4,5)P-2 was shown to form microdomains in the plasma membrane. In this study, we investigated the relationship between the spatial organization of PI(4,5)P-2 microdomains and exocytotic machineries in clonal rat pheochromocytoma PC12 cells. Both PI(4,5)P-2 and syntaxin, a soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein essential for exocytosis, exhibited punctate clusters in isolated plasma membranes. The number of PI(4,5)P-2 microdomains colocalizing with syntaxin clusters and large dense core vesicles (LDCVs) was decreased after catecholamine release. Alternatively, the expression of type I phosphatidylinositol-4-phosphate 5-kinase (PIP5KI) increased the number of PI(4,5)P-2 microdomains at syntaxin clusters with docked LDCVs and enhanced exocytotic activity, possibly by increasing the number of release sites. About half of the PI(4,5)P-2 microdomains were not colocalized with Thy-1, a specific marker of lipid rafts, and the colocalization of transfected PIP5KI with syntaxin clusters was observed. These results suggest that the formation of PI(4,5)P-2 microdomains at syntaxin clusters with docked LDCVs is essential for Ca2+-dependent exocytosis.	Kitasato Univ, Sch Med, Dept Biochem, Kanagawa 2288555, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Hamamatsu Univ Sch Med, Photon Med Res Ctr, Shizuoka 4313192, Japan	Kitasato University; University of Tokyo; Kyoto University; Hamamatsu University School of Medicine	Takahashi, M (corresponding author), Kitasato Univ, Sch Med, Dept Biochem, Kanagawa 2288555, Japan.	masami@med.kitasato-u.ac.jp						Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Aoyagi K, 2001, BIOCHEM BIOPH RES CO, V286, P646, DOI 10.1006/bbrc.2001.5443; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mashanov GI, 2004, J BIOL CHEM, V279, P15274, DOI 10.1074/jbc.M312140200; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MAYER S, 1994, SCIENCE, V264, P1948; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; Tsuboi T, 2002, BIOPHYS J, V83, P172, DOI 10.1016/S0006-3495(02)75159-X; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; WICK PF, 1993, J BIOL CHEM, V268, P10983	51	136	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17346	17352		10.1074/jbc.M413307200	http://dx.doi.org/10.1074/jbc.M413307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741173	hybrid			2022-12-27	WOS:000228615500099
J	Demuro, A; Mina, E; Kayed, R; Milton, SC; Parker, I; Glabe, CG				Demuro, A; Mina, E; Kayed, R; Milton, SC; Parker, I; Glabe, CG			Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MISFOLDING DISEASES; ALZHEIMERS-DISEASE; BETA-PEPTIDE; COMMON MECHANISM; LIPID-BILAYERS; PRECURSOR PROTEIN; FIBRIL FORMATION; CHANNELS; HYPOTHESIS; APOPTOSIS	Increasing evidence suggests that amyloid peptides associated with a variety of degenerative diseases induce neurotoxicity in their intermediate oligomeric state, rather than as monomers or fibrils. To test this hypothesis and investigate the possible involvement of Ca2+ signaling disruptions in amyloid-induced cytotoxicity, we made homogeneous preparations of disease-related amyloids (A beta, prion, islet amyloid polypeptide, polyglutamine, and lysozyme) in various aggregation states and tested their actions on fluo-3-loaded SH-SY5Y cells. Application of oligomeric forms of all amyloids tested (0.6 -6 mu g ml(-1)) rapidly (similar to 5 s) elevated intracellular Ca2+, whereas equivalent amounts of monomers and fibrils did not. Ca2+ signals evoked by A beta 42 oligomers persisted after depletion of intracellular Ca2+ stores, and small signals remained in Ca2+-free medium, indicating contributions from both extracellular and intracellular Ca2+ sources. The increased membrane permeability to Ca2+ cannot be attributed to activation of endogenous Ca2+ channels, because responses were unaffected by the potent Ca2+-channel blocker cobalt (20 mu m). Instead, observations that A beta 42 and other oligomers caused rapid cellular leakage of anionic fluorescent dyes point to a generalized increase in membrane permeability. The resulting unregulated flux of ions and molecules may provide a common mechanism for oligomer-mediated toxicity in many amyloidogenic diseases, with dysregulation of Ca2+ ions playing a crucial role because of their strong trans-membrane concentration gradient and involvement in cell dysfunction and death.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3238 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu			NIA NIH HHS [AG00538] Funding Source: Medline; NIGMS NIH HHS [GM48071] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048071, R37GM048071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Arispe N, 2004, J MEMBRANE BIOL, V197, P33, DOI 10.1007/s00232-003-0638-7; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blanchard BJ, 2004, P NATL ACAD SCI USA, V101, P14326, DOI 10.1073/pnas.0405941101; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Dobson CM, 2004, SCIENCE, V304, P1259, DOI 10.1126/science.1093078; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Green JD, 2004, J MOL BIOL, V342, P877, DOI 10.1016/j.jmb.2004.07.052; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0; Lin MCA, 2002, PEPTIDES, V23, P1215, DOI 10.1016/S0196-9781(02)00057-8; Mason RP, 1996, ANN NY ACAD SCI, V777, P368, DOI 10.1111/j.1749-6632.1996.tb34447.x; Mattson MP, 2003, NAT CELL BIOL, V5, P1041, DOI 10.1038/ncb1203-1041; MATTSON MP, 1992, NEUROBIOL AGING, V13, P617, DOI 10.1016/0197-4580(92)90068-9; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SELKOE DJ, 1991, SCI AM, V265, P40, DOI 10.1038/scientificamerican1191-68; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Tucker HM, 1998, J NEUROCHEM, V71, P506	47	788	813	4	145	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17294	17300		10.1074/jbc.M500997200	http://dx.doi.org/10.1074/jbc.M500997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722360	hybrid			2022-12-27	WOS:000228615500093
J	Hernick, M; Gennadios, HA; Whittington, DA; Rusche, KM; Christianson, DW; Fierke, CA				Hernick, M; Gennadios, HA; Whittington, DA; Rusche, KM; Christianson, DW; Fierke, CA			UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-DEPENDENT DEACETYLASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI ENCODES; ENDOTOXIN BIOSYNTHESIS; UDP-3-O-(R-3-HYDROXYMYRISTOYL)-N-ACETYLGLUCOSAMINE DEACETYLASE; MOLECULAR REPLACEMENT; ANTIBACTERIAL AGENTS; ENZYME-SYSTEMS; LPXC; INHIBITORS	UDP-3-O-(( R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase ( LpxC) is a zinc-dependent enzyme that catalyzes the deacetylation of UDP-3-O-(( R)-3-hydroxymyristoyl)N- acetylglucosamine to form UDP-3-O-(R-hydroxymyristoyl) glucosamine and acetate. The structural similarity of the active site of LpxC to metalloproteases led to the proposal that LpxC functions via a metalloprotease-like mechanism. The pH dependence of k(cat)/K-m catalyzed by Escherichia coli and Aquifex aeolicus LpxC displayed a bell-shaped curve ( EcLpxC yields apparent pK(a) values of 6.4 +/- 0.1 and 9.1 +/- 0.1), demonstrating that at least two ionizations are important for maximal activity. Metal substitution and mutagenesis experiments suggest that the basic limb of the pH profile is because of deprotonation of a zinc-coordinated group such as the zinc-water molecule, whereas the acidic limb of the pH profile is caused by protonation of either Glu(78) or His(265). Furthermore, the magnitude of the activity decreases and synergy observed for the active site mutants suggest that Glu(78) and His(265) act as a general acid-base catalyst pair. Crystal structures of LpxC complexed with cacodylate or palmitate demonstrate that both Glu(78) and His(265) hydrogenbond with the same oxygen atom of the tetrahedral intermediate and the product carboxylate. These structural features suggest that LpxC catalyzes deacetylation by using Glu(78) and His(265) as a general acid-base pair and the zinc-bound water as a nucleophile.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Pennsylvania	Fierke, CA (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	fierke@umich.edu		Hernick, Marcy/0000-0002-2839-5767	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040602, R01GM040602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602, GM49758] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; [Anonymous], 2003, COMPREHENSIVE COORDI, DOI DOI 10.1016/B0-08-043748-6/08139-1; Bachovchin WW, 2001, MAGN RESON CHEM, V39, pS199, DOI 10.1002/mrc.951; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; Coggins BE, 2003, NAT STRUCT BIOL, V10, P645, DOI 10.1038/nsb948; Coggins BE, 2005, BIOCHEMISTRY-US, V44, P1114, DOI 10.1021/bi047820z; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fersht A., 1999, STRUCTURE MECH PROTE, P169; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Hernick M, 2005, ARCH BIOCHEM BIOPHYS, V433, P71, DOI 10.1016/j.abb.2004.08.006; Huheey J.E., 1993, INORGANIC CHEM PRINC, P318; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Jackman JE, 2001, BIOCHEMISTRY-US, V40, P514, DOI 10.1021/bi001872g; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Manocha S, 2002, EXPERT OPIN INV DRUG, V11, P1795, DOI 10.1517/13543784.11.12.1795; McClerren AL, 2005, BIOCHEMISTRY-US, V44, P1106, DOI 10.1021/bi048001h; McClure CP, 2003, J INORG BIOCHEM, V94, P78, DOI 10.1016/S0162-0134(02)00611-6; MERKLER DJ, 1993, BIOCHEMISTRY-US, V32, P5792, DOI 10.1021/bi00073a011; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pirrung MC, 2002, J MED CHEM, V45, P4359, DOI 10.1021/jm020183v; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; SRERE PA, 1961, BIOCHIM BIOPHYS ACTA, V50, P184, DOI 10.1016/0006-3002(61)91081-2; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; White RJ, 2003, CURR OPIN PHARMACOL, V3, P502, DOI 10.1016/S1471-4892(03)00115-2; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	43	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16969	16978		10.1074/jbc.M413560200	http://dx.doi.org/10.1074/jbc.M413560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15705580	hybrid			2022-12-27	WOS:000228615500053
J	Singh, S; Korolev, S; Koroleva, O; Zarembinski, T; Collart, F; Joachimiak, A; Christendat, D				Singh, S; Korolev, S; Koroleva, O; Zarembinski, T; Collart, F; Joachimiak, A; Christendat, D			Crystal structure of a novel shikimate dehydrogenase from Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHWAY; SPECIFICITY	To date two classes of shikimate dehydrogenases have been identified and characterized, YdiB and AroE. YdiB is a bifunctional enzyme that catalyzes the reversible reductions of dehydroquinate to quinate and dehydroshikimate to shikimate in the presence of either NADH or NADPH. In contrast, AroE catalyzes the reversible reduction of dehydroshikimate to shikimate in the presence of NADPH. Here we report the crystal structure and biochemical characterization of HI0607, a novel class of shikimate dehydrogenase annotated as shikimate dehydrogenase-like. The kinetic properties of HI0607 are remarkably different from those of AroE and YdiB. In comparison with YdiB, HI0607 catalyzes the oxidation of shikimate but not quinate. The turnover rate for the oxidation of shikimate is similar to 1000-fold lower compared with that of AroE. Phylogenetic analysis reveals three independent clusters representing three classes of shikimate dehydrogenases, namely AroE, YdiB, and this newly characterized shikimate dehydrogenase-like protein. In addition, mutagenesis studies of two invariant residues, Asp-103 and Lys-67, indicate that they are important catalytic groups that may function as a catalytic pair in the shikimate dehydrogenase reaction. This is the first study that describes the crystal structure as well as mutagenesis and mechanistic analysis of this new class of shikimate dehydrogenase.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory	Christendat, D (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	dinesh.christendat@utoronto.ca	Korolev, Sergey/ABA-7517-2020; Singh, Sasha/H-3612-2012	Singh, Sasha/0000-0003-0929-3164; Collart, Frank/0000-0001-6942-4483; Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM062414, GM62414-01, P50 GM062414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALINSKY D, 1971, BIOCHEMISTRY-US, V10, P1947; Campbell SA, 2004, INT J PARASITOL, V34, P5, DOI 10.1016/j.ijpara.2003.10.006; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Christendat D, 1998, BIOCHEMISTRY-US, V37, P15703, DOI 10.1021/bi981412b; DENNIS AW, 1972, INT J BIOCHEM, V3, P93, DOI 10.1016/0020-711X(72)90031-6; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; HERRMANN KM, 1995, PLANT CELL, V7, P907; Herrmann KM, 1999, ANNU REV PLANT PHYS, V50, P473, DOI 10.1146/annurev.arplant.50.1.473; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; McConkey GA, 2000, EXP PARASITOL, V94, P23, DOI 10.1006/expr.1999.4467; Michel G, 2003, J BIOL CHEM, V278, P19463, DOI 10.1074/jbc.M300794200; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Vogan E, 2003, STRUCTURE, V11, P902, DOI 10.1016/S0969-2126(03)00165-5; Watanabe S, 2005, J BIOL CHEM, V280, P10340, DOI 10.1074/jbc.M409443200; Wheeler KA, 1996, BIOCHEM J, V315, P195, DOI 10.1042/bj3150195	25	32	38	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17101	17108		10.1074/jbc.M412753200	http://dx.doi.org/10.1074/jbc.M412753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735308	hybrid, Green Accepted			2022-12-27	WOS:000228615500069
J	Walther, RF; Atlas, E; Carrigan, A; Rouleau, Y; Edgecombe, A; Visentin, L; Lamprecht, C; Addicks, GC; Hache, RJG; Lefebvre, YA				Walther, RF; Atlas, E; Carrigan, A; Rouleau, Y; Edgecombe, A; Visentin, L; Lamprecht, C; Addicks, GC; Hache, RJG; Lefebvre, YA			A serine/threonine-rich motif is one of three nuclear localization signals that determine unidirectional transport of the mineralocorticoid receptor to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; LIVING CELLS; ANDROGEN RECEPTOR; SUBCELLULAR-LOCALIZATION; PROGESTERONE-RECEPTOR; INTRACELLULAR-LOCALIZATION; SUBNUCLEAR TRAFFICKING; ACTIVATION FUNCTION-1	The mineralocorticoid receptor (MR) is a tightly regulated nuclear hormone receptor that selectively transmits corticosteroid signals. Steroid treatment transforms MR from a transcriptionally inert state, in which it is distributed equally between the nucleus and cytoplasm, to an active completely nuclear transcription factor. We report here that MR is an atypical nuclear hormone receptor that moves unidirectionally from the cytoplasm to the nucleus. We show that nuclear import of MR is controlled through three nuclear localization signals (NLSs) of distinct types. Nuclear localization of naive MR was mediated primarily through a novel serine/ threonine-rich NLS (NL0) in the receptor N terminus. Specific amino acid substitutions that mimicked phosphorylation selectively enhanced or repressed NL0 activity, highlighting the potential for active regulation of this new type of NLS. The second NLS (NL2) within the ligand-binding domain also lacks a recognizable basic motif. Nuclear transfer through this signal was strictly dependent on steroid agonist, but was independent of the interaction of MR with coactivator proteins. The third MR NLS (NL1) is a bipartite basic motif localized to the C terminus of the MR DNA-binding domain with properties distinct from those of NL1 of the closely related glucocorticoid receptor. NL1 acted in concert with NL0 and NL2 to stimulate nuclear uptake of the agonist-treated receptor, but also directed the complete nuclear localization of MR in response to treatment with steroid antagonist. These results present MR as a nuclear hormone receptor whose unidirectional transfer to the nucleus may be regulated through multiple pathways.	Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Grad Program Biochem, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Dept Med, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	rhache@ohri.ca						ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fuse H, 2000, MOL ENDOCRINOL, V14, P889, DOI 10.1210/me.14.6.889; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LOMBES M, 1994, BIOCHEM J, V302, P191, DOI 10.1042/bj3020191; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishi M, 2001, MOL ENDOCRINOL, V15, P1077, DOI 10.1210/me.15.7.1077; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ou XM, 2001, J BIOL CHEM, V276, P14299, DOI 10.1074/jbc.M005363200; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Planey SL, 2002, J BIOL CHEM, V277, P42188, DOI 10.1074/jbc.M205085200; Ploski JE, 2004, MOL CELL BIOL, V24, P4824, DOI 10.1128/MCB.24.11.4824-4834.2004; Poukka H, 2000, J CELL SCI, V113, P2991; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; Roozendaal B, 2002, NEUROBIOL LEARN MEM, V78, P578, DOI 10.1006/nlme.2002.4080; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SASANO H, 1992, J ENDOCRINOL, V132, P305, DOI 10.1677/joe.0.1320305; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Savory JGA, 2001, MOL CELL BIOL, V21, P781, DOI 10.1128/MCB.21.3.781-793.2001; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sousa N, 2002, REV NEUROSCIENCE, V13, P59; Steidl S, 2004, J MOL BIOL, V342, P515, DOI 10.1016/j.jmb.2004.07.011; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; vanSteensel B, 1996, J CELL SCI, V109, P787; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wolff T, 2002, J BIOL CHEM, V277, P12151, DOI 10.1074/jbc.M109103200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	67	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17549	17561		10.1074/jbc.M501548200	http://dx.doi.org/10.1074/jbc.M501548200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737989	hybrid			2022-12-27	WOS:000228615500124
J	Handy, DE; Zhang, YF; Loscalzo, J				Handy, DE; Zhang, YF; Loscalzo, J			Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; ENDOPLASMIC-RETICULUM STRESS; CYSTATHIONINE BETA-SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA STABILITY; ACCELERATES ATHEROSCLEROSIS; SELENOPROTEIN SYNTHESIS; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; MEDIATED DECAY	Hyperhomocysteinemia contributes to vascular dysfunction and an increase in the risk of cardiovascular disease. An elevated level of homocysteine in vivo and in cell culture systems results in a decrease in the activity of cellular glutathione peroxidase (GPx1), an intracellular antioxidant enzyme that reduces hydrogen peroxide and lipid peroxides. In this study, we show that homocysteine interferes with GPx1 protein expression without affecting transcript levels. Expression of the selenocysteine (SEC)-containing GPx1 protein requires special translational cofactors to "read-through" a UGA-stop codon that specifies SEC incorporation at the active site of the enzyme. These factors include a selenocysteine incorporation sequence ( SECIS) in the 3'-untranslated region of the GPx1 mRNA and cofactors involved in the biosynthesis and translational insertion of SEC. To monitor SEC incorporation, we used a reporter gene system that has a UGA codon within the protein-coding region of the luciferase mRNA. Addition of either the GPx1 or GPx3 SECIS element in the 3'-untranslated region of the luciferase gene stimulated read-through by 6 - 11-fold in selenium-replete cells; absence of selenium prevented translation. To alter cellular homocysteine production, we used methionine in the presence of aminopterin, a folate antagonist, co-administered with hypoxanthine and thymidine (HAT/Met). This treatment increased homocysteine levels in the media by 30% ( p < 0.01) and decreased GPx1 enzyme activity by 45% ( p = 0.0028). HAT/Met treatment decreased selenium-mediated read-through significantly ( p < 0.001) in luciferase constructs containing the GPx1 or GPx3 SECIS element; most importantly, the suppression of selenium-dependent read-through was similar whether an SV40 promoter or the GPx1 promoter was used to drive transcription of the SECIS-containing constructs. Furthermore, HAT/Met had no effect on steady-state GPx1 mRNA levels but decreased GPx1 protein levels, suggesting that this effect is not transcriptionally mediated. These data support the conclusion that homocysteine decreases GPx1 activity by altering the translational mechanism essential for the synthesis of this selenocysteine-containing protein.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W507, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021	Handy, Diane/0000-0002-4310-8527	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061795, P50HL055993, R37HL061795] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55993, HL58796, N01 HV28178, HL61795] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antony AC, 2004, J CLIN INVEST, V113, P285, DOI 10.1172/JCI200411548; BAKER RD, 1993, ARCH BIOCHEM BIOPHYS, V304, P53, DOI 10.1006/abbi.1993.1320; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; Chen CY, 2000, J SURG RES, V88, P26, DOI 10.1006/jsre.1999.5756; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; CHRISTENSEN B, 1991, J CELL PHYSIOL, V146, P52, DOI 10.1002/jcp.1041460108; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; de Koning ABL, 2003, CLIN BIOCHEM, V36, P431, DOI 10.1016/S0009-9120(03)00062-6; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Grundner-Culemann E, 1999, RNA, V5, P625, DOI 10.1017/S1355838299981542; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Huang RFS, 2001, J NUTR, V131, P33, DOI 10.1093/jn/131.1.33; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; Lescure A, 2002, CURR PROTEIN PEPT SC, V3, P143, DOI 10.2174/1389203023380783; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; Martin GW, 1996, RNA, V2, P171; Martin GW, 2001, GENES CELLS, V6, P121, DOI 10.1046/j.1365-2443.2001.00402.x; Mehta A, 2004, J BIOL CHEM, V279, P37852, DOI 10.1074/jbc.M404639200; Merante F, 2002, MOL CELL BIOCHEM, V229, P73, DOI 10.1023/A:1017921110363; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muller C, 2003, BIOL CHEM, V384, P11, DOI 10.1515/BC.2003.002; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Refsum H, 2004, CLIN CHEM, V50, P3, DOI 10.1373/clinchem.2003.021634; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; SHEN QC, 1995, RNA, V1, P519; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Title LM, 2000, J AM COLL CARDIOL, V36, P758, DOI 10.1016/S0735-1097(00)00809-3; UELAND PM, 1993, CLIN CHEM, V39, P1764; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Wen W, 1998, J BIOL CHEM, V273, P28533, DOI 10.1074/jbc.273.43.28533; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Wingler K, 2001, BIOFACTORS, V14, P43, DOI 10.1002/biof.5520140107; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582	48	101	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15518	15525		10.1074/jbc.M501452200	http://dx.doi.org/10.1074/jbc.M501452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15734734	hybrid			2022-12-27	WOS:000228444800009
J	Hara-Chikuma, M; Sohara, E; Rai, T; Ikawa, M; Okabe, M; Sasaki, S; Uchida, S; Verkman, AS				Hara-Chikuma, M; Sohara, E; Rai, T; Ikawa, M; Okabe, M; Sasaki, S; Uchida, S; Verkman, AS			Progressive adipocyte hypertrophy in aquaporin-7-deficient mice - Adipocyte glycerol permeability as a novel regulator of fat accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; AQUAPORIN ADIPOSE; WATER CHANNEL; POSSIBLE INVOLVEMENT; MOLECULAR-CLONING; SKIN HYDRATION; EXPRESSION; RAT; TESTIS; CELLS	Aquaporin-7 (AQP7) is a water/glycerol transporting protein expressed in adipocyte plasma membranes. We report here remarkable age-dependent hypertrophy in adipocytes in AQP7-deficient mice. Wild type and AQP7 null mice had similar growth at 0 - 16 weeks as assessed by body weight; however, by 16 weeks AQP7 null mice had 3.7-fold increased body fat mass. Adipocytes from AQP7 null mice of age 16 weeks were greatly enlarged ( diameter 118 mu m) compared with wild type mice ( 39 mu m). Adipocytes from AQP7 null mice also accumulated excess glycerol ( 251 versus 86 nmol/mg of protein) and triglycerides (3.4 versus 1.7 mu mol/mg of protein). In contrast, at age 4 weeks, adipocyte volume and body fat mass were comparable in wild type and AQP7 null mice. To investigate the mechanism(s) responsible for the progressive adipocyte hypertrophy, glycerol permeability and fat metabolism were studied in adipocytes isolated from the younger mice. Plasma membrane glycerol permeability measured by [C-14] glycerol uptake was 3-fold reduced in AQP7-deficient adipocytes. However, adipocyte lipolysis, measured by free fatty acid release and hormone-sensitive lipase activity, and lipogenesis, measured by [C-14] glucose incorporation into triglycerides, were not affected by AQP7 deletion. These data suggest that adipocyte hypertrophy in AQP7 deficiency results from defective glycerol exit and consequent accumulation of glycerol and triglycerides. Increasing AQP7 expression/function in adipocytes may reduce adipocyte volume and fat mass in obesity.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Tokyo Med & Dent Univ, Dept Nephrol, Tokyo 1138519, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka 5650871, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tokyo Medical & Dental University (TMDU); Osaka University	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu	ikawa, masahito/A-5315-2009; Rai, Tatemitsu/K-7165-2019; Uchida, Shinichi/D-1111-2013; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL73854, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Calamita G, 2001, BIOCHEM BIOPH RES CO, V288, P619, DOI 10.1006/bbrc.2001.5810; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fasshauer M, 2003, HORM METAB RES, V35, P222; Hara M, 2003, P NATL ACAD SCI USA, V100, P7360, DOI 10.1073/pnas.1230416100; Hara M, 2002, J BIOL CHEM, V277, P46616, DOI 10.1074/jbc.M209003200; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kageyama Y, 2001, ANDROLOGIA, V33, P165, DOI 10.1046/j.1439-0272.2001.00443.x; Kimura Y, 1998, J ETHNOPHARMACOL, V59, P117, DOI 10.1016/S0378-8741(97)00115-3; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Kishida K, 2001, J BIOL CHEM, V276, P36251, DOI 10.1074/jbc.M106040200; Kuriyama H, 2002, DIABETES, V51, P2915, DOI 10.2337/diabetes.51.10.2915; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Maeda N, 2004, P NATL ACAD SCI USA, V101, P17801, DOI 10.1073/pnas.0406230101; Morimoto C, 1997, J LIPID RES, V38, P132; Nejsum LN, 2000, BIOCHEM BIOPH RES CO, V277, P164, DOI 10.1006/bbrc.2000.3638; RODBELL M, 1964, J BIOL CHEM, V239, P375; Saito K, 2004, J UROLOGY, V172, P2073, DOI 10.1097/01.ju.0000141499.08650.ab; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; Zhou ZH, 2003, NAT GENET, V35, P49, DOI 10.1038/ng1225	25	191	209	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15493	15496		10.1074/jbc.C500028200	http://dx.doi.org/10.1074/jbc.C500028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15746100	hybrid			2022-12-27	WOS:000228444800005
J	Martinez-Ceballos, E; Chambon, P; Gudas, LJ				Martinez-Ceballos, E; Chambon, P; Gudas, LJ			Differences in gene expression between wild type and Hoxa1 knockout embryonic stem cells after retinoic acid treatment or leukemia inhibitory factor (LIF) removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HOMEOBOX-CONTAINING GENES; REGION-SPECIFIC EXPRESSION; F9 TERATOCARCINOMA CELLS; ZINC-FINGER GENE; TRANSCRIPTION FACTOR; NEURAL CREST; MOUSE EMBRYO; DNA-BINDING; FUNCTIONAL-ANALYSIS; EARLY HINDBRAIN	Homeobox (Hox) genes encode a family of transcription factors that regulate embryonic patterning and organogenesis. In embryos, alterations of the normal pattern of Hox gene expression result in homeotic transformations and malformations. Disruption of the Hoxa1 gene, the most 3' member of the Hoxa cluster and a retinoic acid ( RA) direct target gene, results in abnormal ossification of the skull, hindbrain, and inner ear deficiencies, and neonatal death. We have generated Hoxa1(-/-) embryonic stem (ES) cells ( named Hoxa1-15) from Hoxa1(-/-) mutant blastocysts to study the Hoxa1 signaling pathway. We have characterized in detail these Hoxa1(-/-) ES cells by performing microarray analyses, and by this technique we have identified a number of putative Hoxa-1 target genes, including genes involved in bone development ( e. g. Col1a1, Postn/Osf2, and the bone sialoprotein gene or BSP), genes that are expressed in the developing brain ( e. g. Nnat, Wnt3a, BDNF, RhoB, and Gbx2), and genes involved in various cellular processes ( e. g. M-RAS, Sox17, Cdkn2b, LamA1, Col4a1, Foxa2, Foxq1, Klf5, and Igf2). Cell proliferation assays and Northern blot analyses of a number of ES cell markers ( e. g. Rex1, Oct3/4, Fgf4, and Bmp4) suggest that the Hoxa1 protein plays a role in the inhibition of cell proliferation by RA in ES cells. Additionally, Hoxa1(-/-) ES cells express high levels of various endodermal markers, including Gata4 and Dab2, and express much less Fgf5 after leukemia inhibitory factor (LIF) withdrawal. Finally, we propose a model in which the Hoxa1 protein mediates repression of endodermal differentiation while promoting expression of ectodermal and mesodermal characteristics.	Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY 10021 USA; Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,Coll France, F-67404 Illkirch Graffenstaden, France	Cornell University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gudas, LJ (corresponding author), Cornell Univ, Dept Pharmacol, Weill Med Coll, 1300 York Ave,Rm E-409, New York, NY 10021 USA.	ljgudas@med.cornell.edu			NCI NIH HHS [R01CA43796] Funding Source: Medline; NICHD NIH HHS [2U19HDO35466] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U19HD035466] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIGNER T, 1995, LAB INVEST, V73, P236; Alexandre D, 1996, DEVELOPMENT, V122, P735; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; AUGUSTINE KA, 1995, TERATOLOGY, V51, P107, DOI 10.1002/tera.1420510209; Avantaggiato V, 1996, DEV BIOL, V175, P347, DOI 10.1006/dbio.1996.0120; Barrow JR, 2000, DEVELOPMENT, V127, P933; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; Borday C, 2004, PROG BIOPHYS MOL BIO, V84, P89, DOI 10.1016/j.pbiomolbio.2003.11.002; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen AC, 2003, ARCH BIOCHEM BIOPHYS, V411, P159, DOI 10.1016/S0003-9861(02)00732-4; Chen AC, 1996, J BIOL CHEM, V271, P14971, DOI 10.1074/jbc.271.25.14971; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228; del Toro ED, 2001, J NEUROSCI, V21, P5637, DOI 10.1523/JNEUROSCI.21-15-05637.2001; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Dupe V, 1997, DEVELOPMENT, V124, P399; FRASCH M, 1995, DEVELOPMENT, V121, P957; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Gavalas A, 2003, DEVELOPMENT, V130, P5663, DOI 10.1242/dev.00802; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Han X, 2002, CONNECT TISSUE RES, V43, P63; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Hempstead BL, 2004, J CLIN INVEST, V113, P811, DOI 10.1172/JCI200421309; Henderson DJ, 2000, MECH DEVELOP, V95, P211, DOI 10.1016/S0925-4773(00)00333-6; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JOSEPH R, 1995, BRAIN RES, V690, P92, DOI 10.1016/0006-8993(95)00621-V; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kanzler B, 1998, DEVELOPMENT, V125, P2587; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kruzynska-Frejtag A, 2004, DEV DYNAM, V229, P857, DOI 10.1002/dvdy.10453; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; Langston AW, 1997, J BIOL CHEM, V272, P2167, DOI 10.1074/jbc.272.4.2167; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115; Liu JP, 1998, DEVELOPMENT, V125, P5055; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MARK M, 1993, DEVELOPMENT, V119, P319; Martin G, 2001, BIOESSAYS, V23, P865, DOI 10.1002/bies.1126; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Murasawa H, 2000, ANAT RECORD, V259, P383, DOI 10.1002/1097-0185(20000801)259:4<383::AID-AR20>3.0.CO;2-N; MURPHY P, 1991, DEVELOPMENT, V111, P61; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakazawa T, 2004, J ORTHOP RES, V22, P520, DOI 10.1016/j.orthres.2003.10.007; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272; Otero JJ, 2004, DEVELOPMENT, V131, P3545, DOI 10.1242/dev.01218; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Papenbrock T, 1998, DEV DYNAM, V212, P540, DOI 10.1002/(SICI)1097-0177(199808)212:4<540::AID-AJA7>3.0.CO;2-H; PARR BA, 1993, DEVELOPMENT, V119, P247; Pelton TA, 2002, J CELL SCI, V115, P329; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perry A, 2004, J NEURO-ONCOL, V70, P183, DOI 10.1007/s11060-004-2749-0; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Qin P, 2004, J CELL BIOCHEM, V92, P147, DOI 10.1002/jcb.20057; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Riley BB, 2004, DEV DYNAM, V231, P278, DOI 10.1002/dvdy.20133; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Rossel M, 1999, DEVELOPMENT, V126, P5027; SASAKI M, 1988, J BIOL CHEM, V263, P16536; Scott LM, 1996, BLOOD, V88, P2517, DOI 10.1182/blood.V88.7.2517.bloodjournal8872517; Shen J, 2000, CELL GROWTH DIFFER, V11, P11; Shen J, 2000, EXP CELL RES, V259, P274, DOI 10.1006/excr.2000.4963; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STORNAIUOLO A, 1990, CELL DIFFER DEV, V31, P119, DOI 10.1016/0922-3371(90)90015-O; Studer M, 1998, DEVELOPMENT, V125, P1025; SUEMORI H, 1995, MECH DEVELOP, V51, P265, DOI 10.1016/0925-4773(95)00371-1; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAM PPL, 1989, DEVELOPMENT, V107, P55; Thompson JR, 1998, CELL GROWTH DIFFER, V9, P969; Tighe AP, 2004, J CELL PHYSIOL, V198, P223, DOI 10.1002/jcp.10424; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VOGEL KS, 1993, MOL NEUROBIOL, V7, P363, DOI 10.1007/BF02769183; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WIJNHOLDS J, 1995, DEV BIOL, V171, P73, DOI 10.1006/dbio.1995.1261; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu LF, 2000, GENE DEV, V14, P585; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6; ZHANG MB, 1994, DEVELOPMENT, V120, P2431; Zhuang Y, 2003, MOL CANCER RES, V1, P619	125	61	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16484	16498		10.1074/jbc.M414397200	http://dx.doi.org/10.1074/jbc.M414397200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722554	hybrid			2022-12-27	WOS:000228444800123
J	West, JD; Ji, CA; Marnett, LJ				West, JD; Ji, CA; Marnett, LJ			Modulation of DNA fragmentation factor 40 nuclease activity by poly(ADP-ribose) polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CHROMATIN CONDENSATION; OXIDATIVE STRESS; CELL-DEATH; APOPTOSIS; CLEAVAGE; ENDONUCLEASE; HISTONE; IDENTIFICATION; INVOLVEMENT	Poly(ADP-ribose) polymerase-1 (PARP-1) influences numerous cellular processes, including DNA repair, transcriptional regulation, and caspase-independent cell death, by utilizing NAD(+) to synthesize long chains of poly( ADP- ribose) ( PAR) on target proteins, including itself. During the apoptotic response, caspases-3 and - 7 cleave PARP-1, thereby inhibiting its activity. Here, we have examined the role of PARP-1 activation and cleavage in the latter stages of apoptosis in response to DNA fragmentation. PARP-1 poly( ADP- ribosyl) ation correlated directly with induction of apoptosis by the lipid peroxidation product, 4-hydroxy-2-nonenal. A significant decrease in PAR accumulation was observed upon caspase or DNA fragmentation factor 40 (DFF40) inhibition. Because DNA fragmentation mediated by DFF40 augmented PARP-1 modification status in apoptotic cells, we hypothesized that PARP-1 alters DFF40 function following PAR accumulation. Indeed, PARP-1, in the presence of NAD(+), significantly decreased DFF40 activity on plasmid substrates. Conversely, PARP-1 enhanced the DNase activity of DFF40 in the absence of NAD(+). The inhibition of DFF40 activity in the presence of NAD(+) was reduced by co-incubation with poly( ADPribose) glycohydrolase and a PARP inhibitor. Additionally, caspase-cleaved PARP-1, in the presence of NAD(+), did not inhibit DFF40 activity significantly. Our results suggest that PARP-1 poly( ADP- ribosyl) ation is a terminal event in the apoptotic response that occurs in response to DNA fragmentation and directly influences DFF40 activity.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Vanderbilt Inst Chem Biol,Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Vanderbilt Inst Chem Biol,Dept Biochem, 854 Robinson Res Bldg,23rd Ave & Pierce, Nashville, TN 37232 USA.	larry.marnett@vanderbilt.edu	West, James D./J-1619-2019	West, James D./0000-0003-0892-5254	NATIONAL CANCER INSTITUTE [P30CA068485, R37CA087819, R01CA087819, T32CA078136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, CA78136, CA87819] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulares AH, 2002, BIOCHEM BIOPH RES CO, V290, P796, DOI 10.1006/bbrc.2001.6280; Boulares AH, 2001, J BIOL CHEM, V276, P38185; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Haynes RL, 2001, FREE RADICAL BIO MED, V30, P884, DOI 10.1016/S0891-5849(01)00476-2; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Ji C, 2001, CHEM RES TOXICOL, V14, P1090, DOI 10.1021/tx000186f; Kruman I, 1997, J NEUROSCI, V17, P5089; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu W, 2000, J CELL SCI, V113, P635; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Shiokawa D, 2002, J BIOL CHEM, V277, P31031, DOI 10.1074/jbc.M204038200; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Talasz H, 2002, CELL DEATH DIFFER, V9, P27, DOI 10.1038/sj.cdd.4400925; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2003, J BIOL CHEM, V278, P26915, DOI 10.1074/jbc.M303807200; WIELCKENS K, 1982, J BIOL CHEM, V257, P2872; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; Yoshida A, 2003, J BIOL CHEM, V278, P37768, DOI 10.1074/jbc.M304914200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	58	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15141	15147		10.1074/jbc.M413147200	http://dx.doi.org/10.1074/jbc.M413147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703174	hybrid			2022-12-27	WOS:000228236800097
J	Liu, D; Zhang, Z; Liman, ER				Liu, D; Zhang, Z; Liman, ER			Extracellular acid block and acid-enhanced inactivation of the Ca2+-activated cation channel TRPM5 involve residues in the S3-S4 and S5-S6 extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; TASTE RECEPTOR-CELLS; CAPSAICIN RECEPTOR; ION-CHANNEL; SWEET TASTE; SUBUNIT STOICHIOMETRY; MOLECULAR MECHANISMS; K+ CHANNELS; BITTER; TRANSDUCTION	TRPM5, a member of the superfamily of transient receptor potential ion channels, is essential for the detection of bitter, sweet, and amino acid tastes. In heterologous cell types it forms a nonselective cation channel that is activated by intracellular Ca2+. TRPM5 is likely to be part of the taste transduction cascade, and regulators of TRPM5 are likely to affect taste sensation. In this report we show that TRPM5, but not the related channel TRPM4b, is potently blocked by extracellular acidification. External acidification has two effects, a fast reversible block of the current (IC50 pH = 6.2) and a slower irreversible enhancement of current inactivation. Mutation of a single Glu residue in the S3-S4 linker and a His residue in the pore region each reduced sensitivity of TRPM5 currents to fast acid block (IC50 pH = 5.8 for both), and the double mutant was nearly insensitive to acidic pH (IC50 pH = 5.0). Prolonged exposure to acidic pH enhanced inactivation of TRPM5 currents, and mutant channels that were less sensitive to acid block were also less sensitive to acid-enhanced inactivation, suggesting an intimate association between the two processes. These processes are, however, distinct because the pore mutant H896N, which has normal sensitivity to acid block, shows significant recovery from acid-enhanced inactivation. These data show that extracellular acidification acts through specific residues on TRPM5 to block conduction through two distinct but related mechanisms and suggest a possible interaction between extracellular pH and activation and adaptation of bitter, sweet, and amino acid taste transduction.	Univ So Calif, Dept Biol Sci, Neurobiol Sect, Div Neurobiol, Los Angeles, CA 90089 USA; Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Liman, ER (corresponding author), Univ So Calif, Dept Biol Sci, Neurobiol Sect, Div Neurobiol, 3641 Watt Way, Los Angeles, CA 90089 USA.	Liman@usc.edu	Liman, Emily/AAC-7383-2021	liman, emily/0000-0003-4765-5496	NIDCD NIH HHS [K02-DC05000, R01-DC04564] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K02DC005000, R01DC004564] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; DeSimone JA, 2001, RESP PHYSIOL, V129, P231, DOI 10.1016/S0034-5687(01)00293-6; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liman ER, 2003, J PHYSIOL-LONDON, V548, P777, DOI 10.1113/jphysiol.2002.037119; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montmayeur JP, 2002, CURR OPIN NEUROBIOL, V12, P366, DOI 10.1016/S0959-4388(02)00345-8; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; PARTRIDGE LD, 1988, TRENDS NEUROSCI, V11, P69, DOI 10.1016/0166-2236(88)90167-1; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schiffman SS, 2000, PHYSIOL BEHAV, V68, P469, DOI 10.1016/S0031-9384(99)00205-X; Starkus JG, 2003, PFLUG ARCH EUR J PHY, V447, P44, DOI 10.1007/s00424-003-1121-0; Steidl JV, 1999, MOL PHARMACOL, V55, P812; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	39	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20691	20699		10.1074/jbc.M414072200	http://dx.doi.org/10.1074/jbc.M414072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15731110	hybrid			2022-12-27	WOS:000229242000067
J	Renfrow, MB; Cooper, HJ; Tomana, M; Kulhavy, R; Hiki, Y; Toma, K; Emmett, MR; Mestecky, J; Marshall, AG; Novak, J				Renfrow, MB; Cooper, HJ; Tomana, M; Kulhavy, R; Hiki, Y; Toma, K; Emmett, MR; Mestecky, J; Marshall, AG; Novak, J			Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED MULTIPHOTON DISSOCIATION; GALACTOSE-DEFICIENT IGA1; HUMAN SERUM IGA1; LINKED OLIGOSACCHARIDES; CARBOHYDRATE MOIETIES; EXTERNAL ACCUMULATION; RHEUMATOID-ARTHRITIS; NEPHROPATHY PATIENTS; IMMUNE-COMPLEXES; GLYCOPEPTIDES	In a number of human diseases of chronic inflammatory or autoimmune character, immunoglobulin molecules display aberrant glycosylation patterns of N- or O-linked glycans. In IgA nephropathy, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes. It is not known whether the Gal deficiency in IgA1 proteins occurs randomly or preferentially at specific sites. To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry. Fourier transform-ion cyclotron resonance mass spectrometry offers two complementary fragmentation techniques for analysis of protein glycosylation by tandem mass spectrometry. Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation. To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation. Multiple sites of O-glycan attachment (including sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely). These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Fujita Hlth Univ, Sch Med, Dept Med, Div Nephrol, Toyoake, Aichi 4701192, Japan; Noguchi Inst, Dept Res, Tokyo 1730003, Japan; Florida State Univ, Dept Chem, Tallahassee, FL 32306 USA	University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida State University; University of Alabama System; University of Alabama Birmingham; Fujita Health University; State University System of Florida; Florida State University	Novak, J (corresponding author), Univ Alabama, Dept Microbiol, 845 19th St S,BBRB 734 Box 1, Birmingham, AL 35294 USA.	Jan_Novak@microbio.uab.edu	Cooper, Helen/M-4488-2017; Emmett, Mark R/C-3478-2013	Cooper, Helen/0000-0003-4590-9384; Emmett, Mark R/0000-0002-9248-5767; Renfrow, Matthew B./0000-0002-4193-7305	NIDCR NIH HHS [DE13694] Funding Source: Medline; NIDDK NIH HHS [DK61525, DK57750] Funding Source: Medline; NIGMS NIH HHS [R01 GM098539] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK061525, R01DK057750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098539] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen A, 1998, ADV EXP MED BIOL, V435, P175; Allen AC, 2001, KIDNEY INT, V60, P969, DOI 10.1046/j.1523-1755.2001.060003969.x; ALLEN AC, 1995, CLIN EXP IMMUNOL, V100, P470; Alving K, 1999, J MASS SPECTROM, V34, P395, DOI 10.1002/(SICI)1096-9888(199904)34:4<395::AID-JMS771>3.3.CO;2-T; ANDRE PM, 1990, J CLIN LAB ANAL, V4, P115, DOI 10.1002/jcla.1860040208; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; Belov ME, 2001, ANAL CHEM, V73, P253, DOI 10.1021/ac000633w; BLAKNEY GT, 2001, 49 ASMS C MASS SPECT; Chalmers MJ, 2004, PROTEOMICS, V4, P970, DOI 10.1002/pmic.200300650; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; Cooper HJ, 2003, EUR J MASS SPECTROM, V9, P221, DOI 10.1255/ejms.555; Cooper HJ, 2005, MASS SPECTROM REV, V24, P201, DOI 10.1002/mas.20014; Coppo R, 2004, KIDNEY INT, V65, P1544, DOI 10.1111/j.1523-1755.2004.05407.x; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; EMMETT MR, 1994, J AM SOC MASS SPECTR, V5, P605, DOI 10.1016/1044-0305(94)85001-1; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; FIELD MC, 1989, BIOCHEM SOC T, V17, P1034, DOI 10.1042/bst0171034; FRANGION.B, 1972, P NATL ACAD SCI USA, V69, P3673, DOI 10.1073/pnas.69.12.3673; Guan SH, 1996, INT J MASS SPECTROM, V157, P5, DOI 10.1016/S0168-1176(96)04461-8; Hakansson K, 2001, ANAL CHEM, V73, P4530, DOI 10.1021/ac0103470; Hakansson K, 2003, ANAL CHEM, V75, P3256, DOI 10.1021/ac030015q; Haselmann KF, 2001, ANAL CHEM, V73, P2998, DOI 10.1021/ac0015523; HENDRICKSON CL, 2004, 52 ASMS C MASS SPECT; HENDRICKSON CL, 2000, 48 ASMS C MASS SPECT; Hiki Y, 2001, KIDNEY INT, V59, P1077, DOI 10.1046/j.1523-1755.2001.00591.x; Hiki Y, 1998, J AM SOC NEPHROL, V9, P577; HIKI Y, 1995, CONTRIB NEPHROL, V111, P73; HIKI Y, 1998, 8 INT IGA NEPHR S NO; Horn DM, 2000, ANAL CHEM, V72, P4778, DOI 10.1021/ac000494i; Iwasaki H, 2003, J BIOL CHEM, V278, P5613, DOI 10.1074/jbc.M211097200; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Julian BA, 2004, CURR OPIN NEPHROL HY, V13, P171, DOI 10.1097/00041552-200403000-00005; Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x; Kobata A, 1998, GLYCOCONJUGATE J, V15, P323, DOI 10.1023/A:1006961532182; Kokubo T, 1999, NEPHROL DIAL TRANSPL, V14, P81, DOI 10.1093/ndt/14.1.81; Kokubo T, 2000, NEPHROL DIAL TRANSPL, V15, P28, DOI 10.1093/ndt/15.1.28; LEDFORD EB, 1984, ANAL CHEM, V56, P2744, DOI 10.1021/ac00278a027; MARSHALL AG, 1985, J AM CHEM SOC, V107, P7893, DOI 10.1021/ja00312a015; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; Marshall AG, 1990, FOURIER TRANSFORMS N; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MCFARLAND MA, 2004, 52 ASMS C MASS SPECT; Medzihradszky KF, 1996, J AM SOC MASS SPECTR, V7, P319, DOI 10.1016/1044-0305(95)00682-6; MEDZIHRADSZKY KF, 1990, BIOMED ENVIRON MASS, V19, P777, DOI 10.1002/bms.1200191205; MESTECKY J, 1986, MONOGR ALLERGY, V19, P277; Mestecky J, 2002, NEPHROLOGY, V7, pS92, DOI 10.1046/j.1440-1797.7.s3.3.x; MESTECKY J, 1993, CONTRIB NEPHROL, V104, P172; Mestecky J, 1997, NEPHROLOGY, V3, P85, DOI 10.1111/j.1440-1797.1997.tb00195.x; Mestecky J, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P153, DOI 10.1016/B978-012491543-5/50013-9; MULLINAX F, 1975, ARTHRITIS RHEUM, V18, P417; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Novak J, 2002, KIDNEY INT, V62, P465, DOI 10.1046/j.1523-1755.2002.00477.x; Novak J, 2001, J CLIN IMMUNOL, V21, P310, DOI 10.1023/A:1012284402054; Novak J, 2000, MOL IMMUNOL, V37, P1047, DOI 10.1016/S0161-5890(01)00019-0; QUINN JP, 1998, 46 ASMS C MASS SPECT, P1388; Ritchie MA, 2002, J AM SOC MASS SPECTR, V13, P1065, DOI 10.1016/S1044-0305(02)00421-X; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1839, DOI 10.1002/(SICI)1097-0231(199611)10:14<1839::AID-RCM718>3.0.CO;2-V; Senko MW, 1997, J AM SOC MASS SPECTR, V8, P970, DOI 10.1016/S1044-0305(97)00126-8; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1824; Shi SDH, 2000, INT J MASS SPECTROM, V195, P591, DOI 10.1016/S1387-3806(99)00226-2; Smith AC, 2003, SPRINGER SEMIN IMMUN, V24, P477, DOI 10.1007/s00281-002-0115-x; TOMANA M, 1984, J LAB CLIN MED, V103, P137; Tomana M, 1999, J CLIN INVEST, V104, P73, DOI 10.1172/JCI5535; Tomana M, 1997, KIDNEY INT, V52, P509, DOI 10.1038/ki.1997.361; Tomana M., 1996, GLYCOPROTEINS DIS, P291; Wilcox BE, 2002, J AM SOC MASS SPECTR, V13, P1304, DOI 10.1016/S1044-0305(02)00622-0; WOLFENST.C, 1972, BIOCHEMISTRY-US, V11, P3971, DOI 10.1021/bi00771a021; Zaia J, 2004, MASS SPECTROM REV, V23, P161, DOI 10.1002/mas.10073; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m; Zubarev RA, 1998, J AM CHEM SOC, V120, P3265, DOI 10.1021/ja973478k; Zubarev RA, 2003, MASS SPECTROM REV, V22, P57, DOI 10.1002/mas.10042	73	112	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19136	19145		10.1074/jbc.M411368200	http://dx.doi.org/10.1074/jbc.M411368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728186	hybrid			2022-12-27	WOS:000228932300070
J	Oka, S; Yanagimoto, S; Ikeda, S; Gokoh, M; Kishimoto, S; Waku, K; Ishima, Y; Sugiura, T				Oka, S; Yanagimoto, S; Ikeda, S; Gokoh, M; Kishimoto, S; Waku, K; Ishima, Y; Sugiura, T			Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; HUMAN IMMUNE; MAP KINASES; AGONIST; ANANDAMIDE; INHIBITION; RELEASE; CELLS; 2-ARACHIDONYL-GLYCEROL	2-Arachidonoylglycerol is an endogenous ligand for the cannabinoid receptors. Two types of cannabinoid receptors have been identified to date. The CB1 receptor is abundantly expressed in the brain, and assumed to be involved in the attenuation of neurotransmission. On the other hand, the physiological roles of the CB2 receptor, mainly expressed in several types of inflammatory cells and immunocompetent cells, have not yet been fully elucidated. In this study, we investigated possible pathophysiological roles of the CB2 receptor and 2-arachidonoylglycerol in acute inflammation in mouse ear induced by the topical application of 12-O-tetradecanoylphorbol-13- acetate. We found that the amount of 2-arachidonoylglycerol was markedly augmented in inflamed mouse ear. In contrast, the amount of anandamide, another endogenous cannabinoid receptor ligand, did not change markedly. Importantly, 12-O-tetradecanoylphorbol-13- acetate-induced ear swelling was blocked by treatment with SR144528, a CB2 receptor antagonist, suggesting that the CB2 receptor is involved in the swelling. On the other hand, the application of AM251, a CB1 receptor antagonist, exerted only a weak suppressive effect. The application of SR144528 also reduced the 12-O-tetradecanoylphorbol-13- acetate-induced production of leukotriene B-4 and the infiltration of neutrophils in the mouse ear. Interestingly, the application of 2-arachidonoylglycerol to the mouse ear evoked swelling, which was abolished by treatment with SR144528. Nitric oxide was suggested to be involved in the ear swelling induced by 2-arachidonoylglycerol. These results suggest that the CB2 receptor and 2-arachidonoylglycerol play crucial stimulative roles during the course of inflammatory reactions.	Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan; Ishima Inst Neurosci, Tokyo 1860002, Japan	Teikyo University	Sugiura, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan.	sugiurat@pharm.teikyo-u.ac.jp						[Anonymous], 2004, PROG INFLAM RES; BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; Bhat NR, 2002, BRAIN RES, V948, P93, DOI 10.1016/S0006-8993(02)02953-0; Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; Bisogno T, 2001, EUR J BIOCHEM, V268, P1982, DOI 10.1046/j.1432-1327.2001.02072.x; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Burkey TH, 1997, EUR J PHARMACOL, V336, P295, DOI 10.1016/S0014-2999(97)01255-7; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103; Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471-4159.2001.00333.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DIMARZO V, 2002, BIOL MARIJUANA, P125; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1995, CANNABINOID RECEPTOR, P145; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420; Jaffee BD, 2000, BIOCHEM BIOPH RES CO, V268, P647, DOI 10.1006/bbrc.2000.2184; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; Jorda MA, 2002, BLOOD, V99, P2786; Kim SH, 2004, PHARMACOL RES, V49, P433, DOI 10.1016/j.phrs.2003.11.004; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Kishimoto S, 2003, J BIOL CHEM, V278, P24469, DOI 10.1074/jbc.M301359200; Kobayashi Y, 2001, J BIOCHEM-TOKYO, V129, P665, DOI 10.1093/oxfordjournals.jbchem.a002904; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; MACKIE K, 1993, MOL PHARMACOL, V44, P498; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; McAllister SD, 1999, J PHARMACOL EXP THER, V291, P618; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; Rawlingson A, 2001, BRIT J PHARMACOL, V134, P1805, DOI 10.1038/sj.bjp.0704436; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Savinainen JR, 2001, BRIT J PHARMACOL, V134, P664, DOI 10.1038/sj.bjp.0704297; Schlicker E, 2001, TRENDS PHARMACOL SCI, V22, P565, DOI 10.1016/S0165-6147(00)01805-8; Smith SR, 2001, EUR J PHARMACOL, V432, P107, DOI 10.1016/S0014-2999(01)01477-7; SOFIA RD, 1974, LIFE SCI, V15, P251; Stefano GB, 2000, PHARMACOL RES, V42, P317, DOI 10.1006/phrs.2000.0702; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014-5793(95)00027-7; YOUNG JM, 1984, J INVEST DERMATOL, V82, P367, DOI 10.1111/1523-1747.ep12260709	67	81	83	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18488	18497		10.1074/jbc.M413260200	http://dx.doi.org/10.1074/jbc.M413260200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749716	hybrid			2022-12-27	WOS:000228807200112
J	Liu, BS; Sutton, A; Sternglanz, R				Liu, BS; Sutton, A; Sternglanz, R			A yeast polyamine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SPERMIDINE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; ACETYLATION; CHROMATIN; BIOSYNTHESIS; METABOLISM; COMPLEXES; OXIDASE	An uncharacterized yeast gene has been shown to encode a polyamine acetyltransferase and named PAA1. The recombinant Paa1 protein readily acetylates various polyamines such as putrescine, spermidine, and spermine. paa1 mutants are viable and grow normally under standard conditions. The mutants are sensitive to hydroxyurea, and they are synthetically temperature-sensitive with a rad53-21 mutation. The mutants also show genetic interactions with components of the transcriptional co-activator complex, SAGA, and partially suppress Spt(-) phenotypes of two spt mutants. These phenotypes suggest that acetylation of polyamines removes them from chromatin and makes the chromatin more accessible. It is known that spermine, but not acetyl spermine, is a precursor in the pathway for synthesis of coenzyme A in yeast. When Paa1 is overexpressed, leading to a lower level of spermine, cells show a growth dependence on either of two downstream compounds in the coenzyme A pathway, pantothenate or beta-alanine. This demonstrates that spermine and perhaps other polyamines are the in vivo targets of Paa1.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Life Sci Bldg, Stony Brook, NY 11794 USA.	rolf@life.bio.sunysb.edu			NIGMS NIH HHS [GM28220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babbar N, 2003, BIOCHEM SOC T, V31, P388, DOI 10.1042/BST0310388; CARPER SW, 1991, J BIOL CHEM, V266, P12439; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; DESIDERIO MA, 1993, BIOCHEM J, V293, P475, DOI 10.1042/bj2930475; DOD B, 1982, EUR J BIOCHEM, V121, P401, DOI 10.1111/j.1432-1033.1982.tb05801.x; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FUKUCHI JI, 1995, J BIOL CHEM, V270, P18831, DOI 10.1074/jbc.270.32.18831; Ganguly S, 2001, J BIOL CHEM, V276, P47239, DOI 10.1074/jbc.M107222200; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Landry J, 2003, BIOCHEM BIOPH RES CO, V303, P771, DOI 10.1016/S0006-291X(03)00416-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; MORGAN DML, 1998, POLYAMINE PROTOCOLS, P77; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Raspaud E, 1999, BIOPHYS J, V77, P1547, DOI 10.1016/S0006-3495(99)77002-5; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tabor H, 1971, METHODS ENZYMOLOGY B, V17, P829; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	27	31	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16659	16664		10.1074/jbc.M414008200	http://dx.doi.org/10.1074/jbc.M414008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723835	hybrid			2022-12-27	WOS:000228615500017
J	O'Connor, CM; Lai, CK; Collins, K				O'Connor, CM; Lai, CK; Collins, K			Two purified domains of telomerase reverse transcriptase reconstitute sequence-specific interactions with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA TELOMERASE; FUNCTIONAL MULTIMERIZATION; CATALYTIC SUBUNIT; TEMPLATE; COMPONENT	Telomerase reverse transcriptase ( TERT) and telomerase RNA (TER) function together to create a uniquely specialized polymerase. Here we have described for the first time domains of bacterially expressed Tetrahymena TERT that interacted directly with TER in the absence of assembly chaperones. We used quantitative binding assays to define TER sequence requirements for recognition by the high affinity RNA binding domain and an independent N-terminal RNA interaction domain. The TERT RNA binding domain and N-terminal RNA interaction domain had distinct, nonoverlapping requirements for TER sequence and structure that together accounted for all of the sites of TER contact inferred for full-length TERT. The TER residues important for TERT binding are only a subset of the residues required for catalytic activity. Our findings demonstrate telomerase functional specialization by an elaborate ribonucleoprotein architecture physically separable from the active site.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	kcollins@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054198] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054198-09, R01 GM054198, GM54198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Chen JL, 2004, TRENDS BIOCHEM SCI, V29, P183, DOI 10.1016/j.tibs.2004.02.003; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Lai CK, 2003, MOL CELL, V11, P1673, DOI 10.1016/S1097-2765(03)00232-6; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; Miller MC, 2002, P NATL ACAD SCI USA, V99, P6585, DOI 10.1073/pnas.102024699; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Sperger JM, 2001, BIOCHEMISTRY-US, V40, P7005, DOI 10.1021/bi0103359; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Witkin KL, 2004, GENE DEV, V18, P1107, DOI 10.1101/gad.1201704; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; ZAUG AJ, 1995, RNA, V1, P363	24	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17533	17539		10.1074/jbc.M501211200	http://dx.doi.org/10.1074/jbc.M501211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731105	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000228615500122
J	Shinoda, T; Arai, K; Shigematsu-Iida, M; Ishikura, Y; Tanaka, S; Yamada, T; Kimber, MS; Pai, EF; Fushinobu, S; Taguchi, H				Shinoda, T; Arai, K; Shigematsu-Iida, M; Ishikura, Y; Tanaka, S; Yamada, T; Kimber, MS; Pai, EF; Fushinobu, S; Taguchi, H			Distinct conformation-mediated functions of an active site loop in the catalytic reactions of NAD-dependent D-lactate dehydrogenase and formate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELBRUECKII SUBSP BULGARICUS; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; D-2-HYDROXYISOCAPROATE DEHYDROGENASE; LACTOBACILLUS-PLANTARUM; NUCLEOTIDE-SEQUENCE; SUBSTRATE-BINDING; LEUCONOSTOC-MESENTEROIDES; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE	The three-dimensional structures of NAD-dependent D-lactate dehydrogenase (D-LDH) and formate dehydrogenase (FDH), which resemble each other, imply that the two enzymes commonly employ certain main chain atoms, which are located on corresponding loop structures in the active sites of the two enzymes, for their respective catalytic functions. These active site loops adopt different conformations in the two enzymes, a difference likely attributable to hydrogen bonds with Asn(97) and Glu(141), which are also located at equivalent positions in D-LDH and FDH, respectively. X-ray crystallography at 2.4-angstrom resolution revealed that replacement of Asn(97) with Asp did not markedly change the overall protein structure but markedly perturbed the conformation of the active site loop in Lactobacillus pentosus D-LDH. The Asn(97) --> Asp mutant D-LDH exhibited virtually the same k(cat), but about 70-fold higher K-M value for pyruvate than the wild-type enzyme. For Paracoccus sp. 12-A FDH, in contrast, replacement of Glu(141) with Gln and Asn induced only 5.5- and 4.3- fold increases in the K-M value, but 110 and 590-fold decreases in the k(cat) values for formate, respectively. Furthermore, these mutant FDHs, particularly the Glu(141) --> Asn enzyme, exhibited markedly enhanced catalytic activity for glyoxylate reduction, indicating that FDH is converted to a 2-hydroxyacid dehydrogenase on the replacement of Glu(141). These results indicate that the active site loops play different roles in the catalytic reactions of D-LDH and FDH, stabilization of substrate binding and promotion of hydrogen transfer, respectively, and that Asn(97) and Glu(141), which stabilize suitable loop conformations, are essential elements for proper loop functioning.	Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Chiba 2788510, Japan; Affinium Pharmaceut Inc, Toronto, ON M5J 1V6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo University of Science; University of Toronto; University of Toronto; University of Tokyo	Taguchi, H (corresponding author), Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, 2641 Yamazaki, Chiba 2788510, Japan.	htaguchi@rs.noda.tus.ac.jp	Fushinobu, Shinya/E-4987-2011; Pai, Emil/R-8908-2019; Kimber, Matthew/Q-8144-2019; Pai, Emil F/D-2526-2013	Fushinobu, Shinya/0000-0003-1346-6435; Pai, Emil/0000-0002-1162-7242; Taguchi, Hayao/0000-0001-5270-581X; Kimber, Matthew/0000-0001-9454-5586				ALLEN SJ, 1995, GENE, V162, P99, DOI 10.1016/0378-1119(95)00347-9; ARTHUR M, 1991, GENE, V103, P133, DOI 10.1016/0378-1119(91)90405-Z; Baker PJ, 1998, NAT STRUCT BIOL, V5, P561, DOI 10.1038/817; BERNARD N, 1991, FEBS LETT, V290, P61, DOI 10.1016/0014-5793(91)81226-X; BERNARD N, 1994, EUR J BIOCHEM, V224, P439, DOI 10.1111/j.1432-1033.1994.00439.x; Bunch PK, 1997, MICROBIOL-UK, V143, P187, DOI 10.1099/00221287-143-1-187; CHOW CM, 1993, J BACTERIOL, V175, P3703, DOI 10.1128/JB.175.12.3703-3709.1993; CLARKE AR, 1989, TRENDS BIOCHEM SCI, V14, P101, DOI 10.1016/0968-0004(89)90131-X; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; COLOWICK SP, 1957, METHOD ENZYMOL, V4, P840, DOI 10.1016/0076-6879(57)04082-3; DARTOIS V, 1995, RES MICROBIOL, V146, P291, DOI 10.1016/0923-2508(96)81052-7; Dengler U, 1997, J MOL BIOL, V267, P640, DOI 10.1006/jmbi.1996.0864; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; FERSHT A, 1977, ENZYME STRUCTURE MEC, P95; FERSHT AR, 1985, NATURE, V314, P35; Flick MJ, 2002, BIOCHEM BIOPH RES CO, V295, P910, DOI 10.1016/S0006-291X(02)00768-4; Galkin A, 1995, APPL MICROBIOL BIOT, V44, P479, DOI 10.1007/BF00169947; GARMYN D, 1995, J BACTERIOL, V177, P3427, DOI 10.1128/jb.177.12.3427-3437.1995; GOLDBERG JD, 1994, J MOL BIOL, V236, P1123, DOI 10.1016/0022-2836(94)90016-7; GRANT GA, 1989, BIOCHEM BIOPH RES CO, V165, P1371, DOI 10.1016/0006-291X(89)92755-1; GREENLER JM, 1989, PLANT MOL BIOL, V13, P139, DOI 10.1007/BF00016133; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; Holbrook JJ., 1975, ENZYMES, P191; KOCHHAR S, 1992, J BIOL CHEM, V267, P8499; KOCHHAR S, 1992, J BIOL CHEM, V267, P20298; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1994, J MOL BIOL, V236, P759, DOI 10.1006/jmbi.1994.1188; Lapierre L, 1999, APPL ENVIRON MICROB, V65, P4002; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; Liang MP, 2003, NUCLEIC ACIDS RES, V31, P3324, DOI 10.1093/nar/gkg553; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Milewski WM, 1996, ANTIMICROB AGENTS CH, V40, P166, DOI 10.1128/AAC.40.1.166; NIKOLAOS EL, 2001, BIOCHEM J, V354, P455; Ohshima T, 2001, EUR J BIOCHEM, V268, P4740, DOI 10.1046/j.1432-1327.2001.02394.x; POPOV VO, 1994, BIOCHEM J, V301, P625, DOI 10.1042/bj3010625; POPOV VO, 1990, BIOORG KHIM+, V16, P324; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; Razeto A, 2002, J MOL BIOL, V318, P109, DOI 10.1016/S0022-2836(02)00086-4; Rumsby G, 1999, BBA-GENE STRUCT EXPR, V1446, P383, DOI 10.1016/S0167-4781(99)00105-0; SALEEBA JA, 1992, MOL GEN GENET, V235, P349, DOI 10.1007/BF00279380; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P68; Shinoda T, 2002, BIOSCI BIOTECH BIOCH, V66, P271, DOI 10.1271/bbb.66.271; Steiner RA, 2003, ACTA CRYSTALLOGR D, V59, P2114, DOI 10.1107/S0907444903018675; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; Stoll VS, 1995, PROTEIN PEPTIDE LETT, V2, P435; Stoll VS, 1996, STRUCTURE, V4, P437, DOI 10.1016/S0969-2126(96)00049-4; TAGUCHI H, 1993, J BIOL CHEM, V268, P18030; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; TAGUCHI H, 1994, J BIOCHEM-TOKYO, V115, P930, DOI 10.1093/oxfordjournals.jbchem.a124441; Taguchi H, 1997, J BIOCHEM-TOKYO, V122, P802; Tishkov VI, 1996, FEBS LETT, V390, P104, DOI 10.1016/0014-5793(96)00641-2; TISHKOV VI, 1993, BIOCHEM BIOPH RES CO, V192, P976, DOI 10.1006/bbrc.1993.1511; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Tokuda C, 2003, J BACTERIOL, V185, P5023, DOI 10.1128/JB.185.16.5023-5026.2003; VINALS C, 1993, BIOCHEM BIOPH RES CO, V192, P182, DOI 10.1006/bbrc.1993.1398	63	20	21	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17068	17075		10.1074/jbc.M500970200	http://dx.doi.org/10.1074/jbc.M500970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734738	hybrid			2022-12-27	WOS:000228615500065
J	Novgorodov, SA; Szulc, ZM; Luberto, C; Jones, JA; Bielawski, J; Bielawska, A; Hannun, YA; Obeid, LM				Novgorodov, SA; Szulc, ZM; Luberto, C; Jones, JA; Bielawski, J; Bielawska, A; Hannun, YA; Obeid, LM			Positively charged ceramide is a potent inducer of mitochondrial permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION PORE; RESPIRATORY-CHAIN; CELL-DEATH; APOPTOSIS; MEMBRANE; PHOSPHORYLATION; MECHANISM; COMMITMENT; ACTIVATION; INDUCTION	Ceramide-induced cell death is thought to be mediated by change in mitochondrial function, although the precise mechanism is unclear. Proposed models suggest that ceramide induces cell death through interaction with latent binding sites on the outer or inner mitochondrial membranes, followed by an increase in membrane permeability, as an intermediate step in ceramide signal propagation. To investigate these models, we developed a new generation of positively charged ceramides that readily accumulate in isolated and in situ mitochondria. Accumulated, positively charged ceramides increased inner membrane permeability and triggered release of mitochondrial cytochrome c. Furthermore, the positively charged ceramide-induced permeability increase was suppressed by cyclosporin A (60%) and 1,3-dicyclohexylcarbodiimide (90%). These observations suggest that the inner membrane permeability increase is due to activation of specific ion transporters, not the generalized loss of lipid bilayer barrier functions. The difference in sensitivity of ceramide-induced ion fluxes to inhibitors of mitochondrial transporters suggests activation of at least two transport systems: the permeability transition pore and the electrogenic H+ channel. Our results indicate the presence of specific ceramide targets in the mitochondrial matrix, the occupation of which triggers permeability alterations of the inner and outer mitochondrial membranes. These findings also suggest a novel therapeutic role for positively charged ceramides.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		Jones, Jeffrey/0000-0002-5133-0427; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [IPO1CA097132] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline; NIDDK NIH HHS [DK59340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKI J, 2005, IN PRESS METHODS; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gudz T, 1997, ARCH BIOCHEM BIOPHYS, V342, P143, DOI 10.1006/abbi.1997.0113; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LI XQ, 1990, J BIOL CHEM, V265, P15316; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MATSUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550, DOI 10.1073/pnas.82.22.7550; Mimeault M, 2002, FEBS LETT, V530, P9, DOI 10.1016/S0014-5793(02)03432-4; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITANO JS, 1987, CANCER RES, V47, P4361; NOVGORODOV S A, 1984, Biokhimiya, V49, P185; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1986, EUR J BIOCHEM, V155, P423, DOI 10.1111/j.1432-1033.1986.tb09508.x; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Siskind LJ, 2003, BIOPHYS J, V85, P1560, DOI 10.1016/S0006-3495(03)74588-3; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Walter L, 2002, FREE RADICAL RES, V36, P405, DOI 10.1080/10715760290021252; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	44	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16096	16105		10.1074/jbc.M411707200	http://dx.doi.org/10.1074/jbc.M411707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722351	hybrid			2022-12-27	WOS:000228444800077
J	Kovacs, M; Wang, F; Sellers, JR				Kovacs, M; Wang, F; Sellers, JR			Mechanism of action of myosin X, a membrane-associated molecular motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RABBIT SKELETAL-MUSCLE; DICTYOSTELIUM MYOSIN; KINETIC MECHANISM; NUCLEOTIDE-BINDING; SINGLE TRYPTOPHAN; FLUORESCENT-PROBE; HEAVY-MEROMYOSIN; V PROCESSIVITY; SMOOTH-MUSCLE	We have performed a detailed biochemical kinetic and spectroscopic study on a recombinant myosin X head construct to establish a quantitative model of the enzymatic mechanism of this membrane-bound myosin. Our model shows that during steady-state ATP hydrolysis, myosin X exhibits a duty ratio (i.e. the fraction of the cycle time spent strongly bound to actin) of around 16%, but most of the remaining myosin heads are also actin-attached even at moderate actin concentrations in the so-called "weak" actin-binding states. Contrary to the high duty ratio motors myosin V and VI, the ADP release rate constant from actomyosin X is around five times greater than the maximal steady-state ATPase activity, and the kinetic partitioning between different weak actin-binding states is a major contributor to the rate limitation of the enzymatic cycle. Two different ADP states of myosin X are populated in the absence of actin, one of which shows very similar kinetic properties to actomyosin center dot ADP. The nucleotide-free complex of myosin X with actin shows unique spectral and biochemical characteristics, indicating a special mode of actomyosin interaction.	NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kovacs, M (corresponding author), NHLBI, Lab Mol Physiol, NIH, Bldg 10, Bethesda, MD 20892 USA.	kovacsm@mail.nih.gov	Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004231, Z01HL004231] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Belyantseva IA, 2003, P NATL ACAD SCI USA, V100, P13958, DOI 10.1073/pnas.2334417100; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chen LF, 2002, J STRUCT BIOL, V138, P92, DOI 10.1016/S1047-8477(02)00013-8; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Klopfenstein DR, 2004, MOL BIOL CELL, V15, P3729, DOI 10.1091/mbc.E04-04-0326; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mashanov GI, 2004, J BIOL CHEM, V279, P15274, DOI 10.1074/jbc.M312140200; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tokuo H, 2004, BIOCHEM BIOPH RES CO, V319, P214, DOI 10.1016/j.bbrc.2004.04.167; TRENTHAM DR, 1972, BIOCHEM J, V126, P635, DOI 10.1042/bj1260635; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136	50	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15071	15083		10.1074/jbc.M500616200	http://dx.doi.org/10.1074/jbc.M500616200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705568	hybrid			2022-12-27	WOS:000228236800090
J	Wingate, H; Zhang, N; McGarhen, MJ; Bedrosian, I; Harper, JW; Keyomarsi, K				Wingate, H; Zhang, N; McGarhen, MJ; Bedrosian, I; Harper, JW; Keyomarsi, K			The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN; P27(KIP1) EXPRESSION; DEPENDENT KINASES; PROGNOSTIC FACTOR; REDUNDANT CYCLIN; E OVEREXPRESSION; CDK INHIBITORS; GENE; D1	The low molecular weight (LMW) isoforms of cyclin E are unique to cancer cells. In breast cancer, such alteration of cyclin E is a very strong predictor of poor patient outcome. Here we show that alteration in binding properties of these LMW isoforms to CDK2 and the CDK inhibitors (CKIs), p21 and p27, results in their functional hyperactivity. The LMW forms of cyclin E are severalfold more effective at binding to CDK2. Additionally, compared with the full-length cyclin E-CDK2 complexes, the LMW cyclin E-CDK2 complexes are significantly more resistant to inhibition by p21 and p27, despite equal binding of the CKIs to the LMW complexes. When both the full-length and the LMW cyclin E are co-expressed, p27 preferentially binds to the LMW forms yet is unable to inhibit the CDK2 activity. Thus, the LMW forms of cyclin E may contribute to tumorigenesis through their resistance to the inhibitory activities of p21 and p27 while sequestering these CKIs from the full-length cyclin E.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [P30-CA16672, R01-CA87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087548, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahamed S, 2002, MOL CARCINOGEN, V34, P45, DOI 10.1002/mc.10048; Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Ciaparrone M, 1998, CANCER RES, V58, P114; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GERLOFF DL, 1993, BIOCHEM BIOPH RES CO, V194, P560, DOI 10.1006/bbrc.1993.1856; GRANT AJ, 1990, BIOCH INT, V22; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harwell RM, 2000, CANCER RES, V60, P481; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loden M, 2002, ONCOGENE, V21, P4680, DOI 10.1038/sj.onc.1205578; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; NEVINS JR, 1992, SCIENCE, V258, P424; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1999, BREAST CANCER RES TR, V56, P105; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sgambato A, 1999, MOL CARCINOGEN, V26, P172, DOI 10.1002/(SICI)1098-2744(199911)26:3<172::AID-MC6>3.0.CO;2-8; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sgambato A, 2000, CANCER-AM CANCER SOC, V89, P2247, DOI 10.1002/1097-0142(20001201)89:11<2247::AID-CNCR13>3.0.CO;2-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tsuchida R, 2002, JPN J CANCER RES, V93, P1000, DOI 10.1111/j.1349-7006.2002.tb02476.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11; ZEYDEL M, 1986, CANCER RES, V46, P6438	53	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15148	15157		10.1074/jbc.M409789200	http://dx.doi.org/10.1074/jbc.M409789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708847	hybrid			2022-12-27	WOS:000228236800098
J	Zito, SR; Antony, E; Hunt, JF; Oliver, DB; Hingorani, MM				Zito, SR; Antony, E; Hunt, JF; Oliver, DB; Hingorani, MM			Role of a conserved glutamate residue in the Escherichia coli SecA ATPase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; BACILLUS-SUBTILIS; BINDING-SITE; INORGANIC-PHOSPHATE; CATALYTIC CYCLE; ABC TRANSPORTER; PREPROTEIN TRANSLOCATION; NUCLEOTIDE EXCHANGE; MODEL MEMBRANES; INNER MEMBRANE	Escherichia coli SecA uses ATP to drive the transport of proteins across cell membranes. Glutamate 210 in the "DEVD" Walker B motif of the SecA ATP-binding site has been proposed as the catalytic base for ATP hydrolysis (Hunt, J. F., Weinkauf, S., Henry, L., Fak, J. J., McNicholas, P., Oliver, D. B., and Deisenhofer, J. (2002) Science 297, 2018-2026). Consistent with this hypothesis, we find that mutation of glutamate 210 to aspartate results in a 90-fold reduction of the ATP hydrolysis rate compared with wild type SecA, 0.3 s(-1) versus 27 s(-1), respectively. SecA-E210D also releases ADP at a slower rate compared with wild type SecA, suggesting that in addition to serving as the catalytic base, glutamate 210 might aid turnover as well. Our results contradict an earlier report that proposed aspartate 133 as the catalytic base (Sato, K., Mori, H., Yoshida, M., and Mizushima, S. (1996) J. Biol. Chem. 271, 17439-17444). Re-evaluation of the SecA-D133N mutant used in that study confirms its loss of ATPase and membrane translocation activities, but surprisingly, the analogous SecA-D133A mutant retains full activity, revealing that this residue does not play a key role in catalysis.	Wesleyan Univ, Dept Mol Biol & Biochem, Hall Atwater Labs 205, Middletown, CT 06459 USA; Columbia Univ, New York, NY 10027 USA	Wesleyan University; Columbia University	Hingorani, MM (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Hall Atwater Labs 205, Middletown, CT 06459 USA.	mhingorani@wesleyan.edu	Antony, Edwin/AAA-3596-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064514, R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64514, R01 GM042033, R01 GM064514, GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; de Keyzer J, 2003, J BIOL CHEM, V278, P29581, DOI 10.1074/jbc.M303490200; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 2002, MOL MEMBR BIOL, V19, P159, DOI 10.1080/09687680210152609; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Fak JJ, 2004, BIOCHEMISTRY-US, V43, P7307, DOI 10.1021/BI0357208; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jeong YJ, 2002, J BIOL CHEM, V277, P43778, DOI 10.1074/jbc.M208634200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Miller A, 2002, BIOCHEMISTRY-US, V41, P5325, DOI 10.1021/bi025639p; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Natale P, 2004, J BIOL CHEM, V279, P13769, DOI 10.1074/jbc.M312892200; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Shilton B, 1998, FEBS LETT, V436, P277, DOI 10.1016/S0014-5793(98)01141-7; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; vanderWolk JPW, 1997, BIOCHEMISTRY-US, V36, P14924, DOI 10.1021/bi971766n; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200	49	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14611	14619		10.1074/jbc.M414224200	http://dx.doi.org/10.1074/jbc.M414224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710614	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000228236800035
J	Williams, JC; Xie, H; Hendrickson, WA				Williams, JC; Xie, H; Hendrickson, WA			Crystal structure of dynein light chain TcTex-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; SUBUNIT HETEROGENEITY; PROTEIN; INTERACTS; COMPLEX; LC8; INHIBITOR; RECEPTOR; FAMILY; IDENTIFICATION	TcTex-1, one of three dynein light chains of the dynein motor complex, has been implicated in targeting and binding cargoes to cytoplasmic dynein for retrograde or apical transport. Interactions between TcTex-1 and a diverse set of proteins such as the dynein intermediate chain, Fyn, DOC2, FIP1, the poliovirus receptor, CD155, and the rhodopsin cytoplasmic tail have been reported; yet, despite the broad range of targets, a consensus binding sequence remains uncertain. Consequently, we have solved the crystal structure of the full-length Drosophila homolog of TcTex-1 to 1.7 angstrom resolution using MAD phasing to gain insight into its function and target specificity. The structure is homodimeric with a domain swapping of beta-strand 2 and has a fold similar to the dynein light chain, LC8. Based on structural alignment, the TcTex-1 1 and LC8 sequences show no identity, although the root mean square deviation between secondary structural elements is less than 1.6 angstrom. Moreover, the N terminus, which is equivalent to beta-strand 1 in LC8, is splayed out and binds to a crystallographic dimer as an anti-parallel beta-strand at the same position as the neuronal nitric-oxide synthase peptide in the LC8 complex. Similarity to LC8 and comparison to the LC8-neuronal nitricoxide synthase complex suggest that TcTex-1 binds its targets in a similar manner as LC8 and provides insight to the lack of strict sequence identity among the targets for TcTex-1.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034102, R01GM034102] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; BODE W, 1986, EMBO J, V5, P813, DOI 10.1002/j.1460-2075.1986.tb04286.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Caggese C, 2001, MOL GENET GENOMICS, V265, P436, DOI 10.1007/s004380000431; Campbell KS, 1998, J IMMUNOL, V161, P1728; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L, PYMOL MOL GRAPHICS S; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kai N, 1997, J NEUROSCI RES, V48, P407, DOI 10.1002/(SICI)1097-4547(19970601)48:5<407::AID-JNR3>3.3.CO;2-F; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lukashok SA, 2000, J VIROL, V74, P4705, DOI 10.1128/JVI.74.10.4705-4709.2000; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7; Miki F, 2002, MOL BIOL CELL, V13, P930, DOI 10.1091/mbc.01-11-0543; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nadano D, 2002, BIOCHEM J, V364, P669, DOI 10.1042/BJ20011836; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P436; SAMBROOK J, 1989, MOL CLONING LAB MANU, V2, P436; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Sugai M, 2003, BIOCHEM BIOPH RES CO, V311, P24, DOI 10.1016/j.bbrc.2003.09.157; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; VAUGHAN KT, 1995, BIOCHEM SOC T, V23, P50, DOI 10.1042/bst0230050; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Wu HW, 2001, J BIOMOL NMR, V20, P89, DOI 10.1023/A:1011299813395; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001	53	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21981	21986		10.1074/jbc.M414643200	http://dx.doi.org/10.1074/jbc.M414643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15701632	hybrid			2022-12-27	WOS:000229557900040
J	Arima, Y; Nitta, M; Kuninaka, S; Zhang, DW; Fujiwara, T; Taya, Y; Nakao, M; Saya, H				Arima, Y; Nitta, M; Kuninaka, S; Zhang, DW; Fujiwara, T; Taya, Y; Nakao, M; Saya, H			Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-CYCLE ARREST; DNA-DAMAGE; RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; CDK INHIBITORS; ALPHA-AMANITIN; LARGE SUBUNIT; CANCER CELLS; IN-VIVO	The tumor suppressor p53 functions as a transcriptional activator to induce cell cycle arrest and apoptosis in response to DNA damage. Although p53 was also shown to mediate apoptosis in a manner independent of its transactivation activity, the mechanism and conditions that trigger such cell death have remained largely unknown. We have now shown that inhibition of RNA polymerase II-mediated transcription by alpha-amanitin or RNA interference induced p53-dependent apoptosis. Inhibition of pol II-mediated transcription resulted in down-regulation of p21(Cip1), which was caused by both transcriptional suppression and protein degradation, despite eliciting p53 accumulation, allowing the cells to progress into S phase and then to undergo apoptosis. This cell death did not require the transcription of p53 target genes and was preceded by translocation of the accumulated p53 to mitochondria. Our data thus suggested that blockade of pol II-mediated transcription induced p53 accumulation in mitochondria and was the critical factor for eliciting p53-dependent but transcription-independent apoptosis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan	Kumamoto University; Okayama University; National Cancer Center - Japan; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013; Arima, Yoshimi/J-8057-2013	Arima, Yoshimi/0000-0002-2384-1406				Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Attardi LD, 2000, GENE DEV, V14, P704; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gottifredi V, 2000, COLD SPRING HARB SYM, V65, P483, DOI 10.1101/sqb.2000.65.483; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khan QA, 2002, MOL CARCINOGEN, V33, P1, DOI 10.1002/mc.10013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	56	129	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19166	19176		10.1074/jbc.M410691200	http://dx.doi.org/10.1074/jbc.M410691200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753095	hybrid			2022-12-27	WOS:000228932300073
J	Mishra, SK; Keyel, PA; Edeling, MA; Dupin, AL; Owen, DJ; Traub, LM				Mishra, SK; Keyel, PA; Edeling, MA; Dupin, AL; Owen, DJ; Traub, LM			Functional dissection of an AP-2 beta 2 appendage-binding sequence within the autosomal recessive hypercholesterolemia protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; DENSITY-LIPOPROTEIN RECEPTOR; COATED PITS; TERMINAL DOMAIN; ACCESSORY PROTEINS; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; SORTING SIGNALS; ALPHA-APPENDAGE; ADAPTER PROTEIN	The autosomal recessive hypercholesterolemia (ARH) protein plays a critical role in regulating plasma low density lipoprotein (LDL) levels. Inherited defects in ARH lead to a hypercholesterolemia that closely phenocopies that caused by a defective LDL receptor. The elevated serum LDL-cholesterol levels typical of ARH patients and the pronounced accumulation of the LDL receptor at the cell surface of hepatocytes in ARH-null mice argue that ARH operates by promoting the internalization of the LDL receptor within clathrin-coated vesicles. ARH contains an amino-terminal phosphotyrosine-binding domain that associates physically with the LDL receptor internalization sequence and with phosphoinositides. The carboxyl-terminal half of ARH contains a clathrin-binding sequence and a separate AP-2 adaptor binding region providing a plausible mechanism for how ARH can act as an endocytic adaptor or CLASP (clathrin-associated sorting protein) to couple LDL receptors with the clathrin machinery. Because the interaction with AP-2 is highly selective for the independently folded appendage domain of the beta 2 subunit, we have characterized the ARH beta 2 appendage-binding sequence in detail. Unlike the known alpha appendage-binding motifs, ARH requires an extensive sequence tract to bind the beta appendage with comparably high affinity. A minimal 16-residue sequence functions autonomously and depends upon ARH residues Asp(253), Phe(259), Leu(262), and Arg(266). We suggested that biased beta subunit engagement by ARH and the only other beta 2 appendage selective adaptor, beta-arrestin, promotes efficient incorporation of this mechanistically distinct subset of CLASPs into clathrin-coated buds.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Cambridge	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325 BST, Pittsburgh, PA 15261 USA.	traub@pitt.edu	Mishra, Santosh/S-7516-2017	Mishra, Santosh/0000-0001-8616-2606; Traub, Linton/0000-0002-1303-0298	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK053249] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK53249, 5T32 DK061296-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jha A, 2004, J BIOL CHEM, V279, P2281, DOI 10.1074/jbc.M305644200; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Miele AE, 2004, NAT STRUCT MOL BIOL, V11, P242, DOI 10.1038/nsmb736; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2004, J BIOL CHEM, V279, P46191, DOI 10.1074/jbc.M408095200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Owen DJ, 2004, BIOCHEM SOC T, V32, P1, DOI 10.1042/BST0320001; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ricotta D, 2002, J CELL BIOL, V156, P791, DOI 10.1083/jcb.200111068; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Santini F, 2000, J CELL SCI, V113, P2463; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Soutar AK, 2003, ARTERIOSCL THROM VAS, V23, P1963, DOI 10.1161/01.ATV.0000094410.66558.9A; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tulipano G, 2004, J BIOL CHEM, V279, P21374, DOI 10.1074/jbc.M313522200; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhou Y, 2003, J BIOL CHEM, V278, P44584, DOI 10.1074/jbc.M308870200	57	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19270	19280		10.1074/jbc.M501029200	http://dx.doi.org/10.1074/jbc.M501029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728179	hybrid			2022-12-27	WOS:000228932300084
J	Espeseth, AS; Xu, M; Huang, Q; Coburn, CA; Jones, KLG; Ferrer, M; Zuck, PD; Strulovic, B; Price, EA; Wu, GX; Wolfe, AL; Lineberger, JE; Sardana, M; Tugusheva, K; Pietrak, BL; Crouthamel, MC; Lai, MT; Dodson, EC; Bazzo, R; Shi, XP; Simon, AJ; Li, YM; Hazuda, DJ				Espeseth, AS; Xu, M; Huang, Q; Coburn, CA; Jones, KLG; Ferrer, M; Zuck, PD; Strulovic, B; Price, EA; Wu, GX; Wolfe, AL; Lineberger, JE; Sardana, M; Tugusheva, K; Pietrak, BL; Crouthamel, MC; Lai, MT; Dodson, EC; Bazzo, R; Shi, XP; Simon, AJ; Li, YM; Hazuda, DJ			Compounds that bind APP and inhibit A beta processing in vitro suggest a novel approach to Alzheimer disease therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; STRUCTURE-BASED DESIGN; BACE INHIBITORS; CELL-SURFACE; PEPTIDOMIMETIC INHIBITORS; NOTCH; SITE; PEPTIDE	Extracellular deposits of aggregated amyloid-beta (A beta) peptides are a hallmark of Alzheimer disease; thus, inhibition of A beta production and/or aggregation is an appealing strategy to thwart the onset and progression of this disease. The release of A beta requires processing of the amyloid precursor protein (APP) by both beta- and gamma-secretase. Using an assay that incorporates full-length recombinant APP as a substrate for beta-secretase ( BACE), we have identified a series of compounds that inhibit APP processing, but do not affect the cleavage of peptide substrates by BACE1. These molecules also inhibit the processing of APP and A beta by BACE2 and selectively inhibit the production of A beta(42) species by gamma-secretase in assays using CTF99. The compounds bind directly to APP, likely within the A beta domain, and therefore, unlike previously described inhibitors of the secretase enzymes, their mechanism of action is mediated through APP. These studies demonstrate that APP binding agents can affect its processing through multiple pathways, providing proof of concept for novel strategies aimed at selectively modulating A beta production.	Merck Res Labs, Virus & Cell Biol, Dept Biol Chem, West Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA; Merck Res Labs, Dept Automated Biotechnol, West Point, PA 19486 USA; Inst Ric Biol Mol, Dept Pharmacol, I-00040 Rome, Italy	Merck & Company; Merck & Company; Merck & Company	Hazuda, DJ (corresponding author), Merck Res Labs, Virus & Cell Biol, Dept Biol Chem, POB 4, West Point, PA 19486 USA.	daria_hazuda@merck.com						Agdeppa ED, 2003, NEUROSCIENCE, V117, P723, DOI 10.1016/S0306-4522(02)00907-7; Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Brady SF, 2004, BIOORG MED CHEM LETT, V14, P601, DOI 10.1016/j.bmcl.2003.11.061; Chen SH, 2004, BIOORG MED CHEM LETT, V14, P245, DOI 10.1016/j.bmcl.2003.09.085; Churcher I, 2003, J MED CHEM, V46, P2275, DOI 10.1021/jm034058a; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Coburn CA, 2004, J MED CHEM, V47, P6117, DOI 10.1021/jm049388p; DE SB, 1999, NATURE, V398, P518; Dingwall C, 2001, J CLIN INVEST, V108, P1243, DOI 10.1172/JCI200114402; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Hom RK, 2004, J MED CHEM, V47, P158, DOI 10.1021/jm0304008; Hom RK, 2003, J MED CHEM, V46, P1799, DOI 10.1021/jm025619l; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Hu JD, 2003, BIOORG MED CHEM LETT, V13, P4335, DOI 10.1016/j.bmcl.2003.09.037; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lamar J, 2004, BIOORG MED CHEM LETT, V14, P239, DOI 10.1016/j.bmcl.2003.09.084; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Ono M, 2002, NUCL MED BIOL, V29, P633, DOI 10.1016/S0969-8051(02)00326-8; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2003, J BIOL CHEM, V278, P21286, DOI 10.1074/jbc.M209859200; Shi XP, 2002, NEUROBIOL AGING, V23, pS180; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; SHI XP, 2005, JAD, V7, P2; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tung JS, 2002, J MED CHEM, V45, P259, DOI 10.1021/jm0155695; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Xu M, 2002, NEUROBIOL AGING, V23, P1023, DOI 10.1016/S0197-4580(02)00126-4; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	53	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17792	17797		10.1074/jbc.M414331200	http://dx.doi.org/10.1074/jbc.M414331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15737955	hybrid			2022-12-27	WOS:000228807200030
J	Josefsson, EC; Gebhard, HH; Stossel, TP; Hartwig, JH; Hoffmeister, KM				Josefsson, EC; Gebhard, HH; Stossel, TP; Hartwig, JH; Hoffmeister, KM			The macrophage alpha(M)beta(2) integrin alpha(M) lectin domain mediates the phagocytosis of chilled platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; BETA-GLUCAN; MAC-1 CD11B/CD18; BINDING-SITE; SPECIFICITY	alpha(M)beta(2) integrin receptors on myeloid cells mediate the adhesion or uptake of diverse ligands. Ligand binding occurs in the alpha(M) chain, which is composed of an I domain and a lectin domain. The alpha(M) I domain binds iC3b, fibrinogen, intercellular adhesion molecule-1, and other ligands and mediates the adhesion of neutrophils to platelet glycoprotein Ib alpha (GPIb alpha). alpha(M)beta(2) also recognizes beta-GlcNAc residues on GPIb alpha that are clustered on platelets after cooling. The phagocytosis of chilled platelets could be reconstituted when Chinese hamster ovary cells were transfected with alpha(M)beta(2). Replacement of the I domain or the lectin domain of the alpha(M) chain with the corresponding domain from the alpha(X) chain (p150) revealed that the activity of the alpha(M)beta(2) integrin toward chilled platelets resides within the lectin domain and does not require the I domain. Additional evidences for this conclusion are: 1) Sf9 cells expressing solely the alpha(M) lectin domain bound chilled platelets, and 2) soluble recombinant alpha(M) lectin domain inhibited the phagocytosis of chilled platelets by alpha(M)beta(2)-expressing THP-1 cells, whereas I domain substrates showed no inhibitory effect. Therefore chilled platelets are removed from blood by an interaction between beta-GlcNAc residues on clustered GPIb alpha and the lectin domain of alpha(M) chain of the alpha(M)beta(2) integrin, distinguishing this interaction from those mediated by the alpha(M) I domain.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Gothenburg Univ, Dept Rheumat & Inflammat Res, S-41346 Gothenburg, Sweden	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Gothenburg	Hoffmeister, KM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, 75 Francis St,CHRB 6th Floor, Boston, MA 02115 USA.	khoffmeister@rics.bwh.harvard.edu	Josefsson, Emma/CAF-4970-2022	Josefsson, Emma/0000-0001-6478-5204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; CAIN JA, 1987, COMPLEMENT INFLAMMAT, V4, P75, DOI 10.1159/000463011; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Ehlers R, 2003, J EXP MED, V198, P1077, DOI 10.1084/jem.20022181; Falet H, 2000, BLOOD, V96, P3786, DOI 10.1182/blood.V96.12.3786.h8003786_3786_3792; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hoffmeister KM, 2003, SCIENCE, V301, P1531, DOI 10.1126/science.1085322; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; MCCULLOUGH J, 2003, TRANSFUSION MED BLOO, P2011; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; *NAT STROK ASS, 2003, COMPL GUID STROK, P3; PETTY HR, 1993, J LEUKOCYTE BIOL, V54, P492, DOI 10.1002/jlb.54.5.492; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sugimori T, 1997, KIDNEY INT, V51, P1454, DOI 10.1038/ki.1997.199; Sutterwala FS, 1996, J LEUKOCYTE BIOL, V59, P883, DOI 10.1002/jlb.59.6.883; Thornton BP, 1996, J IMMUNOL, V156, P1235; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; Xia Y, 1999, J IMMUNOL, V162, P7285; Xia Y, 2000, CONT IMMUN, V9, P171	29	75	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18025	18032		10.1074/jbc.M501178200	http://dx.doi.org/10.1074/jbc.M501178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741160	hybrid			2022-12-27	WOS:000228807200058
J	Sellak, H; Choi, CS; Browner, N; Lincoln, TM				Sellak, H; Choi, CS; Browner, N; Lincoln, TM			Upstream stimulatory factors (USF-1/USF-2) regulate human cGMP-dependent protein kinase I gene expression in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; TRANSCRIPTION FACTOR USF; CYCLIC-GMP; PROMOTER ELEMENTS; NITRIC-OXIDE; TATA BOX; ALPHA; IDENTIFICATION; OSTEOPONTIN; CLONING	Cyclic GMP-dependent protein kinase I plays a pivotal role in regulating smooth muscle cell relaxation, growth, and differentiation. Expression of the enzyme varies greatly in smooth muscle and in other tissues and cell types, yet little is known regarding the mechanisms regulating cGMP-dependent protein kinase gene expression. The present work was undertaken to characterize the mechanisms controlling kinase gene expression in vascular smooth muscle cells. A 2-kb human cGMP-dependent protein kinase I 5'-noncoding promoter sequence was characterized by serial deletion, and functional studies demonstrated that a 591-bp 5'-promoter construct possessed the highest activity compared with all other constructs generated from the larger promoter. Analysis of the sequence between - 472 and - 591 bp from the transcriptional start site revealed the existence of two E-like boxes known to bind upstream stimulatory factors. Electrophoretic mobility shift assays and functional studies using luciferase reporter gene assays identified upstream stimulatory factors as the transcription factors bound to the E-boxes in the 591-bp promoter. Site-directed mutagenesis of the E-boxes abolished the binding of upstream stimulatory factor proteins and decreased the activity of the cGMP-dependent protein kinase I 591-bp promoter, thus confirming the involvement of these transcription factors in mediating gene expression. Cotransfection experiments demonstrated that overexpression of upstream stimulatory factors 1 and 2 increased cGMP-dependent protein kinase I promoter activity. Collectively, these data suggest that the human proximal cGMP-dependent protein kinase I promoter is regulated by tandem E-boxes that bind upstream stimulatory factors.	Univ S Alabama, Coll Med, Dept Physiol, Mobile, AL 36688 USA	University of South Alabama	Lincoln, TM (corresponding author), Univ S Alabama, Coll Med, Dept Physiol, Med Sci Bldg,Rm 3024, Mobile, AL 36688 USA.	tlincoln@usouthal.edu						Anderson PG, 2000, ARTERIOSCL THROM VAS, V20, P2192, DOI 10.1161/01.ATV.20.10.2192; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Browner NC, 2004, J BIOL CHEM, V279, P46631, DOI 10.1074/jbc.M408518200; Browner NC, 2004, AM J PHYSIOL-CELL PH, V287, pC88, DOI 10.1152/ajpcell.00039.2004; CHEN AS, 1990, MOL CELL BIOL, V10, P3314, DOI 10.1128/MCB.10.7.3314; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dey NB, 1998, CIRC RES, V82, P139; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gao YS, 2004, AM J PHYSIOL-LUNG C, V286, pL786, DOI 10.1152/ajplung.00314.2003; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; Hofmann F, 2000, J CELL SCI, V113, P1671; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Li N, 1998, J BIOL CHEM, V273, P28170, DOI 10.1074/jbc.273.43.28170; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; Manabe I, 2001, J BIOL CHEM, V276, P39076, DOI 10.1074/jbc.M105402200; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898; Sinnaeve P, 2002, CIRCULATION, V105, P2911, DOI 10.1161/01.CIR.0000018169.59205.CA; SINNEAVE P, 2003, CIRC RES, V93, P907; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; STEWART DJ, 1994, AM J PHYSIOL, V266, pH944, DOI 10.1152/ajpheart.1994.266.3.H944; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; UHLER MD, 1993, J BIOL CHEM, V268, P13586; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008	42	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18425	18433		10.1074/jbc.M500775200	http://dx.doi.org/10.1074/jbc.M500775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741164	hybrid			2022-12-27	WOS:000228807200105
J	Subramanian, P; Stahelin, RV; Szulc, Z; Bielawska, A; Cho, W; Chalfant, CE				Subramanian, P; Stahelin, RV; Szulc, Z; Bielawska, A; Cho, W; Chalfant, CE			Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A(2)alpha and enhances the interaction of the enzyme with phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MIXED MICELLES; KINETIC-ANALYSIS; LOXOSCELES-RECLUSA; CATALYTIC DOMAIN; MEMBRANE-BINDING; CELL-LINE; A(2)	Previous findings from our laboratory have demonstrated that cPLA(2)alpha is directly activated by the emerging bioactive sphingolipid, ceramide 1-phosphate (C-1-P) (1). In this study, a Triton X-100/phosphatidylcholine (PC) mixed micelle assay was utilized to determine the kinetics and specificity of this lipid-enzyme interaction. Using this assay, the addition of C-1-P induced a dramatic increase in the activity of cPLA(2)alpha (>15-fold) with a K-a of 2.4 mol % C-1-P/Triton X-100 micelle. This activation was highly specific as the addition of other lipids had insignificant effects on cPLA(2)alpha activity. Studies using surface-dilution kinetics revealed that C-1-P had no effect on the Michaelis-Menten constant, K-m(B), but decreased the dissociation constant (K-s(A)) value by 87%. Thus, C-1-P not only increases the membrane affinity of cPLA(2)alpha but also may act as an allosteric activator of the enzyme. Surface plasmon resonance analysis of the C-1-P/cPLA(2)alpha interaction verified a decrease in the dissociation constant, demonstrating that cPLA(2)alpha bound PC vesicles containing C-1-P with increased affinity (5-fold) compared with PC vesicles alone. The effect on the dissociation rate of cPLA(2)alpha was also found to be lipid-specific with the exception of phosphatidylinositol 4,5-bisphosphate, which caused a modest increase in vesicle affinity (2-fold). Lastly, the binding site for C-1-P was determined to be within the C2-domain of cPLA(2)alpha, unlike phosphatidylinositol 4,5-bisphosphate. These data demonstrate a novel interaction site for C-1-P and suggest that C-1-P may function to recruit cPLA(2)alpha to intracellular membranes as well as allosterically activate the membrane-associated enzyme.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University of South Carolina; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,Rm 2-016,Sanger Hall,110, Richmond, VA 23298 USA.	cechalfant@vcu.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863; , Preeti/0000-0002-6062-6158	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM068849, R01GM053987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL072925] Funding Source: Medline; NIGMS NIH HHS [GM53987, GM68849, GM52598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold R E, 1976, JACEP, V5, P262, DOI 10.1016/S0361-1124(76)80005-6; Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; BYUN HS, 1994, J ORG CHEM, V59, P6495, DOI 10.1021/jo00100a069; CARBONARO PA, 1995, CUTIS, V56, P256; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Carre A, 2004, BIOCHEM BIOPH RES CO, V324, P1215, DOI 10.1016/j.bbrc.2004.09.181; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; REES RS, 1988, TOXICON, V26, P1035, DOI 10.1016/0041-0101(88)90202-4; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; ROBSON RJ, 1979, BIOCHIM BIOPHYS ACTA, V573, P489, DOI 10.1016/0005-2760(79)90223-6; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079	43	98	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17601	17607		10.1074/jbc.M414173200	http://dx.doi.org/10.1074/jbc.M414173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743759	hybrid			2022-12-27	WOS:000228807200006
J	Yu, CD; Wang, F; Jin, CL; Huang, XQ; McKeehan, WL				Yu, CD; Wang, F; Jin, CL; Huang, XQ; McKeehan, WL			Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; NEGATIVE FEEDBACK-REGULATION; 7 ALPHA-HYDROXYLASE; HEPARAN-SULFATE; TYROSINE KINASE; METABOLIC-RATE; MICE LACKING; CYP7A1 GENE; CHOLESTEROL; RECEPTOR	The fibroblast growth factor (FGF) receptor complex is a regulator of adult organ homeostasis in addition to its central role in embryonic development and wound healing. FGF receptor 4 (FGFR4) is the sole FGFR receptor kinase that is significantly expressed in mature hepatocytes. Previously, we showed that mice lacking mouse FGFR4 (mR4(-/-)) exhibited elevated fecal bile acids, bile acid pool size, and expression of liver cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme for canonical neutral bile acid synthesis. To prove that hepatocyte FGFR4 was a negative regulator of cholesterol metabolism and bile acid synthesis independent of background, we generated transgenic mice overexpressing a constitutively active human FGFR4 (CahR4) in hepatocytes and crossed them with the FGFR4-deficient mice to generate CahR4/mR4(-/-) mice. In mice expressing active FGFR4 in liver, fecal bile acid excretion was 64%, bile acid pool size was 47%, and Cyp7a1 expression was 10-30% of wild-type mice. The repressed level of Cyp7a1 expression was resistant to induction by a high cholesterol diet relative to wild-type mice. Expression of CahR4 in mR4(-/-) mouse livers depressed bile acid synthesis below wild-type levels from the elevated levels observed in mR4(-/-). Levels of phosphorylated c-Jun N-terminal kinase (JNK), which is part of a pathway implicated in bile acid-mediated repression of synthesis, was 30% of wild-type levels in mR4(-/-) livers, whereas CahR4 livers exhibited an average 2-fold increase. However, cholate still strongly induced phospho-JNK in mR4(-/-) livers. These results confirm that hepatocyte FGFR4 regulates bile acid synthesis by repression of Cyp7a1 expression. Hepatocyte FGFR4 may contribute to the repression of bile acid synthesis through JNK signaling but is not required for activation of JNK signaling by bile acids.	Texas A&M Univ, Ctr Canc Biol & Nutr, Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; University of Texas System	McKeehan, WL (corresponding author), Texas A&M Univ, Ctr Canc Biol & Nutr, Inst Biosci & Technol, Syst Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	wmckeeha@ibt.tamu.edu	Yu, C/G-4626-2010		NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bange J, 2002, CANCER RES, V62, P840; Chen JY, 2002, J BIOL CHEM, V277, P42588, DOI 10.1074/jbc.M205117200; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Fu L, 2004, ENDOCRINOLOGY, V145, P2594, DOI 10.1210/en.2003-1671; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; Jin CL, 2003, CANCER RES, V63, P8784; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; Katoh M, 2003, INT J MOL MED, V12, P45; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miyake JH, 2002, ARTERIOSCL THROM VAS, V22, P121, DOI 10.1161/hq0102.102588; Naski M C, 1998, Front Biosci, V3, pd781; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Ornitz DM, 2001, GENOME BIOL, V2; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 2001, J LIPID RES, V42, P1594; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Thorgeirsson SS, 1996, BRIT J CLIN PHARMACO, V42, P43, DOI 10.1046/j.1365-2125.1996.03748.x; Tiemann M, 2004, P NATL ACAD SCI USA, V101, P1846, DOI 10.1073/pnas.0308426100; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; WANG F, 2002, HDB CELL SIGNALING, V1, P265; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weinstein M, 1998, DEVELOPMENT, V125, P3615; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Wright TJ, 2004, DEV BIOL, V269, P264, DOI 10.1016/j.ydbio.2004.02.003; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yu CD, 2002, AM J PATHOL, V161, P2003, DOI 10.1016/S0002-9440(10)64478-1; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zakim D, 1996, HEPATOLOGY TXB LIVER	47	80	84	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17707	17714		10.1074/jbc.M411771200	http://dx.doi.org/10.1074/jbc.M411771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15750181	hybrid			2022-12-27	WOS:000228807200020
J	Zhan, YG; Tremblay, MR; Melian, N; Carbonetto, S				Zhan, YG; Tremblay, MR; Melian, N; Carbonetto, S			Evidence that dystroglycan is associated with dynamin and regulates endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; GROWTH-FACTOR-RECEPTOR; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; DIFFERENTIAL DISTRIBUTION; MEDIATED ENDOCYTOSIS; MUSCULAR-DYSTROPHY; BINDING-PROTEIN; DOMAIN; NERVE	Disruption of the dystroglycan gene in humans and mice leads to muscular dystrophies and nervous system defects including malformation of the brain and defective synaptic transmission. To identify proteins that interact with dystroglycan in the brain we have used immunoaffinity purification followed by mass spectrometry (LC/MS-MS) and found that the GTPase dynamin 1 is a novel dystroglycan-associated protein. The beta-dystroglycandynamin 1 complex also included alpha-dystroglycan and Grb2. Overlay assays indicated that dynamin interacts directly with dystroglycan, and immunodepletion showed that only a pool of dynamin is associated with dystroglycan. Dystroglycan was associated and colocalized immunohistochemically with dynamin 1 in the central nervous system in the outer plexiform layer of retina where photoreceptor terminals are found. Endocytosis in neurons is both constitutive, as in non-neural cells, and regulated by neural activity. To assess the function of dystroglycan in the former, we have assayed transferrin uptake in fibroblastic cells differentiated from embryonic stem cells null for both dystroglycan alleles. In wild-type cells, dystroglycan formed a complex with dynamin and codistributed with cortactin at membrane ruffles, which are organelles implicated in endocytosis. Dystroglycan-null cells had a significantly greater transferrin uptake, a process well known to require dynamin. Expression of dystroglycan in null cells by infection with an adenovirus containing dystroglycan reduced transferrin uptake to levels seen in wildtype embryonic stem cells. These data suggest that dystroglycan regulates endocytosis possibly as a result of its interaction with dynamin.	McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Biol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	sal.carbonetto@mcgill.ca						Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Blank M, 2002, NEUROSCIENCE, V111, P259, DOI 10.1016/S0306-4522(02)00032-5; Blank M, 1999, EUR J NEUROSCI, V11, P2121, DOI 10.1046/j.1460-9568.1999.00636.x; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Brunig I, 2002, J NEUROSCI, V22, P4805, DOI 10.1523/JNEUROSCI.22-12-04805.2002; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chen YJ, 2003, BIOCHEM J, V375, P329, DOI 10.1042/BJ20030808; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Dalloz C, 2001, MOL CELL NEUROSCI, V17, P908, DOI 10.1006/mcne.2001.0978; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Estes PS, 1996, J NEUROSCI, V16, P5443; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gingras J, 2001, J NEUROBIOL, V48, P228, DOI 10.1002/neu.1053; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Koulen P, 1998, J NEUROSCI RES, V51, P735, DOI 10.1002/(SICI)1097-4547(19980315)51:6<735::AID-JNR7>3.0.CO;2-C; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Leschziner A, 2000, J NEUROCHEM, V74, P70, DOI 10.1046/j.1471-4159.2000.0740070.x; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; MONTANARO F, 1995, J NEUROSCI RES, V42, P528, DOI 10.1002/jnr.490420411; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Moukhles H, 2001, J NEUROCHEM, V78, P824, DOI 10.1046/j.1471-4159.2001.00466.x; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Spence HJ, 2004, HUM MOL GENET, V13, P1657, DOI 10.1093/hmg/ddh170; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Tian M, 1996, EUR J NEUROSCI, V8, P2739, DOI 10.1111/j.1460-9568.1996.tb01568.x; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yamazaki T, 2002, J CELL SCI, V115, P1791; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	87	25	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18015	18024		10.1074/jbc.M409682200	http://dx.doi.org/10.1074/jbc.M409682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728588	hybrid			2022-12-27	WOS:000228807200057
J	Cipriani, G; Rapizzi, E; Vannacci, A; Rizzuto, R; Moroni, F; Chiarugi, A				Cipriani, G; Rapizzi, E; Vannacci, A; Rizzuto, R; Moroni, F; Chiarugi, A			Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; NECROTIC CELL-DEATH; DNA-DAMAGE; IN-VITRO; PERMEABILITY TRANSITION; CEREBRAL-ISCHEMIA; NAD(+) DEPLETION; ADP-RIBOSE; INHIBITORS; PARP	To obtain further information on time course and mechanisms of cell death after poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, we used HeLa cells exposed for 1 h to the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine. This treatment activated PARP-1 and caused a rapid drop of cellular NAD(H) and ATP contents, culminating 8-12 h later in cell death. PARP-1 antagonists fully prevented nucleotide depletion and death. Interestingly, in the early 60 min after challenge with N-methyl-N'-nitro-N-nitrosoguanidine, mitochondrial membrane potential and superoxide production significantly increased, whereas cellular ADP contents decreased. Again, these events were prevented by PARP-1 inhibitors, suggesting that PARP-1 hyperactivity leads to mitochondrial state 4 respiration. Mitochondrial membrane potential collapsed at later time points ( 3 h), when mitochondria released apoptosis-inducing factor and cytochrome c. Using immunocytochemistry and targeted luciferase transfection, we found that, despite an exclusive localization of PARP-1 and poly(ADP-ribose) in the nucleus, ATP levels first decreased in mitochondria and then in the cytoplasm of cells undergoing PARP-1 activation. PARP-1 inhibitors rescued ATP ( but not NAD( H) levels) in cells undergoing hyper-poly(ADP-ribosyl)ation. Glycolysis played a central role in the energy recovery, whereas mitochondria consumed ATP in the early recovery phase and produced ATP in the late phase after PARP-1 inhibition, further indicating that nuclear poly(ADP-ribosyl) ation rapidly modulates mitochondrial functioning. Together, our data provide evidence for rapid nucleus-mitochondria cross-talk during hyper-poly(ADP-ribosyl)ation-dependent cell death.	Univ Florence, Dept Pharmacol, I-50139 Florence, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	University of Florence; University of Ferrara	Chiarugi, A (corresponding author), Univ Florence, Dept Pharmacol, Viale Pieraccini 6, I-50139 Florence, Italy.	alberto.chiarugi@unifi.it	Rizzuto, Rosario/B-6312-2008; Vannacci, Alfredo/A-1708-2008	Vannacci, Alfredo/0000-0001-5259-2026; Rizzuto, Rosario/0000-0001-7044-5097				Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chance B, 2004, METHOD ENZYMOL, V385, P361; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2003, J PHARMACOL EXP THER, V305, P943, DOI 10.1124/jpet.103.048934; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Donzelli M, 1997, HISTOCHEM J, V29, P831, DOI 10.1023/A:1026485622824; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Dumitriu IE, 2004, CELL DEATH DIFFER, V11, P314, DOI 10.1038/sj.cdd.4401348; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HERCEG Z, 2001, BIOCHEM J, V477, P97; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KAUFMANN SH, 1991, EXP CELL RES, V192, P524, DOI 10.1016/0014-4827(91)90072-3; Kawamoto Y, 1998, ANAL BIOCHEM, V262, P33, DOI 10.1006/abio.1998.2729; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Magni G, 2004, CELL MOL LIFE SCI, V61, P19, DOI 10.1007/s00018-003-3161-1; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls D., 2002, BIOENERGETICS, V3; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; O'Reilly CM, 2004, AM J PHYSIOL-CELL PH, V286, pC1139, DOI 10.1152/ajpcell.00371.2003; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	52	129	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17227	17234		10.1074/jbc.M414526200	http://dx.doi.org/10.1074/jbc.M414526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15750180	hybrid			2022-12-27	WOS:000228615500085
J	Qiao, B; Padilla, SR; Benya, PD				Qiao, B; Padilla, SR; Benya, PD			Transforming growth factor (TGF)-beta-activated kinase 1 mimics and mediates TGF-beta-induced stimulation of type II collagen synthesis in chondrocytes independent of Col2a1 transcription and Smad3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; N-TERMINAL KINASE; KAPPA-B PATHWAY; ARTICULAR CHONDROCYTES; GENE-EXPRESSION; IN-VITRO; HYPERTROPHIC DIFFERENTIATION; REGULATORY SEQUENCES; TRANSDUCTION PATHWAY; CARTILAGE FORMATION	Transforming growth factor (TGF)-beta, bone morphogenetic protein (BMP), and interleukin-1 beta activate TGF-beta-activated kinase 1 (TAK1), which lies upstream of the p38 MAPK, JNK, and NF-kappa B pathways. Our knowledge remains incomplete of TAK1 target genes, requirement for cooperative signaling, and capacity for shared or segregated ligand-dependent responses. We show that adenoviral overexpression of TAK1a in articular chondrocytes stimulated type II collagen protein synthesis 3 - 6-fold and mimicked the response to TGF-beta 1 and BMP2. Both factors activated endogenous TAK1 and its activating protein, TAB1, and the collagen response was inhibited by dominant-negative TAK1a. Isoform-specific antibodies to TGF-beta blocked the response to endogenous and exogenous TGF-beta but not the response to TAK1a. Expression of Smad3 did not stimulate type II collagen synthesis or enhance that caused by TGF-beta 1 or TAK1a, in contrast to its effects on its endogenous targets, CTGF and plasminogen-activated inhibitor-1. TAK1a, overexpressed alone and immunoprecipitated, phosphorylated MKK6 and stimulated the plasminogen-activated inhibitor-1 promoter following transient transfection; both effects were enhanced by TAB1 coexpression, but type II collagen synthesis was not. Stimulation by TAK1a or TGF-beta did not require increased Col2a1 mRNA, and TAK1 actually reduced Col2a1 mRNA in parallel with the cartilage markers, SRY-type HMG box 9 (Sox9) and aggrecan. Thus, TAK1 increased target gene expression ( Col2a1) by translational or posttranslational mechanisms as a Smad3-independent response shared by TGF-beta 1 and BMP2.	Univ Calif Los Angeles, David Geffen Sch Med UCLA, UCLA Orthopaed Hosp, Dept Orthopaed Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Orthoped Hosp, J Vernon Luck Sr MD Res Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Benya, PD (corresponding author), Orthoped Hosp, 2400 S Flower St, Los Angeles, CA 90007 USA.	pbenya@LAOH.ucla.edu	Benya, Paul/I-3449-2015	Benya, Paul/0000-0002-1060-7127	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042894] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR42894] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvarez J, 2002, DEVELOPMENT, V129, P1913; BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BENYA PD, 1981, COLLAGEN REL RES, V1, P17; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRADHAM DM, 1994, J CELL PHYSIOL, V158, P61, DOI 10.1002/jcp.1041580109; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHANG SC, 1994, J BIOL CHEM, V269, P28227; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chimal-Monroy J, 1999, INT J DEV BIOL, V43, P59; ChimalMonroy J, 1997, INT J DEV BIOL, V41, P91; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Metsaranta M, 1996, MATRIX BIOL, V15, P39, DOI 10.1016/S0945-053X(96)90125-0; Miura Y, 2002, J BONE JOINT SURG AM, V84A, P793, DOI 10.2106/00004623-200205000-00015; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moustakas A, 2001, J CELL SCI, V114, P4359; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nyberg-Hoffman C, 1999, NAT MED, V5, P955, DOI 10.1038/11400; Ohnishi H, 2004, J BIOL CHEM, V279, P8873, DOI 10.1074/jbc.M309698200; Pateder DB, 2001, J CELL PHYSIOL, V188, P343, DOI 10.1002/jcp.1118; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; ROSEN V, 1994, J BONE MINER RES, V9, P1759; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Scharstuhl A, 2002, J IMMUNOL, V169, P507, DOI 10.4049/jimmunol.169.1.507; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Settle SH, 2003, DEV BIOL, V254, P116, DOI 10.1016/S0012-1606(02)00022-2; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Shuler FD, 2000, J ORTHOPAED RES, V18, P585, DOI 10.1002/jor.1100180411; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Sonenberg N, 2000, TRANSLATIONAL CONTRO; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200; Yi SE, 2000, DEVELOPMENT, V127, P621; Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	80	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17562	17571		10.1074/jbc.M500646200	http://dx.doi.org/10.1074/jbc.M500646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743758	hybrid			2022-12-27	WOS:000228615500125
J	Torrents, E; Poplawski, A; Sjoberg, BM				Torrents, E; Poplawski, A; Sjoberg, BM			Two proteins mediate class II ribonucleotide reductase activity in pseudomonas aeruginosa - Expression and transcriptional analysis of the aerobic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VITAMIN-B-12 METABOLISM; SEQUENCE; STREPTOMYCES; SPECIFICITY; PROKARYOTES; STRATEGIES; EVOLUTION; BACTERIA; GENES	The opportunistic human pathogen Pseudomonas aeruginosa is one of a few microorganisms that code for three different classes ( I, II, and III) of the enzyme ribonucleotide reductase (RNR). Class II RNR of P. aeruginosa differs from all hitherto known class II enzymes by being encoded by two consecutive open reading frames denoted nrdJa and nrdJb and separated by 16 bp. Split nrdJ genes were also found in the few other gamma-proteobacteria that code for a class II RNR. Interestingly, the two genes encoding the split nrdJ in P. aeruginosa were co-transcribed, and both proteins were expressed. Exponentially growing aerobic cultures were predominantly expressing the class I RNR ( encoded by the nrdAB operon) compared with the class II RNR ( encoded by the nrdJab operon). Upon entry to stationary phase, the relative amount of nrdJa transcript increased about 6 - 7-fold concomitant with a 6-fold decrease in the relative amount of nrdA transcript. Hydroxyurea treatment known to knock out the activity of class I RNR caused strict growth inhibition of P. aeruginosa unless 5'-deoxyadenosylcobalamin, a cofactor specifically required for activity of class II RNRs, was added to the rich medium. Rescue of the hydroxyurea-treated cells in the presence of the vitamin B-12 cofactor strongly implies that P. aeruginosa produces a functionally active NrdJ protein. Biochemical studies showed for the first time that presence of both NrdJa and NrdJb subunits were absolutely essential for enzyme activity. Based on combined genetic and biochemical results, we suggest that the two-component class II RNR in P. aeruginosa is primarily used for DNA repair and/or possibly DNA replication at low oxygen tension.	Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Arrhenius Labs Nat Sci, Svante Arrhenius Vag 16-18 F3, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008	Torrents, Eduard/0000-0002-3010-1609; Sjoberg, Britt-Marie/0000-0001-5953-3360				*APPL BIOS, 1997, US B APPL BIOS, V2, P1; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Borovok I, 2004, MOL MICROBIOL, V54, P1022, DOI 10.1111/j.1365-2958.2004.04325.x; Borovok I, 2002, MICROBIOL-SGM, V148, P391, DOI 10.1099/00221287-148-2-391; de Lorenzo V, 2000, Environ Microbiol, V2, P349; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; GALE GR, 1964, CANCER RES, V24, P1012; Jacobson BA, 1998, MOL MICROBIOL, V28, P1307, DOI 10.1046/j.1365-2958.1998.00896.x; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kasai S, 2002, EUR J BIOCHEM, V269, P5851, DOI 10.1046/j.1432-1033.2002.03304.x; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Larsson K, 2004, THESIS STOCKHOLM U S; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Mayhew C N, 2002, Antivir Chem Chemother, V13, P305; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rodionov DA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r90; Rodionov DA, 2003, J BIOL CHEM, V278, P41148, DOI 10.1074/jbc.M305837200; Sabra W, 2002, MICROBIOL-SGM, V148, P3195, DOI 10.1099/00221287-148-10-3195; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savli H, 2003, J MED MICROBIOL, V52, P403, DOI 10.1099/jmm.0.05132-0; SHINE J, 1975, EUR J BIOCHEM, V57, P221, DOI 10.1111/j.1432-1033.1975.tb02294.x; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; SITJES J, 1992, MUTAGENESIS, V7, P47, DOI 10.1093/mutage/7.1.47; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Thelander L, 1978, Methods Enzymol, V51, P227; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torrents E, 2003, MICROBIOL-SGM, V149, P1011, DOI 10.1099/mic.0.26133-0; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; Vitreschak AG, 2003, RNA, V9, P1084, DOI 10.1261/rna.5710303; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	43	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16571	16578		10.1074/jbc.M501322200	http://dx.doi.org/10.1074/jbc.M501322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722359	hybrid			2022-12-27	WOS:000228615500006
J	Yamakoshi, Y; Hu, JCC; Fukae, M; Zhang, HM; Simmer, JP				Yamakoshi, Y; Hu, JCC; Fukae, M; Zhang, HM; Simmer, JP			Dentin glycoprotein - The protein in the middle of the dentin sialophosphoprotein chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPERFECTA TYPE-II; DENTINOGENESIS IMPERFECTA; SEQUENCE DETERMINATION; MATRIX PROTEINS; LINKED OLIGOSACCHARIDES; MAPPING TECHNIQUE; DSPP; PHOSPHOPROTEIN; SIALOPROTEIN; MUTATION	Dentin sialophosphoprotein ( DSPP) is a major secretory product of odontoblasts and is critical for proper dentin formation. DSPP is believed to be processed into only two structural/functional domains: dentin sialoprotein (DSP) and dentin phosphoprotein ( DPP). Here we report the isolation and characterization of a third domain of DSPP, designated dentin glycoprotein (DGP). DGP was isolated from a guanidine/EDTA extract of porcine tooth dentin by ion exchange, hydroxyapatite affinity, size exclusion, and RP-HPL chromatography. Endoproteinase lysine C digestion products of DGP were characterized by Edman sequencing and mass spectrometry. The porcine DGP backbone is the 81-amino acid segment of DSPP (Ser(392) to Gly(472)) between the DSP and DPP domains. DGP has four phosphorylated serine residues (Ser(453), Ser(455), Ser(457), and Ser(462)) and one glycosylated asparagine (Asn(397)). There are no other posttranslational modifications. DGP is a stains-all positive protein with an apparent molecular mass on SDS-PAGE of 19 kDa, which is reduced by glycopeptidase A digestion to 16 kDa. A variety of glycans can be linked to Asn(397). All are complex biantennary structures with a common N-linked pentasaccharide core (mannose(3)-N-acetylglucosamine(2)), most with a fucosyl residue on the innermost N-acetylglucosamine. The alpha 1-3 and alpha 1-6 arms are always galactose beta 1-4 N-acetylglucosamine beta 1-2 mannose, and either or both arms can be unsialidated or monosialidated. The calculated monoisotopic molecular masses of the different glycosylated forms of the DGP phosphoprotein are: unsialidated 10,523 and 10,670, monosialidated 10,815 and 10,961, and disialidated 11,106, and 11,252 Da, with the disialidated forms being the most abundant.	Univ Michigan, Dent Res Lab, Ann Arbor, MI 48108 USA; Tsurumi Univ, Sch Dent Med, Dept Biochem, Tsurumi Ku, Yokohama, Kanagawa 230, Japan	University of Michigan System; University of Michigan; Tsurumi University	Simmer, JP (corresponding author), Univ Michigan, Dent Res Lab, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.	jsimmer@umich.edu	Hu, Jan C-C./F-5679-2015	Hu, Jan C-C./0000-0002-9294-0248	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011301, R01DE012769, R29DE011301, R56DE011301] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12769, DE15846, DE11301] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Fukae M, 1996, Adv Dent Res, V10, P111; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; JONSSON M, 1978, J CHROMATOGR, V157, P235, DOI 10.1016/S0021-9673(00)92338-0; Kim JW, 2005, HUM GENET, V116, P186, DOI 10.1007/s00439-004-1223-6; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; LINDE A, 1989, ANAT REC, V224, P154, DOI 10.1002/ar.1092240206; MacDougall M, 1997, CYTOGENET CELL GENET, V79, P121, DOI 10.1159/000134697; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Malmgren B, 2004, HUM GENET, V114, P491, DOI 10.1007/s00439-004-1084-z; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; O'Connell AC, 1999, ORAL SURG ORAL MED O, V87, P189, DOI 10.1016/S1079-2104(99)70272-6; Pallos D, 2001, ARCH ORAL BIOL, V46, P459, DOI 10.1016/S0003-9969(00)00130-8; Patel PI, 2001, NAT GENET, V27, P129, DOI 10.1038/84728; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; SHIELDS ED, 1973, ARCH ORAL BIOL, V18, P543, DOI 10.1016/0003-9969(73)90075-7; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TANABE T, 1990, CALCIFIED TISSUE INT, V46, P205, DOI 10.1007/BF02555046; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; Wallwork ML, 2002, CALCIFIED TISSUE INT, V71, P249, DOI 10.1007/s00223-001-1011-4; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yamakoshi Y, 2005, J BIOL CHEM, V280, P1552, DOI 10.1074/jbc.M409606200; YAMAKOSHI Y, 1995, CALCIFIED TISSUE INT, V56, P323, DOI 10.1007/BF00318054; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; Yamakoshi Y, 1998, CONNECT TISSUE RES, V39, P39, DOI 10.3109/03008209809023910; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	35	78	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17472	17479		10.1074/jbc.M413220200	http://dx.doi.org/10.1074/jbc.M413220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728577	hybrid			2022-12-27	WOS:000228615500114
J	Baba, T; Shimizu, T; Suzuki, Y; Ogawara, M; Isono, K; Koseki, H; Kurosawa, H; Shirasawa, T				Baba, T; Shimizu, T; Suzuki, Y; Ogawara, M; Isono, K; Koseki, H; Kurosawa, H; Shirasawa, T			Estrogen, insulin, and dietary signals cooperatively regulate longevity signals to enhance resistance to oxidative stress in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MN-SUPEROXIDE DISMUTASE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; ADIPOSE-TISSUE; GENE-EXPRESSION; KNOCKOUT MICE; RECEPTOR GENE; DWARF MICE; DROSOPHILA; EXTENSION	To investigate the biological significance of a longevity mutation found in daf-2 of Caenorhabditis elegans, we generated a homologous murine model by replacing Pro-1195 of insulin receptors with Leu using a targeted knock-in strategy. Homozygous mice died in the neonatal stage from diabetic ketoacidosis, whereas heterozygous mice showed the suppressed kinase activity of the insulin receptor but grew normally without spontaneously developing diabetes during adulthood. We examined heterozygous insulin receptor mutant mice for longevity phenotypes. Under 80% oxygen, mutant female mice survived 33.3% longer than wild-type female mice, whereas mutant male mice survived 18.2% longer than wild-type male mice. These results suggested that mutant mice acquired more resistance to oxidative stress, but the benefit of the longevity mutation was more pronounced in females than males. Manganese superoxide dismutase activity in mutant mice was significantly upregulated, suggesting that the suppressed insulin signaling leads to an enhanced antioxidant defense. To analyze the molecular basis of the gender difference, we administered estrogen to mutant mice. It was found that the survival of mice under 80% oxygen was extended when they were administered estradiol. In contrast, mutant and wild-type female mice showed shortened survivals when their ovaries were removed. The influence of estrogen is remarkable in mutant mice compared with wild-type mice, suggesting that estrogen modulates insulin signaling in mutant mice. Furthermore, we showed additional extension of survival under oxidative conditions when their diet was restricted. Collectively, we show that three distinct signals; insulin, estrogen, and dietary signals work in independent and cooperative ways to enhance the resistance to oxidative stress in mice.	Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabashi Ku, Tokyo 1730015, Japan; Chiba Univ, Grad Sch Med, Chiba 2608670, Japan; Juntendo Univ, Dept Orthoped, Bunkyo Ku, Tokyo 1138421, Japan	Tokyo Metropolitan Institute of Gerontology; Chiba University; Juntendo University	Shirasawa, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	sirasawa@tmig.or.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854; Isono, Kyoichi/0000-0002-4609-8985				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; BAILEY CJ, 1980, DIABETOLOGIA, V19, P475, DOI 10.1007/BF00281829; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bartke A, 2000, RES PRO CEL, V29, P181; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6; Imanaka T, 1998, J BIOL CHEM, V273, P25347, DOI 10.1074/jbc.273.39.25347; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; Lee SS, 2002, NATURE, V418, P287, DOI 10.1038/418287a; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; NAGY ZP, 1993, HUM REPROD, V8, P2180, DOI 10.1093/oxfordjournals.humrep.a138000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PEDERSEN SB, 1992, MOL CELL ENDOCRINOL, V85, P13, DOI 10.1016/0303-7207(92)90120-U; Phillips JP, 2000, EXP GERONTOL, V35, P1157, DOI 10.1016/S0531-5565(00)00117-0; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; SMITH DWE, 1989, BIOL REV, V64, P1, DOI 10.1111/j.1469-185X.1989.tb00635.x; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tchernof A, 1998, CORONARY ARTERY DIS, V9, P503, DOI 10.1097/00019501-199809080-00006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200	48	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16417	16426		10.1074/jbc.M500924200	http://dx.doi.org/10.1074/jbc.M500924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713666	hybrid			2022-12-27	WOS:000228444800115
J	Banno, Y; Ohguchi, K; Matsumoto, N; Koda, M; Ueda, M; Hara, A; Dikic, I; Nozawa, Y				Banno, Y; Ohguchi, K; Matsumoto, N; Koda, M; Ueda, M; Hara, A; Dikic, I; Nozawa, Y			Implication of phospholipase D2 in oxidant-induced phosphoinositide 3-kinase signaling via Pyk2 activation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-KINASE-B; GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; HYDROGEN-PEROXIDE; MAP KINASE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE DEPOLARIZATION; POSSIBLE INVOLVEMENT	The role of phospholipase D (PLD) activation in hydrogen peroxide (H2O2)-induced signal transduction and cellular responses is not completely understood. Here we present evidence that Ca2+-dependent tyrosine kinase, Pyk2, requires PLD activation to mediate survival pathways in rat pheochromocytoma PC12 cells under oxidative stress. The H2O2-induced phosphorylation of two Pyk2 sites (Tyr(580), and Tyr(881)) was suppressed by 1-butanol, an inhibitor of transphosphatidylation by PLD, and also by transfection of catalytically negative mouse PLD2K758R (PLD2KR). Furthermore, we found that PLD2 was associated with Pyk2 and Src, and that activation of PLD2 was required for H2O2-enhanced association of Src with Pyk2 leading to full activation of Pyk2. H2O2-induced phosphorylation of Akt and p70S6K was dependent on phosphatidylinositol 3-kinase (PI3K) activity and was abolished by 1-butanol but not t-butanol. Furthermore, the PI3K/Akt activation in response to H2O2 was reduced by transfection of either PLD2KR or the dominant negative Pyk2DN. This study is the first demonstration that PLD2 activation is implicated in Src-dependent phosphorylation of Pyk2 (Tyr(580) and Tyr(881)) by promoting the complex formation between Pyk2 and activated Src in PC12 cells exposed to H2O2, thereby resulting in activation of the survival signaling pathway PI3K/Akt/p70S6K.	Gifu Univ, Grad Sch Med, Dept Cell Signalling, Gifu 5011194, Japan; Gifu Int Inst Biotechnol, Kakamigahara 5040838, Japan; Gifu Pharmaceut Univ, Dept Biochem, Gifu 5028585, Japan; Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany	Gifu University; Gifu Pharmaceutical University; Goethe University Frankfurt	Banno, Y (corresponding author), Gifu Univ, Grad Sch Med, Dept Cell Signalling, Yanagido 1-1, Gifu 5011194, Japan.	banno@cc.gifu-u.ac.jp	Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Banno Y, 2001, NEUROREPORT, V12, P2271, DOI 10.1097/00001756-200107200-00045; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; Foster DA, 2003, MOL CANCER RES, V1, P789; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito Y, 1998, J NEUROCHEM, V71, P2278; Ito Y, 1997, J NEUROCHEM, V69, P729; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KISS Z, 1994, ARCH BIOCHEM BIOPHYS, V311, P450; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kumada H, 1999, BIOMED RES-TOKYO, V20, P87, DOI 10.2220/biomedres.20.87; Lee BD, 2000, J LEUKOCYTE BIOL, V67, P630, DOI 10.1002/jlb.67.5.630; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Mehta S, 2003, BBA-MOL CELL BIOL L, V1631, P246, DOI 10.1016/S1388-1981(03)00023-4; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NATARAJAN V, 1996, AM J PHYSIOL, V271, P400; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Yamada M, 2004, BIOCHEM J, V378, P649, DOI 10.1042/BJ20031398; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16319	16324		10.1074/jbc.M410903200	http://dx.doi.org/10.1074/jbc.M410903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705590	hybrid			2022-12-27	WOS:000228444800103
J	Byers, SA; Price, JP; Cooper, JJ; Li, QT; Price, DH				Byers, SA; Price, JP; Cooper, JJ; Li, QT; Price, DH			HEXIM2, a HEXIM1-related protein, regulates positive transcription elongation factor b through association with 7SK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SMOOTH-MUSCLE-CELLS; RECRUITS P-TEFB; GENE-EXPRESSION; HIV-1 TAT; IN-VITRO; IDENTIFICATION; BINDING; KINASE; COMPLEXES	The kinase activity of positive transcription elongation factor b (P-TEFb), composed of cyclin-dependent kinase 9 and cyclin T1 or T2, is required for the transition of RNA polymerase II into productive elongation. P-TEFb activity has been shown to be negatively regulated by association with the small nuclear RNA 7SK and the HEXIM1 protein. Here, we characterize HEXIM2, a previously predicted protein with sequence similarity to HEXIM1. HEXIM2 is expressed in HeLa and Jurkat cells, and glycerol gradient analysis and immunoprecipitations indicate that HEXIM2, like HEXIM1, has a regulated association with P-TEFb. As HEXIM1 is knocked down, HEXIM2 functionally compensates for its association with P-TEFb. Electrophoretic mobility shift assays and in vitro kinase assays demonstrate that HEXIM2 forms complexes containing 7SK and P-TEFb and, in conjunction with 7SK, inhibits P-TEFb kinase activity. Our results provide strong evidence that HEXIM2 is a regulator of P-TEFb function. Furthermore, our results support the idea that the utilization of HEXIM1 or HEXIM2 to bind and inhibit P-TEFb can be differentially regulated in vivo.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, 375 Newton Rd, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X; Li, Qintong/0000-0002-8447-9770	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Ghatpande S, 1999, DEV BIOL, V208, P210, DOI 10.1006/dbio.1998.9180; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Jiang Y, 2004, CELL CYCLE, V3, P1151; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kulkarni PA, 2004, RECENT PROG HORM RES, V59, P125, DOI 10.1210/rp.59.1.125; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2003, CELL CYCLE, V2, P99, DOI 10.4161/cc.2.2.332; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900; ULLU E, 1982, NUCLEIC ACIDS RES, V10, P2209, DOI 10.1093/nar/10.7.2209; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wittmann BM, 2003, CANCER RES, V63, P5151; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	42	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16360	16367		10.1074/jbc.M500424200	http://dx.doi.org/10.1074/jbc.M500424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713662	hybrid			2022-12-27	WOS:000228444800108
J	Fabbro, C; de Gemmis, P; Braghetta, P; Colombatti, A; Volpin, D; Bonaldo, P; Bressan, GM				Fabbro, C; de Gemmis, P; Braghetta, P; Colombatti, A; Volpin, D; Bonaldo, P; Bressan, GM			Analysis of regulatory regions of Emilin1 gene and their combinatorial contribution to tissue-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(VI) COLLAGEN GENE; FAR-UPSTREAM ENHANCER; REPORTER GENES; DNA ELEMENTS; EXPRESSION; PROMOTER; CELLS; ACTIVATION; COMPONENT; DOMAINS	The location of regions that regulate transcription of the murine Emilin1 gene was investigated in a DNA fragment of 16.8 kb, including the entire gene and about 8.7 and 0.6 kb of 5 '- and 3 '- flanking sequences, respectively. The 8.7- kb segment contains the 5 '- end of the putative 2310015E02Rik gene and the sequence that separates it from Emilin1, whereas the 0.6- kb fragment covers the region between Emilin1 and Ketohexokinase genes. Sequence comparison between species identified several conserved regions in the 5 '- flanking sequence. Most of them contained chromatin DNase I- hypersensitive sites, which were located at about - 950 ( HS1), - 3100 ( HS2), - 4750 ( HS3), and - 5150 ( HS4) in cells expressing Emilin1 mRNA. Emilin1 transcription initiates at multiple sites, the major of which correspond to two Initiator sequences. Promoter assays suggest that core promoter activity was mainly dependent on Initiator1 and on Sp1- binding sites close to the Initiators. Moreover, one important regulatory region was contained between - 1 and - 169 bp and a second one between - 630 bp and - 1.1 kb. The latter harbors a putative binding site for transcription factor AP1 matching the location of HS1. The function of different regions was studied by expressing lacZ constructs in transgenic mice. The results show that the 16.8- kb segment contains regulatory sequences driving high level transcription in all the tissues where Emilin1 is expressed. Moreover, the data suggest that transcription in different tissues is achieved through combinatorial cooperation between various regions, rather than being dependent on a single cis- activating region specific for each tissue.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35131 Padua, Italy; Ctr Riferimento Oncol, IRCCS, Div Expt Oncol, I-33081 Aviano, Italy; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Padua; IRCCS Aviano (CRO); University of Udine	Bressan, GM (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Viale G Colombo 3, I-35131 Padua, Italy.	bressan@civ.bio.unipd.it	Braghetta, Paola/K-5478-2016	Braghetta, Paola/0000-0003-2547-8679; Bonaldo, Paolo/0000-0002-9571-8140; colombatti, alfonso/0000-0002-3676-2379				Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Braghetta P, 1996, J CELL BIOL, V135, P1163, DOI 10.1083/jcb.135.4.1163; Braghetta P, 2002, MATRIX BIOL, V21, P603, DOI 10.1016/S0945-053X(02)00072-0; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Doliana R, 2000, J BIOL CHEM, V275, P785, DOI 10.1074/jbc.275.2.785; Doliana R, 2000, FEBS LETT, V484, P164, DOI 10.1016/S0014-5793(00)02140-2; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fabbro C, 1999, J BIOL CHEM, V274, P1759, DOI 10.1074/jbc.274.3.1759; GHIGO D, 1995, J EXP MED, V181, P9, DOI 10.1084/jem.181.1.9; Girotto D, 2000, J BIOL CHEM, V275, P17381, DOI 10.1074/jbc.M000075200; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Kaufman M.H., 1999, ANATOMICAL BASIS MOU; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; Leimeister C, 2002, DEV BIOL, V249, P204, DOI 10.1006/dbio.2002.0764; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; Nagy A., 2003, MANIPULATING MOUSE E; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; PICCOLO S, 1995, J BIOL CHEM, V270, P19583, DOI 10.1074/jbc.270.33.19583; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sambrook J., 2001, MOL CLONING LAB MANU; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Taniuchi I, 2004, ONCOGENE, V23, P4341, DOI 10.1038/sj.onc.1207671; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS RL, 1988, CELL, V52, P121; Zanetti M, 2004, MOL CELL BIOL, V24, P638, DOI 10.1128/MCB.24.2.638-650.2004	38	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15749	15760		10.1074/jbc.M412548200	http://dx.doi.org/10.1074/jbc.M412548200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705587	hybrid			2022-12-27	WOS:000228444800037
J	Hubalek, F; Binda, C; Khalil, A; Li, M; Mattevi, A; Castagnoli, N; Edmondson, DE				Hubalek, F; Binda, C; Khalil, A; Li, M; Mattevi, A; Castagnoli, N; Edmondson, DE			Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; BENZYLAMINE ANALOGS; SUBSTRATE; OXIDATION	Several reversible inhibitors selective for human monoamine oxidase B ( MAO B) that do not inhibit MAO A have been described in the literature. The following compounds: 8-( 3- chlorostyryl) caffeine, 1,4- diphenyl- 2-butene, and trans, trans- farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K-i values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A. In contrast, the reversible competitive inhibitor isatin binds to all known MAO B and MAO A with similar affinities. Sequence alignments and the crystal structures of human MAO B in complex with 1,4- diphenyl- 2-butene or with trans, trans- farnesol provide molecular insights into these specificities. These inhibitors span the substrate and entrance cavities with the side chain of Ile- 199 rotated out of its normal conformation suggesting that Ile- 199 is gating the substrate cavity. Ile- 199 is conserved in all known MAO B sequences except bovine MAO B, which has Phe in this position ( the sequence of sheep MAO B is unknown). Phe is conserved in the analogous position in MAO A sequences. The human MAO B I199F mutant protein of MAO B binds to isatin ( K-i = 3 mu M) but not to the three inhibitors listed above. The crystal structure of this mutant demonstrates that the side chain of Phe- 199 interferes with the binding of those compounds. This suggests that the Ile-199 " gate" is a determinant for the specificity of these MAO B inhibitors and provides a molecular basis for the development of MAO B- specific reversible inhibitors without interference with MAO A function in neurotransmitter metabolism.	Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA	Emory University; Emory University; University of Pavia; Virginia Polytechnic Institute & State University	Edmondson, DE (corresponding author), Emory Univ, Dept Biochem, 1510 Clifton Rd,Rollins Res Bldg, Atlanta, GA 30322 USA.	deedmon@emory.edu	Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012	Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; Binda, Claudia/0000-0003-2038-9845; Hubalek, Frantisek/0000-0003-3983-7900	NIGMS NIH HHS [GM-29433] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Binda C, 2004, J MED CHEM, V47, P1767, DOI 10.1021/jm031087c; Binda C, 2003, P NATL ACAD SCI USA, V100, P9750, DOI 10.1073/pnas.1633804100; Chen JF, 2002, J BIOL CHEM, V277, P36040, DOI 10.1074/jbc.M206830200; Edmondson DE, 2004, CURR MED CHEM, V11, P1983, DOI 10.2174/0929867043364784; Fowler JS, 2003, P NATL ACAD SCI USA, V100, P11600, DOI 10.1073/pnas.1833106100; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; Grimsby J, 1996, LIFE SCI, V58, P777, DOI 10.1016/0024-3205(95)02356-9; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Hubalek F, 2004, J MED CHEM, V47, P1760, DOI 10.1021/jm0310885; Hubalek F, 2003, ACTA CRYSTALLOGR D, V59, P1874, DOI 10.1107/S0907444903016883; HUSAIN M, 1982, BIOCHEMISTRY-US, V21, P595, DOI 10.1021/bi00532a028; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar MJ, 2003, J BIOL CHEM, V278, P46432, DOI 10.1074/jbc.M306378200; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li M, 2002, PROTEIN EXPRES PURIF, V24, P152, DOI 10.1006/prep.2001.1546; Ma JC, 2004, J MOL BIOL, V338, P103, DOI 10.1016/j.jmb.2004.02.032; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller JR, 1999, BIOCHEMISTRY-US, V38, P13670, DOI 10.1021/bi990920y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newton-Vinson P, 2000, PROTEIN EXPRES PURIF, V20, P334, DOI 10.1006/prep.2000.1309; Sharkey TD, 2001, ANNU REV PLANT PHYS, V52, P407, DOI 10.1146/annurev.arplant.52.1.407; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Tsugeno Y, 1997, J BIOL CHEM, V272, P14033, DOI 10.1074/jbc.272.22.14033; WALKER MC, 1994, BIOCHEMISTRY-US, V33, P7088, DOI 10.1021/bi00189a011; Yu J, 1999, BIOORGAN MED CHEM, V7, P231, DOI 10.1016/S0968-0896(98)00201-6	32	182	190	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15761	15766		10.1074/jbc.M500949200	http://dx.doi.org/10.1074/jbc.M500949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710600	hybrid			2022-12-27	WOS:000228444800038
J	Klyachko, NL; Shchedrina, VA; Efimov, AV; Kazakov, SV; Gazaryan, IG; Kristal, BS; Brown, AM				Klyachko, NL; Shchedrina, VA; Efimov, AV; Kazakov, SV; Gazaryan, IG; Kristal, BS; Brown, AM			pH-dependent substrate preference of pig heart lipoamide dehydrogenase varies with oligomeric state - Response to mitochondrial matrix acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE; REVERSED MICELLES; DIHYDROLIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; PERMEABILITY TRANSITION; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; ORGANIC-SOLVENTS; PROTEIN; ENZYMES	Cycling of intracellular pH has recently been shown to play a critical role in ischemia-reperfusion injury. Ischemia-reperfusion also leads to mitochondrial matrix acidification and dysfunction. However, the mechanism by which matrix acidification contributes to mitochondrial dysfunction, oxidative stress, and the resultant cellular injury has not been elucidated. We observe pH-dependent equilibria between monomeric, dimeric, and a previously undescribed tetrameric form of pig heart lipoamide dehydrogenase (LADH), a mitochondrial matrix enzyme. Dynamic light scattering studies of native LADH in aqueous solution indicate that lowering pH favors a shift in average molecular mass from higher oligomeric states to monomer. Sedimentation velocity of LADH entrapped in reverse micelles reveals dimer and tetramer at both pH 5.8 and 7.5, but monomer was observed only at pH 5.8. Enzyme activity measurements in reverse Aerosol OT micelles in octane indicate that LADH dimer and tetramer possess lipoamide dehydrogenase and diaphorase activities at pH 7.5. Upon acidification to pH 5.8 only the LADH monomer is active and only the diaphorase activity is observed. These results indicate a correlation between pH-dependent changes in the LADH reaction specificity and its oligomeric state. The acidification of mitochondrial matrix that occurs during ischemia-reperfusion injury is sufficient to alter the structure and enzymatic specificity of LADH, thereby reducing mitochondrial defenses, increasing oxidative stress, and slowing the recovery of energy metabolism. Matrix acidification may also disrupt the quaternary structure of other mitochondrial protein complexes critical for cellular homeostasis and survival.	Burke Med Res Inst, Dementia Res Serv, White Plains, NY 10605 USA; Moscow MV Lomonosov State Univ, Dept Chem Enzymol, Moscow 119899, Russia; Russian Acad Sci, Inst Prot Res, Pushchino, Moscow region, Russia; Pace Univ, Dept Chem & Phys Sci, Pleasantville, NY 10570 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Lomonosov Moscow State University; Russian Academy of Sciences; Pace University; Cornell University; Cornell University	Brown, AM (corresponding author), Burke Med Res Inst, Dementia Res Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	ambrown@med.cornell.edu	Gazaryan, Irina G/T-8578-2017; Kazakov, Sergey/K-4789-2019; brown, abraham/R-8823-2019; Efimov, Alexander V/L-9720-2015; Klyachko, Natalia L/J-9512-2013; Klyachko, Natalia L./AAU-8856-2021; shchedrina, valentina a/B-8398-2015	Gazaryan, Irina G/0000-0002-9670-5579; Klyachko, Natalia L./0000-0002-9357-8236; shchedrina, valentina a/0000-0003-1627-982X	NINDS NIH HHS [R01 NS038741, NS38741] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038741] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; ASSAF HM, 1990, METAB BRAIN DIS, V5, P143, DOI 10.1007/BF00999841; Awaji T, 2001, BIOCHEM BIOPH RES CO, V289, P457, DOI 10.1006/bbrc.2001.6004; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; Das D K, 1996, EXS, V76, P155; de Gomez-Puyou MT, 1998, CRIT REV BIOCHEM MOL, V33, P53, DOI 10.1080/10409239891204170; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; Eicke H F, 1980, Top Curr Chem, V87, P85; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Gazaryan IG, 1997, BIOCHEM J, V328, P643; Ghafourifar P, 1999, BIOL CHEM, V380, P1025, DOI 10.1515/BC.1999.127; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halle B, 2003, P NATL ACAD SCI USA, V100, P12135, DOI 10.1073/pnas.2033320100; Igamberdiev AU, 2004, FEBS LETT, V568, P146, DOI 10.1016/j.febslet.2004.05.024; KABANOV AV, 1991, PROTEIN ENG, V4, P1009, DOI 10.1093/protein/4.8.1009; KABANOV AV, 1991, FEBS LETT, V278, P143, DOI 10.1016/0014-5793(91)80103-A; Kazakov SV, 2002, INT J THERMOPHYS, V23, P161, DOI 10.1023/A:1013957127723; Klyachko NL, 2003, CURR OPIN COLLOID IN, V8, P179, DOI 10.1016/S1359-0294(03)00016-5; KLYACHKO NL, 1990, BIOL MEMBRANY, V7, P467; KOBAYASHI K, 1983, J MOL CELL CARDIOL, V15, P359, DOI 10.1016/0022-2828(83)90320-6; Kohling R, 2002, LANGMUIR, V18, P8626, DOI 10.1021/la020405s; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; KOTLARCHYK M, 1985, J PHYS CHEM-US, V89, P4382, DOI 10.1021/j100266a046; LEICHUS BN, 1992, BIOCHEMISTRY-US, V31, P3065, DOI 10.1021/bi00127a006; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEVASHOV AV, 1982, J COLLOID INTERF SCI, V88, P444, DOI 10.1016/0021-9797(82)90273-9; Levashov AV, 2001, RUSS CHEM B+, V50, P1718, DOI 10.1023/A:1014361508512; LEVASHOV AV, 1981, ANAL BIOCHEM, V118, P42, DOI 10.1016/0003-2697(81)90153-6; LUISI PL, 1988, BIOCHIM BIOPHYS ACTA, V947, P209, DOI 10.1016/0304-4157(88)90025-1; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MARTINEK K, 1986, EUR J BIOCHEM, V155, P453, DOI 10.1111/j.1432-1033.1986.tb09512.x; MARTINEK K, 1989, BIOCHIM BIOPHYS ACTA, V981, P161, DOI 10.1016/0005-2736(89)90024-2; MARTINEK K, 1982, SCIENCE, V218, P889, DOI 10.1126/science.6753152; MASSEY V, 1962, J BIOL CHEM, V237, P3820; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATUDA S, 1982, J BIOCHEM, V91, P553, DOI 10.1093/oxfordjournals.jbchem.a133727; Muiswinkel-Voetberg H.v., 1973, EUR J BIOCHEM, V33, P265; NAKAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V267, P249, DOI 10.1016/0005-2728(72)90113-2; Oldfield C, 1994, Biotechnol Genet Eng Rev, V12, P255; Orlich B, 2002, ADV BIOCHEM ENG BIOT, V75, P185; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; POPOV VO, 1985, BIOCHIM BIOPHYS ACTA, V827, P466, DOI 10.1016/0167-4838(85)90234-1; RACEYBURNS LA, 1989, LIFE SCI, V44, P2015, DOI 10.1016/0024-3205(89)90347-0; Raddatz G, 1997, J MOL MODEL, V3, P423, DOI 10.1007/s008940050060; REED JK, 1973, J BIOL CHEM, V248, P4834; RENDON JL, 1989, ARCH BIOCHEM BIOPHYS, V268, P255, DOI 10.1016/0003-9861(89)90587-0; ROSS J, 1988, J GEN MICROBIOL, V134, P1131; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORPE C, 1976, J BIOL CHEM, V251, P3553; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; TSAI CS, 1981, ARCH BIOCHEM BIOPHYS, V206, P77, DOI 10.1016/0003-9861(81)90068-0; VANBERKEL WJH, 1991, EUR J BIOCHEM, V202, P1049; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; Veeger C., 1973, EUR J BIOCHEM, V33, P271; VISSER J, 1968, BIOCHIM BIOPHYS ACTA, V159, P265, DOI 10.1016/0005-2744(68)90075-2; WILKINSON KD, 1979, J BIOL CHEM, V254, P852; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	70	36	38	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16106	16114		10.1074/jbc.M414285200	http://dx.doi.org/10.1074/jbc.M414285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710613	hybrid			2022-12-27	WOS:000228444800078
J	Sattlegger, E; Hinnebusch, AG				Sattlegger, E; Hinnebusch, AG			Polyribosome binding by GCN1 is required for full activation of eukaryotic translation initiation factor 2 alpha kinase GCN2 during amino acid starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; N-TERMINUS; RNA; ASSOCIATION; GENE; PHOSPHORYLATION; REINITIATION; RIBOSOMES; COMPLEX	The protein kinase GCN2 mediates translational control of gene expression in amino acid-starved cells by phosphorylating eukaryotic translation initiation factor 2 alpha. In Saccharomyces cerevisiae, activation of GCN2 by uncharged tRNAs in starved cells requires its direct interaction with both the GCN1 center dot GCN20 regulatory complex and ribosomes. GCN1 also interacts with ribosomes in cell extracts, but it was unknown whether this activity is crucial for its ability to stimulate GCN2 function in starved cells. We describe point mutations in two conserved, noncontiguous segments of GCN1 that lead to reduced polyribosome association by GCN1 center dot GCN20 in living cells without reducing GCN1 expression or its interaction with GCN20. Mutating both segments simultaneously produced a greater reduction in polyribosome binding by GCN1 center dot GCN20 and a stronger decrease in eukaryotic translation initiation factor 2 alpha phosphorylation than did mutating in one segment alone. These findings provide strong evidence that ribosome binding by GCN1 is required for its role as a positive regulator of GCN2. A particular mutation in the GCN1 domain, related in sequence to translation elongation factor 3 (eEF3), decreased GCN2 activation much more than it reduced ribosome binding by GCN1. Hence, the eEF3-like domain appears to have an effector function in GCN2 activation. This conclusion supports the model that an eEF3-related activity of GCN1 influences occupancy of the ribosomal decoding site by uncharged tRNA in starved cells.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDMAN E, 1990, MOL MICROBIOL, V4, P2035, DOI 10.1111/j.1365-2958.1990.tb00563.x; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; SIKORSKI RS, 1989, GENETICS, V122, P19; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	21	48	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16514	16521		10.1074/jbc.M414566200	http://dx.doi.org/10.1074/jbc.M414566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722345	hybrid			2022-12-27	WOS:000228444800126
J	Schonherr, E; Sunderkotter, C; Iozzo, RV; Schaefer, L				Schonherr, E; Sunderkotter, C; Iozzo, RV; Schaefer, L			Decorin, a novel player in the insulin-like growth factor system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; FACTOR-I RECEPTOR; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CARCINOMA-CELLS; UP-REGULATION; EXPRESSION; COLLAGEN; BINDING	Decorin is a multifunctional proteoglycan that is expressed by sprouting endothelial cells. Its expression supports capillary formation and cell survival. Previously, it was shown that some effects of decorin are mediated by protein kinase B and the cyclin- dependent kinase inhibitor, p21. However, the cell surface receptor responsible for these effects was unknown. We demonstrate that decorin binds to the insulin- like growth factor-I ( IGF- I) receptor on endothelial cells with an affinity in the nanomolar range ( K-D = 18 nM), which is comparable with IGF- I ( K-D = 1.2 nM). Furthermore, decorin can bind IGF- I itself, but with a lower affinity ( K-D = 190 nM) than classical IGF- I- binding proteins. Decorin addition causes IGF- I receptor phosphorylation and activation, which is followed by receptor down- regulation. These effects are caused by the core protein of decorin, and the binding region could be mapped to the N terminus of the molecule. The physiological relevance of the decorin/ IGF- I receptor interaction was corroborated in two animal models ( e. g. inflammatory angiogenesis in the cornea and unilateral ureteral obstruction). In both models the IGF- I receptor was up- regulated in decorin- deficient mice compared with controls and the up- regulation could not compensate the decorin deficiency in the disease models. These data indicate that decorin is an important player in the IGF system and its loss cannot fully be compensated in different types of diseases.	Cardiff Univ Dent Sch, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, S Glam, Wales; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Internal Med D, D-48149 Munster, Germany; Univ Hosp Munster, D-48149 Munster, Germany; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Ulm, Dept Dermatol, D-8901 Ulm, Germany; Univ Hosp Ulm, D-8901 Ulm, Germany	Cardiff University; University of Munster; University of Munster; University of Munster; University of Munster; University of Munster; Jefferson University; Jefferson University; Ulm University; Ulm University	Schonherr, E (corresponding author), Cardiff Univ Dent Sch, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, S Glam, Wales.	schonherreh@cardiff.ac.uk	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112; Schaefer, Liliana/0000-0002-3318-3005; Sunderkotter, Cord/0000-0002-2929-145X	NCI NIH HHS [R01 CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chevalier RL, 2000, KIDNEY INT, V57, P882, DOI 10.1046/j.1523-1755.2000.057003882.x; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Diamond JR, 1997, KIDNEY INT, V51, P1133, DOI 10.1038/ki.1997.156; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Han RNN, 2003, AM J RESP CELL MOL, V28, P159, DOI 10.1165/rcmb.4764; Henger A, 2004, KIDNEY INT, V65, P904, DOI 10.1111/j.1523-1755.2004.00499.x; Jansson M, 1997, FEBS LETT, V416, P259, DOI 10.1016/S0014-5793(97)01149-6; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Strazynski M, 2004, J BIOL CHEM, V279, P21266, DOI 10.1074/jbc.M309782200; Su EJ, 2003, AM J PHYSIOL-HEART C, V284, pH1429, DOI 10.1152/ajpheart.00885.2002; Tralhao JG, 2003, FASEB J, V17, P464, DOI 10.1096/fj.02-0534fje; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124	34	172	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15767	15772		10.1074/jbc.M500451200	http://dx.doi.org/10.1074/jbc.M500451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701628	hybrid			2022-12-27	WOS:000228444800039
J	Wu, JJ; Bennett, AM				Wu, JJ; Bennett, AM			Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CONDITIONAL EXPRESSION; MKP-1 EXPRESSION; P38; TRANSDUCTION; APOPTOSIS; TRANSCRIPTION; INHIBITION; ENCODES; 3CH134	Mitogen-activated protein kinase ( MAPK) phosphatases (MKPs) constitute a family of 11 dual-specificity phosphatases that inactivate the MAPKs by dephosphorylation. Although the contribution of MAPKs to cell growth and cell death has been examined extensively, it remains unclear whether MKPs play an essential role in the regulation of these processes. To clarify the role of MKP-1, we determined the effects on the MAPKs and cell growth and death in primary fibroblasts derived from mice lacking MKP-1. Here we have shown that MKP-1 is critical for the inactivation of p38 MAPK and JNK following stimulation with serum, anisomycin, and osmotic stress. In addition, MKP-1 was identified as a critical negative regulator of the cAMP-mediated p38 MAPK pathway. MKP-1-deficient mouse embryonic fibroblasts (MEFs) displayed enhanced p38 MAPK activity and cAMP-response element-dependent transcriptional activation in response to forskolin. Surprisingly, MKP-1-deficient fibroblasts exhibited reduced cell growth compared with wild type MEFs as a result of enhanced cell death. The enhanced level of cell death in MKP-1-deficient MEFs was rescued by SB203580, an inhibitor of p38 MAPK. MKP-1-deficient MEFs were also sensitive to anisomycin-induced apoptosis. Collectively, these data demonstrate that MKP-1 promotes cell survival by attenuating stress-responsive MAPK-mediated apoptosis.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, POB 208066, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599	NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK057751] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09085] Funding Source: Medline; NIDDK NIH HHS [DK57751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dorfman K, 1996, ONCOGENE, V13, P925; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lornejad-Schafer MR, 2003, BIOCHEM J, V371, P609, DOI 10.1042/BJ20021357; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Nimah M, 2005, SHOCK, V23, P80, DOI 10.1097/01.shk.0000145206.28812.60; Nishina H, 1999, DEVELOPMENT, V126, P505; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Shifrin VI, 1999, J BIOL CHEM, V274, P13985, DOI 10.1074/jbc.274.20.13985; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou A, 2002, GENOME BIOL, V3; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Zhao Q, 2005, J BIOL CHEM, V280, P8101, DOI 10.1074/jbc.M411760200	39	135	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16461	16466		10.1074/jbc.M501762200	http://dx.doi.org/10.1074/jbc.M501762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722358	hybrid			2022-12-27	WOS:000228444800120
J	Murphy, HN; Stewart, GR; Mischenko, VV; Apt, AS; Harris, R; McAlister, MSB; Driscoll, PC; Young, DB; Robertson, BD				Murphy, HN; Stewart, GR; Mischenko, VV; Apt, AS; Harris, R; McAlister, MSB; Driscoll, PC; Young, DB; Robertson, BD			The OtsAB pathway is essential for trehalose biosynthesis in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; PHOSPHATE PHOSPHATASE; PURIFICATION; EXPRESSION; SMEGMATIS; SYNTHASE; CLONING; GROWTH; MICE; TREHALOSE-6-PHOSPHATE	The disaccharide trehalose is the major free sugar in the cytoplasm of mycobacteria; it is a constituent of cell wall glycolipids, and it plays a role in mycolic acid transport during cell wall biogenesis. The pleiotropic role of trehalose in the biology of Mycobacterium tuberculosis and its absence from mammalian cells suggests that its biosynthesis may provide a useful target for novel drugs. However, there are three potential pathways for trehalose biosynthesis in M. tuberculosis, and the aim of the present study was to introduce mutations into each of the pathways to determine whether or not they are functionally redundant. The results show that the OtsAB pathway, which generates trehalose from glucose and glucose-6-phosphate, is the dominant pathway required for M. tuberculosis growth in laboratory culture and for virulence in a mouse model. Of the two otsB homologues annotated in the genome sequence of M. tuberculosis, only OtsB2 (Rv3372) has a functional role in the pathway. OtsB2, trehalose-6-phosphate phosphatase, is strictly essential for growth and provides a tractable target for high throughput screening. Inactivation of the TreYZ pathway, which can generate trehalose from alpha-1,4-linked glucose polymers, had no effect on the growth of M. tuberculosis in vitro or in mice. Deletion of the treS gene altered the late stages of pathogenesis of M. tuberculosis in mice, significantly increasing the time to death in a chronic infection model. Because the TreS enzyme catalyzes the interconversion of trehalose and maltose, the mouse phenotype could reflect either a requirement for synthesis of additional trehalose or, conversely, a requirement for breakdown of stored trehalose to liberate free glucose.	Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Cent Inst TB, Immunogenet Lab, Moscow 107564, Russia; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England	Imperial College London; University of London; University College London; University of London; Birkbeck University London	Robertson, BD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, S Kensington Campus, London SW7 2AZ, England.	b.robertson@imperial.ac.uk	Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950; mcalister, mark/0000-0003-3986-1767; Apt, Alexander/0000-0002-3683-3085; Stewart, Graham/0000-0002-6867-6248; Harris, Richard/0000-0001-7459-1745; Robertson, Brian D./0000-0001-5785-5307	Medical Research Council [MC_U117533887, MC_U117581288] Funding Source: Medline; MRC [MC_U117581288, MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alvarez-Peral FJ, 2002, MICROBIOL-SGM, V148, P2599, DOI 10.1099/00221287-148-8-2599; Andersson U, 2001, J BIOL CHEM, V276, P42707, DOI 10.1074/jbc.M108279200; Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; BLAZQUEZ MA, 1993, FEBS LETT, V329, P51, DOI 10.1016/0014-5793(93)80191-V; Chen QF, 2004, J EXP BIOL, V207, P3125, DOI 10.1242/jeb.01133; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; Edavana VK, 2004, ARCH BIOCHEM BIOPHYS, V426, P250, DOI 10.1016/j.abb.2004.02.014; Elbein AD, 2003, GLYCOBIOLOGY, V13, p17R, DOI 10.1093/glycob/cwg047; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Klutts S, 2003, J BIOL CHEM, V278, P2093, DOI 10.1074/jbc.M209937200; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Lyadova I, 1998, INFECT IMMUN, V66, P4981, DOI 10.1128/IAI.66.10.4981-4988.1998; MATULA M, 1971, J BACTERIOL, V107, P217, DOI 10.1128/JB.107.1.217-222.1971; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Mischenko VV, 2004, J INFECT DIS, V190, P2137, DOI 10.1086/425909; Nikonenko BV, 2000, TUBERCLE LUNG DIS, V80, P15, DOI 10.1054/tuld.1999.0225; Pan YT, 2004, EUR J BIOCHEM, V271, P4259, DOI 10.1111/j.1432-1033.2004.04365.x; Pan YT, 2002, EUR J BIOCHEM, V269, P6091, DOI 10.1046/j.1432-1033.2002.03327.x; Ryll R, 2001, MICROBIOL IMMUNOL, V45, P801, DOI 10.1111/j.1348-0421.2001.tb01319.x; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Stewart GR, 2002, MICROBIOL-SGM, V148, P3129, DOI 10.1099/00221287-148-10-3129; Stewart GR, 2001, NAT MED, V7, P732, DOI 10.1038/89113; Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Woodruff PJ, 2004, J BIOL CHEM, V279, P28835, DOI 10.1074/jbc.M313103200	32	104	112	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14524	14529		10.1074/jbc.M414232200	http://dx.doi.org/10.1074/jbc.M414232200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703182	hybrid			2022-12-27	WOS:000228236800023
J	Purusharth, RI; Klein, F; Sulthana, S; Jager, S; Jagannadham, MV; Evguenieva-Hackenberg, E; Ray, MK; Klug, G				Purusharth, RI; Klein, F; Sulthana, S; Jager, S; Jagannadham, MV; Evguenieva-Hackenberg, E; Ray, MK; Klug, G			Exoribonuclease R interacts with endoribonuclease e and an RNA helicase in the psychrotrophic Bacterium pseudomonas syringae Lz4W	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) POLYMERASE I; ESCHERICHIA-COLI; MESSENGER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; RIBOSOMAL-RNA; TRANSCRIPTIONAL ACTIVITY; RHODOBACTER-CAPSULATUS; QUALITY-CONTROL; DEGRADOSOME; PNPASE	Endoribonuclease E, a key enzyme involved in RNA decay and processing in bacteria, organizes a protein complex called degradosome. In Escherichia coli, Rhodobacter capsulatus, and Streptomyces coelicolor, RNase E interacts with the phosphate-dependent exoribonuclease polynucleotide phosphorylase, DEAD-box helicase(s), and additional factors in an RNA-degrading complex. To characterize the degradosome of the psychrotrophic bacterium Pseudomonas syringae Lz4W, RNase E was enriched by cation exchange chromatography and fractionation in a glycerol density gradient. Most surprisingly, the hydrolytic exoribonuclease RNase R was found to co-purify with RNase E. Co-immunoprecipitation and Ni2+-affinity pull-down experiments confirmed the specific interaction between RNase R and RNase E. Additionally, the DEAD-box helicase RhlE was identified as part of this protein complex. Fractions comprising the three proteins showed RNase E and RNase R activity and efficiently degraded a synthetic stem-loop containing RNA in the presence of ATP. The unexpected association of RNase R with RNase E and RhlE in an RNA-degrading complex indicates that the cold-adapted P. syringae has a degradosome of novel structure. The identification of RNase R instead of polynucleotide phosphorylase in this complex underlines the importance of the interaction between endo- and exoribonucleases for the bacterial RNA metabolism. The physical association of RNase E with an exoribonuclease and an RNA helicase apparently is a common theme in the composition of bacterial RNA-degrading complexes.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Univ Giessen, Inst Mikrobiol & Molekularbiol, D-35392 Giessen, Germany	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Justus Liebig University Giessen	Ray, MK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	malay@ccmb.res.in	Klug, Gabriele/K-5322-2014; Jagannadham, Medicharla V. V./AAW-6773-2021; Evguenieva-Hackenberg, Elena/ABA-8876-2020	Klug, Gabriele/0000-0002-3527-5093; Evguenieva-Hackenberg, Elena/0000-0001-7270-3168; RAJYAGURU, PURUSHARTH/0000-0003-3794-418X				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Baginsky S, 2001, RNA, V7, P1464; Bernstein JA, 2004, P NATL ACAD SCI USA, V101, P2758, DOI 10.1073/pnas.0308747101; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Bidle KA, 1999, J BACTERIOL, V181, P2330, DOI 10.1128/JB.181.8.2330-2337.1999; Bizebard T, 2004, BIOCHEMISTRY-US, V43, P7857, DOI 10.1021/bi049852s; BLUELL CR, 2003, P NATL ACAD SCI USA, V100, P10181; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; Bollenbach TJ, 2004, PROG NUCLEIC ACID RE, V78, P305, DOI 10.1016/S0079-6603(04)78008-3; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Callaghan AJ, 2004, J MOL BIOL, V340, P965, DOI 10.1016/j.jmb.2004.05.046; Callaghan AJ, 2003, BIOCHEMISTRY-US, V42, P13848, DOI 10.1021/bi0351099; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Charollais J, 2003, MOL MICROBIOL, V48, P1253, DOI 10.1046/j.1365-2958.2003.03513.x; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; Conrad C, 1998, NUCLEIC ACIDS RES, V26, P4446, DOI 10.1093/nar/26.19.4446; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; Favaro R, 2003, J BACTERIOL, V185, P5279, DOI 10.1128/JB.185.17.5279-5286.2003; FRITSCH J, 1995, MOL MICROBIOL, V15, P1017, DOI 10.1111/j.1365-2958.1995.tb02277.x; Goverde RLJ, 1998, MOL MICROBIOL, V28, P555, DOI 10.1046/j.1365-2958.1998.00816.x; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Janiyani KL, 2002, APPL ENVIRON MICROB, V68, P1, DOI 10.1128/AEM.68.1.1-10.2002; Jiang XQ, 2000, J BACTERIOL, V182, P2468, DOI 10.1128/JB.182.9.2468-2475.2000; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; KALMAN M, 1991, NEW BIOL, V3, P886; Karzai AW, 2001, P NATL ACAD SCI USA, V98, P3040, DOI 10.1073/pnas.051628298; Khemici V, 2004, MOL MICROBIOL, V51, P777, DOI 10.1046/j.1365-2958.2003.03862.x; KOBE T, 1992, J BACTERIOL, V174, P6359; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; Liou GG, 2002, J BIOL CHEM, V277, P41157, DOI 10.1074/jbc.M206618200; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mohanty BK, 1999, MOL MICROBIOL, V34, P1094, DOI 10.1046/j.1365-2958.1999.01673.x; Polissi A, 2003, RES MICROBIOL, V154, P573, DOI 10.1016/S0923-2508(03)00167-0; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Ray MK, 1999, CURR MICROBIOL, V38, P143, DOI 10.1007/PL00006778; Raynal LC, 1999, MOL MICROBIOL, V32, P765, DOI 10.1046/j.1365-2958.1999.01394.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Uma S, 1999, FEBS LETT, V453, P313, DOI 10.1016/S0014-5793(99)00660-2; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Zangrossi S, 2000, MOL MICROBIOL, V36, P1470, DOI 10.1046/j.1365-2958.2000.01971.x; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	55	98	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14572	14578		10.1074/jbc.M413507200	http://dx.doi.org/10.1074/jbc.M413507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705581	hybrid			2022-12-27	WOS:000228236800029
J	Siegenthaler, RK; Christen, P				Siegenthaler, RK; Christen, P			The importance of having thermosensor control in the DnaK chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEAT-SHOCK; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; HSP70 CHAPERONES; ATP HYDROLYSIS; FACTOR GRPE; PROTEIN; MECHANISM; BINDING	In addition to the sigma(32)-mediated heat shock response, the DnaK/DnaJ/GrpE molecular chaperone system of Escherichia coli directly adapts to elevated temperatures by sequestering a higher fraction of substrate. This immediate heat shock response is due to the differential temperature dependence of the activity of DnaJ, which stimulates the hydrolysis of DnaK-bound ATP, and the activity of GrpE, which facilitates ADP/ATP exchange and converts DnaK from its high-affinity ADP-liganded state into its low-affinity ATP-liganded state. GrpE acts as thermosensor with its ADP/ATP exchange activity decreasing above 40 degrees C. To assess the importance of this reversible thermal adaptation for the chaperone action of the DnaK/DnaJ/GrpE system during heat shock, we used glucose-6-phosphate dehydrogenase and luciferase as substrates. We compared the performance of wild-type GrpE as a component of the chaperone system with that of GrpE R40C. In this mutant, the thermosensing helices are stabilized with an intersubunit disulfide bond and its nucleotide exchange activity thus increases continuously with increasing temperature. Wild-type GrpE with intact thermosensor proved superior to GrpE R40C with desensitized thermosensor. The chaperone system with wild-type GrpE yielded not only a higher fraction of refolding-competent protein at the end of a heat shock but also protected luciferase more efficiently against inactivation during heat shock. Consistent with their differential thermal behavior, the protective effects of wild-type GrpE and GrpE R40C diverged more and more with increasing temperature. Thus, the direct thermal adaptation of the DnaK chaperone system by thermosensing GrpE is essential for efficient chaperone action during heat shock.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ben-Zvi A, 2004, J BIOL CHEM, V279, P37298, DOI 10.1074/jbc.M405627200; Bischofberger P, 2003, J BIOL CHEM, V278, P19044, DOI 10.1074/jbc.M300922200; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Gelinas AD, 2003, BIOCHEMISTRY-US, V42, P9050, DOI 10.1021/bi034416b; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU X, 2002, THESIS U ZURICH ZURI; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Siegenthaler RK, 2004, FEBS LETT, V562, P105, DOI 10.1016/S0014-5793(04)00190-5; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	39	16	17	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14395	14401		10.1074/jbc.M413803200	http://dx.doi.org/10.1074/jbc.M413803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705578	hybrid			2022-12-27	WOS:000228236800007
J	Yang, WC; Lu, YB; Kalajzic, I; Guo, DY; Harris, MA; Gluhak-Heinrich, J; Kotha, S; Bonewald, LF; Feng, JQ; Rowe, DW; Turner, CH; Robling, AG; Harris, SE				Yang, WC; Lu, YB; Kalajzic, I; Guo, DY; Harris, MA; Gluhak-Heinrich, J; Kotha, S; Bonewald, LF; Feng, JQ; Rowe, DW; Turner, CH; Robling, AG; Harris, SE			Dentin matrix protein 1 gene cis-regulation - Use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; CHROMOSOME 4Q21; GAP-JUNCTIONS; NITRIC-OXIDE; EXPRESSION; CELLS; DMP1; DIFFERENTIATION; OSTEOBLASTS; RECEPTOR	Dentin matrix protein 1 (DMP1) is highly expressed in osteocytes and is mechanically responsive. To study osteocyte-specific and mechanically regulated DMP1 gene expression, the transcriptional activity of three cis-regulatory regions was first examined in an osteoblast differentiation model in vitro using a green fluorescent protein (GFP) reporter. Expression of the -9624 to -1996 bp ( 10 kb) and -7892 to +4439 bp ( 8 kb) DMP1 cis-regulatory regions dramatically increased in areas of mineralized matrix, in dendritic, osteocyte-like cells. Mineralizing cultures expressing the 8-kb construct show dramatic GFP increases in response to loading in cells with a dendritic morphology. Transgenic mice expressing the 8-kb DMP1-GFP and -2433 to +4439 bp (2.5 kb) DMP1-LacZ were generated. Osteocyte-specific expression was found with the 8 kb but not with the 2.5 kb in postnatal animals. However, the 2.5 kb could support expression in rapidly forming osteoblasts and pre-osteocytes in the embryo. Primary calvarial osteoblast cultures demonstrated that the 2.5 kb supports weak expression in a subset of osteoblasts and pre-osteocytes, but not in mature osteocytes. However, the 8 kb supports robust expression in primary bone marrow cultures. Therefore the region -7892 to -2433 bp, termed a 5.5-kb "Osteocyte Enhancer Module," appears to be required for osteocyte specificity. Ulnae of mice with the 8-kb DMP1-GFP were subjected to mechanical loading where GFP expression increased selectively and locally in osteocytes, distal to the mid-shaft and near the surface of the bone. Thus, the 8-kb region of the DMP1 gene is a target for mechanotransduction in osteocytes, and its cis-regulatory activity may be correlated to local strain in bone.	Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Missouri, Dept Oral Biol, Kansas City, MO 64109 USA; Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78229 USA; Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Health San Antonio; University of Connecticut; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Harris, SE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	harris@uthscsa.edu	Bonewald, Lynda/Q-3638-2019	Lu, Yongbo/0000-0003-3692-1736	NIAMS NIH HHS [AR046530, AR46798, AR44728, AR43457] Funding Source: Medline; NIDDK NIH HHS [DK 63478] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046530, R01AR043457, P01AR046798, R01AR044728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063478] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223-002-1057-y; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chambers TJ, 1999, OSTEOARTHR CARTILAGE, V7, P422, DOI 10.1053/joca.1998.0231; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Gottgens B, 2000, NAT BIOTECHNOL, V18, P181, DOI 10.1038/72635; Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; HUGHES DE, 1994, J BONE MINER RES, V9, P39; Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006; Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002-220821; Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223-001-1025-y; Liu YF, 2004, NEW CARBON MATER, V19, P197; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MacDougall M, 2002, CONNECT TISSUE RES, V43, P320, DOI 10.1080/03008200290000556; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Marotti G, 1996, Ital J Anat Embryol, V101, P25; MAROTTI G, 1992, BONE, V13, P363, DOI 10.1016/8756-3282(92)90452-3; McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930; NAKAMURA H, 1995, CELL TISSUE RES, V280, P225, DOI 10.1007/BF00307793; Okabayashi K, 2004, BONE, V34, P124, DOI 10.1016/j.bone.2003.08.010; Robling AG, 2002, BONE, V31, P562, DOI 10.1016/S8756-3282(02)00871-2; Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200; Strauss W M, 1996, Methods Mol Biol, V54, P307; Tanaka-Kamioka K, 1998, J BONE MINER RES, V13, P1555, DOI 10.1359/jbmr.1998.13.10.1555; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357-2725(03)00241-3; Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021-9290(03)00123-4; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Yang W., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P386; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200; You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050	49	85	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20680	20690		10.1074/jbc.M500104200	http://dx.doi.org/10.1074/jbc.M500104200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15728181	hybrid			2022-12-27	WOS:000229242000066
J	Li, XA; Guo, L; Dressman, JL; Asmis, R; Smart, EJ				Li, XA; Guo, L; Dressman, JL; Asmis, R; Smart, EJ			A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL APOPTOSIS; DEFICIENT MICE; OXIDIZED LDL; SR-BII; ATHEROSCLEROSIS; ACTIVATION; DYSFUNCTION; INHIBITION; CAVEOLAE; DISEASE	Scavenger receptor class B, type I (SR-BI)/ApoE double null mice develop severe atherosclerosis within 4 weeks, whereas ApoE null mice take several months to develop the disease, indicating that SR-BI plays a pivotal role in atherosclerosis. Importantly, SR-BI/ApoE double null mice have lower plasma cholesterol levels than ApoE null mice, suggesting involvement of a nonlipids mechanism. In the present study, we revealed a novel ligand-independent apoptotic pathway induced by SR-BI, and regulated by endothelial nitric-oxide synthase ( eNOS) and high density lipoprotein (HDL). SR-BI significantly induces apoptosis in three independent cell systems. In contrast to known ligand-dependent apoptotic pathways, SR-BI-induced apoptosis is ligand-independent. We further showed that SR-BI-induced apoptosis is suppressed by eNOS and HDL. By using a single site mutation, we demonstrated that SR-BI induces apoptosis through a highly conserved CXXS redox motif. We finally demonstrated that SR-BI-induced apoptosis is via the caspase-8 pathway. We hypothesize that in healthy cells, the SR-BI apoptotic pathway is turned off by eNOS and HDL which prevents inappropriate apoptotic damage to the vascular wall. When HDL levels are low, oxidative stress causes the relocation of eNOS away from caveolae, which turns on SR-BI-induced apoptosis and rapidly clears damaged cells to prevent further inflammatory damage to neighboring cells. The current studies offer a new paradigm in which to study the non-cholesterol effects of SR-BI, HDL, and eNOS on the development of atherosclerosis and potentially other cardiovascular diseases.	Univ Kentucky, Sch Med, Dept Pediat, Lexington, KY 40536 USA; Univ Kentucky, Sch Med, Dept Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Sch Med, Dept Pediat, 423 Sanders Brown,800 Limestone St, Lexington, KY 40536 USA.	ejsmart@uky.edu	Asmis, Reto/W-1344-2019		NHLBI NIH HHS [HL64056, HL68509, HL62844] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068509, R01HL062844, R01HL064056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Asai K, 2000, ARTERIOSCL THROM VAS, V20, P1493, DOI 10.1161/01.ATV.20.6.1493; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen JW, 2004, CIRC RES, V94, P370, DOI 10.1161/01.RES.0000113782.07824.BE; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Dimmeler S, 1997, CIRCULATION, V95, P1760; Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; Estevez AG, 2002, ANN NY ACAD SCI, V962, P207, DOI 10.1111/j.1749-6632.2002.tb04069.x; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HANSSON GK, 1985, AM J PATHOL, V121, P123; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Kolodgie FD, 1999, APOPTOSIS, V4, P5, DOI 10.1023/A:1009645730270; Kotamraju S, 2001, J BIOL CHEM, V276, P17316, DOI 10.1074/jbc.M011731200; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Norata GD, 2002, NUTR METAB CARDIOVAS, V12, P297; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Shaul PW, 2003, J PHYSIOL-LONDON, V547, P21, DOI 10.1113/jphysiol.2002.031534; Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Tall AR, 2002, CIRC RES, V90, P244, DOI 10.1161/res.90.3.244; TYMMS MJ, 2001, GENE KNOCKOUT PROTOC, P205; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	46	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19087	19096		10.1074/jbc.M500944200	http://dx.doi.org/10.1074/jbc.M500944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749707	hybrid			2022-12-27	WOS:000228932300065
J	Willets, JM; Nahorski, SR; Challiss, RAJ				Willets, JM; Nahorski, SR; Challiss, RAJ			Roles of phosphorylation-dependent and -independent mechanisms in the regulation of M-1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE REGULATION; HOMOLOGY DOMAIN; DESENSITIZATION; ACTIVATION; SIGNAL; G-ALPHA(Q); ARRESTINS; MICE; M1	When co-expressed with the inositol 1,4,5-trisphosphate biosensor eGFP-PHPLC delta, G protein-coupled receptor kinase 2 (GRK2) can suppress M-1 muscarinic acetylcholine (mACh) receptor-mediated phospholipase C signaling in hippocampal neurons through a phosphorylation-independent mechanism, most likely involving the direct binding of the RGS homology domain of GRK2 to G alpha(q/11). To define the importance of this mechanism in comparison with classical, phosphorylation-dependent receptor regulation by GRKs, we have examined M-1 mACh receptor signaling in hippocampal neurons following depletion of GRK2 and also in the presence of non-G alpha(q/11)-binding GRK2 mutants. Depletion of neuronal GRK2 using an antisense strategy almost completely inhibited M-1 mACh receptor desensitization without enhancing acute agonist-stimulated phospholipase C activity. By stimulating neurons with a submaximal agonist concentration before (R1) and after (R2) a period of exposure to a maximal agonist concentration, an index (R2/R1) of agonist-induced desensitization of signaling could be obtained. Co-transfection of neurons with either a non-G alpha(q/11)-binding (D110A) GRK2 mutant or the catalytically inactive (D110A,K220R)GRK2 did not suppress acute M-1 mACh receptor-stimulated inositol 1,4,5-trisphosphate production. However, using the desensitization (R2/R1) protocol, it could be shown that expression of (D110A)GRK2 enhanced, whereas (D110A,K220R)GRK2 inhibited, agonist-induced M-1 mACh receptor desensitization. In Chinese hamster ovary cells, the loss of G alpha(q/11) binding did not affect the ability of the (D110A)GRK2 mutant to phosphorylate M-1 mACh receptors, whereas expression of (D110A,K220R)GRK2 had no effect on receptor phosphorylation. These data indicate that in hippocampal neurons endogenous GRK2 is a key regulator of M-1 mACh receptor signaling and that the regulatory process involves both phosphorylation-dependent and -independent mechanisms.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willets, JM (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England.	jmw23@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Anagnostaras SG, 2003, NAT NEUROSCI, V6, P51, DOI 10.1038/nn992; Berkeley JL, 2003, MOL PHARMACOL, V63, P128, DOI 10.1124/mol.63.1.128; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FROTSCHER M, 1985, J COMP NEUROL, V239, P237, DOI 10.1002/cne.902390210; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Hamilton SE, 1997, P NATL ACAD SCI USA, V94, P13311, DOI 10.1073/pnas.94.24.13311; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miyakawa T, 2001, J NEUROSCI, V21, P5239, DOI 10.1523/JNEUROSCI.21-14-05239.2001; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Nash MS, 2004, J BIOL CHEM, V279, P49036, DOI 10.1074/jbc.M407277200; Ovsepian SV, 2004, EUR J NEUROSCI, V20, P1267, DOI 10.1111/j.1460-9568.2004.03582.x; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Power AE, 2003, NEUROBIOL LEARN MEM, V80, P178, DOI 10.1016/S1074-7427(03)00086-8; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Santini F, 2000, J CELL SCI, V113, P2463; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WAINER BH, 1985, NEUROSCI LETT, V54, P45, DOI 10.1016/S0304-3940(85)80116-6; Waugh MG, 1999, BIOCHEM J, V338, P175, DOI 10.1042/0264-6021:3380175; Wess J, 2004, ANNU REV PHARMACOL, V44, P423, DOI 10.1146/annurev.pharmtox.44.101802.121622; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; Willets JM, 1999, J NEUROCHEM, V73, P1781, DOI 10.1046/j.1471-4159.1999.0731781.x; Willets JM, 2004, J NEUROSCI, V24, P4157, DOI 10.1523/JNEUROSCI.5506-03.2004; Willets JM, 2003, MOL PHARMACOL, V64, P1059, DOI 10.1124/mol.64.5.1059; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321	43	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18950	18958		10.1074/jbc.M412682200	http://dx.doi.org/10.1074/jbc.M412682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743771	hybrid			2022-12-27	WOS:000228932300048
J	Munoz-Alonso, MJ; Acosta, JC; Richard, C; Delgado, MD; Sedivy, J; Leon, J				Munoz-Alonso, MJ; Acosta, JC; Richard, C; Delgado, MD; Sedivy, J; Leon, J			p21(Cip1) and p27(Kip1) induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; ERYTHROID-DIFFERENTIATION; CDK-INHIBITORS; MEGAKARYOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; 1,25-DIHYDROXYVITAMIN D-3; DEPENDENT KINASES; FUNCTIONAL-ROLE; K562 CELLS; P21	The cyclin-dependent kinase (Cdk) inhibitors p21(Cip1) and p27(Kip1) have been proposed to exert redundant functions in cell cycle progression and differentiation programs, although nonoverlapping functions have also been described. To gain further insights into the relevant mechanisms and to detect possible functional differences between both proteins, we conditionally expressed p21(Cip1) and p27(Kip1) in K562, a multipotent human leukemia cell line. Temporal ectopic expression of either p21(Cip1) or p27(Kip1) arrested proliferation, inhibited Cdk2 and Cdk4 activities, and suppressed retinoblastoma phosphorylation. However, whereas p21(Cip1) arrested cells in both G(1) and G(2) cell cycle phases, p27(Kip1) blocked the G(1)/S-phase transition. Furthermore, although both p21(Cip1) and p27(Kip1) associated with Cdk6, only p27(Kip1) significantly inhibited its activity. Most importantly, each protein promoted differentiation along a distinct pathway; p21(Cip1) triggered megakaryocytic maturation, whereas p27(Kip1) resulted in the expression of erythroid markers. Consistently, p21(Cip1) and p27(Kip1) were rapid and transiently up-regulated when K562 cells are differentiated into megakaryocytic and erythroid lineages, respectively. These findings demonstrate distinct functions of p21(Cip1) and p27(Kip1) in cell cycle regulation and differentiation and indicate that these two highly related proteins possess unique biological activities and are not functionally interchangeable.	Univ Cantabria, CSIC, Dept Biol Mol & Unidad Biomed, Grp Biol Mol Canc, Santander 39011, Spain; Hosp Univ Marques Valdecilla, Serv Hematol, Santander 39008, Spain; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV); Brown University	Leon, J (corresponding author), Fac Med, Dept Biol Mol, Santander 39011, Spain.	leonj@unican.es	Acosta, Juan/AAE-6320-2021; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Acosta, Juan/0000-0002-7989-7329; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040	NIGMS NIH HHS [GM41690] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DELGADO MD, 1995, ONCOGENE, V10, P1659; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Drexler HCA, 2003, CELL DEATH DIFFER, V10, P290, DOI 10.1038/sj.cdd.4401159; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matushansky I, 2003, ONCOGENE, V22, P4143, DOI 10.1038/sj.onc.1206484; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Minami R, 2003, EXP HEMATOL, V31, P355, DOI 10.1016/S0301-472X(03)00040-7; Munoz-Alonso MJ, 2003, MOL B INT U, P236; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Steinman RA, 2001, ONCOGENE, V20, P6524, DOI 10.1038/sj.onc.1204800; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; Wang ZL, 2000, DIFFERENTIATION, V66, P1, DOI 10.1046/j.1432-0436.2000.066001001.x; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou P, 1999, ANTICANCER RES, V19, P4935; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	54	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18120	18129		10.1074/jbc.M500758200	http://dx.doi.org/10.1074/jbc.M500758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746092	hybrid			2022-12-27	WOS:000228807200069
J	Neeli, R; Roitel, O; Scrutton, NS; Munro, AW				Neeli, R; Roitel, O; Scrutton, NS; Munro, AW			Switching pyridine nucleotide specificity in P450BM3 - Mechanistic analysis of the W1046H AND W1046A enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN CYTOCHROME-P450 REDUCTASE; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; OXIDIZED FLAVODOXIN; REDOX POTENTIALS; BINDING SITE; PROTEIN; DOMAIN; NADPH	Flavocytochrome P450 BM3 is a member of the diflavin reductase enzyme family. Members include cytochrome P450 reductase, nitric-oxide synthase, methionine synthase reductase, and novel oxidoreductase 1. These enzymes show a strong preference for NADPH over NADH as reducing coenzyme. An aromatic residue stacks over the FAD isoalloxazine ring in each enzyme, and in some cases it is important in controlling coenzyme specificity. In P450 BM3, the aromatic residue inferred from sequence alignments to stack over the FAD is Trp-1046. Mutation to Ala-1046 and His-1046 effected a remarkable coenzyme specificity switch. P450 BM3 W1046A/W106H FAD and reductase domains are efficient NADH-dependent ferricyanide reductases with selectivity coefficients (k(cat)/K-m(NADPH)/k(cat)/K-m(NADH)) of 1.5, 67, and 8571 for the W1046A, W1046H, and wild-type reductase domains, respectively. Stopped-flow photodiode array absorption studies indicated a charge-transfer intermediate accumulated in the W1046A FAD domain (and to a lesser extent in the W1046H FAD domain) and was attributed to formation of a reduced FADH(2)-NAD(P)(+) charge-transfer species, suggesting a relatively slow rate of release of NAD(P)(+) from reduced enzymes. Unlike wild-type enzymes, there was no formation of the blue semiquinone species observed during reductive titration of the W0146A/W146H FAD and reductase domains with dithionite or NAD(P) H. This was a consequence of elevation of the semiquinone/hydroquinone couple of the FAD with respect to the oxidized/semiquinone couple, and a concomitant similar to 100-mV elevation in the 2-electron redox couple for the enzyme-bound FAD (-320, -220, and -224 mV in the wild-type, W1046A, and W1046H FAD domains, respectively).	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk; awm9@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X				Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Carmichael AB, 2001, EUR J BIOCHEM, V268, P3117, DOI 10.1046/j.1432-1327.2001.02212.x; Daff S, 1996, BIOCHEMISTRY-US, V35, P6351, DOI 10.1021/bi9522561; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Dunford AJ, 2004, EUR J BIOCHEM, V271, P2548, DOI 10.1111/j.1432-1033.2004.04185.x; Dutton P L, 1978, Methods Enzymol, V54, P411; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Gutierrez A, 2003, BIOCHEM SOC T, V31, P497, DOI 10.1042/BST0310497; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; Ost TWB, 2000, FEBS LETT, V486, P173, DOI 10.1016/S0014-5793(00)02267-5; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Peters MW, 2003, J AM CHEM SOC, V125, P13442, DOI 10.1021/ja0303790; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolthers KR, 2004, BIOCHEMISTRY-US, V43, P490, DOI 10.1021/bi0356303; Wolthers KR, 2003, BIOCHEMISTRY-US, V42, P3911, DOI 10.1021/bi027290b	43	48	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17634	17644		10.1074/jbc.M413826200	http://dx.doi.org/10.1074/jbc.M413826200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710617	hybrid			2022-12-27	WOS:000228807200010
J	Nissim, I; Luhovyy, B; Horyn, O; Daikhin, Y; Nissim, I; Yudkoff, M				Nissim, I; Luhovyy, B; Horyn, O; Daikhin, Y; Nissim, I; Yudkoff, M			The role of mitochondrially bound arginase in the regulation of urea synthesis - Studies with [U-N-15(4)]arginine, isolated mitochondria, and perfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMYL-PHOSPHATE; CITRULLINE SYNTHESIS; NITROGEN-METABOLISM; DIETARY-PROTEIN; ARGININE; ORNITHINE; ACETYLGLUTAMATE; PH; CATABOLISM; EXPRESSION	The main goal of the current study was to elucidate the role of mitochondrial arginine metabolism in the regulation of N-acetylglutamate and urea synthesis. We hypothesized that arginine catabolism via mitochondrially bound arginase augments ureagenesis by supplying ornithine for net synthesis of citrulline, glutamate, N-acetylglutamate, and aspartate. [U-N-15(4)] arginine was used as precursor and isolated mitochondria or liver perfusion as a model system to monitor arginine catabolism and the incorporation of N-15 into various intermediate metabolites of the urea cycle. The results indicate that similar to 8% of total mitochondrial arginase activity is located in the matrix, and 90% is located in the outer membrane. Experiments with isolated mitochondria showed that similar to 60-70% of external [U-N-15(4)] arginine catabolism was recovered as N-15-labeled ornithine, glutamate, N-acetylglutamate, citrulline, and aspartate. The production of N-15-labeled metabolites was time- and dose-dependent. During liver perfusion, urea containing one (Um+1) or two (Um+2) N-15 was generated from perfusate [U-N-15(4)] arginine. The output of Um+2 was between 3 and 8% of total urea, consistent with the percentage of activity of matrix arginase. Um+1 was formed following mitochondrial production of [N-15] glutamate from [alpha,delta-N-15(2)]ornithine and transamination of [N-15] glutamate to [N-15] aspartate. The latter is transported to cytosol and incorporated into argininosuccinate. Approximately 70, 75, 7, and 5% of hepatic ornithine, citrulline, N-acetylglutamate, and aspartate, respectively, were derived from perfusate [U-N-15(4)] arginine. The results substantiate the hypothesis that intramitochondrial arginase, presumably the arginase-II isozyme, may play an important role in the regulation of hepatic ureagenesis by furnishing ornithine for net synthesis of N-acetylglutamate, citrulline, and aspartate.	Univ Penn, Childrens Hosp Philadelphia, Sch Med,Div Child Dev & Rehabil Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Nissim, I (corresponding author), Abramson Pediat Res Ctr, Div Child Dev, Rm 510C,34th St & Civic Ctr, Philadelphia, PA 19104 USA.			Luhovyy, Bohdan/0000-0002-5699-218X	NATIONAL CANCER INSTITUTE [R01CA079495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053761, R01DK053761] Funding Source: NIH RePORTER; NCI NIH HHS [CA79495] Funding Source: Medline; NIDDK NIH HHS [DK53761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ash DE, 2004, J NUTR, V134, p2760S, DOI 10.1093/jn/134.10.2760S; Brosnan JT, 2001, J BIOL CHEM, V276, P31876, DOI 10.1074/jbc.M103890200; Camacho JA, 1999, NAT GENET, V22, P151, DOI 10.1038/9658; CAREY GB, 1993, BIOCHEM J, V292, P241, DOI 10.1042/bj2920241; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; Chang CI, 2000, J IMMUNOL, V165, P2134, DOI 10.4049/jimmunol.165.4.2134; CHEUNG CW, 1981, ARCH BIOCHEM BIOPHYS, V209, P643, DOI 10.1016/0003-9861(81)90324-6; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COHEN NS, 1987, J BIOL CHEM, V262, P203; COHEN NS, 1982, J BIOL CHEM, V257, P6898; COHEN NS, 1980, J BIOL CHEM, V255, P248; Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; FREEDLAND RA, 1984, BIOCHIM BIOPHYS ACTA, V802, P407, DOI 10.1016/0304-4165(84)90357-X; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HORMAN I, 1974, BIOMED MASS SPECTROM, V1, P115, DOI 10.1002/bms.1200010206; HORYN O, 2005, IN PRESS BIOCH J; Indiveri C, 1997, BIOCHEM J, V327, P349, DOI 10.1042/bj3270349; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KAMEMOTO ES, 1985, ARCH BIOCHEM BIOPHYS, V243, P100, DOI 10.1016/0003-9861(85)90777-5; KAWAMOTO S, 1985, BIOCHEM J, V232, P329, DOI 10.1042/bj2320329; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MCGIVAN JD, 1976, BIOCHEM J, V154, P415, DOI 10.1042/bj1540415; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MORIMOTO BH, 1990, BIOCHEM J, V272, P671, DOI 10.1042/bj2720671; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S; Morris SM, 2004, CURR OPIN CLIN NUTR, V7, P45, DOI 10.1097/00075197-200401000-00009; Naganuma Y, 1997, J NUTR SCI VITAMINOL, V43, P387, DOI 10.3177/jnsv.43.387; Nissim I, 2003, BIOCHEM J, V376, P179, DOI 10.1042/BJ20030997; Nissim I, 1999, J BIOL CHEM, V274, P28958, DOI 10.1074/jbc.274.41.28958; Nissim I, 1996, J BIOL CHEM, V271, P31234, DOI 10.1074/jbc.271.49.31234; Nissim I, 2002, AM J PHYSIOL-ENDOC M, V283, pE1123, DOI 10.1152/ajpendo.00246.2002; O'Sullivan D, 1998, BIOCHEM J, V330, P627, DOI 10.1042/bj3300627; O'Sullivan D, 2000, AM J PHYSIOL-ENDOC M, V278, pE516, DOI 10.1152/ajpendo.2000.278.3.E516; RECZKOWSKI RS, 1994, ARCH BIOCHEM BIOPHYS, V312, P31, DOI 10.1006/abbi.1994.1276; REYES AA, 1994, AM J PHYSIOL, V267, pF331, DOI 10.1152/ajprenal.1994.267.3.F331; STEWART PM, 1980, J BIOL CHEM, V255, P5270; SZWEDA LI, 1989, J BIOL CHEM, V264, P15357; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P439, DOI 10.1016/S0753-3322(02)00284-6; Vatamaniuk MZ, 2003, LIFE SCI, V72, P1871, DOI 10.1016/S0024-3205(02)02506-7; Vockley JG, 1996, GENOMICS, V38, P118, DOI 10.1006/geno.1996.0606; Waterlow JC, 1999, NUTR RES REV, V12, P25, DOI 10.1079/095442299108728857; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yang DW, 1999, J MASS SPECTROM, V34, P1130; Yeh CL, 2004, NUTRITION, V20, P581, DOI 10.1016/j.nut.2004.03.004	48	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17715	17724		10.1074/jbc.M500607200	http://dx.doi.org/10.1074/jbc.M500607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753084	hybrid			2022-12-27	WOS:000228807200021
J	Morimura, T; Hattori, M; Ogawa, M; Mikoshiba, K				Morimura, T; Hattori, M; Ogawa, M; Mikoshiba, K			Disabled1 regulates the intracellular trafficking of Reelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTORS; BRAIN-DEVELOPMENT; NEURONAL MIGRATION; STIMULATED NEURONS; MOUSE DISABLED-1; PLASMA-MEMBRANE; PROTEIN; ADAPTER; FAMILY; PHOSPHORYLATION	Reelin is a huge secreted protein that controls proper laminar formation in the developing brain. It is generally believed that tyrosine phosphorylation of Disabled1 (Dab1) by Src family tyrosine kinases is the most critical downstream event in Reelin signaling. The receptors for Reelin belong to the low density lipoprotein receptor family, most of whose members undergo regulated intracellular trafficking. In this study, we propose novel roles for Dab1 in Reelin signaling. We first demonstrated that cell surface expression of Reelin receptors was decreased in Dab1-deficient neurons. In heterologous cells, Dab1 enhanced cell surface expression of Reelin receptors, and this effect was mediated by direct interaction with the receptors. Moreover, Dab1 did not stably associate with the receptors at the plasma membrane in the resting state. When Reelin was added to primary cortical neurons, Dab1 was recruited to the receptors, and its tyrosine residues were phosphorylated. Although Reelin and Dab1 colocalized well shortly after the addition of Reelin, Dab1 was no longer associated with internalized Reelin. When Src family tyrosine kinases were inhibited, internalization of Reelin was severely abrogated, and Reelin colocalized with Dab1 near the plasma membrane for a prolonged period. Taken together, these results indicate that Dab1 regulates both cell surface expression and internalization of Reelin receptors, and these regulations may play a role in correct laminar formation in the developing brain.	RIKEN, Lab Cell Culture Dev, BSI, Wako, Saitama 3510198, Japan; Univ Tokyo, Div Mol Neurobiol, Dept Basic Med Sci, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, Saitama, Japan; Japan Sci & Technol Agcy, Calcium Oscillat Project, ICORP, Chiyoda Ku, Tokyo 1020084, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Morimura, T (corresponding author), RIKEN, Lab Cell Culture Dev, BSI, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morimura@brain.riken.jp	Hattori, Mitsuharu/F-3859-2010; Mikoshiba, Katsuhiko/N-7943-2015	Hattori, Mitsuharu/0000-0002-0503-4969; 				Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Beglova N, 2004, MOL CELL, V16, P281, DOI 10.1016/j.molcel.2004.09.038; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Melker AA, 2001, J CELL SCI, V114, P2167; deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Gleeson JG, 2000, TRENDS NEUROSCI, V23, P352, DOI 10.1016/S0166-2236(00)01607-6; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hoppe HC, 2000, CELL MICROBIOL, V2, P569, DOI 10.1046/j.1462-5822.2000.00081.x; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang YC, 2004, BIOCHEM BIOPH RES CO, V318, P204, DOI 10.1016/j.bbrc.2004.04.023; Kamikura DM, 2003, GENE DEV, V17, P2798, DOI 10.1101/gad.1136103; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Magrane J, 1999, FEBS LETT, V451, P56, DOI 10.1016/S0014-5793(99)00494-9; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Riddell DR, 2001, J LIPID RES, V42, P998; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Shah BH, 2002, MOL ENDOCRINOL, V16, P610, DOI 10.1210/me.16.3.610; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Yoneshima H, 1997, NEUROSCI RES, V29, P217, DOI 10.1016/S0168-0102(97)00088-6; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200	43	65	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16901	16908		10.1074/jbc.M409048200	http://dx.doi.org/10.1074/jbc.M409048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718228	hybrid			2022-12-27	WOS:000228615500044
J	Adegbola, O; Pasternack, GR				Adegbola, O; Pasternack, GR			Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; CELL-CYCLE; NUCLEAR PHOSPHOPROTEIN; G(1) CONTROL; RB; GENE; IDENTIFICATION; ACTIVATION; ARREST; DEATH	The retinoblastoma gene product (Rb) is a tumor suppressor that affects apoptosis paradoxically. Most sporadic cancers inactivate Rb by preferentially targeting the pathway that regulates Rb phosphorylation, resulting in resistance to apoptosis; this contrasts with Rb inactivation by mutation, which is associated with high rates of apoptosis. How phosphorylated Rb protects cells from apoptosis is not well understood, but there is evidence that Rb may sequester a pro-apoptotic nuclear factor. pp32 (ANP32A) is a pro-apoptotic nuclear phosphoprotein, the expression of which is commonly increased in cancer. We report that hyperphosphorylated Rb interacts with pp32 but not with the closely related proteins pp32r1 and pp32r2. We further demonstrate that pp32-Rb interaction inhibits the apoptotic activity of pp32 and stimulates proliferation. These results suggest a mechanism whereby cancer cells gain both a proliferative and survival advantage when Rb is inactivated by hyperphosphorylation.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 417 N Caroline St,Rm B300, Baltimore, MD 21231 USA.	gpastern@jhmi.edu		Adegbola, Onikepe/0000-0002-7339-3015	NATIONAL CANCER INSTITUTE [T32CA067751] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA67751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berry DE, 1996, ONCOGENE, V12, P1809; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MALEK SN, 1990, J BIOL CHEM, V265, P13400; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; Rassidakis GZ, 2004, AM J PATHOL, V164, P2259, DOI 10.1016/S0002-9440(10)63782-0; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WALENSKY LD, 1993, CANCER RES, V53, P4720; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang H, 1996, ONCOGENE, V13, P373; Wang J, 1997, CANCER RES, V57, P351; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829	44	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15497	15502		10.1074/jbc.M411382200	http://dx.doi.org/10.1074/jbc.M411382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716273	hybrid			2022-12-27	WOS:000228444800006
J	Kim, MS; Day, CJ; Morrison, NA				Kim, MS; Day, CJ; Morrison, NA			MCP-1 is induced by receptor activator of nuclear factor-kappa B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION; FAMILY; GENES; NFAT2; MICE	Human osteoclast formation from monocyte precursors under the action of receptor activator of nuclear factor-kappa B ligand ( RANKL) was suppressed by granulocyte macrophage colony-stimulating factor (GM-CSF), with down-regulation of critical osteoclast-related nuclear factors. GM-CSF in the presence of RANKL and macrophage colony-stimulating factor resulted in mononuclear cells that were negative for tartrate-resistant acid phosphatase ( TRAP) and negative for bone resorption. CD1a, a dendritic cell marker, was expressed in GM-CSF, RANKL, and macrophage colony-stimulating factor-treated cells and absent in osteoclasts. Microarray showed that the CC chemokine, monocyte chemotactic protein 1 (MCP-1), was profoundly repressed by GMCSF. Addition of MCP-1 reversed GM-CSF suppression of osteoclast formation, recovering the bone resorption phenotype. MCP-1 and chemokine RANTES ( regulated on activation normal T cell expressed and secreted) permitted formation of TRAP-positive multinuclear cells in the absence of RANKL. However, these cells were negative for bone resorption. In the presence of RANKL, MCP-1 significantly increased the number of TRAP-positive multinuclear bone-resorbing osteoclasts ( p = 0.008). When RANKL signaling through NFATc1 was blocked with cyclosporin A, both MCP-1 and RANTES expression was down-regulated. Furthermore, addition of MCP-1 and RANTES reversed the effects of cyclosporin A and recovered the TRAP-positive multinuclear cell phenotype. Our model suggests that RANKL-induced chemokines are involved in osteoclast differentiation at the stage of multinucleation of osteoclast precursors and provides a rationale for increased osteoclast activity in inflammatory conditions where chemokines are abundant.	Griffith Univ, Sch Med Sci, Gold Coast, Qld 4215, Australia	Griffith University	Morrison, NA (corresponding author), Griffith Univ, Sch Med Sci, Gold Coast Campus,PMB50, GCMC, Qld 9726, Australia.	N.Morrison@griffith.edu.au	Morrison, Nigel A/F-4082-2012	Morrison, Nigel A/0000-0003-4774-3808; Day, Christopher/0000-0001-7953-4408				Cakouros D, 2001, J IMMUNOL, V167, P302, DOI 10.4049/jimmunol.167.1.302; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780; Fujikawa Y, 2001, BONE, V28, P261, DOI 10.1016/S8756-3282(00)00453-1; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Granfar RMS, 2005, MOL CELL PROBE, V19, P119, DOI 10.1016/j.mcp.2004.10.003; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; KASINRERK W, 1993, J IMMUNOL, V150, P579; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002-9440(10)65301-1; Sakiyama H, 2001, J BONE MINER METAB, V19, P220, DOI 10.1007/s007740170024; Sambrook J., 2002, MOL CLONING LAB MANU; SHUTO T, 1994, ENDOCRINOLOGY, V134, P831, DOI 10.1210/en.134.2.831; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	21	202	211	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16163	16169		10.1074/jbc.M412713200	http://dx.doi.org/10.1074/jbc.M412713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722361	hybrid			2022-12-27	WOS:000228444800085
J	Kuznetsov, VY; Blair, E; Farmer, PJ; Poulos, TL; Pifferitti, A; Sevrioukova, IF				Kuznetsov, VY; Blair, E; Farmer, PJ; Poulos, TL; Pifferitti, A; Sevrioukova, IF			The putidaredoxin reductase-putidaredoxin electron transfer complex - Theoretical and experimental studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450CAM MONOOXYGENASE SYSTEM; CRYSTAL-STRUCTURE; OXIDIZED PUTIDAREDOXIN; PSEUDOMONAS-PUTIDA; REDOX PARTNERS; ADRENODOXIN REDUCTASE; GLUTATHIONE-REDUCTASE; MOLECULAR RECOGNITION; CYTOCHROME P450CAM; CARBOXYLATE GROUPS	Interaction and electron transfer between putidaredoxin reductase (Pdr) and putidaredoxin (Pdx) from Pseudomonas putida was studied by molecular modeling, mutagenesis, and stopped flow techniques. Based on the crystal structures of Pdr and Pdx, a complex between the proteins was generated using computer graphics methods. In the model, Pdx is docked above the isoalloxazine ring of FAD of Pdr with the distance between the flavin and [2Fe-2S] of 14.6 angstrom. This mode of interaction allows Pdx to easily adjust and optimize orientation of its cofactor relative to Pdr. The key residues of Pdx located at the center, Asp(38) and Trp(106), and at the edge of the protein-protein interface, Tyr(33) and Arg(66), were mutated to test the Pdr-Pdx computer model. The Y33F, Y33A, D38N, D38A, R66A, R66E, W106F, W106A, and Delta 106 mutations did not affect assembly of the [2Fe-2S] cluster and resulted in a marginal change in the redox potential of Pdx. The electron-accepting ability of Delta 106 Pdx was similar to that of the wild-type protein, whereas electron transfer rates from Pdr to other mutants were diminished to various degrees with the smallest and largest effects on the kinetic parameters of the Pdr-to-Pdx electron transfer reaction caused by the Trp(106) and Tyr(33)/Arg(66) substitutions, respectively. Compared with wild-type Pdx, the binding affinity of all studied mutants to Pdr was significantly higher. Experimental results were in agreement with theoretical predictions and suggest that: (i) Pdr-Pdx complex formation is mainly driven by steric complementarity, (ii) bulky side chains of Tyr(33), Arg(66), and Trp(106) prevent tight binding of oxidized Pdx and facilitate dissociation of the reduced iron-sulfur protein from Pdr, and (iii) transfer of an electron from FAD to [2Fe-2S] can occur with various orientations between the cofactors through multiple electron transfer pathways that do not involve Trp(106) but are likely to include Asp(38) and Cys(39).	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92612 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92612 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Sevrioukova, IF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 McGaugh Hall, Irvine, CA 92697 USA.	sevrioui@uci.edu	Farmer, Patrick J/J-3757-2019	Farmer, Patrick J/0000-0001-9911-999X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688, R01GM067637] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM67637, GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P168, DOI 10.1016/S0167-4838(98)00091-0; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1386, P157, DOI 10.1016/S0167-4838(98)00094-6; Aoki M, 1998, BBA-PROTEIN STRUCT M, V1384, P180, DOI 10.1016/S0167-4838(98)00017-X; Avila L, 1999, J BIOL INORG CHEM, V4, P664, DOI 10.1007/s007750050390; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1988, PROTEINS, V4, P63, DOI 10.1002/prot.340040109; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; GEREN L, 1986, J BIOL CHEM, V261, P5491; GEREN LM, 1984, J BIOL CHEM, V259, P2155; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; Ivanov YD, 2001, ARCH BIOCHEM BIOPHYS, V391, P255, DOI 10.1006/abbi.2001.2405; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurnikov IV., 2000, HARLEM MOL MODELING; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mo HP, 1999, BIOCHEMISTRY-US, V38, P5666, DOI 10.1021/bi983063r; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; MURPHY MM, 1991, ANAL CHEM, V63, P2743, DOI 10.1021/ac00023a015; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; Pochapsky TC, 1999, BIOCHEMISTRY-US, V38, P4681, DOI 10.1021/bi983030b; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Purdy MM, 2004, BIOCHEMISTRY-US, V43, P271, DOI 10.1021/bi0356045; ROOME PW, 1983, J BIOL CHEM, V258, P2593; ROOME PW, 1988, ARCH BIOCHEM BIOPHYS, V266, P41, DOI 10.1016/0003-9861(88)90234-2; Senda T, 2000, J MOL BIOL, V304, P397, DOI 10.1006/jmbi.2000.4200; Sevrioukova IF, 2004, J MOL BIOL, V336, P889, DOI 10.1016/j.jmb.2003.12.067; Sevrioukova IF, 2003, J MOL BIOL, V333, P377, DOI 10.1016/j.jmb.2003.08.028; Sevrioukova IF, 2002, J BIOL CHEM, V277, P25831, DOI 10.1074/jbc.M201110200; Sevrioukova IF, 2001, BIOCHEMISTRY-US, V40, P10592, DOI 10.1021/bi010874d; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; Teixeira VH, 2004, BIOPHYS J, V86, P2773, DOI 10.1016/S0006-3495(04)74331-3; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; Xia ZX, 2003, J BIOL INORG CHEM, V8, P843, DOI 10.1007/s00775-003-0485-0	50	40	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16135	16142		10.1074/jbc.M500771200	http://dx.doi.org/10.1074/jbc.M500771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716266	hybrid			2022-12-27	WOS:000228444800081
J	Rouached, H; Berthomieu, P; El Kassis, E; Cathala, N; Catherinot, V; Labesse, G; Davidian, JC; Fourcroy, P				Rouached, H; Berthomieu, P; El Kassis, E; Cathala, N; Catherinot, V; Labesse, G; Davidian, JC; Fourcroy, P			Structural and functional analysis of the C-terminal STAS (sulfate transporter and anti-sigma antagonist) domain of the Arabidopsis thaliana sulfate transporter SULTR1.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(F); REGULATORY DOMAIN; GENE; MUTATIONS; SPOIIAA; PROTEIN; PHOSPHORYLATION; YEAST; EXPRESSION; ENCODES	The C-terminal region of sulfate transporters from plants and animals belonging to the SLC26 family members shares a weak but significant similarity with the Bacillus sp. anti-anti-sigma protein SpoIIAA, thus defining the STAS domain ( sulfate transporter and anti-sigma antagonist). The present study is a structure/function analysis of the STAS domain of SULTR1.2, an Arabidopsis thaliana sulfate transporter. A three-dimensional model of the SULTR1.2 STAS domain was built which indicated that it shares the SpoIIAA folds. Moreover, the phosphorylation site, which is necessary for SpoIIAA activity, is conserved in the SULTR1.2 STAS domain. The model was used to direct mutagenesis studies using a yeast mutant defective for sulfate transport. Truncation of the whole SULTR1.2 STAS domain resulted in the loss of sulfate transport function. Analyses of small deletions and mutations showed that the C-terminal tail of the SULTR1.2 STAS domain and particularly two cysteine residues plays an important role in sulfate transport by SULTR1.2. All the substitutions made at the putative phosphorylation site Thr-587 led to a complete loss of the sulfate transport function of SULTR1.2. The reduction or suppression of sulfate transport of the SULTR1.2 mutants in yeast was not due to an incorrect targeting to the plasma membrane. Both our three-dimensional modeling and mutational analyses strengthen the hypothesis that the SULTR1.2 STAS domain is involved in protein-protein interactions that could control sulfate transport.	Univ Montpellier 2, INRA, Ecole Natl Super Agron Montpellier, CNRS,UMR 5004, F-34060 Montpellier, France; Univ Montpellier I, CNRS,UMR 5048, INSERM,U554, Ctr Biochim Struct, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Fourcroy, P (corresponding author), Univ Montpellier 2, INRA, Ecole Natl Super Agron Montpellier, CNRS,UMR 5004, F-34060 Montpellier, France.	fourcroy@ensam.inra.fr	Kassis, Elie Girgis El/AAP-6511-2020	Rouached, Hatem/0000-0002-7751-0477; El Kassis, Elie Girgis/0000-0002-8397-9482; Berthomieu, Pierre/0000-0003-3358-2417; Labesse, Gilles/0000-0002-6861-3300				Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Bignell DRD, 2003, FEMS MICROBIOL LETT, V225, P93, DOI 10.1016/S0378-1097(03)00504-4; Cherest H, 1997, GENETICS, V145, P627; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Clarkson J, 2003, BIOCHEM J, V372, P113, DOI 10.1042/BJ20021748; Clarkson J, 2001, J MOL BIOL, V314, P359, DOI 10.1006/jmbi.2001.5142; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Fizames C, 2004, PLANT PHYSIOL, V134, P67, DOI 10.1104/pp.103.030536; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hastbacka J, 1996, AM J HUM GENET, V58, P255; HAWKESFORD MJ, 1993, PLANTA, V190, P297, DOI 10.1007/BF00196957; Hedfalk K, 2004, J BIOL CHEM, V279, P14954, DOI 10.1074/jbc.M313126200; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Karniski LP, 2001, HUM MOL GENET, V10, P1485, DOI 10.1093/hmg/10.14.1485; Kitamura K, 2000, ACTA OTO-LARYNGOL, V120, P137, DOI 10.1080/000164800750000775; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Kovacs H, 1998, P NATL ACAD SCI USA, V95, P5067, DOI 10.1073/pnas.95.9.5067; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; Liu KH, 2003, EMBO J, V22, P1005, DOI 10.1093/emboj/cdg118; Lopez-Bigas N, 2001, Hum Mutat, V18, P548, DOI 10.1002/humu.1238; Lord M, 1996, J BACTERIOL, V178, P6730, DOI 10.1128/jb.178.23.6730-6735.1996; Markovich D, 2001, PHYSIOL REV, V81, P1499, DOI 10.1152/physrev.2001.81.4.1499; Maruyama-Nakashita A, 2003, PLANT PHYSIOL, V132, P597, DOI 10.1104/pp.102.019802; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Seavers PR, 2001, STRUCTURE, V9, P605, DOI 10.1016/S0969-2126(01)00623-2; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Shelden MC, 2001, BIOCHEM J, V356, P589, DOI 10.1042/0264-6021:3560589; Shibagaki N, 2004, J BIOL CHEM, V279, P30791, DOI 10.1074/jbc.M403248200; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; Smith FW, 1997, PLANT J, V12, P875, DOI 10.1046/j.1365-313X.1997.12040875.x; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tamas MJ, 2003, J BIOL CHEM, V278, P6337, DOI 10.1074/jbc.M209792200; Vidmar JJ, 2000, FEBS LETT, V475, P65, DOI 10.1016/S0014-5793(00)01615-X; WANG YH, 1992, J BIOL CHEM, V267, P16759; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Yoshimoto N, 2003, PLANT PHYSIOL, V131, P1511, DOI 10.1104/pp.014712	46	90	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15976	15983		10.1074/jbc.M501635200	http://dx.doi.org/10.1074/jbc.M501635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718229	hybrid, Green Published			2022-12-27	WOS:000228444800064
J	Shin, SW; Kokoza, V; Bian, GW; Cheon, HM; Kim, YJ; Raikhel, AS				Shin, SW; Kokoza, V; Bian, GW; Cheon, HM; Kim, YJ; Raikhel, AS			REL1, a homologue of Drosophila dorsal, regulates Toll antifungal immune pathway in the female mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE GENES; ANOPHELES-GAMBIAE; HOST-DEFENSE; DIF; EXPRESSION; INDUCTION; RELISH; INFECTION; PROTEINS; SEQUENCE	Signaling by Drosophila Toll pathway activates two Rel/NF-kappa B transcription factors, Dorsal (Dl) and Dorsal-related immune factor (Dif). Dl plays a central role in the establishment of dorsoventral polarity during early embryogenesis, whereas Dif mediates the Toll receptor-dependent antifungal immune response in adult Drosophila. The absence of a Dif ortholog in mosquito genomes suggests that Dl may play its functional role in the mosquito Toll-mediated innate immune responses. We have cloned and molecularly characterized the gene homologous to Drosophila Dl and to Anopheles gambiae REL1 (Gambif1) from the yellow fever mosquito Aedes aegypti, named AaREL1. AaREL1 alternative transcripts encode two isoforms, AaREL1-A and AaREL1-B. Both transcripts are enriched during embryogenesis and are inducible by septic injury in larval and female mosquitoes. AaREL1 and AaREL2 ( Aedes Relish) selectively bind to different kappa B motifs from insect immune gene promoters. Ectopic expression of AaREL1-A in both Drosophila mbn-2 cells and transgenic flies specifically activates Drosomycin and results in increased resistance against the fungus Beauveria bassiana. AaREL1-B acted cooperatively with AaREL1-A to enhance the immune gene activation in Aag-2 cells. The RNA interference knock-outs revealed that AaREL1 affected the expression of Aedes homologue of Drosophila Serpin-27A and mediated specific antifungal immune response against B. bassiana. These results indicate that the homologue of Dl, but not that of Dif, is a key regulator of the Toll antifungal immune pathway in A. aegypti female mosquitoes.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Bian, Guowu/B-1572-2010	Shin, Sang Woon/0000-0001-9467-0803	NIAID NIH HHS [R01 AI059492] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaty BJ, 2000, P NATL ACAD SCI USA, V97, P10295, DOI 10.1073/pnas.97.19.10295; Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; BRILLASMURY C, 1996, EMBO J, V15, P4691; CANTON Y, 2001, IMMUNOGENETICS, V52, P157; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Curtis CF, 2000, PARASITOL TODAY, V16, P119, DOI 10.1016/S0169-4758(99)01605-1; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Enserink M, 2002, SCIENCE, V297, P1988, DOI 10.1126/science.297.5589.1988; Fallon AM, 2001, INSECT BIOCHEM MOLEC, V31, P263, DOI 10.1016/S0965-1748(00)00146-6; Gross I, 1999, GENE, V228, P233, DOI 10.1016/S0378-1119(98)00595-2; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Lindmark H, 2001, J IMMUNOL, V167, P6920, DOI 10.4049/jimmunol.167.12.6920; Lycett GJ, 2002, NATURE, V417, P387, DOI 10.1038/417387a; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; Osta MA, 2004, J EXP BIOL, V207, P2551, DOI 10.1242/jeb.01066; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; Qiu P, 1998, DEVELOPMENT, V125, P1909; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Shin SW, 2002, P NATL ACAD SCI USA, V99, P9978, DOI 10.1073/pnas.162345999; Shin SW, 2003, P NATL ACAD SCI USA, V100, P2616, DOI 10.1073/pnas.0537347100; WATTAM AR, 1992, P NATL ACAD SCI USA, V89, P6502, DOI 10.1073/pnas.89.14.6502	41	92	94	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16499	16507		10.1074/jbc.M500711200	http://dx.doi.org/10.1074/jbc.M500711200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722339	hybrid			2022-12-27	WOS:000228444800124
J	Zoccarato, F; Toscano, P; Alexandre, A				Zoccarato, F; Toscano, P; Alexandre, A			Dopamine-derived dopaminochrome promotes H2O2 release at mitochondrial complex I - Stimulation by rotenone, control by Ca2+, and relevance to Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; HUMAN SUBSTANTIA-NIGRA; HYDROGEN-PEROXIDE; ALPHA-SYNUCLEIN; NADPH OXIDASE; INDUCED DEGENERATION; BRAIN MITOCHONDRIA; SUPEROXIDE ANION; OXIDATIVE STRESS; MOUSE MODEL	Inhibitors of Complex I of the mitochondrial respiratory chain, such as rotenone, promote Parkinson disease-like symptoms and signs of oxidative stress. Dopamine (DA) oxidation products may be implicated in such a process. We show here that the o-quinone dopaminochrome (DACHR), a relatively stable DA oxidation product, promotes concentration (0.1 - 0.2 mu M)- and respiration-dependent generation of H2O2 at Complex I in brain mitochondria, with further stimulation by low concentrations of rotenone ( 5 - 30 nM). The rotenone effect required that contaminating Ca2+ ( 8 - 10 mu M) was not removed. DACHR apparently extracts an electron from the constitutively autoxidizable site in Complex I, producing a semiquinone, which then transfers an electron to O-2, generating O-2(radical anion) and then H2O2. Mitochondrial removal of H2O2, formed by either monoamine oxidase activity or DACHR, was performed largely by glutathione peroxidase and glutathione reductase, which were negatively regulated by low intramitochondrial Ca2+ levels. Thus, the H2O2 formed accumulated in the medium if contaminating Ca2+ was present; in the absence of Ca2+, H2O2 was completely removed if it originated from monoamine oxidase, but was less completely removed if it originated from DACHR. We propose that the primary action of rotenone is to promote extracellular O-2. release via activation of NADPH oxidase in the microglia. In turn, O-2. oxidizes DA to DACHR extracellularly. ( The reaction is favored by the lack of GSH, which would otherwise preferably produce GSH adducts of dopaminoquinone.) Once formed, DACHR ( which is resistant to GSH) enters neurons to activate the rotenone-stimulated redox cycle described.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, CNR, Ist Neurosci, Sez Biomembrane, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Alexandre, A (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	adolfo.alexandre@unipd.it						Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BINDOLI A, 1990, BIOCHIM BIOPHYS ACTA, V1016, P349, DOI 10.1016/0005-2728(90)90168-4; BINDOLI A, 1992, FREE RADICAL BIO MED, V13, P391, DOI 10.1016/0891-5849(92)90182-G; CARSTAM R, 1991, BIOCHIM BIOPHYS ACTA, V1097, P152, DOI 10.1016/0925-4439(91)90100-N; CHIBA K, 1985, DRUG METAB DISPOS, V13, P342; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FAHAN S, 2000, MERRITTS NEUROLOGY, P679; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Floor E, 1998, J NEUROCHEM, V70, P268; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2003, TRENDS PHARMACOL SCI, V24, P395, DOI 10.1016/S0165-6147(03)00176-7; Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hudasek K, 2004, BIOCHEM BIOPH RES CO, V318, P135, DOI 10.1016/j.bbrc.2004.04.011; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kalivendi SV, 2004, J BIOL CHEM, V279, P15240, DOI 10.1074/jbc.M312497200; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; Kamsler A, 2003, J NEUROSCI, V23, P269; Kaur D, 2002, AGING CELL, V1, P17, DOI 10.1046/j.1474-9728.2002.00001.x; KITAHAMA K, 1991, NEUROSCIENCE, V44, P185, DOI 10.1016/0306-4522(91)90260-U; Lavi R, 2003, J BIOL CHEM, V278, P40917, DOI 10.1074/jbc.M303034200; Li H, 1997, J NEUROCHEM, V69, P1530; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MISRA HP, 1972, J BIOL CHEM, V247, P3170; ODH G, 1994, J NEUROCHEM, V62, P2030; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Schmidt N, 2001, J NEURAL TRANSM, V108, P1263, DOI 10.1007/s007020100004; Sherer TB, 2003, NEUROSCI LETT, V341, P87, DOI 10.1016/S0304-3940(03)00172-1; Sherer TB, 2002, J NEUROSCI, V22, P7006; Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; ZHANG F, 1993, BIOORG CHEM, V21, P392, DOI 10.1006/bioo.1993.1033; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zoccarato F, 2004, J BIOL CHEM, V279, P4166, DOI 10.1074/jbc.M308143200	56	77	79	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15587	15594		10.1074/jbc.M500657200	http://dx.doi.org/10.1074/jbc.M500657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710606	hybrid			2022-12-27	WOS:000228444800017
J	Martin, MC; Allan, LA; Lickrish, M; Sampson, C; Morrice, N; Clarke, PR				Martin, MC; Allan, LA; Lickrish, M; Sampson, C; Morrice, N; Clarke, PR			Protein kinase A regulates caspase-9 activation by Apaf-1 downstream of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CYCLIC-AMP; NEUTROPHIL APOPTOSIS; CANCER CELLS; PHOSPHORYLATION; CAMP; BAD; PROCASPASE-9; INHIBITION; SITE	The cyclic AMP signal transduction pathway modulates apoptosis in diverse cell types, although the mechanism is poorly understood. A critical component of the intrinsic apoptotic pathway is caspase-9, which is activated by Apaf-1 in the apoptosome, a large complex assembled in response to release of cytochrome c from mitochondria. Caspase-9 cleaves and activates effector caspases, predominantly caspase-3, resulting in the demise of the cell. Here we identified a distinct mechanism by which cyclic AMP regulates this apoptotic pathway through activation of protein kinase A. We show that protein kinase A inhibits activation of caspase-9 and caspase-3 downstream of cytochrome c in Xenopus egg extracts and in a human cell-free system. Protein kinase A directly phosphorylates human caspase-9 at serines 99, 183, and 195. However, mutational analysis demonstrated that phosphorylation at these sites is not required for the inhibitory effect of protein kinase A on caspase-9 activation. Importantly, protein kinase A inhibits cytochrome c-dependent recruitment of procaspase-9 to Apaf-1 but not activation of caspase-9 by a constitutively activated form of Apaf-1. These data indicate that extracellular signals that elevate cyclic AMP and activate protein kinase A may suppress apoptosis by inhibiting apoptosome formation downstream of cytochrome c release from mitochondria.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Clarke, PR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	paul.clarke@cancer.org.uk	Clarke, Paul R./AAA-6803-2020; Clarke, Paul/B-1684-2009	Clarke, Paul/0000-0003-3525-2622; Martin, Morag/0000-0002-8667-6057				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLARKE PR, 2002, APOPTOSIS MOL BIOL P, V40, P176; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kwon G, 2004, J BIOL CHEM, V279, P8938, DOI 10.1074/jbc.M310330200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rossi AG, 1998, J IMMUNOL, V160, P3562; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Knethen A, 2000, MOL CELL BIOCHEM, V212, P35, DOI 10.1023/A:1007124203607; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	71	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15449	15455		10.1074/jbc.M414325200	http://dx.doi.org/10.1074/jbc.M414325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703181	hybrid			2022-12-27	WOS:000228236800132
J	van der Wel, H; Ercan, A; West, CM				van der Wel, H; Ercan, A; West, CM			The Skp1 prolyl hydroxylase from Dictyostelium is related to the hypoxia-inducible factor-alpha class of animal prolyl 4-hydroxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN LIGASE; SPORE COAT; CYTOSOLIC GLYCOPROTEIN; PROLINE HYDROXYLATION; GLCNAC-TRANSFERASE; BINDING DOMAIN; MODIFIES SKP1; HIF; EXPRESSION; GLYCOSYLATION	Skp1 is a cytoplasmic and nuclear protein of eukaryotes best known as an adaptor in SCF ubiquitin-protein isopeptide ligases. In Dictyostelium, Skp1 is subject to 4-hydroxylation at Pro(143) and subsequent O-glycosylation by alpha-linked GlcNAc and other sugars. Soluble cytosolic extracts have Skp1 prolyl 4-hydroxylase (P4H) activity, which can be measured based on hydroxylation-dependent transfer of [H-3]GlcNAc to recombinant Skp1 by recombinant (Skp1-protein)-hydroxyproline alpha-N-acetyl-D-glucosaminyltransferase. The Dictyostelium Skp1 P4H gene (phyA) was predicted using a bioinformatics approach, and the expected enzyme activity was confirmed by expression of phyA cDNA in Escherichia coli. The purified recombinant enzyme (P4H1) was dependent on physiological concentrations of O-2, alpha-ketoglutarate, and ascorbate and was inhibited by CoCl2, 3,4-dihydroxybenzoate, and 3,4-dihydroxyphenyl acetate, as observed for known animal cytoplasmic P4Hs of the hypoxia-inducible factor-alpha (HIF alpha) class. Overexpression of phyA cDNA in Dictyostelium yielded increased enzyme activity in a soluble cytosolic extract. Disruption of the phyA locus by homologous recombination resulted in loss of detectable activity in extracts and blocked hydroxylation-dependent glycosylation of Skp1 based on molecular weight analysis by SDS-PAGE, demonstrating a requirement for P4H1 in vivo. The sequence and functional similarities of P4H1 to animal HIF alpha-type P4Hs suggest that hydroxylation of Skp1 may, like that of animal HIF alpha, be regulated by availability of O-2, alpha-ketoglutarate, and ascorbate, which might exert novel control over Skp1 glycosylation.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 937, Oklahoma City, OK 73104 USA.	Cwest2@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAVIND L, 2001, GENOME BIOL; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Dalgard CL, 2004, BIOCHEM J, V380, P419, DOI 10.1042/BJ20031647; de Bruin Eric C., 2002, FEMS Yeast Research, V1, P291, DOI 10.1016/S1567-1356(01)00042-3; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; ERCAN A, 2005, IN PRESS GLYCOBIOLOG; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; KASKA DD, 1987, BIOCHEM J, V241, P483, DOI 10.1042/bj2410483; Ketcham C, 2004, J BIOL CHEM, V279, P29050, DOI 10.1074/jbc.M313858200; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Knowles HJ, 2003, CANCER RES, V63, P1764; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Mohanty S, 2001, GENE DEV, V15, P1435, DOI 10.1101/gad.871101; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Oehme F, 2004, ANAL BIOCHEM, V330, P74, DOI 10.1016/j.ab.2004.03.066; Pang KM, 1999, PLASMID, V41, P187, DOI 10.1006/plas.1999.1391; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Puta F, 1998, FOLIA BIOL-PRAGUE, V44, P185; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; SANDONA D, 1995, J BIOL CHEM, V270, P5587, DOI 10.1074/jbc.270.10.5587; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; STERNFELD J, 1977, P NATL ACAD SCI USA, V74, P268, DOI 10.1073/pnas.74.1.268; STERNFELD J, 1981, J CELL SCI, V50, P9; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vervoort EB, 2000, NUCLEIC ACIDS RES, V28, P2069, DOI 10.1093/nar/28.10.2069; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; Wang F, 2003, J BIOL CHEM, V278, P51395, DOI 10.1074/jbc.M308756200; West C. M., 2005, DICTYOSTELIUM GENOMI, P235; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2004, BBA-GEN SUBJECTS, V1673, P29, DOI 10.1016/j.bbagen.2004.04.007; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; Zhang YY, 1998, BIOCHEMISTRY-US, V37, P10766, DOI 10.1021/bi9808013; Zhang YY, 1999, J CELL SCI, V112, P4367; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	62	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14645	14655		10.1074/jbc.M500600200	http://dx.doi.org/10.1074/jbc.M500600200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705570	hybrid			2022-12-27	WOS:000228236800039
J	Manchanda, N; Lyubimova, A; Ho, HYH; James, MF; Gusella, JF; Ramesh, N; Snapper, SB; Ramesh, V				Manchanda, N; Lyubimova, A; Ho, HYH; James, MF; Gusella, JF; Ramesh, N; Snapper, SB; Ramesh, V			The NF2 tumor suppressor merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIGELLA-FLEXNERI; ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTRACELLULAR MOTILITY; EPITHELIAL-CELLS; F-ACTIN; ASSOCIATION; MECHANISM; ACTIVATION; NUCLEATION	The function of the NF2 tumor suppressor merlin has remained elusive despite increasing evidence for its role in actin cytoskeleton reorganization. The closely related ERM proteins (ezrin, radixin, and moesin) act as linkers between the cell membrane and cytoskeleton, and have also been implicated as active actin reorganizers. We report here that merlin and the ERMs can interact with and regulate N-WASP, a critical regulator of actin dynamics. Merlin and moesin were found to inhibit N-WASP-mediated actin assembly in vitro, a function that appears independent of their ability to bind actin. Furthermore, exogenous expression of a constitutively active ERM inhibits N-WASP-dependent Shigella tail formation, suggesting that the ERMs may function as inhibitors of N- WASP function in vivo. This novel function of merlin and the ERMs illustrates a mechanism by which these proteins directly exert their effects on actin reorganization and also provides new insight into N-WASP regulation.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Inflammatory Bowel Dis, Boston, MA 02114 USA; Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Bldg 149,13th St,Rm 6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59561] Funding Source: Medline; NIAID NIH HHS [AI052354] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Kato M, 2002, BIOCHEM BIOPH RES CO, V291, P41, DOI 10.1006/bbrc.2002.6406; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mounier J, 1999, J CELL SCI, V112, P2069; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shibata T, 2002, CURR BIOL, V12, P341, DOI 10.1016/S0960-9822(02)00689-9; Skoudy A, 1999, J CELL SCI, V112, P2059; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wiederhold T, 2004, ONCOGENE, V23, P8815, DOI 10.1038/sj.onc.1208110	33	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12517	12522		10.1074/jbc.C400583200	http://dx.doi.org/10.1074/jbc.C400583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15699051	hybrid			2022-12-27	WOS:000227922000055
J	Ortega-Perez, I; Cano, E; Were, F; Villar, M; Vazquez, J; Redondo, JM				Ortega-Perez, I; Cano, E; Were, F; Villar, M; Vazquez, J; Redondo, JM			c-jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; TRAP MASS-SPECTROMETRY; T-CELLS; GENE-EXPRESSION; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; PHOSPHATASE CALCINEURIN; IDENTIFICATION	The nuclear factor of activated T cells ( NFAT) family of transcription factors regulates the transcription of cytokine genes and other genes involved in the regulation and function of the immune system. NFAT activity is regulated by the phosphatase calcineurin, which binds and dephosphorylates the NFAT N-terminal regulatory domain, a critical step required for nuclear translocation and transcriptional activity. Here we show that the mitogen-activated protein kinase ( MAPK) JNK activates NFATc2-dependent transcription. Mass spectrometry revealed that JNK phosphorylates at least six residues within the NFATc2 regulatory domain in vitro. Transfection of cells with a chimeric construct encoding the GAL-4 DNA binding domain linked to wild-type NFATc2 showed that JNK stimulates the NFATc2 transactivation domain in activated Jurkat T lymphocytes, an effect that is inhibited by dominant-negative versions of JNK. Likewise, the mutation of the phosphorylation sites identified revealed that Thr(116) and Ser(170) are critical for the transactivation of NFATc2 by JNK. In addition, clustered mutation of the SP-conserved motifs of NFATc2 showed that SP1 and SP2, but not SP3, are also important for the inducible transactivation of NFATc2. Furthermore, mass spectrometry analysis of NFATc2-transfected cells indicated that the activation of the JNK pathway results in the in vivo phosphorylation of Thr(116). Our results indicate that, unlike other NFAT members, the transcriptional activity of NFATc2 is up-regulated by JNK. JNK-mediated phosphorylation of NFATs thus appears to play a differential physiological role among NFAT family members.	Ctr Nacl Invest Cardiovasc, Madrid 28760, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), Ctr Nacl Invest Cardiovasc, Ronda Poniente 5, Madrid 28760, Spain.	jmredondo@cbm.uam.es	Cano, Eva/A-2049-2010; Villar-Rayo, Marga M/J-4155-2012; Vazquez, Jesus/B-7697-2015; Redondo, Juan Miguel/H-6351-2015	Cano, Eva/0000-0003-2750-6135; Villar-Rayo, Marga M/0000-0003-4172-9079; Vazquez, Jesus/0000-0003-1461-5092; Redondo, Juan Miguel/0000-0001-5779-9122				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Ogueta S, 2000, J MASS SPECTROM, V35, P556; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Yang TTC, 2005, MOL CELL BIOL, V25, P907, DOI 10.1128/MCB.25.3.907-920.2005; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	54	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20867	20878		10.1074/jbc.M501898200	http://dx.doi.org/10.1074/jbc.M501898200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15743762	hybrid			2022-12-27	WOS:000229242000085
J	de Garavilla, L; Greco, MN; Sukumar, N; Chen, ZW; Pineda, AO; Mathews, FS; Di Cera, E; Giardino, EC; Wells, GI; Haertlein, BJ; Kauffman, JA; Corcoran, TW; Derian, CK; Eckardt, AJ; Damiano, BP; Andrade-Gordon, P; Maryanoff, BE				de Garavilla, L; Greco, MN; Sukumar, N; Chen, ZW; Pineda, AO; Mathews, FS; Di Cera, E; Giardino, EC; Wells, GI; Haertlein, BJ; Kauffman, JA; Corcoran, TW; Derian, CK; Eckardt, AJ; Damiano, BP; Andrade-Gordon, P; Maryanoff, BE			A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase - Molecular mechanisms and anti-inflammatory activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ANGSTROM CRYSTAL-STRUCTURE; ANGIOTENSIN-II; NEUTROPHIL RECRUITMENT; INDUCED SPUTUM; CELL BIOLOGY; INFLAMMATION; ADHESION; PROTEINASES; CYTOKINE	Certain leukocytes release serine proteases that sustain inflammatory processes and cause disease conditions, such as asthma and chronic obstructive pulmonary disease. We identified beta-ketophosphonate 1 (JNJ-10311795; RWJ-355871) as a novel, potent dual inhibitor of neutrophil cathepsin G ( K-i = 38 nM) and mast cell chymase ( K-i = 2.3 nM). The x-ray crystal structures of 1 complexed with human cathepsin G ( 1.85 angstrom) and human chymase ( 1.90 angstrom) reveal the molecular basis of the dual inhibition. Ligand 1 occupies the S-1 and S-2 subsites of cathepsin G and chymase similarly, with the 2-naphthyl in S-1, the 1-naphthyl in S-2, and the phosphonate group in a complex network of hydrogen bonds. Surprisingly, however, the carboxamido- N-(naphthalene-2-carboxyl) piperidine group is found to bind in two distinct conformations. In cathepsin G, this group occupies the hydrophobic S-3/S-4 subsites, whereas in chymase, it does not; rather, it folds onto the 1-naphthyl group of the inhibitor itself. Compound 1 exhibited noteworthy anti-inflammatory activity in rats for glycogen-induced peritonitis and lipopolysaccharide-induced airway inflammation. In addition to a marked reduction in neutrophil influx, 1 reversed increases in inflammatory mediators interleukin-1 alpha, interleukin-1 beta, tissue necrosis factor-alpha, and monocyte chemotactic protein-1 in the glycogen model and reversed increases in airway nitric oxide levels in the lipopolysaccharide model. These findings demonstrate that it is possible to inhibit both cathepsin G and chymase with a single molecule and suggest an exciting opportunity in the treatment of asthma and chronic obstructive pulmonary disease.	Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA 19477 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Johnson & Johnson; Johnson & Johnson USA; Washington University (WUSTL)	Maryanoff, BE (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, Spring House, PA 19477 USA.	bmaryano@prdus.jnj.com			NHLBI NIH HHS [HL58141, HL73813, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL058141, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; BORISH L, 1992, MED CLIN N AM, V76, P765, DOI 10.1016/S0025-7125(16)30325-X; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER CW, 1979, J BIOL CHEM, V254, P2219; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; CAUGHEY GH, 1995, CLIN ALLERGY IMMUNOL, V6, P305; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Compton SJ, 1998, J IMMUNOL, V161, P1939; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Greco MN, 2002, J AM CHEM SOC, V124, P3810, DOI 10.1021/ja017506h; HANSON RD, 1990, J BIOL CHEM, V265, P1524; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; Huang XR, 2003, J AM SOC NEPHROL, V14, P1738, DOI 10.1097/01.ASN.0000071512.93927.4E; Iwamura H, 2002, INFLAMM RES, V51, P160, DOI 10.1007/PL00000288; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehr H A, 1994, Curr Opin Hematol, V1, P92; Lindberg BF, 1997, PEPTIDES, V18, P847, DOI 10.1016/S0196-9781(97)00011-9; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Mulligan MS, 1998, INFLAMM RES, V47, P251, DOI 10.1007/s000110050326; MUROHARA T, 1995, J PHARMACOL EXP THER, V274, P1246; Nishimoto M, 2001, CIRCULATION, V104, P1274, DOI 10.1161/hc3601.094304; Orito K, 2004, TOHOKU J EXP MED, V203, P287, DOI 10.1620/tjem.203.287; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; Owen CA, 1998, J IMMUNOL, V160, P1436; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132, DOI 10.1016/S0091-6749(99)70308-8; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PICCIONI PD, 1992, CHEST, V102, P1470, DOI 10.1378/chest.102.5.1470; Rhee JS, 2003, CURR MOL MED, V3, P387, DOI 10.2174/1566524033479753; Richards D, 2003, 11TH IEEE INTERNATIONAL REQUIREMENTS ENGINEERING CONFERENCE, PROCEEDINGS, P373; RICHARDSON D, 1993, PIANO KEYBOARD, P15; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SCHECHTER NM, 2000, MAST CELLS BASOPHILS, P275; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; Simon S R, 1993, Agents Actions Suppl, V42, P27; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Tomimori Y, 2003, EUR J PHARMACOL, V478, P179, DOI 10.1016/j.ejphar.2003.08.050; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; Tremblay Guy M, 2003, Curr Opin Investig Drugs, V4, P556; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Yao V, 2003, ANZ J SURG, V73, P1052, DOI 10.1046/j.1445-2197.2003.t01-18-.x; [No title captured]	55	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18001	18007		10.1074/jbc.M501302200	http://dx.doi.org/10.1074/jbc.M501302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741158	hybrid			2022-12-27	WOS:000228807200055
J	Imamura, T; Imamura, C; Iwamoto, Y; Sandell, LJ				Imamura, T; Imamura, C; Iwamoto, Y; Sandell, LJ			Transcriptional co-activators CREB-binding protein/p300 increase chondrocyte Cd-rap gene expression by multiple mechanisms including sequestration of the repressor CCAAT/enhancer-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COL2A1 PROMOTER ACTIVITY; II COLLAGEN GENE; MESSENGER-RNA; C/EBP-BETA; CAMPOMELIC DYSPLASIA; FACTOR SOX9; TGF-BETA; P300; CARTILAGE	Cartilage-derived retinoic acid-sensitive protein (CD-RAP) is a small secreted matrix protein expressed in developing and adult cartilage and by chondrocytes in culture. We have previously shown that the expression of Cd-rap, like many other cartilage matrix proteins, is repressed by interleukin 1 beta and that the transcription factor CCAAT/enhancer-binding protein (C/EBP) beta plays an important role in the interleukin 1 beta-induced repression ( Okazaki, K., Li, J., Yu, H., Fukui, N., and Sandell, L. J. ( 2002) J. Biol. Chem. 277, 31526 - 31533). The coactivators CREB-binding protein (CBP) and p300 are transcriptional co-regulators that participate in the activities of many different transcription factors including C/EBP. Here we show that CBP/p300 can reverse the inhibitory effect of C/EBP and moreover can stimulate expression of Cd-rap. The mechanism of this effect is shown to involve a unique synergy whereby CBP/p300 stimulate Cd-rap gene expression by at least two mechanisms. First, binding of CBP/p300 to C/EBP beta leads to sequestration of C/EBP eliminating DNA binding and subsequent repression; second, binding of CBP/p300 to the transcriptional activator Sox9 increases Sox9 DNA binding to the Cd-rap promoter leading to further stimulation of gene transcription. This is an example of a complementary transcriptional network whereby two very different mechanisms act together to confer a functional increase in transcription. This new paradigm is likely generally applicable to cartilage genes as Col2a1 cartilage collagen gene responds similarly.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Kyushu University	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Surg, 660 S Euclid Ave,Box 8233, St Louis, MO 63110 USA.	sandelll@wustl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994, R01AR045550] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR36994, R01 AR045550] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Chen X, 1999, MOL CELL BIOL, V19, P4695; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hou CH, 2002, CELL RES, V12, P79, DOI 10.1038/sj.cr.7290113; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Huang ZM, 2004, J BONE MINER RES, V19, P245, DOI 10.1359/jbmr.2004.19.2.245; Iioka T, 2003, J BONE MINER RES, V18, P1419, DOI 10.1359/jbmr.2003.18.8.1419; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; Janknecht R, 1996, ONCOGENE, V12, P1961; Kondo SJ, 2001, J ORTHOP RES, V19, P712, DOI 10.1016/S0736-0266(00)00068-1; Kuang PP, 2003, AM J PHYSIOL-CELL PH, V285, pC1349, DOI 10.1152/ajpcell.00173.2003; Kypriotou M, 2003, DNA CELL BIOL, V22, P119, DOI 10.1089/104454903321515922; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mochizuki K, 2002, GENE, V291, P271, DOI 10.1016/S0378-1119(02)00625-X; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Okazaki K, 2002, J BIOL CHEM, V277, P31526, DOI 10.1074/jbc.M202815200; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Raval-Pandya M, 2001, MOL ENDOCRINOL, V15, P1035, DOI 10.1210/me.15.6.1035; RUBINSTEIN JH, 1990, AM J MED GENET, P3; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sock E, 2003, HUM MOL GENET, V12, P1439, DOI 10.1093/hmg/ddg158; STRYER L, 1995, BIOCHEMISTRY-US, P581; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Watanabe M, 2003, AM J PATHOL, V163, P633, DOI 10.1016/S0002-9440(10)63690-5; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002	43	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16625	16634		10.1074/jbc.M411469200	http://dx.doi.org/10.1074/jbc.M411469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722556	hybrid			2022-12-27	WOS:000228615500013
J	Moir, RD; Tseitlin, KA; Soscia, S; Hyman, BT; Irizarry, MC; Tanzi, RE				Moir, RD; Tseitlin, KA; Soscia, S; Hyman, BT; Irizarry, MC; Tanzi, RE			Autoantibodies to redox-modified oligomeric A beta are attenuated in the plasma of Alzheimer's disease patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL AMYLOID ANGIOPATHY; CENTRAL-NERVOUS-SYSTEM; MOUSE MODEL; PROTEIN; ANTIBODIES; PEPTIDE; BRAIN; PATHOLOGY; DEMENTIA; SERUM	Accumulation of A beta protein in beta-amyloid deposits is a hallmark event in Alzheimer's disease ( AD). Recent findings suggest anti-A beta autoantibodies may have a role in AD pathology. However, a consensus has yet to emerge as to whether endogenous anti-A beta autoantibodies are elevated, depressed, or unchanged in AD patients. Whereas experiments to date have used synthetic unmodified monomeric A beta (A beta(mon)) to test autoimmunity, up to 40% of the A beta pool in AD brain consists of low molecular weight oligomeric cross-linked beta-amyloid protein species ( CAPS). Recent studies also suggest that CAPS may be the primary neurotoxic agent in AD. In the present study, AD and nondemented control plasma were analyzed for immunoreactivity to CAPS and A beta(mon). Plasma of both nondemented and AD patients were found to contain autoantibodies specific for soluble CAPS. Nondemented control and AD plasmas demonstrated similar immunoreactivity to A beta(mon). In contrast, anti-CAPS antibodies in AD plasma were found to be significantly reduced compared with nondemented controls ( p = 0.018). Furthermore, age at onset for AD correlated significantly ( p = 0.041) with plasma immunoreactivity to CAPS. These data suggest that autoantibodies to CAPS are depleted in AD patients and raise the prospect that immunization with anti-CAPS antibodies might provide therapeutic benefit for AD.	Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Tanzi, RE (corresponding author), Massachusetts Gen Hosp E, Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Moir, Robert D./M-7612-2017	Tanzi, Rudolph/0000-0002-7032-1454; Moir, Robert D./0000-0001-5431-3553				Atwood CS, 2000, CELL MOL BIOL, V46, P777; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 2004, BIOCHEMISTRY-US, V43, P560, DOI 10.1021/bi0358824; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSH AI, 1995, SCIENCE, V268, P1921, DOI 10.1126/science.268.5219.1921; Bush AI, 2002, P NATL ACAD SCI USA, V99, P7317, DOI 10.1073/pnas.122249699; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; CITRON M, 1993, NEUROBIOL AGING, V14, P571, DOI 10.1016/0197-4580(93)90041-9; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Du Y, 2001, NEUROLOGY, V57, P801, DOI 10.1212/WNL.57.5.801; Fukumoto H, 2003, ARCH NEUROL-CHICAGO, V60, P958, DOI 10.1001/archneur.60.7.958; Galeazzi L, 1999, AMYLOID, V6, P7, DOI 10.3109/13506129908993282; Games D, 2000, ANN NY ACAD SCI, V920, P274; GASKIN F, 1993, J EXP MED, V177, P1181, DOI 10.1084/jem.177.4.1181; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P325; HAWKINS PN, 1994, BIOCHEM BIOPH RES CO, V201, P722, DOI 10.1006/bbrc.1994.1760; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hyman BT, 2001, ANN NEUROL, V49, P808, DOI 10.1002/ana.1061; Iwatsubo T, 1998, NEUROBIOL AGING, V19, P161, DOI 10.1016/S0197-4580(98)00015-3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leblhuber F, 1998, DEUT MED WOCHENSCHR, V123, P787, DOI 10.1055/s-2007-1024069; LEONARDI A, 1985, J NEUROL SCI, V67, P253, DOI 10.1016/0022-510X(85)90121-2; Matsuoka Y, 2003, J NEUROSCI, V23, P29; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Mehta PD, 1998, NEUROSCI LETT, V241, P13, DOI 10.1016/S0304-3940(97)00966-X; MONNING U, 1991, BASIC MECH DIAGNOSIS, P557; Myagkova MA, 2001, B EXP BIOL MED+, V131, P127, DOI 10.1023/A:1017527508878; Nath A, 2003, NEUROMOL MED, V3, P29, DOI 10.1385/NMM:3:1:29; Oppezzo P, 2003, PATHOL BIOL, V51, P297, DOI 10.1016/S0369-8114(02)00318-8; Rensink AAM, 2003, BRAIN RES REV, V43, P207, DOI 10.1016/j.brainresrev.2003.08.001; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, AM J PATHOL, V145, P452; Tamaoka A, 1998, Nihon Ronen Igakkai Zasshi, V35, P273; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Weksler ME, 2002, EXP GERONTOL, V37, P943, DOI 10.1016/S0531-5565(02)00029-3; Weksler ME, 2002, EXP GERONTOL, V37, P971, DOI 10.1016/S0531-5565(02)00091-8; Xu SH, 1997, MECH AGEING DEV, V94, P213, DOI 10.1016/S0047-6374(96)01861-1; Yoburn JC, 2003, CHEM RES TOXICOL, V16, P531, DOI 10.1021/tx025666g	55	83	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17458	17463		10.1074/jbc.M414176200	http://dx.doi.org/10.1074/jbc.M414176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728175	hybrid			2022-12-27	WOS:000228615500112
J	Toh, WH; Kyo, S; Sabapathy, K				Toh, WH; Kyo, S; Sabapathy, K			Relief of p53-mediated telomerase suppression by p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; CONFERS RESISTANCE; SPONTANEOUS TUMORS; P53 HOMOLOG; DNA-BINDING; HTERT GENE; LIFE-SPAN	Reactivation of telomerase is a feature in many cancer cells. Telomerase activation inhibits telomere shortening, thereby preventing cell cycle arrest and apoptosis activated by shortened telomeres or chromosomal rearrangements. The tumor-suppressor gene product, p53, was previously shown to transcriptionally suppress the activation of the catalytic subunit of telomerase ( hTERT). Here we have evaluated the role of p73 in hTERT regulation. We found that ectoptic expression of p73 beta, in contrast to p73 alpha or p53, in p53 null H1299 cells does not lead to suppression of hTERT transcription. However co-expression of p73 alpha or p73 beta together with p53 abolished p53-mediated hTERT suppression. This phenomenon was found to be dependent on the DNA binding ability of p73. We also show that p53-mediated suppression of hTERT transcription requires a minimum threshold level of p53, and p73 abrogates p53-mediated suppression by reducing p53 levels through the activation of HDM2. Moreover, p53-mediated hTERT suppression was not relieved by p73 beta in cells depleted of HDM2 through small interfering RNA-mediated gene silencing. In addition, knockdown of HDM2 in MCF7 cells, which express moderately high levels of p73 and p53, resulted in the reduction of endogenous hTERT levels. Finally, knockdown of p73 in MCF7 cells resulted in increased p53 protein levels and a concomitant decrease in hTERT levels. Together, our data indicate a plausible way by which p73, through HDM2, can oppose p53 tumor suppressor function, thereby possibly contributing to tumorigenesis.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National Cancer Centre Singapore (NCCS); Kanazawa University; National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Akiyama M, 2002, CANCER RES, V62, P3876; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dimri GP, 2002, CANCER RES, V62, P4736; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Naggar AK, 2001, CARCINOGENESIS, V22, P729, DOI 10.1093/carcin/22.5.729; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Misawa M, 2002, INT J ONCOL, V21, P1087; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Ozaki T, 1999, CANCER RES, V59, P5902; Saito M, 2004, INT J ONCOL, V24, P1213; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Takakura M, 1999, CANCER RES, V59, P551; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang XQ, 2001, CANCER RES, V61, P1598; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan Zhang, 2002, Hematol J, V3, P201, DOI 10.1038/sj.thj.6200177; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhu JH, 1998, CANCER RES, V58, P5061	45	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17329	17338		10.1074/jbc.M500044200	http://dx.doi.org/10.1074/jbc.M500044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734740	hybrid			2022-12-27	WOS:000228615500097
J	Tripathi, MK; Misra, S; Khedkar, SV; Hamilton, N; Irvin-Wilson, C; Sharan, C; Sealy, L; Chaudhuri, G				Tripathi, MK; Misra, S; Khedkar, SV; Hamilton, N; Irvin-Wilson, C; Sharan, C; Sealy, L; Chaudhuri, G			Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS SNAIL; DOWN-REGULATION; IN-VIVO; PROMOTER; BINDING; SILENCER; FAMILY; RNA	The expression of the breast cancer susceptibility protein BRCA2 is highly regulated in human breast, ovary, and pancreatic cells. BRCA2 is not expressed in the nondividing cells, and expression is cell cycle stage-dependent and is elevated in the sporadic cancer cells. Mutational analysis of the upstream sequence of the human BRCA2 gene revealed an E2-box-containing silencer at the - 701 to - 921 position. The E2-box is essential for the cell-cycle stage-dependent activity of the silencer. We affinity-purified a 29-kDa silencer-binding protein (SBP) from the nuclear extracts of human breast cells BT-549 and MDA-MB-231. We explored whether the E2-box- binding repressor protein SLUG, which is of similar molecular size, is involved in the silencing process. Supershift assay with the purified SBP and anti-SLUG antibody revealed the identity of the SBP as SLUG. We found that silencer is inactive in the human breast cancer cells such as MDA-MB-468 and MCF-7 that do not express SLUG, further suggesting the involvement of SLUG in the BRCA2 gene silencing. Inducible expression of human SLUG in the dividing MDA-MB-468 cells reduced BRCA2 RNA levels with the activation of the silencer. Furthermore, small interfering RNA-mediated knockdown of SLUG mRNA in the BT-549 cells caused inhibition of the silencer function. Chromatin immunoprecipitation assays suggested that SLUG mediates its action by recruiting C-terminal-binding protein-1 (CtBP-1) and histone deacetylase-1 (HDAC-1) at the silencer E2-box. The general HDAC inhibitor, trichostatin A, inhibited the SLUG-mediated regulation of the silencer function. It thus appears that SLUG is a negative regulator for BRCA2 gene expression.	Meharry Med Coll, Dept Biomed Sci, Div Canc Biol, Nashville, TN 37208 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37208 USA	Meharry Medical College; Vanderbilt University	Chaudhuri, G (corresponding author), Meharry Med Coll, Dept Biomed Sci, Div Canc Biol, 1005 DB Todd Jr Blvd, Nashville, TN 37208 USA.	gchaudhuri@mmc.edu			NATIONAL CANCER INSTITUTE [U54CA091408] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA091408-01, U54 CA091408, 1U54CA091408-010003] Funding Source: Medline; NIMHD NIH HHS [U54 MD007593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Bertwistle D, 1997, CANCER RES, V57, P5485; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; CAMPBELL MJ, 1994, MED STAT COMMONSENSE; Chodosh LA, 1998, J MAMMARY GLAND BIOL, V3, P389, DOI 10.1023/A:1018784031651; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Hajra KM, 2002, CANCER RES, V62, P1613; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; Humphrey GW, 1996, GENE EXPRESSION, V6, P151; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Kropotov A, 1999, EUR J BIOCHEM, V260, P336, DOI 10.1046/j.1432-1327.1999.00162.x; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Sambrook J., 2001, MOL CLONING LAB MANU; Scully R, 2004, J MAMMARY GLAND BIOL, V9, P237, DOI 10.1023/B:JOMG.0000048771.93906.3e; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SPECTOR DL, 1997, CELLS LAB MANUAL; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V328, P43, DOI 10.1016/j.bbrc.2004.12.142; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Zwijsen A, 2001, MOL CELL ENDOCRINOL, V180, P13, DOI 10.1016/S0303-7207(01)00505-6	31	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17163	17171		10.1074/jbc.M501375200	http://dx.doi.org/10.1074/jbc.M501375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734731	Green Accepted, hybrid			2022-12-27	WOS:000228615500077
J	Lee, MH; Rapti, M; Murphy, G				Lee, MH; Rapti, M; Murphy, G			Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting - Fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; ESCHERICHIA-COLI; APOPTOSIS; SEQUENCE; EXPRESSION; INVASION; DEATH	Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous inhibitors of the matrix metalloproteinases, the ADAMs ( a disintegrin and metalloproteinase) and the ADAM-TS ( ADAM with thrombospondin repeats) proteinases. There are four mammalian TIMPs (TIMP-1 to -4), and each TIMP has its own profile of metalloproteinase inhibition. TIMP-4 is the latest member of the TIMPs to be cloned, and it has never been reported to be active against the tumor necrosis factor-alpha-converting enzyme ( TACE, ADAM-17). Here we examined the inhibitory properties of the full-length and the N-terminal domain form of TIMP-4 ( N-TIMP-4) with TACE and showed that N- TIMP-4 is a far superior inhibitor than its full-length counterpart. Although full-length TIMP-4 displayed negligible activity against TACE, N- TIMP-4 is a slow tight-binding inhibitor with low nanomolar binding affinity. Our findings suggested that the C-terminal subdomains of the TIMPs have a significant impact over their activities with the ADAMs. To elucidate further the molecular basis that underpins TIMP/TACE interactions, we sculpted N-TIMP-4 with the surface residues of TIMP-3, the only native TIMP inhibitor of the enzyme. Transplantation of only three residues, Pro-Phe-Gly, onto the AB-loop of N- TIMP-4 resulted in a 10-fold enhancement in binding affinity; the K-i values of the resultant mutant were almost comparable with that of TIMP-3. Further mutation at the EF-loop supported our earlier findings on the preference of TACE for leucine at this locus. Drawing together our previous experience in TACE-targeted mutagenesis by using TIMP-1 and -2 scaffolds, we have finally resolved the mystery of the selective sensitivity of TACE to TIMP-3.	Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Davis D, 2000, METH MOL B, V151, P267, DOI 10.1385/1-59259-046-2:267; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Lee MH, 2004, J BIOL CHEM, V279, P45121, DOI 10.1074/jbc.M406611200; Lee MH, 2004, J BIOL CHEM, V279, P17562, DOI 10.1074/jbc.M312589200; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; NEGRO A, 1995, FEBS LETT, V360, P52, DOI 10.1016/0014-5793(95)00073-I; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; Stratmann B, 2001, BIOL CHEM, V382, P987, DOI 10.1515/BC.2001.124; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2000, METH MOL B, V151, P257, DOI 10.1385/1-59259-046-2:257; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; WILLIAMSON RA, 1994, PROTEIN ENG, V7, P1035, DOI 10.1093/protein/7.8.1035	32	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15967	15975		10.1074/jbc.M500897200	http://dx.doi.org/10.1074/jbc.M500897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713681	hybrid			2022-12-27	WOS:000228444800063
J	Charvet, C; Canonigo, AJ; Billadeau, DD; Altman, A				Charvet, C; Canonigo, AJ; Billadeau, DD; Altman, A			Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; LYMPHOCYTE DEVELOPMENT; BIOLOGICAL-ACTIVITY; IMMUNE-RECOGNITION; PLASMA-MEMBRANE; FAMILY PROTEINS; GENE ACTIVATION; RHO-FAMILY; PKC-THETA; B-CELLS	The Vav family of guanine exchange factors plays a critical role in lymphocyte proliferation, cytoskeletal reorganization, and gene transcription upon immunoreceptor engagement. Although the role of Vav1 in T cells is well documented, the role of Vav3 is less clear. We investigated the subcellular localization of Vav3 during T cell activation. We report here that phosphorylation of Vav3 on tyrosine residue Tyr(173) is not required for T cell receptor (TCR)-induced Vav3 membrane translocation or immunological synapse (IS) recruitment, but mutation of this residue enhanced TCR-induced nuclear factor of activated T cells ( NFAT) activation. However, Vav3 mutants either containing an Src homology 2 (SH2)-disabled point mutation (R697L) or lacking its SH3-SH2-SH3 domains were unable to bind SLP-76 did not translocate to the membrane or to the IS and furthermore failed to activate NFAT. Importantly, the membrane translocation of Vav3 was abrogated in Lck, ZAP-70, LAT, and SLP-76-deficient T cells, where Vav3 binding to SLP-76 was disrupted. Finally, we confirmed and underlined the critical role of Vav3 in NFAT activation by knocking down Vav3 expression in Vav1-deficient T cells. Altogether, our data show that TCR-induced association of Vav3 with SLP-76 is required for its membrane/IS localization and function.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA	La Jolla Institute for Immunology; Mayo Clinic; Mayo Clinic	Charvet, C (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.	charvet@liai.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Altman A, 1999, ADV IMMUNOL, V72, P1, DOI 10.1016/S0065-2776(08)60017-6; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Charvet C, 2002, J BIOL CHEM, V277, P15376, DOI 10.1074/jbc.M111627200; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Lin J, 2001, J CELL SCI, V114, P243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu Y, 1997, J EXP MED, V185, P251, DOI 10.1084/jem.185.2.251; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Raab M, 2001, IMMUNITY, V15, P921, DOI 10.1016/S1074-7613(01)00248-5; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; Schuebel KE, 1996, ONCOGENE, V13, P363; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zakaria S, 2004, J EXP MED, V199, P429, DOI 10.1084/jem.20031228; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	46	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15289	15299		10.1074/jbc.M500275200	http://dx.doi.org/10.1074/jbc.M500275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708849	hybrid			2022-12-27	WOS:000228236800114
J	Sherameti, I; Shahollari, B; Venus, Y; Altschmied, L; Varma, A; Oelmuller, R				Sherameti, I; Shahollari, B; Venus, Y; Altschmied, L; Varma, A; Oelmuller, R			The endophytic fungus Piriformospora indica stimulates the expression of nitrate reductase and the starch-degrading enzyme glucan-water dikinase in tobacco and Arabidopsis roots through a homeodomain transcription factor that binds to a conserved motif in their promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; GENE-EXPRESSION; DISEASE RESISTANCE; PROTEIN; BENZOTHIADIAZOLE; PHOSPHORYLATION; MEMBRANE; SUBUNIT; GROWTH; ACID	Piriformospora indica, an endophytic fungus of the Sebacinaceae family, promotes growth of Arabidopsis and tobacco seedlings and stimulates nitrogen accumulation and the expression of the genes for nitrate reductase and the starch-degrading enzyme glucan-water dikinase (SEX1) in roots. Neither growth promotion nor stimulation of the two enzymes requires heterotrimeric G proteins. P. indica also stimulates the expression of the uidA gene under the control of the Arabidopsis nitrate reductase (Nia2) promoter in transgenic tobacco seedlings. At least two regions (-470/-439 and -103/-89) are important for Nia2 promoter activity in tobacco roots. One of the regions contains an element, ATGATAGATAAT, that binds to a homeodomain transcription factor in vitro. The message for this transcription factor is up-regulated by P. indica. The transcription factor also binds to a CTGATAGATCT segment in the SEX1 promoter in vitro. We propose that the growth-promoting effect initiated by P. indica is accompanied by a co-regulated stimulation of enzymes involved in nitrate and starch metabolisms.	Univ Jena, Inst Gen Bot & Plant Physiol, D-07743 Jena, Germany; IPK, D-064566 Gatersleben, Germany; Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India	Friedrich Schiller University of Jena; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Jawaharlal Nehru University, New Delhi	Oelmuller, R (corresponding author), Univ Jena, Inst Gen Bot & Plant Physiol, Dornburger Str 159, D-07743 Jena, Germany.	b7oera@hotmail.com		Altschmied, Lothar/0000-0002-7692-2971				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Boukcim H, 2003, J PLANT PHYSIOL, V160, P1211, DOI 10.1078/0176-1617-00973; Chen H, 2003, PLANT PHYSIOL, V132, P1391, DOI 10.1104/pp.103.022434; Chen IP, 2003, PLANT J, V35, P771, DOI 10.1046/j.1365-313X.2003.01847.x; Esseling JJ, 2004, J MICROSC-OXFORD, V214, P104, DOI 10.1111/j.0022-2720.2004.01322.x; FIALA ES, 1989, CANCER RES, V49, P5518; FLIEGER K, 1993, PLANT J, V4, P9, DOI 10.1046/j.1365-313X.1993.04010009.x; Gage DJ, 2004, MICROBIOL MOL BIOL R, V68, P280, DOI 10.1128/MMBR.68.2.280-300.2004; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; Guescini M, 2003, MOL GENET GENOMICS, V269, P807, DOI 10.1007/s00438-003-0894-3; Hanawa F, 2000, PHYTOCHEMISTRY, V53, P55, DOI 10.1016/S0031-9422(99)00443-4; Hildebrandt U, 2002, PHYSIOL PLANTARUM, V115, P125, DOI 10.1034/j.1399-3054.2002.1150115.x; HITE M, 1979, ENVIRON MUTAGEN, V1, P383, DOI 10.1002/em.2860010411; Hoth S, 2002, J CELL SCI, V115, P4891, DOI 10.1242/jcs.00175; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Jeon JS, 2000, PLANT CELL, V12, P871, DOI 10.1105/tpc.12.6.871; Kaldorf M, 1998, MOL PLANT MICROBE IN, V11, P439, DOI 10.1094/MPMI.1998.11.6.439; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kumari R, 2003, CURR SCI INDIA, V85, P1672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawton KA, 1996, PLANT J, V10, P71, DOI 10.1046/j.1365-313X.1996.10010071.x; MARX DH, 1969, PHYTOPATHOLOGY, V59, P153; Mikaelian I, 1996, Methods Mol Biol, V57, P193; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OELMULLER R, 1993, MOL GEN GENET, V237, P261, DOI 10.1007/BF00282808; OELMULLER R, 2004, ENDOCYT CELL RES, V15, P504; Peskan T, 2000, PLANT MOL BIOL, V42, P915, DOI 10.1023/A:1006477631166; Peskan-Berghofer T, 2005, PLANTA, V220, P737, DOI 10.1007/s00425-004-1393-4; Peskan-Berghofer T, 2004, PHYSIOL PLANTARUM, V122, P465, DOI 10.1111/j.1399-3054.2004.00424.x; Pham GH, 2004, PLANT SURFACE MICROBIOLOGY, P237; Reboutier D, 2002, MOL PLANT MICROBE IN, V15, P932, DOI 10.1094/MPMI.2002.15.9.932; Reimann R, 2004, PLANT PHYSIOL, V135, P121, DOI 10.1104/pp.103.036236; Ritte G, 2004, PLANT PHYSIOL, V135, P2068, DOI 10.1104/pp.104.041301; Ritte G, 2002, P NATL ACAD SCI USA, V99, P7166, DOI 10.1073/pnas.062053099; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sauerborn J, 2002, PHYTOPATHOLOGY, V92, P59, DOI 10.1094/PHYTO.2002.92.1.59; SHAHOLLARI B, 2005, IN PRESS J PLANT PHY; Sherameti I, 2004, PLANT J, V38, P578, DOI 10.1111/j.1365-313X.2004.02069.x; Sherameti I, 2002, J BIOL CHEM, V277, P46594, DOI 10.1074/jbc.M202924200; SINGH A, 2001, J ORCHID, V15, P89; Singh Anjana, 2003, Indian Journal of Biotechnology, V2, P65; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Stockel J, 2004, J BIOL CHEM, V279, P10243, DOI 10.1074/jbc.M309246200; Varma A, 1999, APPL ENVIRON MICROB, V65, P2741; Verma S, 1998, MYCOLOGIA, V90, P896, DOI 10.2307/3761331	45	169	197	3	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26241	26247		10.1074/jbc.M500447200	http://dx.doi.org/10.1074/jbc.M500447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15710607	hybrid			2022-12-27	WOS:000230386800039
J	Persikov, AV; Ramshaw, JAM; Brodsky, B				Persikov, AV; Ramshaw, JAM; Brodsky, B			Prediction of collagen stability from amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL STRUCTURE; I COLLAGEN; OSTEOGENESIS IMPERFECTA; MOLECULAR-STRUCTURE; ASYMMETRIC ACETYLCHOLINESTERASE; ELECTROSTATIC INTERACTIONS; THERMODYNAMIC SCALE; FORMING TENDENCIES; THERMAL-STABILITY; PEPTIDE MODELS	An algorithm was derived to relate the amino acid sequence of a collagen triple helix to its thermal stability. This calculation is based on the triple helical stabilization propensities of individual residues and their intermolecular and intramolecular interactions, as quantitated by melting temperature values of host-guest peptides. Experimental melting temperature values of a number of triple helical peptides of varying length and sequence were successfully predicted by this algorithm. However, predicted T-m values are significantly higher than experimental values when there are strings of oppositely charged residues or concentrations of like charges near the terminus. Application of the algorithm to collagen sequences highlights regions of unusually high or low stability, and these regions often correlate with biologically significant features. The prediction of stability from sequence indicates an understanding of the major forces maintaining this protein motif. The use of highly favorable KGE and KGD sequences is seen to complement the stabilizing effects of imino acids in modulating stability and may become dominant in the collagenous domains of bacterial proteins that lack hydroxyproline. The effect of single amino acid mutations in the X and Y positions can be evaluated with this algorithm. An interactive collagen stability calculator based on this algorithm is available online.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; CSIRO, Parkville, Vic 3052, Australia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu	Ramshaw, John AM/A-9411-2011	Ramshaw, John A.M./0000-0002-2131-3685	NIGMS NIH HHS [GM60048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U; Andersson EC, 1998, P NATL ACAD SCI USA, V95, P7574, DOI 10.1073/pnas.95.13.7574; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; Ballo R, 1998, AM J MED GENET, V80, P6, DOI 10.1002/(SICI)1096-8628(19981102)80:1<6::AID-AJMG2>3.0.CO;2-0; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Beck K, 2000, P NATL ACAD SCI USA, V97, P4273, DOI 10.1073/pnas.070050097; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; Buevich AV, 2004, J BIOL CHEM, V279, P46890, DOI 10.1074/jbc.M407061200; CHAN D, 1993, J BIOL CHEM, V268, P15238; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Deprez P, 2000, BIOCHEM J, V350, P283, DOI 10.1042/0264-6021:3500283; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Doss-Pepe E, 2004, BBA-PROTEINS PROTEOM, V1698, P187, DOI 10.1016/j.bbapap.2003.11.034; Doss-Pepe E, 2000, BIOCHEMISTRY-US, V39, P14884, DOI 10.1021/bi001108u; Emsley J, 2004, J MOL BIOL, V335, P1019, DOI 10.1016/j.jmb.2003.11.030; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; KADLER KE, 1988, J BIOL CHEM, V263, P10517; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Mohs A, 2005, BIOCHEMISTRY-US, V44, P1793, DOI 10.1021/bi0482708; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2003, J AM CHEM SOC, V125, P11500, DOI 10.1021/ja036673+; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; Persikov AV, 2004, HUM MUTAT, V24, P330, DOI 10.1002/humu.20091; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; Persikov AV, 2002, J MOL BIOL, V316, P385, DOI 10.1006/jmbi.2001.5342; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RAMACHANDRAN GN, 1963, INT REV CONNECT TISS, V68, P127; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Shah NK, 1997, BIOCHEMISTRY-US, V36, P5878, DOI 10.1021/bi963146c; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Steplewski A, 2004, J STRUCT BIOL, V148, P326, DOI 10.1016/j.jsb.2004.07.006; SUTOH K, 1974, BIOPOLYMERS, V13, P2391, DOI 10.1002/bip.1974.360131118; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22; WERKMEISTER JA, 2003, BIOMATERIALS HDB, P229; Xu Y, 2002, J BIOL CHEM, V277, P27312, DOI 10.1074/jbc.M201163200; Xu YJ, 2003, BIOCHEMISTRY-US, V42, P8696, DOI 10.1021/bi034006n; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	52	267	283	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19343	19349		10.1074/jbc.M501657200	http://dx.doi.org/10.1074/jbc.M501657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753081	hybrid			2022-12-27	WOS:000228932300091
J	Carattino, MD; Edinger, RS; Grieser, HJ; Wise, R; Neumann, D; Schlattner, U; Johnson, JP; Kleyman, TR; Hallows, KR				Carattino, MD; Edinger, RS; Grieser, HJ; Wise, R; Neumann, D; Schlattner, U; Johnson, JP; Kleyman, TR; Hallows, KR			Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TOAD URINARY-BLADDER; NA+ CHANNEL; SURFACE EXPRESSION; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; GLUT4 TRANSLOCATION; FATTY-ACID; A6 CELLS; ENAC	The epithelial Na+ channel (ENaC) regulates epithelial salt and water reabsorption, processes that require significant expenditure of cellular energy. To test whether the ubiquitous metabolic sensor AMP-activated kinase (AMPK) regulates ENaC, we examined the effects of AMPK activation on amiloride-sensitive currents in Xenopus oocytes and polarized mouse collecting duct mpkCCD(c14) cells. Microinjection of oocytes expressing mouse ENaC (mENaC) with either active AMPK protein or an AMPK activator inhibited mENaC currents relative to controls as measured by two-electrode voltage-clamp studies. Similarly, pharmacological AMPK activation or overexpression of an activating AMPK mutant in mpkCCDc14 cells inhibited amiloride-sensitive short circuit currents. Expression of a degenerin mutant beta-mENaC subunit (S518K) along with wild type alpha and gamma increased the channel open probability (P-o) to similar to 1. However, AMPK activation inhibited currents similarly with expression of either degenerin mutant or wild type mENaC. Single channel recordings under these conditions demonstrated that neither Po nor channel conductance was affected by AMPK activation. Moreover, expression of a Liddle's syndrome-type beta-mENaC mutant (Y618A) greatly enhanced ENaC whole cell currents relative to wild type ENaC controls and prevented AMPK-dependent inhibition. These findings indicate that AMPK-dependent ENaC inhibition is mediated through a decrease in the number of active channels at the plasma membrane (N), presumably through enhanced Nedd4-2-dependent ENaC endocytosis. The AMPK-ENaC interaction appears to be indirect; AMPK did not bind ENaC in cells, as assessed by in vivo pull-down assays, nor did it phosphorylate ENaC in vitro. In summary, these results suggest a novel mechanism for coupling ENaC activity and renal Na+ handling to cellular metabolic status through AMPK, which may help prevent cellular Na+ loading under hypoxic or ischemic conditions.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hallows, KR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, S976 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hallows@pitt.edu	Schlattner, Uwe/D-1267-2009	Schlattner, Uwe/0000-0003-1159-5911; Hallows, Kenneth/0000-0002-2964-2440; Neumann, Dietbert/0000-0002-4316-684X	NIDDK NIH HHS [R03 DK068390, R01 DK047874, K08 DK059477-03, K08 DK059477, R03 DK068390-01, DK057718, R01 DK054354, K08 DK059477-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057718, R03DK068390, R01DK054354, K08DK059477, R01DK047874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Carattino MD, 2005, J BIOL CHEM, V280, P4393, DOI 10.1074/jbc.M413123200; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Condliffe SB, 2004, J BIOL CHEM, V279, P10085, DOI 10.1074/jbc.M313592200; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 2004, P NATL ACAD SCI USA, V101, P11886, DOI 10.1073/pnas.0402178101; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; Gilmore ES, 2001, J BIOL CHEM, V276, P42610, DOI 10.1074/jbc.M106919200; GULLANS SR, 2000, KIDNEY PHYSL PATHOPH, V1, P443; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARRIS SI, 1981, J BIOL CHEM, V256, P319; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Iglesias MA, 2004, DIABETES, V53, P1649, DOI 10.2337/diabetes.53.7.1649; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Light PE, 2003, CIRCULATION, V107, P1962, DOI 10.1161/01.CIR.0000069269.60167.02; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; MANDEL LJ, 1981, AM J PHYSIOL, V240, pF357, DOI 10.1152/ajprenal.1981.240.5.F357; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mohan S, 2004, J BIOL CHEM, V279, P32071, DOI 10.1074/jbc.M405091200; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Neumann D, 2003, BIOCHEM SOC T, V31, P169, DOI 10.1042/bst0310169; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Thome UH, 2003, AM J PHYSIOL-LUNG C, V284, pL376, DOI 10.1152/ajplung.00218.2002; Verrey F, 2003, CELL PHYSIOL BIOCHEM, V13, P21, DOI 10.1159/000070246; Yue G, 2000, AM J PHYSIOL-CELL PH, V279, pC81, DOI 10.1152/ajpcell.2000.279.1.C81; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	60	122	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17608	17616		10.1074/jbc.M501770200	http://dx.doi.org/10.1074/jbc.M501770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753079	hybrid			2022-12-27	WOS:000228807200007
J	Demine, R; Walden, P				Demine, R; Walden, P			Testing the role of gp96 as peptide chaperone in antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN GP96; MASS-SPECTROMETRY DATA; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; BINDING-SITE; PROTEASOMAL CLEAVAGES; DENDRITIC CELLS; IDENTIFICATION; AMINOPEPTIDASE; GP96/GRP94	gp96 is a 96-kDa glycoprotein of the endoplasmic reticulum that is believed to be involved in antigen processing as an intermediate carrier of peptides for presentation by major histocompatibility complex (MHC) class I molecules. This function implies that gp96 carries a large array of different peptides that represent the antigenicity of the cell and can serve all MHC class I molecules. So far, the evidence regarding these peptides is largely indirect and based on experiments where mice immunized with gp96 from tumor or virus-infected cells developed T cellular immune responses with the corresponding specificities. We analyzed by mass spectrometry peptides isolated from gp96 and found a number of different peptides derived from the proteins of different cellular compartments but mostly cytoplasm and nucleus. The sequences of these peptides provide information on the specificity of antigen processing and reveal structural requirements for binding to gp96 that only partially correspond to those of peptides presented by MHC class I molecules. The yield of peptides extracted from gp96 was far substoichiometric with an estimated occupancy of this chaperone of between 0.1% and 0.4%. These results strongly argue against a regular role for gp96 as a peptide chaperone in antigen processing.	Humboldt Univ, Charite Univ Med Berlin, Dept Dermatol, D-10117 Berlin, Germany; Clin Res Grp Tumor Immunol, Dept Dermatol & Allergy, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walden, P (corresponding author), Humboldt Univ, Charite Univ Med Berlin, Dept Dermatol, Schumannstr 20-21, D-10117 Berlin, Germany.	peter.walden@charite.de						Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Binder RJ, 2004, P NATL ACAD SCI USA, V101, P6128, DOI 10.1073/pnas.0308180101; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blythe MJ, 2002, BIOINFORMATICS, V18, P434, DOI 10.1093/bioinformatics/18.3.434; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Creasy DM, 2002, PROTEOMICS, V2, P1426, DOI 10.1002/1615-9861(200210)2:10<1426::AID-PROT1426>3.0.CO;2-5; Demine R, 2004, RAPID COMMUN MASS SP, V18, P907, DOI 10.1002/rcm.1420; Demine R, 2003, MOL BIOTECHNOL, V25, P71, DOI 10.1385/MB:25:1:71; FALK K, 1994, IMMUNOGENETICS, V39, P230; Fleischer K, 2004, J IMMUNOL, V172, P162, DOI 10.4049/jimmunol.172.1.162; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gidalevitz T, 2004, J BIOL CHEM, V279, P16543, DOI 10.1074/jbc.M313060200; Holzhutter HG, 1999, J MOL BIOL, V286, P1251, DOI 10.1006/jmbi.1998.2530; Holzhutter HG, 2000, BIOPHYS J, V79, P1196, DOI 10.1016/S0006-3495(00)76374-0; Ishii T, 1999, J IMMUNOL, V162, P1303; KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161; Kesmir C, 2002, PROTEIN ENG, V15, P287, DOI 10.1093/protein/15.4.287; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Kuttler C, 2000, J MOL BIOL, V298, P417, DOI 10.1006/jmbi.2000.3683; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Linderoth NA, 2001, J BIOL CHEM, V276, P11049, DOI 10.1074/jbc.M010059200; Linderoth NA, 2000, J BIOL CHEM, V275, P5472, DOI 10.1074/jbc.275.8.5472; McSparron H, 2003, J CHEM INF COMP SCI, V43, P1276, DOI 10.1021/ci030461e; Meng SD, 2002, J IMMUNOL METHODS, V264, P29, DOI 10.1016/S0022-1759(02)00093-5; Meng SD, 2001, LANCET, V357, P528, DOI 10.1016/S0140-6736(00)04050-2; Menoret A, 2001, J BIOL CHEM, V276, P33313, DOI 10.1074/jbc.M103383200; Nagorsen D, 2004, CANCER IMMUNOL IMMUN, V53, P817, DOI 10.1007/s00262-004-0532-x; Nicchitta CV, 2004, CELL STRESS CHAPERON, V9, P325, DOI 10.1379/CSC-62.1; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Nussbaum AK, 2001, IMMUNOGENETICS, V53, P87, DOI 10.1007/s002510100300; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Zheng H, 2001, J IMMUNOL, V167, P6731, DOI 10.4049/jimmunol.167.12.6731	46	42	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17573	17578		10.1074/jbc.M501233200	http://dx.doi.org/10.1074/jbc.M501233200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728573	hybrid			2022-12-27	WOS:000228807200002
J	Gao, NG; Shang, J; Lehrman, MA				Gao, NG; Shang, J; Lehrman, MA			Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis - Implications for extracellular glucose and intracellular mannose 6-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT GLYCOPROTEIN SYNDROME; CONGENITAL DISORDERS; LINKED OLIGOSACCHARIDES; ABNORMAL SYNTHESIS; N-GLYCOSYLATION; DEFECT; TRANSPORT; CORRECTS; SUPPLEMENTATION; GLYCOGEN	Phosphomannomutase (PMM) deficiency causes congenital disorder of glycosylation (CDG)-Ia, a broad spectrum disorder with developmental and neurological abnormalities. PMM converts mannose 6-phosphate (M6P) to mannose-1-phosphate, a precursor of GDP-mannose used to make Glc(3)Man(9)GlcNAc(2)-P-P-dolichol ( lipid-linked oligosaccharide; LLO). LLO, in turn, is the donor substrate of oligosaccharyltransferase for protein N-linked glycosylation. Hepatically produced N-linked glycoproteins in CDG-Ia blood are hypoglycosylated. Upon labeling with [H-3] mannose, CDG-Ia fibroblasts have been widely reported to accumulate [ 3H] LLO intermediates. Since these are thought to be poor oligosaccharyltransferase substrates, LLO intermediate accumulation has been the prevailing explanation for hypoglycosylation in patients. However, this is discordant with sporadic reports of specific glycoproteins ( detected with antibodies) from CDG-Ia fibroblasts being fully glycosylated. Here, fluorophore-assisted carbohydrate electrophoresis ( FACE, a nonradioactive technique) was used to analyze steady-state LLO compositions in CDG-Ia fibroblasts. FACE revealed that low glucose conditions accounted for previous observations of accumulated [H-3] LLO intermediates. Additional FACE experiments demonstrated abundant Glc(3)Man(9)GlcNAc(2)-P-P-dolichol, without hypoglycosylation, in CDG-Ia fibroblasts grown with physiological glucose. This suggested a "missing link" to explain hypoglycosylation in CDG-Ia patients. Because of the possibility of its accumulation, the effects of M6P on glycosylation were explored in vitro. Surprisingly, M6P was a specific activator for cleavage of Glc(3)Man(9)GlcNAc(2)-P-P-dolichol. This led to futile cycling of the LLO pathway, exacerbated by GDP-mannose/ PMM deficiency. The possibilities that M6P may accumulate in hepatocytes and that M6P-stimulated LLO cleavage may account for both hypoglycosylation and the clinical failure of dietary mannose therapy with CDG-Ia patients are discussed.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Blvd, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NIGMS NIH HHS [GM38545, R01 GM038545, R56 GM038545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; ASIKIN N, 1979, BIOCHEM BIOPH RES CO, V89, P279, DOI 10.1016/0006-291X(79)90975-6; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; Bohles H, 2001, J INHERIT METAB DIS, V24, P858, DOI 10.1023/A:1013944308881; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; Frank CG, 2004, AM J HUM GENET, V75, P146, DOI 10.1086/422367; Gao NG, 2003, GLYCOBIOLOGY, V13, p1G, DOI 10.1093/glycob/cwg009; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Gao NG, 2002, J BIOL CHEM, V277, P39425, DOI 10.1074/jbc.M205195200; Grunewald S, 2001, AM J HUM GENET, V68, P347, DOI 10.1086/318199; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Karaoglu D, 2001, BIOCHEMISTRY-US, V40, P12193, DOI 10.1021/bi0111911; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; KNAUER R, 1994, J INHERIT METAB DIS, V17, P541, DOI 10.1007/BF00711588; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRASNEWICH DM, 1995, GLYCOBIOLOGY, V5, P503, DOI 10.1093/glycob/5.5.503; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Leuzzi R, 2001, BIOCHEM J, V357, P557, DOI 10.1042/0264-6021:3570557; Marquardt T, 1996, J INHERIT METAB DIS, V19, P246, DOI 10.1007/BF01799441; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARQUARDT T, 1995, EUR J CELL BIOL, V66, P268; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Ohkura T, 1997, J BIOL CHEM, V272, P6868, DOI 10.1074/jbc.272.11.6868; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; POWELL LD, 1994, J CLIN INVEST, V94, P1901, DOI 10.1172/JCI117540; Rush JS, 2000, GLYCOBIOLOGY, V10, P829, DOI 10.1093/glycob/10.8.829; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Shang J, 2004, J BIOL CHEM, V279, P9703, DOI 10.1074/jbc.M310837200; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307	36	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17901	17909		10.1074/jbc.M500510200	http://dx.doi.org/10.1074/jbc.M500510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15708848	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000228807200043
J	Harada, A; Katoh, H; Negishi, M				Harada, A; Katoh, H; Negishi, M			Direct interaction of Rnd1 with FRS2 beta regulates Rnd1-induced down-regulation of RhoA activity and is involved in fibroblast growth factor-induced neurite outgrowth in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85 BETA-PIX; ACTIN CYTOSKELETON; SMALL GTPASES; FAMILY; ACTIVATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; KINASE; ROLES	The Rho family of small GTPases has been implicated in the reorganization of the actin cytoskeleton and subsequent morphological changes in various cells. Rnd1, a member of this family, has a low intrinsic GTPase activity and exerts antagonistic effects on RhoA signaling. However, how the activity of Rnd1 is regulated has not yet been elucidated. Here we have demonstrated that Rnd1 directly associates with FRS2 alpha and FRS2 beta, which are docking proteins of fibroblast growth factor (FGF) receptors and play important roles in the intracellular signals induced by FGFs. The interaction of FRS2 beta with Rnd1 suppresses the inhibitory effect of Rnd1 on RhoA. Rnd1 binds to the COOH-terminal region of FRS2 beta including tyrosine residues essential for the interaction with Shp2. When FGF receptor 1 is activated, it phosphorylates FRS2 beta, recruits Shp2, and releases Rnd1 from FRS2 beta. The liberated Rnd1 then inhibits RhoA activity. Furthermore, knockdown of Rnd1 by Rnd1-specific short interfering RNAs suppress the FGF-induced neurite outgrowth in PC12 cells. These results suggest that the activity of Rnd1 is regulated by FGF receptor through FRS2 beta and that Rnd1 plays an important role in the FGF signaling during neurite outgrowth.	Kyoto Univ, Grad Sch Biostat, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostat, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp		Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gritti A, 1996, J NEUROSCI, V16, P1091; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Li AJ, 2002, EUR J NEUROSCI, V16, P1313, DOI 10.1046/j.1460-9568.2002.02193.x; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; REN XD, 2000, METHOD ENZYMOL, V256, P215; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; TOGARI A, 1985, J NEUROSCI, V5, P307; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wunnenberg-Stapleton K, 1999, DEVELOPMENT, V126, P5339; XU H, 1998, J BIOL CHEM, V20, P13049	33	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18418	18424		10.1074/jbc.M411356200	http://dx.doi.org/10.1074/jbc.M411356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15738000	hybrid			2022-12-27	WOS:000228807200104
J	Iype, T; Francis, J; Garmey, JC; Schisler, JC; Nesher, R; Weir, GC; Becker, TC; Newgard, CB; Griffen, SC; Mirmira, RG				Iype, T; Francis, J; Garmey, JC; Schisler, JC; Nesher, R; Weir, GC; Becker, TC; Newgard, CB; Griffen, SC; Mirmira, RG			Mechanism of insulin gene regulation by the pancreatic transcription factor Pdx-1 - Application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; BETA-CELLS; ACTIVATION DOMAINS; DIABETES-MELLITUS; POLYMERASE-II; TARGET GENES; IN-VITRO; EXPRESSION; GLUCOSE; P300	The homeodomain factor Pdx-1 regulates an array of genes in the developing and mature pancreas, but whether regulation of each specific gene occurs by a direct mechanism ( binding to promoter elements and activating basal transcriptional machinery) or an indirect mechanism ( via regulation of other genes) is unknown. To determine the mechanism underlying regulation of the insulin gene by Pdx-1, we performed a kinetic analysis of insulin transcription following adenovirus-mediated delivery of a small interfering RNA specific for pdx-1 into insulinoma cells and pancreatic islets to diminish endogenous Pdx-1 protein. insulin transcription was assessed by measuring both a long half-life insulin mRNA ( mature mRNA) and a short half-life insulin pre-mRNA species by real-time reverse transcriptase-PCR. Following progressive knock-down of Pdx-1 levels, we observed coordinate decreases in pre-mRNA levels ( to about 40% of normal levels at 72 h). In contrast, mature mRNA levels showed strikingly smaller and delayed declines, suggesting that the longer half-life of this species underestimates the contribution of Pdx-1 to insulin transcription. Chromatin immunoprecipitation assays revealed that the decrease in insulin transcription was associated with decreases in the occupancies of Pdx-1 and p300 at the proximal insulin promoter. Although there was no corresponding change in the recruitment of RNA polymerase II to the proximal promoter, its recruitment to the insulin coding region was significantly reduced. Our results suggest that Pdx-1 directly regulates insulin transcription through formation of a complex with transcriptional coactivators on the proximal insulin promoter. This complex leads to enhancement of elongation by the basal transcriptional machinery.	Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Diabet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27704 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA	University of Virginia; University of Virginia; University of Virginia; Duke University; Duke University; Duke University; Duke University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of California System; University of California Davis	Mirmira, RG (corresponding author), Univ Virginia Hlth Syst, 450 Ray C Hunt Dr,Box 801407, Charlottesville, VA 22908 USA.	mirmira@virginia.edu	Schisler, Jonathan C./C-1301-2008; Mirmira, Raghavendra G/AAD-7592-2020	Schisler, Jonathan C./0000-0001-7382-2783; Mirmira, Raghavendra G/0000-0002-5013-6075	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R13DK056047, U19DK061251, R01DK060581, K08DK002619] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19 DK61251, K08 DK002619, R01 DK60581, U01 DK56047] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Burger LL, 2004, ENDOCRINOLOGY, V145, P71, DOI 10.1210/en.2003-1047; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cissell MA, 2003, J BIOL CHEM, V278, P751, DOI 10.1074/jbc.M205905200; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FROMONTRACINE M, 1990, MOL ENDOCRINOL, V4, P669, DOI 10.1210/mend-4-5-669; GIDDINGS SJ, 1988, J BIOL CHEM, V263, P3845; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Kajimoto Y, 1997, J CLIN INVEST, V100, P1840, DOI 10.1172/JCI119712; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; KORANYI L, 1989, MOL ENDOCRINOL, V3, P1895, DOI 10.1210/mend-3-11-1895; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Le Lay J, 2004, J BIOL CHEM, V279, P22228, DOI 10.1074/jbc.M312673200; Liberzon A, 2004, NUCLEIC ACIDS RES, V32, P54, DOI 10.1093/nar/gkh156; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Peshavaria M, 2000, MOL ENDOCRINOL, V14, P1907, DOI 10.1210/me.14.12.1907; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Prendergast KA, 2004, BIOL REPROD, V70, P364, DOI 10.1095/biolreprod.103.021733; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang JH, 1997, P NATL ACAD SCI USA, V94, P4360, DOI 10.1073/pnas.94.9.4360; WELSH M, 1985, J BIOL CHEM, V260, P3590; Yang ZD, 2004, TRANSPLANTATION, V77, P55, DOI 10.1097/01.TP.0000104844.48064.81; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	55	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16798	16807		10.1074/jbc.M414381200	http://dx.doi.org/10.1074/jbc.M414381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743769	hybrid			2022-12-27	WOS:000228615500032
J	Roessner, CA; Williams, HJ; Scott, AI				Roessner, CA; Williams, HJ; Scott, AI			Genetically engineered production of 1-desmethylcobyrinic acid, 1-desmethylcobyrinic acid a,c-diamide, and cobyrinic acid a,c-diamide in Escherichia coli implies a role for CbiD in c-1 methylation in the anaerobic pathway to cobalamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-DENITRIFICANS; VITAMIN-B-12 BIOSYNTHESIS; UROPORPHYRINOGEN-III; TIGHT REGULATION; EXPRESSION; GENES; IDENTIFICATION; VECTORS; CLONING	Co-expression of the cobA gene from Propionibacterium freudenreichii and the cbiA, - C, - D, - E, - T, - F, - G, - H, - J, - K, - L, and - P genes from Salmonella enterica serovar typhimurium in Escherichia coli resulted in the production of cobyrinic acid a, c-diamide. A cbiD deletion mutant of this strain produced 1-desmethylcobyrinic acid a, c-diamide, indicating that CbiD is involved in C-1 methylation in the anaerobic pathway to cobalamin. Strains that did not have the cbiP gene also produced 1-desmethylcobyrinic acid a, c-diamide, and strains that had neither cbiP nor cbiA synthesized 1-desmethylcobyrinic acid even in the presence of cbiD, suggesting that CbiA and CbiP are necessary for CbiD activity.	Texas A&M Univ, Dept Chem, Ctr Biol NMR, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Roessner, CA (corresponding author), Texas A&M Univ, Dept Chem, Ctr Biol NMR, College Stn, TX 77843 USA.	c-roessner@tamu.edu			NIDDK NIH HHS [DK32034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032034, R37DK032034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BATTERSBY AR, 1982, J CHEM SOC PERK T 1, P2265, DOI 10.1039/p19820002265; BLANCHE F, 1991, J BACTERIOL, V173, P6046, DOI 10.1128/jb.173.19.6046-6051.1991; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; Bruggemann H, 2004, SCIENCE, V305, P671, DOI 10.1126/science.1100330; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; LUNDRIGAN MD, 1989, J BACTERIOL, V171, P154, DOI 10.1128/jb.171.1.154-161.1989; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; Roessner CA, 2001, VITAM HORM, V61, P267; ROESSNER CA, 1992, FEBS LETT, V301, P73, DOI 10.1016/0014-5793(92)80213-Z; Roper JM, 2000, J BIOL CHEM, V275, P40316, DOI 10.1074/jbc.M007146200; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; SATTLER I, 1995, J BACTERIOL, V177, P1564, DOI 10.1128/jb.177.6.1564-1569.1995; SCHREIBER SL, 1991, TETRAHEDRON, V47, P2543, DOI 10.1016/S0040-4020(01)81788-9; SCOTT AI, 1984, BIOORG CHEM, V12, P356, DOI 10.1016/0045-2068(84)90017-8; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16748	16753		10.1074/jbc.M501805200	http://dx.doi.org/10.1074/jbc.M501805200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741157	hybrid			2022-12-27	WOS:000228615500026
J	Fierobe, HP; Mingardon, F; Mechaly, A; Belaich, A; Rincon, MT; Pages, S; Lamed, R; Tardif, C; Belaich, JP; Bayer, EA				Fierobe, HP; Mingardon, F; Mechaly, A; Belaich, A; Rincon, MT; Pages, S; Lamed, R; Tardif, C; Belaich, JP; Bayer, EA			Action of designer cellulosomes on homogeneous versus complex substrates - Controlled incorporation of three distinct enzymes into a defined trifunctional scaffoldin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-CELLULOLYTICUM CELLULOSOME; THERMOCELLUM CELLULOSOME; SEQUENCE-ANALYSIS; ENDOGLUCANASE-A; COHESIN; CELLULASE; PURIFICATION; DEGRADATION; BINDING; PROTEIN	In recent work (Fierobe, H.- P., Bayer, E. A., Tardif, C., Czjzek, M., Mechaly, A., Belai " ch, A., Lamed, R., Shoham, Y., and Belaich, J.- P. ( 2002) J. Biol. Chem. 277, 49621 49630), we reported the self-assembly of a comprehensive set of defined " bifunctional" chimeric cellulosomes. Each complex contained the following: ( i) a chimeric scaffoldin possessing a cellulose-binding module and two cohesins of divergent specificity and (ii) two cellulases, each bearing a dockerin complementary to one of the divergent cohesins. This approach allowed the controlled integration of desired enzymes into a multiprotein complex of predetermined stoichiometry and topology. The observed enhanced synergy on recalcitrant substrates by the bifunctional designer cellulosomes was ascribed to two major factors: substrate targeting and proximity of the two catalytic components. In the present work, the capacity of the previously described chimeric cellulosomes was amplified by developing a third divergent cohesin-dockerin device. The resultant trifunctional designer cellulosomes were assayed on homogeneous and complex substrates ( microcrystalline cellulose and straw, respectively) and found to be considerably more active than the corresponding free enzyme or bifunctional systems. The results indicate that the synergy between two prominent cellulosomal enzymes ( from the family-48 and -9 glycoside hydrolases) plays a crucial role during the degradation of cellulose by cellulosomes and that one dominant family-48 processive endoglucanase per complex is sufficient to achieve optimal levels of synergistic activity. Furthermore cooperation within a cellulosome chimera between cellulases and a hemicellulase from different microorganisms was achieved, leading to a trifunctional complex with enhanced activity on a complex substrate.	CNRS, Inst Biol Struct & Microbiol, F-13402 Marseille, France; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Rowett Res Inst, Microbial Genet Grp, Aberdeen AB21 9SD, Scotland; Univ Aix Marseille 1, F-13331 Marseille, France; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Centre National de la Recherche Scientifique (CNRS); Weizmann Institute of Science; University of Aberdeen; UDICE-French Research Universities; Aix-Marseille Universite; Tel Aviv University	Fierobe, HP (corresponding author), CNRS, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	hpfierob@ibsm.cnrs-mrs.fr	Rincon, Marco T/T-4798-2019; FIEROBE, Henri-Pierre/P-4372-2019					BAGNARATARDIF C, 1992, GENE, V119, P17, DOI 10.1016/0378-1119(92)90062-T; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; BAYER EA, 1994, TRENDS BIOTECHNOL, V12, P379, DOI 10.1016/0167-7799(94)90039-6; BAYER EA, 2000, PROKARYOTES EVOLVING; Belaich A, 2002, J BACTERIOL, V184, P1378, DOI 10.1128/JB.184.5.1378-1384.2002; Blum DL, 2000, J BACTERIOL, V182, P1346, DOI 10.1128/JB.182.5.1346-1351.2000; FIEROBE HP, 1993, EUR J BIOCHEM, V217, P557, DOI 10.1111/j.1432-1033.1993.tb18277.x; FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; Gal L, 1997, APPL ENVIRON MICROB, V63, P903, DOI 10.1128/AEM.63.3.903-909.1997; Gal L, 1997, J BACTERIOL, V179, P6595, DOI 10.1128/jb.179.21.6595-6601.1997; Gaudin C, 2000, J BACTERIOL, V182, P1910, DOI 10.1128/JB.182.7.1910-1915.2000; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; Hammel M, 2004, J BIOL CHEM, V279, P55985, DOI 10.1074/jbc.M408979200; HUGGETT ASG, 1957, LANCET, V2, P368; Jindou S, 2004, J BIOL CHEM, V279, P9867, DOI 10.1074/jbc.M308673200; LAMED R, 1983, J BACTERIOL, V156, P828, DOI 10.1128/JB.156.2.828-836.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maamar H, 2004, MOL MICROBIOL, V51, P589, DOI 10.1046/j.1365-2958.2003.03859.x; Mohand-Oussaid O, 1999, J BACTERIOL, V181, P4035, DOI 10.1128/JB.181.13.4035-4040.1999; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; PARK JT, 1949, J BIOL CHEM, V181, P149; Perret S, 2004, J BACTERIOL, V186, P6544, DOI 10.1128/JB.186.19.6544-6552.2004; RALET MC, 1994, CARBOHYD RES, V263, P257, DOI 10.1016/0008-6215(94)00177-4; ReverbelLeroy C, 1997, J BACTERIOL, V179, P46, DOI 10.1128/jb.179.1.46-52.1997; Rincon MT, 2004, J BACTERIOL, V186, P2576, DOI 10.1128/JB.186.9.2576-2585.2004; Rincon MT, 2003, J BACTERIOL, V185, P703, DOI 10.1128/JB.185.3.703-713.2003; Schaeffer F, 2002, BIOCHEMISTRY-US, V41, P2106, DOI 10.1021/bi011853m; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J; Yu PQ, 2003, J AGR FOOD CHEM, V51, P218, DOI 10.1021/jf020476x	33	199	211	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16325	16334		10.1074/jbc.M414449200	http://dx.doi.org/10.1074/jbc.M414449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705576	hybrid			2022-12-27	WOS:000228444800104
J	Lemeshko, VV; Arias, M; Orduz, S				Lemeshko, VV; Arias, M; Orduz, S			Mitochondria permeabilization by a novel polycation peptide BTM-P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THURINGIENSIS SUBSP-MEDELLIN; CANCER CELL-LINES; BACILLUS-THURINGIENSIS; CYTOCHROME-C; TRANSITION PORE; OXIDATIVE-PHOSPHORYLATION; ANTIMICROBIAL PEPTIDE; ANALOG PEPTIDES; MOSQUITO LARVAE; OUTER-MEMBRANE	Bacillus thuringiensis subsp. medellin is known to produce the Cry11Bb protein of 94 kDa, which is toxic for mosquito larvae due to permeabilization of the plasma membrane of midgut epithelial cells. Earlier we found that a 2.8-kDa novel peptide BTM-P1, which was artificially synthesized taking into account the primary structure of Cry11Bb endotoxin, is active against several species of bacteria. In this work we show that BTM-P1 induces cyclosporin A-insensitive swelling of rat liver mitochondria in various salt solutions but not in the sucrose medium. Inorganic phosphate and Ca2+ significantly increased this effect of the peptide. The uncoupling action of BTM-P1 on oxidative phosphorylation was stronger in the potassium-containing media and correlated with a decrease of the inner membrane potential of mitochondria. In isotonic KNO3, KCl, or NH4NO3 media, a complete drop of the inner membrane potential was observed at 1 - 2 mu g/ml of the peptide. The peptide-induced swelling was increased by energization of mitochondria in the potassium-containing media, but it was inhibited in the NaNO3, NH4NO3, and Tris-NO3 media. All mitochondrial effects of the peptide were completely prevented by adding a single N-terminal tryptophan residue to the peptide sequence. We suggest a mechanism of membrane permeabilization that includes a transmembrane- and surface potential-dependent insertion of the polycation peptide into the lipid bilayer and its oligomerization leading to formation of ion channels and also to the mitochondrial permeability transition pore opening in a cyclosporin A-insensitive manner.	Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Medellin AA3840, Colombia; Corp Invest Biol, Unidad Biotecnol & Control Biol, Medellin AA7378, Colombia; Univ Pamplona, Fac Ciencias Basicas, Pamplona, Colombia	Universidad Nacional de Colombia	Lemeshko, VV (corresponding author), Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Calle 65,Cra 64, Medellin AA3840, Colombia.	vvasilie@unalmed.edu.co	Orduz, Sergio/Q-7437-2017	Orduz, Sergio/0000-0001-7587-3816				BAKER MA, 1993, CANCER RES, V53, P3052; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cabrera MPD, 2004, J PEPT RES, V64, P95, DOI 10.1111/j.1399-3011.2004.00173.x; de Planque MRR, 2003, BIOCHEMISTRY-US, V42, P5341, DOI 10.1021/bi027000r; del Rio G, 2001, FEBS LETT, V494, P213, DOI 10.1016/S0014-5793(01)02348-1; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Fujita N, 2000, DRUG RESIST UPDATE, V3, P149, DOI 10.1054/drup.2000.0142; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Gutierrez P, 2001, MEM I OSWALDO CRUZ, V96, P357, DOI 10.1590/S0074-02762001000300013; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; IBSEN KH, 1961, CANCER RES, V21, P829; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Ito A, 2004, J BIOL CHEM, V279, P21282, DOI 10.1074/jbc.M401881200; Iwai T, 2002, J MOL CELL CARDIOL, V34, P725, DOI 10.1006/jmcc.2002.2002; Killian JA, 2003, FEBS LETT, V555, P134, DOI 10.1016/S0014-5793(03)01154-2; Kim SK, 2003, PEPTIDES, V24, P945, DOI 10.1016/S0196-9781(03)00194-3; Kling K, 1999, AM J SURG, V178, P411, DOI 10.1016/S0002-9610(99)00209-3; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Lee DG, 2002, BBA-PROTEINS PROTEOM, V1598, P185, DOI 10.1016/S0167-4838(02)00373-4; Lemeshko SV, 2004, MOL CELL BIOCHEM, V256, P127, DOI 10.1023/B:MCBI.0000009864.77216.00; Lemeshko VV, 2000, FEBS LETT, V472, P5, DOI 10.1016/S0014-5793(00)01419-8; Lemeshko VV, 2003, ARCH BIOCHEM BIOPHYS, V412, P176, DOI 10.1016/S0003-9861(03)00034-1; Lemeshko VV, 2002, J BIOL CHEM, V277, P17751, DOI 10.1074/jbc.M201002200; Lemeshko VV, 2002, BIOPHYS J, V82, P684, DOI 10.1016/S0006-3495(02)75431-3; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Liu CD, 1996, AM J SURG, V171, P192, DOI 10.1016/S0002-9610(99)80098-1; Mather M, 2001, BBA-BIOENERGETICS, V1503, P357, DOI 10.1016/S0005-2728(00)00231-0; Morin D, 2001, ADV DRUG DELIVER REV, V49, P151, DOI 10.1016/S0169-409X(01)00132-6; Nicholls D., 2002, BIOENERGETICS, V3; NORDENBERG J, 1987, BRIT J CANCER, V55, P41, DOI 10.1038/bjc.1987.9; OHSAKI Y, 1992, CANCER RES, V52, P3534; Orduz S, 1998, BBA-PROTEIN STRUCT M, V1388, P267, DOI 10.1016/S0167-4838(98)00168-X; ORDUZ S, 1992, J INVERTEBR PATHOL, V59, P99, DOI 10.1016/0022-2011(92)90118-N; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Popova AV, 2002, BBA-BIOMEMBRANES, V1561, P109, DOI 10.1016/S0005-2736(01)00462-X; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Regula KM, 2003, J MOL CELL CARDIOL, V35, P559, DOI 10.1016/S0022-2828(03)00118-4; RIGOBELLO MP, 1995, BIOCHEM BIOPH RES CO, V217, P144, DOI 10.1006/bbrc.1995.2756; Rodriguez-Enriquez S, 2001, EUR J BIOCHEM, V268, P2512, DOI 10.1046/j.1432-1327.2001.02140.x; Ruiz LM, 2004, MEM I OSWALDO CRUZ, V99, P73, DOI 10.1590/S0074-02762004000100013; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; Segura C, 2000, J INVERTEBR PATHOL, V76, P56, DOI 10.1006/jipa.2000.4945; Shinohara Y, 1997, BBA-BIOENERGETICS, V1319, P319, DOI 10.1016/S0005-2728(97)00002-9; Sokolove PM, 1996, ARCH BIOCHEM BIOPHYS, V336, P69, DOI 10.1006/abbi.1996.0533; Tatsumi T, 2003, CARDIOVASC RES, V59, P428, DOI 10.1016/S0008-6363(03)00391-2; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; Wojtczak L, 1999, EUR J BIOCHEM, V263, P495, DOI 10.1046/j.1432-1327.1999.00522.x; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Yamagiwa M, 2004, BIOSCI BIOTECH BIOCH, V68, P523, DOI 10.1271/bbb.68.523; Zakharov SD, 2002, BIOCHIMIE, V84, P465, DOI 10.1016/S0300-9084(02)01453-0; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	68	17	17	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15579	15586		10.1074/jbc.M414064200	http://dx.doi.org/10.1074/jbc.M414064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713682	hybrid			2022-12-27	WOS:000228444800016
J	Raman, B; Ban, T; Yamaguchi, K; Sakai, M; Kawai, T; Naiki, H; Goto, Y				Raman, B; Ban, T; Yamaguchi, K; Sakai, M; Kawai, T; Naiki, H; Goto, Y			Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER A-BETA; INDUCED AGGREGATION; TRANSGENIC MICE; COPPER-BINDING; DISEASE; ZINC; PROTEIN; NEUROTOXICITY; COMPLEXES; INSIGHTS	Although metal ions such as Cu2+, Zn2+, and Fe3+ are implicated to play a key role in Alzheimer disease, their role is rather complex, and comprehensive understanding is not yet obtained. We show that Cu2+ and Zn2+ but not Fe3+ renders the amyloid beta peptide, A beta(1-40), non-fibrillogenic in nature. However, preformed fibrils of A beta(1-40) were stable when treated with these metal ions. Consequently, fibril growth of A beta(1-40) could be switched on/off by switching the molecule between its apo- and holo-forms. Clioquinol, a potential drug for Alzheimer disease, induced resumption of the Cu2+-suppressed but not the Zn2+-suppressed fibril growth of A beta(1-40). The observed synergistic effect of clioquinol and Zn2+ suggests that Zn2+-clioquinol complex effectively retards fibril growth. Thus, clioquinol has dual effects; although it disaggregates the metal ion-induced aggregates of A beta(1-40) through metal chelation, it further retards the fibril growth along with Zn2+. These results indicate the mechanism of metal ions in suppressing A beta amyloid formation, as well as providing information toward the use of metal ion chelators, particularly clioquinol, as potential drugs for Alzheimer disease.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Osaka 5650871, Japan; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Osaka University; University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Ban T, 2004, J MOL BIOL, V344, P757, DOI 10.1016/j.jmb.2004.09.078; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; BUSCAGLIO J, 1993, P NATL ACAD SCI USA, V90, P2090; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Di Vaira M, 2004, INORG CHEM, V43, P3795, DOI 10.1021/ic0494051; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Esler WP, 1996, J NEUROCHEM, V66, P723; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gnjec A, 2002, FRONT BIOSCI, V7, pD1016, DOI 10.2741/gnjec; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klug GMJA, 2003, EUR J BIOCHEM, V270, P4282, DOI 10.1046/j.1432-1033.2003.03815.x; Lane TJ, 1960, J AM CHEM SOC, V82, P4462, DOI 10.1021/ja01502a006; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Syme CD, 2004, J BIOL CHEM, V279, P18169, DOI 10.1074/jbc.M313572200; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	41	143	151	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16157	16162		10.1074/jbc.M500309200	http://dx.doi.org/10.1074/jbc.M500309200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718230	hybrid, Green Published			2022-12-27	WOS:000228444800084
J	Wei, Z; Lyon, M; Gallagher, JT				Wei, Z; Lyon, M; Gallagher, JT			Distinct substrate specificities of bacterial heparinases against N-unsubstituted glucosamine residues in heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICALLY-MODIFIED HEPARINS; FLAVOBACTERIUM-HEPARINUM; AMINO-GROUPS; PROTEOGLYCANS; GROWTH; DEGRADATION; HEPARITINASE; PURIFICATION; DIVERSITY; LYASES	The rare N- unsubstituted glucosamine ( GlcNH(3)(+)) residues in heparan sulfate have important biological and pathophysiological roles. In this study, four GlcNH(3)(+)-containing disaccharides were obtained from partially de- N- sulfated forms of heparin and the N- sulfated K5 polysaccharide by digestion with combined heparinases I, II, and III. These were identified as Delta HexA- GlcNH(3)(+), Delta HexA- GlcNH(3)(+)( 6S), Delta HexA(2S)- GlcNH(3)(+), and Delta HexA-( 2S)- GlcNH(3)(+) ( 6S). Digestions with individual enzymes revealed that heparinase I did not cleave at GlcNH(3)(+) residues; however, heparinases II and III showed selective and distinct activities. Heparinase II generated Delta HexA- GlcNH(3)(+)( 6S), Delta HexA( 2S)- GlcNH(3)(+), and Delta HexA( 2S)- GlcNH(3)(+) ( 6S) disaccharides, whereas heparinase III yielded only the Delta HexA- GlcNH(3)(+) unit. Thus, the action of heparinase II requires O- sulfation, whereas heparinase III acts only on the corresponding non- sulfated unit. These striking distinctions in substrate specificities of heparinases could be used to isolate oligosaccharides with novel sequences of GlcNH(3)(+) residues. Finally, heparinases were used to identify and quantify GlcNH(3)(+)-containing disaccharides in native bovine kidney and porcine intestinal mucosal heparan sulfates. The relatively high content of O- sulfated GlcNH(3)(+)- disaccharides in kidney HS raises questions about how these sequences are generated.	Christie Hosp NHS Trust, Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Lyon, M (corresponding author), Christie Hosp NHS Trust, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	MLyon@picr.man.ac.uk		Lyon, Malcolm/0000-0001-9575-6879				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chai WG, 2004, BIOCHEMISTRY-US, V43, P8590, DOI 10.1021/bi036250k; CONRAD HE, 1998, HEPARIN BINDING PROT, P10; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; HOVINGH P, 1970, J BIOL CHEM, V245, P6170; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINKER A, 1960, BIOCHIM BIOPHYS ACTA, V43, P366, DOI 10.1016/0006-3002(60)90460-1; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; LYON M, 1997, LAB GUIDE GLYCOCONJU, P61; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; MOFFAT CF, 1991, EUR J BIOCHEM, V202, P531, DOI 10.1111/j.1432-1033.1991.tb16405.x; MOFFAT CF, 1991, EUR J BIOCHEM, V197, P449, DOI 10.1111/j.1432-1033.1991.tb15931.x; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; PERLIN AS, 1971, CARBOHYD RES, V18, P185, DOI 10.1016/S0008-6215(00)80341-9; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P12232, DOI 10.1073/pnas.95.21.12232; Robinson CJ, 2001, J CELL SCI, V114, P853; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	40	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15742	15748		10.1074/jbc.M501102200	http://dx.doi.org/10.1074/jbc.M501102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705564	hybrid			2022-12-27	WOS:000228444800036
J	Vidal, GA; Naresh, A; Marrero, L; Jones, FE				Vidal, GA; Naresh, A; Marrero, L; Jones, FE			Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MAMMARY-GLAND; CLEAVAGE; RECEPTOR; NOTCH; ACTIVATION; PROTEOLYSIS; EXPRESSION; ISOFORM; DOMAIN	Transmembrane receptors typically transmit cellular signals following growth factor stimulation by coupling to and activating downstream signaling cascades. Reports of proteolytic processing of cell surface receptors to release an intracellular domain (ICD) has raised the possibility of novel signaling mechanisms directly mediated by the receptor ICD. The receptor tyrosine kinase ERBB4/HER4 ( referred to here as ERBB4) undergoes sequential processing by tumor necrosis factor-alpha converting enzyme and presenilin-dependent gamma-secretase to release the ERBB4 ICD (4ICD). Our recent data suggests that regulation of gene expression by the ERBB4 nuclear protein and the proapoptotic activity of ERBB4 involves the gamma-secretase release of 4ICD. To determine the role gamma-secretase processing plays in ERBB4 signaling, we generated an ERBB4 allele with the transmembrane residue substitution V673I (ERBB4-V673I). We demonstrate that ERBB4-V673I fails to undergo processing by gamma-secretase but retains normal cell surface signaling activity. In contrast to wild-type ERBB4, however, ERBB4-V673I was excluded from the nuclei of transfected cells and failed to activate STAT5A stimulation of the beta-casein promoter. These results support the contention that gamma-secretase processing of ERBB4 is necessary to release a functional 4ICD nuclear protein which directly regulates gene expression. We also demonstrate that 4ICD failed to accumulate within mitochondria of ERBB4-V673I transfected cells and the potent proapoptotic activity of ERBB4 was completely abolished in cells expressing ERBB4-V673I. Our results provide the first formal demonstration that proteolytic processing of ERBB4 is a critical event regulating multiple receptor signaling activities.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Morphol & Imaging Core Lab, New Orleans, LA 70112 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jones, FE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, Tulane Canc Ctr, New Orleans, LA 70112 USA.	fjones@tulane.edu		Vidal, Gregory/0000-0003-3325-6224	NCI NIH HHS [R01CA96717, R01CA95783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095783, R01CA096717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bouillet P, 2002, J CELL SCI, V115, P1567; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Lai C, 2004, BIOCHEM BIOPH RES CO, V314, P535, DOI 10.1016/j.bbrc.2003.12.131; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	40	108	116	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19777	19783		10.1074/jbc.M412457200	http://dx.doi.org/10.1074/jbc.M412457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15746097	hybrid			2022-12-27	WOS:000229113700044
J	Winn, RA; Marek, L; Han, SY; Rodriguez, K; Rodriguez, N; Hammond, M; Van Scoyk, M; Acosta, H; Mirus, J; Barry, N; Bren-Mattison, Y; Van Raay, TJ; Nemenoff, RA; Heasley, LE				Winn, RA; Marek, L; Han, SY; Rodriguez, K; Rodriguez, N; Hammond, M; Van Scoyk, M; Acosta, H; Mirus, J; Barry, N; Bren-Mattison, Y; Van Raay, TJ; Nemenoff, RA; Heasley, LE			Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; FACTOR RECEPTOR; C-JUN; CONVERGENT EXTENSION; MUTATIONS; PROTEIN; GENE; JNK; MOUSE	The Wnt signaling pathway is critical in normal development, and mutation of specific components is frequently observed in carcinomas of diverse origins. However, the potential involvement of this pathway in lung tumorigenesis has not been established. In this study, analysis of multiple Wnt mRNAs in non-small cell lung cancer (NSCLC) cell lines and primary lung tumors revealed markedly decreased Wnt-7a expression compared with normal short-term bronchial epithelial cell lines and normal uninvolved lung tissue. Wnt-7a transfection in NSCLC cell lines reversed cellular transformation, decreased anchorage-independent growth, and induced epithelial differentiation as demonstrated by soft agar and three-dimensional cell culture assays in a subset of the NSCLC cell lines. The action of Wnt-7a correlated with expression of the specific Wnt receptor Frizzled-9 (Fzd-9), and transfection of Fzd-9 into a Wnt-7a-insensitive NSCLC cell line established Wnt-7a sensitivity. Moreover, Wnt-7a was present in Fzd-9 immunoprecipitates, indicating a direct interaction of Wnt-7a and Fzd-9. In NSCLC cells, Wnt-7a and Fzd-9 induced both cadherin and Sprouty-4 expression and stimulated the JNK pathway, but not beta-catenin/T cell factor activity. In addition, transfection of gain-of-function JNK strongly inhibited anchorage-independent growth. Thus, this study demonstrates that Wnt-7a and Fzd-9 signaling through activation of the JNK pathway induces cadherin proteins and the receptor tyrosine kinase inhibitor Sprouty-4 and represents a novel tumor suppressor pathway in lung cancer that is required for maintenance of epithelial differentiation and inhibition of transformed cell growth in a subset of human NSCLCs.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, Denver, CO 80262 USA; Vet Affairs Med Ctr, Denver, CO 80220 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care Med, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.	robert.winn@uchsc.edu	Bren-Mattison, Yvette/AAC-1137-2022; Acosta, Hector/GQP-3049-2022; Van Raay, Terry/AAA-7342-2021	Van Raay, Terence/0000-0003-0196-1041	NATIONAL CANCER INSTITUTE [P50CA058187, R01CA103618] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA58187, CA103618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beekman A, 1998, CANCER RES, V58, P910; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Fukuchi T, 1998, CANCER RES, V58, P3526; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; HEASLEY LE, 1998, BIOL LUNG CANC, P371; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Jonsson M, 2002, CANCER RES, V62, P409; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LEVAYYOUNG BK, 1992, AM J PHYSIOL, V262, pL672, DOI 10.1152/ajplung.1992.262.6.L672; Li SF, 2001, J CLIN ENDOCR METAB, V86, P454, DOI 10.1210/jc.86.1.454; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ohsaki Y, 2000, ONCOL REP, V7, P603; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Polakis P, 2000, GENE DEV, V14, P1837; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Sassoon D, 1999, MOL CELL ENDOCRINOL, V158, P1, DOI 10.1016/S0303-7207(99)00170-7; Sato N, 2003, CANCER RES, V63, P3735; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Wada M, 1997, J MOL MED-JMM, V75, P139, DOI 10.1007/s001090050098; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	60	135	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19625	19634		10.1074/jbc.M409392200	http://dx.doi.org/10.1074/jbc.M409392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15705594	hybrid			2022-12-27	WOS:000229113700026
J	Wang, XS; Mader, MM; Toth, JE; Yu, XH; Jin, NJ; Campbell, RM; Smallwood, JK; Christe, ME; Chatterjee, A; Goodson, T; Vlahos, CJ; Matter, WF; Bloem, LJ				Wang, XS; Mader, MM; Toth, JE; Yu, XH; Jin, NJ; Campbell, RM; Smallwood, JK; Christe, ME; Chatterjee, A; Goodson, T; Vlahos, CJ; Matter, WF; Bloem, LJ			Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; IN-VIVO; THERAPEUTIC TARGETS; MAP KINASES; CELL-CYCLE; PROTEIN; STRESS; EXPRESSION; PATHWAY; ZAK	Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC50 of 70 nM for inhibition of pJNK formation in COS-7 cell MLK7/JNK co-transfection assays. In stimulated cells, DHP-2 at 200 nM or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1 beta or tumor necrosis factor-alpha-induced p38 and JNK activation. Additionally, the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Cardiovasc Discovery Res, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lead Optimizat Biol, Indianapolis, IN 46285 USA; Eli Lilly & Co, Discovery Chem Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Bloem, LJ (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Cardiovasc Discovery Res, Indianapolis, IN 46285 USA.	L.Bloem@lilly.com						Bloem LJ, 2001, J MOL CELL CARDIOL, V33, P1739, DOI 10.1006/jmcc.2001.1437; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; CHATTERJEE A, 2004, CHEM ABSTR 2358, V141; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Christe M, 2004, J MOL CELL CARDIOL, V37, P705, DOI 10.1016/j.yjmcc.2004.06.004; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mao XH, 2004, EXP CELL RES, V292, P304, DOI 10.1016/j.yexcr.2003.09.012; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney Anna C., 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P143, DOI 10.2174/1568015023358201; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Tosti E, 2004, J BIOL CHEM, V279, P47652, DOI 10.1074/jbc.M409961200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vlahos CJ, 2003, NAT REV DRUG DISCOV, V2, P99, DOI 10.1038/nrd1009; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Yang JJ, 2003, BIOCHEM BIOPH RES CO, V301, P71, DOI 10.1016/S0006-291X(02)02980-7; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yu XH, 2003, BIOCHEM BIOPH RES CO, V310, P452, DOI 10.1016/j.bbrc.2003.09.075	35	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19298	19305		10.1074/jbc.M413059200	http://dx.doi.org/10.1074/jbc.M413059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737997	hybrid			2022-12-27	WOS:000228932300087
J	Anai, M; Shojima, N; Katagiri, H; Ogihara, T; Sakoda, H; Onishi, Y; Ono, H; Fujishiro, M; Fukushima, Y; Horike, N; Viana, A; Kikuchi, M; Noguchi, N; Takahashi, S; Takata, K; Oka, Y; Uchijima, Y; Kurihara, H; Asano, T				Anai, M; Shojima, N; Katagiri, H; Ogihara, T; Sakoda, H; Onishi, Y; Ono, H; Fujishiro, M; Fukushima, Y; Horike, N; Viana, A; Kikuchi, M; Noguchi, N; Takahashi, S; Takata, K; Oka, Y; Uchijima, Y; Kurihara, H; Asano, T			A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; AKT; INSULIN; INHIBITION; SURVIVAL; PHOSPHORYLATION; PKB/AKT; HOMOLOG; GROWTH; ENTRY	Protein kinase B (PKB)/Akt reportedly plays a role in the survival and/or proliferation of cells. We identified a novel protein, which binds to PKB, using a yeast two-hybrid screening system. This association was demonstrated not only in vivo by overexpressing both proteins or by coimmunoprecipitation of the endogenous proteins, but also in vitro using glutathione S-transferase fusion proteins. Importantly, this protein specifically associates with the C terminus of PKB but not with other AGC kinases and enhances PKB phosphorylation and kinase activation without growth factor stimulation. Thus, we termed this Akt-specific binding protein APE (Akt-phosphorylation enhancer). Since APE-induced phosphorylation of PKB did not occur in cells treated with wortmannin or LY294002, APE itself is not a kinase but seems to enhance or prolong the phosphoinositide 3-kinase-dependent phosphorylation of PKB. In cells in which APE was suppressed by small interfering RNA, DNA synthesis was significantly reduced with suppression of PKB phosphorylation, suggesting a synergistic role of APE in PKB-induced proliferation. On the other hand, in cells overexpressing both PKB and APE, despite markedly increased basal phosphorylation of PKB, both DNA rereplication and subsequent Chk2 phosphorylation and apoptosis were seen, suggesting the involvement of APE in the regulation of cell cycling replication licensing. Taking these observations together, APE appears to be a novel regulator of PKB phosphorylation. Furthermore, the interaction between APE and PKB, possibly dependent on the expression levels of both proteins, may be a novel molecular mechanism leading to proliferation and/or apoptosis.	Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, Tokyo 1138655, Japan; Asahi Life Fdn, Inst Adult Dis, Dept Internal Med, Chiyoda Ku, Tokyo 1000005, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet,Aoba Ku, Sendai, Miyagi 9808574, Japan; Gunma Univ, Inst Cellular & Mol Regulat, Dept Cell Biol, Gunma 3718512, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Sci, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; Asahi Life Foundation; Tohoku University; Gunma University; University of Tokyo; University of Tokyo	Asano, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	asano-tky@umin.ac.jp	Onishi, Yukiko/AAU-9057-2021	Onishi, Yukiko/0000-0003-1180-5982; Kurihara, Hiroki/0000-0002-6476-5593				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iynedjian PB, 2005, BIOCHEM J, V386, P113, DOI 10.1042/BJ20041425; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Yamada T, 2001, J BIOL CHEM, V276, P5339, DOI 10.1074/jbc.M005685200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	30	100	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18525	18535		10.1074/jbc.M500586200	http://dx.doi.org/10.1074/jbc.M500586200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753085	hybrid			2022-12-27	WOS:000228807200117
J	Baumli, S; Hoeppner, S; Cramer, P				Baumli, S; Hoeppner, S; Cramer, P			A conserved mediator hinge revealed in the structure of the MED7 center dot MED21 (Med7 center dot Srb7) heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; PROTEIN-STRUCTURE; REPEAT DOMAIN; YEAST; ACTIVATOR; COMPLEX; REQUIREMENT; ORGANIZATION; ASSOCIATION	The Mediator of transcriptional regulation is the central coactivator that enables a response of RNA polymerase II (Pol II) to activators and repressors. We present the 3.0-angstrom crystal structure of a highly conserved part of the Mediator, the MED7 center dot MED21 (Med7 center dot Srb7) heterodimer. The structure is very extended, spanning one-third of the Mediator length and almost the diameter of Pol II. It shows a four-helix bundle domain and a coiled-coil protrusion connected by a flexible hinge. Four putative protein binding sites on the surface allow for assembly of the Mediator middle module and for binding of the conserved subunit MED6, which is shown to bridge to the Mediator head module. A flexible MED6 bridge and the MED7 center dot MED21 hinge could account for changes in overall Mediator structure upon binding to Pol II or activators. Our results support the idea that transcription regulation involves conformational changes within the general machinery.	Univ Munich, Dept Chem & Biochem, Gene Ctr, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Dept Chem & Biochem, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.	cramer@LMB.uni-muenchen.de						Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bjorklund S, 2004, ADV PROTEIN CHEM, V67, P43; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Gromoller A, 2000, FEBS LETT, V484, P48, DOI 10.1016/S0014-5793(00)02123-2; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kwon JY, 2001, FEBS LETT, V508, P305, DOI 10.1016/S0014-5793(01)03072-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Linder T, 2004, J BIOL CHEM, V279, P49455, DOI 10.1074/jbc.M409046200; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NONET ML, 1989, GENETICS, V123, P715; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rost B, 1996, METHOD ENZYMOL, V266, P525; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Taatjes DJ, 2004, NAT STRUCT MOL BIOL, V11, P664, DOI 10.1038/nsmb789; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Tudor M, 1999, GENE DEV, V13, P2365, DOI 10.1101/gad.13.18.2365; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	53	56	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18171	18178		10.1074/jbc.M413466200	http://dx.doi.org/10.1074/jbc.M413466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710619	Green Published, hybrid			2022-12-27	WOS:000228807200075
J	Lutzmann, M; Kunze, R; Stangl, K; Stelter, P; Toth, KF; Bottcher, B; Hurt, E				Lutzmann, M; Kunze, R; Stangl, K; Stelter, P; Toth, KF; Bottcher, B; Hurt, E			Reconstitution of Nup157 and Nup145N into the Nup84 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SCANNING-ELECTRON-MICROSCOPY; BIOGENESIS PATHWAY; PROTEOMIC ANALYSIS; IMPORTIN-BETA; NUCLEOPORIN; TRANSPORT; PURIFICATION; ORGANIZATION	About 30 different nucleoporins (Nups) constitute the nuclear pore complex. We have affinity-purified 28 of these nuclear pore proteins and identified new nucleoporin interactions by this analysis. We found that Nup157 and Nup170, two members of the large structural Nups, and the Gly-Leu-Phe-Gly nucleoporin Nup145N specifically co-purified with members of the Nup84 complex. In addition, Nup145N co-enriched during Nup157 purification. By in vitro reconstitution, we demonstrate that Nup157 and Nup145N form a nucleoporin subcomplex. Moreover, we show that Nup157 and Nup145N bind to the heptameric Nup84 complex. This assembly thus represents approximately one-third of all nucleoporins. To characterize Nup157 structurally, we purified and analyzed it by electron microscopy. Nup157 is a hollow sphere that resembles a clamp or a gripping hand. Thus, we could reconstitute an interaction between a large structural Nup, an FG repeat Nup, and a major structural module of the nuclear pore complex.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-6900 Heidelberg, Germany; Heidelberg Univ, Kirchhoff Inst Phys, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Bottcher, Bettina/E-9397-2010	Ed Hurt, Dr./0000-0002-4535-8255; Bottcher, Bettina/0000-0002-7962-4849				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Berke IC, 2004, J CELL BIOL, V167, P591, DOI 10.1083/jcb.200408109; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; Devos D, 2004, PLOS BIOL, V2, P2085, DOI 10.1371/journal.pbio.0020380; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOLDBERG MW, 1992, J CELL BIOL, V119, P1429, DOI 10.1083/jcb.119.6.1429; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Harel A, 2003, MOL CELL, V11, P853, DOI 10.1016/S1097-2765(03)00116-3; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kosova B, 1999, J BIOL CHEM, V274, P22646, DOI 10.1074/jbc.274.32.22646; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ris H, 1997, SCANNING, V19, P368, DOI 10.1002/sca.4950190504; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2003, TRENDS CELL BIOL, V13, P622, DOI 10.1016/j.tcb.2003.10.007; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Walther TC, 2003, CELL, V113, P195, DOI 10.1016/S0092-8674(03)00235-6; Weirich CS, 2004, MOL CELL, V16, P749, DOI 10.1016/j.molcel.2004.10.032; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141	48	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18442	18451		10.1074/jbc.M412787200	http://dx.doi.org/10.1074/jbc.M412787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741174	Green Accepted, hybrid			2022-12-27	WOS:000228807200107
J	Urizar, E; Claeysen, S; Deupi, X; Govaerts, C; Costagliola, S; Vassart, G; Pardo, L				Urizar, E; Claeysen, S; Deupi, X; Govaerts, C; Costagliola, S; Vassart, G; Pardo, L			An activation switch in the rhodopsin family of G protein-coupled receptors - The thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN HORMONE-RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; LUTROPIN RECEPTOR; CRYSTAL-STRUCTURE; FUNCTIONAL-ROLE; CONSERVED ASN; TSH RECEPTOR; SIDE-CHAIN; MUTATIONS; HELIX-7	We aimed at understanding molecular events involved in the activation of a member of the G protein-coupled receptor family, the thyrotropin receptor. We have focused on the transmembrane region and in particular on a network of polar interactions between highly conserved residues. Using molecular dynamics simulations and site-directed mutagenesis techniques we have identified residue Asn-7.49, of the NPxxY motif of TM 7, as a molecular switch in the mechanism of thyrotropin receptor (TSHr) activation. Asn-7.49 appears to adopt two different conformations in the inactive and active states. These two states are characterized by specific interactions between this Asn and polar residues in the transmembrane domain. The inactive gauche + conformation is maintained by interactions with residues Thr-6.43 and Asp-6.44. Mutation of these residues into Ala increases the constitutive activity of the receptor by factors of similar to 14 and similar to 10 relative to wild type TSHr, respectively. Upon receptor activation Asn-7.49 adopts the trans conformation to interact with Asp-2.50 and a putatively charged residue that remains to be identified. In addition, the conserved Leu-2.46 of the (N/S) LxxxD motif also plays a significant role in restraining the receptor in the inactive state because the L2.46A mutation increases constitutive activity by a factor of similar to 13 relative to wild type TSHr. As residues Leu-2.46, Asp-2.50, and Asn-7.49 are strongly conserved, this molecular mechanism of TSHr activation can be extended to other members of the rhodopsin-like family of G protein-coupled receptors.	Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Bellaterra 08193, Spain; Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Nucl, B-1070 Brussels, Belgium; Univ Autonoma Barcelona, Inst Neurociencies, Bellaterra 08193, Spain; Univ Basque Country, Fac Farm, Dept Neurofarmacol, Vitoria 1006, Spain	Autonomous University of Barcelona; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Autonomous University of Barcelona; University of Basque Country	Pardo, L (corresponding author), Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Edifici M,Campus Univ, Bellaterra 08193, Spain.	Leonardo.Pardo@uab.es	Deupi, Xavier/B-2424-2009; costagliola, sabine/D-4864-2012; Claeysen, Sylvie/C-8599-2014	Deupi, Xavier/0000-0003-4572-9316; Claeysen, Sylvie/0000-0002-0576-5518; Pardo, Leonardo/0000-0003-1778-7420				Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Angelova K, 2002, J BIOL CHEM, V277, P32202, DOI 10.1074/jbc.M203272200; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; CASE D, 2003, AMBER 8; Claeysen S, 2002, FEBS LETT, V517, P195, DOI 10.1016/S0014-5793(02)02620-0; Costagliola S, 1998, J IMMUNOL, V160, P1458; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Horn F, 2003, NUCLEIC ACIDS RES, V31, P294, DOI 10.1093/nar/gkg103; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Li B, 2005, J BIOL CHEM, V280, P5664, DOI 10.1074/jbc.M411623200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Montanelli L, 2004, MOL ENDOCRINOL, V18, P2061, DOI 10.1210/me.2004-0036; Neumann S, 2001, MOL ENDOCRINOL, V15, P1294, DOI 10.1210/me.15.8.1294; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHI L, 2002, J BIOL CHEM, V277, P40989; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; ZHOU W, 1994, MOL PHARMACOL, V45, P165	46	100	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17135	17141		10.1074/jbc.M414678200	http://dx.doi.org/10.1074/jbc.M414678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722344	hybrid, Green Published			2022-12-27	WOS:000228615500073
J	Urschel, S; Bassermann, F; Bai, RY; Munch, S; Peschel, C; Duyster, J				Urschel, S; Bassermann, F; Bai, RY; Munch, S; Peschel, C; Duyster, J			Phosphorylation of Grb10 regulates its interaction with 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN GRB10; INSULIN-RECEPTOR; SIGNALING PROTEINS; TYROSINE KINASE; BINDING; SUBSTRATE; IDENTIFICATION; AKT; LOCALIZATION; SPECIFICITY	Grb10 is a member of adapter proteins that are thought to play a role in receptor tyrosine kinase-mediated signal transduction. Grb10 expression levels can influence Akt activity, and Grb10 may act as an adapter involved in the relocalization of Akt to the cell membrane. Here we identified 14-3-3 as a binding partner of Grb10 by employing a yeast two-hybrid screen. The 14-3-3 center dot Grb10 interaction requires phosphorylation of Grb10, and only the phosphorylated form of Grb10 coimmunoprecipitates with endogenous 14-3-3. We could identify a putative phosphorylation site in Grb10, which is located in a classical 14-3-3 binding motif, RSVSEN. Mutation of this site in Grb10 diminished binding to 14-3-3. Thus, Grb10 exists in two different states of phosphorylation and complexes with 14-3-3 when phosphorylated on serine 428. We provide evidence that Akt directly binds Grb10 and is able to phosphorylate Grb10 in an in vitro kinase assay. Based on these findings, we propose a regulatory circuitry involving a phosphorylation-regulated complex formation of Grb10 with 14-3-3 and Akt.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany	Technical University of Munich; University of Munich	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismanigerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de						Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng YP, 2003, J BIOL CHEM, V278, P39311, DOI 10.1074/jbc.M304599200; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Langlais P, 2004, MOL ENDOCRINOL, V18, P350, DOI 10.1210/me.2003-0117; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	17	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16987	16993		10.1074/jbc.M501477200	http://dx.doi.org/10.1074/jbc.M501477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722337	hybrid			2022-12-27	WOS:000228615500055
J	Voss, OH; Kim, S; Wewers, MD; Doseff, AI				Voss, OH; Kim, S; Wewers, MD; Doseff, AI			Regulation of monocyte apoptosis by the protein kinase C delta-dependent phosphorylation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC ACTIVATION; INHIBITOR; SURVIVAL; IDENTIFICATION; ENDOTOXIN; CLEAVAGE; CPP32; CELLS	Monocytes are central components of the innate immune response and normally circulate for a short period of time before undergoing spontaneous apoptosis. During inflammation, differentiation, or oncogenic transformation, the life span of monocytes is prolonged by preventing the activation of the apoptotic program. Here we showed that caspase-3, a cysteine protease required for monocyte apoptosis, is a phosphoprotein. We identified protein kinase C delta (PKC delta) as a member of the protein kinase C family that associates with and phosphorylates caspase-3. The PKC delta-dependent phosphorylation of caspase-3 resulted in an increase in the activity of caspase-3. This effect of PKC delta is specific to caspase-3, as evidenced by the absence of similar effects on caspase-9. The activity of PKC delta precedes the activation of caspase-3 during spontaneous monocyte apoptosis and in monocyte-induced apoptosis. We found that the overexpression of PKC delta resulted in an increase of apoptosis, whereas its inhibition blocked caspase-3 activity and decreased apoptosis. Our results provided evidence that the PKC delta-dependent phosphorylation of caspase-3 provided a novel pro-apoptotic mechanism involved in the regulation of monocyte life span.	Ohio State Univ, Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Div Pulm & Crit Care, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Doseff, AI (corresponding author), Ohio State Univ, Heart & Lung Res Inst 201, 473 W 12th Ave, Columbus, OH 43210 USA.	doseff-1@medctr.osu.edu	Doseff, Andrea/E-2991-2011; Kim, Sunghan/ABH-3874-2020; Wewers, Mark/AAB-6202-2021	Kim, Sunghan/0000-0002-4955-8780				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Doseff AI, 2004, STEM CELLS DEV, V13, P473, DOI 10.1089/1547328042417255; Doseff AI, 2003, AM J RESP CELL MOL, V29, P367, DOI 10.1165/rcmb.2002-0158OC; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fahy RJ, 1999, J IMMUNOL, V163, P1755; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GEAHLEN RL, 1989, J NAT PROD, V52, P982, DOI 10.1021/np50065a011; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Jang BC, 2004, BIOCHEM PHARMACOL, V67, P1819, DOI 10.1016/j.bcp.2004.01.018; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; MANGAN DF, 1993, J PERIODONTOL, V64, P461; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SHAW MT, 1980, HUM PATHOL, V11, P215, DOI 10.1016/S0046-8177(80)80003-7; Shizukuda Y, 2002, AM J PHYSIOL-HEART C, V282, pH1625, DOI 10.1152/ajpheart.00783.2001; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zeigler MM, 2003, J BIOL CHEM, V278, P12894, DOI 10.1074/jbc.M213125200	53	69	72	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17371	17379		10.1074/jbc.M412449200	http://dx.doi.org/10.1074/jbc.M412449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15716280	hybrid			2022-12-27	WOS:000228615500102
J	Han, J; Goldstein, LA; Gastman, BR; Rabinovitz, A; Rabinowich, H				Han, J; Goldstein, LA; Gastman, BR; Rabinovitz, A; Rabinowich, H			Disruption of Mcl-1 center dot Bim complex in granzyme B-mediated mitochondrial apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; CELL-DEATH; BH4 DOMAIN; PHOSPHATIDYLSERINE EXPOSURE; NEUTROPHIL APOPTOSIS; CYTOSOLIC DELIVERY; MCL-1; EXPRESSION; CLEAVAGE	Recently, we reported the identification of a novel mitochondrial apoptotic pathway for granzyme B (GrB) (Han, J., Goldstein, L. A., Gastman, B. R., Froelich, C. J., Yin, X. M., and Rabinowich, H. ( 2004) J. Biol. Chem. 279, 22020 - 22029). The newly identified GrB-mediated mitochondrial cascade was initiated by the cleavage and subsequent degradation of Mcl-1, resulting in the release of mitochondrial Bim from Mcl-1 sequestration. To investigate the biological significance of Mcl-1 cleavage by GrB, we mapped the major GrB cleavage sites and evaluated the apoptotic potential of the cleavage products. GrB cleaves Mcl-1 after aspartic acid residues 117, 127, and 157, generating C-terminal fragments that all contain BH-1, BH-2, BH-3, and transmembrane domains. These fragments accumulate at an early apoptotic phase but are eliminated by further degradation during the apoptotic process. The major Mcl-1 C-terminal fragment generated by GrB ( residues 118 - 350) was unable to induce or enhance apoptosis when transfected into tumor cells. Instead, this Mcl-1 C-terminal fragment maintained a partial protective capability against GrB-mediated apoptosis via its lower affinity to Bim. In comparison with ectopically expressed full-length Mcl-1, the stably transfected C-terminal fragments of Mcl-1 were less efficiently localized to the mitochondria. Knockdown of Mcl-1, as achieved by transfection with Mcl-1-specific short interfering RNA, resulted in a significant level of apoptosis in the absence of external apoptotic stimulation and, in addition, enhanced the susceptibility of breast carcinoma cells to GrB cytotoxicity. The significance of Bim in this GrB apoptotic cascade was indicated by the marked protection against GrB-mediated apoptosis endowed on these cells through Bim knockdown. Our studies suggest that the disruption of the Mcl-1 center dot Bim complex by GrB initiates a major Bim-mediated cellular cytotoxic mechanism that requires the elimination of Mcl-1 following its initial cleavage.	Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Plast Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Res Pavill,Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA109285] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 109285] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Browne KA, 1999, MOL CELL BIOL, V19, P8604; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Droin NM, 2004, BBA-MOL CELL RES, V1644, P179, DOI 10.1016/j.bbamcr.2003.10.011; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Froelich CJ, 2004, CELL DEATH DIFFER, V11, P369, DOI 10.1038/sj.cdd.4401381; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Gleiss B, 2002, FEBS LETT, V519, P153, DOI 10.1016/S0014-5793(02)02743-6; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johnson DE, 2000, CANCER RES, V60, P1818; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lord SJ, 2003, IMMUNOL REV, V193, P31, DOI 10.1034/j.1600-065X.2003.00044.x; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pelletier M, 2002, FEBS LETT, V532, P164, DOI 10.1016/S0014-5793(02)03668-2; Rinkenberger JL, 2000, GENE DEV, V14, P23; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	44	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16383	16392		10.1074/jbc.M411377200	http://dx.doi.org/10.1074/jbc.M411377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713684	hybrid			2022-12-27	WOS:000228444800111
J	Tocilj, A; Schrag, JD; Li, YG; Schneider, BL; Reitzer, L; Matte, A; Cygler, M				Tocilj, A; Schrag, JD; Li, YG; Schneider, BL; Reitzer, L; Matte, A; Cygler, M			Crystal structure of N-succinylarginine dihydrolase AstB, bound to substrate and product, an enzyme from the arginine catabolic pathway of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINYLTRANSFERASE PATHWAY; DATABASE; DEIMINASE; AMINOTRANSFERASE; BIOSYNTHESIS; RECOGNITION; SUPERFAMILY; PSEUDOMONAS; HYDROLYSIS; MECHANISM	The ammonia-producing arginine succinyltransferase pathway is the major pathway in Escherichia coli and related bacteria for arginine catabolism as a sole nitrogen source. This pathway consists of five steps, each catalyzed by a distinct enzyme. Here we report the crystal structure of N-succinylarginine dihydrolase AstB, the second enzyme of the arginine succinyltransferase pathway, providing the first structural insight into enzymes from this pathway. The enzyme exhibits a pseudo 5-fold symmetric alpha/beta propeller fold of circularly arranged beta beta alpha beta modules enclosing the active site. The crystal structure indicates clearly that this enzyme belongs to the amidinotransferase ( AT) superfamily and that the active site contains a Cys-His-Glu triad characteristic of the AT superfamily. Structures of the complexes of AstB with the reaction product and a C365S mutant with bound the N-succinylarginine substrate suggest a catalytic mechanism that consists of two cycles of hydrolysis and ammonia release, with each cycle utilizing a mechanism similar to that proposed for arginine deiminases. Like other members of the AT superfamily of enzymes, AstB possesses a flexible loop that is disordered in the absence of substrate and assumes an ordered conformation upon substrate binding, shielding the ligand from the bulk solvent, thereby controlling substrate access and product release.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	National Research Council Canada; University of Texas System; University of Texas Dallas	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Das K, 2004, STRUCTURE, V12, P657, DOI 10.1016/j.str.2004.02.017; Fraley CD, 1998, J BACTERIOL, V180, P4287, DOI 10.1128/JB.180.16.4287-4290.1998; Galkin A, 2004, J BIOL CHEM, V279, P14001, DOI 10.1074/jbc.M313410200; Groft CM, 2000, NAT STRUCT BIOL, V7, P1156; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Itoh Y, 1997, J BACTERIOL, V179, P7280, DOI 10.1128/jb.179.23.7280-7290.1997; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; Kiupakis AK, 2002, J BACTERIOL, V184, P2940, DOI 10.1128/JB.184.11.2940-2950.2002; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu WS, 2004, BIOCHEMISTRY-US, V43, P10896, DOI 10.1021/bi049218e; Lu XF, 2004, J AM CHEM SOC, V126, P5374, DOI 10.1021/ja049543p; Makarova KS, 1999, J MOL BIOL, V292, P11, DOI 10.1006/jmbi.1999.3059; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; Shah SA, 1997, STRUCTURE, V5, P1067, DOI 10.1016/S0969-2126(97)00258-X; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shirai H, 2003, FEBS LETT, V555, P505, DOI 10.1016/S0014-5793(03)01314-0; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; STALON V, 1987, J GEN MICROBIOL, V133, P2487; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	36	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15800	15808		10.1074/jbc.M413833200	http://dx.doi.org/10.1074/jbc.M413833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703173	hybrid			2022-12-27	WOS:000228444800043
J	Chowdhury, B; Tsokos, CG; Krishnan, S; Robertson, J; Fisher, CU; Warke, RG; Warke, VG; Nambiar, MP; Tsokos, GC				Chowdhury, B; Tsokos, CG; Krishnan, S; Robertson, J; Fisher, CU; Warke, RG; Warke, VG; Nambiar, MP; Tsokos, GC			Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3 '-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; TCR-ZETA; SUSCEPTIBILITY GENES; TCR/CD3 COMPLEX; EXPRESSION; BINDING; PROTEIN; CYCLOOXYGENASE-2; IDENTIFICATION	The molecular mechanisms involved in the aberrant expression of T cell receptor (TCR) zeta chain of patients with systemic lupus erythematosus are not known. Previously we demonstrated that although normal T cells express high levels of TCR zeta mRNA with wild-type (WT) 3' untranslated region (3' UTR), systemic lupus erythematosus T cells display significantly high levels of TCR zeta mRNA with the alternatively spliced (AS) 3' UTR form, which is derived by splice deletion of nucleotides 672-1233 of the TCR zeta transcript. Here we report that the stability of TCR zeta mRNA with an AS 3' UTR is low compared with TCR zeta mRNA with WT 3' UTR. AS 3' UTR, but not WT 3' UTR, conferred similar instability to the luciferase gene. Immunoblotting of cell lysates derived from transfected COS-7 cells demonstrated that TCR zeta with AS 3' UTR produced low amounts of 16-kDa protein. In vitro transcription and translation also produced low amounts of protein from TCR zeta with AS 3' UTR. Taken together our findings suggest that nucleotides 672-1233 bp of TCR zeta 3' UTR play a critical role in its stability and also have elements required for the translational regulation of TCR zeta chain expression in human T cells.	Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD 20910 USA; Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Uniformed Services University of the Health Sciences - USA	Tsokos, CG (corresponding author), Walter Reed Army Inst Res, Dept Cellular Injury, Bldg 503,Rm 1A32,503 Robert Grant Ave, Silver Spring, MD 20910 USA.	gtsokos@usuhs.mil	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042269] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI42269] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brundula V, 1999, ARTHRITIS RHEUM-US, V42, P1908, DOI 10.1002/1529-0131(199909)42:9<1908::AID-ANR17>3.0.CO;2-7; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Caballero JJ, 2004, BIOCHEM BIOPH RES CO, V319, P247, DOI 10.1016/j.bbrc.2004.04.178; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Day NE, 2003, LEUKEMIA RES, V27, P1027, DOI 10.1016/S0145-2126(03)00072-9; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Enyedy EJ, 2001, ARTHRITIS RHEUM, V44, P1114, DOI 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Gay E, 2000, BIOCHEM BIOPH RES CO, V267, P509, DOI 10.1006/bbrc.1999.2000; Giunchi L, 1999, MOL CELL BIOCHEM, V195, P47; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JENSEN JP, 1992, J IMMUNOL, V148, P2563; Jensen LE, 2004, J IMMUNOL, V173, P6248, DOI 10.4049/jimmunol.173.10.6248; Krishnan S, 2004, J IMMUNOL, V172, P7821, DOI 10.4049/jimmunol.172.12.7821; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Nambiar MP, 2003, ARTHRITIS RHEUM, V48, P1948, DOI 10.1002/art.11072; Nambiar MP, 2002, ARTHRITIS RHEUM-US, V46, P163, DOI 10.1002/1529-0131(200201)46:1<163::AID-ART10065>3.0.CO;2-J; Nambiar MP, 2001, J AUTOIMMUN, V16, P133, DOI 10.1006/jaut.2000.0475; Nambiar MP, 2001, ARTHRITIS RHEUM, V44, P1336, DOI 10.1002/1529-0131(200106)44:6<1336::AID-ART226>3.0.CO;2-8; Nishimori T, 2004, LIFE SCI, V74, P2505, DOI 10.1016/j.lfs.2003.10.017; NOCENTINI G, 1995, EUR J IMMUNOL, V25, P1405, DOI 10.1002/eji.1830250540; Pang M, 1998, ARTHRITIS RHEUM, V41, P1456, DOI 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Roe DF, 2004, MOL BRAIN RES, V120, P91, DOI 10.1016/j.molbrainres.2003.09.019; Ronchetti S, 1997, CELL IMMUNOL, V178, P124, DOI 10.1006/cimm.1997.1131; Rydziel S, 2004, J BIOL CHEM, V279, P5397, DOI 10.1074/jbc.M311984200; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Shai R, 1999, HUM MOL GENET, V8, P639, DOI 10.1093/hmg/8.4.639; Stacey M., 1997, Chromosome Research, V5, P279, DOI 10.1023/A:1018484006430; Takeuchi T, 1998, Nihon Naika Gakkai Zasshi, V87, P1724; Takeuchi T, 1998, INT IMMUNOL, V10, P911, DOI 10.1093/intimm/10.7.911; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Tsokos GC, 2003, TRENDS IMMUNOL, V24, P259, DOI 10.1016/S1471-4906(03)00100-5; Tsuzaka K, 2003, J IMMUNOL, V171, P2496, DOI 10.4049/jimmunol.171.5.2496; Tsuzaka K, 1998, J AUTOIMMUN, V11, P381, DOI 10.1006/jaut.1998.0223; VASSILOPOULOS D, 1995, J IMMUNOL, V155, P2269; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; Wilson GM, 1999, MOL CELL BIOL, V19, P4056; Yu H, 2003, J BIOL CHEM, V278, P13912, DOI 10.1074/jbc.M213027200	47	58	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18959	18966		10.1074/jbc.M501048200	http://dx.doi.org/10.1074/jbc.M501048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15743765	hybrid			2022-12-27	WOS:000228932300049
J	Shi, LF; Zhao, GH; Qiu, DM; Godfrey, WR; Vogel, H; Rando, TA; Hu, H; Kao, PN				Shi, LF; Zhao, GH; Qiu, DM; Godfrey, WR; Vogel, H; Rando, TA; Hu, H; Kao, PN			NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3 '-untranslated region of MyoD and p21(WAF1/CIP1) mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SKELETAL-MUSCLE DEVELOPMENT; ACTIVATED T-CELLS; DNA-BINDING; MICE DEFICIENT; TRANSCRIPTION FACTOR; NUCLEAR FACTOR-90; EXPRESSION; MUTATION; CLONING	NF90 and splice variant NF110/ILF3/NFAR are double-stranded RNA-binding proteins that regulate gene expression. Mice with targeted disruption of NF90 were engineered. NF90(-/-) mice were born small and weak and succumbed to perinatal death within 12 h because of neuromuscular respiratory failure. Lung inflation and morphology were normal in NF90(-/-) mice. The diaphragm and other skeletal muscles in NF90(-/-) mice demonstrated disorganized arrangement and paucity of myofibers, evidence of myocyte degeneration and increased apoptosis. The expression of myogenic regulators, MyoD, myogenin, and p21(WAF1/CIP1), was severely decreased in NF90(-/-) mice. These myogenic transcription factors and cell cycle inhibitors are regulated in part through post-transcriptional mRNA stabilization. Northwestern blotting revealed that NF90 is the principal and specific p21(WAF1/CIP1) and MyoD 3'-untranslated region RNA-binding protein in developing skeletal muscles. NF90 regulates transcription factors and a cell cycle inhibitor essential for skeletal muscle differentiation and for survival.	Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Dendreon Corp, Cellular Immunol, Seattle, WA 98121 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Dendreon; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Kao, PN (corresponding author), Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.	peterkao@stanford.edu	Godfrey, Wayne/AAL-7219-2020	Vogel, Otto Hannes/0000-0002-0960-3508; Rando, Thomas/0000-0001-5843-8564	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039624] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62588] Funding Source: Medline; NIAID NIH HHS [R01-AI39624] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Inanlou MR, 2003, DEV BIOL, V261, P324, DOI 10.1016/S0012-1606(03)00319-1; Isken O, 2003, EMBO J, V22, P5655, DOI 10.1093/emboj/cdg562; Kablar B, 2000, HISTOL HISTOPATHOL, V15, P649, DOI 10.14670/HH-15.649; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Larcher JC, 2004, FASEB J, V18, P1761, DOI 10.1096/fj.04-1763fje; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Meagher MJ, 2001, MOL CELL BIOL, V21, P2880, DOI 10.1128/MCB.21.8.2880-2890.2001; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pires-daSilva A, 2001, DEV BIOL, V233, P319, DOI 10.1006/dbio.2001.0169; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Satoh M, 1999, J BIOL CHEM, V274, P34598, DOI 10.1074/jbc.274.49.34598; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; Scarlett GP, 2004, J BIOL CHEM, V279, P52447, DOI 10.1074/jbc.M406107200; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shin HJ, 2002, ARCH VIROL, V147, P471, DOI 10.1007/s007050200001; St Johnston D, 2001, EMBO J, V20, P6169, DOI 10.1093/emboj/20.22.6169; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; Vivian JL, 1999, DEV BIOL, V208, P44, DOI 10.1006/dbio.1998.9182; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao GH, 2005, EXP CELL RES, V305, P312, DOI 10.1016/j.yexcr.2004.12.030; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	62	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18981	18989		10.1074/jbc.M411034200	http://dx.doi.org/10.1074/jbc.M411034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15746098	hybrid			2022-12-27	WOS:000228932300052
J	Obata, T; Shiraiwa, Y				Obata, T; Shiraiwa, Y			A novel eukaryotic selenoprotein in the haptophyte alga Emiliania huxleyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; CHLAMYDOMONAS-REINHARDTII; SELENIUM; SELENOCYSTEINE; PROTOZOA; SYSTEM	The diversity of selenoproteins raises the question of why many life forms require selenium. Especially in photosynthetic organisms, the biochemical basis for the requirement for selenium is unclear because there is little information on selenoproteins. We found six selenium-containing proteins in a haptophyte alga, Emiliania huxleyi, which requires selenium for growth. The 27-kDa protein EhSEP2 was isolated, and its cDNA was cloned. The deduced amino acid sequence revealed that EhSEP2 is homologous to protein disulfide isomerase (PDI) and contains a highly conserved thioredoxin domain. The nucleotide sequence contains an in-frame TGA codon encoding selenocysteine at the position corresponding to the cysteine residue in the reaction center of known PDIs. However, no typical selenocysteine insertion sequence was found in the EhSEP2 cDNA. The EhSEP2 mRNA level was related to the abundance of selenium. E. huxleyi possesses a novel PDI-like selenoprotein and may have a novel type of selenocysteine insertion machinery.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Shiraiwa, Y (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.	emilhux@biol.tsukuba.ac.jp	Shiraiwa, Yoshihiro/AAD-2501-2022; Obata, Toshihiro/AAX-4353-2020	Obata, Toshihiro/0000-0001-8931-7722				Cavalier-Smith T, 2003, EUR J PROTISTOL, V39, P338, DOI 10.1078/0932-4739-00002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Danbara A, 1999, PLANT CELL PHYSIOL, V40, P762, DOI 10.1093/oxfordjournals.pcp.a029603; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Doblin MA, 1999, J PLANKTON RES, V21, P1153, DOI 10.1093/plankt/21.6.1153; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Fu LH, 2002, J BIOL CHEM, V277, P25983, DOI 10.1074/jbc.M202912200; Hanawa Y., 2004, JPN J PHYCOL S, V52, P95; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LoSchiavo F, 2000, EUR J CELL BIOL, V79, P294, DOI 10.1078/S0171-9335(04)70032-1; Novoselov SV, 2002, EMBO J, V21, P3681, DOI 10.1093/emboj/cdf372; Obata T, 2004, PLANT CELL PHYSIOL, V45, P1434, DOI 10.1093/pcp/pch164; Osaka T, 2003, BIOCHEM BIOPH RES CO, V300, P236, DOI 10.1016/S0006-291X(02)02806-1; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PRICE NM, 1988, PLANT PHYSIOL, V86, P192, DOI 10.1104/pp.86.1.192; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Sun XL, 2002, METHOD ENZYMOL, V347, P49; Weiss SL, 1998, RNA, V4, P816, DOI 10.1017/S1355838298971990	26	37	41	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18462	18468		10.1074/jbc.M501517200	http://dx.doi.org/10.1074/jbc.M501517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743763	hybrid			2022-12-27	WOS:000228807200109
J	Olufsen, M; Smalas, AO; Moe, E; Brandsdal, BO				Olufsen, M; Smalas, AO; Moe, E; Brandsdal, BO			Increased flexibility as a strategy for cold adaptation - A comparative molecular dynamics study of cold- and warm-active uracil DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COD GADUS-MORHUA; BASE-EXCISION-REPAIR; PSYCHROPHILIC ENZYMES; STRUCTURAL BASIS; TEMPERATURES; SUBSTRATE; FEATURES	Uracil DNA glycosylase (UDG) is a DNA repair enzyme in the base excision repair pathway and removes uracil from the DNA strand. Atlantic cod UDG (cUDG), which is a cold-adapted enzyme, has been found to be up to 10 times more catalytically active in the temperature range 15 - 37 degrees C as compared with the warm-active human counterpart. The increased catalytic activity of cold-adapted enzymes as compared with their mesophilic homologues are partly believed to be caused by an increase in the structural flexibility. However, no direct experimental evidence supports the proposal of increased flexibility of cold-adapted enzymes. We have used molecular dynamics simulations to gain insight into the structural flexibility of UDG. The results from these simulations show that an important loop involved in DNA recognition ( the Leu(272) loop) is the most flexible part of the cUDG structure and that the human counterpart has much lower flexibility in the Leu(272) loop. The flexibility in this loop correlates well with the experimental k(cat)/K-m values. Thus, the data presented here add strong support to the idea that flexibility plays a central role in adaptation to cold environments.	Univ Tromso, Norwegian Struct Biol Ctr, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Brandsdal, BO (corresponding author), Univ Tromso, Norwegian Struct Biol Ctr, N-9037 Tromso, Norway.	Bjorn-Olav.Brandsdal@chem.uit.no	Moe, Elin/J-4367-2013; Brandsdal, Bjørn O/J-7099-2015; Smalås, Arne/C-4131-2016; Olufsen, Magne/V-4777-2019; Moe, Elin/Q-6131-2019	Moe, Elin/0000-0002-7923-1471; Brandsdal, Bjørn O/0000-0002-4681-8081; Smalås, Arne/0000-0002-4651-9911; Moe, Elin/0000-0002-7923-1471; Olufsen, Magne/0000-0003-1401-6786				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bianchet MA, 2003, BIOCHEMISTRY-US, V42, P12455, DOI 10.1021/bi035372+; Brandsdal BO, 2001, FEBS LETT, V499, P171, DOI 10.1016/S0014-5793(01)02552-2; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Georlette D, 2003, J BIOL CHEM, V278, P37015, DOI 10.1074/jbc.M305142200; Georlette D, 2004, FEMS MICROBIOL REV, V28, P25, DOI 10.1016/j.femsre.2003.07.003; Gerday C, 2000, TRENDS BIOTECHNOL, V18, P103, DOI 10.1016/S0167-7799(99)01413-4; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lanes O, 2000, COMP BIOCHEM PHYS B, V127, P399, DOI 10.1016/S0305-0491(00)00271-6; Lanes O, 2002, EXTREMOPHILES, V6, P73, DOI 10.1007/s007920100225; Leiros I, 2003, ACTA CRYSTALLOGR D, V59, P1357, DOI 10.1107/S0907444903011144; Leiros I, 2001, ACTA CRYSTALLOGR D, V57, P1706, DOI 10.1107/S0907444901013427; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; MERRITT EA, 1997, METHODS ENZYMOL, V277; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Moe E, 2004, J MOL BIOL, V343, P1221, DOI 10.1016/j.jmb.2004.09.004; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Ravishankar R, 1998, NUCLEIC ACIDS RES, V26, P4880, DOI 10.1093/nar/26.21.4880; Russell RJM, 1998, STRUCTURE, V6, P351, DOI 10.1016/S0969-2126(98)00037-9; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Smalas A O, 2000, Biotechnol Annu Rev, V6, P1, DOI 10.1016/S1387-2656(00)06018-X	35	55	57	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18042	18048		10.1074/jbc.M500948200	http://dx.doi.org/10.1074/jbc.M500948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749696	hybrid			2022-12-27	WOS:000228807200060
J	Purohit, VS; Ramani, K; Sarkar, R; Kazazian, HH; Balasubramanian, SV				Purohit, VS; Ramani, K; Sarkar, R; Kazazian, HH; Balasubramanian, SV			Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; C2 DOMAIN; MEMBRANE-BINDING; LIGHT-CHAIN; AGGREGATION; MODEL; PHOSPHATIDYLSERINE; IMMUNOGENICITY; STABILITY	Factor VIII is a multidomain protein composed of A1, A2, B, A3, C1, and C2 domains. Deficiency or dysfunction of factor VIII causes hemophilia A, a bleeding disorder. Administration of exogenous recombinant factor VIII as a replacement leads to development of inhibitory antibodies against factor VIII in 15-30% of hemophilia A patients. Hence, less immunogenic preparations of factor VIII are highly desirable. Inhibitory antibodies against factor VIII are mainly directed against immunodominant epitopes in C2, A3, and A2 domains. Further, several universal epitopes for CD4+ T-cells have been identified within the C2 domain. The C2 domain is also known to interact specifically with phosphatidyl-serine-rich lipid vesicles. Here, we have investigated the hypothesis that complexation of O-phospho-L-serine, the head group of phosphatidylserine, with the C2 domain can reduce the overall immunogenicity of factor VIII. The biophysical (circular dichroism and fluorescence) and biochemical studies (ELISA and size exclusion chromatography) showed that O-phospho-L-serine binds to the phospholipid-binding region in the C2 domain, and this interaction causes subtle changes in the tertiary structure of the protein. O-Phospho-L-serine also prevented aggregation of the protein under thermal stress. The immunogenicity of the factor VIII-O-phospho-L-serine complex was evaluated in hemophilia A mice. The total and inhibitory antibody titers were lower for factor VIII-O-phospho-L-serine complex compared with factor VIII alone. Moreover, factor VIII administered as a complex with O-phospho-L-serine retained in vivo activity in hemophilia A mice. Our results suggest that factor VIII-O-phospho-L-serine complex may be beneficial to increase the physical stability and reduce immunogenicity of recombinant factor VIII preparations.	SUNY Buffalo, Dept Pharmaceut Sci, Amherst, NY 14260 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Pennsylvania	Balasubramanian, SV (corresponding author), SUNY Buffalo, Dept Pharmaceut Sci, 527 Hochstetter Hall, Amherst, NY 14260 USA.	svb@acsu.buffalo.edu	Purohit, Vivek/GXH-0278-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070227] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070227-02, R01 HL-70227, R01 HL070227] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananyeva NM, 2004, BLOOD COAGUL FIBRIN, V15, P109, DOI 10.1097/00001721-200403000-00001; Behrmann M, 2002, THROMB HAEMOSTASIS, V88, P221; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789; Chirino AJ, 2004, DRUG DISCOV TODAY, V9, P82, DOI 10.1016/S1359-6446(03)02953-2; Crowther J. R., 2000, METHODS MOL BIOL, V149, DOI [10.1134/s000629790909017x, DOI 10.1134/S000629790909017X]; Derrick TS, 2004, J PHARM SCI-US, V93, P2549, DOI 10.1002/jps.20167; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; Gensana M, 2001, HAEMOPHILIA, V7, P369, DOI 10.1046/j.1365-2516.2001.00526.x; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Grillo AO, 2001, BIOCHEMISTRY-US, V40, P586, DOI 10.1021/bi001547t; Ho AYL, 2000, DRUGS, V60, P547, DOI 10.2165/00003495-200060030-00003; Ingerslev J., 2000, Haematologica, V85, P15; Jacquemin MG, 1998, HAEMOPHILIA, V4, P552, DOI 10.1046/j.1365-2516.1998.440552.x; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KEMBALLCOOK G, 1992, THROMB RES, V67, P57, DOI 10.1016/0049-3848(92)90258-C; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lollar P, 2001, ADV EXP MED BIOL, V489, P65; MATERA M, 1993, INT J CLIN PHARM RES, V13, P93; Pace CN, 1998, J MOL BIOL, V279, P271, DOI 10.1006/jmbi.1998.1760; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Pratt KP, 2004, THROMB HAEMOSTASIS, V92, P522, DOI 10.1160/TH03-12-0755; Purohit VS, 2003, BBA-BIOMEMBRANES, V1617, P31, DOI 10.1016/j.bbamem.2003.08.012; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; Raju R, 1995, EUR J IMMUNOL, V25, P3207, DOI 10.1002/eji.1830251202; RAMANI K, 2003, AAPS PHARMSCI, V5, pT2091; Reding MT, 2003, J THROMB HAEMOST, V1, P1777, DOI 10.1046/j.1538-7836.2003.00251.x; Reipert BM, 2000, THROMB HAEMOSTASIS, V84, P826, DOI 10.1055/s-0037-1614124; Remmele RL, 2000, BIOPHARM-APPL T BIO, V13, P36; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Sarkar R, 2003, J THROMB HAEMOST, V1, P220, DOI 10.1046/j.1538-7836.2003.00096.x; Scandella DH, 2001, THROMB RES, V101, P377, DOI 10.1016/S0049-3848(00)00418-7; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; Taschner N, 2001, J MOL BIOL, V310, P169, DOI 10.1006/jmbi.2001.4736; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSAI PK, 1993, PHARMACEUT RES, V10, P649, DOI 10.1023/A:1018939228201; VanAken WG, 1997, TRANSFUS MED REV, V11, P6, DOI 10.1016/S0887-7963(97)80005-3; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VERBRUGGEN B, 1995, THROMB HAEMOSTASIS, V73, P247; Vermeer AWP, 2000, BIOPHYS J, V78, P394, DOI 10.1016/S0006-3495(00)76602-1; Wang W, 2003, PHARM RES-DORDR, V20, P693, DOI 10.1023/A:1023271405005; Wu HY, 2001, THROMB HAEMOSTASIS, V85, P125, DOI 10.1055/s-0037-1612915; Zhai X, 2002, BIOCHEMISTRY-US, V41, P5675, DOI 10.1021/bi011844d	49	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17593	17600		10.1074/jbc.M500163200	http://dx.doi.org/10.1074/jbc.M500163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728582	hybrid, Green Accepted			2022-12-27	WOS:000228807200005
J	Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB				Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB			Role of regulatory F-domain in hepatocyte nuclear factor-4 alpha ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ACID-BINDING PROTEIN; ACYL-COA THIOESTERS; CIRCULAR-DICHROISM; FATTY-ACIDS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; HETERODIMERIC COMPLEX; ANDROGEN RECEPTOR; REPRESSOR DOMAIN	The F-domain of rat HNF-4 alpha 1 has a crucial impact on the ligand binding affinity, ligand specificity and secondary structure of HNF-4 alpha. (i) Fluorescent binding assays indicate that wild-type, full-length HNF-4 alpha ( amino acids 1 - 455) has high affinity (K-d = 0.06 - 12 nM) for long chain fatty acyl-CoAs (LCFA-CoA) and low affinity (K-d = 58 - 296 nM) for unesterified long chain fatty acids (LCFAs). LCFA-CoA binding was due to close molecular interaction as shown by fluorescence resonance energy transfer ( FRET) from full-length HNF-4 alpha tryptophan ( FRET donor) to bound cis-parinaroyl-CoA ( FRET acceptor), which yielded an intermolecular distance of 33 angstrom, although no FRET to cis-parinaric acid was detected. (ii) Deleting the N-terminal A-D-domains, comprising the AF1 and DNA binding functions, only slightly affected affinities for LCFA-CoAs (K-d = 0.9 - 4 nM) and LCFAs (K-d = 93 - 581 nM). ( iii) Further deletion of the F-domain robustly reduced affinities for LCFA-CoA and reversed ligand specificity ( i. e. high affinity for LCFAs (K-d = 1.5 - 32 nM) and low affinity for LCFA-CoAs (K-d = 54 - 302 nM)). No FRET from HNF-4 alpha-E ( amino acids 132-370) tryptophan ( FRET donor) to bound cis-parinaroyl-CoA ( FRET acceptor) was detected, whereas an intermolecular distance of 28 angstrom was calculated from FRET between HNF-4 alpha-E and cis-parinaric acid. (iv) Circular dichroism showed that LCFA-CoA, but not LCFA, altered the secondary structure of HNF-4 alpha only when the F-domain was present. ( v) cis-Parinaric acid bound to HNF-4 alpha with intact F-domain was readily displaceable by S-hexadecyl-CoA, a nonhydrolyzable thioether analogue of LCFA-CoAs. Truncation of the F-domain significantly decreased cis-parinaric acid displacement. Hence, the C-terminal F-domain of HNF-4 alpha regulated ligand affinity, ligand specificity, and ligand-induced conformational change of HNF-4 alpha. Thus, characteristics of F-domain-truncated mutants may not reflect the properties of full-length HNF-4 alpha.	Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Physiol & Pharmacol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Hebrew University of Jerusalem	Kier, AB (corresponding author), Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA.	akier@cvm.tamu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072041] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIGMS NIH HHS [NIH P20 GM072041] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Couette B, 1998, MOL ENDOCRINOL, V12, P855, DOI 10.1210/me.12.6.855; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FORSTER T., 1967, COMPR BIOCHEM, V22, P61; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; Iyemere VP, 1998, NUCLEIC ACIDS RES, V26, P2098, DOI 10.1093/nar/26.9.2098; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1999, BBA-MOL CELL BIOL L, V1436, P413, DOI 10.1016/S0005-2760(98)00150-7; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARKER CA, 1968, PHOTOLUMINESCENCE SO, P260; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; Schwartz JA, 2002, J BIOL CHEM, V277, P13202, DOI 10.1074/jbc.M112215200; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P5100, DOI 10.1021/bi00642a024; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Suaud L, 1997, BIOCHEM BIOPH RES CO, V235, P820, DOI 10.1006/bbrc.1997.6888; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Tahiri B, 2001, BIOCHEMISTRY-US, V40, P8431, DOI 10.1021/bi010146q; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	53	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16714	16727		10.1074/jbc.M405906200	http://dx.doi.org/10.1074/jbc.M405906200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741159	hybrid			2022-12-27	WOS:000228615500023
J	Vyas, AA; Blixt, O; Paulson, JC; Schnaar, RL				Vyas, AA; Blixt, O; Paulson, JC; Schnaar, RL			Potent glycan inhibitors of myelin-associated glycoprotein enhance axon outgrowth in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; ADULT MAMMALIAN CNS; NOGO-66 RECEPTOR; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; SIGNALING PATHWAY; GROWTH-INHIBITORS; YOUNG-ADULT; REGENERATION; GANGLIOSIDES	Myelin-associated glycoprotein (MAG, Siglec-4) is one of several endogenous axon regeneration inhibitors that limit recovery from central nervous system injury and disease. Molecules that block such inhibitors may enhance axon regeneration and functional recovery. MAG, a member of the Siglec family of sialic acid-binding lectins, binds to sialoglycoconjugates on axons and particularly to gangliosides GD1a and GT1b, which may mediate some of the inhibitory effects of MAG. In a prior study (Blixt, O., Collins, B. E., van den Nieuwenhof, I. M., Crocker, P. R., and Paulson, J. C. ( 2003) J. Biol. Chem. 278, 31007 - 31019), we identified potent monovalent sialoside inhibitors of MAG using a novel screening platform. In the current study, the most potent of these were tested for their ability to reverse MAG-mediated inhibition of axon outgrowth from rat cerebellar granule neurons in vitro. Monovalent sialoglycans enhanced axon regeneration in proportion to their MAG binding affinities. The most potent glycoside was disialyl T antigen (NeuAc alpha 2 - 3Gal beta 1 - 3[NeuAc alpha 2 - 6] GalNAc-R), followed by 3-sialyl T antigen (NeuAc alpha 2 - 3Gal beta 1 - 3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides. Prior studies indicated that blocking gangliosides reversed MAG inhibition (Vyas, A. A., Patel, H. V., Fromholt, S. E., Heffer-Lauc, M., Vyas, K. A., Dang, J., Schachner, M., and Schnaar, R. L. ( 2002) Proc. Natl. Acad. Sci. USA 99, 8412 - 8417). In the current study, blocking O-linked glycoprotein sialylation with benzyl-alpha GalNAc had no effect. The ability to reverse MAG inhibition with monovalent glycosides encourages further exploration of glycans and glycan mimetics as blockers of MAG-mediated axon outgrowth inhibition.	Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Johns Hopkins University; Johns Hopkins University; Scripps Research Institute; Scripps Research Institute	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Paulson, James/AAG-3565-2019; Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Blixt, Ola/0000-0003-4143-6276	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, R37NS037096] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60938] Funding Source: Medline; NINDS NIH HHS [R01 NS037096, NS37096] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; Asher R A, 2001, Prog Brain Res, V132, P611; Blixt O, 2002, J AM CHEM SOC, V124, P5739, DOI 10.1021/ja017881+; Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Collins BE, 1999, J BIOL CHEM, V274, P37637, DOI 10.1074/jbc.274.53.37637; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; Dergham P, 2002, J NEUROSCI, V22, P6570; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Josephson A, 2002, J COMP NEUROL, V453, P292, DOI 10.1002/cne.10408; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; KOTANI M, 1993, GLYCOBIOLOGY, V3, P137, DOI 10.1093/glycob/3.2.137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sato Y, 1998, GLYCOCONJUGATE J, V15, P1133, DOI 10.1023/A:1006911821339; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Sun J, 2004, GLYCOBIOLOGY, V14, P851, DOI 10.1093/glycob/cwh107; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Zaccai NR, 2003, STRUCTURE, V11, P557, DOI 10.1016/S0969-2126(03)00073-X; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	51	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16305	16310		10.1074/jbc.M500250200	http://dx.doi.org/10.1074/jbc.M500250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701648	hybrid, Green Accepted			2022-12-27	WOS:000228444800101
J	Witting, PK; Wu, BJ; Raftery, M; Southwell-Keely, P; Stocker, R				Witting, PK; Wu, BJ; Raftery, M; Southwell-Keely, P; Stocker, R			Probucol protects against hypochlorite-induced endothelial dysfunction - Identification of a novel pathway of probucol oxidation to a biologically active intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; HERITABLE HYPERLIPIDEMIC RABBIT; HUMAN ATHEROSCLEROTIC LESIONS; SUPEROXIDE-PRODUCTION; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR EVENTS; CORONARY-ARTERIES; MODIFIED PROTEINS; BALLOON INJURY	Atherosclerosis is associated with endothelial dysfunction and a heightened state of inflammation characterized, in part, by an increase in vascular myeloperoxidase and proteins modified by its principal oxidant, hypochlorous acid (HOCl). Here we examined whether probucol could protect against endothelial dysfunction induced by the two-electron oxidant HOCl. Hypochlorous acid eliminated endothelium-dependent relaxation of rabbit aorta, whereas endothelial function and tissue cGMP was preserved and elevated, respectively, in animals pretreated with probucol. Exogenously added probucol also protected against HOCl-induced endothelial dysfunction. In vitro, HOCl oxidized probucol in a two-phase process with rate constants k(1) = 2.7 +/- 0.3 x 10(2) and k(2) = 0.7 +/- 0.2 x 10(2) M-1 s(-1) that resulted in a dose- and time-dependent accumulation of probucol-derived disulfoxide, 4,4'-dithiobis(2,6-di-tert-butyl-phenol) ( DTBP), DTBP-derived thiosulfonate, disulfone, and sulfonic acid, together with 3,3',5,5'-tetra-tert-butyl-4,4'-diphenoquinone (DPQ) as determined by high performance liquid chromatography and mass spectrometry. Like HOCl, selected one-electron oxidants converted probucol into DTBP and DPQ. Also, dietary and in vitro added DTBP protected aortic rings from HOCl-induced endothelial dysfunction and in vitro oxidation by HOCl gave rise to the thiosulfonate, disulfone, and sulfonic acid intermediates and DPQ. However, the product profiles of the in vitro oxidation systems were different from those in aortas of rabbits receiving dietary probucol or DTBP +/- HOCl treatment. Together, the results show that both probucol and DTBP react with HOCl and protect against HOCl-induced endothelial dysfunction, although direct scavenging of HOCl is unlikely to be responsible for the vascular protection by the two compounds.	Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Chem, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Stocker, R (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia.	r.stocker@unsw.edu.au	Stocker, Roland/AAV-4489-2021; Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Witting, Paul/0000-0003-2237-7004; Wu, Ben/0000-0003-2826-4190				Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Araki T, 2001, CHEM PHARM BULL, V49, P943, DOI 10.1248/cpb.49.943; Baldus S, 2001, J CLIN INVEST, V108, P1759; BARNHART RL, 1989, J LIPID RES, V30, P1703; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Braun A, 2003, P NATL ACAD SCI USA, V100, P7283, DOI 10.1073/pnas.1237725100; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; FERNS GAA, 1992, P NATL ACAD SCI USA, V89, P11312, DOI 10.1073/pnas.89.23.11312; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4; Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47; Hattori Y, 2000, J CONTROL RELEASE, V69, P369, DOI 10.1016/S0168-3659(00)00338-2; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hollenberg SM, 2001, CIRCULATION, V104, P3091, DOI 10.1161/hc5001.100796; Kajinami K, 1996, ATHEROSCLEROSIS, V120, P181, DOI 10.1016/0021-9150(95)05699-8; KALYANARAMAN B, 1992, J BIOL CHEM, V267, P6789; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Lau AK, 2003, CIRCULATION, V107, P2031, DOI 10.1161/01.CIR.0000062682.40051.43; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MARCH J, 1977, ADV ORGANIC CHEM REA, P110; McNally JS, 2003, AM J PHYSIOL-HEART C, V285, pH2290, DOI 10.1152/ajpheart.00515.2003; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; PELTER A, 1988, TETRAHEDRON LETT, V29, P677, DOI 10.1016/S0040-4039(00)80182-3; RADI R, 1991, J BIOL CHEM, V266, P4244; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; Sawayama Y, 2002, J AM COLL CARDIOL, V39, P610, DOI 10.1016/S0735-1097(01)01783-1; SCHNEIDER JE, 1993, CIRCULATION, V88, P628, DOI 10.1161/01.CIR.88.2.628; Stocker R, 2004, ARTERIOSCL THROM VAS, V24, P2028, DOI 10.1161/01.ATV.0000143388.20994.fa; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Witting P, 1999, J CLIN INVEST, V104, P213, DOI 10.1172/JCI6391; Witting PK, 1999, FASEB J, V13, P667, DOI 10.1096/fasebj.13.6.667; Witting PK, 2002, BIOCHEMISTRY-US, V41, P11495, DOI 10.1021/bi025835w; Yan LJ, 1996, ARCH BIOCHEM BIOPHYS, V327, P330, DOI 10.1006/abbi.1996.0130; Zhang CX, 2001, J BIOL CHEM, V276, P27159, DOI 10.1074/jbc.M100191200; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	54	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15612	15618		10.1074/jbc.M414256200	http://dx.doi.org/10.1074/jbc.M414256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722355	hybrid			2022-12-27	WOS:000228444800020
J	Rozengurt, E; Rey, O; Waldron, RT				Rozengurt, E; Rey, O; Waldron, RT			Protein kinase D signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIVATION LOOP PHOSPHORYLATION; INTESTINAL EPITHELIAL-CELLS; PLECKSTRIN HOMOLOGY DOMAIN; TRANS-GOLGI NETWORK; COUPLED RECEPTOR ACTIVATION; POTENTIATES DNA-SYNTHESIS; D-DEPENDENT ACTIVATION; CYSTEINE-RICH DOMAIN/; D PKD ACTIVATION; FACTOR-KAPPA-B		Univ Calif Los Angeles, Sch Med, Dept Med,UCLA CURE Digest Dis Res Ctr, Div Digest Dis,Unit Signal Transduct & Gastrointe, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med,UCLA CURE Digest Dis Res Ctr, Div Digest Dis,Unit Signal Transduct & Gastrointe, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002; Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [DK 56930, DK 55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Brose N, 2004, CURR OPIN NEUROBIOL, V14, P328, DOI 10.1016/j.conb.2004.05.006; Cabrera-Poch N, 2004, J BIOL CHEM, V279, P28592, DOI 10.1074/jbc.M312242200; Carnegie GK, 2004, MOL CELL, V15, P889, DOI 10.1016/j.molcel.2004.09.015; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Guha S, 2002, CANCER RES, V62, P1632; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; Haworth RS, 2004, CIRC RES, V95, P1091, DOI 10.1161/01.RES.0000149299.34793.3c; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Rey O, 2004, J BIOL CHEM, V279, P34361, DOI 10.1074/jbc.M403265200; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rey O, 2001, BIOCHEM BIOPH RES CO, V287, P21, DOI 10.1006/bbrc.2001.5530; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Stafford MJ, 2003, BLOOD, V101, P1392, DOI 10.1182/blood-2002-08-2384; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Tsybouleva N, 2004, CIRCULATION, V109, P1284, DOI 10.1161/01.CIR.0000121426.43044.2B; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Wang QMJ, 2003, MOL PHARMACOL, V64, P1342, DOI 10.1124/mol.64.6.1342; Wang Y, 2004, J BIOL CHEM, V279, P53674, DOI 10.1074/jbc.M410331200; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	84	347	360	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13205	13208		10.1074/jbc.R500002200	http://dx.doi.org/10.1074/jbc.R500002200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701647	hybrid			2022-12-27	WOS:000228095500002
J	Raibaud, S; Schwarz-Linek, US; Kim, JH; Jenkins, HT; Baines, ER; Gurusiddappa, S; Hook, M; Potts, JR				Raibaud, S; Schwarz-Linek, US; Kim, JH; Jenkins, HT; Baines, ER; Gurusiddappa, S; Hook, M; Potts, JR			Borrelia burgdorferi binds fibronectin through a tandem beta-zipper, a common mechanism of fibronectin binding in staphylococci, streptococci, and spirochetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ADHERENCE; MODULE PAIR; PROTEIN; PROGRAM; F1; IDENTIFICATION; PYOGENES; SEQUENCE; AFFINITY; MSCRAMMS	BBK32 is a fibronectin-binding protein from the Lyme disease-causing spirochete Borrelia burgdorferi. In this study, we show that BBK32 shares sequence similarity with fibronectin module-binding motifs previously identified in proteins from Streptococcus pyogenes and Staphylococcus aureus. Nuclear magnetic resonance spectroscopy and isothermal titration calorimetry are used to confirm the binding sites of BBK32 peptides within the N-terminal domain of fibronectin and to measure the affinities of the interactions. Comparison of chemical shift perturbations in fibronectin F1 modules on binding of peptides from BBK32, FnBPA from S. aureus, and SfbI from S. pyogenes provides further evidence for a shared mechanism of binding. Despite the different locations of the bacterial attachment sites in BBK32 compared with SfbI from S. pyogenes and FnBPA from S. aureus, an antiparallel orientation is observed for binding of the N-terminal domain of fibronectin to each of the pathogens. Thus, these phylogenetically and morphologically distinct bacterial pathogens have similar mechanisms for binding to human fibronectin.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	University of Oxford; University of Texas System; University of Texas Health Science Center Houston	Potts, JR (corresponding author), Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.	jennifer.potts@bioch.ox.ac.uk	Jenkins, Huw/E-1094-2011	Jenkins, Huw/0000-0002-3302-6966; Schwarz-Linek, Ulrich/0000-0003-0526-223X				Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Grab DJ, 1998, BBA-MOL BASIS DIS, V1407, P135, DOI 10.1016/S0925-4439(98)00038-6; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Heikkila T, 2003, J INFECT DIS, V187, P1888, DOI 10.1086/375371; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Ingham KC, 2004, J BIOL CHEM, V279, P42945, DOI 10.1074/jbc.M406984200; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim JH, 2004, J BIOL CHEM, V279, P41706, DOI 10.1074/jbc.M401691200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MA Y, 1991, INFECT IMMUN, V59, P671, DOI 10.1128/IAI.59.2.671-678.1991; MADIGAN M, 2000, BROCK BIOL MICRORGAN; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Probert WS, 2001, INFECT IMMUN, V69, P4129, DOI 10.1128/IAI.69.6.4129-4133.2001; Schwarz-Linek U, 2004, J BIOL CHEM, V279, P39017, DOI 10.1074/jbc.M405083200; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365-2958.2004.04027.x; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Smith R, 2000, EMERG INFECT DIS, V6, P404, DOI 10.3201/eid0604.000416; SOFFE N, 1995, J MAGN RESON SER A, V116, P117, DOI 10.1006/jmra.1995.1197; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083	30	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18803	18809		10.1074/jbc.M501731200	http://dx.doi.org/10.1074/jbc.M501731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737988	hybrid			2022-12-27	WOS:000228932300032
J	Tanos, T; Marinissen, MJ; Leskow, FC; Hochbaum, D; Martinetto, H; Gutkind, JS; Coso, OA				Tanos, T; Marinissen, MJ; Leskow, FC; Hochbaum, D; Martinetto, H; Gutkind, JS; Coso, OA			Phosphorylation of c-fos by members of the p38 MAPK family - Role in the AP-1 response to UV light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; JUN PROMOTER; CELLULAR-TRANSFORMATION; MESSENGER-RNA	Exposure to sources of UV radiation, such as sunlight, induces a number of cellular alterations that are highly dependent on its ability to affect gene expression. Among them, the rapid activation of genes coding for two subfamilies of proto-oncoproteins, Fos and Jun, which constitute the AP-1 transcription factor, plays a key role in the subsequent regulation of expression of genes involved in DNA repair, cell proliferation, cell cycle arrest, death by apoptosis, and tissue and extracellular matrix remodeling proteases. Besides being regulated at the transcriptional level, Jun and Fos transcriptional activities are also regulated by phosphorylation as a result of the activation of intracellular signaling cascades. In this regard, the phosphorylation of c-Jun by UV-induced JNK has been readily documented, whereas a role for Fos proteins in UV-mediated responses and the identification of Fos-activating kinases has remained elusive. Here we identify p38 MAPKs as proteins that can associate with c-Fos and phosphorylate its transactivation domain both in vitro and in vivo. This phosphorylation is transduced into changes in its transcriptional ability as p38-activated c-Fos enhances AP1-driven gene expression. Our findings indicate that as a consequence of the activation of stress pathways induced by UV light, endogenous c-Fos becomes a substrate of p38 MAPKs and, for the first time, provide evidence that support a critical role for p38 MAPKs in mediating stress-induced c-Fos phosphorylation and gene transcription activation. Using a specific pharmacological inhibitor for p38 alpha and -beta, we found that most likely these two isoforms mediate UV-induced c-Fos phosphorylation in vivo. Thus, these newly described pathways act concomitantly with the activation of c-Jun by JNK/MAPKs, thereby contributing to the complexity of AP1-driven gene transcription regulation.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Fisiol & Biol Mol, Ifibyne Conicet, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Invest & Ingn Genet, Ingebi Conicet, RA-1428 Buenos Aires, DF, Argentina; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Coso, OA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Fisiol & Biol Mol, Ifibyne Conicet, RA-1428 Buenos Aires, DF, Argentina.	ocoso@fbmc.fcen.uba.ar	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Tanos, Tamara/0000-0002-3217-3104; Hochbaum, Daniel/0000-0001-6387-7529	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BODE AM, 2003, SCI STKE, pRE2; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DB, 2003, MOL CELL ENDOCRINOL, V200, P141, DOI 10.1016/S0303-7207(02)00379-9; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Isoherranen K, 1998, CELL SIGNAL, V10, P191, DOI 10.1016/S0898-6568(97)00100-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; MATSUI M, 1990, ONCOGENE, V5, P249; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Oldenhof AD, 2002, AM J PHYSIOL-CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; Silvers AL, 2003, NEOPLASIA, V5, P319, DOI 10.1016/S1476-5586(03)80025-8; SMITH MF, 1992, J IMMUNOL, V149, P2000; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	151	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18842	18852		10.1074/jbc.M500620200	http://dx.doi.org/10.1074/jbc.M500620200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15708845	hybrid			2022-12-27	WOS:000228932300036
J	Bachler, C; Flukiger-Bruhwiler, K; Schneider, P; Bahler, P; Erni, B				Bachler, C; Flukiger-Bruhwiler, K; Schneider, P; Bahler, P; Erni, B			From ATP as substrate to ADP as coenzyme - Functional evolution of the nucleotide binding subunit of dihydroxyacetone kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; CITROBACTER-FREUNDII; PHOSPHOENOLPYRUVATE; TRANSCRIPTION; MECHANISM; GLYCEROL; PROTEIN	Dihydroxyacetone kinases are a family of sequence-related enzymes that utilize either ATP or a protein of the phosphoenolpyruvate: sugar phosphotransferase system (PTS) as a source of high energy phosphate. The PTS is a multicomponent system involved in carbohydrate uptake and control of carbon metabolism in bacteria. Phylogenetic analysis suggests that the PTS-dependent dihydroxyacetone kinases evolved from an ATP-dependent ancestor. Their nucleotide binding subunit, an eight-helix barrel of regular up-down topology, retains ADP as phosphorylation site for the double displacement of phosphate from a phospho-histidine of the PTS protein to dihydroxyacetone. ADP is bound essentially irreversibly with a t(1/2) of 100 min. Complexation with ADP increases the thermal unfolding temperature of dihydroxyacetone L from 40 (apo- form) to 65 degrees C (holoenzyme). ADP assumes the same role as histidines, cysteines, and aspartic acids in histidine kinases and PTS proteins. This conversion of a substrate binding site into a cofactor binding site reflects a remarkable instance of parsimonious evolution.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						Bachler C, 2005, EMBO J, V24, P283, DOI 10.1038/sj.emboj.7600517; BACHLER C, 2004, EMBO J; DANIEL R, 1995, J BACTERIOL, V177, P4392, DOI 10.1128/jb.177.15.4392-4401.1995; Deppenmeier U, 2002, APPL MICROBIOL BIOT, V60, P233, DOI 10.1007/s00253-002-1114-5; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; Garcia-Alles LF, 2004, BIOCHEMISTRY-US, V43, P13037, DOI 10.1021/bi048575m; Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480; Herz S, 2002, PHYTOCHEMISTRY, V60, P3, DOI 10.1016/S0031-9422(02)00056-0; KUNDIG W, 1971, J BIOL CHEM, V246, P1392; Luers GH, 1998, YEAST, V14, P759; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; Molin M, 2003, J BIOL CHEM, V278, P1415, DOI 10.1074/jbc.M203030200; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Siebold C, 2003, J BIOL CHEM, V278, P48236, DOI 10.1074/jbc.M305942200; Siebold C, 2003, P NATL ACAD SCI USA, V100, P8188, DOI 10.1073/pnas.0932787100; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	21	31	31	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18321	18325		10.1074/jbc.M500279200	http://dx.doi.org/10.1074/jbc.M500279200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753087	hybrid			2022-12-27	WOS:000228807200091
J	Leroch, M; Kirchberger, S; Haferkamp, I; Wahl, M; Neuhaus, HE; Tjaden, J				Leroch, M; Kirchberger, S; Haferkamp, I; Wahl, M; Neuhaus, HE; Tjaden, J			Identification and characterization of a novel plastidic adenine nucleotide uniporter from Solanum tuberosum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; PHOSPHATE-TRANSLOCATOR; STARCH SYNTHESIS; ADP/ATP CARRIER; MOLECULAR CHARACTERIZATION; ENVELOPE MEMBRANES; TRANSPORT PROTEINS; MAIZE ENDOSPERM; EXPRESSION; MITOCHONDRIAL	Homologs of BT1 ( the Brittle1 protein) are found to be phylogenetically related to the mitochondrial carrier family and appear to occur in both mono- and dicotyle-donous plants. Whereas BT1 from cereals is probably involved in the transport of ADP-glucose, which is essential for starch metabolism in endosperm plastids, BT1 from a noncereal plant, Solanum tuberosum (StBT1), catalyzes an adenine nucleotide uniport when functionally integrated into the bacterial cytoplasmic membrane. Import studies into intact Escherichia coli cells harboring StBT1 revealed a narrow substrate spectrum with similar affinities for AMP, ADP, and ATP of about 300 - 400 mu M. Transiently expressed StBT1-green fluorescent protein fusion protein in tobacco leaf protoplasts showed a plastidic localization of the StBT1. In vitro synthesized radioactively labeled StBT1 was targeted to the envelope membranes of isolated spinach chloroplasts. Furthermore, we showed by real time reverse transcription-PCR a ubiquitous expression pattern of the StBT1 in autotrophic and heterotrophic potato tissues. We therefore propose that StBT1 is a plastidic adenine nucleotide uniporter used to provide the cytosol and other compartments with adenine nucleotides exclusively synthesized inside plastids.	Tech Univ Kaiserslautern, D-67663 Kaiserslautern, Germany	University of Kaiserslautern	Tjaden, J (corresponding author), Tech Univ Kaiserslautern, Erwin Schroedinger Str 22, D-67663 Kaiserslautern, Germany.	tjaden@rhrk.uni-kl.de						ANDERSON JD, 1979, PLANT PHYSIOL, V63, P100, DOI 10.1104/pp.63.1.100; ApRees T, 1995, CUR TOP PL, V14, P143; BATZ O, 1994, BBA-GEN SUBJECTS, V1200, P148, DOI 10.1016/0304-4165(94)90129-5; Beckles DM, 2001, PLANT PHYSIOL, V126, P261, DOI 10.1104/pp.126.1.261; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; Boldt R, 2003, PHYSIOL PLANTARUM, V117, P297, DOI 10.1034/j.1399-3054.2003.00030.x; Burton RA, 2002, PLANT PHYSIOL, V130, P1464, DOI 10.1104/pp.010363; CAO HP, 1995, PHYSIOL PLANTARUM, V95, P176, DOI 10.1111/j.1399-3054.1995.tb00825.x; Catoni E, 2003, FEBS LETT, V534, P87, DOI 10.1016/S0014-5793(02)03782-1; Clausen C, 2004, PLANTA, V220, P30, DOI 10.1007/s00425-004-1325-3; Dean JD, 2002, PLANT MOL BIOL REP, V20, P347, DOI 10.1007/BF02772122; Denyer K, 1996, PLANT PHYSIOL, V112, P779, DOI 10.1104/pp.112.2.779; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Eicks M, 2002, PLANT PHYSIOL, V128, P512, DOI 10.1104/pp.010576; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; EMES MJ, 1999, PLANT CARBOHYDRATE B, P231; Fischer K, 1997, PLANT CELL, V9, P453, DOI 10.1105/tpc.9.3.453; Flugge UI, 1999, ANNU REV PLANT PHYS, V50, P27, DOI 10.1146/annurev.arplant.50.1.27; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; Geigenberger P, 2001, PLANT PHYSIOL, V125, P1667, DOI 10.1104/pp.125.4.1667; Haferkamp I, 2002, EUR J BIOCHEM, V269, P3172, DOI 10.1046/j.1432-1033.2002.02991.x; Kammerer B, 1998, PLANT CELL, V10, P105, DOI 10.1105/tpc.10.1.105; Klingenberg M, 1979, Methods Enzymol, V56, P245; KLINGENBERG M, 1993, SOC GEN PHY, V48, P201; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Knappe S, 2003, PLANT PHYSIOL, V131, P1178, DOI 10.1104/pp.016519; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; KRAUSE DC, 1985, P NATL ACAD SCI USA, V82, P3015, DOI 10.1073/pnas.82.9.3015; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linka N, 2003, GENE, V306, P27, DOI 10.1016/S0378-1119(03)00429-3; LIU TTY, 1992, PLANT PHYSIOL, V99, pS39; MAHE A, 1992, MOL PLANT MICROBE IN, V5, P242, DOI 10.1094/MPMI-5-242; MANGOLD HK, 1967, DUNNSCHICHT CHROMATO, P749; Miguel E, 2000, MOL PLANT MICROBE IN, V13, P421, DOI 10.1094/MPMI.2000.13.4.421; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Moffatt Barbara A, 2002, Arabidopsis Book, V1, pe0018, DOI 10.1199/tab.0018; MOHLMANN T, 1994, PLANTA, V194, P492, DOI 10.1007/BF00714461; Mohlmann T, 1998, EUR J BIOCHEM, V252, P353, DOI 10.1046/j.1432-1327.1998.2520353.x; Mohlmann T, 1997, BIOCHEM J, V324, P503, DOI 10.1042/bj3240503; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; Neuhaus HE, 1996, BIOCHEM J, V318, P945, DOI 10.1042/bj3180945; Neuhaus HE, 2000, BBA-BIOMEMBRANES, V1465, P307, DOI 10.1016/S0005-2736(00)00146-2; NEUHAUS HE, 1993, PLANT PHYSIOL, V101, P573, DOI 10.1104/pp.101.2.573; Neuhaus HE, 1997, PLANT J, V11, P73, DOI 10.1046/j.1365-313X.1997.11010073.x; Neuhaus HE, 2000, ANNU REV PLANT PHYS, V51, P111, DOI 10.1146/annurev.arplant.51.1.111; Niittyla T, 2004, SCIENCE, V303, P87, DOI 10.1126/science.1091811; OKITA TW, 1992, PLANT PHYSIOL, V100, P560, DOI 10.1104/pp.100.2.560; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Patron NJ, 2004, PLANT PHYSIOL, V135, P2088, DOI 10.1104/pp.104.045203; Picault N, 2002, J BIOL CHEM, V277, P24204, DOI 10.1074/jbc.M202702200; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sancenon V, 2004, J BIOL CHEM, V279, P15348, DOI 10.1074/jbc.M313321200; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Shannon JC, 1996, PLANT PHYSIOL, V110, P835, DOI 10.1104/pp.110.3.835; Shannon JC, 1998, PLANT PHYSIOL, V117, P1235, DOI 10.1104/pp.117.4.1235; Spetea C, 2004, P NATL ACAD SCI USA, V101, P1409, DOI 10.1073/pnas.0308164100; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; Stasolla C, 2004, FRONT BIOSCI-LANDMRK, V9, P1506, DOI 10.2741/1343; Stasolla C, 2003, J PLANT PHYSIOL, V160, P1271, DOI 10.1078/0176-1617-01169; STUBBS M, 1981, INT ENCYCL PHARM TH, V107, P283; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturzenbaum SR, 2001, COMP BIOCHEM PHYS B, V130, P281, DOI 10.1016/S1096-4959(01)00440-7; SULLIVAN TD, 1991, PLANT CELL, V3, P1337, DOI 10.1105/tpc.3.12.1337; SULLIVAN TD, 1995, PLANTA, V196, P477, DOI 10.1007/BF00203647; Thorbjornsen T, 1996, PLANT J, V10, P243, DOI 10.1046/j.1365-313X.1996.10020243.x; Tjaden J, 1998, PLANT J, V16, P531, DOI 10.1046/j.1365-313X.1998.00317.x; Tjaden J, 2004, MOL MICROBIOL, V51, P1439, DOI 10.1111/j.1365-2958.2004.03918.x; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Versaw WK, 2002, PLANT CELL, V14, P1751, DOI 10.1105/tpc.002220; Voncken F, 2002, MOL MICROBIOL, V44, P1441, DOI 10.1046/j.1365-2958.2002.02959.x; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; Weber A, 2002, J EXP BOT, V53, P865, DOI 10.1093/jexbot/53.370.865; Wendt UK, 2000, PLANT J, V23, P723, DOI 10.1046/j.1365-313x.2000.00840.x; Winkler HH, 1999, TRENDS BIOCHEM SCI, V24, P64, DOI 10.1016/S0968-0004(98)01334-6; WINKLER HH, 1986, METHOD ENZYMOL, V125, P253; YAGIL E, 1975, J BACTERIOL, V121, P401, DOI 10.1128/JB.121.2.401-405.1975; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	83	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17992	18000		10.1074/jbc.M412462200	http://dx.doi.org/10.1074/jbc.M412462200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15737999	hybrid			2022-12-27	WOS:000228807200054
J	Reguera, J; Grueso, E; Carreira, A; Sanchez-Martinez, C; Almendral, JM; Mateu, MG				Reguera, J; Grueso, E; Carreira, A; Sanchez-Martinez, C; Almendral, JM; Mateu, MG			Functional relevance of amino acid residues involved in interactions with ordered nucleic acid in a spherical virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARVOVIRUS MINUTE VIRUS; PROTEIN-RNA INTERACTIONS; BACTERIOPHAGE-MS2 COAT PROTEIN; CHLOROTIC MOTTLE VIRUS; TOBACCO-MOSAIC-VIRUS; CANINE PARVOVIRUS; 3-DIMENSIONAL STRUCTURE; OPERATOR FRAGMENTS; CRYSTAL-STRUCTURES; ICOSAHEDRAL VIRUS	In the spherical virion of the parvovirus minute virus of mice, several amino acid side chains of the capsid were previously found to be involved in interactions with the viral single-stranded DNA molecule. We have individually truncated by mutation to alanine many ( ten) of these side chains and analyzed the effects on capsid assembly, stability and conformation, viral DNA encapsidation, and virion infectivity. Mutation of residues Tyr-270, Asp-273, or Asp-474 led to a drastic reduction in infectivity. Mutant Y270A was defective in capsid assembly; mutant D273A formed stable capsids, but it was essentially unable to encapsidate the viral DNA or to externalize the N terminus of the capsid protein VP2, a connected conformational event. Mutation of residues Asp-58, Trp-60, Asn-183, Thr-267, or Lys-471 led to a moderate reduction in infectivity. None of these mutations had an effect on capsid assembly or stability, or on the DNA encapsidation process. However, those five mutant virions were substantially less stable than the parental virion in thermal inactivation assays. The results with this model spherical virus indicate that several capsid residues that are found to be involved in polar interactions or multiple hydrophobic contacts with the viral DNA molecule contribute to preserving the active conformation of the infectious viral particle. Their effect appears to be mediated by the non-covalent interactions they establish with the viral DNA. In addition, at least one acidic residue at each DNA-binding region is needed for DNA packaging.	Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mateu, MG (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mgarcia@cbm.uam.es	Vidaechea, Juan J Reguera/G-7451-2012; Sanchez-Martinez, Maria/A-2948-2009; Grueso, Elia/F-3182-2012; Reguera, Juan/A-7551-2017; Mateu, Mauricio/ABF-2146-2021; Hierro, Esther Grueso/C-8107-2019; Almendral, Jose M/I-2510-2015	Sanchez-Martinez, Maria/0000-0002-2703-7511; Grueso, Elia/0000-0002-1397-6104; Reguera, Juan/0000-0003-4977-7948; Mateu, Mauricio/0000-0002-2915-1529; Grueso, Esther/0000-0002-5365-5129; Almendral, Jose M/0000-0003-3457-0389; Carreira, Aura/0000-0001-5489-4343				Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; ASTELL CR, 1986, J VIROL, V57, P656, DOI 10.1128/JVI.57.2.656-669.1986; Bernal RA, 2004, J MOL BIOL, V337, P1109, DOI 10.1016/j.jmb.2004.02.033; Bink HHJ, 2002, ARCH VIROL, V147, P2261, DOI 10.1007/s00705-002-0891-6; Carreira A, 2004, J BIOL CHEM, V279, P6517, DOI 10.1074/jbc.M307662200; Casjens S., 1997, STRUCTURAL BIOL VIRU, P3; Chapman MS, 1996, ACTA CRYSTALLOGR D, V52, P129, DOI 10.1107/S0907444995007268; Chapman MS, 2003, ADV PROTEIN CHEM, V64, P125; CHAPMAN MS, 1995, STRUCTURE, V3, P151, DOI 10.1016/S0969-2126(01)00146-0; CHAPMAN MS, 1993, VIROLOGY, V194, P491, DOI 10.1006/viro.1993.1288; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; Cotmore SF, 1999, VIROLOGY, V254, P169, DOI 10.1006/viro.1998.9520; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CURRY S, 1995, J VIROL, V69, P430, DOI 10.1128/JVI.69.1.430-438.1995; Da Poian AT, 2002, J BIOL CHEM, V277, P47596, DOI 10.1074/jbc.M209174200; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; Dertinger D, 2001, J MOL BIOL, V314, P649, DOI 10.1006/jmbi.2001.5132; Dong XF, 1998, J VIROL, V72, P6024, DOI 10.1128/JVI.72.7.6024-6033.1998; Farr GA, 2004, VIROLOGY, V323, P243, DOI 10.1016/j.virol.2004.03.006; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GARDINER EM, 1988, J VIROL, V62, P2605, DOI 10.1128/JVI.62.8.2605-2613.1988; Hafenstein S, 2002, J VIROL, V76, P5350, DOI 10.1128/JVI.76.11.5350-5356.2002; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; HOHN T, 1969, J MOL BIOL, V43, P191, DOI 10.1016/0022-2836(69)90088-6; ILAG LL, 1993, J MOL BIOL, V229, P671, DOI 10.1006/jmbi.1993.1071; Johansson HE, 1998, P NATL ACAD SCI USA, V95, P9244, DOI 10.1073/pnas.95.16.9244; Johnson J. E., 1999, ENCY VIROLOGY, P1946; JOHNSON JE, 1997, STRUCTURAL BIOL VIRU, P269; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; Larson SB, 1998, J MOL BIOL, V277, P37, DOI 10.1006/jmbi.1997.1570; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; LI TS, 1992, BIOCHEMISTRY-US, V31, P6673, DOI 10.1021/bi00144a006; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Lima SMB, 2004, EUR J BIOCHEM, V271, P135, DOI 10.1046/j.1432-1033.2003.03911.x; LlamasSaiz AL, 1997, ACTA CRYSTALLOGR D, V53, P93, DOI 10.1107/S0907444996010566; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Lopez-Bueno A, 2003, J VIROL, V77, P2701, DOI 10.1128/JVI.77.4.2701-2708.2003; Maroto B, 2004, J VIROL, V78, P10685, DOI 10.1128/jvi.78.19.10685-10694.2004; Mateo R, 2003, J BIOL CHEM, V278, P41019, DOI 10.1074/jbc.M304990200; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MCKENNA R, 1994, J MOL BIOL, V237, P517, DOI 10.1006/jmbi.1994.1253; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; RAMIREZ JC, 1995, VIROLOGY, V206, P57, DOI 10.1016/S0042-6822(95)80019-0; Reguera J, 2004, P NATL ACAD SCI USA, V101, P2724, DOI 10.1073/pnas.0307748101; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SACHER R, 1989, J VIROL, V63, P4545, DOI 10.1128/JVI.63.11.4545-4552.1989; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STOCKLEY PG, 1992, CURR OPIN STRUC BIOL, V2, P143; STUBBS G, 1989, PROTEIN NUCLEIC ACID, P87; Tang L, 2001, NAT STRUCT BIOL, V8, P77, DOI 10.1038/83089; TATTERSALL P, 1983, J VIROL, V46, P944, DOI 10.1128/JVI.46.3.944-955.1983; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; Tihova M, 2004, J VIROL, V78, P2897, DOI 10.1128/JVI.78.6.2897-2905.2004; TIMMINS PA, 1994, STRUCTURE, V2, P1191, DOI 10.1016/S0969-2126(94)00121-9; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345; VIRUDACHALAM R, 1985, VIROLOGY, V146, P138, DOI 10.1016/0042-6822(85)90060-1; VRIEND G, 1986, J MOL BIOL, V191, P453, DOI 10.1016/0022-2836(86)90140-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WHITERELL GW, 1991, PROGR NUCL ACIDS RES, V40, P185; WU H, 1993, J MOL BIOL, V233, P231, DOI 10.1006/jmbi.1993.1502; Xie Q, 1996, J MOL BIOL, V264, P497, DOI 10.1006/jmbi.1996.0657	68	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17969	17977		10.1074/jbc.M500867200	http://dx.doi.org/10.1074/jbc.M500867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728575	hybrid			2022-12-27	WOS:000228807200051
J	Hunt, J; Beavil, RL; Calvert, RA; Gould, HJ; Sutton, BJ; Beavil, AJ				Hunt, J; Beavil, RL; Calvert, RA; Gould, HJ; Sutton, BJ; Beavil, AJ			Disulfide linkage controls the affinity and stoichiometry of IgE Fc epsilon 3-4 binding to Fc epsilon RI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GAMMA RECEPTOR; FRAGMENT; COMPLEX; REVEALS; DOMAIN; GLYCOSYLATION; FLEXIBILITY; C-EPSILON-3; RESIDUES	IgE antibodies cause long-term sensitization of tissue mast cells and blood basophils toward allergen-induced cross-linking and triggering of allergic inflammation. This persistence of IgE binding is due to its uniquely high affinity for the receptor Fc epsilon RI and in particular its slow rate of dissociation once bound. The binding interface consists of two subsites, one contributed by each C epsilon 3 domain of IgE Fc in a 1: 1 complex. We have investigated the contributions of C epsilon 3 disulfide linkage and glycosylation to the kinetics and affinity of binding of an Fc subfragment (Fc epsilon 3 - 4) to a soluble receptor fragment (sFc epsilon RI alpha). In contrast to IgG Fc where deglycosylation abrogates receptor binding activity, the removal of the N-linked carbohydrate at Asn-394 in Fc epsilon 3-4 only reduces binding affinity by a factor of 4, principally because of a faster off-rate. Removal of the inter-heavy chain disulfide bond unexpectedly resulted in a fragment with a much faster off-rate and the potential to form a complex with a 2: 1 stoichiometry (sFc epsilon RI alpha: Fc epsilon 3 4). This permitted the determination of the affinity of a single, natively folded C epsilon 3 domain for the first time. The low affinity K-a approximate to 10(5)-10(6) M-1, similar to that determined previously for an isolated and partially folded C epsilon 3 domain, demonstrates that substantial reduction in affinity can be achieved by preventing the engagement of one of the two C epsilon 3 domains. Recent structural data indicate that conformational change in IgE is required to allow both C epsilon 3 domains to bind, and thus an allosteric inhibitor that prevents access to the second C epsilon 3 has the potential to reduce the ability of IgE to sensitize allergic effector cells.	Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Kings Coll London, Div Asthma Allergy & Lung Biol, London SE1 1UL, England	University of London; King's College London; University of London; King's College London	Beavil, AJ (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	andrew.beavil@kcl.ac.uk	Beavil, Andrew/B-5624-2009	Beavil, Andrew/0000-0002-0768-122X; Gould, Hannah/0000-0003-0411-688X				BASU M, 1993, J BIOL CHEM, V268, P13118; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Henry AJ, 2000, BIOCHEMISTRY-US, V39, P7406, DOI 10.1021/bi9928391; HENRY AJ, 1996, HUMAN IGE INTERACTIO; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; KENTEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6661, DOI 10.1073/pnas.79.21.6661; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Price NE, 2005, J BIOL CHEM, V280, P2324, DOI 10.1074/jbc.M409458200; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stamos J, 2004, STRUCTURE, V12, P1289, DOI 10.1016/j.str.2004.04.015; TAKATSU K, 1975, J IMMUNOL, V114, P1838; TAYLOR MAJ, 1992, PROTEIN ENG, V5, P455, DOI 10.1093/protein/5.5.455; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4	30	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16808	16814		10.1074/jbc.M500965200	http://dx.doi.org/10.1074/jbc.M500965200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15743766	hybrid			2022-12-27	WOS:000228615500033
J	Kessl, JJ; Ha, KH; Merritt, AK; Lange, BB; Hill, P; Meunier, B; Meshnick, SR; Trumpower, BL				Kessl, JJ; Ha, KH; Merritt, AK; Lange, BB; Hill, P; Meunier, B; Meshnick, SR; Trumpower, BL			Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc(1) complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ATOVAQUONE RESISTANCE; IN-VITRO; MALARIA PROPHYLAXIS; MOLECULAR-BASIS; Q(O) SITE; HYDROXYNAPHTHOQUINONE; PROGUANIL; 566C80; VIVO	Atovaquone is a new anti-malarial agent that specifically targets the cytochrome bc(1) complex and inhibits parasite respiration. A growing number of failures of this drug in the treatment of malaria have been genetically linked to point mutations in the mitochondrial cytochrome b gene. To better understand the molecular basis of atovaquone resistance in malaria, we introduced five of these mutations, including the most prevalent variant found in Plasmodium falciparum (Y268S), into the cytochrome b gene of the budding yeast Saccharomyces cerevisiae and thus obtained cytochrome bc(1) complexes resistant to inhibition by atovaquone. By modeling the variations in cytochrome b structure and atovaquone binding with the mutated bc(1) complexes, we obtained the first quantitative explanation for the molecular basis of atovaquone resistance in malaria parasites.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Dartmouth College; University of London; University College London; University of North Carolina; University of North Carolina Chapel Hill	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Kessl, Jacques/AAV-2526-2021; Kessl, Jacques/J-6073-2015	Meunier, Brigitte/0000-0002-6988-4663				ARAUJO FG, 1991, ANTIMICROB AGENTS CH, V35, P293, DOI 10.1128/AAC.35.2.293; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Billington OJ, 1999, ANTIMICROB AGENTS CH, V43, P1866, DOI 10.1128/AAC.43.8.1866; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Camus D, 2004, CLIN INFECT DIS, V38, P1716, DOI 10.1086/421086; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; David KP, 2003, SCAND J INFECT DIS, V35, P897, DOI 10.1080/00365540310016862; Devereux HL, 2001, J MED VIROL, V65, P218, DOI 10.1002/jmv.2023; Farnert A, 2003, BMJ-BRIT MED J, V326, P628, DOI 10.1136/bmj.326.7390.628; Fisher N, 2004, J BIOL CHEM, V279, P12951, DOI 10.1074/jbc.M313866200; Fivelman Quinton L, 2002, Malar J, V1, P1; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Gil JP, 2003, MOL CELL PROBE, V17, P85, DOI 10.1016/S0890-8508(03)00006-9; Hill P, 2003, ANTIMICROB AGENTS CH, V47, P2725, DOI 10.1128/AAC.47.9.2725-2731.2003; HUDSON AT, 1993, PARASITOL TODAY, V9, P66, DOI 10.1016/0169-4758(93)90040-M; HUGHES WT, 1995, J INFECT DIS, V172, P1042, DOI 10.1093/infdis/172.4.1042; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Peters JM, 2002, ANTIMICROB AGENTS CH, V46, P2435, DOI 10.1128/AAC.46.8.2435-2441.2002; Petersen E, 2003, J TRAVEL MED, V10, pS13; Schwartz E, 2003, CLIN INFECT DIS, V37, P450, DOI 10.1086/375599; Schwobel B, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-5; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Suswam E, 2001, EXP PARASITOL, V98, P180, DOI 10.1006/expr.2001.4639; Syafruddin D, 1999, MOL BIOCHEM PARASIT, V104, P185, DOI 10.1016/S0166-6851(99)00148-6; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224; Wichmann O, 2004, J INFECT DIS, V190, P1541, DOI 10.1086/424469	33	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17142	17148		10.1074/jbc.M500388200	http://dx.doi.org/10.1074/jbc.M500388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718226	hybrid, Green Published			2022-12-27	WOS:000228615500074
J	Qiu, RD; Pei, WH; Zhang, LS; Lin, JQ; Ji, GY				Qiu, RD; Pei, WH; Zhang, LS; Lin, JQ; Ji, GY			Identification of the putative staphylococcal AgrB catalytic residues involving the proteolytic cleavage of AgrD to generate autoinducing peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; COMPLETE GENOME SEQUENCE; BIOSYNTHESIS-ACTIVATING PHEROMONE; BACILLUS-SUBTILIS; ENTEROCOCCUS-FAECALIS; TRANSMEMBRANE TOPOLOGY; SIGNAL-TRANSDUCTION; CELL COMMUNICATION; AUREUS; VIRULENCE	The P2 operon of the staphylococcal accessory gene regulator (agr) encodes four genes (agrA, - B, - C, and - D) whose products compose a quorum sensing system: AgrA and AgrC resemble a two-component signal transduction system of which AgrC is a sensor kinase and AgrA is a response regulator; AgrD, a polypeptide that is integrated into the cytoplasmic membrane via an amphipathic alpha-helical motif in its N-terminal region, is the propeptide for an autoinducing peptide that is the ligand for AgrC; and AgrB is a novel membrane protein that involves in the processing of AgrD propeptide and possibly the secretion of the mature autoinducing peptide. In this study, we demonstrated that AgrB had endopeptidase activity, and identified 2 amino acid residues in AgrB ( cysteine 84 and histidine 77) that might form a putative cysteine endopeptidase catalytic center in the proteolytic cleavage of AgrD at its C-terminal processing site. Computer analysis revealed that the cysteine and histidine residues were conserved among the potential AgrB homologous proteins, suggesting that the Agr quorum sensing system homologues might also exist in other Gram-positive bacteria.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Catholic University of America; Uniformed Services University of the Health Sciences - USA	Ji, GY (corresponding author), Catholic Univ Amer, Dept Biol, 620 Michigan Ave NE, Washington, DC 20064 USA.	ji@cua.edu		Qiu, Rongde/0000-0003-2078-9718	NIAID NIH HHS [R01AI46445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANHOLT R, 1982, J BIOL CHEM, V257, P7122; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; Coorssen JR, 2003, J CELL SCI, V116, P2087, DOI 10.1242/jcs.00374; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; Donvito B, 1997, FEMS MICROBIOL LETT, V151, P139, DOI 10.1016/S0378-1097(97)00149-3; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; Dufour P, 2002, J BACTERIOL, V184, P1180, DOI 10.1128/jb.184.4.1180-1186.2002; Glaser P, 2001, SCIENCE, V294, P849; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Hoffmaster AR, 2004, P NATL ACAD SCI USA, V101, P8449, DOI 10.1073/pnas.0402414101; JI G, 2004, IN PRESS J BACTERIOL; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Jiang M, 2000, J BACTERIOL, V182, P303, DOI 10.1128/JB.182.2.303-310.2000; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Kane CD, 2002, J BACTERIOL, V184, P4409, DOI 10.1128/JB.184.16.4409-4419.2002; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Koenig RL, 2004, J BACTERIOL, V186, P7549, DOI 10.1128/JB.186.22.7549-7555.2004; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lyon GJ, 2002, BIOCHEMISTRY-US, V41, P10095, DOI 10.1021/bi026049u; Lyon GJ, 2002, J BIOL CHEM, V277, P6247, DOI 10.1074/jbc.M109989200; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McDowell P, 2001, MOL MICROBIOL, V41, P503, DOI 10.1046/j.1365-2958.2001.02539.x; Nakayama J, 2001, MOL MICROBIOL, V41, P145, DOI 10.1046/j.1365-2958.2001.02486.x; Nakayama J, 2001, BIOSCI BIOTECH BIOCH, V65, P2322, DOI 10.1271/bbb.65.2322; Nelson KE, 2004, NUCLEIC ACIDS RES, V32, P2386, DOI 10.1093/nar/gkh562; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; Novick RP, 1999, CURR OPIN MICROBIOL, V2, P40, DOI 10.1016/S1369-5274(99)80007-1; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Otto M, 1998, FEBS LETT, V424, P89, DOI 10.1016/S0014-5793(98)00145-8; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/pnas.94.16.8612; Qin X, 2000, INFECT IMMUN, V68, P2579, DOI 10.1128/IAI.68.5.2579-2586.2000; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Stephenson S, 2003, J BACTERIOL, V185, P4861, DOI 10.1128/JB.185.16.4861-4871.2003; Sturme MHJ, 2002, ANTON LEEUW INT J G, V81, P233, DOI 10.1023/A:1020522919555; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Van Wamel WJB, 1998, FEMS MICROBIOL LETT, V163, P1, DOI 10.1016/S0378-1097(98)00132-3; VANDENESCH F, 1993, FEMS MICROBIOL LETT, V111, P115, DOI 10.1016/0378-1097(93)90191-4; Zhang LS, 2004, J BACTERIOL, V186, P6706, DOI 10.1128/JB.186.20.6706-6713.2004; Zhang LS, 2004, J BIOL CHEM, V279, P19448, DOI 10.1074/jbc.M311349200; Zhang LS, 2002, J BIOL CHEM, V277, P34736, DOI 10.1074/jbc.M205367200; Zhang SP, 2000, J BACTERIOL, V182, P2321, DOI 10.1128/JB.182.8.2321-2325.2000	52	56	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16695	16704		10.1074/jbc.M411372200	http://dx.doi.org/10.1074/jbc.M411372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734745	hybrid			2022-12-27	WOS:000228615500021
J	Yamamoto, T; Suzuki, N				Yamamoto, T; Suzuki, N			Expression and function of cGMP-dependent protein kinase type I during medaka fish embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES NUCLEAR TRANSLOCATION; SOLUBLE GUANYLYL CYCLASE; CREB PHOSPHORYLATION; GENE-EXPRESSION; GLI PROTEINS; HEDGEHOG; PROTEOLYSIS; ACTIVATION; PROMOTER; SUBUNIT	We isolated and characterized cDNA clones (PKG I alpha and PKG I beta) for medaka fish cGMP-dependent protein kinase ( PKG) I alpha and I beta, and demonstrated that both are expressed in the embryos after late gastrula stage. Whole-mount in situ hybridization using each isoform-specific probe revealed that the transcripts of the PKG I alpha gene were present in the spinal cord and gill arch, whereas those of the PKG I beta gene were only weakly expressed in these organs, but highly expressed in the otic vesicles. Injection of PKG I alpha-specific morpholino antisense oligonucleotides (I alpha-MO) into two-cell stage medaka fish embryos caused severe abnormalities in the developing embryos, such as the development of a hammer-like head, fusion of the developing eyes, and degeneration of cells around the eyes, whereas injection of PKG I alpha-specific morpholino antisense oligonucleotides ( I beta-MO) caused fewer abnormalities in the embryos, even when injected at higher concentrations than I alpha-MO. The PKG I-overexpressing embryos exhibited smaller eyes and enlargement of the forebrain, a phenotype similar to that observed in the cAMP-dependent protein kinase (PKA)-depressed embryos. In the PKG-deficient embryos, a sonic hedgehog (shh)-target gene, HNF-3 beta, was expressed weakly, and this phenotype was similar to that observed in the PKA-overexpressing embryos suggesting that the cGMP/PKG signaling pathway is involved in some steps of shh signaling. We also demonstrated that Gli proteins, shh-downstream molecules, are phosphorylated by the NO/cGMP signaling pathway, probably by PKG in NG108-15 neuroblastoma cells. These results imply that PKG and PKA share common substrates and work in an opposite manner during the early embryogenesis of medaka fish.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Yamamoto, T (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	take-y@sc.itc.keio.ac.jp						Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Amieux PS, 2002, J BIOL CHEM, V277, P27294, DOI 10.1074/jbc.M200302200; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dontchev VD, 2003, J HISTOCHEM CYTOCHEM, V51, P435, DOI 10.1177/002215540305100405; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Gendron L, 2002, NEUROENDOCRINOLOGY, V75, P70, DOI 10.1159/000048222; Goldberg N D, 1975, Adv Cyclic Nucleotide Res, V5, P307; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; IWAMATSU T, 1994, ZOOL SCI, V11, P825; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Koebernick K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/j.1432-0436.2002.700201.x; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Lefers MA, 2002, CURR BIOL, V12, pR422, DOI 10.1016/S0960-9822(02)00914-4; Lu YF, 1999, J NEUROSCI, V19, P10250; Lucas KA, 2000, PHARMACOL REV, V52, P375; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Mikami T, 1999, J BIOL CHEM, V274, P18567, DOI 10.1074/jbc.274.26.18567; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Qian YF, 1996, J NEUROSCI, V16, P3130; Robertson CP, 2001, DEV BIOL, V238, P157, DOI 10.1006/dbio.2001.0392; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schmidt H, 2002, J CELL BIOL, V159, P489, DOI 10.1083/jcb.200207058; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Song BH, 2003, DEV DYNAM, V227, P91, DOI 10.1002/dvdy.10296; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Yamagami S, 2001, J BIOCHEM-TOKYO, V130, P39, DOI 10.1093/oxfordjournals.jbchem.a002960; Yamamoto T, 2002, BIOCHEM J, V361, P337, DOI 10.1042/0264-6021:3610337; Yamamoto T, 2003, ZOOL SCI, V20, P181, DOI 10.2108/zsj.20.181	45	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16979	16986		10.1074/jbc.M412433200	http://dx.doi.org/10.1074/jbc.M412433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710621	hybrid			2022-12-27	WOS:000228615500054
J	Baldwin, SA; Yao, SYM; Hyde, RJ; Ng, AML; Foppolo, S; Barnes, K; Ritzel, MWL; Cass, CE; Young, JD				Baldwin, SA; Yao, SYM; Hyde, RJ; Ng, AML; Foppolo, S; Barnes, K; Ritzel, MWL; Cass, CE; Young, JD			Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOBASE TRANSPORTERS; RECOMBINANT HUMAN; ANTICANCER DRUGS; CELLULAR UPTAKE; PROTEINS; FAMILY; CELLS; IDENTIFICATION; EXPRESSION; LYSOSOMES	The first mammalian examples of the equilibrative nucleoside transporter family to be characterized, hENT1 and hENT2, were passive transporters located predominantly in the plasma membranes of human cells. We now report the functional characterization of members of a third subgroup of the family, from human and mouse, which differ profoundly in their properties from previously characterized mammalian nucleoside transporters. The 475-residue human and mouse proteins, designated hENT3 and mENT3, respectively, are 73% identical in amino acid sequence and possess long N-terminal hydrophilic domains that bear typical ( DE) XXXL(LI) endosomal/lysosomal targeting motifs. ENT3 transcripts and proteins are widely distributed in human and rodent tissues, with a particular abundance in placenta. However, in contrast to ENT1 and ENT2, the endogenous and green fluorescent protein-tagged forms of the full-length hENT3 protein were found to be predominantly intracellular proteins that co-localized, in part, with lysosomal markers in cultured human cells. Truncation of the hydrophilic N-terminal region or mutation of its dileucine motif to alanine caused the protein to be relocated to the cell surface both in human cells and in Xenopus oocytes, allowing characterization of its transport activity in the latter. The protein proved to be a broad selectivity, low affinity nucleoside transporter that could also transport adenine. Transport activity was relatively insensitive to the classical nucleoside transport inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep and was sodium ion-independent. However, it was strongly dependent upon pH, and the optimum pH value of 5.5 probably reflected the location of the transporter in acidic, intracellular compartments.	Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada	University of Leeds; University of Alberta; University of Alberta; University of Alberta	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England.	s.a.baldwin@leeds.ac.uk						Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; DAVIES A, 1990, BIOCHEM J, V266, P799; Engel K, 2004, J BIOL CHEM, V279, P50042, DOI 10.1074/jbc.M407913200; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HEYDRICK SJ, 1991, J BIOL CHEM, V266, P8790; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200; Landfear SM, 2004, EUKARYOT CELL, V3, P245, DOI 10.1128/EC.3.2.245-254.2004; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Musa H, 2002, J HISTOCHEM CYTOCHEM, V50, P305, DOI 10.1177/002215540205000302; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PISONI RL, 1989, J BIOL CHEM, V264, P4850; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Towler MC, 2000, EXP CELL RES, V259, P167, DOI 10.1006/excr.2000.4958; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318	37	250	259	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15880	15887		10.1074/jbc.M414337200	http://dx.doi.org/10.1074/jbc.M414337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701636	hybrid			2022-12-27	WOS:000228444800053
J	Gan, YH; Shen, YH; Wang, J; Wang, XW; Utama, B; Wang, J; Wang, XL				Gan, YH; Shen, YH; Wang, J; Wang, XW; Utama, B; Wang, J; Wang, XL			Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESS TRANSCRIPTION; GENE-EXPRESSION; DNA METHYLATION; BINDING PROTEIN; SP1 SITE; PROMOTER; INHIBITORS; ACETYLATION; COMPLEX; HTERT	Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in cell-specific expression of endothelial nitric-oxide synthase ( eNOS) are not fully understood. In this study we investigated whether histone deacetylation was involved in repression of eNOS expression in non-endothelial cells. Induction of eNOS expression by histone deacetylase ( HDAC) inhibitors trichostatin A (TSA) and sodium butyrate was observed in all four different types of non-endothelial cells examined. Chromatin immunoprecipitation assays showed that the induction of eNOS expression by TSA was accompanied by a remarkable increase of acetylation of histone H3 associated with the eNOS 5'-flanking region in the non-endothelial cells. Moreover, DNA methylation-mediated repression of eNOS promoter activity was partially reversed by TSA treatment, and combined treatment of TSA and 5-aza-2'-deoxycytidine (AzadC) synergistically induced eNOS expression in non-endothelial cells. The proximal Sp1 site is critical for basal activity of eNOS promoter. The induction of eNOS by inhibition of HDACs in non-endothelial cells, however, appeared not mediated by the changes in Sp1 DNA binding activity. We further showed that Sp1 bound to the endogenous eNOS promoter and associated with HDAC1 in non-endothelial HeLa cells. Combined TSA and AzadC treatment increased Sp1 binding to the endogenous eNOS promoter but decreased the association between HDAC1 and Sp1 in HeLa cells. Our data suggest that HDAC1 plays a critical role in eNOS repression, and the proximal Sp1 site may serve a key target for HDCA1-mediated eNOS repression in non-endothelial cells.	Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA; Peking Univ, Sch Stomatol, Ctr TMJ Disorders, Beijing 100081, Peoples R China	Baylor College of Medicine; Peking University	Wang, XL (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, MS NAB 2010, Houston, TX 77030 USA.	xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022		NHLBI NIH HHS [R01 HL066053, R01-HL066053, R01 HL066053-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066053] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Davie JR, 1999, J CELL BIOCHEM, P141; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kim HS, 2003, BIOCHEM BIOPH RES CO, V312, P950, DOI 10.1016/j.bbrc.2003.11.012; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P149, DOI 10.1016/S1089-8603(02)00111-8; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; van Haperen R, 2003, AM J PATHOL, V163, P1677, DOI 10.1016/S0002-9440(10)63524-9; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang R, 2002, ARTERIOSCL THROM VAS, V22, pE1, DOI 10.1161/01.ATV.0000016248.51577.1F; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhao SJ, 2003, CANCER RES, V63, P2624	31	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16467	16475		10.1074/jbc.M412960200	http://dx.doi.org/10.1074/jbc.M412960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722551	Green Accepted, hybrid			2022-12-27	WOS:000228444800121
J	Hambsch, B; Grinevich, V; Seeburg, PH; Schwarz, MK				Hambsch, B; Grinevich, V; Seeburg, PH; Schwarz, MK			gamma-Protocadherins, presenilin-mediated release of C-terminal fragment promotes locus expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-ADHESION; E-CADHERIN; INTRACELLULAR DOMAIN; SECRETASE ACTIVITY; N-CADHERIN; DIVERSITY; CLEAVAGE; MICE; PROTEOLYSIS	gamma-Protocadherins (gamma-pcdhs) are type I membrane-spanning glycoproteins, widely expressed in the mammal and required for survival. These cell adhesion molecules are expressed from a complex locus comprising 22 functional variable exons arranged in tandem, each encoding extracellular, transmembrane and intracellular sequence, and three exons for an invariant C-terminal domain (gamma-ICD). However, the signaling mechanisms that lie downstream of gamma-pcdhs have not been elucidated. Here we report that gamma-pcdhs are subject to presenilin-dependent intramembrane cleavage (PS-IP), accompanied by shedding of the extracellular domain. The cleaved intracellular domain (gamma-ICD) translocates to the cell nucleus and was detected in subsets of cortical neurons. Notably, gene-targeted mice lacking functional gamma-ICD sequence showed severely reduced gamma-pcdh mRNA levels and neonatal lethality. Most importantly, inhibition of gamma-secretase decreased gamma-pcdh locus expression. Luciferase reporter assays demonstrated that gamma-pcdh promoter activity is increased by gamma-ICD. These results reveal an intracellular signaling mechanism for gamma-pcdhs and identify a novel vital target for the gamma-secretase complex.	Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society	Seeburg, PH (corresponding author), Max Planck Inst Med Res, Dept Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.	seeburg@mpimf-heidelberg.mpg.de						Angst BD, 2001, J CELL SCI, V114, P629; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DE SB, 1999, NATURE, V398, P518; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Mack V, 2001, SCIENCE, V292, P2501, DOI 10.1126/science.1059365; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; MURATA Y, 2004, J BIOL CHEM; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Phillips GR, 2003, J NEUROSCI, V23, P5096; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Silver RA, 2003, SCIENCE, V302, P1981, DOI 10.1126/science.1087160; Suchanek B, 1997, BIOL CHEM, V378, P929; Suzuki ST, 1996, J CELL SCI, V109, P2609; Tanaka H, 2000, NEURON, V25, P93, DOI 10.1016/S0896-6273(00)80874-0; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; WISDEN W, 2002, IN SITU HYBRIDIZATIO, V47; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; ZABORSZKY L, 1989, NEUROANATOMICAL TRAC, V2, P49; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	49	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15888	15897		10.1074/jbc.M414359200	http://dx.doi.org/10.1074/jbc.M414359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711011	hybrid			2022-12-27	WOS:000228444800054
J	Reversi, A; Rimoldi, V; Marrocco, T; Cassoni, P; Bussolati, G; Parenti, M; Chini, B				Reversi, A; Rimoldi, V; Marrocco, T; Cassoni, P; Bussolati, G; Parenti, M; Chini, B			The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVEOLIN-1 ENRICHED DOMAINS; G-PROTEINS; IN-VITRO; VASOPRESSIN RECEPTOR; CANCER CELLS; ACTIVATION; BINDING; LIGAND; PROLIFERATION; DESIGN	In human myometrial cells, the promiscuous coupling of the oxytocin receptors (OTRs) to G(q) and G(i) leads to contraction. However, the activation of OTRs coupled to different G protein pathways can also trigger opposite cellular responses, e.g. OTR coupling to G(i) inhibits, whereas its coupling to G(q) stimulates, cell proliferation. Drug analogues capable of promoting a selective receptor-G protein coupling may be of great pharmacological and clinical importance because they may target only one specific signal transduction pathway. Here, we report that atosiban, an oxytocin derivative that acts as a competitive antagonist on OTR/G(q) coupling, displays agonistic properties on OTR/G(i) coupling, as shown by specific S-35-labeled guanosine 5'-3-O-(thio) trisphosphate ([S-35] GTP gamma S) binding. Moreover, atosiban, by acting on a G(i)-mediated pathway, inhibits cell growth of HEK293 and Madin-Darby canine kidney cells stably transfected with OTRs and of DU145 prostate cancer cells expressing endogenous OTRs. Notably, atosiban leads to persistent ERK1/2 activation and p21(WAF1/CIP1) induction, the same signaling events leading to oxytocin-mediated cell growth inhibition via a Gi pathway. Finally, atosiban exposure did not cause OTR internalization and led to only a modest decrease (20%) in the number of high affinity cell membrane OTRs, two observations consistent with the finding that atosiban did not lead to any desensitization of the oxytocin-induced activation of the G(q)-phospholipase C pathway. Taken together, these observations indicate that atosiban acts as a "biased agonist" of the human OTRs and thus belongs to the class of compounds capable of selectively discriminating only one among the multiple possible active conformations of a single G protein-coupled receptor, thereby leading to the selective activation of a unique intracellular signal cascade.	CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy; Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, I-20052 Monza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Turin; University of Milano-Bicocca	Chini, B (corresponding author), CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, Via Vanvitelli 32, I-20129 Milan, Italy.	B.Chini@in.cnr.it	Cassoni, Paola/I-8544-2018; Rimoldi, Valeria/AAB-4865-2020	Rimoldi, Valeria/0000-0002-5598-3986; Chini, Bice/0000-0002-1686-284X; Reversi, Alessandra/0000-0002-9934-5636				AKERLUND M, 1987, BRIT J OBSTET GYNAEC, V94, P1040, DOI 10.1111/j.1471-0528.1987.tb02287.x; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; BERDE B, 1968, HDB EXPERIMENTAL PHA, V23, P802; Bestervelt L, 2000, CELL SIGNAL, V12, P53, DOI 10.1016/S0898-6568(99)00067-4; BOSSMAR T, 1994, AM J OBSTET GYNECOL, V171, P1634, DOI 10.1016/0002-9378(94)90415-4; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Cassoni P, 2004, INT J ONCOL, V25, P899; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1996, INT J CANCER, V66, P817, DOI 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#; Chan DC, 2002, CLIN CANCER RES, V8, P1280; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 2000, EXP PHYSIOL, V85, p59S, DOI 10.1111/j.1469-445X.2000.tb00008.x; Coomarasamy Aravinthan, 2002, Med Sci Monit, V8, pRA268; Drube S, 2000, BRIT J PHARMACOL, V131, P1553, DOI 10.1038/sj.bjp.0703764; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Hasbi A, 2004, MOL ENDOCRINOL, V18, P1277, DOI 10.1210/me.2003-0440; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKinnon AC, 2001, J BIOL CHEM, V276, P28083, DOI 10.1074/jbc.M009772200; MANNING M, 1993, J RECEPTOR RES, V13, P195, DOI 10.3109/10799899309073655; MANNING M, 1995, INT J PEPT PROT RES, V46, P244; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Moody TW, 2001, PEPTIDES, V22, P109, DOI 10.1016/S0196-9781(00)00362-4; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; PHANEUF S, 1994, AM J OBSTET GYNECOL, V171, P1627, DOI 10.1016/0002-9378(94)90414-6; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Rimoldi V, 2003, ONCOGENE, V22, P6054, DOI 10.1038/sj.onc.1206612; Sanborn BM, 2001, EXP PHYSIOL, V86, P223, DOI 10.1113/eph8602179; Slusarz MJ, 2003, PROTEIN PEPTIDE LETT, V10, P295, DOI 10.2174/0929866033478898; Stirnweis J, 2002, PEPTIDES, V23, P1503, DOI 10.1016/S0196-9781(02)00089-X; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Thornton S, 2001, EXP PHYSIOL, V86, P297, DOI 10.1113/eph8602186; Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023; Tong WG, 2002, CLIN CANCER RES, V8, P3232; WIELAND T, 1994, METHOD ENZYMOL, V237, P3	45	95	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16311	16318		10.1074/jbc.M409945200	http://dx.doi.org/10.1074/jbc.M409945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705593	hybrid			2022-12-27	WOS:000228444800102
J	Yik, JHN; Chen, RC; Pezda, AC; Zhou, Q				Yik, JHN; Chen, RC; Pezda, AC; Zhou, Q			Compensatory contributions of HEXIM1 and HEXIM2 in maintaining the balance of active and inactive positive transcription elongation factor b complexes for control of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; P-TEFB; 7SK SNRNA; CLP-1 GENE; TAT; KINASE; INHIBITION; ACTIVATION; EXPRESSION; MECHANISM	Human positive transcriptional elongation factor b (P-TEFb), consisting of a cyclin-dependent kinase 9-cyclin T heterodimer, stimulates general and disease-specific transcriptional elongation by phosphorylating RNA polymerase II. The HEXIM1 protein, aided by the 7SK snRNA, sequesters P-TEFb into an inactive 7SK center dot HEXIM1 center dot P-TEFb small nuclear ribonucleic acid particle for inhibition of transcription and, consequently, cell proliferation. Here we show that, like HEXIM1, a highly homologous protein named HEXIM2 also possesses the ability to inactivate P-TEFb to suppress transcription through a 7SK-mediated interaction with P-TEFb. Furthermore, HEXIM1 and HEXIM2 can form stable homo- and hetero-oligomers ( most likely dimers), which may nucleate the formation of the 7SK small nuclear ribonucleic acid particle. Despite their similar functions, HEXIM1 and HEXIM2 exhibit distinct expression patterns in various human tissues and established cell lines. In HEXIM1-knocked down cells, HEXIM2 can functionally and quantitatively compensate for the loss of HEXIM1 to maintain a constant level of the 7SK/ HEXIM-bound P-TEFb. Our results demonstrate that there is a tightly regulated cellular process to maintain the balance between active and inactive P-TEFb complexes, which controls global transcription as well as cell growth and differentiation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China	University of California System; University of California Berkeley; Xiamen University	Zhou, Q (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 622 Barker Hall 3202, Berkeley, CA 94720 USA.	qzhou@uclink4.berkeley.edu	Chen, Ruichuan/G-4618-2010; Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIAID NIH HHS [AI41757, AI058400] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041757, F32AI058400] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Huang F, 2004, MECH DEVELOP, V121, P559, DOI 10.1016/j.mod.2004.04.012; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Wittmann BM, 2003, CANCER RES, V63, P5151; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	25	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16368	16376		10.1074/jbc.M500912200	http://dx.doi.org/10.1074/jbc.M500912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713661	hybrid			2022-12-27	WOS:000228444800109
J	Berg, DT; Myers, LJ; Richardson, MA; Sandusky, G; Grinnell, BW				Berg, DT; Myers, LJ; Richardson, MA; Sandusky, G; Grinnell, BW			Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TGF-BETA; RESPONSIVE ELEMENT; GENE-EXPRESSION; INDUCIBLE ELEMENTS; ENDOTHELIAL-CELLS; DIRECT BINDING; MESSENGER-RNA; TYPE-1 GENE; PKC-BETA	Plasminogen activator inhibitor-1 (PAI-1) is a serpin class protease inhibitor that plays a central role in the regulation of vascular function and tissue remodeling by modulating thrombosis, inflammation, and the extracellular matrix. A central mediator controlling PAI-1 is transforming growth factor-beta(TGF-beta), which induces its expression and promotes fibrosis. We have found that a unique member of the Smad family of signal transduction molecules, Smad6s, modulates the expression of PAI-1. Overexpression of Smad6s in endothelial cells increases promoter activity and PAI-1 secretion, and an antisense to Smad6s suppresses the induction of PAI-1 by TGF-beta. The effect of Smad6s on the PAI-1 promoter appeared to be the result of increase binding of the forkhead winged helix factor FoxD1 to a TGF-beta-responsive element. Furthermore, the effect of Smad6s on PAI-1 up-regulation and on FoxD1 binding was found to result from up-regulation of TGF-beta and could be inhibited by the blocking TGF-beta signaling with Smad7. The ability of Smad6s to regulate the TGF-beta promoter and subsequent PAI-1 induction was suppressed by a selective protein kinase C-beta (PKC-beta) inhibitor. Consistent with the in vitro data, we found that increased Smad6s in diseased vessels correlated with increased TGF-beta and PAI-1 levels. Overall, our results demonstrate that the level of Smad6s can alter the level of TGF-beta and the subsequent induction of PAI-1 via a FoxD1 transcription site. Furthermore, our data suggest that this process, which is up-regulated in diseased vessels, can be modulated by the inhibition of PKC-beta.	Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol Discovery Res, Indianapolis, IN 46285 USA	Eli Lilly	Grinnell, BW (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol Discovery Res, Indianapolis, IN 46285 USA.	bgrinnell@lilly.com						Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bard J, 1996, BIOESSAYS, V18, P705, DOI 10.1002/bies.950180905; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Brown NJ, 2002, SEMIN NEPHROL, V22, P399, DOI 10.1053/snep.2002.34725; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763; Chorostowska-Wynimko J, 2004, INT J MOL MED, V13, P759; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong C, 2002, J HEART LUNG TRANSPL, V21, P999, DOI 10.1016/S1053-2498(02)00403-5; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Fay WP, 2004, TRENDS CARDIOVAS MED, V14, P196, DOI 10.1016/j.tcm.2004.03.002; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gomez-Skarmeta JL, 1999, MECH DEVELOP, V80, P15, DOI 10.1016/S0925-4773(98)00190-7; GRINNELL BW, 1986, MOL CELL BIOL, V6, P3596, DOI 10.1128/MCB.6.11.3596; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Khatib AM, 2001, INT J CANCER, V91, P300, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1055>3.3.CO;2-E; KIM SJ, 1989, J BIOL CHEM, V264, P402; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Kutz SM, 2001, CELL MOTIL CYTOSKEL, V48, P163, DOI 10.1002/1097-0169(200103)48:3<163::AID-CM1006>3.0.CO;2-C; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; Loskutoff DJ, 1997, CIRCULATION, V96, P2772; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P152, DOI 10.1161/01.ATV.18.2.152; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Mur C, 2004, LIFE SCI, V75, P611, DOI 10.1016/j.lfs.2003.12.026; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; Ren S, 2000, AM J PHYSIOL-ENDOC M, V278, pE656, DOI 10.1152/ajpendo.2000.278.4.E656; Richardson MA, 2000, ENDOCRINOLOGY, V141, P3908, DOI 10.1210/en.141.10.3908; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Rossini M., 2004, DRUG DISCOV TODAY, V1, P65; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; Sandusky G, 2002, J BIOL CHEM, V277, P49815, DOI 10.1074/jbc.C200543200; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Westendorp RGJ, 1999, LANCET, V354, P561, DOI 10.1016/S0140-6736(98)09376-3; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wileman SM, 2000, BRIT J OPHTHALMOL, V84, P417, DOI 10.1136/bjo.84.4.417; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	58	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14943	14947		10.1074/jbc.C400579200	http://dx.doi.org/10.1074/jbc.C400579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15716278	hybrid			2022-12-27	WOS:000228236800074
J	Goncalves, I; Nesbitt, WS; Yuan, YP; Jackson, SP				Goncalves, I; Nesbitt, WS; Yuan, YP; Jackson, SP			Importance of temporal flow gradients and integrin alpha(IIb)beta(3) mechanotransduction for shear activation of platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CAROTID BIFURCATION; INTEGRIN ALPHA(IIB)BETA(3); ADHESIVE INTERACTIONS; GLYCOPROTEIN IB/V/IX; CALCIUM SIGNALS; DISTINCT ROLES; PULSATILE FLOW; STRESS; AGGREGATION	Disturbances of blood flow play an important role in promoting platelet activation and arterial thrombus formation in stenosed, injured, atherosclerotic arteries. To date, glycoprotein Ib ( GPIb) has been considered the primary platelet mechanosensory receptor, responding to increased shear with enhanced adhesive and signaling function. We demonstrate here that von Willebrand factor-GPIb interaction is inefficient at inducing platelet activation even when platelets are exposed to very high wall shear stresses (60 dyn/cm(2)). Rapid platelet activation under flow was only observed under experimental conditions in which transiently adherent platelets were exposed to sudden accelerations in blood flow. Platelet responsiveness to temporal shear gradients was integrin alpha(IIb)beta(3)-dependent and occurred only on a von Willebrand factor substrate, as platelets forming integrin alpha(IIb)beta(3) adhesive contacts with immobilized fibrinogen were unresponsive to sudden increases in shear. The calcium response induced by temporal shear gradients was distinct from previously identified integrin alpha(IIb)beta(3) calcium responses in terms of its transient nature, its requirement for platelet co-stimulation by the P2Y(1) purinergic ADP receptor, and its dependence on the influx of extracellular calcium. Our studies demonstrate a key role for temporal shear gradients in promoting platelet activation. Moreover, they define for the first time the involvement of P2Y receptors in integrin mechanotransduction.	Monash Univ, Dept Med, Australian Ctr Blood Dis, Alfred Med Res & Educ Precinct, Prahran, Vic 3181, Australia	Monash University	Jackson, SP (corresponding author), Monash Univ, Dept Med, Australian Ctr Blood Dis, Alfred Med Res & Educ Precinct, 6th Floor,Burnet Tower,Commercial Rd, Prahran, Vic 3181, Australia.	shaun.jackson@med.monash.edu.au	Goncalves, Isaac/AAO-8371-2020	Nesbitt, Warwick/0000-0001-5644-7053; Jackson, Shaun/0000-0002-4750-1991				ALENGHAT FJ, 2002, SCI STKE; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; Jarvis GE, 2000, BRIT J PHARMACOL, V129, P275, DOI 10.1038/sj.bjp.0703046; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Kroll MH, 1996, BLOOD, V88, P1525; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KU DN, 1983, ARTERIOSCLEROSIS, V3, P31, DOI 10.1161/01.ATV.3.1.31; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; MAILHAC A, 1994, CIRCULATION, V90, P988, DOI 10.1161/01.CIR.90.2.988; Mazzucato M, 2004, BLOOD, V104, P3221, DOI 10.1182/blood-2004-03-1145; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; MOAKE JL, 1988, BLOOD, V71, P1366; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Putney JW, 2001, J CELL SCI, V114, P2223; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Sage SO, 1997, EXP PHYSIOL, V82, P807, DOI 10.1113/expphysiol.1997.sp004066; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; STRONY J, 1993, AM J PHYSIOL, V265, pH1787; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; White CR, 2001, CIRCULATION, V103, P2508; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502	34	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15430	15437		10.1074/jbc.M410235200	http://dx.doi.org/10.1074/jbc.M410235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701653	hybrid			2022-12-27	WOS:000228236800130
J	Gronert, K; Maheshwari, N; Khan, N; Hassan, IR; Dunn, M; Schwartzman, ML				Gronert, K; Maheshwari, N; Khan, N; Hassan, IR; Dunn, M; Schwartzman, ML			A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGERED 15-EPI-LIPOXIN A(4); BOVINE CORNEAL EPITHELIUM; NECROSIS-FACTOR-ALPHA; INDUCED LIPOXIN A(4); DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; ARACHIDONATE 15-LIPOXYGENASE; SUPPRESSES INFLAMMATION; NEUTROPHIL RECRUITMENT; TARGETED DISRUPTION	The surface of the eye actively suppresses inflammation while maintaining a remarkable capacity for epithelial wound repair. Our understanding of mechanisms that balance inflammatory/reparative responses to provide effective host defense while preserving tissue function is limited, in particular, in the cornea. Lipoxin A(4) (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1) are lipid autacoids formed by 12/15-lipoxy-genase (LOX) pathways that exhibit anti-inflammatory and neuroprotective properties. Here, we demonstrate that mouse corneas generate endogenous LXA(4) and NPD1. 12/15-LOX (Alox15) and LXA(4) receptor mRNA expression as well as LXA(4) formation were abrogated by epithelial removal and restored during wound healing. Amplification of these pathways by topical treatment with LXA(4) or NPD1 (1 mu g) increased the rate of re-epithelialization (65-90%, n = 6-10, p < 0.03) and attenuated the sequelae of thermal injury. In contrast, the proinflammatory eicosanoids, LTB4 and 12R-hydroxyeicosatrienoic acid, had no impact on corneal re-epithelialization. Epithelial removal induced a temporally defined influx of neutrophils into the stroma as well as formation of the proinflammatory chemokine KC. Topical treatment with LXA(4) and NPD1 significantly increased PMNs in the cornea while abrogating KC formation by 60%. More importantly, Alox15-deficient mice exhibited a defect in both corneal re-epithelialization and neutrophil recruitment that correlated with a 43% reduction in endogenous LXA(4) formation. Collectively, these results identify a novel action for the mouse 12/15-LOX ( Alox15) and its products, LXA(4) and NPD1, in wound healing that is distinct from their well established anti-inflammatory properties.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Gronert, K (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	karsten_gronert@nymc.edu			NATIONAL EYE INSTITUTE [R01EY016136, R01EY006513] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY016136, EY06513, R01 EY016136-02] Funding Source: Medline; NIDDK NIH HHS [DK6053] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Bannenberg GL, 2004, J EXP MED, V199, P515, DOI 10.1084/jem.20031325; Bazan HEP, 1997, INVEST OPHTH VIS SCI, V38, P2492; BAZAN HEP, 1985, CURR EYE RES, V4, P175, DOI 10.3109/02713688509000847; BAZAN NG, 1997, SURV OPHTHALMOL, V41, P23; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Conners MS, 1997, INVEST OPHTH VIS SCI, V38, P1963; CUBITT CL, 1993, INVEST OPHTH VIS SCI, V34, P3199; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; DECATERINA R, 1993, N3 FATTY ACIDS VASCU; Devchand PR, 2003, FASEB J, V17, P652, DOI 10.1096/fj.02-0770com; Fraunfelder F., 2001, DRUG INDUCED OCULAR, V5th ed.; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gan L, 1999, INVEST OPHTH VIS SCI, V40, P575; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Gronert K, 1999, METH MOL B, V120, P119; Hamrah P, 2003, J LEUKOCYTE BIOL, V74, P172, DOI 10.1189/jlb.1102544; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; HURST JS, 1991, J BIOL CHEM, V266, P6726; Johnson EN, 1999, J INVEST DERMATOL, V112, P861, DOI 10.1046/j.1523-1747.1999.00595.x; Kelavkar Uddhav, 2002, Curr Urol Rep, V3, P207, DOI 10.1007/s11934-002-0066-8; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; KROMANN N, 1980, ACTA MED SCAND, V208, P401; Kumar V., 2004, ROBBINS COTRAN PATHO, P47; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liminga M, 1999, BBA-MOL CELL BIOL L, V1437, P124, DOI 10.1016/S1388-1981(99)00004-9; LIMINGA M, 1994, BBA-LIPID LIPID MET, V1210, P288, DOI 10.1016/0005-2760(94)90231-3; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McDonnell M, 2001, PROSTAG OTH LIPID M, V63, P93, DOI 10.1016/S0090-6980(00)00100-3; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Niederkorn JY, 2003, J LEUKOCYTE BIOL, V74, P167, DOI 10.1189/jlb.1102543; Ono SJ, 2003, J LEUKOCYTE BIOL, V74, P149, DOI 10.1189/jlb.0403191; ROSENBAUM JT, 1995, INVEST OPHTH VIS SCI, V36, P2151; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schottelius AJ, 2002, J IMMUNOL, V169, P7063, DOI 10.4049/jimmunol.169.12.7063; Schwartzman ML, 1997, ADVANCES IN OCULAR TOXICOLOGY, P3; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; Shappell SB, 2003, CANCER RES, V63, P2256; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Simopoulos Artemis P., 1999, Journal of the American College of Nutrition, V18, P487, DOI 10.1046/j.1440-6047.1999.00123.x; SIMPSON DM, 1972, J CLIN INVEST, V51, P2009, DOI 10.1172/JCI107007; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Spandau UHM, 2003, ARCH OPHTHALMOL-CHIC, V121, P825, DOI 10.1001/archopht.121.6.825; Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; Tomobe YI, 2000, LIPIDS, V35, P61, DOI 10.1007/s11745-000-0495-0; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vance RE, 2004, P NATL ACAD SCI USA, V101, P2135, DOI 10.1073/pnas.0307308101; VERBEY NLJ, 1990, INVEST OPHTH VIS SCI, V31, P1526; WEIMAR V, 1957, J EXP MED, V105, P141, DOI 10.1084/jem.105.2.141	71	236	265	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15267	15278		10.1074/jbc.M410638200	http://dx.doi.org/10.1074/jbc.M410638200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708862	hybrid			2022-12-27	WOS:000228236800112
J	Kneass, ZT; Marchase, RB				Kneass, ZT; Marchase, RB			Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; PLATELET-ACTIVATING-FACTOR; PANCREATIC BETA-CELLS; P38 MAP KINASE; INSULIN-RESISTANCE; SMOOTH-MUSCLE; NUCLEOCYTOPLASMIC PROTEINS; HEXOSAMINE PATHWAY; MURINE NEUTROPHILS; POTENTIAL ROLE	The modification of serine/threonine residues on cytoplasmic and nuclear proteins by N-acetylglucosamine (O-GlcNAc) is suggested to play a role in the regulation of a variety of signal transduction pathways. We have previously shown that glucosamine (GlcNH(2)), a metabolic precursor of O-GlcNAcylation, increases O-GlcNAc and enhances motility in neutrophils. Here, we extend this correlation by showing that a mechanistically distinct means of increasing O-GlcNAc, achieved by inhibition of O-GlcNAc removal with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), increases basal cellular motility and directional migration induced by the chemoattractant formyl-methionine-leucine-phenylalanine ( fMLP). Furthermore, we demonstrate that O- GlcNAc modulates the activities of signaling intermediates known to regulate neutrophil movement. GlcNH(2) and PUGNAc increase both the basal and fMLP-induced activity of a central mediator of cellular motility, the small GTPase Rac. Phosphoinositide 3-kinase, an important regulator of Rac activity and neutrophil motility, is shown to regulate the signaling pathway on which GlcNH(2) and PUGNAc act. Rac is an important upstream regulatory element in p38 and p44/42 mitogen-activated protein kinase ( MAPK) signaling in neutrophils, and these MAPKs are implicated in chemotactic signal transduction. We show that GlcNH(2) and PUGNAc treatment increases p42/44 and p38 MAPK activities and that these increases are associated with activation of upstream MAPK kinases. These data indicate that O-GlcNAcylation is an important signaling element in neutrophils that modulates the activities of several critical signaling intermediates involved in the regulation of cellular movement.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Marchase, RB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 690, Birmingham, AL 35294 USA.	rbmarchase@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055647] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55647] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreozzi F, 2004, ENDOCRINOLOGY, V145, P2845, DOI 10.1210/en.2003-0939; Anello M, 2004, AM J PHYSIOL-ENDOC M, V287, pE602, DOI 10.1152/ajpendo.00320.2003; Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Burt DJ, 2003, DIABETOLOGIA, V46, P531, DOI 10.1007/s00125-003-1075-y; Campbell M, 2004, CIRC RES, V95, P380, DOI 10.1161/01.RES.0000138019.82184.5d; Coffer PJ, 1998, BIOCHEM J, V329, P121; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Coxon PY, 2003, CELL SIGNAL, V15, P993, DOI 10.1016/S0898-6568(03)00074-3; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; ERIKSSON G, 1984, ARCH BIOCHEM BIOPHYS, V235, P692, DOI 10.1016/0003-9861(84)90245-5; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; Fujita T, 2005, CELL SIGNAL, V17, P167, DOI 10.1016/j.cellsig.2004.06.008; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hannigan M, 2001, J LEUKOCYTE BIOL, V69, P497; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hii CS, 2004, J BIOL CHEM, V279, P49825, DOI 10.1074/jbc.M406892200; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; Hirano S, 2004, CELL STRESS CHAPERON, V9, P29, DOI 10.1379/1466-1268(2004)009<0029:HRFAMA>2.0.CO;2; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Hsieh TJ, 2003, ENDOCRINOLOGY, V144, P4338, DOI 10.1210/en.2003-0220; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kawamura H, 2004, ARTERIOSCL THROM VAS, V24, P276, DOI 10.1161/01.ATV.0000112012.33770.2a; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kneass ZT, 2004, J BIOL CHEM, V279, P45759, DOI 10.1074/jbc.M407911200; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehman JA, 2001, AM J PHYSIOL-CELL PH, V280, pC183, DOI 10.1152/ajpcell.2001.280.1.C183; Li SJ, 2002, J IMMUNOL, V169, P5043, DOI 10.4049/jimmunol.169.9.5043; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Marshall S, 2004, J BIOL CHEM, V279, P35313, DOI 10.1074/jbc.M404133200; Nagata T, 2001, BRIT J ANAESTH, V86, P853, DOI 10.1093/bja/86.6.853; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; OKADA T, 1994, J BIOL CHEM, V269, P3563; Okuyama R, 2001, BIOCHEM BIOPH RES CO, V287, P366, DOI 10.1006/bbrc.2001.5607; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sun CX, 2004, BLOOD, V104, P3758, DOI 10.1182/blood-2004-03-0781; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang CJ, 2002, J IMMUNOL, V169, P415, DOI 10.4049/jimmunol.169.1.415; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Wu Y, 2004, BIOCHEM BIOPH RES CO, V316, P666, DOI 10.1016/j.bbrc.2004.02.107; Yao PJ, 1998, J NEUROSCI, V18, P2399; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zu YL, 1998, J IMMUNOL, V160, P1982	85	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14579	14585		10.1074/jbc.M414066200	http://dx.doi.org/10.1074/jbc.M414066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703172	hybrid			2022-12-27	WOS:000228236800030
J	Zampieri, N; Xu, CF; Neubert, TA; Chao, MV				Zampieri, N; Xu, CF; Neubert, TA; Chao, MV			Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-ECTODOMAIN; NOGO RECEPTOR; CELL-SURFACE; DEATH DOMAIN; IN-VITRO; TNF; METALLOPROTEASE; PROTEOLYSIS; P75(NTR)	The p75 neurotrophin receptor (p75(NTR)), a member of the tumor necrosis factor superfamily of receptors, undergoes multiple proteolytic cleavage events. These events are initiated by an alpha-secretase-mediated release of the extracellular domain followed by a gamma-secretase-mediated intramembrane cleavage. However, the specific determinants of p75(NTR) cleavage events are unknown. Many other substrates of gamma-secretase cleavage have been identified, including Notch, amyloid precursor protein, and ErbB4, indicating there is broad substrate recognition by gamma-secretase. Using a series of deletion mutations and chimeric receptors of p75(NTR) and the related Fas receptor, we have identified domains that are essential for p75(NTR) proteolysis. The initial alpha-secretase cleavage was extracellular to the transmembrane domain. Unfortunately, deletion mutants were not capable of defining the requirements of ectodomain shedding. Although this cleavage is promiscuous with respect to amino acid sequence, its position with respect to the transmembrane domain is invariant. The generation of chimeric receptors exchanging different domains of noncleavable Fas receptor with p75(NTR), however, revealed that a discrete domain above the membrane is sufficient for efficient cleavage of p75(NTR). Mass spectrometric analysis confirmed the cleavage can occur with a truncated p75(NTR) displaying only 15 extracellular amino acids in the stalk region.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Chao, MV (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu		Chao, Moses/0000-0002-6969-3744; Zampieri, Niccolo/0000-0002-2228-9453	NCI NIH HHS [CA56490] Funding Source: Medline; NCRR NIH HHS [S10 RR01-7990] Funding Source: Medline; NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BANDTLOW C, 2004, SCI STKE, V235, pPE24; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DISTEFANO PS, 1990, BRAIN RES, V534, P340, DOI 10.1016/0006-8993(90)90154-4; DISTEFANO PS, 1988, J NEUROSCI, V8, P231; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Frade JM, 1996, NATURE, V383, P166; GALARDY RE, 1994, CANCER RES, V54, P4715; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; KLEITMAN N, 1991, CULTURING NERVE CELL; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; LEMKE G, 1988, DEVELOPMENT, V102, P499; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200	47	82	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14563	14571		10.1074/jbc.M412957200	http://dx.doi.org/10.1074/jbc.M412957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701642	hybrid			2022-12-27	WOS:000228236800028
J	Ait-Mamar, B; Cailleret, M; Rucker-Martin, C; Bouabdallah, A; Candiani, G; Adamy, C; Duvaldestin, P; Pecker, F; Defer, N; Pavoine, C				Ait-Mamar, B; Cailleret, M; Rucker-Martin, C; Bouabdallah, A; Candiani, G; Adamy, C; Duvaldestin, P; Pecker, F; Defer, N; Pavoine, C			The cytosolic phospholipase A(2) pathway, a safeguard of beta(2)-adrenergic cardiac effects in rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT ATRIAL MYOCYTES; ARACHIDONIC-ACID PATHWAY; NITRIC-OXIDE; G-PROTEIN; PHOSPHOLAMBAN PHOSPHORYLATION; VENTRICULAR CARDIOMYOCYTES; PHYSIOLOGICAL RELEVANCE; SARCOPLASMIC-RETICULUM; CAVEOLAE MICRODOMAINS; ADENYLYL-CYCLASE	We have recently demonstrated that in human heart, beta(2)-adrenergic receptors (beta(2)-ARs) are biochemically coupled not only to the classical adenylyl cyclase (AC) pathway but also to the cytosolic phospholipase A(2) (cPLA(2)) pathway (Pavoine, C., Behforouz, N., Gauthier, C., Le Gouvello, S., Roudot-Thoraval, F., Martin, C. R., Pawlak, A., Feral, C., Defer, N., Houel, R., Magne, S., Amadou, A., Loisance, D., Duvaldestin, P., and Pecker, F. (2003) Mol. Pharmacol. 64, 1117-1125). In this study, using Fura-2-loaded cardiomyocytes isolated from adult rats, we showed that stimulation of beta(2)-ARs triggered an increase in the amplitude of electrically stimulated [Ca2+](i) transients and contractions. This effect was abolished with the PKA inhibitor, H89, but greatly enhanced upon addition of the selective cPLA(2) inhibitor, AACOCF(3). The beta(2)-AR/cPLA(2) inhibitory pathway involved G(i) and MSK1. Potentiation of beta(2)-AR/AC/PKA-induced Ca2+ responses by AACOCF3 did not rely on the enhancement of AC activity but was associated with eNOS phosphorylation (Ser(1177)) and L-NAME-sensitive NO production. This was correlated with PKA-dependent phosphorylation of PLB (Ser(16)). The constraint exerted by the beta(2)-AR/cPLA(2) pathway on the beta(2)-AR/AC/PKA-induced Ca2+ responses required integrity of caveolar structures and was impaired by Filipin III treatment. Immunoblot analyses demonstrated zinterol-induced translocation of cPLA(2) and its cosedimentation with MSK1, eNOS, PLB, and sarcoplasmic reticulum Ca2+ pump (SERCA) 2a in a low density caveolin-3-enriched membrane fraction. This inferred the gathering of beta(2)-AR signaling effectors around caveolae/sarcoplasmic reticulum (SR) functional platforms. Taken together, these data highlight cPLA(2) as a cardiac beta(2)-AR signaling pathway that limits beta(2)-AR/AC/PKA-induced Ca2+ responses in adult rat cardiomyocytes through the impairment of eNOS activation and PLB phosphorylation.	Univ Paris 12, INSERM, U581, F-94010 Creteil, France; Hop Henri Mondor, Serv Anesthesie & Reanimat, F-94010 Creteil, France; Hop Marie Lannelongue, CNRS, UMR 8078, F-92350 Le Plessis Robinson, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Pavoine, C (corresponding author), Hop Henri Mondor, INSERM, U581, F-94010 Creteil, France.	pavoine@im3.inserm.fr	Candiani, Gabriele/A-9744-2009; Pavoine, Catherine/N-4405-2018	Candiani, Gabriele/0000-0003-0575-068X; Pavoine, Catherine/0000-0002-0598-5545; Rucker-Martin, Catherine/0000-0002-1593-7432				Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001; Bergdahl A, 2004, CAN J PHYSIOL PHARM, V82, P289, DOI 10.1139/Y04-033; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Bolte S, 2004, J CELL SCI, V117, P943, DOI 10.1242/jcs.00920; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brodde OE, 1999, PHARMACOL REV, V51, P651; Brown WJ, 2003, TRAFFIC, V4, P214, DOI 10.1034/j.1600-0854.2003.00078.x; Cailleret M, 2004, CIRCULATION, V109, P406, DOI 10.1161/01.CIR.0000109499.00587.FF; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dedkova EN, 2003, CIRC RES, V93, P1233, DOI 10.1161/01.RES.0000106133.92737.27; Dedkova EN, 2002, J PHYSIOL-LONDON, V542, P711, DOI 10.1113/jphysiol.2002.023341; DELCAYRE C, 1988, J CLIN INVEST, V82, P460, DOI 10.1172/JCI113619; Evans JH, 2004, J BIOL CHEM, V279, P6005, DOI 10.1074/jbc.M311246200; Foerster K, 2003, P NATL ACAD SCI USA, V100, P14475, DOI 10.1073/pnas.1936026100; Gaudreault SB, 2004, J BIOL CHEM, V279, P356, DOI 10.1074/jbc.M304777200; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hagemann D, 2002, TRENDS CARDIOVAS MED, V12, P51, DOI 10.1016/S1050-1738(01)00145-1; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; Harrison JG, 2004, BBA-MOL CELL RES, V1644, P17, DOI 10.1016/j.bbamcr.2003.10.008; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Jo SH, 2002, CIRC RES, V91, P46, DOI 10.1161/01.RES.0000024115.67561.54; JORGENSEN AO, 1982, J CELL BIOL, V93, P883, DOI 10.1083/jcb.93.3.883; Kuo KH, 2003, RESP PHYSIOL NEUROBI, V137, P197, DOI 10.1016/S1569-9048(03)00147-2; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Liggett SB, 2000, CIRCULATION, V101, P1707; Magne S, 2001, J BIOL CHEM, V276, P39539, DOI 10.1074/jbc.M100954200; Markou T, 2002, BIOCHEM J, V365, P757, DOI 10.1042/BJ20011828; Markou T, 2003, MOL CELL BIOCHEM, V242, P163, DOI 10.1023/A:1021110300652; Massion PB, 2003, J PHYSIOL-LONDON, V546, P63, DOI 10.1113/jphysiol.2002.025973; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; MERY PF, 1993, J BIOL CHEM, V268, P26286; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Palomba L, 2004, FREE RADICAL BIO MED, V36, P319, DOI 10.1016/j.freeradbiomed.2003.10.026; Pavoine C, 2005, CELL SIGNAL, V17, P141, DOI 10.1016/j.cellsig.2004.09.001; Pavoine C, 2003, MOL PHARMACOL, V64, P1117, DOI 10.1124/mol.64.5.1117; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Rucker-Martin C, 2002, CARDIOVASC RES, V55, P38, DOI 10.1016/S0008-6363(02)00338-3; Rybin VO, 2003, MOL PHARMACOL, V63, P1338, DOI 10.1124/mol.63.6.1338; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; Sauvadet A, 1996, CIRC RES, V78, P102, DOI 10.1161/01.RES.78.1.102; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Steinberg SF, 1999, CIRC RES, V85, P1101; Thomas MJ, 2003, J MOL CELL CARDIOL, V35, P1325, DOI 10.1016/j.yjmcc.2003.08.005; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Vangheluwe P, 2003, CELL CALCIUM, V34, P457, DOI 10.1016/S0143-4160(03)00126-X; Wang YG, 2002, J GEN PHYSIOL, V119, P69, DOI 10.1085/jgp.119.1.69; Xiao RP, 2004, J MOL CELL CARDIOL, V36, P7, DOI 10.1016/j.yjmcc.2003.10.013; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	66	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18881	18890		10.1074/jbc.M410305200	http://dx.doi.org/10.1074/jbc.M410305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728587	hybrid			2022-12-27	WOS:000228932300040
J	Banno, T; Gazel, A; Blumenberg, M				Banno, T; Gazel, A; Blumenberg, M			Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; SKIN-CANCER; TNF-ALPHA; IKK-ALPHA; APOPTOSIS; KINASE; DISEASE; COMPLEX	Identification of tumor necrosis factor alpha (TNF alpha) as the key agent in inflammatory disorders led to new therapies specifically targeting TNF alpha and avoiding many side effects of earlier anti-inflammatory drugs. However, because of the wide spectrum of systems affected by TNF alpha, drugs targeting TNF alpha have a potential risk of delaying wound healing, secondary infections, and cancer. Indeed, increased risks of tuberculosis and carcinogenesis have been reported as side effects after anti-TNF alpha therapy. TNF alpha regulates many processes (e.g. immune response, cell cycle, and apoptosis) through several signal transduction pathways that convey the TNF alpha signals to the nucleus. Hypothesizing that specific TNF alpha-dependent pathways control specific processes and that inhibition of a specific pathway may yield even more precisely targeted therapies, we used oligonucleotide microarrays and parthenolide, an NF-kappa B-specific inhibitor, to identify the NF-kappa B-dependent set of the TNF alpha-regulated genes in human epidermal keratinocytes. Expression of similar to 40% of all TNF alpha-regulated genes depends on NF-kappa B; 17% are regulated early (1-4 h post-treatment), and 23% are regulated late (24-48 h). Cytokines and apoptosis-related and cornification proteins belong to the "early" NF-kappa B-dependent group, and antigen presentation proteins belong to the "late" group, whereas most cell cycle, RNA-processing, and metabolic enzymes are not NF-kappa B-dependent. Therefore, inflammation, immunomodulation, apoptosis, and differentiation are on the NF-kappa B pathway, and cell cycle, metabolism, and RNA processing are not. Most early genes contain consensus NF-kappa B binding sites in their promoter DNA and are, presumably, directly regulated by NF-kappa B, except, curiously, the cornification markers. Using siRNA silencing, we identified cFLIP/CFLAR as an essential NF-kappa B-dependent antiapoptotic gene. The results confirm our hypothesis, suggesting that inhibiting a specific TNF alpha-dependent signaling pathway may inhibit a specific TNF alpha-regulated process, leaving others unaffected. This could lead to more specific anti-inflammatory agents that are both more effective and safer.	NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY USA; Univ Tsukuba, Inst Clin Med, Dept Dermatol, Ibaraki 3058575, Japan	New York University; New York University; New York University; University of Tsukuba	Blumenberg, M (corresponding author), NYU, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu		Blumenberg, Miroslav/0000-0002-8672-7774	NIAMS NIH HHS [AR41850] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi M, 2003, DNA CELL BIOL, V22, P665, DOI 10.1089/104454903770238148; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152; Banno T, 2003, ANTIVIR THER, V8, P541; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1996, SCIENCE, V274, P784; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Kataoka T, 1998, J IMMUNOL, V161, P3936; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Legg J, 2003, DEVELOPMENT, V130, P6049, DOI 10.1242/dev.00837; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lind MH, 2004, P NATL ACAD SCI USA, V101, P4972, DOI 10.1073/pnas.0307106101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McDermott MF, 2001, CELL MOL BIOL, V47, P619; Nahar IK, 2003, ANN PHARMACOTHER, V37, P1256, DOI 10.1345/aph.1C039; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wolf R, 2002, CLIN DERMATOL, V20, P522, DOI 10.1016/S0738-081X(02)00273-0; Won YK, 2004, CARCINOGENESIS, V25, P1449, DOI 10.1093/carcin/bgh151; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	44	84	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18973	18980		10.1074/jbc.M411758200	http://dx.doi.org/10.1074/jbc.M411758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15722350	hybrid			2022-12-27	WOS:000228932300051
J	Zhang, W; Zheng, SS; Storz, P; Min, W				Zhang, W; Zheng, SS; Storz, P; Min, W			Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP PHOSPHORYLATION; NF-KAPPA-B; INDUCED ASK1 ACTIVATION; D-DEPENDENT ACTIVATION; OXIDATIVE STRESS; CELL-DEATH; ASK1-MEDIATED APOPTOSIS; INDEPENDENT MANNER; ENDOTHELIAL-CELLS; INHIBITOR 14-3-3	Although both tumor necrosis factor (TNF) and H2O2 induce activation of c-Jun N-terminal kinase (JNK) kinase cascades, it is not known whether they utilize distinct intracellular signaling pathways. In this study, we first examined a variety of pharmacological inhibitors on TNF and H2O2-induced JNK activation. Go6983 or staurosporine, which inhibits protein kinase C isoforms had no effects on TNF or H2O2-induced JNK activation. However, Go6976 and calphostin, which can inhibit protein kinase C as well as protein kinase D (PKD), blocked H2O2- but not TNF-induced JNK activation, suggesting that PKD may be specifically involved in H2O2-induced JNK activation. Consistently, H2O2, but not TNF, induced phosphorylation of PKD and translocation of PKD from endothelial cell membrane to cytoplasm where it associates with the JNK upstream activator, apoptosis signal-regulating kinase 1 (ASK1). The association is mediated through the pleckstrin homology domain of PKD and the C-terminal domain of ASK1. Inhibition of PKD by Go6976 or by small interfering RNA of PKD blocked H2O2-induced ASK1-JNK activation and endothelial cell apoptosis. Interestingly, H2O2 induced 14-3-3 binding to PKD via the phospho-Ser-205/208 and phospho-Ser-219/223 and H2O2-induced 14-3-3 binding of PKD was specifically blocked by Go6976 but not by Go6983. More significantly, the 14-3-3-binding defective forms of PKD failed to associate with ASK1 and to activate JNK signaling, highlighting the importance of 143-3 binding of PKD in H2O2-induced activation of ASK1-JNK cascade. Thus, our data have identified PKD as a critical mediator in H2O2- but not TNF-induced ASK1-JNK signaling.	Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdisciplinary Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Zhejiang Univ, Coll Med, Affiliated Hosp 1,Minist Hlth China, Key Lab Combined Multiorgan Transplantat, Hangzhou 310003, Peoples R China; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Yale University; Zhejiang University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdisciplinary Program Vasc Biol & Transplanta, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL65978-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	33	80	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19036	19044		10.1074/jbc.M414674200	http://dx.doi.org/10.1074/jbc.M414674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755722	hybrid			2022-12-27	WOS:000228932300059
J	Alvarez-Fernandez, M; Liang, YH; Abrahamson, M; Su, XD				Alvarez-Fernandez, M; Liang, YH; Abrahamson, M; Su, XD			Crystal structure of human cystatin D, a cysteine peptidase inhibitor with restricted inhibition profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; EGG-WHITE CYSTATIN; N-TERMINAL SEGMENT; PROTEINASE-INHIBITOR; CATHEPSIN-B; CHICKEN CYSTATIN; ASPARAGINYL ENDOPEPTIDASE; PORPHYROMONAS-GINGIVALIS; MAMMALIAN LEGUMAIN; STEFIN-A	Cystatins are natural inhibitors of papain-like (family C1) and legumain-related (family C13) cysteine peptidases. Cystatin D is a type 2 cystatin, a secreted inhibitor found in human saliva and tear fluid. Compared with its homologues, cystatin D presents an unusual inhibition profile with a preferential inhibition cathepsin S > cathepsin H > cathepsin L and no inhibition of cathepsin B or pig legumain. To elucidate the structural reasons for this specificity, we have crystallized recombinant human Arg(26)-cystatin D and solved its structures at room temperature and at cryo conditions to 2.5- and 1.8-angstrom resolution, respectively. Human cystatin D presents the typical cystatin fold, with a five-stranded anti-parallel beta-sheet wrapped around a five-turn alpha-helix. The structures reveal differences in the peptidase-interacting regions when compared with other cystatins, providing plausible explanations for the restricted inhibitory specificity of cystatin D for some papain-like peptidases and its lack of reactivity toward legumain-related enzymes.	Lund Univ, Dept Clin Chem, Inst Lab Med, SE-22185 Lund, Sweden; Peking Univ, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China; Ctr Chem & Chem Engn, Dept Mol Biophys, SE-22100 Lund, Sweden	Lund University; Peking University	Abrahamson, M (corresponding author), Lund Univ, Dept Clin Chem, Inst Lab Med, SE-22185 Lund, Sweden.	Magnus.Abrahamson@klinkem.lu.se; su-xd@pku.edu.cn	, LiangYH/B-6704-2012; Abrahamson, Magnus/CAG-9507-2022					ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BALBIN M, 1994, J BIOL CHEM, V269, P23156; BALBIN M, 1993, HUM GENET, V90, P668; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bjork I, 1996, BIOCHEMISTRY-US, V35, P10720, DOI 10.1021/bi960420u; BJORK I, 1995, BIOCHEM J, V306, P513; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BODE W, 1990, BIOL CHEM H-S, V371, P111; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; CUDNEY B, 1994, ACTA CRYSTALLOGR D, V50, P414, DOI 10.1107/S0907444994002660; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; LINDAHL P, 1992, BIOCHEM J, V286, P165, DOI 10.1042/bj2860165; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; MARTIN JR, 1995, J MOL BIOL, V246, P331, DOI 10.1006/jmbi.1994.0088; Mason RW, 1998, BIOCHEM J, V330, P833; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagata K, 2000, BIOCHEMISTRY-US, V39, P14753, DOI 10.1021/bi0006971; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nycander M, 1998, FEBS LETT, V422, P61, DOI 10.1016/S0014-5793(97)01604-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; PIKE R, 1994, J BIOL CHEM, V269, P406; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x	53	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18221	18228		10.1074/jbc.M411914200	http://dx.doi.org/10.1074/jbc.M411914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728581	Green Submitted, hybrid			2022-12-27	WOS:000228807200080
J	Biswal, BK; Cherney, MM; Wang, MT; Chan, L; Yannopoulos, CG; Bilimoria, D; Nicolas, O; Bedard, J; James, MNG				Biswal, BK; Cherney, MM; Wang, MT; Chan, L; Yannopoulos, CG; Bilimoria, D; Nicolas, O; Bedard, J; James, MNG			Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HCVNS5B POLYMERASE; THIOPHENE-2-CARBOXYLIC ACIDS; REVERSE-TRANSCRIPTASE; POTENT INHIBITORS; IDENTIFICATION; SITE; PROGRAM; REPLICATION; DISCOVERY; COMPLEX	Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus (HCV) from two crystal forms have been determined. Similar to the three-dimensional structures of HCV polymerase genotype 1b and other known polymerases, the structures of the HCV polymerase genotype 2a in both crystal forms can be depicted in the classical right-hand arrangement with fingers, palm, and thumb domains. The main structural differences between the molecules in the two crystal forms lie at the interface of the fingers and thumb domains. The relative orientation of the thumb domain with respect to the fingers and palm domains and the beta-flap region is altered. Structural analysis reveals that the NS5B polymerase in crystal form I adopts a "closed" conformation that is believed to be the active form, whereas NS5B in crystal form II adopts an "open" conformation and is thus in the inactive form. In addition, we have determined the structures of two NS5B polymerase/ non-nucleoside inhibitor complexes. Both inhibitors bind at a common binding site, which is nearly 35 angstrom away from the polymerase active site and is located in the thumb domain. The binding pocket is predominantly hydrophobic in nature, and the enzyme inhibitor complexes are stabilized by hydrogen bonding and van der Waals interactions. Inhibitors can only be soaked in crystal form I and not in form II; examination of the enzyme-inhibitor complex reveals that the enzyme has undergone a dramatic conformational change from the form I ( active) complex to the form II ( inactive).	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; ViroChem Pharma Inc, Laval, PQ H7V 4A7, Canada	University of Alberta	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Michael.james@ualberta.ca	Wang, Meitian/D-3208-2013	Biswal, Bichitra/0000-0002-5927-3244; Wang, Meitian/0000-0002-5340-3036				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Alaoui-Ismaili MH, 2000, J HUMAN VIROL, V3, P306; Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chan L, 2004, BIOORG MED CHEM LETT, V14, P793, DOI 10.1016/j.bmcl.2003.10.067; Chan L, 2004, BIOORG MED CHEM LETT, V14, P797, DOI 10.1016/j.bmcl.2003.10.068; Chan L, 2003, J MED CHEM, V46, P1283, DOI 10.1021/jm0340400; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; DeLano WL, 2002, PYMOL USERS MANUAL; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hagedorn CH, 2000, CURR TOP MICROBIOL, V242, P225; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg C A, 2000, Curr Opin Investig Drugs, V1, P289; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Love RA, 2003, J VIROL, V77, P7575, DOI 10.1128/JVI.77.13.7575-7581.2003; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200	35	170	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18202	18210		10.1074/jbc.M413410200	http://dx.doi.org/10.1074/jbc.M413410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746101	hybrid			2022-12-27	WOS:000228807200078
J	Langlois, MA; Boniface, C; Wang, G; Alluin, J; Salvaterra, PM; Puymirat, J; Rossi, JJ; Lee, NS				Langlois, MA; Boniface, C; Wang, G; Alluin, J; Salvaterra, PM; Puymirat, J; Rossi, JJ; Lee, NS			Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEAT; ARGONAUTE FAMILY; MAMMALIAN-CELLS; GENE DELIVERY; PROTEIN; TRANSCRIPTS; EXPRESSION; LOCALIZATION; ELEGANS; BINDING	Small interfering RNA ( siRNA) duplexes induce the specific cleavage of target RNAs in mammalian cells. Their involvement in down-regulation of gene expression is termed RNA interference (RNAi). It is widely believed that RNAi predominates in the cytoplasm. We report here the co-existence of cytoplasmic and nuclear RNAi phenomena in primary human myotonic dystrophy type 1 (DM1) cells by targeting myotonic dystrophy protein kinase ( DMPK) mRNAs. Heterozygote DM1 myoblasts from a human DM1 fetus produce a nuclear retained mutant DMPK transcript with large CUG repeats ( similar to 3,200) from one allele of the DMPK gene and a wild type transcript with 18 CUG repeats, thus providing for both a nuclear and cytoplasmic expression profile to be evaluated. We demonstrate here for the first time downregulation of the endogenous nuclear retained mutant DMPK mRNAs targeted with lentivirus-delivered short hairpin RNAs (shRNAs). This nuclear RNAi(-like) phenomenon was not observed when synthetic siRNAs were delivered by cationic lipids, suggesting either a link between processing of the shRNA and nuclear import or a separate pathway for processing shRNAs in the nuclei. Our observation of simultaneous RNAi on both cytoplasmic and nuclear retained DMPK has important implications for post-transcriptional gene regulation in both compartments of mammalian cells.	City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Grad Sch Biol Sci, Duarte, CA 91010 USA; Univ Laval, Med Res Ctr, Lab Human Genet, CHUQ, Ste Foy, PQ G1V 7P4, Canada	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Laval University	Lee, NS (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA.	nlee@coh.org	Langlois, Marc-Andre/J-2103-2012	Langlois, Marc-Andre/0000-0003-4652-3029				Astriab-Fisher A, 2004, BIOCHEM PHARMACOL, V68, P403, DOI 10.1016/j.bcp.2004.03.040; Bosher JM, 1999, GENETICS, V153, P1245; BROOK, 1992, CELL, V69, P385; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DESHAYES S, 1967, BIOCHIM BIOPHYS ACTA, P141; Dudley NR, 2003, CURR OPIN MOL THER, V5, P113; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fardaei M, 2001, NUCLEIC ACIDS RES, V29, P2766, DOI 10.1093/nar/29.13.2766; Furling D, 2001, NEUROMUSCULAR DISORD, V11, P728, DOI 10.1016/S0960-8966(01)00226-7; Furling D, 2003, AM J PATHOL, V162, P1001, DOI 10.1016/S0002-9440(10)63894-1; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Langlois MA, 2003, MOL THER, V7, P670, DOI 10.1016/S1525-0016(03)00068-6; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Mankodi A, 2002, CURR OPIN NEUROL, V15, P545, DOI 10.1097/00019052-200210000-00005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Shinagawa T, 2003, GENE DEV, V17, P1340, DOI 10.1101/gad.1073003; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Taneja KL, 1998, BIOTECHNIQUES, V24, P472, DOI 10.2144/98243rr02; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Waddington SN, 2003, GENE THER, V10, P1234, DOI 10.1038/sj.gt.3301991; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071	35	92	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16949	16954		10.1074/jbc.M501591200	http://dx.doi.org/10.1074/jbc.M501591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722335	hybrid			2022-12-27	WOS:000228615500050
J	Rauch, BH; Millette, E; Kenagy, RD; Daum, G; Fischer, JW; Clowes, AW				Rauch, BH; Millette, E; Kenagy, RD; Daum, G; Fischer, JW; Clowes, AW			Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-C; EGF RECEPTOR TRANSACTIVATION; FOCAL ADHESION FORMATION; CYTOPLASMIC DOMAIN; ALPHA; ATHEROSCLEROSIS; PROTEOGLYCANS; MODULATION; ACTIVATION	Thrombin is a mitogen and chemoattractant for vascular smooth muscle cells (SMCs) and may contribute to vascular lesion formation. We have previously shown that human SMCs, when stimulated with thrombin, release basic fibroblast growth factor ( bFGF), causing phosphorylation of FGF receptor-1 (FGFR-1). Treatment with bFGF-neutralizing antibodies (anti-bFGF) or heparin inhibits thrombin-induced DNA synthesis. We concluded that thrombin may stimulate entry into the cell cycle via bFGF release and FGFR-1 activation. In the present study, we demonstrate a requirement for not only FGFR-1 but also syndecan-4, a transmembrane heparan-sulfate proteoglycan. Inhibition of syndecan-4 expression using small interfering RNA ( siRNA) resulted in reduced DNA synthesis by human SMCs after stimulation with thrombin ( 10 nmol/liter). Anti-bFGF antibody, which inhibits DNA synthesis in control cells, had no inhibitory effect when syndecan-4 expression was reduced by siRNA. Thrombin- or bFGF-induced SMC migration, determined in Boyden chamber assays, was reduced in cells treated with syndecan-4 or FGFR-1 siRNA or by anti-bFGF. Thrombin induced phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in a biphasic pattern. Although thrombin-mediated ERK phosphorylation at 5 min was not affected by syndecan-4 or FGFR-1 siRNA, ERK phosphorylation at later time points was reduced. We conclude that thrombin-released bFGF binds to syndecan-4 and FGFR-1, which is required for thrombin-induced mitogenesis and migration.	Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Rauch, BH (corresponding author), Univ Klinikum Dusseldorf, Inst Pharmakol & Klin Pharmakol, Univ Str1, D-40225 Dusseldorf, Germany.	rauchb@uni-duesseldorf.de	Rauch, Bernhard/Q-6205-2018	Rauch, Bernhard/0000-0002-6003-4662; Kenagy, Richard/0000-0002-2021-5565	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bellin R, 2002, GLYCOCONJUGATE J, V19, P295, DOI 10.1023/A:1025352501148; Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082; Debey S, 2003, BIOCHEM PHARMACOL, V65, P979, DOI 10.1016/S0006-2952(02)01661-1; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Longley RL, 1999, J CELL SCI, V112, P3421; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wilcox-Adelman SA, 2002, GLYCOCONJUGATE J, V19, P305, DOI 10.1023/A:1025304602057; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4	29	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17507	17511		10.1074/jbc.M410848200	http://dx.doi.org/10.1074/jbc.M410848200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731100	hybrid			2022-12-27	WOS:000228615500118
J	Jin, ZJ; Xin, MG; Deng, XM				Jin, ZJ; Xin, MG; Deng, XM			Survival function of protein kinase C iota as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated Bad kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; LUNG-CARCINOMA CELLS; SRC TYROSINE KINASE; BH3 DOMAIN; PHOSPHORYLATION; PATHWAY; DEATH; NICOTINE; RECEPTOR; CANCER	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is formed by nitrosation of nicotine and has been identified as the most potent carcinogen in cigarette smoke. NNK cannot only induce DNA damage but also promotes the survival of human lung cancer cells. Protein kinase C (PKC) iota is an atypical PKC isoform and plays an important role in cell survival, but the downstream survival substrate(s) is not yet identified. Bad, a proapoptotic BH3-only member of Bcl2 family, is co-expressed with PKC iota in both small cell lung cancer and non-small cell lung cancer cells. We discovered that NNK potently induces multisite Bad phosphorylation at Ser-112, Ser-136, and Ser-155 via activation of PKC iota in association with increased survival of human lung cancer cells. Purified, active PKC iota can directly phosphorylate both endogenous and recombinant Bad at these three sites and disrupt Bad/Bcl-XL binding in vitro. Overexpression of PKC iota results in an enhancement of Bad phosphorylation. NNK also stimulates activation of c-Src, which is a known PKC iota upstream kinase. Treatment of cells with the PKC inhibitor (staurosporine) or a Src-specific inhibitor (PP2) can block NNK-induced Bad phosphorylation and promote apoptotic cell death. The beta-adrenergic receptor inhibitor propranolol blocks both NNK-induced activation of PKC iota and Bad phosphorylation, indicating that NNK-induced Bad phosphorylation occurs at least in part through the upstream beta-adrenergic receptor. Mechanistically, NNK-induced Bad phosphorylation prevents its interaction with Bcl-XL. Because the specific depletion of PKC iota by RNA interference inhibits both NNK-induced Bad phosphorylation and survival, this confirms that PKC iota is a necessary component in NNK-mediated survival signaling. Collectively, these findings reveal a novel role for PKC iota as an NNK-activated physiological Bad kinase that can directly phosphorylate and inactivate this proapoptotic BH3-only protein, which leads to enhanced survival and chemoresistance of human lung cancer cells.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAI-5562-2020; Jin, Zhaohui/AAQ-2893-2021	Jin, Zhaohui/0000-0001-7844-5833; 	NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112183-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; *AM CANC SOC, 2003, CANC FACTS FIG, P13; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang JY, 2004, J BIOL CHEM, V279, P21637, DOI 10.1074/jbc.M400956200; IKEGAKI N, 1994, CANCER RES, V54, P6; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Kelly A, 2001, J WOMEN HEALTH GEN-B, V10, P515, DOI 10.1089/15246090152543085; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; PARK PG, 1995, CANCER RES, V55, P3504; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schuller HM, 1999, CANCER RES, V59, P4510; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Suemaru K, 1997, N-S ARCH PHARMACOL, V355, P571, DOI 10.1007/PL00004985; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Trombino S, 2004, CANCER RES, V64, P135, DOI 10.1158/0008-5472.CAN-03-1672; Uchida S, 2002, AUTON NEUROSCI-BASIC, V96, P126, DOI 10.1016/S1566-0702(02)00004-8; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zheng TZ, 1996, INT J CANCER, V68, P172, DOI 10.1002/(SICI)1097-0215(19961009)68:2<172::AID-IJC5>3.0.CO;2-V; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	51	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16045	16052		10.1074/jbc.M413488200	http://dx.doi.org/10.1074/jbc.M413488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705582	hybrid			2022-12-27	WOS:000228444800072
J	Tran, NH; Wu, XC; Frost, JA				Tran, NH; Wu, XC; Frost, JA			B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; A-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE/THREONINE KINASE; ONCOGENIC MUTATIONS; NEGATIVE REGULATION; GROWTH-FACTOR; MAP KINASE; C-TERMINUS; SERINE 338	B-Raf is a key regulator of the ERK pathway and is mutationally activated in two-thirds of human melanomas. In this work, we have investigated the activation mechanism of B-Raf and characterized the roles of Ras and of B-Raf phosphorylation in this regulation. Raf-1 is regulated by an N-terminal autoinhibitory domain whose actions are blocked by interaction with Ras and subsequent phosphorylation of Ser(338). We observed that B-Raf also contains an N-terminal autoinhibitory domain and that the interaction of this domain with the catalytic domain was inhibited by binding to active H-Ras. However, unlike Raf-1, the phosphorylation of B-Raf at Ser(445) was constitutive and was only moderately increased by expression of constitutively active H-Ras or constitutively active PAK1. Ser(445) phosphorylation is important to the B-Raf activation mechanism, however, because mutation of this site to alanine increased the affinity of the regulatory domain for the catalytic domain and increased autoinhibition. Similarly, expression of constitutively active PAK1 also decreased autoinhibition. B-Raf autoinhibition was negatively regulated by acidic substitutions at phosphorylation sites within the activation loop of B-Raf and by the oncogenic substitution V599E. However, these substitutions did not affect the ability of the regulatory domain to co-immunoprecipitate with the catalytic domain. These data demonstrate that B-Raf activity is autoregulated, that constitutive phosphorylation of Ser(445) primes B-Raf for activation, and that a key feature of phosphorylation within the activation loop or of oncogenic mutations within this region is to block autoinhibition.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Frost, JA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	jeffrey.a.frost@uth.tmc.edu		Frost, Jeffrey/0000-0001-9722-1536				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Brose MS, 2002, CANCER RES, V62, P6997; Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dong JL, 2003, CANCER RES, V63, P3883; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Xu XL, 2003, CANCER RES, V63, P4561; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, EXP LUNG RES, V27, P269, DOI 10.1080/019021401300054046; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	50	100	107	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16244	16253		10.1074/jbc.M501185200	http://dx.doi.org/10.1074/jbc.M501185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710605	hybrid			2022-12-27	WOS:000228444800094
J	Balland, V; Bouzhir-Sima, L; Kiger, L; Marden, MC; Vos, MH; Liebl, U; Mattioli, TA				Balland, V; Bouzhir-Sima, L; Kiger, L; Marden, MC; Vos, MH; Liebl, U; Mattioli, TA			Role of arginine 220 in the oxygen sensor FixL from Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; LIGAND-BINDING; ESCHERICHIA-COLI; HEME DOMAIN; PAS DOMAINS; SIGNAL-TRANSDUCTION; CARBON-MONOXIDE; KINASE-ACTIVITY; PROTEIN; DOS	In the heme-based oxygen sensor protein FixL, conformational changes induced by oxygen binding to the heme sensor domain regulate the activity of a neighboring histidine kinase, eventually restricting expression of specific genes to hypoxic conditions. The conserved arginine 220 residue is suggested to play a key role in the signal transduction mechanism. To obtain detailed insights into the role of this residue, we replaced Arg(220) by histidine (R220H), glutamine (R220Q), glutamate (R220E), and isoleucine (R220I) in the heme domain FixLH from Bradyrhizobium japonicum. These mutations resulted in dramatic changes in the O-2 affinity with K-d values in the order R220I < R220Q < wild type < R220H. For the R220H and R220Q mutants, residue 220 interacts with the bound O-2 or CO ligands, as seen by resonance Raman spectroscopy. For the oxy-adducts, this H-bond modifies the pi acidity of the O-2 ligand, and its strength is correlated with the back-bonding-sensitive nu(4) frequency, the k(off) value for O-2 dissociation, and heme core-size conformational changes. This effect is especially strong for the wild-type protein where Arg(220) is, in addition, positively charged. These observations strongly suggest that neither strong ligand fixation nor the displacement of residue 220 into the heme distal pocket are solely responsible for the reported heme conformational changes associated with kinase activity regulation, but that a significant decrease of the heme pi* electron density because of strong back-bonding toward the oxygen ligand also plays a key role.	CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, Lab Biophys Stress Oxydant, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Ecole Polytech, CNRS, INSERM, U451,UMR 7645ENSTA,Lab Opt & Biosci, F-91128 Palaiseau, France; INSERM, U473, F-94275 Le Kremlin Bicetre, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mattioli, TA (corresponding author), CEA Saclay, Dept Biol Joliot Curie, Serv Bioenerget, Lab Biophys Stress Oxydant, F-91191 Gif Sur Yvette, France.	tony.mattioli@cea.fr	Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Balland, Véronique/AAD-7548-2022; Balland, Véronique/D-2479-2013	Marden, Michael C/0000-0002-5254-6385; Balland, Véronique/0000-0001-9534-9659; Vos, Marten/0000-0003-0493-4831; LIEBL, Ursula/0000-0003-0869-4388				Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DESBOIS A, 1989, INORG CHEM, V28, P825, DOI 10.1021/ic00304a007; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HIROTA S, 1994, J AM CHEM SOC, V116, P10564, DOI 10.1021/ja00102a025; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KERR EA, 1985, J BIOL CHEM, V260, P8360; LI T, 1994, BIOCHEMISTRY-US, V33, P1344; Liebl U, 2002, P NATL ACAD SCI USA, V99, P12771, DOI 10.1073/pnas.192311699; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Nellen-Anthamatten D, 1998, J BACTERIOL, V180, P5251, DOI 10.1128/JB.180.19.5251-5255.1998; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RAMDSEN J, 1989, BIOCHEMISTRY-US, V28, P3125; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Sciotti MA, 2003, J BACTERIOL, V185, P5639, DOI 10.1128/JB.185.18.5639-5642.2003; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Taguchi S, 2004, J BIOL CHEM, V279, P3340, DOI 10.1074/jbc.M301013200; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Tuckerman JR, 2002, BIOCHEMISTRY-US, V41, P6170, DOI 10.1021/bi025628w; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057	42	32	32	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15279	15288		10.1074/jbc.M413928200	http://dx.doi.org/10.1074/jbc.M413928200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711013	hybrid			2022-12-27	WOS:000228236800113
J	Doppler, H; Storz, P; Li, J; Comb, MJ; Toker, A				Doppler, H; Storz, P; Li, J; Comb, MJ; Toker, A			A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTACT-CELLS; ACTIVATION; PATHWAY; MOTIFS; IDENTIFICATION	The use of phosphorylation state-specific antibodies has revolutionized the field of cellular signaling by Ser/ Thr protein kinases. A more recent application of this technology is the development of phospho-specific antibodies that specifically recognize the consensus substrate phosphorylated motif of a given protein kinase. Here, we describe the development and use of such an antibody which is directed against the optimal phosphorylation motif of protein kinase D (PKD). A degenerate phosphopeptide library with fixed residues corresponding to the consensus LXR(Q/K/E/M)(M/L/K/E/Q/ A) S*XXXX was used as an antigen to generate an antibody that recognizes this motif. We characterized the antibody by enzyme-linked immunosorbent assay and with immobilized peptide arrays and also detected immunoreactive phosphoproteins in HeLa cells stimulated with agonists known to activate PKD. Silencing PKD expression using RNA interference validated the specificity of this antibody immunoreactive against putative substrates. The antibody also detected the PKD substrates RIN1 and HDAC5. Knowledge of the PKD consensus motif also enabled us to identify Ser(82) in the human heat shock protein Hsp27 as a novel substrate for PKD. We term this antibody anti-PKD pMOTIF and predict that it will enable the discovery of novel PKD substrate proteins in cells.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA; Cell Signaling Technol, Beverly, MA 01915 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Toker, A (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, 330 Brookline Ave,RN-237, Boston, MA 02215 USA.	atoker@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NCI NIH HHS [CA75134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MANNING BD, 2002, SCI STKE; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PERLMANN H, 1994, CELL BIOL LAB HDB; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou SY, 2001, METHOD ENZYMOL, V332, P171; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	23	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15013	15019		10.1074/jbc.C400575200	http://dx.doi.org/10.1074/jbc.C400575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15728188	hybrid			2022-12-27	WOS:000228236800083
J	Nie, LP; Feng, WH; Diaz, R; Gratton, MA; Doyle, KJ; Yamoah, EN				Nie, LP; Feng, WH; Diaz, R; Gratton, MA; Doyle, KJ; Yamoah, EN			Functional consequences of polyamine synthesis inhibition by L-alpha-difluoromethylornithine (DFMO) - Cellular mechanisms for DFMO-mediated ototoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; RECTIFIER K+ CHANNEL; COCHLEAR STRIA VASCULARIS; INNER-EAR; ORNITHINE-DECARBOXYLASE; NULL MUTATION; INWARD RECTIFICATION; TARGETED DISRUPTION; INTERMEDIATE CELLS; MARGINAL CELLS	L-alpha-Difluoromethylornithine (DFMO) is a chemopreventive agent for colon cancer in clinical trials. Yet, the drug produces an across-frequency elevation of the hearing threshold, suggesting that DFMO may affect a common trait along the cochlear spiral. The mechanism for the ototoxic effects of DFMO remains uncertain. The cochlear duct is exclusively endowed with endocochlear potential (EP). EP is a requisite for normal sound transduction, as it provides the electromotive force that determines the magnitude of the receptor potential of hair cells. EP is generated by the high throughput of K+ across cells of the stria vascularis, conferred partly by the activity of Kir4.1 channels. Here, we show that the ototoxicity of DFMO may be mediated by alteration of the inward rectification of Kir4.1 channels, resulting in a marked reduction in EP. These findings are surprising given that the present model for EP generation asserts that Kir4.1 confers the outflow of K+ in the stria vascularis. We have proposed an alternative model. These findings should also enable the rational design of new pharmaceuticals devoid of the untoward effect of DFMO.	Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, Davis, CA 95616 USA; Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	University of California System; University of California Davis; University of Pennsylvania	Yamoah, EN (corresponding author), Univ Calif Davis, Dept Otolaryngol, Ctr Neurosci, 1544 Newton Ct, Davis, CA 95616 USA.	enyamoah@ucdavis.edu			NIDCD NIH HHS [DC006442, DC007592, DC004523] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004523, R01DC006442, R01DC007592] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ando M, 1999, CELL TISSUE RES, V298, P179, DOI 10.1007/s004419900066; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bianchi L, 1996, J BIOL CHEM, V271, P6114, DOI 10.1074/jbc.271.11.6114; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; BROCK M, 1994, HEARING RES, V72, P37, DOI 10.1016/0378-5955(94)90203-8; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; COLQUHOUN D, 1995, SINGLE CHANNEL RECOR, P191; DALLOS P, 2001, COCHLEA, V8, P1; DAVIS H, 1957, PHYSIOL REV, V37, P1; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Dou HV, 2004, JARO-J ASSOC RES OTO, V5, P215, DOI 10.1007/s10162-003-4020-3; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle KJ, 2001, LARYNGOSCOPE, V111, P781, DOI 10.1097/00005537-200105000-00005; Doyle KJ, 2001, ARCH OTOLARYNGOL, V127, P553, DOI 10.1001/archotol.127.5.553; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Furuta H, 1998, HEARING RES, V123, P10, DOI 10.1016/S0378-5955(98)00091-4; Gratton M A, 1996, Hear Res, V102, P181, DOI 10.1016/S0378-5955(96)90017-9; Hayashi M, 2003, J PHYSIOL-LONDON, V547, P255, DOI 10.1113/jphysiol.2002.035857; HENLEY CM, 1995, HEARING RES, V84, P99, DOI 10.1016/0378-5955(95)00017-X; Hibino H, 1997, J NEUROSCI, V17, P4711; HILLE B, 1992, IONIC CHANNELS EXCIT, P131; Ishii M, 1997, J NEUROSCI, V17, P7725; Ishii M, 2003, AM J PHYSIOL-CELL PH, V285, pC260, DOI 10.1152/ajpcell.00560.2002; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kubo Y, 1996, J BIOL CHEM, V271, P15729, DOI 10.1074/jbc.271.26.15729; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Li LY, 2001, GLIA, V33, P57, DOI 10.1002/1098-1136(20010101)33:1<57::AID-GLIA1006>3.0.CO;2-0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Marcus DC, 2002, AM J PHYSIOL-CELL PH, V282, pC403, DOI 10.1152/ajpcell.00312.2001; MARKS SC, 1991, HEARING RES, V53, P230, DOI 10.1016/0378-5955(91)90057-G; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nicolas MT, 2003, HEARING RES, V181, P20, DOI 10.1016/S0378-5955(03)00162-X; NIE L, 2004, 27 ANN MIDW RES M AS; OFFNER FF, 1987, HEARING RES, V29, P117, DOI 10.1016/0378-5955(87)90160-2; Orias M, 1997, AM J PHYSIOL-RENAL, V273, pF663, DOI 10.1152/ajprenal.1997.273.4.F663; Pasic TR, 1997, ARCH OTOLARYNGOL, V123, P1281; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Rozengurt N, 2003, HEARING RES, V177, P71, DOI 10.1016/S0378-5955(02)00799-2; Sage CL, 2001, HEARING RES, V160, P1, DOI 10.1016/S0378-5955(01)00308-2; SALT AN, 1987, LARYNGOSCOPE, V97, P984; SALZER SJ, 1990, HEARING RES, V46, P101, DOI 10.1016/0378-5955(90)90143-D; Schmiedt RA, 2002, J NEUROSCI, V22, P9643; SCHULTE BA, 1992, HEARING RES, V61, P35, DOI 10.1016/0378-5955(92)90034-K; SEWELL WF, 1984, J PHYSIOL-LONDON, V347, P685, DOI 10.1113/jphysiol.1984.sp015090; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; STEEL KP, 1989, DEVELOPMENT, V107, P453; Tachibana M, 1999, PIGM CELL RES, V12, P344, DOI 10.1111/j.1600-0749.1999.tb00518.x; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Takeuchi S, 1996, HEARING RES, V101, P181, DOI 10.1016/S0378-5955(96)00151-7; Takeuchi S, 1998, NEUROSCI LETT, V247, P175, DOI 10.1016/S0304-3940(98)00318-8; Takeuchi S, 2000, BIOPHYS J, V79, P2572, DOI 10.1016/S0006-3495(00)76497-6; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; TASAKI I, 1959, J NEUROPHYSIOL, V22, P149, DOI 10.1152/jn.1959.22.2.149; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33	71	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15097	15102		10.1074/jbc.M409856200	http://dx.doi.org/10.1074/jbc.M409856200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15718247	hybrid			2022-12-27	WOS:000228236800092
J	Shi, DS; Morizono, H; Yu, XL; Roth, L; Caldovic, L; Allewell, NM; Malamy, MH; Tuchman, M				Shi, DS; Morizono, H; Yu, XL; Roth, L; Caldovic, L; Allewell, NM; Malamy, MH; Tuchman, M			Crystal structure of N-acetylornithine Transcarbamylase from Xanthomonas campestris - A novel enzyme in a new arginine biosynthetic pathway found in several eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE TRANSCARBAMYLASE; PROTEIN; PROGRAM	We have identified in Xanthomonas campestris a novel N-acetylornithine transcarbamylase that replaces ornithine transcarbamylase in the canonic arginine biosynthetic pathway of several Eubacteria. The crystal structures of the protein in the presence and absence of the reaction product, N-acetylcitrulline, were determined. This new family of transcarbamylases lacks the DxxSMG motif that is characteristic of all ornithine transcarbamylases (OTCases) and contains a novel proline-rich loop that forms part of the active site. The specificity for N-acetylornithine is conferred by hydrogen bonding with residues in the proline- rich loop via water molecules and by hydrophobic interactions with residues from the adjacent 80' s, 120' s, and proline- rich loops. This novel protein structure provides a starting point for rational design of specific analogs that may be useful in combating human and plant pathogens that utilize acetylornithine transcarbamylase rather than ornithine transcarbamylase.	Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Univ Maryland, Coll Life Sci, Dept Chem & Biochem, College Pk, MD 20742 USA	Children's National Health System; Tufts University; University System of Maryland; University of Maryland College Park	Shi, DS (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, 111 Michigan Ave NW, Washington, DC 20010 USA.	dshi@cnmcresearch.org	Morizono, Hiroki/E-9737-2013	Morizono, Hiroki/0000-0002-9678-5564; Shi, Dashuang/0000-0002-5491-1104; Caldovic, Ljubica/0000-0002-9140-5585	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047870, K01DK067935] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NICHD NIH HHS [HD-32652] Funding Source: Medline; NIDDK NIH HHS [DK-067935, DK-47870] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADFORD M, 1976, ANAL BIOCHEM, V72, P1219; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Massant J, 2003, ACTA CRYSTALLOGR D, V59, P2140, DOI 10.1107/S0907444903019231; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shi DS, 2002, J MOL BIOL, V320, P899, DOI 10.1016/S0022-2836(02)00539-9; Shi DS, 2001, BIOCHEM J, V354, P501, DOI 10.1042/0264-6021:3540501	19	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14366	14369		10.1074/jbc.C500005200	http://dx.doi.org/10.1074/jbc.C500005200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15731101	hybrid			2022-12-27	WOS:000228236800003
J	Hoffert, JD; Chou, CL; Fenton, RA; Knepper, MA				Hoffert, JD; Chou, CL; Fenton, RA; Knepper, MA			Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY ADENYLYL-CYCLASE; WATER CHANNELS; UREA TRANSPORTER; RAT-KIDNEY; KINASE-II; CELLS; CALCIUM; PHOSPHORYLATION; MEMBRANE; AQUAPORIN-2	Calmodulin plays a critical role in regulation of renal collecting duct water permeability by vasopressin. However, specific targets for calmodulin action have not been thoroughly addressed. In the present study, we investigated whether Ca2+/calmodulin regulates adenylyl cyclase activity in the renal inner medullary collecting duct. Rat inner medullary collecting duct suspensions were incubated in the presence or absence of 0.1 nM vasopressin and the calmodulin inhibitors, monodansylcadaverine, W-7, and trifluoperazine, followed by measurement of cAMP. Vasopressin-stimulated cAMP elevation was significantly attenuated in the presence of calmodulin inhibitors. Analysis of transglutaminase 2 knock-out mice confirmed that these compounds were not acting through inhibition of transglutaminase 2 activity. Calmodulin inhibitors also blocked both cholera toxin- and forskolin-stimulated cAMP accumulation. In isolated perfused tubules, W-7 reversibly blocked vasopressin-stimulated urea permeability, a process that requires a rise in intracellular cAMP but does not appear to involve protein trafficking to the apical plasma membrane. These results suggest that calmodulin is required for vasopressin-stimulated adenylyl cyclase activity in the intact inner medullary collecting duct. Reverse transcription-PCR, immunoblotting, and immunohistochemistry revealed the presence of the calmodulin-sensitive adenylyl cyclase type 3 in the rat collecting duct, an isoform previously not known to be expressed in the collecting duct. Long-term treatment of Brattleboro rats with a vasopressin analog markedly decreased adenylyl cyclase type 3 protein abundance, providing an explanation for long-term down-regulation of vasopressin response in the collecting duct. These studies demonstrate the importance of calmodulin in the regulation of collecting duct adenylyl cyclase activity and transport function.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Knepper, MA (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bldg 10,Rm 6N260,10 Ctr Dr,MSC 1603, Bethesda, MD 20892 USA.	knep@helix.nih.gov	Knepper, Mark/AAF-8412-2020; Fenton, Robert A/ABD-9824-2021; Fenton, Robert/AFR-6983-2022	Fenton, Robert/0000-0003-1623-199X	Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline; NHLBI NIH HHS [Z01-HL-01282-KE] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001282, Z01HL001285] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSIELLO DA, 1981, J BIOL CHEM, V256, P9796; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; Chaudhry A, 1996, AM J PHYSIOL-REG I, V270, pR755, DOI 10.1152/ajpregu.1996.270.4.R755; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Chou CL, 2004, J BIOL CHEM, V279, P49026, DOI 10.1074/jbc.M408565200; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; CORNWELL MM, 1983, BIOCHIM BIOPHYS ACTA, V762, P414, DOI 10.1016/0167-4889(83)90006-X; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; Defer N, 1998, FEBS LETT, V424, P216, DOI 10.1016/S0014-5793(98)00178-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; DEVINCENZO L, 2001, MOL CELL BIOL, V21, P148; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; Ecelbarger CA, 1998, AM J PHYSIOL-RENAL, V274, pF1161, DOI 10.1152/ajprenal.1998.274.6.F1161; GRANTHAM JJ, 1966, AM J PHYSIOL, V211, P255, DOI 10.1152/ajplegacy.1966.211.1.255; Helies-Toussaint C, 2000, AM J PHYSIOL-RENAL, V279, pF185, DOI 10.1152/ajprenal.2000.279.1.F185; Hoffert JD, 2004, AM J PHYSIOL-RENAL, V286, pF170, DOI 10.1152/ajprenal.00223.2003; Imbert-Teboul Martine, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P151; Inoue T, 1999, AM J PHYSIOL-RENAL, V276, pF559, DOI 10.1152/ajprenal.1999.276.4.F559; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KNEPPER MA, 1994, SEMIN NEPHROL, V14, P302; Kusano E, 2001, TOHOKU J EXP MED, V193, P207, DOI 10.1620/tjem.193.207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CY, 1999, BRAIN RES, V826, P253, DOI 10.1016/S0006-8993(99)01269-X; Mamluk R, 1999, ENDOCRINOLOGY, V140, P4601, DOI 10.1210/en.140.10.4601; Mhaouty-Kodja S, 1997, J BIOL CHEM, V272, P31100, DOI 10.1074/jbc.272.49.31100; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Nickols HH, 2004, J BIOL CHEM, V279, P46969, DOI 10.1074/jbc.M407351200; NIELSEN S, 1993, AM J PHYSIOL, V265, pF204, DOI 10.1152/ajprenal.1993.265.2.F204; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Stewart GS, 2004, AM J PHYSIOL-RENAL, V286, pF979, DOI 10.1152/ajprenal.00334.2003; STOKES JB, 1987, AM J PHYSIOL, V253, pF251, DOI 10.1152/ajprenal.1987.253.2.F251; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; SUNDAN A, 1983, BIOCHEM BIOPH RES CO, V117, P562, DOI 10.1016/0006-291X(83)91237-8; TAKAICHI K, 1988, AM J PHYSIOL, V255, pF834, DOI 10.1152/ajprenal.1988.255.5.F834; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; van Balkom BWM, 2004, AM J PHYSIOL-RENAL, V286, pF216, DOI 10.1152/ajprenal.00307.2003; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YAMAKI M, 1992, AM J PHYSIOL, V262, P957; Yip KP, 2002, J PHYSIOL-LONDON, V538, P891, DOI 10.1113/jphysiol.2001.012606; Zhang C, 2002, AM J PHYSIOL-RENAL, V282, pF85, DOI 10.1152/ajprenal.0054.2001	50	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13624	13630		10.1074/jbc.M500040200	http://dx.doi.org/10.1074/jbc.M500040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15710610	Green Accepted, hybrid			2022-12-27	WOS:000228095500056
J	Le-Niculescu, H; Niesman, I; Fischer, T; DeVries, L; Farquhar, MG				Le-Niculescu, H; Niesman, I; Fischer, T; DeVries, L; Farquhar, MG			Identification and characterization of GIV, a novel G alpha(i/s)-interacting protein found on COPI, endoplasmic reticulum-Golgi transport vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC-G-PROTEINS; GTP-BINDING PROTEINS; TRIMERIC G-PROTEIN; BETA-COP; 2-HYBRID SYSTEM; LEUCINE-ZIPPER; ALPHA-SUBUNITS; COILED-COIL; RAT-LIVER; CELLS	In this report, we characterize GIV (G alpha-interacting vesicle-associated protein), a novel protein that binds members of the G alpha(i) and G alpha(s) subfamilies of heterotrimeric G proteins. The G alpha interaction site was mapped to an 83-amino acid region of GIV that is enriched in highly charged amino acids. BLAST searches revealed two additional mammalian family members, Daple and an uncharacterized protein, FLJ00354. These family members share the highest homology at the G alpha binding domain, are homologous at the N terminus and central coiled coil domain but diverge at the C terminus. Using affinity-purified IgG made against two different regions of the protein, we localized GIV to COPI, endoplasmic reticulum (ER)-Golgi transport vesicles concentrated in the Golgi region in GH3 pituitary cells and COS7 cells. Identification as COPI vesicles was based on colocalization with beta-COP, a marker for these vesicles. GIV also codistributes in the Golgi region with endogenous calnuc and the KDEL receptor, which are cis Golgi markers and with G alpha(i3)-yellow fluorescent protein expressed in COS7 cells. By immunoelectron microscopy, GIV colocalizes with beta-COP and G alpha(i3) on vesicles found in close proximity to ER exit sites and to cis Golgi cisternae. In cell fractions prepared from rat liver, GIV is concentrated in a carrier vesicle fraction (CV2) enriched in ER-Golgi transport vesicles. beta-COP and several G alpha(i3) subunits (G alpha (i1-3), G alpha s) are also most enriched in CV2. Our results demonstrate the existence of a novel G alpha-interacting protein associated with COPI transport vesicles that may play a role in G alpha-mediated effects on vesicle trafficking within the Golgi and/or between the ER and the Golgi.	Univ Calif San Diego, Dept Cellular & Mol Med, George Palade Labs Cellular & Mol Med, La Jolla, CA 92093 USA; Inst Rech Pierre Fabre CRPF, Dept Biol Cellulaire & Mol, F-81106 Castres, France	University of California System; University of California San Diego	Farquhar, MG (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, George Palade Labs Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mfarquhar@ucsd.edu		Fischer, Thierry/0000-0002-9542-322X; Niesman, Ingrid/0000-0001-9767-6629	NATIONAL CANCER INSTITUTE [R01CA100768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017780, R01DK017780] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100768] Funding Source: Medline; NIDDK NIH HHS [DK 17780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Chen NF, 2003, J BIOL CHEM, V278, P15285, DOI 10.1074/jbc.M300841200; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; Crouch MF, 2000, IMMUNOL CELL BIOL, V78, P408, DOI 10.1046/j.1440-1711.2000.00929.x; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 2002, METHOD ENZYMOL, V344, P657; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Elenko E, 2003, MOL PHARMACOL, V64, P11, DOI 10.1124/mol.64.1.11; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Malsam J, 2005, SCIENCE, V307, P1095, DOI 10.1126/science.1108061; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Oshita A, 2003, GENES CELLS, V8, P1005, DOI 10.1111/j.1365-2443.2003.00692.x; PIMPLIKAR SW, 1993, J CELL SCI, P27; RASENICK MM, 1990, ADV SEC MESS PHOSPH, V24, P381; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1993, J CELL SCI, P33; Sunio A, 1999, MOL BIOL CELL, V10, P847, DOI 10.1091/mbc.10.4.847; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WADA I, 1991, J BIOL CHEM, V266, P19599; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zheng B, 2004, MOL BIOL CELL, V15, p322A, DOI 10.1091/mbc.e04-06-0446; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	63	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22012	22020		10.1074/jbc.M501833200	http://dx.doi.org/10.1074/jbc.M501833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15749703	hybrid			2022-12-27	WOS:000229557900044
J	Hari-Dass, R; Shah, C; Meyer, DJ; Raynes, JG				Hari-Dass, R; Shah, C; Meyer, DJ; Raynes, JG			Serum amyloid A protein binds to outer membrane protein A of Gram-negative bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; COUPLED RECEPTOR; OMPA PROTEIN; EXPRESSION; INDUCTION; IDENTIFICATION; ADHESION; ANTIGEN; DOMAIN	Serum amyloid A (SAA) is the major acute phase protein in man and most mammals. We observed SAA binding to a surprisingly large number of Gram-negative bacteria, including Escherichia coli, Salmonella typhimurium, Shigella flexneri, Klebsiella pneumoniae, Vibrio cholerae, and Pseudomonas aeruginosa. The binding was found to be high affinity and rapid. Importantly, this binding was not inhibited by high density lipoprotein with which SAA is normally complexed in serum. Binding was also observed when bacteria were offered serum containing SAA. Ligand blots following SDS-PAGE or two-dimensional gels revealed two major ligands of 29 and 35 kDa that bound SAA when probing with radiolabeled SAA or SAA and monoclonal anti-SAA. Following fractionation the ligand was found in the outer membrane fraction of E. coli and was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry to be outer membrane protein A ( OmpA). OmpA-deficient E. coli did not bind SAA, and following purification of OmpA the protein retained binding activity. The ligands on other bacteria were likely to be homologues of OmpA because wild type, but not OprF-deficient, P. aeruginosa bound SAA.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Raynes, JG (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, Keppel St, London WC1E 7HT, England.	john.raynes@lshtm.ac.uk	Raynes, John G/G-7932-2011	Raynes, John G/0000-0002-8536-1328				Ancsin JB, 1997, J BIOL CHEM, V272, P406; Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; Baranova IN, 2005, J BIOL CHEM, V280, P8031, DOI 10.1074/jbc.M405009200; BEHER MG, 1980, J BACTERIOL, V143, P906, DOI 10.1128/JB.143.2.906-913.1980; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; Cai L, 2005, J BIOL CHEM, V280, P2954, DOI 10.1074/jbc.M411555200; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Ogawa H, 2000, AM J PHYSIOL-GASTR L, V279, pG492, DOI 10.1152/ajpgi.2000.279.3.G492; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Prasadarao NV, 2002, INFECT IMMUN, V70, P4556, DOI 10.1128/IAI.70.8.4556-4563.2002; PRASADARO NV, 2000, INFECT IMMUN, V71, P1680; PreciadoPatt L, 1996, J IMMUNOL, V156, P1189; PRUZANSKI W, 1995, BIOCHEM J, V309, P461, DOI 10.1042/bj3090461; RAYNES JG, 1988, ANAL BIOCHEM, V173, P116, DOI 10.1016/0003-2697(88)90168-6; Santiago-Cardona PG, 2003, DEV COMP IMMUNOL, V27, P105, DOI 10.1016/S0145-305X(02)00068-X; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; Singh SP, 2003, INFECT IMMUN, V71, P3937, DOI 10.1128/IAI.71.7.3937-3946.2003; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Soulas C, 2000, J IMMUNOL, V165, P2335, DOI 10.4049/jimmunol.165.5.2335; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; Sukumaran SK, 2003, INFECT IMMUN, V71, P5951, DOI 10.1128/IAI.71.10.5951-5961.2003; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 2002, BLOOD, V99, P1224, DOI 10.1182/blood.V99.4.1224; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; Walder K, 2002, DIABETES, V51, P1859, DOI 10.2337/diabetes.51.6.1859; Wang Y, 2002, BIOCHEM BIOPH RES CO, V292, P396, DOI 10.1006/bbrc.2002.6657; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216	37	100	106	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18562	18567		10.1074/jbc.M500490200	http://dx.doi.org/10.1074/jbc.M500490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705572	hybrid			2022-12-27	WOS:000228932300003
J	Johnsen, L; Dalhus, B; Leiros, I; Nissen-Meyer, J				Johnsen, L; Dalhus, B; Leiros, I; Nissen-Meyer, J			1.6-angstrom crystal structure of EntA-im - A bacterial immunity protein conferring immunity to the antimicrobial activity of the pediocin-like bacteriocin enterocin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS IIA BACTERIOCINS; LEUCONOSTOC-MESENTEROIDES; 3-DIMENSIONAL STRUCTURE; MUTATIONAL ANALYSIS; SAKACIN-P; MEMBRANE; RESIDUES; MODEL; GENE; RECOGNITION	Many Gram-positive bacteria produce ribosomally synthesized antimicrobial peptides, often termed bacteriocins. Genes encoding pediocin-like bacteriocins are generally cotranscribed with or in close vicinity to a gene encoding a cognate immunity protein that protects the bacteriocin-producer from their own bacteriocin. We present the first crystal structure of a pediocin-like immunity protein, EntA-im, conferring immunity to the bacteriocin enterocin A. Determination of the structure of this 103-amino acid protein revealed that it folds into an antiparallel four-helix bundle with a flexible C-terminal part. The fact that the immunity protein conferring immunity to carnobacteriocin B2 also consists of a four-helix bundle (Sprules, T., Kawulka, K. E., and Vederas, J. C. ( 2004) Biochemistry 43, 11740-11749) strongly indicates that this is a conserved structural motif in all pediocin-like immunity proteins. The C-terminal half of the immunity protein contains a region that recognizes the C-terminal half of the cognate bacteriocin, and the flexibility in the C-terminal end of the immunity protein might thus be an important characteristic that enables the immunity protein to interact with its cognate bacteriocin. By homology modeling of three other pediocin-like immunity proteins and calculation of the surface charge distribution for EntA-im and the three structure models, different charge distributions were observed. The differences in the latter part of helix 3, the beginning of helix 4, and the loop connecting these helices might also be of importance in determining the specificity.	Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, N-0316 Oslo, Norway; Natl Univ Hosp, Sect Mol Microbiol, Inst Med Microbiol, N-0027 Oslo, Norway; European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble, France	University of Oslo; University of Oslo; National Hospital Norway; European Synchrotron Radiation Facility (ESRF)	Johnsen, L (corresponding author), Univ Oslo, Dept Mol Biosci, Program Biochem & Mol Biol, POB 1041, N-0316 Oslo, Norway.	line.johnsen@biokjemi.uio.no	Nissen-Meyer, Jon/Y-8727-2019; Leiros, Ingar/AAM-2940-2020; Dalhus, Bjørn/AAK-2895-2020; Nissen-Meyer, Jon/A-5581-2008	Leiros, Ingar/0000-0001-9333-4541				AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YH, 1997, APPL ENVIRON MICROB, V63, P4770, DOI 10.1128/AEM.63.12.4770-4777.1997; CHIKINDAS ML, 1993, APPL ENVIRON MICROB, V59, P3577, DOI 10.1128/AEM.59.11.3577-3584.1993; Dalhus B, 2003, ACTA CRYSTALLOGR D, V59, P1291, DOI 10.1107/S0907444903009879; Dayem MA, 1996, FEMS MICROBIOL LETT, V138, P251, DOI 10.1016/0378-1097(96)00119-X; Eijsink VGH, 1998, APPL ENVIRON MICROB, V64, P3275; Ennahar S, 2000, FEMS MICROBIOL REV, V24, P85, DOI 10.1111/j.1574-6976.2000.tb00534.x; Fimland G, 1996, APPL ENVIRON MICROB, V62, P3313, DOI 10.1128/AEM.62.9.3313-3318.1996; Fimland G, 2002, BIOCHEMISTRY-US, V41, P9508, DOI 10.1021/bi025856q; Fimland G, 2002, MICROBIOL-SGM, V148, P3661, DOI 10.1099/00221287-148-11-3661; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Gallagher NLF, 1997, BIOCHEMISTRY-US, V36, P15062, DOI 10.1021/bi971263h; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; Huhne K, 1996, MICROBIOL-SGM, V142, P1437, DOI 10.1099/13500872-142-6-1437; Johnsen L, 2004, APPL ENVIRON MICROB, V70, P2647, DOI 10.1128/AEM.70.5.2647-2652.2004; Johnsen L, 2005, J BIOL CHEM, V280, P9243, DOI 10.1074/jbc.M412712200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazazic M, 2002, MICROBIOL-SGM, V148, P2019, DOI 10.1099/00221287-148-7-2019; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Metivier A, 1998, MICROBIOL-SGM, V144, P2837, DOI 10.1099/00221287-144-10-2837; Miller KW, 1998, APPL ENVIRON MICROB, V64, P1997; Moll GN, 1999, ANTON LEEUW INT J G, V76, P185, DOI 10.1023/A:1002002718501; NES IF, 2002, UNMODIFIED PEPTIDE B, P81; NISSENMEYER J, 1993, J GEN MICROBIOL, V139, P1503, DOI 10.1099/00221287-139-7-1503; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; QUADRI LEN, 1995, J BACTERIOL, V177, P1144, DOI 10.1128/JB.177.5.1144-1151.1995; Quadri LEN, 1997, J BACTERIOL, V179, P6163, DOI 10.1128/jb.179.19.6163-6171.1997; Sprules T, 2004, BIOCHEMISTRY-US, V43, P11740, DOI 10.1021/bi048854+; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uteng M, 2003, BIOCHEMISTRY-US, V42, P11417, DOI 10.1021/bi034572i; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; Wang YJ, 1999, BIOCHEMISTRY-US, V38, P15438, DOI 10.1021/bi991351x	41	32	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19045	19050		10.1074/jbc.M501386200	http://dx.doi.org/10.1074/jbc.M501386200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753083	hybrid			2022-12-27	WOS:000228932300060
J	Kwade, Z; Swiatek, A; Azmi, A; Goossens, A; Inze, D; Van Onckelen, H; Roef, L				Kwade, Z; Swiatek, A; Azmi, A; Goossens, A; Inze, D; Van Onckelen, H; Roef, L			Identification of four adenosine kinase Isoforms in tobacco BY-2 cells and their putative role in the cell cycle-regulated cytokinin metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CYTOKININS; QUANTITATIVE-ANALYSIS; MESSENGER-RNA; BIOSYNTHESIS; PURIFICATION; ARABIDOPSIS; GENE; PHOSPHORYLATION; EXPRESSION; INDUCTION	Adenosine kinase (ADK), a key enzyme in the regulation of the intracellular level of adenosine is also speculated to be responsible for the conversion of cytokinin ribosides to their respective nucleotides. To elucidate the role of ADK in the cytokinin metabolism of tobacco BY-2 cells ( Nicotiana tabacum cv. "Bright Yellow-2"; TBY-2), we have identified and characterized the full-length cDNAs encoding four ADK isoforms of N. tabacum and determined their catalytic properties. The four TBY-2 ADK isoforms ( designated 1S, 2S, 1T, and 2T) display a high affinity for both adenosine ( K-m 1.88 - 7.30 mu M) and three distinct types of cytokinin ribosides: isopentenyladenosine; zeatin riboside; and dihydrozeatin riboside (K-m 0.30 - 8.71 mu M). The V-max/K-m values suggest that ADK2S exhibits in vitro an overall higher efficiency in the metabolism of cytokinin ribosides than the other three isoforms. The expression pattern of NtADK genes is modulated significantly during the cell cycle. We suggest that the increased transcript accumulation of NtADK coupled to an increased ADK activity just prior to mitosis is associated with a very active cytokinin metabolism at that phase of the cell cycle of synchronized TBY-2 cells.	Univ Antwerp, Dept Biol, Lab Plant Biochem & Physiol, B-2610 Antwerp, Belgium; State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	University of Antwerp; Flanders Institute for Biotechnology (VIB); Ghent University	Van Onckelen, H (corresponding author), Univ Antwerp, Dept Biol, Lab Plant Biochem & Physiol, Univ Pl 1, B-2610 Antwerp, Belgium.	harry.vanonckelen@ua.ac.be	Inzé, Dirk/AAW-6381-2021; Ding, Cheng-Qiang/B-6287-2011	Inzé, Dirk/0000-0002-3217-8407; Goossens, Alain/0000-0002-1599-551X; Swiatek, Agnieszka/0000-0003-0744-888X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; Auer CA, 2002, J PLANT GROWTH REGUL, V21, P24, DOI 10.1007/s003440010044; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Azmi A, 2001, PLANTA, V213, P29, DOI 10.1007/s004250000476; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIELESKI RL, 1964, ANAL BIOCHEM, V9, P431, DOI 10.1016/0003-2697(64)90204-0; Breyne P, 2002, P NATL ACAD SCI USA, V99, P14825, DOI 10.1073/pnas.222561199; CHEN CM, 1977, PLANT PHYSIOL, V59, P443, DOI 10.1104/pp.59.3.443; Chen CM, 1997, PHYSIOL PLANTARUM, V101, P665, DOI 10.1111/j.1399-3054.1997.tb01051.x; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; Cronn RC, 2003, BIOTECHNIQUES, V34, P726, DOI 10.2144/03344st01; CROWELL DN, 1992, PLANT PHYSIOL, V100, P2090, DOI 10.1104/pp.100.4.2090; Davies Peter J., 1995, P1; Faye F, 1997, PLANT PHYSIOL BIOCH, V35, P15; Goossens A, 2003, P NATL ACAD SCI USA, V100, P8595, DOI 10.1073/pnas.1032967100; GURANOWSKI A, 1979, ARCH BIOCHEM BIOPHYS, V196, P220, DOI 10.1016/0003-9861(79)90569-1; Haberer G, 2002, PLANT PHYSIOL, V128, P354, DOI 10.1104/pp.010773; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Hammerton RD, 1996, PHYSIOL PLANTARUM, V96, P77, DOI 10.1111/j.1399-3054.1996.tb00186.x; Hedtke B, 2002, PLANT J, V30, P625, DOI 10.1046/j.1365-313X.2002.01318.x; Hoth S, 2003, FEBS LETT, V554, P373, DOI 10.1016/S0014-5793(03)01194-3; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jameson P.E., 1994, CYTOKININS CHEM ACTI, P113; KAMINEK M, 1992, TRENDS BIOTECHNOL, V10, P159, DOI 10.1016/0167-7799(92)90204-9; Laukens K, 2003, FEBS LETT, V533, P63, DOI 10.1016/S0014-5793(02)03750-X; Laureys F, 1998, FEBS LETT, V426, P29, DOI 10.1016/S0014-5793(98)00297-X; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; Long MC, 2003, J BACTERIOL, V185, P6548, DOI 10.1128/JB.185.22.6548-6555.2003; Maj MC, 2000, BIOCHEM BIOPH RES CO, V275, P386, DOI 10.1006/bbrc.2000.3307; McGaw Brian A., 1995, P98; McNally T, 1997, BIOCHEM BIOPH RES CO, V231, P645, DOI 10.1006/bbrc.1997.6157; Mlejnek P, 2003, PLANT CELL ENVIRON, V26, P1723, DOI 10.1046/j.1365-3040.2003.01090.x; Mlejnek P, 2002, PLANTA, V215, P158, DOI 10.1007/s00425-002-0733-5; Moffatt BA, 2002, PLANT PHYSIOL, V128, P812, DOI 10.1104/pp.010880; Moffatt BA, 2000, PLANT PHYSIOL, V124, P1775, DOI 10.1104/pp.124.4.1775; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok DWS, 1994, CYTOKININS CHEM ACTI, P129; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; OKAMURO JK, 1985, MOL GEN GENET, V198, P290, DOI 10.1007/BF00383009; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS IDJ, 1975, ANNU REV PLANT PHYS, V26, P341, DOI 10.1146/annurev.pp.26.060175.002013; PRINSEN E, 1995, RAPID COMMUN MASS SP, V9, P948, DOI 10.1002/rcm.1290091016; RAES J, 1999, EMBNET NEWS EUROPEAN, V61; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; Rock Christopher D., 1995, P671; Sambrook J., 2001, MOL CLONING LAB MANU; Schorlemmer HU, 1997, INT J IMMUNOTHER, V13, P9; Schulz PA, 2001, PLANT PHYSIOL, V126, P1224, DOI 10.1104/pp.126.3.1224; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Spychala J, 1996, P NATL ACAD SCI USA, V93, P1232, DOI 10.1073/pnas.93.3.1232; Staden J. Van, 1979, Plant, Cell and Environment, V2, P93, DOI 10.1111/j.1365-3040.1979.tb00780.x; Stasolla C, 2003, J PLANT PHYSIOL, V160, P1271, DOI 10.1078/0176-1617-01169; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; Veselov D, 2003, PLANTA, V216, P512, DOI 10.1007/s00425-002-0883-5; von Schwartzenberg K, 1998, PLANT J, V13, P249, DOI 10.1046/j.1365-313X.1998.00011.x; Wang H, 2003, PLANT CELL, V15, P3020, DOI 10.1105/tpc.015180; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928; Yamaguchi M, 2003, P NATL ACAD SCI USA, V100, P8019, DOI 10.1073/pnas.1332637100	63	34	35	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17512	17519		10.1074/jbc.M411428200	http://dx.doi.org/10.1074/jbc.M411428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731114	hybrid			2022-12-27	WOS:000228615500119
J	Lee, YS; Kim, HK; Chung, SM; Kim, KS; Dutta, A				Lee, YS; Kim, HK; Chung, SM; Kim, KS; Dutta, A			Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the downregulation of putative targets during differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL TEMPORAL RNAS; C-ELEGANS; INTERFERENCE; EXPRESSION; IDENTIFICATION; PROTEIN; DICER; CONSERVATION; SEQUENCE; LIN-28	Micro-RNAs are small non-coding RNAs that regulate target gene expression post-transcriptionally through base pairing with the target messenger RNA. Functional characterization of micro-RNAs awaits robust experimental methods to knock-down a micro-RNA as well as to assay its function in vivo. In addition to the recently developed method to sequester micro-RNA with 2'-O-methyl antisense oligonucleotide, we report that small interfering RNA against the loop region of a micro-RNA precursor can be used to deplete the micro-RNA. The depletion of miR-125b by this method had a profound effect on the proliferation of adult differentiated cancer cells, and this proliferation defect was rescued by cotransfected mature micro-RNA. This technique has unique advantages over the 2'-O-methyl antisense oligonucleotide and can be used to determine micro-RNA function, assay micro-RNAs in vivo, and identify the contribution of a predicted micro-RNA precursor to the pool of mature micro-RNA in a given cell. miR-125b and let-7 micro-RNAs are induced, whereas their putative targets, lin-28 and lin-41, are decreased during in vitro differentiation of Tera-2 or embryonic stem cells. Experimental increase or decrease of micro-RNA concentrations did not, however, affect the levels of the targets, a finding that is explained by the fact that the down-regulation of the targets appears to be mostly at the transcriptional level in these in vitro differentiation systems. Collectively these results reveal the importance of micro-RNA depletion strategies for directly determining micro-RNA function in vivo.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02478 USA	University of Virginia; Seoul National University (SNU); Harvard University; McLean Hospital	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Huang, H/E-9490-2010	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA89406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bashirullah A, 2003, DEV BIOL, V259, P1, DOI 10.1016/S0012-1606(03)00063-0; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Feinbaum R, 1999, DEV BIOL, V210, P87, DOI 10.1006/dbio.1999.9272; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; GREENBERG ME, 2002, SHORT PROTOCOLS MOL, V1, P4; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kawasaki H, 2003, NATURE, V426, P100, DOI 10.1038/nature02141; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; THOMPSON S, 1984, J CELL SCI, V72, P37; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404	48	277	321	5	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16635	16641		10.1074/jbc.M412247200	http://dx.doi.org/10.1074/jbc.M412247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722555	hybrid			2022-12-27	WOS:000228615500014
J	Charriere, F; Tan, THP; Schneider, A				Charriere, F; Tan, THP; Schneider, A			Mitochondrial initiation factor 2 of Trypanosoma brucei binds imported formylated elongator-type tRNA(Met)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR IF2; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNA; FACTOR-II; TRANSLATION; FORMYLTRANSFERASE; INTERFERENCE	The mitochondrion of Trypanosoma brucei lacks tRNA genes. Its translation system therefore depends on the import of nucleus-encoded tRNAs. Thus, except for the cytosol-specific initiator tRNA(Met), all trypanosomal tRNAs function in both the cytosol and the mitochondrion. The only tRNA(Met) present in T. brucei mitochondria is therefore the one which, in the cytosol, is involved in translation elongation. Mitochondrial translation initiation depends on an initiator tRNA(Met) carrying a formylated methionine. This tRNA is then recognized by initiation factor 2, which brings it to the ribosome. To guarantee mitochondrial translation initiation, T. brucei has an unusual methionyl-tRNA formyltransferase that formylates elongator tRNA(Met). In the present study, we have identified initiation factor 2 of T. brucei and shown that its carboxyl-terminal domain specifically binds formylated trypanosomal elongator tRNA(Met). Furthermore, the protein also recognizes the structurally very different Escherichia coli initiator tRNA(Met), suggesting that the main determinant recognized is the formylated methionine. In vivo studies using stable RNA interference cell lines showed that knockdown of initiation factor 2, depending on which construct was used, causes slow growth or even growth arrest. Moreover, concomitantly with ablation of the protein, a loss of oxidative phosphorylation was observed. Finally, although ablation of the methionyl-tRNA formyltransferase on its own did not impair growth, a complete growth arrest was observed when it was combined with the initiation factor 2 RNA interference cell line showing the slow growth phenotype. Thus, these experiments illustrate the importance of mitochondrial translation initiation for growth of procyclic T. brucei.	Univ Fribourg, Dept Biol Zool, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneider, A (corresponding author), Univ Fribourg, Dept Biol Zool, Chemin Musee 10, CH-1700 Fribourg, Switzerland.	andre.schneider@unifr.ch						Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Beverley S M, 1993, Methods Mol Biol, V21, P333; Blanquet S, 2000, CURR OPIN STRUC BIOL, V10, P95, DOI 10.1016/S0959-440X(99)00055-X; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Boelens R, 2002, CURR PROTEIN PEPT SC, V3, P107, DOI 10.2174/1389203023380765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; Garofalo C, 2003, ARCH BIOCHEM BIOPHYS, V413, P243, DOI 10.1016/S0003-9861(03)00119-X; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; LIAO HX, 1991, J BIOL CHEM, V266, P20714; LIAO HX, 1990, J BIOL CHEM, V265, P13618; Martin NC, 2002, P NATL ACAD SCI USA, V99, P1110, DOI 10.1073/pnas.042011199; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; Newton DT, 1999, J BIOL CHEM, V274, P22143, DOI 10.1074/jbc.274.32.22143; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; Spremulli LL, 2004, PROG NUCLEIC ACID RE, V77, P211, DOI 10.1016/S0079-6603(04)77006-3; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Steiner-Mosonyi M, 2004, J BIOL CHEM, V279, P52262, DOI 10.1074/jbc.M408086200; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; Tan THP, 2002, P NATL ACAD SCI USA, V99, P1152, DOI 10.1073/pnas.022522299; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Tibbetts AS, 2003, J BIOL CHEM, V278, P31774, DOI 10.1074/jbc.M304962200; Vial L, 2003, BIOCHEMISTRY-US, V42, P932, DOI 10.1021/bi026901x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	34	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15659	15665		10.1074/jbc.M411581200	http://dx.doi.org/10.1074/jbc.M411581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15731104	hybrid			2022-12-27	WOS:000228444800026
J	Vainauskas, S; Menon, AK				Vainauskas, S; Menon, AK			Endoplasmic reticulum localization of Gaa1 and PIG-T, subunits of the glycosylphosphatidylinositol transamidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPII-DEPENDENT EXPORT; GPI ANCHOR ATTACHMENT; SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE DOMAIN; MEMBRANE-PROTEINS; RETENTION SIGNAL; ER RETENTION; BULK-FLOW; RECEPTOR; MOTIF	After integration into the endoplasmic reticulum ( ER) membrane, ER-resident membrane proteins must be segregated from proteins that are exported to post-ER compartments. Here we analyze how human Gaa1 and PIG-T, two of the five subunits of the ER-localized glycosylphosphatidylinositol transamidase complex, are retained in the ER. Neither protein contains a known ER localization signal. Gaa1 is a polytopic membrane glycoprotein with a cytoplasmic N terminus and a large luminal loop between its first two transmembrane spans; PIG-T is a type I membrane glycoprotein. To simplify our analyses, we studied Gaa1 and PIG-T constructs that could not interact with other subunits of the transamidase. We now show that Gaa1(282), a truncated protein consisting of the first TM domain and luminal loop of Gaa1, is correctly oriented, N-glycosylated, and ER-localized. Removal of a potential ER localization signal in the form of a triple arginine cluster near the N terminus of Gaa1 or Gaa1(282) had no effect on ER localization. Fusion proteins consisting of different elements of Gaa1(282) appended to alpha 2,6-sialyltransferase or transferrin receptor could exit the ER, indicating that Gaa1(282), and by implication Gaa1, does not contain any dominant ER-sorting determinants. The data suggest that Gaa1 is passively retained in the ER by a signalless mechanism. In contrast, similar analyses of PIG-T revealed that it is ER-localized because of information in its transmembrane span; fusion of the PIG-T transmembrane span to Tac antigen, a plasma membrane-localized protein, caused the fusion protein to remain in the ER. These data are discussed in the context of models that have been proposed to account for retention of ER membrane proteins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Vainauskas, S (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	saulius@biochem.wisc.edu		Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; De Beeck AO, 2004, J VIROL, V78, P12591, DOI 10.1128/JVI.78.22.12591-12602.2004; Eisen TG, 2000, ONCOLOGY-NY, V14, P17; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; Grimme SJ, 2004, MOL BIOL CELL, V15, P2758, DOI 10.1091/mbc.E04-01-0035; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Ohishi K, 2003, J BIOL CHEM, V278, P13959, DOI 10.1074/jbc.M300586200; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Parker AKT, 2004, J BIOL CHEM, V279, P23797, DOI 10.1074/jbc.M402098200; Pentcheva T, 2002, J IMMUNOL, V168, P1538, DOI 10.4049/jimmunol.168.4.1538; Pottekat A, 2004, J BIOL CHEM, V279, P15743, DOI 10.1074/jbc.M313537200; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wrzeszczynski KO, 2004, CELL MOL LIFE SCI, V61, P1341, DOI 10.1007/s00018-004-4005-3; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	51	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16402	16409		10.1074/jbc.M414253200	http://dx.doi.org/10.1074/jbc.M414253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713669	hybrid			2022-12-27	WOS:000228444800113
J	Misra, V; Rapin, N; Akhova, O; Bainbridge, M; Korchinski, P				Misra, V; Rapin, N; Akhova, O; Bainbridge, M; Korchinski, P			Zhangfei is a potent and specific inhibitor of the host cell factor-binding transcription factor luman	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-INDUCING FACTOR; SIMPLEX-VIRUS VP16; ACTIVATION DOMAIN; MESSENGER-RNA; ER STRESS; K-BZIP; PROTEIN; DNA; HCF-1; CHOP	Host cell factor (HCF) was initially discovered as a cellular co-factor required for the activation of herpes simplex virus immediate early gene expression by the virion associated transactivator VP16. HCF also participates in a variety of cellular processes, although the mechanism of its action is not known. VP16 binds to HCF through a 4-amino acid motif (EHAY), which closely resembles the HCF binding domain of two cellular basic leucine-zipper proteins, Luman and Zhangfei. Luman is a powerful transcription factor that, in transient expression assays, activates promoters containing cAMP or unfolded protein response elements (UPRE). In contrast, Zhangfei neither binds consensus recognition elements for basic leucine-zipper proteins nor does it activate promoters containing them. Here we show that Zhangfei suppresses the ability of Luman to activate transcription. HCF appeared to be required for efficient suppression. A mutant of Zhangfei, which was unable to bind HCF, was impaired in its ability to suppress Luman. Zhangfei did not suppress ATF6, a transcription factor closely related to Luman but that does not bind HCF, unless the HCF binding motif of Luman was grafted onto it. Zhangfei inhibited the HCF-dependent activation of a UPRE-containing promoter by a Gal4-Luman fusion protein but was unable to inhibit the HCF-independent activation by Gal4-Luman of a promoter that contained Gal4 binding motifs. Binding of HCF by Zhangfei was required for the co-localization of Luman and Zhangfei to nuclear domains, suggesting that HCF might target the proteins to a common location.	Univ Saskatchewan, Western Coll Vet Med, Dept Microbiol, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Comp Sci, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan	Misra, V (corresponding author), Univ Saskatchewan, Western Coll Vet Med, Dept Microbiol, Saskatoon, SK S7N 5B4, Canada.	vikram.misra@usask.ca	Misra, Vikram/AAC-4266-2020	Misra, Vikram/0000-0001-6818-7156				Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GOTO H, 1907, GENE DEV, V11, P726; HITT M, 1995, METH MOL G, V7, P13; Izumiya Y, 2003, J VIROL, V77, P1441, DOI 10.1128/JVI.77.2.1441-1451.2003; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Khurana B, 2004, J BIOL CHEM, V279, P33673, DOI 10.1074/jbc.M401255200; La Boissiere S, 1999, EMBO J, V18, P480; Liao W, 2003, J VIROL, V77, P3809, DOI 10.1128/JVI.77.6.3809-3815.2003; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Luciano RL, 2003, J BIOL CHEM, V278, P51116, DOI 10.1074/jbc.M303470200; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2002, J BIOL CHEM, V277, P44292, DOI 10.1074/jbc.M205440200; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MISRA V, 1995, J VIROL, V69, P5209, DOI 10.1128/JVI.69.9.5209-5216.1995; Misra V, 1996, MOL CELL BIOL, V16, P4404; Moore DD, 1995, GLOB MOB SURV; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2001, MOL CLONING LAB MANU; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ubeda M, 2003, J BIOL CHEM, V278, P40514, DOI 10.1074/jbc.M306404200; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	50	32	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15257	15266		10.1074/jbc.M500728200	http://dx.doi.org/10.1074/jbc.M500728200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705566	hybrid			2022-12-27	WOS:000228236800111
J	Zhang, XL; Li, J; Sejas, DP; Pang, QS				Zhang, XL; Li, J; Sejas, DP; Pang, QS			The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FANCONI-ANEMIA; DNA-DAMAGE; C-MYC; IN-VIVO; ATM; P53; INSTABILITY; HYPOXIA	Hematopoietic cells are often exposed to transient hypoxia as they develop and migrate between blood and tissues. We tested the hypothesis that hypoxia-thenreoxygenation represent a stress for hematopoietic progenitor cells. Here we report that reoxygenation-generated oxidative stress induced senescence, tested as staining for SA-beta-galactosidase (SA-beta-gal), of bone marrow progenitor cells. Reoxygenation induced significant DNA damage and inhibited colony formation in lineage-depleted bone marrow cells enriched for progenitor cells. These reoxygenated cells exhibited a prolonged G(0)/G(1) accumulation without significant apoptosis after 24 h of treatments. Reoxygenated bone marrow progenitor cells expressed SA-beta-gal and senescence-associated proteins p53 and p21(WAF1). Reoxygenated Fancc(-/-) progenitor cells, which underwent significant apoptosis and senescence, tested as staining for SA-beta-gal, also expressed p16(INK4A). Suppression of apoptosis by the pancaspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone dramatically increased senescent Fancc(-/-) progenitor cells. Senescence induction, tested as staining for SA-beta-gal, in reoxygenated progenitor cells was closely correlated with extent of DNA damage and phosphorylation of ATM at Ser-1981 and p53 at Ser-15. Moreover, inhibition of ATM signaling reduced SA-beta-gal positivity but increased apoptosis of reoxygenated progenitor cells. Thus, these results suggest that the ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells.	Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pang, QS (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	qishen.pang@cchmc.org						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Huang S, 2003, ONCOGENE, V22, P3721, DOI 10.1038/sj.onc.1206490; KOGURE K, 1982, NEUROCHEM RES, V7, P437, DOI 10.1007/BF00965496; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Maciejewski JP, 2003, ARCH MED RES, V34, P520, DOI 10.1016/j.arcmed.2003.09.009; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tischkowitz M, 2004, BRIT J HAEMATOL, V126, P176, DOI 10.1111/j.1365-2141.2004.05023.x; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8	23	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19635	19640		10.1074/jbc.M502262200	http://dx.doi.org/10.1074/jbc.M502262200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753076	hybrid			2022-12-27	WOS:000229113700027
J	Mathieu, M; Debousker, G; Vincent, S; Viviani, F; Bamas-Jacques, N; Mikol, V				Mathieu, M; Debousker, G; Vincent, S; Viviani, F; Bamas-Jacques, N; Mikol, V			Escherichia coli FolC structure reveals an unexpected dihydrofolate binding site providing an attractive target for anti-microbial therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; BIOSYNTHESIS; REPLACEMENT; CLONING; LIGASE; MURD; GENE	In some bacteria, such as Escherichia coli, the addition of L-glutamate to dihydropteroate ( dihydrofolate synthetase activity) and the subsequent additions of L-glutamate to tetrahydrofolate ( folylpolyglutamate synthetase (FPGS) activity) are catalyzed by the same enzyme, FolC. The crystal structure of E. coli FolC is described in this paper. It showed strong similarities to that of the FPGS enzyme of Lactobacillus casei within the ATP binding site and the catalytic site, as do all other members of the Mur synthethase superfamily. FolC structure revealed an unexpected dihydropteroate binding site very different from the folate site identified previously in the FPGS structure. The relevance of this site is exemplified by the presence of phosphorylated dihydropteroate, a reaction intermediate in the DHFS reaction. L. casei FPGS is considered a relevant model for human FPGS. As such, the presence of a folate binding site in E. coli FolC, which is different from the one seen in FPGS enzymes, provides avenues for the design of specific inhibitors of this enzyme in antimicrobial therapy.	Aventis Pharma, Dept Biol Struct, F-94403 Vitry Sur Seine, France	Sanofi-Aventis; Sanofi France	Mathieu, M (corresponding author), Aventis Pharma, Dept Biol Struct, 13 Quai J Guesde, F-94403 Vitry Sur Seine, France.	magali.mathieu@sanofi-aventis.com						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand JA, 2000, J MOL BIOL, V301, P1257, DOI 10.1006/jmbi.2000.3994; Bertrand JA, 1997, EMBO J, V16, P3416, DOI 10.1093/emboj/16.12.3416; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; Burger A, 1998, FEMS MICROBIOL LETT, V159, P283, DOI 10.1016/S0378-1097(97)00540-5; Cherest H, 2000, J BIOL CHEM, V275, P14056, DOI 10.1074/jbc.275.19.14056; Costi MP, 2001, CURR DRUG TARGETS, V2, P135, DOI 10.2174/1389450013348669; Dementin S, 2001, EUR J BIOCHEM, V268, P5800, DOI 10.1046/j.0014-2956.2001.02524.x; Fussenegger M, 1996, MOL GEN GENET, V250, P277; Gordon E, 2001, J BIOL CHEM, V276, P10999, DOI 10.1074/jbc.M009835200; KESHAVJEE K, 1991, J BIOL CHEM, V266, P19925; Moran RG, 1999, SEMIN ONCOL, V26, P24; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; PYNE C, 1992, J BACTERIOL, V174, P1750, DOI 10.1128/jb.174.6.1750-1759.1992; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rosowsky A, 1999, J MED CHEM, V42, P3510, DOI 10.1021/jm9807205; Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490; SHANE B, 1980, J BIOL CHEM, V255, P5663; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; Sun XL, 2001, J MOL BIOL, V310, P1067, DOI 10.1006/jmbi.2001.4815	22	39	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18916	18922		10.1074/jbc.M413799200	http://dx.doi.org/10.1074/jbc.M413799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705579	hybrid			2022-12-27	WOS:000228932300044
J	Caillaud, A; Hovanessian, AG; Levy, DE; Marie, IJ				Caillaud, A; Hovanessian, AG; Levy, DE; Marie, IJ			Regulatory serine residues mediate phosphorylation-dependent and phosphorylation-independent activation of interferon regulatory factor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IKK-EPSILON; POSITIVE FEEDBACK; CRYSTAL-STRUCTURE; VIRAL-INFECTION; VIRUS-INFECTION; KINASES; COMPLEX; GENES; FACTOR-7	Interferon regulatory factor (IRF)7 is a key transcription factor required for establishment of antiviral resistance. In response to infection, IRF7 is activated by phosphorylation through the action of the non-canonical I kappa B kinases, I kappa B kinase-epsilon and TANK-binding kinase 1. Activation leads to nuclear retention, DNA binding, and derepression of transactivation ability. Clusters of serine residues located in the carboxyl-terminal regulatory domain of IRF7 are putative targets of virus-activated kinases. However, the exact sites of phosphorylation have not yet been established. Here, we report a comprehensive structure-activity examination of potential IRF7 phosphorylation sites through analysis of mutant proteins in which specific serine residues were altered to alanine or aspartate. Phosphorylation patterns of these mutants were analyzed by two-dimensional gel electrophoresis, and their transcriptional activity was monitored by reporter assays. Essential phosphorylation events were mapped to amino acids 437-438 and a redundant set of sites at either amino acids 429-431 or 441. IRF7 recovered from infected cells was heterogeneously phosphorylated at these sites, and greater phosphorylation correlated with increased transactivation. Interestingly, a distinct serine cluster conserved in the related protein IRF3 was also essential for IRF7 activation and distal phosphorylation. However, the essential role of this motif did not appear to be fulfilled by phosphorylation. Rather, these serine residues and an adjacent leucine were required for phosphorylation at distal sites and may determine a conformational element required for function.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA; Inst Pasteur, Unite Virol & Immunol Cellulaire, F-75724 Paris, France	New York University; New York University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Marie, IJ (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.	mariei01@med.nyu.edu	Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; Marie, Isabelle/0000-0002-3091-7624	NIAID NIH HHS [P01 AI048204, R01 AI028900, R01 AI046503, U54 AI05715801, P01 AI48204] Funding Source: Medline; PHS HHS [R01 A146503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046503, P01AI048204, R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200	26	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17671	17677		10.1074/jbc.M411389200	http://dx.doi.org/10.1074/jbc.M411389200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743772	Green Accepted, hybrid			2022-12-27	WOS:000228807200015
J	Changela, A; Martins, A; Shuman, S; Mondragon, A				Changela, A; Martins, A; Shuman, S; Mondragon, A			Crystal structure of baculovirus RNA triphosphatase complexed with phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING ENZYME LEF4; MUTATIONAL ANALYSIS; TUMOR-SUPPRESSOR; DIFFRACTION DATA; ACTIVE-SITE; PROTEIN; 5'-TRIPHOSPHATASE; POLYMERASE; MECHANISM; PROGRAM	Baculovirus RNA 5'-triphosphatase (BVP) exemplifies a family of RNA-specific cysteine phosphatases that includes the RNA triphosphatase domains of metazoan and plant mRNA capping enzymes. Here we report the crystal structure of BVP in a phosphate-bound state at 1.5 angstrom resolution. BVP adopts the characteristic cysteine-phosphatase alpha/beta fold and binds two phosphate ions in the active site region, one of which is proposed to mimic the phosphate of the product complex after hydrolysis of the covalent phosphoenzyme intermediate. The crystal structure highlights the role of backbone amides and side chains of the P-loop motif (118)HCTHGXNRT(126) in binding the cleavable phosphate and stabilizing the transition state. Comparison of the BVP structure to the apoenzyme of mammalian RNA triphosphatase reveals a concerted movement of the Arg-125 side chain ( to engage the phosphate directly) and closure of an associated surface loop over the phosphate in the active site. The structure highlights a direct catalytic role of Asn-124, which is the signature P-loop residue of the RNA triphosphatase family and a likely determinant of the specificity of BVP for hydrolysis of phosphoanhydride linkages.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Northwestern University; Memorial Sloan Kettering Cancer Center	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498, R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051350, GM42498, GM51350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Guarino LA, 1998, J VIROL, V72, P7985, DOI 10.1128/JVI.72.10.7985-7991.1998; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Martins A, 2002, VIROLOGY, V304, P167, DOI 10.1006/viro.2002.1606; Martins A, 2002, BIOCHEMISTRY-US, V41, P13403, DOI 10.1021/bi0265426; Martins A, 2001, J BIOL CHEM, V276, P45522, DOI 10.1074/jbc.M107615200; Martins A, 2000, J BIOL CHEM, V275, P35070, DOI 10.1074/jbc.M005748200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	37	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17848	17856		10.1074/jbc.M500885200	http://dx.doi.org/10.1074/jbc.M500885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15713658	hybrid			2022-12-27	WOS:000228807200037
J	Ling, M; Troller, U; Zeidman, R; Stensman, H; Schultz, A; Larsson, C				Ling, M; Troller, U; Zeidman, R; Stensman, H; Schultz, A; Larsson, C			Identification of conserved amino acids N-terminal of the PKC epsilon C1b domain crucial for protein kinase C epsilon-mediated induction of neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTORS; NERVE GROWTH-FACTOR; PKC-EPSILON; REGULATORY DOMAINS; CATALYTIC DOMAIN; PHOSPHOLIPASE-D; BINDING DOMAIN; DELTA; NEUROBLASTOMA; GOLGI	We have shown previously that protein kinase C (PKC) epsilon can induce neurite outgrowth independently of its catalytic activity via a region encompassing its C1 domains. In this study we aimed at identifying specific amino acids in this region crucial for induction of neurite outgrowth. Deletion studies demonstrated that only 4 amino acids N-terminal and 20 residues C-terminal of the C1 domains are necessary for neurite induction. The corresponding regions from all other novel isoforms but not from PKC alpha were also neuritogenic. Further mutation studies indicated that amino acids immediately N-terminal of the C1a domain are important for plasma membrane localization and thereby for neurite induction. Addition of phorbol ester made this construct neurite-inducing. However, mutation of amino acids flanking the C1b domain reduced the neurite-inducing capacity even in the presence of phorbol esters. Sequence alignment highlighted an 8-amino acid-long sequence N-terminal of the C1b domain that is conserved in all novel PKC isoforms. Specifically, we found that mutations of either Phe-237, Val-239, or Met-241 in PKC epsilon completely abolished the neurite-inducing capacity of PKC epsilon C1 domains. Phorbol ester treatment could not restore neurite induction but led to a plasma membrane translocation. Furthermore, if 12 amino acids were included N-terminal of the C1b domain, the C1a domain was dispensable for neurite induction. In conclusion, we have identified a highly conserved sequence N-terminal of the C1b domain that is crucial for neurite induction by PKC epsilon, indicating that this motif may be critical for some morphological effects of PKC.	Lund Univ, Malmo Univ Hosp, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Larsson, C (corresponding author), Lund Univ, UMAS, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.	Christer.Larsson@molmed.mas.lu.se						Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hernandez RM, 2001, J CELL BIOCHEM, V83, P532, DOI 10.1002/jcb.1246; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Hurley JH, 1997, PROTEIN SCI, V6, P477; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kiss Z, 1999, ARCH BIOCHEM BIOPHYS, V363, P121, DOI 10.1006/abbi.1998.1066; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Mikule K, 2003, J BIOL CHEM, V278, P21168, DOI 10.1074/jbc.M211828200; Oka M, 2003, FEBS LETT, V554, P179, DOI 10.1016/S0014-5793(03)01158-X; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Schultz A, 2004, J BIOL CHEM, V279, P31750, DOI 10.1074/jbc.M313017200; Schultz A, 2004, J NEUROCHEM, V89, P1427, DOI 10.1111/j.1471-4159.2004.02431.x; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Singer WD, 1996, J BIOL CHEM, V271, P4504; Troller U, 2004, CELL SIGNAL, V16, P245, DOI 10.1016/S0898-6568(03)00135-9; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	37	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17910	17919		10.1074/jbc.M412036200	http://dx.doi.org/10.1074/jbc.M412036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718244	hybrid			2022-12-27	WOS:000228807200044
J	Marshall, CB; Chakrabartty, A; Davies, PL				Marshall, CB; Chakrabartty, A; Davies, PL			Hyperactive antifreeze protein from winter flounder is a very long rod-like dimer of alpha-helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM ELLIPTICITIES; ICE CRYSTAL MORPHOLOGY; SMELT OSMERUS-MORDAX; I ANTIFREEZE; FREEZING RESISTANCE; THERMAL HYSTERESIS; COILED-COILS; BINDING; ADSORPTION; PEPTIDES	The winter flounder ( Pseudopleuronectes americanus) produces short, monomeric alpha-helical antifreeze proteins ( type I AFP), which adsorb to and inhibit the growth of ice crystals. These proteins alone are not sufficiently active to protect this fish against freezing at -1.9 degrees C, the freezing point of seawater. We have recently isolated a hyperactive antifreeze protein from the plasma of the flounder with activity 10 - 100-fold higher than type I AFP. It is comparable in activity to the AFPs produced by insects, and is capable of conferring freeze resistance to the flounder. This novel AFP has a molecular mass of 16,683 Da and a remarkable amino acid composition that is > 60% alanine. CD spectra indicate that the protein is almost entirely alpha-helical at 4 degrees C but partially denatures at 20 degrees C, resulting in a species with a moderately reduced helix content that is stable at up to 50 degrees C. This transformation correlates with irreversible loss of activity. Analytical ultracentrifugation ( sedimentation velocity and equilibrium) indicates that the predominant species in solution is dimeric ( molecular weight, 32,275). Size-exclusion chromatography reveals a 2-fold higher apparent molecular weight suggesting that this molecule has an unusually large Stokes radius. The axial ratio of the dimer calculated from the sedimentation velocity data is 18: 1, confirming that this protein has an extraordinarily long, rod-like structure, consistent with a novel dimeric alpha-helical arrangement. The structural model that best fits these data is one in which the similar to 195 amino acids of each monomer form one similar to 290-angstrom long alpha-helix and associate via a unique dimerization motif that is distinct from that of the leucine zipper and any other coiled-coil.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Queens University - Canada; University of Toronto	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Botterell Hall, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Marshall, Christopher/K-8943-2019	Marshall, Christopher/0000-0002-7571-5700; Chakrabartty, Avi/0000-0001-7002-8381				Achenbach JC, 2002, EUR J BIOCHEM, V269, P1219, DOI 10.1046/j.1432-1033.2002.02761.x; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2003, J BIOL CHEM, V278, P38942, DOI 10.1074/jbc.M306776200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BURCHAM TS, 1984, BIOPOLYMERS, V23, P1379, DOI 10.1002/bip.360230720; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; Chao H, 1996, PROTEIN SCI, V5, P1150; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Davies PL, 2002, PHILOS T R SOC B, V357, P927, DOI 10.1098/rstb.2002.1081; DAVIES PL, 1992, GENE, V112, P171, DOI 10.1016/0378-1119(92)90373-W; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P388, DOI 10.1016/0005-2795(77)90395-6; DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0; Evans RP, 2001, BBA-PROTEIN STRUCT M, V1547, P235, DOI 10.1016/S0167-4838(01)00190-X; EWART KV, 1990, CAN J ZOOL, V68, P1652, DOI 10.1139/z90-245; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; Gronwald W, 1996, BIOCHEMISTRY-US, V35, P16698, DOI 10.1021/bi961934w; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Job GE, 2004, ANGEW CHEM INT EDIT, V43, P5649, DOI 10.1002/anie.200460536; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Kuiper MJ, 2003, BIOCHEM BIOPH RES CO, V300, P645, DOI 10.1016/S0006-291X(02)02900-5; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Leinala EK, 2002, J BIOL CHEM, V277, P33349, DOI 10.1074/jbc.M205575200; Liou YC, 2000, NATURE, V406, P322, DOI 10.1038/35018604; Marshall CB, 2004, BIOCHEMISTRY-US, V43, P11637, DOI 10.1021/bi0488909; Marshall CB, 2004, NATURE, V429, P153, DOI 10.1038/429153a; Marshall CB, 2004, BIOCHEMISTRY-US, V43, P148, DOI 10.1021/bi035605x; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; NEMETHY G, 1967, NATURE, V214, P363, DOI 10.1038/214363a0; Nishimiya Y, 2003, J BIOL CHEM, V278, P32307, DOI 10.1074/jbc.M304390200; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCOTT GK, 1988, J MOL EVOL, V27, P29, DOI 10.1007/BF02099727; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Starzyk A, 2005, BIOCHEMISTRY-US, V44, P369, DOI 10.1021/bi0481444; Tyshenko MG, 1997, NAT BIOTECHNOL, V15, P887, DOI 10.1038/nbt0997-887; Wallimann P, 1999, ANGEW CHEM INT EDIT, V38, P1290, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1290::AID-ANIE1290>3.0.CO;2-E; Wallimann P, 2003, J AM CHEM SOC, V125, P1203, DOI 10.1021/ja0275360; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang W, 1999, FEBS LETT, V455, P372, DOI 10.1016/S0014-5793(99)00906-0; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	50	66	71	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17920	17929		10.1074/jbc.M500622200	http://dx.doi.org/10.1074/jbc.M500622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15716269	hybrid			2022-12-27	WOS:000228807200045
J	Wei, Q; Xia, Y				Wei, Q; Xia, Y			Roles of 3-phosphoinositide-dependent kinase 1 in the regulation of endothelial nitric-oxide synthase phosphorylation and function by heat shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; AKT-DEPENDENT PHOSPHORYLATION; INDEPENDENT ENOS ACTIVATION; NO RELEASE; HSP90; KINASE; GELDANAMYCIN; BINDING; CELLS; GROWTH	The 90-kDa heat shock protein (Hsp90) plays an important role in endothelial nitric-oxide synthase ( eNOS) regulation. Besides acting as an allosteric enhancer, Hsp90 was shown to serve as a module recruiting Akt to phosphorylate the serine 1179/1177 (bovine/human) residue of eNOS. Akt is activated by the phosphorylation of 3-phosphoinositide-dependent kinase 1 (PDK1). Whether PDK1 is involved in the actions of Hsp90 on eNOS phosphorylation and function remains unknown. To address this issue, we treated bovine eNOS stably transfected human embryonic kidney 293 cells with Hsp90 inhibitors and determined the alterations of phospho-eNOS, Akt, and PDK1. Both geldanamycin and radicicol, two structurally different Hsp90 inhibitors, selectively reduced serine 1179-phosphorylated eNOS, leading to decreased enzyme activity. In Hsp90-inhibited cells, eNOS-associated phospho-Akt was decreased, but the total amount of Akt associated with eNOS remained the same. Further studies showed that Hsp90 inhibition dramatically depleted intracellular PDK1. Proteasome but not caspase blockade prevented the loss of PDK1 caused by Hsp90 inhibition. Silencing the PDK1 gene by small interfering RNA was sufficient to induce reduction of phospho-Akt and consequent loss of serine 1179-phosphorylated eNOS. Moreover, overexpression of PDK1, but not Akt, reversed Hsp90 inhibition-induced loss of eNOS serine 1179 phosphorylation and salvaged enzymatic activity. Thus, in addition to functioning as a module to recruit Akt to eNOS, Hsp90 also critically stabilized PDK1 by preventing it from proteasomal degradation. Inhibition of Hsp90 function resulted in PDK1 depletion and thus triggered a cascade of Akt deactivation, loss of eNOS serine 1179 phosphorylation, and decrease of enzyme function.	Ohio State Univ, Davis Heart & Lung Res Inst 605, Med Ctr, Dept Mol & Cellular Biochem,Div Cardiovasc Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Xia, Y (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 605, Med Ctr, Dept Mol & Cellular Biochem,Div Cardiovasc Med, 473 W 12th Ave, Columbus, OH 43210 USA.	xia-3@medctr.osu.edu			NHLBI NIH HHS [R01-HL77575] Funding Source: Medline; PHS HHS [AB00835] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balligand JL, 2002, CIRC RES, V90, P838, DOI 10.1161/01.RES.0000018173.10175.FF; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BRASSO AD, 2002, J BIOL CHEM, V277, P39858; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MONCADA S, 1991, PHARMACOL REV, V43, P109; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SON Y, 2001, AM J PHYSIOL, V281, pC1819; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	39	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18081	18086		10.1074/jbc.M413607200	http://dx.doi.org/10.1074/jbc.M413607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15737995	hybrid			2022-12-27	WOS:000228807200065
J	Fu, MF; Rao, M; Bouras, T; Wang, CG; Wu, KM; Zhang, XP; Li, ZP; Yao, TP; Pestell, RG				Fu, MF; Rao, M; Bouras, T; Wang, CG; Wu, KM; Zhang, XP; Li, ZP; Yao, TP; Pestell, RG			Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; CELL-CYCLE; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; PPAR-GAMMA; TUMOR-ANTIGEN; D1; COMPLEX; TRANSACTIVATION; TRANSCRIPTION	The cyclin D1 gene encodes the labile serum-inducible regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein. Overexpression of cyclin D1 promotes cellular proliferation and normal physiological levels of cyclin D1 function to inhibit adipocyte differentiation in vivo. We have previously shown that cyclin D1 inhibits peroxisome proliferator-activated receptor ( PPAR) gamma-dependent activity through a cyclin-dependent kinase- and retinoblastoma protein-binding-independent mechanism. In this study, we determined the molecular mechanism by which cyclin D1 regulated PPAR gamma function. Herein, murine embryonic fibroblast (MEF) differentiation by PPAR gamma ligand was associated with a reduction in histone deacetylase (HDAC1) activity. Cyclin D1(-/-) MEFs showed an increased propensity to undergo differentiation into adipocytes. Genetic deletion of cyclin D1 reduced HDAC1 activity. Reconstitution of cyclin D1 into the cyclin D1(-/-) MEFs increased HDAC1 activity and blocked PPAR gamma-mediated adipogenesis. PPAR gamma activity was enhanced in cyclin D1(-/-) cells. Reintroduction of cyclin D1 inhibited basal and ligand-induced PPAR gamma activity and enhanced HDAC repression of PPAR gamma activity. Cyclin D1 bound HDAC in vivo and preferentially physically associated with HDAC1, HDAC2, HDAC3, and HDAC5. Chromatin immunoprecipitation assay demonstrated that cyclin D1 enhanced recruitment of HDAC1 and HDAC3 and histone methyltransferase SUV39H1 to the PPAR response element of the lipoprotein lipase promoter and decreased acetylation of total histone H3 and histone H3 lysine 9. Collectively, these studies suggest an important role of cyclin D1 in regulation of PPAR gamma-mediated adipocyte differentiation through recruitment of HDACs to regulate PPAR response element local chromatin structure and PPAR gamma function.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Georgetown University; Duke University	Pestell, RG (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Res Bldg,Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA086072, R01CA107382, R01CA070896, R01CA075503, R01CA093596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065220] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA93596, R01CA75503, R01CA70896, R01CA86072, R01CA107382] Funding Source: Medline; NIDDK NIH HHS [1 R21DK065220-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alexander DL, 1998, J CELL SCI, V111, P3311; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bouzahzah B, 2000, CANCER RES, V60, P4531; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Holnthoner W, 2002, J BIOL CHEM, V277, P45847, DOI 10.1074/jbc.M209354200; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Knudsen KE, 1999, CANCER RES, V59, P2297; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tang QQ, 2004, BIOCHEM BIOPH RES CO, V319, P235, DOI 10.1016/j.bbrc.2004.04.176; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	47	226	232	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16934	16941		10.1074/jbc.M500403200	http://dx.doi.org/10.1074/jbc.M500403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713663	hybrid			2022-12-27	WOS:000228615500048
J	Nemoto, S; Fergusson, MM; Finkel, T				Nemoto, S; Fergusson, MM; Finkel, T			SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; CELL-SURVIVAL; NAD(+)-DEPENDENT DEACETYLASES; MITOCHONDRIAL BIOGENESIS; PROTEIN DEACETYLASES; GAMMA COACTIVATOR-1; NAD; LONGEVITY	In lower organisms, increased expression of the NAD-dependent deacetylase Sir2 augments lifespan. The mechanism through which this life extension is mediated remains incompletely understood. Here we have examined the cellular effects of overexpression of SIRT1, the closest mammalian ortholog of Sir2. In PC12 cells, increased expression of the NAD-dependent deacetylase SIRT1 reduces cellular oxygen consumption by similar to 25%. We further demonstrate that SIRT1 expression can alter the transcriptional activity of the mitochondrial biogenesis coactivator PGC-1 alpha. In addition, SIRT1 and PGC-1 alpha directly interact and can be co-immunoprecipitated as a molecular complex. A single amino acid mutation in the putative ADP-ribosyltransferase domain of SIRT1 inhibits the interaction of SIRT1 with PGC-1 alpha but does not effect the interaction of SIRT1 with either p53 or Foxo3a. We further show that PGC-1 alpha is acetylated in vivo. This acetylation is augmented by treatment with the SIRT1 inhibitor nicotinamide or by expression of the transcriptional coactivator p300. Finally we demonstrate that SIRT1 catalyzes PGC-1 alpha deacetylation both in vitro and in vivo. These results provide a direct link between the sirtuins, a family of proteins linked to lifespan determination and PGC-1 alpha, a coactivator that regulates cellular metabolism.	NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiovasc Branch, NIH, Bldg 10 CRC,Rm 5-3330, Bethesda, MD 20892 USA.	Finkelt@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RM, 2003, SCIENCE, V302, P2124, DOI 10.1126/science.1088697; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Dumble M, 2004, ANN NY ACAD SCI, V1019, P171, DOI 10.1196/annals.1297.027; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TRAN H, 2003, SCI STKE; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	37	801	826	0	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16456	16460		10.1074/jbc.M501485200	http://dx.doi.org/10.1074/jbc.M501485200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716268	hybrid			2022-12-27	WOS:000228444800119
J	Pfeffer, SR				Pfeffer, SR			Structural clues to Rab GTPase functional diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CRYSTAL-STRUCTURE; EFFECTOR; PROTEIN; SPECIFICITY; REGIONS; DETERMINANT; MECHANISM; INSIGHTS; REVEALS; COMPLEX	Rab GTPases are key regulators of membrane trafficking in eukaryotes. Recent structural analysis of a number of Rabs, either alone or in complex with partner proteins, has provided new insight into the importance of both conserved and non-conserved features of these proteins that specify their unique functions and localizations. This review will highlight what we have learned from crystallographic analysis of this important protein family.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Dept Biochem, Sch Med, 279 Campus Dr B400, Stanford, CA 94305 USA.	pfeffer@stanford.edu			NIDDK NIH HHS [DK33732] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali BR, 2004, J CELL SCI, V117, P6401, DOI 10.1242/jcs.01542; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Chen LQ, 2004, J BIOL CHEM, V279, P40204, DOI 10.1074/jbc.M407114200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Constantinescu AT, 2002, STRUCTURE, V10, P569, DOI 10.1016/S0969-2126(02)00737-2; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Merithew E, 2003, J BIOL CHEM, V278, P8494, DOI 10.1074/jbc.M211514200; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Neu M, 1997, PROTEINS, V27, P204, DOI 10.1002/(SICI)1097-0134(199702)27:2<204::AID-PROT6>3.0.CO;2-F; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pasqualato S, 2004, J BIOL CHEM, V279, P11480, DOI 10.1074/jbc.M310558200; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rak A, 2004, CELL, V117, P749, DOI 10.1016/j.cell.2004.05.017; Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Wittmann JG, 2004, FEBS LETT, V568, P23, DOI 10.1016/j.febslet.2004.05.004; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu GY, 2004, NAT STRUCT MOL BIOL, V11, P975, DOI 10.1038/nsmb832	31	121	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15485	15488		10.1074/jbc.R500003200	http://dx.doi.org/10.1074/jbc.R500003200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15746102	hybrid			2022-12-27	WOS:000228444800003
J	Shorer, H; Amar, N; Meerson, A; Elazar, Z				Shorer, H; Amar, N; Meerson, A; Elazar, Z			Modulation of N-ethylmaleimide-sensitive factor activity upon amino acid deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; SYNTAXIN HOMOLOG; SNARE COMPLEX; PROTEIN; GOLGI; TRANSPORT; NSF; ATPASE; EXOCYTOSIS; PATHWAY	Adaptation of eukaryotic cells to changing environmental conditions entails rapid regulation of protein targeting and transport to specific organelles. Such adaptation is well exemplified in mammalian cells exposed to nitrogen starvation that are triggered to form and transport autophagosomes to lysosomes, thus constituting an inducible intracellular trafficking pathway. Here we investigated the relationship between the general secretory machinery and the autophagic pathway in Chinese hamster ovary cells grown in the absence of amino acid. Utilizing VSVG-YFP ( vesicular stomatitis virus G protein fused to yellow fluorescent protein) and norepinephrine as markers for constitutive and regulated exocytosis, respectively, we found that secretion is attenuated in cells grown in media lacking amino acid. Such decrease in exocytosis stems from partial inhibition of N-ethylmaleimide-sensitive factor ATPase activity, which in turn causes an accumulation of SNARE complexes at both the Golgi apparatus and the plasma membrane of the starved cells. These findings expose a novel cellular strategy to attenuate secretion of proteins under conditions of limited amino acid supply.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@wicc.weizmann.ac.il	Meerson, Ari/N-2338-2019	Meerson, Ari/0000-0002-5811-7952				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Grusovin J, 2003, FRONT BIOSCI-LANDMRK, V8, pD620, DOI 10.2741/1052; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	45	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16219	16226		10.1074/jbc.M500554200	http://dx.doi.org/10.1074/jbc.M500554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708857	hybrid			2022-12-27	WOS:000228444800091
J	Altman, S				Altman, S			Masters of DNA (Reprinted from JBC Papers in Press, February, 2005)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Reprint							T4 DEOXYRIBONUCLEIC ACID; GENETIC TRANSFORMATION; ESCHERICHIA-COLI; BACTERIOPHAGE; ENDONUCLEASE; POLYMERASE; CELLULOSE; PROTEINS; ENZYME		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Altman, S (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	sidney.altman@yale.edu						ALBERTS BM, 1968, COLD SPRING HARB SYM, V33, P289, DOI 10.1101/SQB.1968.033.01.033; ALTMAN S, 1970, J MOL BIOL, V50, P263, DOI 10.1016/0022-2836(70)90191-9; ALTMAN S, 1970, P NATL ACAD SCI USA, V66, P716, DOI 10.1073/pnas.66.3.716; ALTMAN S, 1971, NATURE-NEW BIOL, V229, P19, DOI 10.1038/newbio229019a0; Altman S, 2003, GENETICS, V165, P1633; ALTMAN S, 1970, J MOL BIOL, V50, P235, DOI 10.1016/0022-2836(70)90190-7; ALTMAN S, 2005, J BIOL CHEM     0217; Altman S., 1999, RNA WORLD; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; Holmes F. L., 2001, MESELSON STAHL REPLI; KAEMPFER RO, 1968, J MOL BIOL, V31, P277, DOI 10.1016/0022-2836(68)90444-0; KAISER VL, 1995, P NATL ACAD SCI USA, V92, P2234, DOI 10.1073/pnas.92.6.2234; LERMAN LS, 1961, J MOL BIOL, V3, P18, DOI 10.1016/S0022-2836(61)80004-1; LERMAN LS, 1959, BIOCHIM BIOPHYS ACTA, V33, P371, DOI 10.1016/0006-3002(59)90127-1; LERMAN LS, 1964, J MOL BIOL, V10, P367, DOI 10.1016/S0022-2836(64)80058-9; LERMAN LS, 1957, BIOCHIM BIOPHYS ACTA, V26, P68, DOI 10.1016/0006-3002(57)90055-0; LERMAN LS, 1953, NATURE, V172, P635, DOI 10.1038/172635a0; LERMAN LS, 1963, P NATL ACAD SCI USA, V49, P94, DOI 10.1073/pnas.49.1.94; LITMAN RM, 1959, VIROLOGY, V8, P125, DOI 10.1016/0042-6822(59)90025-X; LITMAN RM, 1968, J BIOL CHEM, V243, P6222; MANIATIS T, 1974, J MOL BIOL, V84, P37, DOI 10.1016/0022-2836(74)90211-3; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; MESELSON M, 1961, P NATL ACAD SCI USA, V47, P857, DOI 10.1073/pnas.47.6.857; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; RHOADES M, 1973, J BIOL CHEM, V248, P521; RIPLEY LS, 1990, ANNU REV GENET, V211, P63; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367	30	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14361	14365		10.1074/jbc.X400012200	http://dx.doi.org/10.1074/jbc.X400012200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15718237	hybrid			2022-12-27	WOS:000228236800002
J	Birgander, PL; Bug, S; Kasrayan, A; Dahlroth, SL; Westman, MA; Gordon, E; Sjoberg, BM				Birgander, PL; Bug, S; Kasrayan, A; Dahlroth, SL; Westman, MA; Gordon, E; Sjoberg, BM			Nucleotide-dependent formation of catalytically competent dimers from engineered monomeric ribonucleotide reductase protein R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY REGULATION; ESCHERICHIA-COLI; ALLOSTERIC REGULATION; SUBUNIT INTERACTION; DIPHOSPHATE REDUCTASE; COMPREHENSIVE MODEL; EFFECTOR-BINDING; CELL-CYCLE; ENZYME; MOUSE	Each catalytic turnover by aerobic ribonucleotide reductase requires the assembly of the two proteins, R1 (alpha(2)) and R2 (beta(2)), to produce deoxyribonucleotides for DNA synthesis. The R2 protein forms a tight dimer, whereas the strength of the R1 dimer differs between organisms, being monomeric in mouse R1 and dimeric in Escherichia coli. We have used the known E. coli R1 structure as a framework for design of eight different mutations that affect the helices and proximal loops that comprise the dimer interaction area. Mutations in loop residues did not affect dimerization, whereas mutations in the helices had very drastic effects on the interaction resulting in monomeric proteins with very low or no activity. The monomeric N238A protein formed an interesting exception, because it unexpectedly was able to reduce ribonucleotides with a comparatively high capacity. Gel filtration studies revealed that N238A was able to dimerize when bound by both substrate and effector, a result in accordance with the monomeric R1 protein from mouse. The effects of the N238A mutation, fit well with the notion that E. coli protein R1 has a comparatively small dimer interaction surface in relation to its size, and the results illustrate the stabilization effects of substrates and effectors in the dimerization process. The identification of key residues in the dimerization process and the fact that there is little sequence identity between the interaction areas of the mammalian and the prokaryotic enzymes may be of importance in drug design, similar to the strategy used in treatment of HSV infection.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, Svante Arrhenius Vag 16, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; CORY JG, 1978, J BIOL CHEM, V253, P2898; EKBERG M, 2000, THESIS SWEDISH U AGR; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Himo F, 2003, CHEM REV, V103, P2421, DOI 10.1021/cr020436s; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kasrayan A, 2004, J BIOL CHEM, V279, P31050, DOI 10.1074/jbc.M400693200; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Poole AM, 2002, J MOL EVOL, V55, P180, DOI 10.1007/s00239-002-2315-3; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; Scott CP, 2001, BIOCHEMISTRY-US, V40, P1651, DOI 10.1021/bi002335z; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; SUN L, 1994, J BACTERIOL, V176, P2415, DOI 10.1128/JB.176.8.2415-2426.1994; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1980, J BIOL CHEM, V255, P7426; THELANDER L, 1973, J BIOL CHEM, V248, P4591; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uhlin U, 1996, J MOL BIOL, V262, P358, DOI 10.1006/jmbi.1996.0519; UPPSTEN M, 2004, THESIS SWEDISH U AGR, P52	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14997	15003		10.1074/jbc.M500565200	http://dx.doi.org/10.1074/jbc.M500565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699052	hybrid			2022-12-27	WOS:000228236800081
J	Bullesbach, EE; Schwabe, C				Bullesbach, EE; Schwabe, C			LGR8 signal activation by the relaxin-like factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-LIKE PEPTIDE; RECEPTOR; CRYPTORCHIDISM; LINKS	The relaxin-like factor (RLF) is thought to be responsible for the intra-abdominal migration of the testis during mammalian development. Our latest studies of RLF and LGR8 have revealed that the N-terminal region of the A chain is not required for receptor binding but is indispensable for cyclic AMP generation. RLF derivatives with six residues deleted from the N terminus of the A chain are active, whereas further truncation, up to the first A chain cysteine (A-10), yields tightly binding ligands devoid of signaling activity. These derivatives are specific competitive inhibitors (RLFi) of RLF. Although receptor binding is dependent upon B chain residues, the N-terminal region of the A chain is a generic trigger of the trans-membrane signaling activity.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bullesbach, EE (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	bullesee@musc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040406] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R01-HD40406] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Adler A J, 1973, Methods Enzymol, V27, P675; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; Bullesbach EE, 2002, BIOCHEMISTRY-US, V41, P274, DOI 10.1021/bi0117302; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; BURKHARDT E, 1994, GENOMICS, V20, P13, DOI 10.1006/geno.1994.1121; Drapeau G R, 1977, Methods Enzymol, V47, P189; Gorlov IP, 2002, HUM MOL GENET, V11, P2309, DOI 10.1093/hmg/11.19.2309; Hsu SYT, 2003, MOL CELL ENDOCRINOL, V202, P165, DOI 10.1016/S0303-7207(03)00078-9; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; MARUYAMA K, 1992, J PROTEIN CHEM, V11, P1, DOI 10.1007/BF01025086; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Overbeek PA, 2001, GENESIS, V30, P26, DOI 10.1002/gene.1029; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Truong A, 2003, BIOL REPROD, V69, P1658, DOI 10.1095/biolreprod.103.019166; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	22	48	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14586	14590		10.1074/jbc.M414443200	http://dx.doi.org/10.1074/jbc.M414443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708846	hybrid			2022-12-27	WOS:000228236800031
J	Fraley, TS; Pereira, CB; Tran, TC; Singleton, C; Greenwood, JA				Fraley, TS; Pereira, CB; Tran, TC; Singleton, C; Greenwood, JA			Phosphoinositide binding regulates alpha-actinin dynamics - Mechanism for modulating cytoskeletal remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN MUTANTS; GREEN FLUORESCENT PROTEIN; FOCAL ADHESIONS; STRESS FIBERS; PI 3-KINASE; IN-VIVO; KINASE; ACTIVATION; LINK; RAS	The active association-dissociation of dynamic protein-protein interactions is critical for the ability of the actin cytoskeleton to remodel. To determine the influence of phosphoinositide binding on the dynamic interaction of alpha-actinin with actin filaments and integrin adhesion receptors, fluorescence recovery after photobleaching (FRAP) microscopy was carried out comparing wild-type green fluorescent protein (GFP)-alpha-actinin and a GFP-alpha-actinin mutant with a decreased affinity for phosphoinositides (Fraley, T. S., Tran, T. C., Corgan, A. M., Nash, C. A., Hao, J., Critchley, D. R., and Greenwood, J. A. (2003) J. Biol. Chem. 278, 24039-24045). In fibroblasts, recovery of the mutant alpha-actinin protein was 2.2 times slower than the wild type along actin stress fibers and 1.5 times slower within focal adhesions. FRAP was also measured in U87MG glioblastoma cells, which have higher levels of 3-phosphorylated phosphoinositides. As expected, alpha-actinin turnover for both the stress fiber and focal adhesion populations was faster in U87MG cells compared with fibroblasts with recovery of the mutant protein slower than the wild type along actin stress fibers. To understand the influence of alpha-actinin turnover on the modulation of the actin cytoskeleton, wild-type or mutant alpha-actinin was co-expressed with constitutively active phosphoinositide (PI) 3-kinase. Co-expression with the alpha-actinin mutant inhibited actin reorganization with the appearance of enlarged alpha-actinin containing focal adhesions. These results demonstrate that the binding of phosphoinositides regulates the association-dissociation rate of alpha-actinin with actin filaments and integrin adhesion receptors and that the dynamics of alpha-actinin is important for PI 3-kinase-induced reorganization of the actin cytoskeleton. In conclusion, phosphoinositide regulation of alpha-actinin dynamics modulates the plasticity of the actin cytoskeleton influencing remodeling.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Dept Stat, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Greenwood, JA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.	jeffrey.greenwood@orst.edu		Greenwood, Juliet/0000-0001-6438-964X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063711] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR107903-01] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NIGMS NIH HHS [GM63711] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatt A, 2002, J CELL SCI, V115, P3415; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Corgan AM, 2004, BIOCHEM J, V378, P1067, DOI 10.1042/BJ20031124; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Greene DK, 2003, J BIOL CHEM, V278, P7617, DOI 10.1074/jbc.M207123200; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; Peterson LJ, 2004, MOL BIOL CELL, V15, P3497, DOI 10.1091/mbc.E03-09-0696; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; van Drogen Frank, 2004, Methods Mol Biol, V284, P287; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	28	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15479	15482		10.1074/jbc.M500631200	http://dx.doi.org/10.1074/jbc.M500631200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710624	hybrid			2022-12-27	WOS:000228236800136
J	Mayr, BM; Guzman, E; Montminy, M				Mayr, BM; Guzman, E; Montminy, M			Glutamine rich and basic region/leucine zipper (bZIP) domains stabilize cAMP-response element-binding protein (CREB) binding to chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER IN-VIVO; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATOR; TFIID COMPLEX; REVEALS; PHOSPHORYLATION; SITES; EXPRESSION; SUBDOMAINS; INDUCTION	We have examined the dynamics of cAMP-response element-binding protein ( CREB) binding to chromatin in live cells using fluorescence recovery after photobleaching ( FRAP). CREB was found to bind to target sites with a residence time of 100 s, and exposure to a cAMP agonist had no effect on these kinetics. In addition to the basic region/leucine zipper ( bZIP) domain, a glutamine-rich trans-activation domain in CREB called Q2 also appeared to be critical for promoter occupancy. Indeed, mutations in Q2 that reduced residence time by FRAP assay disrupted target gene activation via CREB in cells exposed to a cAMP agonist. Notably, insertion of the glutamine-rich B trans-activation domain of SP1 into a mutant CREB polypeptide lacking Q2 stabilized CREB occupancy and rescued target gene activation. These results suggest a novel mechanism by which the family of glutamine-rich activators promotes cellular gene expression.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA	Salk Institute	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Mayr, Bernhard M/F-6936-2012	Mayr, Bernhard M/0000-0002-8973-4494	NIGMS NIH HHS [R01 GM037828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Halder SK, 2002, MOL ENDOCRINOL, V16, P1853, DOI 10.1210/me.2001-0262; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Zou MX, 2004, ONCOGENE, V23, P330, DOI 10.1038/sj.onc.1207053	29	29	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15103	15110		10.1074/jbc.M414144200	http://dx.doi.org/10.1074/jbc.M414144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703171	hybrid			2022-12-27	WOS:000228236800093
J	Shenoy, SK; Lefkowitz, RJ				Shenoy, SK; Lefkowitz, RJ			Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; REGULATED KINASES; MAP KINASE; DEPENDENT DEGRADATION; ADRENERGIC-RECEPTOR; ERK ACTIVATION; GENE; TRANSDUCTION	Angiotensin II type 1a (AT1a), vasopressin V2, and neurokinin 1 (NK1) receptors are seven-transmembrane receptors (7TMRs) that bind and co-internalize with the multifunctional adaptor protein, beta-arrestin. These receptors also lead to robust and persistent activation of extracellular-signal regulated kinase 1/2 (ERK1/2) localized on endosomes. Recently, the co-trafficking of receptor-beta-arrestin complexes to endosomes was demonstrated to require stable beta-arrestin ubiquitination (Shenoy, S. K., and Lefkowitz, R. J. (2003) J. Biol. Chem. 278, 14498-14506). We now report that lysines at positions 11 and 12 in beta-arrestin2 are specific and required sites for its AngII-mediated sustained ubiquitination. Thus, upon AngII stimulation the mutant beta-arrestin2(K11,12R) is only transiently ubiquitinated, does not form stable endocytic complexes with the AT1aR, and is impaired in scaffolding-activated ERK1/2. Fusion of a ubiquitin moiety in-frame to beta-arrestin2(K11,12R) restores AngII-mediated trafficking and signaling. Wild type beta-arrestin2 and beta-arrestin2(K11R),(K12R)-Ub, but not beta-arrestin2(K11R,K12R), prevent nuclear translocation of pERK. These findings imply that sustained beta-arrestin ubiquitination not only directs co-trafficking of receptor-beta-arrestin complexes but also orchestrates the targeting of "7TMR signalosomes" to microcompartments within the cell. Surprisingly, binding of beta-arrestin2(K11R,K12R) to V2R and NK1R is indistinguishable from that of wild type beta-arrestin2. Moreover, ubiquitination patterns and ERK scaffolding of beta-arrestin2(K11,12R) are unimpaired with respect to V2R stimulation. In contrast, a quintuple lysine mutant (beta-arrestin2(K18R,K107R,K108R,K207R,K296R)) is impaired in endosomal trafficking in response to V2R but not AT1aR stimulation. Our findings delineate a novel regulatory mechanism for 7TMR signaling, dictated by the ubiquitination of beta-arrestin on specific lysines that become accessible for modification due to the specific receptor-bound conformational states of beta-arrestin2.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NHLBI NIH HHS [HL16037, HL 70631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL070631, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; HERSHKO A, 1981, J BIOL CHEM, V256, P1525; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LEE RM, 1992, J BIOL CHEM, V267, P1088; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Teis D, 2003, CELL MOL LIFE SCI, V60, P2020, DOI 10.1007/s00018-003-3010-2; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	46	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15315	15324		10.1074/jbc.M412418200	http://dx.doi.org/10.1074/jbc.M412418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699045	hybrid			2022-12-27	WOS:000228236800117
J	Wisniewski, HG; Snitkin, ES; Mindrescu, C; Sweet, MH; Vilcek, J				Wisniewski, HG; Snitkin, ES; Mindrescu, C; Sweet, MH; Vilcek, J			TSG-6 protein binding to glycosaminoglycans - Formation of stable complexes with hyaluronan and binding to chondroitin sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; COLLAGEN-INDUCED ARTHRITIS; FACTOR-STIMULATED GENE-6; T-CELL EXTRAVASATION; SMOOTH-MUSCLE-CELLS; LINK MODULE; EXTRACELLULAR-MATRIX; PRIMARY ADHESION; HEAVY-CHAIN; DBA/1J MICE	TSG-6 protein, up-regulated in inflammatory lesions and in the ovary during ovulation, shows anti-inflammatory activity and plays an essential role in female fertility. Studies in murine models of acute inflammation and experimental arthritis demonstrated that TSG-6 has a strong anti-inflammatory and chondroprotective effect. TSG-6 protein is composed of the N-terminal link module that binds hyaluronan and a C-terminal CUB domain, present in a variety of proteins. Interactions between the isolated link module and hyaluronan have been studied extensively, but little is known about the binding of full-length TSG-6 protein to hyaluronan and other glycosaminoglycans. We show that TSG-6 protein and hyaluronan, in a temperature-dependent fashion, form a stable complex that is resistant to dissociating agents. The formation of such stable complexes may underlie the activities of TSG-6 protein in inflammation and fertility, e. g. the TSG-6-dependent cross-linking of hyaluronan in the cumulus cell-oocyte complex during ovulation. Because adhesion to hyaluronan is involved in cell trafficking in inflammatory processes, we also studied the effect of TSG-6 on cell adhesion. TSG-6 binding to immobilized hyaluronan did not interfere with subsequent adhesion of lymphoid cells. In addition to immobilized hyaluronan, full-length TSG-6 also binds free hyaluronan and all chondroitin sulfate isoforms under physiological conditions. These interactions may contribute to the localization of TSG-6 in cartilage and to its chondroprotective and anti-inflammatory effects in models of arthritis.	NYU Med Ctr, Dept Microbiol, Sch Med, New York, NY 10016 USA	New York University	Wisniewski, HG (corresponding author), NYU Med Ctr, Dept Microbiol, Sch Med, 550 1st Ave, New York, NY 10016 USA.	hans-georg.wisniewski@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044351] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-44351] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bardos T, 2002, J IMMUNOL, V168, P6013, DOI 10.4049/jimmunol.168.12.6013; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Calvete JJ, 1996, FEBS LETT, V379, P207, DOI 10.1016/0014-5793(95)01513-2; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUANG L, 1993, J BIOL CHEM, V268, P26725; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Odum L, 2002, REPRODUCTION, V124, P249, DOI 10.1530/reprod/124.2.249; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PERIN JP, 1987, J BIOL CHEM, V262, P13269; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; SANZ L, 1993, MOL REPROD DEV, V35, P37, DOI 10.1002/mrd.1080350107; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; SCOTT JE, 1961, BIOCHEM J, V81, P418, DOI 10.1042/bj0810418; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Topfer-Petersen E, 1998, ANDROLOGIA, V30, P217; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	58	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14476	14484		10.1074/jbc.M411734200	http://dx.doi.org/10.1074/jbc.M411734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699048	hybrid			2022-12-27	WOS:000228236800017
J	Sellers, JA; Hou, L; Schoenberg, DR; de Medeiros, SRB; Wahli, W; Shelness, GS				Sellers, JA; Hou, L; Schoenberg, DR; de Medeiros, SRB; Wahli, W; Shelness, GS			Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; APOLIPOPHORIN-II/I; EXPRESSION; LIPOVITELLIN; CELLS; GENE; ABETALIPOPROTEINEMIA; METABOLISM	Vitellogenins (Vtg) are ancient lipid transport and storage proteins and members of the large lipid transfer protein (LLTP) gene family, which includes insect apolipophorin II/I, apolipoprotein B ( apoB), and the microsomal triglyceride transfer protein (MTP). Lipidation of Vtg occurs at its site of synthesis in vertebrate liver, insect fat body, and nematode intestine; however, the mechanism of Vtg lipid acquisition is unknown. To explore whether Vtg biogenesis requires the apoB cofactor and LLTP family member, MTP, Vtg was expressed in COS cells with and without coexpression of the 97-kDa subunit of human MTP. Expression of Vtg alone gave rise to a similar to 220-kDa apoprotein, which was predominantly confined to an intracellular location. Coexpression of Vtg with human MTP enhanced Vtg secretion by 5-fold, without dramatically affecting its intracellular stability. A comparison of wild type and a triglyceride transfer-defective form of MTP revealed that both were capable of promoting Vtg secretion, whereas only wild type MTP could promote the secretion of apoB41 (amino-terminal 41% of apoB). These studies demonstrate that the biogenesis of Vtg is MTP-dependent and that MTP is the likely ancestral member of the LLTP gene family.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Lausanne, Ctr Integrat Genom, CH-10015 Lausanne, Switzerland	Wake Forest University; Wake Forest Baptist Medical Center; University System of Ohio; Ohio State University; University of Lausanne	Shelness, GS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu	Wahli, Walter/B-1398-2009; Batistuzzo de Medeiros, Silvia/H-2117-2015; DE MEDEIROS, SILVIA REGINA BATISTUZZO/ABC-2811-2020; Wahli, Walter/I-3194-2019; Schoenberg, Daniel/J-3423-2019	Wahli, Walter/0000-0002-5966-9089; Batistuzzo de Medeiros, Silvia/0000-0003-2431-0479; DE MEDEIROS, SILVIA REGINA BATISTUZZO/0000-0003-2431-0479; Schoenberg, Daniel/0000-0003-4570-1946	NHLBI NIH HHS [HL49373, HL07867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Brozovic S, 2004, NAT MED, V10, P535, DOI 10.1038/nm1043; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; CHAPMAN MJ, 1980, J LIPID RES, V21, P789; DEMEDEIROS SRB, 1993, THESIS U LAUSANNE LA; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Hui TY, 2002, J LIPID RES, V43, P785; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; NARDELLI D, 1987, J BIOL CHEM, V262, P15377; Ohashi K, 2000, J LIPID RES, V41, P1199; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2003, J BIOL CHEM, V278, P20367, DOI 10.1074/jbc.M300271200; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shibata Y, 2003, SCIENCE, V302, P1779, DOI 10.1126/science.1087167; Smolenaars MMW, 2005, J LIPID RES, V46, P412, DOI 10.1194/jlr.M400374-JLR200; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277	32	28	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13902	13905		10.1074/jbc.M500769200	http://dx.doi.org/10.1074/jbc.M500769200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15701598	hybrid			2022-12-27	WOS:000228095500090
J	Wang, CG; Hou, XH; Mohapatra, S; Ma, YH; Cress, WD; Pledger, WJ; Chen, JD				Wang, CG; Hou, XH; Mohapatra, S; Ma, YH; Cress, WD; Pledger, WJ; Chen, JD			Activation of p27(Kip1) expression by E2F1 - A negative feedback mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GENE P27(KIP1); APOPTOSIS; MEDIATE; MICE; P27; FIBROBLASTS; INHIBITORS; INDUCTION; P21(CIP1)	The E2F1 transcription factor is a critical regulator of cell cycle due to its ability to promote S phase entry. However, E2F1 overexpression also sensitizes cells to apoptosis and E2F1-null mice are predisposed to tumor development, suggesting that it also has properties of a growth suppressor. E2F1 transcription function is regulated by interaction with hypophosphorylated pRb. Cdk inhibitors such as p16(INK4a) and p27(Kip1) inhibit pRb phosphorylation by the cyclin D/Cdk4 and cyclin E/Cdk2 complexes, thus keeping E2F1 in an inactive state. We found that E2F1 binds to the p27 promoter in vivo and activates p27 mRNA and protein expression. Depletion of endogenous E2F1 by siRNA causes a reduction in basal p27 expression level. Inhibition of endogenous p27 expression by siRNA increases E2F1 transcriptional activity and permits accelerated cell cycle progression by exogenous E2F1. These observations suggest that induction of p27 acts as a negative feedback mechanism for E2F1 and may also contribute to other functions of E2F1.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA		Chen, JD (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu	Mohapatra, Subhra/A-1381-2012					Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciaparrone M, 1998, CANCER RES, V58, P114; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; HARVEY M, 1993, ONCOGENE, V8, P2457; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Tsihlias J, 1999, ANNU REV MED, V50, P401; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	30	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12339	12343		10.1074/jbc.C400536200	http://dx.doi.org/10.1074/jbc.C400536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15713665	hybrid			2022-12-27	WOS:000227922000034
J	Arbel-Goren, R; Levy, Y; Ronen, D; Zick, Y				Arbel-Goren, R; Levy, Y; Ronen, D; Zick, Y			Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTOR; T-CELLS; ACTIVATION; EXPRESSION; INDUCTION; ADHESION; P21; PHOSPHORYLATION	Galectin-8, a mammalian beta-galactoside binding lectin, functions as an extracellular matrix protein that forms high affinity interactions with integrins. Here we demonstrated that soluble galectin-8 inhibits cell cycle progression and induces growth arrest. These effects cannot be attributed to interference with cell adhesion but can be attributed to a 4-5-fold increase in the cellular content of the cyclin-dependent kinase inhibitor p21, which was already evident following a 4-h incubation of H1299 cells with galectin-8. The increase in p21 levels was preceded by a 3-5-fold increase in JNK and protein kinase B (PKB) activities. Accordingly, SP600125, the inhibitor of JNK, and wortmannin, the inhibitor of phosphatidylinositol 3-kinase, which is the upstream activator of PKB, inhibited the increase in the cellular content of p21. Furthermore, overexpression of a dominant inhibitory form of SEK1, the upstream kinase regulator of JNK, inhibited both JNK activation and p21 accumulation. When p21 expression was inhibited by cycloheximide, galectin-8 directed the cells toward apoptosis, which involves induction of poly(ADP-ribose) polymerase cleavage. Indeed, galectin-8-induced apoptosis was 2-fold higher in HTC (p21-null) cells when compared with parental HTC cells. Because overexpression of galectin-8 attenuates the rate of DNA synthesis, stable colonies that overexpress and secrete galectin-8 can be generated only in cells overexpressing a growth factor receptor, such as the insulin receptor. These results implicate galectin-8 as a modulator of cellular growth through up-regulation of p21. This process involves activation of JNK, which enhances the synthesis of p21, combined with the activation of PKB, which inhibits p21 degradation. These effects of the lectin depended upon protein-sugar interactions and were induced when galectin-8 was present as a soluble ligand or when it was overexpressed in cells.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Zick, Yehiel/K-1479-2012					Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cambier S, 2000, CANCER RES, V60, P7084; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Coffman JA, 2004, DEV CELL, V6, P321, DOI 10.1016/S1534-5807(04)00067-X; Danguy A, 2001, HISTOL HISTOPATHOL, V16, P861, DOI 10.14670/HH-16.861; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hadari YR, 2000, J CELL SCI, V113, P2385; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kashio Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/jimmunol.170.7.3631; Kim HRC, 1999, CANCER RES, V59, P4148; Kobayashi K, 2001, BBA-MOL BASIS DIS, V1537, P79, DOI 10.1016/S0925-4439(01)00059-X; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Lundberg AS, 1999, EUR J CANCER, V35, P531; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Nagy N, 2003, CANCER, V97, P1849, DOI 10.1002/cncr.11268; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Novelli F, 1999, J CELL PHYSIOL, V178, P102, DOI 10.1002/(SICI)1097-4652(199901)178:1<102::AID-JCP13>3.0.CO;2-6; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Poirier F, 2002, BIOCHEM SOC SYMP, V69, P95; Rabinovich GA, 2000, CELL DEATH DIFFER, V7, P747, DOI 10.1038/sj.cdd.4400708; Rabinovich GA, 2002, J LEUKOCYTE BIOL, V71, P741; RODAN SB, 1987, CANCER RES, V47, P4961; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sangfelt O, 2000, FRONT BIOSCI-LANDMRK, V5, pD479, DOI 10.2741/Sangfelt; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Zick Y, 2002, GLYCOCONJUGATE J, V19, P517, DOI 10.1023/B:GLYC.0000014081.55445.af	69	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19105	19114		10.1074/jbc.M502060200	http://dx.doi.org/10.1074/jbc.M502060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753078	hybrid			2022-12-27	WOS:000228932300067
J	Savchenko, A; Krogan, N; Cort, JR; Evdokimova, E; Lew, JM; Yee, AA; Sanchez-Pulido, L; Andrade, MA; Bochkarev, A; Watson, JD; Kennedy, MA; Greenblatt, J; Hughes, T; Arrowsmith, CH; Rommens, JM; Edwards, AM				Savchenko, A; Krogan, N; Cort, JR; Evdokimova, E; Lew, JM; Yee, AA; Sanchez-Pulido, L; Andrade, MA; Bochkarev, A; Watson, JD; Kennedy, MA; Greenblatt, J; Hughes, T; Arrowsmith, CH; Rommens, JM; Edwards, AM			The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; YEAST NSR1 PROTEIN; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-PROTEINS; GENETIC-ANALYSIS; SPLICING FACTORS; NUCLEAR-PROTEIN; FISSION YEAST; NMR; SIMILARITY	A combination of structural, biochemical, and genetic studies in model organisms was used to infer a cellular role for the human protein (SBDS) responsible for Shwachman-Bodian-Diamond syndrome. The crystal structure of the SBDS homologue in Archaeoglobus fulgidus, AF0491, revealed a three domain protein. The N-terminal domain, which harbors the majority of disease-linked mutations, has a novel three-dimensional fold. The central domain has the common winged helix-turn-helix motif, and the C-terminal domain shares structural homology with known RNA-binding domains. Proteomic analysis of the SBDS sequence homologue in Saccharomyces cerevisiae, YLR022C, revealed an association with over 20 proteins involved in ribosome biosynthesis. NMR structural genomics revealed another yeast protein, YHR087W, to be a structural homologue of the AF0491 N-terminal domain. Sequence analysis confirmed them as distant sequence homologues, therefore related by divergent evolution. Synthetic genetic array analysis of YHR087W revealed genetic interactions with proteins involved in RNA and rRNA processing including Mdm20/Nat3, Nsr1, and Npl3. Our observations, taken together with previous reports, support the conclusion that SBDS and its homologues play a role in RNA metabolism.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Ontario Ctr Struct Proteom, Toronto, ON M5G 1L6, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Pacific NW Natl Lab, NE Struct Genom Consortium, Richland, WA 99352 USA; Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA; Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; CSIC, Ctr Nacl Biotecnol, Prot Design Grp, E-28049 Madrid, Spain; Ottawa Hlth Res Inst, Ontario Genom Innovat Ctr, Bioinformat Grp, Ottawa, ON K1H 8L6, Canada; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; European Bioinformat Inst, European Mol Biol Lab, Cambridge CB10 1SD, England; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; Structural Genomics Consortium; University of Toronto; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Ottawa; Ottawa Hospital Research Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; European Molecular Biology Laboratory (EMBL); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Edwards, AM (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	aled.edwards@utoronto.ca	Andrade, Miguel A/B-6565-2008; Kennedy, Michael/ABE-6002-2021; Rommens, Johanna/AAT-7465-2021; Kennedy, Michael/M-2578-2019	Andrade, Miguel A/0000-0001-6650-1711; Arrowsmith, Cheryl/0000-0002-4971-3250; Sanchez Pulido, Luis/0000-0002-2300-8502; Edwards, Aled/0000-0002-4782-6016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413, P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50-GM62413-02, P50-GM62414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bu DB, 2003, NUCLEIC ACIDS RES, V31, P2443, DOI 10.1093/nar/gkg340; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P411; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Cummings L, 2002, FEMS MICROBIOL LETT, V216, P133, DOI 10.1016/S0378-1097(02)00955-2; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dror Y, 2002, BRIT J HAEMATOL, V118, P701, DOI 10.1046/j.1365-2141.2002.03585.x; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Ginzberg H, 2000, AM J HUM GENET, V66, P1413, DOI 10.1086/302856; Gottschalk A, 1998, RNA, V4, P374; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Inoue K, 2000, J BIOL CHEM, V275, P32793, DOI 10.1074/jbc.M004560200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lecompte O, 2002, NUCLEIC ACIDS RES, V30, P5382, DOI 10.1093/nar/gkf693; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Luscombe NM, 2000, GENOME BIOL, V1; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Nakashima E, 2004, HUM GENET, V114, P345, DOI 10.1007/s00439-004-1081-2; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicholls A., 1992, GRASP GRAPHICAL REPR; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Omer AD, 2003, MOL MICROBIOL, V48, P617, DOI 10.1046/j.1365-2958.2003.03483.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Sanchez-Pulido L, 2000, BIOINFORMATICS, V16, P656, DOI 10.1093/bioinformatics/16.7.656; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SCHWACHMAN H, 1964, J PEDIATR-US, V65, P645; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Shammas C, 2005, J BIOL CHEM, V280, P19221, DOI 10.1074/jbc.M414656200; SINGLETON DR, 1995, J CELL SCI, V108, P265; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wolf YI, 1999, GENOME RES, V9, P689; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Yee A, 2002, P NATL ACAD SCI USA, V99, P1825, DOI 10.1073/pnas.042684599; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	68	84	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19213	19220		10.1074/jbc.M414421200	http://dx.doi.org/10.1074/jbc.M414421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15701634	hybrid			2022-12-27	WOS:000228932300078
J	Van Craenenbroeck, K; Clark, SD; Cox, MJ; Oak, JN; Liu, F; Van Tol, HHM				Van Craenenbroeck, K; Clark, SD; Cox, MJ; Oak, JN; Liu, F; Van Tol, HHM			Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIT HYPERACTIVITY DISORDER; MESSENGER-RNA LEVELS; ENDOPLASMIC-RETICULUM; PHARMACOLOGICAL CHAPERONES; QUALITY-CONTROL; CHEMICAL CHAPERONES; TARDIVE-DYSKINESIA; 7-REPEAT ALLELE; NOVELTY SEEKING; D4 GENE	Dopamine receptors are G protein-coupled receptors that are critically involved in locomotion, reward, and cognitive processes. The D2 class of dopamine receptors (DRD2, -3, and -4) is the target for antipsychotic medication. DRD4 has been implicated in cognition, and genetic studies have found an association between a highly polymorphic repeat sequence in the human DRD4 coding region and attention deficit hyperactivity disorder. Using DRD4 as a model, we show that antipsychotics can function as potent pharmacological chaperones up-regulating receptor expression and can also rescue a non-functional DRD4 folding mutant. This chaperone-mediated up-regulation involves reduced degradation by the 26 S proteasome; likely via the stabilization of newly synthesized receptor in the endoplasmic reticulum. Dopamine itself can function as a chaperone when shuttled into the cell by means of the dopamine transporter. Furthermore, different repeat variants of DRD4 display differential sensitivity to this chaperone effect. These data suggest that folding efficiency may be rate-limiting for dopamine receptor biogenesis and that this efficiency differs between receptor variants. Consequently, the clinical profile of dopaminergic ligands, including antipsychotics, may include their ability to serve as pharmacological chaperones.	Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto	Van Tol, HHM (corresponding author), Ctr Addict & Mental Hlth, Mol Neurobiol Lab, 250 Coll St, Toronto, ON M5T 1R8, Canada.	hubert.van.tol@utoronto.ca						ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x; Attaix D, 2001, CURR OPIN CLIN NUTR, V4, P45, DOI 10.1097/00075197-200101000-00009; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BLIN J, 1989, J NEUROL NEUROSUR PS, V52, P1248, DOI 10.1136/jnnp.52.11.1248; Chang FM, 1996, HUM GENET, V98, P91, DOI 10.1007/s004390050166; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Damask SP, 1996, MOL BRAIN RES, V41, P241, DOI 10.1016/0169-328X(96)00101-5; Ding YC, 2002, P NATL ACAD SCI USA, V99, P309, DOI 10.1073/pnas.012464099; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Faraone SV, 2001, AM J PSYCHIAT, V158, P1052, DOI 10.1176/appi.ajp.158.7.1052; FILTZ TM, 1993, MOL PHARMACOL, V44, P371; FILTZ TM, 1994, J PHARMACOL EXP THER, V271, P1574; FOX CA, 1994, EXP NEUROL, V130, P288, DOI 10.1006/exnr.1994.1207; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; MELHUS H, 1992, J BIOL CHEM, V267, P12036; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Ohashi T, 2003, HISTOCHEM CELL BIOL, V119, P257, DOI 10.1007/s00418-003-0511-x; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; QIAN YF, 1993, J PHARMACOL EXP THER, V267, P1582; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Schoots O, 2003, PHARMACOGENOMICS J, V3, P343, DOI 10.1038/sj.tpj.6500208; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; See RE, 1996, NEUROSCIENCE, V72, P99, DOI 10.1016/0306-4522(95)00540-4; Seeman P, 2000, P NATL ACAD SCI USA, V97, P7673, DOI 10.1073/pnas.97.14.7673; SEEMAN P, 1984, SCIENCE, V225, P728, DOI 10.1126/science.6147018; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; Segman R, 1999, MOL PSYCHIATR, V4, P247, DOI 10.1038/sj.mp.4000511; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; SRIVASTAVA LK, 1990, J MOL NEUROSCI, V2, P155, DOI 10.1007/BF02896840; Swanson J, 2000, P NATL ACAD SCI USA, V97, P4754, DOI 10.1073/pnas.080070897; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turrone P, 2003, PSYCHOPHARMACOLOGY, V165, P166, DOI 10.1007/s00213-002-1259-z; VANTOL HHM, 1992, NATURE, V358, P149; VANTOL HHM, 1990, NEUROSCI LETT, V111, P303, DOI 10.1016/0304-3940(90)90279-I; Wong AHC, 2003, PROG NEURO-PSYCHOPH, V27, P1091, DOI 10.1016/j.pnpbp.2003.09.005	52	93	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19350	19357		10.1074/jbc.M414043200	http://dx.doi.org/10.1074/jbc.M414043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755724	hybrid			2022-12-27	WOS:000228932300092
J	Nishida, M; Tanabe, S; Maruyama, Y; Mangmool, S; Urayama, K; Nagamatsu, Y; Takagahara, S; Turner, JH; Kozasa, T; Kobayashi, H; Sato, Y; Kawanishi, T; Inoue, R; Nagao, T; Kurose, H				Nishida, M; Tanabe, S; Maruyama, Y; Mangmool, S; Urayama, K; Nagamatsu, Y; Takagahara, S; Turner, JH; Kozasa, T; Kobayashi, H; Sato, Y; Kawanishi, T; Inoue, R; Nagao, T; Kurose, H			G alpha(12/13)- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CARDIAC MYOCYTES; SIGNAL-TRANSDUCTION; RECOMBINANT ADENOVIRUSES; TYROSINE KINASE; GROWTH-FACTORS; P115 RHOGEF; BETA-GAMMA; HYPERTROPHY; PATHWAYS	In the present study, we examined signal transduction mechanism of reactive oxygen species (ROS) production and the role of ROS in angiotensin II-induced activation of mitogen-activated protein kinases (MAPKs) in rat neonatal cardiomyocytes. Among three MAPKs, c-Jun NH2-terminal kinase (JNK) and p38 MAPK required ROS production for activation, as an NADPH oxidase inhibitor, diphenyleneiodonium, inhibited the activation. The angiotensin II-induced activation of JNK and p38 MAPK was also inhibited by the expression of the G alpha(12/13)-specific regulator of G protein signaling (RGS) domain, a specific inhibitor of G alpha(12/13), but not by an RGS domain specific for G alpha(q). Constitutively active G alpha(12)- or G alpha(13)-induced activation of JNK and p38 MAPK, but not extracellular signal-regulated kinase (ERK), was inhibited by diphenyleneiodonium. Angiotensin II receptor stimulation rapidly activated G alpha(13), which was completely inhibited by the G alpha(12/13)-specific RGS domain. Furthermore, the G alpha(12/13)-specific but not the G alpha(q)-specific RGS domain inhibited angiotensin II-induced ROS production. Dominant negative Rac inhibited angiotensin II-stimulated ROS production, JNK activation, and p38 MAPK activation but did not affect ERK activation. Rac activation was mediated by Rho and Rho kinase, because Rac activation was inhibited by C3 toxin and a Rho kinase inhibitor, Y27632. Furthermore, angiotensin II-induced Rho activation was inhibited by G alpha(12/13)-specific RGS domain but not dominant negative Rac. An inhibitor of epidermal growth factor receptor kinase AG1478 did not affect angiotensin II-induced JNK activation cascade. These results suggest that G alpha(12/13)-mediated ROS production through Rho and Rac is essential for JNK and p38 MAPK activation.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cellular Signaling, Tokyo 1130033, Japan; Med Univ S Carolina, Dept Med & Nephrol, Charleston, SC 29425 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Natl Inst Hlth Sci, Tokyo 1588501, Japan; Kyushu Univ, Grad Sch Med, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University; University of Tokyo; Medical University of South Carolina; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institute of Health Sciences - Japan; Kyushu University	Kurose, H (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kurose@phar.kyushu-u.ac.jp	Tanabe, Shihori/AAH-6584-2019; Kawanishi, Tetsuya/V-3860-2019; Turner, Justin/AAD-8607-2020; Kobayashi, Hiroyuki/F-6386-2013	Tanabe, Shihori/0000-0003-3706-0616; Kobayashi, Hiroyuki/0000-0003-4965-0883; Nishida, Motohiro/0000-0002-2587-5458; Turner, Justin/0000-0002-5501-9900				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; KUROSE H, 1993, MOL PHARMACOL, V43, P444; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Nishida M, 1999, BIOCHEM BIOPH RES CO, V262, P350, DOI 10.1006/bbrc.1999.1218; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Schmitz U, 1997, TRENDS ENDOCRIN MET, V8, P261, DOI 10.1016/S1043-2760(97)00101-X; Schmitz U, 2001, J BIOL CHEM, V276, P22003, DOI 10.1074/jbc.M102450200; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	45	118	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18434	18441		10.1074/jbc.M409710200	http://dx.doi.org/10.1074/jbc.M409710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743761	hybrid			2022-12-27	WOS:000228807200106
J	Ribeiro, CMP; Paradiso, AM; Schwab, U; Perez-Vilar, J; Jones, L; O'Neal, W; Boucher, RC				Ribeiro, CMP; Paradiso, AM; Schwab, U; Perez-Vilar, J; Jones, L; O'Neal, W; Boucher, RC			Chronic airway Infection/Inflammation induces a Ca-i(2+)-dependent hyperinflammatory response in human cystic fibrosis airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; INTRACELLULAR CALCIUM; ER STRESS; CELL DIFFERENTIATION; GENE-EXPRESSION; KINASE-C; INFECTION; ACTIVATION	Hyperinflammatory responses to infection have been postulated as a component of cystic fibrosis (CF) lung disease. Studies have linked intracellular calcium (Ca-i(2+)) mobilization with inflammatory responses in several systems. We have reported that the pro-inflammatory mediator bradykinin (BK) promotes larger Ca-i(2+) signals in CF compared with normal bronchial epithelia, a response that reflects endoplasmic reticulum (ER)/Ca2+ store expansion induced by chronic luminal airway infection/inflammation. The present study investigated whether CF airway epithelia were hyperinflammatory and, if so, whether the hyperinflammatory CF phenotype was linked to larger Ca2+ stores in the ER. We found that Delta F508 CF bronchial epithelia were hyperinflammatory as defined by an increased basal and mucosal BK-induced interleukin (IL)-8 secretion. However, the CF hyperinflammation expressed in short-term ( 6 - 11-day-old) primary cultures of Delta F508 bronchial epithelia was lost in long-term ( 30 - 40-day-old) primary cultures of Delta F508 bronchial epithelia, indicating this response was independent of mutant cystic fibrosis transmembrane conductance regulator. Exposure of 30 - 40-day-old cultures of normal airway epithelia to supernatant from mucopurulent material (SMM) from CF airways reproduced the increased basal and mucosal BK-stimulated IL-8 secretion of short-term CF cultures. The BK-triggered increased IL-8 secretion in SMM-treated cultures was mediated by an increased Ca-i(2+) mobilization consequent to an ER expansion associated with increases in protein synthesis ( total, cytokines, and antimicrobial factors). The increased ER-dependent, Ca-i(2+)-mediated hyperinflammatory epithelial response may represent a general beneficial airway epithelial adaptation to transient luminal infection. However, in CF airways, the Ca-i(2+)-mediated hyperinflammation may be ineffective in promoting the eradication of infection in thickened mucus and, consequently, may have adverse effects in the lung.	Univ N Carolina, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ribeiro, CMP (corresponding author), Univ N Carolina, Cyst Fibrosis Ctr, CB 7248,7013 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	carla_ribeiro@med.unc.edu	Ribeiro, Carla Maria P/A-6955-2009		NHLBI NIH HHS [HL60280, HL34322] Funding Source: Medline; NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL060280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197, DOI 10.1164/ajrccm.156.4.96-11058; Bals R, 1999, J CLIN INVEST, V103, P303, DOI 10.1172/JCI6277; Berger M, 2002, AM J RESP CRIT CARE, V165, P857, DOI 10.1164/ajrccm.165.7.2202030a; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Charlier N, 2002, J GEN VIROL, V83, P1887, DOI 10.1099/0022-1317-83-8-1887; COLIGAN JE, 1983, METHOD ENZYMOL, V91, P413; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Eremeeva ME, 1998, MICROBIOL-SGM, V144, P2037, DOI 10.1099/00221287-144-8-2037; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Guo Q, 1997, J NEUROSCI, V17, P4212; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hsuan SL, 1999, MICROB PATHOGENESIS, V26, P263, DOI 10.1006/mpat.1998.0271; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Jefferson KK, 1999, J IMMUNOL, V163, P5183; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Koller DY, 1997, AM J RESP CRIT CARE, V155, P1050, DOI 10.1164/ajrccm.155.3.9116985; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LEIGH MW, 1998, DISORDERS RESP TRACT; LEVINE SJ, 1995, J INVEST MED, V43, P241; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; LOOK DC, 2004, PEDIATR PULM, V27, P165; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Muhlebach MS, 2002, AM J RESP CRIT CARE, V165, P911, DOI 10.1164/ajrccm.165.7.2107114; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Ouellet M, 1999, J BIOL CHEM, V274, P35029, DOI 10.1074/jbc.274.49.35029; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Quinlan KL, 1999, J IMMUNOL, V163, P5656; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Rodgers HC, 2002, AM J PHYSIOL-LUNG C, V283, pL612, DOI 10.1152/ajplung.00483.2001; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, J CELL SCI, V113, P3697; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	57	117	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17798	17806		10.1074/jbc.M410618200	http://dx.doi.org/10.1074/jbc.M410618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746099	hybrid			2022-12-27	WOS:000228807200031
J	Singh, V; Evans, GB; Lenz, DH; Mason, JM; Clinch, K; Mee, S; Painter, GF; Tyler, PC; Furneaux, RH; Lee, JE; Howell, PL; Schramm, VL				Singh, V; Evans, GB; Lenz, DH; Mason, JM; Clinch, K; Mee, S; Painter, GF; Tyler, PC; Furneaux, RH; Lee, JE; Howell, PL; Schramm, VL			Femtomolar transition state analogue inhibitors of 5 '-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUORUM-SENSING SIGNAL; PHOSPHORYLASE; LUXS; DYNAMICS	Escherichia coli 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) hydrolyzes its substrates to form adenine and 5-methylthioribose (MTR) or S-ribosylhomocysteine (SRH). 5'-Methylthioadenosine (MTA) is a by-product of polyamine synthesis and SRH is a precursor to the biosynthesis of one or more quorum sensing autoinducer molecules. MTAN is therefore involved in quorum sensing, recycling MTA from the polyamine pathway via adenine phosphoribosyltransferase and recycling MTR to methionine. Hydrolysis of MTA by E. coli MTAN involves a highly dissociative transition state with ribooxacarbenium ion character. Iminoribitol mimics of MTA at the transition state of MTAN were synthesized and tested as inhibitors. 5'-Methylthio-Immucillin-A (MT-ImmA) is a slow-onset tight-binding inhibitor giving a dissociation constant (K-i*) of 77 pM. Substitution of the methylthio group with a p-Cl-phenylthio group gives a more powerful inhibitor with a dissociation constant of 2 pM. DADMe-Immucillins are better inhibitors of E. coli MTAN, since they are more closely related to the highly dissociative nature of the transition state. MT-DADMe-Immucillin-A binds with a K-i* value of 2 pM. Replacing the 5'-methyl group with other hydrophobic groups gave 17 transition state analogue inhibitors with dissociation constants from 10(-12) to 10(-14) M. The most powerful inhibitor was 5'-p-Cl-phenylthio-DADMe-Immucillin-A (pClPhT-DADMe-ImmA) with a K-i* value of 47 fM (47 x 10(-15) M). These are among the most powerful non-covalent inhibitors reported for any enzyme, binding 9-91 million times tighter than the MTA and SAH substrates, respectively. The inhibitory potential of these transition state analogue inhibitors supports a transition state structure closely resembling a fully dissociated ribooxacarbenium ion. Powerful inhibitors of MTAN are candidates to disrupt key bacterial pathways including methylation, polyamine synthesis, methionine salvage, and quorum sensing. The accompanying article reports crystal structures of MTAN with these analogues.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand; Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Clinch, Keith/0000-0002-3300-4396				Birck MR, 2004, J AM CHEM SOC, V126, P2447, DOI 10.1021/ja039260h; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Chen XY, 2000, J AM CHEM SOC, V122, P1609, DOI 10.1021/ja992750i; Cornell KA, 1996, BIOCHEM BIOPH RES CO, V228, P724, DOI 10.1006/bbrc.1996.1723; Daniels R, 2004, FEMS MICROBIOL REV, V28, P261, DOI 10.1016/j.femsre.2003.09.004; Evans GB, 2004, J MED CHEM, V47, P3275, DOI 10.1021/jm0306475; Evans GB, 2004, J ORG CHEM, V69, P2217, DOI 10.1021/jo035744k; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, ORG LETT, V5, P3639, DOI 10.1021/ol035293q; Evans GB, 2000, TETRAHEDRON, V56, P3053, DOI 10.1016/S0040-4020(00)00194-0; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Lee JE, 2005, J BIOL CHEM, V280, P18274, DOI 10.1074/jbc.M414471200; Lee JE, 2004, BIOCHEMISTRY-US, V43, P5159, DOI 10.1021/bi035492h; Lee JE, 2003, J BIOL CHEM, V278, P8761, DOI 10.1074/jbc.M210836200; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Lee JE, 2001, ACTA CRYSTALLOGR D, V57, P150, DOI 10.1107/S0907444900014669; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Mendieta J, 2004, BIOCHEMISTRY-US, V43, P405, DOI 10.1021/bi034793o; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MYERS RW, 1989, J BIOL CHEM, V264, P10547; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; RAGIONE ED, 1985, BIOCHEM J, V232, P335, DOI 10.1042/bj2320335; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; Schramm VL, 2005, ARCH BIOCHEM BIOPHYS, V433, P13, DOI 10.1016/j.abb.2004.08.035; Schramm VL, 2003, ACCOUNTS CHEM RES, V36, P588, DOI 10.1021/ar0200495; Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420; TABOR CW, 1983, METHOD ENZYMOL, V94, P29; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Winzer K, 2002, MICROBIOL-SGM, V148, P909, DOI 10.1099/00221287-148-4-909; Withers H, 2001, CURR OPIN MICROBIOL, V4, P186, DOI 10.1016/S1369-5274(00)00187-9; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Zappia V, 1988, Adv Exp Med Biol, V250, P165; Zhao G, 2003, BIOORG MED CHEM LETT, V13, P3897, DOI 10.1016/j.bmcl.2003.09.015; Zhou GC, 2004, J AM CHEM SOC, V126, P5690, DOI 10.1021/ja038159+	43	114	127	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18265	18273		10.1074/jbc.M414472200	http://dx.doi.org/10.1074/jbc.M414472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749708	hybrid			2022-12-27	WOS:000228807200085
J	Cohen, DM; Chen, H; Johnson, RP; Choudhury, B; Craig, SW				Cohen, DM; Chen, H; Johnson, RP; Choudhury, B; Craig, SW			Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITE; ALPHA-ACTININ; N-WASP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTRAMOLECULAR ASSOCIATION; CYTOSKELETAL PROTEINS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL MECHANICS; ADHESION	Vinculin is autoinhibited by an intramolecular interaction that masks binding sites for talin and F-actin. Although a recent structural model explains autoinhibition solely in terms of the interaction between vinculin tail (V-t) and residues 1 - 258 (D1), we find an absolute requirement for an interface involving the D4 domain of head (V-h residues 710 - 836) and V-t. Charge-to-alanine mutations in V-t revealed a class of mutants, T12 and T19, distal to the V-(1-258) binding site, which showed increases in their K-d values for head binding of 100- and 42-fold, respectively. Reciprocal mutation of residues in the D4 domain that contact V-t yielded a head-tail interaction mutant of comparable magnitude to T19. These findings account for the approximately 120-fold difference in K-d values between V-t binding to V-( 1 - 258), as opposed to full-length V-h-( 1 - 851). The significance of a bipartite autoinhibitory site is evidenced by its effects on talin binding to V-h. Whereas V-t fails to compete with the talin rod domain for binding to V-( 1 - 258), competition occurs readily with full-length V-h, and this requires the D4 interface. Moreover in intact vinculin, mutations in the D4-V-t interface stabilize association of vinculin and talin rod. In cells, these head-tail interaction mutants induce hypertrophy and elongation of focal adhesions. Definition of a second autoinhibitory site, the D4-V-t interface, supports the competing model of vinculin activation that invokes cooperative action of ligands at two sites. Together the D1-V-t and D4-V-t interfaces provide the high affinity ( similar to 10(-9)) autoinhibition observed in full-length vinculin.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Johns Hopkins University; Northwestern University	Craig, SW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	scraig@jhmi.edu		Cohen, Daniel/0000-0002-7963-668X	NIGMS NIH HHS [GM41605] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM041605, R01GM041605] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 2004, J BIOL CHEM, V279, P28889, DOI 10.1074/jbc.M402161200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COHEN DM, 2004, MOL BIOL CELL S, V15, P81; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Isenberg G, 1996, FEBS LETT, V397, P316, DOI 10.1016/S0014-5793(96)01203-3; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Prehoda KE, 2002, CURR OPIN CELL BIOL, V14, P149, DOI 10.1016/S0955-0674(02)00307-1; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; SILICIANO JD, 1986, METHOD ENZYMOL, V134, P78; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Xu WM, 1998, DEVELOPMENT, V125, P327; Zemljic-Harpf AE, 2004, AM J PATHOL, V165, P1033, DOI 10.1016/S0002-9440(10)63364-0; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264	55	124	124	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17109	17117		10.1074/jbc.M414704200	http://dx.doi.org/10.1074/jbc.M414704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728584	hybrid			2022-12-27	WOS:000228615500070
J	Cohen, E; Goldshleger, R; Shainskaya, A; Tal, DM; Ebel, C; le Maire, M; Karlish, SJD				Cohen, E; Goldshleger, R; Shainskaya, A; Tal, DM; Ebel, C; le Maire, M; Karlish, SJD			Purification of Na+,K+-ATPase expressed in Pichia pastoris reveals an essential role of phospholipid-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; ATPASE ACTIVITY; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; OXIDATIVE CLEAVAGE; MEMBRANE-PROTEINS; RENAL NA,K-ATPASE; CRYSTAL-STRUCTURE; MAMMALIAN KIDNEY	Na+, K+-ATPase ( porcine alpha/his(10)-beta) has been expressed in Pichia Pastoris, solubilized in n-dodecyl-beta-maltoside and purified to 70 - 80% purity by nickel-nitrilotriacetic acid chromatography combined with size exclusion chromatography. The recombinant protein is inactive if the purification is done without added phospholipids. The neutral phospholipid, dioleoylphosphatidylcholine, preserves Na+, K+-ATPase activity of protein prepared in a Na+-containing medium, but activity is lost in a K+-containing medium. By contrast, the acid phospholipid, dioleoylphosphatidylserine, preserves activity in either Na+- or K+-containing media. In optimal conditions activity is preserved for about 2 weeks at 0 degrees C. Both recombinant Na+, K+-ATPase and native pig kidney Na+, K+-ATPase, dissolved in n-dodecyl-beta-maltoside, appear to be mainly stable monomers (alpha/beta) as judged by size exclusion chromatography and sedimentation velocity. Na+, K+-ATPase activities at 37 degrees C of the size exclusion chromatography-purified recombinant and renal Na+, K+-ATPase are comparable but are lower than that of membrane-bound renal Na+, K+-ATPase. The beta subunit is expressed in Pichia Pastoris as two lightly glycosylated polypeptides and is quantitatively deglycosylated by endoglycosidase- H at 0 degrees C, to a single polypeptide. Deglycosylation inactivates Na+, K+-ATPase prepared with dioleoylphosphatidylcholine, whereas dioleoylphosphatidylserine protects after deglycosylation, and Na+, K+-ATPase activity is preserved. This work demonstrates an essential role of phospholipid interactions with Na+, K+-ATPase, including a direct interaction of dioleoylphosphatidylserine, and possibly another interaction of either the neutral or acid phospholipid. Additional lipid effects are likely. A role for the beta subunit in stabilizing conformations of Na+, K+-ATPase ( or H+, K+-ATPase) with occluded K+ ions can also be inferred. Purified recombinant Na+, K+-ATPase could become an important experimental tool for various purposes, including, hopefully, structural work.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel; Univ Paris 11, CEA Saclay, DBJC SBFM, CNRS,URA 2096, F-91191 Gif Sur Yvette, France; Univ Paris 11, CEA Saclay, LRD17V, F-91191 Gif Sur Yvette, France; UJF, CNRS,UMR 5075, CEA, Inst Biol Struct JP Ebel,Lab Biophys Mol, F-38027 Grenoble, France	Weizmann Institute of Science; Weizmann Institute of Science; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Steven.Karlish@weizmann.ac.il		Ebel, Christine/0000-0002-6912-500X				Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Beggah AT, 1997, J BIOL CHEM, V272, P10318; Bretthauer RK, 1999, BIOTECHNOL APPL BIOC, V30, P193; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; Champeil P, 2000, J BIOL CHEM, V275, P18623, DOI 10.1074/jbc.M000470200; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CORNELIUS F, 1984, BIOCHIM BIOPHYS ACTA, V772, P357, DOI 10.1016/0005-2736(84)90153-6; Cornelius F, 2003, BIOCHEMISTRY-US, V42, P8541, DOI 10.1021/bi034532e; CORNELIUS F, 1995, BBA-BIOMEMBRANES, V1235, P205, DOI 10.1016/0005-2736(95)80006-2; Cornelius F, 2001, BIOCHEMISTRY-US, V40, P8842, DOI 10.1021/bi010541g; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JOHANNSSON A, 1981, BIOCHIM BIOPHYS ACTA, V641, P416, DOI 10.1016/0005-2736(81)90498-3; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KATES M, 1972, LABORATORY TECHNIQUE, V3, P347; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery M, 2004, J BIOL CHEM, V279, P36339, DOI 10.1074/jbc.M402778200; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MARCUS MM, 1986, BIOCHIM BIOPHYS ACTA, V854, P270, DOI 10.1016/0005-2736(86)90120-3; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shinji N, 2003, ANN NY ACAD SCI, V986, P235, DOI 10.1111/j.1749-6632.2003.tb07168.x; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strugatsky D, 2003, J BIOL CHEM, V278, P46064, DOI 10.1074/jbc.M308303200; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Winstone TL, 2005, BIOCHEM BIOPH RES CO, V327, P437, DOI 10.1016/j.bbrc.2004.11.164; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; Zhang HM, 2003, P NATL ACAD SCI USA, V100, P5160, DOI 10.1073/pnas.0931431100	58	54	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16610	16618		10.1074/jbc.M414290200	http://dx.doi.org/10.1074/jbc.M414290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15708860	hybrid			2022-12-27	WOS:000228615500011
J	Katchalski-Katzir, E				Katchalski-Katzir, E			My contributions to science and society	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Katchalski-Katzir, E (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	ephraim.katzir@weizmann.ac.il						BARELI A, 1960, NATURE, V188, P856, DOI 10.1038/188856a0; Eisenstein M, 2004, CR BIOL, V327, P409, DOI 10.1016/j.crvi.2004.03.006; Goldstein L., 1976, SERIES APPL BIOCH BI, V1, P1; GREEN H, 1994, P NATL ACAD SCI USA, V91, P4298, DOI 10.1073/pnas.91.10.4298; KATCHALSKI E, 1958, ADV PROTEIN CHEM, V13, P243, DOI 10.1016/S0065-3233(08)60600-2; Katchalski E., 1964, PROTEINS, V2, P405; KATCHALSKIKATZIR E, 1993, TRENDS BIOTECHNOL, V11, P471, DOI 10.1016/0167-7799(93)90080-S; NATARAJAN V, 2002, PEPTIDES, V23, P570; Scherf T, 2001, P NATL ACAD SCI USA, V98, P6629, DOI 10.1073/pnas.111164298; STAHMANN MA, 1962, POLYAMINO ACIDS POLY, P347; WOODWARD RB, 1947, J AM CHEM SOC, V69, P551	11	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16529	16541		10.1074/jbc.X400013200	http://dx.doi.org/10.1074/jbc.X400013200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718236	hybrid			2022-12-27	WOS:000228615500001
J	Li, K; Chen, ZH; Kato, N; Gale, M; Lemon, SM				Li, K; Chen, ZH; Kato, N; Gale, M; Lemon, SM			Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C-VIRUS; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; PATTERN-RECOGNITION RECEPTORS; RESPIRATORY SYNCYTIAL VIRUS; CELL-LINES; ADAPTIVE IMMUNITY; VIRAL-INFECTION; GENE-EXPRESSION; DENDRITIC CELLS	Innate cellular antiviral defenses are likely to influence the outcome of infections by many human viruses, including hepatitis B and C viruses, agents that frequently establish persistent infection leading to chronic hepatitis, cirrhosis, and liver cancer. However, little is known of the pathways by which hepatocytes, the cell type within which these hepatitis agents replicate, sense infection, and initiate protective responses. We show that cultured hepatoma cells, including Huh7 cells, do not activate the interferon (IFN)-beta promoter in response to extracellular poly(I-C). In contrast, the addition of poly(I-C) to culture media activates the IFN-beta promoter and results in robust expression of IFN-stimulated genes (ISG) in PH5CH8 cells, which are derived from non-neoplastic hepatocytes transformed with large T antigen. Small interfering RNA knockdown of TLR3 or its adaptor, Toll-interleukin-1 receptor domain-containing adaptor inducing IFN-beta ( TRIF), blocked extracellular poly(I-C) signaling in PH5CH8 cells, whereas poly(I-C) responsiveness could be conferred on Huh7 hepatoma cells by ectopic expression of Toll-like receptor 3 ( TLR3). In contrast to poly(I-C), both cell types signal the presence of Sendai virus infection through a TLR3-independent intracellular pathway requiring expression of retinoic acid-inducible gene I (RIG-I), a putative cellular RNA helicase. Silencing of RIG-I expression impaired only the response to Sendai virus and not extracellular poly( I-C). We conclude that hepatocytes contain two distinct antiviral signaling pathways leading to expression of type I IFNs, one dependent upon TLR3 and the other dependent on RIG-I, with little cross-talk between these pathways.	Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Okayama Univ, Grad Sch Med & Dent, Dept Mol Biol, Okayama 7008558, Japan; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Medical Branch Galveston; Okayama University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, K (corresponding author), Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	kuli@utmb.edu; smlemon@utmb.edu		Gale, Michael/0000-0002-6332-7436	NIAID NIH HHS [U19-AI40035, U01-AI48235] Funding Source: Medline; NIDA NIH HHS [R21-DA018054] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048235, U19AI040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018054] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bartenschlager R, 2001, ANTIVIR RES, V52, P1, DOI 10.1016/S0166-3542(01)00164-4; Bartenschlager R, 2003, ANTIVIR RES, V60, P91, DOI 10.1016/j.antiviral.2003.08.016; Beignon AS, 2003, NAT IMMUNOL, V4, P939, DOI 10.1038/ni1003-939; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Cocude C, 2003, J GEN VIROL, V84, P3215, DOI 10.1099/vir.0.19300-0; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dolganiuc A, 2004, GASTROENTEROLOGY, V127, P1513, DOI 10.1053/j.gastro.2004.08.067; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Kang DC, 2004, ONCOGENE, V23, P1789, DOI 10.1038/sj.onc.1207300; Kato N, 1996, JPN J CANCER RES, V87, P787, DOI 10.1111/j.1349-7006.1996.tb02101.x; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lanford RE, 2003, J VIROL, V77, P1092, DOI 10.1128/JVI.77.2.1092-1104.2003; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 2003, CURR OPIN IMMUNOL, V15, P52, DOI 10.1016/S0952-7915(02)00011-0; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; LOHMANN V, 1999, SCIENCE, V285, P110; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; McCormick CJ, 2004, J GEN VIROL, V85, P429, DOI 10.1099/vir.0.19676-0; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Noguchi M, 1996, IN VITRO CELL DEV-AN, V32, P135; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; Scholle F, 2004, J VIROL, V78, P1513, DOI 10.1128/JVI.78.3.1513-1524.2004; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SUMPTER R, 2005, J VIROL, V79, P2689, DOI DOI 10.1128/JVI.79.5.2689-2699.2005; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; TWU JS, 1988, P NATL ACAD SCI USA, V85, P252, DOI 10.1073/pnas.85.1.252; WHITTEN TM, 1991, J VIROL, V65, P4699, DOI 10.1128/JVI.65.9.4699-4704.1991; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yi M, 2002, J VIROL, V76, P1171, DOI 10.1128/JVI.76.3.1171-1180.2002; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhu Q, 2003, J VIROL, V77, P9204, DOI 10.1128/JVI.77.17.9204-9210.2003	60	291	306	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16739	16747		10.1074/jbc.M414139200	http://dx.doi.org/10.1074/jbc.M414139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737993	hybrid			2022-12-27	WOS:000228615500025
J	Verschuur, M; de Jong, M; Felida, L; de Maat, MPM; Vos, HL				Verschuur, M; de Jong, M; Felida, L; de Maat, MPM; Vos, HL			A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent-148C/T polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; GENETIC-VARIATION; RISK-FACTORS; ATHEROTHROMBOTIC DISEASE; LINKAGE DISEQUILIBRIUM; ALPHA-FIBRINOGEN; FACTOR-VII; BINDING	An elevated plasma fibrinogen level is an independent risk factor for cardiovascular disease. Therefore, an understanding of the regulation of fibrinogen expression is important. Inflammation and genetic variation of the fibrinogen beta gene regulate plasma fibrinogen levels, and there are indications that inflammation and genetic variation interact. The aim of our study was to gain more understanding of the regulation of the inflammatory response of the fibrinogen beta gene and to determine the effects of genetic variation. Luciferase reporter gene assays in hepatoma cells, mutation analysis, and electrophoretic mobility shift assays were used to investigate the transcriptional regulation of the fibrinogen beta promoter. We identified a hepatocyte nuclear factor-3 (HNF-3) site located just upstream of previously identified interleukin-6 (IL6)-responsive sequences. This HNF-3 site is essential for a full response of the promoter to IL6, which is a new function for HNF-3. The activity of the CCAAT box/enhancer-binding protein site ( located 18 nucleotides downstream of the HNF-3 site and important to the IL6 response) depends on the integrity of the HNF-3 site and vice versa, explaining the necessity of HNF-3 in the IL6 response of the fibrinogen beta promoter. Furthermore, small interfering RNA to HNF-3 reduces the fibrinogen beta mRNA levels. The rare T allele of the - 148C/T polymorphism, which is present between the binding sites of HNF-3 and CCAAT box/ enhancer-binding protein, interferes with this mechanism, and this polymorphism is in our assay system the only genetic determinant of IL6-induced promoter activity among six polymorphisms in the fibrinogen beta promoter.	Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, NL-2300 RC Leiden, Netherlands; TNO Qual Life, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Erasmus MC, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Erasmus University Rotterdam; Erasmus MC	Vos, HL (corresponding author), Leiden Univ, Med Ctr, Ctr Hemostasis & Thrombosis Res, Dept Hematol, POB 9600, NL-2300 RC Leiden, Netherlands.	h.l.vos@lumc.nl						ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; BAUMANN RE, 1994, HUM GENET, V94, P165; BAUMANN RE, 1993, THROMB HAEMOSTASIS, V69, P961; Brown ET, 1998, BLOOD, V92, P3286, DOI 10.1182/blood.V92.9.3286.421k20_3286_3293; Brull DJ, 2002, THROMB HAEMOSTASIS, V87, P37; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cook DG, 2001, AM J EPIDEMIOL, V153, P799, DOI 10.1093/aje/153.8.799; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; Cotton JM, 2000, THROMB HAEMOSTASIS, V84, P926, DOI 10.1055/s-0037-1614144; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; de Maat MPM, 1998, ARTERIOSCL THROM VAS, V18, P265, DOI 10.1161/01.ATV.18.2.265; Erren M, 1999, ARTERIOSCL THROM VAS, V19, P2355, DOI 10.1161/01.ATV.19.10.2355; Ferrer-Antunes C, 1998, THROMB RES, V92, P207, DOI 10.1016/S0049-3848(98)00143-1; Folsom AR, 2001, THROMB HAEMOSTASIS, V86, P366; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; Green FR, 2001, ANN NY ACAD SCI, V936, P549; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; Humphries SE, 1997, THROMB HAEMOSTASIS, V78, P457; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; KOOPMAN JL, 1997, MED INTELL UNIT, P125; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LOCKER J, 1996, TRANSCRIPTION FACTOR, P12; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Montgomery HE, 1996, ARTERIOSCL THROM VAS, V16, P386, DOI 10.1161/01.ATV.16.3.386; NAITO M, 1990, ATHEROSCLEROSIS, V83, P9, DOI 10.1016/0021-9150(90)90124-2; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROY SN, 1990, J BIOL CHEM, V265, P6389; SCARABIN PY, 1993, ARTERIOSCLER THROMB, V13, P886, DOI 10.1161/01.ATV.13.6.886; Scarabin PY, 1998, THROMB HAEMOSTASIS, V80, P749; Schuit AJ, 1997, THROMB HAEMOSTASIS, V78, P845; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; THOMAS A, 1994, HUM MUTAT, V3, P79, DOI 10.1002/humu.1380030117; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; van't Hooft FM, 1999, ARTERIOSCL THROM VAS, V19, P3063, DOI 10.1161/01.ATV.19.12.3063; Vasse M, 1996, BRIT J HAEMATOL, V93, P955, DOI 10.1046/j.1365-2141.1996.d01-1731.x; WRAGG S, 2001, THROMB HAEMOSTASIS S; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; Zito F, 1997, ARTERIOSCL THROM VAS, V17, P3489, DOI 10.1161/01.ATV.17.12.3489	46	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16763	16771		10.1074/jbc.M501973200	http://dx.doi.org/10.1074/jbc.M501973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737987	hybrid, Green Published			2022-12-27	WOS:000228615500028
J	Yang, F; Jiang, Q; Zhao, JH; Ren, Y; Sutton, MD; Feng, J				Yang, F; Jiang, Q; Zhao, JH; Ren, Y; Sutton, MD; Feng, J			Parkin stabilizes microtubules through strong binding mediated by three independent domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ROTENONE INHIBITION; ALPHA-SYNUCLEIN; LEWY BODIES; PC12 CELLS; DISEASE; PROTEIN; TUBULIN; DEGRADATION; COMPLEX	Mutations of parkin, a protein-ubiquitin isopeptide ligase (E3), appear to be the most frequent cause of familial Parkinson's disease (PD). Our previous studies have demonstrated that parkin binds strongly to alpha/beta tubulin heterodimers and microtubules. Here we show that the strong binding between parkin and tubulin, as well as that between parkin and microtubules, was mediated by three independent domains: linker, RING1, and RING2. These redundant strong interactions made it virtually impossible to separate parkin from microtubules by high concentrations of salt (3.8 M) or urea (0.5 M). Parkin co-purified with tubulin and was found in highly purified tubulin preparation. Expression of either full-length parkin or any of its three microtubule-binding domains significantly attenuated colchicine-induced microtubule depolymerization. The abilities of parkin to bind to and stabilize microtubules were not affected by PD-linked mutations that abrogate its E3 ligase activity. Thus, the tubulin/microtubule-binding activity of parkin and its E3 ligase activity are independent. The strong binding between parkin and tubulin/ microtubules through three redundant interaction domains may not only stabilize microtubules but also guarantee the anchorage of this E3 ligase on microtubules. Because many misfolded proteins are transported on microtubules, the localization of parkin on microtubules may provide an important environment for its E3 ligase activity toward misfolded substrates.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu			NINDS NIH HHS [NS41722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; CHANCE B, 1963, J BIOL CHEM, V238, P418; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; Feng Jian, 2003, Current Neuropharmacology, V1, P301, DOI 10.2174/1570159033477053; GALLOWAY PG, 1992, AM J PATHOL, V140, P809; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Imai Y, 2003, J BIOL CHEM, V278, P51901, DOI 10.1074/jbc.M309655200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ren Y, 2003, J NEUROSCI, V23, P3316; Shen J, 2004, NEURON, V44, P575, DOI 10.1016/j.neuron.2004.11.008; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	34	102	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17154	17162		10.1074/jbc.M500843200	http://dx.doi.org/10.1074/jbc.M500843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737990	hybrid			2022-12-27	WOS:000228615500076
J	Fasciano, S; Patel, RC; Handy, I; Patel, CV				Fasciano, S; Patel, RC; Handy, I; Patel, CV			Regulation of vascular smooth muscle proliferation by heparin - Inhibition of cyclin-dependent kinase 2 activity by p27(kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DOUBLE-STRANDED-RNA; RAT CAROTID-ARTERY; MYC MESSENGER-RNA; CELL-CYCLE; C-FOS; GROWTH-FACTOR; IN-VITRO; S PHASE; POSTTRANSCRIPTIONAL REGULATION	Uncontrolled proliferation of vascular smooth muscle cells ( VSMCs) contribute to intimal hyperplasia during atherosclerosis and restenosis. Heparin is an antiproliferative agent for VSMCs and has been shown to block VSMC proliferation both in tissue culture systems and in animals. Despite the well documented antiproliferative actions of heparin, its cellular targets largely remain unknown. In an effort to characterize the mechanism of the antiproliferative property of heparin, we have analyzed the effect of heparin on cell cycle in VSMC. Our results indicate that the heparin- induced block in G(1) to S phase transition is imposed by p27(kip1) -mediated inhibition of cyclin- dependent kinase 2 activity. Further analysis of p27(kip1) mRNA levels showed that the increase in p27(kip1) protein levels in heparin- treated VSMC occurs at posttranscriptional levels. We present evidence that heparin causes stabilization of p27(kip1) protein during G(1) phase and thereby prevents activation of cyclin- dependent kinase 2.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Patel, RC (corresponding author), Univ S Carolina, Dept Biol Sci, 700 Sumter St, Columbia, SC 29208 USA.	patelr@sc.edu	Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NHLBI NIH HHS [R01 HL063359, R01 HL63359] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063359] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Boehm Manfred, 2003, Prog Cell Cycle Res, V5, P19; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Castro C, 2004, ATHEROSCLEROSIS, V172, P31, DOI 10.1016/j.atherosclerosis.2003.09.003; Castro C, 2003, J BIOL CHEM, V278, P4482, DOI 10.1074/jbc.M204716200; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CLOWES AW, 1989, TRANSPLANT P, V21, P3700; CLOWES AW, 1987, INT ANGIOL, V6, P45; Coleman J, 2001, BMC Mol Biol, V2, P12, DOI 10.1186/1471-2199-2-12; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Daum G, 1997, CIRC RES, V81, P17, DOI 10.1161/01.RES.81.1.17; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Diez-Juan A, 2004, BLOOD, V103, P158, DOI 10.1182/blood-2003-07-2319; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Gopfert U, 2003, HUM MOL GENET, V12, P1767, DOI 10.1093/hmg/ddg177; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hedin U, 1998, J VASC SURG, V27, P512, DOI 10.1016/S0741-5214(98)70326-X; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Horiuchi A, 1999, MOL HUM REPROD, V5, P139, DOI 10.1093/molehr/5.2.139; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; KENAGY RD, 1995, THROMB RES, V77, P55, DOI 10.1016/0049-3848(95)90864-C; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; Kleiman N S, 2000, J Invasive Cardiol, V12 Suppl F, p20F; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kouzarides Tony, 1993, Trends in Cell Biology, V3, P211, DOI 10.1016/0962-8924(93)90113-F; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Marks AR, 2003, TRANSPLANT P, V35, p231S, DOI 10.1016/S0041-1345(03)00243-4; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; Miralem T, 1996, AM J PHYSIOL-RENAL, V270, pF960, DOI 10.1152/ajprenal.1996.270.6.F960; Mishra-Gorur K, 2002, AM J PATHOL, V161, P1893, DOI 10.1016/S0002-9440(10)64465-3; Mishra-Gorur K, 2002, J BIOL CHEM, V277, P33537, DOI 10.1074/jbc.C200342200; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; NIKKARI ST, 1994, AM J PATHOL, V144, P1348; Noble MEM, 1997, TRENDS BIOCHEM SCI, V22, P482, DOI 10.1016/S0968-0004(97)01144-4; OLASHAW N, 2002, SCI STKE; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Patel RC, 2002, ARTERIOSCL THROM VAS, V22, P1439, DOI 10.1161/01.ATV.0000028817.20351.FE; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Roque M, 2001, LAB INVEST, V81, P895, DOI 10.1038/labinvest.3780298; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; SNOW AD, 1990, AM J PATHOL, V137, P313; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; Wang G, 2003, J CELL BIOCHEM, V90, P548, DOI 10.1002/jcb.10621; Woods TC, 2002, J BIOL CHEM, V277, P1924, DOI 10.1074/jbc.M108189200; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; Young J J, 2000, J Invasive Cardiol, V12 Suppl E, pE14; YOUNG JJ, 2000, J INVASIVE CARDIO SE, V12, pE25; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	100	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15682	15689		10.1074/jbc.M411458200	http://dx.doi.org/10.1074/jbc.M411458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15731113	Green Accepted, hybrid			2022-12-27	WOS:000228444800029
J	Marraffini, LA; Schneewind, O				Marraffini, LA; Schneewind, O			Anchor structure of staphylococcal surface proteins - V. Anchor structure of the sortase B substrate IsdC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; AUREUS STRAIN COPENHAGEN; SENSITIVE ENZYMATIC REACTIONS; D-ALANINE CARBOXYPEPTIDASE; CELL-WALL; ESCHERICHIA-COLI; SORTING REACTION; CROSS-LINKING; LPXTG MOTIF; PEPTIDOGLYCAN	Staphylococcus aureus sortase A cleaves surface protein precursors bearing C-terminal LPXTG motif sorting signals between the threonine and glycine residues. Using lipid II precursor as cosubstrate, sortase A catalyzes the amide linkage between the carboxyl group of threonine and the amino group of pentaglycine cross-bridges, thereby tethering C-terminal ends of surface proteins to the bacterial cell wall envelope. Staphylococcal sortase B also anchors its only known substrate, the IsdC precursor with a C-terminal NPQTN motif sorting signal, to the cell wall envelope. Herein, we determined the cell wall anchor structure of IsdC. The sorting signal of IsdC is cleaved between threonine and asparagine of the NPQTN motif, and the carboxyl group of threonine is amide-linked to the amino group of pentaglycine cross-bridges. In contrast to sortase A substrates, the anchor structure of IsdC displays shorter glycan strands and significantly less cell wall cross-linking. A model is proposed whereby sortases A and B recognize unique features of sorting signals and peptidoglycan substrates to deposit proteins with distinct topologies in the cell wall envelope.	Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Dept Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@bsd.uchicago.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052474, R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897, AI52474] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; Bae T, 2003, J BACTERIOL, V185, P2910, DOI 10.1128/JB.185.9.2910-2919.2003; Bera A, 2005, MOL MICROBIOL, V55, P778, DOI 10.1111/j.1365-2958.2004.04446.x; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Bierne H, 2004, J BACTERIOL, V186, P1972, DOI 10.1128/JB.186.7.1972-1982.2004; Boneca IG, 2000, J BIOL CHEM, V275, P9910, DOI 10.1074/jbc.275.14.9910; CALANDRA GB, 1980, INFECT IMMUN, V28, P1033; CHATTERJEE AN, 1964, P NATL ACAD SCI USA, V51, P9, DOI 10.1073/pnas.51.1.9; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLE RM, 1962, SCIENCE, V135, P722, DOI 10.1126/science.135.3505.722; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GALLY D, 1993, J GEN MICROBIOL, V139, P1907, DOI 10.1099/00221287-139-8-1907; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; JENSEN KLAUS, 1958, ACTA PATHOL ET MICROBIOL SCAND, V44, P421; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MAZMANIAN SK, 2002, BACILLUS SUBTILIS IT, P57; MUNOZ E, 1966, BIOCHEMISTRY-US, V5, P3748, DOI 10.1021/bi00876a004; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; PETIT JF, 1968, J BIOL CHEM, V243, P757; Rivas JM, 2004, CURR OPIN DRUG DISC, V7, P223; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; SNOWDEN MA, 1989, J GEN MICROBIOL, V135, P3015; STEERS E, 1965, J BIOL CHEM, V240, P2478; Strominger J L, 1968, Harvey Lect, V64, P179; STROMINGER JL, 1967, FED PROC, V26, P9; SYDNER AP, 2000, INTERPRETING PROTEIN; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xiong AM, 2000, MICROBIOL-UK, V146, P659, DOI 10.1099/00221287-146-3-659; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156; Zhang RG, 2004, STRUCTURE, V12, P1147, DOI 10.1016/j.str.2004.06.001; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	62	59	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16263	16271		10.1074/jbc.M500071200	http://dx.doi.org/10.1074/jbc.M500071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718231	hybrid			2022-12-27	WOS:000228444800096
J	Rottmann, S; Menkel, AR; Bouchard, C; Mertsching, J; Loidl, P; Kremmer, E; Eilers, M; Luscher-Firzlaff, J; Lilischkis, R; Luscher, B				Rottmann, S; Menkel, AR; Bouchard, C; Mertsching, J; Loidl, P; Kremmer, E; Eilers, M; Luscher-Firzlaff, J; Lilischkis, R; Luscher, B			Mad1 function in cell proliferation and transcriptional repression is antagonized by cyclin E/CDK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES CENTROSOME DUPLICATION; TRANSFORMATION; PROGRESSION; INHIBITION; COMPLEXES; PROTEINS; FAMILY; GROWTH; CANCER; E-CDK2	The transcription factors of the Myc/Max/Mad network play essential roles in the regulation of cellular behavior. Mad1 inhibits cell proliferation by recruiting an mSin3-corepressor complex that contains histone deacetylase activity. Here we demonstrate that Mad1 is a potent inhibitor of the G(1) to S phase transition, a function that requires Mad1 to heterodimerize with Max and to bind to the corepressor complex. Cyclin E/CDK2, but not cyclin D and cyclin A complexes, fully restored S phase progression. In addition inhibition of colony formation and gene repression by Mad1 were also efficiently antagonized by cyclin E/CDK2. This was the result of cyclin E/CDK2 interfering with the interaction of Mad1 with HDAC1 and reducing HDAC activity. Our findings define a novel interplay between the cell cycle regulator cyclin E/CDK2 and Mad1 and its associated repressor complex and suggests an additional mechanism how cyclin E/CDK2 affects the G1 to S phase transition.	Klinikum RWTH, Abt Biochem & Mol Biol, Inst Biochem, D-52057 Aachen, Germany; Klinikum RWTH, Inst Arbeitsmed, D-52057 Aachen, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Inst Mol Tumorforsch, D-35033 Marburg, Germany; Med Univ Innsbruck, Inst Mol Biol, A-6020 Innsbruck, Austria; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Hannover Medical School; Medical University of Innsbruck; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Luscher, B (corresponding author), Klinikum RWTH, Abt Biochem & Mol Biol, Inst Biochem, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Eilers, Martin/0000-0002-0376-6533				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CERNI C, 1995, ONCOGENE, V11, P587; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; ROTTMANN S, 2005, IN PRESS CURR TOP MI; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	24	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15489	15492		10.1074/jbc.C400611200	http://dx.doi.org/10.1074/jbc.C400611200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722557	hybrid			2022-12-27	WOS:000228444800004
J	Sun, YP; Leaman, DW				Sun, YP; Leaman, DW			Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GENE FACTOR-3; ALPHA-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; BCL-2 FAMILY; REGULATORY FACTOR-3; BH3-ONLY PROTEINS; IMMUNE-RESPONSE; DEATH AGONIST; FACTOR DRAF1; VIRAL BCL-2	Double-stranded RNA ( dsRNA) accumulates in virally infected cells, leading to induction of genes encoding proteins involved in signaling, apoptosis, protein synthesis/ processing, and cell metabolism. Noxa is a BH3-containing mitochondrial protein that contributes to apoptosis by disrupting mitochondrial outer membrane integrity. Here we demonstrate potent induction of Noxa expression by exposure of cells to dsRNA, interferon (IFN), and virus. Noxa induction was confirmed by using reverse transcriptase-PCR and immunoblot analyses in multiple human tumor cell lines. Importantly, Noxa regulation by IFN and dsRNA was independent of p53, thereby identifying a novel mechanism of Noxa induction. Ectopic expression of Noxa in HT1080 fibrosarcoma cells enhanced cellular sensitivity to viral or dsRNA/actinomycin D-induced apoptosis, typified by enhanced cytochrome c release from the mitochondrial to the cytosolic fraction and increased cleavage of caspases 3 and 9. Point and deletion mutations of Noxa confirmed that both the BH3 domain and the mitochondrial-targeting domain were necessary for enhanced cellular apoptotic responses to dsRNA, IFN, or virus. Treatment of cells with dsRNA or virus, but not etoposide, induced interaction between Noxa and Bax that required an intact Noxa BH3 domain. Interestingly, the Noxa mitochondrial-targeting domain deletion mutant interacted with Bax in a dsRNA-dependent manner and redirected Bax away from the mitochondria, thus acting as a dominant-negative protein. Together, these data suggest that Noxa is an important component of the innate immune response of cells to viral infection, leading to enhanced cellular apoptosis that may play a role in limiting viral dissemination.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Leaman, DW (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	dleaman@utnet.utoledo.edu			NATIONAL CANCER INSTITUTE [R01CA090837] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA90837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Brassard DL, 2004, J INTERF CYTOK RES, V24, P455, DOI 10.1089/1079990041689638; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Colletier PJ, 2000, INT J RADIAT ONCOL, V48, P1507, DOI 10.1016/S0360-3016(00)01409-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Gangappa S, 2002, J EXP MED, V195, P931, DOI 10.1084/jem.20011825; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kaiser WJ, 2004, J IMMUNOL, V172, P1699, DOI 10.4049/jimmunol.172.3.1699; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kelly JD, 2004, BRIT J CANCER, V91, P164, DOI 10.1038/sj.bjc.6601895; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; LASTELLI J, 1998, BIOMED PHARMACOTHER, V52, P386; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sun YP, 2004, J INTERF CYTOK RES, V24, P350, DOI 10.1089/107999004323142213; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Wei MC, 2000, GENE DEV, V14, P2060; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	56	53	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15561	15568		10.1074/jbc.m412630200	http://dx.doi.org/10.1074/jbc.m412630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705586	hybrid			2022-12-27	WOS:000228444800014
J	Ayalon, G; Segev, E; Elgavish, S; Stern-Bach, Y				Ayalon, G; Segev, E; Elgavish, S; Stern-Bach, Y			Two regions in the N-terminal domain of ionotropic glutamate receptor 3 form the subunit oligomerization interfaces that control subtype-specific receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; LIGAND-BINDING PROPERTIES; FOLD-RECOGNITION; ION CHANNELS; MOLECULAR DETERMINANTS; LOCAL-STRUCTURE; PROTEIN; MUTATION; SITE; MICE	The N-terminal domain (NTD) of alpha-amino-3-hydroxy-5- methylisoxazolepropionate ( AMPA) and kainate glutamate receptors plays an important role in controlling subtype specific receptor assembly. To identify NTD subdomains involved in this process we generated AMPA glutamate receptor 3 (GluR3) mutants having intra-NTD substitutions with the corresponding regions of the kainate receptor GluR6 and tested their ability to form functional heteromers with wild-type subunits. The chimeric design was based on the homology of the NTD to the NTD of the metabotropic GluR1, shown to form two globular lobes and to assemble in dimers. Accordingly, the NTD was divided into four regions, termed here N1 - N4, of which N1 and N3 correspond to the regions forming lobe-1 and N2 and N4 to those forming lobe-2. Substituting N1 or N3 impaired functional heteromerization but allowed protein-protein interactions. Conversely, exchanging N2 or N4 preserved functional heteromerization, although it significantly decreased homomeric activity, indicating a role in subunit folding. Moreover, a deletion in GluR3 corresponding to the hotfoot mouse mutation of the glutamate receptor delta 2, covering part of N2, N3, and N4, impaired both homomeric and heteromeric oligomerization, thus explaining the null-like mouse phenotype. Finally, computer modeling suggested that the dimer interface, largely formed by N1, is highly hydrophobic in GluR3, whereas in GluR6 it contains electrostatic interactions, hence offering an explanation for the subtype assembly specificity conferred by this region. N3, however, is positioned perpendicular to the dimer interface and therefore may be involved in secondary interactions between dimers in the assembled tetrameric receptor.	Hebrew Univ Jerusalem, Hadassah Dent Sch, Inst Basic Dent Sci, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Struct Biol Bioinformat Unit, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Stern-Bach, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Dent Sch, Inst Basic Dent Sci, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel.	yaelb@cc.huji.ac.il						ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fischer D, 1999, PROTEINS, P209; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Karchin R, 2003, PROTEINS, V51, P504, DOI 10.1002/prot.10369; Karplus K, 2001, PROTEINS, P86, DOI 10.1002/prot.10021; Karplus K, 2003, PROTEINS, V53, P491, DOI 10.1002/prot.10540; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; Perin-Dureau F, 2002, J NEUROSCI, V22, P5955; Robert A, 2002, NEUROSCIENCE, V115, P1199, DOI 10.1016/S0306-4522(02)00534-1; SAPER MA, 1983, J BIOL CHEM, V258, P1057; Seeburg PH, 1996, J NEUROCHEM, V66, P1; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; Wells GB, 2001, J BIOL CHEM, V276, P3031, DOI 10.1074/jbc.M006668200; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	42	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15053	15060		10.1074/jbc.M408413200	http://dx.doi.org/10.1074/jbc.M408413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703162	hybrid			2022-12-27	WOS:000228236800088
J	Romero, JR; Rivera, A; Lanca, V; Bicho, MDP; Conlin, PR; Ricupero, DA				Romero, JR; Rivera, A; Lanca, V; Bicho, MDP; Conlin, PR; Ricupero, DA			Na+/Ca2+ exchanger activity modulates connective tissue growth factor mRNA expression in transforming growth factor beta 1- and Des-Arg(10)-kallidin-stimulated myofibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; IDIOPATHIC PULMONARY-FIBROSIS; SODIUM-CALCIUM EXCHANGE; HUMAN LUNG FIBROBLASTS; CARDIAC MYOCYTES; MESANGIAL CELLS; IN-VIVO; RECEPTOR; BRADYKININ; KINASE	Transforming growth factor (TGF)-beta and des-Arg(10)-kallidin stimulate the expression of connective tissue growth factor ( CTGF), a matrix signaling molecule that is frequently overexpressed in fibrotic disorders. Because the early signal transduction events regulating CTGF expression are unclear, we investigated the role of Ca2+ homeostasis in CTGF mRNA expression in TGF-beta 1- and des-Arg(10)-kallidin-stimulated human lung myofibroblasts. Activation of the kinin B1 receptor with des-Arg(10)-kallidin stimulated a rise in cytosolic Ca2+ that was extracellular Na+-dependent and extracellular Ca2+ dependent. The des-Arg(10)-kallidin-stimulated increase of cytosolic Ca2+ was blocked by KB-R7943, a specific inhibitor of Ca2+ entry mode operation of the plasma membrane Na+/Ca2+ exchanger. TGF-beta 1 similarly stimulated a KB-R7943-sensitive increase of cytosolic Ca2+ with kinetics distinct from the des-Arg(10)-kallidin- stimulated Ca2+ response. We also found that KB-R7943 or 2', 4'-dichlorobenzamil, an amiloride analog that inhibits the Na+/Ca2+ exchanger activity, blocked the TGF-beta 1- and des-Arg(10)-kallidin- stimulated increases of CTGF mRNA. Pretreatment with KB-R7943 also reduced the basal and TGF-beta 1-stimulated levels of alpha 1( I) collagen and alpha smooth muscle actin mRNAs. These data suggest that, in addition to regulating ion homeostasis, Na+/Ca2+ exchanger acts as a signal transducer regulating CTGF, alpha 1( I) collagen, and alpha smooth muscle actin expression. Consistent with a more widespread role for Na+/Ca2+ exchanger in fibrogenesis, we also observed that KB-R7943 likewise blocked TGF-beta 1-stimulated levels of CTGF mRNA in human microvascular endothelial and human osteoblast-like cells. We conclude that Ca2+ entry mode operation of the Na+/Ca2+ exchanger is required for des- Arg(10)-kallidin- and TGF-beta 1-stimulated fibrogenesis and participates in the maintenance of the myofibroblast phenotype.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA; Childrens Hosp Boston, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Lisbon, Fac Med, Genet Lab, Ctr Metab & Endocrinol, P-1200 Lisbon, Portugal; Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Universidade de Lisboa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; Boston University	Romero, JR (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.	jromero@rics.bwh.harvard.edu		Bicho, Manuel/0000-0002-5773-5687; Romero, Jose Ricardo/0000-0001-8225-0772; Lanca, Vasco/0000-0001-9996-5088	NHLBI NIH HHS [HL67699] Funding Source: Medline; NIDDK NIH HHS [DK064841, DK002817, DK63214] Funding Source: Medline; NIEHS NIH HHS [ES11443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064841, K01DK002817, K24DK063214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Carrillo C, 1998, CELL MOL BIOL, V44, P543; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Condrescu M, 2002, ANN NY ACAD SCI, V976, P214; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DAVIS AJ, 1994, NEUROPHARMACOLOGY, V33, P127, DOI 10.1016/0028-3908(94)90107-4; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; Gooch JL, 2004, J BIOL CHEM, V279, P15561, DOI 10.1074/jbc.M308759200; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kimchi-Sarfaty C, 2002, J BIOL CHEM, V277, P2505, DOI 10.1074/jbc.M109154200; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kucich U, 2001, ARCH BIOCHEM BIOPHYS, V395, P103, DOI 10.1006/abbi.2001.2571; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KUHN C, 1991, AM J PATHOL, V138, P1257; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; LOW RB, 1985, J CELL BIOL, V101, P500, DOI 10.1083/jcb.101.2.500; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Mashburn NA, 1999, AM J PHYSIOL-RENAL, V276, pF574, DOI 10.1152/ajprenal.1999.276.4.F574; McGowan TA, 2002, AM J PHYSIOL-RENAL, V282, pF910, DOI 10.1152/ajprenal.00252.2001; Nakamura T, 1998, P NATL ACAD SCI USA, V95, P5389, DOI 10.1073/pnas.95.9.5389; Nesti LJ, 2002, ANN NY ACAD SCI, V961, P178, DOI 10.1111/j.1749-6632.2002.tb03078.x; Oemar BS, 1997, CIRCULATION, V95, P831; PERKINS MN, 1995, CAN J PHYSIOL PHARM, V73, P832, DOI 10.1139/y95-113; Phagoo SB, 2001, J PHARMACOL EXP THER, V298, P77; REGOLI D, 1980, PHARMACOL REV, V32, P1; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; SIMONSSON BG, 1973, RESPIRATION, V30, P378, DOI 10.1159/000193051; Stains JP, 2001, J BONE MINER RES, V16, P1434, DOI 10.1359/jbmr.2001.16.8.1434; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; ZHANG K, 1994, AM J PATHOL, V145, P114	45	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14378	14384		10.1074/jbc.M410052200	http://dx.doi.org/10.1074/jbc.M410052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703175	hybrid			2022-12-27	WOS:000228236800005
J	Connor, JH; Lyles, DS				Connor, JH; Lyles, DS			Inhibition of host and viral translation during vesicular stomatitis virus infection - eIF2 is responsible for the inhibition of viral but not host translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; PROTEIN-KINASE PKR; MATRIX PROTEIN; MALIGNANT-TRANSFORMATION; INNATE IMMUNITY; INITIATION; RNA; PHOSPHORYLATION; CELLS; RESISTANCE	In cells that allow replication of vesicular stomatitis virus (VSV), there are two phases of translation inhibition: an early block of host translation and a later inhibition of viral translation. We investigated the phosphorylation of the alpha subunit of the eIF2 complex during these two phases of viral infection. In VSV-infected cells, the accumulation of phosphorylated (inactivated) eIF2 alpha did not begin until well after host protein synthesis was inhibited, suggesting that it only plays a role in blocking viral translation later after infection. Consistent with this, cells expressing an unphosphorylatable eIF2 alpha showed prolonged viral protein synthesis without an effect on host protein synthesis inhibition. Induction of eIF2 alpha phosphorylation at early times of viral infection by treatment with thapsigargin showed that virus and host translation are similarly inhibited, demonstrating that viral and host messages are similarly sensitive to eIF2 alpha phosphorylation. A recombinant virus that expresses a mutant matrix protein and is defective in the inhibition of host and virus protein synthesis showed an altered phosphorylation of eIF2 alpha, demonstrating an involvement of viral protein function in inducing this antiviral response. This analysis of eIF2 alpha phosphorylation, coupled with earlier findings that the eIF4F complex is modified earlier during VSV infection, supports a temporal/kinetic model of translation control, where at times soon after infection, changes in the eIF4F complex result in the inhibition of host protein synthesis; at later times, inactivation of the eIF2 complex blocks VSV protein synthesis.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Connor, JH (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	jconnor@wfubmc.edu		Lyles, Douglas/0000-0002-8401-3073; Connor, John/0000-0002-8867-7256	NCI NIH HHS [CA09422] Funding Source: Medline; NIAID NIH HHS [R01 AI052304, AI051805, R01 AI032983, AI052304, AI32983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032983, R21AI052304, F32AI051805, R01AI052304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2004, J VIROL, V78, P12747, DOI 10.1128/JVI.78.23.12747-12761.2004; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; CENTRELLA M, 1982, J VIROL, V41, P781, DOI 10.1128/JVI.41.3.781-791.1982; Chesler DA, 2002, CYTOKINE GROWTH F R, V13, P441, DOI 10.1016/S1359-6101(02)00044-8; Connor JH, 2004, J VIROL, V78, P8960, DOI 10.1128/JVI.78.17.8960-8970.2004; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DRATEWKAKOS E, 1984, BIOCHEMISTRY-US, V23, P6184, DOI 10.1021/bi00320a045; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; JAYE MC, 1982, VIROLOGY, V116, P148, DOI 10.1016/0042-6822(82)90410-X; Kopecky SA, 2003, J VIROL, V77, P5524, DOI 10.1128/JVI.77.9.5524-5528.2003; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Perkins DJ, 2004, MOL CELL BIOL, V24, P2025, DOI 10.1128/MCB.24.5.2025-2040.2004; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Rose JK, 2001, FIELDS VIROLOGY, P1221; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6	32	66	69	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13512	13519		10.1074/jbc.M501156200	http://dx.doi.org/10.1074/jbc.M501156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705563	hybrid			2022-12-27	WOS:000228095500042
J	Berasain, C; Garcia-Trevijano, ER; Castillo, J; Erroba, E; Santamaria, M; Lee, DC; Prieto, J; Avila, MA				Berasain, C; Garcia-Trevijano, ER; Castillo, J; Erroba, E; Santamaria, M; Lee, DC; Prieto, J; Avila, MA			Novel role for amphiregulin in protection from liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ANTI-FAS ANTIBODY; RAT-LIVER; HEPATOCYTE APOPTOSIS; CARBON-TETRACHLORIDE; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PARTIAL-HEPATECTOMY; MOUSE HEPATOCYTES; FACTOR RECEPTOR	Clinically, the Fas and Fas ligand system plays a central role in the development of hepatocyte apoptosis, a process contributing to a broad spectrum of liver diseases. Therefore, the development of therapies aimed at the inhibition of hepatocyte apoptosis is a major issue. Activation of the epidermal growth factor receptor has been shown to convey survival signals to the hepatocyte. To learn about the endogenous response of epidermal growth factor receptor ligands during Fas-mediated liver injury we investigated the expression of epidermal growth factor, transforming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, betacellulin, epiregulin, and amphiregulin in the liver of mice challenged with Fas-agonist antibody. Amphiregulin expression, barely detectable in healthy liver, was significantly up-regulated. Amphiregulin administration abrogated Fas-mediated liver injury in mice and showed direct anti-apoptotic effects in primary hepatocytes. Amphiregulin activated the Akt and signal transducer and activator of transcription-3 survival pathways, and up-regulated Bcl-xL expression. Amphiregulin knock-out mice showed signs of chronic liver damage in the absence of any noxious treatment, and died faster than wild type mice in response to lethal doses of Fas-agonist antibody. In contrast, these mice were more resistant against sublethal liver damage, supporting the hypothesis that chronic liver injury can precondition hepatocytes inducing resistance to subsequent cell death. These results show that amphiregulin is a protective factor induced in response to liver damage and that it may be therapeutic in liver diseases.	Univ Navarra, Clin Univ, Dept Med,Ctr Invest Med Aplicada, Div Hepatol & Gene Therapy,Fac Med, Pamplona 31008, Spain; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Navarra; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Prieto, J (corresponding author), Univ Navarra, Clin Univ, Dept Med,Ctr Invest Med Aplicada, Div Hepatol & Gene Therapy,Fac Med, Pio XII 55, Pamplona 31008, Spain.	jprieto@unav.es; maavila@unav.es	Berasain, Carmen/E-4139-2016; Santamaria, Monica/H-4737-2013; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021	Berasain, Carmen/0000-0001-7075-2476; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Castillo Aliaga, Josefa/0000-0002-4092-0085; Prieto, Jesus/0000-0002-1091-9593	NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43793, CA 49793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berasain C, 2005, GASTROENTEROLOGY, V128, P424, DOI 10.1053/j.gastro.2004.11.006; Berasain C, 2004, BBA-MOL BASIS DIS, V1690, P276, DOI 10.1016/j.bbadis.2004.08.002; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Bustos M, 2003, GASTROENTEROLOGY, V125, P192, DOI 10.1016/S0016-5085(03)00698-X; Canbay A, 2004, HEPATOLOGY, V39, P273, DOI 10.1002/hep.20051; Carver RS, 2002, GASTROENTEROLOGY, V123, P2017, DOI 10.1053/gast.2002.37060; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; Czaja MJ, 2003, AM J PHYSIOL-GASTR L, V284, pG875, DOI 10.1152/ajpgi.00549.2002; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Deaciuc IV, 2002, ALCOHOL CLIN EXP RES, V26, P864, DOI 10.1097/00000374-200206000-00017; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; Eichhorst ST, 2004, NAT MED, V10, P602, DOI 10.1038/nm1049; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Faouzi S, 2001, J BIOL CHEM, V276, P49077, DOI 10.1074/jbc.M109791200; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Galun E, 2002, BBA-MOL CELL RES, V1592, P345, DOI 10.1016/S0167-4889(02)00326-9; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Kanda D, 2002, FEBS LETT, V519, P11, DOI 10.1016/S0014-5793(02)02677-7; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kiso S, 1996, BIOCHEM BIOPH RES CO, V220, P285, DOI 10.1006/bbrc.1996.0397; Koniaris LG, 2003, J AM COLL SURGEONS, V197, P634, DOI 10.1016/S1072-7515(03)00374-0; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Lin MT, 2001, CARCINOGENESIS, V22, P1947, DOI 10.1093/carcin/22.12.1947; LU GL, 2002, AM J PHYSIOL, V283, pG256; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; Musallam L, 2001, AM J PHYSIOL-GASTR L, V280, pG1360, DOI 10.1152/ajpgi.2001.280.6.G1360; Natori S, 2001, J HEPATOL, V34, P248, DOI 10.1016/S0168-8278(00)00089-1; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peralta C, 2000, AM J PHYSIOL-GASTR L, V279, pG163, DOI 10.1152/ajpgi.2000.279.1.G163; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Roberts RA, 2000, HEPATOLOGY, V31, P420, DOI 10.1002/hep.510310223; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Selzner M, 2003, GASTROENTEROLOGY, V125, P256, DOI 10.1016/S0016-5085(03)00811-4; Selzner N, 2003, GASTROENTEROLOGY, V125, P917, DOI 10.1016/S0016-5085(03)01048-5; Shi JL, 1998, AM J PATHOL, V153, P515, DOI 10.1016/S0002-9440(10)65594-0; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Vogel A, 2004, HEPATOLOGY, V39, P433, DOI 10.1002/hep.20077; WEBBER EM, 1993, HEPATOLOGY, V18, P1422, DOI 10.1016/0270-9139(93)90234-E; Wuestefeld T, 2003, J BIOL CHEM, V278, P11281, DOI 10.1074/jbc.M208470200	60	106	107	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19012	19020		10.1074/jbc.M413344200	http://dx.doi.org/10.1074/jbc.M413344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753092	hybrid, Green Published			2022-12-27	WOS:000228932300056
J	Cooper, DS; Saxena, NC; Yang, HS; Lee, HJ; Moring, AG; Lee, A; Choi, IY				Cooper, DS; Saxena, NC; Yang, HS; Lee, HJ; Moring, AG; Lee, A; Choi, IY			Molecular and functional characterization of the electroneutral Na/HCO3 cotransporter NBCn1 in rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORTER; CYTOPLASMIC DOMAIN; PYRAMIDAL NEURONS; INTRACELLULAR PH; EXTERNAL PH; TRANSPORTER; CLONING; ASTROCYTES; KIDNEY; BRAIN	We examined molecular and electrophysiological properties of the electroneutral sodium/bicarbonate cotransporter (NBCn1) that is present in rat hippocampal neurons. By PCR, a deletion variant (NBCn1-E) that lacks 123 amino acids in the cytoplasmic N-terminal domain was found in adult neurons. The previously characterized NBCn1-B, which does not have the deletion, was detected in embryonic neurons. In Xenopus oocytes, NBCn1-E raised the intracellular pH in the presence of HCO3 without significantly affecting the membrane potential. Despite this electroneutral cotransport activity, the transporter mediated a steady-state current that positively shifted the resting potential by almost 30 mV. The mean reversal potential of the steady-state current was - 21.2 mV, close to the resting potential of - 21.4 mV. The reversal potential shifted 26 mV in response to a 10-fold increase of external Na+ for concentrations above 10 mM. The current activity mediated by the transporter was unaffected by K+, Mg2+, Ca2+, or Cl-. Stable expression of NBCn1-E in human embryonic kidney cells also evoked an inward current that shifted the resting potentials more positive compared with the sham-transfected controls. In primary cultures of embryonic hippocampal neurons, the NBCn1 protein was localized in somatodendrites and synapses. NBCn1 protein was partially colocalized with the postsynaptic density protein PSD-95. Single-cell PCR showed that NBCn1 mRNA expression was present in both gamma-aminobutyric acid ( GABA) ergic and non-GABAergic neurons. We propose that NBCn1 in hippocampal neurons may affect neuronal activity by regulating local pH as well as steady-state inward currents at synapses.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Choi, IY (corresponding author), Emory Univ, Sch Med, Dept Physiol, 615 Michael St, Atlanta, GA 30322 USA.	ichoi@physio.emory.edu	choi, inyeong/AAM-4826-2021	Lee, Amy/0000-0001-8021-0443	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044922] Funding Source: NIH RePORTER; NINDS NIH HHS [NS044922] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baxter KA, 1996, J PHYSIOL-LONDON, V493, P457, DOI 10.1113/jphysiol.1996.sp021396; BENSON DL, 1994, J NEUROCYTOL, V23, P279, DOI 10.1007/BF01188497; Bevensee Mark O., 1998, P211; BEVENSEE MO, 1995, FASEB J, V9, pA308; Bok D, 2003, NAT GENET, V34, P313, DOI 10.1038/ng1176; Boron W F, 2001, JOP, V2, P176; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Choi I, 1997, FEBS LETT, V405, P133, DOI 10.1016/S0014-5793(97)00155-5; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; COOPER DS, 2004, SOC NEUR 2004 ABSTR; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Freedman JC, 1997, J GEN PHYSIOL, V109, P201, DOI 10.1085/jgp.109.2.201; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; Goslin K., 1998, CULTURING NERVE CELL, P339; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1071, DOI 10.1016/0306-4522(94)90344-1; IIJIMA T, 1986, P NATL ACAD SCI USA, V83, P654, DOI 10.1073/pnas.83.3.654; Kang TC, 2002, MOL BRAIN RES, V109, P226, DOI 10.1016/S0169-328X(02)00559-4; Katsura K., 1998, P563; Kwon TH, 2002, AM J PHYSIOL-RENAL, V282, pF341, DOI 10.1152/ajprenal.00104.2001; Loiselle FB, 2003, MOL MEMBR BIOL, V20, P307, DOI 10.1080/0968768031000122520; OCONNOR ER, 1994, J NEUROPHYSIOL, V72, P2580, DOI 10.1152/jn.1994.72.6.2580; Odgaard E, 2004, J PHYSIOL-LONDON, V555, P205, DOI 10.1113/jphysiol.2003.046474; Park M, 2002, J BIOL CHEM, V277, P50503, DOI 10.1074/jbc.M201862200; Parker MD, 2001, BIOCHEM BIOPH RES CO, V282, P1103, DOI 10.1006/bbrc.2001.4692; PASTERNACK M, 1993, ACTA PHYSIOL SCAND, V148, P229, DOI 10.1111/j.1748-1716.1993.tb09553.x; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; RANSOM BR, 1992, PROG BRAIN RES, V94, P37; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Schmitt BM, 2000, J NEUROSCI, V20, P6839, DOI 10.1523/JNEUROSCI.20-18-06839.2000; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; Vorum H, 2000, AM J PHYSIOL-RENAL, V279, pF901, DOI 10.1152/ajprenal.2000.279.5.F901; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WYBORSKI RJ, 1990, MOL BRAIN RES, V8, P193, DOI 10.1016/0169-328X(90)90016-7; Zhang DC, 2000, BLOOD, V96, P2925	40	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17823	17830		10.1074/jbc.M408646200	http://dx.doi.org/10.1074/jbc.M408646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718246	hybrid			2022-12-27	WOS:000228807200034
J	Huseby, D; Barklis, RL; Alfadhli, A; Barklis, E				Huseby, D; Barklis, RL; Alfadhli, A; Barklis, E			Assembly of human immunodeficiency virus precursor Gag proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA-VIRUS; HIV-1 CAPSID PROTEIN; PARTICLES IN-VITRO; ELECTRON-MICROSCOPY; HEXAGONAL ORGANIZATION; CRYSTAL-STRUCTURE; LIPID MONOLAYER; TYPE-1; DOMAIN; DIMERIZATION	To investigate the mechanism by which human immunodeficiency virus (HIV) precursor Gag (PrGag) proteins assemble to form immature virus particles, we examined the in vitro assembly of MACANC proteins, composed of the PrGag matrix, capsid, and nucleocapsid domains. In the absence of other components, MACANC proteins assembled efficiently at physiological temperature but inefficiently at lower temperatures. However, the addition of RNA reduced the temperature sensitivity of assembly reactions. Assembly of MACANC proteins also was affected by pH because the proteins preferentially formed tubes at pH 6.0, whereas spheres were obtained at pH 8.0. Because neither tubes nor spheres were amenable to analysis of protein-protein contacts, we also examined the membrane-bound assemblies of MACANC proteins. Interestingly, MACANC proteins organized on membranes in tightly packed hexameric rings. The observed hexamer spacing of 79.7 angstrom is consistent with the notion that more PrGag proteins assemble into virions than are needed to provide capsid proteins for mature virus cores. Our data are also consistent with a model for PrGag contacts in immature virions where capsid hexamers are tightly packed, where nucleocapsid domains align beneath capsid C-terminal domains, and where matrix domains form trimers at the nexus of three neighbor hexamers.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Microbiol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Barklis, RL (corresponding author), Mail Code L220,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	barklis@ohsu.edu		Huseby, Douglas/0000-0001-9974-578X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM060170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Arvidson B, 2003, VIROLOGY, V308, P166, DOI 10.1016/S0042-6822(02)00142-3; Barklis E, 1998, J BIOL CHEM, V273, P7177, DOI 10.1074/jbc.273.13.7177; Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Ehrlich LS, 2001, BIOPHYS J, V81, P586, DOI 10.1016/S0006-3495(01)75725-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80; Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Johnson MC, 2002, J VIROL, V76, P11177, DOI 10.1128/JVI.76.22.11177-11185.2002; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004; Ma YM, 2002, J VIROL, V76, P5452, DOI 10.1128/JVI.76.11.5452-5462.2002; Mayo K, 2003, J MOL BIOL, V325, P225, DOI 10.1016/S0022-2836(02)01176-2; Mayo K, 2002, VIROLOGY, V298, P30, DOI 10.1006/viro.2002.1452; Mayo K, 2002, J MOL BIOL, V316, P667, DOI 10.1006/jmbi.2001.5354; McDermott J, 2000, J MOL BIOL, V302, P121, DOI 10.1006/jmbi.2000.4030; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 2004, J BIOL CHEM, V279, P31964, DOI 10.1074/jbc.M313432200; Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Swanstrom R., 1997, P263; Tang C, 2002, NAT STRUCT BIOL, V9, P537, DOI 10.1038/nsb806; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001; Zhang YQ, 1998, J VIROL, V72, P1782, DOI 10.1128/JVI.72.3.1782-1789.1998	43	41	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17664	17670		10.1074/jbc.M412325200	http://dx.doi.org/10.1074/jbc.M412325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734744	hybrid			2022-12-27	WOS:000228807200014
J	Pastushok, L; Moraes, TF; Ellison, MJ; Xiao, W				Pastushok, L; Moraes, TF; Ellison, MJ; Xiao, W			A single Mms2 "key" residue insertion into a Ubc13 pocket determines the interface specificity of a human Lys63 ubiquitin conjugation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POSTREPLICATION REPAIR; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; ANGSTROM RESOLUTION; PROTEIN; YEAST; PATHWAY; MUTAGENESIS	Human Ubc13 and Mms2 ( or its homolog, Uev1) form a unique ubiquitin-conjugating enzyme (Ubc) complex that generates atypical Lys(63)-linked ubiquitin conjugates. Such conjugates are attached to specific targets that modulate the activity of various cellular processes including DNA repair, mitotic progression, and nuclear factor-kappa B signaling. Whereas Ubc13 is a typical Ubc, Mms2 is a non-catalytic Ubc variant. Substantial biochemical evidence has revealed a mechanism whereby Mms2 properly orients ubiquitin to allow for Lys(63) conjugation by Ubc13; however, how this specific Ubc13-Mms2 complex is formed and why Mms2 does not form a complex with other Ubcs have not been reported. In order to address these questions, we used a structure-based approach to design mutations and characterize the human Ubc13-Mms2 interface. We used the yeast two-hybrid assay, glutathione S-transferase pull-downs, and surface plasmon resonance to test in vivo and in vitro binding. These experiments were paired with functional complementation and ubiquitin conjugation studies to provide in vivo and in vitro functional data. The results in this study allowed us to identify important residues of the Ubc13-Mms2 interface, determine a correlation between heterodimer formation and function, and conclude why Mms2 forms a specific complex with Ubc13 but not other Ubc proteins.	Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Inst Biomol Design, Edmonton, AB T6G 2H7, Canada	University of Saskatchewan; University of Alberta; University of Alberta	Xiao, W (corresponding author), Univ Saskatchewan, Dept Microbiol & Immunol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wei.xiao@usask.ca		Xiao, Wei/0000-0001-7568-0782				ADAMES AG, 1997, METHODS YEAST GENETI; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ashley C, 2002, GENE, V285, P183, DOI 10.1016/S0378-1119(02)00409-2; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Franko J, 2001, BBA-GENE STRUCT EXPR, V1519, P70, DOI 10.1016/S0167-4781(01)00223-8; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Pastushok L, 2004, ADV PROTEIN CHEM, V69, P279; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	42	41	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17891	17900		10.1074/jbc.M410469200	http://dx.doi.org/10.1074/jbc.M410469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749714	hybrid			2022-12-27	WOS:000228807200042
J	Levinson, JN; Chery, N; Huang, K; Wong, TP; Gerrow, K; Kang, R; Prange, O; Wang, YT; El-Husseini, A				Levinson, JN; Chery, N; Huang, K; Wong, TP; Gerrow, K; Kang, R; Prange, O; Wang, YT; El-Husseini, A			Neuroligins mediate excitatory and inhibitory synapse formation - Involvement of PSD-95 and neurexin-1 beta in neuroligin-induced synaptic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; HIPPOCAMPAL-NEURONS; MENTAL-RETARDATION; BETA-NEUREXINS; AUTISM; PROTEINS; SYNAPTOGENESIS; PLASTICITY; MOLECULES; BINDING	The balance between excitatory and inhibitory synapses is a tightly regulated process that requires differential recruitment of proteins that dictate the specificity of newly formed contacts. However, factors that control this process remain unidentified. Here we show that members of the neuroligin (NLG) family, including NLG1, NLG2, and NLG3, drive the formation of both excitatory and inhibitory presynaptic contacts. The enrichment of endogenous NLG1 at excitatory contacts and NLG2 at inhibitory synapses supports an important in vivo role for these proteins in the development of both types of contacts. Immunocytochemical and electrophysiological analysis showed that the effects on excitatory and inhibitory synapses can be blocked by treatment with a fusion protein containing the extracellular domain of neurexin-1 beta. We also found that overexpression of PSD-95, a postsynaptic binding partner of NLGs, resulted in a shift in the distribution of NLG2 from inhibitory to excitatory synapses. These findings reveal a critical role for NLGs and their synaptic partners in controlling the number of inhibitory and excitatory synapses. Furthermore, relative levels of PSD-95 alter the ratio of excitatory to inhibitory synaptic contacts by sequestering members of the NLG family to excitatory synapses.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	El-Husseini, A (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	alaa@interchange.ubc.ca	Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015	Wong, Tak Pan/0000-0001-8611-4911				Bao JX, 2004, NAT NEUROSCI, V7, P1250, DOI 10.1038/nn1342; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brose N, 1999, NATURWISSENSCHAFTEN, V86, P516, DOI 10.1007/s001140050666; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; CHIH B, 2004, HUM MOL GENET; Craig AM, 2001, NAT NEUROSCI, V4, P569, DOI 10.1038/88388; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Levi S, 2004, J NEUROSCI, V24, P207, DOI 10.1523/JNEUROSCI.1661-03.2004; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Prange O, 2004, P NATL ACAD SCI USA, V101, P13915, DOI 10.1073/pnas.0405939101; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Todd PK, 2003, P NATL ACAD SCI USA, V100, P14374, DOI 10.1073/pnas.2336265100; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Varoqueaux F, 2004, EUR J CELL BIOL, V83, P449, DOI 10.1078/0171-9335-00410; Washbourne P, 2004, J NEUROSCI, V24, P9244, DOI 10.1523/JNEUROSCI.3339-04.2004; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4; Ziv NE, 2001, NEUROSCIENTIST, V7, P365, DOI 10.1177/107385840100700505	38	207	224	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17312	17319		10.1074/jbc.M413812200	http://dx.doi.org/10.1074/jbc.M413812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723836	hybrid			2022-12-27	WOS:000228615500095
J	Otto, BR; Sijbrandi, R; Luirink, J; Oudega, B; Heddle, JG; Mizutani, K; Park, SY; Tame, JRH				Otto, BR; Sijbrandi, R; Luirink, J; Oudega, B; Heddle, JG; Mizutani, K; Park, SY; Tame, JRH			Crystal structure of hemoglobin protease, a heme binding autotransporter protein from pathogenic Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-FRAGILIS; TSH AUTOTRANSPORTER; SHIGELLA-FLEXNERI; SECRETION PATHWAY; SERINE-PROTEASE; IRON UPTAKE; VIRULENCE; GENE; FAMILY; DOMAIN	The acquisition of iron is essential for the survival of pathogenic bacteria, which have consequently evolved a wide variety of uptake systems to extract iron and heme from host proteins such as hemoglobin. Hemoglobin protease (Hbp) was discovered as a factor involved in the symbiosis of pathogenic Escherichia coli and Bacteroides fragilis, which cause intra-abdominal abscesses. Released from E. coli, this serine protease autotransporter degrades hemoglobin and delivers heme to both bacterial species. The crystal structure of the complete passenger domain of Hbp (110 kDa) is presented, which is the first structure from this class of serine proteases and the largest parallel beta-helical structure yet solved.	Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands	Yokohama City University; Vrije Universiteit Amsterdam	Tame, JRH (corresponding author), Yokohama City Univ, Prot Design Lab, Suehiro Cho 1-7-29, Yokohama, Kanagawa 2300045, Japan.	jtame@tsurumi.yokohama-cu.ac.jp	Luirink, Joen/AAB-8658-2021; Heddle, Jonathan/AAP-7167-2020; Heddle, Jonathan G/H-4586-2014	Luirink, J./0000-0001-8431-0804				ALDRIDGE KE, 1995, AM J SURG, V169, pS2; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benjelloun-Touimi Z, 1998, MICROBIOL-SGM, V144, P1815, DOI 10.1099/00221287-144-7-1815; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; BRUNGER AT, 1996, XPLOR VERSION 3 85; Clantin B, 2004, P NATL ACAD SCI USA, V101, P6194, DOI 10.1073/pnas.0400291101; Dozois CM, 2000, INFECT IMMUN, V68, P4145, DOI 10.1128/IAI.68.7.4145-4154.2000; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; Farthmann EH, 1998, INFECTION, V26, P329, DOI 10.1007/BF02962266; Guyer DM, 2000, MOL MICROBIOL, V38, P53, DOI 10.1046/j.1365-2958.2000.02110.x; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 1999, INFECT IMMUN, V67, P5587, DOI 10.1128/IAI.67.11.5587-5596.1999; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSE J, 1995, MOL MICROBIOL, V18, P378, DOI 10.1111/j.1365-2958.1995.mmi_18020378.x; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; Kostakioti M, 2004, INFECT IMMUN, V72, P5548, DOI 10.1128/IAI.72.10.5548-5554.2004; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navarro-Garcia F, 2001, INFECT IMMUN, V69, P1053, DOI 10.1128/IAI.69.2.1053-1060.2001; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; OTTO BR, 1988, MICROB PATHOGENESIS, V4, P279, DOI 10.1016/0882-4010(88)90088-5; Otto BR, 1998, J EXP MED, V188, P1091, DOI 10.1084/jem.188.6.1091; Otto BR, 2002, INFECT IMMUN, V70, P5, DOI 10.1128/IAI.70.1.5-10.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parreira VR, 2003, INFECT IMMUN, V71, P5087, DOI 10.1128/IAI.71.9.5087-5096.2003; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PROVENCE DL, 1994, INFECT IMMUN, V62, P1369, DOI 10.1128/IAI.62.4.1369-1380.1994; ROTSTEIN OD, 1989, J MED MICROBIOL, V29, P269, DOI 10.1099/00222615-29-4-269; Roussel A., 1989, TURBO FRODO; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott DJ, 2002, J MOL BIOL, V315, P1179, DOI 10.1006/jmbi.2001.5306; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Stathopoulos C, 1999, INFECT IMMUN, V67, P772, DOI 10.1128/IAI.67.2.772-781.1999; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; Tame JRH, 2002, ACTA CRYSTALLOGR D, V58, P843, DOI 10.1107/S0907444902003499; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; WILLIAMS PH, 1979, INFECT IMMUN, V26, P925, DOI 10.1128/IAI.26.3.925-932.1979	47	137	144	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17339	17345		10.1074/jbc.M412885200	http://dx.doi.org/10.1074/jbc.M412885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728184	Green Published, hybrid			2022-12-27	WOS:000228615500098
J	Genes, O; Ilbert, M; Mejean, V; Iobbi-Nivol, C				Genes, O; Ilbert, M; Mejean, V; Iobbi-Nivol, C			TorD, an essential chaperone for TorA molybdoenzyme maturation at high temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER-BINDING-PROTEIN; N-OXIDE REDUCTASE; ESCHERICHIA-COLI; NITRATE REDUCTASE; SHEWANELLA-MASSILIA; INVOLVEMENT; BIOSYNTHESIS; PATHWAY; FORMS; DMSD	TorD has been recognized as an accessory protein that improves maturation of TorA, the molybdenum cofactor-containing trimethylamine oxide reductase of Escherichia coli. In this study, we show that at 42 degrees C and in the absence of TorD TorA is poorly matured and almost completely degraded. Strikingly, TorD restores TorA maturation to the same level whatever the growth temperature. In vitro experiments in which apoTorA was incubated with or without TorD at various temperatures confirm that TorD is an essential chaperone for TorA at elevated temperatures preventing apoTorA misfolding before cofactor insertion.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille, France	Centre National de la Recherche Scientifique (CNRS)	Iobbi-Nivol, C (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	iobbi@ibsm.cnrs-mrs.fr	Ilbert, marianne/ABG-5015-2021; Genest, Olivier/GQZ-3215-2022	Genest, Olivier/0000-0003-1240-2827; ilbert, marianne/0000-0002-9070-2334; Mejean, Vincent/0000-0001-6533-5846				CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Gon S, 2001, J BIOL CHEM, V276, P11545, DOI 10.1074/jbc.M008875200; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HILLE R, 2000, SUBCELLULAR BIOCH EN, P445; Ilbert M, 2004, MICROBIOL-SGM, V150, P935, DOI 10.1099/mic.0.26909-0; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Miller J.H., 1972, EXPT MOL GENETICS; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Ray N, 2003, FEBS LETT, V534, P156, DOI 10.1016/S0014-5793(02)03839-5; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sarfo KJ, 2004, BIOCHEM BIOPH RES CO, V315, P397, DOI 10.1016/j.bbrc.2004.01.070; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Tranier S, 2003, STRUCTURE, V11, P165, DOI 10.1016/S0969-2126(03)00008-X; Tranier S, 2002, PROTEIN SCI, V11, P2148, DOI 10.1110/ps.0202902; Turner RJ, 2004, CAN J MICROBIOL, V50, P225, DOI 10.1139/W03-117; Vergnes A, 2004, J BIOL CHEM, V279, P41398, DOI 10.1074/jbc.M407087200	22	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15644	15648		10.1074/jbc.M501119200	http://dx.doi.org/10.1074/jbc.M501119200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15723832	hybrid			2022-12-27	WOS:000228444800024
J	Gibbons, JA; Weiser, DC; Shenolikar, S				Gibbons, JA; Weiser, DC; Shenolikar, S			Importance of a surface hydrophobic pocket on protein phosphatase-1 catalytic subunit in recognizing cellular regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASES; PHOSPHORYLASE-PHOSPHATASE; AFFINITY-CHROMATOGRAPHY; TARGETING SUBUNITS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; SKELETAL-MUSCLE; GROWTH ARREST; NEURABIN-I	Cellular functions of protein phosphatase-1 (PP1), a major eukaryotic serine/threonine phosphatase, are defined by the association of PP1 catalytic subunits with endogenous protein inhibitors and regulatory subunits. Many PP1 regulators share a consensus RVXF motif, which docks within a hydrophobic pocket on the surface of the PP1 catalytic subunit. Although these regulatory proteins also possess additional PP1-binding sites, mutations of the RVXF sequence established a key role of this PP1-binding sequence in the function of PP1 regulators. WT PP1 alpha, the C-terminal truncated PP1 alpha- ( 1 - 306), a chimeric PP1 alpha containing C-terminal sequences from PP2A, another phosphatase, PP1 alpha- ( 1 - 306) with the RVXF-binding pocket substitutions L289R, M290K, and C291R, and PP2A were analyzed for their regulation by several mammalian proteins. These studies established that modifications of the RVXF-binding pocket had modest effects on the catalytic activity of PP1, as judged by recognition of substrates and sensitivity to toxins. However, the selected modifications impaired the sensitivity of PP1 to the inhibitor proteins, inhibitor-1 and inhibitor-2. In addition, they impaired the ability of PP1 to bind neurabin-I, the neuronal regulatory subunit, and GM, the skeletal muscle glycogen-targeting subunit. These data suggested that differences in RVXF interactions with the hydrophobic pocket dictate the affinity of PP1 for cellular regulators. Substitution of a distinct RVXF sequence in inhibitor-1 that enhanced its binding and potency as a PP1 inhibitor emphasized the importance of the RVXF sequence in defining the function of this and other PP1 regulators. Our studies suggest that the diversity of RVXF sequences provides for dynamic physiological regulation of PP1 functions in eukaryotic cells.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Shenolikar, S (corresponding author), Pfizer Global Res & Dev, Cardiovasc Mol Sci, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	shirish.shenolikar@Pfizer.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52054] Funding Source: Medline; NIEHS NIH HHS [T32-ES-07031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Baker SH, 1997, GENETICS, V145, P615; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 1998, METH MOL B, V93, P41; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; PARK IK, 1994, J BIOL CHEM, V269, P944; RICHARDSON DC, 1992, PROTEIN SCI, V1, P3; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; VILLAMORUZZI E, 1986, ARCH BIOCHEM BIOPHYS, V247, P155, DOI 10.1016/0003-9861(86)90544-8; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	50	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15903	15911		10.1074/jbc.M500871200	http://dx.doi.org/10.1074/jbc.M500871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703180	hybrid			2022-12-27	WOS:000228444800056
J	Horton, JK; Stefanick, DF; Naron, JM; Kedar, PS; Wilson, SH				Horton, JK; Stefanick, DF; Naron, JM; Kedar, PS; Wilson, SH			Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; S-PHASE; MAMMALIAN-CELLS; INDUCED CYTOTOXICITY; DAMAGE CHECKPOINT; ATR; REPLICATION; BETA; CHK1; ACTIVATION	Mouse fibroblasts, deficient in DNA polymerase beta, are hypersensitive to monofunctional DNA methylating agents such as methyl methanesulfonate ( MMS). Both wild- type and, in particular, repair- deficient DNA polymerase beta null cells are highly sensitized to the cytotoxic effects of MMS by 4- amino- 1,8- naphthalimide ( 4-AN), an inhibitor of poly( ADP- ribose) polymerase ( PARP) activity. Experiments with synchronized cells suggest that exposure during S- phase of the cell cycle is required for the 4- AN effect. 4- AN elicits a similar extreme sensitization to the thymidine analog, 5- hydroxymethyl-2' -deoxyuridine, implicating the requirement for an intermediate of DNA repair. In PARP- 1- expressing fibroblasts treated with a combination of MMS and 4- AN, a complete inhibition of DNA synthesis is apparent after 4 h, and by 24 h, all cells are arrested in S- phase of the cell cycle. Continuous incubation with 4- AN is required to maintain the cell cycle arrest. Caffeine, an inhibitor of the upstream checkpoint kinases ATM ( ataxia telangiectasia-mutated) and ATR ( ATM and Rad3- related), has no effect on the early inhibition of DNA synthesis, but cells are no longer able to maintain the block after 8 h. Instead, the addition of caffeine leads to arrest of cells in G(2)/ M rather than S- phase after 24 h. Analysis of signaling pathways in cell extracts reveals an activation of Chk1 after treatment with MMS and 4- AN, which can be suppressed by caffeine. Our results suggest that inhibition of PARP activity results in sensitization to MMS through maintenance of an ATR and Chk1- dependent S- phase checkpoint.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119, ZIADK036119, Z01DK060004, ZIADK061000, Z01DK061000, ZIADK060004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, Z01ES061060, ZIAES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000311, Z01AG000294, ZIAAG000294, ZIAAG000311] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P345, DOI 10.1002/jcp.1041200313; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BOULTON S, 1995, BRIT J CANCER, V72, P849, DOI 10.1038/bjc.1995.423; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Joerges C, 2003, ONCOGENE, V22, P6119, DOI 10.1038/sj.onc.1206613; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu L, 1999, CLIN CANCER RES, V5, P2908; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Pascucci B, 2002, NUCLEIC ACIDS RES, V30, P2124, DOI 10.1093/nar/30.10.2124; Rothstein R, 2000, GENE DEV, V14, P1; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schlicker A, 1999, INT J RADIAT BIOL, V75, P91, DOI 10.1080/095530099140843; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Tentori L, 2002, GLIA, V40, P44, DOI 10.1002/glia.10113; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15773	15785		10.1074/jbc.M413841200	http://dx.doi.org/10.1074/jbc.M413841200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701627	hybrid			2022-12-27	WOS:000228444800040
J	Kitiphongspattana, K; Mathews, CE; Leiter, EH; Gaskins, HR				Kitiphongspattana, K; Mathews, CE; Leiter, EH; Gaskins, HR			Proteasome inhibition alters glucose-stimulated (pro) insulin secretion and turnover in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; NEWLY SYNTHESIZED PROTEINS; TRANSLATIONAL CONTROL; QUALITY-CONTROL; ISLET FUNCTION; MUTANT PROINSULIN; CYSTEINE PROTEASE; RAPID DEGRADATION; MEMBRANE-PROTEIN	Metabolic labeling studies were conducted in freshly isolated mouse islets and a beta- cell line ( MIN6) to examine the effects of proteasome inhibition on glucose- stimulated ( pro) insulin synthesis and secretion. Glucose- stimulated ( pro) insulin synthesis, as determined by the incorporation of [ H-3] tyrosine, decreased significantly by 90% in islets and 71% in MIN6 cells pretreated with the proteasome inhibitor lactacystin ( 10 mu M) for 2 h. To follow the fate of newly synthesized ( pro) insulin, islets were pulse- labeled with [H-3] tyrosine ( 40 mu Ci) for 20 min and chased +/- lactacystin ( 10 mu M) for up to 4 h. The release of newly synthesized ( pro) insulin ([H-3] tyrosine-labeled) was similar between lactacystin- treated and control islets despite a 51% decrease ( p < 0.05) in total immunoreactive ( pro) insulin secretion by lactacystin-treated islets. The specific radioactivity of [H-3] tyrosine-labeled ( pro) insulin in the extracellular medium of lactacystin-treated islets ( 0.52 +/- 0.16 cpm/ microunits) was 2- fold greater relative to control islets ( 0.25 +/- 0.06 cpm/ microunits). Induction of the unfolded protein response by lactacystin, as evidenced by the up- regulation of endoplasmic reticulum ( ER) chaperones ( GRP78/ BiP, GRP94, protein disulfide isomerase) and induction of the stress- inducible transcription factor C/ EBP- homologous protein/ GADD153 ( CHOP/ GADD153), likely contributed to the release of newly synthesized ( pro) insulin to relieve ER stress. The present data indicate proteasome inhibition did not prevent, but increased ( p < 0.05), the intracellular degradation of [H-3] tyrosine- labeled ( pro) insulin from 8 to 24% in islets. Collectively, these data indicate beta- cells may balance glucose- stimulated ( pro) insulin synthesis and secretion with the activity of the proteasome to regulate protein concentrations in the ER.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Pathobiol, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; Univ Pittsburgh, Rangos Res Ctr, Inst Diabet, Pittsburgh, PA 15213 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jackson Laboratory	Gaskins, HR (corresponding author), Univ Illinois, Div Nutr Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	hgaskins@uiuc.edu		Gaskins, H. Rex/0000-0002-1249-535X	NIDDK NIH HHS [DK27722, DK49192, 5T32 DK59802, DK365175, DK09864] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049192, R37DK027722, T32DK059802, R01DK027722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablamunits V, 1999, CLIN EXP IMMUNOL, V115, P260, DOI 10.1046/j.1365-2249.1999.00802.x; Baldeon ME, 1997, DIABETES, V46, P770, DOI 10.2337/diabetes.46.5.770; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Cardozo C, 2002, BIOCHEMISTRY-US, V41, P10105, DOI 10.1021/bi025749w; CARROLL RJ, 1988, P NATL ACAD SCI USA, V85, P8943, DOI 10.1073/pnas.85.23.8943; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; GOLD G, 1982, SCIENCE, V218, P56, DOI 10.1126/science.6181562; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1980, BIOCHEM PHARMACOL, V29, P2625, DOI 10.1016/0006-2952(80)90077-5; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; Halban PA, 2003, MOL BIOL CELL, V14, P1195, DOI 10.1091/mbc.E02-05-0299; HALBAN PA, 1987, DIABETOLOGIA, V30, P348, DOI 10.1007/BF00299029; HALBAN PA, 1982, ENDOCRINOLOGY, V110, P1183, DOI 10.1210/endo-110-4-1183; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANDSTROM AHS, 1988, DIABETES, V37, P309, DOI 10.2337/diabetes.37.3.309; LANDSTROM AHS, 1991, METABOLISM, V40, P399, DOI 10.1016/0026-0495(91)90151-L; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORAN CR, 1963, DIABETES, V12, P115; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Okamoto T, 2001, J BIOL CHEM, V276, P742, DOI 10.1074/jbc.M003078200; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; SCHNELL AH, 1988, CELL TISSUE RES, V252, P9; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Urade R, 1999, BIOSCI BIOTECH BIOCH, V63, P610, DOI 10.1271/bbb.63.610; URADE R, 1993, J BIOL CHEM, V268, P22004; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; WHEATLEY DN, 1982, J THEOR BIOL, V98, P283, DOI 10.1016/0022-5193(82)90265-X; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887	65	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15727	15734		10.1074/jbc.M410876200	http://dx.doi.org/10.1074/jbc.M410876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705591	hybrid			2022-12-27	WOS:000228444800034
J	Li, SG; Zhou, H; Luo, YP; Zhang, P; Qu, LH				Li, SG; Zhou, H; Luo, YP; Zhang, P; Qu, LH			Identification and functional analysis of 20 box H/ACA small nucleolar RNAs (snoRNAs) from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U6 SPLICEOSOMAL RNA; NON-MESSENGER RNAS; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; 2'-O-RIBOSE METHYLATION; PRERIBOSOMAL RNA; GUIDE SNORNAS; PSEUDOURIDINE; GENE; YEAST	Considering all small nucleolar RNAs (snoRNAs) enriched in the nucleolus, we generated a specialized cDNA library of small nuclear RNAs from Schizosaccharomyces pombe and isolated, for the first time, 20 novel box H/ACA snoRNAs. Thirteen of these were characterized as novel guides that were predicted to direct 19 pseudouridylations in 18 S and 25 S rRNAs. The remaining seven snoRNAs were considered as orphan guides that lack sequence complementarity to either rRNAs or snRNAs. We have experimentally demonstrated the function of the 10 novel snoRNAs by gene deletion in the fission yeast. The snoRNAs were shown to be dispensable for the viability of S. pombe, although an impact of snR94 depletion on yeast growth, especially at 23 degrees C, was revealed. A total of 30 pseudouridylation sites were precisely mapped in the S. pombe rRNAs, showing a distinctive pseudouridylation pattern in the budding yeast. Interestingly, the absence of pseudouridylation on U2347 in S. pombe 25 S rRNA pointed out a critical role for Psi 2345 in conferring a growth advantage for yeast. In contrast to the intron-encoded box C/D snoRNAs in yeast, all box H/ACA snoRNAs appeared to be transcribed independently from intergenic regions between two protein-coding genes, except for snR35, which was nested in an open reading frame encoding for a hypothetical protein, although expressed from the opposite strand. Remarkably, snR90 was cotranscribed with an intron-encoded box C/D snoRNA, and this is the first demonstration of a non-coding RNA gene that encodes two different types of snoRNAs by its exon and intron. A detailed comparison of the S. pombe snoRNAs, with their functional homologues in diverse organisms, suggests a mechanism by which the snoRNAs have evolved in coordination with rRNAs to preserve the post-transcriptional modification sites among distant eukaryotes.	Zhongshan Univ, Biotechnol Res Ctr, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Peoples R China	Sun Yat Sen University	Qu, LH (corresponding author), Zhongshan Univ, Biotechnol Res Ctr, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Peoples R China.	lsbrc04@zsu.edu.cn	Zhang, Peng/F-9664-2013	Qu, Liang-Hu/0000-0003-3657-2863				Atzorn V, 2004, MOL CELL BIOL, V24, P1769, DOI 10.1128/MCB.24.4.1769-1778.2004; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Badis G, 2003, RNA, V9, P771, DOI 10.1261/rna.5240503; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Brown JWS, 2003, TRENDS PLANT SCI, V8, P42, DOI 10.1016/S1360-1385(02)00007-9; Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Chen CL, 2003, NUCLEIC ACIDS RES, V31, P2601, DOI 10.1093/nar/gkg373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; d'Orval BC, 2001, NUCLEIC ACIDS RES, V29, P4518, DOI 10.1093/nar/29.22.4518; Darzacq X, 2002, EMBO J, V21, P2746, DOI 10.1093/emboj/21.11.2746; Dove JE, 1998, METHOD CELL BIOL, V53, P33; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Huang ZP, 2004, J MOL BIOL, V341, P669, DOI 10.1016/j.jmb.2004.06.041; Huttenhofer A, 2002, CURR OPIN CHEM BIOL, V6, P835, DOI 10.1016/S1367-5931(02)00397-6; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; King TH, 2003, MOL CELL, V11, P425, DOI 10.1016/S1097-2765(03)00040-6; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Kruszka K, 2003, EMBO J, V22, P621, DOI 10.1093/emboj/cdg040; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Schattner P, 2004, NUCLEIC ACIDS RES, V32, P4281, DOI 10.1093/nar/gkh768; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Vitali P, 2003, NUCLEIC ACIDS RES, V31, P6543, DOI 10.1093/nar/gkg849; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Zhou H, 2002, NUCLEIC ACIDS RES, V30, P894, DOI 10.1093/nar/30.4.894; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	45	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16446	16455		10.1074/jbc.M500326200	http://dx.doi.org/10.1074/jbc.M500326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716270	hybrid			2022-12-27	WOS:000228444800118
J	Poppelmann, B; Klimmek, K; Strozyk, E; Voss, R; Schwarz, T; Kulms, D				Poppelmann, B; Klimmek, K; Strozyk, E; Voss, R; Schwarz, T; Kulms, D			NF kappa B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTS TRANSFORMED KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; IN-VIVO; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; JNK ACTIVATION; LIGAND; TRAF1	Activation of the transcription factor nuclear factor-kappa B (NF kappa B) by inflammatory cytokines like tumor necrosis (TNF) factor and interleukin-1 (IL-1) is generally associated with the induction of antiapoptotic pathways. Therefore, NF kappa B inhibits both intrinsically and extrinsically induced apoptosis and thus is regarded to act universally in an antiapoptotic fashion. Accordingly, activation of NF kappa B by IL-1 was shown to result in reduction of death ligand-induced apoptosis via up-regulation of antiapoptotic inhibitor of apoptosis proteins (IAPs). In contrast, apoptosis induced by ultraviolet-B radiation (UVB) was shown to be enhanced in an NF kappa B-dependent manner, indicating that NF kappa B can also act in a proapoptotic fashion. This study investigates the molecular mechanisms underlying IL-1-mediated enhancement of UVB-induced apoptosis. We show that NF kappa B activation in costimulation with UVB treatment results in repression of antiapoptotic genes and consequently in down-regulation of the respective proteins, like c-IAP, FLICE-inhibitory protein ( FLIP), and some members of the TNF receptor-associated ( TRAF) 2 protein family. In parallel, TNF alpha is released, leading to activation of signaling pathways mediated by TNF receptor-1 (TNF-R1). Although TNF is well known to induce both proapoptotic and antiapoptotic effects, the down-regulated levels of TRAF-1, -2, and -6 proteins by IL-1 plus UVB action leads to a shift toward promotion of the proapoptotic pathway. In concert with the down-regulation of IAPs and FLIP, TNF-R1 activation as an additional proapoptotic stimulus now results in significant enhancement of UVB-induced apoptosis. Taken together, elucidation of the molecular mechanisms underlying IL-1-mediated enhancement of UVB-induced apoptosis revealed that NF kappa B does not exclusively act in an antiapoptotic fashion but may also mediate proapoptotic effects.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Integrated Funct Genom, D-48149 Munster, Germany; Univ Munster, Inst Clin Chem & Lab Med, D-48149 Munster, Germany; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Stuttgart; University of Munster; University of Munster; University of Munster; University of Kiel	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014; Schwarz, Thomas/A-9148-2010					Aota K, 2002, EXP CELL RES, V276, P111, DOI 10.1006/excr.2002.5515; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Duffey DC, 1999, CANCER RES, V59, P3468; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jang HD, 2001, BIOCHEM BIOPH RES CO, V281, P499, DOI 10.1006/bbrc.2001.4369; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGER TA, 1992, PHARM SKIN, P283; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	48	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15635	15643		10.1074/jbc.M413006200	http://dx.doi.org/10.1074/jbc.M413006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15723831	hybrid			2022-12-27	WOS:000228444800023
J	Tang, L; Stith, L; Jaffe, EK				Tang, L; Stith, L; Jaffe, EK			Substrate-induced interconversion of protein quaternary structure isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC LIGHT-SCATTERING; X-RAY-STRUCTURE; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; 5-AMINOLEVULINIC ACID DEHYDRATASE; SYNTHASE CATALYZED REACTION; PORPHOBILINOGEN SYNTHASE; ESCHERICHIA-COLI; ALLOSTERIC REGULATION; COMPREHENSIVE MODEL; MECHANISM	Human porphobilinogen synthase ( PBGS) can exist in two dramatically different quaternary structure isoforms, which have been proposed to be in dynamic equilibrium ( Breinig, S., Kervinen, J., Stith, L., Wasson, A. S., Fairman, R., Wlodawer, A., Zdanov, A., and Jaffe, E. K. ( 2003) Nat. Struct. Biol. 10, 757 - 763). The quaternary structure isoforms of PBGS result from two alternative conformations of the monomer; one monomer structure assembles into a high activity octamer, whereas the other monomer structure assembles into a low activity hexamer. The kinetic behavior of these oligomers led to the hypothesis that turnover facilitates the interconversion of the oligomeric structures. The current work demonstrates that the interactions of ligands at the enzyme active site promote the structural interconversion between human PBGS quaternary structure isoforms, favoring formation of the octamer. This observation illustrates that the assembly and disassembly of oligomeric proteins can be facilitated by the protein motions that accompany enzymatic catalysis.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Eileen.Jaffe@fccc.edu			NCI NIH HHS [CA006927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Battersby AR, 2000, NAT PROD REP, V17, P507, DOI 10.1039/b002635m; BERU N, 1985, J BIOL CHEM, V260, P9251; Breinig S, 2003, NAT STRUCT BIOL, V10, P757, DOI 10.1038/nsb963; Erskine PT, 2003, BIOCHEM J, V373, P733, DOI 10.1042/BJ20030513; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; Erskine PT, 2001, J MOL BIOL, V312, P133, DOI 10.1006/jmbi.2001.4947; FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Gast K, 1997, FEBS LETT, V403, P245, DOI 10.1016/S0014-5793(97)00058-6; Jaffe EK, 2004, BIOORG CHEM, V32, P316, DOI 10.1016/j.bioorg.2004.05.010; Jaffe EK, 2003, CHEM BIOL, V10, P25, DOI 10.1016/S1074-5521(02)00296-X; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; Jaffe EK, 2002, J BIOL CHEM, V277, P19792, DOI 10.1074/jbc.M201486200; Jaffe EK, 2001, J BIOL CHEM, V276, P1531, DOI 10.1074/jbc.M007663200; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Kervinen J, 2000, BIOCHEMISTRY-US, V39, P9018, DOI 10.1021/bi000620c; Kundrat L, 2003, J BIOL CHEM, V278, P31325, DOI 10.1074/jbc.M304124200; MILLSDAVIES NL, 2000, THESIS U SOUTHAMPTON; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; Schonfeld HJ, 1998, BIOCHEM SOC T, V26, P753, DOI 10.1042/bst0260753; SEGEL IH, 1975, ENZYME KINETICS, P64; Senior NM, 1996, BIOCHEM J, V320, P401; SHEMIN D, 1976, PHILOS T ROY SOC B, V273, P109, DOI 10.1098/rstb.1976.0004; STELLA AM, 1977, MOL CELL BIOCHEM, V16, P97, DOI 10.1007/BF01732049; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; Van Holde KKE, 1998, PRINCIPLES PHYS BIOC, P312; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0	34	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15786	15793		10.1074/jbc.M500218200	http://dx.doi.org/10.1074/jbc.M500218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710608	hybrid			2022-12-27	WOS:000228444800041
J	Tie, JK; Nicchitta, C; von Heijne, G; Stafford, DW				Tie, JK; Nicchitta, C; von Heijne, G; Stafford, DW			Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; GAMMA-GLUTAMYL CARBOXYLASE; 2,3-EPOXIDE REDUCTASE; ACTIVE-SITE; RAT-LIVER; DEPENDENT CARBOXYLASE; THIOREDOXIN SYSTEM; PROTEIN TOPOLOGY; PURIFICATION; PREDICTION	Vitamin K epoxide reductase (VKOR) catalyzes the conversion of vitamin K 2,3-epoxide into vitamin K in the vitamin K redox cycle. Recently, the gene encoding the catalytic subunit of VKOR was identified as a 163-amino acid integral membrane protein. In this study we report the experimentally derived membrane topology of VKOR. Our results show that four hydrophobic regions predicted as the potential transmembrane domains in VKOR can individually insert across the endoplasmic reticulum membrane in vitro. However, in the intact enzyme there are only three transmembrane domains, residues 10 - 29, 101 - 123, and 127 - 149, and membrane-integration of residues 75 - 97 appears to be suppressed by the surrounding sequence. Results of N-linked glycosylation-tagged full-length VKOR shows that the N terminus of VKOR is located in the endoplasmic reticulum lumen, and the C terminus is located in the cytoplasm. Further evidence for this topological model of VKOR was obtained with freshly prepared intact microsomes from insect cells expressing HPC4-tagged full-length VKOR. In these experiments an HPC4 tag at the N terminus was protected from proteinase K digestion, whereas an HPC4 tag at the C terminus was susceptible. Altogether, our results suggest that VKOR is a type III membrane protein with three transmembrane domains, which agrees well with the prediction by the topology prediction program TMHMM.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Stockholm University	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	dws@E-mail.unc.edu	von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Tie, Jian-Ke/0000-0002-8447-3408	NHLBI NIH HHS [HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Begent LA, 2001, J PHARM PHARMACOL, V53, P481, DOI 10.1211/0022357011775776; BELL R G, 1970, Archives of Biochemistry and Biophysics, V141, P473, DOI 10.1016/0003-9861(70)90164-5; Cain D, 1997, J BIOL CHEM, V272, P29068, DOI 10.1074/jbc.272.46.29068; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; LEE JJ, 1985, BIOCHEMISTRY-US, V24, P7063, DOI 10.1021/bi00346a007; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; MUKHARJI I, 1985, P NATL ACAD SCI USA, V82, P2713, DOI 10.1073/pnas.82.9.2713; Mutucumarana VP, 2000, J BIOL CHEM, V275, P32572, DOI 10.1074/jbc.M006808200; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; PREUSCH PC, 1990, FREE RADICAL RES COM, V8, P401, DOI 10.3109/10715769009053374; PREUSCH PC, 1992, FEBS LETT, V305, P257, DOI 10.1016/0014-5793(92)80681-6; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Saxena SP, 2001, APOPTOSIS, V6, P57, DOI 10.1023/A:1009624111275; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1248, DOI 10.1016/S0006-291X(88)81274-9; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1986, HAEMOSTASIS, V16, P193; Taylor PD, 2003, NUCLEIC ACIDS RES, V31, P3698, DOI 10.1093/nar/gkg554; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Wajih N, 2005, J BIOL CHEM, V280, P10540, DOI 10.1074/jbc.M413982200; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; WALLIN R, 1987, INT J BIOCHEM, V19, P1063, DOI 10.1016/0020-711X(87)90307-7; Wallin R, 1997, METHOD ENZYMOL, V282, P395; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; WALTER P, 1983, METHOD ENZYMOL, V96, P84	39	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16410	16416		10.1074/jbc.M500765200	http://dx.doi.org/10.1074/jbc.M500765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716279	Green Published, hybrid			2022-12-27	WOS:000228444800114
J	Davoodpour, P; Landstrom, M				Davoodpour, P; Landstrom, M			2-methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; (TGF-BETA)-INDUCED APOPTOSIS; RECEPTOR; BIM; BAX; PHOSPHORYLATION; PROLIFERATION; ANGIOGENESIS; MECHANISMS; INDUCTION	Prostate cancer is the second most common cause of death related to cancer in Western society. 2-Methoxyestradiol (2-ME), an endogenous metabolite of estradiol-17 beta, inhibits tumor angiogenesis while also exerting potent cytotoxic effects on various cancer cells. 2-ME has been shown to activate the p38 MAPK and JNK pathways and to induce apoptosis in cells, although the underlying molecular mechanisms for this are unknown. Here we report that the expression of Smad7, an adaptor molecule required to activate p38 MAPK in the transforming growth factor beta signaling pathway, is also required for 2-ME-induced p38 activation and apoptosis in human prostate cancer cells (PC-3U). PC-3U/AS-S7 cells stably transfected with an antisense Smad7 construct, or PC-3U cells transiently transfected with short interfering RNA for Smad7, were protected against 2-ME-induced apoptosis. 2-ME-induced apoptosis was found to involve p38 MAPK and JNK, because simultaneous treatments with 2-ME and a specific p38 inhibitor (SB203580) or an inhibitor of JNK (L-JNK1) prevented 2-ME-induced apoptosis. Most interestingly, Smad7 was shown by both antisense and short interfering RNA techniques to affect levels of beta-catenin, which has been implicated previously in the regulation of apoptosis. Moreover, Smad7 was found to be important for the basal expression of Bim, a pro-apoptotic Bcl-2 family member, and for 2-ME-induced expression of Bim. These results suggest that expression of Smad7 is crucial for 2-ME-induced apoptosis in human prostate cancer cells.	Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Uppsala Univ, Imanet, SE-75185 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Landstrom, M (corresponding author), Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	Marene.Landstrom@licr.uu.se		Landstrom, Marene/0000-0001-6737-7230				Barker N, 2000, BIOESSAYS, V22, P961; Bu SZ, 2002, FEBS LETT, V531, P141, DOI 10.1016/S0014-5793(02)03478-6; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davoodpour P, 2004, NUCL MED BIOL, V31, P867, DOI 10.1016/j.nucmedbio.2004.03.015; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Harris CA, 2001, J BIOL CHEM, V276, P37754; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kent EC, 2003, UROLOGY, V62, P134, DOI 10.1016/j.urology.2003.09.005; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; LaVallee TM, 2002, CANCER RES, V62, P3691; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; MacCarthy-Morrogh L, 2000, CANCER RES, V60, P5441; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Moustakas A, 2001, J CELL SCI, V114, P4359; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Quan TH, 2005, J BIOL CHEM, V280, P8079, DOI 10.1074/jbc.M409647200; Quan TH, 2001, J BIOL CHEM, V276, P26349, DOI 10.1074/jbc.M010835200; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391	46	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14773	14779		10.1074/jbc.M414470200	http://dx.doi.org/10.1074/jbc.M414470200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708859	hybrid			2022-12-27	WOS:000228236800054
J	Saavalainen, K; Pasonen-Seppanen, S; Dunlop, TW; Tammi, R; Tammi, MI; Carlberg, C				Saavalainen, K; Pasonen-Seppanen, S; Dunlop, TW; Tammi, R; Tammi, MI; Carlberg, C			The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; VITAMIN-D; HEPARIN-BINDING; CELL-GROWTH; IN-VITRO; IDENTIFICATION; ELEMENTS; KERATINOCYTES; ACTIVATION; TRANSCRIPTION	Hyaluronan is an abundant and rapidly turned over matrix molecule between the vital cell layers of the epidermis and subject to large concentration changes associated with keratinocyte proliferation, migration, and differentiation induced by paracrine and endocrine factors like epidermal growth factor (EGF) and all-trans-retinoic acid ( RA). We found that in REK cells EGF and all-trans-RA up-regulated hyaluronan synthase 2 (Has2) gene expression within 2 h 4-fold each and in HaCaT human immortal keratinocytes 8- and 33-fold, respectively. The first 10 kb of the human Has2 promoter were scanned in silico and in vitro for potential response elements of signal transducer and activator of transcription ( STAT) or RA receptor (RAR) proteins. We identified a STAT-response element in the proximal promoter region and confirmed its functionality in response to EGF by chromatin immunoprecipitation (ChIP) assays. Direct in vitro binding of RARs to four RARE candidates within the Has2 promoter could not be observed at stringent gel shift conditions, but reporter gene assays demonstrated functionality of a complex of two of these RAREs located similar to 1200 bp upstream of the transcription start site. Moreover, ChIP assays using antibodies against nine nuclear proteins monitored all-trans-RA-dependent binding of RAR, retinoid X receptor, mediator protein, and RNA polymerase II and also histone 4 acetylation to a promoter region containing the complex RARE. Taken together, the human Has2 gene is a potent primary EGF and all-trans-RA responding gene with a complex regulation.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Glass CK, 2000, GENE DEV, V14, P121; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hiltunen ELJ, 2002, CANCER RES, V62, P6410; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pasonen-Seppanen S, 2001, J INVEST DERMATOL, V117, P1322, DOI 10.1046/j.0022-202x.2001.01529.x; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Quack M, 2000, J MOL BIOL, V296, P743, DOI 10.1006/jmbi.2000.3499; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Xiao JH, 1999, EMBO J, V18, P1539, DOI 10.1093/emboj/18.6.1539	38	87	89	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14636	14644		10.1074/jbc.M500206200	http://dx.doi.org/10.1074/jbc.M500206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15722343	hybrid			2022-12-27	WOS:000228236800038
J	Madonna, R; Di Napoli, P; Massaro, M; Grilli, A; Felaco, M; De Caterina, A; Tang, DM; De Caterina, R; Geng, YJ				Madonna, R; Di Napoli, P; Massaro, M; Grilli, A; Felaco, M; De Caterina, A; Tang, DM; De Caterina, R; Geng, YJ			Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COA REDUCTASE INHIBITOR; ENDOTHELIAL PROGENITOR CELLS; NECROSIS-FACTOR-ALPHA; COENZYME-A REDUCTASE; HEART-FAILURE; PRIMARY ASTROCYTES; INTERFERON-GAMMA; APOPTOTIC DEATH; STATIN THERAPY	Cardiac stem cells or myoblasts are vulnerable to inflammatory stimulation in hearts with infarction or ischemic injury. Widely used for the prevention and treatment of atherosclerotic heart disease, the cholesterol-lowering drugs statins may exert anti-inflammatory effects. In this study, we examined the impact of inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase with simvastatin on the expression of inducible nitric-oxide synthase (iNOS) in embryonic cardiac myoblasts stimulated with the proinflammatory cytokines, interleukin-1 or tumor necrosis factor. Treatment with simvastatin significantly reduced the levels of iNOS mRNA and protein in cytokine-treated rat H9c2 cardiac embryonic myoblasts. Addition of the HMG-CoA reductase product, L-mevalonate, and the by-product of cholesterol synthesis, geranylgeranyl pyrophosphate, could reverse the statin inhibitory effect on iNOS expression. Simvastatin treatment lowered the Rho GTPase activities, whereas the Rho-associated kinase inhibitor Y27632 partially blocked the statin inhibitory effect on nitrite production in the cytokine-treated H9c2 cells. Treatment with simvastatin led to inactivation of NF-kappa B by elevation of the NF-kappa B inhibitor I kappa B and reduction of the NF-kappa B nuclear contents in the cytokine-stimulated H9c2 cells. Hence, treatment with simvastatin can attenuate iNOS expression and NO synthesis in cytokine-stimulated embryonic cardiac myoblasts. The statin inhibitory effect may occur through isoprenoid-mediated intracellular signal transduction, which involves several key signal proteins, such as Rho kinase and I kappa B/NF-kappa B. These data suggest that statin therapy may protect the cardiac myocyte progenitors against the cytotoxicity of cytokine-induced high output of NO production in infarcted or ischemic hearts with inflammation.	Univ G DAnnunzio, Inst Cardiol, I-66100 Chieti, Italy; Univ G DAnnunzio, Ctr Excellence Aging, I-66100 Chieti, Italy; Univ G DAnnunzio, Dept Biomorphol, I-66100 Chieti, Italy; CNR, Inst Clin Physiol, I-73100 Lecce, Italy; Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Texas System; University of Texas Health Science Center Houston	De Caterina, R (corresponding author), Univ G DAnnunzio, Osped S Camillo de Lellis, Dept Cardiol, Via Forlanini 50, I-66100 Chieti, Italy.	rdcater@unich.it; yong-jian.geng@uth.tmc.edu	De Caterina, Raffaele/K-3857-2016; massaro, marika/AAQ-1204-2020	De Caterina, Raffaele/0000-0003-1637-574X; massaro, marika/0000-0001-6124-5077; grilli, alfredo/0000-0002-5746-5007; Madonna, Rosalinda/0000-0001-6455-2777	NHLBI NIH HHS [R01HL59249, R01HL69509] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069509, R01HL059249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birks EJ, 2000, TRANSPLANTATION, V70, P1498, DOI 10.1097/00007890-200011270-00018; Birks EJ, 1997, CORONARY ARTERY DIS, V8, P389, DOI 10.1097/00019501-199706000-00007; Bloch W, 2001, MICROSC RES TECHNIQ, V55, P259, DOI 10.1002/jemt.1175; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088-199631050-00003; Di Napoli P, 2001, CARDIOVASC RES, V51, P283, DOI 10.1016/S0008-6363(01)00306-6; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Geng YJ, 2003, ANN NY ACAD SCI, V1010, P687, DOI 10.1196/annals.1299.126; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Geng YJ, 1996, CANCER RES, V56, P866; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GENG YJ, 1994, EXP CELL RES, V214, P418, DOI 10.1006/excr.1994.1275; Gotto AM, 2001, AM J CARDIOL, V87, p13B; Gotto AM, 2001, AM J CARDIOL, V88, p36F; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; Hattori Y, 2002, CARDIOVASC RES, V54, P649, DOI 10.1016/S0008-6363(02)00266-3; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Hescheler J, 1999, CELLS TISSUES ORGANS, V165, P153, DOI 10.1159/000016695; Ikeda Y, 2003, J CARDIOVASC PHARM, V41, P649, DOI 10.1097/00005344-200304000-00019; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kaneta S, 2003, ATHEROSCLEROSIS, V170, P237, DOI 10.1016/S0021-9150(03)00301-0; Kim SJ, 2002, AM J PHYSIOL-HEART C, V282, pH423, DOI 10.1152/ajpheart.00609.2001; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Massion PB, 2003, CIRC RES, V93, P388, DOI 10.1161/01.RES.0000088351.58510.21; Ogata Y, 2002, J CARDIOVASC PHARM, V40, P907, DOI 10.1097/00005344-200212000-00012; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Rasmussen LM, 2001, BIOCHEM J, V360, P363, DOI 10.1042/0264-6021:3600363; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; von Haehling S, 2003, HEART FAIL REV, V8, P99, DOI 10.1023/A:1022103222857; Wassmann S, 2001, HYPERTENSION, V37, P1450, DOI 10.1161/01.HYP.37.6.1450; XIE QW, 1994, J BIOL CHEM, V269, P4705	41	75	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13503	13511		10.1074/jbc.M411859200	http://dx.doi.org/10.1074/jbc.M411859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705589	Green Published, hybrid			2022-12-27	WOS:000228095500041
J	Collins, RF; Frye, SA; Balasingham, S; Ford, RC; Tonjum, T; Derrick, JP				Collins, RF; Frye, SA; Balasingham, S; Ford, RC; Tonjum, T; Derrick, JP			Interaction with type IV pili induces structural changes in the bacterial outer membrane secretin PilQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING PROTEIN PILIN; NEISSERIA-GONORRHOEAE; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; FILAMENTOUS PHAGE; ESCHERICHIA-COLI; NEEDLE COMPLEX; BIOGENESIS; MENINGITIDIS; MOTILITY	Type IV pili are cell surface organelles found on many Gram-negative bacteria. They mediate a variety of functions, including adhesion, twitching motility, and competence for DNA uptake. The type IV pilus is a helical polymer of pilin protein subunits and is capable of rapid polymerization or depolymerization, generating large motor forces in the process. Here we show that a specific interaction between the outer membrane secretin PilQ and the type IV pilus fiber can be detected by far-Western analysis and sucrose density gradient centrifugation. Transmission electron microscopy of preparations of purified pili, to which the purified PilQ oligomer had been added, showed that PilQ was uniquely located at one end of the pilus fiber, effectively forming a "mallet-type" structure. Determination of the three-dimensional structure of the PilQ-type IV pilus complex at 26-angstrom resolution showed that the cavity within the protein complex was filled. Comparison with a previously determined structure of PilQ at 12-angstrom resolution indicated that binding of the pilus fiber induced a dissociation of the "cap" feature and lateral movement of the "arms" of the PilQ oligomer. The results demonstrate that the PilQ structure exhibits a dynamic response to the binding of its transported substrate and suggest that the secretin could play an active role in type IV pilus assembly as well as secretion.	Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Oslo, Rikshosp, Inst Microbiol, NO-0027 Oslo, Norway; Univ Oslo, Rikshosp, Ctr Mol Biol & Neurosci, NO-0027 Oslo, Norway	University of Manchester; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Derrick, JP (corresponding author), Univ Manchester, Fac Life Sci, Sackville St,POB 88, Manchester M60 1QD, Lancs, England.	Jeremy.Derrick@manchester.ac.uk	Tønjum, Tone/J-4581-2014	Tonjum, Tone/0000-0002-1709-6921; Ford, Robert/0000-0002-0958-1505; Frye, Stephan/0000-0002-0786-8481; Derrick, Jeremy/0000-0002-4350-5354				Aas FE, 2002, MOL MICROBIOL, V46, P1441, DOI 10.1046/j.1365-2958.2002.03265.x; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bitter W, 1999, TRENDS MICROBIOL, V7, P4, DOI 10.1016/S0966-842X(98)01398-5; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Blom AM, 2001, J IMMUNOL, V166, P6764, DOI 10.4049/jimmunol.166.11.6764; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; Brinton C., 1978, IMMUNOBIOLOGY NEISER, P155; Collins RF, 2004, J BIOL CHEM, V279, P39750, DOI 10.1074/jbc.M405971200; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Darzins A, 1997, GENE, V192, P109, DOI 10.1016/S0378-1119(97)00037-1; Drake SL, 1997, MOL MICROBIOL, V23, P657, DOI 10.1046/j.1365-2958.1997.2511618.x; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; FROHOLM LO, 1973, ACTA PATH MICRO IM B, VB 81, P525; FROSCH M, 1990, MOL MICROBIOL, V4, P1215, DOI 10.1111/j.1365-2958.1990.tb00697.x; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Guilvout I, 1999, J BACTERIOL, V181, P7212, DOI 10.1128/JB.181.23.7212-7220.1999; Hahn E, 2000, J STRUCT BIOL, V132, P241, DOI 10.1006/jsbi.2000.4323; HECKELS JE, 1989, CLIN MICROBIOL REV, V2, pS66, DOI 10.1128/CMR.2.Suppl.S66-S73.1989; Herdendorf TJ, 2002, J BACTERIOL, V184, P6465, DOI 10.1128/JB.184.23.6465-6471.2002; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HOLZENBURG A, 1994, MICRON, V25, P447, DOI 10.1016/0968-4328(94)00034-4; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; Hwang JW, 2003, J BACTERIOL, V185, P6695, DOI 10.1128/JB.185.22.6695-6701.2003; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; Kimbrough TG, 2002, MICROBES INFECT, V4, P75, DOI 10.1016/S1286-4579(01)01512-X; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Maier B, 2002, P NATL ACAD SCI USA, V99, P16012, DOI 10.1073/pnas.242523299; McBride MJ, 2001, ANNU REV MICROBIOL, V55, P49, DOI 10.1146/annurev.micro.55.1.49; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Morand PC, 2004, EMBO J, V23, P2009, DOI 10.1038/sj.emboj.7600200; Mu XQ, 2002, J BACTERIOL, V184, P4868, DOI 10.1128/JB.184.17.4868-4874.2002; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Nunn D, 1999, TRENDS CELL BIOL, V9, P402, DOI 10.1016/S0962-8924(99)01634-7; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; PARGE HE, 1990, J BIOL CHEM, V265, P2278; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; POTTS WJ, 1988, MOL MICROBIOL, V2, P647, DOI 10.1111/j.1365-2958.1988.tb00073.x; Prince SM, 2001, ACTA CRYSTALLOGR D, V57, P1164, DOI 10.1107/S0907444901009416; PUGSLEY AP, 1993, MOL MICROBIOL, V10, P665, DOI 10.1111/j.1365-2958.1993.tb00938.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; SWANSON J, 1971, J EXP MED, V134, P886, DOI 10.1084/jem.134.4.886; Thanassi DG, 2002, J MOL MICROB BIOTECH, V4, P11; Tonjum T, 1998, MOL MICROBIOL, V29, P111, DOI 10.1046/j.1365-2958.1998.00910.x; Tonjum T, 1997, GENE, V192, P155, DOI 10.1016/S0378-1119(97)00018-8; TONJUM T, 1995, MOL MICROBIOL, V16, P451, DOI 10.1111/j.1365-2958.1995.tb02410.x; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Winther-Larsen HC, 2001, P NATL ACAD SCI USA, V98, P15276, DOI 10.1073/pnas.261574998; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973; ZHANG QY, 1992, P NATL ACAD SCI USA, V89, P5366, DOI 10.1073/pnas.89.12.5366	64	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18923	18930		10.1074/jbc.M411603200	http://dx.doi.org/10.1074/jbc.M411603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753075	hybrid			2022-12-27	WOS:000228932300045
J	Yang, SH; Shrivastav, A; Kisinski, C; Sharma, RK; Chen, MH; Berthiaume, LG; Peters, LL; Chuang, PT; Young, SG; Bergo, MO				Yang, SH; Shrivastav, A; Kisinski, C; Sharma, RK; Chen, MH; Berthiaume, LG; Peters, LL; Chuang, PT; Young, SG; Bergo, MO			N-myristoyltransferase 1 is essential in early mouse development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; MYRISTOYL-COA; ESSENTIAL ENZYME; CELLS; RNAI	N-Myristoyltransferase (NMT) transfers myristate to an amino-terminal glycine of many eukaryotic proteins. In yeast, worms, and flies, this enzyme is essential for viability of the organism. Humans and mice possess two distinct but structurally similar enzymes, NMT1 and NMT2. These two enzymes have similar peptide specificities, but no one has examined the functional importance of the enzymes in vivo. To address this issue, we performed both genetic and biochemical studies. Northern blots with RNA from adult mice and in situ hybridization studies of day 13.5 embryos revealed widespread expression of both Nmt1 and Nmt2. To determine whether the two enzymes are functionally redundant, we generated Nmt1-deficient mice carrying a beta-galactosidase marker gene. beta-Galactosidase staining of tissues from heterozygous Nmt1-deficient (Nmt1+/-) mice and embryos confirmed widespread expression of Nmt1. Intercrosses of Nmt1+/- mice yielded no viable homozygotes (Nmt1-/-), and heterozygotes were born at a less than predicted frequency. Nmt1-/- embryos died between embryonic days 3.5 and 7.5. Northern blots revealed lower levels of Nmt2 expression in early development than at later time points, a potential explanation for the demise of Nmt1-/- embryos. To explore this concept, we generated Nmt1-/- embryonic stem (ES) cells. The Nmt2 mRNA could be detected in Nmt1-/- ES cells, but the total NMT activity levels were reduced by similar to 95%, suggesting that Nmt2 contributes little to total enzyme activity levels in these early embryo cells. The Nmt1-/- ES cells were functionally abnormal; they yielded small embryoid bodies in in vitro differentiation experiments and did not contribute normally to organogenesis in chimeric mice. We conclude that Nmt1 is not essential for the viability of mammalian cells but is required for development, likely because it is the principal N-myristoyltransferase in early embryogenesis.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Saskatchewan, Coll Med, Dept Pathol, Saskatoon, SK S7N 4H4, Canada; Saskatchewan Canc Agcy, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of Saskatchewan; University of Saskatchewan; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Alberta; University of California System; University of California San Francisco	Young, SG (corresponding author), Univ Calif Los Angeles, Dept Med, Div Cardiol, 650 Charles E Young Dr,S 47-123,CHS Bldg, Los Angeles, CA 90095 USA.	sgyoung@mednet.ucla.edu		Berthiaume, Luc/0000-0003-0926-059X; Peters, Luanne/0000-0002-0784-0534; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066621, U01HL066600, U01HL066590, U01HL066611] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66590, U01 HL066611, HL66600, HL66621] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; CRONMILLER C, 1978, DEV BIOL, V67, P465, DOI 10.1016/0012-1606(78)90212-9; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; HUANG L, 1995, J CLIN INVEST, V95, P5152; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Ntwasa M, 2001, EXP CELL RES, V262, P134, DOI 10.1006/excr.2000.5086; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; Raju RVS, 1999, BIOCHEM BIOPH RES CO, V257, P284, DOI 10.1006/bbrc.1999.0439; Raju RVS, 1998, BIOCHEMISTRY-US, V37, P14928, DOI 10.1021/bi980891b; Raju RVS, 1997, ARCH BIOCHEM BIOPHYS, V348, P134, DOI 10.1006/abbi.1997.0333; Selvakumar P, 2002, INT J MOL MED, V10, P493; Shiraishi T, 2001, BIOCHEM BIOPH RES CO, V282, P1201, DOI 10.1006/bbrc.2001.4696; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Takamune N, 2002, FEBS LETT, V527, P138, DOI 10.1016/S0014-5793(02)03199-X; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	25	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18990	18995		10.1074/jbc.M412917200	http://dx.doi.org/10.1074/jbc.M412917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753093	hybrid			2022-12-27	WOS:000228932300053
J	Boulanger, J; Vezina, A; Mongrain, S; Boudreau, F; Perreault, N; Auclair, BA; Laine, J; Asselin, C; Rivard, N				Boulanger, J; Vezina, A; Mongrain, S; Boudreau, F; Perreault, N; Auclair, BA; Laine, J; Asselin, C; Rivard, N			Cdk2-dependent phosphorylation of homeobox transcription factor CDX2 regulates its nuclear translocation and proteasome-mediated degradation in human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NF-KAPPA-B; COLORECTAL CARCINOMAS; GENE-TRANSCRIPTION; TUMOR SUPPRESSION; ISOMALTASE GENE; TRANSGENIC MICE; MESSENGER-RNA; INHIBITOR P27; COLON-CANCER	By having demonstrated previously that p27(Kip1), a potent inhibitor of G(1) cyclin-cyclin-dependent kinases complexes, increases markedly during intestinal epithelial cell differentiation, we examined the effect of p27(Kip1) on the activity of the transcription factor CDX2. The present results revealed the following. 1) p27(Kip1) interacts with the CDX2 transcription factor. 2) In contrast to CDX2 mRNA levels, CDX2 protein expression levels significantly increased as soon as Caco-2/15 cells reached confluence, slowed their proliferation, and began their differentiation. The mechanism of CDX2 regulation is primarily related to protein stability, because inhibition of proteasome activity increased CDX2 levels. The half-life of CDX2 protein was significantly enhanced in differentiated versus undifferentiated proliferative intestinal epithelial cells. 3) Cdk2 interacted with CDX2 and phosphorylated CDX2, as determined by pull-down glutathione S-transferase and immunoprecipitation experiments with proliferating undifferentiated Caco-2/15 cell extracts. 4) Treatment of Caco-2/15 cells with MG132 ( a proteasome inhibitor) and ( R)-roscovitine ( a specific Cdk2 inhibitor) induced an increase in CDX2 protein levels. 5) Conversely, ectopic expression of Cdk2 resulted in decreased expression of CDX2 protein. 6) Of note, treatment of proliferative Caco-2/15 cells with ( R)roscovitine or leptomycin ( an inhibitor of nuclear export through CRM1) led to an accumulation of CDX2 into the nucleus. These data suggest that CDX2 undergoes CRM1-dependent nuclear export and cytoplasmic degradation in cells in which Cdk2 is activated, such as in proliferative intestinal epithelial cells. The targeted degradation of CDX2 following its phosphorylation by Cdk2 identifies a new mechanism through which CDX2 activity can be regulated in coordination with the cell cycle machinery.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst,Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst,Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Rivard@USherbrooke.ca						BEAULIEU JF, 1991, BIOCHEM J, V15, P599; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brown G, 2003, EXP CELL RES, V291, P282, DOI 10.1016/S0014-4827(03)00393-8; CAIRNIE AB, 1965, EXP CELL RES, V39, P539, DOI 10.1016/0014-4827(65)90056-X; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding IM, 2000, AM J PHYSIOL-CELL PH, V278, pC110, DOI 10.1152/ajpcell.2000.278.1.C110; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; DOELL RG, 1965, P NATL ACAD SCI USA, V54, P1268, DOI 10.1073/pnas.54.4.1268; EE HC, 1995, AM J PATHOL, V147, P586; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Evers BM, 1999, AM J PHYSIOL-CELL PH, V276, pC1243, DOI 10.1152/ajpcell.1999.276.6.C1243; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; JAMES R, 1994, J BIOL CHEM, V269, P15229; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149; LEACH FS, 1993, CANCER RES, V53, P1986; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; Li JQ, 2002, HUM PATHOL, V33, P1006, DOI 10.1053/hupa.2002.125774; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mallow EB, 1996, J BIOL CHEM, V271, P4038; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MENARD D, 1987, J PEDIATR GASTR NUTR, V6, P509, DOI 10.1097/00005176-198707000-00003; MENARD D, 1989, GROWTH PROMOTING FAC, P123; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Song BL, 2003, ACTA BIOCH BIOPH SIN, V35, P6; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Streeter GL, 1920, CONTRIB EMBRYOL, V11, P145; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1989, MOL CELL BIOL, V9, P5169; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	79	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18095	18107		10.1074/jbc.M502184200	http://dx.doi.org/10.1074/jbc.M502184200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741163	hybrid			2022-12-27	WOS:000228807200067
J	Caprini, M; Fava, M; Valente, P; Fernandez-Ballester, G; Rapisarda, C; Ferroni, S; Ferrer-Montiel, A				Caprini, M; Fava, M; Valente, P; Fernandez-Ballester, G; Rapisarda, C; Ferroni, S; Ferrer-Montiel, A			Molecular compatibility of the channel gate and the N terminus of S5 segment for voltage-gated channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; DEPENDENT K+ CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE; SENSOR; PORE; S6; MODEL; MECHANISM; MOVEMENT	Voltage-gated ion channels are modular proteins designed by the structural linkage of a voltage sensor and a pore domain. The functional coupling of these two protein modules is a subject of intense research. A major focus has been directed to decipher the role of the S4-S5 linker and the C-end of the inner pore helix in channel gating. However, the contribution of the cytosolic N terminus of S5 remains elusive. To address this issue, we used a chimeric subunit that linked the voltage sensor of the Shaker channel to the prokaryotic KcsA pore domain (denoted as Shaker-KcsA). This chimera preserved the Shaker sequences at both the N terminus of S5 and the C-end of S6. Chimeric Shaker-KcsA subunits did not form functional homomeric channels but were synthesized, folded, and trafficked to the cell surface, as evidenced by their co-assembly with Shaker wild type subunits. Sequential substitution of Shaker amino acids at the C-end of S6 and the N terminus of S5 by the corresponding KcsA created voltage-sensitive channels with voltage-dependent properties that asymptotically approached those of the wild type Shaker channel. Noteworthy, substitution of the region encompassing Phe(401)-Phe(404) at the N-end of Shaker S5 by KcsA residues resulted in a significant gain in voltage sensitivity of the chimeras. Furthermore, analysis of channel function at high [K+](o) revealed that the Phe(401)-Phe(404) region is an important molecular determinant for competent coupling of voltage sensing and pore opening. Taken together, these findings indicate that complete replacement of Shaker S5 and S6 by KcsA M1 and M2 is required for voltage-dependent gating of the prokaryotic channel. In addition, our results imply that the region encompassing Phe(401)-Phe(404) in Shaker is involved in protein-protein interactions with the voltage sensor, and signal to the Phe(401) in the S5 segment as a key molecular determinant to pair the voltage sensor and the pore domain.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; Univ Bologna, Dept Human & Gen Physiol, I-40127 Bologna, Italy	Universidad Miguel Hernandez de Elche; University of Bologna	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Av Univ S-N, Alicante 03202, Spain.	aferrer@umh.es	Valente, Pierluigi/AAF-2802-2021; Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607				Ahern CA, 2004, TRENDS NEUROSCI, V27, P303, DOI 10.1016/j.tins.2004.03.008; Bell DC, 2004, J GEN PHYSIOL, V123, P5, DOI 10.1085/jgp.200308918; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; Broomand A, 2003, J GEN PHYSIOL, V122, P741, DOI 10.1085/jgp.200308927; Caprini M, 2001, J BIOL CHEM, V276, P21070, DOI 10.1074/jbc.M100487200; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; Cohen BE, 2003, NEURON, V39, P395, DOI 10.1016/S0896-6273(03)00472-0; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Ding SH, 2002, J GEN PHYSIOL, V120, P87, DOI 10.1085/jgp.20028611; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2004, BIOPHYS J, V87, P2116, DOI 10.1529/biophysj.104.040618; Elliott DJS, 2004, EMBO J, V23, P4717, DOI 10.1038/sj.emboj.7600484; Espinosa F, 2001, J GEN PHYSIOL, V118, P157, DOI 10.1085/jgp.118.2.157; Ferrer-Montiel Antonio V., 1994, Methods (Orlando), V6, P60, DOI 10.1006/meth.1994.1008; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; HILL B, 1992, ION CHANNEL EXCITABL; Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kanevsky M, 1999, J GEN PHYSIOL, V114, P215, DOI 10.1085/jgp.114.2.215; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Labro AJ, 2003, J BIOL CHEM, V278, P50724, DOI 10.1074/jbc.M306097200; Laine M, 2004, FEBS LETT, V564, P257, DOI 10.1016/S0014-5793(04)00273-X; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Neale EJ, 2003, J BIOL CHEM, V278, P29079, DOI 10.1074/jbc.M301991200/6493; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Patten CD, 1999, FEBS LETT, V463, P375, DOI 10.1016/S0014-5793(99)01659-2; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; Shrivastava IH, 2004, BIOPHYS J, V87, P2255, DOI 10.1529/biophysj.104.040592; Silverman WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI 10.1073/pnas.0636603100; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905; Treptow W, 2004, BIOPHYS J, V87, P2365, DOI 10.1529/biophysj.104.039628; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zakharian E, 2004, BIOCHEM BIOPH RES CO, V316, P429, DOI 10.1016/j.bbrc.2004.02.069	47	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18253	18264		10.1074/jbc.M413389200	http://dx.doi.org/10.1074/jbc.M413389200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749711	hybrid			2022-12-27	WOS:000228807200084
J	Cieslik, KA; Zhu, Y; Shtivelband, M; Wu, KK				Cieslik, KA; Zhu, Y; Shtivelband, M; Wu, KK			Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SODIUM-SALICYLATE; C/EBP-BETA; REGULATORY DOMAIN; PROMOTER ACTIVITY; PHOSPHORYLATION; ASPIRIN; TRANSCRIPTION; SIGNAL; ACID	We have previously shown that salicylate at a pharmacological concentration suppresses CCAAT/enhancerbinding protein beta (C/EBP beta) binding, thereby reducing cyclooxygenase-2 (COX-2) and inducible nitric-oxide synthase expression (Saunders, M. A., Sansores-Garcia, L., Gilroy, D. W., and Wu, K. K. ( 2001) J. Biol. Chem. 276, 18897 - 18904; Cieslik, K., Zhu, Y., and Wu, K. K. ( 2002) J. Biol. Chem. 277, 49304 - 49310). We postulated that salicylate targets a kinase that phosphorylates and activates C/EBP beta. Here we report the identification of p90 ribosomal S6 kinase (RSK) as a target of salicylate. Salicylate inhibited RSK in vivo and blocked the activity of RSK2 purified from cells stimulated by phorbol 12-myristate 13-acetate (PMA). Mutation of the RSK-phosphorylation site (T266A) of C/EBP beta abrogated PMA-stimulated C/EBP beta binding activity. RSK activation was required for PMA-induced COX-2 transcriptional activation. Salicylate also inhibited Ras and extracellular signal-regulated kinase (ERK) activation induced by PMA. We conclude that salicylate inhibits C/EBP beta-mediated COX-2 transcriptional activation by blocking RSK activity and Ras signaling pathway.	Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Sch Med, Houston, TX 77030 USA; Texas Heart Inst, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Texas Heart Institute	Wu, KK (corresponding author), Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77030 USA.	Kenneth.K.Wu@uth.tmc.edu	Cieslik, Katarzyna/AAO-1982-2021; Wu, Kenneth Kun-Yu/B-1070-2010; Shtivelband, Mikhail/GXN-0194-2022	Cieslik, Katarzyna/0000-0002-2167-7921; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-50675] Funding Source: Medline; NINDS NIH HHS [P50 NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chrestensen CA, 2002, J BIOL CHEM, V277, P27733, DOI 10.1074/jbc.M202663200; Cieslik K, 2002, J BIOL CHEM, V277, P49304, DOI 10.1074/jbc.M205030200; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; Deng WG, 2001, FASEB J, V15, P2463, DOI 10.1096/fj.01-0259com; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KWONG TC, 1987, J LIQ CHROMATOGR, V10, P305, DOI 10.1080/01483918708066721; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; REILLY IAG, 1988, DRUGS, V35, P154, DOI 10.2165/00003495-198835020-00005; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Schroer K, 2002, CIRCULATION, V105, P2760, DOI 10.1161/01.CIR.0000018127.10968.34; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Stevenson MA, 1999, J IMMUNOL, V163, P5608; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	41	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18411	18417		10.1074/jbc.M410017200	http://dx.doi.org/10.1074/jbc.M410017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15738002	hybrid			2022-12-27	WOS:000228807200103
J	El Omari, K; Bird, LE; Nicholes, CE; Ren, JS; Stammers, DK				El Omari, K; Bird, LE; Nicholes, CE; Ren, JS; Stammers, DK			Crystal structure of CC3 (TIP30) - Implications for its role as a tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-ACTIVATED TRANSCRIPTION; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; HIV-1 TAT; CARBONYL REDUCTASE; NUCLEAR IMPORT; PROTEIN; COMPLEX; KINASE; COACTIVATOR; METASTASIS	CC3 (TIP30) is a protein with pro-apoptotic and anti-metastatic properties. The tumor suppressor effect of CC3 has been suggested to result from inhibition of nuclear transport by binding to importin beta s or by regulating transcription through interaction in a complex with co-activator independent of AF-2 function (CIA) and the c-myc gene. Previous biochemical studies indicated that CC3 has protein kinase activity, and a structural similarity to cAMP-dependent protein kinase catalytic subunit was proposed. By contrast, bioinformatics studies suggested a relationship of CC3 to the short chain dehydrogenase reductase family. To clarify details of the CC3 structural family and ligand binding properties, we have determined the crystal structure of CC3 at 1.7-angstrom resolution. CC3 has a short chain dehydrogenase reductase fold and binding specificity for NADPH, yet it is unlikely to be normally enzymatically active because it is monomeric. These structural results, in conjunction with data from earlier mutagenesis work on the nucleotide binding motif, suggest that NADPH binding is important for the biological activity of CC3, including interaction with importins and with the CIA/c-myc system. CC3 provides an example of the adaptation of a metabolic enzyme fold to include a regulatory role, as also seen in the case of the NADH-binding co-repressor CtBP.	Univ Oxford, Struct Biol Div, Oxford OX3 7BN, England; Univ Oxford, Oxford Prot Prod Facil, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Stammers, DK (corresponding author), Univ Oxford, Struct Biol Div, Roosevelt Dr, Oxford OX3 7BN, England.	daves@strubi.ox.ac.uk	Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; El Omari, Kamel/0000-0003-3506-6045; Bird, Louise/0000-0002-9846-5716				Baker ME, 2000, CELL MOL LIFE SCI, V57, P851, DOI 10.1007/s000180050047; Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shi YJ, 2004, TRENDS GENET, V20, P445, DOI 10.1016/j.tig.2004.07.004; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146	32	23	24	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18229	18236		10.1074/jbc.M501113200	http://dx.doi.org/10.1074/jbc.M501113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728189	hybrid			2022-12-27	WOS:000228807200081
J	Liao, BS; Hu, Y; Herrick, DJ; Brewer, G				Liao, BS; Hu, Y; Herrick, DJ; Brewer, G			The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; C-MYC; BIOLOGICAL ACTIONS; NEURONAL CELLS; TAU-PROTEIN; KH-DOMAIN; IN-VITRO; CRD-BP; IGF-II; CANCER	IMP-3, a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein ( IMP) family, is expressed mainly during embryonic development and in some tumors. Thus, IMP-3 is considered to be an oncofetal protein. The functional significance of IMP-3 is not clear. To identify the functions of IMP-3 in target gene expression and cell proliferation, RNA interference was employed to knock down IMP-3 expression. Using human K562 leukemia cells as a model, we show that IMP-3 protein associates with IGF-II leader-3 and leader-4 mRNAs and H19 RNA but not c-myc and beta-actin mRNAs in vivo by messenger ribonucleoprotein immunoprecipitation analyses. IMP-3 knock down significantly decreased levels of intracellular and secreted IGF-II without affecting IGF-II leader-3, leader-4, c-myc, or beta-actin mRNA levels and H19 RNA levels compared with the negative control siRNA treatment. Moreover, IMP-3 knock down specifically suppressed translation of chimeric IGF-II leader-3/luciferase mRNA without altering reporter mRNA levels. Together, these results suggest that IMP-3 knock down reduced IGF-II expression by inhibiting translation of IGF-II mRNA. IMP-3 knock down also markedly inhibited cell proliferation. The addition of recombinant human IGF-II peptide to these cells restored cell proliferation rates to normal. IMP-3 and IMP-1, two members of the IMP family with significant structural similarity, appear to have some distinct RNA targets and functions in K562 cells. Thus, we have identified IMP-3 as a translational activator of IGF-II leader-3 mRNA. IMP-3 plays a critical role in regulation of cell proliferation via an IGF-II-dependent pathway in K562 leukemia cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brewerga@umdnj.edu			NCI NIH HHS [CA094243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; Aronov S, 2002, J CELL SCI, V115, P3817, DOI 10.1242/jcs.00058; Aronov S, 2001, J NEUROSCI, V21, P6577, DOI 10.1523/JNEUROSCI.21-17-06577.2001; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; HAMMARBERG B, 1991, J BIOL CHEM, V266, P11058; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Mori H, 2001, J NEUROSCI RES, V64, P132, DOI 10.1002/jnr.1060; Mueller F, 2003, BRIT J CANCER, V88, P699, DOI 10.1038/sj.bjc.6600790; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nielsen J, 2004, NUCLEIC ACIDS RES, V32, P4368, DOI 10.1093/nar/gkh754; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Wagner M, 2003, GASTROENTEROLOGY, V124, P1901, DOI 10.1016/S0016-5085(03)00402-5; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yaniv K, 2003, DEVELOPMENT, V130, P5649, DOI 10.1242/dev.00810; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101; Zhang JY, 2001, CLIN IMMUNOL, V100, P149, DOI 10.1006/clim.2001.5048; Zhang QM, 1997, J BIOL CHEM, V272, P23703, DOI 10.1074/jbc.272.38.23703	46	183	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18517	18524		10.1074/jbc.M500270200	http://dx.doi.org/10.1074/jbc.M500270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753088	hybrid			2022-12-27	WOS:000228807200116
J	Burns, KL; Gelbaum, LT; Sullards, MC; Bostwick, DE; May, SW				Burns, KL; Gelbaum, LT; Sullards, MC; Bostwick, DE; May, SW			Iso-coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; CHOLINE-ACETYLTRANSFERASE; THIAZOLINE INTERMEDIATE; ACID; NUCLEOTIDE; ANALOGS; INTERCONVERSION; IDENTIFICATION; CONFORMATION; PHOSPHATE	Iso-coenzyme A is an isomer of coenzyme A in which the monophosphate is attached to the 2'-carbon of the ribose ring. Although iso-CoA was first reported in 1959 (Moffatt, J. G., and Khorana, H. G. ( 1959) J. Am. Chem. Soc. 81, 1265 - 1265) to be a by-product of the chemical synthesis of CoA, relatively little attention has been focused on iso-CoA or on acyl-iso-CoA compounds in the literature. We now report structural characterizations of iso-CoA, acetyl-iso-CoA, acetoacetyl-iso-CoA, and beta-hydroxybutyryl-iso-CoA using mass spectrometry ( MS), tandem MS, and homonuclear and heteronuclear NMR analyses. Although the 2'-phosphate isomer of malonyl-CoA was recently identified in commercial samples, previous characterizations of iso-CoA itself have been based on chromatographic analyses, which ultimately rest on comparisons with the degradation products of CoA and NADPH or have been based on assumptions regarding enzyme specificity. We describe a high performance liquid chromatography methodology for separating the isomers of several CoA-containing compounds. We also report here the first examples of iso-CoA-containing compounds acting as substrates in enzymatic acyl transfer reactions. Finally, we describe a simple synthesis of iso-CoA from CoA, which utilizes beta-cyclodextrin to produce iso-CoA with high regioselectivity, and we demonstrate a plausible mechanism that accounts for the existence of iso-CoA isomers in commercial preparations of CoA-containing compounds. We anticipate that these results will provide methodology and impetus for investigating iso-CoA compounds as potential pseudo-substrates or inhibitors of the > 350 known CoA-utilizing enzymes.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	May, SW (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	sheldon.may@chemistry.gatech.edu			NCRR NIH HHS [1S10RR012008-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEINERT H, 1953, J BIOL CHEM, V200, P385; BEINERT H, 1952, J AM CHEM SOC, V74, P854, DOI 10.1021/ja01123a531; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; BRENDELBERGER V, 1989, ISRAEL J CHEM, V29, P195; BROWN DM, 1951, J CHEM SOC, P2952; BUYSKE DM, 1951, J BIOL CHEM, V193, P307; CIARDELLI TL, 1981, LIEBIGS ANN CHEM, V5, P828; Cobas JC, 2003, CONCEPT MAGN RESON A, V19A, P80, DOI 10.1002/cmr.a.10089; DORDINE RL, 1995, BIOORG CHEM, V23, P169, DOI 10.1006/bioo.1995.1014; HASHIMOTO M, 1972, CHEM LETT, P595, DOI 10.1246/cl.1972.595; INGEBRETSEN OC, 1979, ANAL BIOCHEM, V96, P181, DOI 10.1016/0003-2697(79)90571-2; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; KHYM JX, 1954, J AM CHEM SOC, V76, P5523, DOI 10.1021/ja01650a075; KOMIYAMA M, 1992, J AM CHEM SOC, V114, P1070, DOI 10.1021/ja00029a040; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; KUROOKA S, 1967, CHEM PHARM BULL, V15, P944; LEE CH, 1975, J AM CHEM SOC, V97, P1225, DOI 10.1021/ja00838a043; Lee J, 2001, J BIOL CHEM, V276, P14804, DOI 10.1074/jbc.M009434200; LIPMANN F, 1950, J BIOL CHEM, V186, P235; MAUTNER HG, 1981, P NATL ACAD SCI-BIOL, V78, P7449, DOI 10.1073/pnas.78.12.7449; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; MICHELSON A, 1961, BIOCHIM BIOPHYS ACTA, V50, P605, DOI 10.1016/0006-3002(61)90033-6; MICHELSON AM, 1964, BIOCHIM BIOPHYS ACTA, V93, P71, DOI 10.1016/0304-4165(64)90261-2; MICHENFELDER M, 1986, ANGEW CHEM INT EDIT, V25, P366, DOI 10.1002/anie.198603661; MICHENFELDER M, 1987, EUR J BIOCHEM, V168, P659, DOI 10.1111/j.1432-1033.1987.tb13467.x; MIEYAL JJ, 1974, J BIOL CHEM, V249, P2633; MIKHAILOV SN, 1992, J ORG CHEM, V57, P4122, DOI 10.1021/jo00041a014; MILLER TL, 1966, J AM CHEM SOC, V88, P2299, DOI 10.1021/ja00962a037; Minkler PE, 2004, ANAL BIOCHEM, V328, P203, DOI 10.1016/j.ab.2004.01.015; MOFFATT JG, 1959, J AM CHEM SOC, V81, P1265, DOI 10.1021/ja01514a073; MOFFATT JG, 1961, J AM CHEM SOC, V83, P663, DOI 10.1021/ja01464a036; NORWOOD DL, 1990, J CHROMATOGR-BIOMED, V527, P289, DOI 10.1016/S0378-4347(00)82113-1; OIVANEN M, 1989, J ORG CHEM, V54, P2556, DOI 10.1021/jo00272a018; OIVANEN M, 1991, J ORG CHEM, V56, P3623, DOI 10.1021/jo00011a032; PATEL SS, 1988, ANAL BIOCHEM, V170, P355, DOI 10.1016/0003-2697(88)90642-2; Rosenfeld S, 1997, J AM CHEM SOC, V119, P8395, DOI 10.1021/ja9759048; ROSSIER J, 1977, BIOCHEM J, V165, P321, DOI 10.1042/bj1650321; SAWATA S, 1992, J PHYS ORG CHEM, V5, P502, DOI 10.1002/poc.610050812; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; Shimazu M, 2004, ANAL BIOCHEM, V328, P51, DOI 10.1016/j.ab.2004.01.025; SHIMIZU M, 1965, CHEM PHARM BULL, V13, P1142; SHIMIZU M, 1967, CHEM PHARM BULL, V15, P655; SHUSTER L, 1955, J BIOL CHEM, V215, P183; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; STADTMAN ER, 1953, J BIOL CHEM, V203, P47; STEWART CJ, 1978, LIEBIGS ANN CHEM, V1, P57; Tachibana A, 1998, J FERMENT BIOENG, V86, P523, DOI 10.1016/S0922-338X(98)80166-9; TAGUCHI Y, 1976, B CHEM SOC JPN, V49, P1122, DOI 10.1246/bcsj.49.1122; THORPE C, 1981, EUR J BIOCHEM, V118, P279; Vogel KW, 2000, BIOORGAN MED CHEM, V8, P2451, DOI 10.1016/S0968-0896(00)00189-9; WAGNER AP, 1991, EUR J BIOCHEM, V195, P699, DOI 10.1111/j.1432-1033.1991.tb15756.x; WANG HY, 1991, ARCH BIOCHEM BIOPHYS, V289, P274, DOI 10.1016/0003-9861(91)90472-U; WANG TP, 1952, J AM CHEM SOC, V74, P3204, DOI 10.1021/ja01132a542; WANG TP, 1954, J BIOL CHEM, V206, P299; WANG TP, 1954, J BIOL CHEM, V206, P311; WILSON GE, 1975, J AM CHEM SOC, V97, P2907, DOI 10.1021/ja00843a053; WU DH, 1995, J BIOL CHEM, V270, P29111, DOI 10.1074/jbc.270.49.29111; ZHAO YM, 1994, CAN J CHEM, V72, P164, DOI 10.1139/v94-025	58	20	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16550	16558		10.1074/jbc.M411898200	http://dx.doi.org/10.1074/jbc.M411898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15708855	hybrid			2022-12-27	WOS:000228615500004
J	Doss-Pepe, EW; Chen, L; Madura, K				Doss-Pepe, EW; Chen, L; Madura, K			alpha-Synuclein and Parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; PLASMA-MEMBRANE; DOWN-REGULATION; DNA-REPAIR; IN-VITRO; SACCHAROMYCES-CEREVISIAE; MULTIVESICULAR BODIES; POLYUBIQUITIN CHAINS; CONJUGATING ENZYMES; PROTEOLYTIC PATHWAY	Mutations in alpha-synuclein, Parkin, and UCH-L1 cause heritable forms of Parkinson disease. Unlike alpha-synuclein, for which no precise biochemical function has been elucidated, Parkin functions as a ubiquitin E3 ligase, and UCH-L1 is a deubiquitinating enzyme. The E3 ligase activity of Parkin in Parkinson disease is poorly understood and is further obscured by the fact that multiubiquitin chains can be formed through distinct types of linkages that regulate diverse cellular processes. For instance, ubiquitin lysine 48-linked multiubiquitin chains target substrates to the proteasome, whereas ubiquitin lysine 63-linked chains control ribosome function, protein sorting and trafficking, and endocytosis of membrane proteins. It is notable in this regard that ubiquitin lysine 63-linked chains promote the degradation of membrane proteins by the lysosome. Because both Parkin and alpha-synuclein can regulate the activity of the dopamine transporter, we investigated whether they influenced ubiquitin lysine 63-linked chain assembly. These studies revealed novel biochemical activities for both Parkin and alpha-synuclein. We determined that Parkin functions with UbcH13/Uev1a, a dimeric ubiquitin-conjugating enzyme, to assemble ubiquitin lysine 63-linked chains. Our results and the results of others indicate that Parkin can promote both lysine 48- and lysine 63-linked ubiquitin chains. alpha-Synuclein also stimulated the assembly of lysine 63-linked ubiquitin chains. Because UCH-L1, a ubiquitin hydrolase, was recently reported to form lysine 63-linked conjugates, it is evident that three proteins that are genetically linked to Parkinson disease can contribute to lysine 63 multiubiquitin chain formation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Doss-Pepe, EW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 683 Hoes Lane,Rm 372, Piscataway, NJ 08854 USA.	dosspeew@umdnj.edu; maduraki@umdnj.edu			NCI NIH HHS [CA83875] Funding Source: Medline; NIA NIH HHS [AG01047] Funding Source: Medline; NINDS NIH HHS [NS044081] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG001047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Buckley KM, 2000, J PHYSIOL-LONDON, V525, P11, DOI 10.1111/j.1469-7793.2000.t01-2-00011.x; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; Cabin DE, 2002, J NEUROSCI, V22, P8797; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dalfo E, 2004, NEUROBIOL DIS, V16, P92, DOI 10.1016/j.nbd.2004.01.001; Dalfo E, 2004, J NEUROPATH EXP NEUR, V63, P302, DOI 10.1093/jnen/63.4.302; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lehmensiek V, 2002, NEUROREPORT, V13, P1279, DOI 10.1097/00001756-200207190-00013; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, J CELL SCI, V112, P1375; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2004, BIOCHEMISTRY-US, V43, P1242, DOI 10.1021/bi035308s; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje; Wersinger C, 2003, MOL CELL NEUROSCI, V24, P91, DOI 10.1016/S1044-7431(03)00124-6; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	68	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16619	16624		10.1074/jbc.M413591200	http://dx.doi.org/10.1074/jbc.M413591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718234	hybrid			2022-12-27	WOS:000228615500012
J	Jones, LH; Pearson, AR; Tang, Y; Wilmot, CM; Davidson, VL				Jones, LH; Pearson, AR; Tang, Y; Wilmot, CM; Davidson, VL			Active site aspartate residues are critical for tryptophan tryptophylquinone biogenesis in methylamine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOHEMOPROTEIN AMINE DEHYDROGENASE; QUINONE COFACTOR BIOGENESIS; CRYSTAL-STRUCTURE; PARACOCCUS-DENITRIFICANS; SUBSTRATE-SPECIFICITY; ENZYME; MUTAGENESIS; PROTEIN; OXIDASE; MAUG	The biosynthesis of methylamine dehydrogenase ( MADH) requires formation of six intrasubunit disulfide bonds, incorporation of two oxygens into residue beta Trp(57) and covalent cross-linking of beta Trp(57) to beta Trp(108) to form the protein-derived cofactor tryptophan tryptophylquinone (TTQ). Residues beta Asp(76) and beta Asp(32) are located in close proximity to the quinone oxygens of TTQ in the enzyme active site. These residues are structurally conserved in quinohemoprotein amine dehydrogenase, which possesses a cysteine tryptophylquinone cofactor. Relatively conservative beta D76N and beta D32N mutations resulted in very low levels of MADH expression. Analysis of the isolated proteins by mass spectrometry revealed that each mutation affected TTQ biogenesis. beta D76N MADH possessed the six disulfides but had no oxygen incorporated into beta Trp(57) and was completely inactive. The beta D32N MADH preparation contained a major species with six disulfides but no oxygen incorporated into beta Trp(57) and a minor species with both oxygens incorporated, which was active. The steady-state kinetic parameters for the beta D32N mutant were significantly altered by the mutation and exhibited a 1000-fold increase in the K-m value for methylamine. These results have allowed us to more clearly define the sequence of events that lead to TTQ biogenesis and to define novel roles for aspartate residues in the biogenesis of a protein-derived cofactor.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Mississippi; University of Mississippi Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Davidson, VL (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	vdavidson@biochem.umsmed.edu		Pearson, Arwen/0000-0001-8499-7490; Wilmot, Carrie/0000-0002-8706-0000; Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041574, R01GM066569, R37GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-66569, GM-41574, R01 GM066569] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Chistoserdov AY, 2001, MICROBIOL-SGM, V147, P2195, DOI 10.1099/00221287-147-8-2195; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; Davidson VL, 2001, ADV PROTEIN CHEM, V58, P95; Dove JE, 2001, ADV PROTEIN CHEM, V58, P141; Firbank SJ, 2001, P NATL ACAD SCI USA, V98, P12932, DOI 10.1073/pnas.231463798; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; Graichen ME, 1999, J BACTERIOL, V181, P4216, DOI 10.1128/JB.181.14.4216-4222.1999; Hevel JM, 1999, BIOCHEMISTRY-US, V38, P3683, DOI 10.1021/bi982199m; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Pearson AR, 2004, BIOCHEMISTRY-US, V43, P5494, DOI 10.1021/bi049863l; Pearson AR, 2003, BIOCHEMISTRY-US, V42, P3224, DOI 10.1021/bi027073a; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun DP, 2001, PROTEIN ENG, V14, P675, DOI 10.1093/protein/14.9.675; Wang YT, 2003, BIOCHEMISTRY-US, V42, P7318, DOI 10.1021/bi034243q; Wang YT, 2002, J BIOL CHEM, V277, P4119, DOI 10.1074/jbc.M109270200; Zhu ZY, 2000, BIOCHEMISTRY-US, V39, P11184, DOI 10.1021/bi001568n; Zhu ZY, 1998, J BIOL CHEM, V273, P14254, DOI 10.1074/jbc.273.23.14254	24	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17392	17396		10.1074/jbc.M500943200	http://dx.doi.org/10.1074/jbc.M500943200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734739	hybrid			2022-12-27	WOS:000228615500104
J	Koolpe, M; Burgess, R; Dail, M; Pasquale, EB				Koolpe, M; Burgess, R; Dail, M; Pasquale, EB			EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSE CRANIOFRONTONASAL SYNDROME; CRYSTAL-STRUCTURE; TYROSINE KINASES; PROTEIN HORMONE; TUMOR-GROWTH; LIGANDS; AGONIST; POTENT; CELLS; EMBRYOGENESIS	The Eph receptor tyrosine kinases are overexpressed in many pathologic tissues and have therefore emerged as promising drug target candidates. However, there are few molecules available that can selectively bind to a single Eph receptor and not other members of this large receptor family. Here we report the identification by phage display of peptides that bind selectively to different receptors of the EphB class, including EphB1, EphB2, and EphB4. Peptides with the same EphB receptor specificity compete with each other for binding, suggesting that they have partially overlapping binding sites. In addition, several of the peptides contain amino acid motifs found in the G-H loop of the ephrin-B ligands, which is the region that mediates high-affinity interaction with the EphB receptors. Consistent with targeting the ephrin-binding site, the higher affinity peptides antagonize ephrin binding to the EphB receptors. We also designed an optimized EphB4-binding peptide with affinity comparable with that of the natural ligand, ephrin-B2. These peptides should be useful as selective inhibitors of the pathological activities of EphB receptors and as targeting agents for imaging probes and therapeutic drugs.	Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@burnham.org			NCI NIH HHS [CA82713] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Landon LA, 2003, J PROTEIN CHEM, V22, P193, DOI 10.1023/A:1023483232397; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; McConnell SJ, 1999, COMB CHEM HIGH T SCR, V2, P155; Moore KB, 2004, DEV CELL, V6, P55, DOI 10.1016/S1534-5807(03)00395-2; Murai KK, 2003, MOL CELL NEUROSCI, V24, P1000, DOI 10.1016/j.mcn.2003.08.006; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; PASQUALE EB, 2005, IN PRESS NAT REV MOL; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Twigg SRF, 2004, P NATL ACAD SCI USA, V101, P8652, DOI 10.1073/pnas.0402819101; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wieland I, 2004, AM J HUM GENET, V74, P1209, DOI 10.1086/421532; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261	50	117	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17301	17311		10.1074/jbc.M500363200	http://dx.doi.org/10.1074/jbc.M500363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722342	hybrid			2022-12-27	WOS:000228615500094
J	Koyanagi, M; Haendeler, J; Badorff, C; Brandes, RP; Hoffmann, J; Pandur, P; Zeiher, AM; Kuhl, M; Dimmeler, S				Koyanagi, M; Haendeler, J; Badorff, C; Brandes, RP; Hoffmann, J; Pandur, P; Zeiher, AM; Kuhl, M; Dimmeler, S			Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; IN-VITRO; CARDIOMYOCYTES; MYOCARDIUM; PATHWAY; MUSCLE; TRANSDIFFERENTIATION; REGENERATION	Human endothelial circulating progenitor cells (CPCs) can differentiate to cardiomyogenic cells during co-culture with neonatal rat cardiomyocytes. Wnt proteins induce myogenic specification and cardiac myogenesis. Here, we elucidated the effect of Wnts on differentiation of CPCs to cardiomyogenic cells. CPCs from peripheral blood mononuclear cells were isolated from healthy volunteers and co-cultured with neonatal rat cardiomyocytes. 6 - 10 days after co-culture, cardiac differentiation was determined by alpha-sarcomeric actinin staining of human lymphocyte antigen-positive cells (fluorescence-activated cell-sorting analysis) and mRNA expression of human myosin heavy chain and atrial natriuretic peptide. Supplementation of co-cultures with Wnt11-conditioned medium significantly enhanced the differentiation of CPCs to cardiomyocytes (1.7 +/- 0.3-fold), whereas Wnt3A-conditioned medium showed no effect. Cell fusion was not affected by Wnt11-conditioned medium. Because Wnts inhibit glycogen synthase kinase-3 beta, we further determined whether the glycogen synthase kinase-3 beta inhibitor LiCl also enhanced cardiac differentiation of CPCs. However, LiCl ( 10 mM) did not affect CPC differentiation. In contrast, Wnt11-conditioned medium time-dependently activated protein kinase C (PKC). Moreover, the PKC inhibitors bisindolylmaleimide I and III significantly blocked differentiation of CPCs to cardiomyocytes. PKC activation by phorbol 12-myristate 13-acetate significantly increased CPC differentiation to a similar extent as compared with Wnt11-conditioned medium. Our data demonstrate that Wnt11, but not Wnt3A, augments cardiomyogenic differentiation of human CPCs. Wnt11 promotes cardiac differentiation via the non-canonical PKC-dependent signaling pathway.	Univ Frankfurt, Dept Mol Cardiol, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Univ Ulm, Dept Biochem, D-89081 Ulm, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Ulm University	Dimmeler, S (corresponding author), Univ Frankfurt, Dept Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de	Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048; Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Terami H, 2004, BIOCHEM BIOPH RES CO, V325, P968, DOI 10.1016/j.bbrc.2004.10.103; Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225; Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70	25	108	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16838	16842		10.1074/jbc.M500323200	http://dx.doi.org/10.1074/jbc.M500323200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701629	hybrid			2022-12-27	WOS:000228615500037
J	Phelps, M; Phillips, A; Darley, M; Blaydes, JP				Phelps, M; Phillips, A; Darley, M; Blaydes, JP			MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FEEDBACK LOOP; P53 FUNCTION; MDM2; PROTEIN; PHOSPHORYLATION	The physical and functional interaction between the transcription factor p53 and its negative regulatory partner protein Hdm2 (Mdm2 in mouse) is a key point of convergence of multiple signaling pathways that regulates cell proliferation and survival. hdm2 mRNA transcription is induced by p53, forming the basis of an auto-regulatory feedback loop. Growth and survival factor-activated Ras-Raf-MEK-ERK signaling can also regulate Hdm2 expression independently of p53, contributing to the pro-survival effect of these factors. In murine fibroblasts, this occurs through the regulation of mdm2 mRNA transcription. Here we show that, in human breast cancer epithelial cells, MEK-dependent regulation of Hdm2 expression also occurs at a post-transcriptional level. Pharmacological blockade of MEK activity in T47D cells inhibits Hdm2 protein synthesis by 80 - 90%. This occurs in the absence of changes in the expression of the major hdm2-P1 mRNA transcript and only an similar to 40% reduction in hdm2-P2 transcript levels. The amounts of both transcripts that are associated with polyribosomes and are, hence, being actively translated are reduced by > 80% by the MEK inhibitor, U0126. We show here that this is due to the inhibition of hdm2 mRNA export from the nucleus when MEK activity is inhibited. In MCF-7 breast cancer cells that express wild-type p53, Hdm2 is required to suppress p53-dependent transcription when MEK kinase is active. Regulation of the nuclear export of hdm2 mRNA provides, therefore, a mechanism whereby mitogen-stimulated cells avoid p53-dependent cell cycle arrest or apoptosis by maintaining the dynamic equilibrium of the Hdm2-p53 feedback loop.	Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Sci Div, MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; DENOME RM, 1989, NUCLEIC ACIDS RES, V17, P2081, DOI 10.1093/nar/17.5.2081; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gupta AK, 2001, CANCER RES, V61, P4278; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; HERRERA R, 2002, TRENDS MOL MED S, V8, P27, DOI DOI 10.1016/S1471-4914(02)02307-9; Hori M, 2002, BREAST CANCER RES TR, V71, P77, DOI 10.1023/A:1013350419426; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; KOMMINOTH P, 2002, RADIOACTIVE IN SITU, P149; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; MARAIA RJ, 1994, NUCLEIC ACIDS RES, V22, P3045, DOI 10.1093/nar/22.15.3045; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOSNER J, 1994, ONCOGENE, V9, P3321; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Phelps M, 2003, CANCER RES, V63, P2616; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	67	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16651	16658		10.1074/jbc.M412334200	http://dx.doi.org/10.1074/jbc.M412334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723837	Green Accepted, hybrid			2022-12-27	WOS:000228615500016
J	Takada, Y; Kobayashi, Y; Aggarwal, BB				Takada, Y; Kobayashi, Y; Aggarwal, BB			Evodiamine abolishes constitutive and inducible NF-kappa B activation by inhibiting I kappa B alpha kinase activation, thereby suppressing NF-kappa B-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CYCLIN D1; TRANSCRIPTIONAL REGULATION; DEPENDENT INDUCTION; P65 PHOSPHORYLATION; MEDIATED INDUCTION; ENDOTHELIAL-CELLS; TNF-ALPHA; CYCLOOXYGENASE-2	Evodiamine, an alkaloidal component extracted from the fruit of Evodiae fructus (Evodia rutaecarpa Benth., Rutaceae), exhibits antiproliferative, antimetastatic, and apoptotic activities through a poorly defined mechanism. Because several genes that regulate cellular proliferation, carcinogenesis, metastasis, and survival are regulated by nuclear factor-kappa B (NF-kappa B), we postulated that evodiamine mediates its activity by modulating NF-kappa B activation. In the present study, we investigated the effect of evodiamine on NF-kappa B and NF-kappa B-regulated gene expression activated by various carcinogens. We demonstrate that evodiamine was a highly potent inhibitor of NF-kappa B activation, and it abrogated both inducible and constitutive NF-kappa B activation. The inhibition corresponded with the sequential suppression of I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acetylation. Evodiamine also inhibited tumor necrosis factor (TNF)-induced Akt activation and its association with IKK. Suppression of Akt activation was specific, because it had no effect on JNK or p38 MAPK activation. Evodiamine also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B-regulated gene products such as Cyclin D1, c-Myc, COX-2, MMP-9, ICAM-1, MDR1, Survivin, XIAP, IAP1, IAP2, FLIP, Bcl-2, Bcl-x(L), and Bfl-1/A1 were all down-regulated by evodiamine. This down-regulation potentiated the apoptosis induced by cytokines and chemotherapeutic agents and suppressed TNF-induced invasive activity. Overall, our results indicated that evodiamine inhibits both constitutive and induced NF-kappa B activation and NF-kappa B-regulated gene expression and that this inhibition may provide a molecular basis for the ability of evodiamine to suppress proliferation, induce apoptosis, and inhibit metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Immunol, Houston, TX 77030 USA; Niigata Univ Pharm & Appl Sci, Fac Appl Life Sci, Niigata 9568603, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Niigata University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Kobayashi, Yoshinori/0000-0002-4289-7392	NCI NIH HHS [CA16672, P01 CA91844, P50 CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; ALBINI A, 1987, CANCER RES, V47, P3239; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chiou WF, 1997, J NAT PROD, V60, P708, DOI 10.1021/np960495z; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fei XF, 2003, CANCER SCI, V94, P92, DOI 10.1111/j.1349-7006.2003.tb01358.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang YC, 2004, LIFE SCI, V75, P35, DOI 10.1016/j.lfs.2003.11.025; Kan SF, 2004, INT J CANCER, V110, P641, DOI 10.1002/ijc.20138; KING CL, 1980, J NAT PROD, V43, P577, DOI 10.1021/np50011a008; Kobayashi Y, 2003, PLANTA MED, V69, P425, DOI 10.1055/s-2003-39701; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ogasawara M, 2004, BIOL PHARM BULL, V27, P578, DOI 10.1248/bpb.27.578; Ogasawara M, 2002, BIOL PHARM BULL, V25, P1491, DOI 10.1248/bpb.25.1491; Ogasawara M, 2001, BIOL PHARM BULL, V24, P917, DOI 10.1248/bpb.24.917; Ogasawara M, 2001, BIOL PHARM BULL, V24, P720, DOI 10.1248/bpb.24.720; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Richardson MA, 2002, SEMIN ONCOL, V29, P531, DOI 10.1053/sonc.2002.50002; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shiraga M, 2002, CANCER RES, V62, P5967; SHOJI N, 1986, J PHARM SCI, V75, P612, DOI 10.1002/jps.2600750619; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; YAMAHARA J, 1989, J ETHNOPHARMACOL, V27, P185, DOI 10.1016/0378-8741(89)90090-1; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang Y, 2003, BIOL PHARM BULL, V26, P1543, DOI 10.1248/bpb.26.1543; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; [No title captured]	66	156	173	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17203	17212		10.1074/jbc.M500077200	http://dx.doi.org/10.1074/jbc.M500077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710601	hybrid			2022-12-27	WOS:000228615500082
J	Gemmill, TR; Wu, XY; Hanes, SD				Gemmill, TR; Wu, XY; Hanes, SD			Vanishingly low levels of Ess1 prolyl-isomerase activity are sufficient for growth in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; CIS/TRANS-ISOMERASE; 3'-END FORMATION; CYCLOPHILIN-A; IN-VIVO; POL-II; TRANSCRIPTION; BINDING	Ess1 is an essential peptidylprolyl-cis/trans-isomerase in the yeast Saccharomyces cerevisiae. Ess1 and its human homolog, Pin1, bind to phospho-Ser-Pro sites within proteins, including the carboxyl-terminal domain (CTD) of Rpb1, the largest subunit of RNA polymerase II (pol II). Ess1 and Pin1 are thought to control mRNA synthesis by catalyzing conformational changes in Rpb1 that affect interaction of cofactors with the pol II transcription complex. Here we have characterized wild-type and mutant Ess1 proteins in vitro and in vivo. We found that Ess1 preferentially binds and isomerizes CTD heptad-repeat (YSPTSPS) peptides that are phosphorylated on Ser5. Binding by the mutant proteins in vitro was essentially normal, and the proteins were largely stable in vivo. However, their catalytic activities were reduced > 1,000-fold. These data along with results of in vivo titration experiments indicate that Ess1 isomerase activity is required for growth, but only at vanishingly low levels. We found that although wildtype cells contain about similar to 200,000 molecules of Ess1, a level of fewer than 400 molecules per cell is sufficient for growth. In contrast, higher levels of Ess1 were required for growth in the presence of certain metabolic inhibitors, suggesting that Ess1 is important for tolerance to environmental challenge.	New York State Dept Hlth, Wadsworth Ctr, Ctr Med Sci, Albany, NY 12208 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Hanes, SD (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Ctr Med Sci, 120 New Scotland Ave, Albany, NY 12208 USA.	hanes@wadsworth.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055108] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM55108] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arevalo-Rodriguez M, 2004, FRONT BIOSCI-LANDMRK, V9, P2420, DOI 10.2741/1405; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Devasahayam G, 2002, GENETICS, V160, P37; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Fujimori F, 2001, BIOCHEM BIOPH RES CO, V289, P181, DOI 10.1006/bbrc.2001.5925; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hanes S.D., 1988, THESIS BROWN U PROVI; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Huang HK, 2001, J CELL SCI, V114, P3779; Joseph JD, 2004, J BIOL CHEM, V279, P32373, DOI 10.1074/jbc.M405415200; KERN D, 1993, FEBS LETT, V323, P198, DOI 10.1016/0014-5793(93)81338-Z; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lin PS, 2003, CHEM REC, V3, P235, DOI 10.1002/tcr.10063; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2003, BIOESSAYS, V25, P174, DOI 10.1002/bies.10223; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Palancade B, 2004, J MOL BIOL, V335, P415, DOI 10.1016/j.jmb.2003.10.036; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Stafford GA, 1998, J BIOL CHEM, V273, P34240, DOI 10.1074/jbc.273.51.34240; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wilcox CB, 2004, GENETICS, V167, P93, DOI 10.1534/genetics.167.1.93; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Wu XY, 2003, GENETICS, V165, P1687; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	47	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15510	15517		10.1074/jbc.M412172200	http://dx.doi.org/10.1074/jbc.M412172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728580	hybrid			2022-12-27	WOS:000228444800008
J	Tong, X; Yin, L; Joshi, S; Rosenberg, DW; Giardina, C				Tong, X; Yin, L; Joshi, S; Rosenberg, DW; Giardina, C			Cyclooxygenase-2 regulation in colon cancer cells - Modulation of RNA polymerase II elongation by histone deacetylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; NF-KAPPA-B; TUMOR VIRUS PROMOTER; MESSENGER-RNA; SODIUM-BUTYRATE; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; COLORECTAL-CANCER; GROWTH-INHIBITION; EPITHELIAL-CELLS	We are interested in the mechanism of cyclooxygenase-2 (Cox-2) regulation in colon cancer cells because this knowledge could provide insight into colon carcinogenesis and suggest ways to suppress Cox-2 expression in colon tumors. Studying the HT-29 colon cancer cell line as a model, we found that Cox-2 mRNA and protein levels were activated over 10-fold by the inflammatory cytokine tumor necrosis factor (TNF)-alpha. Moreover, we found that the histone deacetylase inhibitors butyrate and trichostatin A could block Cox-2 activation in a gene-specific manner. TNF-alpha and butyrate did not significantly affect Cox-2 promoter activity, mRNA stability, or negative regulation by the Cox-2 3'-untranslated RNA region. A nuclear run-on assay showed that TNF-alpha increased Cox-2 transcription, whereas butyrate was suppressive. Because butyrate has been reported to suppress polymerase elongation on the c-myc gene, we employed the chromatin immunoprecipitation assay to determine the influence of butyrate and trichostatin A on polymerase distribution on the Cox-2 gene. These data indicated that butyrate restricted polymerase elongation from exon 1 to 2 on both the c-myc and Cox-2 genes. We propose that histone deacetylases regulate a transcriptional block on the Cox-2 and c- myc genes and that this block may be a potential target for pharmacological intervention.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Penn, Sch Med, Dept Endocrinol & Metab, Philadelphia, PA 19104 USA; Univ Connecticut, Ctr Hlth, Dept Mol Med, Farmington, CT 06030 USA	University of Connecticut; University of Pennsylvania; University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 91 N Eagleville Rd, Storrs, CT 06269 USA.	Giardina@uconnvm.uconn.edu		TONG, XIN/0000-0002-4832-8940	NCI NIH HHS [R29 CA79656-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA079656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; AZUMA M, 1986, CANCER RES, V46, P770; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen ZY, 2004, J NUTR, V134, P792, DOI 10.1093/jn/134.4.792; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Dehm SM, 2004, MOL CELL BIOL, V24, P2296, DOI 10.1128/MCB.24.6.2296-2307.2004; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; FREDSTROM SB, 1994, JPEN-PARENTER ENTER, V18, P14, DOI 10.1177/014860719401800114; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; HEERDT BG, 1994, CANCER RES, V54, P3288; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Mariadason JM, 2000, CANCER RES, V60, P4561; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; O'Leary KA, 2004, MUTAT RES-FUND MOL M, V551, P245, DOI 10.1016/j.mrfmmm.2004.01.015; Ogawa H, 2003, BIOCHEM BIOPH RES CO, V309, P512, DOI 10.1016/j.bbrc.2003.08.026; Osada H, 2001, CANCER RES, V61, P8331; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rosenkranz HS, 2003, ONCOL RES, V13, P529, DOI 10.3727/000000003108748054; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Siavoshian S, 1997, CELL BIOL INT, V21, P281, DOI 10.1006/cbir.1997.0153; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Tabuchi Y, 2002, BIOCHEM BIOPH RES CO, V293, P1287, DOI 10.1016/S0006-291X(02)00365-0; Tong X, 2004, BIOCHEM BIOPH RES CO, V317, P463, DOI 10.1016/j.bbrc.2004.03.066; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Wilson AJ, 2002, CANCER RES, V62, P6006; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200; Wu GD, 1999, J LEUKOCYTE BIOL, V66, P1049, DOI 10.1002/jlb.66.6.1049; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	62	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15503	15509		10.1074/jbc.M411978200	http://dx.doi.org/10.1074/jbc.M411978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713675	hybrid			2022-12-27	WOS:000228444800007
J	Wang, DK; Li, ZB; Messing, EM; Wu, G				Wang, DK; Li, ZB; Messing, EM; Wu, G			The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIF-ALPHA; RAS; DEGRADATION; RANBPM; ACTIVATION; EFFECTORS; GAP; PHOSPHORYLATION; HYDROXYLATION; DESTRUCTION	The suppressor of cytokine signaling ( SOCS) protein family includes a SPRY ( repeats in splA and RyR) domain-containing SOCS box protein (SSB) subfamily, which consists of four members, SSB-1, SSB-2, SSB-3, and SSB-4. These proteins contain a central SPRY domain and a C-terminal SOCS box. Although some of the SOCS protein subfamilies function as adaptors for a large family of ubiquitin-protein isopeptide ligases to regulate certain signaling pathways, the function of the SSB subfamily remains to be determined. In our previous studies, we have found that two SPRY domain-containing proteins, RanBP9 and RanBP10, interact with MET through the SPRY domain. In the present study, we explored the function of SSB proteins in the regulation of the hepatocyte growth factor (HGF)-MET signaling. Our results showed that all four SSB proteins also interacted with the MET. The MET interaction with SSB-1 was further investigated. We demonstrated that SSB-1 bound to MET tyrosine kinase domain through its SPRY domain. MET interacted with SSB-1 in both the absence and the presence of HGF, but HGF treatment resulted in the recruitment of more SSB-1 by MET. We showed that overexpression of SSB-1 but not other SSB proteins enhanced the HGF-induced serum response element (SRE)-luciferase activity. Overexpression of SSB-1 exhibited no effect on the basal level or epidermal growth factor-induced SRE-luciferase activity. SSB-1 also enhanced HGF-induced Erk phosphorylation. Suppression of SSB-1 by the RNA interference method down-regulated HGF-induced SRE-luciferase activity and decreased Elk-1 activation. These results suggest that SSB-1 may play an important role in enhancing the HGF-induced Erk-Elk-1-SRE pathway. Furthermore, we demonstrated that in response to HGF stimulation, the SSB-1 protein became phosphorylated at tyrosine residue 31. The phosphorylated SSB-1 protein bound to p120Ras-GTPase-activating protein ( GAP) but did not promote the degradation of p120RasGAP, indicating that enhanced HGF-MET signaling by overexpression of SSB-1 was not dependent on p120RasGAP degradation.	Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.	Guan_Wu@urmc.rochester.edu						BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Midgley RS, 2002, CRIT REV ONCOL HEMAT, V44, P109, DOI 10.1016/S1040-8428(01)00189-5; Mikolajczyk M, 2003, BIOCHEM BIOPH RES CO, V310, P14, DOI 10.1016/j.bbrc.2003.08.116; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wang DK, 2004, BIOCHEM BIOPH RES CO, V313, P320, DOI 10.1016/j.bbrc.2003.11.124; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	28	42	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16393	16401		10.1074/jbc.M413897200	http://dx.doi.org/10.1074/jbc.M413897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713673	hybrid			2022-12-27	WOS:000228444800112
J	Guo, Q; Sousa, R				Guo, Q; Sousa, R			Weakening of the T7 promoter-polymerase interaction facilitates promoter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISUBUNIT RNA-POLYMERASES; INITIAL BUBBLE COLLAPSE; ELONGATION COMPLEX; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; DNA; BACTERIOPHAGE-T7; STABILITY; TERMINATION; TRANSITION	During transcription initiation, RNA polymerases retain interactions with their promoters until the RNA is extended to 8-13 nucleotides, at which point the polymerase releases the promoter and moves downstream. It has been shown that release of the T7 promoter is inhibited when the T7 RNA polymerase-promoter interaction is strengthened. Here we asked whether release would be facilitated when the T7 promoter-polymerase interaction is weakened by the introduction of promoter mutations known to reduce promoter activity. Using chemical and enzymatic probes to monitor the position of the polymerase as a function of RNA length, we found that promoter mutations upstream of -4 facilitated release of the polymerase from the promoter, but more downstream mutations did not have such effects. We also found that released complexes turn over more slowly than promoter-bound complexes, indicating that retention of promoter interactions contributes to the dissociation of short RNAs during initial transcription.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sousa, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	sousa@biochem.uthscsa.edu		Sousa, Rui/0000-0003-4314-121X	NIGMS NIH HHS [R01 GM052522, GM52522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mukherjee S, 2003, EMBO J, V22, P6483, DOI 10.1093/emboj/cdg618; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Mukherjee Srabani, 2003, Biological Procedures Online, V5, P78, DOI 10.1251/bpo49; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SHI YB, 1988, J BIOL CHEM, V263, P527; Sousa R, 2003, PROG NUCLEIC ACID RE, V73, P1, DOI 10.1016/S0079-6603(03)01001-8; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	27	10	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14956	14961		10.1074/jbc.M500518200	http://dx.doi.org/10.1074/jbc.M500518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711016	hybrid			2022-12-27	WOS:000228236800076
J	Liu, M; Li, YL; Cavener, D; Arvan, P				Liu, M; Li, YL; Cavener, D; Arvan, P			Proinsulin disulfide maturation and misfolding in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKITA DIABETIC MOUSE; TRANSLATIONAL CONTROL; SECRETORY PATHWAY; KINETIC TRAP; C-PEPTIDE; INSULIN; PROTEIN; INSULIN-LIKE-GROWTH-FACTOR-1; DYSFUNCTION; BEHAVIOR	Upon nonreducing Tris-Tricine-urea-SDS-PAGE, newly synthesized proinsulin from pancreatic islets of normal rodents forms a band fast mobility representing the native disulfide isomer, which is efficiently secreted. In addition at least two slower migrating "isomer 1 and 2" bands are recovered, not discernible under reducing conditions, which represent minor species that exhibit less efficient secretion. Although rats and mice have two proinsulin genes, three distinct migrating species are also produced upon proinsulin expression from a single wildtype human proinsulin cDNA. The "Akita-type" proinsulin mutation, which causes dominant-negative diabetes mellitus due to point mutation C(A7)Y that leaves B7-cysteine without its disulfide pairing partner, is recovered as a form that near quantitatively co-migrates with the aberrant isomer 1 band of proinsulin. Anomalous migration is also demonstrated for several other mutants lacking a single cysteine. In islets from PERK-/- mice, which exhibit premature loss of pancreatic beta cells, hypersynthesis of proinsulin increases the amount of nonnative proinsulin isomers. Such findings appear consistent with an hypothesis that supranormal production of nonnative proinsulin may predispose to pancreatic beta cell toxicity.	Univ Michigan, Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Arvan, P (corresponding author), Univ Michigan, Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, MSRB2 Rm 5560,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Cavener, Douglas R/E-3524-2010	Liu, Ming/0000-0003-2665-4072	NIDDK NIH HHS [R01 DK048280, DK 48280, R01 DK048280-12A2] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAI Y, 1994, BIOCHEM MOL BIOL INT, V33, P1049; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu M, 2003, J BIOL CHEM, V278, P14798, DOI 10.1074/jbc.M212070200; Min CY, 2004, EUR J BIOCHEM, V271, P1737, DOI 10.1111/j.1432-1033.2004.04079.x; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Qiao ZS, 2003, J BIOL CHEM, V278, P17800, DOI 10.1074/jbc.M300906200; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887; Zhang BY, 2003, J BIOL CHEM, V278, P3687, DOI 10.1074/jbc.M209474200; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zuber C, 2004, FASEB J, V18, P917, DOI 10.1096/fj.03-1210fje	23	89	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13209	13212		10.1074/jbc.C400475200	http://dx.doi.org/10.1074/jbc.C400475200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15705595	hybrid, Green Accepted			2022-12-27	WOS:000228095500003
J	Choudhuri, T; Pal, S; Das, T; Sa, G				Choudhuri, T; Pal, S; Das, T; Sa, G			Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G(2) phase of cell cycle in a p53-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASES; CDK INHIBITORS; D1; EXPRESSION; CARCINOMA; PROTEINS; RAS; PROLIFERATION; HYPERPLASIA; PROTECTION	Curcumin (diferuloylmethane) is known to induce apoptosis in tumor cells. In asynchronous cultures, with time-lapse video-micrography in combination with quantitative fluorescence microscopy, we have demonstrated that curcumin induces apoptosis at G(2) phase of cell cycle in deregulated cyclin D1-expressed mammary epithelial carcinoma cells, leaving its normal counterpart unaffected. In our search toward delineating the molecular mechanisms behind such differential activities of curcumin, we found that it selectively increases p53 expression at G2 phase of carcinoma cells and releases cytochrome c from mitochondria, which is an essential requirement for apoptosis. Further experiments using p53-null as well as dominant-negative and wildtype p53-transfected cells have established that curcumin induces apoptosis in carcinoma cells via a p53-dependent pathway. On the other hand, curcumin reversibly inhibits normal mammary epithelial cell cycle progression by down-regulating cyclin D1 expression and blocking its association with Cdk4/Cdk6 as well as by inhibiting phosphorylation and inactivation of retinoblastoma protein. In addition, curcumin significantly up-regulates cell cycle inhibitory protein (p21Waf-1) in normal cells and arrests them in G(0) phase of cell cycle. Therefore, these cells escape from curcumin-induced apoptosis at G2 phase. Interestingly, these processes remain unaffected by curcumin in carcinoma cells where cyclin D1 expression is high. Similarly, in ectopically overexpressed system, curcumin cannot down-regulate cyclin D1 and thus block cell cycle progression. Hence, these cells progress into G2 phase and undergo apoptosis. These observations together suggest that curcumin may have a possible therapeutic potential in breast cancer patients.	Bose Inst, Calcutta Improvement Trust Scheme 7 M P 1 12, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Sa, G (corresponding author), Bose Inst, Calcutta Improvement Trust Scheme 7 M P 1 12, Kolkata 700054, W Bengal, India.	gauri@boseinst.ernet.in	Choudhuri, Tathagata/F-8139-2011					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Chuang SE, 2000, FOOD CHEM TOXICOL, V38, P991, DOI 10.1016/S0278-6915(00)00101-0; COCO MJ, 1999, CANCER RES, V59, P1134; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOX PL, 1994, ONCOGENE, V9, P3519; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Holy JM, 2002, MUTAT RES-GEN TOX EN, V518, P71, DOI 10.1016/S1383-5718(02)00076-1; Kawamori T, 1999, CANCER RES, V59, P597; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIYASHITA T, 1995, CELL, V80, P293; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Oyama Y, 1998, EUR J PHARMACOL, V360, P65, DOI 10.1016/S0014-2999(98)00635-9; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Park MJ, 2002, INT J ONCOL, V21, P379; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Rinaldi AL, 2002, CANCER RES, V62, P5451; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sikora E, 1997, BIOCHEM PHARMACOL, V54, P899, DOI 10.1016/S0006-2952(97)00251-7; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	41	256	268	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20059	20068		10.1074/jbc.M410670200	http://dx.doi.org/10.1074/jbc.M410670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15738001	hybrid			2022-12-27	WOS:000229113700076
J	Shogomori, H; Hammond, AT; Ostermeyer-Fay, AG; Barr, DJ; Feigenson, GW; London, E; Brown, DA				Shogomori, H; Hammond, AT; Ostermeyer-Fay, AG; Barr, DJ; Feigenson, GW; London, E; Brown, DA			Palmitoylation and intracellular domain interactions both contribute to raft targeting of linker for activation of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORDERED-LIPID DOMAINS; INFLUENZA-VIRUS HEMAGGLUTININ; MODEL MEMBRANES; ANCHORED PROTEINS; ANTIGEN RECEPTOR; PLASMA-MEMBRANE; TRITON X-100; CHOLESTEROL; LOCALIZATION; LAT	Some transmembrane proteins must associate with lipid rafts to function. However, even if acylated, transmembrane proteins should not pack well with ordered raft lipids, and raft targeting is puzzling. Acylation is necessary for raft targeting of linker for activation of T cells (LAT). To determine whether an acylated transmembrane domain is sufficient, we examined raft association of palmitoylated and nonpalmitoylated LAT transmembrane peptides in lipid vesicles by a fluorescence quenching assay, by microscopic examination, and by association with detergent-resistant membranes (DRMs). All three assays detected very low raft association of the nonacylated LAT peptide. DRM association was the same as a control random transmembrane peptide. Acylation did not measurably enhance raft association by the first two assays but slightly enhanced DRM association. The palmitoylated LAT peptide and a FLAG-tagged LAT transmembrane domain construct expressed in cells showed similar DRM association when both were reconstituted into mixed vesicles ( containing cell-derived proteins and lipids and excess artificial raft-forming lipids) before detergent extraction. We conclude that the acylated LAT transmembrane domain has low inherent raft affinity. Full-length LAT in mixed vesicles associated better with DRMs than the peptide. However, cells appeared to contain two pools of LAT, with very different raft affinities. Since some LAT ( but not the transmembrane domain construct) was isolated in a protein complex, and the Myc- and FLAG-tagged forms of LAT could be mutually co-immunoprecipitated, oligomerization or interactions with other proteins may enhance raft affinity of one pool of LAT. We conclude that both acylation and other factors, possibly protein-protein interactions, target LAT to rafts.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Cornell University	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	deborah.brown@sunysb.edu			NIGMS NIH HHS [GM48596, GM47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Akashi K, 1996, BIOPHYS J, V71, P3242, DOI 10.1016/S0006-3495(96)79517-6; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fastenberg ME, 2003, BIOCHEMISTRY-US, V42, P12376, DOI 10.1021/bi034718d; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JING SQ, 1990, J BIOL CHEM, V265, P11555; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Kosugi A, 2001, IMMUNITY, V14, P669, DOI 10.1016/S1074-7613(01)00146-7; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lew S, 1997, ANAL BIOCHEM, V251, P113, DOI 10.1006/abio.1997.2232; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1939, DOI 10.1021/bi00510a033; LONDON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P89, DOI 10.1016/0005-2736(81)90012-2; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Puertollano R, 1998, J BIOL CHEM, V273, P12740, DOI 10.1074/jbc.273.21.12740; Rawat SS, 2003, MOL MEMBR BIOL, V20, P243, DOI 10.1080/0968768031000104944; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Sommers CL, 2004, BIOESSAYS, V26, P61, DOI 10.1002/bies.10384; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; van Duyl BY, 2002, FEBS LETT, V523, P79, DOI 10.1016/S0014-5793(02)02939-3; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	67	100	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18931	18942		10.1074/jbc.M500247200	http://dx.doi.org/10.1074/jbc.M500247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753089	hybrid			2022-12-27	WOS:000228932300046
J	Yamada, T; Ohoka, Y; Kogo, M; Inagaki, S				Yamada, T; Ohoka, Y; Kogo, M; Inagaki, S			Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-ASSOCIATED RHO; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; NEURITE RETRACTION; G(12) FAMILY; P115 RHOGEF; ACTIVATION; KINASE; LARG; PLEXIN-B1	Lysophosphatidic acid (LPA) is a serum-derived phospholipid that induces a variety of biological responses in various cells via heterotrimeric G protein-coupled receptors (GPCRs) including LPA1, LPA2, and LPA3. LPA-induced cytoskeletal changes are mediated by Rho family small GTPases, such as RhoA, Rac1, and Cdc42. One of these small GTPases, RhoA, may be activated via G alpha(12/13)-linked Rho-specific guanine nucleotide exchange factors (RhoGEFs) under LPA stimulation although the detailed mechanisms are poorly understood. Here, we show that the C terminus of LPA1 and LPA2 but not LPA3 interact with the PDZ domains of PDZ domain-containing RhoGEFs, PDZ-RhoGEF, and LARG, which are comprised of PDZ, RGS, Dbl homology (DH), and pleckstrin homology (PH) domains. In LPA(1)- and LPA(2)-transfected HEK293 cells, LPA-induced RhoA activation was observed although the C terminus of LPA1 and LPA2 mutants, which failed to interact with the PDZ domains, did not cause LPA-induced RhoA activation. Furthermore, overexpression of the PDZ domains of PDZ domain-containing RhoGEFs served as dominant negative mutants for LPA-induced RhoA activation. Taken together, these results indicate that formation of the LPA receptor/PDZ domain-containing RhoGEF complex plays a pivotal role in LPA-induced RhoA activation.	Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Oral & Maxillafacial Surg 1, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Ohoka, Y (corresponding author), Osaka Univ, Fac Med, Sch Allied Hlth Sci, Neurobiol Grp, Yamadaoka 1-7, Suita, Osaka 5650871, Japan.	yohoka@sahs.med.osaka-u.ac.jp; inagaki@sahs.med.osaka-u.ac.jp	Kogo, Mikihiko/ABD-7080-2020	Kogo, Mikihiko/0000-0002-4556-2491				Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gavarini S, 2004, BIOL CELL, V96, P373, DOI 10.1016/j.biolcel.2004.03.001; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hirotani M, 2002, BIOCHEM BIOPH RES CO, V297, P32, DOI 10.1016/S0006-291X(02)02122-8; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii M, 2003, LIFE SCI, V74, P163, DOI 10.1016/j.lfs.2003.09.004; Jeanneteau F, 2004, MOL BIOL CELL, V15, P696, DOI 10.1091/mbc.E03-05-0293; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Oh YS, 2004, MOL CELL BIOL, V24, P5069, DOI 10.1128/MCB.24.11.5069-5079.2004; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wang Q, 2004, J BIOL CHEM, V279, P28831, DOI 10.1074/jbc.C400105200; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xiang Y, 2003, P NATL ACAD SCI USA, V100, P10776, DOI 10.1073/pnas.1831718100; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yoshida A, 2001, JPN J PHARMACOL, V87, P104, DOI 10.1254/jjp.87.104; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	45	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19358	19363		10.1074/jbc.M414561200	http://dx.doi.org/10.1074/jbc.M414561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755723	hybrid			2022-12-27	WOS:000228932300093
J	Stokes, DL; Delavoie, F; Rice, WJ; Champeil, P; McIntosh, DB; Lacapere, JJ				Stokes, DL; Delavoie, F; Rice, WJ; Champeil, P; McIntosh, DB; Lacapere, JJ			Structural studies of a stabilized phosphoenzyme intermediate of Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; CALCIUM-PUMP; FLUORESCEIN ISOTHIOCYANATE; CROSS-LINKING; ACTIVE-SITE; ATP BINDING; CA-ATPASE; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY	Ca2+-ATPase belongs to the family of P-type ATPases and maintains low concentrations of intracellular Ca2+. Its reaction cycle consists of four main intermediates that alternate ion binding in the transmembrane domain with phosphorylation of an aspartate residue in a cytoplasmic domain. Previous work characterized an ultrastable phosphoenzyme produced first by labeling with fluorescein isothiocyanate, then by allowing this labeled enzyme to establish a maximal Ca2+ gradient, and finally by removing Ca2+ from the solution. This phosphoenzyme is characterized by very low fluorescence and has specific enzymatic properties suggesting the existence of a high energy phosphoryl bond. To study the structural properties of this phosphoenzyme, we used cryoelectron microscopy of two-dimensional crystals formed in the presence of decavanadate and determined the structure at 8-angstrom resolution. To our surprise we found that at this resolution the low fluorescence phosphoenzyme had a structure similar to that of the native enzyme crystallized under equivalent conditions. We went on to use glutaraldehyde cross-linking and proteolysis for independent structural assessment and concluded that, like the unphosphorylated native enzyme, Ca2+ and vanadate exert a strong influence over the global structure of this low fluorescence phosphoenzyme. Based on a structural model with fluorescein isothiocyanate bound at the ATP site, we suggest that the stability as well as the low fluorescence of this phosphoenzyme is due to a fluorescein-mediated cross-link between two cytoplasmic domains that prevents hydrolysis of the aspartyl phosphate. Finally, we consider the alternative possibility that phosphate transfer to fluorescein itself could explain the properties of this low fluorescence species.	Univ Paris 07, INSERM, U410, F-75870 Paris, France; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10012 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10012 USA; New York Struct Biol Ctr, New York, NY 10027 USA; CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, SBPM DBCM, F-91191 Gif Sur Yvette, France; Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; New York University; New York University; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Cape Town	Stokes, DL (corresponding author), Univ Paris 07, INSERM, U410, 16 Rue Henri Huchard,BP 416, F-75870 Paris, France.	stokes@saturn.med.nyu.edu; Jean-Jacques.Lacapere@bichat.inserm.fr	DELAVOIE, Franck/AAP-3126-2021	DELAVOIE, Franck/0000-0001-9692-0386; Rice, William/0000-0002-5187-255X	NIGMS NIH HHS [R01-GM56960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; Beroukhim R, 1997, ULTRAMICROSCOPY, V70, P57, DOI 10.1016/S0304-3991(97)00070-3; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; CSERMELY P, 1985, EUR J BIOCHEM, V150, P455, DOI 10.1111/j.1432-1033.1985.tb09043.x; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; Delavoie F, 2003, ANN NY ACAD SCI, V986, P17, DOI 10.1111/j.1749-6632.2003.tb07133.x; DELAVOIE F, 2001, BIOL CELL, V93, P363; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; EVERTS ME, 1989, BIOCHEM J, V260, P443, DOI 10.1042/bj2600443; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Henao F, 2001, J BIOL CHEM, V276, P24284, DOI 10.1074/jbc.M103905200; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; Hua SM, 2000, J BIOL CHEM, V275, P30546, DOI 10.1074/jbc.M003218200; Huang SH, 1998, BIOCHEMISTRY-US, V37, P18064, DOI 10.1021/bi981997+; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Korndorfer IP, 2003, PROTEINS, V53, P121, DOI 10.1002/prot.10497; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; ROSS DC, 1991, J BIOL CHEM, V266, P4613; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; Tani K, 1996, ULTRAMICROSCOPY, V65, P31, DOI 10.1016/S0304-3991(96)00052-6; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WHITLOW M, 1995, PROTEIN ENG, V8, P749, DOI 10.1093/protein/8.8.749; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	56	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18063	18072		10.1074/jbc.M500031200	http://dx.doi.org/10.1074/jbc.M500031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734741	Green Published, hybrid			2022-12-27	WOS:000228807200063
J	Allen, DL; Weber, JN; Sycuro, LK; Leinwand, LA				Allen, DL; Weber, JN; Sycuro, LK; Leinwand, LA			Myocyte enhancer factor-2 and serum response factor binding elements regulate fast myosin heavy chain transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GENE-EXPRESSION; SKELETAL; MUSCLE; CALCINEURIN; MEF2; SLOW; SEQUENCES; ACTIVATION; PROTEINS	Adult fast muscle fibers express distinct myosin heavy chains (MyHC) in differing proportions, but the mechanisms underlying their differential expression remain undefined. We used a variety of in vitro and in vivo approaches to explore the contribution of transcriptional regulation to adult fast MyHC expression. Here we show that 800 - 1000 bp of a sequence upstream of the three mouse adult fast MyHC genes (Ia, IIb, and IId/x) are sufficient to drive muscle-specific and fiber-specific expression in vivo. We show that the upstream promoter region of the gene most abundantly expressed in mouse skeletal muscles, IIb MyHC, retains binding activity and transcriptional activation for three positive transcription factors, the serum response factor, Oct-1, and myocyte enhancer factor-2, whereas the other two genes (IIa and IId/x) have nucleotide substitutions in these sites that reduce binding and transcriptional activation. Finally, we demonstrate that regions upstream of 300 bp modulate the effects of these elements. Together, these data demonstrate that the quantitative differences in MyHC expression in mouse skeletal muscle have evolved at least in part through the elimination of positive-acting transcription factor binding sites.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Campus Box 347, Boulder, CO 80309 USA.	leinwand@stripe.colorado.edu	Weber, Jesse N/I-8685-2019	Weber, Jesse N/0000-0003-4839-6684; LEINWAND, LESLIE/0000-0003-1470-4810; Sycuro, Laura/0000-0002-2011-6305	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; ALLEN DL, 2000, AM J PHYSIOL, V280, pC637; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; Calvo S, 1999, MOL CELL BIOL, V19, P515; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; Gordon SE, 2001, J APPL PHYSIOL, V90, P1174, DOI 10.1152/jappl.2001.90.3.1174; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Hayes A, 1996, J APPL PHYSIOL, V80, P670, DOI 10.1152/jappl.1996.80.2.670; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Lucas CA, 2000, BIOCHEM BIOPH RES CO, V272, P303, DOI 10.1006/bbrc.2000.2768; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; REGGIANI C, 1992, MUSCLE NERVE, V15, P199, DOI 10.1002/mus.880150212; Sakuma K, 2004, ACTA NEUROPATHOL, V108, P241, DOI 10.1007/s00401-004-0884-5; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; Talmadge Robert J., 1993, Current Opinion in Rheumatology, V5, P695; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	34	42	44	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17126	17134		10.1074/jbc.M501207200	http://dx.doi.org/10.1074/jbc.M501207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728583	hybrid			2022-12-27	WOS:000228615500072
J	Lah, J; Simic, M; Vesnaver, G; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Loris, R				Lah, J; Simic, M; Vesnaver, G; Marianovsky, I; Glaser, G; Engelberg-Kulka, H; Loris, R			Energetics of structural transitions of the addiction antitoxin MazE - Is a programmed bacterial cell death dependent on the intrinsically flexible nature of the antitoxins?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NATIVELY UNFOLDED PROTEINS; HEAT-CAPACITY CHANGES; ESCHERICHIA-COLI; TOXIN-ANTITOXIN; UNSTRUCTURED PROTEINS; CRYSTAL-STRUCTURE; F-PLASMID; SECONDARY STRUCTURE; NUTRITIONAL STRESS; PROTHYMOSIN-ALPHA	The Escherichia coli mazEF addiction module plays a crucial role in the cell death program that is triggered under various stress conditions. It codes for the toxin MazF and the antitoxin MazE, which interferes with the lethal action of the toxin. To better understand the role of various conformations of MazE in bacterial life, its order-disorder transitions were monitored by differential scanning calorimetry, spectropolarimetry, and fluorimetry. The changes in spectral and thermodynamic properties accompanying MazE dimer denaturation can be described in terms of a compensating reversible process of the partial folding of the unstructured C-terminal half ( high mean net charge, low mean hydrophobicity) and monomerization coupled with the partial unfolding of the structured N-terminal half ( low mean net charge, high mean hydrophobicity). At pH <= 4.5 and T < 50 degrees C, the unstructured polypeptide chains of the MazE dimer fold into (pre) molten globule-like conformations that thermally stabilize the dimeric form of the protein. The simulation based on the thermodynamic and structural information on various addiction modules suggests that both the conformational adaptability of the dimeric antitoxin form ( binding to the toxins and DNA) and the reversible transformation to the more flexible monomeric form are essential for the regulation of bacterial cell life and death.	Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Free Univ Brussels, Inst Mol Biol, Lab Ultrastruct, B-1050 Brussels, Belgium; Vlaams Inst Biotechnol, B-1050 Brussels, Belgium	University of Ljubljana; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB)	Lah, J (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Askerceva 5, Ljubljana 1000, Slovenia.	jurij.lah@fkkt.uni-lj.si	Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Amitai S, 2004, J BACTERIOL, V186, P8295, DOI 10.1128/JB.186.24.8295-8300.2004; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BECH FW, 1985, EMBO J, V4, P1059, DOI 10.1002/j.1460-2075.1985.tb03739.x; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Brady GP, 1997, BIOPHYS J, V72, P913, DOI 10.1016/S0006-3495(97)78725-3; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chaires JB, 1997, BIOPOLYMERS, V44, P201, DOI 10.1002/(SICI)1097-0282(1997)44:3<201::AID-BIP2>3.0.CO;2-Z; Cherny I, 2004, J BIOL CHEM, V279, P8252, DOI 10.1074/jbc.M308263200; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; EBERL L, 1992, MOL MICROBIOL, V6, P1969, DOI 10.1111/j.1365-2958.1992.tb01370.x; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Engelberg-Kulka H, 2001, ASM NEWS, V67, P617; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; Gast K, 2003, EUR BIOPHYS J BIOPHY, V31, P586, DOI 10.1007/s00249-002-0254-y; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; Gurney R.W., 1953, IONIC PROCESSES SOLU; Hayes F, 2003, SCIENCE, V301, P1496, DOI 10.1126/science.1088157; Hazan R, 2004, MOL GENET GENOMICS, V272, P227, DOI 10.1007/s00438-004-1048-y; Hazan R, 2004, J BACTERIOL, V186, P3663, DOI 10.1128/JB.186.11.3663-3669.2004; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOLTZER A, 1995, BIOPOLYMERS, V35, P595, DOI 10.1002/bip.360350605; HORTON N, 1992, PROTEIN SCI, V1, P169; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janin J, 1996, PROTEINS, V24, pR1, DOI 10.1002/prot.340240402; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lah J, 2004, J MOL BIOL, V342, P73, DOI 10.1016/j.jmb.2004.07.005; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; Lah N, 2003, J BIOL CHEM, V278, P24673, DOI 10.1074/jbc.M303194200; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; METZGER S, 1988, J BIOL CHEM, V263, P15699; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; OBERER M, 1999, BIOCHEM J, V361, P41; PAGE MI, 1977, ANGEW CHEM INT EDIT, V16, P449, DOI 10.1002/anie.197704491; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; Privalov P L, 1986, Methods Enzymol, V131, P4; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rawlings DE, 1999, FEMS MICROBIOL LETT, V176, P269, DOI 10.1111/j.1574-6968.1999.tb13672.x; Ren JS, 2000, BIOCHEMISTRY-US, V39, P8439, DOI 10.1021/bi000474a; RODIONOVA NA, 1989, MOL BIOL+, V23, P528; RUIZECHEVARRIA MJ, 1995, J MOL BIOL, V247, P568, DOI 10.1006/jmbi.1995.0163; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; Sat B, 2003, J BACTERIOL, V185, P1803, DOI 10.1128/JB.185.6.1803-1807.2003; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; Uversky VN, 1999, BIOCHEMISTRY-US, V38, P15009, DOI 10.1021/bi990752+; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2002, FEBS LETT, V514, P181, DOI 10.1016/S0014-5793(02)02359-1; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200	103	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17397	17407		10.1074/jbc.M501128200	http://dx.doi.org/10.1074/jbc.M501128200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735309	hybrid			2022-12-27	WOS:000228615500105
J	Wang, W; Jobbagy, Z; Bird, TH; Eiden, MV; Anderson, WB				Wang, W; Jobbagy, Z; Bird, TH; Eiden, MV; Anderson, WB			Cell signaling through the protein kinases cAMP-dependent protein kinase, protein kinase C epsilon, and RAF-1 regulates amphotropic murine leukemia virus envelope protein-induced syncytium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-UPTAKE; RETROVIRUS RECEPTOR; MEMBRANE-FUSION; UP-REGULATION; PKC-EPSILON; LIPID RAFTS; VIRAL ENTRY; HERV-W; ACTIVATION; EXPRESSION	Amphotropic murine leukemia virus ( A-MuLV) utilizes the PiT2 sodium-dependent phosphate transporter as its cell surface receptor to infect mammalian cells. The process of A-MuLV infection requires cleavage of the R peptide from the envelope protein. This occurs within virions thereby rendering them competent to fuse with target cells. Envelope proteins lacking the inhibitory R peptide ( e. g. envelope ( R-) proteins) induce viral envelope-mediated cell-cell fusion ( syncytium). Here we have performed studies to determine if cell signaling through protein kinases is involved in the regulation of PiT2-mediated A-MuLV envelope ( R-)-induced syncytium formation. Truncated A-MuLV retroviral envelope protein lacking the inhibitory R peptide ( R-) was used to induce viral envelope-mediated cell-cell fusion. Signaling through cyclic AMP to activate PKA was found to inhibit envelope-induced cell-cell fusion, whereas treatment of cells with PKA inhibitors H89, KT5720, and PKA Cat alpha siRNA all enhanced this cell fusion process. It was noted that activation of PKC, as well as overexpression of PKC epsilon, up-regulated A-MuLV envelope protein-induced cell-cell fusion, whereas exposure to PKC inhibitors and expression of a kinase-inactive dominant-negative mutant of PKC epsilon (K437R) inhibited syncytium formation. v-ras transformed NIH3T3 cells were highly susceptible to A-MuLV envelope-induced cell-cell fusion, whereas expression of a dominant-negative mutant of Ras (N17Ras) inhibited this cell fusion process. Importantly, activation of Raf-1 protein kinase also is required for A-MuLV envelope-induced syncytium formation. Expression of constitutively active BXB Raf supported, whereas expression of a dominant-negative mutant of Raf-1 (Raf301) blocked, A-MuLV-induced cell-cell fusion. These results indicate that specific cell signaling components are involved in regulating PiT2-mediated A-MuLV-induced cell-cell fusion. Selective pharmacological modulation of these signaling components may be an effective means of altering cell susceptibility to viral-mediated cytopathic effects.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Anderson, WB (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 37,Rm 4124,37 Convent Dr, Bethesda, MD 20892 USA.	andersow@mail.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002592, Z01MH002592] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; Bell R M, 1986, Symp Fundam Cancer Res, V39, P145; Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BURGER KNJ, 1990, EXPERIENTIA, V46, P631, DOI 10.1007/BF01939702; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chien ML, 1998, VIROLOGY, V240, P109, DOI 10.1006/viro.1997.8933; Chien ML, 1997, J VIROL, V71, P4564, DOI 10.1128/JVI.71.6.4564-4570.1997; COFFIN JMF, 1996, FIELDS VIROLOGY, V2; Cole SW, 1999, J IMMUNOL, V162, P1392; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cristillo AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0744com; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Farrell KB, 2002, J VIROL, V76, P4267, DOI 10.1128/JVI.76.9.4267-4274.2002; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Forestell SP, 1997, GENE THER, V4, P600, DOI 10.1038/sj.gt.3300420; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hong DH, 1999, AM J PHYSIOL-GASTR L, V277, pG1041, DOI 10.1152/ajpgi.1999.277.5.G1041; Jobbagy Z, 1999, J BIOL CHEM, V274, P7067, DOI 10.1074/jbc.274.11.7067; Jobbagy Z, 2000, J VIROL, V74, P2847, DOI 10.1128/JVI.74.6.2847-2854.2000; JONES JS, 1993, J VIROL, V67, P67, DOI 10.1128/JVI.67.1.67-74.1993; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Keryer G, 1998, J CELL SCI, V111, P995; Lee M, 2003, BIOCHEM BIOPH RES CO, V311, P1026, DOI 10.1016/j.bbrc.2003.10.107; LEHEL C, 1994, J BIOL CHEM, V269, P4761; Lu XB, 2000, VIROLOGY, V276, P251, DOI 10.1006/viro.2000.0555; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MILLER DG, 1993, J VIROL, V67, P5346, DOI 10.1128/JVI.67.9.5346-5352.1993; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOHAGHEGHPOUR N, 1991, J BIOL CHEM, V266, P7233; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OCHO M, 1980, EXP CELL BIOL, V48, P421; OLAH Z, 1995, BIOCHEM BIOPH RES CO, V214, P340, DOI 10.1006/bbrc.1995.2293; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; Pastan I, 1974, Adv Cancer Res, V19, P303, DOI 10.1016/S0065-230X(08)60057-3; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PINTER A, 1979, J VIROL, V30, P157, DOI 10.1128/JVI.30.1.157-165.1979; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAGHEB JA, 1994, J VIROL, V68, P3220, DOI 10.1128/JVI.68.5.3220-3231.1994; REIN A, 1994, J VIROL, V68, P1773, DOI 10.1128/JVI.68.3.1773-1781.1994; Rodrigues P, 1999, J VIROL, V73, P3789, DOI 10.1128/JVI.73.5.3789-3799.1999; Root CN, 2000, J GEN VIROL, V81, P2697, DOI 10.1099/0022-1317-81-11-2697; Salaun C, 2002, J VIROL, V76, P4304, DOI 10.1128/JVI.76.9.4304-4311.2002; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tsurudome M, 2000, CRIT REV IMMUNOL, V20, P167; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; WILSON CA, 1992, J VIROL, V66, P7262, DOI 10.1128/JVI.66.12.7262-7269.1992	56	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16772	16783		10.1074/jbc.M411537200	http://dx.doi.org/10.1074/jbc.M411537200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741175	hybrid			2022-12-27	WOS:000228615500029
J	Das, BB; Sen, N; Dasgupta, SB; Ganguly, A; Majumder, HK				Das, BB; Sen, N; Dasgupta, SB; Ganguly, A; Majumder, HK			N-terminal region of the large subunit of leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CRYSTAL-STRUCTURES; CAMPTOTHECIN; DOMAIN; RECONSTITUTION; MECHANISM; TRYPANOSOMES; INHIBITOR; FRAGMENT; COMPLEX	Leishmania donovani topoisomerase I is an unusual bisubunit enzyme. We have demonstrated earlier that the large and small subunit could be reconstituted in vitro to show topoisomerase I activity. We extend our biochemical study to evaluate the role of the large subunit in topoisomerase activity. The large subunit (LdTOP1L) shows a substantial degree of homology with the core DNA binding domain of the topoisomerase IB family. Two N-terminal truncation constructs, LdTOP1 Delta 39L ( lacking amino acids 1 - 39) and LdTOP1 Delta 99L ( lacking amino acids 1 - 99) of the large subunit were generated and mixed with intact small subunit (LdTOP1S). Our observations reveal that residues within amino acids 1 - 39 of the large subunit have significant roles in modulating topoisomerase I activity (i.e. in vitro DNA relaxation, camptothecin sensitivity, cleavage activity, and DNA binding affinity). Interestingly, the mutant LdTOP1 Delta 99LS was unable to show topoisomerase I activity. Investigation of the loss of activity indicates that LdTOP1 Delta 99L was unable to pull down glutathione S-transferase-LdTOP1S in an Ni2+-nitrilotriacetic acid co-immobilization experiment. For further analysis, we co-expressed LdTOP1L and LdTOP1S in Escherichia coli BL21(DE3) pLysS cells. The lysate shows topoisomerase I activity. Immunoprecipitation revealed that LdTOP1L could interact with LdTOP1S, indicating the subunit interaction in bacterial cells, whereas immunoprecipitation of bacterial lysate co-expressing LdTOP1 Delta 99L and LdTOP1S reveals that LdTOP1 Delta 99L was significantly deficient at interacting with LdTOP1S to reconstitute topoisomerase I activity. This study demonstrates that heterodimerization between the large and small subunits of the bisubunit enzyme appears to be an absolute requirement for topoisomerase activity. The residue within amino acids 1 - 39 from the N-terminal end of the large subunit regulates DNA topology during relaxation by controlling noncovalent DNA binding or by coordinating DNA contacts by other parts of the enzyme.	Indian Inst Chem Biol, Dept Mol Parasitol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Majumder, HK (corresponding author), Indian Inst Chem Biol, Dept Mol Parasitol, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	hkmajumder@iicb.res.in	Das, Benu Brata/AAC-3452-2022; DAS, BENU BRATA BRATA/AAX-4347-2021; Sen, Nilkantha/AAW-9788-2020	DAS, BENU BRATA BRATA/0000-0003-2519-7105; 				Bodley AL, 2003, P NATL ACAD SCI USA, V100, P7539, DOI 10.1073/pnas.1330762100; BODLEY AL, 1995, P NATL ACAD SCI USA, V92, P3726, DOI 10.1073/pnas.92.9.3726; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Das A, 2004, TRENDS PARASITOL, V20, P381, DOI 10.1016/j.pt.2004.06.005; Das BB, 2004, FEBS LETT, V565, P81, DOI 10.1016/j.febslet.2004.03.078; Frohlich RF, 2004, J MOL BIOL, V336, P93, DOI 10.1016/j.jmb.2003.12.007; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LI CJ, 1993, J BIOL CHEM, V268, P22463; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lisby M, 2001, J BIOL CHEM, V276, P20220, DOI 10.1074/jbc.M010991200; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Sen N, 2004, J BIOL CHEM, V279, P52366, DOI 10.1074/jbc.M406705200; Sen N, 2004, CELL DEATH DIFFER, V11, P924, DOI 10.1038/sj.cdd.4401435; Sengupta T, 2003, NUCLEIC ACIDS RES, V31, P5305, DOI 10.1093/nar/gkg727; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Villa H, 2003, J BIOL CHEM, V278, P3521, DOI 10.1074/jbc.M203991200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang Z, 2002, J BIOL CHEM, V277, P30815, DOI 10.1074/jbc.M205302200; Yao N, 2003, J BIOL CHEM, V278, P50744, DOI 10.1074/jbc.M309206200	33	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16335	16344		10.1074/jbc.M412417200	http://dx.doi.org/10.1074/jbc.M412417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15711017	hybrid			2022-12-27	WOS:000228444800105
J	Gupta, N; Zahn, MM; Coppens, I; Joiner, KA; Voelker, DR				Gupta, N; Zahn, MM; Coppens, I; Joiner, KA; Voelker, DR			Selective disruption of phosphatidylcholine metabolism of the intracellular parasite Toxoplasma gondii arrests its growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLSERINE DECARBOXYLASE; PHOSPHOLIPID-METABOLISM; PARASITOPHOROUS VACUOLE; ANTIMALARIAL ACTIVITY; CULTURED FIBROBLASTS; ESCHERICHIA-COLI; HOST; BIOSYNTHESIS; MEMBRANE; ERYTHROCYTES	Toxoplasma gondii is an intracellular protozoan parasite capable of causing devastating infections in immunocompromised and immunologically immature individuals. In this report, we demonstrate the relative independence of T. gondii from its host cell for aminoglycerophospholipid synthesis. The parasite can acquire the lipid precursors serine, ethanolamine, and choline from its environment and use them for the synthesis of its major lipids, phosphatidylserine ( PtdSer), phosphatidylethanolamine (PtdEtn), and phosphatidylcholine (PtdCho), respectively. Dimethylethanolamine (Etn(Me)(2)), a choline analog, dramatically interfered with the PtdCho metabolism of T. gondii and caused a marked inhibition of its growth within human foreskin fibroblasts. In tissue culture medium supplemented with 2 mM Etn(Me)(2), the parasite-induced lysis of the host cells was dramatically attenuated, and the production of parasites was inhibited by more than 99%. The disruption of parasite growth was paralleled by structural abnormalities in its membranes. In contrast, no negative effect on host cell growth and morphology was observed. The data also reveal that the Etn(Me)(2)-supplemented parasite had a time-dependent decrease in its PtdCho content and an equivalent increase in phosphatidyldimethylethanolamine, whereas other major lipids, PtdSer, PtdEtn, and PtdIns, remained largely unchanged. Relative to host cells, the parasites incorporated more than 7 times as much Etn( Me)(2) into their phospholipid. These findings reveal that Etn( Me)(2) selectively alters parasite lipid metabolism and demonstrate how selective inhibition of PtdCho synthesis is a powerful approach to arresting parasite growth.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, Denver, CO 80206 USA; Johns Hopkins Univ, Blomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Infect Dis Sect, Investigat Med Program, New Haven, CT 06520 USA	National Jewish Health; Johns Hopkins University; Yale University	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org	Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Gupta, Nishith/0000-0003-1452-5126	NIAID NIH HHS [AI030060] Funding Source: Medline; NIGMS NIH HHS [2R37GM32453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Calas M, 1997, J MED CHEM, V40, P3557, DOI 10.1021/jm9701886; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Charron AJ, 2002, J CELL SCI, V115, P3049; Coppens I, 2003, MOL BIOL CELL, V14, P3804, DOI 10.1091/mbc.E02-12-0830; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P272; KUGE O, 1991, J BIOL CHEM, V266, P6370; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MAZIERE C, 1986, BIOCHEM BIOPH RES CO, V137, P43, DOI 10.1016/0006-291X(86)91173-3; OHTA A, 1981, J BIOL CHEM, V256, P2219; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; Sinai AP, 2001, J CELL BIOL, V154, P95, DOI 10.1083/jcb.200101073; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; SussToby E, 1996, P NATL ACAD SCI USA, V93, P8413, DOI 10.1073/pnas.93.16.8413; Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; VIAL HJ, 1990, BLOOD CELLS, V16, P531; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853	26	64	67	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16345	16353		10.1074/jbc.M501523200	http://dx.doi.org/10.1074/jbc.M501523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15708856	hybrid			2022-12-27	WOS:000228444800106
J	Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV				Aquilina, JA; Benesch, JLP; Ding, LL; Yaron, O; Horwitz, J; Robinson, CV			Subunit exchange of polydisperse proteins - Mass spectrometry reveals consequences of alpha A-crystallin truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN LENS CRYSTALLINS; AGE-RELATED-CHANGES; C-TERMINAL REGION; POSTTRANSLATIONAL MODIFICATION; LIGHT-SCATTERING; B-CRYSTALLIN; CALPAIN LP82; CHAPERONE; BOVINE	The small heat shock protein, alpha-crystallin, plays a key role in maintaining lens transparency by chaperoning structurally compromised proteins. This is of particular importance in the human lens, where proteins are exposed to post-translational modifications over the lifetime of an individual. Here, we examine the structural and functional consequences of one particular modification of alpha A-crystallin involving the truncation of 5 C-terminal residues (alpha A(1-168)). Using novel mass spectrometry approaches and established biophysical techniques, we show that alpha A(1-168) forms oligomeric assemblies with a lower average molecular mass than wild-type alpha A-crystallin (alpha A(WT)). Also apparent from the mass spectra of both alpha A(WT) and alpha A(1-168) assemblies is the predominance of oligomers containing even numbers of subunits; interestingly, this preference is more marked for alpha A(1-168). To examine the rate of exchange of subunits between assemblies, we mixed alpha B crystallin with either alpha A(WT) or alpha A(1-168) and monitored in a real-time mass spectrometry experiment the formation of heteroligomers. The results show that there is a significant decrease in the rate of exchange when alpha A(1-168) is involved. These reduced exchange kinetics, however, have no effect upon chaperone efficiency, which is found to be closely similar for both alpha A(WT) and alpha A(1-168). Overall, therefore, our results allow us to conclude that, in contrast to mechanisms established for analogous proteins from plants, yeast, and bacteria, the rate of subunit exchange is not the critical parameter in determining efficient chaperone behavior for mammalian alpha A-crystallin.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of Cambridge; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Aquilina, John Andrew/AGF-4013-2022; Benesch, Justin/A-4250-2008; Aquilina, J. Andrew/A-5366-2013	Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NATIONAL EYE INSTITUTE [R01EY003897, R37EY003897] Funding Source: NIH RePORTER; NEI NIH HHS [EY-3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; ASSELBERGS FAM, 1978, EUR J BIOCHEM, V91, P65, DOI 10.1111/j.1432-1033.1978.tb20937.x; Benesch JLP, 2003, ANAL CHEM, V75, P2208, DOI 10.1021/ac034132x; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Colvis C, 2002, ARCH BIOCHEM BIOPHYS, V397, P319, DOI 10.1006/abbi.2001.2669; de Jong W W, 1974, Eur J Biochem, V48, P271; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; Fougerousse F, 2000, HUM MOL GENET, V9, P165, DOI 10.1093/hmg/9.2.165; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Harding J., 1991, CATARACT BIOCH EPIDE; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Kamei A, 2001, BIOL PHARM BULL, V24, P96, DOI 10.1248/bpb.24.96; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; Moroni M, 2001, BBA-PROTEIN STRUCT M, V1546, P282, DOI 10.1016/S0167-4838(01)00154-6; Nakamura Y, 2000, INVEST OPHTH VIS SCI, V41, P1460; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PALMER WG, 1969, P NATL ACAD SCI USA, V64, P404, DOI 10.1073/pnas.64.1.404; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; Sharma KK, 1996, BIOCHEM BIOPH RES CO, V218, P365, DOI 10.1006/bbrc.1996.0064; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Takemoto LJ, 1997, INT J BIOCHEM CELL B, V29, P311, DOI 10.1016/S1357-2725(96)00111-2; TAKEMOTO LJ, 1995, CURR EYE RES, V14, P837, DOI 10.3109/02713689508995806; Thampi P, 2003, BIOCHEMISTRY-US, V42, P11857, DOI 10.1021/bi030129w; Thampi P, 2002, INVEST OPHTH VIS SCI, V43, P3265; Treweek TM, 2005, FEBS J, V272, P711, DOI 10.1111/j.1742-4658.2004.04507.x; Treweek TM, 2003, AUST J CHEM, V56, P357, DOI 10.1071/CH03031; Ueda Y, 2001, EXP EYE RES, V73, P625, DOI 10.1006/exer.2001.1071; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Vanhoudt J, 1998, INT J BIOL MACROMOL, V22, P229, DOI 10.1016/S0141-8130(98)00020-8; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; WALSH MT, 1991, J BIOL CHEM, V266, P20079; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	47	91	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14485	14491		10.1074/jbc.M500135200	http://dx.doi.org/10.1074/jbc.M500135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701626	hybrid			2022-12-27	WOS:000228236800018
J	Funa, N; Funabashi, M; Yoshimura, E; Horinouchi, S				Funa, N; Funabashi, M; Yoshimura, E; Horinouchi, S			A novel quinone-forming monooxygenase family involved in modification of aromatic polyketides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); COMBINATORIAL BIOSYNTHESIS; ACTINORHODIN BIOSYNTHESIS; TETRACENOMYCIN-C; GENOME SEQUENCE; SYNTHASE; EXPRESSION; RECONSTITUTION; PURIFICATION; SUPERFAMILY	RppA is a type III polyketide synthase (PKS) that catalyzes condensation of five molecules of malonyl-CoA to form 1,3,6,8-tetrahydroxynaphthalene (THN). In Streptomyces antibioticus IFO13271 and several other Streptomyces species, an open reading frame, named momA, is present as a neighbor of rppA. MomA belonged to the "cupin" superfamily because it contained a set of two motifs that is responsible for binding one equivalent of metal ions. MomA catalyzed monooxygenation of the THN produced from malonyl-CoA by the action of RppA to form flaviolin. In addition, it used several polyketides as substrates and formed the corresponding quinones. MomA required redox-active transition metal ions (Ni2+, Cu2+, Fe3+, Fe2+, Mn2+, and Co2+) for its activity, whereas it was inhibited by a redox-inert transition metal ion (Zn2+). MomA neither possessed any flavin prosthetic group nor required nicotinamide cofactors for monooxygenation, which shows that MomA as a member of the cupin superfamily is a novel monooxygenase. Consistent with the catalytic property of MomA, WhiE-ORFII showing similarity in amino acid sequence to MomA and containing a cupin domain also catalyzed monooxygenation of THN. whiE-ORFII is located immediately upstream of the "minimal PKS" gene within the whiE type II PKS gene cluster for biosynthesis of a gray spore pigment in Streptomyces coelicolor A3(2), and a number of whiE-ORFII homologues are present in the biosynthetic gene cluster for polyketides of type II in various Streptomyces species. These findings show that a novel class of quinone-forming monooxygenases is involved in modification of aromatic polyketides synthesized by PKSs of types II and III.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp						Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; Chung JY, 2002, J BACTERIOL, V184, P6115, DOI 10.1128/JB.184.22.6115-6122.2002; Cortes J, 2002, MOL MICROBIOL, V44, P1213, DOI 10.1046/j.1365-2958.2002.02975.x; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; FALK H, 1993, MONATSH CHEM, V124, P339, DOI 10.1007/BF00810594; Fetzner S, 2002, APPL MICROBIOL BIOT, V60, P243, DOI 10.1007/s00253-002-1123-4; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2002, BIOCHEM J, V367, P781, DOI 10.1042/BJ20020953; Gaisser S, 1997, J BACTERIOL, V179, P6271, DOI 10.1128/jb.179.20.6271-6278.1997; Hayaishi O., 1974, MOL MECH OXYGEN ACTI; HOPWOOD DA, 1985, GENETIC MANIPULATION, P1; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Ichinose K, 2001, CHEM PHARM BULL, V49, P192, DOI 10.1248/cpb.49.192; Maniatis T., 1982, MOL CLONING; OHAGEN D, 1991, POLYKETIDE METABOLIT; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Pochapsky TC, 2002, NAT STRUCT BIOL, V9, P966, DOI 10.1038/nsb863; Rawlings BJ, 2001, NAT PROD REP, V18, P231, DOI 10.1039/b100191o; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; Swan MK, 2003, J BIOL CHEM, V278, P47261, DOI 10.1074/jbc.M308603200; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; YU TW, 1995, MICROBIOL-UK, V141, P2779, DOI 10.1099/13500872-141-11-2779	32	43	52	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14514	14523		10.1074/jbc.M500190200	http://dx.doi.org/10.1074/jbc.M500190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701630	hybrid			2022-12-27	WOS:000228236800022
J	Sturla, LM; Amorino, G; Alexander, MS; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK				Sturla, LM; Amorino, G; Alexander, MS; Mikkelsen, RB; Valerie, K; Schmidt-Ullrich, RK			Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SQUAMOUS CARCINOMA-CELLS; PHOSPHOLIPASE-C; BINDING-SITES; EGF RECEPTOR; ACTIVATION; KINASES; SHC; DEPHOSPHORYLATION; IDENTIFICATION	The epidermal growth factor receptor ( EGFR) is activated by ionizing radiation (IR) in many human carcinomas, mediating a cytoprotective response and subsequent radioresistance. The underlying molecular mechanisms remain to be understood, and we propose here a specific role for the Tyr-992 residue of EGFR and examine its regulation by the phosphatase, SHP2. The -fold increase in phosphorylation of Tyr-992 in response to IR is twice that seen with ligand (EGF) binding. Mutation of Tyr-992 blocked completely IR-induced EGFR phosphorylation and reduced activation of the downstream signaling molecule, phospholipase C gamma. IR has previously been demonstrated to inhibit activity of protein-tyrosine phosphatases. Following protein-tyrosine phosphatase inhibition by sodium vanadate both EGFR expressing Chinese hamster ovary (CHO) and A431 exhibited up to an 8-fold increase in the basal level of Tyr-992 phosphorylation, significantly higher than that seen with Tyr-1173, Tyr-1068, and total EGFR Tyr. CHO cells expressing a SHP2 mutant also demonstrated up to an 8-fold increase in the basal level of Tyr-992 phosphorylation. In this study we show the unique association of SHP2 with EGFR in response to IR, with up to a 2.5-fold increase in the direct association of endogenous SHP2 with EGFR-wt in response to 2 gray of IR in both CHO and A431 cells. Mutation of Tyr-992 abolished this response. In conclusion we have identified several differentially activated Tyr residues, one of which is not only more sensitive to activation by IR, translating into differential activation of downstream signaling, but uniquely modulated by the phosphatase SHP2.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Mikkelsen, RB (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058, Richmond, VA 23298 USA.	RMIKKELS@VCU.EDU	Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA90881, R01CA65896, P01CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896, R01CA090881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRIGALE A, 2004, HUM MUTAT, V23, P267; Hagg M, 2002, INT J MOL MED, V10, P655; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Schmidt-Ullrich RK, 2003, ONCOGENE, V22, P5855, DOI 10.1038/sj.onc.1206698; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; TODD DG, 1994, CANCER RES, V54, P5224; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386	41	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14597	14604		10.1074/jbc.M413287200	http://dx.doi.org/10.1074/jbc.M413287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708852	hybrid			2022-12-27	WOS:000228236800033
J	Nomura, T; Kushiro, T; Yokota, T; Kamiya, Y; Bishop, GJ; Yamaguchi, S				Nomura, T; Kushiro, T; Yokota, T; Kamiya, Y; Bishop, GJ; Yamaguchi, S			The last reaction producing brassinolide is catalyzed by cytochrome P-450s, CYP85A3 in tomato and CYP85A2 in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRASSINOSTEROID SIGNAL-TRANSDUCTION; PLANT-GROWTH; GENE; EXPRESSION; STEPS; CASTASTERONE; ELONGATION; RECEPTOR; ENCODES; PATHWAY	Brassinosteroids are steroidal hormones essential for the growth and development of plants. Brassinolide, the most biologically active brassinosteroid, has a seven-membered lactone ring that is formed by a Baeyer-Villiger oxidation of its immediate precursor castasterone. Despite its potential key role in controlling plant development, brassinolide synthase has not been identified. Previous work has shown that the formation of castasterone from 6-deoxocastasterone is catalyzed by members of the CYP85A family of cytochrome P-450 monooxygenases. A null mutation in the tomato Dwarf (CYP85A1) gene, extreme dwarf (d(x)), causes severe dwarfism due to brassinosteroid deficiency, but the dx mutant still produces fruits. Here, we show that dx fruits contain brassinolide at a higher level than wild-type fruits and that a new CYP85A gene, CYP85A3, is preferentially expressed in tomato fruits. Tomato CYP85A3 catalyzed the Baeyer-Villiger oxidation to produce brassinolide from castasterone in yeast, in addition to the conversion of 6-deoxocastasterone to castasterone. We also show that Arabidopsis CYP85A2, which was initially characterized as castasterone synthase, also has brassinolide synthase activity. Exogenous application of castasterone and brassinolide to the Arabidopsis cyp85a1/cyp85a2 double mutant suggests that castasterone can function as an active brassinosteroid but that its conversion into brassinolide is necessary for normal vegetative development in Arabidopsis. We postulate that castasterone is the major active brassinosteroid during vegetative growth in tomato, whereas brassinolide may play an organ-specific role in fruit development in this species.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Tsurumi Ku, Kanagawa 2300045, Japan; Teikyo Univ, Dept Biosci, Utsunomiya, Tochigi 3208551, Japan; Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales	RIKEN; Teikyo University; Aberystwyth University	Bishop, GJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Wye Campus, Ashford TN25 5AH, Kent, England.	g.bishop@imperial.ac.uk	Kamiya, Yuji/F-9420-2010; Yamaguchi, Shinjiro/F-9684-2010; Nomura, Takahito/C-7327-2012	Kamiya, Yuji/0000-0003-4415-520X; Kushiro, Tetsuo/0000-0002-7598-4791; Nomura, Takahito/0000-0002-3655-3243				AKHTAR M, 1993, J STEROID BIOCHEM, V44, P375, DOI 10.1016/0960-0760(93)90241-N; Bajguz A, 2003, PHYTOCHEMISTRY, V62, P1027, DOI 10.1016/S0031-9422(02)00656-8; Bancos S, 2002, PLANT PHYSIOL, V130, P504, DOI 10.1104/pp.005439; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Castle J, 2005, PLANT MOL BIOL, V57, P129, DOI 10.1007/s11103-004-6851-7; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Clouse SD, 2002, MOL CELL, V10, P973, DOI 10.1016/S1097-2765(02)00744-X; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; Fujioka S, 2003, ANNU REV PLANT BIOL, V54, P137, DOI 10.1146/annurev.arplant.54.031902.134921; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; Helliwell CA, 1999, PLANT PHYSIOL, V119, P507, DOI 10.1104/pp.119.2.507; Hong Z, 2003, PLANT CELL, V15, P2900, DOI 10.1105/tpc.014712; Hong Z, 2002, PLANT J, V32, P495, DOI 10.1046/j.1365-313X.2002.01438.x; Kim TW, 2004, PHYTOCHEMISTRY, V65, P679, DOI 10.1016/j.phytochem.2004.01.007; MAK AY, 1992, J AM CHEM SOC, V114, P8309, DOI 10.1021/ja00047a063; Mihovilovic MD, 2002, EUR J ORG CHEM, V2002, P3711; Montoya T, 2005, PLANT J, V42, P262, DOI 10.1111/j.1365-313X.2005.02376.x; Montoya T, 2002, PLANT CELL, V14, P3163, DOI 10.1105/tpc.006379; Mori M, 2002, PLANT PHYSIOL, V130, P1152, DOI 10.1104/pp.007179; Nomura T, 2001, PHYTOCHEMISTRY, V57, P171, DOI 10.1016/S0031-9422(00)00440-4; Peng P, 2003, J PLANT GROWTH REGUL, V22, P298, DOI 10.1007/s00344-003-0059-y; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Sakurai A, 1999, PLANT PHYSIOL BIOCH, V37, P351, DOI 10.1016/S0981-9428(99)80041-2; Shimada Y, 2003, PLANT PHYSIOL, V131, P287, DOI 10.1104/pp.013029; Shimada Y, 2001, PLANT PHYSIOL, V126, P770, DOI 10.1104/pp.126.2.770; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Yokota T, 1999, N COMP BIOC, V33, P277; YOKOTA T, 1990, AGR BIOL CHEM TOKYO, V54, P1107, DOI 10.1080/00021369.1990.10870046	31	147	168	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17873	17879		10.1074/jbc.M414592200	http://dx.doi.org/10.1074/jbc.M414592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710611	hybrid			2022-12-27	WOS:000228807200040
J	Owegi, MA; Carenbauer, AL; Wick, NM; Brown, JF; Terhune, KL; Bilbo, SA; Weaver, RS; Shircliff, R; Newcomb, N; Parra-Belky, KJ				Owegi, MA; Carenbauer, AL; Wick, NM; Brown, JF; Terhune, KL; Bilbo, SA; Weaver, RS; Shircliff, R; Newcomb, N; Parra-Belky, KJ			Mutational analysis of the stator subunit E of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; SITE-DIRECTED MUTAGENESIS; AMINO-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; B-SUBUNIT; CATALYTIC SUBUNIT; PERIPHERAL STALK; CROSS-LINKING; C-SUBUNIT	Subunit E is a component of the peripheral stalk(s) that couples membrane and peripheral subunits of the V-ATPase complex. In order to elucidate the function of subunit E, site-directed mutations were performed at the amino terminus and carboxyl terminus. Except for S78A and D233A/T202A, which exhibited V1Vo assembly defects, the function of subunit E was resistant to mutations. Most mutations complemented the growth phenotype of vma4 Delta mutants, including T6A and D233A, which only had 25% of the wild-type ATPase activity. Residues Ser-78 and Thr-202 were essential for V1Vo assembly and function. The mutation S78A destabilized subunit E and prevented assembly of V-1 subunits at the membranes. Mutant T202A membranes exhibited 2-fold increased V-max and about 2-fold less of V1Vo assembly; the mutation increased the specific activity of V1Vo by enhancing the k(cat) of the enzyme 4-fold. Reduced levels of V1Vo and V-o complexes at T202A membranes suggest that the balance between V1Vo and V-o was not perturbed; instead, cells adjusted the amount of assembled V-ATPase complexes in order to compensate for the enhanced activity. These results indicated communication between subunit E and the catalytic sites at the A(3)B(3) hexamer and suggest potential regulatory roles for the carboxyl end of subunit E. At the carboxyl end, alanine substitution of Asp-233 significantly reduced ATP hydrolysis, although the truncation 229 - 233 Delta and the point mutation K230A did not affect assembly and activity. The implication of these results for the topology and functions of subunit E within the V-ATPase complex are discussed.	Ball State Univ, Dept Chem, Muncie, IN 47306 USA	Ball State University	Parra-Belky, KJ (corresponding author), Ball State Univ, Dept Chem, Muncie, IN 47306 USA.	kparrabelky@bsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM064490] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R15GM064490] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Aviezer-Hagai K, 2000, BBA-BIOENERGETICS, V1459, P489, DOI 10.1016/S0005-2728(00)00188-2; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Drory O, 2004, EMBO REP, V5, P1148, DOI 10.1038/sj.embor.7400294; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Grabar TB, 2004, J BIOL CHEM, V279, P31205, DOI 10.1074/jbc.M404420200; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; Ikeda M, 2001, EUR J BIOCHEM, V268, P6097, DOI 10.1046/j.0014-2956.2001.ejb.2556.x; Imai-Senga Y, 2002, GENE, V289, P7, DOI 10.1016/S0378-1119(02)00542-5; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kawamura Y, 2001, EUR J BIOCHEM, V268, P2801, DOI 10.1046/j.1432-1327.2001.02139.x; Kawasaki-Nishi S, 2003, FEBS LETT, V545, P76, DOI 10.1016/S0014-5793(03)00396-X; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kim W, 1999, PLANT J, V17, P501, DOI 10.1046/j.1365-313X.1999.00402.x; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P46396, DOI 10.1074/jbc.M303924200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; SUPEK F, 1994, J BIOL CHEM, V269, P26479; Supekova L, 1996, J EXP BIOL, V199, P1147; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; Tavakoli N, 2001, PLANT J, V28, P51, DOI 10.1046/j.1365-313X.2001.01130.x; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200	77	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18393	18402		10.1074/jbc.M412567200	http://dx.doi.org/10.1074/jbc.M412567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15718227	hybrid			2022-12-27	WOS:000228807200101
J	Tsubouchi, T; Mineki, R; Taka, H; Kaga, N; Murayama, K; Nishiyama, C; Yamane, H; Kuzuyama, T; Nishiyama, M				Tsubouchi, T; Mineki, R; Taka, H; Kaga, N; Murayama, K; Nishiyama, C; Yamane, H; Kuzuyama, T; Nishiyama, M			Leader peptide-mediated transcriptional attenuation of lysine biosynthetic gene cluster in Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STRUCTURE; ALPHA-GALACTOSIDASE; SALMONELLA-TYPHIMURIUM; COMPARATIVE GENOMICS; ESCHERICHIA-COLI; TRANSPORT GENES; EXPRESSION; BACTERIA; ACID; AMINOADIPATE	The molecular mechanism for regulation of the genes involved in the biosynthesis of amino acids is poorly identified in Thermus thermophilus. In this study, we analyzed the transcriptional control of the major lysine biosynthetic gene cluster in T. thermophilus. S1 nuclease mapping revealed that the transcription, which is repressed by lysine, starts at 111 bp, upstream of the translational start codon, ATG, for the homocitrate synthase (hcs) gene. The 5'-leader region of 111 bp carries a sequence that can encode a short peptide of 14 amino acids with tandem-arranged lysine residues in its sequence. The nucleotide sequence of the region suggests that the transcript can form complicated secondary structures. Deletion of most of the 5'-leader region or mutation of the tandem lysine codons suppressed the transcriptional repression by lysine. Mutation of the tandem codons from lysine to glutamine resulted in glutamine-dependent repression of the gene connected downstream, indicating that the leader peptide mediated the transcriptional attenuation of the gene expression. This is the first report demonstrating the transcriptional regulation of amino acid biosynthesis in T. thermophilus.	Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan; Juntendo Univ, Sch Med, Atopy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Biomed Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan	University of Tokyo; Juntendo University; Juntendo University	Nishiyama, M (corresponding author), Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	umanis@mail.ecc.u-tokyo.ac.jp		Nishiyama, Makoto/0000-0001-8143-8052; Kuzuyama, Tomohisa/0000-0002-7221-5858; Tsubouchi, Taishi/0000-0002-1635-2604				BENNETT GN, 1976, P NATL ACAD SCI USA, V73, P2351, DOI 10.1073/pnas.73.7.2351; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broquist HP., 1971, METHODS ENZYMOL, V17B, P112; DAS A, 1983, P NATL ACAD SCI-BIOL, V80, P2879, DOI 10.1073/pnas.80.10.2879; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fridjonsson O, 1999, FEMS MICROBIOL LETT, V176, P147, DOI 10.1016/S0378-1097(99)00231-1; Fridjonsson O, 2002, J BACTERIOL, V184, P3385, DOI 10.1128/JB.184.12.3385-3391.2002; Fridjonsson O, 2001, APPL ENVIRON MICROB, V67, P4192, DOI 10.1128/AEM.67.9.4192-4198.2001; Fridjonsson O, 2000, EXTREMOPHILES, V4, P23, DOI 10.1007/s007920050134; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Grundy FJ, 2003, P NATL ACAD SCI USA, V100, P12057, DOI 10.1073/pnas.2133705100; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; Hancock WS, 2002, PROTEOMICS, V2, P352, DOI 10.1002/1615-9861(200204)2:4<352::AID-PROT352>3.0.CO;2-U; HIDAKA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1338, DOI 10.1271/bbb.58.1338; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; Kobashi N, 1999, J BACTERIOL, V181, P1713, DOI 10.1128/JB.181.6.1713-1718.1999; Kosuge T, 1998, FEMS MICROBIOL LETT, V169, P361, DOI 10.1016/S0378-1097(98)00502-3; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; Landick R, 1996, ESCHERICHIA COLI SAL, P1263; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Miyazaki J, 2003, J BIOL CHEM, V278, P1864, DOI 10.1074/jbc.M205133200; Miyazaki J, 2002, FEBS LETT, V512, P269, DOI 10.1016/S0014-5793(02)02290-1; Miyazaki J, 2001, J BACTERIOL, V183, P5067, DOI 10.1128/JB.183.17.5067-5073.2001; Miyazaki T, 2004, MICROBIOL-SGM, V150, P2327, DOI 10.1099/mic.0.27037-0; Moll I, 2002, MOL MICROBIOL, V43, P239, DOI 10.1046/j.1365-2958.2002.02739.x; Nishida H, 1999, GENOME RES, V9, P1175, DOI 10.1101/gr.9.12.1175; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; Rodionov DA, 2003, NUCLEIC ACIDS RES, V31, P6748, DOI 10.1093/nar/gkg900; Sambrook J., 2001, MOL CLONING LAB MANU; Sudarsan N, 2003, GENE DEV, V17, P2688, DOI 10.1101/gad.1140003; Vitreschak AG, 2004, FEMS MICROBIOL LETT, V234, P357, DOI 10.1016/j.femsle.2004.04.005; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Vitreschak AG, 2003, RNA, V9, P1084, DOI 10.1261/rna.5710303; Vitreschak AG, 2002, NUCLEIC ACIDS RES, V30, P3141, DOI 10.1093/nar/gkf433; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Wulandari AP, 2002, FEBS LETT, V522, P35, DOI 10.1016/S0014-5793(02)02877-6; Yanofsky C, 2004, TRENDS GENET, V20, P367, DOI 10.1016/j.tig.2004.06.007	40	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18511	18516		10.1074/jbc.M414456200	http://dx.doi.org/10.1074/jbc.M414456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753090	hybrid			2022-12-27	WOS:000228807200115
J	von Arnim, CAF; Kinoshita, A; Peltan, ID; Tangredi, MM; Herl, L; Lee, BM; Spoelgen, R; Hshieh, TT; Ranganathan, S; Battey, FD; Liu, CX; Bacskai, BJ; Sever, S; Irizarry, MC; Strickland, DK; Hyman, BT				von Arnim, CAF; Kinoshita, A; Peltan, ID; Tangredi, MM; Herl, L; Lee, BM; Spoelgen, R; Hshieh, TT; Ranganathan, S; Battey, FD; Liu, CX; Bacskai, BJ; Sever, S; Irizarry, MC; Strickland, DK; Hyman, BT			The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; LIFETIME IMAGING MICROSCOPY; RESONANCE ENERGY-TRANSFER; ALZHEIMERS-DISEASE; LIPID RAFTS; CLEAVING ENZYME; TYROSINE PHOSPHORYLATION; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; ASPARTYL PROTEASE	BACE is a transmembrane protease with beta-secretase activity that cleaves the amyloid precursor protein (APP). After BACE cleavage, APP becomes a substrate for gamma-secretase, leading to release of amyloid-beta peptide (A beta), which accumulates in senile plaques in Alzheimer disease. APP and BACE are co-internalized from the cell surface to early endosomes. APP is also known to interact at the cell surface and be internalized by the low density lipoprotein receptor-related protein (LRP), a multifunctional endocytic and signaling receptor. Using a new fluorescence resonance energy transfer ( FRET)based assay of protein proximity, fluorescence lifetime imaging (FLIM), and co-immunoprecipitation we demonstrate that the light chain of LRP interacts with BACE on the cell surface in association with lipid rafts. Surprisingly, the BACE-LRP interaction leads to an increase in LRP C-terminal fragment, release of secreted LRP in the media and subsequent release of the LRP intracellular domain from the membrane. Taken together, these data suggest that there is a close interaction between BACE and LRP on the cell surface, and that LRP is a novel BACE substrate.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Alzheimer Unit,Alzheimer Dis Res Lab, Charlestown, MA 02129 USA; Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Alzheimer Unit,Alzheimer Dis Res Lab, 114 16th St 2009, Charlestown, MA 02129 USA.	bhyman@partners.org	Bacskai, Brian/AAE-9583-2021; Peltan, Ithan/J-1853-2019	Peltan, Ithan/0000-0003-1730-234X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012406, P01AG015379, P50AG005134, R37AG012406] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NIA NIH HHS [AG12406, P50AG05134, AG15379] Funding Source: Medline; NIBIB NIH HHS [EB00768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Abbenante G, 2000, BIOCHEM BIOPH RES CO, V268, P133, DOI 10.1006/bbrc.2000.2098; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 2003, J NEUROSCI, V23, P4560; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Li YH, 2001, MOL NEUROBIOL, V23, P53; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Liscum L, 2002, J LIPID RES, V43, P1708, DOI 10.1194/jlr.M200179-JLR200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Orlando LR, 2002, NEUROPHARMACOLOGY, V43, P161, DOI 10.1016/S0028-3908(02)00113-2; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2004, J CELL SCI, V117, P5437, DOI 10.1242/jcs.01422; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	50	216	220	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17777	17785		10.1074/jbc.M414248200	http://dx.doi.org/10.1074/jbc.M414248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749709	hybrid			2022-12-27	WOS:000228807200028
J	Xian-Cheng, J; Li, ZQ; Liu, RJ; Yang, XP; Pan, MH; Lagrost, L; Fisher, EA; Williams, KJ				Xian-Cheng, J; Li, ZQ; Liu, RJ; Yang, XP; Pan, MH; Lagrost, L; Fisher, EA; Williams, KJ			Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	75th Annual Scientific Session of the American-Heart-Association	NOV 17-20, 2002	CHICAGO, IL	Amer Heart Assoc			LOW-DENSITY LIPOPROTEINS; LDL RECEPTOR; LIPID-PEROXIDATION; TRANSGENIC MICE; ATHEROSCLEROSIS; CELLS; VLDL; HYPERLIPIDEMIA; ACCUMULATION; ANTIOXIDANTS	Genetic deficiency of the plasma phospholipid transfer protein (PLTP) in mice unexpectedly causes a substantial impairment in liver secretion of apolipoprotein-B (apoB), the major protein of atherogenic lipoproteins. To explore the mechanism, we examined the three known pathways for hepatic apoB secretory control, namely endoplasmic reticulum (ER)/proteasome-associated degradation (ERAD), post-ER pre-secretory proteolysis (PERPP), and receptor-mediated degradation, also known as re-uptake. First, we found that ERAD and cell surface re-uptake were not active in PLTP-null hepatocytes. Moreover, ER-to-Golgi blockade by brefeldin A, which enhances ERAD, equalized total apoB recovery from PLTP-null and wildtype cells, indicating that the relevant process occurs post-ER. Second, because PERPP can be stimulated by intracellular reactive oxygen species (ROS), we examined hepatic redox status. Although we found previously that PLTP-null mice exhibit elevated plasma concentrations of vitamin E, a lipid anti-oxidant, we now discovered that their livers contain significantly less vitamin E and significantly more lipid peroxides than do livers of wild-type mice. Third, to establish a causal connection, the addition of vitamin E or treatment with an inhibitor of intracellular iron-dependent peroxidation, desferrioxamine, abolished the elevation in cellular ROS as well as the defect in apoB secretion from PLTP-null hepatocytes. Overall, we conclude that PLTP deficiency decreases liver vitamin E content, increases hepatic oxidant tone, and substantially enhances ROS-dependent destruction of newly synthesized apoB via a post-ER process. These findings are likely to be broadly relevant to hepatic apoB secretory control in vivo.	Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; NYU, Sch Med, New York, NY 10016 USA; INSERM, U498, F-21079 Dijon, France; Thomas Jefferson Univ, Jefferson Med Coll, Dorrance H Hamilton Res Labs, Dept Med,Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; New York University; Institut National de la Sante et de la Recherche Medicale (Inserm); Jefferson University	Williams, KJ (corresponding author), Suny Downstate Med Ctr, 450 Clarkson Ave Rm 2-31, Brooklyn, NY 11203 USA.	K_Williams@mail.jci.tju.edu	Fisher, Edward/ABE-7469-2020	Williams, Kevin Jon/0000-0002-0000-2159; Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069817, P50HL056984, R01HL058541, R01HL064735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-69817, HL-64735, HL56984, HL58541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; Colhoun HM, 2002, DIABETES, V51, P3300, DOI 10.2337/diabetes.51.11.3300; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; Krauss RM, 2004, J CLIN INVEST, V113, P1253, DOI 10.1172/JCI200421637; Larsson SL, 2004, J BIOL CHEM, V279, P831, DOI 10.1074/jbc.M303057200; Lie J, 2002, J LIPID RES, V43, P1875, DOI 10.1194/jlr.M200166-JLR200; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Nassir F, 2004, J LIPID RES, V45, P1649, DOI 10.1194/jlr.M300505-JLR200; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; Pan MH, 2004, J CLIN INVEST, V113, P1277, DOI 10.1172/JCI200419197; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; SORCITHOMAS M, 1992, J LIPID RES, V33, P1147; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1986, J LIPID RES, V27, P359; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; van Haperen R, 2002, J BIOL CHEM, V277, P48938, DOI 10.1074/jbc.M209128200; Williams KJ, 2000, ARTERIOSCL THROM VAS, V20, P1033, DOI 10.1161/01.ATV.20.4.1033; Williams KJ, 2005, CURR OPIN CLIN NUTR, V8, P139, DOI 10.1097/00075197-200503000-00006; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; Willoughby JJ, 2001, DEV BIOL, V235, P237; Yamaguchi J, 2003, J BIOL CHEM, V278, P42643, DOI 10.1074/jbc.M306920200	35	82	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18336	18340		10.1074/jbc.M500007200	http://dx.doi.org/10.1074/jbc.M500007200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	922AH	15734742	hybrid			2022-12-27	WOS:000228807200093
J	Debidda, M; Wang, L; Zang, H; Poli, V; Zheng, Y				Debidda, M; Wang, L; Zang, H; Poli, V; Zheng, Y			A role of STAT3 in rho GTPase-regulated cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; FAMILY GTPASES; IL-6 RESPONSE; ACTIVATION; BINDING; PATHWAYS; PROTEIN; GROWTH; CDC42; TRANSCRIPTION	Rho family GTPases and STAT3 act as mediators of cytokine and growth factor signaling in a variety of cellular functions involved in inflammation, tumorigenesis, and development. In the course of searching for their functional connections, we found by using STAT3 knock-out mouse embryonic fibroblasts that RhoA, Rac1, and Cdc42 could cause nonspecific activation of STAT3 promoter-driven luciferase reporter in the absence of STAT3, raising concerns to a body of literature where STAT3 was associated with Rho GTPases based on the reporter system. We also found that although active RhoA, Rac1, and Cdc42 could all mediate Ser-727 and Tyr-705 phosphorylation and nuclear translocation of STAT3, the Rho GTPases were able to induce STAT3 activation independently of the interleukin-6 autocrine pathway, and active RhoA, Rac1, or Cdc42 could not form a stable complex with STAT3 as previously suggested, indicating an unappreciated mechanism of STAT3 activation by the Rho GTPases. The RhoA-induced STAT3 activation partly depended on Rho-associated kinase (ROK) and involved multiple effector signals as revealed by the examination of effector domain mutants of RhoA. Genetic deletion of STAT3 led to a loss of response to RhoA in myosin light chain phosphorylation and actin stress fiber induction but sensitized the cells to RhoA or ROK-stimulated cell migration. STAT3 was required for the RhoA-induced NF-kappa B and cyclin D1 transcription and was involved in NF-kappa B nuclear translocation. Furthermore, loss of STAT3 expression inhibited RhoA-promoted cell proliferation and blocked RhoA or ROK induced anchorage-independent growth. These phenotypic changes in STAT3(-/-) cells could be rescued by reconstituting STAT3 gene. Our studies carried out in STAT3 null cells demonstrate unambiguously that STAT3 represents an essential effector pathway of Rho GTPases in regulating multiple cellular functions including actin cytoskeleton reorganization, cell migration, gene activation, and proliferation.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Turin	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015; Poli, Valeria/A-9215-2012	Zheng, Yi/0000-0001-7089-6074; Poli, Valeria/0000-0002-3739-3966	NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sartor CI, 1997, CANCER RES, V57, P978; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sivko GS, 2004, J CELL BIOCHEM, V93, P844, DOI 10.1002/jcb.20224; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VAN AL, 1997, GENE DEV, V11, P2295; Wang L, 2004, BIOCHEMISTRY-US, V43, P14584, DOI 10.1021/bi048574u	39	112	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17275	17285		10.1074/jbc.M413187200	http://dx.doi.org/10.1074/jbc.M413187200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15705584	hybrid			2022-12-27	WOS:000228615500091
J	He, QY; Shu, HJ; Cheng, P; Chen, S; Wang, LX; Liu, Y				He, QY; Shu, HJ; Cheng, P; Chen, S; Wang, LX; Liu, Y			Light-independent phosphorylation of WHITE COLLAR-1 regulates its function in the Neurospora circadian negative feedback loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOCK PROTEIN FREQUENCY; KINASE-I-EPSILON; BLUE-LIGHT; DEPENDENT PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PERIOD PROTEIN; GENE-FREQUENCY; DOUBLE-TIME; CRASSA; TRANSCRIPTION	Phosphorylation is a major regulatory mechanism controlling circadian clocks. In the Neurospora circadian clock, the PER-ARNT-SIM ( PAS) domain-containing transcription factor, WHITE COLLAR (WC)-1, acts both as the blue light photoreceptor of the clock and as a positive element in the circadian negative feedback loop in constant darkness, by activating the transcription of the frequency (frq) gene. To understand the role of WC-1 phosphorylation, five in vivo WC-1 phosphorylation sites, located immediately downstream of the WC-1 zinc finger DNA binding domain, were identified by tandem mass spectrometry using biochemically purified endogenous WC-1 protein. Mutations of these phosphorylation sites suggest that they are major WC-1 phosphorylation sites under constant conditions but are not responsible for the light-induced hyperphosphorylation of WC-1. Although phosphorylation of these sites does not affect the light function of WC-1, strains carrying mutations of these sites show short period, low amplitude, or arrhythmic conidiation rhythms in constant darkness. Furthermore, normal or slightly higher levels of frq mRNA and FRQ proteins were observed in a mutant strain containing mutations of all five sites despite its low WC-1 levels. Together, these data suggest that phosphorylation of these sites negatively regulates the function of WC-1 in the circadian negative feedback loop and is important for the function of the Neurospora circadian clock.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, Y (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Rm L4-235,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Yi.Liu@UTsouthwestern.edu	He, qiyang/AAT-5826-2021; He, qiyang/GQA-4070-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062591, R01GM068496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068496, GM062591] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Arpaia G, 1999, MOL GEN GENET, V262, P314, DOI 10.1007/s004380051089; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Cheng P, 2005, GENE DEV, V19, P234, DOI 10.1101/gad.1266805; Cheng P, 2003, P NATL ACAD SCI USA, V100, P5938, DOI 10.1073/pnas.1031791100; Cheng P, 2003, J BIOL CHEM, V278, P3801, DOI 10.1074/jbc.M209592200; Cheng P, 2002, MOL CELL BIOL, V22, P517, DOI 10.1128/MCB.22.2.517-524.2002; Cheng P, 2001, P NATL ACAD SCI USA, V98, P7408, DOI 10.1073/pnas.121170298; Cheng P, 2001, EMBO J, V20, P101, DOI 10.1093/emboj/20.1.101; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Collett MA, 2002, GENETICS, V160, P149; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Froehlich AC, 2003, P NATL ACAD SCI USA, V100, P5914, DOI 10.1073/pnas.1030057100; Froehlich AC, 2002, SCIENCE, V297, P815, DOI 10.1126/science.1073681; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gorl M, 2001, EMBO J, V20, P7074, DOI 10.1093/emboj/20.24.7074; He Q, 2003, EMBO J, V22, P4421, DOI 10.1093/emboj/cdg425; He QY, 2002, SCIENCE, V297, P840, DOI 10.1126/science.1072795; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Lee K, 2000, SCIENCE, V289, P107, DOI 10.1126/science.289.5476.107; Lee K, 2003, GENETICS, V163, P103; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Linden H, 1997, FUNGAL GENET BIOL, V22, P141, DOI 10.1006/fgbi.1997.1013; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; Liu Y, 2000, P NATL ACAD SCI USA, V97, P234, DOI 10.1073/pnas.97.1.234; Liu Y, 2003, CELL MOL LIFE SCI, V60, P2131, DOI 10.1007/s00018-003-3109-5; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; Liu Y, 2003, J BIOL RHYTHM, V18, P195, DOI 10.1177/0748730403018003002; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Merrow M, 2001, EMBO J, V20, P307, DOI 10.1093/emboj/20.3.307; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Roenneberg T, 2000, METHOD ENZYMOL, V305, P104; Sasaki T, 2002, J BIOL CHEM, V277, P36032, DOI 10.1074/jbc.M206674200; Schwerdtfeger C, 2000, EUR J BIOCHEM, V267, P414, DOI 10.1046/j.1432-1327.2000.01016.x; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; SHU H, 2003, AFCS RES REPORTS; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Yang YH, 2004, GENE DEV, V18, P255, DOI 10.1101/gad.1152604; Yang YH, 2003, MOL CELL BIOL, V23, P6221, DOI 10.1128/MCB.23.17.6221-6228.2003; Yang YH, 2002, GENE DEV, V16, P994, DOI 10.1101/gad.965102; Yang YH, 2001, J BIOL CHEM, V276, P41064, DOI 10.1074/jbc.M106905200; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	53	83	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17526	17532		10.1074/jbc.M414010200	http://dx.doi.org/10.1074/jbc.M414010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731099	hybrid			2022-12-27	WOS:000228615500121
J	Taha, TA; Kitatani, K; Bielawski, J; Cho, W; Hannun, YA; Obeid, LM				Taha, TA; Kitatani, K; Bielawski, J; Cho, W; Hannun, YA; Obeid, LM			Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; CELL-DEATH; TNF-ALPHA; LYSOSOMAL PERMEABILIZATION; PROTEASE PATHWAYS; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; RELEASE; CASPASE	Sphingosine kinase-1 (SK1) has emerged as a key component of cytokine responses, including roles in apoptosis, yet the specific mechanisms by which cytokines regulate SK1 in the apoptotic responses have not been studied. In this study, we show that prolonged treatment of MCF-7 cells with tumor necrosis factor (TNF) induces a dose- and time-dependent decrease in SK1 protein. Inhibition of the upstream caspase 8 by IETD significantly rescued TNF effects on SK1, yet the caspase 7 inhibitor DEVD failed to have any effect, suggesting that the decline in SK1 occurs downstream of the initiator caspase but upstream of the effector caspase. In addition to caspase activation, TNF caused disruption of lysosomes with relocation of the cysteine protease cathepsin B into the cytosol. Down-regulation of cathepsin B using small interfering RNA significantly restored SK1 levels following exposure to TNF, suggesting that SK1 loss was dependent on cathepsin B activity. The regulation of SK1 by the lysosomal protease was further supported by the colocalization of SK1 with the lysosome and cathepsin B in cells and the loss of the colocalization following exposure to TNF. The ability of cathepsin B to regulate SK1 was further corroborated by an in vitro approach where recombinant cathepsin B cleaved SK1 at multiple sites to produce several cleavage fragments. Therefore, these studies show that SK1 down-regulation by TNF is dependent on the "lysosomal pathway" of apoptosis and specifically on cathepsin B, which functions as an SK1 protease in cells.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847	NCI NIH HHS [P01 CA097132] Funding Source: Medline; NIDDK NIH HHS [DK59340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	21	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17196	17202		10.1074/jbc.M413744200	http://dx.doi.org/10.1074/jbc.M413744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710602	hybrid			2022-12-27	WOS:000228615500081
J	Ouyang, K; Wu, CH; Cheng, HP				Ouyang, K; Wu, CH; Cheng, HP			Ca2+-induced Ca2+ release in sensory neurons - Low gain amplification confers intrinsic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; RYANODINE RECEPTORS; CALCIUM-RELEASE; LOCAL-CONTROL; MUSCLE; SPARKS; ADAPTATION; MODULATION; CHANNEL	Ca2+-induced Ca2+ release (CICR) is a ubiquitous mechanism by which Ca2+ release from the endoplasmic reticulum amplifies the trigger Ca2+ entry and generates propagating Ca2+ waves. To elucidate the mechanisms that control this positive feedback, we investigated the spatial and temporal kinetics and measured the gain function of CICR in small sensory neurons from mammalian dorsal root ganglions ( DRGs). We found that subsurface Ca2+ release units (CRUs) are under tight local control by Ca2+ entry, whereas medullar CRUs as a "common pool" system are recruited by inwardly propagating CICR. Active CRUs often displayed repetitive Ca2+ sparks, conferring the ability to encode a "memory" of neuronal activity well beyond the duration of an action potential. Store Ca2+ reserve was able to support all CRUs each to fire similar to 15 sparks, excluding use-dependent inactivation or store depletion as the major CICR termination mechanism. Importantly, CICR in DRG neurons operated in a low gain, linear regime ( gain = 0.54), which conferred intrinsic stability to CICR. Combined with high Ca2+ current density ( - 156 pA/pF at - 10 mV), such a low gain CICR system generated large intracellular Ca2+ transients without jeopardizing the stability. These findings provide the first demonstration that CICR operating in a low gain regime can be harnessed to provide a robust and graded amplification of Ca2+ signal in the absence of counteracting inhibitory mechanism.	Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Natl Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China; NIA, Lab Cardiovasc Sci, NIH, Baltimore, MD 21224 USA	Peking University; Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Cheng, HP (corresponding author), Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.	chengp@grc.nia.nih.gov	Heping, Cheng/AAE-2680-2019; cheng, heping/A-7299-2011; ouyang, kunfu/B-3073-2011	Heping, Cheng/0000-0002-9604-6702; ouyang, kunfu/0000-0003-0292-375X				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bers DM, 2001, EXCITATION CONTRACTI; Brochet DXP, 2005, P NATL ACAD SCI USA, V102, P3099, DOI 10.1073/pnas.0500059102; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gyorke I, 1998, BIOPHYS J, V75, P2801, DOI 10.1016/S0006-3495(98)77723-9; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hua SY, 2000, CELL CALCIUM, V27, P195, DOI 10.1054/ceca.2000.0114; Lokuta AJ, 2002, FEBS LETT, V511, P90, DOI 10.1016/S0014-5793(01)03312-9; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; Sham JSK, 1998, P NATL ACAD SCI USA, V95, P15096, DOI 10.1073/pnas.95.25.15096; Shannon TR, 2003, CIRC RES, V93, P40, DOI 10.1161/01.RES.0000079967.11815.19; Song LS, 1998, J PHYSIOL-LONDON, V512, P677, DOI 10.1111/j.1469-7793.1998.677bd.x; Stern MD, 2004, CELL CALCIUM, V35, P591, DOI 10.1016/j.ceca.2004.01.013; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Szentesi P, 2004, CIRC RES, V95, P807, DOI 10.1161/01.RES.0000146029.80463.7d; Trafford AW, 2000, J PHYSIOL-LONDON, V522, P259, DOI 10.1111/j.1469-7793.2000.t01-2-00259.x; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang SQ, 2004, CIRC RES, V94, P1011, DOI 10.1161/01.RES.0000125883.68447.A1; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200	32	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15898	15902		10.1074/jbc.C500026200	http://dx.doi.org/10.1074/jbc.C500026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15749692	hybrid, Green Submitted			2022-12-27	WOS:000228444800055
J	Toledo, MS; Suzuki, E; Handa, K; Hakomori, S				Toledo, MS; Suzuki, E; Handa, K; Hakomori, S			Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; CELL-ADHESION; SIGNAL-TRANSDUCTION; GM3 GANGLIOSIDE; GLUCOSYLCERAMIDE SYNTHASE; IMMUNOLOGICAL SYNAPSE; MEDIATED MODULATION; CAVEOLAE MEMBRANE; PHOSPHORYLATION; GLYCOSYLATION	The functional interaction ("cross-talk") of integrins with growth factor receptors has become increasingly clear as a basic mechanism in cell biology, defining cell growth, adhesion, and motility. However, no studies have addressed the microdomains in which such interaction takes place nor the effect of gangliosides and tetraspanins (TSPs) on such interaction. Growth of human embryonal WI38 fibroblasts is highly dependent on fibroblast growth factor (FGF) and its receptor ( FGFR), stably associated with ganglioside GM3 and TSPs CD9 and CD81 in the ganglioside-enriched microdomain. Adhesion and motility of these cells are mediated by laminin-5 ((LN5) and fibronectin (FN) through alpha 3 beta 1 and alpha 5 beta 1 integrin receptors, respectively. When WI38 cells or its transformant VA13 cells were adhered to LN5 or FN, alpha 3 beta 1 or alpha 5 beta 1 were stimulated, giving rise to signaling to activate FGFR through tyrosine phosphorylation and inducing cell proliferation under serum-free conditions without FGF addition. Types and intensity of signaling during the time course differed significantly depending on the type of integrin stimulated (alpha 3 beta 1 versus alpha 5 beta 1), and on cell type ( WI38 versus VA13). Such effect of cross-talk between integrins and FGFR was influenced strongly by the change of GM3 and TSPs. (i) GM3 depletion by P4 caused enhanced tyrosine phosphorylation of FGFR and Akt followed by MAPK activation, without significant change of ceramide level. GM3 depletion also caused enhanced co-immunoprecipitation of FGFR with alpha 3/alpha 5/beta 1 and of these integrins with CD9/CD81. (ii) LN5- or FN-dependent proliferation of both WI38 and VA13 was strongly enhanced by GM3 depletion and by CD9/ CD81 knockdown by siRNA. Thus, integrin-FGFR crosstalk is strongly influenced by GM3 and/or TSPs within the ganglioside-enriched microdomain.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu	de Toledo, Marcos Sergio/M-7185-2019; Toledo, Marcos S/B-6243-2008; Suzuki, Erika/B-3456-2008	de Toledo, Marcos Sergio/0000-0002-6605-0874; Suzuki, Erika/0000-0002-4010-8716	NCI NIH HHS [R01 CA80054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bektas M, 2003, ANAL BIOCHEM, V320, P259, DOI 10.1016/S0003-2697(03)00388-9; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COHEN S, 1980, J BIOL CHEM, V255, P4834; DITTMER JC, 1964, J LIPID RES, V5, P126; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HANNUN YA, 1997, SPHINGOLIPID MEDIATE, P188; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Selzner M, 2001, CANCER RES, V61, P1233; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Signorelli P, 2002, METHOD ENZYMOL, V345, P275; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	54	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16227	16234		10.1074/jbc.M413713200	http://dx.doi.org/10.1074/jbc.M413713200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710618	hybrid			2022-12-27	WOS:000228444800092
J	Wang, L; Li, G; Sugita, S				Wang, L; Li, G; Sugita, S			A central kinase domain of type I phosphatidylinositol phosphate kinases is sufficient to prime exocytosis - Isoform specificity and its underlying mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRACKED PC12 CELLS; PLASMA-MEMBRANE; CA2+-ACTIVATED SECRETION; VESICLE EXOCYTOSIS; CA2+ SENSOR; PROTEIN; FAMILY; 5-KINASES; BINDING; CLONING	Exocytosis, a critical process for neuronal communication and hormonal regulation, involves several distinct steps including MgATP-dependent priming ( which involves the synthesis of phosphatidylinositol 4,5-bisphosphate). Type I phosphatidylinositol phosphate kinases (PIPKIs) were purified biochemically as a priming factor. PIPKI consists of three domains: the N-terminal region, the central kinase domain, and the C-terminal region. Three isoforms (alpha, beta, and gamma) of PIPKI have been identified, and each is alternatively spliced at the C-terminal region. In the present study, we conducted a structure/function analysis of PIPKIs in the priming of exocytosis, and we found that recombinant PIPKI alpha and PIPKI gamma had priming activity. However, an unexpected finding of these results was that PIPKI beta did not prime exocytosis. The N- or C-terminal region of PIPKI alpha and PIPKI gamma was not required for priming, which indicates that the central kinase domain is sufficient for this process. Alternative splicing in each isoform did not affect the isoform specificity in priming. Priming activity by isoforms is strongly correlated with their phosphatidylinositol phosphate kinase activity because PIPKI alpha and PIPKI gamma had higher kinase activity than PIPKI beta. These results suggest that PIPKI alpha and PIPKI gamma are the critical priming factors for exocytosis; it also suggests that the levels of phosphatidylinositol phosphate kinase activity in producing phosphatidylinositol 4,5-bisphosphate specify the function of PIPKI isoforms in priming.	Univ Hlth Network, Div Cellular & Mol Biol, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Sugita, S (corresponding author), Univ Hlth Network, Div Cellular & Mol Biol, Toronto Western Res Inst, MC 11-432,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	ssugita@uhnres.utoronto.ca		Sugita, Shuzo/0000-0002-9182-873X; Wang, Li/0000-0002-3460-2080				Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Barbieri MA, 2001, J BIOL CHEM, V276, P47212, DOI 10.1074/jbc.C100490200; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Grishanin RN, 2002, J BIOL CHEM, V277, P22025, DOI 10.1074/jbc.M201614200; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Holz RW, 2002, ANN NY ACAD SCI, V971, P232, DOI 10.1111/j.1749-6632.2002.tb04467.x; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1	29	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16522	16527		10.1074/jbc.M413263200	http://dx.doi.org/10.1074/jbc.M413263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728183	hybrid			2022-12-27	WOS:000228444800127
J	Kim, YS; Kim, JM; Jung, DL; Kang, JE; Lee, S; Kim, JS; Seol, W; Shin, HC; Kwon, HS; Van Lint, C; Hernandez, N; Hur, MW				Kim, YS; Kim, JM; Jung, DL; Kang, JE; Lee, S; Kim, JS; Seol, W; Shin, HC; Kwon, HS; Van Lint, C; Hernandez, N; Hur, MW			Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING PROTEINS; LONG TERMINAL REPEAT; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; HUMAN-CELLS; TAT; RNA; PROMOTER; RECEPTOR	Tat activates transcription by interacting with Sp1, NF-kappa B, positive transcription elongation factor b, and trans-activator-responsive element (TAR). Tat and Sp1 play major roles in transcription by protein-protein interactions at human immunodeficiency virus, type 1 (HIV-1) long terminal repeat. Sp1 activates transcription by interacting with cyclin T1 in the absence of Tat. To disrupt the transcription activation by Tat and Sp1, we fused Sp1-inhibiting polypeptides, zinc finger polypeptide, and the TAR-binding mutant Tat (TatdMt) together. A designed or natural zinc finger and Tat mutant fusion was used to target the fusion to the key regulatory sites (GC box and TAR) on the long terminal repeat and nascent short transcripts to disrupt the molecular interaction that normally result in robust transcription. The designed zinc finger and TatdMt fusions were targeted to the TAR, and they potently repressed both transcription and replication of HIV-1. The Sp1-yinhibiting POZ domain, TatdMt, and zinc fingers are key functional domains important in repression of transcription and replication. The designed artificial zinc fingers were targeted to the high affinity Sp1-binding site, and by being fused with TatdMt and POZ domain, they strongly block both Sp1-cyclin T1-dependent transcription and Tat-dependent transcription, even in the presence of excess expressed Tat.	Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Inje Univ, Indang Inst Mol Biol, Lab Retroviruses & Gene Therapy, Seoul 100032, South Korea; Inje Univ, Dept Med Lab Sci, Seoul 100032, South Korea; BK21 Project Med Sci, Seoul 120752, South Korea; VectorCore A Inc, Taejon 305345, South Korea; Toolgen Inc, Taejon 305390, South Korea; Univ Libre Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Yonsei University; Inje University; Inje University; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol, 134 ShinChonDong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr	KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306; Hernandez, Nouria/0000-0003-1465-4585; Hur, Man-Wook/0000-0002-3416-1334				Amado RG, 1999, HUM GENE THER, V10, P2255, DOI 10.1089/10430349950017239; Bae KH, 2003, NAT BIOTECHNOL, V21, P275, DOI 10.1038/nbt796; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Gea-Banacloche JC, 1999, AIDS, V13, pS25; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kim YS, 1996, J NEUROSCI RES, V43, P652, DOI 10.1002/(SICI)1097-4547(19960315)43:6<652::AID-JNR2>3.0.CO;2-D; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lee DK, 2003, CURR TOP MED CHEM, V3, P645, DOI 10.2174/1568026033452384; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 2004, J BIOL CHEM, V279, P14509, DOI 10.1074/jbc.M400349200; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200	31	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21545	21552		10.1074/jbc.m414136200	http://dx.doi.org/10.1074/jbc.m414136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15743774	Green Accepted, hybrid			2022-12-27	WOS:000229438800077
J	Bogan, MJ; Agnes, GR; Pio, F; Cornell, RB				Bogan, MJ; Agnes, GR; Pio, F; Cornell, RB			Interdomain and membrane interactions of CTP : phosphocholine cytidylyltransferase revealed via limited proteolysis and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; BINDING DOMAIN; IDENTIFICATION; ENZYME; ALPHA; PEPTIDES; HELIX	CTP:phosphocholine cytidylyltransferase (CCT) is a multi-domain enzyme that regulates phosphatidylcholine synthesis. It converts to an active form upon binding cell membranes, and interdomain dissociations have been hypothesized to accompany this process. To identify these interdomain and membrane interactions, the tertiary structures of three forms of CCT alpha were probed by monitoring accessibility to proteases. Time-limited digestion with chymotrypsin or arginine C of soluble CCT alpha (CCTsol), phospholipid vesicle-bound CCT (CCTmem), and a soluble constitutively active CCT truncated at amino acid 236 generated complex mixtures of peptides that were resolved and identified by gel electrophoresis/immunoblotting and by matrix-assisted laser desorption/ionization-mass spectrometry, with or without coupling to capillary liquid chromatography. Identification of cleavage sites enabled assembly of peptide bond accessibility maps for each CCT form. Our results reveal a similar to 80-residue core within the catalytic domain (domain C) as the most inaccessible region in all three forms and the C- terminal phosphorylation domain as the most accessible. Membrane binding has little effect on the protease accessibility of these domains. To map the protease sites onto the catalytic domain, its three-dimensional structure was modeled from the atomic coordinates of glycerolphosphate cytidylyltransferase (Protein Data Bank code 1COZ). The protease inaccessibility of most sites in domain C could be explained by burial or location within secondary structural elements. The accessibility of the N-terminal domain (domain N) was enhanced upon membrane binding. Residues Phe(234)-Leu(303) were inaccessible in CCTmem, suggesting burial in the membrane. Surprisingly, residues Leu(274)-Leu(303) of this domain were also inaccessible in CCTsol. We propose that this region is buried by interdomain contacts with domain N in CCTsol. Membrane binding and burial of domain M in the lipid bilayer may disrupt this interaction, leading to increased exposure of sites in domain N.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University; Simon Fraser University	Cornell, RB (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	cornell@sfu.ca	Bogan, Mike/I-6962-2012	Bogan, Mike/0000-0001-9318-3333; pio, frederic/0000-0003-2050-847X				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Bujnicki JM, 2001, PROTEIN SCI, V10, P352, DOI 10.1110/ps.40501; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; Helmink BA, 2003, BIOCHEMISTRY-US, V42, P5043, DOI 10.1021/bi027431+; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KEIL B, 1992, SPECIFICIYT PROTEOLY; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Knochenmuss R, 2003, CHEM REV, V103, P441, DOI 10.1021/cr0103773; Kratzer R, 1998, ELECTROPHORESIS, V19, P1910, DOI 10.1002/elps.1150191109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Pattridge KA, 2003, J BIOL CHEM, V278, P51863, DOI 10.1074/jbc.M306174200; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; Taneva S, 2003, BIOCHEMISTRY-US, V42, P11768, DOI 10.1021/bi035234k; van Meer G, 2004, CURR OPIN CELL BIOL, V16, P373, DOI 10.1016/j.ceb.2004.06.004; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; Wall DB, 2002, ELECTROPHORESIS, V23, P3193, DOI 10.1002/1522-2683(200209)23:18<3193::AID-ELPS3193>3.0.CO;2-Y; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Xie MT, 2004, J BIOL CHEM, V279, P28817, DOI 10.1074/jbc.M403311200	38	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19613	19624		10.1074/jbc.M414028200	http://dx.doi.org/10.1074/jbc.M414028200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15713672	hybrid			2022-12-27	WOS:000229113700025
J	Covarrubias, AS; Larsson, AM; Hogbom, M; Lindberg, J; Bergfors, T; Bjorkelid, C; Mowbray, SL; Unge, T; Jones, TA				Covarrubias, AS; Larsson, AM; Hogbom, M; Lindberg, J; Bergfors, T; Bjorkelid, C; Mowbray, SL; Unge, T; Jones, TA			Structure and function of carbonic anhydrases from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MODEL; PARAMETERS; MECHANISM; MOTIFS; ENZYME; SITE	Carbonic anhydrases catalyze the reversible hydration of carbon dioxide to form bicarbonate. This activity is universally required for fatty acid biosynthesis as well as for the production of a number of small molecules, pH homeostasis, and other functions. At least three different carbonic anhydrase families are known to exist, of which the alpha-class found in humans has been studied in most detail. In the present work, we describe the structures of two of the three beta-class carbonic anhydrases that have been identified in Mycobacterium tuberculosis, i.e. Rv1284 and Rv3588c. Both structures were solved by molecular replacement and then refined to resolutions of 2.0 and 1.75 angstrom, respectively. The active site of Rv1284 is small and almost completely shielded from solvent, whereas that of Rv3588c is larger and quite open to solution. Differences in coordination of the active site metal are also observed. In Rv3588c, an aspartic acid side chain displaces a water molecule and coordinates directly to the zinc ion, thereby closing the zinc coordination sphere and breaking the salt link to a nearby arginine that is a feature of Rv1284. The two carbonic anhydrases thus exhibit both of the metal coordination geometries that have previously been observed for structures in this family. Activity studies demonstrate that Rv3588c is a completely functional carbonic anhydrase. The apparent lack of activity of Rv1284 in the present assay system is likely exacerbated by the observed depletion of zinc in the preparation.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Mol Biol, S-75124 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Jones, TA (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	alwyn@xray.bmc.uu.se	Mowbray, Sherry L/D-2141-2013	Bjorkelid, Christofer/0000-0002-2780-7424; Hogbom, Martin/0000-0001-5574-9383				ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Branden C., 1999, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; Maren T H, 1995, J Glaucoma, V4, P49; McPherson A, 1982, PREPARATION ANAL PRO; Merlin C, 2003, J BACTERIOL, V185, P6415, DOI 10.1128/JB.185.21.6415-6424.2003; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMBERG P, 1995, ARCH OPHTHALMOL-CHIC, V113, P985, DOI 10.1001/archopht.1995.01100080035025; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rowlett RS, 2002, ARCH BIOCHEM BIOPHYS, V404, P197, DOI 10.1016/S0003-9861(02)00243-6; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Smith KS, 2002, J BACTERIOL, V184, P4240, DOI 10.1128/JB.184.15.4240-4245.2002; Smith KS, 1999, J BACTERIOL, V181, P6247, DOI 10.1128/JB.181.20.6247-6253.1999; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	40	122	128	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18782	18789		10.1074/jbc.M414348200	http://dx.doi.org/10.1074/jbc.M414348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753099	hybrid			2022-12-27	WOS:000228932300029
J	Vogt, A; Tamewitz, A; Skoko, J; Sikorski, RP; Giuliano, KA; Lazo, JS				Vogt, A; Tamewitz, A; Skoko, J; Sikorski, RP; Giuliano, KA; Lazo, JS			The benzo[c] phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; KOLMOGOROV-SMIRNOV TEST; CATALYTIC ACTIVATION; DRUG DISCOVERY; APOPTOSIS; MKP-1; EXPRESSION; DEATH; PYST1; OVEREXPRESSION	Mitogen-activated protein kinase phosphatase-1 (MKP-1) is a dual specificity phosphatase that is overexpressed in many human tumors and can protect cells from apoptosis caused by DNA-damaging agents or cellular stress. Small molecule inhibitors of MKP-1 have not been reported, in part because of the lack of structural guidance for inhibitor design and definitive assays for MKP-1 inhibition in intact cells. Herein we have exploited a high content chemical complementation assay to analyze a diverse collection of pure natural products for cellular MKP-1 inhibition. Using two-dimensional Kolmogorov-Smirnov statistics, we identified sanguinarine, a plant alkaloid with known antibiotic and antitumor activity but no primary cellular target, as a potent and selective inhibitor of MKP-1. Sanguinarine inhibited cellular MKP-1 with an IC50 of 10 mu M and showed selectivity for MKP-1 over MKP-3. Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 mu M, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B(2), or protein-tyrosine phosphatase 1B. In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation. A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whole cells, and activated ERK and JNK/SAPK. In contrast, sanguinarine analogs lacking the benzophenanthridine scaffold did not inhibit MKP-1 in vitro or in cells nor did they cause ERK or JNK/SAPK phosphorylation. These data illustrate the utility of a chemical complementation assay linked with multiparameter high content cellular screening.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Hillman Canc Ctr G-27A, Pittsburgh, PA 15213 USA.	lazo@pitt.edu	Skoko, John/AAL-1885-2021	Skoko, John/0000-0002-1885-6929	NATIONAL CANCER INSTITUTE [U01CA052995, P01CA078039, U19CA052995] Funding Source: NIH RePORTER; NCI NIH HHS [CA78039, CA52995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, MOL CANCER THER, V3, P933; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Colombo ML, 1996, PHARMACOL RES, V33, P127, DOI 10.1006/phrs.1996.0019; COX C, 1988, CYTOMETRY, V9, P291, DOI 10.1002/cyto.990090404; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Ding ZH, 2002, BIOCHEM PHARMACOL, V63, P1415, DOI 10.1016/S0006-2952(02)00902-4; Dowd S, 1998, J CELL SCI, V111, P3389; Eun JP, 2004, BIOCHEM BIOPH RES CO, V317, P618, DOI 10.1016/j.bbrc.2004.03.077; FASANO G, 1987, MON NOT R ASTRON SOC, V225, P155, DOI 10.1093/mnras/225.1.155; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Giuliano KA, 2004, J BIOMOL SCREEN, V9, P557, DOI 10.1177/1087057104265387; Giuliano KA, 1997, J BIOMOL SCREEN, V2, P249, DOI 10.1177/108705719700200410; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Lampariello F, 2000, CYTOMETRY, V39, P179, DOI 10.1002/(SICI)1097-0320(20000301)39:3<179::AID-CYTO2>3.0.CO;2-I; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Lee SS, 2001, PHYTOTHER RES, V15, P167, DOI 10.1002/ptr.703; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MAJNO G, 1995, AM J PATHOL, V146, P3; PEACOCK JA, 1983, MON NOT R ASTRON SOC, V202, P615, DOI 10.1093/mnras/202.3.615; Press W. H., 1992, NUMERICAL RECIPES FO, P640; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Tanaka S, 2001, PLANTA MED, V67, P108, DOI 10.1055/s-2001-11514; Vogt A, 2003, CHEM BIOL, V10, P733, DOI 10.1016/S1074-5521(03)00170-4; Vogt A, 2001, J BIOL CHEM, V276, P20544, DOI 10.1074/jbc.M100078200; Wang BH, 1997, PLANTA MED, V63, P494, DOI 10.1055/s-2006-957749; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Watson JV, 2001, CYTOMETRY, V43, P55, DOI 10.1002/1097-0320(20010101)43:1<55::AID-CYTO1019>3.0.CO;2-T; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; 2002, EUROPEAN PHARMACOPOE, V4, P2841	41	159	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19078	19086		10.1074/jbc.M501467200	http://dx.doi.org/10.1074/jbc.M501467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15753082	hybrid			2022-12-27	WOS:000228932300064
J	Kotoshiba, S; Kamura, T; Hara, T; Ishida, N; Nakayama, KI				Kotoshiba, S; Kamura, T; Hara, T; Ishida, N; Nakayama, KI			Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G(1) phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAST-CANCER; P27(KIP1) GENE; MUTATIONAL ANALYSIS; MICE LACKING; CYCLIN-E; S-PHASE; DEGRADATION; PHOSPHORYLATION	The cyclin-dependent kinase (CDK) inhibitor p27 is degraded at the G(0)-G(1) transition of the cell cycle by the ubiquitin-proteasome pathway in a Skp2-independent manner. We recently identified a novel ubiquitin ligase, KPC (Kip1 ubiquitylation-promoting complex), consisting of KPC1 and KPC2, which regulates the ubiquitin-dependent degradation of p27 at G(1) phase. We have now investigated the structural requirements for the interactions of KPC1 with KPC2 and p27. The NH2-terminal region of KPC1 was found to be responsible for binding to KPC2 and to p27. KPC1 mutants that lack this region failed to mediate polyubiquitylation of p27 in vitro and expression of one such mutant delayed p27 degradation in vivo. We also generated a series of deletion mutants of p27 and found that KPC failed to polyubiquitylate a p27 mutant that lacks the CDK inhibitory domain. Interestingly, the cyclin E.CDK2 complex prevented both the interaction of KPC with p27 as well as KPC-mediated polyubiquitylation of p27. A complex of cyclin E with a kinase-negative mutant of CDK2 also exhibited these inhibitory effects, suggesting that cyclin E.CDK2 competes with KPC1 for access to the CDK inhibitory domain of p27. These results suggest that free p27 is recognized by the NH2-terminal region of KPC1, which also associates with KPC2, and that p27 is then polyubiquitylated by the COOH-terminal RING-finger domain of KPC1.	Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawagoe, Saitama 3320012, Japan; Tohoku Univ, Dept Dev Biol, Ctr Translat & Adv Anim Res Human Dis, Aoba Ku,Grad Sch Med, Sendai, Miyagi 9808575, Japan	Kyushu University; Japan Science & Technology Agency (JST); Tohoku University	Nakayama, KI (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp						Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kawamata N, 1996, CANCER, V77, P570; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mikolajczyk M, 2003, BIOCHEM BIOPH RES CO, V310, P14, DOI 10.1016/j.bbrc.2003.08.116; Minamishima YA, 2002, CANCER RES, V62, P995; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Seriu T, 1996, LEUKEMIA, V10, P345; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spirin KS, 1996, CANCER RES, V56, P2400; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stegmaier K, 1996, CANCER RES, V56, P1413; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	54	72	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17694	17700		10.1074/jbc.M500866200	http://dx.doi.org/10.1074/jbc.M500866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746103	hybrid			2022-12-27	WOS:000228807200018
J	Crouch, E; Tu, YZ; Briner, D; McDonald, B; Smith, K; Holmskov, U; Hartshorn, K				Crouch, E; Tu, YZ; Briner, D; McDonald, B; Smith, K; Holmskov, U; Hartshorn, K			Ligand specificity of human surfactant protein D - Expression of a mutant trimeric collectin that shows enhanced interactions with influenza a virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; C-TYPE LECTIN; MANNOSE-BINDING PROTEINS; PULMONARY HOST-DEFENSE; HELICAL COILED-COIL; INNATE IMMUNITY; SERUM LECTIN; LUNG; CL-43; CONGLUTININ	Surfactant protein D is a pattern recognition molecule that plays diverse roles in immune regulation and antimicrobial host defense. Its interactions with known ligands are calcium-dependent and involve binding to the trimeric, C-type carbohydrate recognition domain. Surfactant protein D preferentially binds to glucose and related sugars. However, CL-43, a bovine serum lectin, which evolved through duplication of the surfactant protein D gene in ruminants, prefers mannose and mannose-rich polysaccharides. Surfactant protein D is characterized by two relatively conserved motifs at the binding face, along the edges of the shallow carbohydrate-binding groove. For CL-43, sequence alignments demonstrate a basic insertion, Arg-Ala-Lys (RAK), immediately N-terminal to the first motif. We hypothesized that this insertion contributes to the differences in saccharide selectivity and host defense function and compared the activities of recombinant trimeric neck + carbohydrate recognition domains of human surfactant protein D (NCRD) with CL-43 (RCL-43-NCRD) and selected NCRD mutants. Insertion of the CL-43 RAK sequence or a control Ala-Ala-Ala sequence ( AAA) into the corresponding position in NCRD increased the efficiency of binding to mannan and changed the inhibitory potencies of competing saccharides to more closely resemble those of CL-43. In addition, RAK resembled CL-43 in its greater capacity to inhibit the infectivity of influenza A virus and to increase uptake of influenza by neutrophils.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ So Denmark, Inst Med Biol, Odense, Denmark; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Washington University (WUSTL); University of Southern Denmark; Boston University	Crouch, E (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	crouch@path.wustl.edu	Holmskov, Uffe/AAA-3056-2022	Holmskov, Uffe/0000-0002-2391-9445; Hartshorn, Kevan/0000-0002-7196-7433	NHLBI NIH HHS [HL-44015, HL-69031, HL-29594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069031, P01HL029594, R01HL044015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen MJ, 2004, GLYCOBIOLOGY, V14, P693, DOI 10.1093/glycob/cwh088; Allen MJ, 2001, BIOCHEMISTRY-US, V40, P7789, DOI 10.1021/bi002901q; Bouyain S, 2001, GLYCOBIOLOGY, V11, P989, DOI 10.1093/glycob/11.11.989; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, AM J PATHOL, V142, P241; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Crouch E C, 2000, Respir Res, V1, P93; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; CROUCH EC, 2002, INNATE IMMUNITY; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hansen S, 2002, IMMUNOBIOLOGY, V205, P498, DOI 10.1078/0171-2985-00150; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449; Hartshorn KL, 2002, BIOCHEM J, V366, P87, DOI 10.1042/BJ20011868; Hawgood S, 2004, J VIROL, V78, P8565, DOI 10.1128/JVI.78.16.8565-8572.2004; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; Holmskov U, 1996, FEBS LETT, V393, P314, DOI 10.1016/0014-5793(96)00915-5; Holmskov UL, 2000, APMIS, V108, P7; HOPPE HJ, 1994, STRUCTURE, V2, P1129, DOI 10.1016/S0969-2126(94)00115-4; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Kishore U, 2001, Results Probl Cell Differ, V33, P225; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LIM BL, 1994, J BIOL CHEM, V269, P11820; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LOVELESS RW, 1995, IMMUNOLOGY, V85, P651; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; PERSSON A, 1990, J BIOL CHEM, V265, P5755; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; van Eijk M, 2003, J IMMUNOL, V171, P1431, DOI 10.4049/jimmunol.171.3.1431; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	43	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17046	17056		10.1074/jbc.M413932200	http://dx.doi.org/10.1074/jbc.M413932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711012	hybrid			2022-12-27	WOS:000228615500062
J	Lee, KW; Ma, LQ; Yan, XM; Liu, BR; Zhang, XK; Cohen, P				Lee, KW; Ma, LQ; Yan, XM; Liu, BR; Zhang, XK; Cohen, P			Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXR alpha/Nur77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; BREAST-CANCER CELLS; ORPHAN RECEPTOR TR3; PROSTATE-CANCER; RETINOIC ACID; LUNG-CANCER; NUCLEAR EXPORT; NGFI-B; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY	Insulin-like growth factor-binding protein-3 (IGFBP-3) induces apoptosis by its ability to bind insulin-like growth factors (IGFs) as well as its IGF-independent effects involving binding to other molecules including the retinoid X receptor-alpha (RXR alpha). Here we describe that in response to IGFBP-3, the RXR alpha binding partner nuclear receptor Nur77 rapidly undergoes translocation from the nucleus to the mitochondria, initiating an apoptotic cascade resulting in caspase activation within 6 h. This translocation is a type 1 IGF receptor-signaling independent event as IGFBP-3 induces Nur77 translocation in R-cells. IGFBP-3 and Nur77 are additive in inducing apoptosis. GFP-Nur77 transfection into RXR alpha wildtype and knock-out mouse embryonic fibroblasts and subsequent treatment with IGFBP-3 show that RXR alpha is required for IGFBP-3-induced Nur77 translocation and apoptosis. Addition of IGFBP-3 to 22RV1 cell lysates enhanced the ability of GST-RXR alpha to "pull down" Nur77, and overexpression of IGFBP-3 enhanced the accumulation of mitochondrial RXR alpha. This unique nongenotropic nuclear pathway supports an emerging role for IGFBP-3 as a novel, multicompartmental signaling molecule involved in induction of apoptosis in malignant cells.	Univ Calif Los Angeles, Div Pediat Endocrinol, Mattel Childrens Hosp, David Geffen Sch Med, Los Angeles, CA 90095 USA; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sanford Burnham Prebys Medical Discovery Institute	Cohen, P (corresponding author), Univ Calif Los Angeles, Div Pediat Endocrinol, Mattel Childrens Hosp, David Geffen Sch Med, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu			NCI NIH HHS [R01CA100938, P50CA92131] Funding Source: Medline; NIA NIH HHS [R01AG20954] Funding Source: Medline; NICHD NIH HHS [2K12HD34610] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA092131, R01CA100938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali O, 2003, HORM METAB RES, V35, P726; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022-5347(01)69892-6; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; Chang YS, 2004, ONCOGENE, V23, P6569, DOI 10.1038/sj.onc.1207882; Cheung CW, 2004, KIDNEY INT, V65, P1272, DOI 10.1111/j.1523-1755.2004.00535.x; Dawson MI, 2001, CANCER RES, V61, P4723; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Gucev ZS, 1996, CANCER RES, V56, P1545; Hampel OZ, 1998, J UROLOGY, V159, P2220, DOI 10.1016/S0022-5347(01)63309-3; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HINTZ RL, 1991, J UROLOGY, V146, P1160, DOI 10.1016/S0022-5347(17)38031-X; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Hwa V, 1997, ENDOCRINE, V6, P235, DOI 10.1007/BF02820498; Ikezoe T, 2004, BLOOD, V104, P237, DOI 10.1182/blood-2003-07-2203; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kaplan PJ, 1999, CANCER RES, V59, P2203; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kim HS, 2004, CANCER RES, V64, P2229, DOI 10.1158/0008-5472.CAN-03-1675; Kirman I, 2004, SURGERY, V136, P205, DOI 10.1016/j.surg.2004.04.020; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Lee HY, 2004, JNCI-J NATL CANCER I, V96, P1536, DOI 10.1093/jnci/djh286; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin XF, 2004, J CELL SCI, V117, P5609, DOI 10.1242/jcs.01474; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; London SJ, 2002, JNCI-J NATL CANCER I, V94, P749, DOI 10.1093/jnci/94.10.749; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P988, DOI 10.1016/S0006-291X(02)00569-7; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; QINGNAN Y, 2003, AM ASS CANC RES WASH; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917	68	130	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16942	16948		10.1074/jbc.M412757200	http://dx.doi.org/10.1074/jbc.M412757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731112	hybrid			2022-12-27	WOS:000228615500049
J	Miralem, T; Hu, ZB; Torno, MD; Lelli, KM; Maines, MD				Miralem, T; Hu, ZB; Torno, MD; Lelli, KM; Maines, MD			Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; IX-ALPHA REDUCTASE; NF-KAPPA-B; CARBON-MONOXIDE; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; HYDROGEN-PEROXIDE; BETA REDUCTASE; MESSENGER-RNA; BILE-PIGMENTS	BVR reduces biliverdin, the HO-1 and HO-2 product, to bilirubin. Human biliverdin ( BVR) is a serine/threonine kinase activated by free radicals. It is a leucine zipper (bZip) DNA-binding protein and a regulatory factor for 8/7-bp AP-1-regulated genes, including HO-1 and ATF-2/CREB. Presently, small interference ( si) RNA constructs were used to investigate the role of human BVR in sodium arsenite (As)-mediated induction of HO-1 and in cytoprotection against apoptosis. Activation of BVR involved increased serine/threonine phosphorylation but not its protein or transcript levels. The peak activity at 1 h ( 4 -5-fold) after treatment of 293A cells with 5 mu M As preceded induction of HO-1 expression by 3 h. The following suggests BVR involvement in regulating oxidative stress response of HO-1: siBVR attenuated As-mediated increase in HO-1 expression; siBVR, but not siHO-1, inhibited As-dependent increased c-jun promoter activity; treatment of cells with As increased AP-1 binding of nuclear proteins; BVR was identified in the DNA-protein complex; and AP-1 binding of the in vitro translated BVR was phosphorylation-dependent and was attenuated by biliverdin. Most unexpectedly, cells transfected with siBVR, but not siHO-1, displayed a 4-fold increase in apoptotic cells when treated with 10 mu M As as detected by flow cytometry. The presence of BVR small interference RNA augmented the effect of As on levels of cytochrome c, TRAIL, and DR-5 mRNA and cleavage of poly( ADP-ribose) polymerase. The findings describe the function of BVR in HO-1 oxidative response and, demonstrate, for the first time, not only that BVR advances the role of HO-1 in cytoprotection but also affords cytoprotection independent of heme degradation.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14624 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14624 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [R01/ES12187, R01/ES04066] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; ALAM J, 1994, J BIOL CHEM, V269, P25049; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen Nan-Yue, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P297; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen YH, 2003, EXP BIOL MED, V228, P447, DOI 10.1177/15353702-0322805-03; CHIKUBA K, 1994, BIOCHEM BIOPH RES CO, V198, P1170, DOI 10.1006/bbrc.1994.1165; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Durante W, 1997, AM J PHYSIOL-HEART C, V273, pH317, DOI 10.1152/ajpheart.1997.273.1.H317; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; Falchuk KH, 2002, P NATL ACAD SCI USA, V99, P251, DOI 10.1073/pnas.012616099; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Haga Y, 1996, BBA-MOL BASIS DIS, V1316, P29, DOI 10.1016/0925-4439(96)00004-X; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Komuro A, 1996, BIOL PHARM BULL, V19, P796; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; KUTTY RK, 1984, BIOCHEM BIOPH RES CO, V122, P40, DOI 10.1016/0006-291X(84)90436-4; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Liao WT, 2004, J INVEST DERMATOL, V122, P125, DOI 10.1046/j.0022-202X.2003.22109.x; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maines MD, 2003, TOXICOL SCI, V71, P9, DOI 10.1093/toxsci/71.1.9; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 2001, J PHARMACOL EXP THER, V296, P1091; MAINES MD, 1992, HEME OXYGENASE CLIN, P1; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Morse D, 2002, CRIT CARE MED, V30, pS12, DOI 10.1097/00003246-200201001-00002; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Parry N, 1999, TRANSPLANTATION, V67, pS252, DOI 10.1097/00007890-199904150-01006; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; Qian Y, 2003, J INORG BIOCHEM, V96, P271, DOI 10.1016/S0162-0134(03)00235-6; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Shalloe F, 1996, BIOCHEM J, V316, P385, DOI 10.1042/bj3160385; Shen ZY, 2002, WORLD J GASTROENTERO, V8, P40, DOI 10.3748/wjg.v8.i1.40; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; Song RP, 2004, J IMMUNOL, V172, P1220, DOI 10.4049/jimmunol.172.2.1220; Stocker R, 2004, ANTIOXID REDOX SIGN, V6, P841, DOI 10.1089/1523086041797999; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Wijayanti N, 2004, ANTIOXID REDOX SIGN, V6, P802, DOI 10.1089/1523086041798132; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; YAMAGUCHI T, 1994, J BIOL CHEM, V269, P24343; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200	71	85	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17084	17092		10.1074/jbc.M413121200	http://dx.doi.org/10.1074/jbc.M413121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741166	hybrid			2022-12-27	WOS:000228615500067
J	Pederson, BA; Cope, CR; Schroeder, JM; Smith, MW; Irimia, JM; Thurberg, BL; DePaoli-Roach, AA; Roach, PJ				Pederson, BA; Cope, CR; Schroeder, JM; Smith, MW; Irimia, JM; Thurberg, BL; DePaoli-Roach, AA; Roach, PJ			Exercise capacity of mice genetically lacking muscle glycogen synthase - In mice, muscle glycogen is not essential for exercise	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CARBOHYDRATE; DIET; INTERLEUKIN-6; HOMEOSTASIS; LIVER; HEART	The glucose storage polymer glycogen is generally considered to be an important source of energy for skeletal muscle contraction and a factor in exercise endurance. A genetically modified mouse model lacking muscle glycogen was used to examine whether the absence of the polysaccharide affects the ability of mice to run on a treadmill. The MGSKO mouse has the GYS1 gene, encoding the muscle isoform of glycogen synthase, disrupted so that skeletal muscle totally lacks glycogen. The morphology of the soleus and quadriceps muscles from MGSKO mice appeared normal. MGSKO-null mice, along with wild type littermates, were exercised to exhaustion. There were no significant differences in the work performed by MGSKO mice as compared with their wild type littermates. The amount of liver glycogen consumed during exercise was similar for MGSKO and wild type animals. Fasting reduced exercise endurance, and after overnight fasting, there was a trend to reduced exercise endurance for the MGSKO mice. These studies provide genetic evidence that in mice muscle glycogen is not essential for strenuous exercise and has relatively little effect on endurance.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA; Genzyme Corp, Dept Pathol, Framingham, MA 01701 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Sanofi-Aventis; Genzyme Corporation	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	proach@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221, U24DK059637] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; BALDWIN KM, 1973, AM J PHYSIOL, V225, P1045, DOI 10.1152/ajplegacy.1973.225.5.1045; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Gleeson M, 2000, IMMUNOL CELL BIOL, V78, P554, DOI 10.1046/j.1440-1711.2000.00953.x; Hawley JA, 1997, SPORTS MED, V24, P73, DOI 10.2165/00007256-199724020-00001; HERMANSE.L, 1967, ACTA PHYSIOL SCAND, V71, P129, DOI 10.1111/j.1748-1716.1967.tb03719.x; Holloszy JO, 1998, FRONT BIOSCI, V3, pD1011, DOI DOI 10.2741/A342; Hribal ML, 2002, AM J PHYSIOL-ENDOC M, V282, pE977, DOI 10.1152/ajpendo.00561.2001; Ivy JL, 1999, CLIN SPORT MED, V18, P469, DOI 10.1016/S0278-5919(05)70162-9; KARLSSON J, 1971, J APPL PHYSIOL, V31, P203, DOI 10.1152/jappl.1971.31.2.203; Kasuga M, 2003, J CLIN INVEST, V111, P1282, DOI 10.1172/JCI200318526; Lightfoot JT, 2004, PHYSIOL GENOMICS, V19, P270, DOI 10.1152/physiolgenomics.00125.2004; Mason SD, 2004, PLOS BIOL, V2, P1540, DOI 10.1371/journal.pbio.0020288; MCARDLE B, 1951, CLIN SCI, V10, P12; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; Pedersen BK, 2003, J MUSCLE RES CELL M, V24, P113, DOI 10.1023/A:1026070911202; Pederson BA, 2004, MOL CELL BIOL, V24, P7179, DOI 10.1128/MCB.24.16.7179-7187.2004; REITMAN J, 1973, P SOC EXP BIOL MED, V142, P628; ROACH PJ, 2001, ENDOCRINE PANCREAS R; SHERMAN WM, 1981, INT J SPORTS MED, V2, P114, DOI 10.1055/s-2008-1034594; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P457, DOI 10.1073/pnas.98.2.457; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; Tamashiro KLK, 2002, NAT MED, V8, P262, DOI 10.1038/nm0302-262; TERJUNG RL, 1972, AM J PHYSIOL, V223, P549, DOI 10.1152/ajplegacy.1972.223.3.549; Wallberg-Henriksson H, 2001, MOL MEMBR BIOL, V18, P205; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294	31	84	85	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17260	17265		10.1074/jbc.M410448200	http://dx.doi.org/10.1074/jbc.M410448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711014	hybrid			2022-12-27	WOS:000228615500089
J	Rishal, I; Porozov, Y; Yakubovich, D; Varon, D; Dascal, N				Rishal, I; Porozov, Y; Yakubovich, D; Varon, D; Dascal, N			G beta gamma-dependent and G beta gamma-independent basal activity of G protein-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; POTASSIUM CHANNEL; XENOPUS-OOCYTES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SUBUNITS; RECEPTOR; GIRK1; IDENTIFICATION; BINDING; MODULATION	Cardiac and neuronal G protein-activated K+ channels (GIRK; Kir3) open following the binding of G beta gamma subunits, released from G(i/o) proteins activated by neurotransmitters. GIRKs also possess basal activity contributing to the resting potential in neurons. It appears to depend largely on free G beta gamma, but a G beta gamma-independent component has also been envisaged. We investigated G beta gamma dependence of the basal GIRK activity (A(GIRK,basal)) quantitatively, by titrated expression of G beta gamma scavengers, in Xenopus oocytes expressing GIRK1/2 channels and muscarinic m2 receptors. The widely used G beta gamma scavenger, myristoylated C terminus of beta-adrenergic kinase (m-c beta ARK), reduced A(GIRK,basal) by 70 - 80% and eliminated the acetylcholine-evoked current (I-ACh). However, we found that m-c beta ARK directly binds to GIRK, complicating the interpretation of physiological data. Among several newly constructed G beta gamma scavengers, phosducin with an added myristoylation signal (m-phosducin) was most efficient in reducing GIRK currents. m-phosducin relocated to the membrane fraction and did not bind GIRK. Titrated expression of m-phosducin caused a reduction of A(GIRK, basal) by up to 90%. Expression of GIRK was accompanied by an increase in the level of G beta gamma and G alpha in the plasma membrane, supporting the existence of preformed complexes of GIRK with G protein subunits. Increased expression of G beta gamma and its constitutive association with GIRK may underlie the excessively high AGIRK, basal observed at high expression levels of GIRK. Only 10 - 15% of A(GIRK, basal) persisted upon expression of both m-phosducin and c beta ARK. These results demonstrate that a major part of I-basal is G beta gamma-dependent at all levels of channel expression, and only a small fraction (< 10%) may be G beta gamma-independent.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	dascaln@post.tau.ac.il	Porozov, Yuri/AAD-5285-2019; Porozov, Yuri/N-9088-2016; Dascal, Nathan/O-3915-2015; RISHAL, IDA/K-1691-2012	Porozov, Yuri/0000-0002-5450-3135; Dascal, Nathan/0000-0002-5397-4146; 	NIGMS NIH HHS [R01 GM68493] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068493] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Finley M, 2004, J PHYSIOL-LONDON, V555, P643, DOI 10.1113/jphysiol.2003.056101; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; HILGEMANN DW, 2001, SCI STKE; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; ITO H, 1994, J PHYSIOL-LONDON, V476, P55; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; Ivanina T, 2003, J BIOL CHEM, V278, P29174, DOI 10.1074/jbc.M304518200; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kenakin T, 2004, MOL PHARMACOL, V65, P2, DOI 10.1124/mol.65.1.2; KIM CM, 1993, J BIOL CHEM, V268, P15412; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Kurachi Y, 2004, J PHYSIOL-LONDON, V554, P285, DOI 10.1113/jphysiol.2003.048439; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; MIRSHAHI T, 2003, SCI STKE; Nikolov EN, 2004, J BIOL CHEM, V279, P23630, DOI 10.1074/jbc.M312861200; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rishal I, 2003, J BIOL CHEM, V278, P3840, DOI 10.1074/jbc.C200605200; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Ruiz-Velasco V, 1998, J PHYSIOL-LONDON, V513, P761, DOI 10.1111/j.1469-7793.1998.761ba.x; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Schulz R, 2001, PHARMACOL RES, V43, P1, DOI 10.1006/phrs.2000.0757; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Singer-Lahat D, 2000, PFLUG ARCH EUR J PHY, V440, P627, DOI 10.1007/s004240000341; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Takigawa T, 2002, J PHYSIOL-LONDON, V539, P67, DOI 10.1113/jphysiol.2001.012883; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; Yakubovich D, 2005, J MOL NEUROSCI, V25, P7, DOI 10.1385/JMN:25:1:007; Yevenes GE, 2003, NAT NEUROSCI, V6, P819, DOI 10.1038/nn1095; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	62	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16685	16694		10.1074/jbc.M412196200	http://dx.doi.org/10.1074/jbc.M412196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728579	hybrid			2022-12-27	WOS:000228615500020
J	Efendiev, R; Chen, ZP; Krmar, RT; Uhles, S; Katz, AI; Pedemonte, CH; Bertorello, AM				Efendiev, R; Chen, ZP; Krmar, RT; Uhles, S; Katz, AI; Pedemonte, CH; Bertorello, AM			The 14-3-3 protein translates the NA(+),K+-ATPase alpha(1)-subunit phosphorylation signal into binding and activation of phosphoinositide 3-kinase during endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; NA+-K+-ATPASE; PROXIMAL TUBULE NA+,K+-ATPASE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; PKC-BETA; DOPAMINE; CELLS; RECEPTOR; KINASE	Clathrin-dependent endocytosis of Na+, K+-ATPase molecules in response to G protein-coupled receptor signals is triggered by phosphorylation of the alpha-subunit and the binding of phosphoinositide 3-kinase. In this study, we describe a molecular mechanism linking phosphorylation of Na+, K+-ATPase alpha-subunit to binding and activation of phosphoinositide 3-kinase. Co-immunoprecipitation studies, as well as experiments using confocal microscopy, revealed that dopamine favored the association of 14-3-3 protein with the basolateral plasma membrane and its co-localization with the Na+, K+-ATPase alpha-subunit. The functional relevance of this interaction was established in opossum kidney cells expressing a 14-3-3 dominant negative mutant, where dopamine failed to decrease Na+, K+-ATPase activity and to promote its endocytosis. The phosphorylated Ser-18 residue within the alpha-subunit N terminus is critical for 14-3-3 binding. Activation of phosphoinositide 3-kinase by dopamine during Na+, K+-ATPase endocytosis requires the binding of the kinase to a proline-rich domain within the alpha-subunit, and this effect was blocked by the presence of a 14-3-3 dominant negative mutant. Thus, the 14-3-3 protein represents a critical linking mechanism for recruiting phosphoinositide 3-kinase to the site of Na+, K+-ATPase endocytosis.	Karolinska Univ Hosp Solna, King Gustaf V Res Inst, Karolinska Inst,Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden; Karolinska Univ Hosp Solna, Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden; Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Houston System; University of Houston; University of Chicago	Bertorello, AM (corresponding author), Karolinska Univ Hosp Solna, King Gustaf V Res Inst, Karolinska Inst,Dept Med, Atherosclerosis Res Unit, M1-01, S-17176 Stockholm, Sweden.	alejandro.bertorello@medks.ki.se		Uhles, Sabine/0000-0002-2836-8726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062195] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK62195] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Aperia AC, 2000, ANNU REV PHYSIOL, V62, P621, DOI 10.1146/annurev.physiol.62.1.621; BERTORELLO AM, 1992, J CELL SCI, V101, P343; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budu CE, 2002, BRIT J PHARMACOL, V137, P1380, DOI 10.1038/sj.bjp.0704962; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Cornelius F, 2003, ANN NY ACAD SCI, V986, P579, DOI 10.1111/j.1749-6632.2003.tb07256.x; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Efendiev R, 2003, J BIOL CHEM, V278, P28719, DOI 10.1074/jbc.M303741200; Efendiev R, 2002, J BIOL CHEM, V277, P44108, DOI 10.1074/jbc.M205173200; Efendiev R, 2002, J BIOL CHEM, V277, P11489, DOI 10.1074/jbc.M108182200; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Khundmiri SJ, 2002, AM J PHYSIOL-RENAL, V282, pF512, DOI 10.1152/ajprenal.00111.2000; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Pagel P, 2003, ANN NY ACAD SCI, V986, P360, DOI 10.1111/j.1749-6632.2003.tb07215.x; Pedemonte CH, 2001, J BIOENERG BIOMEMBR, V33, P439, DOI 10.1023/A:1010675708820; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Teixeira VL, 2003, ANN NY ACAD SCI, V986, P587, DOI 10.1111/j.1749-6632.2003.tb07257.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	39	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16272	16277		10.1074/jbc.M500486200	http://dx.doi.org/10.1074/jbc.M500486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722354	hybrid			2022-12-27	WOS:000228444800097
J	Lengner, CJ; Hassan, MQ; Serra, RW; Lepper, C; van Wijnen, AJ; Stein, JL; Lian, JB; Stein, GS				Lengner, CJ; Hassan, MQ; Serra, RW; Lepper, C; van Wijnen, AJ; Stein, JL; Lian, JB; Stein, GS			Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; DENSITY MICROMASS CULTURES; IN-VITRO MODEL; SONIC HEDGEHOG; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; CHONDROCYTE DIFFERENTIATION; MESENCHYMAL CELLS; SOMITIC CHONDROGENESIS; GENE-EXPRESSION	Runx2, a transcription factor known to be essential for osteoblast maturation and skeletogenesis, is also expressed in pre-cartilaginous mesenchymal condensations in the developing embryo. It is therefore necessary to understand the control and consequential regulatory activity of the Runx2 gene within the context of chondrogenic differentiation of a mesenchymal progenitor cell. We identify the homeodomain protein Nkx3.2 as a potent sequence-specific repressor of the Runx2 promoter that acts through a regulatory element 0.1 kb upstream from the site of transcriptional initiation. The biological significance of this repression is established by utilizing bone morphogenic protein 2 (BMP-2)-induced chondrogenic differentiation of pluripotent C3H10T1/2 cells as a model for the initial events of mesenchymal chondrogenesis. We demonstrate that induction of the chondrogenic phenotype and endogenous Nkx3.2 expression is accompanied by a repression of Runx2 gene activity. Bypassing Runx2 repression by adenoviral-mediated introduction of Runx2 into C3H10T1/2 cells can prevent the induction of chondrogenesis, but cannot reverse the chondrogenic phenotype once it has been initiated, as evidenced by Sox9 and type II collagen expression and extracellular matrix deposition. Our results demonstrate that Runx2 is a direct transcriptional target of Nkx3.2, and that repression of Runx2 at the onset of chondrogenesis is a prerequisite for the activation of a chondrocyte-specific program of gene expression. We postulate that Runx2 is a critical link in BMP-2-mediated initiation of mesenchymal chondrogenesis that results in activation of Sox9 at least in part through the Nkx3.2-dependent repression of Runx2.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	Hassan, Mohammad/GZA-7507-2022; van Wijnen, Andre J./AAG-3578-2019	Hassan, Mohammad/0000-0002-1712-0004; van Wijnen, Andre J./0000-0002-4458-0946; Lengner, Christopher/0000-0002-0574-5189	NIAMS NIH HHS [AR39588, P01 AR48818, R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [P30 DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069, P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Akazawa H, 2000, GENES CELLS, V5, P499, DOI 10.1046/j.1365-2443.2000.00339.x; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003-0273; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eames BF, 2004, DEV BIOL, V274, P188, DOI 10.1016/j.ydbio.2004.07.006; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Enomoto-Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS76, DOI 10.1053/joca.2001.0448; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Haas AR, 2000, METH MOL B, V137, P383; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; Kim DW, 2003, MOL CELL BIOL, V23, P8704, DOI 10.1128/MCB.23.23.8704-8717.2003; Kim DW, 2003, J BIOL CHEM, V278, P27532, DOI 10.1074/jbc.M301461200; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Lettice LA, 1999, P NATL ACAD SCI USA, V96, P9695, DOI 10.1073/pnas.96.17.9695; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Marcelle C, 1999, DEV BIOL, V214, P277, DOI 10.1006/dbio.1999.9389; Marcelle C, 1997, DEVELOPMENT, V124, P3955; Mello MA, 1999, IN VITRO CELL DEV-AN, V35, P262; Murtaugh LC, 2001, DEV CELL, V1, P411, DOI 10.1016/S1534-5807(01)00039-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; North T, 1999, DEVELOPMENT, V126, P2563; Ohyama Y, 2004, ENDOCRINOLOGY, V145, P4685, DOI 10.1210/en.2003-1492; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rabie ABM, 2004, ARCH ORAL BIOL, V49, P109, DOI 10.1016/j.archoralbio.2003.09.006; Singh R, 2003, ENDOCRINOLOGY, V144, P5081, DOI 10.1210/en.2003-0741; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467; Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925-4773(03)00101-1; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186; Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002	56	68	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15872	15879		10.1074/jbc.M411144200	http://dx.doi.org/10.1074/jbc.M411144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15703179	hybrid			2022-12-27	WOS:000228444800052
J	Zhu, CB; Carneiro, AM; Dostmann, WR; Hewlett, WA; Blakely, RD				Zhu, CB; Carneiro, AM; Dostmann, WR; Hewlett, WA; Blakely, RD			p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOGENIC-AMINE TRANSPORTERS; HUMAN DOPAMINE TRANSPORTER; LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; NOREPINEPHRINE TRANSPORTER; SYNTAXIN 1A; SURFACE EXPRESSION; GABA TRANSPORTERS; KINASE; CELLS	Presynaptic, plasma membrane serotonin (5-hydroxytryptamine; 5-HT) transporters (SERTs) clear 5-HT following vesicular release and are regulated through trafficking-dependent pathways. Recently, we (Zhu, C.- B., Hewlett, W. A., Feoktistov, I., Biaggioni, I., and Blakely, R. D. ( 2004) Mol. Pharmacol. 65, 1462 - 1474) provided evidence for a trafficking-independent mode of SERT regulation downstream of adenosine receptor (AR) activation that is sensitive to p38 MAPK inhibitors. Here, we probe this pathway in greater detail, demonstrating elevation of 5-HT transport by multiple p38 MAPK activators (anisomycin, H2O2, and UV radiation), in parallel with p38 MAPK phosphorylation, as well as suppression of anisomycin stimulation by p38 MAPK siRNA treatments. Studies with transporter-transfected Chinese hamster ovary cells reveal that SERT stimulation is shared with the human norepinephrine transporter but not the human dopamine transporter. Saturation kinetic analyses of anisomycin-SERT activity reveal a selective reduction in 5-HT Km supported by a commensurate increase in 5-HT potency (K-i) for displacing surface antagonist binding. Anisomycin treatments that stimulate SERT activity do not elevate surface SERT surface density whereas stimulation is lost with preexposure of cells to the surface-SERT inactivating reagent, 2-(trimethylammonium) ethyl methane thiosulfonate. Guanylyl cyclase (1H-( 1,2,4)- oxadiazolo[4,3-a]quinoxalin- 1-one) and protein kinase G inhibitors (H8, DT-2) block AR stimulation of SERT yet fail to antagonize SERT stimulation by anisomycin. We thus place p38 MAPK activation downstream of protein kinase G in a SERT-catalytic regulatory pathway, distinct from events controlling SERT surface density. In contrast, the activity of protein phosphatase 2A inhibitors ( fostriecin and calyculin A) to attenuate anisomycin stimulation of 5-HT transport suggests that protein phosphatase 2A is a critical component of the pathway responsible for p38 MAPK up-regulation of SERT catalytic activity.	Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Vermont	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Suite 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu		Marin Dias Carneiro, Ana/0000-0002-1204-9202; Zhu, Chongbin/0000-0003-4530-7949; MD Carneiro, Ana/0000-0002-7470-7047	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68991] Funding Source: Medline; NIDA NIH HHS [DA07390] Funding Source: Medline; NIMH NIH HHS [T32-MH65782-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anisman H, 2003, ANN MED, V35, P2, DOI 10.1080/07853890310004075; Ansah TA, 2003, J PHARMACOL EXP THER, V305, P956, DOI 10.1124/jpet.102.047134; Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; Bauman AL, 2000, J NEUROSCI, V20, P7571; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Bunyard P, 2003, MOL IMMUNOL, V39, P815, DOI 10.1016/S0161-5890(02)00262-6; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Cook Edwin H. Jr., 1996, Current Opinion in Pediatrics, V8, P348, DOI 10.1097/00008480-199608000-00008; Daws LC, 2000, J NEUROCHEM, V75, P2113, DOI 10.1046/j.1471-4159.2000.0752113.x; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; Flattem NL, 2000, MOL PSYCHIATR, V5, P110, DOI 10.1038/sj.mp.4000585; Furtado LM, 2002, BIOCHEM CELL BIOL, V80, P569, DOI 10.1139/O02-156; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GIROS B, 1992, MOL PHARMACOL, V42, P383; Haase J, 2001, BIOCHEM SOC T, V29, P722, DOI 10.1042/BST0290722; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmes A, 2003, BIOL PSYCHIAT, V54, P953, DOI 10.1016/j.biopsych.2003.09.003; Horschitz S, 2003, J NEUROCHEM, V86, P958, DOI 10.1046/j.1471-4159.2003.01899.x; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Kelly A, 2003, J BIOL CHEM, V278, P19453, DOI 10.1074/jbc.M301938200; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAUNAY JM, 1994, AM J PHYSIOL, V266, P526; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Liu QH, 2003, AM J PHYSIOL-HEART C, V285, pH97, DOI 10.1152/ajpheart.00956.2002; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Magnani F, 2004, J BIOL CHEM, V279, P38770, DOI 10.1074/jbc.M400831200; McNicol A., 1996, PRACT APPROACH SER, P1; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Murphy DL, 2003, GENES BRAIN BEHAV, V2, P350, DOI 10.1046/j.1601-1848.2003.00049.x; Murphy DL, 2004, MOL INTERV, V4, P109, DOI 10.1124/mi.4.2.8; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nestler EJ, 2001, MOL NEUROPHARMACOLOG, P191; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; OWENS MJ, 1994, CLIN CHEM, V40, P288; Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pampolina C, 1999, THROMB RES, V96, P27, DOI 10.1016/S0049-3848(99)00062-6; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; Ramamoorthy Sammanda, 2002, P1; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P5300, DOI 10.1021/bi00617a033; Sakai N, 1997, J NEUROCHEM, V68, P2618; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; White S, 2002, CRIT REV BIOTECHNOL, V22, P1, DOI 10.1080/07388550490465817; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zhu CB, 2004, EUR J PHARMACOL, V504, P1, DOI 10.1016/j.ejphar.2004.09.023	69	165	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15649	15658		10.1074/jbc.M410858200	http://dx.doi.org/10.1074/jbc.M410858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15728187	hybrid			2022-12-27	WOS:000228444800025
J	Hasegawa, M; Imamura, R; Kinoshita, T; Matsumoto, N; Masumoto, J; Inohara, N; Suda, T				Hasegawa, M; Imamura, R; Kinoshita, T; Matsumoto, N; Masumoto, J; Inohara, N; Suda, T			ASC-mediated NF-kappa B activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL MEDITERRANEAN FEVER; CONTAINING APAF1-LIKE PROTEIN; REGULATES ACTIVATION; HOST RECOGNITION; FAS LIGAND; T-CELLS; APOPTOSIS; PYRIN; GENE; MEMBER	ASC is an adaptor molecule that mediates apoptotic and inflammatory signals from several Apaf-1-like molecules, including CARD12/Ipaf, cryopyrin/PYPAF1, PYPAF5, PYPAF7, and NALP1. To characterize the signaling pathway mediated by ASC, we established cell lines in which muramyl dipeptide, the bacterial component recognized by another Apaf-1-like molecule, Nod2, induced an interaction between a CARD12-Nod2 chimeric protein and ASC, and elicited cell autonomous NF-kappa B activation. This response required caspase-8, and was suppressed by CLARP/FLIP, an inhibitor of caspase-8. The catalytic activity of caspase-8 was required for the ASC-mediated NF-kappa B activation when caspase-8 was expressed at an endogenous level, although it was not essential when caspase-8 was overexpressed. In contrast, FADD, the adaptor protein linking Fas and caspase-8, was not required for this response. Consistently, ASC recruited caspase-8 and CLARP but not FADD and Nod2 to its speck-like aggregates in cells. Finally, muramyl dipeptide induced interleukin-8 production in MAIL8 cells. These results are the first to indicate that caspase-8 plays an important role in the ASC-mediated NF-kappa B activation, and that the ASC-mediated NF-kappa B activation actually induces physiologically relevant gene expression.	Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Kanazawa University; University of Michigan System; University of Michigan	Suda, T (corresponding author), Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	IMAMURA, Ryu/D-8433-2015; KINOSHITA, Takeshi/D-8436-2015					Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Conway KE, 2000, CANCER RES, V60, P6236; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lee ZH, 2001, J LEUKOCYTE BIOL, V69, P490; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Suda T, 1996, J IMMUNOL, V157, P3918; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081; Zhang YK, 1999, J BIOL CHEM, V274, P34657, DOI 10.1074/jbc.274.49.34657	42	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15122	15130		10.1074/jbc.M412284200	http://dx.doi.org/10.1074/jbc.M412284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701651	hybrid, Green Submitted			2022-12-27	WOS:000228236800095
J	Pon, YL; Auersperg, N; Wong, AST				Pon, YL; Auersperg, N; Wong, AST			Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase a pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; PERFUSED RAT OVARY; EXTRACELLULAR-MATRIX; LUTEINIZING-HORMONE; GRANULOSA-CELLS; IN-VITRO; SIGNALING PATHWAYS; BETA-CATENIN; EXPRESSION; OVULATION	Gonadotropins are the major regulators of ovarian function and may be involved in the etiology of ovarian cancer. In this study, we report a new mechanism whereby gonadotropins regulate the survival of human ovarian surface epithelium (OSE), the tissue of origin of epithelial ovarian carcinomas. Our results indicate that disruption of N-cadherin-mediated cell-cell adhesion is an important molecular event in the apoptosis of human OSE. Treatment with surge serum concentrations of gonadotropins reduced the amount of N-cadherin with a concomitant induction of apoptosis, and this effect was mediated by a cAMP/protein kinase A pathway but not the ERK1/2 and protein kinase C cascades. We further demonstrated that activation of the gonadotropins/cAMP signaling pathway in human OSE led to a rapid down-regulation of N-cadherin protein level followed by a reduction at the level of N-cadherin mRNA, indicating that expression of N-cadherin was regulated by post-translational and transcriptional mechanisms. The former mechanism was mediated by increased turnover of N-cadherin protein and could be reversed by inhibition of proteasomal or matrix metalloproteinase (MMP-2) activity. On the other hand, at the transcriptional level, the addition of actinomycin D abolished the cAMP-mediated decrease in N-cadherin mRNA but did not change its stability. Inhibition of protein kinase A or expressing a dominant negative mutant of cAMP-response element-binding protein blocked this decrease of N-cadherin mRNA. Together, the combined operation of post-translational and transcriptional mechanisms suggests that regulation of N-cadherin is a crucial event and emphasizes the important role that N-cadherin has in controlling the survival capability of human OSE.	Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V6H 3V5, Canada	University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Dept Zool, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475				AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; AKTIPIS S, 1981, BIOCHIM BIOPHYS ACTA, V655, P278, DOI 10.1016/0005-2787(81)90038-1; Amsterdam A, 2003, MOL CELL ENDOCRINOL, V202, P77, DOI 10.1016/S0303-7207(03)00066-2; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Auersperg N, 2003, GYNECOL ONCOL, V88, pS47, DOI 10.1006/gyno.2002.6683; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BJERSING L, 1975, EXPERIENTIA, V31, P605, DOI 10.1007/BF01932485; BRABANT G, 1995, ENDOCRINOLOGY, V136, P3113, DOI 10.1210/en.136.7.3113; BRANNSTROM M, 1988, ENDOCRINOLOGY, V122, P1715; Breckwoldt M, 1996, Zentralbl Gynakol, V118, P176; BUTLER TA, 1991, BIOL REPROD, V44, P1183, DOI 10.1095/biolreprod44.6.1183; Campbell BK, 1998, J REPROD FERTIL, V112, P69, DOI 10.1530/jrf.0.1120069; Chamson-Reig A, 2003, ENDOCRINOLOGY, V144, P2957, DOI 10.1210/en.2003-0011; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; Colgin DC, 1997, ANIM REPROD SCI, V47, P197, DOI 10.1016/S0378-4320(97)00011-0; D'Ascenzo S, 2004, EUR J ENDOCRINOL, V151, P87, DOI 10.1530/eje.0.1510087; Davies BR, 1999, GYNECOL ENDOCRINOL, V13, P75, DOI 10.3109/09513599909167536; Emonard H, 1999, ANN NY ACAD SCI, V878, P647, DOI 10.1111/j.1749-6632.1999.tb07751.x; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRAG PP, 1998, GYNECOLOGY, V92, P472; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HOFFMAN AG, 1993, INT J CANCER, V54, P828, DOI 10.1002/ijc.2910540518; HUNTER MG, 1981, J REPROD FERTIL, V63, P285; Ivarsson K, 2001, HUM REPROD, V16, P18, DOI 10.1093/humrep/16.1.18; Julie PM, 2003, ENDOCR RES, V29, P327, DOI 10.1081/ERC-120025040; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; KRUK PA, 1994, IN VITRO CELL DEV-AN, V30A, P217; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Machell NH, 2003, REPRODUCTION, V125, P791, DOI 10.1530/rep.0.1250791; MACLACHLAN NJ, 1987, ENVIRON HEALTH PERSP, V73, P27, DOI 10.2307/3430595; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; Makrigiannakis A, 1999, AM J PATHOL, V154, P1391, DOI 10.1016/S0002-9440(10)65393-X; Mandai M, 1997, EUR J CANCER, V33, P1501, DOI 10.1016/S0959-8049(97)00166-4; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; MURDOCH WJ, 1995, J REPROD FERTIL, V105, P161, DOI 10.1530/jrf.0.1050161; Murdoch WJ, 2004, EXP BIOL MED, V229, P546, DOI 10.1177/153537020422900613; OSTERHOLZER HO, 1985, BIOL REPROD, V33, P247, DOI 10.1095/biolreprod33.1.247; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; REVILLION F, 1993, ANTICANCER RES, V13, P1625; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Riley SC, 2004, ANIM REPROD SCI, V81, P329, DOI 10.1016/j.anireprosci.2003.10.011; Rowlands TM, 2000, REV REPROD, V5, P53; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Sundfeldt K, 2000, J REPROD FERTIL, V118, P375, DOI 10.1530/reprod/118.2.375; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; Syed V, 2001, CANCER RES, V61, P6768; Thomas FH, 2005, ENDOCRINOLOGY, V146, P941, DOI 10.1210/en.2004-0826; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Tsafriri A, 1999, EXP CLIN ENDOCR DIAB, V107, P1, DOI 10.1055/s-0029-1212066; Wong AST, 1999, INT J CANCER, V81, P180; Zheng WX, 2000, GYNECOL ONCOL, V76, P80, DOI 10.1006/gyno.1999.5628	58	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15438	15448		10.1074/jbc.M410766200	http://dx.doi.org/10.1074/jbc.M410766200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701645	hybrid			2022-12-27	WOS:000228236800131
J	Browne, RJ; Stitt, BL				Browne, RJ; Stitt, BL			Active site occupancy required for catalytic cooperativity by Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; ATP HYDROLYSIS; PROTEIN RHO; NUCLEOTIDE-BINDING; AMP DEAMINASE; RAPID QUENCH; MECHANISM; F-1-ATPASE; ENZYME; YEAST	Escherichia coli transcription termination factor Rho exhibits the phenomenon of catalytic cooperativity. The catalytic rate per site is 30-fold faster when all three sites are filled with substrate ATP than when only a single site is occupied (Stitt, B. L., and Xu, Y. (1998) J. Biol. Chem. 273, 26477-26486). Experiments presented here investigate whether all three active sites must be filled or whether only two occupied sites are required for catalytic cooperativity. The results indicate that all three Rho catalytic sites must be filled with substrate to achieve the enhanced catalytic rate, both in pre-steady-state and in steady-state hydrolysis. They further suggest that, once the enzyme is saturated with ATP, a V-max enzyme conformation is achieved that is stable for at least three catalytic cycles.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	stitt@temple.edu			NIGMS NIH HHS [GM60247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Browne RJ, 2005, J BIOL CHEM, V280, P13292, DOI 10.1074/jbc.M500221200; Cao H, 2002, BIOCHEMISTRY-US, V41, P3520, DOI 10.1021/bi012148g; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; MERKLER DJ, 1990, J BIOL CHEM, V265, P4420; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; Milgrom YM, 1998, BIOCHEM J, V330, P1037; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; Skordalakes E, 2005, STRUCTURE, V13, P99, DOI 10.1016/j.str.2004.10.013; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; WILKINSON KD, 1979, J BIOL CHEM, V254, P2567	31	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13300	13303		10.1074/jbc.M500222200	http://dx.doi.org/10.1074/jbc.M500222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15703177	hybrid			2022-12-27	WOS:000228095500015
J	Samuelson, AV; Narita, M; Chan, HM; Jin, JP; de Stanchina, E; McCurrach, ME; Narita, M; Fuchs, M; Livingston, DM; Lowe, SW				Samuelson, AV; Narita, M; Chan, HM; Jin, JP; de Stanchina, E; McCurrach, ME; Narita, M; Fuchs, M; Livingston, DM; Lowe, SW			p400 is required for E1A to promote apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; REGULATES P53-DEPENDENT APOPTOSIS; HISTONE ACETYLASE COMPLEX; REGION 1A PROTEINS; ONCOGENIC TRANSFORMATION; DNA-DAMAGE; C-MYC; P53; P300; INDUCTION	The adenovirus E1A oncoprotein promotes proliferation and transformation by binding cellular proteins, including members of the retinoblastoma protein family, the p300/CREB-binding protein transcriptional coactivators, and the p400-TRRAP chromatin-remodeling complex. E1A also promotes apoptosis, in part, by engaging the ARF-p53 tumor suppressor pathway. We show that E1A induces ARF and p53 and promotes apoptosis in normal fibroblasts by physically associating with the retinoblastoma protein and a p400-TRRAP complex and that its interaction with p300 is largely dispensable for these effects. We further show that E1A increases p400 expression and, conversely, that suppression of p400 using stable RNA interference reduces the levels of ARF, p53, and apoptosis in E1A-expressing cells. Therefore, whereas E1A inactivates the retinoblastoma protein, it requires p400 to efficiently promote cell death. These results identify p400 as a regulator of the ARF-p53 pathway and a component of the cellular machinery that couples proliferation to cell death.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cold Spring Harbor Laboratory; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.org	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; Samuelson, Andrew/0000-0002-3071-5766; Narita, Masako/0000-0002-9774-4908; Narita, Masashi/0000-0001-7764-577X	NCI NIH HHS [CA 13106, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kawamura T, 2004, BIOCHEM BIOPH RES CO, V315, P733, DOI 10.1016/j.bbrc.2004.01.105; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEVINS JR, 1992, SCIENCE, V258, P424; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yageta M, 1999, ONCOGENE, V18, P4767, DOI 10.1038/sj.onc.1203063; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	66	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21915	21923		10.1074/jbc.M414564200	http://dx.doi.org/10.1074/jbc.M414564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15741165	hybrid			2022-12-27	WOS:000229557900032
J	Cabral, WA; Makareeva, E; Colige, A; Letocha, AD; Ty, JM; Yeowell, HN; Pals, G; Leikin, S; Marini, JC				Cabral, WA; Makareeva, E; Colige, A; Letocha, AD; Ty, JM; Yeowell, HN; Pals, G; Leikin, S; Marini, JC			Mutations near amino end of alpha 1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-VII; SPLICE ACCEPTOR SITE; I PROCOLLAGEN; PRO-ALPHA-1(I) CHAIN; COL1A2 GENE; CLINICAL-FEATURES; BASE SUBSTITUTION; THERMAL-STABILITY; ALPHA-2(I) CHAIN; PROTEINASE	Patients with OI/EDS form a distinct subset of osteogenesis imperfecta (OI) patients. In addition to skeletal fragility, they have characteristics of Ehlers-Danlos syndrome (EDS). We identified 7 children with types III or IV OI, plus severe large and small joint laxity and early progressive scoliosis. In each child with OI/EDS, we identified a mutation in the first 90 residues of the helical region of alpha 1(I) collagen. These mutations prevent or delay removal of the procollagen N-propeptide by purified N-proteinase (ADAMTS-2) in vitro and in pericellular assays. The mutant pN-collagen which results is efficiently incorporated into matrix by cultured fibroblasts and osteoblasts and is prominently present in newly incorporated and immaturely cross-linked collagen. Dermal collagen fibrils have significantly reduced cross-sectional diameters, corroborating incorporation of pN-collagen into fibrils in vivo. Differential scanning calorimetry revealed that these mutant collagens are less stable than the corresponding procollagens, which is not seen with other type I collagen helical mutations. These mutations disrupt a distinct folding region of high thermal stability in the first 90 residues at the amino end of type I collagen and alter the secondary structure of the adjacent N-proteinase cleavage site. Thus, these OI/EDS collagen mutations are directly responsible for the bone fragility of OI and indirectly responsible for EDS symptoms, by interference with N-propeptide removal.	NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA; NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; Univ Liege, Lab Connect Tissue Biol, B-4000 Liege, Belgium; Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA; VU Med Ctr, NL-1007 MB Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Liege; Duke University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Marini, JC (corresponding author), NICHD, Bone & Extracellular Matrix Branch, NIH, Bldg 10,Rm 9s239,9000 Rockville Pike, Bethesda, MD 20892 USA.	oidoc@helix.nih.gov	Makareeva, Elena/F-5183-2011; Leikin, Sergey/A-5518-2008	Makareeva, Elena/0000-0002-5815-0760; Leikin, Sergey/0000-0001-7095-0739; Pals, Gerard/0000-0003-4091-7115	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000408, ZIAHD000256] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; Byers PH, 1997, AM J MED GENET, V72, P94, DOI 10.1002/(SICI)1096-8628(19971003)72:1<94::AID-AJMG20>3.0.CO;2-O; Cabral WA, 2003, J BIOL CHEM, V278, P10006, DOI 10.1074/jbc.M212523200; CARR AJ, 1994, J MED GENET, V31, P306, DOI 10.1136/jmg.31.4.306; CHIODO AA, 1992, J BIOL CHEM, V267, P6361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; COLE WG, 1986, J BIOL CHEM, V261, P5496; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DALESSIO M, 1991, AM J HUM GENET, V49, P400; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FESHCHENKO S, 1997, HUM MUTAT, V12, P138; Giunta C, 1999, J BONE JOINT SURG AM, V81A, P225, DOI 10.2106/00004623-199902000-00010; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HO KKY, 1994, HUM MUTAT, V3, P358, DOI 10.1002/humu.1380030406; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; JONES EY, 1987, BIOPOLYMERS, V26, P463, DOI 10.1002/bip.360260403; Kuznetsova NV, 2003, J MOL BIOL, V331, P191, DOI 10.1016/S0022-2836(03)00715-0; LEHMANN HW, 1994, ARCH DERMATOL RES, V286, P425, DOI 10.1007/BF00371566; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; MARINI JC, 1993, J BIOL CHEM, V268, P2667; Marini JC, 2004, NELSON TXB PEDIAT, P2336; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; Nicholls A C, 2000, J Med Genet, V37, pE33, DOI 10.1136/jmg.37.11.e33; NICHOLLS AC, 1991, HUM GENET, V87, P193, DOI 10.1007/BF00204180; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; OTTER A, 1989, BIOCHEMISTRY-US, V28, P8003, DOI 10.1021/bi00446a006; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raff ML, 2000, HUM GENET, V106, P19, DOI 10.1007/s004390051004; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sarafova AP, 1998, HUM MUTAT, V11, P395, DOI 10.1002/(SICI)1098-1004(1998)11:5<395::AID-HUMU7>3.3.CO;2-W; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SIPPOLA M, 1984, J BIOL CHEM, V259, P4094; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; VASAN NS, 1991, AM J HUM GENET, V48, P305; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WEIL D, 1989, J BIOL CHEM, V264, P16804; WILLING MC, 1994, AM J HUM GENET, V55, P638; WIRTZ MK, 1987, J BIOL CHEM, V262, P16376	49	90	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19259	19269		10.1074/jbc.M414698200	http://dx.doi.org/10.1074/jbc.M414698200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15728585	hybrid			2022-12-27	WOS:000228932300083
J	Billault, I; Duan, JR; Guiet, S; Robins, RJ				Billault, I; Duan, JR; Guiet, S; Robins, RJ			Quantitative deuterium isotopic profiling at natural abundance indicates mechanistic differences for Delta(12)-epoxidase and Delta(12)-desaturase in Vernonia galamensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-2 NMR-SPECTROSCOPY; FATTY-ACIDS; EUPHORBIA-LAGASCAE; RICINOLEIC ACID; MICROSOMAL PREPARATIONS; THYMIDYLATE SYNTHETASE; RICINUS-COMMUNIS; ELECTRON-DONOR; BIOSYNTHESIS; CYTOCHROME-P450	Quantitative H-2 NMR spectroscopy can determine the natural abundance (H-2/H-1) ratio at each site of a molecule. In natural products, variation in these values is related to the reaction mechanisms in the pertinent biosynthetic pathway. For the first time, this novel approach has been exploited to probe for mechanistic differences in the introduction of different functionalities into a long-chain fatty acid. Vernolic acid, a major component of the seed oil of Vernonia galamensis, contains both an epoxide and a desaturation. The site-specific isotopic distribution (H-2/H-1)(i) has been determined for both vernolic acid and linoleic acid isolated from the same V. galamensis oil. It is found that the ((2) H/H-1) ratio of vernolic acid shows a pattern along the entire length of the chain, consistent with linoleic acid being its immediate precursor. Notably, the C13 relates to the C13 of linoleic acid but not to the C13 of oleic acid. Furthermore, the C12 and C13 positions in vernolic acid are less depleted, consistent with a change in hybridization state from sp(2) to sp(3). However, the C11 position shows a marked relative enrichment in the vernolic acid, implying that it plays a role in the epoxidase but not the desaturase mechanism. Thus, although it can be concluded that the catalytic mechanisms for the epoxidase and desaturase activities are similar, marked differences in the residual (H-2/H-1) patterns indicate that the reaction mechanisms are not identical.	Univ Nantes, LAIEM, CNRS, UMR6006,Grp Fractionnement Isotop Metab, F-44322 Nantes, France	Centre National de la Recherche Scientifique (CNRS); Nantes Universite	Billault, I (corresponding author), Univ Nantes, LAIEM, CNRS, UMR6006,Grp Fractionnement Isotop Metab, BP 99208, F-44322 Nantes, France.	isabelle.billault@univ-nantes.fr		Robins, Richard/0000-0002-5325-8983				BAFOR M, 1993, ARCH BIOCHEM BIOPHYS, V303, P145, DOI 10.1006/abbi.1993.1265; BARR PJ, 1983, BIOCHEMISTRY-US, V22, P1696, DOI 10.1021/bi00276a027; Behrouzian B., 2003, Phytochemistry Reviews, V2, P103, DOI 10.1023/B:PHYT.0000004179.31385.0a; Billault I, 2004, J AM CHEM SOC, V126, P3250, DOI 10.1021/ja038814d; Billault I, 2002, ANAL CHEM, V74, P5902, DOI 10.1021/ac025867p; Billault I, 2001, CHEMBIOCHEM, V2, P425; BLEE E, 1993, BIOCHEM BIOPH RES CO, V197, P778, DOI 10.1006/bbrc.1993.2546; BLEE E, 1990, J BIOL CHEM, V265, P12887; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Cahoon EB, 2002, PLANT PHYSIOL, V128, P615, DOI 10.1104/pp.010768; Coon MJ, 2003, BIOCHEM BIOPH RES CO, V312, P163, DOI 10.1016/j.bbrc.2003.10.084; Duan JR, 2002, CHEMBIOCHEM, V3, P752, DOI 10.1002/1439-7633(20020802)3:8<752::AID-CBIC752>3.0.CO;2-G; DUAN JR, 2002, THESIS U NANTES NANT, P200; GARRETT C, 1979, BIOCHEMISTRY-US, V18, P2798, DOI 10.1021/bi00580a017; GRECHKIN AN, 1990, PLANT SCI, V70, P175, DOI 10.1016/0168-9452(90)90131-7; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; Guiet S, 2003, PHYTOCHEMISTRY, V64, P227, DOI 10.1016/S0031-9422(03)00278-4; Harwood J.L., 1997, PLANT BIOCH, P237; Hitz WD, 1998, U.S. Patent, Patent No. [5,846,784, 5846784]; Kim H, 2000, J IND MICROBIOL BIOT, V24, P167, DOI 10.1038/sj.jim.2900804; Koerner T, 1999, J ORG CHEM, V64, P196, DOI 10.1021/jo981652x; Kolot V, 2004, J APPL POLYM SCI, V91, P3835, DOI 10.1002/app.13583; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; MARTIN GJ, 1998, FRESEN Z ANAL CHEM, V322, P648; Martin M. L., 1990, NMR-BASIC PRINC PROG, V23, P1; MAZLIAK P, 1994, J PLANT PHYSIOL, V143, P399, DOI 10.1016/S0176-1617(11)81799-2; MORRIS LJ, 1970, BIOCHEM J, V118, P681, DOI 10.1042/bj1180681g; Robins Richard J., 2003, Phytochemistry Reviews, V2, P87, DOI 10.1023/B:PHYT.0000004301.52646.a8; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; SALAUN JP, 1989, FEBS LETT, V2, P120; Schmidt Hanns-Ludwig, 2003, Phytochemistry Reviews, V2, P61, DOI 10.1023/B:PHYT.0000004185.92648.ae; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; Sperling P, 2001, EUR J LIPID SCI TECH, V103, P158, DOI 10.1002/1438-9312(200103)103:3<158::AID-EJLT158>3.0.CO;2-1; VALENTINE JS, 1995, SEARCH SERIES; Vaz ADN, 1998, P NATL ACAD SCI USA, V95, P3555, DOI 10.1073/pnas.95.7.3555; WEISSBART D, 1992, BIOCHIM BIOPHYS ACTA, V1124, P135, DOI 10.1016/0005-2760(92)90089-E	40	12	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17645	17651		10.1074/jbc.M500909200	http://dx.doi.org/10.1074/jbc.M500909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722338	hybrid			2022-12-27	WOS:000228807200011
J	Busschots, K; Vercammen, J; Emiliani, S; Benarous, R; Engelborghs, Y; Christ, F; Debyser, Z				Busschots, K; Vercammen, J; Emiliani, S; Benarous, R; Engelborghs, Y; Christ, F; Debyser, Z			The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FLUORESCENCE CORRELATION SPECTROSCOPY; NUCLEAR-LOCALIZATION SIGNAL; GROWTH-FACTOR LEDGF/P75; HIV-1 INTEGRASE; TYPE-1 INTEGRASE; ESCHERICHIA-COLI; HUMAN-CELLS; IN-VITRO; PREINTEGRATION COMPLEXES	We have previously shown that the p75 isoform of the transcriptional co-activator lens epithelium-derived growth factor ( LEDGF) interacts tightly with human immunodeficiency virus (HIV)-1 integrase ( IN) and is essential for nuclear targeting of this protein in human cells (Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., and Debyser, Z. ( 2003) J. Biol. Chem. 278, 372 - 381; Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., and Engelborghs, Y. ( 2003) J. Biol. Chem. 278, 33528 - 33539). Here the interaction between recombinant LEDGF/p75 and HIV-1 IN was examined in a pull-down binding test. LEDGF/p75 was shown to increase the solubility of HIV-1 IN. Next, fluorescent correlation spectroscopy was used to measure the interaction of LEDGF/p75 or the complex of HIV-1 IN and LEDGF/p75 with a specific double-stranded DNA oligonucleotide. Whereas LEDGF/p75 displayed only a moderate affinity for DNA, it strongly promoted the binding of HIV-1 IN to DNA. This effect was specific for the p75 isoform of LEDGF and was not seen with p52. In the pull-down assay LEDGF/p75 interacted with HIV-1, HIV-2, and feline immunodeficiency virus IN, but not with the IN of human T-cell lymphotropic virus type 2, Moloney murine leukemia virus, or Rous sarcoma virus. These results strongly suggest that the interaction of LEDGF/p75 with IN is specific to lentiviridae. LEDGF/ p75 stimulated the binding of HIV-1 and HIV-2 IN, but not Moloney murine leukemia virus or Rous sarcoma virus IN, to an aspecific DNA. These results provide supporting evidence for our hypothesis that LEDGF/ p75 plays a role in the tethering of lentiviral IN to the chromosomal DNA.	Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Flanders, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, B-3000 Louvain, Flanders, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Flanders, Belgium; Inst Cochin Genet Mol, Dept Infect Dis, CNRS, UMR8104,INSERM,U567, F-75104 Paris, France	KU Leuven; KU Leuven; KU Leuven; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Debyser, Z (corresponding author), Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Kapucijnenvoer 33, B-3000 Louvain, Flanders, Belgium.	zeger.debyser@med.kuleuven.ac.be	Christ, Frauke/H-7513-2018	Christ, Frauke/0000-0001-9580-3874				Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BROWN PO, 1997, CURR TOP MICROBIOL, V157, P19; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Chiu R, 2003, J VIROL, V77, P6482, DOI 10.1128/JVI.77.11.6482-6492.2003; Coffin J. M., 1997, RETROVIRUSES, P1; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONSSON CB, 1993, J BIOL CHEM, V268, P1462; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MILLER MD, 1995, CURR BIOL, V5, P368, DOI 10.1016/S0960-9822(95)00074-1; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; PRUSS D, 1994, J BIOL CHEM, V269, P25031; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; Van Craenenbroeck E, 1999, BIOCHEMISTRY-US, V38, P5082, DOI 10.1021/bi9821925; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Van Craenenbroeck E, 2001, BIOL CHEM, V382, P355; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; Villanueva RA, 2003, VIROLOGY, V316, P146, DOI 10.1016/S0042-6822(03)00559-2; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; Violot S, 2003, J VIROL, V77, P12507, DOI 10.1128/JVI.77.23.12507-12522.2003; Wang T, 2001, J BIOL CHEM, V276, P14710, DOI 10.1074/jbc.M007754200; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	56	164	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17841	17847		10.1074/jbc.M411681200	http://dx.doi.org/10.1074/jbc.M411681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749713	hybrid			2022-12-27	WOS:000228807200036
J	El Bakkouri, K; Wullaert, A; Haegman, M; Heyninck, K; Beyaert, R				El Bakkouri, K; Wullaert, A; Haegman, M; Heyninck, K; Beyaert, R			Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE; INCREASED EXPRESSION; EOTAXIN EXPRESSION; IN-VIVO; ACTIVATION; TRANSCRIPTION; EOSINOPHILS; REGULATORS; APOPTOSIS	Airway inflammation is a characteristic of many lung disorders, including asthma and chronic obstructive pulmonary disease. Using a murine model of allergen-induced asthma, we have demonstrated that adenovirus-mediated delivery of the nuclear factor-kappa B (NF-kappa B) inhibitory protein ABIN-1 to the lung epithelium results in a considerable reduction of allergen-induced eosinophil infiltration into the lungs. This is associated with an ABIN-1-induced decrease in allergen-specific immunoglobulin E levels in serum, as well as a significant reduction of eotaxin, interleukin-4, and interleukin-1 beta in bronchoalveolar lavage fluid. These findings not only prove that NF-kappa B plays a critical role in the pathogenesis of allergic inflammation but also illustrate that inhibiting NF-kappa B could have therapeutic value in the treatment of asthma and potentially other chronic inflammatory lung diseases.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.UGent.be	Bakkouri, Karim El/C-2992-2009; El Bakkouri, Karim/H-9253-2018; Wullaert, Andy/D-2975-2018; Beyaert, Rudi/B-2589-2009; Wullaert, Andy/R-1924-2019	El Bakkouri, Karim/0000-0001-9102-9877; Wullaert, Andy/0000-0001-5012-654X; Wullaert, Andy/0000-0001-5012-654X; Beyaert, Rudi/0000-0002-5704-582X; Haegman, Mira/0000-0002-4883-312X				Adcock IM, 2003, CURR ALLERGY ASTHM R, V3, P249, DOI 10.1007/s11882-003-0047-0; Barnes PJ, 2003, CYTOKINE GROWTH F R, V14, P511, DOI 10.1016/S1359-6101(03)00058-3; Barnes PJ, 2001, RESPIR RES, V2, P64, DOI 10.1186/rr39; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Corry David B, 2002, Am J Respir Med, V1, P185; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; Desmet C, 2004, J IMMUNOL, V173, P5766, DOI 10.4049/jimmunol.173.9.5766; Donovan CE, 1999, J IMMUNOL, V163, P6827; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Grempler R, 2004, BIOCHEM J, V382, P471, DOI 10.1042/BJ20040160; Hastie AT, 1996, CYTOKINE, V8, P730, DOI 10.1006/cyto.1996.0097; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517; Jedrzkiewicz S, 2000, AM J PHYSIOL-LUNG C, V279, pL1058, DOI 10.1152/ajplung.2000.279.6.L1058; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Kumar RK, 2002, LAB INVEST, V82, P495, DOI 10.1038/labinvest.3780442; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Pastva A, 2004, J IMMUNOL, V172, P4520, DOI 10.4049/jimmunol.172.7.4520; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Popescu FD, 2003, J CELL MOL MED, V7, P475, DOI 10.1111/j.1582-4934.2003.tb00251.x; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Sadikot RT, 2003, J IMMUNOL, V170, P1091, DOI 10.4049/jimmunol.170.2.1091; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Thorne PS, 1999, AM J RESP CELL MOL, V20, P1155, DOI 10.1165/ajrcmb.20.6.3632; van der Velden VHJ, 1998, EUR CYTOKINE NETW, V9, P585; Williams TJ, 2000, CHEM IMMUNOL, V78, P166; Wright Jeffrey G, 2003, Am J Respir Med, V2, P211; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	37	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17938	17944		10.1074/jbc.M413588200	http://dx.doi.org/10.1074/jbc.M413588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722346	hybrid			2022-12-27	WOS:000228807200047
J	Li, WM; Pi, RB; Chan, HHN; Fu, HJ; Lee, NTK; Tsang, HW; Pu, YM; Chang, DC; Li, CY; Luo, JL; Xiong, KM; Li, ZW; Xue, H; Carlier, PR; Pang, YP; Tsim, KWK; Li, MT; Han, YF				Li, WM; Pi, RB; Chan, HHN; Fu, HJ; Lee, NTK; Tsang, HW; Pu, YM; Chang, DC; Li, CY; Luo, JL; Xiong, KM; Li, ZW; Xue, H; Carlier, PR; Pang, YP; Tsim, KWK; Li, MT; Han, YF			Novel dimeric acetylcholinesterase inhibitor bis(7)-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-ALZHEIMERS AGENT; ACTIVATION; P38; EXCITOTOXICITY; EXPRESSION; DISEASE; DEATH; INVOLVEMENT; ANTAGONIST; MEMANTINE	The neuroprotective properties of bis(7)-tacrine, a novel dimeric acetylcholinesterase (AChE) inhibitor, on glutamate-induced excitotoxicity were investigated in primary cultured cerebellar granule neurons (CGNs). Exposure of CGNs to 75 mu M glutamate resulted in neuronal apoptosis as demonstrated by Hoechst staining, TUNEL, and DNA fragmentation assays. The bis(7)-tacrine treatment ( 0.01 - 1 mu M) on CGNs markedly reduced glutamate-induced apoptosis in dose-and time-dependent manners. However, donepezil and other AChE inhibitors, even at concentrations of inhibiting AChE to the similar extents as 1 mu M bis( 7)- tacrine, failed to prevent glutamate-induced excitotoxicity in CGNs; moreover, both atropine and dihydro-beta-erythroidine, the cholinoreceptor antagonists, did not affect the anti-apoptotic properties of bis( 7)- tacrine, suggesting that the neuroprotection of bis( 7)- tacrine appears to be independent of inhibiting AChE and cholinergic transmission. In addition, ERK1/2 and p38 pathways, downstream signals of N-methyl-D-aspartate ( NMDA) receptors, were rapidly activated after the exposure of glutamate to CGNs. Bis(7)-tacrine inhibited the apoptosis and the activation of these two signals with the same efficacy as the coapplication of PD98059 and SB203580. Furthermore, using fluorescence Ca2+ imaging, patch clamp, and receptor-ligand binding techniques, bis( 7)- tacrine was found effectively to buffer the intracellular Ca2+ increase triggered by glutamate, to reduce NMDA-activated currents and to compete with [H-3] MK-801 with an IC50 value of 0.763 mu M in rat cerebellar cortex membranes. These findings strongly suggest that bis( 7)- tacrine prevents glutamate-induced neuronal apoptosis through directly blocking NMDA receptors at the MK-801-binding site, which offers a new and clinically significant modality as to how the agent exerts neuroprotective effects.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Mol & Cellular Neurobiol, Wuhan 430030, Peoples R China; NIAAA, Mol & Cellular Neurobiol Lab, Bethesda, MD 20892 USA; Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA; Mayo Fdn Med Educ & Res, Rochester, MN 55905 USA; Sun Yat Sen Univ, Dept Pharmacol, Guangzhou 510080, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Huazhong University of Science & Technology; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Virginia Polytechnic Institute & State University; Mayo Clinic; Sun Yat Sen University	Han, YF (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	bcyfhan@ust.hk	Chang, Donald/AAV-7180-2021; FU, HONGJUN/H-4498-2011; Fu, Hongjun/ABB-3558-2021	FU, HONGJUN/0000-0001-5346-7075; Carlier, Paul/0000-0002-6683-285X; Xue, Hong/0000-0002-8133-9828; Tsim, Karl/0000-0003-4808-1674; Han, Yifan/0000-0002-5833-069X; Pang, Yuan-Ping/0000-0003-0838-2560				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Blandini F, 1996, FUNCT NEUROL, V11, P3; Calderon FH, 1998, MOL PSYCHIATR, V3, P247, DOI 10.1038/sj.mp.4000383; Chen RW, 2003, J NEUROCHEM, V84, P566, DOI 10.1046/j.1471-4159.2003.01548.x; Danysz W, 2003, INT J GERIATR PSYCH, V18, pS23, DOI 10.1002/gps.938; De Ferrari GV, 2001, BIOCHEMISTRY-US, V40, P10447, DOI 10.1021/bi0101392; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Han YF, 2000, NEUROSCI LETT, V288, P95, DOI 10.1016/S0304-3940(00)01198-8; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liu J, 2000, NEUROSCI LETT, V282, P165, DOI 10.1016/S0304-3940(00)00905-8; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Meyer EL, 2002, J BIOL CHEM, V277, P10869, DOI 10.1074/jbc.M106744200; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pang YP, 1996, J BIOL CHEM, V271, P23646, DOI 10.1074/jbc.271.39.23646; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Rees T, 2003, NEUROBIOL AGING, V24, P777, DOI 10.1016/S0197-4580(02)00230-0; Robitzki A, 1998, J NEUROCHEM, V71, P1413; Santos MD, 2002, MOL PHARMACOL, V61, P1222, DOI 10.1124/mol.61.5.1222; Small DH, 2004, TRENDS NEUROSCI, V27, P245, DOI 10.1016/j.tins.2004.03.006; Soreq H, 2000, ISRAEL MED ASSOC J, V2, P81; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Standridge JB, 2004, CLIN THER, V26, P615, DOI 10.1016/S0149-2918(04)90064-1; Sugimoto H, 2000, CURR MED CHEM, V7, P303, DOI 10.2174/0929867003375191; Villarroya M, 2004, CURR PHARM DESIGN, V10, P3177, DOI 10.2174/1381612043383368; Voisin T, 2004, CNS DRUGS, V18, P575, DOI 10.2165/00023210-200418090-00003; Wang H, 1999, NEUROREPORT, V10, P789, DOI 10.1097/00001756-199903170-00023; Wang R, 2002, MOL BRAIN RES, V107, P1, DOI 10.1016/S0169-328X(02)00402-3; Wang R, 2001, EUR J PHARMACOL, V421, P149, DOI 10.1016/S0014-2999(01)01030-5; Weinstock M, 1995, NEURODEGENERATION, V4, P349, DOI 10.1006/neur.1995.0042; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; Xiao XQ, 2000, NEUROSCI LETT, V290, P197, DOI 10.1016/S0304-3940(00)01357-4; Xiao XQ, 2002, J NEUROSCI RES, V67, P30, DOI 10.1002/jnr.10075; YAN GM, 1995, MOL PHARMACOL, V47, P248; Yan XZ, 2000, BRAIN RES BULL, V51, P465, DOI 10.1016/S0361-9230(99)00255-5; Yang L, 2002, NEUROSCI RES, V42, P261, DOI 10.1016/S0168-0102(02)00005-6; Zhang XJ, 2002, CELL DEATH DIFFER, V9, P790, DOI 10.1038/sj.cdd.4401034; ZILBERTER Y, 1991, MOL PHARMACOL, V40, P337	49	97	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18179	18188		10.1074/jbc.M411085200	http://dx.doi.org/10.1074/jbc.M411085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15710623	hybrid, Green Submitted			2022-12-27	WOS:000228807200076
J	Sarsour, EH; Agarwal, M; Pandita, TK; Oberley, LW; Goswami, PC				Sarsour, EH; Agarwal, M; Pandita, TK; Oberley, LW; Goswami, PC			Manganese superoxide dismutase protects the proliferative capacity of confluent normal human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT DROSOPHILA-MELANOGASTER; DEPENDENT KINASE INHIBITORS; REPLICATIVE LIFE-SPAN; CANCER CELL-GROWTH; OXIDATIVE STRESS; FREE-RADICALS; N-ACETYLCYSTEINE; EPITHELIAL-CELLS; CYCLE ARREST; SENESCENCE	We tested the hypothesis that manganese superoxide dismutase (MnSOD), an antioxidant enzyme, regulates the proliferative potential of confluent human fibroblasts. Normal human skin ( AG01522) and lung (WI38, CCL-75) fibroblasts kept in confluence (> 95% G(0)/G(1)) showed a significant decrease in their capacity to reenter the proliferation cycle after 40 - 60 days. The inhibition of re-entry was accompanied with the age-dependent increase of p16 protein levels in the confluent culture. Adenoviral mediated overexpression of MnSOD during confluent growth suppressed p16, enhanced p21 protein accumulation, and protected fibroblasts against the loss of proliferation potential. Increases in p21 protein levels in MnSOD overexpressing confluent fibroblasts were independent of p53 protein levels. p53 protein levels did not change in control, replication-defective adenovirus containing an insertless vector (AdBgl II), or AdMnSOD-infected confluent cells cultured for 20 and 60 days. In addition, MnSOD-induced protection of the proliferation capacity of confluent fibroblasts was independent of their telomerase activity. However, telomerase-transformed fibroblasts showed increased MnSOD expression in confluent growth, maintaining their capacity to re-enter the proliferation cycle. Although inactivation of the retinoblastoma protein in cells subcultured from the 60-day confluent control, AdBgl II-, and AdMnSOD-infected fibroblasts was identical, only MnSOD-overexpressing cells showed a higher percentage of S-phase. These results support the hypothesis that a redox-sensitive checkpoint regulated the progression of fibroblasts from G(0)/G(1) to S-phase.	Univ Iowa, Dept Radiat Oncol, Med Labs B180, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63108 USA	University of Iowa; Washington University (WUSTL)	Goswami, PC (corresponding author), Univ Iowa, Dept Radiat Oncol, Med Labs B180, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA.	prabhat-goswami@uiowa.edu	Pandita, Tej K/AAM-9188-2020	Goswami, Prabhat/0000-0002-5700-2096; Sarsour, Ehab/0000-0002-9384-5509	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NCI NIH HHS [5P01 CA66081] Funding Source: Medline; NINDS NIH HHS [NS34736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dulic V, 2000, MOL CELL BIOL, V20, P6741, DOI 10.1128/MCB.20.18.6741-6754.2000; Fabrizio P, 2004, FEBS LETT, V557, P136, DOI 10.1016/S0014-5793(03)01462-5; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GRANA X, 1995, ONCOGENE, V11, P211; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200; Liu JR, 2004, HUM GENE THER, V15, P239, DOI 10.1089/104303404322886093; Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Menon SG, 2003, CANCER RES, V63, P2109; Munro J, 2001, ONCOGENE, V20, P3541, DOI 10.1038/sj.onc.1204460; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NEVINS JR, 1992, SCIENCE, V258, P424; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; Serra V, 2003, J BIOL CHEM, V278, P6824, DOI 10.1074/jbc.M207939200; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Sun JT, 2002, GENETICS, V161, P661; Sun JT, 1999, MOL CELL BIOL, V19, P216; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Weydert CJD, 2003, FREE RADICAL BIO MED, V34, P316, DOI 10.1016/S0891-5849(02)01245-5; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	52	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18033	18041		10.1074/jbc.M501939200	http://dx.doi.org/10.1074/jbc.M501939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743756	hybrid			2022-12-27	WOS:000228807200059
J	Tottene, A; Pivotto, F; Fellin, T; Cesetti, T; van den Maagdenberg, AMJM; Pietrobon, D				Tottene, A; Pivotto, F; Fellin, T; Cesetti, T; van den Maagdenberg, AMJM; Pietrobon, D			Specific kinetic alterations of human Ca(V)2.1 calcium channels produced by mutation S218L causing familial hemiplegic migraine and delayed cerebral edema and coma after minor head trauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL SPREADING DEPRESSION; EPISODIC ATAXIA TYPE-2; CEREBELLAR-ATAXIA; FUNCTIONAL CONSEQUENCES; CENTRAL NEURONS; CA2+ CHANNELS; SUBUNIT; DEPOLARIZATION; MECHANISMS; MICE	Mutation S218L in the Ca(V)2.1 alpha(1) subunit of P/Q-type Ca2+ channels produces a severe clinical phenotype in which typical attacks of familial hemiplegic migraine (FHM) triggered by minor head trauma are followed, after a lucid interval, by deep (even fatal) coma and long lasting severe cerebral edema. We investigated the functional consequences of this mutation on human Ca(V)2.1 channels expressed in human embryonic kidney 293 cells and in neurons from Ca(V)2.1 alpha(-/-)(1) mice by combining single channel and whole cell patch clamp recordings. Mutation S218L produced a shift to lower voltages of the single channel activation curve and a consequent increase of both single channel and whole cell Ba2+ influx in both neurons and human embryonic kidney 293 cells. Compared with the other FHM-1 mutants, the S218L shows one of the largest gains of function, especially for small depolarizations, which are insufficient to open the wild-type channel. S218L channels open at voltages close to the resting potential of many neurons. Moreover, the S218L mutation has unique effects on the kinetics of inactivation of the channel because it introduces a large component of current that inactivates very slowly, and it increases the rate of recovery from inactivation. During long depolarizations at voltages that are attained during cortical spreading depression, the extent of inactivation of the S218L channel is considerably smaller than that of the wild-type channel. We discuss how the unique combination of a particularly slow inactivation during cortical spreading depression and a particularly low threshold of channel activation might lead to delayed severe cerebral edema and coma after minor head trauma.	Univ Padua, Dept Biomed Sci, CNR Inst Neurosci, I-35121 Padua, Italy; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands	Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Padua; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Pietrobon, D (corresponding author), Univ Padua, Dept Biomed Sci, CNR Inst Neurosci, Viale G Colombo 3, I-35121 Padua, Italy.	daniela.pietrobon@unipd.it	van den Maagdenberg, Arn M.J.M./AAE-9052-2019		Telethon [E.1297] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Alonso I, 2004, CLIN GENET, V65, P70, DOI 10.1111/j..2004.00187.x; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ayata C, 2000, NEUROSCIENCE, V95, P639; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Bowyer SM, 2001, ANN NEUROL, V50, P582, DOI 10.1002/ana.1293; Cao YQ, 2004, NEURON, V43, P387, DOI 10.1016/j.neuron.2004.07.014; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FITZSIMONS RB, 1985, BRAIN, V108, P555, DOI 10.1093/brain/108.3.555-a; Fletcher CF, 2001, FASEB J, V15, P1288, DOI 10.1096/fj.00-0562fje; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Haan Joost, 2004, Curr Pain Headache Rep, V8, P238, DOI 10.1007/s11916-004-0058-0; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hans M, 1999, J NEUROSCI, V19, P1610; KAJA S, 2004, SOC NEUR 34 ANN M OC; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kors EE, 2004, NEUROLOGY, V63, P1136, DOI 10.1212/01.WNL.0000138571.48593.FC; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Mullner C, 2004, J BIOL CHEM, V279, P51844, DOI 10.1074/jbc.M408756200; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; PIETROBON D, 2005, IN PRESS NEUROSCIENT; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; SHAPOVALOVA M, 2004, SOC NEUR 34 ANN M OC; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Thomsen LL, 2002, BRAIN, V125, P1379, DOI 10.1093/brain/awf132; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Wappl E, 2002, J BIOL CHEM, V277, P6960, DOI 10.1074/jbc.M110948200; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403	42	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17678	17686		10.1074/jbc.M501110200	http://dx.doi.org/10.1074/jbc.M501110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743764	hybrid			2022-12-27	WOS:000228807200016
J	Tummala, H; Jung, C; Tiwari, A; Higgins, CMJ; Hayward, LJ; Xu, ZS				Tummala, H; Jung, C; Tiwari, A; Higgins, CMJ; Hayward, LJ; Xu, ZS			Inhibition of chaperone activity is a shared property of several Cu,Zn-superoxide dismutase mutants that cause amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN-SUPEROXIDE-DISMUTASE; TRANSGENIC-MOUSE MODEL; MOTOR-NEURON DISEASE; ALS-LINKED SOD1; CELL-DEATH; HYDROGEN-PEROXIDE; UP-REGULATION; NEURODEGENERATIVE DISEASES; MOTONEURON DEGENERATION; MOLECULAR CHAPERONES	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron degeneration, paralysis, and death. Mutant Cu, Zn-superoxide dismutase (SOD1) causes a subset of ALS by an unidentified toxic property. Increasing evidence suggests that chaperone dysfunction plays a role in motor neuron degeneration in ALS. To investigate the relationship between mutant SOD1 expression and chaperone dysfunction, we measured chaperone function in central nervous system tissue lysates from normal mice and transgenic mice expressing human SOD1 variants. We observed a significant decrease in chaperone activity in tissues from mice expressing ALS-linked mutant SOD1 but not control mice expressing human wild type SOD1. This decrease was detected only in the spinal cord, became apparent by 60 days of age ( before the onset of muscle weakness and significant motor neuron loss), and persisted throughout the late stages. In addition, this impairment of chaperone activity occurred only in cytosolic but not in mitochondrial and nuclear fractions. Furthermore, multiple recombinant human SOD1 mutants with differing biochemical and biophysical properties inhibited chaperone function in a cell-free extract of normal mouse spinal cords. Thus, mutant SOD1 proteins may impair chaperone function independent of gene expression in vivo, and this inhibition may be a shared property of ALS-linked mutant SOD1 proteins.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Neurosci Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Xu, ZS (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, 364 Plantat St, Worcester, MA 01605 USA.	zuoshang.xu@umassmed.edu	Tiwari, Ashutosh/A-7458-2008	Tiwari, Ashutosh/0000-0001-7373-349X; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170, R01NS041739] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS44170, R01 NS41739, R01 NS044170] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X; Batulan Z, 2003, J NEUROSCI, V23, P5789; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Behndig A, 2001, FREE RADICAL BIO MED, V31, P738, DOI 10.1016/S0891-5849(01)00651-7; Bommel H, 2002, J CELL BIOL, V159, P563, DOI 10.1083/jcb.200208001; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bush AI, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919a; Chen YZ, 2004, AM J HUM GENET, V74, P1128, DOI 10.1086/421054; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Flood DG, 1999, AM J PATHOL, V155, P663, DOI 10.1016/S0002-9440(10)65162-0; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Heath PR, 2002, MUSCLE NERVE, V26, P438, DOI 10.1002/mus.10186; Hemachand T, 2002, J CELL SCI, V115, P2053; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052; Higgins CMJ, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-16; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; Hosler BA, 2000, JAMA-J AM MED ASSOC, V284, P1664, DOI 10.1001/jama.284.13.1664; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jung CW, 2002, J NEUROCHEM, V83, P535, DOI 10.1046/j.1471-4159.2002.01112.x; Kawase M, 1999, STROKE, V30, P1962, DOI 10.1161/01.STR.30.9.1962; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kondo T, 1997, J NEUROSCI, V17, P4180; Kong JM, 1998, J NEUROSCI, V18, P3241; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Lee JP, 2002, J NEUROCHEM, V82, P1229, DOI 10.1046/j.1471-4159.2002.01056.x; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Liochev SI, 2003, FREE RADICAL BIO MED, V34, P1383, DOI 10.1016/S0891-5849(03)00153-9; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Maatkamp A, 2004, EUR J NEUROSCI, V20, P14, DOI 10.1111/j.1460-9568.2004.03430.x; Martin N, 2002, NAT GENET, V32, P443, DOI 10.1038/ng1016; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Matz PG, 2000, STROKE, V31, P2450, DOI 10.1161/01.STR.31.10.2450; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; McFadden SL, 2001, AUDIOLOGY, V40, P313; MONTGOMERY R, 1976, QUANTITATIVE PROBLEM, P222; Muqit MMK, 2002, NAT REV NEUROSCI, V3, P237, DOI 10.1038/nrn751; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Puttaparthi K, 2003, J NEUROCHEM, V87, P851, DOI 10.1046/j.1471-4159.2003.02028.x; Rajapakse N, 2001, BRAIN RES PROTOC, V8, P176, DOI 10.1016/S1385-299X(01)00108-8; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1996, NEUROLOGY, V47, P19; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sapp PC, 2003, AM J HUM GENET, V73, P397, DOI 10.1086/377158; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Shefner JM, 1999, NEUROLOGY, V53, P1239, DOI 10.1212/WNL.53.6.1239; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Takeuchi H, 2002, BRAIN RES, V949, P11, DOI 10.1016/S0006-8993(02)02568-4; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vleminckx V, 2002, J NEUROPATH EXP NEUR, V61, P968, DOI 10.1093/jnen/61.11.968; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Wong PC, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919b; Xu ZS, 2000, AMYOTROPH LATERAL SC, V1, P225, DOI 10.1080/14660820050515052; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Yim HS, 1997, J BIOL CHEM, V272, P8861; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307	90	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17725	17731		10.1074/jbc.M501705200	http://dx.doi.org/10.1074/jbc.M501705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753080	hybrid			2022-12-27	WOS:000228807200022
J	Dhakshinamoorthy, S; Jain, AK; Bloom, DA; Jaiswal, AK				Dhakshinamoorthy, S; Jain, AK; Bloom, DA; Jaiswal, AK			Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H : quinone oxidoreductase 1 gene expression and induction in response to antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; MAF RECOGNITION ELEMENT; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; MEDIATED EXPRESSION; FUNCTIONAL-CHARACTERIZATION; NUCLEAR EXPORT; ACTIVATION; REPRESSOR; NAD(P)H	The antioxidant response element ( ARE) and Nrf2 are known to regulate the expression and coordinated induction of genes encoding detoxifying enzymes including NAD( P) H: quinone oxidoreductase1 (NQO1) in response to antioxidants. In this report, we demonstrate that overexpression of the transcription factor Bach1 in Hep-G2 cells negatively regulated NQO1 gene expression and induction in response to antioxidant t-BHQ. Bandshift and supershift assays revealed that Bach1 binds to the ARE as a heterodimer with small Maf proteins but not as a homodimer or heterodimer with Nrf2. The transfection and ChIP assays revealed that Bach1 and Nrf2 competed with each other to regulate ARE-mediated gene expression. Heme, a negative regulator of Bach1 relieved the Bach1 repression of NQO1 gene expression in transfected cells. The transcription of Bach1 and Nrf2 did not change in response to t-BHQ. Immunofluorescence assays and Western blot analysis revealed that both Bach1 and Nrf2 localized in the cytoplasm and nucleus of the untreated cells. The treatment of cells with t-BHQ resulted in the nuclear accumulation of both Bach1 and Nrf2. Interestingly, the t-BHQ-induced nuclear accumulation of Bach1 was significantly delayed over that of Nrf2. These results led to the conclusion that a balance of Nrf2 versus Bach1 inside the nucleus influences up- or down-regulation of ARE-mediated gene expression. The results further suggest that antioxidant-induced delayed accumulation of Bach1 contributes to the down-regulation of ARE-regulated genes, presumably to reduce the antioxidant enzymes to normal levels.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Jain, Abhinav K/A-2540-2013	Jain, Abhinav/0000-0003-3268-514X	NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200; KANNAN S, 2004, J BIOL CHEM, V279, P50810; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Radjendirane Venugopal, 1997, P441; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	37	298	316	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16891	16900		10.1074/jbc.M500166200	http://dx.doi.org/10.1074/jbc.M500166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734732	hybrid			2022-12-27	WOS:000228615500043
J	Lonskaya, I; Potaman, VN; Shlyakhtenko, LS; Oussatcheva, EA; Lyubchenko, YL; Soldatenkov, VA				Lonskaya, I; Potaman, VN; Shlyakhtenko, LS; Oussatcheva, EA; Lyubchenko, YL; Soldatenkov, VA			Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; ADP-RIBOSYLTRANSFERASE; CHROMATIN; PARP; PROMOTER; RIBOSYLATION; SEQUENCES; COMPLEX; ELEMENT; PROTEIN	Poly(ADP-ribose) polymerase-1 (PARP-1) is an intracellular sensor of DNA strand breaks and plays a critical role in cellular responses to DNA damage. In normally functioning cells, PARP-1 enzymatic activity has been linked to the alterations in chromatin structure associated with gene expression. However, the molecular determinants for PARP-1 recruitment to specific sites in chromatin in the absence of DNA strand breaks remain obscure. Using gel shift and enzymatic footprinting assays and atomic force microscopy, we show that PARP-1 recognizes distortions in the DNA helical backbone and that it binds to three- and four-way junctions as well as to stably unpaired regions in double-stranded DNA. PARP-1 interactions with non-B DNA structures are functional and lead to its catalytic activation. DNA hairpins, cruciforms, and stably unpaired regions are all effective co-activators of PARP-1 auto-modification and poly( ADP-ribosyl) ation of histone H1 in the absence of free DNA ends. Enzyme kinetic analyses revealed that the structural features of non-B form DNA co-factors are important for PARP-1 catalysis activated by undamaged DNA. K-0.5 constants for DNA co-factors, which are structurally different in the degree of base pairing and spatial DNA organization, follow the order: cruciform <= hairpin << loop. DNA structure also influenced the reaction rate; when a hairpin was substituted with a stably unpaired region, the maximum reaction velocity decreased almost 2-fold. These data suggest a link between PARP-1 binding to non-B DNA structures in genome and its function in the dynamics of local modulation of chromatin structure in the normal physiology of the cell.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Radiat Med, Washington, DC 20057 USA; Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA	Georgetown University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Nebraska System; University of Nebraska Medical Center	Soldatenkov, VA (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Radiat Med, 3970 Reservoir Rd NW,Res Bldg,Rm E-204A,Box 57148, Washington, DC 20057 USA.	soldates@georgetown.edu			NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062235] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175-07] Funding Source: Medline; NIGMS NIH HHS [GM62235] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DESNOYERS S, 1995, BIOCHIMIE, V77, P433, DOI 10.1016/0300-9084(96)88156-9; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GAAL JC, 1985, BIOCHEM J, V230, P1; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GRADWOHL G, 1987, BIOCHEM BIOPH RES CO, V148, P913, DOI 10.1016/S0006-291X(87)80219-X; Kramer PR, 1999, J BIOL CHEM, V274, P28590, DOI 10.1074/jbc.274.40.28590; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kun E, 2004, BIOCHEMISTRY-US, V43, P210, DOI 10.1021/bi0301791; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LOETSCHER P, 1987, P NATL ACAD SCI USA, V84, P1286, DOI 10.1073/pnas.84.5.1286; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OEI SL, 1994, MOL CELL BIOCHEM, V138, P99, DOI 10.1007/BF00928449; Oussatcheva EA, 1999, J MOL BIOL, V292, P75, DOI 10.1006/jmbi.1999.3043; Pion E, 2003, BIOCHEMISTRY-US, V42, P12409, DOI 10.1021/bi0344432; Pomerantz JL, 1998, BIOCHEMISTRY-US, V37, P965, DOI 10.1021/bi972464o; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shlyakhtenko LS, 2000, NUCLEIC ACIDS RES, V28, P3472, DOI 10.1093/nar/28.18.3472; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P138; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Soldatenkov VA, 2004, CURR DRUG TARGETS, V5, P357, DOI 10.2174/1389450043345498; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	40	145	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17076	17083		10.1074/jbc.M413483200	http://dx.doi.org/10.1074/jbc.M413483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737996	hybrid			2022-12-27	WOS:000228615500066
J	Matsushima, Y; Adan, C; Garesse, R; Kaguni, LS				Matsushima, Y; Adan, C; Garesse, R; Kaguni, LS			Drosophila mitochondrial transcription factor B1 modulates mitochondrial translation but not transcription or DNA copy number in Schneider cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA METHYLTRANSFERASE; DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; KASUGAMYCIN RESISTANCE; GENETIC INTERFERENCE; 3' END; PROMOTER; ADENINE; BINDING	We report the cloning and molecular analysis of Drosophila mitochondrial transcription factor (d-mtTF) B1. An RNA interference (RNAi) construct was designed that reduces expression of d-mtTFB1 to 5% of its normal level in Schneider cells. In striking contrast with our previous study on d-mtTFB2, we found that RNAi knockdown of d-mtTFB1 does not change the abundance of specific mitochondrial RNA transcripts, nor does it affect the copy number of mitochondrial DNA. In a corollary manner, overexpression of d-mtTFB1 did not increase either the abundance of mitochondrial RNA transcripts or mitochondrial DNA copy number. Our data suggest that, unlike d-mtTFB2, d-mtTFB1 does not have a critical role in either transcription or regulation of the copy number of mitochondrial DNA. Instead, because we found that RNAi knockdown of d-mtTFB1 reduces mitochondrial protein synthesis, we propose that it serves its primary role in modulating translation. Our work represents the first study to document the role of mtTFB1 in vivo and establishes clearly functional differences between mtTFB1 and mtTFB2.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Univ Autonoma Madrid, Dept Bioquim, Inst Invest Biomed Alberto Sols, Consejo Super Invest Cient,Fac Med, Madrid 28029, Spain	Michigan State University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	lskaguni@msu.edu	Garesse, Rafael/F-3836-2012	Garesse, Rafael/0000-0002-0338-2281	NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; HELSER TL, 1972, NATURE-NEW BIOL, V235, P6, DOI 10.1038/newbio235006a0; HELSER TL, 1971, NATURE-NEW BIOL, V233, P12, DOI 10.1038/newbio233012a0; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; IGARASHI K, 1981, EUR J BIOCHEM, V113, P587, DOI 10.1111/j.1432-1033.1981.tb05103.x; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLOOTWIJK J, 1975, J MOL BIOL, V97, P337, DOI 10.1016/S0022-2836(75)80044-1; Lam G, 2000, CURR BIOL, V10, P957, DOI 10.1016/S0960-9822(00)00631-X; Lu Q, 1998, J BACTERIOL, V180, P5243, DOI 10.1128/JB.180.19.5243-5246.1998; Maravic G, 2003, J MOL BIOL, V332, P99, DOI 10.1016/S0022-2836(03)00863-5; Maravic G, 2003, NUCLEIC ACIDS RES, V31, P4941, DOI 10.1093/nar/gkg666; Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200; McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; O'Farrell HC, 2004, J MOL BIOL, V339, P337, DOI 10.1016/j.jmb.2004.02.068; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; POLDERMANS B, 1979, J BIOL CHEM, V254, P9094; Schluckebier G, 1999, J MOL BIOL, V289, P277, DOI 10.1006/jmbi.1999.2788; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; Seidel-Rogol BL, 2003, NAT GENET, V33, P23, DOI 10.1038/ng1064; Shadel GS, 2004, TRENDS GENET, V20, P513, DOI 10.1016/j.tig.2004.08.005; Tavernarakis N, 2000, J NEUROGENET, V13, P257, DOI 10.3109/01677060009084497; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Knippenberg PH, 1986, STRUCTURE FUNCTION G, P412; VANBUUL CPJJ, 1984, FEBS LETT, V177, P119, DOI 10.1016/0014-5793(84)80994-1; VANKNIPPENBERG PH, 1984, NUCLEIC ACIDS RES, V12, P2595, DOI 10.1093/nar/12.6.2595	39	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16815	16820		10.1074/jbc.M500569200	http://dx.doi.org/10.1074/jbc.M500569200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749697	hybrid			2022-12-27	WOS:000228615500034
J	Planavila, A; Laguna, JC; Vazquez-Carrera, M				Planavila, A; Laguna, JC; Vazquez-Carrera, M			Nuclear factor-kappa B activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIOMYOCYTE HYPERTROPHY; SKELETAL-MUSCLE; RECEPTOR-ALPHA; PPAR-ALPHA; EXPRESSION; RAT; GROWTH; HEART; DELTA; BETA	Little is known about the mechanisms responsible for the fall in fatty acid oxidation during the development of cardiac hypertrophy. We focused on the effects of nuclear factor (NF)-kappa B activation during cardiac hypertrophy on the activity of peroxisome proliferator-activated receptor (PPAR) beta/delta, which is the predominant PPAR subtype in cardiac cells and plays a prominent role in the regulation of cardiac lipid metabolism. Phenylephrine-induced cardiac hypertrophy in neonatal rat cardiomyocytes caused a reduction in the expression of pyruvate dehydrogenase kinase 4 (Pdk4), a target gene of PPAR beta/delta involved in fatty acid utilization, and a fall in palmitate oxidation that was reversed by NF-kappa B inhibitors. Lipopolysaccharide stimulation of NF-kappa B in embryonic rat heart-derived H9c2 myotubes, which only express PPAR beta/delta, caused both a reduction in Pdk4 expression and DNA binding activity of PPAR beta/delta to its response element, effects that were reversed by NF-kappa B inhibitors. Coimmunoprecipitation studies demonstrated that lipopolysaccharide strongly stimulated the physical interaction between the p65 subunit of NF-kappa B and PPAR beta/delta, providing an explanation for the reduced activity of PPAR beta/delta. Finally, we assessed whether this mechanism was present in vivo in pressure overload-induced cardiac hypertrophy. In hypertrophied hearts of banded rats the reduction in the expression of Pdk4 was accompanied by activation of NF-kappa B and enhanced interaction between p65 and PPAR beta/delta. These results indicate that NF-kappa B activation during cardiac hypertrophy down-regulates PPAR beta/delta activity, leading to a fall in fatty acid oxidation, through a mechanism that involves enhanced protein-protein interaction between the p65 subunit of NF-kappa B and PPAR beta/delta.	Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Unit, E-08028 Barcelona, Spain	University of Barcelona	Vazquez-Carrera, M (corresponding author), Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Unit, Diagonal 643, E-08028 Barcelona, Spain.	mvazquezcarrera@ub.edu	Laguna, JCLaguna - Juan C./C-5481-2017; Vázquez-Carrera, Manuel/H-2612-2015	Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Vázquez-Carrera, Manuel/0000-0001-7138-8207; Anna, Planavila Porta/0000-0001-5474-4724				Auwerx J, 1999, CELL, V97, P161; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cabrero A, 2002, J BIOL CHEM, V277, P10100, DOI 10.1074/jbc.M110321200; Cabrero A, 2001, DIABETES, V50, P1883, DOI 10.2337/diabetes.50.8.1883; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Force T, 2002, CIRCULATION, V105, P402, DOI 10.1161/circ.105.4.402; Gilde AJ, 2003, CIRC RES, V92, P518, DOI 10.1161/01.RES.0000060700.55247.7C; Gupta S, 2002, J CELL BIOL, V159, P1019, DOI 10.1083/jcb.200207149; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Higuchi Y, 2002, J MOL CELL CARDIOL, V34, P233, DOI 10.1006/jmcc.2001.1505; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; KELLY DP, 1994, NEW ENGL J MED, V330, P913; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KIMURA Y, 1994, J MOL CELL CARDIOL, V26, P1145, DOI 10.1006/jmcc.1994.1133; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lorell BH, 2000, CIRCULATION, V102, P470; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Shin WS, 2002, ATHEROSCLEROSIS, V160, P91, DOI 10.1016/S0021-9150(01)00571-8; TAEGTMEYER H, 1988, HYPERTENSION, V11, P416, DOI 10.1161/01.HYP.11.5.416; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Westergaard M, 2003, J INVEST DERMATOL, V121, P1104, DOI 10.1046/j.1523-1747.2003.12536.x; Wu P, 1997, FASEB J, V11, pA1355	33	105	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17464	17471		10.1074/jbc.M414220200	http://dx.doi.org/10.1074/jbc.M414220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728586	hybrid			2022-12-27	WOS:000228615500113
J	Bare, DJ; Kettlun, CS; Liang, M; Bers, DM; Mignery, GA				Bare, DJ; Kettlun, CS; Liang, M; Bers, DM; Mignery, GA			Cardiac type 2 inositol 1,4,5-trisphosphate receptor - Interaction and modulation by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNELS; CA2+ RELEASE; RYANODINE RECEPTOR; NUCLEAR-ENVELOPE; SARCOPLASMIC-RETICULUM; EXPRESSION; INSP(3); BINDING; LOCALIZATION; MYOCYTES	The type 2 inositol 1,4,5-trisphosphate receptor (InsP(3)R2) was identified previously as the predominant isoform in cardiac ventricular myocytes. Here we reported the subcellular localization of InsP(3)R2 to the cardiomyocyte nuclear envelope (NE). The other major known endo/sarcoplasmic reticulum calcium-release channel ( ryanodine receptor) was not localized to the NE, indicating functional segregation of these channels and possibly a unique role for InsP(3)R2 in regulating nuclear calcium dynamics. Immunoprecipitation experiments revealed that the NE InsP(3)R2 associates with Ca2+/calmodulin-dependent protein kinase II delta (CaMKII delta), the major isoform expressed in cardiac myocytes. Recombinant InsP(3)R2 and CaMKII delta(B) also coimmunoprecipitated after co-expression in COS-1 cells. Additionally, the amino-terminal 1078 amino acids of the InsP(3)R2 were sufficient for interaction with CaMKII delta(B) and associated upon mixing following separate expression. CaMKII can also phosphorylate InsP(3)R2, as demonstrated by P-32 labeling. Incorporation of CaMKII-treated InsP(3)R2 into planar lipid bilayers revealed that InsP(3)-mediated channel open probability is significantly reduced ( similar to 11 times) by phosphorylation via CaMKII. We concluded that the InsP(3)R2 and CaMKII delta likely represent two central components of a multiprotein signaling complex, and this raises the possibility that calcium release via InsP(3)R2 in the myocyte NE may activate local CaMKII signaling, which may feedback on InsP(3)R2 function.	Loyola Univ, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Cardiovasc Inst, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	gmigner@lumc.edu	Bers, Donald M/C-4507-2012	Bers, Donald/0000-0002-2237-9483	NHLBI NIH HHS [HL30077] Funding Source: Medline; NIMH NIH HHS [MH53367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030077, R01HL030077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053367, R29MH053367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; Bootman MD, 2000, CELL MOL LIFE SCI, V57, P371, DOI 10.1007/PL00000699; Czubryt MP, 1996, J MOL CELL CARDIOL, V28, P455, DOI 10.1006/jmcc.1996.0042; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Furuichi T, 1999, CALCIUM AS A CELLULAR REGULATOR, P200; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; Guihard G, 1997, FEBS LETT, V414, P89, DOI 10.1016/S0014-5793(97)00949-6; Huh YH, 2003, FEBS LETT, V555, P411, DOI 10.1016/S0014-5793(03)01273-0; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; Kapiloff MS, 2001, J CELL SCI, V114, P3167; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Kockskamper J, 2001, BIOPHYS J, V81, P2590, DOI 10.1016/S0006-3495(01)75903-6; Laflamme K, 2002, J CELL BIOCHEM, V85, P219, DOI 10.1002/jcb.10124; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Matifat F, 2001, PFLUG ARCH EUR J PHY, V441, P796, DOI 10.1007/s004240000479; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugiyama T, 2000, FEBS LETT, V466, P29, DOI 10.1016/S0014-5793(99)01732-9; Tasker PN, 2000, BIOCHEM BIOPH RES CO, V273, P907, DOI 10.1006/bbrc.2000.3036; Wu X, 2004, CIRCULATION, V110, P285; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h; ZIMA A, 2005, BIOPHYS J S, V88, P433; Zima AV, 2004, J PHYSIOL-LONDON, V555, P607, DOI 10.1113/jphysiol.2003.058529; Zima AV, 2003, J PHYSIOL-LONDON, V550, P765, DOI 10.1113/jphysiol.2003.040345	42	141	144	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15912	15920		10.1074/jbc.M414212200	http://dx.doi.org/10.1074/jbc.M414212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710625	hybrid			2022-12-27	WOS:000228444800057
J	Liu, MZ; Durfee, T; Cabrera, JE; Zhao, K; Jin, DJ; Blattner, FR				Liu, MZ; Durfee, T; Cabrera, JE; Zhao, K; Jin, DJ; Blattner, FR			Global transcriptional programs reveal a carbon source foraging strategy by Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE LIFETIME IMAGES; RATE-DEPENDENT REGULATION; LAC OPERON EXPRESSION; GROWTH-RATE; RNA-POLYMERASE; CATABOLITE REPRESSION; SALMONELLA-TYPHIMURIUM; REGULATORY MECHANISMS; SIGMA(S) SUBUNIT; TEXTURE ANALYSIS	By exploring global gene expression of Escherichia coli growing on six different carbon sources, we discovered a striking genome transcription pattern: as carbon substrate quality declines, cells systematically increase the number of genes expressed. Gene induction occurs in a hierarchical manner and includes many factors for uptake and metabolism of better but currently unavailable carbon sources. Concomitantly, cells also increase their motility. Thus, as the growth potential of the environment decreases, cells appear to devote progressively more energy on the mere possibility of improving conditions. This adaptation is not what would be predicated by classic regulatory models alone. We also observe an inverse correlation between gene activation and rRNA synthesis suggesting that reapportioning RNA polymerase ( RNAP) contributes to the expanded genome activation. Significant differences in RNAP distribution in vivo, monitored using an RNAP-green fluorescent protein fusion, from energy-rich and energy-poor carbon source cultures support this hypothesis. Together, these findings represent the integration of both substrate-specific and global regulatory systems, and may be a bacterial approximation to metazoan risk-prone foraging behavior.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; NCI, Transcript Control Sect, Gene Regulat & Crhomosome Biol Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blattner, FR (corresponding author), Univ Wisconsin, Dept Genet, 445 Henry Mall, Madison, WI 53706 USA.	fred@genome.wisc.edu			NATIONAL CANCER INSTITUTE [Z01BC010632, ZIABC010632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35682-17S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; Anthony LC, 2003, METHOD ENZYMOL, V370, P181; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Bockhorst J, 2003, BIOINFORMATICS, V19, P1227, DOI 10.1093/bioinformatics/btg147; BOTSFORD JL, 1975, J BACTERIOL, V124, P380, DOI 10.1128/JB.124.1.380-390.1975; Bremer H., 1996, E COLI SALMONELLA CE, V2, P1553; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; Cabrera JE, 2003, MOL MICROBIOL, V50, P1493, DOI 10.1046/j.1365-2958.2003.03805.x; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Crasnier M, 1996, RES MICROBIOL, V147, P479, DOI 10.1016/0923-2508(96)84002-2; Cunning C, 1999, J BACTERIOL, V181, P4853, DOI 10.1128/JB.181.16.4853-4862.1999; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; HASTJARJO T, 1990, J EXP ANAL BEHAV, V53, P155, DOI 10.1901/jeab.1990.53-155; Hengge-Aronis R, 2002, MICROBIOL MOL BIOL R, V66, P373, DOI 10.1128/MMBR.66.3.373-395.2002; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hua Q, 2004, APPL ENVIRON MICROB, V70, P2354, DOI 10.1128/AEM.70.4.2354-2366.2004; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Kuo JT, 2003, FEBS LETT, V553, P397, DOI 10.1016/S0014-5793(03)01071-8; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LENDENMANN U, 1995, MICROBIOL-SGM, V141, P71, DOI 10.1099/00221287-141-1-71; MANDELSTAM J, 1962, BIOCHEM J, V82, P489, DOI 10.1042/bj0820489; MIURA A, 1981, CELL, V25, P773, DOI 10.1016/0092-8674(81)90185-9; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Murata S, 2001, CYTOMETRY, V43, P94, DOI 10.1002/1097-0320(20010201)43:2<94::AID-CYTO1023>3.0.CO;2-4; Murata S, 2001, J HISTOCHEM CYTOCHEM, V49, P1443, DOI 10.1177/002215540104901112; NEIDHARDT FC, 1957, J BACTERIOL, V73, P260, DOI 10.1128/JB.73.2.260-263.1957; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NORRIS TE, 1972, J MOL BIOL, V64, P633, DOI 10.1016/0022-2836(72)90088-5; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Rosenow C, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e112; Ruiz N, 2003, J BACTERIOL, V185, P5984, DOI 10.1128/JB.185.20.5984-5992.2003; Saier MH, 1998, BIOTECHNOL BIOENG, V58, P170, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<170::AID-BIT9>3.0.CO;2-I; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; Schauder S, 2001, GENE DEV, V15, P1468, DOI 10.1101/gad.899601; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Sperandio V, 2002, MOL MICROBIOL, V43, P809, DOI 10.1046/j.1365-2958.2002.02803.x; Taga ME, 2003, MOL MICROBIOL, V50, P1411, DOI 10.1046/j.1365-2958.2003.03781.x; TSENG CP, 1994, J BACTERIOL, V176, P6599, DOI 10.1128/JB.176.21.6599-6605.1994; VanBogelen RA, 1996, J BACTERIOL, V178, P4344, DOI 10.1128/jb.178.15.4344-4366.1996; WANNER BL, 1978, J BACTERIOL, V136, P947, DOI 10.1128/JB.136.3.947-954.1978; Weyn B, 2000, ANAL QUANT CYTOL, V22, P373; Wick LM, 2001, ENVIRON MICROBIOL, V3, P588, DOI 10.1046/j.1462-2920.2001.00231.x; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Zhi HJ, 2003, J BIOL CHEM, V278, P47340, DOI 10.1074/jbc.M305430200; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	51	152	156	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15921	15927		10.1074/jbc.M414050200	http://dx.doi.org/10.1074/jbc.M414050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705577	hybrid			2022-12-27	WOS:000228444800058
J	Okura, M; Fang, JM; Salto, ML; Singer, RS; Docampo, R; Moreno, SNJ				Okura, M; Fang, JM; Salto, ML; Singer, RS; Docampo, R; Moreno, SNJ			A lipid-modified phosphoinositide-specific phospholipase C (TcPI-PLC) is involved in differentiation of trypomastigotes to amastigotes of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAMMALIAN-CELLS; INVASION; EXPRESSION; OLIGONUCLEOTIDES; OVEREXPRESSION; PALMITOYLATION; DIACYLGLYCEROL; TRANSFORMATION; LEISHMANIA	The phosphoinositide-specific phospholipase C ( PIPLC) is an important component of the inositol phosphate/ diacylglycerol signaling pathway. A newly discovered Trypanosoma cruzi PI-PLC (TcPI-PLC) is lipid modified in its N terminus, targeted to its plasma membrane, and believed to play a role in differentiation of the parasite because its expression increases during the differentiation of trypomastigote to amastigote stages. To determine whether TcPI-PLC is involved in this differentiation step, antisense inhibition using phosphorothioate-modified oligonucleotides, and overexpression of the gene were performed. Antisense oligonucleotide-treated parasites showed a reduced rate of differentiation in comparison to controls, as well as accumulation of intermediate forms. Overexpression of TcPI-PLC led to a faster differentiation rate. In contrast, overexpression of a mutant TcPI-PLC that lacked the lipid modification at its N terminus did not affect the differentiation rate. Therefore, TcPI-PLC is involved, when expressed in the plasma membrane, in the differentiation of trypomastigotes to amastigotes, an essential step for the intracellular replication of these parasites.	Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA; Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University System of Georgia; University of Georgia	Moreno, SNJ (corresponding author), Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA.	s-moreno@cb.uga.edu			NCRR NIH HHS [C06 RR16515-01] Funding Source: Medline; NIAID NIH HHS [AI-48039] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHKTAR S, 1991, LIFE SCI, V49, P1793; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; DOCAMPO R, 1991, BIOCHEM J, V275, P407, DOI 10.1042/bj2750407; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; Gomez ML, 1999, INT J PARASITOL, V29, P981, DOI 10.1016/S0020-7519(99)00041-7; GOMEZ ML, 1989, MOL BIOCHEM PARASIT, V36, P101, DOI 10.1016/0166-6851(89)90182-5; Gonzalez J, 2003, BIOCHEM J, V374, P647, DOI 10.1042/BJ20030215; Grellier P, 1999, MOL BIOCHEM PARASIT, V98, P239, DOI 10.1016/S0166-6851(98)00172-8; Hall B. Fenton, 1993, Seminars in Cell Biology, V4, P323, DOI 10.1006/scel.1993.1039; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HOSMER DW, 1991, AM J PUBLIC HEALTH, V81, P1630, DOI 10.2105/AJPH.81.12.1630; IRVINE R, 1996, NATURE, V380, P582; KANBARA H, 1990, Japanese Journal of Parasitology, V39, P226; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; Malaga S, 2001, INFECT IMMUN, V69, P353, DOI 10.1128/IAI.69.1.353-359.2001; Minning TA, 2003, MOL BIOCHEM PARASIT, V131, P55, DOI 10.1016/S0166-6851(03)00189-0; Mortara RA, 2001, J EUKARYOT MICROBIOL, V48, P27, DOI 10.1111/j.1550-7408.2001.tb00413.x; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nozaki T, 1999, MOL BIOCHEM PARASIT, V102, P283, DOI 10.1016/S0166-6851(99)00108-5; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMATZ DM, 1982, PARASITOLOGY, V85, P115, DOI 10.1017/S0031182000054202; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; Temperton NJ, 1998, MOL BIOCHEM PARASIT, V96, P167, DOI 10.1016/S0166-6851(98)00127-3; Tomas AM, 1997, EUR J BIOCHEM, V244, P596, DOI 10.1111/j.1432-1033.1997.t01-1-00596.x; TOMLINSON S, 1995, PARASITOLOGY, V110, P547, DOI 10.1017/S0031182000065264; Woolsey AM, 2003, J CELL SCI, V116, P3611, DOI 10.1242/jcs.00666; Zar J. H., 1984, BIOSTAT ANAL, P718	40	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16235	16243		10.1074/jbc.M414535200	http://dx.doi.org/10.1074/jbc.M414535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710612	hybrid			2022-12-27	WOS:000228444800093
J	Burden, AF; Manley, NC; Clark, AD; Gartler, SM; Laird, CD; Hansen, RS				Burden, AF; Manley, NC; Clark, AD; Gartler, SM; Laird, CD; Hansen, RS			Hemimethylation and non-CpG methylation levels in a promoter region of human LINE-1 (L1) repeated elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRPIN-BISULFITE PCR; DNA METHYLATION; GENE; PATTERNS; SITES; DEMETHYLATION; INHERITANCE; KINETICS; CELLS	DNA methylation within the promoter region of human LINE1 (L1) transposable elements is important for maintaining transcriptional inactivation and for inhibiting L1 transposition. Determining methylation patterns on the complementary strands of repeated sequences is difficult using standard bisulfite methylation analysis. Evolutionary changes in each repeat and the variations between cells or alleles of the same repeat lead to a heterogeneous population of sequences. Potential sequence biases can arise during analyses that are different for the converted sense and antisense strands. These problems can be avoided with hairpin-bisulfite PCR, a double-stranded PCR method in which complementary strands of individual molecules are attached by a hairpin linker ligated to genomic DNA. Using human L1 elements to study methylation of repeated sequences, (i) we distinguish valid L1 sequences from redundant and contaminant sequences by applying the powerful new method of molecular barcodes, (ii) we resolve a controversy on the level of hemimethylation of L1 sequences in fetal fibroblasts in favor of relatively little hemimethylation, (iii) we report that human L1 sequences in different cell types also have primarily concordant CpG methylation patterns on complementary strands, and (iv) we provide evidence that non-CpG cytosines within the regions analyzed are rarely methylated.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Burden, AF (corresponding author), Univ Washington, Dept Biol, Box 351800, Seattle, WA 98195 USA.	afb4@u.washington.edu; cdlaird@u.washington.edu	Hu, Ruogu/B-2203-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016659, R01HD016659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053805] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 02274, HD 16659] Funding Source: Medline; NIGMS NIH HHS [GM 53805] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Edwards Matthew J., 1992, Human Mutation, V1, P47, DOI 10.1002/humu.1380010108; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Laird CD, 2004, P NATL ACAD SCI USA, V101, P204, DOI 10.1073/pnas.2536758100; Miner BE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh132; OTTO SP, 1990, GENETICS, V124, P429; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PONCZ M, 1982, HEMOGLOBIN, V6, P27, DOI 10.3109/03630268208996930; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Stirzaker C, 1997, CANCER RES, V57, P2229; THAYER RE, 1993, GENE, V133, P273, DOI 10.1016/0378-1119(93)90651-I; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; WIGLER MH, 1981, CELL, V24, P285, DOI 10.1016/0092-8674(81)90317-2; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Zhou YX, 1998, GENOME, V41, P23, DOI 10.1139/gen-41-1-23	19	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14413	14419		10.1074/jbc.M413836200	http://dx.doi.org/10.1074/jbc.M413836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710616	hybrid			2022-12-27	WOS:000228236800009
J	Chen, CC; Wu, HY				Chen, CC; Wu, HY			LeuO protein delimits the transcriptionally active and repressive domains on the bacterial chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RELAY MECHANISM; P1 PLASMID CENTROMERE; COLI BGL PROMOTER; ESCHERICHIA-COLI; LAC REPRESSOR; H-NS; SALMONELLA-TYPHIMURIUM; SACCHAROMYCES-CEREVISIAE; CHROMATIN INSULATOR; BOUNDARY ELEMENTS	LeuO protein relieves bacterial gene silencer AT8-mediated transcriptional repression as part of a promoter relay mechanism found in the ilvIH-leuO-leuABCD gene cluster. The gene silencing activity has recently been characterized as a nucleoprotein filament initiated at the gene silencer. In this gene locus, the nucleoprotein filament cis-spreads toward the target leuO promoter and results in the repression of the leuO gene. Although the cis-spreading nature of the transcriptionally repressive nucleoprotein filament has been revealed, the mechanism underlying LeuO-mediated gene silencing relief remains unknown. We have demonstrated here that LeuO functions analogously to the eukaryotic boundary element that delimits the transcriptionally active and repressive domains on the chromosome by blocking the cis-spreading pathway of the transcriptionally repressive heterochromatin. Given that one LeuO-binding site is positioned between the gene silencer and the target promoter, the simultaneous presence of a second LeuO-binding site synergistically enhances the blockade, resulting in a cooperative increase in LeuO-mediated gene silencing relief. A known DNA loop-forming protein, the lac repressor (LacI), was used to confirm that cooperative protein binding via DNA looping is responsible for the blocking synergy. Indeed, a distal LeuO site located downstream cooperates with the LeuO sites located upstream of the leuO gene, resulting in synergistic relief for the repressed leuO gene via looping out the intervening DNA between LeuO sites in the ilvIH-leuO-leuABCD gene cluster.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Chen, CC (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	haiwu@med.wayne.edu			NIGMS NIH HHS [GM-53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053617, R01GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; BESSE M, 1986, EMBO J, V5, P1377, DOI 10.1002/j.1460-2075.1986.tb04370.x; Bi X, 1999, P NATL ACAD SCI USA, V96, P11934, DOI 10.1073/pnas.96.21.11934; Blanton J, 2003, GENE DEV, V17, P664, DOI 10.1101/gad.1052003; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Capelson M, 2004, BIOL CELL, V96, P617, DOI 10.1016/j.biolcel.2004.06.004; Caramel A, 1998, J MOL BIOL, V284, P875, DOI 10.1006/jmbi.1998.2191; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chen CC, 2005, J BIOL CHEM, V280, P5101, DOI 10.1074/jbc.M411840200; Chen CC, 2003, J BIOL CHEM, V278, P38094, DOI 10.1074/jbc.M300461200; Chen CC, 2003, FRONT BIOSCI, V8, pD430, DOI 10.2741/968; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; Chen SQ, 2001, GENETICS, V159, P1649; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 2002, BIOESSAYS, V24, P344, DOI 10.1002/bies.10072; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; Fernandez-Mora M, 2004, J BACTERIOL, V186, P2909, DOI 10.1128/JB.186.10.2909-2920.2004; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; Hao JJ, 2002, J BACTERIOL, V184, P4857, DOI 10.1128/JB.184.17.4857-4867.2002; Harmer T, 2001, P NATL ACAD SCI USA, V98, P427, DOI 10.1073/pnas.98.2.427; HENDRICH BD, 1995, HUM MOL GENET, V4, P1765, DOI 10.1093/hmg/4.suppl_1.1765; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; Jordi BJAM, 1997, J BIOL CHEM, V272, P12083, DOI 10.1074/jbc.272.18.12083; Jordi JAM, 2000, J BIOL CHEM, V275, P12123, DOI 10.1074/jbc.275.16.12123; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Kamakaka RT, 2003, CURR BIOL, V13, pR317, DOI 10.1016/S0960-9822(03)00236-7; Kamakaka RT, 2002, CURR BIOL, V12, pR535, DOI 10.1016/S0960-9822(02)01032-1; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; Kim SK, 1999, P NATL ACAD SCI USA, V96, P8557, DOI 10.1073/pnas.96.15.8557; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNCH AS, 1995, P NATL ACAD SCI USA, V92, P1896, DOI 10.1073/pnas.92.6.1896; Mukerji M, 1997, MOL MICROBIOL, V24, P617, DOI 10.1046/j.1365-2958.1997.3621725.x; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; Oki M, 2002, CURR OPIN CELL BIOL, V14, P299, DOI 10.1016/S0955-0674(02)00327-7; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Rimsky S, 2004, CURR OPIN MICROBIOL, V7, P109, DOI 10.1016/j.mib.2004.02.001; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; Wu HY, 2003, PROG NUCLEIC ACID RE, V73, P43, DOI 10.1016/S0079-6603(03)01002-X; Yarmolinsky M, 2000, CURR OPIN MICROBIOL, V3, P138, DOI 10.1016/S1369-5274(00)00065-5; Zhimulev I. F., 2003, Genetika, V39, P187	70	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15111	15121		10.1074/jbc.M414544200	http://dx.doi.org/10.1074/jbc.M414544200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15711009	hybrid			2022-12-27	WOS:000228236800094
J	Dietrich, LEP; LaGrassa, TJ; Rohde, J; Cristodero, M; MEiringer, CTA; Ungermann, C				Dietrich, LEP; LaGrassa, TJ; Rohde, J; Cristodero, M; MEiringer, CTA; Ungermann, C			ATP-independent control of Vac8 palmitoylation by a SNARE subcomplex on yeast vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO REACTIONS; SACCHAROMYCES-CEREVISIAE; FUSION REQUIRES; EARLY-STAGE; ALPHA-SNAP; R-SNARE; PROTEIN; COMPLEX; MEMBRANE; DOCKING	Yeast vacuole fusion requires palmitoylated Vac8. We previously showed that Vac8 acylation occurs early in the fusion reaction, is blocked by antibodies against Sec18 (yeast N-ethylmaleimide-sensitive fusion protein (NSF)), and is mediated by the R-SNARE Ykt6. Here we analyzed the regulation of this reaction on purified vacuoles. We show that Vac8 acylation is restricted to a narrow time window, is independent of ATP hydrolysis by Sec18, and is stimulated by the ion chelator EDTA. Analysis of vacuole protein complexes indicated that Ykt6 is part of a complex distinct from the second R-SNARE, Nyv1. We speculate that during vacuole fusion, Nyv1 is the classical R-SNARE, whereas the Ykt6-containing complex has a novel function in Vac8 palmitoylation.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Ungermann, C (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cu2@ix.urz.uni-heidelberg.de	Cristodero, Marina/AAK-5703-2021; Cristodero, Marina/AAC-8824-2022	Dietrich, Lars/0000-0003-2049-1137				Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Brachmann CB, 1998, YEAST, V14, P115; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Dietrich LEP, 2005, EMBO REP, V6, P245, DOI 10.1038/sj.embor.7400350; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; Dilcher M, 2001, J BIOL CHEM, V276, P34537, DOI 10.1074/jbc.M101551200; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fleckenstein D, 1998, J CELL SCI, V111, P3109; Fukasawa M, 2004, P NATL ACAD SCI USA, V101, P4815, DOI 10.1073/pnas.0401183101; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Horsnell WGC, 2002, BIOCHEMISTRY-US, V41, P5230, DOI 10.1021/bi0160359; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kweon Y, 2003, MOL BIOL CELL, V14, P1868, DOI 10.1091/mbc.E02-10-0687; Lewis MJ, 2002, TRAFFIC, V3, P922, DOI 10.1034/j.1600-0854.2002.31207.x; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MORGAN A, 1994, J BIOL CHEM, V269, P29347; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Pan XZ, 1998, J CELL SCI, V111, P2137; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Steel GJ, 2000, MOL BIOL CELL, V11, P1345, DOI 10.1091/mbc.11.4.1345; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Veit M, 2003, FEBS LETT, V540, P101, DOI 10.1016/S0014-5793(03)00232-1; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang CW, 2003, J CELL BIOL, V163, P973, DOI 10.1083/jcb.200308071; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Weisman LS, 2003, ANNU REV GENET, V37, P435, DOI 10.1146/annurev.genet.37.050203.103207; Zhang T, 2001, J BIOL CHEM, V276, P27480, DOI 10.1074/jbc.M102786200	47	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15348	15355		10.1074/jbc.M410582200	http://dx.doi.org/10.1074/jbc.M410582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701652	Green Accepted, hybrid			2022-12-27	WOS:000228236800120
J	Ren, LP; Feoktistova, A; McDonald, WH; Den Haese, G; Morrell, JL; Gould, KL				Ren, LP; Feoktistova, A; McDonald, WH; Den Haese, G; Morrell, JL; Gould, KL			Analysis of the role of phosphorylation in fission yeast Cdc13p/cyclinB function*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-TYPE CYCLIN; ANAPHASE-PROMOTING COMPLEX; WD-REPEAT PROTEIN; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; DNA-DAMAGE; NUCLEAR-LOCALIZATION; S-PHASE; CDC2; MITOSIS	The Cdk1p-cyclin B complex drives entry into mitosis in all eukaryotes. Cdc13p is the single essential cyclin in Schizosaccharomyces pombe and a member of the cyclin B family. Cdc13p abundance rises during G(2)-phase and falls as cells progress through mitosis and G(1). Cdc13p degradation, mediated by the anaphase-promoting complex, is an important mechanism of Cdk1p inhibition and mitotic exit. Cdk1p-cyclin B1 complexes shuttle between the nucleus and cytoplasm, and preventing nuclear accumulation of Cdk1p-cyclin B1 in mammalian cells appears to be one mechanism of preventing entry into mitosis during a DNA damage-induced checkpoint delay. In vertebrates, phosphorylation plays a key role in regulating the intracellular distribution of cyclins. Previous mass spectrometric analysis identified sites of Cdc13p phosphorylation. Here, we have confirmed that these sites are the sole in vivo Cdc13p phosphorylation sites and have studied the role that phosphorylation plays in Cdc13p localization and function. Our data indicate that Cdc13p accumulates in the nucleolus in response to G(2) checkpoint delays, rather than in the cytoplasm, and that phosphorylation plays no role in Cdc13p localization or function.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	Kathy.gould@vanderbilt.edu	Morrell-Falvey, Jennifer L/A-6615-2011; McDonald, W. Hayes/B-4109-2016	Morrell-Falvey, Jennifer L/0000-0002-9362-7528; McDonald, W. Hayes/0000-0002-3510-426X; Gould, Kathleen/0000-0002-3810-4070	NIGMS NIH HHS [GM47728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1989, J CELL SCI, P9; ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; Asakawa H, 2001, MOL GENET GENOMICS, V265, P424, DOI 10.1007/s004380000429; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Berry LD, 1999, MOL CELL BIOL, V19, P2535; Berry LD, 1996, MOL GEN GENET, V251, P635; Blanco MA, 2001, J CELL SCI, V114, P2135; Blanco MA, 2000, EMBO J, V19, P3945, DOI 10.1093/emboj/19.15.3945; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang L, 2001, MOL CELL BIOL, V21, P6681, DOI 10.1128/MCB.21.19.6681-6694.2001; Creanor J, 1996, J CELL SCI, V109, P1647; Decottignies A, 2001, J CELL SCI, V114, P2627; DENHAESE GJ, 1995, MOL BIOL CELL, V6, P371, DOI 10.1091/mbc.6.4.371; Dunaway S, 2004, METHODS, V33, P260, DOI 10.1016/j.ymeth.2003.11.022; FISHER D, 1995, SEMIN CELL BIOL, V6, P73, DOI 10.1016/1043-4682(95)90003-9; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GALLAGHER IM, 1993, MOL BIOL CELL, V4, P1087, DOI 10.1091/mbc.4.11.1087; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RUSSELL P, 1989, MOL BIOL FISSION YEA; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Yamada HY, 2000, J CELL SCI, V113, P3989; Yamaguchi S, 1997, MOL BIOL CELL, V8, P2475, DOI 10.1091/mbc.8.12.2475; Yamaguchi S, 2000, EMBO J, V19, P3968, DOI 10.1093/emboj/19.15.3968; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	50	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14591	14596		10.1074/jbc.M500560200	http://dx.doi.org/10.1074/jbc.M500560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705571	hybrid			2022-12-27	WOS:000228236800032
J	Diaz-Moreno, I; Diaz-Quintana, A; De la Rosa, MA; Ubbink, M				Diaz-Moreno, I; Diaz-Quintana, A; De la Rosa, MA; Ubbink, M			Structure of the complex between plastocyanin and cytochrome f from the cyanobacterium Nostoc sp PCC 7119 as determined by paramagnetic NMR - The balance between electrostatic and hydrophobic interactions within the transient complex determines the relative orientation of the two proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWNIAN DYNAMICS; ESCHERICHIA-COLI; HEME; RESIDUES; PATCH; B(6)F; RECOGNITION; ASSOCIATION; SIMULATION; EXPRESSION	The complex between cytochrome f and plastocyanin from the cyanobacterium Nostoc has been characterized by NMR spectroscopy. The binding constant is 16 mM(-1), and the lifetime of the complex is much less than 10 ms. Intermolecular pseudo-contact shifts observed for the plastocyanin amide nuclei, caused by the heme iron, as well as the chemical-shift perturbation data were used as the sole experimental restraints to determine the orientation of plastocyanin relative to cytochrome f with a precision of 1.3. The data show that the hydrophobic patch surrounding tyrosine 1 in cytochrome f docks the hydrophobic patch of plastocyanin. Charge complementarities are found between the rims of the respective recognition sites of cytochrome f and plastocyanin. Significant differences in the relative orientation of both proteins are found between this complex and those previously reported for plants and Phormidium, indicating that electrostatic and hydrophobic interactions are balanced differently in these complexes.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Leiden University; Leiden University - Excl LUMC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	Ubbink, M (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, POB 9502, NL-2300 RA Leiden, Netherlands.	m.ubbink@chem.leidenuniv.nl	De la Rosa, Miguel/B-2545-2014; Ubbink, Marcellus/E-2158-2011; Díaz-Moreno, Irene/E-7181-2010; Díaz-Quintana, Antonio/A-1946-2011	De la Rosa, Miguel/0000-0003-1187-5737; Ubbink, Marcellus/0000-0002-2615-6914; Díaz-Moreno, Irene/0000-0002-5318-7644; Díaz-Quintana, Antonio/0000-0001-8973-8009				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Allen JF, 2004, TRENDS PLANT SCI, V9, P130, DOI 10.1016/j.tplants.2004.01.009; Andersson P, 1998, J BIOMOL NMR, V11, P279, DOI 10.1023/A:1008227631084; [Anonymous], 2002, PHOTOSYNTHETICA; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; Bendall D. S., 1996, P43; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Castenholz R.W., 1970, SCHWEIZ Z HYDROL, V32, P538; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; COLEMAN PM, 1978, J MOL BIOL, V211, P617; Crowley PB, 2003, ACCOUNTS CHEM RES, V36, P723, DOI 10.1021/ar0200955; Crowley PB, 2004, BIOCHEM J, V378, P45, DOI 10.1042/BJ20031423; Crowley PB, 2002, BIOCHEMISTRY-US, V41, P15698, DOI 10.1021/bi026349b; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Crowley PB, 2004, PROTEINS, V55, P603, DOI 10.1002/prot.20043; De Rienzo F, 2001, BIOPHYS J, V81, P3090, DOI 10.1016/S0006-3495(01)75947-4; Diaz-Moreno I, 2005, BIOCHEMISTRY-US, V44, P3176, DOI 10.1021/bi047855z; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; Gong XS, 2000, EUR J BIOCHEM, V267, P3461, DOI 10.1046/j.1432-1327.2000.01366.x; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; Gross EL, 2003, BIOPHYS J, V85, P2055, DOI 10.1016/S0006-3495(03)74633-5; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hart SE, 2003, BIOCHEMISTRY-US, V42, P4829, DOI 10.1021/bi020674h; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LANGE C, 2005, IN PRESS BIOENERGETI; LEE BH, 1995, J BIOCHEM, V117, P1209; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Pearson DC, 1998, BIOPHYS J, V75, P2698, DOI 10.1016/S0006-3495(98)77714-8; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; Prudencio M, 2004, J MOL RECOGNIT, V17, P524, DOI 10.1002/jmr.686; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; REGAN JJ, 1994, GREENPATH SOFTWARE V; SANDMANN G, 1983, ARCH MICROBIOL, V134, P23, DOI 10.1007/BF00429401; Schlarb-Ridley BG, 2002, BIOCHEMISTRY-US, V41, P3279, DOI 10.1021/bi0116588; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SKOURTIS SS, 1993, CHEM PHYS LETT, V209, P171, DOI 10.1016/0009-2614(93)87219-S; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Soriano GM, 1997, BIOPHYS J, V73, P3265, DOI 10.1016/S0006-3495(97)78351-6; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; UBBINK M, 1992, J BACTERIOL, V174, P3707, DOI 10.1128/JB.174.11.3707-3714.1992; Ubbink M, 1996, EUR J BIOCHEM, V242, P132, DOI 10.1111/j.1432-1033.1996.0132r.x; UBBINK M, 2001, HDB METALLOPROTEINS, P182; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Wodak SJ, 2003, ADV PROTEIN CHEM, V61, P9; Worrall JAR, 2002, BIOCHEMISTRY-US, V41, P11721, DOI 10.1021/bi026296y	65	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18908	18915		10.1074/jbc.M413298200	http://dx.doi.org/10.1074/jbc.M413298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15705583	hybrid, Green Published			2022-12-27	WOS:000228932300043
J	Larsen, R; Kok, J; Kuipers, OP				Larsen, R; Kok, J; Kuipers, OP			Interaction between ArgR and AhrC controls regulation of arginine metabolism in Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DNA-BINDING; BACILLUS-STEAROTHERMOPHILUS; OPERATOR INTERACTIONS; REPRESSOR; GENE; PROTEIN; EXPRESSION; SEQUENCE; PLASMID	The expression of arginine metabolism in Lactococcus lactis is controlled by the two homologous transcriptional regulators ArgR and AhrC. Genome sequence analyses have shown that the occurrence of multiple homologues of the ArgR family of transcriptional regulators is a common feature of many low-G + C Gram-positive bacteria. Detailed studies of ArgR type regulators have previously only been carried out in bacteria containing single regulators. Here, we present a first characterization of the two L. lactis arginine regulators by means of gel retardation and DNase I footprinting. ArgR of L. lactis was shown to bind to the promoter regions of both the arginine biosynthetic argCJDBF operon and the arginine catabolic arcABD1C1C2TD2yvaD operon, but in an arginine-independent manner. Surprisingly, AhrC alone was unable to bind to DNA. Arginine-dependent DNA binding was obtained by mixing the two regulators in gel retardation assays. With both regulators present, the addition of arginine led to increased binding of ArgR-AhrC to the biosynthetic argC promoter but also to diminished binding to the catabolic arcA promoter. Footprinting showed ArgR-AhrC protection of regions containing ARG box operator sequences preceding argC. In the absence of AhrC, ArgR protected sites in the arcA promoter region with similarity to ARG box half-sites, here called ARC boxes. We propose a model for repression of arginine biosynthesis and activation of catabolism by anti-repression, involving arginine-dependent interaction between the two L. lactis regulator proteins, ArgR and AhrC.	Univ Groningen, Dept Mol Genet, NL-9751 NN Haren, Netherlands	University of Groningen	Kuipers, OP (corresponding author), Univ Groningen, Dept Mol Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	O.P.Kuipers@rug.nl	Larsen, Rasmus/I-9204-2012; Kok, Jan/C-9972-2012; Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				Archibald RM, 1944, J BIOL CHEM, V156, P121; Barcelona-Andres B, 2002, J BACTERIOL, V184, P6289, DOI 10.1128/JB.184.22.6289-6300.2002; Belitsky, 2001, BACILLUS SUBTILIS IT, P203; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE M, 1994, MOL MICROBIOL, V13, P609, DOI 10.1111/j.1365-2958.1994.tb00455.x; CHARLIER D, 1992, J MOL BIOL, V226, P367, DOI 10.1016/0022-2836(92)90953-H; Chen SH, 1997, MOL MICROBIOL, V24, P1143, DOI 10.1046/j.1365-2958.1997.4301791.x; CZAPLEWSKI LG, 1992, MOL MICROBIOL, V6, P267, DOI 10.1111/j.1365-2958.1992.tb02008.x; Dennis CA, 2002, ACTA CRYSTALLOGR D, V58, P421, DOI 10.1107/S0907444901021692; Dimova D, 2000, MOL GEN GENET, V263, P119, DOI 10.1007/PL00008670; Dion M, 1997, MOL MICROBIOL, V25, P385, DOI 10.1046/j.1365-2958.1997.4781845.x; EBBOLE DJ, 1989, J BIOL CHEM, V264, P3553; GARDAN R, 1995, J MOL BIOL, V249, P843, DOI 10.1006/jmbi.1995.0342; GASSON MJ, 1983, J BACTERIOL, V154, P1; Hamoen LW, 1998, GENE DEV, V12, P1539, DOI 10.1101/gad.12.10.1539; Holo H, 1995, Methods Mol Biol, V47, P195; JOHANSEN E, 1992, PLASMID, V27, P200, DOI 10.1016/0147-619X(92)90022-3; Kleerebezem M, 2003, CURR OPIN BIOTECH, V14, P232, DOI 10.1016/S0958-1669(03)00033-8; KLINGEL U, 1995, MOL GEN GENET, V248, P329, DOI 10.1007/BF02191600; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; Larsen R, 2004, J BACTERIOL, V186, P1147, DOI 10.1128/JB.186.4.1147-1157.2004; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; LIM D, 1987, P NATL ACAD SCI USA, V84, P6697, DOI 10.1073/pnas.84.19.6697; LU CD, 1992, J MOL BIOL, V225, P11, DOI 10.1016/0022-2836(92)91022-H; MAAS WK, 1994, MICROBIOL REV, V58, P631, DOI 10.1128/MMBR.58.4.631-640.1994; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; Makarova KS, 2001, GENOME BIOL, V2; Miller CM, 1997, MOL MICROBIOL, V26, P37, DOI 10.1046/j.1365-2958.1997.5441907.x; Morin A, 2003, J MOL BIOL, V332, P537, DOI 10.1016/S0022-2836(03)00951-3; Ni JP, 1999, NAT STRUCT BIOL, V6, P427; Nicoloff H, 2004, J BACTERIOL, V186, P6059, DOI 10.1128/JB.186.18.6059-6069.2004; RodriguezGarcia A, 1997, MOL MICROBIOL, V25, P219, DOI 10.1046/j.1365-2958.1997.4511815.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Song H, 2002, J MOL BIOL, V315, P255, DOI 10.1006/jmbi.2001.5236; Sunnerhagen M, 1997, NAT STRUCT BIOL, V4, P819, DOI 10.1038/nsb1097-819; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TIAN GL, 1994, MOL MICROBIOL, V13, P599, DOI 10.1111/j.1365-2958.1994.tb00454.x; TIAN GL, 1992, J MOL BIOL, V226, P387, DOI 10.1016/0022-2836(92)90954-I; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	36	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19319	19330		10.1074/jbc.M413983200	http://dx.doi.org/10.1074/jbc.M413983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749710	Green Published, hybrid			2022-12-27	WOS:000228932300089
J	Feige, JN; Gelman, L; Tudor, C; Engelborghs, Y; Wahli, W; Desvergne, B				Feige, JN; Gelman, L; Tudor, C; Engelborghs, Y; Wahli, W; Desvergne, B			Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor retinoid X receptor heterodimers in the absence and presence of ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D RECEPTORS; LIVING CELLS; GLUCOCORTICOID-RECEPTOR; HORMONE-RECEPTORS; CORRELATION SPECTROSCOPY; INTRANUCLEAR MOBILITY; MOLECULAR-DYNAMICS; ANDROGEN RECEPTOR; LIVE CELLS; IN-VIVO	In a global approach combining fluorescence recovery after photobleaching ( FRAP), fluorescence correlation spectroscopy (FCS), and fluorescence resonance energy transfer ( FRET), we address the behavior in living cells of the peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors involved in lipid and glucose metabolism, inflammation control, and wound healing. We first demonstrate that unlike several other nuclear receptors, PPARs do not form speckles upon ligand activation. The subnuclear structures that may be observed under some experimental conditions result from overexpression of the protein and our immunolabeling experiments suggest that these structures are subjected to degradation by the proteasome. Interestingly and in contrast to a general assumption, PPARs readily heterodimerize with retinoid X receptor (RXR) in the absence of ligand in living cells. PPAR diffusion coefficients indicate that all the receptors are engaged in complexes of very high molecular masses and/or interact with relatively immobile nuclear components. PPARs are not immobilized by ligand binding. However, they exhibit a ligand-induced reduction of mobility, probably due to enhanced interactions with cofactors and/or chromatin. Our study draws attention to the limitations and pitfalls of fluorescent chimera imaging and demonstrates the usefulness of the combination of FCS, FRAP, and FRET to assess the behavior of nuclear receptors and their mode of action in living cells.	Univ Lausanne, NCCR Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium	University of Lausanne; KU Leuven	Desvergne, B (corresponding author), Univ Lausanne, NCCR Frontiers Genet, Ctr Integrat Genom, Batiment Biol, CH-1015 Lausanne, Switzerland.	beatrice.desvergne@unil.ch	Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Gelman, Laurent/0000-0003-3277-3115				Akiyama TE, 2002, MOL ENDOCRINOL, V16, P707, DOI 10.1210/me.16.4.707; Auwerx J, 1999, CELL, V97, P161; Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; Dittrich P, 2001, BIOL CHEM, V382, P491, DOI 10.1515/BC.2001.061; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Grande MA, 1997, J CELL SCI, V110, P1781; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Krouglova T, 2004, BIOPHYS J, V87, P2635, DOI 10.1529/biophysj.104.040717; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Patel H, 2005, J CELL SCI, V118, P175, DOI 10.1242/jcs.01600; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 2000, J CELL BIOCHEM, P99; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	55	92	99	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17880	17890		10.1074/jbc.M500786200	http://dx.doi.org/10.1074/jbc.M500786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15731109	hybrid			2022-12-27	WOS:000228807200041
J	Fuzesi, M; Gottschalk, KE; Lindzen, M; Shainskaya, A; Kuster, B; Garty, H; Karlish, SJD				Fuzesi, M; Gottschalk, KE; Lindzen, M; Shainskaya, A; Kuster, B; Garty, H; Karlish, SJD			Covalent cross-links between the gamma subunit (FXYD2) and alpha and beta subunits of Na,K-ATPase - Modeling the alpha-gamma interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL NA,K-ATPASE; FUNCTIONAL INTERACTION; STRUCTURE PREDICTION; CALCIUM-PUMP; NA/K-ATPASE; PROTEIN; CLEAVAGE; TRANSPORT; SITES; NA+,K+-ATPASE	This study describes specific intramolecular covalent cross-linking of the gamma to alpha and gamma to beta subunits of pig kidney Na,K-ATPase and rat gamma to alpha co-expressed in HeLa cells. For this purpose pig gamma a and gamma b sequences were determined by cloning and mass spectrometry. Three bifunctional reagents were used: N-hydroxysuccinimidyl-4-azidosalicylic acid (NHS-ASA), disuccinimidyl tartrate (DST), and 1-ethyl-3-[3dimethylaminopropyl]carbodiimide (EDC). NHS-ASA induced alpha-gamma, DST induced alpha-gamma and beta-gamma, and EDC induced primarily beta-gamma cross-links. Specific proteolytic and Fe2+-catalyzed cleavages located NHS-ASA- and DST-induced alpha-gamma cross- links on the cytoplasmic surface of the alpha subunit, downstream of His(283) and upstream of Val(440). Additional considerations indicated that the DST-induced and NHS-ASA-induced cross-links involve either Lys(347) or Lys(352) in the S4 stalk segment. Mutational analysis of the rat gamma subunit expressed in HeLa cells showed that the DST-induced cross-link involves Lys(55) and Lys(56) in the cytoplasmic segment. DST and EDC induced two beta-gamma cross-links, a major one at the extracellular surface within the segment Gly(143)-Ser(302) of the beta subunit and another within Ala(1)-Arg(142). Based on the cross- linking and other data on alpha-gamma proximities, we modeled interactions of the transmembrane alpha-helix and an unstructured cytoplasmic segment SKRLRCG-GKKHR of gamma with a homology model of the pig alpha 1 subunit. According to the model, the transmembrane segment fits in a groove between M2, M6, and M9, and the cytoplasmic segment interacts with loops L6/7 and L8/9 and stalk S5.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel; Univ So Denmark, Prot Interact Lab, DK-5230 Odense, Denmark	Weizmann Institute of Science; Weizmann Institute of Science; University of Southern Denmark	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	steven.karlish@weizmann.ac.il	Gottschalk, Kay/D-6503-2012; Kuster, Bernhard/Q-6031-2016	Gottschalk, Kay/0000-0002-7951-0972; Kuster, Bernhard/0000-0002-9094-1677				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, pRE1; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2005, IN PRESS SEMIN NEPHR; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Gottschalk KE, 2004, J MOL GRAPH MODEL, V23, P99, DOI 10.1016/j.jmgm.2004.02.002; Gottschalk KE, 2004, BIOPHYS J, V86, P3335, DOI 10.1529/biophysj.103.034546; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Karlish SJD, 2003, ANN NY ACAD SCI, V986, P39, DOI 10.1111/j.1749-6632.2003.tb07137.x; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lindzen M, 2003, ANN NY ACAD SCI, V986, P530, DOI 10.1111/j.1749-6632.2003.tb07242.x; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; PARK LS, 1986, J BIOL CHEM, V261, P205; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; van Gunsteren W. F., 1998, ENCY COMPUTATIONAL C, V2, P1211, DOI DOI 10.1002/0470845015.CGA011; VANDERHORST GTJ, 1990, J BIOL CHEM, V265, P10801; Wang SG, 1998, J BIOL CHEM, V273, P29400, DOI 10.1074/jbc.273.45.29400; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	57	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18291	18301		10.1074/jbc.M500080200	http://dx.doi.org/10.1074/jbc.M500080200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15743768	hybrid			2022-12-27	WOS:000228807200088
J	Maiti, B; Li, J; de Bruin, A; Gordon, F; Timmers, C; Opavsky, R; Patil, K; Tuttle, J; Cleghorn, W; Leone, G				Maiti, B; Li, J; de Bruin, A; Gordon, F; Timmers, C; Opavsky, R; Patil, K; Tuttle, J; Cleghorn, W; Leone, G			Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferatio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; S-PHASE; REPRESS TRANSCRIPTION; CYCLE; COMPLEX; BINDING; GENES; RB	The E2F transcription factor family plays a crucial and well established role in cell cycle progression. Deregulation of E2F activities in vivo leads to developmental defects and cancer. Based on current evidence in the field, mammalian E2Fs can be functionally categorized into either transcriptional activators ( E2F1, E2F2, and E2F3a) or repressors (E2F3b, E2F4, E2F5, E2F6, and E2F7). We have identified a novel E2F family member, E2F8, which is conserved in mice and humans and has its counterpart in Arabidopsis thaliana (E2Ls). Interestingly, E2F7 and E2F8 share unique structural features that distinguish them from other mammalian E2F repressor members, including the presence of two distinct DNA-binding domains and the absence of DP-dimerization, retinoblastoma-binding, and transcriptional activation domains. Similar to E2F7, overexpression of E2F8 significantly slows down the proliferation of primary mouse embryonic fibroblasts. These observations, together with the fact that E2F7 and E2F8 can homodimerize and are expressed in the same adult tissues, suggest that they may have overlapping and perhaps synergistic roles in the control of cellular proliferation.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet Comprehens Canc Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.	Leone-1@medctr.osu.edu	de Bruin, Alain/AAL-9195-2020; Martin, Faye/I-1759-2012; LI, JING/F-5318-2011	de Bruin, Alain/0000-0001-8579-2649	PHS HHS [T32] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mariconti L, 2002, J BIOL CHEM, V277, P9911, DOI 10.1074/jbc.M110616200; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	32	146	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18211	18220		10.1074/jbc.M501410200	http://dx.doi.org/10.1074/jbc.M501410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722552	hybrid			2022-12-27	WOS:000228807200079
J	Meigs, TE; Juneja, J; DeMarco, CT; Stemmle, LN; Kaplan, DD; Casey, PJ				Meigs, TE; Juneja, J; DeMarco, CT; Stemmle, LN; Kaplan, DD; Casey, PJ			Selective uncoupling of G alpha(12) from rho-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; LEUKEMIA-ASSOCIATED RHOGEF; HETEROTRIMERIC G-PROTEINS; SERUM RESPONSE ELEMENT; ALPHA-SUBUNIT; CYTOPLASMIC DOMAIN; POINT MUTATION; P115 RHOGEF; ACTIVATION; EXCHANGE	The heterotrimeric G protein G(12) has been implicated in such cellular regulatory processes as cytoskeletal rearrangement, cell-cell adhesion, and oncogenic transformation. Although the activated alpha-subunit of G(12) has been shown to interact directly with a number of protein effectors, the roles of many of these protein-protein interactions in G(12)-mediated cell physiology are poorly understood. To begin dissecting the specific cellular pathways engaged upon G(12) activation, we produced a series of substitution mutants in the regions of G alpha(12) predicted to play a role in effector binding. Here we report the identification and characterization of an altered form of G alpha(12) that is functionally uncoupled from signaling through the monomeric G protein Rho, a protein known to propagate several G alpha(12)-mediated signals. This mutant of G alpha(12) fails to bind the Rho-specific guanine nucleotide exchange factors p115RhoGEF and LARG (leukemia-associated RhoGEF), fails to stimulate Rho-dependent transcriptional activation, and fails to trigger activation of RhoA and the Rho-mediated cellular responses of cell rounding and c-jun N-terminal kinase activation. Importantly, this mutant of G alpha(12) retains coupling to the effector protein E-cadherin, as evidenced by its ability both to bind E-cadherin in vitro and to disrupt E-cadherin-mediated cell-cell adhesion. Furthermore, this mutant retains the ability to trigger beta-catenin release from the cytoplasmic domain of cadherin. This identification of a variant of G alpha(12) that is selectively uncoupled from one signaling pathway while retaining signaling capacity through a separate pathway will facilitate investigations into the mechanisms through which G(12) proteins mediate diverse biological responses.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Kaplan, Daniel/0000-0001-8297-560X	NCI NIH HHS [CA100869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dermott JM, 2001, J CELL BIOCHEM, V81, P1; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	38	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18049	18055		10.1074/jbc.M500445200	http://dx.doi.org/10.1074/jbc.M500445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746095	hybrid			2022-12-27	WOS:000228807200061
J	Moss, CX; Matthews, SP; Lamont, DJ; Watts, C				Moss, CX; Matthews, SP; Lamont, DJ; Watts, C			Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; T-CELL RECOGNITION; TETANUS TOXIN; TISSUE TRANSGLUTAMINASE; CELIAC-DISEASE; H-C; ENDOPEPTIDASE; PEPTIDES; FRAGMENT; BINDING	Post-translational protein modifications can be recognized by B and T lymphocytes and can potentially make "self"-proteins appear foreign to the immune system. Such modifications may directly affect major histocompatibility complex-restricted T cell recognition of processed peptides or may perturb the processing events that generate such peptides. Using the tetanus toxin C fragment protein as a test case, we show that spontaneous deamidation of asparagine residues interferes with processing by the enzyme asparagine endopeptidase (AEP) and contributes to diminished antigen presentation. Deamidation inhibits AEP action either directly, when asparagine residues targeted by AEP are modified, or indirectly, when adjacent Asn residues are deamidated. Thus, deamidation of long-lived self-proteins may qualitatively or quantitatively affect the spectrum of self-peptides displayed to T cells and may thereby contribute to the onset or exacerbation of autoimmune disease.	Univ Dundee, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Watts, C (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk		Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X				Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen WS, 1996, J IMMUNOL, V157, P1000; Cirrito TP, 2001, J EXP MED, V194, P1165, DOI 10.1084/jem.194.8.1165; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DAUMY GO, 1991, FEBS LETT, V278, P98, DOI 10.1016/0014-5793(91)80093-I; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; Emsley P, 2000, J BIOL CHEM, V275, P8889, DOI 10.1074/jbc.275.12.8889; Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200; GEIGER T, 1987, J BIOL CHEM, V262, P785; HALLAHAN TW, 1992, BIOCHEMISTRY-US, V31, P8022, DOI 10.1021/bi00149a036; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Hewitt EW, 1997, J IMMUNOL, V159, P4693; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; Manoury B, 2003, IMMUNITY, V18, P489, DOI 10.1016/S1074-7613(03)00085-2; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; McAdam SN, 2001, J EXP MED, V193, P1239, DOI 10.1084/jem.193.11.1239; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P4367, DOI 10.1073/pnas.071066498; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; TESHIMA G, 1991, BIOCHEMISTRY-US, V30, P3916, DOI 10.1021/bi00230a016; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; Watts C, 2003, ANN NY ACAD SCI, V987, P9, DOI 10.1111/j.1749-6632.2003.tb06028.x; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	34	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18498	18503		10.1074/jbc.M501241200	http://dx.doi.org/10.1074/jbc.M501241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749706	hybrid			2022-12-27	WOS:000228807200113
J	Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ				Velkov, T; Chuang, S; Wielens, J; Sakellaris, H; Charman, WN; Porter, CJH; Scanlon, MJ			The interaction of lipophilic drugs with intestinal fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ESCHERICHIA-COLI; DIFFERENT MECHANISMS; SERUM-ALBUMIN; MODEL SYSTEM; LIVER; RAT; EXPRESSION; TRANSPORT; NMR	Intestinal fatty acid-binding protein (I-FABP) is a small protein that binds long-chain dietary fatty acids in the cytosol of the columnar absorptive epithelial cells (enterocytes) of the intestine. The binding cavity of IFABP is much larger than is necessary to bind a fatty acid molecule, which suggests that the protein may be able to bind other hydrophobic and amphipathic ligands such as lipophilic drugs. Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP. The rank order of affinity for I-FABP determined for these compounds was found to be R- ibuprofen approximate to bezafibrate > S-ibuprofen >> nitrazepam. The binding affinities were not directly related to aqueous solubility or partition coefficient of the compounds; however, the freely water-soluble drug diltiazem showed no affinity for I-FABP. Drug-I-FABP interaction interfaces were defined by analysis of chemical shift perturbations in NMR spectra, which revealed that the drugs bound within the central fatty acid binding cavity. Each drug participated in a different set of interactions within the cavity; however, a number of common contacts were observed with residues also involved in fatty acid binding. These data suggest that the binding of non-fatty acid lipophilic drugs to I-FABP may increase the cytosolic solubility of these compounds and thereby facilitate drug transport from the intestinal lumen across the enterocyte to sites of distribution and metabolism.	Monash Univ, Victorian Coll Pharm, Dept Med Chem, Parkville, Vic 3052, Australia; Monash Univ, Dept Pharmaceut, Parkville, Vic 3052, Australia; Monash Univ, Dept Microbiol, Parkville, Vic 3052, Australia	Monash University; Monash University; Monash University	Scanlon, MJ (corresponding author), Monash Univ, Victorian Coll Pharm, Dept Med Chem, 381 Royal Parade, Parkville, Vic 3052, Australia.	Martin.Scanlon@vcp.monash.edu.au	Porter, Christopher JH/C-6333-2011	Porter, Christopher JH/0000-0003-3474-7551; Scanlon, Martin/0000-0002-9230-7506; Charman, William/0000-0002-7051-2023; Chuang, Sara/0000-0001-7738-5613; Wielens, Jerome/0000-0003-3406-4136; velkov, tony/0000-0002-0017-7952				Arighi CN, 2003, BIOCHEMISTRY-US, V42, P7539, DOI 10.1021/bi020680d; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; EADS J, 1993, J BIOL CHEM, V268, P26375; GLATZ JFC, 1988, NEWS PHYSIOL SCI, V3, P41; GORDON JI, 1985, J BIOL CHEM, V260, P1995; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Hidalgo Ismael J., 2001, Current Topics in Medicinal Chemistry, V1, P385, DOI 10.2174/1568026013395010; HILLGREN KM, 1995, MED RES REV, V15, P83, DOI 10.1002/med.2610150202; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KANDA T, 1990, BIOCHEM BIOPH RES CO, V168, P1053, DOI 10.1016/0006-291X(90)91136-G; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LACHAU S, 1992, J PHARM SCI, V81, P287, DOI 10.1002/jps.2600810319; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Motulsky H, 2003, PRACTICAL GUIDE CURV; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pastukhov AV, 2003, PROTEINS, V53, P607, DOI 10.1002/prot.10401; PAULUSSEN RJA, 1990, INT J BIOCHEM, V22, P393, DOI 10.1016/0020-711X(90)90142-P; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; Shen DD, 1997, ADV DRUG DELIV REV, V27, P99; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 2000, J LIPID RES, V41, P647; THUMSER AEA, 1994, BIOCHEM J, V301, P801, DOI 10.1042/bj3010801; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; Vorum H, 1999, DAN MED BULL, V46, P379; Weisiger RA, 2002, MOL CELL BIOCHEM, V239, P35, DOI 10.1023/A:1020550405578; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u	50	49	52	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17769	17776		10.1074/jbc.M410193200	http://dx.doi.org/10.1074/jbc.M410193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15722357	hybrid			2022-12-27	WOS:000228807200027
J	Bour, G; Plassat, JL; Bauer, A; Lalevee, S; Rochette-Egly, C				Bour, G; Plassat, JL; Bauer, A; Lalevee, S; Rochette-Egly, C			Vinexin beta interacts with the non-phosphorylated AF-1 domain of retinoid receptor gamma(RAR gamma) and represses RAR gamma-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ACTIVATION FUNCTIONS AF-1; EPIDERMAL-GROWTH-FACTOR; F9 CELLS; TRANSACTIVATION FUNCTIONS; ACID; PHOSPHORYLATION; PROTEIN; ALPHA; COMPLEX	Nuclear retinoic acid receptors (RARs) are ligand-dependent transcription factors that regulate the expression of retinoic acid target genes. Although the importance of RAR phosphorylation in their N-terminal domain is clearly established, the underlying mechanism for the phosphorylation-dependent transcriptional activity of the receptors had not been elucidated yet. Here, using a yeast two-hybrid system, we report the isolation of vinexin beta as a new cofactor that interacts with the N-terminal A/B domain of the RAR gamma isotype. Vinexin beta is a multiple SH3 motif-containing protein associated with the cytoskeleton and also present in the nucleus. We demonstrate that vinexin beta colocalizes with RAR gamma in the nucleus and interacts with the non-phosphorylated form of the AF-1 domain of RAR gamma. We also show that this interaction is prevented upon phosphorylation of the AF-1 domain. Using F9 cells stably overexpressing vinexin beta or vinexin knockdown by RNA interference, we demonstrate that vinexin beta is an inhibitor of RAR gamma-mediated transcription. We propose a model in which phosphorylation of the AF-1 domain controls RAR gamma-mediated transcription through triggering the dissociation of vinexin beta.	Univ Strasbourg 1, Dept Cell Biol & Signal Transduct, IGBMC, INSERM,CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, Communaute Urba, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg 1, Dept Cell Biol & Signal Transduct, IGBMC, INSERM,CNRS,UMR 7104, BP 10142, F-67404 Illkirch Graffenstaden, Communaute Urba, France.	cegly@igbmc.u-strasbg.fr						Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Bommer M, 2002, J BIOL CHEM, V277, P37961, DOI 10.1074/jbc.M206001200; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Germain P, 2003, PURE APPL CHEM, V75, P1619, DOI 10.1351/pac200375111619; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glass CK, 2000, GENE DEV, V14, P121; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kumar R, 2003, MOL ENDOCRINOL, V17, P1, DOI 10.1210/me.2002-0258; Laudet V., 2001, NUCL RECEPTOR FACTSB; Le Douarin B, 2001, METH MOL B, V176, P227; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Loinder K, 2003, J STEROID BIOCHEM, V84, P15, DOI 10.1016/S0960-0760(03)00007-4; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Mitsushima M, 2004, J BIOL CHEM, V279, P34570, DOI 10.1074/jbc.M402304200; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Tujague M, 2004, J BIOL CHEM, V279, P9255, DOI 10.1074/jbc.M312160200; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; VOM BE, 1996, EMBO J, V15, P110; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	49	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17027	17037		10.1074/jbc.M501344200	http://dx.doi.org/10.1074/jbc.M501344200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734736	hybrid			2022-12-27	WOS:000228615500060
J	Fushinobu, S; Hidaka, M; Honda, Y; Wakagi, T; Shoun, H; Kitaoka, M				Fushinobu, S; Hidaka, M; Honda, Y; Wakagi, T; Shoun, H; Kitaoka, M			Structural basis for the specificity of the reducing end xylose-releasing exo-oligoxylanase from Bacillus halodurans C-125	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; XYLANASE; PROGRAM; GLYCOSIDASE; EXPRESSION; HYDROLASE; COMPLEX; PROTEIN; CLONING	Reducing end xylose-releasing exo-oligoxylanase from Bacillus halodurans C-125 (Rex) hydrolyzes xylooligosaccharides whose degree of polymerization is greater than or equal to 3, releasing the xylose unit at the reducing end. It is a unique exo-type glycoside hydrolase that recognizes the xylose unit at the reducing end in a very strict manner, even discriminating the beta-anomeric hydroxyl configuration from the alpha-anomer or 1-deoxyxylose. We have determined the crystal structures of Rex in unliganded and complex forms at 1.35 - 2.20-angstrom resolution and revealed the structural aspects of its three subsites ranging from - 2 to + 1. The structure of Rex was compared with those of endo-type enzymes in glycoside hydrolase subfamily 8a (GH-8a). The catalytic machinery of Rex is basically conserved with other GH-8a enzymes. However, subsite + 2 is blocked by a barrier formed by a kink in the loop before helix alpha(10). His-319 in this loop forms a direct hydrogen bond with the beta-hydroxyl of xylose at subsite + 1, contributing to the specific recognition of anomers at the reducing end.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	University of Tokyo; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Fushinobu, S (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	asfushi@mail.ecc.u-tokyo.ac.jp	Fushinobu, Shinya/E-4987-2011; Wakagi, Takayoshi/AAJ-4145-2021; Kitaoka, Motomitsu/R-1536-2019	Fushinobu, Shinya/0000-0003-1346-6435; Kitaoka, Motomitsu/0000-0002-0083-1838				Adachi W, 2004, J MOL BIOL, V343, P785, DOI 10.1016/j.jmb.2004.08.028; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barr BK, 1996, BIOCHEMISTRY-US, V35, P586, DOI 10.1021/bi9520388; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Divne C, 1998, J MOL BIOL, V275, P309, DOI 10.1006/jmbi.1997.1437; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Guimaraes BG, 2002, J MOL BIOL, V320, P587, DOI 10.1016/S0022-2836(02)00497-7; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONDA H, 1985, J BACTERIOL, V161, P784, DOI 10.1128/JB.161.2.784-785.1985; HONDA H, 1985, CAN J MICROBIOL, V31, P538, DOI 10.1139/m85-100; Honda Y, 2005, ACTA CRYSTALLOGR F, V61, P291, DOI 10.1107/S1744309105003635; Honda Y, 2004, J BIOL CHEM, V279, P55097, DOI 10.1074/jbc.M409832200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MH, 2002, BIOCHEM BIOPH RES CO, V295, P818, DOI 10.1016/S0006-291X(02)00748-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Pell G, 2004, J BIOL CHEM, V279, P11777, DOI 10.1074/jbc.M311947200; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; TAPIO S, 1991, J BIOL CHEM, V266, P19450; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Yaoi K, 2002, J BIOL CHEM, V277, P48276, DOI 10.1074/jbc.M208443200	30	50	53	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17180	17186		10.1074/jbc.M413693200	http://dx.doi.org/10.1074/jbc.M413693200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718242	hybrid			2022-12-27	WOS:000228615500079
J	Gomez, MD; Nasi, E				Gomez, MD; Nasi, E			A direct signaling role for phosphatidylinositol 4,5-bisphosphate (PIP2) in the visual excitation process of microvillar receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; LIGHT-SENSITIVE CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PDZ-DOMAIN PROTEIN; K-ATP CHANNELS; DROSOPHILA PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; RHABDOMERIC PHOTORECEPTORS; INTRACELLULAR INJECTION; POTASSIUM CHANNELS	In microvillar photoreceptors the pivotal role of phospholipase C in light transduction is undisputed, but previous attempts to account for the photoresponse solely in terms of downstream products of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis have proved wanting. In other systems PIP2 has been shown to possess signaling functions of its own, rather than simply serving as a precursor molecule. Because illumination of microvillar photoreceptors cells leads to PIP2 breakdown, a potential role for this phospholipid in phototransduction would be to help maintain some element(s) of the transduction cascade in the inactive state. We tested the effect of intracellular dialysis of PIP2 on voltage-clamped molluscan photoreceptors and found a marked reduction in the amplitude of the photocurrent; by contrast, depolarization-activated calcium and potassium currents were unaffected, thus supporting the notion of a specific effect on light signaling. In the dark, PIP2 caused a gradual outward shift of the holding current; this change was due to a decrease in membrane conductance and may reflect the suppression of basal openings of the light-sensitive conductance. The consequences of depleting PIP2 were examined in patches of light-sensitive microvillar membrane screened for the exclusive presence of light-activated ion channels. After excision, superfusion with anti-PIP2 antibodies induced the appearance of single-channel currents. Replenishment of PIP2 by exogenous application reverted the effect. These data support the notion that PIP2, in addition to being the source of inositol trisphosphate and diacylglycerol, two messengers of visual excitation, may also participate in a direct fashion in the control of the light-sensitive conductance.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Boston University; Marine Biological Laboratory - Woods Hole	Gomez, MD (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.	mpgomez@bu.edu			NEI NIH HHS [EY07559] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007559] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BAER KM, 1988, J BIOL CHEM, V263, P17; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOLSOVER SR, 1985, J PHYSIOL-LONDON, V364, P381, DOI 10.1113/jphysiol.1985.sp015751; BROWN HM, 1971, FED PROC, V30, P69; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Cook B, 1999, CELL CALCIUM, V25, P161, DOI 10.1054/ceca.1998.0018; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; FADDIS MN, 1993, J GEN PHYSIOL, V101, P909, DOI 10.1085/jgp.101.6.909; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; Fein A, 2000, VISUAL NEUROSCI, V17, P911, DOI 10.1017/S0952523800176102; FRANK TM, 1991, J GEN PHYSIOL, V97, P697, DOI 10.1085/jgp.97.4.697; Gomez MD, 1998, J NEUROSCI, V18, P5253, DOI 10.1523/JNEUROSCI.18-14-05253.1998; Gomez MD, 2001, BIOPHYS J, V80, p606A; Gomez MD, 1996, J GEN PHYSIOL, V107, P715, DOI 10.1085/jgp.107.6.715; Hardie RC, 2004, J BIOL CHEM, V279, P47773, DOI 10.1074/jbc.M407525200; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Irvine R, 2004, CURR BIOL, V14, pR308, DOI 10.1016/j.cub.2004.03.051; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Lee SJ, 2004, P NATL ACAD SCI USA, V101, P11874, DOI 10.1073/pnas.0402205101; LISMAN JE, 1975, J GEN PHYSIOL, V66, P489, DOI 10.1085/jgp.66.4.489; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; NASI E, 1991, J GEN PHYSIOL, V97, P35, DOI 10.1085/jgp.97.1.35; NASI E, 1992, J GEN PHYSIOL, V99, P747, DOI 10.1085/jgp.99.5.747; NASI E, 1991, J GEN PHYSIOL, V97, P17, DOI 10.1085/jgp.97.1.17; NASI E, 2000, HDB BIOL PHYS, V0003, P00389; PAK WL, 1969, NATURE, V222, P351, DOI 10.1038/222351a0; PAYNE R, 1986, J GEN PHYSIOL, V88, P107, DOI 10.1085/jgp.88.1.107; PAYNE R, 1986, J GEN PHYSIOL, V87, P243, DOI 10.1085/jgp.87.2.243; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; Piccoli G, 2002, J PHYSIOL-LONDON, V543, P481, DOI 10.1113/jphysiol.2002.022772; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; SZUTS EZ, 1993, VISUAL NEUROSCI, V10, P921, DOI 10.1017/S0952523800006131; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Womack KB, 2000, J NEUROSCI, V20, P2792; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929	59	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16784	16789		10.1074/jbc.M414538200	http://dx.doi.org/10.1074/jbc.M414538200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15741162	hybrid, Green Published			2022-12-27	WOS:000228615500030
J	Lee, DW; Zhao, XH; Scarselletta, S; Schweinsberg, PJ; Eisenberg, E; Grant, BD; Greene, LE				Lee, DW; Zhao, XH; Scarselletta, S; Schweinsberg, PJ; Eisenberg, E; Grant, BD; Greene, LE			ATP binding regulates oligomerization and endosome association of RME-1 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN ATPASE; MEMBRANE; EHD1; COMPARTMENT; MECHANISM; RECEPTOR	Members of the RME-1/mRme-1/EHD1 protein family have recently been shown to function in the recycling of membrane proteins from recycling endosomes to the plasma membrane. RME-1 family proteins are normally found in close association with recycling endosomes and the vesicles and tubules emanating from these endosomes, consistent with the proposal that these proteins directly participate in endosomal transport. RME-1 family proteins contain a C-terminal EH (eps15 homology) domain thought to be involved in linking RME-1 to other endocytic proteins, a coiled-coil domain thought to be involved in homo-oligomerization and an N-terminal P-loop domain thought to mediate nucleotide binding. In the present study, we show that both Caenorhabditis elegans and mouse RME-1 proteins bind and hydrolyze ATP. No significant GTP binding or hydrolysis was detected. Mutation or deletion of the ATP-binding P-loop prevented RME-1 oligomerization and at the same time dissociated RME-1 from endosomes. In addition, ATP depletion caused RME-1 to lose its endosome association in the cell, resulting in cytosolic localization. Taken together, these results indicate that ATP binding is required for oligomerization of mRme-1/EHD1, which in turn is required for its association with endosomes.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rutgers State University New Brunswick	Greene, LE (corresponding author), NHLBI, Cell Biol Lab, NIH, 50 South Dr,Rm 2537,MSC 8017, Bethesda, MD 20892 USA.	greenel@helix.nih.gov		Grant, Barth/0000-0002-5943-8336	NIGMS NIH HHS [R01 GM067237-02, R01 GM067237, GM67237-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; CHOCK SP, 1979, J BIOL CHEM, V254, P3236; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; Galperin E, 2002, TRAFFIC, V3, P575, DOI 10.1034/j.1600-0854.2002.30807.x; Guilherme A, 2004, J BIOL CHEM, V279, P40062, DOI 10.1074/jbc.M401918200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Naslavsky N, 2004, MOL BIOL CELL, V15, P2410, DOI 10.1091/mbc.E03-10-0733; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wendland B, 2001, NAT CELL BIOL, V3, pE133, DOI 10.1038/35078592; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Zeng XC, 2004, J CELL SCI, V117, P4991, DOI 10.1242/jcs.01373; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	23	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17213	17220		10.1074/jbc.M412751200	http://dx.doi.org/10.1074/jbc.M412751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710626	hybrid			2022-12-27	WOS:000228615500083
J	Zheng, ZY; Bay, BH; Aw, SE; Lin, VCL				Zheng, ZY; Bay, BH; Aw, SE; Lin, VCL			A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; CROSS-TALK; IN-VIVO; GROWTH; MCF-7; 4-HYDROXYLATION; PROLIFERATION; PROGESTINS; METABOLISM	The expression of progesterone receptor ( PR) is normally estrogen-dependent, and progesterone is only active in target cells following estrogen exposure. This study revealed that the effect of estrogen was markedly disrupted by estrogen-independent expression of PR. Transfection of PR in estrogen receptor (ER)-positive MCF-7 cells abolished the estradiol-17 beta growth stimulatory effect that was observed in the parental cells and the vector-transfected controls in a ligand-independent manner. The antiestrogenic effect was also observed at the level of gene transcription. Estradiol-17 beta (E2)-induced gene expression of pS2 and GREB1 was impaired by 50 - 75% after 24 - 72 h of E2 treatment in PR-transfected cells. Promoter interference assay revealed that PR transfection drastically inhibited E2-mediated ER binding to estrogen response elements ( ERE). The antiestrogenic effects of transfected PR are associated with enhanced metabolism of E2. HPLC analysis of [H-3] E2 in the samples indicated that the percentage of [H-3] E2 metabolized by PR-transfected cells in 6 h is similar to that by vector-transfected control cells in 24 h ( 77 and 80%, respectively). The increased metabolism of E2 may, in turn, be caused by increased cellular uptake of E2, as demonstrated by whole cell binding of [H-3] E2. The findings open up a new window for a hitherto unknown functional relationship between the PR and ER. The antiestrogenic effect of transfected PR also provides a potential therapeutic strategy for estrogen-dependent breast cancer.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117597, Singapore; Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Singapore General Hospital	Lin, VCL (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	cllin@ntu.edu.sg	LIU, JIANG Jimmy/AHB-8921-2022; Chun Ling, Valerie Lin/A-2188-2011	LIU, JIANG Jimmy/0000-0001-6281-6505; 				Berstein LM, 2003, ENDOCR-RELAT CANCER, V10, P267, DOI 10.1677/erc.0.0100267; BRUEGGEMEIER RW, 1989, MOL CELL ENDOCRINOL, V64, P161, DOI 10.1016/0303-7207(89)90142-1; Brueggemeier RW, 2001, ANN NY ACAD SCI, V948, P51; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; DEHENNIN L, 1984, J STEROID BIOCHEM, V20, P465, DOI 10.1016/0022-4731(84)90255-3; DRUEGE PM, 1986, NUCLEIC ACIDS RES, V14, P9329, DOI 10.1093/nar/14.23.9329; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; GOTTARDIS MM, 1989, CANCER RES, V49, P4765; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; JENG MH, 1992, CANCER RES, V52, P6539; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Katzenellenbogen BS, 2000, J SOC GYNECOL INVEST, V7, pS33, DOI 10.1177/1071557600007001S10; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Lakhani NJ, 2003, CURR DRUG METAB, V4, P505, DOI 10.2174/1389200033489244; Lavigne JA, 2001, CANCER RES, V61, P7488; LIN CL, 1991, J ENDOCRINOL, V130, P251, DOI 10.1677/joe.0.1300251; Lin VCL, 2001, CLIN CANCER RES, V7, P2880; Lin VCL, 2000, MOL ENDOCRINOL, V14, P348, DOI 10.1210/me.14.3.348; Lin VCL, 1999, CLIN CANCER RES, V5, P395; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MCGUIRE W, 1975, ESTROGEN HUMAN BREAS; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1; Pasqualini J R, 2001, Gynecol Endocrinol, V15 Suppl 6, P44; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; REDDEL RR, 1987, CANCER RES, V47, P5323; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; SUTHERLAND RL, 1998, CANCER RES, V48, P5084; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; WILD MJ, 1991, J STEROID BIOCHEM, V39, P535, DOI 10.1016/0960-0760(91)90248-4; Wilson AM, 2001, CARCINOGENESIS, V22, P257, DOI 10.1093/carcin/22.2.257	37	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17480	17487		10.1074/jbc.M501261200	http://dx.doi.org/10.1074/jbc.M501261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728178	hybrid			2022-12-27	WOS:000228615500115
J	Liu, J; DeYoung, SM; Zhang, M; Dold, LH; Saltiel, AR				Liu, J; DeYoung, SM; Zhang, M; Dold, LH; Saltiel, AR			The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; LIPID RAFTS; CELL-SURFACE; CYTOSKELETAL ORGANIZATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ANCHORED PROTEINS; GOLGI-COMPLEX; RECEPTOR; ACTIN	Flotillin-1 is a lipid raft-associated protein that has been implicated in various cellular processes. We examined the subcellular distribution of flotillin-1 in different cell types and found that localization is cell type-specific. Flotillin-1 relocates from a cytoplasmic compartment to the plasma membrane upon the differentiation of 3T3-L1 adipocytes. To delineate the structural determinants necessary for its localization, we generated a series of truncation mutants of flotillin-1. Wild type flotillin-1 has two putative hydrophobic domains and is localized to lipid raft microdomains at the plasma membrane. Flotillin-1 fragments lacking the N-terminal hydrophobic stretch are excluded from the lipid raft compartments but remain at the plasma membrane. On the other hand, mutants with the second hydrophobic region deleted fail to traffic to the plasma membrane but are instead found in intracellular granule-like structures. Flotillin-1 specifically interacts with the adaptor protein CAP, the Src family kinase Fyn, and cortical F-actin in lipid raft microdomains in adipocytes. Furthermore, CAP and Fyn associate with different regions in the N-terminal sequences of flotillin-1. These results furthered our understanding for how flotillin-1 can function as a molecular link between lipid rafts of the plasma membrane and a multimeric signaling complex at the actin cytoskeleton.	Univ Michigan, Inst Life Sci, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Dept Physiol, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Inst Life Sci, Dept Internal Med, Med Ctr, 210 Washtenaw Ave,3rd Floor 2216, Ann Arbor, MI 48109 USA.	saltiel@umich.edu	Zhang, Mei/O-6070-2015; Saltiel, Alan/L-3632-2019	Zhang, Mei/0000-0002-3960-9978; Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK60591, F32 DK064551, DK61618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061618, R01DK060591, F32DK064551] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Muller G, 2001, MOL CELL BIOL, V21, P4553, DOI 10.1128/MCB.21.14.4553-4567.2001; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Schulte T, 1997, DEVELOPMENT, V124, P577; Sevlever D, 1999, BIOCHEM J, V343, P627, DOI 10.1042/0264-6021:3430627; Shumay E, 2002, MOL BIOL CELL, V13, P3943, DOI 10.1091/mbc.E02-03-0174; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Solomon S, 2002, IMMUNOBIOLOGY, V205, P108, DOI 10.1078/0171-2985-00114; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Tu XL, 2004, J PROTEOME RES, V3, P445, DOI 10.1021/pr0340779; Zhang M, 2003, MOL MED, V9, P18, DOI 10.1007/BF03402103	41	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16125	16134		10.1074/jbc.M500940200	http://dx.doi.org/10.1074/jbc.M500940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713660	hybrid			2022-12-27	WOS:000228444800080
J	Li, XH; Zhang, R; Luo, DH; Park, SJ; Wang, Q; Kim, Y; Min, W				Li, XH; Zhang, R; Luo, DH; Park, SJ; Wang, Q; Kim, Y; Min, W			Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ASK1 ACTIVATION; CELL-DEATH; ASK1-MEDIATED APOPTOSIS; SERINE/THREONINE KINASE; INDEPENDENT MANNER; PROTEIN KINASE-2; INHIBITOR 14-3-3; MAP KINASES; STRESS; SUMO-1	The apoptosis signal-regulating kinase 1 (ASK1)-JNK/ p38 signaling pathway is pivotal component in cell apoptosis and can be activated by a variety of death stimuli including tumor necrosis factor (TNF) alpha and oxidative stress ( reactive oxygen species). However, the mechanism for ASK1 activation is not fully understood. We have recently identified ASK1-interacting protein (AIP1) as novel signal transducer in TNF alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. In the present study, we employed yeast two-hybrid system using the N-terminal domain of AIP1 as bait and identified homeodomain-interacting protein kinase 1 (HIPK1) as an AIP1-associated protein. Interestingly, we showed that TNF alpha induced HIPK1 desumoylation concomitant with a translocation from nucleus to cytoplasm at 15 min followed by a return to nucleus by 60 min. The kinetics of HIPK1 translocation correlates with those of stress-induced ASK1-JNK/P38 activation. A specific JNK inhibitor blocked the reverse but not the initial translocation of HIPK1, suggesting that the initial translocation is an upstream event of ASK1-JNK/p38 signaling and JNK activation regulates the reverse translocation as a feedback mechanism. Consistently, expression of HIPK1 increased, whereas expression of a kinase-inactive form (HIPK1-D315N) or small interference RNA of HIPK1 decreased stress-induced ASK1-JNK/P38 activation without effects on IKK-NF-kappa B signaling. Moreover, a sumoylation-defective mutant of HIPK1 (KR5) localizes to the cytoplasm and is constitutively active in ASK1-JNK/P38 activation. Furthermore, HIPK1-KR5 induces dissociation of ASK1 from its inhibitors 14-3-3 and thioredoxin and synergizes with AIP1 to induce ASK1 activation. Our study suggests that TNF alpha-induced desumoylation and cytoplasmic translocation of HIPK1 are critical in TNF alpha-induced ASK1-JNK/p38 activation.	Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA; NHLBI, Lab Res Program, NIH, Bethesda, MD 20892 USA; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou 510080, Peoples R China	Yale University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sun Yat Sen University	Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol,Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NHLBI NIH HHS [HL-65978] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; GOLDMAN EH, 2003, J BIOL CHEM; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hay RT, 2004, NAT CELL BIOL, V6, P89, DOI 10.1038/ncb0204-89; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	44	62	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15061	15070		10.1074/jbc.M414262200	http://dx.doi.org/10.1074/jbc.M414262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701637	hybrid			2022-12-27	WOS:000228236800089
J	Sakakibara, K; Sato, K; Yoshino, K; Oshiro, N; Hirahara, S; Hasan, AKMM; Iwasaki, T; Ueda, Y; Iwao, Y; Yonezawa, K; Fukami, Y				Sakakibara, K; Sato, K; Yoshino, K; Oshiro, N; Hirahara, S; Hasan, AKMM; Iwasaki, T; Ueda, Y; Iwao, Y; Yonezawa, K; Fukami, Y			Molecular identification and characterization of Xenopus egg uroplakin III, an egg raft-associated transmembrane protein that is tyrosine-phosphorylated upon fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEPENDENT ACTIVATION; PHOSPHOLIPASE C-GAMMA; LIPID RAFTS; MEMBRANE MICRODOMAIN; BLADDER EPITHELIUM; CD9-DEFICIENT MICE; ESCHERICHIA-COLI; CALCIUM-RELEASE; SPERM FACTOR; SRC	Here we describe mass spectrometric identification, molecular cloning, and biochemical characterization of a lipid/membrane raft-associated protein that is tyrosine-phosphorylated upon Xenopus egg fertilization. This protein is homologous to mammalian uroplakin III, a member of the uroplakin family proteins (UPs) that constitute asymmetric unit membranes in the mammalian urothelial tissues, thus termed Xenopus uroplakin III (xUPIII). xUPIII contains N-linked sugars and is highly expressed in Xenopus eggs, ovary, urinary tract, and kidney. In unfertilized eggs, xUPIII is predominantly localized to the lipid/membrane rafts and exposed on the cell surface, as judged by surface biotinylation experiments and indirect immunofluorescent studies. After fertilization or hydrogen peroxide-induced egg activation, xUPIII becomes rapidly phosphorylated on tyrosine residue-249, which locates in the carboxyl-terminal cytoplasmic tail of the molecule. Raft localization and tyrosine phosphorylation of xUPIII can be reconstituted in HEK293 cells by coexpression of xUPIII, and Xenopus c-Src, a tyrosine kinase whose fertilization-induced activation in egg rafts is required for initiation of development. In mammals, UPIII is forming a complex with a tetraspanin molecule uroplakin Ib. As another tetraspanin, CD9, is known to be a critical component for sperm-egg fusion in the mouse, we have assumed that xUPIII is involved in sperm-egg interaction. An antibody against the extracellular domain of xUPIII blocks sperm-egg interaction, as judged by the occurrence of egg activation and first cell cleavage. Thus, xUPIII represents an egg raft-associated protein that is likely involved in sperm-egg interaction as well as subsequent Src-dependent intracellular events of egg activation in Xenopus.	Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Yamaguchi Univ, Fac Sci, Dept Biol Sci, Yamaguchi 7538512, Japan	Kobe University; Kobe University; Kobe University; Japan Science & Technology Agency (JST); Yamaguchi University	Sato, K (corresponding author), Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan.	kksato@kobe-u.ac.jp						Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bodin S, 2003, BBA-BIOMEMBRANES, V1610, P247, DOI 10.1016/S0005-2736(03)00022-1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Deng FM, 2002, J CELL BIOL, V159, P685, DOI 10.1083/jcb.200204102; Duncan MJ, 2004, J BIOL CHEM, V279, P18944, DOI 10.1074/jbc.M400769200; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hu P, 2000, J CELL BIOL, V151, P961, DOI 10.1083/jcb.151.5.961; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; Kachar B, 1999, J MOL BIOL, V285, P595, DOI 10.1006/jmbi.1998.2304; Kaji K, 2004, REPRODUCTION, V127, P423, DOI 10.1530/rep.1.00163; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; Kurokawa M, 2004, BIOL CELL, V96, P37, DOI 10.1016/j.biolcel.2003.11.003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Liang FX, 2001, BIOCHEM J, V355, P13, DOI 10.1042/0264-6021:3550013; Maekawa S, 2003, BBA-BIOMEMBRANES, V1610, P261, DOI 10.1016/S0005-2736(03)00023-3; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Mizote A, 1999, DEV BIOL, V208, P79, DOI 10.1006/dbio.1999.9195; Olsburgh J, 2003, J PATHOL, V199, P41, DOI 10.1002/path.1252; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rossi P, 2003, ANDROLOGIA, V35, P71, DOI 10.1046/j.1439-0272.2003.00539.x; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Santella L, 2004, TRENDS BIOCHEM SCI, V29, P400, DOI 10.1016/j.tibs.2004.06.009; Sato K, 2004, BBA-PROTEINS PROTEOM, V1697, P103, DOI 10.1016/j.bbapap.2003.11.017; Sato K, 2003, J BIOL CHEM, V278, P38413, DOI 10.1074/jbc.M302617200; Sato K, 1999, DEV BIOL, V209, P308, DOI 10.1006/dbio.1999.9255; Sato K, 1998, FEBS LETT, V424, P113, DOI 10.1016/S0014-5793(98)00123-9; Sato K, 2002, DEVELOPMENT, V129, P885; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; Sato KI, 2000, DEV BIOL, V224, P453, DOI 10.1006/dbio.2000.9782; SCHULTZ RM, 1995, CURR TOP DEV BIOL, V30, P21, DOI 10.1016/S0070-2153(08)60563-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tu LY, 2002, MOL BIOL CELL, V13, P4221, DOI 10.1091/mbc.E02-04-0211; Williams CJ, 2002, HUM REPROD UPDATE, V8, P313, DOI 10.1093/humupd/8.4.313; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; WU XR, 1994, J BIOL CHEM, V269, P13716; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171; Zhou G, 2001, J CELL SCI, V114, P4095	49	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15029	15037		10.1074/jbc.M410538200	http://dx.doi.org/10.1074/jbc.M410538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15699050	hybrid			2022-12-27	WOS:000228236800085
J	Jin, SG; Jiang, CL; Rauch, T; Li, HW; Pfeifer, GP				Jin, SG; Jiang, CL; Rauch, T; Li, HW; Pfeifer, GP			MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEINS; HISTONE DEACETYLASE COMPLEX; TRANSCRIPTIONAL REPRESSOR; DNA METHYLATION; CHROMOSOMAL-PROTEIN; MAMMALIAN PROTEIN; GENE ACTIVATION; CHROMATIN; MECP2; DOMAIN	MBD2 and MBD3 are two proteins that contain methyl-CpG binding domains and have a transcriptional repression function. Both proteins are components of a large CpG-methylated DNA binding complex named MeCP1, which consists of the nucleosome remodeling and histone deacetylase complex Mi2-NuRD and MBD2. MBD3L2 ( methyl-CpG-binding protein 3-like 2) is a protein with substantial homology to MBD2 and MBD3, but it lacks the methyl-CpG-binding domain. Unlike MBD3L1, which is specifically expressed in haploid male germ cells, MBD3L2 expression is more widespread. MBD3L2 interacts with MBD3 in vitro and in vivo, colocalizes with MBD3 but not MBD2, and does not localize to methyl-CpG-rich regions in the nucleus. In glutathione S-transferase pull-down assays, MBD3L2 is found associated with several known components of the Mi2-NuRD complex, including HDAC1, HDAC2, MTA1, MBD3, p66, RbAp46, and RbAp48. Gel shift experiments with nuclear extracts and a CpG-methylated DNA probe indicate that recombinant MBD3L2 can displace a form of the MeCP1 complex from methylated DNA. MBD3L2 acts as a transcriptional repressor when tethered to a GAL4-DNA binding domain. Repression by GAL4MBD3L2 is relieved by MBD2 and vice versa, and repression by MBD2 from a methylated promoter is relieved by MBD3L2. The data are consistent with a role of MBD3L2 as a transcriptional modulator that can interchange with MBD2 as an MBD3-interacting component of the NuRD complex. Thus, MBD3L2 has the potential to recruit the MeCP1 complex away from methylated DNA and reactivate transcription.	Beckman Res Inst City Hope, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), Beckman Res Inst City Hope, Div Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org		Jin, Seung-Gi/0000-0001-5041-0559	NATIONAL CANCER INSTITUTE [R01CA104967] Funding Source: NIH RePORTER; NCI NIH HHS [CA104967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Jiang CL, 2004, J BIOL CHEM, V279, P52456, DOI 10.1074/jbc.M409149200; Jiang CL, 2002, GENOMICS, V80, P621, DOI 10.1006/geno.2002.7001; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Stancheva I, 2000, GENE DEV, V14, P313; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	38	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	2005	280	13					12700	12709		10.1074/jbc.M413492200	http://dx.doi.org/10.1074/jbc.M413492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	910HP	15701600	hybrid			2022-12-27	WOS:000227922000077
J	Xu, HP; Kurihara, H; Ito, T; Kikuchi, H; Yoshida, K; Yamanokuchi, H; Asari, A				Xu, HP; Kurihara, H; Ito, T; Kikuchi, H; Yoshida, K; Yamanokuchi, H; Asari, A			The keratan sulfate disaccharide gal(6S03) beta 1,4-GlcNAc(6S03) modulates interleukin 12 production by macrophages in murine Thy-1 type autoimmune disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR CORNEAL-DYSTROPHY; NECROSIS-FACTOR-ALPHA; CYSTEINE-RICH DOMAIN; MRL-LPR/LPR MICE; MANNOSE RECEPTOR; T-CELLS; IN-VIVO; PROTEIN-KINASE; P40 HOMODIMER; IL-12	It has been reported that disaccharides of the glyco-saminoglycans (GAGs), heparin, or heparan sulfate suppress the production of cytokines. Therefore, we examined the effects of GAGs (keratan sulfate, hyaluronan, chondroitin, chondroitin sulfate, and heparin sulfate) disaccharides on production of interleukin (IL)-12, a pivotal cytokine in the Th-1 type immune system. Among the GAG disaccharides, only a keratan sulfate disaccharide, Gal(6SO(3))- GlcNAc(6-SO3) (L4), suppressed IL-12 production in macrophages stimulated with lipopolysaccharides and interferon-gamma. Neither keratan sulfate chains nor keratan sulfate tetrasaccharides elicited any change in the IL-12 production. N-Acetyl-lactosamine, Gal-GlcNAc ( LacNAc), also did not change IL-12 production. These results indicated that a certain size, i.e. disaccharide and sulfate, are essential to suppress IL-12 production. L4 was then applied to MRL-lpr/lpr mice, a Th-1 type autoimmune disease model. The treatment of MRL-lpr/lpr mice with L41) decreased in serum IL-12, 2) induced apoptosis in T cells in lymph nodes thereby suppressing lymphoaccumulation, and 3) suppressed hypergammaglobulinemia and glomerulonephritis. We showed previously that IL-12 suppresses cell death of T cells, thereby enhancing the lymphoaccumulation in MRL-lpr/lpr mice. Moreover, it has been reported that IL-12 deficiency in MRL-lpr/lpr mice diminishes lymphoaccumulation and delays glomerulonephritis. The treatment with L4 suppressed phosphoprotein kinase C and phosphoinositide 3-kinase expression in macrophages, suggesting that L4 suppresses IL-12 production by inhibiting phosphoprotein kinase C and phosphoinositide 3-kinase pathways.	Seikagaku Corp, Chuo Ku, Tokyo 1030023, Japan; Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland; Mizutani Fdn Glycosci, Chuo Ku, Tokyo 1030023, Japan	Seikagaku Corporation; University of Aberdeen	Asari, A (corresponding author), Seikagaku Corp, Chuo Ku, 1-5,Nihonbashi Honcho 2 Chome, Tokyo 1030023, Japan.	aaquira@hotmail.com	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X				Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Cahalon L, 1997, INT IMMUNOL, V9, P1517, DOI 10.1093/intimm/9.10.1517; Chowers Y, 2001, GASTROENTEROLOGY, V120, P449, DOI 10.1053/gast.2001.21202; COHEN GM, 1993, PROGRAMMED CELL DEAT, P123; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; FABIO R, 2001, J BIOL CHEM, V276, P37692; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; GATELY MK, 1991, J IMMUNOL, V147, P874; Gately MK, 1996, ANN NY ACAD SCI, V795, P1, DOI 10.1111/j.1749-6632.1996.tb52650.x; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ha SJ, 1999, J IMMUNOL, V163, P2902; Hascall V C, 1982, Prog Clin Biol Res, V110 Pt B, P3; Hasegawa N, 2000, INVEST OPHTH VIS SCI, V41, P3670; Kaposzta R, 1999, J CELL SCI, V112, P3237; Kato K, 1996, P NATL ACAD SCI USA, V93, P9085, DOI 10.1073/pnas.93.17.9085; Kikawada E, 2003, J IMMUNOL, V170, P3915, DOI 10.4049/jimmunol.170.7.3915; Kubota M, 2000, EUR J MASS SPECTROM, V6, P193, DOI 10.1255/ejms.338; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Lewis D, 2000, GLYCOBIOLOGY, V10, P305, DOI 10.1093/glycob/10.3.305; Linehan SA, 2001, EUR J IMMUNOL, V31, P1857, DOI 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D; Liu TF, 1998, CYTOKINE, V10, P140, DOI 10.1006/cyto.1997.0268; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Martinez-Pomares L, 2001, IMMUNOBIOLOGY, V204, P527, DOI 10.1078/0171-2985-00089; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; Mehal WZ, 1998, J IMMUNOL, V161, P1686; Neumann A, 1999, FEBS LETT, V453, P283, DOI 10.1016/S0014-5793(99)00731-0; NIEDUSZYNSKI IA, 1990, BIOCHEM SOC T, V18, P792, DOI 10.1042/bst0180792; Piccotti JR, 1997, J IMMUNOL, V158, P643; Quantock AJ, 2001, INVEST OPHTH VIS SCI, V42, P1750; Rempel JD, 1997, J IMMUNOL, V159, P1490; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Xu HP, 2001, J AUTOIMMUN, V16, P87, DOI 10.1006/jaut.2000.0468; Xu HP, 2002, J BIOL CHEM, V277, P17308, DOI 10.1074/jbc.M112371200; Yoo JK, 2002, J IMMUNOL, V169, P3637, DOI 10.4049/jimmunol.169.7.3637; Yu QG, 2004, J IMMUNOL, V172, P6047, DOI 10.4049/jimmunol.172.10.6047	38	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20879	20886		10.1074/jbc.M411954200	http://dx.doi.org/10.1074/jbc.M411954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15749717	hybrid			2022-12-27	WOS:000229242000086
J	Gingerich, DJ; Gagne, JM; Salter, DW; Hellmann, H; Estelle, M; Ma, LG; Vierstra, RD				Gingerich, DJ; Gagne, JM; Salter, DW; Hellmann, H; Estelle, M; Ma, LG; Vierstra, RD			Cullins 3a and 3b assemble with members of the broad complex/tramtrack/bric-a-brac (BTB) protein family to form essential ubiquitin-protein ligases (E3s) in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RESPONSIVE GENE-EXPRESSION; POZ-DOMAIN; INTERACTING PROTEIN; INTERACTION MOTIF; BOX PROTEIN; S-PHASE; SCF; COMPLEX; DEGRADATION	Selective modification of proteins by ubiquitination is directed by diverse families of ubiquitin-protein ligases (or E3s). A large collection of E3s use Cullins (CULs) as scaffolds to form multisubunit E3 complexes in which the CUL binds a target recognition subcomplex and the RBX1 docking protein, which delivers the activated ubiquitin moiety. Arabidopsis and rice contain a large collection of CUL isoforms, indicating that multiple CUL-based E3s exist in plants. Here we show that Arabidopsis CUL3a and CUL3b associate with RBX1 and members of the broad complex/tramtrack/bric-a-brac (BTB) protein family to form BTB E3s. Eighty genes encoding BTB domain-containing proteins were identified in the Arabidopsis genome, indicating that a diverse array of BTB E3s is possible. In addition to the BTB domain, the encoded proteins also contain various other interaction motifs that likely serve as target recognition elements. DNA microarray analyses show that BTB genes are expressed widely in the plant and that tissue-specific and isoform-specific patterns exist. Arabidopsis defective in both CUL3a and CUL3b are embryo-lethal, indicating that BTB E3s are essential for plant development.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Free Univ Berlin, Inst Biol & Appl Genet, D-14195 Berlin, Germany; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	University of Wisconsin System; University of Wisconsin Madison; Indiana University System; Indiana University Bloomington; Free University of Berlin; Yale University	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425-G Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu	Gagne, Jennifer M/B-2866-2009	Gagne, Jennifer M/0000-0003-2563-087X; Gingerich, Derek/0000-0003-3553-1613	NIGMS NIH HHS [F32-GM68361] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM068361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Azevedo C, 2001, TRENDS PLANT SCI, V6, P354, DOI 10.1016/S1360-1385(01)01960-4; Banno H, 2000, PLANT CELL PHYSIOL, V41, P617, DOI 10.1093/pcp/41.5.617; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Capron A, 2003, PLANT CELL, V15, P2370, DOI 10.1105/tpc.013847; Capron A, 2003, TRENDS PLANT SCI, V8, P83, DOI 10.1016/S1360-1385(02)00028-6; Cheung AY, 2004, PLANT CELL, V16, P257, DOI 10.1105/tpc.016550; Chiba T, 2004, CURR PROTEIN PEPT SC, V5, P177, DOI 10.2174/1389203043379783; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dong XN, 2004, CURR OPIN PLANT BIOL, V7, P547, DOI 10.1016/j.pbi.2004.07.005; Downes BP, 2003, PLANT J, V35, P729, DOI 10.1046/j.1365-313X.2003.01844.x; Du LQ, 2004, PLANT MOL BIOL, V54, P549, DOI 10.1023/B:PLAN.0000038269.98972.bb; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Ha CM, 2004, PLANT CELL PHYSIOL, V45, P1361, DOI 10.1093/pcp/pch201; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Inada S, 2004, PLANT CELL, V16, P887, DOI 10.1105/tpc.019901; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kim S, 2004, PLANT PHYSIOL, V136, P3639, DOI 10.1104/pp.104.049189; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Laux T, 1997, PLANT CELL, V9, P989, DOI 10.1105/tpc.9.7.989; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MA L, 2005, IN PRESS PLANT PHYSL; Meyers BC, 2004, PLANT PHYSIOL, V135, P801, DOI 10.1104/pp.104.039495; Michel JJ, 2003, J BIOL CHEM, V278, P22828, DOI 10.1074/jbc.M210358200; Motchoulski A, 1999, SCIENCE, V286, P961, DOI 10.1126/science.286.5441.961; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Risseeuw EP, 2003, PLANT J, V34, P753, DOI 10.1046/j.1365-313X.2003.01768.x; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Shen WH, 2002, MOL BIOL CELL, V13, P1916, DOI 10.1091/mbc.E02-02-0077; Shiu SH, 2003, PLANT PHYSIOL, V132, P530, DOI 10.1104/pp.103.021964; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smalle J, 2004, ANNU REV PLANT BIOL, V55, P555, DOI 10.1146/annurev.arplant.55.031903.141801; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Thelander M, 2002, PLANT MOL BIOL, V49, P69, DOI 10.1023/A:1014440531842; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang KLC, 2004, NATURE, V428, P945, DOI 10.1038/nature02516; Weber H, 2005, PLANT PHYSIOL, V137, P83, DOI 10.1104/pp.104.052654; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Woodger FJ, 2004, PLANT CELL PHYSIOL, V45, P945, DOI 10.1093/pcp/pch100; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	73	118	204	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18810	18821		10.1074/jbc.M413247200	http://dx.doi.org/10.1074/jbc.M413247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15749712	hybrid			2022-12-27	WOS:000228932300033
J	Vellaichamy, E; Khurana, ML; Fink, J; Pandey, KN				Vellaichamy, E; Khurana, ML; Fink, J; Pandey, KN			Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ADULT-RAT CARDIOMYOCYTES; CONGESTIVE-HEART-FAILURE; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE; ACTIVATOR PROTEIN-1; TISSUE INHIBITORS; GENE-EXPRESSION; TRANSGENIC MICE; CYCLIC-GMP	Mice carrying a targeted disruption of the Npr1 gene (coding for guanylyl cyclase/natriuretic peptide receptor A (NPRA)) exhibit increased blood pressure, cardiac hypertrophy, and congestive heart failure, similar to untreated human hypertensive patients. The objective of this study was to determine whether permanent ablation of NPRA signaling in mice alters the expression of matrix metalloproteinase (MMP)-2 and MMP-9 and pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), leading to myocardial collagen remodeling. Here, we report that expression levels of the MMP-2 and MMP-9 genes were increased by 3-5-fold and that the expression of the TNF-alpha gene was enhanced by 8-fold in Npr1 homozygous null mutant (Npr1(-/-)) mouse hearts compared with wild-type (Npr1(+/+)) control mouse hearts. Myocardial fibrosis, total collagen, and the collagen type I/III ratio (p < 0.01) were dramatically increased in adult Npr1(-/-) mice compared with age-matched wild-type counterparts. Hypertrophic marker genes, including the beta-myosin heavy chain and transforming growth factor-beta 1, were significantly up-regulated (3-5-fold) in both young and adult Npr1(-/-) mouse hearts. NF-kappa B binding activity in ventricular tissues was enhanced by 4-fold with increased translocation of the p65 subunit from the cytoplasmic to nuclear fraction in Npr1(-/-) mice. Our results show that reduced NPRA signaling activates MMP, transforming growth factor-beta 1, and TNF-alpha expression in Npr1(-/-) mouse hearts. The findings of this study demonstrate that disruption of NPRA/cGMP signaling promotes hypertrophic growth and extracellular matrix remodeling, leading to the development of cardiac hypertrophy, myocardial fibrosis, and congestive heart failure.	Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Physiol & Hypertens, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Sch Med, Renal Ctr Excellence, New Orleans, LA 70112 USA	Tulane University; Tulane University	Pandey, KN (corresponding author), Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, SL-39,1430 Tulane Ave, New Orleans, LA 70112 USA.	kpandey@tulane.edu			NHLBI NIH HHS [HL 62147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; Collard CD, 1999, ARTERIOSCL THROM VAS, V19, P2623, DOI 10.1161/01.ATV.19.11.2623; COLUCCI WS, 1997, AM J CARDIOL, V80, P15; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DENT CL, 1999, TRANSCRIPTION FACTOR, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon IMC, 1997, J MOL CELL CARDIOL, V29, P1837, DOI 10.1006/jmcc.1997.0420; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Eagleton MJ, 2002, J SURG RES, V104, P15, DOI 10.1006/jsre.2002.6396; Ellmers LJ, 2002, AM J PHYSIOL-HEART C, V283, pH707, DOI 10.1152/ajpheart.00677.2001; Frantz S, 2003, CARDIOVASC RES, V57, P749, DOI 10.1016/S0008-6363(02)00723-X; HOLTWICK R, 2003, J CLIN INVEST, V111, P1275; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Kapoun AM, 2004, CIRC RES, V94, P453, DOI 10.1161/01.RES.0000117070.86556.9F; Kiemer AK, 2002, BIOCHEM BIOPH RES CO, V295, P1068, DOI 10.1016/S0006-291X(02)00807-0; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; KLINGER JR, 1993, J APPL PHYSIOL, V75, P198, DOI 10.1152/jappl.1993.75.1.198; Knipp BS, 2004, J SURG RES, V116, P70, DOI 10.1016/S0022-4804(03)00306-8; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuwahara F, 2002, CIRCULATION, V106, P130, DOI 10.1161/01.CIR.0000020689.12472.E0; Levin ER, 1998, NEW ENGL J MED, V339, P321; Li CF, 2001, AM J PHYSIOL-HEART C, V280, pH1264, DOI 10.1152/ajpheart.2001.280.3.H1264; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Li YY, 2000, P NATL ACAD SCI USA, V97, P12746, DOI 10.1073/pnas.97.23.12746; Li YY, 2002, AM J PHYSIOL-HEART C, V282, pH983, DOI 10.1152/ajpheart.00233.2001; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; MARTIN AF, 1982, CIRC RES, V50, P117, DOI 10.1161/01.RES.50.1.117; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUKHERJEE D, 1991, J CLIN INVEST, V88, P1141, DOI 10.1172/JCI115414; Oliver PM, 1998, P NATL ACAD SCI USA, V95, P2547, DOI 10.1073/pnas.95.5.2547; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Pandey KN, 2000, BIOCHEM BIOPH RES CO, V271, P374, DOI 10.1006/bbrc.2000.2627; Pandey KN, 2000, MOL PHARMACOL, V57, P259; Peterson JT, 2001, CIRCULATION, V103, P2303; Polyakova V, 2004, J AM COLL CARDIOL, V44, P1609, DOI 10.1016/j.jacc.2004.07.023; Ritchie RH, 1998, AM J PHYSIOL-HEART C, V275, pH1370, DOI 10.1152/ajpheart.1998.275.4.H1370; Rosenkranz AC, 2003, CARDIOVASC RES, V57, P515, DOI 10.1016/S0008-6363(02)00667-3; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Shi SJ, 2003, AM J PHYSIOL-RENAL, V285, pF694, DOI 10.1152/ajprenal.00097.2003; Shi SJ, 2001, AM J PHYSIOL-RENAL, V281, pF665, DOI 10.1152/ajprenal.2001.281.4.F665; Spinale FG, 1998, CIRC RES, V82, P482, DOI 10.1161/01.RES.82.4.482; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; Strauss BH, 1996, CIRC RES, V79, P541, DOI 10.1161/01.RES.79.3.541; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; Tsuruda T, 2002, CIRC RES, V91, P1127, DOI 10.1161/01.RES.0000046234.73401.70; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Zahabi A, 2003, J BIOL CHEM, V278, P47694, DOI 10.1074/jbc.M309661200	58	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19230	19242		10.1074/jbc.M411373200	http://dx.doi.org/10.1074/jbc.M411373200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15710627	hybrid			2022-12-27	WOS:000228932300080
J	Wilker, EW; Grant, RA; Artim, SC; Yaffe, MB				Wilker, EW; Grant, RA; Artim, SC; Yaffe, MB			A structural basis for 14-3-3 sigma functional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CRYSTAL-STRUCTURE; SIGMA GENE; KINASE; HYPERMETHYLATION; PHOSPHORYLATION; PROTEINS; ISOFORMS; BINDING; 14-3-3-PROTEINS	The 14-3-3 family of proteins includes seven isotypes in mammalian cells that play numerous diverse roles in intracellular signaling. Most 14-3-3 proteins form homodimers and mixed heterodimers between different isotypes, with overlapping roles in ligand binding. In contrast, one mammalian isoform, 14-3-3 sigma, expressed primarily in epithelial cells, appears to play a unique role in the cellular response to DNA damage and in human oncogenesis. The biological and structural basis for these 14-3-3-specific functions is unknown. We demonstrate that endogenous 14-3-3 sigma preferentially forms homodimers in cells. We have solved the x-ray crystal structure of 14-3-3 sigma bound to an optimal phosphopeptide ligand at 2.4 angstrom resolution. The structure reveals the presence of stabilizing ring-ring and salt bridge interactions unique to the 14-3-3 sigma homodimer structure and potentially destabilizing electrostatic interactions between subunits in 14-3-3 sigma-containing heterodimers, rationalizing preferential homodimerization of 14-3-3 sigma in vivo. The interaction of the phosphopeptide with 14-3-3 reveals a conserved mechanism for phospho-dependent ligand binding, implying that the phosphopeptide binding cleft is not the critical determinant of the unique biological properties of 14-3-3 sigma. Instead, the structure suggests a second ligand binding site involved in 14-3-3 sigma-specific ligand discrimination. We have confirmed this by site-directed mutagenesis of three sigma-specific residues that uniquely define this site. Mutation of these residues to the alternative sequence that is absolutely conserved in all other 14-3-3 isotypes confers upon 14-3-3 sigma the ability to bind to Cdc25C, a ligand that is known to bind to other 14-3-3 proteins but not to sigma.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Div Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, Dept Biol, 77 Massachusetts Ave,E18-580, Cambridge, MA 02139 USA.	myaffe@mit.edu		/0000-0003-4503-9024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594, P50GM068762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68762, GM60594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chaudhri M, 2003, BIOCHEM BIOPH RES CO, V300, P679, DOI 10.1016/S0006-291X(02)02902-9; Dalal SN, 2004, CELL CYCLE, V3, P672; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Nguyen A, 2004, NAT BIOTECHNOL, V22, P993, DOI 10.1038/nbt997; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Suzuki H, 2000, CANCER RES, V60, P4353; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	40	183	187	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18891	18898		10.1074/jbc.M500982200	http://dx.doi.org/10.1074/jbc.M500982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15731107	hybrid			2022-12-27	WOS:000228932300041
J	Oskouian, B; Mendel, J; Shocron, E; Lee, MA; Fyrst, H; Saba, JD				Oskouian, B; Mendel, J; Shocron, E; Lee, MA; Fyrst, H; Saba, JD			Regulation of sphingosine-1-phosphate lyase gene expression by members of the GATA family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTORS; DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION; INDUCED APOPTOSIS; CELLS; ENDODERM; YEAST; DIFFERENTIATION; ENCODES	Sphingosine-1-phosphate is a bioactive sphingolipid that regulates proliferation, differentiation, migration, and apoptosis. Sphingosine-1-phosphate is irreversibly degraded by the highly conserved enzyme sphingosine-1-phosphate lyase. Recent studies have suggested that sphingosine-1-phosphate lyase expression affects animal development and cell fate decisions. Despite its crucial role, mechanisms affecting expression of sphingosine-1- phosphate lyase remain poorly understood. In this study, regulation of sphingosine-1- phosphate lyase gene expression was investigated in Caenorhabditis elegans, where lyase expression is spatially restricted to cells of the developing and adult gut and is essential for normal development. Deletion analysis and generation of transgenic worms combined with fluorescence microscopy identified a 350-nucleotide sequence upstream of the ATG start site necessary for maximal lyase expression in adult worms. Site-specific mutagenesis of a GATA transcription factor-binding motif in the promoter led to loss of reporter expression. Knockdown of the gut-specific GATA transcription factor ELT-2 by RNA interference similarly led to loss of reporter expression. ELT-2 interacted with the GATA factor-binding motif in vitro and was also capable of driving expression of a Caenorhabditis elegans lyase promoter-beta-galactosidase reporter in a heterologous yeast system. These studies demonstrate that ELT-2 regulates sphingosine-1- phosphate lyase expression in vivo. Additionally, we demonstrate that the human sphingosine-1-phosphate lyase gene is regulated by a GATA transcription factor. Overexpression of GATA-4 led to both an increase in activity of a reporter gene as well as an increase in endogenous sphingosine-1- phosphate lyase protein.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; California Institute of Technology	Saba, JD (corresponding author), Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.	jsaba@chori.org		Lee, Michael/0000-0002-4809-0856	NCI NIH HHS [1R01CA77528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brooks DR, 2003, J BIOL CHEM, V278, P52340, DOI 10.1074/jbc.M308858200; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; EPSTEIN H, 1995, METHOD CELL BIOL, V48, P3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Fukushige T, 2003, GENETICS, V165, P575; Fukushige T, 2005, DEV BIOL, V279, P446, DOI 10.1016/j.ydbio.2004.12.012; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HAWKINS MG, 1995, J BIOL CHEM, V270, P14666, DOI 10.1074/jbc.270.24.14666; Herr DR, 2004, J BIOL CHEM, V279, P12685, DOI 10.1074/jbc.M310647200; Herr DR, 2003, DEVELOPMENT, V130, P2443, DOI 10.1242/dev.00456; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Karliner JS, 2002, BBA-MOL CELL BIOL L, V1582, P216, DOI 10.1016/S1388-1981(02)00174-9; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Koh K, 2001, DEVELOPMENT, V128, P2867; Koh K, 2002, DEVELOPMENT, V129, P5171; Kohara Y, 2001, Tanpakushitsu Kakusan Koso, V46, P2425; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KRAUSE M, 1994, DEV BIOL, V166, P133, DOI 10.1006/dbio.1994.1302; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Maduro MF, 2002, DEV BIOL, V246, P68, DOI 10.1006/dbio.2002.0655; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; Moilanen LH, 1999, J BIOL CHEM, V274, P29655, DOI 10.1074/jbc.274.42.29655; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; ORKIN SH, 1992, BLOOD, V80, P575; Oskouian B, 2004, SEMIN CELL DEV BIOL, V15, P529, DOI 10.1016/j.semcdb.2004.05.009; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Renault Andrew D., 2002, Gene Expression Patterns, V2, P337, DOI 10.1016/S0925-4773(02)00389-1; REUTER R, 1994, DEVELOPMENT, V120, P1123; SHIM YH, 1995, J MOL BIOL, V253, P665, DOI 10.1006/jmbi.1995.0581; Shoichet SA, 2000, P NATL ACAD SCI USA, V97, P4076, DOI 10.1073/pnas.97.8.4076; Shureiqi I, 2002, CANCER RES, V62, P1178; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Suzuki YJ, 2004, LIFE SCI, V74, P1829, DOI 10.1016/j.lfs.2003.10.002; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993; Zhu JW, 1998, GENE DEV, V12, P3809, DOI 10.1101/gad.12.24.3809; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	62	25	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18403	18410		10.1074/jbc.M410928200	http://dx.doi.org/10.1074/jbc.M410928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734735	Green Accepted, hybrid			2022-12-27	WOS:000228807200102
J	Singh, RR; Song, CY; Yang, ZB; Kumar, R				Singh, RR; Song, CY; Yang, ZB; Kumar, R			Nuclear localization and chromatin targets of p21-activated kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; CELL; TRANSLOCATION; INTERACTS; GTPASES	Pak1 (p21-activated kinase 1), a conserved, mammalian signaling kinase, is a downstream effector of small GTPases Rac1 and Cdc42 and of growth factor signaling. Until now, a major focus of study has been on the cytosolic functions of Pak1, where it is an important modulator of cytoskeletal reorganization, consequently playing a major role in cell survival, migration, and invasion. In this report, we demonstrate the nuclear localization of Pak1 upon stimulation by epidermal growth factor. Three nuclear localization signals (NLSs) were identified in the N-terminal domain of Pak1. With mutational analysis, the importance of each NLS was elucidated. Mutation of all three NLSs eliminated the nuclear localization of Pak1. Expression of Pak1 as a fusion protein with Gal4-DNA binding domain and Gal4-luciferase activity showed that Pak1 might increase transcription. To identify the potential targets of nuclear Pak1, we used a Pak1-specific chromatin immunoprecipitation-based screening assay and identified a series of Pak1-interacting target chromatins, including phosphofructokinase-muscle isoform (PFK-M) and nuclear factor of activated T-cell (NFAT1) genes. Pak1 associated with the upstream enhancer sequence and promoter of PFK-M and was involved in the stimulation of the PFK-M expression. It also associated with a portion of the NFAT1 gene and its upstream region, leading to the repression of NFAT1 expression. These investigations provide proof-of-principle evidence that Pak1 could influence the expression of its putative chromatin targets in both a positive and a negative manner. Together, for the first time, these findings defined the NLSs of the Pak1, its association with chromatin, and the resulting modulation of transcription, thus opening new avenues to further the search for nuclear Pak1 functions and identify putative Pak1-interacting nuclear proteins.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NCI NIH HHS [CA109379, CA 98823, CA90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109379, R01CA090970, R01CA098823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gururaj A, 2004, ONCOGENE, V23, P8118, DOI 10.1038/sj.onc.1207969; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MERNARD RE, 2003, CELL SIGNAL, V15, P1099; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; *NIH, NIH BLAST; Pasqualini C, 2001, MOL ENDOCRINOL, V15, P894, DOI 10.1210/me.15.6.894; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	28	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18130	18137		10.1074/jbc.M412607200	http://dx.doi.org/10.1074/jbc.M412607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15749698	hybrid			2022-12-27	WOS:000228807200070
J	Bai, XC; Lu, D; Liu, AL; Zhang, ZM; Li, XM; Zou, ZP; Zeng, WS; Cheng, BL; Luo, SQ				Bai, XC; Lu, D; Liu, AL; Zhang, ZM; Li, XM; Zou, ZP; Zeng, WS; Cheng, BL; Luo, SQ			Reactive oxygen species stimulates receptor activator of NF-kappa B ligand expression in osteoblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; OSTEOCLASTIC BONE-RESORPTION; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; ESTROGEN-DEFICIENCY; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL; HEAT-SHOCK; P38 MAPK	It has been established that reactive oxygen species (ROS) such as H2O2 or superoxide anion is involved in bone loss-related diseases by stimulating osteoclast differentiation and bone resorption and that receptor activator of NF-kappa B ligand ( RANKL) is a critical osteoclastogenic factor expressed on stromal/osteoblastic cells. However, the roles of ROS in RANKL expression and signaling mechanisms through which ROS regulates RANKL genes are not known. Here we report that increased intracellular ROS levels by H2O2 or xanthine/ xanthine oxidase-generated superoxide anion stimulated RANKL mRNA and protein expression in human osteoblast-like MG63 cell line and primary mouse bone marrow stromal cells and calvarial osteoblasts. Further analysis revealed that ROS promoted phosphorylation of cAMP response element-binding protein (CREB)/ ATF2 and its binding to CRE-domain in the murine RANKL promoter region. Moreover, the results of protein kinase A (PKA) inhibitor KT5720 and CREB1 RNA interference transfection clearly showed that PKA-CREB signaling pathway was necessary for ROS stimulation of RANKL in mouse osteoblasts. In human MG63 cells, however, we found that ROS promoted heat shock factor 2 (HSF2) binding to heat shock element in human RANKL promoter region and that HSF2, but not PKA, was required for ROS up-regulation of RANKL as revealed by KT5720 and HSF2 RNA interference transfection. We also found that ROS stimulated phosphorylation of extracellular signal-regulated kinases ( ERKs) and that PD98059, the inhibitor for ERKs suppressed ROS-induced RANKL expression either in mouse osteoblasts or in MG63 cells. These results demonstrate that ROS stimulates RANKL expression via ERKs and PKA-CREB pathway in mouse osteoblasts and via ERKs and HSF2 in human MG63 cells.	So Med Univ, Dept Cell Biol, Guangzhou 510515, Peoples R China; Kunming Med Coll, Inst Neurosci, Kunming 650032, Peoples R China; Nanfang Hosp, Dept Orthopaed & Spinal Surg, Saoguan 510515, Guangzhou, Peoples R China; Saoguan Coll, Dept Biol, Saoguan 512005, Guangzhou, Peoples R China	Southern Medical University - China; Kunming Medical University; Southern Medical University - China	Bai, XC (corresponding author), So Med Univ, Dept Cell Biol, Guangzhou 510515, Peoples R China.	baixc15@fimmu.com		Bai, Xiaochun/0000-0001-9631-4781				Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270; Cao LH, 2003, J CELL BIOCHEM, V89, P152, DOI 10.1002/jcb.10486; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756-3282(96)00177-9; Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200; GARRETT JR, 1990, J CLIN INVEST, V85, P632; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005; Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035; HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Henriksen K, 2003, J BIOL CHEM, V278, P48745, DOI 10.1074/jbc.M309193200; Ichiki T, 2003, HYPERTENSION, V42, P177, DOI 10.1161/01.HYP.0000079791.26014.04; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200; Kodama I, 2004, J BONE MINER RES, V19, P200, DOI 10.1359/JBMR.0301229; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003-0166; Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002-021496; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378-1119(03)00841-2; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; SONTAKKE AN, 1992, CLIN CHIM ACTA, V318, P145; Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097-4652(199809)176:3<574::AID-JCP14>3.0.CO;2-#; SUDA N, 1993, BIOCHIM BIOPHYS ACTA, V1157, P318, DOI 10.1016/0304-4165(93)90116-P; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531-5565(03)00069-X; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Yoneda T, 2004, ENDOCRINOLOGY, V145, P2384, DOI 10.1210/en.2003-1536; Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599	51	247	266	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17497	17506		10.1074/jbc.M409332200	http://dx.doi.org/10.1074/jbc.M409332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731115	hybrid			2022-12-27	WOS:000228615500117
J	Connor, KM; Subbaram, S; Regan, KJ; Nelson, KK; Mazurkiewicz, JE; Bartholomew, PJ; Aplin, AE; Tai, YT; Aguirre-Ghiso, J; Flores, SC; Melendez, JA				Connor, KM; Subbaram, S; Regan, KJ; Nelson, KK; Mazurkiewicz, JE; Bartholomew, PJ; Aplin, AE; Tai, YT; Aguirre-Ghiso, J; Flores, SC; Melendez, JA			Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PTEN; MATRIX-METALLOPROTEINASE EXPRESSION; PROTEIN-TYROSINE PHOSPHATASES; INDUCIBLE FACTOR 1-ALPHA; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; REDOX REGULATION; IN-VITRO; ACTIVATION	Recent studies have demonstrated that the tumor suppressor PTEN ( phosphatase and tensin homolog deleted from chromosome 10), the antagonist of the phosphosphoinositol-3- kinase ( PI3K) signaling cascade, is susceptible to H2O2-dependent oxidative inactivation. This study describes the use of redox-engineered cell lines to identify PTEN as sensitive to oxidative inactivation by mitochondrial H2O2. Increases in the steady state production of mitochondrial derived H2O2, as a result of manganese superoxide dismutase ( Sod2) overexpression, led to PTEN oxidation that was reversed by the coexpression of the H2O2- detoxifying enzyme catalase. The accumulation of an oxidized inactive fraction of PTEN favored the formation of phosphatidylinositol 3,4,5-triphosphate at the plasma membrane, resulting in increased activation of Akt and modulation of its downstream targets. PTEN oxidation in response to mitochondrial H2O2 enhanced PI3K signaling, leading to increased expression of the key regulator of angiogenesis, vascular endothelial growth factor. Overexpression of PTEN prevented the H2O2- dependent increase in vascular endothelial growth factor promoter activity and immunoreactive protein, whereas a mutant PTEN (G129R), lacking phosphatase activity, did not. Furthermore, mitochondrial generation of H2O2 by Sod2 promoted endothelial cell sprouting in a three-dimensional in vitro angiogenesis assay that was attenuated by catalase coexpression or the PI3K inhibitor LY2949002. Moreover, Sod2 overexpression resulted in increased in vivo blood vessel formation that was H2O2- dependent as assessed by the chicken chorioallantoic membrane assay. Our findings provide the first evidence for the involvement of mitochondrial H2O2 in regulating PTEN function and the angiogenic switch, indicating that Sod2 can serve as an alternative physiological source of the potent signaling molecule, H2O2.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; SUNY Albany, Dept Biomed Sci, Sch Publ Hlth, Rensselaer, NY 12144 USA; Univ Colorado, Hlth Sci Ctr, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA	Albany Medical College; Albany Medical College; Albany Medical College; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Melendez, JA (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, MC 151,47 New Scotland Ave, Albany, NY 12208 USA.	melenda@mail.amc.edu		Melendez, Juan/0000-0001-8021-3097; Aguirre-Ghiso, Julio/0000-0002-6694-6507; Connor, Kip/0000-0002-2048-9080	NATIONAL CANCER INSTITUTE [K22CA095011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049822] Funding Source: NIH RePORTER; NCI NIH HHS [CA095011, CA77068] Funding Source: Medline; NIAID NIH HHS [AI49822] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Blancher C, 2001, CANCER RES, V61, P7349; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Dickinson ME, 2001, BIOTECHNIQUES, V31, P1272, DOI 10.2144/01316bt01; DIMINO MJ, 1987, BIOL REPROD, V36, P97, DOI 10.1095/biolreprod36.1.97; Downes CP, 2004, BIOCHEM SOC T, V32, P338, DOI 10.1042/BST0320338; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lansford R, 2001, J BIOMED OPT, V6, P311, DOI 10.1117/1.1383780; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Monte M, 1997, EUR J CANCER, V33, P676, DOI 10.1016/S0959-8049(96)00506-0; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nelson KK, 2003, CLIN CANCER RES, V9, P424; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RHEE SG, 2000, SCI STKE, pE1; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tsugawa K, 2002, FRONT BIOSCI-LANDMRK, V7, pE245, DOI 10.2741/tsugawa; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; Yamada KM, 2001, J CELL SCI, V114, P2375; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Zhong H, 2000, CANCER RES, V60, P1541	65	190	196	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16916	16924		10.1074/jbc.M410690200	http://dx.doi.org/10.1074/jbc.M410690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701646	hybrid			2022-12-27	WOS:000228615500046
J	Desai, SA; Alkhalil, A; Kang, M; Ashfaq, U; Nguyen, ML				Desai, SA; Alkhalil, A; Kang, M; Ashfaq, U; Nguyen, ML			Plasmodial surface anion channel-independent phloridzin resistance in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; HUMAN ERYTHROCYTES; TRANSPORT; MEMBRANE; PERMEATION; TRANSFECTION; NA+	The plasmodial surface anion channel (PSAC) is an unusual ion channel induced on the human red blood cell membrane after infection with the malaria parasite, Plasmodium falciparum. Because PSAC is permeant to small metabolic precursors essential for parasite growth and is present on red blood cells infected with geographically divergent parasite isolates, it may be an ideal target for future antimalarial development. Here, we used chemically induced mutagenesis and known PSAC antagonists that inhibit in vitro parasite growth to examine whether resistance mutations in PSAC can be readily induced. Stable mutants resistant to phloridzin were generated and selected within 3 weeks after treatment with 1-methyl-3-nitro-1-nitrosoguanidine. These mutants were evaluated with osmotic lysis and electrophysiological transport assays, which indicate that PSAC inhibition by phloridzin is complex with at least two different modes of inhibition. Mutants resistant to the growth inhibitory effects of phloridzin expressed PSAC activity indistinguishable from that on sensitive parasites, indicating selection of resistance via mutations in one or more other parasite targets. Failure to induce mutations in PSAC activity is consistent with a highly constrained channel protein less susceptible to resistance mutations; whether this protein is parasiteor host-encoded remains to be determined.	NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Desai, SA (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rm 3W-01,12735 Twinbrook Pkwy, Rockville, MD 20852 USA.	sdesai@niaid.nih.gov	Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000882] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000882-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; Alkhalil A, 2004, BLOOD, V104, P4279, DOI 10.1182/blood-2004-05-2047; Anderson PAV, 2001, COMP BIOCHEM PHYS B, V129, P17, DOI 10.1016/S1096-4959(01)00376-1; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; Crabb BS, 2004, METH MOL B, V270, P263; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; DESAI SA, 2005, IN PRESS NANOMEDICIN; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; Elliott JL, 2001, BIOCHEM J, V355, P733, DOI 10.1042/bj3550733; Gardiner DL, 2003, TRENDS PARASITOL, V19, P381, DOI 10.1016/S1471-4922(03)00187-9; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; INSELBURG J, 1984, MOL BIOCHEM PARASIT, V10, P89, DOI 10.1016/0166-6851(84)90021-5; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; KIRK K, 1994, J BIOL CHEM, V269, P3339; KUTNER S, 1987, BIOCHEM PHARMACOL, V36, P123, DOI 10.1016/0006-2952(87)90389-3; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MELNIK E, 1977, J GEN PHYSIOL, V69, P243, DOI 10.1085/jgp.69.2.243; Rokitskaya TI, 2002, BIOPHYS J, V82, P865, DOI 10.1016/S0006-3495(02)75448-9; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Staines HM, 2000, BBA-BIOMEMBRANES, V1463, P88, DOI 10.1016/S0005-2736(99)00187-X; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Verloo P, 2004, J BIOL CHEM, V279, P10316, DOI 10.1074/jbc.M311540200; Wagner MA, 2003, BIOPHYS J, V84, P116, DOI 10.1016/S0006-3495(03)74836-X; Wang Z, 2003, MUTAT RES-FUND MOL M, V528, P29, DOI 10.1016/S0027-5107(03)00079-4; Wickham ME, 2003, J BIOL CHEM, V278, P37658, DOI 10.1074/jbc.M305252200	37	25	25	2	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16861	16867		10.1074/jbc.M414629200	http://dx.doi.org/10.1074/jbc.M414629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15701633	hybrid			2022-12-27	WOS:000228615500040
J	Hanamoto, T; Ozaki, T; Furuya, H; Hosoda, M; Hayashi, S; Nakanshi, M; Yamamoto, H; Kikuchi, H; Todo, S; Nakagawara, A				Hanamoto, T; Ozaki, T; Furuya, H; Hosoda, M; Hayashi, S; Nakanshi, M; Yamamoto, H; Kikuchi, H; Todo, S; Nakagawara, A			Identification of protein kinase A catalytic subunit beta as a novel binding partner of p73 and regulation of p73 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; TRANSCRIPTIONAL ACTIVATION; P53-RELATED PROTEIN; SPLICE VARIANTS; P53; DELTA-NP73; PHOSPHORYLATION	Post-translational modifications play a crucial role in regulation of the protein stability and pro-apoptotic function of p53 as well as its close relative p73. Using a yeast two-hybrid screening based on the Sos recruitment system, we identified protein kinase A catalytic subunit beta (PKA-C beta) as a novel binding partner of p73. Co-immunoprecipitation and glutathione S-transferase pull-down assays revealed that p73 alpha associated with PKA-C beta in mammalian cells and that their interaction was mediated by both the N- and C-terminal regions of p73 alpha. In contrast, p53 failed to bind to PKA-C beta. In vitro phosphorylation assay demonstrated that glutathione S-transferase-p73 alpha- ( 1 - 130), which has one putative PKA phosphorylation site, was phosphorylated by PKA. Enforced expression of PKA-C beta resulted in significant inhibition of the transactivation function and pro-apoptotic activity of p73 alpha, whereas a kinase-deficient mutant of PKA-C beta had no detectable effect. Consistent with this notion, treatment with H-89 ( an ATP analog that functions as a PKA inhibitor) reversed the dibutyryl cAMP-mediated inhibition of p73 alpha. Of particular interest, PKA-C beta facilitated the intramolecular interaction of p73 alpha, thereby masking the N- terminal transactivation domain with the C-terminal inhibitory domain. Thus, our findings indicate a PKA-C beta-mediated inhibitory mechanism of p73 function.	Chiba Canc Ctr Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Hosoda, Mitsuchika/A-7534-2012					Agami R, 1999, NATURE, V399, P809; Anderson CNG, 1999, J NEUROSCI, V19, P664; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu QH, 2000, GENE DEV, V14, P1448; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura Y, 1997, EUR J CANCER, V33, P1986, DOI 10.1016/S0959-8049(97)00333-X; Orstavik S, 2001, EUR J BIOCHEM, V268, P5066, DOI 10.1046/j.0014-2956.2001.02429.x; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SMETS LA, 1987, J CELL PHYSIOL, V133, P395, DOI 10.1002/jcp.1041330227; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2002, CANCER RES, V62, P3598; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	57	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16665	16675		10.1074/jbc.M414323200	http://dx.doi.org/10.1074/jbc.M414323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15723830	hybrid			2022-12-27	WOS:000228615500018
J	Hansen, AM; Gu, YJ; Li, M; Andrykovitch, M; Waugh, DS; Jin, DJ; Ji, XH				Hansen, AM; Gu, YJ; Li, M; Andrykovitch, M; Waugh, DS; Jin, DJ; Ji, XH			Structural basis for the function of stringent starvation protein A as a transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; RNA-POLYMERASE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ACID TOLERANCE; NULL MUTATION; LENS; EXPRESSION; EVOLUTION; REFINEMENT	Stringent starvation protein A ( SspA) of Escherichia coli is an RNA polymerase-associated transcriptional activator for the lytic development of phage P1 and is essential for stationary phase-induced acid tolerance of E. coli. We report the crystal structure of Yersinia pestis SspA, which is 83% identical to E. coli SspA in amino acid sequence and is functionally complementary in supporting the lytic growth of phage P1 and acid resistance of an E. coli sspA mutant. The structure reveals that SspA assumes the characteristic fold of glutathione S-transferase (GST). However, SspA lacks GST activity and does not bind glutathione. Three regions of SspA are flexible, the N and C termini and the alpha 2-helix. The structure also reveals a conserved surface-exposed pocket composed of residues from a loop between helices alpha 3 and alpha 4. The functional roles of these structural features were investigated by assessing the ability of deletion and site-directed mutants to confer acid resistance of E. coli and to activate transcription from a phage P1 late promoter, thereby supporting the lytic growth of phage P1. The results indicate that the flexible regions are not critical for SspA function, whereas the surface pocket is important for both transcriptional activation of the phage P1 late promoter and acid resistance of E. coli. The size, shape, and property of the pocket suggest that it mediates protein-protein interactions. SspA orthologs from Y. pestis, Vibrio cholerae, and Pseudomonas aeruginosa are all functional in acid resistance of E. coli, whereas only Y. pestis SspA supports phage P1 growth.	NCI, Transcript Control Sect, Gene Regulat & Chromosome Biol Lab, NIH, Frederick, MD 21702 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern Denmark; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Jin, DJ (corresponding author), NCI, Transcript Control Sect, Gene Regulat & Chromosome Biol Lab, NIH, 1050 Boyles St,Bldg 469,Rm 127, Frederick, MD 21702 USA.	djjin@helix.nih.gov; jix@ncifcrf.gov	Gu, Yijun/B-6017-2012; Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NATIONAL CANCER INSTITUTE [Z01BC010326, Z01BC010632] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-24000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Andrykovitch M, 2003, ACTA CRYSTALLOGR D, V59, P881, DOI 10.1107/S0907444903005699; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baron GS, 1998, MOL MICROBIOL, V29, P247, DOI 10.1046/j.1365-2958.1998.00926.x; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess R.R., 1987, RNA POLYM REGULATION, P3; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Chuang CC, 1999, BIOPHYS J, V76, P679, DOI 10.1016/S0006-3495(99)77235-8; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeReuse H, 1997, RES MICROBIOL, V148, P289, DOI 10.1016/S0923-2508(97)81585-9; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hansen AM, 2005, MOL MICROBIOL, V56, P719, DOI 10.1111/j.1365-2958.2005.04567.x; Hansen AM, 2003, MOL MICROBIOL, V48, P1621, DOI 10.1046/j.1365-2958.2003.03533.x; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; ISHIHAMA A, 1979, J MOL BIOL, V129, P517, DOI 10.1016/0022-2836(79)90466-2; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauriano CM, 2004, P NATL ACAD SCI USA, V101, P4246, DOI 10.1073/pnas.0307690101; LIN JS, 1995, J BACTERIOL, V177, P4097, DOI 10.1128/jb.177.14.4097-4104.1995; Merrell DS, 2002, CURR OPIN MICROBIOL, V5, P51, DOI 10.1016/S1369-5274(02)00285-0; Merrell DS, 2002, MOL MICROBIOL, V43, P1471, DOI 10.1046/j.1365-2958.2002.02857.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Rife CL, 2003, PROTEINS, V53, P777, DOI 10.1002/prot.10452; ROSNER JL, 1972, VIROLOGY, V48, P679, DOI 10.1016/0042-6822(72)90152-3; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; Tomarev SI, 1995, J MOL EVOL, V41, P1048; TOUNG YPS, 1992, BIOCHEM BIOPH RES CO, V182, P355, DOI 10.1016/S0006-291X(05)80152-4; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WILLIAMS MD, 1994, MOL MICROBIOL, V11, P1029, DOI 10.1111/j.1365-2958.1994.tb00381.x; WILLIAMS MD, 1991, GENE, V109, P21, DOI 10.1016/0378-1119(91)90584-X; Xu Q, 2003, P NATL ACAD SCI USA, V100, P1286, DOI 10.1073/pnas.0337479100; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	68	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17380	17391		10.1074/jbc.M501444200	http://dx.doi.org/10.1074/jbc.M501444200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735307	hybrid			2022-12-27	WOS:000228615500103
J	Anand, P; Gruppuso, PA				Anand, P; Gruppuso, PA			The regulation of hepatic protein synthesis during fasting in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; BRANCHED-CHAIN AMINO; S6 PHOSPHORYLATION; LIVER DEVELOPMENT; GROWTH-FACTOR; RAPAMYCIN; ACTIVATION; INITIATION; STARVATION; KINASE	We have studied translational control in the model of 48 h of fasting in the rat. Our initial observations showed a paradoxical increase in ribosomal protein S6 (rpS6) phosphorylation and a decrease in eukaryotic initiation factor 2 alpha (eIF2 alpha) phosphorylation. These effects, which would favor an increase in protein synthesis, could be attributed to increased circulating concentrations of branched-chain amino acids in fasting. To determine what mechanisms might account for decreased hepatic translation in fasting, we examined the cap binding complex. eIF4E-bound 4E-BP1 did not increase. However, eIF4E-bound eIF4G and total cellular eIF4G were profoundly decreased in fasted liver. eIF4G mRNA levels were not lower after fasting. Based on the hypothesis that decreased eIF4G translation might account for the reduced eIF4G content, we fractionated ribosomes by sucrose density centrifugation. Immunoblotting for rpS6 showed modest polysomal disaggregation upon fasting. PCR analysis of polysome profiles revealed that a spectrum of mRNAs undergo different translational regulation in the fasted state. In particular, eIF4G was minimally affected by fasting. This indicated that reduced eIF4G abundance in fasting may be a function of its stability, whereas its recovery upon refeeding is necessarily independent of its own involvement in the cap binding complex. Western immunoblotting of polysome fractions showed that phosphorylated rpS6 was disproportionately present in translating polysomes in fed and fasted animals, consistent with a role in translational control. However, the translation of rpS8, an mRNA with a 5'-oligopyrimidine tract, did not coincide with rpS6 phosphorylation, thus dissociating rpS6 phosphorylation from the translational control of this subset of mRNAs.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Brown Univ, Dept Pediat, Providence, RI 02912 USA	Brown University; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.	Philip_Gruppuso@brown.edu			NICHD NIH HHS [HD35831, HD24455] Funding Source: Medline; NIDDK NIH HHS [DK59815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059815] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1976, METABOLISM, V25, P1287, DOI 10.1016/S0026-0495(76)80012-1; Anand P, 2002, AM J PHYSIOL-ENDOC M, V283, pE844, DOI 10.1152/ajpendo.00111.2002; Awad MM, 2000, FEBS LETT, V483, P160, DOI 10.1016/S0014-5793(00)02108-6; Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Barth-Baus D, 2002, NUCLEIC ACIDS RES, V30, P1919, DOI 10.1093/nar/30.9.1919; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Boylan JM, 2001, J BIOL CHEM, V276, P44457, DOI 10.1074/jbc.M103457200; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DARNELL J, 1990, MOL CELL BIOL, P261; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gruppuso PA, 2000, BBA-GENE STRUCT EXPR, V1494, P242, DOI 10.1016/S0167-4781(00)00244-X; Gruppuso PA, 2005, PEDIATR RES, V57, P185, DOI 10.1203/01.PDR.0000151646.55587.0F; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HOWARD G, 1986, P SOC EXP BIOL MED, V181, P312; HUTSON NJ, 1982, J BIOL CHEM, V257, P9548; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jenniskens FA, 2002, PEDIATR RES, V52, P437, DOI 10.1203/00006450-200209000-00022; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PREEDY VR, 1988, BIOCHEM J, V250, P179, DOI 10.1042/bj2500179; PRINCEN JMG, 1983, ANN NUTR METAB, V27, P182, DOI 10.1159/000176651; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHULLER E, 1995, TRANSFUS CLIN BIOL, V2, P57, DOI 10.1016/S1246-7820(05)80023-0; Shigemitsu K, 1999, FEBS LETT, V447, P303, DOI 10.1016/S0014-5793(99)00304-X; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; TAS PWL, 1987, EUR J BIOCHEM, V163, P561, DOI 10.1111/j.1432-1033.1987.tb10904.x; WEBER G, 1957, AM J PHYSIOL, V190, P229, DOI 10.1152/ajplegacy.1957.190.2.229; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	50	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16427	16436		10.1074/jbc.M410576200	http://dx.doi.org/10.1074/jbc.M410576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716276	hybrid			2022-12-27	WOS:000228444800116
J	Chou, TF; Bieganowski, P; Shilinski, K; Cheng, JL; Brenner, C; Wagner, CR				Chou, TF; Bieganowski, P; Shilinski, K; Cheng, JL; Brenner, C; Wagner, CR			P-31 NMR and genetic analysis establish hinT as the only Escherchia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRIAD SUPERFAMILY; NUCLEOTIDE-BINDING PROTEINS; AVIAN SEX DETERMINATION; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; BIOLOGICAL-ACTIVITY; HIT FAMILY; MECHANISM; FHIT; DECOMPOSITION	Eukaryotic cells encode AMP-lysine (AMP-N-epsilon-(N-alpha-acetyl lysine methyl ester) 5'-phosphoramidate) hydrolases related to the rabbit histidine triad nucleotide-binding protein 1 (Hint1) sequence. Bacterial and archaeal cells have Hint homologs annotated in a variety of ways, but the enzymes have not been characterized, nor have phenotypes been described due to loss of enzymatic activity. We developed a quantitative P-31 NMR assay to determine whether Escherichia coli possesses an adenosine phosphoramidase activity. Indeed, soluble lysates prepared from wild-type laboratory E. coli exhibited activity on the model substrate adenosine 5'-monophosphoramidate (AMP-NH2). The E. coli Hint homolog, which had been comprehensively designated ycfF and is here named hinT, was cloned, overexpressed, purified, and characterized with respect to purine nucleoside phosphoramidate substrates. Bacterial hinT was several times more active than human or rabbit Hint1 on five model substrates. In addition, bacterial and mammalian enzymes preferred guanosine versus adenosine phosphoramidates as substrates. Analysis of the lysates from a constructed hinT knock-out strain of E. coli demonstrated that all of the cellular purine nucleoside phosphoramidase activity is due to hinT. Physiological analysis of this mutant revealed that the loss of hinT results in failure to grow in media containing 0.75 M KCl, 0.9 M NaCl, 0.5 M NaOAc, or 10 mM MnCl2. Thus, cation-resistant bacterial cell growth may be dependent on the hydrolysis of adenylylated and/or guanylylated phosphoramidate substrates by hinT.	Univ Minnesota, Dept Med Chem, Coll Pharm, Minneapolis, MN 55455 USA; Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Wagner, CR (corresponding author), Univ Minnesota, Dept Med Chem, Coll Pharm, 8-174 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA.	wagne003@umn.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [CA075954, R01 CA075954, R01 CA075954-08, CA55334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055334, R55CA055334, R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham TW, 1996, J MED CHEM, V39, P4569, DOI 10.1021/jm9603680; Abraham TW, 1997, NUCLEOS NUCLEOT NUCL, V16, P2079, DOI 10.1080/07328319708002557; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BUSTOS SA, 1990, J BACTERIOL, V172, P1998, DOI 10.1128/jb.172.4.1998-2004.1990; Chang SL, 2001, J MED CHEM, V44, P223, DOI 10.1021/jm000260r; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Drontle DP, 2004, MINI-REV MED CHEM, V4, P409; DUDKIN SM, 1971, FEBS LETT, V16, P48, DOI 10.1016/0014-5793(71)80682-8; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Jaggi R, 1997, EMBO J, V16, P5562, DOI 10.1093/emboj/16.18.5562; Kim J, 2004, MOL PHARMACEUT, V1, P102, DOI 10.1021/mp0340338; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Korsisaari N, 2003, MOL CELL BIOL, V23, P3929, DOI 10.1128/MCB.23.11.3929-3935.2003; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; LEDNEVA RK, 1970, DOKL AKAD NAUK SSSR+, V193, P1308; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; McGuigan C, 1996, BIOORG MED CHEM LETT, V6, P1183, DOI 10.1016/0960-894X(96)00195-3; MCGUIGAN C, 1993, BIOORG MED CHEM LETT, V3, P1207, DOI 10.1016/S0960-894X(00)80316-9; McIntee EJ, 1997, J MED CHEM, V40, P3323, DOI 10.1021/jm960694f; MOFFATT JG, 1961, J AM CHEM SOC, V83, P649, DOI 10.1021/ja01464a034; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Salehi Z, 2002, MOL MICROBIOL, V46, P49, DOI 10.1046/j.1365-2958.2002.03151.x; Song H, 2003, PHARMACEUT RES, V20, P448, DOI 10.1023/A:1022616523678; Sticha KRK, 1997, PROTEIN EXPRES PURIF, V10, P141, DOI 10.1006/prep.1997.0734; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z	39	45	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15356	15361		10.1074/jbc.M500434200	http://dx.doi.org/10.1074/jbc.M500434200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15703176	Green Accepted, hybrid			2022-12-27	WOS:000228236800121
J	Flatten, K; Dai, NT; Vroman, BT; Loegering, D; Erlichman, C; Karnitz, LM; Kaufmann, SH				Flatten, K; Dai, NT; Vroman, BT; Loegering, D; Erlichman, C; Karnitz, LM; Kaufmann, SH			The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; DNA-DAMAGE CHECKPOINT; CANCER CELL-LINES; IONIZING-RADIATION; CAMPTOTHECIN CYTOTOXICITY; REPLICATION FORKS; POLYMERASE-ALPHA; MAMMALIAN-CELLS; PROTECTS CELLS; STRAND BREAKS	Agents that target topoisomerase I are widely utilized to treat human cancer. Previous studies have indicated that both the ataxia telangiectasia mutated (ATM)/checkpoint kinase (Chk) 2 and ATM- and Rad 3-related (ATR)/Chk1 checkpoint pathways are activated after treatment with these agents. The relative contributions of these two pathways to survival of cells after treatment with topoisomerase I poisons are currently unknown. To address this issue, we assessed the roles of ATR, Chk1, ATM, and Chk2 in cells treated with the topoisomerase I poisons camptothecin and 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan. Colony forming assays demonstrated that down-regulation of ATR or Chk1 sensitized cells to SN-38 and camptothecin. In contrast, ATM and Chk2 had minimal effect of sensitivity to SN-38 or camptothecin. Additional experiments demonstrated that the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin, which down-regulates Chk1, also sensitized a variety of human carcinoma cell lines to SN-38. Collectively, these results show that the ATR/Chk1 pathway plays a predominant role in the response to topoisomerase I inhibitors in carcinoma cells and identify a potential approach for enhancing the efficacy of these drugs.	Mayo Clin & Mayo Fdn, Coll Med, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Oncol Res, Guggenheim 1301,200 1st St SW, Rochester, MN 55905 USA.	Karnitz.Larry@Mayo.edu; Kaufmann.Scott@Mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA104378, R01 CA073709, CA90390, CA73709] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adjei AA, 1997, CLIN CANCER RES, V3, P761; Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bible KC, 1997, CANCER RES, V57, P3375; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Busby EC, 2000, CANCER RES, V60, P2108; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COVEY JM, 1989, CANCER RES, V49, P5016; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Loegering D, 2004, J BIOL CHEM, V279, P18641, DOI 10.1074/jbc.M313536200; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; MATTERN MR, 1987, CANCER RES, V47, P1793; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sagata N, 2002, SCIENCE, V298, P1905, DOI 10.1126/science.1079225; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Shao RG, 1997, CANCER RES, V57, P4029; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Siu WY, 2004, MOL CANCER THER, V3, P621; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solit DB, 2003, CANCER RES, V63, P2139; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; TAKIMOTO CH, 2001, CANC CHEMOTHERAPY BI, V20, P579; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang HY, 2002, CANCER RES, V62, P2483; Wang X, 2004, NUCLEIC ACIDS RES, V32, P767, DOI 10.1093/nar/gkh243; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	71	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14349	14355		10.1074/jbc.M411890200	http://dx.doi.org/10.1074/jbc.M411890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699047	Green Published, hybrid			2022-12-27	WOS:000228095500140
J	Gwizdek, C; Hobeika, M; Kus, B; Ossareh-Nazari, B; Dargemont, C; Rodriguez, MS				Gwizdek, C; Hobeika, M; Kus, B; Ossareh-Nazari, B; Dargemont, C; Rodriguez, MS			The mRNA nuclear export factor Hpr1 is regulated by Rsp5-mediated ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE RSP5P; SACCHAROMYCES-CEREVISIAE; WW DOMAIN; FUNCTIONAL INTERACTION; PROTEIN LIGASE; POLYMERASE-II; YEAST; TRANSCRIPTION; PROTEASOME; TRANSPORT	Ubiquitin conjugation and in particular two distinct HECT ubiquitin ligases, Rsp5p and Tom1p, have been shown to participate in the regulation of mRNA export in Saccharomyces cerevisiae. The identification of the ubiquitin ligase substrates represents a major challenge in understanding how this modification may modulate mRNA export. Here, we identified Hpr1p, a member of the THO/TREX (transcription/export) complex that couples mRNA transcription to nuclear export as a target of the ubiquitin-proteasome pathway. Hpr1p degradation is enhanced at high temperature and appears linked to on-going RNA-polymeraseII-mediated transcription. Interestingly, the stability of the other THO complex components is not affected under these conditions indicating that Hpr1p turnover could control the formation of the THO/TREX complex and consequently mRNA export. Using in vivo and in vitro approaches we demonstrate that Rsp5p is responsible for the ubiquitylation of Hpr1p that also involves the ubiquitin-conjugating enzyme Ubc4p. Thus, Hpr1p represents the first nuclear export factor regulated by ubiquitylation, strongly suggesting that this post-translational modification participates in the coordination of transcription and mRNA export processes.	Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, F-75251 Paris, France; Univ Toronto, Toronto, ON M5G 1L6, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Toronto	Dargemont, C (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7592, Inst Jacques Monod, 2 Pl Jussieu,Tour 43, F-75251 Paris, France.	dargemont@ijm.jussieu.fr						Azad AK, 1997, MOL BIOL CELL, V8, P825, DOI 10.1091/mbc.8.5.825; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kus BM, 2004, PROTEINS, V54, P455, DOI 10.1002/prot.10620; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Neumann S, 2003, EMBO REP, V4, P1156, DOI 10.1038/sj.embor.7400026; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rodriguez MS, 2003, TRAFFIC, V4, P566, DOI 10.1034/j.1600-0854.2003.00115.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz G, 2000, ARCH ANDROLOGY, V44, P117; Utsugi T, 1999, GENE, V234, P285, DOI 10.1016/S0378-1119(99)00197-3; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001	40	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13401	13405		10.1074/jbc.C500040200	http://dx.doi.org/10.1074/jbc.C500040200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15713680	Green Published, hybrid			2022-12-27	WOS:000228095500027
J	Prakash, P; Aruna, B; Sardesai, AA; Hasnain, SE				Prakash, P; Aruna, B; Sardesai, AA; Hasnain, SE			Purified recombinant hypothetical protein coded by open reading frame Rv1885c of Mycobacterium tuberculosis exhibits a monofunctional AroQ class of periplasmic chorismate mutase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID BIOSYNTHESIS; HUMAN-IMMUNODEFICIENCY-VIRUS; SITE-DIRECTED MUTAGENESIS; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; PREPHENATE DEHYDRATASE; ALLOSTERIC REGULATION; ALKALINE-PHOSPHATASE; CRYSTAL-STRUCTURE	Naturally occurring variants of the enzyme chorismate mutase are known to exist that exhibit diversity in enzyme structure, regulatory properties, and association with other proteins. Chorismate mutase was not annotated in the initial genome sequence of Mycobacterium tuberculosis (Mtb) because of low sequence similarity between known chorismate mutases. Recombinant protein coded by open reading frame Rv1885c of Mtb exhibited chorismate mutase activity in vitro. Biochemical and biophysical characterization of the recombinant protein suggests its resemblance to the AroQ class of chorismate mutases, prototype examples of which include the Escherichia coli and yeast chorismate mutases. We also demonstrate that unlike the corresponding proteins of E. coli, Mtb chorismate mutase does not have any associated prephenate dehydratase or dehydrogenase activity, indicating its monofunctional nature. The Rv1885c- encoded chorismate mutase showed allosteric regulation by pathway-specific as well as cross-pathway-specific ligands, as evident from proteolytic cleavage protection and enzyme assays. The predicted N-terminal signal sequence of Mtb chorismate mutase was capable of functioning as one in E. coli, suggesting that Mtb chorismate mutase belongs to the AroQ class of chorismate mutases. It was evident that Rv1885c may not be the only enzyme with chorismate mutase enzyme function within Mtb, based on our observation of the presence of chorismate mutase activity displayed by another hypothetical protein coded by open reading frame Rv0948c, a novel instance of the existence of two monofunctional chorismate mutases ever reported in any pathogenic bacterium.	Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India; Ctr DNA Fingerprinting & Diagnost, Lab Bacterial Genet, Hyderabad 500076, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Hasnain, SE (corresponding author), Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India.	hasnain@cdfd.org.in	HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				Ahmed N, 2003, J CLIN MICROBIOL, V41, P1712, DOI 10.1128/JCM.41.4.1712-1716.2003; Aslund F, 1999, J BACTERIOL, V181, P1375; Bange FC, 1996, INFECT IMMUN, V64, P1794, DOI 10.1128/IAI.64.5.1794-1799.1996; Bekal S, 2003, MOL PLANT MICROBE IN, V16, P439, DOI 10.1094/MPMI.2003.16.5.439; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Calhoun DH, 2001, GENOME BIOL, V2; Chakhaiyar P, 2004, MED PRIN PRACT, V13, P177, DOI 10.1159/000078312; Chen SQ, 2003, EUR J BIOCHEM, V270, P757, DOI 10.1046/j.1432-1033.2003.03438.x; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; Christendat D, 1998, BIOCHEMISTRY-US, V37, P15703, DOI 10.1021/bi981412b; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DAVIDSON BE, 1987, METHOD ENZYMOL, V142, P440; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Dosselaere F, 2001, CRIT REV MICROBIOL, V27, P75, DOI 10.1080/20014091096710; Gaille C, 2002, J BIOL CHEM, V277, P21768, DOI 10.1074/jbc.M202410200; GETHING MJH, 1977, EUR J BIOCHEM, V78, P111, DOI 10.1111/j.1432-1033.1977.tb11719.x; GIBSON F, 1963, NATURE, V198, P388, DOI 10.1038/198388a0; Gold B, 2001, MOL MICROBIOL, V42, P851, DOI 10.1046/j.1365-2958.2001.02684.x; Gordhan BG, 2002, INFECT IMMUN, V70, P3080, DOI 10.1128/IAI.70.6.3080-3084.2002; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P376, DOI 10.1021/bi00454a011; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HALL GC, 1982, J BACTERIOL, V149, P65, DOI 10.1128/JB.149.1.65-78.1982; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Haslam E., 1993, SHIKIMIC ACID METABO; Helmstaedt K, 2002, P NATL ACAD SCI USA, V99, P6631, DOI 10.1073/pnas.092130899; Helmstaedt K, 2001, MICROBIOL MOL BIOL R, V65, P404, DOI 10.1128/MMBR.65.3.404-421.2001; HUANG L, 1974, J BIOL CHEM, V249, P4467; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Krappmann S, 1999, J BIOL CHEM, V274, P22275, DOI 10.1074/jbc.274.32.22275; Lakowicz JR, 2000, PHOTOCHEM PHOTOBIOL, V72, P421, DOI 10.1562/0031-8655(2000)072<0421:OSRIP>2.0.CO;2; Lambert KN, 1999, MOL PLANT MICROBE IN, V12, P328, DOI 10.1094/MPMI.1999.12.4.328; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; MADDOCK JR, 1993, SCIENCE, V259, P1717; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Parish T, 2002, MICROBIOL-SGM, V148, P3069, DOI 10.1099/00221287-148-10-3069; POHNERT G, BIOCHEMISTRY, V38, P12212; PRAKASH P, 2005, IN PRESS J BIOL CHEM; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schnappauf G, 1997, P NATL ACAD SCI USA, V94, P8491, DOI 10.1073/pnas.94.16.8491; Siddiqi N, 2002, ANTIMICROB AGENTS CH, V46, P443, DOI 10.1128/AAC.46.2.443-450.2002; Strater N, 1997, STRUCTURE, V5, P1437, DOI 10.1016/S0969-2126(97)00294-3; Strater N, 1996, P NATL ACAD SCI USA, V93, P3330, DOI 10.1073/pnas.93.8.3330; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; XIA TH, 1993, J BACTERIOL, V175, P4729, DOI 10.1128/JB.175.15.4729-4737.1993; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; Zhang S, 1998, J BIOL CHEM, V273, P6248, DOI 10.1074/jbc.273.11.6248; Zhang S, 2000, BIOCHEMISTRY-US, V39, P4722, DOI 10.1021/bi9926680	54	28	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19641	19648		10.1074/jbc.M413026200	http://dx.doi.org/10.1074/jbc.M413026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15737998	hybrid			2022-12-27	WOS:000229113700028
J	Shammas, C; Menne, TF; Hilcenko, C; Michell, SR; Goyenechea, B; Boocock, GRB; Durie, PR; Rommens, JM; Warren, AJ				Shammas, C; Menne, TF; Hilcenko, C; Michell, SR; Goyenechea, B; Boocock, GRB; Durie, PR; Rommens, JM; Warren, AJ			Structural and mutational analysis of the SBDS protein family - Insight into the leukemia-associated Shwachman-Diamond syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; CRYSTAL-STRUCTURE; GLOBAL ANALYSIS; BUDDING YEAST; GENE; REFINEMENT; PREDICTION; DATABASE; BINDING; MODEL	Shwachman-Diamond Syndrome (SDS) is an autosomal recessive disorder characterized by bone marrow failure with significant predisposition to the development of poor prognosis myelodysplasia and leukemia, exocrine pancreatic failure and metaphyseal chondrodysplasia. Although the SBDS gene mutated in this disorder is highly conserved in Archaea and all eukaryotes, the function is unknown. To interpret the molecular consequences of SDS-associated mutations, we have solved the crystal structure of the Archaeoglobus fulgidus SBDS protein orthologue at a resolution of 1.9 angstrom, revealing a three domain architecture. The N-terminal (FYSH) domain is the most frequent target for disease mutations and contains a novel mixed alpha/beta-fold identical to the single domain yeast protein Yhr087wp that is implicated in RNA metabolism. The central domain consists of a three-helical bundle, whereas the C-terminal domain has a ferredoxin-like fold. By genetic complementation analysis of the essential Saccharomyces cerevisiae SBDS orthologue YLR022C, we demonstrate an essential role in vivo for the FYSH domain and the central three-helical bundle. We further show that the common SDS-related K62X truncation is non-functional. Most SDS-related missense mutations that alter surface epitopes do not impair YLR022C function, but mutations affecting residues buried in the hydrophobic core of the FYSH domain severely impair or abrogate complementation. These data are consistent with absence of homozygosity for the common K62X truncation mutation in individuals with SDS, indicating that the SDS disease phenotype is a consequence of expression of hypomorphic SBDS alleles and that complete loss of SBDS function is likely to be lethal.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Hematol, Cambridge CB2 2XY, England; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	MRC Laboratory Molecular Biology; University of Cambridge; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Warren, AJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ajw@mrc-lmb.cam.ac.uk	Rommens, Johanna/AAT-7465-2021	hilcenko, christine/0000-0002-9596-7833				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BODIAN M, 1964, ACTA PAEDIATR, V53, P282, DOI 10.1111/j.1651-2227.1964.tb07237.x; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Donadieu J, 2005, HAEMATOLOGICA, V90, P45; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Ginzberg H, 1999, J PEDIATR-US, V135, P81, DOI 10.1016/S0022-3476(99)70332-X; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Haase SB, 1997, METHOD ENZYMOL, V283, P322; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakashima E, 2004, HUM GENET, V114, P345, DOI 10.1007/s00439-004-1081-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Park F, 2004, PROTEINS, V55, P775, DOI 10.1002/prot.20087; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Savchenko A, 2005, J BIOL CHEM, V280, P19213, DOI 10.1074/jbc.M414421200; SCHWACHMAN H, 1964, J PEDIATR-US, V65, P645; Smith OP, 1996, BRIT J HAEMATOL, V94, P279, DOI 10.1046/j.1365-2141.1996.d01-1788.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woloszynek JR, 2004, BLOOD, V104, P3588, DOI 10.1182/blood-2004-04-1516; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	45	86	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19221	19229		10.1074/jbc.M414656200	http://dx.doi.org/10.1074/jbc.M414656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15701631	hybrid			2022-12-27	WOS:000228932300079
J	Hua, SM; Xu, C; Ma, HL; Inesi, G				Hua, SM; Xu, C; Ma, HL; Inesi, G			Interference with phosphoenzyme isomerization and inhibition of the sarco-endoplasmic reticulum Ca2+ ATPase by 1,3-dibromo-2,4,6-tris(methylisothiouronium) benzene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; CRYSTAL-STRUCTURE; PROTEINASE-K; CA2+-ATPASE; THAPSIGARGIN; MECHANISM; PHOSPHATE	ATP hydrolysis and Ca2+ transport by the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) are inhibited by 1,3-dibromo-2,4,6-tris(methylisothiouronium) benzene (Br-2-TITU) in the micromolar range (Berman, M. C., and Karlish, S. J. (2003) Biochemistry 42, 3556-3566). In a study of the mechanism of inhibition, we found that Br-2-TITU allows the enzyme to bind Ca2+ and undergo phosphorylation by ATP. The level of ADP-sensitive phosphoenzyme (i.e. E1P-2Ca(2+)) observed in the transient state following addition of ATP is much higher in the presence than in the absence of the inhibitor. Br-2-TITU does not interfere with enzyme phosphorylation by Pi in the reverse direction of the cycle (i.e. E2P) and produces only a slight inhibition of its hydrolytic cleavage. The inhibitory effect of Br-2-TITU on steady state ATPase velocity is attributed to interference with the E1P-2Ca(2+) to E2P-2Ca(2+) transition. In fact, experiments on conformation-dependent protection from proteolytic digestion suggest that, in the presence of Br-2-TITU, the loops connecting the "A" domain to the ATPase transmembrane region undergo greater fluctuation than expected in the E2 and E2P states. Optimal stability of the gathered headpiece domains is thereby prevented. These effects are opposite to those of thapsigargin, in which the mechanism of inhibition is related to stabilization of a highly compact ATPase conformation and interference with Ca2+ binding and phosphoenzyme formation. Our experiments with Br-2-TITU provide the first demonstration of a kinetic limit posed by an inhibitor on the wild-type enzyme.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69830] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berman MC, 2003, BIOCHEMISTRY-US, V42, P3556, DOI 10.1021/bi026071n; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; TAL DM, 1995, TETRAHEDRON, V51, P3823, DOI 10.1016/0040-4020(95)00105-H; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944	17	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17579	17583		10.1074/jbc.M500472200	http://dx.doi.org/10.1074/jbc.M500472200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746094	hybrid			2022-12-27	WOS:000228807200003
J	Holden, P; Keene, DR; Lunstrum, GP; Bachinger, HP; Horton, WA				Holden, P; Keene, DR; Lunstrum, GP; Bachinger, HP; Horton, WA			Secretion of cartilage oligomeric matrix protein is affected by the signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; 5-STRANDED COILED-COIL; EGF-LIKE MOTIF; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CALCIUM-BINDING; PSEUDOACHONDROPLASIA; COMP; MUTATION; DOMAIN	Cartilage oligomeric matrix protein ( COMP) is a secreted glycoprotein found in the extracellular matrices of skeletal tissues. Mutations associated with two human skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia, disturb COMP secretion leading to intracellular accumulation of mutant COMP, especially in chondrocytes. Here we show that the manifestation of this secretory defect is dramatically influenced by the signal peptide that targets COMP for secretion. The comparison of wild type and mutant COMP secretion directed by the COMP or BM40 signal peptide in HEK-293 cells and rat chondrosarcoma cells revealed that the BM40 signal peptide substantially enhances secretion of mutant COMP that accumulates in endoplasmic reticulum-like structures when targeted by its own signal peptide. Additionally, we demonstrate that mutant COMP forms mixed pentamers with wild type COMP. Our findings suggest that the secretory defect in pseudoachondroplasia and multiple epiphyseal dysplasia is not specific for chondrocytes, nor does it require interaction of mutant COMP with other matrix proteins prior to transport from the cell. They also imply a previously unappreciated role for the signal peptide in the regulation of protein secretion beyond targeting to the endoplasmic reticulum.	Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Horton, WA (corresponding author), Shriners Hosp Children, Res Ctr, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	wah@shcc.org						BIRD P, 1990, J BIOL CHEM, V265, P8420; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Cho JY, 2001, AM J MED GENET, V106, P251, DOI 10.1002/ajmg.10230; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Froeschke M, 2003, J BIOL CHEM, V278, P41914, DOI 10.1074/jbc.M302343200; Guo Y, 1998, EMBO J, V17, P5265, DOI 10.1093/emboj/17.18.5265; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LOHMANDER LS, 1994, ANN RHEUM DIS, V53, P8, DOI 10.1136/ard.53.1.8; Loughlin J, 1998, HUM MUTAT, pS10; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Mabuchi A, 2003, HUM GENET, V112, P84, DOI 10.1007/s00439-002-0845-9; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muller G, 1998, CONNECT TISSUE RES, V39, P233, DOI 10.3109/03008209809021499; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Riessen R, 2001, ARTERIOSCL THROM VAS, V21, P47, DOI 10.1161/01.ATV.21.1.47; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Smith RKW, 2002, EQUINE VET J, V34, P726, DOI 10.2746/042516402776250423; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; Svensson L, 2002, MOL CELL BIOL, V22, P4366, DOI 10.1128/MCB.22.12.4366-4371.2002; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Unger S, 2001, AM J MED GENET, V106, P244, DOI 10.1002/ajmg.10234; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Zheng T, 1999, J BIOL CHEM, V274, P36623, DOI 10.1074/jbc.274.51.36623	56	24	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17172	17179		10.1074/jbc.M411716200	http://dx.doi.org/10.1074/jbc.M411716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749701	hybrid			2022-12-27	WOS:000228615500078
J	Kim, SW; Ho, SC; Hong, SJ; Kim, KM; So, EC; Christoffolete, M; Harney, JW				Kim, SW; Ho, SC; Hong, SJ; Kim, KM; So, EC; Christoffolete, M; Harney, JW			A novel mechanism of thyroid hormone-dependent negative regulation by thyroid hormone receptor, nuclear receptor corepressor (NCoR), and GAGA-binding factor on the rat CD44 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE CLEAVAGE; INTRACELLULAR DOMAIN; STIMULATING HORMONE; MEDIATES REPRESSION; RESPONSE ELEMENT; GENE-EXPRESSION; COMPLEX; TRANSCRIPTION; LOCALIZATION	CD44 is an adhesion molecule in the extracellular matrix that shows various functions, including tumor genesis and metastasis. A recent study showed that CD44 expression level was strongly correlated with the generation of papillary thyroid carcinomas, the most prevalent malignancy of the thyroid gland. We report here that CD44 is negatively regulated by thyroid hormone (T-3) through a novel mechanism. We demonstrate that nuclear receptor corepressor ( NCoR) enhances thyroid hormone receptor (TR)-mediated basal transactivation by a weak TR center dot DNA interaction in the absence of T-3, which is repressed by T-3 through a transient TR center dot DNA interaction. Initially, we identified that CD44 was negatively directly transcriptionally T-3-responsive. Deletion and mutation analysis indicated that both a weak TR and a GAGA-binding factor (GAF) binding sites on the CD44 promoter were required for negative regulation by T-3. The weak TR center dot DNA interaction was further confirmed by electrophoretic gel mobility shift assay, chromatin immunoprecipitation, and transfection assays using a non-DNA-binding TR alpha 1 mutant. More interestingly, NCoR acted as a co-activator to enhance TR-mediated basal transactivation in the absence of T-3. This effect was eliminated by removal of TR or NCoR binding. Most strikingly, T-3 induced a remarkable increase in TR center dot DNA binding at 40 - 60 min after T-3 exposure that rapidly returned to basal levels, suggesting a T-3-induced remodeling of chromatin structure at the early stage of T-3 stimulation resulting in repression. Therefore, we propose a mechanism by which NCoR, GAF, and TR interact with the CD44 negative T-3-responsive element to enhance basal transactivation, whereas T-3 induces the remodeling of chromatin structure for repression.	Brigham & Womens Hosp, Harvard Inst Med, Dept Med, Div Endocrinol Diabet & Hypertens,Thyroid Sect, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kim, SW (corresponding author), Brigham & Womens Hosp, Harvard Inst Med, Dept Med, Div Endocrinol Diabet & Hypertens,Thyroid Sect, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	swkim@rics.bwh.harvard.edu		Christoffolete, Marcelo/0000-0003-0374-0795	NIDDK NIH HHS [DK02867, DK44128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044128, K01DK002867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Castellone MD, 2004, ONCOGENE, V23, P2188, DOI 10.1038/sj.onc.1207322; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DE SB, 1999, NATURE, V398, P518; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim SW, 1996, MOL CELL BIOL, V16, P4465; KIM SW, 2004, MOL ENDOCRINOL; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehmann M, 2004, TRENDS GENET, V20, P15, DOI 10.1016/j.tig.2003.11.005; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Lutz M, 2003, EMBO J, V22, P1579, DOI 10.1093/emboj/cdg147; Lutz M, 2000, BIOCHEM SOC T, V28, P386, DOI 10.1042/0300-5127:0280386; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Pombo PMG, 2000, J BIOL CHEM, V275, P37510, DOI 10.1074/jbc.M006440200; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Villa A, 2004, MOL ENDOCRINOL, V18, P863, DOI 10.1210/me.2003-0260; Waters KM, 1997, BIOCHEM BIOPH RES CO, V233, P838, DOI 10.1006/bbrc.1997.6550; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; XU J, 1993, J BIOL CHEM, V268, P16065; ZHANG WG, 1992, J BIOL CHEM, V267, P15056	50	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14545	14555		10.1074/jbc.M411517200	http://dx.doi.org/10.1074/jbc.M411517200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701601	hybrid			2022-12-27	WOS:000228236800026
J	Barsotti, C; Pesi, R; Giannecchini, M; Ipata, PL				Barsotti, C; Pesi, R; Giannecchini, M; Ipata, PL			Evidence for the involvement of cytosolic 5 '-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; RAT-BRAIN; MYCOPHENOLIC-ACID; XANTHINE; PURINE; SALVAGE; ADENOSINE; INOSINE; CLONING; ENZYME	In this paper, we show that in vitro xanthosine does not enter any of the pathways known to salvage the other three main natural purine nucleosides: guanosine; inosine; and adenosine. In rat brain extracts and in intact LoVo cells, xanthosine is salvaged to XMP via the phosphotransferase activity of cytosolic 5'-nucleotidase. IMP is the preferred phosphate donor (IMP + xanthosine -> XMP + inosine). XMP is not further phosphorylated. However, in the presence of glutamine, it is readily converted to guanyl compounds. Thus, phosphorylation of xanthosine by cytosolic 5'-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides. Mycophenolic acid, an inhibitor of IMP dehydrogenase, inhibits the guanyl compound synthesis via the IMP dehydrogenase pathway but has no effect on the cytosolic 5'-nucleotidase pathway of guanine nucleotides synthesis. We propose that the latter pathway might contribute to the reversal of the in vitro antiproliferative effect exerted by IMP dehydrogenase inhibitors routinely seen with repletion of the guanine nucleotide pools.	Univ Pisa, Dept Physiol & Biochem, I-56127 Pisa, Italy	University of Pisa	Ipata, PL (corresponding author), Univ Pisa, Dept Physiol & Biochem, Via San Zeno 51, I-56127 Pisa, Italy.	ipata@dfb.unipi.it	Pesi, Rossana/AAQ-3102-2020	Pesi, Rossana/0000-0003-4785-7282				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; ALLSOP J, 1984, ADV EXP MED BIOL, V165, P21; Barsotti C, 2004, INT J BIOCHEM CELL B, V36, P2214, DOI 10.1016/j.biocel.2004.04.015; Barsotti C, 2003, CELL MOL LIFE SCI, V60, P786, DOI 10.1007/s00018-003-2371-x; Barsotti C, 2002, J BIOL CHEM, V277, P9865, DOI 10.1074/jbc.M111418200; BERGER SJ, 1985, J NEUROCHEM, V44, P1736, DOI 10.1111/j.1471-4159.1985.tb07162.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cappiello M, 1998, BBA-GEN SUBJECTS, V1425, P273, DOI 10.1016/S0304-4165(98)00071-3; CHABNER BA, 1995, CANC CHEMOTHERAPY BI, P235; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; EUGUI EM, 1991, TRANSPLANT P, V23, P15; Gille A, 2003, J BIOL CHEM, V278, P7822, DOI 10.1074/jbc.M210162200; Giorgelli F, 1997, BBA-GEN SUBJECTS, V1335, P16, DOI 10.1016/S0304-4165(96)00117-1; Jardim A, 1999, J BIOL CHEM, V274, P34403, DOI 10.1074/jbc.274.48.34403; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Liu HY, 2002, BIOCHEM PHARMACOL, V64, P583, DOI 10.1016/S0006-2952(02)01251-0; MARKLEY HG, 1973, BIOCHIM BIOPHYS ACTA, V309, P23, DOI 10.1016/0005-2744(73)90313-6; MOMPARLER RL, 1968, J BIOL CHEM, V243, P4298; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Niwa T, 1998, KIDNEY INT, V53, P1801, DOI 10.1046/j.1523-1755.1998.00944.x; Paletzki RF, 2002, NEUROSCIENCE, V109, P15, DOI 10.1016/S0306-4522(01)00352-9; Pankiewicz KW, 2004, CURR MED CHEM, V11, P887, DOI 10.2174/0929867043455648; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Pesi R, 1996, BBA-PROTEIN STRUCT M, V1294, P191, DOI 10.1016/0167-4838(96)00021-0; Phillis JW, 1996, J NEUROCHEM, V67, P1525; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; STONE TW, 1991, PURINES BASIC CLIN A, P8; Stoychev G, 2002, EUR J BIOCHEM, V269, P4048, DOI 10.1046/j.1432-1033.2002.03097.x; Torrecilla A, 2001, J NEUROCHEM, V76, P1291, DOI 10.1046/j.1471-4159.2001.00084.x; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TURRIANI M, 1994, J BIOCHEM TOXICOL, V9, P51, DOI 10.1002/jbt.2570090108; YAMADA Y, 1980, BIOCHIM BIOPHYS ACTA, V616, P199, DOI 10.1016/0005-2744(80)90138-2; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	33	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13465	13469		10.1074/jbc.M413347200	http://dx.doi.org/10.1074/jbc.M413347200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15699053	hybrid			2022-12-27	WOS:000228095500035
J	Dugast, M; Toussaint, LN; Dousset, C; Benaroch, P				Dugast, M; Toussaint, LN; Dousset, C; Benaroch, P			AP2 clathrin adaptor complex, but not AP1, controls the access of the major histocompatibility complex (MHC) class II to endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVARIANT CHAIN COMPLEXES; ANTIGEN-PRESENTING CELLS; SORTING SIGNALS; HLA-DR; MEDIATED ENDOCYTOSIS; PROTEIN ANTIGENS; CYTOPLASMIC TAIL; MOLECULES; TRAFFICKING; PEPTIDE	Newly synthesized MHC II alpha- and beta-chains associated with the invariant chain chaperone (Ii) enter the endocytic pathway for Ii degradation and loading with peptides before transport to the cell surface. It is unclear how alpha beta Ii complexes are sorted from the Golgi apparatus and directed to endosomes. However, indirect evidence tends to support direct transport involving the AP1 clathrin adaptor complex. Surprisingly, we show here that knocking down the production of AP1 by RNA interference did not affect the trafficking of alpha beta Ii complexes. In contrast, AP2 depletion led to a large increase in surface levels of alpha beta Ii complexes, inhibited their rapid internalization, and strongly delayed the appearance of mature MHC II in intracellular compartments. Thus, in the cell systems studied here, rapid internalization of alpha beta Ii complexes via an AP2-dependent pathway represents a key step for MHC II delivery to endosomes and lysosomes.	INSERM, Inst Curie, Sect Rech, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Benaroch, P (corresponding author), INSERM, Inst Curie, U520, 26 Rue Ulm, F-75248 Paris, France.	benaroch@curie.fr		Benaroch, Philippe/0000-0002-2655-0129				ADAMS TE, 1983, IMMUNOLOGY, V50, P613; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; BANIA J, 2003, P NATL ACAD SCI USA; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; Brachet V, 1999, MOL BIOL CELL, V10, P2891, DOI 10.1091/mbc.10.9.2891; BREMNES B, 1994, J CELL SCI, V107, P2021; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplan S, 2000, IMMUNOL LETT, V72, P113, DOI 10.1016/S0165-2478(00)00176-0; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; Davidson HW, 1999, J BIOL CHEM, V274, P27315, DOI 10.1074/jbc.274.38.27315; Driessen C, 1999, J CELL BIOL, V147, P775, DOI 10.1083/jcb.147.4.775; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; Griffin JP, 1997, J IMMUNOL, V158, P1523; HACKETT CJ, 1991, J IMMUNOL, V146, P2944; Hansen HJ, 1996, BIOCHEM J, V320, P293, DOI 10.1042/bj3200293; Hiltbold EM, 2002, CURR OPIN IMMUNOL, V14, P30, DOI 10.1016/S0952-7915(01)00295-3; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; KONGSVIK TL, 2002, J BIOL CHEM; LAMB CA, 1992, J IMMUNOL, V148, P3478; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Meyer C, 2001, J CELL SCI, V114, P4469; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PARHAM P, 1979, J IMMUNOL, V123, P342; PIETERS J, 1993, J CELL SCI, V106, P831; Pond L, 1999, J BIOL CHEM, V274, P18049, DOI 10.1074/jbc.274.25.18049; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Saint-Pol A, 2004, DEV CELL, V6, P525, DOI 10.1016/S1534-5807(04)00100-5; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Saudrais C, 1998, J IMMUNOL, V160, P2597; Sevilla LM, 2001, CELL IMMUNOL, V210, P143, DOI 10.1006/cimm.2001.1817; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; STPIERRE Y, 1990, J IMMUNOL, V145, P812; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Stumptner-Cuvelette P, 2002, BBA-MOL CELL RES, V1542, P1, DOI 10.1016/S0167-4889(01)00166-5; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	59	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19656	19664		10.1074/jbc.M501357200	http://dx.doi.org/10.1074/jbc.M501357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15749704	hybrid			2022-12-27	WOS:000229113700030
J	Keith, N; Parodi, AJ; Caramelo, JJ				Keith, N; Parodi, AJ; Caramelo, JJ			Glycoprotein tertiary and quaternary structures are monitored by the same quality control mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLTRANSFERASE RECOGNIZES; SOYBEAN AGGLUTININ; CALNEXIN; LECTINS	Folding of glycoproteins entering the secretory pathway is strictly surveyed in the endoplasmic reticulum by a quality control system. Folding intermediates and proteins irreparably misfolded are marked via glucosylation by the UDPglucose: glycoprotein glucosyltransferase, an enzyme that acts as a folding sensor by exclusively labeling glycoproteins not displaying their native structures. Here we show that this sensing mechanism also applies to the oligomerization of protein complexes, as the glucosyltransferase appeared to be able to glucosylate folded complex subunits lacking the full complement of oligomer components.	Fdn Inst Leloir, Lab Glycobiol, RA-1405 Buenos Aires, DF, Argentina	Leloir Institute	Caramelo, JJ (corresponding author), Fdn Inst Leloir, Lab Glycobiol, Avenida Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	jcaramelo@leloir.org.ar			NIGMS NIH HHS [GM44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN HJ, 1976, CARBOHYD RES, V50, P121; Caramelo JJ, 2004, J BIOL CHEM, V279, P46280, DOI 10.1074/jbc.M408404200; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Chatterjee M, 2003, BIOCHEMISTRY-US, V42, P12217, DOI 10.1021/bi034642l; Gardner TG, 1999, J BIOL CHEM, V274, P14094, DOI 10.1074/jbc.274.20.14094; Ghosh M, 2001, INT J BIOL MACROMOL, V29, P273, DOI 10.1016/S0141-8130(01)00175-1; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jones S, 2003, J MOL BIOL, V325, P249, DOI 10.1016/S0022-2836(02)01227-5; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061	18	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18138	18141		10.1074/jbc.M501710200	http://dx.doi.org/10.1074/jbc.M501710200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746090	Green Published, hybrid			2022-12-27	WOS:000228807200071
J	Kobayashi, T; Takematsu, H; Yamaji, T; Hiramoto, S; Kozutsumi, Y				Kobayashi, T; Takematsu, H; Yamaji, T; Hiramoto, S; Kozutsumi, Y			Disturbance of sphingolipid biosynthesis abrogates the signaling of Mss4, phosphatidylinositol-4-phosphate 5-kinase, in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CELL-GROWTH; ACTIN CYTOSKELETON; SERINE PALMITOYLTRANSFERASE; PHOSPHATIDIC-ACID; BASE SYNTHESIS; LIPID RAFTS	The functional relationships between phosphoinositides and sphingolipids have not been well characterized to date. ISP-1/myriocin is a potent inhibitor of sphingolipid biosynthesis and induces severe growth defects in eukaryotic cells because of the sphingolipid deprivation. We characterized a novel multicopy suppressor gene of ISP-1-mediated cell death in yeast, MSS4. MSS4 encodes a phosphatidylinositol-4-phosphate5-kinase that synthesizes phosphatidylinositol ( 4,5)-bisphosphate (PI4,5P(2)). We demonstrate here that ISP-1 treatment of yeast causes defects both in the activity and subcellular localization of Mss4. The effect of the Mss4 defect on the downstream signaling was examined, because interaction between the Mss4 product, PI4,5P2, and the pleckstrin-homology domain of Rom2 mediates recruitment of Rom2 to the membrane, which is the crucial step for subsequent Rho1/2 activation. Indeed, failure of Rom2 recruitment was observed in ISP-1-treated cells as well as in csg2-deleted cells, which have reduced mannosylated inositolphosphorylceramide. These data suggested that proper sphingolipids are required for the signaling pathway involving Mss4.	RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Membrane Biochem & Biophys, Sakyo Ku, Kyoto 6068501, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan	RIKEN; Kyoto University; Japan Science & Technology Agency (JST)	Kozutsumi, Y (corresponding author), RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Kawaguchi, Saitama 3320012, Japan.	yasu@pharm.kyoto-u.ac.jp	Kobayashi, Toshihide/B-6298-2015	Kobayashi, Toshihide/0000-0002-4811-7270				Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chung JH, 2003, J BIOL CHEM, V278, P28872, DOI 10.1074/jbc.M300943200; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Kozutsumi Y, 2002, BBA-MOL CELL BIOL L, V1582, P138, DOI 10.1016/S1388-1981(02)00148-8; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Marcoux N, 2000, GENETICS, V156, P579; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Momoi M, 2004, BIOCHEM J, V381, P321, DOI 10.1042/BJ20040108; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Uemura S, 2003, J BIOL CHEM, V278, P45049, DOI 10.1074/jbc.M305498200; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZHAO C, 1994, J BIOL CHEM, V269, P21480	55	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18087	18094		10.1074/jbc.M414138200	http://dx.doi.org/10.1074/jbc.M414138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15741172	hybrid			2022-12-27	WOS:000228807200066
J	Lee, JE; Singh, V; Evans, GB; Tyler, PC; Furneaux, RH; Cornell, KA; Riscoe, MK; Schramm, VL; Howell, PL				Lee, JE; Singh, V; Evans, GB; Tyler, PC; Furneaux, RH; Cornell, KA; Riscoe, MK; Schramm, VL; Howell, PL			Structural rationale for the affinity of pico- and femtomolar transition state analogues of Escherichia coli 5 '-methylthioadenosine/S-adenosylhomocysteine nucleosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; QUORUM-SENSING SIGNAL; CATALYTIC MECHANISM; MYCOBACTERIUM-TUBERCULOSIS; PLASMODIUM-FALCIPARUM; ENZYMATIC CATALYSIS; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; IMMUCILLIN-H; DRUG DESIGN	Immucillin and DADMe-Immucillin inhibitors are tight binding transition state mimics of purine nucleoside phosphorylases (PNP). 5'-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) is proposed to form a similar transition state structure as PNP. The companion paper describes modifications of the Immucillin and DADMe-Immucillin inhibitors to better match transition state features of MTAN and have led to 5'-thio aromatic substitutions that extend the inhibition constants to the femtomolar range (Singh, V., Evans, G. B., Lenz, D. H., Mason, J., Clinch, K., Mee, S., Painter, G. F., Tyler, P. C., Furneaux, R. H., Lee, J. E., Howell, P. L., and Schramm, V. L. (2005) J. Biol. Chem. 280, 18265-18273). 5'-Methylthio-Immucillin A (MT-ImmA) and 5'-methylthio-DADMe-Immucillin A (MT-DADMe-ImmA) exhibit slow-onset inhibition with K-i* of 77 and 2 pM, respectively, and were selected for structural analysis as the parent compounds of each class of transition state analogue. The crystal structures of Escherichia coli MTAN complexed with MT-ImmA and MT-DADMe-ImmA were determined to 2.2 angstrom resolution and compared with the existing MTAN inhibitor complexes. These MTAN-transition state complexes are among the tightest binding enzyme-ligand complexes ever described and analysis of their mode of binding provides extraordinary insight into the structural basis for their affinity. The MTAN-MT-ImmA complex reveals the presence of a new ion pair between the 4'-iminoribitol atom and the nucleophilic water (WAT3) that captures key features of the transition state. Similarly, in the MTAN-MT-DADMe-ImmA complex a favorable hydrogen bond or ion pair interaction between the cationic 1'-pyrrolidine atom and WAT3 is crucial for tight affinity. Distance analysis of the nucleophile and leaving group show that MT-ImmA is a mimic of an early transition state, while MT-DADMe-ImmA is a better mimic of the highly dissociated transition state of E. coli MTAN.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Fac Med, Toronto, ON M5S 1A8, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem Team, Lower Hutt, New Zealand; Boise State Univ, Dept Chem, Boise, ID 83725 USA; Vet Affairs Med Ctr, Med Res Serv, Portland, OR 97021 USA; Portland State Univ, Dept Chem, Portland, OR 97207 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation; Idaho; Boise State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland State University	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.ca	Evans, Gary/B-8343-2011; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606				Allart B, 1999, NUCLEOS NUCLEOT NUCL, V18, P861, DOI 10.1080/15257779908041582; Allart B, 1998, EUR J BIOCHEM, V256, P155, DOI 10.1046/j.1432-1327.1998.2560155.x; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; Basso LA, 2001, BIOCHEMISTRY-US, V40, P8196, DOI 10.1021/bi010584x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berti PJ, 2002, ADV PHYS ORG CHEM, V37, P239, DOI 10.1016/S0065-3160(02)37004-7; Blessing R. H., 1987, CRYSTALLOGR REV, V1, P3; BORCHARDT RT, 1986, BIOL METHYLATION DRU, P227; BORKAKOTI N, 1978, ACTA CRYSTALLOGR B, V34, P867, DOI 10.1107/S0567740878004215; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cornell KA, 1996, BIOCHEM BIOPH RES CO, V228, P724, DOI 10.1006/bbrc.1996.1723; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Evans GB, 2004, J MED CHEM, V47, P3275, DOI 10.1021/jm0306475; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, J MED CHEM, V46, P3412, DOI 10.1021/jm030145r; Evans GB, 2003, J MED CHEM, V46, P155, DOI 10.1021/jm0203332; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; Kicska GA, 2002, BIOCHEMISTRY-US, V41, P14489, DOI 10.1021/bi026636f; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JE, 2004, BIOCHEMISTRY-US, V43, P5159, DOI 10.1021/bi035492h; Lee JE, 2003, J BIOL CHEM, V278, P8761, DOI 10.1074/jbc.M210836200; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Lee JE, 2001, ACTA CRYSTALLOGR D, V57, P150, DOI 10.1107/S0907444900014669; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Lewandowicz A, 2003, J BIOL CHEM, V278, P31465, DOI 10.1074/jbc.C300259200; Lewandowicz A, 2003, BIOCHEMISTRY-US, V42, P6057, DOI 10.1021/bi0343830; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; Markham GD, 2002, BIOCHEMISTRY-US, V41, P7636, DOI 10.1021/bi025682c; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miles RW, 1999, BIOCHEMISTRY-US, V38, P13147, DOI 10.1021/bi990829u; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MONTGOMERY JA, 1993, MED RES REV, V13, P209, DOI 10.1002/med.2610130302; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PEGG AE, 1969, J BIOL CHEM, V244, P682; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; RAINA A, 1982, BIOCHEM J, V204, P697, DOI 10.1042/bj2040697; RISCOE MK, 1989, PARASITOL TODAY, V5, P330, DOI 10.1016/0169-4758(89)90128-2; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Shi WX, 2001, BIOCHEMISTRY-US, V40, P8204, DOI 10.1021/bi010585p; Singh V, 2005, J BIOL CHEM, V280, P18265, DOI 10.1074/jbc.M414472200; Singh V, 2004, BIOCHEMISTRY-US, V43, P9, DOI 10.1021/bi0358420; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511	62	68	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18274	18282		10.1074/jbc.M414471200	http://dx.doi.org/10.1074/jbc.M414471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746096	hybrid			2022-12-27	WOS:000228807200086
J	Ley, R; Hadfield, K; Howes, E; Cook, SJ				Ley, R; Hadfield, K; Howes, E; Cook, SJ			Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein Bim(EL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; BAX-DEPENDENT APOPTOSIS; PROAPOPTOTIC ACTIVITY; NEURONAL APOPTOSIS; BIM EXPRESSION; MAP KINASES; SITES; PROMOTES; ACTIVATION; PATHWAY	The BH3-only protein, Bim, exists as three splice variants (Bim(S), Bim(L), and Bim(EL)) of differing pro-apoptotic potency. Bim(EL), the least effective killer, is degraded by the proteasome in response to phosphorylation by extracellular signal-regulated kinases 1 and 2 (ERK1/2). ERK1/2-dependent phosphorylation correlates with the presence of a domain unique to the Bim(EL) splice variant that includes the major ERK1/2 phosphorylation site Ser(65). However, efficient phosphorylation by ERK1/2, c-Jun N-terminal kinase, or p38 requires the presence in the substrate of a discrete kinase-docking domain as well as the phosphoacceptor site. Here we show that the region unique to Bim(EL) (amino acids 41-97) harbors two potential DEF-type ERK1/2 kinase-docking domains, DEF1 and DEF2. Peptide competition assays revealed that the DEF2 peptide could act autonomously to bind active ERK1/2, whereas the DEF1 peptide did not. Truncation analysis identified a minimal region, residues 80-97, containing the DEF2 motif as sufficient for ERK1/2 binding. Mutation of key residues in the DEF2 motif abolished the interaction of ERK1/2 and Bim(EL) and also abolished ERK1/2-dependent phosphorylation of Bim(EL) in vivo, thereby stabilizing the protein and enhancing cytotoxicity. Our results identify a new physiologically relevant functional motif in Bim(EL) that may account for the distinct biological properties of this splice variant.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Ley, R (corresponding author), Babraham Inst, Mol Signalling Lab, Res Campus, Cambridge CB2 4AT, England.	becky.ley@bbsrc.ac.uk; simon.cook@bbsrc.ac.uk			Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H151] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2	32	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17657	17663		10.1074/jbc.M412342200	http://dx.doi.org/10.1074/jbc.M412342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728578	hybrid			2022-12-27	WOS:000228807200013
J	Osawa, M; Dace, A; Tong, KI; Valiveti, A; Ikura, M; Ames, JB				Osawa, M; Dace, A; Tong, KI; Valiveti, A; Ikura, M; Ames, JB			Mg2+ and Ca2+ differentially regulate DNA binding and dimerization of DREAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; SENSOR; SITES; CALSENILIN; MODULATION; RECOVERIN; REPRESSOR	DREAM (calsenilin/KChIP3) is an EF-hand calcium-binding protein that represses transcription of prodynorphin and c-fos genes. Here we present structural and binding studies on single-site mutants of DREAM designed to disable Ca2+ binding to each of the functional EF-hands (EF-2: D150N; EF-3: E186Q; and EF-4: E234Q). Isothermal titration calorimetry (ITC) analysis of Ca2+ binding to the various mutants revealed that, in the absence of Mg2+, Ca2+ binds independently and sequentially to EF-3 (Delta H = - 2.4 kcal/mol), EF-4 (Delta H = +5.2 kcal/mol), and EF-2 (Delta H = + 1 kcal/mol). By contrast, only two Ca2+ bind to DREAM in the presence of physiological levels of Mg2+ for both wild-type and D150N, suggesting that EF-2 binds constitutively to Mg2+. ITC measurements demonstrate that one Mg2+ binds enthalpically with high affinity (K-d = 13 mu M and Delta H = - 0.79 kcal/mol) and two or more Mg2+ bind entropically in the millimolar range. Size-exclusion chromatography studies revealed that Mg2+ stabilizes DREAM as a monomer, whereas Ca2+ induces protein dimerization. Electrophoretic mobility shift assays indicated that Mg2+ is essential for sequence-specific binding of DREAM to DNA response elements (DREs) in prodynorphin and c-fos genes. The EF-hand mutants bind specifically to DRE, suggesting they are functionally intact. None of the EF-hand mutants bind DRE at saturating Ca2+ levels, suggesting that binding of a single Ca2+ at either EF-3 or EF-4 is sufficient to drive conformational changes that abolish DNA binding. NMR structural analysis indicates that metal-free DREAM adopts a folded yet flexible molten globule-like structure. Both Ca2+ and Mg2+ induce distinct conformational changes, which stabilize tertiary structure of DREAM. We propose that Mg2+ binding at EF-2 may structurally bridge DREAM to DNA targets and that Ca2+-induced protein dimerization disrupts DNA binding.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University System of Maryland; University of Maryland Baltimore; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Ames, JB (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	james@carb.nist.gov	Osawa, Masanori/GRS-5726-2022	Osawa, Masanori/0000-0002-1285-4316; Ikura, Mitsuhiko/0000-0002-9524-1303	NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045909] Funding Source: NIH RePORTER; NEI NIH HHS [EY12347] Funding Source: Medline; NINDS NIH HHS [R01 NS045909, NS45909] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Brautigam CA, 1999, BIOCHEMISTRY-US, V38, P696, DOI 10.1021/bi981537g; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Buxbaum JD, 2004, BIOCHEM BIOPH RES CO, V322, P1140, DOI 10.1016/j.bbrc.2004.08.001; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Cates MS, 2002, BIOPHYS J, V82, P1133, DOI 10.1016/S0006-3495(02)75472-6; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; Costigan M, 2002, CELL, V108, P297, DOI 10.1016/S0092-8674(02)00640-2; COX JA, 1994, J BIOL CHEM, V269, P32807; Craig TA, 2002, J BIOL CHEM, V277, P10955, DOI 10.1074/jbc.M109660200; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ledo F, 2002, EMBO J, V21, P4583, DOI 10.1093/emboj/cdf440; Ledo F, 2000, BBA-MOL CELL RES, V1498, P162, DOI 10.1016/S0167-4889(00)00092-6; Lilliehook C, 2003, J NEUROSCI, V23, P9097; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Ochoa WF, 2002, J MOL BIOL, V320, P277, DOI 10.1016/S0022-2836(02)00464-3; Osawa M, 2001, J BIOL CHEM, V276, P41005, DOI 10.1074/jbc.M105842200; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Subirana JA, 2003, ANNU REV BIOPH BIOM, V32, P27, DOI 10.1146/annurev.biophys.32.110601.141726; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Vogt BA, 2002, NEW ENGL J MED, V347, P362, DOI 10.1056/NEJMcibr021152; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamniuk AP, 2004, BIOCHEMISTRY-US, V43, P2558, DOI 10.1021/bi035432b; Zaidi NF, 2004, J NEUROCHEM, V89, P593, DOI 10.1046/j.1471-4159.2004.02362.x; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	41	87	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18008	18014		10.1074/jbc.M500338200	http://dx.doi.org/10.1074/jbc.M500338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15746104	hybrid			2022-12-27	WOS:000228807200056
J	Takayama, Y; May, P; Anderson, RGW; Herz, J				Takayama, Y; May, P; Anderson, RGW; Herz, J			Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CELL-MIGRATION; CYTOPLASMIC DOMAIN; UROKINASE RECEPTOR; KINASE; DEGRADATION; CAVEOLAE; BINDING; GENE; INTERNALIZATION	The low density lipoprotein receptor-related protein 1 (LRP1) has been implicated in intracellular signaling functions as well as in lipid metabolism. Recent in vivo and in vitro studies suggest that LRP1 is a physiological modulator of the platelet-derived growth factor ( PDGF) signaling pathway. Here we show that in mouse fibroblasts LRP1 modulates PDGF-BB signaling by controlling endocytosis and ligand-induced down-regulation of the PDGF receptor beta (PDGFR beta). In LRP1-deficient fibroblasts, basal PDGFR beta tyrosine kinase activity was derepressed, and PDGF-BB-induced endocytosis and degradation of PDGFR beta were accelerated as compared with control cells. This was accompanied by rapid uptake of receptor-bound PDGF-BB into the cells and by attenuated ERK activation in response to PDGF-BB stimulation. Pulse-chase analysis indicated that the steady-state turnover rate of PDGFR beta was also accelerated in LRP-deficient fibroblasts. The rapid degradation of PDGFR beta in the LRP1-deficient fibroblasts was prevented by MG132 and chloroquine. Furthermore, the association of PDGFR beta with c-Cbl, a ubiquitin E3-ligase, as well as the ligand-induced ubiquitination of PDGFR beta were increased in LRP1-deficient fibroblasts. We show that LRP1 can directly interact with c-Cbl, suggesting a Sprouty-like role for LRP1 in regulating the access of the PDGFR beta to the ubiquitination machinery. Thus, LRP1 modulates PDGF signaling by controlling ubiquitination and endocytosis of the PDGFR beta.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Freiburg, Zentrum Neurowissensch, Med Klin 2, D-79104 Freiburg, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Takayama, Yoshiharu/E-3662-2010; Takayama, Yoshiharu/M-8826-2019	Takayama, Yoshiharu/0000-0003-4532-7114; Takayama, Yoshiharu/0000-0003-4532-7114	NHLBI NIH HHS [HL63762, HL20948, R37 HL063762] Funding Source: Medline; NIAMS NIH HHS [AR041940] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, R01HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Chiarugi P, 2002, J CELL SCI, V115, P2219; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kramer S, 1999, DEVELOPMENT, V126, P2515; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Reich A, 1999, DEVELOPMENT, V126, P4139; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Takayama Y, 2003, J BIOL CHEM, V278, P22112, DOI 10.1074/jbc.M300894200; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Webb DJ, 2000, J CELL SCI, V113, P123; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu LH, 2004, J CELL BIOCHEM, V93, P1169, DOI 10.1002/jcb.20288; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhu YJ, 2003, J BIOL CHEM, V278, P36257, DOI 10.1074/jbc.M303171200	45	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18504	18510		10.1074/jbc.M410265200	http://dx.doi.org/10.1074/jbc.M410265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753096	hybrid			2022-12-27	WOS:000228807200114
J	Calamita, G; Ferri, D; Gena, P; Liquori, GE; Cavalier, A; Thomas, D; Svelto, M				Calamita, G; Ferri, D; Gena, P; Liquori, GE; Cavalier, A; Thomas, D; Svelto, M			The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BRAIN MITOCHONDRIA; LIGHT-SCATTERING; TRANSITION; VOLUME; IMMUNOLOCALIZATION; EXPRESSION; APOPTOSIS; CLONING; FAMILY	Mitochondria are remarkably plastic organelles constantly changing their shape to fulfil their various functional activities. Although the osmotic movement of water into and out of the mitochondrion is central for its morphology and activity, the molecular mechanisms and the pathways for water transport across the inner mitochondrial membrane (IMM), the main barrier for molecules moving into and out of the organelle, are completely unknown. Here, we show the presence of a member of the aquaporin family of water channels, AQP8, and demonstrate the strikingly high water permeability (P-f) characterizing the rat liver IMM. Immunoblotting, electron microscopy, and biophysical studies show that the largest mitochondria feature the highest AQP8 expression and IMM Pf. AQP8 was also found in the mitochondria of other organs, whereas no other known aquaporins were seen. The osmotic water transport of liver IMM was partially inhibited by the aquaporin blocker Hg2+, while the related activation energy remained low, suggesting the presence of a Hg2+-insensitive facilitated pathway in addition to AQP8. It is suggested that AQP8-mediated water transport may be particularly important for rapid expansions of mitochondrial volume such as those occurring during active oxidative phosphorylation and those following apoptotic signals.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, Dipartimento Zool, Lab Istol & Anat Comparata, I-70126 Bari, Italy; Univ Rennes 1, CNRS, URA 256, Rennes, France	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Calamita, G (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	calamita@biologia.uniba.it	THOMAS, Danniel/AAJ-5033-2020; Gena, patrizia/AAC-3396-2022; Svelto, Maria/P-6186-2014	THOMAS, Danniel/0000-0002-9650-0434; Svelto, Maria/0000-0002-5584-9541; Calamita, Giuseppe/0000-0003-4666-9546				Agre P, 2003, FEBS LETT, V555, P72, DOI 10.1016/S0014-5793(03)01083-4; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Calamita G, 2001, EUR J CELL BIOL, V80, P711, DOI 10.1078/0171-9335-00210; Calamita G, 1999, CYTOGENET CELL GENET, V85, P237, DOI 10.1159/000015300; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Ferri D, 2003, HEPATOLOGY, V38, P947, DOI 10.1053/jhep.2003.50397; Fujii F, 2004, BRAIN RES, V999, P29, DOI 10.1016/j.brainres.2003.11.017; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; GARLID KD, 1988, MITOCHONDRIAL VOLUME, P259; Gradilone SA, 2003, HEPATOLOGY, V37, P1435, DOI 10.1053/jhep.2003.50241; Guerrieri F, 2002, EUR J BIOCHEM, V269, P3304, DOI 10.1046/j.1432-1033.2002.03010.x; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; Jablonski EM, 2004, AM J PHYSIOL-CELL PH, V286, pC975, DOI 10.1152/ajpcell.00180.2003; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Lanni A, 1996, INT J BIOCHEM CELL B, V28, P337, DOI 10.1016/1357-2725(95)00137-9; Lee WK, 2005, AM J PHYSIOL-RENAL, V288, pF27, DOI 10.1152/ajprenal.00224.2004; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Portincasa P, 2003, J HEPATOL, V39, P864, DOI 10.1016/S0168-8278(03)00294-0; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Zardoya R, 2001, J MOL EVOL, V52, P391, DOI 10.1007/s002390010169; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	28	166	176	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17149	17153		10.1074/jbc.C400595200	http://dx.doi.org/10.1074/jbc.C400595200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15749715	hybrid			2022-12-27	WOS:000228615500075
J	Cha, B; Kim, JH; Hut, H; Hogema, BM; Nadarja, J; Zizak, M; Cavet, M; Lee-Kwon, W; Lohmann, SM; Smolenski, A; Tse, CM; Yun, C; de Jonge, HR; Donowitz, M				Cha, B; Kim, JH; Hut, H; Hogema, BM; Nadarja, J; Zizak, M; Cavet, M; Lee-Kwon, W; Lohmann, SM; Smolenski, A; Tse, CM; Yun, C; de Jonge, HR; Donowitz, M			cGMP inhibition of Na+/H+ antiporter 3 (NHE3) requires PDZ domain adapter NHERF2, a broad specificity protein kinase G-anchoring protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; EXCHANGER REGULATORY FACTOR; BETA(2)-ADRENERGIC RECEPTOR; CA2+-DEPENDENT INHIBITION; MYOSIN PHOSPHATASE; PROXIMAL TUBULE; BINDING; LOCALIZATION; INTERACTS; COMPLEX	Electroneutral NaCl absorption mediated by Na+/H+ exchanger 3 (NHE3) is important in intestinal and renal functions related to water/Na+ homeostasis. cGMP inhibits NHE3 in intact epithelia. However, unexpectedly it failed to inhibit NHE3 stably transfected in PS120 cells, even upon co-expression of cGMP-dependent protein kinase type II (cGKII). Additional co-expression of NHERF2, the tandem PDZ domain adapter protein involved in cAMP inhibition of NHE3, restored cGMP as well as cAMP inhibition, whereas NHERF1 solely restored cAMP inhibition. In vitro conditions were identified in which NHERF2 but not NHERF1 bound cGKII. The NHERF2 PDZ2 C terminus, which binds NHE3, also bound cGKII. A non-myristoylated mutant of cGKII did not support cGMP inhibition of NHE3. Although cGKI also bound NHERF2 in vitro, it did not evoke inhibition of NHE3 unless a myristoylation site was added. These results show that NHERF2, acting as a novel protein kinase G-anchoring protein, is required for cGMP inhibition of NHE3 and that cGKII must be bound both to the plasma membrane by its myristoyl anchor and to NHERF2 to inhibit NHE3.	Johns Hopkins Univ, Sch Med, Dept Physiol, GI Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, GI Div, Baltimore, MD 21205 USA; Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Univ Zagreb, Sch Med, Dept Physiol, Zagreb 41001, Croatia; Univ Med Clin, Dept Clin Biochem, D-97080 Wurzburg, Germany	Johns Hopkins University; Johns Hopkins University; Erasmus University Rotterdam; Erasmus MC; University of Zagreb; University of Wurzburg	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, GI Div, 925 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu		Smolenski, Albert/0000-0001-9210-9406	NCI NIH HHS [R01-CA85428] Funding Source: Medline; NIDDK NIH HHS [P01-DK44484, R01-DK51116, R01-DK61765, R24-DK64388, T32-DK07632, R01-DK26523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061765, R24DK064388, T32DK007632, R01DK051116, P01DK044484, R01DK026523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airhart N, 2003, J BIOL CHEM, V278, P38693, DOI 10.1074/jbc.M304098200; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Bacic D, 2003, KIDNEY INT, V64, P2133, DOI 10.1046/j.1523-1755.2003.00308.x; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Jin XH, 1999, J CLIN INVEST, V103, P167, DOI 10.1172/JCI4327; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang YJ, 2004, CELL SIGNAL, V16, P791, DOI 10.1016/j.cellsig.2003.12.003; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Oh YS, 2004, MOL CELL BIOL, V24, P5069, DOI 10.1128/MCB.24.11.5069-5079.2004; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	45	75	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16642	16650		10.1074/jbc.M500505200	http://dx.doi.org/10.1074/jbc.M500505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722341	hybrid			2022-12-27	WOS:000228615500015
J	Korcok, J; Raimundo, LN; Du, XB; Sims, SM; Dixon, SJ				Korcok, J; Raimundo, LN; Du, XB; Sims, SM; Dixon, SJ			P2Y6 nucleotide receptors activate NF-kappa B and increase survival of osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; BONE-RESORPTION; NERVOUS-SYSTEM; MICE LACKING; CELLS; P2Y(6); ATP; EXPRESSION	Nucleotides, released from cells during inflammation and by mechanical stimulation, act through the P2 family of nucleotide receptors. Previous studies have demonstrated the expression of P2Y1 and P2Y2 receptors in osteoclasts. The aim of this study was to determine whether osteoclast P2Y receptors signal through NF-kappa B, a key transcription factor regulating osteoclastogenesis. Immunofluorescence was used to detect the p65 subunit of NF-kappa B, which upon activation translocates from the cytosol to nuclei. Low levels of NF-kappa B activation were observed in untreated rabbit osteoclasts and in those exposed to 2-methylthio ADP ( P2Y1 agonist) or ATP or UTP ( P2Y2 agonists). In contrast, UDP or INS48823 (P2Y6 agonists) induced a significant increase in the number of cells exhibiting NF-kappa B activation, a process sensitive to the proteasome inhibitor lactacystin. In osteoclasts purified by micromanipulation, reverse transcription-PCR revealed the presence of P2Y1, P2Y2, and P2Y6 receptor transcripts, and application of agonists for these receptors induced the transient rise of cytosolic calcium. Treatment of rat osteoclasts with UDP or INS48823, but not 2-methylthio ADP or UTP, increased osteoclast survival. Osteoprotegerin ( a decoy receptor for RANK ligand) did not significantly alter the effects of UDP on NF-kappa B localization or osteoclast survival, consistent with a direct action. Moreover, SN50 (cell-permeable peptide inhibitor of NF-kappa B) suppressed the enhancement of cell survival induced by UDP and INS48823. Our findings demonstrate the presence of functional P2Y6 receptors in osteoclasts. Thus, nucleotides, following their release at sites of inflammation and mechanical stimulation, can act through P2Y6 receptors to initiate NF-kappa B signaling and enhance osteoclast survival.	Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Div Oral Biol, Fac Med & Dent, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Dixon, SJ (corresponding author), Univ Western Ontario, Canadian Inst Hlth, Res Grp Skeletal Dev & Remodeling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	jeff.dixon@fmd.uwo.ca	Sims, Stephen/G-4510-2013; Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419, DOI 10.1113/jphysiol.1984.sp015385; Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756-3282(01)00430-6; Boyce BF, 1999, LAB INVEST, V79, P83; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756-3282(02)00877-3; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; Chen BC, 2000, BRIT J PHARMACOL, V130, P777, DOI 10.1038/sj.bjp.0703375; Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165-6147(03)00123-8; Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00-0395com; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Hou MY, 2002, AM J PHYSIOL-HEART C, V282, pH784, DOI 10.1152/ajpheart.00997.2000; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jacobson KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/jm020046y; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; Kim SG, 2003, BIOCHEM PHARMACOL, V65, P923, DOI 10.1016/S0006-2952(02)01614-3; Kim SG, 2003, CELL MOL NEUROBIOL, V23, P401, DOI 10.1023/A:1023696806609; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; Naemsch LN, 1999, J CELL SCI, V112, P4425; Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200; Parfitt AM, 1996, J BONE MINER RES, V11, P150; Pendergast W, 2001, BIOORG MED CHEM LETT, V11, P157, DOI 10.1016/S0960-894X(00)00612-0; Ralevic V, 1998, PHARMACOL REV, V50, P413; Weidema AF, 2001, AM J PHYSIOL-CELL PH, V280, pC1531, DOI 10.1152/ajpcell.2001.280.6.C1531; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200; Zimmermann H, 1998, NEUROCHEM INT, V32, P421, DOI 10.1016/S0197-0186(97)00126-5	42	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16909	16915		10.1074/jbc.M410764200	http://dx.doi.org/10.1074/jbc.M410764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722352	hybrid			2022-12-27	WOS:000228615500045
J	Wang, XM; Tang, XL; Li, MT; Marshall, J; Mao, ZX				Wang, XM; Tang, XL; Li, MT; Marshall, J; Mao, ZX			Regulation of neuroprotective activity of myocyte-enhancer factor 2 by cAMP-protein kinase A signaling pathway in neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; GROWTH-FACTOR-I; CYCLASE-ACTIVATING POLYPEPTIDE; TRANSCRIPTION FACTOR MEF2; CENTRAL-NERVOUS-SYSTEM; DNA-BINDING ACTIVITY; CYCLIC-AMP; PHOSPHATIDYLINOSITOL 3-KINASE; NEURITE-OUTGROWTH; INDUCED APOPTOSIS	The transcription factor myocyte-enhancer factor 2 (MEF2) has been shown to be required for the survival of different types of neurons. However, the death- or survival-inducing second messenger pathways that regulate MEF2 activity remain to be fully elucidated. Membrane depolarization by KCl induces neuronal survival that is dependent upon MEF2-mediated gene transactivation. Here we report that membrane depolarization-induced activation of MEF2 requires the cAMP-protein kinase A (PKA) pathway. Inhibition of the activity of cAMP-PKA pathway attenuates membrane depolarization-induced activation of MEF2 activity and neuronal survival, whereas enhancing the activity of this pathway prevents KCl withdrawal-induced inhibition of MEF2 and neuronal apoptosis. Moreover, PKA directly phosphorylates MEF2 at Thr-20 in vitro to increase MEF2 DNA binding activity. A mutation of Thr-20 to Ala renders MEF2 resistant to PKA phosphorylation in vitro and reduces its DNA binding activity. Transfection of this T20A mutant blocks survival and induces apoptosis in cultured cortical and cerebellar granule neurons. This study identifies the transcription factor MEF2 as a target of cAMP-PKA pathway and demonstrates that PKA phosphorylation of MEF2 is a key step in modulating its DNA binding activity and ability to promote neuronal survival.	Brown Univ, Sch Med, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Providence, RI 02903 USA; Sun Yat Sen Univ, Zhongshan med Coll, Dept Pharmacol, Guangzhou 510080, Peoples R China; Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Sun Yat Sen University; Brown University	Mao, ZX (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	zmao@pharm.emory.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039063] Funding Source: NIH RePORTER; NICHD NIH HHS [HD39446] Funding Source: Medline; NINDS NIH HHS [NS39063] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Blair LAC, 1999, J NEUROSCI, V19, P1940; Borodinsky LN, 2002, J NEUROCHEM, V80, P1062, DOI 10.1046/j.1471-4159.2002.00795.x; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Facci L, 2003, NEUROPHARMACOLOGY, V45, P623, DOI 10.1016/S0028-3908(03)00211-9; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Franke B, 2000, EXP NEUROL, V165, P125, DOI 10.1006/exnr.2000.7453; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Hanson MG, 1998, J NEUROSCI, V18, P7361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Koulich E, 2001, J NEUROCHEM, V76, P1188, DOI 10.1046/j.1471-4159.2001.00134.x; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mei YA, 2004, EUR J NEUROSCI, V19, P1446, DOI 10.1111/j.1460-9568.2004.03227.x; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Nguyen PV, 2003, PROG NEUROBIOL, V71, P401, DOI 10.1016/j.pneurobio.2003.12.003; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Poser S, 2003, J NEUROSCI, V23, P4420; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Shalizi A, 2003, J NEUROSCI, V23, P7326; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	57	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16705	16713		10.1074/jbc.M501819200	http://dx.doi.org/10.1074/jbc.M501819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15735306	hybrid			2022-12-27	WOS:000228615500022
J	Dadsetan, S; Shishkin, V; Fomina, AF				Dadsetan, S; Shishkin, V; Fomina, AF			Intracellular Ca2+ release triggers translocation of membrane marker FM1-43 from the extracellular leaflet of plasma membrane into endoplasmic reticulum in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CELLS; FLUORESCENCE; TRAFFICKING; EXPRESSION; MECHANISM; TRANSPORT; GOLGI	Stimulation of T cell receptor in lymphocytes enhances Ca2+ signaling and accelerates membrane trafficking. The relationships between these processes are not well understood. We employed membrane-impermeable lipid marker FM1 - 43 to explore membrane trafficking upon mobilization of intracellular Ca2+ in Jurkat T cells. We established that liberation of intracellular Ca2+ with T cell receptor agonist phytohemagglutinin P or with Ca2+-mobilizing agents ionomycin or thapsigargin induced accumulation of FM1 - 43 within the lumen of the endoplasmic reticulum ( ER), nuclear envelope ( NE), and Golgi. FM1 - 43 loading into ER-NE and Golgi was not mediated via the cytosol because other organelles such as mitochondria and multivesicular bodies located in close proximity to the FM1-43-containing ER were free of dye. Intralumenal FM1 - 43 accumulation was observed even when Ca2+ signaling in the cytosol was abolished by the removal of extracellular Ca2+. Our findings strongly suggest that release of intracellular Ca2+ may create continuity between the extracellular leaflet of the plasma membrane and the lumenal membrane leaflet of the ER by a mechanism that does not require global cytosolic Ca2+ elevation.	Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Fomina, AF (corresponding author), Univ Calif Davis, Dept Physiol & Membrane Biol, 1 Shields Ave, Davis, CA 95616 USA.	affomina@ucdavis.edu						Bootman MD, 2002, CELL CALCIUM, V32, P231, DOI 10.1016/S0143416002002002; Chen SC, 2004, BLOOD, V104, P3233, DOI 10.1182/blood-2003-05-1679; Chow C W, 1995, New Horiz, V3, P342; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Cornelissen M, 2002, APOPTOSIS, V7, P41; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Fomina AF, 2003, EXP CELL RES, V291, P150, DOI 10.1016/S0014-4827(03)00372-0; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Henkel AW, 1996, P NATL ACAD SCI USA, V93, P1918, DOI 10.1073/pnas.93.5.1918; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Narayanan B, 2003, J BIOL CHEM, V278, P44188, DOI 10.1074/jbc.M306538200; Nishikawa S, 1996, J HISTOCHEM CYTOCHEM, V44, P733, DOI 10.1177/44.7.8675994; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390	23	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16377	16382		10.1074/jbc.M501202200	http://dx.doi.org/10.1074/jbc.M501202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15710604	hybrid			2022-12-27	WOS:000228444800110
J	Dolman, NJ; Gerasimenko, JV; Gerasimenko, OV; Voronina, SG; Petersen, OH; Tepikin, AV				Dolman, NJ; Gerasimenko, JV; Gerasimenko, OV; Voronina, SG; Petersen, OH; Tepikin, AV			Stable Golgi-mitochondria complexes and formation of Golgi Ca2+ gradients in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; EXOCRINE CELLS; BREFELDIN-A; CALCIUM; TRANSPORT; SIGNALS; OSCILLATIONS; APPARATUS; STORES	We have determined the localization of the Golgi with respect to other organelles in living pancreatic acinar cells and the importance of this localization to the establishment of Ca2+ gradients over the Golgi. Using confocal microscopy and the Golgi- specific fluorescent probe 6-(( N-( 7- nitrobenz- 2- oxa- 1,3- diazol- 4- yl) amino) hexanoyl) sphingosine, we found Golgi structures localizing to the outer edge of the secretory granular region of individual acinar cells. We also assessed Golgi positioning in acinar cells located within intact pancreatic tissue using two- photon microscopy and found a similar localization. The mitochondria segregate the Golgi from lateral regions of the plasma membrane, the nucleus, and the basal part of the cytoplasm. The Golgi is therefore placed between the principal Ca2+ release sites in the apical region of the cell and the important Ca2+ sink formed by the peri- granular mitochondria. During acetylcholine-induced cytosolic Ca2+ signals in the apical region, large Ca2+ gradients form over the Golgi ( decreasing from trans- to cis- Golgi). We further describe a novel, close interaction of the peri- granular mitochondria and the Golgi apparatus. The mitochondria and the Golgi structures form very close contacts, and these contacts remain stable over time. When the cell is forced to swell, the Golgi and mitochondria remain juxtaposed up to the point of cell lysis. The strategic position of the Golgi ( closer to release sites than the bulk of the mitochondrial belt) makes this organelle receptive to local apical Ca2+ transients. In addition the Golgi is ideally placed to be preferentially supplied by ATP from adjacent mitochondria.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Tepikin, AV (corresponding author), Natl Inst Neurol Disorders & Stroke, Synapt Physiol Unit, NIH, Bldg 35,35 Convent Dr, Bethesda, MD 20892 USA.	a.tepikin@liv.ac.uk	Gerasimenko, Oleg/A-6622-2010; Gerasimenko, Julia/A-7688-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Gerasimenko, Julia/0000-0002-2262-2543; Tepikin, Alexei/0000-0002-8172-7513				Ahluwalia JP, 2001, J BIOL CHEM, V276, P34148, DOI 10.1074/jbc.M105398200; Ashby MC, 2003, J BIOL CHEM, V278, P20860, DOI 10.1074/jbc.M302599200; Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; Bruce JIE, 2004, J BIOL CHEM, V279, P12909, DOI 10.1074/jbc.M309070200; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Csordas G, 2001, CELL CALCIUM, V29, P249, DOI 10.1054/ceca.2000.0191; Gerasimenko OV, 2002, CELL CALCIUM, V32, P261, DOI 10.1016/S0143416002001938; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; Johnson PR, 2003, CELL TISSUE RES, V313, P37, DOI 10.1007/s00441-003-0741-1; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELDOLESI J, 1978, J CELL BIOL, V79, P156, DOI 10.1083/jcb.79.1.156; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Ribeiro CMP, 2003, J GEN PHYSIOL, V122, P377, DOI 10.1085/jgp.200308893; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Thomas DDH, 2004, AM J PHYSIOL-GASTR L, V287, pG253, DOI 10.1152/ajpgi.00033.2004; Thorn P, 2004, P NATL ACAD SCI USA, V101, P6774, DOI 10.1073/pnas.0400336101; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Vanoevelen J, 2004, CELL CALCIUM, V35, P115, DOI 10.1016/j.ceca.2003.08.003; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77	44	76	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15794	15799		10.1074/jbc.M412694200	http://dx.doi.org/10.1074/jbc.M412694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15722348	hybrid			2022-12-27	WOS:000228444800042
J	Simon, MF; Daviaud, D; Pradere, JP; Gres, S; Guigne, C; Wabitsch, M; Chun, J; Valet, P; Saulnier-Blache, JS				Simon, MF; Daviaud, D; Pradere, JP; Gres, S; Guigne, C; Wabitsch, M; Chun, J; Valet, P; Saulnier-Blache, JS			Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREADIPOCYTE PROLIFERATION; 3T3F442A PREADIPOCYTES; EXPRESSION; INVOLVEMENT; GENE	Lysophosphatidic acid (LPA) is a bioactive phospholipid acting via specific G protein-coupled receptors that is synthesized at the extracellular face of adipocytes by a secreted lysophospholipase D (autotaxin). Preadipocytes mainly express the LPA(1) receptor subtype, and LPA increases their proliferation. In monocytes and CV1 cells LPA was recently reported to bind and activate peroxisome proliferator-activated receptor gamma (PPAR gamma), a transcription factor also known to play a pivotal role in adipogenesis. Here we show that, unlike the PPAR gamma agonist rosiglitazone, LPA was unable to increase transcription of PPAR gamma-sensitive genes (PEPCK and ALBP) in the mouse preadipose cell line 3T3F442A. In contrast, treatment with LPA decreased PPAR gamma 2 expression, impaired the response of PPAR gamma-sensitive genes to rosiglitazone, reduced triglyceride accumulation, and reduced the expression of adipocyte mRNA markers. The anti-adipogenic activity of LPA was also observed in the human SGBS (Simpson-Golabi-Behmel syndrome) preadipocyte cell line, as well as in primary preadipocytes isolated from wild type mice. Conversely, the anti-adipogenic activity of LPA was not observed in primary preadipocytes from LPA(1) receptor knock-out mice, which, in parallel, exhibited a higher adiposity than wild type mice. In conclusion, LPA does not behave as a potent PPAR gamma agonist in adipocytes but, conversely, inhibits PPAR gamma expression and adipogenesis via LPA(1) receptor activation. The local production of LPA may exert a tonic inhibitory effect on the development of adipose tissue.	Hop Rangueil, INSERM, Inst Louis Bugnard, U586, F-31432 Toulouse, France; Univ Ulm, Dept Pediat, D-89081 Ulm, Germany; Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, La Jolla, CA 92037 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Ulm University; Scripps Research Institute	Saulnier-Blache, JS (corresponding author), Hop Rangueil, INSERM, Inst Louis Bugnard, U586, BP84225, F-31432 Toulouse, France.	saulnier@toulouse.inserm.fr	Valet, Philippe/N-7472-2017; Chun, Jerold/Y-4670-2019; Saulnier-Blache, Jean Sebastien/X-7729-2018	Valet, Philippe/0000-0001-6520-7393; Pradere, Jean-Philippe/0000-0003-1734-1429; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gesta S, 2002, J LIPID RES, V43, P904; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREGOIRE F, 1991, EXP CELL RES, V196, P270, DOI 10.1016/0014-4827(91)90261-R; Jazet IM, 2003, NETH J MED, V61, P194; Kersten S, 2002, EUR J PHARMACOL, V440, P223, DOI 10.1016/S0014-2999(02)01431-0; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107; Ruiz-Velasco N, 2004, BIOCHEM PHARMACOL, V67, P303, DOI 10.1016/j.bcp.2003.09.006; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	25	119	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14656	14662		10.1074/jbc.M412585200	http://dx.doi.org/10.1074/jbc.M412585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710620	hybrid, Green Submitted			2022-12-27	WOS:000228236800040
J	Finlin, BS; Mosley, AL; Crump, SM; Correll, RN; Ozcan, S; Satin, J; Andres, DA				Finlin, BS; Mosley, AL; Crump, SM; Correll, RN; Ozcan, S; Satin, J; Andres, DA			Regulation of L-type Ca2+ channel activity and insulin secretion by the Rem2 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL DEATH; PANCREATIC-ISLETS; BINDING PROTEIN; GENE-TRANSCRIPTION; RAS FAMILY; GLUCOSE; CALCIUM; GEM; EXPRESSION; PHOSPHORYLATION	Voltage-dependent calcium (Ca2+) channels are involved in many specialized cellular functions and are controlled by a diversity of intracellular signals. Recently, members of the RGK family of small GTPases (Rem, Rem2, Rad, Gem/Kir) have been identified as novel contributors to the regulation of L-type calcium channel activity. In this study, microarray analysis of the mouse insulinoma MIN6 cell line revealed that the transcription of Rem2 gene is strongly induced by exposure to high glucose, which was confirmed by real-time reverse transcriptase-PCR and RNase protection analysis. Because elevation of intracellular Ca2+ in pancreatic beta-cells is essential for insulin secretion, we tested the hypothesis that Rem2 attenuates Ca2+ currents to regulate insulin secretion. Co-expression of Rem2 with Ca(V)1.2 or Ca(V)1.3 L-type Ca2+ channels in a heterologous expression system completely inhibits de novo Ca2+ current expression. In addition, ectopic overexpression of Rem2 both inhibited L-type Ca2+ channel activity and prevented glucose-stimulated insulin secretion in pancreatic beta-cell lines. Co-immunoprecipitation studies demonstrate that Rem2 associates with a variety of Ca-V beta subunits. Importantly, surface biotinylation studies demonstrate that the membrane distribution of Ca2+ channels was not reduced at a time when channel activity was potently inhibited by Rem2 expression, indicating that Rem2 modulates channel function without interfering with membrane trafficking. Taken together, these data suggest that inhibition of L-type Ca2+ channels by Rem2 signaling may represent a new and potentially important mechanism for regulating Ca2+-triggered exocytosis in hormone-secreting cells, including insulin secretion in pancreatic beta-cells.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Rm MS 639 Chandler Med Ctr,800 Rose St, Lexington, KY 40536 USA.	dandres@pop.uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR000171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL074091, R01HL072936, R01HL074091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR0171] Funding Source: Medline; NHLBI NIH HHS [R01 HL072936, R01 HL072936-02, HL-074091, HL-072936] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; Balijepalli RC, 2004, CIRC RES, V95, P337, DOI 10.1161/01.RES.0000141018.33292.21; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bjorklund A, 2000, DIABETES, V49, P1840, DOI 10.2337/diabetes.49.11.1840; Blalock EM, 2003, J NEUROSCI, V23, P3807; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chandra J, 2001, DIABETES, V50, pS44, DOI 10.2337/diabetes.50.2007.S44; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Juntti-Berggren L, 2004, P NATL ACAD SCI USA, V101, P10090, DOI 10.1073/pnas.0403551101; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Levy J, 1998, METABOLISM, V47, P185, DOI 10.1016/S0026-0495(98)90218-9; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Mears D, 2004, J MEMBRANE BIOL, V200, P57, DOI 10.1007/s00232-004-0692-9; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Ohsugi M, 2004, DIABETES, V53, P1496, DOI 10.2337/diabetes.53.6.1496; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; Paulik MA, 1997, J CELL BIOCHEM, V65, P527, DOI 10.1002/(SICI)1097-4644(19970615)65:4<527::AID-JCB8>3.3.CO;2-G; Poitout V, 1996, DIABETES METAB, V22, P7; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROE MW, 1994, J BIOL CHEM, V269, P18279; SATIN LS, 1995, ENDOCRINOLOGY, V136, P4589, DOI 10.1210/en.136.10.4589; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Yang SN, 2005, AM J PHYSIOL-ENDOC M, V288, pE16, DOI 10.1152/ajpendo.00042.2004	39	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	2005	280	51					41864	41871		10.1074/jbc.M414261200	http://dx.doi.org/10.1074/jbc.M414261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993XW	15728182	hybrid			2022-12-27	WOS:000233992700012
J	Kashkar, H; Wiegmann, K; Yazdanpanah, B; Haubert, D; Kronke, M				Kashkar, H; Wiegmann, K; Yazdanpanah, B; Haubert, D; Kronke, M			Acid sphingomyelinase is indispensable for UV light-induced bax conformational change at the mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; CASPASE ACTIVATION; HELA-CELLS; APOPTOSIS; CERAMIDE; INDUCTION; AGENTS; PERMEABILITY; FIBROBLASTS	Ultraviolet light-induced apoptosis can be caused by DNA damage but also involves immediate-early cell death cascades characteristic of death receptor signaling. Here we show that the UV light-induced apoptotic signaling pathway is unique, targeting Bax activation at the mitochondrial membrane independent of caspase-8 or cathepsin D activity. Cells deficient in acid sphingomyelinase (ASMase) do not show UV light-induced Bax activation, cytochrome c release, or apoptosis. In ASMase-deficient cells, the apoptotic UV light response is restored by stable or transient expression of human ASMase. Bax conformational change in ASMase(-/-) cells is also caused by synthetic C-16-ceramide acting on intact cells or isolated mitochondria. The results suggest that UV light-triggered ASMase activation is essentially required for Bax conformational change leading to mitochondrial release of pro-apoptotic factors like cytochrome c and Smac.	Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50935 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50935 Cologne, Germany	University of Cologne; University of Cologne	Kronke, M (corresponding author), Univ Cologne, Inst Med Microbiol Immunol & Hyg, Goldenfelsstr 19-21, D-50935 Cologne, Germany.	Martin.Kroenke@medizin.uni-koeln.de						Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Dai Q, 2004, ONCOGENE, V23, P3650, DOI 10.1038/sj.onc.1207430; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kashkar H, 2002, CELL DEATH DIFFER, V9, P750, DOI 10.1038/sj.cdd.4401024; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tafani M, 2001, CANCER RES, V61, P2459; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yamaguchi H, 2002, CANCER RES, V62, P466; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	108	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20804	20813		10.1074/jbc.M410869200	http://dx.doi.org/10.1074/jbc.M410869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15743760	hybrid			2022-12-27	WOS:000229242000078
J	Humrich, J; Bermel, C; Bunemann, MB; Harmark, LH; Frost, RJA; Quitterer, U; Lohse, MJ				Humrich, J; Bermel, C; Bunemann, MB; Harmark, LH; Frost, RJA; Quitterer, U; Lohse, MJ			Phosducin-like protein regulates G-protein beta gamma folding by interaction with tailless complex polypeptide-1 alpha - Dephosphorylation or splicing of PhLP turns the switch toward regulation of G beta gamma folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; SUBUNIT; PHOSPHORYLATION; EXPRESSION; CHANNELS; CELLS; IDENTIFICATION; INHIBITION; GENES; BRAIN	Phosducin-like protein ( PhLP) exists in two splice variants PhLPLONG (PhLPL) and PhLPSHORT (PhLPS). Whereas PhLPL directly inhibits G beta gamma-stimulated signaling, the G beta gamma-inhibitory mechanism of PhLPS is not understood. We report here that inhibition of G beta gamma signaling in intact HEK cells by PhLPS was independent of direct G beta gamma binding; however, PhLPS caused down-regulation of G beta and G gamma proteins. The down-regulation was partially suppressed by lactacystine, indicating the involvement of proteasomal degradation. N-terminal fusion of G beta or G gamma with a dye-labeling protein resulted in their stabilization against down-regulation by PhLPS but did not lead to a functional rescue. Moreover, in the presence of PhLPS, stabilized G gamma subunits did not coprecipitate with stabilized G beta subunits, suggesting that PhLPS might interfere with G beta gamma folding. PhLPS and several truncated mutants of PhLPS interacted with the subunit tailless complex polypeptide-1 alpha (TCP-1 alpha) of the CCT chaperonin complex, which is involved in protein folding. Knock-down of TCP-1 alpha in HEK cells by small interfering RNA also led to down-regulation of G beta gamma. We therefore conclude that the strong inhibitory action of PhLPS on G beta gamma signaling is the result of a previously unrecognized mechanism of G beta gamma-regulation, inhibition of G beta gamma-folding by interference with TCP-1 alpha.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Humrich J, 2003, J BIOL CHEM, V278, P4474, DOI 10.1074/jbc.M206347200; ITO H, 1994, J PHYSIOL-LONDON, V476, P55; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; LEE RH, 1990, J BIOL CHEM, V265, P15860; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NEER EJ, 1984, J BIOL CHEM, V259, P4222; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Schroder S, 2000, N-S ARCH PHARMACOL, V362, P435, DOI 10.1007/s002100000298; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Thibault C, 1999, BBA-GENE STRUCT EXPR, V1444, P346, DOI 10.1016/S0167-4781(99)00006-8; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	32	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20042	20050		10.1074/jbc.M409233200	http://dx.doi.org/10.1074/jbc.M409233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15745879	hybrid			2022-12-27	WOS:000229113700074
J	Villafuerte, BC; Kaytor, EN				Villafuerte, BC; Kaytor, EN			An insulin-response element-binding protein that ameliorates hyperglycemia in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-B; MALONYL-COA; GLUCOSE; EXPRESSION; LIVER; METABOLISM; GLUT4; DIFFERENTIATION; TRANSLOCATION; ADIPONUTRIN	Insulin modulates glucose homeostasis, but the role of insulin-responsive transcription factors in such actions is not well understood. Recently, we have identified the insulin-response element-binding protein-1 (IRE-BP1) as a transcription factor that appears to mediate insulin action on multiple target genes. To examine the possibility that IRE-BP1 is an insulin-responsive glucoregulatory factor involved in the metabolic actions of insulin, we investigated the effect of adenoviral overexpression of hepatic IRE-BP1 on the glycemic control of insulin-resistant diabetic rats. Adenoviral IRE-BP1 lowered both fasting and postprandial glucose levels, and microarray of hepatic RNA revealed modulation of the expression of genes involved in gluconeogenesis, lipogenesis, and fatty acid oxidation. The insulin mimetic effects of IRE-BP1 were also confirmed in L6 myocytes; stable constitutive expressions of IRE-BP1 enhanced glucose transporter expression, glucose uptake, and glycogen accumulation in these cells. These findings showed physiologic sufficiency of IRE-BP1 as the transcriptional mediator of the metabolic action of insulin. Understanding IRE-BP1 action should constitute a useful probe into the mechanisms of metabolic regulation and an important target to develop therapeutic agents that mimic or enhance insulin action.	Univ Louisville, Sch Med, Dept Med, Div Endocrinol, Louisville, KY 40202 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	University of Louisville; Emory University	Villafuerte, BC (corresponding author), Univ Louisville, Sch Med, Dept Med, Div Endocrinol, 570 S Preston St,Donald Baxter Bldg,Rm 221E, Louisville, KY 40202 USA.	bcvill01@louisville.edu	Core, Vector/CAF-4832-2022					Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; Beck-Nielsen H, 2003, BEST PRACT RES CL EN, V17, P445, DOI 10.1016/S1521-690X(03)00041-1; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Fronhoffs S, 2002, MOL CELL PROBE, V16, P99, DOI 10.1006/mcpr.2002.0405; Green A, 2003, DIABETES-METAB RES, V19, P3, DOI 10.1002/dmrr.340; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hermsdorf T, 1998, CELL SIGNAL, V10, P629, DOI 10.1016/S0898-6568(98)00003-5; Kaytor EN, 2001, ENDOCRINOLOGY, V142, P1041, DOI 10.1210/en.142.3.1041; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Kruszynska YT, 1996, J INVEST MED, V44, P413; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Louet JF, 2001, BIOCHEM SOC T, V29, P310, DOI 10.1042/0300-5127:0290310; Lu HG, 2002, J BIOL CHEM, V277, P46687, DOI 10.1074/jbc.M209643200; Manganiello VC, 1996, CURR TOP CELL REGUL, V34, P63, DOI 10.1016/S0070-2137(96)80003-3; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Monzillo LU, 2003, NUTR REV, V61, P397, DOI 10.1301/nr.2003.dec.397-412; Nakamura MT, 2002, BIOCHEM SOC T, V30, P1076, DOI 10.1042/BST0301076; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; O'Doherty RM, 1999, AM J PHYSIOL-ENDOC M, V277, pE544, DOI 10.1152/ajpendo.1999.277.3.E544; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Peterson R.G., 1990, ILAR NEWS, V32, P16, DOI [10.1093/ilar.32.3.16, DOI 10.1093/ILAR.32.3.16, DOI 10.1093/ILAR.32.3.16)]; Poirier M, 2002, AM J PHYSIOL-HEART C, V283, pH1379, DOI 10.1152/ajpheart.00244.2002; Polson DA, 2003, BIOCHEM BIOPH RES CO, V301, P261, DOI 10.1016/S0006-291X(02)03027-9; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shah Pankaj, 2003, Curr Diab Rep, V3, P214, DOI 10.1007/s11892-003-0066-1; SHIN Y, 2001, DIABETES-METAB RES, V50, P1093; Shintani M, 2001, DIABETES, V50, P2296, DOI 10.2337/diabetes.50.10.2296; Song S, 2002, DIABETES-METAB RES, V18, P5, DOI 10.1002/dmrr.260; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Totzke G, 1996, MOL CELL PROBE, V10, P427, DOI 10.1006/mcpr.1996.0059; TURO KA, 1982, AM J PHYSIOL, V243, pC278, DOI 10.1152/ajpcell.1982.243.5.C278; VANDERLAARSE WJ, 1992, BIOTECH HISTOCHEM, V67, P303, DOI 10.3109/10520299209110039; Villafuerte BC, 1996, MOL ENDOCRINOL, V10, P622, DOI 10.1210/me.10.6.622; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; VILLAFUERTE BC, 1994, ENDOCRINOLOGY, V134, P2044, DOI 10.1210/en.134.5.2044; VILLAFUERTE BC, 1991, DIABETES, V40, P837, DOI 10.2337/diabetes.40.7.837; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yamatani K, 2001, REGUL PEPTIDES, V99, P45, DOI 10.1016/S0167-0115(01)00228-2; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zhu JL, 1999, ENDOCRINOLOGY, V140, P4761, DOI 10.1210/en.140.10.4761	52	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20010	20020		10.1074/jbc.M410817200	http://dx.doi.org/10.1074/jbc.M410817200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753094	hybrid			2022-12-27	WOS:000229113700071
J	Wolins, NE; Quaynor, BK; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bickel, P				Wolins, NE; Quaynor, BK; Skinner, JR; Schoenfish, MJ; Tzekov, A; Bickel, P			S3-12, adipophilin, and TIP47 package lipid in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; DOMINANT-NEGATIVE MUTANT; 3T3-L1 ADIPOCYTES; DROPLETS; PERILIPIN; STORAGE; BODIES; CELL; ASSOCIATION; CAVEOLIN	Animals have evolved mechanisms to maintain circulating nutrient levels when energy demands exceed feeding opportunities. Mammals store most of their energy as triacylglycerol in the perilipin-coated lipid droplets of adipocytes. How newly synthesized triacylglycerol is delivered to perilipin-coated lipid droplets is poorly understood. Perilipin is a member of the evolutionarily related family of PAT proteins (Perilipin, Adipophilin, TIP47), which is defined by sequence similarity and association with lipid droplets. We previously showed that S3-12, which is also a member of this family, associates with a separate pool of lipid droplets that emerge when triacylglycerol storage is driven by adding oleate to the culture medium of adipocytes. Our current data extend these findings to demonstrate that nascent lipid droplets emerge with a coat composed of S3-12, TIP47, and adipophilin. After 100 min of oleate treatment, the nascent lipid droplets are more heterogeneous: S3-12 and TIP47 coat smaller, peripheral droplets and adipophilin coats a more medial population of droplets. Fractionation of untreated and oleate-treated adipocytes shows oleate-dependent redistribution of TIP47 and adipophilin from cytosolic fractions to the lipid droplet fraction. Inhibition of protein synthesis with cycloheximide does not block the oleate-induced formation of the nascent lipid droplets, nor does it prevent TAG accumulation. We suggest that the non-lipid droplet pools of S3-12, adipophilin, and TIP47 constitute a ready reservoir of coat proteins to permit rapid packaging of newly synthesized triacylglycerol and to maximize energy storage during nutrient excess.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Bickel, P (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	pbickel@im.wustl.edu	Bickel, Perry/Q-9185-2019		NIDDK NIH HHS [T32 DK07296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Quittnat F, 2004, MOL BIOCHEM PARASIT, V138, P107, DOI 10.1016/j.molbiopara.2004.08.004; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Spector A A, 1980, Prog Lipid Res, V19, P155; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Than GN, 2001, ANTICANCER RES, V21, P639; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	38	272	290	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19146	19155		10.1074/jbc.M500978200	http://dx.doi.org/10.1074/jbc.M500978200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15731108	hybrid			2022-12-27	WOS:000228932300071
J	Wang, Y; Lam, KSL; Xu, JY; Lu, G; Xu, LY; Cooper, GJS; Xu, AM				Wang, Y; Lam, KSL; Xu, JY; Lu, G; Xu, LY; Cooper, GJS; Xu, AM			Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN ADIPONECTIN; COMPLEMENT-RELATED PROTEIN; INSULIN-RESISTANCE; BINDING-PROTEIN; DEFICIENT MICE; FACTOR-BETA; ADIPOSE; ACRP30/ADIPONECTIN; EXPRESSION; RECEPTOR	Adiponectin, an adipocyte-specific secretory protein, is present in serum as three oligomeric complexes. Apart from its roles as an anti-diabetic and anti-atherogenic hormone, adiponectin has been implicated as an important regulator of cell growth and tissue remodeling. Here we show that some of these functions might be mediated by the specific interactions of adiponectin with several important growth factors. Among six different growth factors examined, adiponectin was found to bind with platelet-derived growth factor BB (PDGF-BB), basic fibroblast growth factor (FGF), and heparin-binding epidermal growth factor-like growth factor (HB EGF) with distinct affinities. The bindings of adiponectin with these growth factors are oligomerization-dependent. PDGF-BB bound to the high molecular weight (HMW) and middle molecular weight (MMW) complexes, but not to the low molecular weight (LMW) complex of adiponectin. Basic FGF preferentially interacted with the HMW form, whereas HB EGF bound to all three forms with comparable affinities. These three growth factors did not compete with each other for their bindings to adiponectin, suggesting the involvement of distinct binding sites. The interactions of adiponectin with PDGF-BB, basic FGF, and HB EGF precluded the bindings to their respective membrane receptors and attenuated the DNA synthesis and cell proliferation induced by these growth factors. Small interfering RNA-mediated down-regulation of adiponectin receptors did not affect the suppressive effects of adiponectin on cell proliferation stimulated by these growth factors. These data collectively suggest that the oligomeric complexes of adiponectin can modulate the biological actions of several growth factors by controlling their bioavailability at a pre-receptor level and that this effect might partly account for the anti-atherogenic, anti-angiogenic, and anti-proliferative functions of adiponectin.	Univ Hong Kong, Genome Res Ctr, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Peoples R China; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1001, New Zealand; Univ Auckland, Sch Biol Sci, Auckland 1001, New Zealand	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Auckland; University of Auckland	Wang, Y (corresponding author), Univ Hong Kong, Genome Res Ctr, Fac Med Bldg,21 Sasson Rd, Hong Kong, Peoples R China.	yuwanghk@hkucc.hku.hk	Xu, Aimin/D-3291-2013; Cooper, Garth JS/I-3201-2015; Wang, Yu/B-4534-2009; Lam, Karen Siu Ling/C-4315-2009	Xu, Aimin/0000-0002-0668-033X; Cooper, Garth JS/0000-0001-5241-3163; wang, yu/0000-0001-8697-2940				Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BONNER JC, 1994, ANN NY ACAD SCI, V737, P324, DOI 10.1111/j.1749-6632.1994.tb44321.x; Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Kamada Y, 2003, GASTROENTEROLOGY, V125, P1796, DOI 10.1053/j.gastro.2003.08.029; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; LAMARRE J, 1991, LAB INVEST, V65, P3; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Margosio B, 2003, BLOOD, V102, P4399, DOI 10.1182/blood-2003-03-0893; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Mensink A, 1996, EUR J PHARMACOL, V310, P73, DOI 10.1016/0014-2999(96)00368-8; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Okamoto Y, 2000, HORM METAB RES, V32, P47, DOI 10.1055/s-2007-978586; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200; WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Wang Y, 2004, PROTEOMICS, V4, P3933, DOI 10.1002/pmic.200400826; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723	46	313	344	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18341	18347		10.1074/jbc.M501149200	http://dx.doi.org/10.1074/jbc.M501149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15734737	hybrid			2022-12-27	WOS:000228807200094
J	Konno, T; Morii, T; Shimizu, H; Oiki, S; Ikura, K				Konno, T; Morii, T; Shimizu, H; Oiki, S; Ikura, K			Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TISSUE TRANSGLUTAMINASE; NEURODEGENERATIVE DISEASES; MOLECULAR CHAPERONES; ALZHEIMERS-DISEASE; PHASE-TRANSITIONS; ENZYMES	Cross-linking of proteins catalyzed by tissue transglutaminase has been suggested to play key roles in a variety of cellular events, including cell apoptosis and human pathogenesis ( e. g. polyglutamine and Alzheimer diseases). It has often been suggested that tissue transglutaminase enhances aggregation and precipitation of damaged or pathogenic proteins. To ascertain whether this is accurate, we investigated the effects of tissue transglutaminase-catalyzed modulation on the aggregation of structurally damaged and unfolded proteins. Our results indicated that the aggregation and precipitation of some unfolded proteins were inhibited by transglutaminase-catalyzed reaction, although the effect was strongly dependent upon the target protein species. To elucidate the molecular events underlying the inhibitory effect, extensive analysis was performed with regard to reduced beta-lactoglobulin using a number of techniques, including chromatography and spectroscopy. The results indicated that cross-linking yields high molecular weight soluble polymers but inhibits the growth of insoluble aggregates. The cross-linked beta-lactoglobulin retained stable secondary structures with a hydrophobic core. We concluded that the transglutaminase-catalyzed intermolecular cross-linking did not necessarily enhance protein aggregation but could sometimes have a suppressive effect. The results of the present study suggested that tissue transglutaminase modifies aggregation and deposition of damaged or pathogenic proteins in vivo in a wide variety of manners depending on the target protein species and solution conditions.	Univ Fukui, Fac Med Sci, Dept Physiol & Mol Biophys, Fukui 9101193, Japan; Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan	University of Fukui; Kyoto University; Kyoto Institute of Technology	Konno, T (corresponding author), Univ Fukui, Fac Med Sci, Dept Physiol & Mol Biophys, Fukui 9101193, Japan.	konno@fmsrsa.fukui-med.ac.jp	Morii, Takashi/AAL-1392-2020	Morii, Takashi/0000-0003-3663-3267				ABOUMAHMOUD R, 1990, J DAIRY SCI, V73, P256, DOI 10.3168/jds.S0022-0302(90)78668-7; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Ellis RJ, 1999, CURR BIOL, V9, pR137; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; IKURA K, 1985, AGR BIOL CHEM TOKYO, V49, P3527, DOI 10.1080/00021369.1985.10867289; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Konno T, 2005, BIOCHEMISTRY-US, V44, P2072, DOI 10.1021/bi047722d; Kulkarni AM, 2003, FARADAY DISCUSS, V123, P37, DOI 10.1039/b204453f; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai TS, 2004, J NEUROCHEM, V88, P1253, DOI 10.1046/j.1471-4159.2003.02249.x; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Matsumura Y, 1996, BBA-PROTEIN STRUCT M, V1292, P69, DOI 10.1016/0167-4838(95)00197-2; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; PEDERSEN JS, 1994, EUR BIOPHYS J BIOPHY, V22, P379, DOI 10.1007/BF00180159; Piazza R, 2000, CURR OPIN COLLOID IN, V5, P38, DOI 10.1016/S1359-0294(00)00034-0; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Roos-Mattjus P, 2004, ANN MED, V36, P285, DOI 10.1080/07853890310016324; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2002, NEUROCHEM INT, V40, P13, DOI 10.1016/S0197-0186(01)00057-2; Stradner A, 2004, NATURE, V432, P492, DOI 10.1038/nature03109; Zainelli GM, 2003, J NEUROPATH EXP NEUR, V62, P14, DOI 10.1093/jnen/62.1.14; Zemaitaitis MO, 2000, J NEUROPATH EXP NEUR, V59, P983, DOI 10.1093/jnen/59.11.983	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17520	17525		10.1074/jbc.M413988200	http://dx.doi.org/10.1074/jbc.M413988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15731111	hybrid			2022-12-27	WOS:000228615500120
J	Abbott, DW; Chadwick, BP; Thambirajah, AA; Ausio, J				Abbott, DW; Chadwick, BP; Thambirajah, AA; Ausio, J			Beyond the Xi - MacroH2A chromatin distribution and post-translational modification in an avian system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; HISTONE H2A VARIANTS; CRYSTAL-STRUCTURE; BARR BODY; CHROMOSOME; PROTEIN; STABILITY; RECRUITMENT; REGION; DOMAIN	MacroH2A (mH2A) is a histone variant that is enriched in the inactivated X-chromosomes of mammalian females. To characterize the role of this protein in other nuclear processes we isolated chromatin particles from chicken liver, a vertebrate system that does not undergo X-inactivation. Chromatin digestion and fractionation studies determined that mH2A is evenly distributed at several levels of chromatin structure and stabilizes the nucleosome core particle in solution. However, at the level of the chromatosome, selective salt precipitation showed the existence of a mutually exclusive relationship between mH2A and H1, which may reveal functional redundancy between these proteins. Two-dimensional gel electrophoresis demonstrated the presence of one major population of mH2A containing nucleosomes, which may become ADP-ribosylated. This report provides new clues into how mH2A distribution and a previously unidentified post-translational modification may help regulate the repression of autosomal chromatin.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA	University of Victoria; Duke University	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca		Chadwick, Brian/0000-0001-5272-8384; Abbott, Wade/0000-0003-4893-5799				Abbott DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i; Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Ausio J, 2002, BIOCHEMISTRY-US, V41, P5945, DOI 10.1021/bi020059d; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Ausio J, 2001, BIOCHEM CELL BIOL, V79, P693, DOI 10.1139/bcb-79-6-693; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; AUSIO J, 2004, CHROMATIN STRUCTURE, P241; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; BLUE ML, 1982, J BIOL CHEM, V257, P1151; CERVANTESLAUREAN D, 1995, J BIOL CHEM, V270, P7929, DOI 10.1074/jbc.270.14.7929; Chadwick BP, 2003, HUM MOL GENET, V12, P2167, DOI 10.1093/hmg/ddg229; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Chadwick BP, 2001, J CELL BIOL, V152, P375, DOI 10.1083/jcb.152.2.375; Changolkar LN, 2002, BIOCHEMISTRY-US, V41, P179, DOI 10.1021/bi0157417; Costanzi C, 2000, DEVELOPMENT, V127, P2283; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; EICKBUSH TH, 1988, J BIOL CHEM, V263, P18972; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; Gautier T, 2004, EMBO REP, V5, P715, DOI 10.1038/sj.embor.7400182; GOLDERER G, 1991, BIOCHEM J, V277, P607, DOI 10.1042/bj2770607; GOMEZCUADRADO A, 1992, EMBO J, V11, P1857, DOI 10.1002/j.1460-2075.1992.tb05237.x; Hoyer-Fender S, 2000, EXP CELL RES, V258, P254, DOI 10.1006/excr.2000.4951; JASON LJ, 2004, J BIOL CHEM; Kuroiwa A, 2002, CYTOGENET GENOME RES, V99, P310, DOI 10.1159/000071609; Ladurner AG, 2003, MOL CELL, V12, P1, DOI 10.1016/S1097-2765(03)00284-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mermoud JE, 1999, J CELL BIOL, V147, P1399, DOI 10.1083/jcb.147.7.1399; NEELIN JM, 1964, CAN J BIOCHEM PHYS, V42, P1743, DOI 10.1139/o64-185; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; Rasmussen TP, 1999, NUCLEIC ACIDS RES, V27, P3685, DOI 10.1093/nar/27.18.3685; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richler C, 2000, CYTOGENET CELL GENET, V89, P118, DOI 10.1159/000015589; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Siino JS, 2002, FEBS LETT, V527, P105, DOI 10.1016/S0014-5793(02)03176-9; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Turner JMA, 2001, J CELL SCI, V114, P3367; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang XY, 2001, J EXP ZOOL, V290, P431, DOI 10.1002/jez.1085; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; YAGER TD, 1984, J BIOL CHEM, V259, P4212	57	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16437	16445		10.1074/jbc.M500170200	http://dx.doi.org/10.1074/jbc.M500170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15718235	hybrid			2022-12-27	WOS:000228444800117
J	Liu, JY; Lou, Y; Yokota, H; Adams, PD; Kim, R; Kim, SH				Liu, JY; Lou, Y; Yokota, H; Adams, PD; Kim, R; Kim, SH			Crystal structure of a PhoU protein homologue - A new class of metalloprotein containing multinuclear iron clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT; ESCHERICHIA-COLI; H-CHAINS; FERRITIN; ALIGNMENT; SOFTWARE; SEQUENCE; SYSTEMS; ROLES	PhoU proteins are known to play a role in the regulation of phosphate uptake. In Thermotoga maritima, two PhoU homologues have been identified bioinformatically. Here we report the crystal structure of one of the PhoU homologues at 2.0 angstrom resolution. The structure of the PhoU protein homologue contains a highly symmetric new structural fold composed of two repeats of a three-helix bundle. The structure unexpectedly revealed a trinuclear and a tetranuclear iron cluster that were found to be bound on the surface. Each of the two multinuclear iron clusters is coordinated by a conserved E(D) XXXD motif pair. Our structure reveals a new class of metalloprotein containing multinuclear iron clusters. The possible functional implication based on the structure are discussed.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA.	SHKim@cchem.berkeley.edu	Adams, Paul David/A-1977-2013	Adams, Paul David/0000-0001-9333-8219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Alexeev D, 2003, NAT STRUCT BIOL, V10, P297, DOI 10.1038/nsb903; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Hogbom M, 2004, FEBS LETT, V567, P179, DOI 10.1016/j.febslet.2004.04.068; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAO NN, 1990, MOL MICROBIOL, V4, P1083, DOI 10.1111/j.1365-2958.1990.tb00682.x; ROSENBERG H, 1977, J BACTERIOL, V131, P505, DOI 10.1128/JB.131.2.505-511.1977; Santambrogio P, 1996, BIOCHEM J, V314, P139, DOI 10.1042/bj3140139; STEED PM, 1993, J BACTERIOL, V175, P6797, DOI 10.1128/jb.175.21.6797-6809.1993; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; SURIN BP, 1986, J BACTERIOL, V168, P631, DOI 10.1128/jb.168.2.631-635.1986; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; Zeth K, 2004, P NATL ACAD SCI USA, V101, P13780, DOI 10.1073/pnas.0401821101; Zhu HZ, 2003, BIOCHEM J, V376, P35, DOI 10.1042/BJ20031283	27	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15960	15966		10.1074/jbc.M414117200	http://dx.doi.org/10.1074/jbc.M414117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15716271	hybrid			2022-12-27	WOS:000228444800062
J	Mariappan, M; Preusser-Kunze, A; Balleininger, M; Eiselt, N; Schmidt, B; Gande, SL; Wenzel, D; Dierks, T; von Figura, K				Mariappan, M; Preusser-Kunze, A; Balleininger, M; Eiselt, N; Schmidt, B; Gande, SL; Wenzel, D; Dierks, T; von Figura, K			Expression, localization, structural, and functional characterization of pFGE, the paralog of the C alpha-formylglycine-generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; PROTEIN MODIFICATION; HUMAN ARYLSULFATASE; CRYSTAL-STRUCTURE; CYSTEINE; GENE; GLYCOSYLATION; CONVERSION; MUTATIONS; MECHANISM	pFGE is the paralog of the formylglycine-generating enzyme (FGE), which catalyzes the oxidation of a specific cysteine to C alpha-formylglycine, the catalytic residue in the active site of sulfatases. The enzymatic activity of sulfatases depends on this posttranslational modification, and the genetic defect of FGE causes multiple sulfatase deficiency. The structural and functional properties of pFGE were analyzed. The comparison with FGE demonstrates that both share a tissue-specific expression pattern and the localization in the lumen of the endoplasmic reticulum. Both are retained in the endoplasmic reticulum by a saturable mechanism. Limited proteolytic cleavage at similar sites indicates that both also share a similar three-dimensional structure. pFGE, however, is lacking the formylglycine-generating activity of FGE. Although overexpression of FGE stimulates the generation of catalytically active sulfatases, overexpression of pFGE has an inhibitory effect. In vitro pFGE interacts with sulfatase-derived peptides but not with FGE. The inhibitory effect of pFGE on the generation of active sulfatases may therefore be caused by a competition of pFGE and FGE for newly synthesized sulfatase polypeptides.	Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Neurobiol, D-37077 Gottingen, Germany	University of Gottingen; Max Planck Society	von Figura, K (corresponding author), Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	kfigura@gwdg.de	Dierks, Thomas/A-3596-2012; mariappan, malaiyalam/K-9024-2012	Dierks, Thomas/0000-0001-6426-1339; 				Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Cosma MP, 2004, HUM MUTAT, V23, P576, DOI 10.1002/humu.20040; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dickmanns A, 2005, J BIOL CHEM, V280, P15180, DOI 10.1074/jbc.M414317200; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GLOSSL J, 1978, CLIN CHIM ACTA, V88, P111, DOI 10.1016/0009-8981(78)90157-2; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; ROMMERSKIRCH W, 1992, P NATL ACAD SCI USA, V89, P2561, DOI 10.1073/pnas.89.7.2561; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; STEIN C, 1989, J BIOL CHEM, V264, P13865; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; VONFIGURA K, 2004, LYSOSOMAL DISORDERS, P131	24	23	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					15173	15179		10.1074/jbc.M413698200	http://dx.doi.org/10.1074/jbc.M413698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15708861	hybrid			2022-12-27	WOS:000228236800101
J	Winfield, MD; Latifi, T; Groisman, EA				Winfield, MD; Latifi, T; Groisman, EA			Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMYXIN-RESISTANT MUTANTS; CATIONIC ANTIMICROBIAL PEPTIDES; ENTERICA SEROVAR TYPHIMURIUM; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; SYSTEM PHOP-PHOQ; SALMONELLA-TYPHIMURIUM; LIPID-A; 2-COMPONENT SYSTEM; RESPONSE REGULATOR	Inducible membrane remodeling is an adaptive mechanism that enables Gram-negative bacteria to resist killing by cationic antimicrobial peptides and to avoid eliciting an immune response. Addition of 4-amino-4-deoxy-L-arabinose (4-aminoarabinose) moieties to the phosphate residues of the lipid A portion of the lipopolysaccharide decreases the net negative charge of the bacterial membrane resulting in protection from the cationic antimicrobial peptide polymyxin B. In Salmonella enterica serovar Typhimurium, the PmrA/PmrB two-component regulatory system governs resistance to polymyxin B by controlling transcription of the 4-aminoarabinose biosynthetic genes. Transcription of PmrA-activated genes is induced by Fe3+, which is sensed by PmrA cognate sensor PmrB, and by low Mg2+, in a mechanism that requires not only the PmrA and PmrB proteins but also the Mg2+-responding PhoP/PhoQ system and the PhoP-activated PmrD protein, a post-translational activator of the PmrA protein. Surprisingly, Yersinia pestis can promote PhoP-dependent modification of its lipid A with 4-aminoarabinose despite lacking a PmrD protein. Here we report that Yersinia uses different promoters to transcribe the 4-aminoarabinose biosynthetic genes pbgP and ugd depending on the inducing signal. This is accomplished by the presence of distinct binding sites for the PmrA and PhoP proteins in the promoters of the pbgP and ugd genes. Our results demonstrate that closely related bacterial species may use disparate regulatory pathways to control genes encoding conserved proteins.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu						Aguirre A, 2000, J BACTERIOL, V182, P3874, DOI 10.1128/JB.182.13.3874-3876.2000; Bengoechea JA, 1998, MICROBIOL-UK, V144, P1509, DOI 10.1099/00221287-144-6-1509; BOLL M, 1994, FEMS IMMUNOL MED MIC, V8, P329; BRADE H, 1999, ENDOTOXIN HLTH DIS, P31; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Brubaker RR, 2004, MICROB ECOL, V47, P293, DOI 10.1007/s00248-003-1022-y; Chamnongpol S, 2000, J MOL BIOL, V300, P291, DOI 10.1006/jmbi.2000.3848; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Deng W, 2002, J BACTERIOL, V184, P4601, DOI 10.1128/JB.184.16.4601-4611.2002; Derzelle S, 2004, J BACTERIOL, V186, P1270, DOI 10.1128/JB.186.5.1270-1279.2004; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Gibbons HS, 2005, MOL MICROBIOL, V55, P425, DOI 10.1111/j.1365-2958.2004.04409.x; GILLELAND HE, 1982, CAN J MICROBIOL, V28, P830, DOI 10.1139/m82-125; Grabenstein JP, 2004, INFECT IMMUN, V72, P4973, DOI 10.1128/IAI.72.9.4973-4984.2004; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; Hitchen PG, 2002, MOL MICROBIOL, V44, P1637, DOI 10.1046/j.1365-2958.2002.02990.x; HOLT JG, 1994, BERGEYS MANUAL DETER, P189; Kato A, 2004, GENE DEV, V18, P2302, DOI 10.1101/gad.1230804; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; Kato A, 2003, P NATL ACAD SCI USA, V100, P4706, DOI 10.1073/pnas.0836837100; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; Lejona S, 2003, J BACTERIOL, V185, P6287, DOI 10.1128/JB.185.21.6287-6294.2003; Marchal K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r9; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; McCue LA, 2002, GENOME RES, V12, P1523, DOI 10.1101/gr.323602; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Oyston PCF, 2000, INFECT IMMUN, V68, P3419, DOI 10.1128/IAI.68.6.3419-3425.2000; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; PERRY RD, 1979, J BACTERIOL, V137, P1290, DOI 10.1128/JB.137.3.1290-1298.1979; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Porwollik S, 2002, P NATL ACAD SCI USA, V99, P8956, DOI 10.1073/pnas.122153699; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rebeil R, 2004, MOL MICROBIOL, V52, P1363, DOI 10.1111/j.1365-2958.2004.04059.x; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shin D, 2005, J BIOL CHEM, V280, P4089, DOI 10.1074/jbc.M412741200; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; STAGGS TM, 1991, J BACTERIOL, V173, P417, DOI 10.1128/jb.173.2.417-425.1991; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; VAARA M, 1979, J BACTERIOL, V139, P664, DOI 10.1128/JB.139.2.664-667.1979; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; Winfield MD, 2004, P NATL ACAD SCI USA, V101, P17162, DOI 10.1073/pnas.0406038101; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; Yamamoto K, 2002, MOL MICROBIOL, V45, P423, DOI 10.1046/j.1365-2958.2002.03017.x; Zhou DS, 2004, J BACTERIOL, V186, P5138, DOI [10.1128/JB.186.15.5138-5146.2004, 10.1128/jb.186.15.5138-5146.2004]; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	64	80	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14765	14772		10.1074/jbc.M413900200	http://dx.doi.org/10.1074/jbc.M413900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15710615	hybrid			2022-12-27	WOS:000228236800053
J	Coffey, JC; Wang, JH; Smith, MJF; Laing, A; Bouchier-Hayes, D; Cotter, TG; Redmond, HP				Coffey, JC; Wang, JH; Smith, MJF; Laing, A; Bouchier-Hayes, D; Cotter, TG; Redmond, HP			Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATION; IN-VITRO; CANCER; SURGERY; CELLS; ANGIOGENESIS; ANGIOSTATIN; LAPAROSCOPY; LAPAROTOMY; CARCINOMA	Tumor removal remains the principal treatment modality in the management of solid tumors. The process of tumor removal may potentiate the resurgent growth of residual neoplastic tissue. Herein, we describe a novel murine model in which flank tumor cytoreduction is followed by accelerated local tumor recurrence. This model held for primary and recurrent tumors generated using a panel of human and murine (LS174T, DU145, SW480, SW640, and 3LL) cell lines and replicated accelerated tumor growth following excisional surgery. In investigating this further, epithelial cells were purified from LS174T primary and corresponding recurrent tumors for comparison. Baseline as well as tumor necrosis factor apoptosis-inducing ligand ( TRAIL)-induced apoptosis were significantly reduced in recurrent tumor epithelia. Primary and recurrent tumor gene expression profiles were then compared. This identified an increase and reduction in the expression of p110g and p85a class Ia phosphoinositide 3-kinase (PI3K) subunits in recurrent tumor epithelia. These changes were further confirmed at the protein level. The targeting of PI3K ex vivo, using LY294002, restored sensitivity to TRAIL in recurrent tumor epithelia. In vivo, adjuvant LY294002 prolonged survival and significantly attenuated recurrent tumor growth by greatly enhancing apoptosis levels. Hence, PI3K plays a role in generating the antiapoptotic and chemoresistant phenotype associated with accelerated local tumor recurrence.	Cork Univ Hosp, Dept Surg, Cork, Munster, Ireland; Cork Univ Hosp, Dept Tumor Biol, Cork, Munster, Ireland; Cork Univ Hosp, Dept Biochem, Cork, Munster, Ireland; Beaumont Hosp, Dept Surg, Dublin 9, Ireland; Royal Coll Surgeons Ireland, Dublin 2, Ireland	University College Cork; University College Cork; University College Cork; Royal College of Surgeons - Ireland	Coffey, JC (corresponding author), Cork Univ Hosp, Dept Surg, Cork, Munster, Ireland.	calvincoffey@hotmail.com	Smith, Myles JF/B-7803-2009	Smith, Myles JF/0000-0002-3254-4817; Cotter, Thomas/0000-0003-4626-5613				Abramovitch R, 1999, BRIT J CANCER, V79, P1392, DOI 10.1038/sj.bjc.6690223; Baum M, 1999, EUR J CANCER, V35, P886, DOI 10.1016/S0959-8049(99)00067-2; BAUM M, 1994, DOES SURG INFLUENCE; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffey JC, 2003, LANCET ONCOL, V4, P760, DOI 10.1016/S1470-2045(03)01282-8; Coffey JC, 2002, ANN SURG ONCOL, V9, pS37; Coffey JC, 2001, J SURG RES, V98, P27, DOI 10.1006/jsre.2001.6129; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Da Costa ML, 1998, BRIT J SURG, V85, P1439; Da Costa ML, 1998, SURGERY, V124, P516, DOI 10.1067/msy.1998.89410; Da Costa ML, 2001, J SURG RES, V101, P111, DOI 10.1006/jsre.2001.6250; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969; Demicheli R, 2000, J NATL CANCER I, V92, P347, DOI 10.1093/jnci/92.4.347; Ellis Harold, 2001, HIST SURG; GIAVAZZI R, 1986, CANCER RES, V46, P1928; Hofer SOP, 1998, ARCH SURG-CHICAGO, V133, P383, DOI 10.1001/archsurg.133.4.383; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOSKINS WJ, 1989, BAILLIERE CLIN OB GY, V3, P59, DOI 10.1016/S0950-3552(89)80042-2; Hu LM, 2002, CANCER RES, V62, P1087; Hu LM, 2000, CLIN CANCER RES, V6, P880; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kandasamy K, 2002, CANCER RES, V62, P4929; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; LANGE PH, 1980, CANCER-AM CANCER SOC, V45, P1498, DOI 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7; Lee SW, 2000, SURG ENDOSC, V14, P490, DOI 10.1007/s004640020061; LEE YTN, 1977, J SURG ONCOL, V9, P425, DOI 10.1002/jso.2930090503; Li TS, 2001, EUR J CANCER, V37, P2283, DOI 10.1016/S0959-8049(01)00281-7; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; MOORE GE, 1980, SURG GYNECOL OBSTET, V150, P395; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patel H, 2002, ANN SURG, V235, P226, DOI 10.1097/00000658-200202000-00010; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Pidgeon GP, 2001, BRIT J CANCER, V85, P273, DOI 10.1054/bjoc.2001.1876; Qadri SSA, 2005, ANN THORAC SURG, V79, P990, DOI 10.1016/j.athoracsur.2004.07.042; ROUSSEAU DL, 2003, MD ANDERSON SURG ONC, V1, P215; Spigel DR, 2003, LANCET, V362, P502, DOI 10.1016/S0140-6736(03)14147-5; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Tyzzer EE, 1913, J MED RES, V28, P309; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang JH, 2003, J IMMUNOL, V170, P795, DOI 10.4049/jimmunol.170.2.795; Weaver SA, 2001, TRENDS MOL MED, V7, P455, DOI 10.1016/S1471-4914(01)02107-4; WONG RJ, 1990, SURG GYNECOL OBSTET, V170, P276; Zhang B, 2003, CLIN CANCER RES, V9, P3073; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	53	31	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20968	20977		10.1074/jbc.M414696200	http://dx.doi.org/10.1074/jbc.M414696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15741161	hybrid			2022-12-27	WOS:000229438800010
J	Liu, HY; MacDonald, JIS; Hryciw, T; Li, CH; Meakin, SO				Liu, HY; MacDonald, JIS; Hryciw, T; Li, CH; Meakin, SO			Human tumorous imaginal disc 1 (TID1) associates with Trk receptor tyrosine kinases and regulates neurite outgrowth in nnr5-TrkA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATION LOOP TYROSINES; HUMAN DNAJ PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; ACIDIC SUBSTITUTION; NEUROTROPHIC FACTOR; HUMAN HOMOLOG; RAT TRKA; DROSOPHILA	The human tumorous imaginal disc 1 (TID1) proteins including TID1(L) and TID1(S), members of the DnaJ domain protein family, are involved in multiple intracellular signaling pathways such as apoptosis induction, cell proliferation, and survival. Here we report that TID1 associates with the Trk receptor tyrosine kinases and regulates nerve growth factor (NGF)-induced neurite outgrowth in PC12-derived nnr5 cells. Binding assays and transfection studies showed that the carboxyl-terminal end of TID1 (residues 224-429) bound to Trk at the activation loop (Tyr(P)(683)-Tyr(684)(P) 684 in rat TrkA) and that TID1 was tyrosine phosphorylated by Trk both in yeast and in transfected cells. Moreover endogenous TID1 was also tyrosine phosphorylated by and co-immunoprecipitated with Trk in neurotrophin-stimulated primary rat hippocampal neurons. Overexpression studies showed that both TID1L and TID1S significantly facilitated NGF-induced neurite outgrowth in TrkA-expressing nnr5 cells possibly through a mechanism involving increased activation of mitogen-activated protein kinase. Consistently knockdown of endogenous TID1, mediated with specific short hairpin RNA, significantly reduced NGF-induced neurite growth in nnr5-TrkA cells. These data provide the first evidence that TID1 is a novel intracellular adaptor that interacts with the Trk receptor tyrosine kinases in an activity-dependent manner to facilitate Trk-dependent intracellular signaling.	John P Robarts Res Inst, Cell Biol Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Cell Biol Grp, POB 5015, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; BERG MM, 1992, J BIOL CHEM, V267, P13; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; GOSILIN K, 1998, CULTURING NERVE CELL, V386, P339; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Gryz EA, 2003, ONCOGENE, V22, P8774, DOI 10.1038/sj.onc.1206890; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; MacDonald JIS, 2004, J CELL BIOL, V164, P851, DOI 10.1083/jcb.200309081; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 2000, REC RES DEV NEUROCH, V3, P75; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Muragaki Y, 1997, J NEUROSCI, V17, P530; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OTTEN U, 1980, NATURE, V287, P158, DOI 10.1038/287158a0; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Robinson KN, 2005, J BIOL CHEM, V280, P225, DOI 10.1074/jbc.M410454200; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TAPLEY P, 1992, ONCOGENE, V7, P371; Tarunina M, 2004, MOL CELL BIOL, V24, P10792, DOI 10.1128/MCB.24.24.10792-10801.2004; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X	59	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19461	19471		10.1074/jbc.M500313200	http://dx.doi.org/10.1074/jbc.M500313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15753086	hybrid			2022-12-27	WOS:000229113700007
J	Hu, JJ; Hubbard, SR				Hu, JJ; Hubbard, SR			Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN BINDING; C-CBL; TYROSINE PHOSPHORYLATION; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; INSULIN-RECEPTOR; KINASE; ACTIVATION; SITE; CAP	The Cbl adapter proteins typically function to down-regulate activated protein tyrosine kinases and other signaling proteins by coupling them to the ubiquitination machinery for degradation by the proteasome. Cbl proteins bind to specific tyrosine-phosphorylated sequences in target proteins via the tyrosine kinase-binding (TKB) domain, which comprises a four-helix bundle, an EF-hand calcium-binding domain, and a non-conventional Src homology-2 domain. The previously derived consensus sequence for phosphotyrosine recognition by the Cbl TKB domain is NXpY(S/T)XXP (X denotes lesser residue preference), wherein specificity is conferred primarily by residues C-terminal to the phosphotyrosine. Cbl is recruited to and phosphorylated by the insulin receptor in adipose cells through the adapter protein APS. APS is phosphorylated by the insulin receptor on a C-terminal tyrosine residue, which then serves as a binding site for the Cbl TKB domain. Using x-ray crystallography, site-directed mutagenesis, and calorimetric studies, we have characterized the interaction between the Cbl TKB domain and the Cbl recruitment site in APS, which contains a sequence motif, RA(V/I)XNQpY(S/T), that is conserved in the related adapter proteins SH2-B and Lnk. These studies reveal a novel mode of phosphopeptide interaction with the Cbl TKB domain, in which N-terminal residues distal to the phosphotyrosine directly contact residues of the four-helix bundle of the TKB domain.	NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Hubbard, SR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Struct Biol Program, New York, NY 10016 USA.	hubbard@saturn.med.nyu.edu	Hu, Junjie/F-9713-2013	Hubbard, Stevan/0000-0002-2707-9383				Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Betancourt MR, 2004, J MOL BIOL, V342, P635, DOI 10.1016/j.jmb.2004.06.091; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi S, 2004, FASEB J, V18, P929, DOI 10.1096/fj.03-0767fje; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohrt T, 2004, CELL SIGNAL, V16, P1291, DOI 10.1016/j.cellsig.2004.03.017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; SANJAY A, 2001, SCI STKE, pPE40; Standaert ML, 2004, BIOCHEMISTRY-US, V43, P15494, DOI 10.1021/bi049222q; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019	37	59	60	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18943	18949		10.1074/jbc.M414157200	http://dx.doi.org/10.1074/jbc.M414157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15737992	hybrid			2022-12-27	WOS:000228932300047
J	Auperin, TC; Bolduc, GR; Baron, MJ; Heroux, A; Filman, DJ; Madoff, LC; Hogle, JM				Auperin, TC; Bolduc, GR; Baron, MJ; Heroux, A; Filman, DJ; Madoff, LC; Hogle, JM			Crystal structure of the n-terminal domain of the group B Streptococcus alpha C protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOTUBERCULOSIS INVASIN PROTEIN; HETERODIMERIC DISINTEGRIN; INTEGRIN ALPHA(5)BETA(1); ANTIGEN GENE; BINDING; HEPARIN; IDENTIFICATION; FIBRONECTIN; ADHERENCE; DISEASE	Group B Streptococcus (GBS) is the leading cause of bacterial pneumonia, sepsis, and meningitis among neonates and an important cause of morbidity among pregnant women and immunocompromised adults. Invasive diseases due to GBS are attributed to the ability of the pathogen to translocate across human epithelial surfaces. The alpha C protein (ACP) has been identified as an invasin that plays a role in internalization and translocation of GBS across epithelial cells. The soluble N-terminal domain of ACP (NtACP) blocks the internalization of GBS. We determined the 1.86-angstrom resolution crystal structure of NtACP comprising residues Ser(52) through Leu(225) of the full-length ACP. NtACP has two domains, an N-terminal beta-sandwich and a C-terminal three-helix bundle. Structural and topological alignments reveal that the beta-sandwich shares structural elements with the type III fibronectin fold (FnIII), but includes structural elaborations that make it unique. We have identified a potential integrin-binding motif consisting of Lys-Thr-Asp(146), Arg(110), and Asp(118). A similar arrangement of charged residues has been described in other invasins. ACP shows a heparin binding activity that requires NtACP. We propose a possible heparin-binding site, including one surface of the three-helix bundle, and nearby portions of the sandwich and repeat domains. We have validated this prediction using assays of the heparin binding and cell-adhesion properties of engineered fragments of ACP. This is the first crystal structure of a member of the highly conserved Gram-positive surface alpha-like protein family, and it will enable the internalization mechanism of GBS to be dissected at the atomic level.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; United States Department of Energy (DOE); Brookhaven National Laboratory	Hogle, JM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	jhogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI038424, R01AI038424, R21AI038424] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38424] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; Baron MJ, 2004, J BIOL CHEM, V279, P24714, DOI 10.1074/jbc.M402164200; Bisig D, 1999, ACTA CRYSTALLOGR D, V55, P1069, DOI 10.1107/S090744499900284X; Bliss SJ, 2002, CLIN INFECT DIS, V34, P184, DOI 10.1086/338258; Bolduc GR, 2002, CELL MICROBIOL, V4, P751, DOI 10.1046/j.1462-5822.2002.00227.x; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BULGAKOVA TN, 1986, FOLIA MICROBIOL, V31, P394, DOI 10.1007/BF02936605; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P473; Creti R, 2004, J CLIN MICROBIOL, V42, P1326, DOI 10.1128/JCM.42.3.1326-1329.2004; Dahl Mats S., 2003, International Journal of Infectious Diseases, V7, P113, DOI 10.1016/S1201-9712(03)90006-3; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; Freissler E, 2000, CELL MICROBIOL, V2, P69, DOI 10.1046/j.1462-5822.2000.00036.x; Gravekamp C, 1998, INFECT IMMUN, V66, P4347; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Gravekamp C, 1997, INFECT IMMUN, V65, P5216, DOI 10.1128/IAI.65.12.5216-5221.1997; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HULSE ML, 1993, INFECT IMMUN, V61, P4835, DOI 10.1128/IAI.61.11.4835-4841.1993; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kling DE, 1997, INFECT IMMUN, V65, P1462, DOI 10.1128/IAI.65.4.1462-1467.1997; Lachenauer CS, 2000, P NATL ACAD SCI USA, V97, P9630, DOI 10.1073/pnas.97.17.9630; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; Li J, 1997, P NATL ACAD SCI USA, V94, P13251, DOI 10.1073/pnas.94.24.13251; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Monleon D, 2003, J BIOL CHEM, V278, P45570, DOI 10.1074/jbc.M307030200; Moreno-Murciano MP, 2003, PROTEIN SCI, V12, P366, DOI 10.1110/ps.0230203; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; RUBENS CE, 1992, INFECT IMMUN, V60, P5157, DOI 10.1128/IAI.60.12.5157-5163.1992; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Shankar N, 2001, INFECT IMMUN, V69, P4366, DOI 10.1128/IAI.69.7.4366-4372.2001; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shimazaki K, 1998, J DAIRY SCI, V81, P2841, DOI 10.3168/jds.S0022-0302(98)75843-6; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Stalhammar-Carlemalm M, 1999, MOL MICROBIOL, V33, P208, DOI 10.1046/j.1365-2958.1999.01470.x; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; TAMURA GS, 1994, INFECT IMMUN, V62, P2450, DOI 10.1128/IAI.62.6.2450-2458.1994; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyrrell GJ, 2000, J INFECT DIS, V182, P168, DOI 10.1086/315699; ValentinWeigand P, 1997, FEMS MICROBIOL LETT, V147, P69, DOI 10.1016/S0378-1097(96)00506-X; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wastfelt M, 1996, J BIOL CHEM, V271, P18892, DOI 10.1074/jbc.271.31.18892; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; ZAWANEH SM, 1979, INFECT IMMUN, V26, P441, DOI 10.1128/IAI.26.2.441-447.1979	71	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18245	18252		10.1074/jbc.M412391200	http://dx.doi.org/10.1074/jbc.M412391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15753100	hybrid			2022-12-27	WOS:000228807200083
J	Eyster, CA; Duggins, QS; Olson, AL				Eyster, CA; Duggins, QS; Olson, AL			Expression of constitutively active Akt/protein kinase B signals GLUT4 translocation in the absence of an intact actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; CELL-SURFACE; SUBCELLULAR TRAFFICKING; INSULIN INCREASES; SKELETAL-MUSCLE; STIMULATION; ENDOCYTOSIS	The actin cytoskeleton has been shown to be required for insulin-dependent GLUT4 translocation; however, the role that the actin network plays is unknown. Actin may play a role in formation of an active signaling complex, or actin may be required for movement of vesicles to the plasma membrane surface. To distinguish between these possibilities, we examined the ability of myr-Akt, a constitutively active form of Akt that signals GLUT4 translocation to the plasma membrane in the absence of insulin, to signal translocation of an HA-GLUT4-GFP reporter protein in the presence or absence of an intact cytoskeleton in 3T3-L1 adipocytes. Expression of myr-Akt signaled the redistribution of the GLUT4 reporter protein to the cell surface in the absence or presence of 10 mu M latrunculin B, a concentration sufficient to completely inhibit insulin-dependent redistribution of the GLUT4 reporter to the cell surface. These data suggest that the actin network plays a primary role in organization of the insulin-signaling complex. To further support this conclusion, we measured the activation of known signaling proteins using a saturating concentration of insulin in cells pretreated without or with 10 mu M latrunculin B. We found that latrunculin treatment did not affect insulin-dependent tyrosine phosphorylation of the insulin receptor beta-subunit and IRS-1 but completely inhibited activation of Akt/PKB enzymatic activity. Phosphorylation of Akt/ PKB at Ser-473 and Thr-308 was inhibited by latrunculin B treatment, indicating that the defect in signaling lies prior to Akt/ PKB activation. In summary, our data support the hypothesis that the actin network plays a role in organization of the insulin-signaling complex but is not required for vesicle trafficking and/or fusion.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 26901,Rm 853-BMSB, Oklahoma City, OK 73190 USA.	ann-olson@ouhsc.edu			NIDDK NIH HHS [DK68438, DK62341, R01 DK068438] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068438, R01DK062341] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Hresko RC, 2003, J BIOL CHEM, V278, P21615, DOI 10.1074/jbc.M302937200; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Khayat ZA, 2000, J CELL SCI, V113, P279; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lampson MA, 2000, J CELL SCI, V113, P4065; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; YANG J, 1993, J BIOL CHEM, V268, P4600; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	57	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17978	17985		10.1074/jbc.M409806200	http://dx.doi.org/10.1074/jbc.M409806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15738003	hybrid			2022-12-27	WOS:000228807200052
J	Merlino, A; Mazzarella, L; Carannante, A; Di Fiore, A; Di Donato, A; Notomista, E; Sica, F				Merlino, A; Mazzarella, L; Carannante, A; Di Fiore, A; Di Donato, A; Notomista, E; Sica, F			The importance of dynamic effects on the enzyme activity - X-ray structure and molecular dynamics of onconase mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; NMR RELAXATION MEASUREMENTS; N-15 RESONANCE ASSIGNMENTS; TERMINAL SWAPPED DIMER; PANCREATIC RIBONUCLEASE; CRYSTAL-STRUCTURE; CYTOTOXIC RIBONUCLEASE; ANTITUMOR-ACTIVITY; DOMAIN MOTIONS; N-TERMINUS	Onconase ( ONC), a member of the RNase A superfamily extracted from oocytes of Rana pipiens, is an effective cancer killer. It is currently used in treatment of various forms of cancer. ONC antitumor properties depend on its ribonucleolytic activity that is low in comparison with other members of the superfamily. The most damaging side effect from Onconase treatment is renal toxicity, which seems to be caused by the unusual stability of the enzyme. Therefore, mutants with reduced thermal stability and/or increased catalytic activity may have significant implications for human cancer chemotherapy. In this context, we have determined the crystal structures of two Onconase mutants (M23L-ONC and C87S, des103-104-ONC) and performed molecular dynamic simulations of ONC and C87S, des103-104-ONC with the aim of explaining on structural grounds the modifications of the activity and thermal stability of the mutants. The results also provide the molecular bases to explain the lower catalytic activity of Onconase compared with RNase A and the unusually high thermal stability of the amphibian enzyme.	Univ Naples Federico II, Complesso Univ Monte SantAngelo, Dipartimento Chim, I-80126 Naples, Italy; Complesso Ristrutturato S Andrea delle Dame, Ctr Reg Competenza Bioteknet, I-80138 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy; Univ Naples Federico II, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Naples Federico II	Sica, F (corresponding author), Univ Naples Federico II, Complesso Univ Monte SantAngelo, Dipartimento Chim, Via Cynthia, I-80126 Naples, Italy.	filomena.sica@unina.it	Di Fiore, Anna/AAW-3780-2020; Di Donato, Alberto/G-5494-2012; Merlino, Antonello/AAI-2114-2020; Di Fiore, Anna/AAX-5655-2020	Di Fiore, Anna/0000-0003-2924-5194; NOTOMISTA, Eugenio/0000-0003-0097-6487; Merlino, Antonello/0000-0002-1045-7720; DI DONATO, Alberto/0000-0001-9129-9850				ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berisio R, 1999, J MOL BIOL, V292, P845, DOI 10.1006/jmbi.1999.3093; Berisio R, 2002, ACTA CRYSTALLOGR D, V58, P441, DOI 10.1107/S0907444901021758; Berman HM, 2000, NAT STRUCT BIOL, V7, P957, DOI 10.1038/80734; Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BORKAKOTI N, 1983, J MOL BIOL, V169, P743, DOI 10.1016/S0022-2836(83)80168-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceruso MA, 1999, PROTEIN SCI, V8, P147; Chatani E, 2002, PROTEIN SCI, V11, P72, DOI 10.1101/ps.31102; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; Daggett V, 2002, ACCOUNTS CHEM RES, V35, P422, DOI 10.1021/ar0100834; Day R, 2003, ADV PROTEIN CHEM, V66, P373; de Bakker PIW, 1999, J MOL BIOL, V285, P1811, DOI 10.1006/jmbi.1998.2397; de Groot BL, 1998, PROTEINS, V31, P116, DOI 10.1002/(SICI)1097-0134(19980501)31:2<116::AID-PROT2>3.0.CO;2-K; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esposito L, 2000, J MOL BIOL, V297, P713, DOI 10.1006/jmbi.2000.3597; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; FORMANKAY JD, 1992, J BIOMOL NMR, V2, P431, DOI 10.1007/BF02192807; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P306; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Gorbatyuk VY, 2004, J BIOL CHEM, V279, P5772, DOI 10.1074/jbc.M311233200; Grottesi A, 2002, PROTEINS, V46, P287, DOI 10.1002/prot.10045; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Kelley JJ, 1997, BIOCHEMISTRY-US, V36, P5029, DOI 10.1021/bi962181g; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laity JH, 1997, BIOCHEMISTRY-US, V36, P12683, DOI 10.1021/bi970878b; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; MATOUSEK J, 1995, COMP BIOCHEM PHYS B, V112, P235, DOI 10.1016/0305-0491(95)00075-5; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Matousek J, 2003, COMP BIOCHEM PHYS C, V136, P343, DOI 10.1016/j.cca.2003.10.005; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; Merlino A, 2005, BIOPHYS J, V88, P2003, DOI 10.1529/biophysj.104.048611; Merlino A, 2004, PROTEINS, V57, P692, DOI 10.1002/prot.20270; Merlino A, 2004, BIOPOLYMERS, V73, P689, DOI 10.1002/bip.20016; Merlino A, 2004, BIOPHYS J, V86, P2383, DOI 10.1016/S0006-3495(04)74295-2; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; Merlino A, 2002, BIOPOLYMERS, V65, P274, DOI 10.1002/bip.10225; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; Notomista E, 2001, BIOCHEMISTRY-US, V40, P9097, DOI 10.1021/bi010741s; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; Shimotakahara S, 1997, BIOCHEMISTRY-US, V36, P6915, DOI 10.1021/bi963024k; Soucek J, 1996, NEOPLASMA, V43, P335; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; van der Spoel D, 1994, GRONINGEN MACHINE CH; vanAalten DMF, 1997, BIOPHYS J, V73, P2891, DOI 10.1016/S0006-3495(97)78317-6; Vasandani VM, 1999, CANCER CHEMOTH PHARM, V44, P164, DOI 10.1007/s002800050962; Vitagliano L, 1998, PROTEIN SCI, V7, P1691, DOI 10.1002/pro.5560070804; Vitagliano L, 2000, PROTEIN SCI, V9, P1217, DOI 10.1110/ps.9.6.1217; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; VOGL T, 1995, J MOL BIOL, V254, P481, DOI 10.1006/jmbi.1995.0632; WU YN, 1993, J BIOL CHEM, V268, P10686; YOULE RJ, 1996, RIBONUCLEASE STRUCTU, P491; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	68	35	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17953	17960		10.1074/jbc.M501339200	http://dx.doi.org/10.1074/jbc.M501339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728177	hybrid			2022-12-27	WOS:000228807200049
J	Ray, N; Nenninger, A; Mullineaux, CW; Robinson, C				Ray, N; Nenninger, A; Mullineaux, CW; Robinson, C			Location and mobility of twin arginine translocase subunits in the Escherichia coli plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROTEIN EXPORT; SIGNAL PEPTIDE; THYLAKOID MEMBRANES; TATABC COMPLEX; PATHWAY; SYSTEM; BACTERIAL; TATC; EXPRESSION; COMPONENTS	The twin arginine translocation ( Tat) system transports folded proteins across the bacterial plasma membrane. Two primary Tat complexes have been identified, comprising TatABC or TatA multimers, which may interact at the point of translocation. We have analyzed green/cyan/yellow fluorescent protein (XFP) fusions to each of the Tat subunits. We show that the TatB and TatC fusions are active and incorporated into purified TatABC complexes. Proteolytic clipping of the TatA-XFP fusion precludes a definitive conclusion regarding activity, but we do find that the full fusion protein is preferentially incorporated into the TatABC complex. A previous study has proposed that TatB and possibly TatC are localized at the cell poles, whereas TatA is distributed more uniformly throughout the plasma membrane. Here, we likewise show that TatA-XFP is primarily distributed around the periphery of the cell. However, whereas much of the TatB-XFP is found at the poles, quantitative imaging studies show that approximately half of the protein is uniformly distributed in the plasma membrane. Moreover, we show that the bulk of TatC-XFP is detected as a halo around the cells, in some cases as punctate areas that are much smaller than those occupied by TatB-green fluorescent protein (GFP), indicating a uniform distribution. No evidence for a polar localization of TatC-GFP was obtained. Although TatC-GFP is found correctly complexed with TatB, a high proportion of TatB-GFP is not linked to TatC, and we propose that this "free" TatB forms unphysiological assemblies, possibly because it is synthesized in excess. Since TatC is invariably complexed with TatB in wildtype complexes, the combined data demonstrate that TatABC complexes are uniformly distributed throughout the plasma membrane. The significance of the punctate TatA/B/C-GFP is unclear; fluorescence recovery after photobleaching measurements show that these pools of proteins are immobile, whereas nonaggregated proteins are highly mobile in the plasma membrane.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; UCL, Dept Biol, London WC1E 6BT, England	University of Warwick; University of London; University College London	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk			Biotechnology and Biological Sciences Research Council [BB/C00437X/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Mangels D, 2005, J MOL BIOL, V345, P415, DOI 10.1016/j.jmb.2004.10.043; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sarcina M, 2004, J BIOL CHEM, V279, P36514, DOI 10.1074/jbc.M405881200; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	29	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17961	17968		10.1074/jbc.M413521200	http://dx.doi.org/10.1074/jbc.M413521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15728576	hybrid			2022-12-27	WOS:000228807200050
J	Tan, NS; Michalik, L; Desvergne, B; Wahli, W				Tan, NS; Michalik, L; Desvergne, B; Wahli, W			Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; PPAR-BETA; TGF-BETA; MYOFIBROBLAST DIFFERENTIATION; TRANSCRIPTIONAL CONTROL; CRITICAL ROLES; SMAD3; MICE; KERATINOCYTES; INFLAMMATION	Advances in wound care are of great importance in clinical injury management. In this respect, the nuclear receptor peroxisome proliferator-activated receptor (PPAR) beta/delta occupies a unique position at the intersection of diverse inflammatory or anti-inflammatory signals that influence wound repair. This study shows how changes in PPAR beta/delta expression have a profound effect on wound healing. Using two different in vivo models based on topical application of recombinant transforming growth factor (TGF)-beta 1 and ablation of the Smad3 gene, we show that prolonged expression and activity of PPAR beta/delta accelerate wound closure. The results reveal a dual role of TGF-beta 1 as a chemoattractant of inflammatory cells and repressor of inflammation-induced PPAR beta/delta expression. Also, they provide insight into the so far reported paradoxical effects of the application of exogenous TGF-beta 1 at wound sites.	Univ Lausanne, Natl Ctr Competence Res Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland	University of Lausanne	Wahli, W (corresponding author), Univ Lausanne, Natl Ctr Competence Res Frontiers Genet, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland.	walter.wahli@unil.ch	Tan, Nguan Soon/A-2220-2011; Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Tan, Nguan Soon/0000-0003-0136-7341; Wahli, Walter/0000-0002-5966-9089; Michalik, Liliane/0000-0003-2963-2100; Desvergne, Beatrice/0000-0001-5483-288X				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Beck LS, 1990, GROWTH FACTORS, V2, P273, DOI 10.3109/08977199009078015; Beck LS, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000293; Beck LS, 1990, GROWTH FACTORS, V3, P267, DOI 10.3109/08977199009003669; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Crowe MJ, 2000, J INVEST DERMATOL, V115, P3, DOI 10.1046/j.1523-1747.2000.00010.x; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Hasan W, 2000, CELL TISSUE RES, V300, P97, DOI 10.1007/s004410050051; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Koch RM, 2000, WOUND REPAIR REGEN, V8, P179, DOI 10.1046/j.1524-475x.2000.00179.x; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; KSANDER GA, 1990, ANN NY ACAD SCI, V593, P135, DOI 10.1111/j.1749-6632.1990.tb16106.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; PUOLAKKAINEN PA, 1995, J SURG RES, V58, P321, DOI 10.1006/jsre.1995.1050; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schmuth M, 2004, J INVEST DERMATOL, V122, P971, DOI 10.1111/j.0022-202X.2004.22412.x; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHAH M, 1995, J CELL SCI, V108, P985; Shephard P, 2004, AM J PATHOL, V164, P2055, DOI 10.1016/S0002-9440(10)63764-9; Tan NS, 2004, BIOCHEM SOC T, V32, P97, DOI 10.1042/BST0320097; Tan NS, 2004, EMBO J, V23, P4211, DOI 10.1038/sj.emboj.7600437; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Yamaguchi Y, 2001, J DERMATOL, V28, P521, DOI 10.1111/j.1346-8138.2001.tb00025.x; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	33	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18163	18170		10.1074/jbc.M412829200	http://dx.doi.org/10.1074/jbc.M412829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15708854	hybrid			2022-12-27	WOS:000228807200074
J	Becker, M; Bunikis, J; Lade, BD; Dunn, JJ; Barbour, AG; Lawson, CL				Becker, M; Bunikis, J; Lade, BD; Dunn, JJ; Barbour, AG; Lawson, CL			Structural investigation of Borrelia burgdorferi OspB, a bactericidalFab target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-SURFACE PROTEIN; LYME-DISEASE SPIROCHETE; ANTILYSOZYME ANTIBODY HYHEL-63; LAYER BETA-SHEET; MONOCLONAL-ANTIBODY; MOLECULAR ANALYSIS; PROTECTIVE IMMUNITY; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; IN-VIVO	Certain antibody Fab fragments directed against the C terminus of outer surface protein B (OspB), a major lipoprotein of the Lyme disease spirochete, Borrelia burgdorferi, have the unusual property of being bactericidal even in the absence of complement. We report here x-ray crystal structures of a C-terminal fragment of B. burgdorferi OspB, which spans residues 152-296, alone at 2.0-angstrom resolution, and in a complex with the bactericidal Fab H6831 at 2.6-angstrom resolution. The H6831 epitope is topologically analogous to the LA-2 epitope of OspA and is centered around OspB Lys-253, a residue essential for H6831 recognition. A beta-sheet present in the free OspB fragment is either disordered or removed by proteolysis in the H6831-bound complex. Other conformational changes between free and H6831-bound structures are minor and appear to be related to this loss. In both crystal structures, OspB C-terminal fragments form artificial dimers connected by intermolecular beta-sheets. OspB structure, stability, and possible mechanisms of killing by H6831 and other bactericidal Fabs are discussed in light of the structural data.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Calif Irvine, Coll Med, Dept Microbiol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Mol & Med Genet, Irvine, CA 92697 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Irvine; University of California System; University of California Irvine; Rutgers State University New Brunswick	Becker, M (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,POB 5000, Upton, NY 11973 USA.	mbecker@bnl.gov; cathy.lawson@rutgers.edu	Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Lawson, Catherine/0000-0002-3261-7035	NIAID NIH HHS [AI37248, AI24424] Funding Source: Medline; PHS HHS [R01-A137256] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037248, R37AI024424, R01AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin E, 1999, INFECT IMMUN, V67, P173, DOI 10.1128/IAI.67.1.173-181.1999; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1985, J INFECT DIS, V152, P478, DOI 10.1093/infdis/152.3.478; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDOC VG, 1989, INFECT IMMUN, V57, P2733, DOI 10.1128/IAI.57.9.2733-2741.1989; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; COLEMAN JL, 1992, INFECT IMMUN, V60, P3098, DOI 10.1128/IAI.60.8.3098-3104.1992; COLEMAN JL, 1994, INFECT IMMUN, V62, P303, DOI 10.1128/IAI.62.1.303-307.1994; Connolly SE, 2004, J IMMUNOL, V172, P1191, DOI 10.4049/jimmunol.172.2.1191; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271; Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Escudero R, 1997, INFECT IMMUN, V65, P1908, DOI 10.1128/IAI.65.5.1908-1915.1997; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fikrig E, 2004, INFECT IMMUN, V72, P1755, DOI 10.1128/IAI.72.3.1755-1759.2004; FIKRIG E, 1995, INFECT IMMUN, V63, P1658, DOI 10.1128/IAI.63.5.1658-1662.1995; FIKRIG E, 1993, P NATL ACAD SCI USA, V90, P4092, DOI 10.1073/pnas.90.9.4092; FIKRIG E, 1992, INFECT IMMUN, V60, P657, DOI 10.1128/IAI.60.2.657-661.1992; FIKRIG E, 1995, J EXP MED, V181, P215, DOI 10.1084/jem.181.1.215; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Golde WT, 1997, INFECT IMMUN, V65, P882, DOI 10.1128/IAI.65.3.882-889.1997; Hertadi R, 2003, J MOL BIOL, V333, P993, DOI 10.1016/j.jmb.2003.09.010; HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554; Huang XL, 2001, J MOL BIOL, V308, P367, DOI 10.1006/jmbi.2001.4579; Katona LI, 2000, J IMMUNOL, V164, P1425, DOI 10.4049/jimmunol.164.3.1425; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1995, ACTA CRYSTALLOGR D, V51, P853, DOI 10.1107/S0907444995002265; Li H, 1995, J STRUCT BIOL, V115, P335, DOI 10.1006/jsbi.1995.1058; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2000, BIOCHEMISTRY-US, V39, P6296, DOI 10.1021/bi000054l; Liang FT, 2004, MICROB PATHOGENESIS, V37, P35, DOI 10.1016/j.micpath.2004.02.007; MA JN, 1995, INFECT IMMUN, V63, P2221, DOI 10.1128/IAI.63.6.2221-2227.1995; Marraffini LA, 2004, J BIOL CHEM, V279, P37763, DOI 10.1074/jbc.M405282200; MORONI A, 1992, MICROBIOLOGICA, V15, P99; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nieva J, 2004, TRENDS BIOCHEM SCI, V29, P274, DOI 10.1016/j.tibs.2004.03.009; Ohnishi S, 2001, PROTEIN SCI, V10, P2083, DOI 10.1110/ps.15901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal U, 2000, J CLIN INVEST, V106, P561, DOI 10.1172/JCI9427; Pal U, 2001, J IMMUNOL, V166, P7398, DOI 10.4049/jimmunol.166.12.7398; Pham TN, 1998, NAT STRUCT BIOL, V5, P115, DOI 10.1038/nsb0298-115; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Probert WS, 1997, VACCINE, V15, P15, DOI 10.1016/S0264-410X(96)00123-5; Rathinavelu S, 2003, INFECT IMMUN, V71, P822, DOI 10.1128/IAI.71.2.822-829.2003; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; ROSA PA, 1992, MOL MICROBIOL, V6, P3031, DOI 10.1111/j.1365-2958.1992.tb01761.x; SADZIENE A, 1995, INFECT IMMUN, V63, P1573, DOI 10.1128/IAI.63.4.1573-1580.1995; SADZIENE A, 1994, INFECT IMMUN, V62, P2037, DOI 10.1128/IAI.62.5.2037-2045.1994; SADZIENE A, 1993, INFECT IMMUN, V61, P3590, DOI 10.1128/IAI.61.9.3590-3596.1993; SCHUBACH WH, 1991, INFECT IMMUN, V59, P1911, DOI 10.1128/IAI.59.6.1911-1915.1991; Schwan TG, 2003, BIOCHEM SOC T, V31, P108, DOI 10.1042/BST0310108; SCHWAN TG, 1993, J CLIN MICROBIOL, V31, P3096, DOI 10.1128/JCM.31.12.3096-3108.1993; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR PW, 1992, EXP CLIN IMMUNOGENET, V9, P48; Williams DC, 1996, J MOL BIOL, V257, P866, DOI 10.1006/jmbi.1996.0207; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; Yan S, 2002, J MOL BIOL, V323, P363, DOI 10.1016/S0022-2836(02)00882-3; Yan SD, 2004, J MOL BIOL, V338, P811, DOI 10.1016/j.jmb.2004.02.063; Yang XFF, 2004, J EXP MED, V199, P641, DOI 10.1084/jem.20031960	75	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17363	17370		10.1074/jbc.M412842200	http://dx.doi.org/10.1074/jbc.M412842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713683	hybrid			2022-12-27	WOS:000228615500101
J	Ermakova, S; Choi, BY; Choi, HS; Kang, BS; Bode, AM; Dong, ZG				Ermakova, S; Choi, BY; Choi, HS; Kang, BS; Bode, AM; Dong, ZG			The intermediate filament protein vimentin is a new target for epigallocatechin gallate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN TEA CATECHINS; CELL-PROLIFERATION; HUMAN PROSTATE; GROWTH-INHIBITION; MOTILE PROPERTIES; PHOSPHORYLATION; APOPTOSIS; CANCER; INDUCTION; KINASE	Epigallocatechin gallate ( EGCG) is the major active polyphenol in green tea. Protein interaction with EGCG is a critical step in the effects of EGCG on the regulation of various key proteins involved in signal transduction. We have identified a novel molecular target of EGCG using affinity chromatography, two-dimensional electrophoresis, and mass spectrometry for protein identification. Spots of interest were identified as the intermediate filament, vimentin. The identification was confirmed by Western blot analysis using an anti-vimentin antibody. Experiments using a pull-down assay with [H-3] EGCG demonstrate binding of EGCG to vimentin with a K-d of 3.3 nM. EGCG inhibited phosphorylation of vimentin at serines 50 and 55 and phosphorylation of vimentin by cyclin-dependent kinase 2 and cAMP- dependent protein kinase. EGCG specifically inhibits cell proliferation by binding to vimentin. Because vimentin is important for maintaining cellular functions and is essential in maintaining the structure and mechanical integration of the cellular space, the inhibitory effect of EGCG on vimentin may further explain its anti-tumor-promoting effect.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Ermakova, Svetlana P/G-2766-2013	Ermakova, Svetlana/0000-0002-5905-2046	NCI NIH HHS [CA88961, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, P01CA088961] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; Bousquet O, 1996, CELL MOTIL CYTOSKEL, V33, P115, DOI 10.1002/(SICI)1097-0169(1996)33:2<115::AID-CM4>3.0.CO;2-B; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Chen AP, 2003, J BIOL CHEM, V278, P23381, DOI 10.1074/jbc.M212042200; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; CHOU YH, 1991, J BIOL CHEM, V266, P7325; Chou YH, 1996, J CELL SCI, V109, P817; Chou YH, 2000, J CELL BIOL, V150, pF101, DOI 10.1083/jcb.150.3.F101; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; Dong ZG, 2000, BIOFACTORS, V12, P17, DOI 10.1002/biof.5520120104; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; He ZW, 2003, CANCER RES, V63, P4396; Helfand BT, 2003, ANNU REV CELL DEV BI, V19, P445, DOI 10.1146/annurev.cellbio.19.111401.092306; HUANG TJ, 1994, J PROTEIN CHEM, V13, P517, DOI 10.1007/BF01901533; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalonde R, 2003, REV NEUROSCIENCE, V14, P369; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; LEA MA, 1993, CANCER LETT, V68, P231, DOI 10.1016/0304-3835(93)90151-X; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; LIAO SS, 1995, CANCER LETT, V96, P239, DOI 10.1016/0304-3835(95)03948-V; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; Okayama N, 2000, IN VITRO CELL DEV-AN, V36, P228; Pianetti S, 2002, CANCER RES, V62, P652; SAEZ R, 1991, NEUROCHEM RES, V16, P737, DOI 10.1007/BF00965682; Sazuka M, 1998, BIOSCI BIOTECH BIOCH, V62, P1031, DOI 10.1271/bbb.62.1031; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; Suzuki Y, 2001, CANCER LETT, V173, P15, DOI 10.1016/S0304-3835(01)00685-1; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Takai Y, 1996, Tanpakushitsu Kakusan Koso, V41, P1920; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Uesato S, 2001, CANCER LETT, V170, P41, DOI 10.1016/S0304-3835(01)00571-7; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yasui Y, 2001, ONCOGENE, V20, P2868, DOI 10.1038/sj.onc.1204407; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	50	126	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16882	16890		10.1074/jbc.M414185200	http://dx.doi.org/10.1074/jbc.M414185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15713670	hybrid			2022-12-27	WOS:000228615500042
J	Finigan, JH; Dudek, SM; Singleton, PA; Chiang, ET; Jacobson, JR; Camp, SM; Ye, SQ; Garcia, JGN				Finigan, JH; Dudek, SM; Singleton, PA; Chiang, ET; Jacobson, JR; Camp, SM; Ye, SQ; Garcia, JGN			Activated protein C mediates novel lung endothelial barrier enhancement - Role of sphingosine 1-phosphate receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; THROMBIN-INDUCED INCREASE; FACTOR PATHWAY INHIBITOR; CELL GAP FORMATION; SEVERE SEPSIS; INTRAVASCULAR COAGULATION; BETA RECEPTOR; PERMEABILITY; DEFICIENCY; EXPRESSION	Increased endothelial cell (EC) permeability is central to the pathophysiology of inflammatory syndromes such as sepsis and acute lung injury (ALI). Activated protein C (APC), a serine protease critically involved in the regulation of coagulation and inflammatory processes, improves sepsis survival through an unknown mechanism. We hypothesized a direct effect of APC to both prevent increased EC permeability and to restore vascular integrity after edemagenic agonists. We measured changes in transendothelial electrical resistance (TER) and observed that APC produced concentration-dependent attenuation of TER reductions evoked by thrombin. We next explored known EC barrier-protective signaling pathways and observed dose-dependent APC-mediated increases in cortical myosin light chain (MLC) phosphorylation in concert with cortically distributed actin polymerization, findings highly suggestive of Rac GTPase involvement. We next determined that APC directly increases Rac1 activity, with inhibition of Rac1 activity significantly attenuating APC-mediated barrier protection to thrombin challenge. Finally, as these signaling events were similar to those evoked by the potent EC barrier-enhancing agonist, sphingosine 1-phosphate (S1P), we explored potential cross-talk between endothelial protein C receptor (EPCR) and S1P(1), the receptors for APC and S1P, respectively. EPCR-blocking antibody (RCR-252) significantly attenuated both APC-mediated barrier protection and increased MLC phosphorylation. We next observed rapid, EPCR and PI 3-kinase-dependent, APC-mediated phosphorylation of S1P(1) on threonine residues consistent with S1P(1) receptor activation. Co-immunoprecipitation studies demonstrate an interaction between EPCR and S1P(1) upon APC treatment. Targeted silencing of S1P(1) expression using siRNA significantly reduced APC-mediated barrier protection against thrombin. These data suggest that novel EPCR ligation and S1P(1) transactivation results in EC cytoskeletal rearrangement and barrier protection, components potentially critical to the improved survival of APC-treated patients with severe sepsis.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,W604, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010					Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Birukov KG, 2004, CIRC RES, V95, P892, DOI 10.1161/01.RES.0000147310.18962.06; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2; BRANSON HE, 1983, LANCET, V2, P1165; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Feistritzer C, 2003, J ALLERGY CLIN IMMUN, V112, P375, DOI 10.1067/mai.2003.1609; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Gando S, 1996, THROMB HAEMOSTASIS, V75, P224; Garcia JGN, 1997, AM J PHYSIOL-LUNG C, V273, pL172, DOI 10.1152/ajplung.1997.273.1.L172; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J INVEST MED, V43, P117; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; Harada N, 1999, BLOOD, V93, P157, DOI 10.1182/blood.V93.1.157.401k08_157_164; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kalil AC, 2004, SHOCK, V21, P222, DOI 10.1097/01.shk.0000116778.27924.79; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; LO SK, 1992, J CELL PHYSIOL, V151, P63, DOI 10.1002/jcp.1041510111; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Schaphorst KL, 1997, AM J RESP CELL MOL, V17, P443, DOI 10.1165/ajrcmb.17.4.2502; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Sturn DH, 2003, BLOOD, V102, P1499, DOI 10.1182/blood-2002-12-3880; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Yuksel M, 2002, THROMB HAEMOSTASIS, V88, P267	56	313	323	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17286	17293		10.1074/jbc.M412427200	http://dx.doi.org/10.1074/jbc.M412427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15710622	hybrid			2022-12-27	WOS:000228615500092
J	Jo, MJ; Thomas, KS; Marozkina, N; Amin, TJ; Silva, CM; Parsons, SJ; Gonias, SL				Jo, MJ; Thomas, KS; Marozkina, N; Amin, TJ; Silva, CM; Parsons, SJ; Gonias, SL			Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; REGULATED KINASE 1; EGF RECEPTOR; TYROSINE KINASE; BREAST-CANCER; C-SRC; HUMAN CARCINOMA; CELL-MIGRATION; CYCLIN D1	The urokinase-type plasminogen activator (uPA) receptor ( uPAR) functions in concert with co-receptors, including integrins, FPR-like receptor-1/lipoxin A4 receptor, and the epidermal growth factor receptor ( EGFR), to initiate cell signaling. uPAR co-receptors may be dynamically organized into a multiprotein signaling receptor complex. In Chinese hamster ovary-K1 (CHO-K1) cells, uPA-binding to uPAR activates ERK/ MAP kinase, even though these cells do not express the EGFR; however, when CHO-K1 cells are transfected to express the EGFR, ERK activation becomes EGFR-dependent. In this study, we demonstrate that ERK activation in response to uPA follows equivalent biphasic kinetics in EGFR-expressing and -deficient CHO-K1 cells. In both cell types, the response is pertussis toxin-sensitive; however, uPA promotes cell proliferation exclusively in the EGFR-expressing cells. uPA-induced mitogenic activity requires activation of both STAT5b and ERK. STAT5b was tyrosine-phosphorylated, in response to uPA, only in EGFR-expressing cells. uPA-induced cell proliferation was blocked by dominant-negative MEK1, dominant-negative STAT5b, and by expression of an EGFR that is mutated at Tyr-845, which is essential for STAT5b activation. In two cell culture models of uPA-stimulated breast cancer growth, MDA-MB 468 cells treated with uPA and MCF-7 cells treated with uPA-plasminogen activator inhibitor-1 complex, proliferation was completely inhibited when EGFR expression or activity was blocked. We conclude that expression and assembly of uPAR co-receptors in a specific cell type determines the response to uPA. The EGFR selectively cooperates with uPAR to mediate mitogenesis.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu						Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Guerrero J, 2004, EXP CELL RES, V292, P201, DOI 10.1016/j.yexcr.2003.08.011; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2003, J BIOL CHEM, V278, P46692, DOI 10.1074/jbc.M308808200; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xu XZ, 2000, ONCOGENE, V19, P3172, DOI 10.1038/sj.onc.1203645; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	53	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17449	17457		10.1074/jbc.M413141200	http://dx.doi.org/10.1074/jbc.M413141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15728176	hybrid			2022-12-27	WOS:000228615500111
J	Li, AM; Harris, DA				Li, AM; Harris, DA			Mammalian prion protein suppresses Bax-induced cell death in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP; EXPRESSION; BCL-2; MUTATIONS; ATAXIA; ALTER; LINE	Several lines of evidence suggest that PrPC, the noninfectious form of the prion protein, may function to protect neurons and other cells from stress or toxicity. In this paper, we report on the use of the yeast Saccharomyces cerevisiae as a model system to assay the cytoprotective activity of PrPC. The mammalian pro-apoptotic protein, Bax, confers a lethal phenotype when expressed in yeast. Since overexpression of PrPC has been found to prevent Bax-mediated cell death in cultured human neurons, we explored whether PrP could also suppress Bax-induced cell death in yeast. We utilized a form of mouse PrP containing a modified signal peptide that we had previously shown is efficiently targeted to the secretory pathway in yeast. We found that this PrP potently suppressed the death of yeast cells expressing mammalian Bax under control of a galactose-inducible promoter. In contrast, cytosolic PrP-( 23 231) failed to rescue growth of Bax-expressing yeast, indicating that protective activity requires targeting of PrP to the secretory pathway. Deletion of the octapeptide repeat region did not affect the rescuing activity of PrP, but deletion of a charged region encompassing residues 23 - 31 partially eliminated activity. We also tested several PrP mutants associated with human familial prion diseases and found that only a mutant containing nine extra octapeptide repeats failed to suppress Bax-induced cell death. These findings establish a simple and genetically tractable system for assaying a putative biological activity of PrPC.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbiology.wustl.edu		Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS40061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Drisaldi B, 2004, J BIOL CHEM, V279, P55443, DOI 10.1074/jbc.M404794200; Greenhalf W, 1999, YEAST, V15, P1307, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.3.CO;2-V; Hoshino S, 2003, ACT NEUR S, V86, P297; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Kong Qingzhong, 2004, VVolume 41, P673; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Li AM, 2004, J BIOL CHEM, V279, P29469, DOI 10.1074/jbc.M402517200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Prusiner SB, 2004, PRION BIOL DIS; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	35	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17430	17434		10.1074/jbc.C500058200	http://dx.doi.org/10.1074/jbc.C500058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15753097	hybrid			2022-12-27	WOS:000228615500109
J	Perez-Vilar, J; Olsen, JC; Chua, M; Boucher, RC				Perez-Vilar, J; Olsen, JC; Chua, M; Boucher, RC			pH-dependent intraluminal organization of mucin granules in live human mucous/goblet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; ISOLATED SECRETORY GRANULES; DISULFIDE-BONDED DIMERS; GEL-FORMING MUCINS; AIRWAY GOBLET-CELL; FLUORESCENCE RECOVERY; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; ION-EXCHANGE; C-TERMINUS	To study the mechanism of gel-forming mucin packaging within mucin granules, we generated human mucous/ goblet cells stably expressing a recombinant MUC5AC domain fused to green fluorescent protein (GFP). The fusion protein, named SHGFP-MUC5AC/CK, accumulated in the granules together with native MUC5AC. Inhibition of protein synthesis or disorganization of the Golgi complex did not result in diminished intragranular SHGFP-MUC5AC/CK signals, consistent with long-term storage of the fusion protein. However, SHGFP-MUC5AC/CK was rapidly discharged from the granules upon incubation of the cells with ATP, an established mucin secretagogue. Several criteria indicated that SHGFP-MUC5AC/CK was not covalently linked to endogenous MUC5AC. Analysis of fluorescence recovery after photobleaching suggested that the intragranular SHGFP-MUC5AC/CK mobile fraction and mobility were significantly lower than in the endoplasmic reticulum lumen. Incubation of the cells with bafilomycin A(1), a specific inhibitor of the vacuolar H+-ATPase, did not alter the fusion protein mobility, although it significantly increased ( similar to 20%) the intragranular SHGFP-MUC5AC/CK mobile fraction. In addition, the granules in bafilomycin-incubated cells typically exhibited a heterogeneous intraluminal distribution of the fluorescent fusion protein. These results are consistent with a model of mucin granule intraluminal organization with two phases: a mobile phase in which secretory proteins diffuse as in the endoplasmic reticulum lumen but at a lower rate and an immobile phase or matrix in which proteins are immobilized by noncovalent pH-dependent interactions. An intraluminal acidic pH, maintained by the vacuolar H+-ATPase, is one of the critical factors for secretory protein binding to the immobile phase and also for its organization.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Perez-Vilar, J (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, CB7248, Chapel Hill, NC 27599 USA.	juan_vilar@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK067404] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67404] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARA J, 1991, INT J CANCER, V47, P304, DOI 10.1002/ijc.2910470222; Barg S, 2001, J CELL SCI, V114, P2145; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bell SL, 2003, BIOCHEM J, V373, P893, DOI 10.1042/BJ20030096; BELL SL, 1998, BIOCHEM J, V357, P203; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Braeckmans K, 2003, BIOPHYS J, V85, P2240, DOI 10.1016/S0006-3495(03)74649-9; Braga J, 2004, MOL BIOL CELL, V15, P4749, DOI 10.1091/mbc.E04-06-0496; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chen Y, 2004, AM J RESP CELL MOL, V30, P155, DOI 10.1165/rcmb.2003-0103OC; Chin WC, 2002, NOVART FDN SYMP, V248, P132; Davis CW, 2002, NOVART FDN SYMP, V248, P113; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Demaurex N, 2002, NEWS PHYSIOL SCI, V17, P1; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Drose S, 1997, J EXP BIOL, V200, P1; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Escande F, 2001, BIOCHEM J, V358, P763, DOI 10.1042/0264-6021:3580763; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GUM JR, 1994, J BIOL CHEM, V269, P2440; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Jackson AD, 2001, TRENDS PHARMACOL SCI, V22, P39, DOI 10.1016/S0165-6147(00)01600-X; Jackson C L, 2000, Subcell Biochem, V34, P233; Johnson LG, 1998, J VIROL, V72, P8861, DOI 10.1128/JVI.72.11.8861-8872.1998; Keeler C, 2004, J MOL NEUROSCI, V22, P43, DOI 10.1385/JMN:22:1-2:43; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Lidell ME, 2003, BIOCHEM J, V372, P335, DOI 10.1042/BJ20030003; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MCCOOL DJ, 1995, BIOCHEM J, V312, P125, DOI 10.1042/bj3120125; Merlin D, 1996, AM J PHYSIOL-CELL PH, V271, pC612, DOI 10.1152/ajpcell.1996.271.2.C612; NEUTRA MR, 1984, CIBA F SYMP, V109, P20, DOI 10.1002/9780470720905.ch3; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Perez-Vilar J, 2004, FREE RADICAL BIO MED, V37, P1564, DOI 10.1016/j.freeradbiomed.2004.07.027; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; PHILLIPS TE, 1995, IN VITRO CELL DEV-AN, V31, P421, DOI 10.1007/BF02634251; Quesada I, 2003, BIOPHYS J, V85, P963, DOI 10.1016/S0006-3495(03)74535-4; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Sheehan JK, 2000, BIOCHEM J, V347, P37, DOI 10.1042/0264-6021:3470037; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Snapp E.L., 2003, CURRENT PROTOCOLS CE; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VERDUGO P, 1987, BIORHEOLOGY, V24, P625; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Ward WW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P45; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	69	25	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16868	16881		10.1074/jbc.M413289200	http://dx.doi.org/10.1074/jbc.M413289200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15718243	hybrid, Green Published			2022-12-27	WOS:000228615500041
J	Prunier, C; Howe, PH				Prunier, C; Howe, PH			Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MOLECULAR MECHANISMS; BINDING PARTNER; ADAPTER PROTEIN; GENE-EXPRESSION; DOMAIN; TRANSDIFFERENTIATION; DOC-2/DAB2; INTEGRINS; OVARIAN	Transforming growth factor beta (TGF beta) induces an epithelial to mesenchymal transition (EMT) during both physiological and pathological processes; however, the mechanism underlying this transition is not fully elucidated. Here, we have demonstrated that TGF beta induces the expression of the adaptor molecule disabled-2 (Dab2) concomitant with the promotion of EMT. We show that TGF beta induces a transient accumulation of Dab2 to the membrane and increases Dab2 binding to beta 1 integrin. Furthermore, small interfering RNA ( siRNA)mediated silencing of Dab2 expression in mouse mammary gland epithelial cells results in inhibition of integrin activation, shown by a decrease of both TGF beta-induced focal adhesion kinase phosphorylation and cellular adherence, leading to apoptosis and inhibition of EMT. Forced re-expression of human Dab2, not targeted by the mouse siRNA sequence, rescues cells from apoptosis and restores TGF beta-mediated integrin activation and EMT. These results are confirmed in the F9 teratocarcinoma cell line, a model for retinoic acid-induced visceral endoderm differentiation in which we demonstrate that ablation of retinoic acid-induced Dab2 expression levels, by stable siRNA silencing of Dab2, blocks visceral endoderm differentiation. Our findings indicate that Dab2 plays an important regulatory role during cellular differentiation and that induction of differentiation in the absence of Dab2 expression commits the cell to apoptosis.	Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	howep@ccf.org	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273	NATIONAL CANCER INSTITUTE [R01CA055536, R01CA080095, R29CA055536] Funding Source: NIH RePORTER; NCI NIH HHS [CA55536, CA80095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang CL, 2004, J BIOL CHEM, V279, P42279, DOI 10.1074/jbc.M402540200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; Kowanetz K, 2003, FEBS LETT, V554, P81, DOI 10.1016/S0014-5793(03)01111-6; Liu SC, 2000, J CELL SCI, V113, P3563; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Piek E, 1999, J CELL SCI, V112, P4557; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tseng CP, 2001, BIOCHEM BIOPH RES CO, V285, P129, DOI 10.1006/bbrc.2001.5133; Valdes F, 2002, MOL CANCER RES, V1, P68; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	52	104	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17540	17548		10.1074/jbc.M500974200	http://dx.doi.org/10.1074/jbc.M500974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15734730	hybrid			2022-12-27	WOS:000228615500123
J	Starai, VJ; Thorngren, N; Fratti, RA; Wickner, W				Starai, VJ; Thorngren, N; Fratti, RA; Wickner, W			Ion regulation of homotypic vacuole fusion in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; VERTEX RING DOMAIN; MEMBRANE-FUSION; SNARE COMPLEX; IN-VITRO; INFLUENZA HEMAGGLUTININ; LYSOPHOSPHATIDIC ACID; PHOSPHATIDIC-ACID; DIVALENT-CATIONS; GOLGI MEMBRANES	Biological membrane fusion employs divalent cations as protein cofactors or as signaling ligands. For example, Mg2+ is a cofactor for the N-ethylmaleimide-sensitive factor (NSF) ATPase, and the Ca2+ signal from neuronal membrane depolarization is required for synaptotagmin activation. Divalent cations also regulate liposome fusion, but the role of such ion interactions with lipid bilayers in Rab- and soluble NSF attachment protein receptor ( SNARE)-dependent biological membrane fusion is less clear. Yeast vacuole fusion requires Mg2+ for Sec18p ATPase activity, and vacuole docking triggers an efflux of luminal Ca2+. We now report distinct reaction conditions where divalent or monovalent ions interchangeably regulate Rab- and SNARE-dependent vacuole fusion. In reactions with 5 mM Mg2+, other free divalent ions are not needed. Reactions containing low Mg2+ concentrations are strongly inhibited by the rapid Ca2+ chelator BAPTA. However, addition of the soluble SNARE Vam7p relieves BAPTA inhibition as effectively as Ca2+ or Mg2+, suggesting that Ca2+ does not perform a unique signaling function. When the need for Mg2+, ATP, and Sec18p for fusion is bypassed through the addition of Vam7p, vacuole fusion does not require any appreciable free divalent cations and can even be stimulated by their chelators. The similarity of these findings to those with liposomes, and the higher ion specificity of the regulation of proteins, suggests a working model in which ion interactions with bilayer lipids permit Rab- and SNARE-dependent membrane fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@Dartmouth.edu						Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BENTZ J, 1985, BIOCHEMISTRY-US, V24, P5436, DOI 10.1021/bi00341a023; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHIANCONE E, 1986, J BIOL CHEM, V261, P6306; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DUNN T, 1994, J BIOL CHEM, V269, P7273; DUZGUNES N, 1981, J MEMBRANE BIOL, V59, P115, DOI 10.1007/BF01875709; Eitzen G, 2000, EMBO J, V19, P6713, DOI 10.1093/emboj/19.24.6713; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gietz RD, 2001, BIOTECHNIQUES, V30, P816, DOI 10.2144/01304rv02; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grote E, 2000, J CELL BIOL, V151, P453, DOI 10.1083/jcb.151.2.453; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hofmann MW, 2004, P NATL ACAD SCI USA, V101, P14776, DOI 10.1073/pnas.0405175101; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; Leikina E, 2000, MOL BIOL CELL, V11, P2359, DOI 10.1091/mbc.11.7.2359; LEVENTIS R, 1986, BIOCHEMISTRY-US, V25, P6978, DOI 10.1021/bi00370a600; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Melikyan GB, 2000, MOL BIOL CELL, V11, P3765, DOI 10.1091/mbc.11.11.3765; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; PERIN MS, 1991, J BIOL CHEM, V266, P623; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PLANKERT U, 1991, EUR J BIOCHEM, V196, P191, DOI 10.1111/j.1432-1033.1991.tb15803.x; Rousset M, 2004, FEBS LETT, V576, P41, DOI 10.1016/j.febslet.2004.08.058; Saoudi Y, 2004, EUR J BIOCHEM, V271, P3255, DOI 10.1111/j.1432-1033.2004.04259.x; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Takeda Y, 2002, J BIOL CHEM, V277, P47756, DOI 10.1074/jbc.M209199200; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241	64	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16754	16762		10.1074/jbc.M500421200	http://dx.doi.org/10.1074/jbc.M500421200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15737991	hybrid			2022-12-27	WOS:000228615500027
J	Trebino, CE; Eskra, JD; Wachtmann, TS; Perez, JR; Carty, TJ; Audoly, LP				Trebino, CE; Eskra, JD; Wachtmann, TS; Perez, JR; Carty, TJ; Audoly, LP			Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-E SYNTHASE; VESICULAR GLAND MICROSOMES; E-2 PRODUCTION; MICE LACKING; INFLAMMATORY RESPONSES; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS; PAIN PERCEPTION; DEFICIENT MICE; HUMAN PLASMA	Microsomal prostaglandin E synthase (mPGES)-1 is one of several prostaglandin E synthases involved in prostaglandin H-2 (PGH(2)) metabolism. In the present report, we characterize the contribution of mPGES-1 to cellular PGH2 metabolism in murine macrophages by studying the synthesis of eicosanoids and expression of eicosanoid metabolism enzymes in wild type and mPGES-1-deficient macrophages. Thioglycollate-elicited macrophages isolated from mPGES-1-/- animals and genetically matched wild type controls were stimulated with diverse pro-inflammatory stimuli. Prostaglandins were released in the following order of decreasing abundance from wild type macrophages stimulated with lipopolysaccharide: prostaglandin E-2 (PGE(2)) > thromboxane B-2 (TxB(2)) > 6-keto prostaglandin F-1 alpha (PGF1 alpha), prostaglandin F-2 alpha (PGF2 alpha), and prostaglandin D-2 (PGD2). In contrast, we detected in mPGES-1-/- macrophages a > 95% reduction in PGE2 production resulting in the following altered prostaglandin profile: TxB2 > 6-keto PGF1 alpha and PGF2 alpha > PGE2, despite the comparable release of total prostaglandins. No significant change in expression pattern of key prostaglandin-synthesizing enzymes was detected between the genotypes. We then further profiled genotype-related differences in the eicosanoid profile using macrophages pre-stimulated with lipopolysaccharide followed by a 10-min incubation with 10 mu M [H-3] arachidonic acid. Eicosanoid products were subsequently identified by reverse phase high pressure liquid chromatography. The dramatic reduction in [H-3] PGE2 formation from mPGES-1 -/- macrophages compared with controls resulted in TxB2 and 6-keto PGF1 alpha becoming the two most abundant prostaglandins in these samples. Our results also suggest a 5-fold increase in 12-[H-3] hydroxyheptadecatrienoic acid release in mPGES-1-/- samples. Our data support the hypothesis that mPGES-1 induction in response to an inflammatory stimulus is essential for PGE2 synthesis. The redirection of prostaglandin production in mPGES-1 -/- cells provides novel insights into how a cell processes the unstable endoperoxide PGH2 during the inactivation of a major metabolic outlet.	Pfizer Inc, Pfizer Global Res & Dev, Groton Labs, Inflammat, Groton, CT 06340 USA	Pfizer	Audoly, LP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Pharmacol, 16711 Trans Canada Highway, Kirkland, PQ H9H 3L1, Canada.	laurent_audoly@merck.com						Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Boutaud O, 2003, J BIOL CHEM, V278, P16926, DOI 10.1074/jbc.M300940200; CIPOLLONE F, 2004, ARTERIOSCLER THROMB, V24, P1; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goulet JL, 2000, J IMMUNOL, V164, P4899, DOI 10.4049/jimmunol.164.9.4899; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HECKER M, 1989, J BIOL CHEM, V264, P141; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KUHN DC, 1993, PROSTAG OTH LIPID M, V46, P195, DOI 10.1016/0090-6980(93)90003-P; Kuroda E, 2003, J IMMUNOL, V170, P757, DOI 10.4049/jimmunol.170.2.757; Lazarus M, 2002, ARCH BIOCHEM BIOPHYS, V397, P336, DOI 10.1006/abbi.2001.2614; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Meja KK, 1997, BRIT J PHARMACOL, V122, P149, DOI 10.1038/sj.bjp.0701360; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271; Naraba H, 1998, J IMMUNOL, V160, P2974; OGINO N, 1977, J BIOL CHEM, V252, P890; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Plastaras JP, 2000, J BIOL CHEM, V275, P11784, DOI 10.1074/jbc.275.16.11784; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Salomon RG, 1997, CHEM RES TOXICOL, V10, P536, DOI 10.1021/tx960157y; Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2; Schuligoi R, 2003, NEUROSCIENCE, V116, P1043, DOI 10.1016/S0306-4522(02)00783-2; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Stock JL, 2001, J CLIN INVEST, V107, P325, DOI 10.1172/JCI6749; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Sweeney FJ, 2003, MOL CELL ENDOCRINOL, V205, P151, DOI 10.1016/S0303-7207(03)00091-1; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Watanabe K, 1999, BBA-MOL CELL BIOL L, V1439, P406, DOI 10.1016/S1388-1981(99)00084-0; Watanabe K, 1997, BIOCHEM BIOPH RES CO, V235, P148, DOI 10.1006/bbrc.1997.6708; Westman M, 2004, ARTHRITIS RHEUM-US, V50, P1774, DOI 10.1002/art.20286; Yokoyama C, 2002, CIRCULATION, V106, P2397, DOI 10.1161/01.CIR.0000034733.93020.BC	46	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16579	16585		10.1074/jbc.M412075200	http://dx.doi.org/10.1074/jbc.M412075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15722356	hybrid			2022-12-27	WOS:000228615500007
J	Zhang, YW; Luo, WJ; Wang, H; Lin, P; Vetrivel, KS; Liao, F; Li, F; Wong, PC; Farquhar, MG; Thinakaran, G; Xu, HA				Zhang, YW; Luo, WJ; Wang, H; Lin, P; Vetrivel, KS; Liao, F; Li, F; Wong, PC; Farquhar, MG; Thinakaran, G; Xu, HA			Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; CELL-SURFACE; INTRACELLULAR TRAFFICKING; INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM; COMPLEX COMPONENTS; ALZHEIMERS-DISEASE; APH-1 INTERACTS; BETA-APP	gamma-Secretase, which is responsible for the intramembranous cleavage of Alzheimer beta-amyloid precursor protein and the signaling receptor Notch, is a multiprotein complex consisting of at least four components: presenilin ( PS); nicastrin (Nct); APH-1 ( anterior pharynx-defective-1); and presenilin enhancer-2 (PEN-2). Presenilin 1 (PS1) is known to be essential for the stability, interaction, and trafficking of the other PS1/gamma-secretase components. However, the precise functions of the other components remain elusive. Here, we investigated the functions of Nct within the PS1/gamma-secretase complex. We demonstrated that the loss of Nct expression in the embryonic fibroblast cells ( Nct KO cells) results in dramatically decreased levels of APH-1, PEN-2, and PS1 fragments accompanied by a significant accumulation of full-length PS1. In the absence of Nct, PEN-2 and full-length PS1 are subjected to proteasome-mediated degradation, whereas the degradation of APH-1 is mediated by both proteasomal and lysosomal pathways. Unlike the case of wild type cells in which the gamma-secretase complex mainly locates in the trans-Golgi network, the majority of residual PEN-2, APH-1, and the uncleaved full-length PS1 in Nct KO cells reside in the endoplasmic reticulum, which remain associated with each other in the absence of Nct. Interestingly, significant amounts of full-length PS1 and PEN-2, but not APH-1, are detected on the plasma membrane in Nct KO cells, suggesting the Nct-independent cell surface delivery of the PEN-2 center dot PS1. Finally, the diminished PEN-2 protein level in Nct-deficient cells can be partially restored by overexpression of exogenous PS1, APH-1, or PEN-2 individually or collectively, indicating a dispensable role for Nct in controlling PEN-2 level. Taken together, our study demonstrates a critical role of Nct in the stability and proper intracellular trafficking of other components of the PS1/ gamma-secretase complex but not in maintaining the association of PEN-2, APH-1, and full-length PS1.	Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Calif San Diego, Dept Cellular & Mol Med & Pathol, La Jolla, CA 92093 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Sanford Burnham Prebys Medical Discovery Institute; Rockefeller University; University of California System; University of California San Diego; University of Chicago; Johns Hopkins University	Xu, HA (corresponding author), Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.	xuh@burnham.org	Xu, Huaxi/AAV-7177-2021; Luo, Wenjie/ABF-8451-2020	Lin, Peter P./0000-0002-6869-9490; Zhang, Yun-wu/0000-0002-7152-7630	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG024895, R01AG021495, R01AG021173, F32AG023432] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021173, AG021495, F32 AG024895-01A1, R01 AG021495, F32 AG023432, AG021173, F32 AG024895, F32 AG023432-01] Funding Source: Medline; NINDS NIH HHS [NS046673, R01 NS046673] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Greenfield JP, 1999, J BIOL CHEM, V274, P33843, DOI 10.1074/jbc.274.48.33843; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Li T, 2003, J NEUROSCI, V23, P3272; Lin P, 2000, P NATL ACAD SCI USA, V97, P674, DOI 10.1073/pnas.97.2.674; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wang H, 2004, J BIOL CHEM, V279, P40560, DOI 10.1074/jbc.M404345200; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	43	95	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					17020	17026		10.1074/jbc.M409467200	http://dx.doi.org/10.1074/jbc.M409467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15711015	Green Accepted, hybrid			2022-12-27	WOS:000228615500059
J	Chen, J; Zhao, M; Rao, R; Inoue, H; Hao, CM				Chen, J; Zhao, M; Rao, R; Inoue, H; Hao, CM			C/EBP beta and its binding element are required for NF kappa B-induced COX2 expression following hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED CYCLOOXYGENASE-2 EXPRESSION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL INHIBITORY PROTEIN; MEDULLARY INTERSTITIAL-CELLS; NUCLEAR-FACTOR; GENE-EXPRESSION; SYNTHASE-2 GENE; PHORBOL ESTER; ACTIVATION; LIPOPOLYSACCHARIDE	NF kappa B plays a critical role mediating COX2 expression in renal medullary interstitial cells (RMICs). The trans-activating ability of NF kappa B can be modified by another nuclear factor C/EBP beta that can physically bind to NF kappa B and regulate its activity. Because the COX2 promoter also contains a C/EBP beta site adjacent to the NF kappa B site, the present study examined whether these two transcription factors cooperate to induce COX2 expression following hypertonic stress. Hypertonicity markedly induced COX2 expression in cultured medullary interstitial cells by immunoblot analysis. The tonicity-induced COX2 expression was suppressed by mutant I kappa B (I kappa Bm) that blocks NF kappa B activation, demonstrating that tonicity-induced COX2 expression depends on NF kappa B activation. However, mutation of the NF kappa B site in the COX2 promoter failed to abolish tonicity-induced COX2 reporter activity. I kappa B kinase-1 (IKK1) significantly induced COX2-luciferase activity by 2.3-fold ( n = 10, p < 0.01); mutation of the NF kappa B site also failed to abolish IKK1-stimulated COX2 reporter activity ( 86 +/- 3.1% of wild type, p > 0.05, n = 4). Interestingly, mutation of the C/EBP beta site of the COX2 gene significantly reduced both IKK1 and hypertonicity-induced COX2 reporter activity ( p < 0.01). To further examine the potential role of C/EBP beta in tonicity-induced COX2 expression, a dominant negative C/EBP beta-p20 was transduced into RMICs. C/EBP beta-p20 markedly suppressed hypertonic ( 550 mOsm) induction of COX2 ( immunoblot) to a similar extent as I kappa Bm. No additional suppression was observed when both NF kappa B and C/EBP beta were simultaneously blocked by I kappa Bm and C/EBP beta-p20. Interestingly, IKK-induced COX2 expression was not only blocked by I kappa Bm, but also completely abolished by C/EBP beta-p20. Further studies demonstrated physical association of C/EBP beta to NF kappa B p65 by coimmunoprecipitation. Importantly, this interaction between C/EBP beta and NF kappa B was greatly enhanced following hypertonic stress. These studies indicate C/EBP beta is required for the transcriptional activation of COX2 by NF kappa B, suggesting a dominant role for the C/EBP beta pathway in regulating induction of RMIC COX2 by hypertonicity.	Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Natl Cardiovasc Ctr Hosp & Res Inst, Dept Pharmacol, Osaka 5658565, Japan; Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai 200040, Peoples R China	Vanderbilt University; National Cerebral & Cardiovascular Center - Japan; Fudan University	Hao, CM (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, S3223 MCN, Nashville, TN 37232 USA.	chuanming.hao@vanderbilt.edu			NIDDK NIH HHS [DK065024, DK37097] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065024, R01DK037097] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams DS, 2000, J CELL BIOCHEM, V77, P221, DOI 10.1002/(SICI)1097-4644(20000501)77:2<221::AID-JCB6>3.0.CO;2-V; Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Breyer M D, 2001, Curr Opin Crit Care, V7, P393, DOI 10.1097/00075198-200112000-00005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; FitzGerald GA, 2001, J CLIN INVEST, V107, P1335, DOI 10.1172/JCI13037; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Hao CM, 2002, J BIOL CHEM, V277, P21341, DOI 10.1074/jbc.M200695200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Ikawa H, 2001, EXP CELL RES, V267, P73, DOI 10.1006/excr.2001.5233; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Jover R, 2002, FASEB J, V16, P1799, DOI 10.1096/fj.02-0195fje; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Lo CJ, 1998, J TRAUMA, V45, P19, DOI 10.1097/00005373-199807000-00004; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Moeckel GW, 2003, J BIOL CHEM, V278, P19352, DOI 10.1074/jbc.M302209200; MUIRHEAD EE, 1973, PROSTAG OTH LIPID M, V3, P581, DOI 10.1016/0090-6980(73)90096-8; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Paik JH, 2000, J BIOL CHEM, V275, P28173; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SEGASOTHY M, 1994, AM J KIDNEY DIS, V24, P17, DOI 10.1016/S0272-6386(12)80155-7; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yan XJ, 2002, BIOL REPROD, V66, P1667, DOI 10.1095/biolreprod66.6.1667; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yoshimoto T, 1996, J IMMUNOL, V156, P1082; Zhang MZ, 2002, AM J PHYSIOL-RENAL, V283, pF509, DOI 10.1152/ajprenal.00236.2001; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	53	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16354	16359		10.1074/jbc.M411134200	http://dx.doi.org/10.1074/jbc.M411134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713664	hybrid			2022-12-27	WOS:000228444800107
J	Gribun, A; Kimber, MS; Ching, R; Sprangers, R; Fiebig, KM; Houry, WA				Gribun, A; Kimber, MS; Ching, R; Sprangers, R; Fiebig, KM; Houry, WA			The ClpP double ring tetradecameric protease exhibits plastic ring-ring interactions, and the N termini of its subunits form flexible loops that are essential for ClpXP and ClpAP complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; 20S PROTEASOME; DEGRADATION; TRANSLOCATION; PROTEINS; BINDING; PROLINE	ClpP is a conserved serine-protease with two heptameric rings that enclose a large chamber containing the protease active sites. Each ClpP subunit can be divided into a handle region, which mediates ring-ring interactions, and a head domain. ClpP associates with the hexameric ATPases ClpX and ClpA, which can unfold and translocate substrate proteins through the ClpP axial pores into the protease lumen for degradation. We have determined the x-ray structure of Streptococcus pneumoniae ClpP(A153P) at 2.5 angstrom resolution. The structure revealed two novel features of ClpP which are essential for ClpXP and ClpAP functional activities. First, the Ala 3 Pro mutation disrupts the handle region, resulting in an altered ring-ring dimerization interface, which, in conjunction with biochemical data, demonstrates the unusual plasticity of this region. Second, the structure shows the existence of a flexible N-terminal loop in each ClpP subunit. The loops line the axial pores in the ClpP tetradecamer and then protrude from the protease apical surface. The sequence of the N-terminal loop is highly conserved in ClpP across all kingdoms of life. These loops are essential determinants for complex formation between ClpP and ClpX/ClpA. Mutation of several amino acid residues in this loop or the truncation of the loop impairs ClpXP and ClpAP complex formation and prevents the coupling between ClpX/ClpA and ClpP activities.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Affinium Pharmaceut, Toronto, ON M5J 1V6, Canada	University of Toronto	Kimber, MS (corresponding author), Univ Toronto, Dept Biochem, 1 Kings Coll Circle,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	mkimber@afnm.com	Kimber, Matthew/Q-8144-2019	Kimber, Matthew/0000-0001-9454-5586; Fiebig, Klaus/0000-0002-9553-2645				Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Chakrabarti A, 1999, PROTEIN SCI, V8, P2455; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Feng HP, 1998, CURR BIOL, V8, pR464, DOI 10.1016/S0960-9822(98)70294-5; Frees D, 1999, MOL MICROBIOL, V31, P79, DOI 10.1046/j.1365-2958.1999.01149.x; Frees D, 2003, MOL MICROBIOL, V48, P1565, DOI 10.1046/j.1365-2958.2003.03524.x; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, P NATL ACAD SCI USA, V95, P2731, DOI 10.1073/pnas.95.6.2731; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gray TM, 1996, PROTEIN SCI, V5, P742; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Gunasekaran K, 1998, J MOL BIOL, V275, P917, DOI 10.1006/jmbi.1997.1505; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Joshi SA, 2004, NAT STRUCT MOL BIOL, V11, P404, DOI 10.1038/nsmb752; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kohler A, 2001, BIOCHIMIE, V83, P325, DOI 10.1016/S0300-9084(01)01242-1; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Ortega J, 2004, J STRUCT BIOL, V146, P217, DOI 10.1016/j.jsb.2003.11.023; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAUER UH, 1992, J BIOL CHEM, V267, P2393; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Seol JH, 1995, FEBS LETT, V377, P41, DOI 10.1016/0014-5793(95)01306-7; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Thomsen LE, 2002, MICROBIOL-SGM, V148, P2727, DOI 10.1099/00221287-148-9-2727; Weichart D, 2003, J BACTERIOL, V185, P115, DOI 10.1128/JB.185.1.115-125.2003; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; WOO KM, 1989, J BIOL CHEM, V264, P2088; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	57	84	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16185	16196		10.1074/jbc.M414124200	http://dx.doi.org/10.1074/jbc.M414124200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15701650	hybrid			2022-12-27	WOS:000228444800088
J	Guse, AH; Gu, XF; Zhang, LR; Weber, K; Kramer, E; Yang, ZJ; Jin, HW; Li, Q; Carrier, L; Zhang, LH				Guse, AH; Gu, XF; Zhang, LR; Weber, K; Kramer, E; Yang, ZJ; Jin, HW; Li, Q; Carrier, L; Zhang, LH			A minimal structural analogue of cyclic ADP-ribose - Synthesis and calcium release activity in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; ADENOSINE-DIPHOSPHORIBOSE CADPR; RYANODINE RECEPTOR; T-LYMPHOCYTES; CA2+ SIGNALS; STORES; PHARMACOLOGY; PROPAGATION; METABOLITES; MESSENGERS	Cyclic ADP-ribose (cADPR) is an endogenous Ca2+-mobilizing second messenger in many cell types and organisms. Although the biological activity of several modified analogues of cADPR has been analyzed, most of these structures were still very similar to the original molecule. Recently, we have introduced simplified analogues in which the northern ribose (N-1-linked ribose) was replaced by an ether strand (Gu, X., Yang, Z., Zhang, L., Kunerth, S., Fliegert, R., Weber, K., Guse, A. H., and Zhang, L. ( 2004) J. Med. Chem. 47, 5674 - 5682). Here we also demonstrate that the southern ribose ( N-9-linked ribose) can be replaced by an ether strand resulting in N-1-[(phosphoryl-O-ethoxy)methyl]- N-9-[(phosphoryl-O-ethoxy)- methyl]-hypoxanthine-cyclic pyrophosphate (cIDP-DE). This minimal structural analogue of cyclic ADP-ribose released Ca2+ from intracellular stores of permeabilized Jurkat T lymphocytes. In intact T lymphocytes initial subcellular Ca2+ release events, global Ca2+ release, and subsequent global Ca2+ entry were observed. Cardiac myocytes freshly prepared from mice responded to cIDP-DE by increased recruitment of localized Ca2+ signals and by global Ca2+ waves.	Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Dept Pharmacol, D-20246 Hamburg, Germany; INSERM, U582, F-75013 Paris, France; Peking Univ, Sch Pharmaceut Sci, Natl Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China	University of Hamburg; University of Hamburg; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Peking University	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de; zdszlh@bjmu.edu.cn						Ashamu GA, 1997, BIOCHEMISTRY-US, V36, P9509, DOI 10.1021/bi9705671; Bailey VC, 1996, FEBS LETT, V379, P227, DOI 10.1016/0014-5793(95)01515-9; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cui Y, 1999, BIOCHEM J, V342, P269, DOI 10.1042/0264-6021:3420269; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Gu XF, 2004, J MED CHEM, V47, P5674, DOI 10.1021/jm040092t; Guo XQ, 1996, CIRC RES, V79, P147, DOI 10.1161/01.RES.79.1.147; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Guse AH, 2002, BIOCHEMISTRY-US, V41, P6744, DOI 10.1021/bi020171b; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang LJ, 2002, J MED CHEM, V45, P5340, DOI 10.1021/jm010530l; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Mendez F, 1998, J PHYSIOL-LONDON, V507, P365, DOI 10.1111/j.1469-7793.1998.365bt.x; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Potter BVL, 2004, CURR MOL MED, V4, P303, DOI 10.2174/1566524043360744; Prakash YS, 2000, AM J PHYSIOL-HEART C, V279, pH1482, DOI 10.1152/ajpheart.2000.279.4.H1482; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; ROBBINS M J, 1991, Canadian Journal of Chemistry, V69, P1468; Robins MJ, 1996, J ORG CHEM, V61, P9207, DOI 10.1021/jo9617023; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Shuto S, 2004, CURR MED CHEM, V11, P827, DOI 10.2174/0929867043455639; WADA T, 1995, NUCLEOS NUCLEOT, V14, P1301, DOI 10.1080/15257779508010692; Wagner GK, 2003, CHEM COMMUN, P1944, DOI 10.1039/b305660k	31	47	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15952	15959		10.1074/jbc.M414032200	http://dx.doi.org/10.1074/jbc.M414032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15713671	hybrid			2022-12-27	WOS:000228444800061
J	ZhuO, J; Qiu, ZH; Wiese, C; Ishii, Y; Friedrichsen, J; Rajashekara, G; Splitter, GA				ZhuO, J; Qiu, ZH; Wiese, C; Ishii, Y; Friedrichsen, J; Rajashekara, G; Splitter, GA			Nuclear and mitochondrial localization signals overlap within bovine herpesvirus 1 tegument protein VP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; PARVOVIRUS MINUTE VIRUS; SELF-ASSOCIATION; UL49 HOMOLOG; HISTONES; CELLS; INFECTION; INTERACTS; SEQUENCE; VIRIONS	VP22, a tegument protein of bovine herpesvirus 1, accumulates in the nucleus of infected and transiently transfected cells. Previous studies indicated a possible regulatory function of VP22 within nuclei, but how VP22 enters nuclei is unknown. Despite the abundance of basic residues within this protein, no classic nuclear localization signal (NLS) motif has been identified. To identify the signal directing nuclear accumulation, a series of truncations, internal deletions, and point mutations were constructed. Fluorescence microscopy of cells transfected with VP22 constructs indicated that a sequence of 103 residues is necessary and sufficient for nuclear localization. This NLS sequence is conformation-sensitive in contrast to a classical sequential NLS. Energy depletion assays and co-immunoprecipitation suggested that this NLS sequence also binds histone H4, resulting in nuclear retention of VP22. In addition, a mitochondrial targeting sequence was identified at the C-terminal 49 amino acids, which overlapped the sequence required for nuclear targeting. Our findings demonstrate the diversity of VP22 protein to localize within the cell and provide the opportunity for VP22 to direct cargo specifically to different subcellular compartments.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Splitter, GA (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	Splitter@svm.vetmed.wisc.edu	Rajashekara, Gireesh/E-3913-2011		NIGMS NIH HHS [R01-GM60986] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060986] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; ELLIOTT G, 1995, J VIROL, V69, P7932, DOI 10.1128/JVI.69.12.7932-7941.1995; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fischer D, 1999, PROTEINS, P209; Freeman L, 1996, P NATL ACAD SCI USA, V93, P12780, DOI 10.1073/pnas.93.23.12780; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Harms JS, 2000, J VIROL, V74, P3301, DOI 10.1128/JVI.74.7.3301-3312.2000; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kretsovali A, 2001, J BIOL CHEM, V276, P32191, DOI 10.1074/jbc.M103164200; LIANG XP, 1995, J VIROL, V69, P3863, DOI 10.1128/JVI.69.6.3863-3867.1995; Liang XP, 1997, VACCINE, V15, P1057, DOI 10.1016/S0264-410X(97)00008-X; Lischka P, 2003, J VIROL, V77, P3734, DOI 10.1128/JVI.77.6.3734-3748.2003; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; Pomeranz LE, 2000, J VIROL, V74, P10041, DOI 10.1128/JVI.74.21.10041-10054.2000; Qiu ZH, 2005, HUM GENE THER, V16, P101, DOI 10.1089/hum.2005.16.101; Ren XD, 2001, J VIROL, V75, P8251, DOI 10.1128/JVI.75.17.8251-8258.2001; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAHR KE, 1993, J BIOL CHEM, V268, P22656; Sciortino MT, 2002, P NATL ACAD SCI USA, V99, P8318, DOI 10.1073/pnas.122231699; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; VAN LH, 2003, J GEN VIROL, V84, P2501; Wang P, 1997, J VIROL, V71, P1850, DOI 10.1128/JVI.71.3.1850-1856.1997	31	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16038	16044		10.1074/jbc.M500054200	http://dx.doi.org/10.1074/jbc.M500054200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15705574	hybrid			2022-12-27	WOS:000228444800071
J	Cheng, JK; Perkins, ND; Yeh, ETH				Cheng, JK; Perkins, ND; Yeh, ETH			Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL PHOSPHORYLATION; ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE-1; ANDROGEN RECEPTOR; MOUSE DEVELOPMENT; ONCOPROTEIN E1A; P300; AP-1; APOPTOSIS	c-Jun is a transcription factor that plays an important role in regulating cell growth, apoptosis, differentiation, and transformation. The transcriptional activity of c-Jun can be regulated by both phosphorylation and sumoylation. It has also been shown that c-Jun transcription can be regulated by SuPr-1, an alternatively spliced form of SUMO-specific protease 2 (SENP2). However, the ability of SuPr-1 to enhance c-Jun transcription is dependent on promyelocytic leukemia but is independent of the desumoylation activity of SuPr-1. Here, we show that SUMO-specific protease 1 (SENP1) also markedly enhances the transcription activity of c-Jun. The action of SENP1 on c-Jun transcription is independent of the sumoylation and phosphorylation status of c-Jun but is critically dependent on the desumoylation activity of SENP1. We further show that p300 is essential for SENP1 to enhance c-Jun-dependent transcription because SENP1 can desumoylate the CRD1 domain of p300, thereby releasing the cis-repression of CRD1 on p300. Thus, two SUMO-specific proteases regulate c-Jun-dependent transcription through entirely different mechanisms.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Ctr Cardiovasc Dis, Brown Fdn Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Dundee	Yeh, ETH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Unit 449, Houston, TX 77030 USA.	etyeh@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA080089] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; Grimm C, 2001, CELL DEATH DIFFER, V8, P859, DOI 10.1038/sj.cdd.4400871; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 2002, CELL CYCLE, V1, P39, DOI 10.4161/cc.1.1.98; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	70	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14492	14498		10.1074/jbc.M412185200	http://dx.doi.org/10.1074/jbc.M412185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15701643	hybrid			2022-12-27	WOS:000228236800019
J	Komura, J; Ono, T				Komura, J; Ono, T			Disappearance of nucleosome positioning in mitotic chromatin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-RESPONSE FACTOR; TRANSCRIPTION FACTORS; DEPENDENT TRANSCRIPTION; PROMOTER; CHROMOSOMES; PROTEIN; GENES; BINDING; MITOSIS; ASSOCIATION	During mitosis, transcription is silenced and most transcription factors are displaced from their recognition sequences. By in vivo footprinting analysis, we have confirmed and extended previous studies showing loss of transcription factors from an RNA polymerase II promoter (c-FOS) and, for the first time, an RNA polymerase III promoter (U6) in HeLa cells. Because little was known about nucleosomal organization in mitotic chromosomes, we performed footprinting analysis for nucleosomes on these promoters in interphase and mitotic cells. During interphase, each of the promoters had a positioned nucleosome in the region intervening between proximal promoter elements and distal enhancer elements, but the strong nucleosome positioning disappeared during mitosis. Thus, the nucleosomal organization that appears to facilitate transcription in interphase cells may be lost in mitotic cells, and nucleosome positioning during mitosis does not seem to be a major component of the epigenetic mechanisms to mark genes for rapid reactivation after this phase.	Tohoku Univ, Grad Sch Med, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tohoku University	Komura, J (corresponding author), Tohoku Univ, Grad Sch Med, Dept Cell Biol, Sendai, Miyagi 9808575, Japan.	junkom@mail.tains.tohoku.ac.jp						Becker PB, 2002, EMBO J, V21, P4749, DOI 10.1093/emboj/cdf486; Boyd DC, 2003, GENE, V315, P103, DOI 10.1016/S0378-1119(03)00717-0; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HERSHKOVITZ M, 1995, P NATL ACAD SCI USA, V92, P2379, DOI 10.1073/pnas.92.6.2379; Jeppesen P, 1997, BIOESSAYS, V19, P67, DOI 10.1002/bies.950190111; Komura J, 2003, BIOCHEMISTRY-US, V42, P15084, DOI 10.1021/bi034802t; Komura J, 1997, J BIOL CHEM, V272, P10975; Komura J, 2001, BIOCHEMISTRY-US, V40, P4096, DOI 10.1021/bi002539f; KUO MT, 1982, NUCLEIC ACIDS RES, V10, P4565, DOI 10.1093/nar/10.15.4565; Lucchini R, 2001, EMBO J, V20, P7294, DOI 10.1093/emboj/20.24.7294; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	35	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2005	280	15					14530	14535		10.1074/jbc.M500637200	http://dx.doi.org/10.1074/jbc.M500637200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	914OI	15705567	hybrid			2022-12-27	WOS:000228236800024
